PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	LEPRINCE, D; CREPIEUX, P; STEHELIN, D				LEPRINCE, D; CREPIEUX, P; STEHELIN, D			C-ETS-1 DNA-BINDING TO THE PEA3 MOTIF IS DIFFERENTIALLY INHIBITED BY ALL THE MUTATIONS FOUND IN V-ETS	ONCOGENE			English	Article							LONG TERMINAL REPEAT; C-ETS; LEUKEMIA-VIRUS; PROTO-ONCOGENE; LYMPHOID-CELLS; E26 RETROVIRUS; SEQUENCE; PROTEINS; GENE; EXPRESSION	The proto-oncogene c-ets-1, one of the two cellular sequences transduced by the avian retrovirus E26, encodes for two transcription factors that activate through a purine-rich motif. The v-ets oncogene differs from its cellular progenitor p68c-ets-1 (i) by its fusion to gag- and myb-derived sequences in the E26 P135gag-myb-ets fusion protein, (ii) by two point mutations, and (iii) by the replacement of the 13 C-terminal amino acids present in c-ets-1 by 16 unrelated residues in v-ets. A 35 kDa protein which binds to the purine-rich PEA3 motif in a sequence-specific manner has been obtained by expression in Escherichia coli of the 311 carboxy-terminal amino acids of c-ets-1. Using various v-/c-ets-1 chimeric 35 kDa proteins expressed in bacteria, we have shown that all the mutations found in v-ets, when introduced into this c-ets-1 protein, diminish or even abolish its sequence-specific DNA binding. These results demonstrate that, in addition to the previously defined 85 amino acids located near the carboxy terminus of the c-ets-1 protein (the ETS domain), other sequences are required for sequence-specific DNA binding. In addition, the c-ets-1 35 kDa polypeptide carrying the two point mutations and the viral-specific carboxy terminus, and thus similar to the v-ets-encoded domain of the E26 P135gag-myb-ets, does not bind to the PEA3 motif.			LEPRINCE, D (corresponding author), INST PASTEUR,INSERM,U186,CNRS,URA 1160,1 RUE CALMETTE,F-59019 LILLE,FRANCE.		Crepieux, Pascale/X-3217-2019	Leprince, Dominique/0000-0002-1999-0775				BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GEGONNE A, 1987, MOL CELL BIOL, V7, P806, DOI 10.1128/MCB.7.2.806; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; Ivanov X, 1962, B I PATHOL COMP ANIM, V9, P5; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; POGNONEC P, 1989, ONCOGENE, V4, P691; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; REDDY ESP, 1990, CANCER RES, V50, P5013; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TREISMAN J, 1989, CELL, V59, P553; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862	38	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					9	17						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741168				2022-12-25	WOS:A1992HC22700002
J	BASSHAM, DC; BARTLING, D; MOULD, RM; DUNBAR, B; WEISBEEK, P; HERRMANN, RG; ROBINSON, C				BASSHAM, DC; BARTLING, D; MOULD, RM; DUNBAR, B; WEISBEEK, P; HERRMANN, RG; ROBINSON, C			TRANSPORT OF PROTEINS INTO CHLOROPLASTS - DELINEATION OF ENVELOPE TRANSIT AND THYLAKOID TRANSFER SIGNALS WITHIN THE PRE-SEQUENCES OF 3 IMPORTED THYLAKOID LUMEN PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; FOREIGN PROTEIN; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; PEA-CHLOROPLASTS; PRECURSOR; PEPTIDE; PLASTOCYANIN; MATURATION; CLEAVAGE	The targeting of cytosolically synthesized proteins into the thylakoid lumen is mediated by an aminoterminal pre-sequence consisting of an "envelope transit" and a "thylakoid transfer" signal in tandem. We have investigated the structural characteristics of several thylakoid transfer signals by determining the intermediate sites at which the stromal processing peptidase cleaves to remove the transit sequences. Using this approach we have found that the thylakoid transfer signals of Silene pratensis plastocyanin, 23-kDa oxygen-evolving complex protein from wheat, and 33-kDa oxygen-evolving complex protein from wheat, are 25, 39, and 48 residues in length, respectively. All of the transfer signals contain hydrophobic core sequences and a "-3,-1" motif reminiscent of those found in signal sequences, but the amino-terminal regions of the transfer signals of the 23- and 33-kDa proteins are both longer and more highly charged. The net charge of each amino-terminal region of the transfer sequences is +1, including the amino-terminal amino group. In each case, the stromal processing peptidase cleaves immediately after a positively charged residue, but otherwise the cleavage sites exhibit no common elements of either primary or secondary structure.	UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND; UNIV MUNICH,DEPT BOT,W-8000 MUNICH 19,GERMANY; UNIV ABERDEEN,DEPT BIOCHEM,ABERDEEN AB9 1AS,SCOTLAND; UNIV UTRECHT,DEPT MOLEC CELL BIOL,3584 CH UTRECHT,NETHERLANDS; UNIV UTRECHT,INST MOLEC BIOL,3584 CH UTRECHT,NETHERLANDS	University of Warwick; University of Munich; University of Aberdeen; Utrecht University; Utrecht University	ROBINSON, C (corresponding author), UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND.							CASHMORE AR, 1983, GENETIC ENG PLANTS A, P29; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; HALPIN C, 1989, EMBO J, V8, P3917, DOI 10.1002/j.1460-2075.1989.tb08572.x; JAMES HE, 1991, PLANT MOL BIOL, V17, P179, DOI 10.1007/BF00036827; JAMES HE, 1989, J BIOL CHEM, V264, P19573; JANSEN T, 1987, FEBS LETT, V216, P234, DOI 10.1016/0014-5793(87)80696-8; KAVANAGH TA, 1988, MOL GEN GENET, V215, P38, DOI 10.1007/BF00331300; KIRWIN PM, 1989, EMBO J, V8, P2251, DOI 10.1002/j.1460-2075.1989.tb08349.x; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUBBEN TH, 1989, PLANT MOL BIOL, V12, P13, DOI 10.1007/BF00017443; MEADOWS JW, 1989, FEBS LETT, V253, P244, DOI 10.1016/0014-5793(89)80968-8; MEADOWS JW, 1991, PLANT MOL BIOL, V16, P1085, DOI 10.1007/BF00016082; MUSGROVE JE, 1989, PLANT PHYSIOL, V90, P1616, DOI 10.1104/pp.90.4.1616; ROBINSON C, 1984, EUR J BIOCHEM, V142, P337, DOI 10.1111/j.1432-1033.1984.tb08291.x; SCHREIER PH, 1985, EMBO J, V4, P25, DOI 10.1002/j.1460-2075.1985.tb02312.x; SEIDLER A, 1990, EMBO J, V9, P1743, DOI 10.1002/j.1460-2075.1990.tb08298.x; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMEEKENS S, 1985, NUCLEIC ACIDS RES, V13, P3179, DOI 10.1093/nar/13.9.3179; SMEEKENS S, 1985, NATURE, V317, P456, DOI 10.1038/317456a0; VANDENBROECK G, 1985, NATURE, V313, P358, DOI 10.1038/313358a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	25	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23606	23610						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748638				2022-12-25	WOS:A1991GV31900016
J	HABUKA, N; MIYANO, M; KATAOKA, J; TSUGE, H; AGO, H; NOMA, M				HABUKA, N; MIYANO, M; KATAOKA, J; TSUGE, H; AGO, H; NOMA, M			SUBSTANTIAL INCREASE OF THE INHIBITORY ACTIVITY OF MIRABILIS ANTIVIRAL PROTEIN BY AN ELIMINATION OF THE DISULFIDE BOND WITH GENETIC-ENGINEERING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICIN-A CHAIN; ESCHERICHIA-COLI; EXPRESSION; SECRETION; STABILITY	Mirabilis antiviral protein (MAP) is a rigid, heat-stable protein composed of 250 amino acids with an intramolecular disulfide bond. MAP inhibits the in vitro protein synthesis of rabbit reticulocyte with approximately one-thirtieth the activity of the ricin A chain, a homologous protein with no such bond (Habuka, N., Murakami, Y., Noma, M., Kudo, T., and Horikoshi, K. (1989) J. Biol. Chem. 264, 6629-6637; Habuka, N., Akiyama, K., Tsuge, H., Miyano, M., Matsumoto, T., and Noma, M. (1990) J. Biol. Chem. 265, 10988-10992). The bond is presumed to induce some structural perturbation that alters the mode of interaction with the substrate ribosome and thus lowers the activity. To confirm this hypothesis, a mutant MAP gene in which the codons of both cysteines were replaced by those of serines was constructed and expressed in Escherichia coli, and its product (C36/220S) was purified. In a sodium dodecyl sulfate-polyacrylamide gel electrophoresis, C36/220S showed the same mobility as that of MAP reduced by 2-mercaptoethanol, whereas nonreduced MAP showed faster migration. The inhibitory activity of C36/220S was approximately 22 times higher than that of native MAP, that is the mutant had an IC50 of 0.16 nM for the protein synthesis of the rabbit reticulocyte system, whereas the native MAP had an IC50 of 3.5 nM. The results indicate that the activity of MAP is increased by the elimination of the disulfide bond, and this supports the hypothesis.			HABUKA, N (corresponding author), JAPAN TOBACCO INC,LIFE SCI RES LAB,6-2 UMEGAOKA,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN.		Tsuge, Hideaki/ABF-6424-2021; Miyano, Masashi/R-2785-2016	Miyano, Masashi/0000-0003-2253-6175; Tsuge, Hideaki/0000-0003-0166-9163				HABUKA N, 1990, J BIOL CHEM, V265, P10988; HABUKA N, 1989, J BIOL CHEM, V264, P6629; HABUKA N, 1991, IN PRESS J MOL BIOL; IKEDA T, 1987, PLANT CELL REP, V6, P216, DOI 10.1007/BF00268483; JACOBSON BL, 1991, J BIOL CHEM, V266, P5220; MATSUMURA M, 1989, P NATL ACAD SCI USA, V86, P6562, DOI 10.1073/pnas.86.17.6562; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; OHARE M, 1987, FEBS LETT, V216, P73, DOI 10.1016/0014-5793(87)80759-7; PACE CN, 1988, J BIOL CHEM, V263, P11820; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PIATAK M, 1988, J BIOL CHEM, V263, P4837; POLLITT S, 1983, J BACTERIOL, V153, P27, DOI 10.1128/JB.153.1.27-32.1983; TAKANAMI Y, 1990, Annals of the Phytopathological Society of Japan, V56, P488, DOI 10.3186/jjphytopath.56.488	13	4	6	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23558	23560						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748633				2022-12-25	WOS:A1991GV31900009
J	MEIKLE, PJ; NG, KF; JOHNSON, E; HOOGENRAAD, NJ; STONE, BA				MEIKLE, PJ; NG, KF; JOHNSON, E; HOOGENRAAD, NJ; STONE, BA			THE BETA-GLUCAN SYNTHASE FROM LOLIUM-MULTIFLORUM - DETERGENT SOLUBILIZATION, PURIFICATION USING MONOCLONAL-ANTIBODIES, AND PHOTOAFFINITY-LABELING WITH A NOVEL PHOTOREACTIVE PYRIMIDINE ANALOG OF URIDINE 5'-DIPHOSPHOGLUCOSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BEAN UDP-GLUCOSE; 5-AZIDO-2'-DEOXYURIDINE 5'-TRIPHOSPHATE; ENZYMATIC-SYNTHESIS; CALLOSE SYNTHASE; PLASMA-MEMBRANE; BINDING-SITE; PLANT-CELLS; VULGARIS L; ENDOSPERM; 5-AZIDO-UDP-GLUCOSE	The membrane-bound beta-glucan synthase from Italian ryegrass (Lolium multiflorum L.) endosperm cells has been solubilized by both non-ionic and zwitterionic detergents. A complex relationship exists between the ratio of (1 --> 3)-, (1 --> 4)-, and (1 --> 3, 1 --> 4)-,beta-glucan products of the solubilized enzyme, the cations present, and the concentration of the uridine 5'-diphosphoglucose substrate. Monoclonal antibodies directed against the beta-glucan synthase complex were generated by immunization of mice with an unfractionated microsomal preparation. Hybridoma cell lines were screened using a combination of indirect enzyme-linked immunosorbent assay followed by an enzyme-capture assay. The purified monoclonal antibodies were used with Pansorbin (stabilized protein A-bearing staphylococcal cells) to immunoprecipitate an active beta-glucan synthase complex which had been solubilized from a microsomal preparation with 0.6% CHAPS. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of the immunoprecipitated synthase complex revealed four major polypeptides of apparent molecular mass 30, 31, 54, and 58 kDa together with several minor components. The immunoprecipitated beta-glucan synthase complex was capable of synthesizing both (1 --> 3)- and (1 --> 4)-,beta-glucans. A new photoreactive pyrimidine analogue of uridine 5'-diphosphoglucose, 5-[3-(p-azidosalicylamide)]allyluridine 5'-diphosphoglucose was synthesized in a three-step reaction sequence involving mercuration of UDP-Glc, alkylation of 5-Hg-UDP-Glc, and acylation of 5-(3-amino)allyl-UDP-Glc and characterized by chemical and spectroscopic analysis. The analogue inhibits (K(i)app 16-mu-M) and, upon UV irradiation, irreversibly inactivates the beta-glucan synthase. The analogue was iodinated with Na I-125 to give a radiolabeled, photoreactive compound, and was used in photoaffinity labeling of UDP-Glc pyrophosphorylase, UDP-Glc dehydrogenase, and several putative UDP-Glc-binding proteins from L. multiflorum. The radiolabeled analogue specifically labeled the 31-kDa polypeptide in the immunoprecipitated synthase complex. The photolabeling of this polypeptide is strictly dependent on UV irradiation, is blocked by uridine 5'-diphosphoglucose and uridine 5'-diphosphate, and reaches saturation at analogue concentrations above 300-mu-M. These results indicate that the 31-kDa polypeptide in the beta-glucan synthase complex bears a uridine 5'-diphosphoglucose-binding site and is involved in the catalysis of beta-glucan synthesis.	LA TROBE UNIV, COMMONWEALTH CTR PROT & ENZYME TECHNOL, BUNDOORA, VIC 3083, AUSTRALIA; LA TROBE UNIV, DEPT BIOCHEM, BUNDOORA, VIC 3083, AUSTRALIA	La Trobe University; La Trobe University			Hoogenraad, Nicholas J/C-7505-2011; Meikle, Peter J/B-4023-2009; Ng, Ken/L-5370-2015	Ng, Ken/0000-0002-1843-0506; Meikle, Peter/0000-0002-2593-4665				ANDERSON MA, 1975, FEBS LETT, V52, P202, DOI 10.1016/0014-5793(75)80806-4; Antonoff R S, 1977, Methods Enzymol, V46, P335; Bacic A., 1988, BIOCHEM PLANT, V14, P297, DOI [DOI 10.1016/B978-0-08-092615-5.50014-X, 10.1016/B978-0-08-092615-5.50014-X]; Bayley H., 1984, AZIDES NITRENES REAC, P433; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BERGSTROM DE, 1978, J AM CHEM SOC, V100, P8106, DOI 10.1021/ja00494a014; BERGSTROM DE, 1976, J AM CHEM SOC, V98, P1587, DOI 10.1021/ja00422a056; BITTNER M, 1980, ANAL BIOCHEM, V102, P459, DOI 10.1016/0003-2697(80)90182-7; BULONE V, 1989, 5TH CELL WALL M ED; CALLAGHAN T, 1988, PLANT PHYSIOL, V86, P1104, DOI 10.1104/pp.86.4.1104; CAMPBELL DG, 1989, EUR J BIOCHEM, V185, P119, DOI 10.1111/j.1432-1033.1989.tb15090.x; CARPITA NC, 1980, PLANT PHYSIOL, V66, P911, DOI 10.1104/pp.66.5.911; CHRISTOPHER AJ, 1969, ANALYST, V94, P397, DOI 10.1039/an9699400397; COOK JA, 1980, MECHANISMS SACCHARID, P301; DALE RMK, 1975, BIOCHEMISTRY-US, V14, P2447, DOI 10.1021/bi00682a027; DELMER DP, 1991, PLANT PHYSIOL, V95, P556, DOI 10.1104/pp.95.2.556; DELMER DP, 1988, BIOCH PLANTS, V14, P373; DELMER DP, 1984, STRUCTURE FUNCTION B, P133; DHUGGA KS, 1991, FEBS LETT, V278, P283, DOI 10.1016/0014-5793(91)80136-Q; DRAKE RR, 1989, J BIOL CHEM, V264, P11928; DRAKE RR, 1988, FASEB J, V2, pA1025; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; EVANS RK, 1987, BIOCHEMISTRY-US, V26, P269, DOI 10.1021/bi00375a037; EVANS RK, 1986, P NATL ACAD SCI USA, V83, P5382, DOI 10.1073/pnas.83.15.5382; FINCHER GB, 1981, ENCY PLANT PHYSL B, V13, P68; FINK J, 1990, PLANTA, V181, P343, DOI 10.1007/BF00195886; FLEET GWJ, 1969, NATURE, V224, P511, DOI 10.1038/224511a0; FROST DJ, 1990, J BIOL CHEM, V265, P2162; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; GIDDINGS TH, 1980, J CELL BIOL, V84, P327, DOI 10.1083/jcb.84.2.327; GIRARD V, 1990, 3RD INT WORKSH PLANT; GORDON R, 1989, PLANT PHYSIOL, V91, P373, DOI 10.1104/pp.91.1.373; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HANNA MM, 1989, BIOCHEMISTRY-US, V28, P5814, DOI 10.1021/bi00440a017; HAYASHI T, 1987, PLANT PHYSIOL, V83, P1054, DOI 10.1104/pp.83.4.1054; HECK RF, 1968, J AM CHEM SOC, V90, P5531, DOI 10.1021/ja01022a036; HECK RF, 1968, J AM CHEM SOC, V90, P5535, DOI 10.1021/ja01022a037; HECK RF, 1968, J AM CHEM SOC, V90, P5518, DOI 10.1021/ja01022a034; HECK RF, 1968, J AM CHEM SOC, V90, P5526, DOI 10.1021/ja01022a035; HENRY RJ, 1982, PLANT PHYSIOL, V69, P632, DOI 10.1104/pp.69.3.632; HOJ PB, 1989, PLANT MOL BIOL, V13, P31, DOI 10.1007/BF00027333; HORIBATA K, 1970, EXP CELL RES, V60, P61, DOI 10.1016/0014-4827(70)90489-1; JACOB SR, 1985, J CELL SCI, P1, DOI 10.1242/jcs.1985.Supplement_2.1; JANSON JC, 1967, J CHROMATOGR, V28, P12, DOI 10.1016/S0021-9673(01)85920-3; JI I, 1985, ANAL BIOCHEM, V151, P348, DOI 10.1016/0003-2697(85)90186-1; JI TH, 1982, ANAL BIOCHEM, V121, P286, DOI 10.1016/0003-2697(82)90481-X; KAUSS H, 1987, ANNU REV PLANT PHYS, V38, P47, DOI 10.1146/annurev.pp.38.060187.000403; King EJ, 1933, BIOCHEM J, V27, P1002, DOI 10.1042/bj0271002; KOHLE H, 1985, PLANT PHYSIOL, V77, P544, DOI 10.1104/pp.77.3.544; KOHNKEN RE, 1987, BIOCHEMISTRY-US, V26, P8727, DOI 10.1021/bi00400a035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633; LAWSON SG, 1989, PLANT PHYSIOL, V90, P101, DOI 10.1104/pp.90.1.101; Lin F. C., 1988, CELLULOSE WOOD CHEM, P473; LIN FC, 1990, J BIOL CHEM, V265, P4782; LOMAKO J, 1990, FEBS LETT, V264, P13, DOI 10.1016/0014-5793(90)80752-5; LOMAKO J, 1990, FEBS LETT, V268, P8, DOI 10.1016/0014-5793(90)80959-M; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MAS MT, 1980, BIOCHEMISTRY-US, V19, P684, DOI 10.1021/bi00545a012; MASON TL, 1990, PHYSIOL PLANTARUM, V79, P439, DOI 10.1111/j.1399-3054.1990.tb02100.x; MAY JM, 1986, J BIOL CHEM, V261, P2542; MAYER R, 1989, 5TH CELL WALL M ED; NODET P, 1988, ANAL BIOCHEM, V174, P662, DOI 10.1016/0003-2697(88)90070-X; NORTHCOTE DH, 1989, PLANTA, V178, P353, DOI 10.1007/BF00391863; Oi V.T., 1980, SELECTED METHODS CEL, P351; ORDIN L, 1967, PLANT PHYSIOL, V42, P205, DOI 10.1104/pp.42.2.205; PEAUDLENOEL C, 1970, FEBS LETT, V8, P224, DOI 10.1016/0014-5793(70)80270-8; QUADER H, 1979, EUR J CELL BIOL, V20, P51; QUIGLEY DR, 1988, EXP MYCOL, V12, P141, DOI 10.1016/0147-5975(88)90003-5; RAY PM, 1980, BIOCHIM BIOPHYS ACTA, V629, P431, DOI 10.1016/0304-4165(80)90149-X; READ SM, 1987, PLANT PHYSIOL, V85, P1008, DOI 10.1104/pp.85.4.1008; REISER A, 1968, T FARADAY SOC, V64, P3265, DOI 10.1039/tf9686403265; ROBINSON DG, 1981, EUR J CELL BIOL, V25, P278; ROBINSON DG, 1983, J EXP BOT, V34, P668, DOI 10.1093/jxb/34.6.668; RUOHO AE, 1973, P NATL ACAD SCI USA, V70, P2567, DOI 10.1073/pnas.70.9.2567; SALVUCCI ME, 1990, ARCH BIOCHEM BIOPHYS, V281, P212, DOI 10.1016/0003-9861(90)90434-Z; SHANAHAN MF, 1985, J BIOL CHEM, V260, P897; SLOAN ME, 1987, PLANT PHYSIOL, V85, P516, DOI 10.1104/pp.85.2.516; SMITH KC, 1969, BIOCHEM BIOPH RES CO, V34, P354, DOI 10.1016/0006-291X(69)90840-7; SMITH MM, 1973, AUST J BIOL SCI, V26, P123; SMITH MM, 1973, BIOCHIM BIOPHYS ACTA, V313, P72, DOI 10.1016/0304-4165(73)90189-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VESTERBERG O, 1972, BIOCHIM BIOPHYS ACTA, V342, P345; WALDMANN T, 1988, PLANTA, V173, P88, DOI 10.1007/BF00394492; WEBER TM, 1985, BIOCHIM BIOPHYS ACTA, V812, P503, DOI 10.1016/0005-2736(85)90325-6; WOODY AYM, 1988, BIOCHEM BIOPH RES CO, V150, P917, DOI 10.1016/0006-291X(88)90716-4	88	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22569	22581						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1834675				2022-12-25	WOS:A1991GR56400080
J	GALLAGHER, PG; TSE, WT; COSTA, F; SCARPA, A; BOIVIN, P; DELAUNAY, J; FORGET, BG				GALLAGHER, PG; TSE, WT; COSTA, F; SCARPA, A; BOIVIN, P; DELAUNAY, J; FORGET, BG			A SPLICE SITE MUTATION OF THE BETA-SPECTRIN GENE CAUSING EXON SKIPPING IN HEREDITARY ELLIPTOCYTOSIS ASSOCIATED WITH A TRUNCATED BETA-SPECTRIN CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE INTERMITTENT PORPHYRIA; PORPHOBILINOGEN DEAMINASE GENE; INSERTION DELETION MUTATIONS; HUMAN-ERYTHROCYTE SPECTRIN; PROTEIN BAND 4.1; OSTEOGENESIS IMPERFECTA; MEMBRANE SKELETON; MESSENGER-RNA; FRAMESHIFT MUTATION; MOLECULAR ANALYSIS	We studied a French kindred with hereditary elliptocytosis associated with a spectrin variant (spectrin LePuy) containing a beta-spectrin chain that is truncated at its C terminus (Dhermy, D., Lecomte, M., Garbarz, M., Bournier, O., Galand, C., Gautero, H., Feo, C., Alloisio, N., Delaunay, J., and Boivin, P. (1982) J. Clin. Invest. 70, 707-715). The structure of the 3' end of the beta-spectrin gene, the region encoding the C terminus of beta-spectrin, was determined. Nucleotide sequencing of amplified genomic DNA revealed a mutation at position +4 (A --> G) of the 5' donor consensus splice site of the intron following the third-to-last exon (exon X) in one beta-spectrin allele of a heterozygous patient. Agarose gel electrophoresis of polymerase chain reaction-amplified cDNA revealed an extra band of lower molecular weight, suggesting that the shortened beta-spectrin chain of spectrin LePuy arises from aberrant mRNA splicing. Nucleotide sequencing of the shorter cDNA amplification product revealed that the sequences encoding exon X were absent. Southern blotting of cDNA amplification products confirmed this result. The skipping of exon X causes a shift in the normal reading frame resulting in the encoding of a new amino acid sequence at the C terminus of the mutant beta-spectrin chain. A new in-frame stop codon is encountered following a single residue of this novel sequence.	YALE UNIV,SCH MED,DEPT PEDIAT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT HUMAN GENET,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510; HOP BEAUJON,INSERM,U160,F-92118 CLICHY,FRANCE; FAC MED GRANCE BLANCHE,CNRS,URA 1171,F-69373 LYON 08,FRANCE	Yale University; Yale University; Yale University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)								ABEI M, 1986, CELL, V47, P555; ABEI M, 1987, TRENDS GENET, V3, P102; ALLOISIO N, 1985, BLOOD, V65, P46; ASAKAI R, 1987, BIOCHEMISTRY-US, V26, P7221, DOI 10.1021/bi00397a004; ASAKAI R, 1989, P NATL ACAD SCI USA, V86, P7667, DOI 10.1073/pnas.86.20.7667; BATEMAN JF, 1989, J BIOL CHEM, V264, P10960; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BRANDT CR, 1984, MOL CELL BIOL, V4, P1270, DOI 10.1128/MCB.4.7.1270; CARSTENS RP, 1991, AM J HUM GENET, V48, P1105; CHOI E, 1980, NATURE, V286, P776, DOI 10.1038/286776a0; CIOE L, 1987, BLOOD, V70, P915; CLADARAS C, 1987, J BIOL CHEM, V262, P2310; CONBOY J, 1990, J CLIN INVEST, V86, P524, DOI 10.1172/JCI114739; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; DELAUNAY J, 1990, MOL ASPECTS MED, V11, P161, DOI 10.1016/0098-2997(90)90001-I; DHERMY D, 1982, J CLIN INVEST, V70, P707, DOI 10.1172/JCI110666; DILELLA AG, 1986, NATURE, V322, P799, DOI 10.1038/322799a0; EBER SW, 1988, J CLIN INVEST, V81, P523, DOI 10.1172/JCI113350; GALLAGHER P, 1990, CLIN RES, V38, pA266; GALLAGHER PG, 1990, SEMIN PERINATOL, V14, P351; GALLAGHER PG, 1990, BLOOD S, V76, pA8; GARBARZ M, 1984, BLOOD, V64, P1006; GAREY JR, 1990, J CLIN INVEST, V86, P1416, DOI 10.1172/JCI114856; GRANDCHAMP B, 1989, P NATL ACAD SCI USA, V86, P661, DOI 10.1073/pnas.86.2.661; GRANDCHAMP B, 1989, NUCLEIC ACIDS RES, V17, P6637, DOI 10.1093/nar/17.16.6637; GRANDCHAMP P, 1989, EUR J CLIN INVEST, V19, P414; HARRIS HW, 1980, J BIOL CHEM, V255, P1512; HIDAKA Y, 1987, J CLIN INVEST, V80, P1409, DOI 10.1172/JCI113219; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; KAN YW, 1975, P NATL ACAD SCI USA, V72, P5140, DOI 10.1073/pnas.72.12.5140; KAZAZIAN HH, 1990, SEMIN HEMATOL, V27, P209; KISHIMOTO TK, 1989, J BIOL CHEM, V264, P3588; KUIVANIEMI H, 1988, J BIOL CHEM, V263, P11407; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LECOMTE MC, 1989, NOUV REV FR HEMATOL, V31, P246; Lux SE, 1989, METABOLIC BASIS INHE, P2367; MARCHESI SL, 1990, J CLIN INVEST, V86, P516, DOI 10.1172/JCI114738; MARCHESI VT, 1985, ANNU REV CELL BIOL, V1, P531, DOI 10.1146/annurev.cellbio.1.1.531; MARVIT J, 1987, NUCLEIC ACIDS RES, V15, P5613, DOI 10.1093/nar/15.14.5613; MOUNT SM, 1983, CELL, V33, P509, DOI 10.1016/0092-8674(83)90432-4; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OHANIAN V, 1985, BRIT J HAEMATOL, V61, P31, DOI 10.1111/j.1365-2141.1985.tb04057.x; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PALEK J, 1990, SEMIN HEMATOL, V27, P290; POTHIER B, 1990, BLOOD, V75, P2061; POTHIER B, 1987, BLOOD, V69, P1759; PRCHAL JT, 1987, P NATL ACAD SCI USA, V84, P7468, DOI 10.1073/pnas.84.21.7468; RUFFNER DE, 1988, P NATL ACAD SCI USA, V85, P2125, DOI 10.1073/pnas.85.7.2125; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOKATA I, 1990, P NATL ACAD SCI USA, V87, P9908, DOI 10.1073/pnas.87.24.9908; SCOBIE GA, 1990, HUM GENET, V85, P631; SEIDMAN JG, 1980, NATURE, V286, P779, DOI 10.1038/286779a0; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SPEICHER DW, 1982, J BIOL CHEM, V257, P9093; TCHERNIA G, 1981, J CLIN INVEST, V68, P454, DOI 10.1172/JCI110275; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; TREISMAN R, 1982, CELL, V29, P903, DOI 10.1016/0092-8674(82)90452-4; TROMP G, 1988, P NATL ACAD SCI USA, V85, P5254, DOI 10.1073/pnas.85.14.5254; TSE WT, 1990, J CLIN INVEST, V86, P909, DOI 10.1172/JCI114792; WEIL D, 1989, J BIOL CHEM, V264, P16804; WILLING MC, 1990, J CLIN INVEST, V85, P282, DOI 10.1172/JCI114424; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; WINKELMANN JC, 1988, BLOOD, V72, P328; YAWATA Y, 1990, BLOOD S, V76, pA22; YU H, 1990, BLOOD S, V76, pA51; ZAIL SS, 1984, J CLIN INVEST, V74, P753, DOI 10.1172/JCI111491; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	69	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15154	15159						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1840591				2022-12-25	WOS:A1991GB09700054
J	LABRECQUE, GF; HOLOWKA, D; BAIRD, B				LABRECQUE, GF; HOLOWKA, D; BAIRD, B			CHARACTERIZATION OF INCREASED K+ PERMEABILITY ASSOCIATED WITH THE STIMULATION OF RECEPTORS FOR IMMUNOGLOBULIN-E ON RAT BASOPHILIC LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LYMPHOCYTE-T; ADENOSINE-TRIPHOSPHATASE; POTASSIUM-TRANSPORT; HISTAMINE-RELEASE; CALCIUM INFLUX; CROSS-LINKING; MAST-CELLS; 2H3 CELLS; CHANNELS; ACTIVATION	Aggregation of immunoglobulin E-receptor complexes on the surface of rat basophilic leukemia cells stimulates an increase in plasma membrane K+ permeability that is monitored as an increase in the rate of efflux of preloaded Rb-86+. A major component of this stimulated Rb-86+ efflux appears to be due to a Ca2+-activated K+ channel because it is inhibited by quinidine in parallel with the inhibition of degranulation and membrane potential repolarization, it is blocked by 0.1 mM La3+, and it is dependent on external Ca2+. Depolarization of the plasma membrane by carbonyl cyanide 3-chlorophenylhydrazone inhibits stimulated Ca2+ influx and prevents antigen-induced Rb-86+ efflux, and increased external Ca2+ partially restores Rb-86+ efflux under these conditions. In addition, potentiation of antigen-stimulated Ca2+ influx by pretreatment with cholera toxin increases the initial rate of stimulated Rb-86+ efflux. Another component of antigen-stimulated K+ efflux appears to be mediated by a guanine nucleotide-binding protein because pretreatment of rat basophilic leukemia cells with pertussis toxin decreases the initial rate of antigen-stimulated Rb-86+ efflux to 40% of that for the untreated cells. Stimulated Rb-86+ efflux is also observed when ionomycin is used to increase cytoplasmic Ca 2, and to trigger membrane depolarization. The efflux stimulated by ionomycin is inhibited by quinidine but not by pertussis toxin pretreatment; thus, it appears to occur through the Ca2+-activated K+ efflux pathway. It is proposed that these K+ efflux pathways serve to sustain the Ca2+ influx that is necessary for receptor-mediated triggering of cellular degranulation.	CORNELL UNIV, DEPT CHEM, BAKER LAB, ITHACA, NY 14853 USA	Cornell University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022449, R01AI018306] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 18306, AI 22449] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AVERDUNK R, 1975, EXP CELL RES, V93, P331, DOI 10.1016/0014-4827(75)90458-9; BAIRD B, 1983, J IMMUNOL METHODS, V64, P365, DOI 10.1016/0022-1759(83)90444-1; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BEAVEN MA, 1984, J BIOL CHEM, V259, P7129; Bonting SL, 1970, MEMBRANES ION TRANSP, V1, P257; CHANDY KG, 1984, J EXP MED, V160, P369, DOI 10.1084/jem.160.2.369; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; FEWTRELL C, 1987, BIOCHEMISTRY-US, V26, P6995, DOI 10.1021/bi00396a021; FEWTRELL C, 1981, BIOCH ACUTE ALLERGIC, P129; FISHMAN MC, 1981, P NATL ACAD SCI-BIOL, V78, P5245, DOI 10.1073/pnas.78.8.5245; HAMILTON LJ, 1977, CAN J BIOCHEM CELL B, V55, P774, DOI 10.1139/o77-113; HERMANN A, 1981, J GEN PHYSIOL, V78, P63, DOI 10.1085/jgp.78.1.63; HILDEN S, 1975, J BIOL CHEM, V250, P6296; HILLE B, 1984, IONIC CHANNELS EXCIT, P113; HOLOWKA D, 1982, MOL IMMUNOL, V19, P219, DOI 10.1016/0161-5890(82)90334-0; HOLOWKA D, 1990, CELLULAR MOL MECHANI, V1, P173; KANNER BI, 1984, J BIOL CHEM, V259, P188; LABRECQUE GF, 1989, J IMMUNOL, V142, P236; LABRECQUE GF, 1989, THESIS CORNELL U ITH; LINDAU M, 1986, J GEN PHYSIOL, V88, P349, DOI 10.1085/jgp.88.3.349; LIU FT, 1980, J IMMUNOL, V124, P2728; MAEYAMA K, 1988, J IMMUNOL, V140, P3919; MCCLOSKEY MA, 1988, P NATL ACAD SCI USA, V85, P7260, DOI 10.1073/pnas.85.19.7260; MCCLOSKEY MA, 1990, J GEN PHYSIOL, V95, P205, DOI 10.1085/jgp.95.2.205; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MOHR FC, 1987, J CELL BIOL, V104, P783, DOI 10.1083/jcb.104.3.783; MOHR FC, 1987, J BIOL CHEM, V262, P10638; MOHR FC, 1987, J IMMUNOL, V138, P1564; NARASIMHAN V, 1990, J BIOL CHEM, V265, P1459; NARASIMHAN V, 1988, J BIOL CHEM, V263, P19626; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; PUTNEY JW, 1976, J PHARMACOL EXP THER, V198, P375; ROBERTSON D, 1986, J IMMUNOL, V136, P4565; SCHWARZ W, 1983, ANNU REV PHYSIOL, V45, P359, DOI 10.1146/annurev.ph.45.030183.002043; SEAMON KB, 1982, J BIOL CHEM, V257, P1591; TAUROG JD, 1979, J IMMUNOL, V122, P2150; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; WOLDEMUSSIE E, 1986, J IMMUNOL, V137, P1674	38	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14912	14917						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1831198				2022-12-25	WOS:A1991GB09700020
J	OHMICHI, M; DECKER, SJ; PANG, L; SALTIEL, AR				OHMICHI, M; DECKER, SJ; PANG, L; SALTIEL, AR			PHOSPHOLIPASE C-GAMMA-1 DIRECTLY ASSOCIATES WITH THE P70 TRK ONCOGENE PRODUCT THROUGH ITS SRC HOMOLOGY DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROWTH-FACTOR RECEPTOR; STIMULATES TYROSINE PHOSPHORYLATION; GAP-ASSOCIATED PROTEINS; HUMAN INSULIN-RECEPTOR; C-II; ANTIPHOSPHOTYROSINE RECOVERY; EXTRACELLULAR CALCIUM; POTENTIAL MECHANISM; SIGNAL TRANSDUCTION; MOLECULAR-CLONING	Tyrosine phosphorylation of proteins was examined in NIH3T3 cells transformed by an oncogenic form of the trk protein. Proteins of 148, 140, 70, and 55 kDa were phosphorylated on tyrosine residues in trk-transformed cells but not control NIH3T3 cells. The 70-kDa protein may represent the trk oncogene protein itself which was shown to be tyrosine-phosphorylated in vivo using trk-specific antiserum. Phospholipase C-gamma-1 (PLC-gamma-1) was also found to be constitutively tyrosine-phosphorylated in trk-transformed cells and the trk protein co-immunoprecipitated with PLC-gamma. The GTPase-activating protein of ras (GAP) and the 62-kDa GAP-associated protein were tyrosine-phosphorylated in trk-transformed cells, and a lesser amount of trk co-immunoprecipitated with GAP relative to with PLC-gamma. The trk oncogene product bound specifically to a bacterially expressed fusion protein containing the src homology domains of PLC-gamma. The data suggest a significant role for PLC-gamma in intracellular signaling by the trk oncogene.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,2800 PLYMOUTH RD,ANN ARBOR,MI 48105; UNIV MICHIGAN,DEPT PHYSIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT MICROBIOL,ANN ARBOR,MI 48109	Pfizer; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	NATIONAL CANCER INSTITUTE [R01CA037754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R23DK033804, R01DK033804] Funding Source: NIH RePORTER; NCI NIH HHS [CA37754] Funding Source: Medline; NIDDK NIH HHS [DK33804] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALONSO T, 1990, BIOCHEM BIOPH RES CO, V171, P14, DOI 10.1016/0006-291X(90)91349-W; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CHAN BNL, 1988, P NATL ACAD SCI USA, V86, P1756; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1990, CELL, V61, P25; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIM UH, 1991, J BIOL CHEM, V266, P1359; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P2832; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MEISENHELDER J, 1989, CELL, V57, P1108; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; PARK M, 1987, P NATL ACAD SCI USA, V84, P6378; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	34	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14858	14861						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1831195				2022-12-25	WOS:A1991GB09700008
J	SUMBILLA, C; CANTILINA, T; COLLINS, JH; MALAK, H; LAKOWICZ, JR; INESI, G				SUMBILLA, C; CANTILINA, T; COLLINS, JH; MALAK, H; LAKOWICZ, JR; INESI, G			STRUCTURAL PERTURBATION OF THE TRANSMEMBRANE REGION INTERFERES WITH CALCIUM-BINDING BY THE CA2+ TRANSPORT ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA-2+-ATPASE; FREQUENCY-DOMAIN FLUOROMETRY; FLUORESCENCE ENERGY-TRANSFER; TIME-RESOLVED FLUORESCENCE; (CA-2+ + MG-2+)-ATPASE; AMINO-ACID-SEQUENCE; ADENOSINE-TRIPHOSPHATASE; MODULATION DATA; DECAY KINETICS; PROTEINS	The Ca2+-ATPase of sarcoplasmic reticulum reacts with N-cyclohexyl-N'-(4-dimethylamino-1-naphthyl) carbodiimide (NCD4) yielding a fluorescence labeling that interferes with calcium binding to activating and transport sites of the enzyme and, thereby, with Ca2+-dependent ATPase activity. On the other hand, the catalytic site does not appear altered, as revealed by the normal occurrence of Ca2+-independent reactions, such as enzyme phosphorylation with P(i) in the reverse direction of the catalytic cycle. This reaction is not inhibited by Ca2+ in the labeled enzyme, while it is inhibited in the native enzyme. The NCD4 reaction which is involved in functional inactivation occurs in the membrane-bound portion of the ATPase. Sodium dodecyl sulfate solubilization of hydrophobic peptides, electrophoresis, and microsequencing of transblotted electrophoretic bands revealed that the fluorescent NCD4 label resides in a segment of tryptic fragment A1, intervening between GlU231 and Glu309. This segment includes two transmembrane helices, and does not include the domain involved in the phosphoryl transfer reaction during catalytic activity. This specific labeling does not occur when the NCD4 derivatization procedure is carried out in the presence of Ca2+ concentrations that also prevent functional inactivation. Fluorescence characterization by steady state and intensity decay measurements shows only negligible energy transfer between the NCD4 label and fluorescein isothiocyanate label of Lys515, indicating that the NCD4 label is unlikely to reside within the extramembranous region of the ATPase. On the other hand, the fluorescence emission of intrinsic tryptophan residues clustered within or near the transmembrane region of the ATPase, is distinctly affected by NCD4 label specifically bound to the ATPase, and NCD4 label nonspecifically bound to the sarcoplasmic reticulum membrane. The combined sequencing and spectroscopic observations indicate that derivatization with NCD4 induces a perturbation within or near the transmembrane region of the ATPase (at a relatively large distance from the catalytic site) that interferes with specific calcium binding. This is in agreement with experiments (Clarke et al., 1989) demonstrating that mutations of any of six amino acids within the transmembrane region of the ATPase interfere with enzyme activation by Ca2+.	UNIV MARYLAND, SCH MED, INST MED BIOTECHNOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	SUMBILLA, C (corresponding author), UNIV MARYLAND, SCH MED, DEPT BIOL CHEM, CTR FLUORESCENCE SPECT, BALTIMORE, MD 21201 USA.				NHLBI NIH HHS [P01-HL27867] Funding Source: Medline; NIGMS NIH HHS [GM-35154] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035154] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEECHEM JM, 1985, ANNU REV BIOCHEM, V54, P43, DOI 10.1146/annurev.biochem.54.1.43; BISHOP JE, 1988, BIOCHEMISTRY-US, V27, P5233, DOI 10.1021/bi00414a043; CHADWICK CC, 1984, BIOCHIM BIOPHYS ACTA, V769, P291, DOI 10.1016/0005-2736(84)90309-2; CHADWICK CC, 1985, BIOCHIM BIOPHYS ACTA, V827, P419, DOI 10.1016/0167-4838(85)90227-4; CHADWICK CC, 1983, BIOCHIM BIOPHYS ACTA, V730, P201, DOI 10.1016/0005-2736(83)90334-6; CHEVALIER J, 1971, BIOCHEMISTRY-US, V27, P2733; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; COAN C, 1990, J BIOL CHEM, V265, P5376; de Meis L, 1974, Biochemistry, V13, P2057, DOI 10.1021/bi00707a009; DEANCOS JG, 1988, BIOCHEMISTRY-US, V27, P1793; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; GRATTON E, 1984, BIOPHYS J, V46, P479, DOI 10.1016/S0006-3495(84)84044-8; GREEN NM, 1986, CIBA F SYMP, V122, P93; GRINVALD A, 1976, BIOCHIM BIOPHYS ACTA, V427, P663, DOI 10.1016/0005-2795(76)90210-5; GRYCZYNSKI I, 1989, BIOCHEMISTRY-US, V28, P3490, DOI 10.1021/bi00434a051; INESI G, 1988, METHOD ENZYMOL, V157, P154; INESI G, 1980, J BIOL CHEM, V255, P3025; INESI G, 1974, BIOCHEMISTRY-US, V13, P3298, DOI 10.1021/bi00713a019; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKOWICZ JR, 1987, CHEM PHYS LETT, V138, P587, DOI 10.1016/0009-2614(87)80130-6; LAKOWICZ JR, 1986, REV SCI INSTRUM, V57, P2499, DOI 10.1063/1.1139215; LAKOWICZ JR, 1986, J BIOL CHEM, V261, P2240; LAKOWICZ JR, 1987, BIOPHYS CHEM, V28, P35, DOI 10.1016/0301-4622(87)80073-X; LAKOWICZ JR, 1984, BIOPHYS J, V46, P463, DOI 10.1016/S0006-3495(84)84043-6; LAKOWICZ JR, 1988, BIOPOLYMERS, V27, P821, DOI 10.1002/bip.360270509; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MATSUDAIRA PT, 1989, PRACTICAL GUIDE PROT, P35; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MUNKONGE F, 1989, BIOCHIM BIOPHYS ACTA, V979, P113, DOI 10.1016/0005-2736(89)90530-0; MURPHY AJ, 1981, J BIOL CHEM, V256, P2046; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; PICK U, 1979, BIOCHEMISTRY-US, V18, P108, DOI 10.1021/bi00568a017; PICK U, 1985, EUR J BIOCHEM, V152, P83, DOI 10.1111/j.1432-1033.1985.tb09166.x; ROSS JBA, 1981, BIOCHEMISTRY-US, V20, P4361, DOI 10.1021/bi00518a020; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCOTT TL, 1988, MOL CELL BIOCHEM, V82, P51; STEWART PS, 1974, J BIOL CHEM, V249, P985; WEBER K, 1969, J BIOL CHEM, V244, P4406	43	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12682	12689						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1829458				2022-12-25	WOS:A1991FV18000090
J	DRIPPS, DJ; BRANDHUBER, BJ; THOMPSON, RC; EISENBERG, SP				DRIPPS, DJ; BRANDHUBER, BJ; THOMPSON, RC; EISENBERG, SP			INTERLEUKIN-1 (IL-1) RECEPTOR ANTAGONIST BINDS TO THE 80-KDA IL-1 RECEPTOR BUT DOES NOT INITIATE IL-1 SIGNAL TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; T-CELLS; HIGH-AFFINITY; INTERNALIZATION; FIBROBLASTS; PROTEIN; PHOSPHORYLATION; EXPRESSION; PURIFICATION; INHIBITOR	The interleukin-1 receptor antagonist (IL-1ra) is a protein capable of inhibiting receptor binding and biological activities of IL-1 without inducing an IL-1-like response. Equilibrium binding and kinetic experiments show that IL-1ra binds to the 80-kDa IL-1 receptor on the murine thymoma cell line EL4 with an affinity (K(D) = 150-pM) approximately equal to that of IL-1-alpha and IL-1-beta for this receptor. However, IL-1ra is unable to induce two early events associated with IL-1 activity. Surface-bound IL-1ra does not undergo receptor-mediated internalization, and IL-1ra does not activate the protein kinase activity responsible for down-modulation of the EGF receptor on the murine 3T3 fibroblast cell line. The failure to induce general, early responses characteristic of IL-1 indicates that IL-1ra is unlikely to act as an agonist on any cell expressing the 80-kDa receptor.	SYNERGEN INC,BOULDER,CO 80301									AREND WP, 1990, J CLIN INVEST, V85, P1694, DOI 10.1172/JCI114622; BIRD TA, 1989, J IMMUNOL, V142, P126; BIRD TA, 1990, J BIOL CHEM, V265, P235; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; COMINELLI F, 1990, J CLIN INVEST, V86, P972, DOI 10.1172/JCI114799; CURTIS BM, 1990, J IMMUNOL, V144, P1295; DELISI C, 1981, P NATL ACAD SCI-BIOL, V78, P5569, DOI 10.1073/pnas.78.9.5569; DEMEYTS P, 1976, J BIOL CHEM, V251, P1877; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; DOWER SK, 1989, J IMMUNOL, V142, P4314; EISENBERG SP, 1990, J BIOL CHEM, V265, P7976; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; EISENBERG SP, 1989, CYTOKINE, V1, P90; EISENBERG SP, 1991, IN PRESS P NATL ACAD; FALK W, 1989, LYMPHOKINE RES, V8, P263; GALLIS B, 1989, J IMMUNOL, V143, P3235; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; KASTELEIN RA, 1986, GENE PROTEIN STEPS D, P225; KAUR P, 1989, FEBS LETT, V258, P269, DOI 10.1016/0014-5793(89)81671-0; KILIAN PL, 1986, J IMMUNOL, V136, P4509; KRONHEIM SR, 1986, BIO-TECHNOL, V4, P1078, DOI 10.1038/nbt1286-1078; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P60; LOWENTHAL JW, 1986, J EXP MED, V164, P1060, DOI 10.1084/jem.164.4.1060; Miller J. H., 1972, EXPT MOL GENETICS, P431; MIZEL SB, 1987, J IMMUNOL, V138, P2906; MIZEL SB, 1989, FASEB J, V3, P2379, DOI 10.1096/fasebj.3.12.2676681; MIZEL SB, 1990, IMMUNOL TODAY, V11, P390, DOI 10.1016/0167-5699(90)90154-2; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P392, DOI 10.1016/0167-5699(90)90155-3; PAGANELLI KA, 1987, J IMMUNOL, V138, P2249; QWARNSTROM EE, 1988, J BIOL CHEM, V263, P8261; RUFFOLO RR, 1982, J AUTON PHARMACOL, V2, P277, DOI 10.1111/j.1474-8673.1982.tb00520.x; WARD TT, 1978, AM J MED, V64, P933, DOI 10.1016/0002-9343(78)90446-1	36	427	433	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10331	10336						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1828071				2022-12-25	WOS:A1991FP08600054
J	STEVENS, VL; RAETZ, CRH				STEVENS, VL; RAETZ, CRH			DEFECTIVE GLYCOSYL PHOSPHATIDYLINOSITOL BIOSYNTHESIS IN EXTRACTS OF 3 THY-1 NEGATIVE LYMPHOMA CELL MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							VARIANT SURFACE GLYCOPROTEINS; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; PHOSPHOLIPID MEMBRANE ANCHOR; STRUCTURAL CHARACTERIZATION; GLYCOLIPID PRECURSORS; RESISTANT GLYCOLIPIDS; GROWTH-FACTOR; INSULIN; GLYCAN; GLYCOSYLPHOSPHATIDYLINOSITOL	The glycosyl phosphatidylinositol (GPI) anchors that attach certain proteins to membranes are preassembled by sequential addition of glycan components to phosphatidylinositol (PI) before being transferred to nascent polypeptide. A cell-free system consisting of trypanosome membranes has been reported to catalyze GPI biosynthesis (Masterson, W. J., Doering, T. L., Hart, G. W., and Englund, P. T. (1989) Cell 56, 793-800; Menon, A. K., Schwarz, R. T., Mayor, S., and Cross, G. A. M. (1990) J. Biol. Chem. 265, 9033-9042). We now describe conditions for studying the initial steps of GPI biosynthesis in extracts of murine lymphoma cells. Two chloroform-soluble products, tentatively identified as [6-H-3]GlcNAc-PI and [6-H-3]GlcN-PI, were generated during incubations of EL4 cell lysates with UDP-[6-H-3]GlcNAc. The involvement of PI in the reaction was established by the sensitivity of the products to hydrolysis by PI-specific phospholipase C and the finding that the addition of exogenous PI to the incubation stimulated the reaction. The minor, more polar product was sensitive to nitrous acid cleavage and was converted to the major product, as judged by TLC, after treatment with acetic anhydride. The glycolipids generated in lymphoma extracts appeared to be the same as the products produced in parallel incubations with trypanosome membranes. Analysis of available lymphoma mutants deficient in Thy-1 surface expression revealed that extracts of the class A, C, and H mutants are completely defective in synthesizing GlcNAc-PI and GlcN-PI.	MERCK SHARP & DOHME LTD,DEPT BIOCHEM,RAHWAY,NJ 07065	Merck & Company								BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; CHAPMAN A, 1980, J BIOL CHEM, V255, P4441; DARNELL JC, 1988, DIABETES, V37, P113; DOERING TL, 1989, J BIOL CHEM, V264, P11168; DOERING TL, 1990, J BIOL CHEM, V265, P611; FARESE RV, 1988, BIOCHEM BIOPH RES CO, V156, P1346, DOI 10.1016/S0006-291X(88)80780-0; FATEMI SH, 1988, J BIOL CHEM, V263, P1288; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; SALTIEL AR, 1986, P NATL ACAD SCI USA, V83, P5793, DOI 10.1073/pnas.83.16.5793; SALTIEL AR, 1988, AM J PHYSIOL, V255, pC1, DOI 10.1152/ajpcell.1988.255.1.C1; STEVENS VL, 1990, J BIOL CHEM, V265, P15653; THAKKAR JK, 1990, J BIOL CHEM, V265, P5475; TROWBRIDGE IS, 1978, CELL, V14, P21, DOI 10.1016/0092-8674(78)90297-0; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; WALTER EI, 1990, J IMMUNOL, V144, P1030	29	109	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10039	10042						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1828068				2022-12-25	WOS:A1991FP08600006
J	KIM, H; STRONG, TV; ANDERSON, SJ				KIM, H; STRONG, TV; ANDERSON, SJ			EVIDENCE FOR TAU-EXPRESSION IN CELLS OF MONOCYTE LINEAGE AND ITS INVITRO PHOSPHORYLATION BY V-FMS KINASE	ONCOGENE			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; PROTO-ONCOGENE; LOCALIZATION; CYTOSKELETAL; PATHOLOGY; FILAMENTS; CSF-1; LONG	The v-fms encoded kinase, which is known to associate with cytoskeletal elements, was shown to phosphorylate histiocytic proteins that had physical and immunological attributes in common with tau. Tau is a microtubule associated protein that is aberrantly phosphorylated in Alzheimer's disease of the brain. Since c-fms expression is normally exclusive to cells of monocyte lineage, these cells were examined for expression of tau. Heat stable tau was identified in cultured peripheral blood monocytes. This represents the first molecular characterization of tau in cells of non-neural origin.	UNIV ALABAMA,DEPT PATHOL,VOLKER HALL G-023,UAB STN,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	ANDERSON, SJ (corresponding author), UNIV ALABAMA,DEPT PATHOL,VOLKER HALL G-023,UAB STN,BIRMINGHAM,AL 35294, USA.		Strong, Theresa/GSM-6652-2022	Strong, Theresa/0000-0001-6783-8703	NIA NIH HHS [R0I-AG 06969] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG006969] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON SJ, 1984, J VIROL, V51, P730, DOI 10.1128/JVI.51.3.730-741.1984; ANDERSON SJ, 1982, J VIROL, V44, P696, DOI 10.1128/JVI.44.2.696-702.1982; BARBACID M, 1981, J VIROL, V40, P812, DOI 10.1128/JVI.40.3.812-821.1981; BINDER LI, 1985, J CELL BIOL, V96, P1523; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BUTLER M, 1986, J NEUROCHEM, V47, P1517, DOI 10.1111/j.1471-4159.1986.tb00788.x; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HAGESTEDT T, 1989, J CELL BIOL, V109, P1643, DOI 10.1083/jcb.109.4.1643; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HORWITZ DA, 1977, CLIN EXP IMMUNOL, V30, P289; JAMESON L, 1981, P NATL ACAD SCI-BIOL, V78, P3413, DOI 10.1073/pnas.78.6.3413; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KOWALL NW, 1987, ANN NEUROL, V22, P639, DOI 10.1002/ana.410220514; LEHTO VP, 1982, LAB INVEST, V47, P391; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LOTZ M, 1988, SCIENCE, V241, P1218, DOI 10.1126/science.2457950; MACDONALD BR, 1986, J BONE MINER RES, V1, P227; MULLER R, 1983, NATURE, V304, P454, DOI 10.1038/304454a0; RALPH P, 1976, J EXP MED, V143, P1528, DOI 10.1084/jem.143.6.1528; RETTENMIER CW, 1985, CELL, V40, P971, DOI 10.1016/0092-8674(85)90357-5; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SELDEN SC, 1983, J BIOL CHEM, V258, P7064; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; STRONG TV, 1990, SOMAT CELL MOLEC GEN, V16, P341, DOI 10.1007/BF01232462; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858	27	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1085	1087						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1829806				2022-12-25	WOS:A1991GU62200028
J	GARCIA, IS; KANEKO, Y; GONZALEZSARMIENTO, R; CAMPBELL, K; WHITE, L; BOEHM, T; RABBITTS, TH				GARCIA, IS; KANEKO, Y; GONZALEZSARMIENTO, R; CAMPBELL, K; WHITE, L; BOEHM, T; RABBITTS, TH			A STUDY OF CHROMOSOME-11P13 TRANSLOCATIONS INVOLVING TCR-BETA AND TCR-DELTA IN HUMAN T-CELL LEUKEMIA	ONCOGENE			English	Article							BREAKPOINT CLUSTER REGION; CHAIN; LEUKEMIA; 11P13; LYMPHOMA; SEQUENCE; ORGANIZATION; INVERSION; DIVERSITY; TUMORS	A frequent site of translocation damage in human T-ALL has been localized to a specific region of chromosome band 11p13. Five new T-ALL cases are described which break in the major T-ALL(bcr) region of 11p13, two involving a novel translocation t(7;11)(q35;p13), with breakage at the T cell receptor (TCR) beta-gene from 7q35, and three involving TCR-delta from 14q11 in the more common t(11;14)(p13;q11). Analysis of the mechanism of one T-ALL(bcr)/TCR-beta translocation and a previously described t(11;14)(p13;q11) was conducted by genomic cloning of translocation breakpoints, using the polymerase chain reaction (PCR). Both seem to have occurred by recombinase error, but only the t(7;11) showed sequence-specific joining. Nonetheless recombinase mediation of the t(11;14) is implied by the presence of N-region addition (a hallmark of recombinase joins) on both derivative chromosomes. These observations reinforce the view that translocations in the T-ALL(bcr) region of chromosome 11p13 are a major lesion in human T-ALL. In addition, these can occur by mimicry of VDJ joining, but sequence specificity is not obligatory.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; SAITAMA CANC CTR,INA,SAITAMA 362,JAPAN; PRINCE WALES CHILDRENS HOSP,DIV HAEMATOL ONCOL,SYDNEY,NSW 2031,AUSTRALIA	MRC Laboratory Molecular Biology			Gonzalez-Sarmiento, Rogelio/V-5526-2019; Rabbitts, Terence/D-6262-2016	Gonzalez-Sarmiento, Rogelio/0000-0002-2726-6795; Rabbitts, Terence/0000-0002-4982-2609				BAER R, 1987, CELL, V50, P97, DOI 10.1016/0092-8674(87)90666-0; BAER R, 1985, CELL, V43, P705, DOI 10.1016/0092-8674(85)90243-0; BARKER PE, 1987, AM J HUM GENET, V39, P661; BOEHM T, 1990, NUCLEIC ACIDS RES, V18, P4298, DOI 10.1093/nar/18.14.4298; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; CHENG JT, 1990, J EXP MED, V171, P489, DOI 10.1084/jem.171.2.489; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; FORONI L, 1990, GENE CHROMOSOME CANC, V1, P301, DOI 10.1002/gcc.2870010407; KANEKO Y, 1989, LEUKEMIA, V3, P886; KANEKO Y, 1988, BLOOD, V72, P534; LOH EY, 1988, P NATL ACAD SCI USA, V85, P9714, DOI 10.1073/pnas.85.24.9714; RABBITTS TH, 1991, IN PRESS ADV IMMUNOL, V50; ROYERPOKORA B, 1989, HUM GENET, V82, P264, DOI 10.1007/BF00291167; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; STADEN R, 1990, COMPUT APPL BIOSCI, V6, P387; TOYONAGA B, 1985, P NATL ACAD SCI USA, V82, P8624, DOI 10.1073/pnas.82.24.8624; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; TUNNACLIFFE A, 1985, NUCLEIC ACIDS RES, V13, P6651, DOI 10.1093/nar/13.18.6651; TUNNACLIFFE A, 1985, P NATL ACAD SCI USA, V82, P5068, DOI 10.1073/pnas.82.15.5068; YOFFE G, 1989, BLOOD, V74, P374	21	33	33	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					577	582						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1827667				2022-12-25	WOS:A1991FR93900011
J	MAEKAWA, T; MATSUDA, S; FUJISAWA, J; YOSHIDA, M; ISHII, S				MAEKAWA, T; MATSUDA, S; FUJISAWA, J; YOSHIDA, M; ISHII, S			CYCLIC-AMP RESPONSE ELEMENT-BINDING PROTEIN, CRE-BP1, MEDIATES THE E1A-INDUCED BUT NOT THE TAX-INDUCED TRANSACTIVATION	ONCOGENE			English	Article							TRANSCRIPTION FACTOR ATF; LEUCINE ZIPPER STRUCTURE; LONG TERMINAL REPEAT; V-MYB ONCOGENE; VIRUS TYPE-I; C-MYB; FUNCTIONAL DOMAINS; INFECTED-CELLS; RECEPTOR GENE; CDNA CLONES	The adenovirus E1A protein and tax protein (Tax) of human T-cell leukemia virus-1 (HTLV-1) are transcriptional regulators that do not bind to DNA directly. The ATF sites/CRE (cyclic AMP response element) of the adenovirus E4 promoter and the long terminal repeat of HTLV-1 have been shown to be required for E1A and Tax inducibility, respectively. Using the c-Myb-CRE-BP1 fusion protein, it was shown that CRE-BP1, which could bind to the ATF sites/CRE, mediated the E1A-induced trans-activation. For this activation, the N-terminal portion of CRE-BP1, which contained the putative metal finger structure, was essential but not sufficient. In contrast, the trans-activation induced by HTLV-1 Tax was not mediated by CRE-BP1. These results strongly suggested that E1A activates transcription through interaction with CRE-BP1, but another CRE-binding protein participates in the Tax-induced trans-activation.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC GENET LAB,IBARAKI 305,JAPAN; UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO 108,JAPAN	RIKEN; University of Tokyo			Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HIRAI SI, 1990, ONCOGENE, V5, P39; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KATOH I, 1989, EMBO J, V8, P497, DOI 10.1002/j.1460-2075.1989.tb03403.x; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; LEONG K, 1988, MOL CELL BIOL, V8, P1765, DOI 10.1128/MCB.8.4.1765; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MULLER U, 1989, GENE DEV, V3, P1991, DOI 10.1101/gad.3.12a.1991; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHMIDT A, 1985, NATURE, V314, P286, DOI 10.1038/314286a0; SEILERTUYNS A, 1984, P NATL ACAD SCI-BIOL, V81, P2980, DOI 10.1073/pnas.81.10.2980; SHI P, 1988, J CELL BIOCHEM     S, V12, P381; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	43	68	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					627	632						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1827668				2022-12-25	WOS:A1991FR93900018
J	ASANO, T; KATAGIRI, H; TAKATA, K; LIN, JL; ISHIHARA, H; INUKAI, K; TSUKUDA, K; KIKUCHI, M; HIRANO, H; YAZAKI, Y; OKA, Y				ASANO, T; KATAGIRI, H; TAKATA, K; LIN, JL; ISHIHARA, H; INUKAI, K; TSUKUDA, K; KIKUCHI, M; HIRANO, H; YAZAKI, Y; OKA, Y			THE ROLE OF N-GLYCOSYLATION OF GLUT1 FOR GLUCOSE-TRANSPORT ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RESPONSIVE TISSUES; HAMSTER OVARY CELLS; HUMAN-ERYTHROCYTE; HEXOSE TRANSPORTER; MESSENGER-RNA; ENDOGLYCOSIDASE-F; SKELETAL-MUSCLE; CYTOCHALASIN-B; RAT-BRAIN; CLONING	To elucidate a functional role of N-glycosylation in glucose transporters, we introduced oligonucleotide-directed mutagenesis in GLUT1 cDNA to remove the possible site for N-linked glycosylation. The wild-type and the mutated GLUT1 cDNAs which induced a mutation of Asn at residue 45 to Asp, Tyr, or Gln were transfected and stably expressed into Chinese hamster ovary cells. The expressed wild-type and the mutated GLUT1 was demonstrated to be a broad band of a 45-60-kDa form and a sharp band of a 38-kDa form on Western blot analysis, respectively, indicating no glycosylation in the mutated GLUT1. Although the cell surface labeling of the glucose transporters demonstrated the presence of the glycosylation-defective glucose transporters on the cells surface, photoaffinity labeling of glycosylation-defective GLUT1 with [H-3] cytochalasin B and a photoreactive mannose derivative, [H-3]2-N-4-(1-azi-2,2,2,trifluoroethyl)benzoyl-1,3-bis-(D-mannos-4-yloxy)-2-propylamine in the membranes was observed to be 40-70 and 15-30% of that of the wild-type GLUT1, respectively. The kinetic study of 2-deoxyglucose uptake revealed that the glycosylation-defective GLUT1 had a 2-2.5-fold greater K(m) value for 2-deoxyglucose uptake compared with the wild-type GLUT1. These observations strongly suggest that 1) N-glycosylation of GLUT1 glucose transporter is only on Asn 45 and 2) N-glycosylation plays an important role in maintaining a structure of glucose transporter with high affinity for glucose, thus, with high transport activity.	KYORIN UNIV,SCH MED,DEPT ANAT,MITAKA,TOKYO 181,JAPAN; ASAHI LIFE FDN,INST ADULT DIS,SHINJUKU KU,TOKYO 160,JAPAN	Kyorin University; Asahi Life Foundation	ASANO, T (corresponding author), UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN.							ASANO T, 1989, NUCLEIC ACIDS RES, V17, P6386, DOI 10.1093/nar/17.15.6386; ASANO T, 1989, J BIOL CHEM, V264, P3416; ASANO T, 1988, BIOCHEM BIOPH RES CO, V154, P1204, DOI 10.1016/0006-291X(88)90268-9; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; CAIRNS MT, 1984, BIOCHEM J, V221, P179, DOI 10.1042/bj2210179; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CLARK AE, 1990, BIOCHEM J, V269, P615, DOI 10.1042/bj2690615; FEUGEAS JP, 1990, BIOCHIM BIOPHYS ACTA, V1030, P60, DOI 10.1016/0005-2736(90)90238-J; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; GORGA FR, 1979, BIOCHEM BIOPH RES CO, V91, P955, DOI 10.1016/0006-291X(79)91972-7; HASPEL HC, 1988, J CELL PHYSIOL, V136, P361, DOI 10.1002/jcp.1041360221; HASPEL HC, 1986, J BIOL CHEM, V261, P6778; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KARIM AR, 1987, BIOCHIM BIOPHYS ACTA, V902, P402, DOI 10.1016/0005-2736(87)90208-2; KAYANO T, 1988, J BIOL CHEM, V263, P15245; KITAGAWA K, 1985, BIOCHIM BIOPHYS ACTA, V821, P67, DOI 10.1016/0005-2736(85)90154-3; KLIP A, 1984, BIOCHEM BIOPH RES CO, V122, P218, DOI 10.1016/0006-291X(84)90462-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIENHARD GE, 1984, BIOCHIM BIOPHYS ACTA, V769, P404, DOI 10.1016/0005-2736(84)90324-9; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; OKA Y, 1988, J BIOL CHEM, V263, P13432; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; WEILERGUTTLER H, 1989, BIOL CHEM H-S, V370, P467, DOI 10.1515/bchm3.1989.370.1.467; WHEELER TJ, 1985, ANNU REV PHYSIOL, V47, P503, DOI 10.1146/annurev.ph.47.030185.002443; WHEELER TJ, 1981, J BIOL CHEM, V256, P8907	30	152	163	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24632	24636						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761560				2022-12-25	WOS:A1991GW84500061
J	CARDOT, P; CHAMBAZ, J; CLADARAS, C; ZANNIS, VI				CARDOT, P; CHAMBAZ, J; CLADARAS, C; ZANNIS, VI			REGULATION OF THE HUMAN APOA-II GENE BY THE SYNERGISTIC ACTION OF FACTORS BINDING TO THE PROXIMAL AND DISTAL REGULATORY ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-II; ENRICHED TRANSCRIPTIONAL ACTIVATOR; HUMAN ALPHA-1-ANTITRYPSIN GENE; CELL-SPECIFIC EXPRESSION; PROMOTER ELEMENTS; CHOLESTEROL ACYLTRANSFERASE; INTESTINAL TRANSCRIPTION; HEPATIC LIPASE; NUCLEAR FACTOR	We have recently shown that the human apoA-II promoter contains a set of 11 distal regulatory elements between nucleotides -903 and -255 and three proximal regulatory elements between nucleotides -126 and -33 that are essential for hepatic and intestinal transcription of the apoA-II gene (Chambaz, J., Cardot, P., Pastier, D., Zannis, V. I., and Cladaras, C. (1991) J. Biol. Chem. 266, 11676-11685). Deletion or nucleotide substitution analysis has shown that alterations in elements L (nucleotides -803 to -773) and K (nucleotides -760 to -743) reduced hepatic transcription to 25 and 20% and intestinal transcription to 8 and 4% of control, respectively, as measured by chloramphenicol acetyltransferase assays, indicating that these elements play an important regulatory role. Nucleotide substitutions in element AB (nucleotides -65 to -33) reduced hepatic and intestinal transcription to 60 and 36% of control, respectively. The factors that recognize regulatory regions L, K, and AB were analyzed by DNA binding gel electrophoretic and competition assays. This analysis has shown that elements AB, K, and L bind with different affinities to a newly characterized heat-stable factor, CIIIB1, which is a transcriptional activator of the human apoC-III gene (Ogami, K., Kardassis, D., Cladaras, C., and Zannis, V. I. (1991) J. Biol. Chem. 266, 9640-9646). In addition, elements AB and K bind a heat-labile activity, designated AIIAB1, and element L binds to several CCAAT box binding activities. Mutations in domain L that prevented the binding of CCAAT box binding activities reduced both hepatic and intestinal transcription to 30% of control, indicating the importance of these factors in transcription. Simultaneous nucleotide substitutions that prevented the binding of CIIIB1 activity in elements AB, K, and L, reduced hepatic and intestinal transcription to 7 and 6% of control, respectively, suggesting that the synergistic interaction of CIIIB1 (bound to the proximal and distal regulatory elements) with CCAAT box proteins (bound to element L) can modulate the level of transcription of the human apoA-II gene.	BOSTON UNIV,SCH MED,HOUSMAN MED RES CTR,DEPT BIOCHEM,BOSTON,MA 02118; CNRS,URA 1283,F-75571 PARIS 12,FRANCE	Boston University; Centre National de la Recherche Scientifique (CNRS)	CARDOT, P (corresponding author), BOSTON UNIV,SCH MED,HOUSMAN MED RES CTR,DEPT MED,INST CARDIOVASC,MOLEC GENET SECT,BOSTON,MA 02118, USA.				NHLBI NIH HHS [HL33952, HL43909] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL043909, R01HL033952] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BARBARAS R, 1986, BIOCHIM BIOPHYS ACTA, V888, P143, DOI 10.1016/0167-4889(86)90015-7; BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P65; BREWER HB, 1972, P NATL ACAD SCI USA, V69, P1304, DOI 10.1073/pnas.69.5.1304; CHAMBAZ J, 1991, J BIOL CHEM, V266, P11676; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DESIMONE V, 1987, EMBO J, V6, P2759, DOI 10.1002/j.1460-2075.1987.tb02570.x; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FIDGE NH, 1985, J BIOL CHEM, V260, P3570; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; FRAIN M, 1989, CELL, V59, P154; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HUSSAIN MM, 1990, BIOCHEMISTRY-US, V29, P209, DOI 10.1021/bi00453a029; JAHN CE, 1983, EUR J BIOCHEM, V131, P25, DOI 10.1111/j.1432-1033.1983.tb07227.x; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KARDASSIS D, 1990, J BIOL CHEM, V265, P21733; KARDASSIS D, 1990, MOL CELL BIOL, V10, P2653, DOI 10.1128/MCB.10.6.2653; KARDASSIS D, 1992, IN PRESS J BIOL CHEM; KILSDONK EPC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P205, DOI 10.1016/0005-2760(90)90121-D; KNOTT TJ, 1984, BIOCHEM BIOPH RES CO, V120, P734, DOI 10.1016/S0006-291X(84)80168-0; LACKNER KJ, 1984, FEBS LETT, V175, P159, DOI 10.1016/0014-5793(84)80590-6; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEFF T, 1989, J BIOL CHEM, V264, P16132; LUCERO MA, 1989, NUCLEIC ACIDS RES, V17, P2283, DOI 10.1093/nar/17.6.2283; LUSIS AJ, 1988, J LIPID RES, V29, P397; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OGAMI K, 1990, J BIOL CHEM, V265, P9808; OGAMI K, 1991, J BIOL CHEM, V266, P9640; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RAMJI DP, 1991, NUCLEIC ACIDS RES, V19, P1139, DOI 10.1093/nar/19.5.1139; RANGAN VS, 1990, J BIOL CHEM, V265, P8874; RITCHIE HH, 1990, NUCLEIC ACIDS RES, V18, P6857, DOI 10.1093/nar/18.23.6857; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHONFELD G, 1982, J CLIN INVEST, V69, P1072, DOI 10.1172/JCI110542; SHARPE CR, 1984, NUCLEIC ACIDS RES, V12, P3917, DOI 10.1093/nar/12.9.3917; SHELLEY CS, 1987, NUCLEIC ACIDS RES, V15, P3801, DOI 10.1093/nar/15.9.3801; SHINOMIYA M, 1982, BIOCHIM BIOPHYS ACTA, V713, P292; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SOUTAR AK, 1975, BIOCHEMISTRY-US, V14, P3057, DOI 10.1021/bi00685a003; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSAO YK, 1985, J BIOL CHEM, V260, P5222; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x	56	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24460	24470						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761546				2022-12-25	WOS:A1991GW84500036
J	MINVIELLE, S; GISCARDDARTEVELLE, S; COHEN, R; TABOULET, J; LABYE, F; JULLIENNE, A; RIVAILLE, P; MILHAUD, G; MOUKHTAR, MS; LASMOLES, F				MINVIELLE, S; GISCARDDARTEVELLE, S; COHEN, R; TABOULET, J; LABYE, F; JULLIENNE, A; RIVAILLE, P; MILHAUD, G; MOUKHTAR, MS; LASMOLES, F			A NOVEL CALCITONIN CARBOXYL-TERMINAL PEPTIDE PRODUCED IN MEDULLARY-THYROID CARCINOMA BY ALTERNATIVE RNA PROCESSING OF THE CALCITONIN/CALCITONIN GENE-RELATED PEPTIDE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; BOP REAGENT; CGRP GENE; EXPRESSION; SEQUENCE; RAT; ACCEPTOR; SITES	The calcitonin/calcitonin gene-related peptide gene expresses two different mRNAs by tissue-specific alternative processing. The calcitonin mRNA is produced in thyroid C cells by splicing of the first three exons to the fourth polyadenylated exon. It encodes a protein precursor containing an amino-terminal peptide, calcitonin, and a carboxyl-terminal peptide (CCP 1). Calcitonin gene-related peptide (CGRP) mRNA is produced in neuronal cells by splicing of the three common exons to the fifth exon and the polyadenylated sixth exon, leading to the production of a CGRP precursor. Our studies concerning the expression of the calcitonin/CGRP gene in human medullary thyroid carcinoma revealed the presence of a new RNA transcript. Amplification by polymerase chain reaction and direct sequencing showed that the novel transcript is composed of exons 1, 2, and 3, part of exon 4, exon 5, and a polyadenylated exon 6. This transcript contains an open reading frame coding for the known amino terminal and calcitonin peptides, as well as for a novel calcitonin carboxyl-terminal peptide, CCP II. This third alternative pathway utilizes an internal donor site within the exon coding for calcitonin. The presence of CCP II was demonstrated in plasma and thyroidal tissues of medullary thyroid carcinoma patients, implying that this novel mRNA is actively translated in medullary thyroid carcinoma.	CHU ST ANTOINE,CNRS,URA 163,F-75571 PARIS 12,FRANCE	Centre National de la Recherche Scientifique (CNRS)	MINVIELLE, S (corresponding author), CHU ST ANTOINE,INSERM,U113,27 RUE CHALIGNY,F-75571 PARIS 12,FRANCE.		Minvielle, Stéphane/K-8251-2015	Minvielle, Stephane/0000-0003-1389-312X				ADEMA GJ, 1990, NUCLEIC ACIDS RES, V18, P5365, DOI 10.1093/nar/18.18.5365; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; AMARA SG, 1984, MOL CELL BIOL, V4, P2151, DOI 10.1128/MCB.4.10.2151; BIRNBAUM RS, 1986, J BIOL CHEM, V261, P699; BOVENBERG RAL, 1989, BIOCHIM BIOPHYS ACTA, V1008, P223, DOI 10.1016/0167-4781(80)90013-5; BOVENBERG RAL, 1986, NUCLEIC ACIDS RES, V14, P8785, DOI 10.1093/nar/14.22.8785; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BROAD PM, 1989, NUCLEIC ACIDS RES, V17, P6999, DOI 10.1093/nar/17.17.6999; COTE GJ, 1990, MOL ENDOCRINOL, V4, P1744, DOI 10.1210/mend-4-11-1744; DANNER D, 1985, P NATL ACAD SCI USA, V82, P8658, DOI 10.1073/pnas.82.24.8658; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; ITOH N, 1979, EUR J BIOCHEM, V97, P1, DOI 10.1111/j.1432-1033.1979.tb13079.x; JONAS V, 1985, P NATL ACAD SCI USA, V82, P1994, DOI 10.1073/pnas.82.7.1994; KAKIZUKA A, 1988, J BIOL CHEM, V263, P3884; LANE LC, 1978, ANAL BIOCHEM, V86, P655, DOI 10.1016/0003-2697(78)90792-3; LASMOLES F, 1985, EMBO J, V4, P2603, DOI 10.1002/j.1460-2075.1985.tb03977.x; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LEFF SE, 1987, CELL, V48, P517, DOI 10.1016/0092-8674(87)90202-9; LEMOULLEC JM, 1984, FEBS LETT, V167, P93, DOI 10.1016/0014-5793(84)80839-X; LENGUYEN D, 1987, J CHEM SOC PERK T 1, P1915, DOI 10.1039/p19870001915; MANIATIS T, 1982, MOL CLONING LABORATO, P383; MARTIAL K, 1990, BIOCHEM BIOPH RES CO, V171, P1111, DOI 10.1016/0006-291X(90)90799-S; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PETERSON ML, 1986, P NATL ACAD SCI USA, V83, P8883, DOI 10.1073/pnas.83.23.8883; POSCHL E, 1987, FEBS LETT, V226, P96, DOI 10.1016/0014-5793(87)80558-6; RIVAILLE P, 1980, TETRAHEDRON, V36, P3413, DOI 10.1016/0040-4020(80)80193-1; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; SOUDAN J, 1991, IN PRESS LEUKEMIA; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014	32	17	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24627	24631						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761559				2022-12-25	WOS:A1991GW84500060
J	DELEDERKREMER, RM; LIMA, C; RAMIREZ, MI; FERGUSON, MAJ; HOMANS, SW; THOMASOATES, J				DELEDERKREMER, RM; LIMA, C; RAMIREZ, MI; FERGUSON, MAJ; HOMANS, SW; THOMASOATES, J			COMPLETE STRUCTURE OF THE GLYCAN OF LIPOPEPTIDOPHOSPHOGLYCAN FROM TRYPANOSOMA-CRUZI EPIMASTIGOTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEISHMANIA-MAJOR; MEMBRANE ANCHOR; PHOSPHOLIPASE-C; LIPOPHOSPHOGLYCAN; GLYCOPROTEIN; GLYCOLIPIDS; INOSITOL	The lipopeptidophosphoglycan is the major cell surface glycoconjugate of the epimastigote forms of the parasitic protozoan Trypanosoma cruzi. A detailed partial structure for this molecule has been reported (Previato, J. O., Gorin, P. A. J., Mazurek, M., Xavier, M. T., Fournet, B., Wieruszesk, J. M., and Mendonca-Previato, L. (1990) J. Biol. Chem. 265, 2518-2526). In this study, we complete the primary structure assignments and describe the microheterogeneity found in the lipopeptidophosphoglycan glycan, using a combination of H-1 and P-31 NMR, fast atom bombardment mass spectrometry, methylation linkage analysis, and exoglycosidase sequencing. The lipopeptidophosphoglycan is a glycosylated inositol-phosphoceramide with striking homology to glycosylphosphatidylinositol membrane anchors found attached to a wide variety of plasma membrane proteins throughout the eukaryotes.	UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	University of Dundee	DELEDERKREMER, RM (corresponding author), UNIV BUENOS AIRES,FAC CIENCIAS EXACTAS & NAT,DEPT QUIM ORGAN,POB 80083,BUENOS AIRES,ARGENTINA.		Ferguson, Michael A. J./F-7829-2010	Ferguson, Michael A. J./0000-0003-1321-8714; Ramirez, Maria Isabel/0000-0001-6294-4419	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CASTELLANI O, 1967, J PROTOZOOL, V14, P447, DOI 10.1111/j.1550-7408.1967.tb02024.x; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAVIES CR, 1990, PARASITOLOGY, V101, P337, DOI 10.1017/S0031182000060522; DEARBORN DG, 1976, J BIOL CHEM, V251, P2976; DELL A, 1987, ADV CARBOHYD CHEM BI, V45, P19, DOI 10.1016/S0065-2318(08)60136-5; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FERGUSON MAJ, 1985, BIOCHIM BIOPHYS ACTA, V842, P39, DOI 10.1016/0304-4165(85)90290-9; FERGUSON MAJ, 1982, BIOCHEM J, V207, P171, DOI 10.1042/bj2070171; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1992, IN PRESS LIPID MODIF; GERWIG GJ, 1989, J BIOL CHEM, V264, P1027; GERWIG GJ, 1991, EUR J BIOCHEM, V196, P115, DOI 10.1111/j.1432-1033.1991.tb15793.x; HAYASHI A, 1990, TRENDS GLYCOSCI GLYC, V2, P381; LEDERKREMER RM, 1990, EUR J BIOCHEM, V192, P337; LEDERKREMER RM, 1985, BIOCH INT, V10, P89; LEDERKREMER RMD, 1978, BIOCHEM BIOPH RES CO, V85, P1268, DOI 10.1016/0006-291X(78)91140-3; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; PREVIATO JO, 1990, J BIOL CHEM, V265, P2518; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; VOLWERK JJ, 1990, BIOCHEMISTRY-US, V29, P8056, DOI 10.1021/bi00487a010; ZINGALES B, 1982, FEBS LETT, V142, P238, DOI 10.1016/0014-5793(82)80143-9	25	68	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23670	23675						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748644				2022-12-25	WOS:A1991GV31900026
J	MEHTA, A; DATTA, A				MEHTA, A; DATTA, A			OXALATE DECARBOXYLASE FROM COLLYBIA-VELUTIPES - PURIFICATION, CHARACTERIZATION, AND CDNA CLONING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; DNA; EXTRACTION; ACID; GELS; RNA	The oxalate-degrading enzyme oxalate decarboxylase (EC 4.1.1.2), which is inducible by oxalic acid, was purified to homogeneity from a crude extract of Collybia velutipes, a basidiomycetous fungus. Two forms of the enzyme were resolved on chromatofocusing. The two isozymes were shown to be related by amino acid composition, peptide mapping, and immunological cross-reactivity. Peak A, eluting at pH 3.3, was used for further study; the K(m) was found to be 4.5 mM, and the V(max) was 166-mu-mol/min/mg. The subunit molecular mass of the glycosylated enzyme was 64 kDa, whereas the mass of the deglycosylated protein was 55 kDa. The enzyme showed an acidic pl, was very stable over a wide pH range, and was moderately thermostable. The cDNA encoding the enzyme was obtained by immunoscreening a lambda-gt11 expression library. In vitro translation of hybrid-selected mRNA gave a 55-kDa protein. Genomic Southern hybridization indicated that oxalate decarboxylase is encoded by a single gene. The cDNA probe hybridized to a single 1.5-kilobase pair species of mRNA. The mRNA was shown to be induced by oxalic acid. A temporal relationship between enzyme activity and mRNA levels was observed, thus suggesting that the expression of oxalate decarboxylase is regulated at the transcriptional level.	JAWAHARLAL NEHRU UNIV,SCH LIFE SCI,NEW DELHI 110067,INDIA	Jawaharlal Nehru University, New Delhi	DATTA, A (corresponding author), JAWAHARLAL NEHRU UNIV,SCH LIFE SCI,NEW DELHI 110067,INDIA.							ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BAETZ AL, 1989, J BACTERIOL, V171, P2605, DOI 10.1128/jb.171.5.2605-2608.1989; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; DECASTRO MDL, 1988, J PHARMACEUT BIOMED, V6, P1, DOI 10.1016/0731-7085(88)80024-4; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; FARACHCARSON MC, 1989, BIOTECHNIQUES, V7, P482; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Garvey JS, 1977, METHODS IMMUNOLOGY, V3rd; HODGKINSON A, 1970, CLIN CHEM, V16, P547; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAGUS R, 1987, METHOD ENZYMOL, V152, P567; JAKOBY WB, 1958, BACTERIOL REV, V22, P75, DOI 10.1128/MMBR.22.2.75-80.1958; JAKOBY WB, 1962, METHOD ENZYMOL, V5, P637; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MAXWELL DP, 1973, PHYSIOL PLANT PATHOL, V3, P279, DOI 10.1016/0048-4059(73)90090-8; MCKELVY JF, 1969, ARCH BIOCHEM BIOPHYS, V132, P99, DOI 10.1016/0003-9861(69)90341-5; Mickelsen O, 1973, MODERN NUTRITION HLT, P412; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARNES JR, 1981, P NATL ACAD SCI-BIOL, V78, P2253, DOI 10.1073/pnas.78.4.2253; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; Sambrook J, 1989, MOL CLONING LABORATO; SAUL A, 1986, ANAL BIOCHEM, V156, P354, DOI 10.1016/0003-2697(86)90265-4; SHIMAZONO H, 1957, J BIOL CHEM, V227, P151; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; ZOLAN ME, 1986, MOL CELL BIOL, V6, P195, DOI 10.1128/MCB.6.1.195	30	56	66	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23548	23553						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748632				2022-12-25	WOS:A1991GV31900007
J	JIANG, P; ANANTHANARAYANAN, VS				JIANG, P; ANANTHANARAYANAN, VS			CONFORMATIONAL REQUIREMENT FOR LYSINE HYDROXYLATION IN COLLAGEN - STRUCTURAL STUDIES ON SYNTHETIC PEPTIDE-SUBSTRATES OF LYSYL HYDROXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTAINING BETA-TURNS; PROLYL 4-HYDROXYLASE; MODEL PEPTIDES; PROLINE; PROTEINS; PROTOCOLLAGEN; RESIDUES	An attempt has been made to understand the conformational determinants that govern the hydroxylation of selected lysyl residues in the nascent collagen molecule by lysyl hydroxylase (EC 1.14.11.4). A series of peptide substrates of the enzyme, ranging in length from 3 to 12 residues, were synthesized. These included: tert-butyloxylcarbonyl (t-Boc)-Ile-Lys-Gly; Boc-Ala-Lys-Gly; N-acetyl-Ala-Lys-Gly-Ser; Gly-Pro-Lys-Gly-Glu; Leu-Hyp-Gly-Ala-Lys-Gly-Glu; Hyp-Phe-Hyp-Gly-Leu-Hyp-Gly-Ala-Lys-Gly-Glu; (Hyp-Gly-Pro-Lys-Gly-Glu)2; and Ala-Arg-Gly-Ile-Lys-Gly-Ile-Arg-Gly-Phe-Ser-Gly. The conformational features of these peptides were studied by spectroscopic methods so as to relate this information with the kinetic parameters for the interaction of these peptides with purified lysyl hydroxylase. Spectroscopic data, supported by conformational energy calculations, indicated that the tripeptides t-Boc-Ile-Lys-Gly and t-Boc-Ala-Lys-Gly adopt a gamma-turn structure in water and trifluoroethanol with Lys in the second position of the turn. In the tetra- and larger peptides two structures, the beta-turn and a polyproline-II (PP-II) type extended conformation, were identified. The proportions of these two structures in a given peptide depended on the polarity of the solvent. All of the peptides were hydroxylated by lysyl hydroxylase isolated from chicken embryos. In contrast, a control peptide, t-Boc-Ala-Gly-Lys which adopted a beta-turn with Lys at the end of the turn, was not hydroxylated. Competitive inhibition of the hydroxylation of protocollagen by some of the peptides showed a common binding site for these substrates in the enzyme's active site. Kinetic data on the peptides indicated improved hydroxylation rate (higher V(max)) in peptides having relatively higher beta-turn content and improved binding (lower K(m)) in peptides with higher content of the PP-II structure. The efficacy of the substrate was also governed by its chain length. These data suggest that the conformational criterion for lysine hydroxylation in collagen-related peptides is the presence of a "bent" structure, such as the gamma- or beta-turn at the catalytic site of lysyl hydroxylase and an "extended" PP-II type structure at the binding site(s) of the enzyme's active site. This suggestion also provides a conformational rationale for earlier observations on the substrate specificity of lysyl hydroxylase.	MCMASTER UNIV, DEPT BIOCHEM, HAMILTON L8N 3Z5, ONTARIO, CANADA	McMaster University								ANANTHANARAYANAN VS, 1988, INT J PEPT PROT RES, V31, P399; ATREYA PL, 1991, J BIOL CHEM, V266, P2852; BERG RA, 1973, BIOCHEM BIOPH RES CO, V52, P115, DOI 10.1016/0006-291X(73)90961-3; BOEDTKER H, 1956, J AM CHEM SOC, V78, P4267, DOI 10.1021/ja01598a024; BRAHMACHARI SK, 1982, BIOPOLYMERS, V21, P1107, DOI 10.1002/bip.360210608; CREIGHTON TE, 1983, PROTEINS, P259; DEWAAL A, 1988, BIOCHEMISTRY-US, V27, P150, DOI 10.1021/bi00401a023; FERSHT A, 1985, ENZYME STRUCTURE MEC, P85; GUNZLER V, 1988, BIOCHEM J, V251, P365, DOI 10.1042/bj2510365; HOLLOSI M, 1987, BIOPOLYMERS, V26, P1527, DOI 10.1002/bip.360260907; HOLLOSI M, 1985, BIOPOLYMERS, V24, P211, DOI 10.1002/bip.360240117; JENNESS DD, 1976, BIOPOLYMERS, V15, P513, DOI 10.1002/bip.1976.360150308; KIKUCHI Y, 1982, B CHEM SOC JPN, V55, P1556, DOI 10.1246/bcsj.55.1556; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; KIVIRIKKO KI, 1972, BIOCHEMISTRY-US, V11, P122, DOI 10.1021/bi00751a021; KIVIRIKKO KI, 1980, ENZYMOLOGY POST TRAN, P53; KIVIRIKKO KI, 1987, CONNECTIVE TISSUE DI, P263; MYLLYLA R, 1991, J BIOL CHEM, V266, P2805; PAUL PKC, 1985, J BIOMOL STRUCT DYN, V2, P879, DOI 10.1080/07391102.1985.10507607; Prockop D.J., 1976, BIOCH COLLAGENS, P163; PUISTOLA U, 1980, BIOCHIM BIOPHYS ACTA, V611, P40, DOI 10.1016/0005-2744(80)90040-6; RAO CP, 1980, BIOCHEMISTRY-US, V19, P425, DOI 10.1021/bi00544a004; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; RYHANEN L, 1975, BIOCHIM BIOPHYS ACTA, V397, P50; RYHANEN L, 1974, BIOCHIM BIOPHYS ACTA, V343, P129, DOI 10.1016/0304-4165(74)90244-X; SMITH JA, 1980, CRC CR REV BIOCH MOL, V8, P315, DOI 10.3109/10409238009105470; STIMSON ER, 1977, MACROMOLECULES, V10, P1049, DOI 10.1021/ma60059a032; TAKAHASHI K, 1987, BIOPOLYMERS, V26, P1781, DOI 10.1002/bip.360261010; TURPEENNIEMI TM, 1977, BIOCHIM BIOPHYS ACTA, V483, P215, DOI 10.1016/0005-2744(77)90024-9; WOODY RW, 1974, PEPTIDES POLYPEPTIDE, P339; ZIJENAH LS, 1987, THESIS MEMORIAL U NE	32	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22960	22967						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744090				2022-12-25	WOS:A1991GT48300031
J	THEILER, R; NIEDERMAN, RA				THEILER, R; NIEDERMAN, RA			LOCALIZATION OF CHROMATOPHORE PROTEINS OF RHODOBACTER-SPHAEROIDES .1. RAPID CA2+-INDUCED FUSION OF CHROMATOPHORES WITH PHOSPHATIDYLGLYCEROL LIPOSOMES FOR PROTEINASE DELIVERY TO THE LUMINAL MEMBRANE-SURFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOPSEUDOMONAS-SPHAEROIDES; ERYTHROCYTE-GHOSTS; COMPLEXES; MECHANISM; CELLS; TOPOGRAPHY; ADSORPTION; VESICLES	A protease delivery system was developed for the exclusive and controlled digestion of proteins exposed at the morphological inside (periplasmic surface) of Rhodobacter sphaeroides chromatophores. In this procedure, proteinase K is encapsulated within large unilamellar liposomes which are fused to the chromatophores in the presence of Ca2+ ions. The liposomes were prepared by a detergent dialysis procedure from native phosphatidylglycerol and found to undergo rapid bilayer fusion with purified chromatophore preparations above a threshold concentration of 12.5 mM CaCl2. The fusion process was complete within 10 min at 35 mM Ca2+ with about 80% of the pigment located in the fusion products. Electron micrographs of freeze-fracture replicas confirmed the intermixing of the lipid bilayers and the unilamellar structure of the fused membrane vesicles. The procedure did not affect the labile B800 chromophore of the B800-850 antenna complex, but reduced slightly the absorption due to the B875 core antenna. Emission from both light-harvesting complexes was increased in the fused membranes, suggesting a partial dissociation of photosynthetic units in the expanded bilayer. The results, together with those presented in the following paper (Theiler, R., and Niederman, R. A. (1991) J. Biol. Chem. 266, 23163-23168), demonstrate that this new method fulfills the stringent requirements for a successful delivery of macromolecules to the chromatophore interior.	RUTGERS STATE UNIV,DEPT MOLEC BIOL & BIOCHEM,POB 1059,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick								BACHMANN RC, 1981, BIOCHEMISTRY-US, V20, P4590, DOI 10.1021/bi00519a012; BEISS U, 1964, J CHROMATOGR, V13, P104, DOI 10.1016/S0021-9673(01)95079-4; CASADIO R, 1984, J BIOL CHEM, V259, P9149; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; COLLINS MLP, 1980, J BACTERIOL, V143, P221, DOI 10.1128/JB.143.1.221-230.1980; CULLIS PR, 1978, NATURE, V271, P672, DOI 10.1038/271672a0; DUZGUNES N, 1981, BIOCHIM BIOPHYS ACTA, V642, P182, DOI 10.1016/0005-2736(81)90148-6; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; FRAKER PJ, 1971, J BACTERIOL, V108, P465, DOI 10.1128/JB.108.1.465-473.1971; HALL RL, 1978, PHOTOCHEM PHOTOBIOL, V28, P273, DOI 10.1111/j.1751-1097.1978.tb07708.x; HUNDLE BS, 1987, BIOCHEMISTRY-US, V26, P4505, DOI 10.1021/bi00388a050; HUNTER CN, 1988, BIOCHEMISTRY-US, V27, P3459, DOI 10.1021/bi00409a050; HUNTER CN, 1979, BIOCHIM BIOPHYS ACTA, V548, P253, DOI 10.1016/0005-2728(79)90133-6; KATES M, 1972, TECHNIQUES LIPIDOLOG, P436; LAU A, 1981, BIOCHIM BIOPHYS ACTA, V645, P279, DOI 10.1016/0005-2736(81)90199-1; LEPAGE M, 1964, J CHROMATOGR, V13, P99, DOI 10.1016/S0021-9673(01)95078-2; LOMMEN MAJ, 1978, J BACTERIOL, V136, P730, DOI 10.1128/JB.136.2.730-741.1978; MARINETTI GV, 1981, CHEM PHYS LIPIDS, V28, P241, DOI 10.1016/0009-3084(81)90011-6; NIEDERMAN RA, 1978, PHOTOSYNTHETIC BACTE, P79; ONISHI JC, 1982, J BACTERIOL, V149, P831, DOI 10.1128/JB.149.3.831-839.1982; PENNOYER JD, 1985, FEBS LETT, V182, P145, DOI 10.1016/0014-5793(85)81172-8; PENNOYER JD, 1984, STRUCTURE FUNCTION M, P437; PHILIPPOT J, 1983, BIOCHIM BIOPHYS ACTA, V734, P137, DOI 10.1016/0005-2736(83)90111-6; PORTIS A, 1979, BIOCHEMISTRY-US, V18, P780, DOI 10.1021/bi00572a007; RIVAS E, 1987, BIOCHIM BIOPHYS ACTA, V904, P290, DOI 10.1016/0005-2736(87)90378-6; ROSENBERG J, 1983, BIOCHIM BIOPHYS ACTA, V735, P173, DOI 10.1016/0005-2736(83)90272-9; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SCHNEIDER H, 1980, P NATL ACAD SCI-BIOL, V77, P442, DOI 10.1073/pnas.77.1.442; SCHWENDENER RA, 1981, BIOCHEM BIOPH RES CO, V100, P1055, DOI 10.1016/0006-291X(81)91930-6; SNOZZI M, 1984, BIOCHIM BIOPHYS ACTA, V766, P451, DOI 10.1016/0005-2728(84)90261-5; TADROS MH, 1988, J BACTERIOL, V170, P2758, DOI 10.1128/jb.170.6.2758-2762.1988; TAKEMOTO J, 1979, ARCH BIOCHEM BIOPHYS, V195, P526, DOI 10.1016/0003-9861(79)90379-5; THEILER R, 1991, J BIOL CHEM, V266, P23163; VALKIRS GE, 1982, J CELL BIOL, V95, P179, DOI 10.1083/jcb.95.1.179; VENTUROLI G, 1986, BIOCHIM BIOPHYS ACTA, V851, P340, DOI 10.1016/0005-2728(86)90070-8; VOS J, 1976, BIOCHEM J, V158, P651, DOI 10.1042/bj1580651; WESTERHUIS WHJ, 1989, BIOL ROLE PLANT LIPI, P227; WIEMKEN V, 1985, PHYSIOL VEG, V23, P789; WIEMKEN V, 1983, FEMS MICROBIOL LETT, V16, P297; YEN GSL, 1982, BIOCHIM BIOPHYS ACTA, V688, P605, DOI 10.1016/0005-2736(82)90372-8; ZAKAI N, 1977, P NATL ACAD SCI USA, V74, P2417, DOI 10.1073/pnas.74.6.2417	41	2	2	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23157	23162						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744115				2022-12-25	WOS:A1991GT48300060
J	ABATE, C; MARSHAK, DR; CURRAN, T				ABATE, C; MARSHAK, DR; CURRAN, T			FOS IS PHOSPHORYLATED BY P34CDC2, CAMP-DEPENDENT PROTEIN-KINASE AND PROTEIN-KINASE-C AT MULTIPLE SITES CLUSTERED WITHIN REGULATORY REGIONS	ONCOGENE			English	Article							DNA-BINDING DOMAINS; OSTEO-SARCOMA VIRUS; LEUCINE ZIPPER; JUN; TRANSCRIPTION; IDENTIFICATION; ACTIVATION; ONCOGENE; INVITRO; SERUM	The proto-oncogene c-fos encodes a nuclear protein (Fos) that functions in transcriptional regulation in response to extracellular signals. Fos is extensively modified in the nucleus by serine and threonine phosphorylation. It has been suggested that phosphorylation may play an important role in regulating Fos function in normal and transformed cells. As a first step in addressing this issue, we have used purified Fos as a substrate for several serine-threonine protein kinases, including cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and p34cdc2. Each of these kinases phosphorylated Fos at several unique sites. These sites were located within two regions that were previously shown to reduce the transcriptional activity of Fos in vitro. Several of the sites modified in vitro were also shown to be phosphorylated in serum-stimulated fibroblasts. These findings demonstrate that Fos is a target for several protein kinases involved in signal transduction and suggest that phosphorylation could regulate the transcriptional properties of Fos.	ROCHE INST MOLEC BIOL, ROCHE RES CTR, DEPT MOLEC ONCOL & VIROL, NUTLEY, NJ 07110 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Roche Holding; Cold Spring Harbor Laboratory			Curran, Tom/C-1164-2008; Curran, Tom/D-7515-2011; Abate-Shen, Cory/O-2520-2014; Curran, Thomas/AAE-7631-2019; Curran, Tom/F-5234-2018	Curran, Tom/0000-0003-1444-7551; Abate-Shen, Cory/0000-0002-5021-0570; Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ABATE C, 1991, MOL CELL BIOL, V11, P3629; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1987, BIOESSAYS, V7, P255, DOI 10.1002/bies.950070606; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1987, ONCOGENE, V2, P79; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; CURRAN T, 1984, CELL, V36, P259; Curran T, 1988, ONCOGENE HDB, P307; CURRAN T, 1991, TRANSCRIPTION REGULA; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HIRAI SI, 1990, ONCOGENE, V5, P39; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KEMP BE, 1983, P NATL ACAD SCI-BIOL, V80, P7471, DOI 10.1073/pnas.80.24.7471; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; LUO K, 1990, ONCOGENE, V5, P921; MARSHAK DR, 1991, J CELL BIOCHEM, V45, P391, DOI 10.1002/jcb.240450413; MARSHAK DR, 1991, METHOD ENZYMOL, V200, P134; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; REDDY EPA, 1988, ONCOGENE HDB; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; TURNER RS, 1985, J BIOL CHEM, V260, P1503	37	83	83	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1991	6	12					2179	2185						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766667				2022-12-25	WOS:A1991GX73500002
J	YU, KT; LYALL, R; JARIWALA, N; ZILBERSTEIN, A; HAIMOVICH, J				YU, KT; LYALL, R; JARIWALA, N; ZILBERSTEIN, A; HAIMOVICH, J			ANTIGEN-INDUCED AND IONOPHORE-INDUCED SIGNAL TRANSDUCTION IN RAT BASOPHILIC LEUKEMIA-CELLS INVOLVES PROTEIN TYROSINE PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTAMINE-RELEASE; IMMUNOGLOBULIN-E; KINASE-C; MAST-CELLS; SYNERGISTIC SIGNALS; CALCIUM SIGNAL; RBL-2H3 CELLS; HIGH-AFFINITY; 2H3 CELLS; RECEPTOR	Treatment of rat basophilic leukemia cells (RBL-2H3) with antigen or ionophore leads to an increase in cellular protein tyrosine phosphorylation. Three major proteins of molecular mass of 72, 92, and 110 kDa are targeted by antigen and a 110-kDa species by ionophore, A23187. The antigen- and ionophore-induced tyrosine phosphorylation responses are dose-dependent and correlate with increases in serotonin release from activated cells. The presence of extracellular Ca2+ is required to sustain the antigen- and ionophore-stimulated tyrosine phosphorylation as well as mediator release. A protein tyrosine kinase inhibitor, RG 50864, differentially inhibits the antigen-stimulated tyrosine phosphorylation in the decreasing order of 72, 91, and 110-kDa proteins. The compound inhibition of the 72-kDa protein tyrosine phosphorylation correlates with that of serotonin release. In ionophore-stimulated cells, the inhibition of the 110-kDa protein tyrosine phosphorylation and serotonin release by RG 50864 occurs in parallel. These results suggest that the 72- and 110-kDa phosphoproteins may represent the respective regulators of serotonin release in antigen- and ionophore-activated cells. The 110-kDa tyrosine phosphorylated proteins from antigen- and ionophore-stimulated cells exhibit identical electrophoretic mobility and V8 protease-generated phosphopeptide maps, suggesting that these two proteins may be the same. These results provide new evidence that both the stimulatory actions of antigen and ionophore on mediator release are mediated through enhanced protein tyrosine phosphorylation in RBL-2H3 cells. Significantly, the present study suggests the presence of multiple tyrosine phosphorylation signaling pathways in RBL cells and that their selective utility may be determined by the nature of the stimulus.			YU, KT (corresponding author), RHONE POULENC RORER CENT RES,DEPT IMMUNOL & CELL BIOL,KING OF PRUSSIA,PA 19406, USA.							ALI H, 1989, J IMMUNOL, V143, P2626; BEAVEN MA, 1987, J CELL BIOL, V105, P1129, DOI 10.1083/jcb.105.3.1129; BEAVEN MA, 1984, J BIOL CHEM, V259, P7137; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BILDER GE, 1991, AM J PHYSIOL, V260, P721; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CUNHAMELO JR, 1989, J IMMUNOL, V143, P2617; CUNHAMELO JR, 1987, J BIOL CHEM, V262, P11455; KATAKAMI Y, 1984, BIOCHEM BIOPH RES CO, V121, P573, DOI 10.1016/0006-291X(84)90220-1; LYALL RM, 1989, J BIOL CHEM, V264, P14503; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; QUARTO R, 1986, MOL IMMUNOL, V23, P1215, DOI 10.1016/0161-5890(86)90154-9; SAGIEISENBERG R, 1985, NATURE, V313, P59, DOI 10.1038/313059a0; SAITO H, 1987, J IMMUNOL, V138, P3927; SCHLEIMER RP, 1982, J IMMUNOL, V128, P136; SHIMIZU A, 1988, P NATL ACAD SCI USA, V85, P1907, DOI 10.1073/pnas.85.6.1907; WHITE JR, 1984, P NATL ACAD SCI-BIOL, V81, P3978, DOI 10.1073/pnas.81.13.3978; WHITE KN, 1988, J IMMUNOL, V141, P942; ZICK Y, 1990, BIOCHEMISTRY-US, V29, P10240, DOI 10.1021/bi00496a013	21	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22564	22568						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1834674				2022-12-25	WOS:A1991GR56400079
J	PANGBURN, MK; ATKINSON, MAL; MERI, S				PANGBURN, MK; ATKINSON, MAL; MERI, S			LOCALIZATION OF THE HEPARIN-BINDING SITE ON COMPLEMENT FACTOR-H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN C4B-BINDING PROTEIN; ALTERNATIVE PATHWAY; SIALIC-ACID; BOUND C3B; AMPLIFICATION CONVERTASE; ANTITHROMBIN-III; FACTOR-I; ACTIVATION; BETA-1H; RECOGNITION	Factor H is a regulator of complement activation and, in this capacity, it prevents activation of the alternative pathway on host cells and tissues when it recognizes markers on these surfaces. This report describes the binding characteristics and location of the site on factor H that is responsible for host recognition. Factor H was found to bind a variety of polyanions, including heparin, heparan sulfate, dextran sulfate, and clusters of sialic acid. In heparin-agarose binding assays it exhibited an affinity for heparin only 2-fold weaker than that of antithrombin III. Factor H exhibited little or no affinity for polyaspartic acid or bacterial colominic acid (polysialic acid). Factor H (M(r) 150,000 with approximate dimensions of 30 x 600 angstrom) is composed of 20 highly homologous domains (SCRs) that are arranged as beads on a string. Polyanions were found to block a tryptic cleavage site in domain 15, and a photoaffinity-tagged heparin probe labeled the region between domains 12 and 15. Affinity chromatography of tryptic fragments on heparin-Sepharose confirmed that this region contained the heparin-binding site. CNBr cleavage at Met787 located between SCRs 13 and 14 split the photoaffinity-tagged region. Sequence analysis strongly suggests that domain 13 contains the primary site of polyanion binding. Factor H expresses its complement regulatory function through a site located in domains 4-6 where C3b binds. Thus, the polyanion-binding site that regulates the affinity of factor H for C3b appears to reside more than 200 angstrom away from the C3b-binding site.	UNIV HELSINKI,DEPT BACTERIOL & IMMUNOL,SF-00100 HELSINKI 10,FINLAND	University of Helsinki	PANGBURN, MK (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,TYLER,TX 75710, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035081, R01DK035081] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-35081] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALSENZ J, 1984, BIOCHEM J, V224, P389, DOI 10.1042/bj2240389; ALSENZ J, 1985, BIOCHEM J, V232, P841, DOI 10.1042/bj2320841; BAKER PJ, 1975, J IMMUNOL, V114, P554; BARLOW PN, 1991, BIOCHEMISTRY-US, V30, P997, DOI 10.1021/bi00218a016; BITTERSUERMANN D, 1981, EUR J IMMUNOL, V11, P291, DOI 10.1002/eji.1830110405; CAPEL PJA, 1978, J IMMUNOL, V121, P2566; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CARRENO MP, 1989, EUR J IMMUNOL, V19, P2145, DOI 10.1002/eji.1830191126; CHRISTOPHERSON RI, 1983, METHOD ENZYMOL, V91, P278; DAHLBACK B, 1984, J BIOL CHEM, V259, P1631; DAHLBACK B, 1983, P NATL ACAD SCI-BIOL, V80, P3461, DOI 10.1073/pnas.80.11.3461; DAWES J, 1988, ANAL BIOCHEM, V174, P177, DOI 10.1016/0003-2697(88)90533-7; FEARON DT, 1977, P NATL ACAD SCI USA, V74, P1683, DOI 10.1073/pnas.74.4.1683; FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FRIES LF, 1984, J EXP MED, V160, P1640, DOI 10.1084/jem.160.6.1640; HESSING M, 1990, J IMMUNOL, V144, P204; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; HORIE S, 1990, THROMB RES, V59, P895, DOI 10.1016/0049-3848(90)90113-Q; JOINER KA, 1988, ANNU REV MICROBIOL, V42, P201, DOI 10.1146/annurev.mi.42.100188.001221; KAZATCHKINE MD, 1979, J EXP MED, V150, P1202, DOI 10.1084/jem.150.5.1202; KAZATCHKINE MD, 1979, J IMMUNOL, V122, P75; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRE C, 1980, ANN VIROL, V131, P530; LINHARDT RJ, 1988, J BIOL CHEM, V263, P13090; MAILLET F, 1988, MOL IMMUNOL, V25, P917, DOI 10.1016/0161-5890(88)90130-7; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MERI S, 1990, EUR J IMMUNOL, V20, P2555, DOI 10.1002/eji.1830201205; MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982; MICHALEK MT, 1988, J IMMUNOL, V140, P1588; MOORE MD, 1989, J BIOL CHEM, V264, P20576; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; NAGASAVA K, 1980, METHODS CARBOHYDR CH, V8, P291; OKADA N, 1983, IMMUNOLOGY, V48, P129; OKADA N, 1982, NATURE, V299, P261, DOI 10.1038/299261a0; PANGBURN MK, 1989, J IMMUNOL, V142, P2766; PANGBURN MK, 1989, J IMMUNOL, V142, P2759; PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257; PANGBURN MK, 1978, P NATL ACAD SCI USA, V75, P2416, DOI 10.1073/pnas.75.5.2416; PANGBURN MK, 1980, J IMMUNOL, V124, P977; PANGBURN MK, 1984, SPRINGER SEMIN IMMUN, V7, P163, DOI 10.1007/BF01893019; PERKINS SJ, 1991, BIOCHEMISTRY-US, V30, P2847, DOI 10.1021/bi00225a017; PILLEMER L, 1954, SCIENCE, V120, P279, DOI 10.1126/science.120.3112.279; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593; SIM RB, 1982, BIOCHEM J, V205, P285, DOI 10.1042/bj2050285; SIM RB, 1989, CURR TOP MICROBIOL I, V153, P209; WEILER JM, 1978, J EXP MED, V147, P409, DOI 10.1084/jem.147.2.409; WESSELS MR, 1989, P NATL ACAD SCI USA, V86, P8983, DOI 10.1073/pnas.86.22.8983; WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147	50	170	174	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16847	16853						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1832158				2022-12-25	WOS:A1991GD63500095
J	PFEIFER, K; BACHMANN, M; SCHRODER, HC; WEILER, BE; UGARKOVIC, D; OKAMOTO, T; MULLER, WEG				PFEIFER, K; BACHMANN, M; SCHRODER, HC; WEILER, BE; UGARKOVIC, D; OKAMOTO, T; MULLER, WEG			FORMATION OF A SMALL RIBONUCLEOPROTEIN PARTICLE BETWEEN TAT PROTEIN AND TRANS-ACTING RESPONSE ELEMENT IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-LYMPHOTROPIC RETROVIRUS; LONG TERMINAL REPEAT; GENE-EXPRESSION; HTLV-III; FUNCTIONAL-CHARACTERIZATION; NUCLEAR MATRIX; ACTIVATION; INVITRO; RNA; AIDS	The trans-acting response element (TAR) within the long terminal repeat of human immunodeficiency virus (HIV) is present in all 5' termini of HIV mRNAs and is recognized by the viral Tat protein. Now we describe that the 59-nucleotide-long TAR-RNA exists as a ribonucleoprotein particle in polysomal and heterogeneous nuclear RNP fractions of HIV-1-infected HeLa-T4+ cells. Applying an immunoprecipitation technique this Tat.TAR complex could be isolated from total cell extracts as well as from polysomal or heterogeneous nuclear RNP fractions. The chain length and the identity of the TAR-RNA were established by RNase protection assays while the Tat protein was confirmed by Western blotting technique. The TAR-RNA in this complex was sequenced and found to comprise nucleotides +2 to +61 and hence includes the 3-nucleotide bulge (nucleotides +23 to +25) and the loop sequence of the TAR stem-and-loop structure. The Tat.TAR complex is present in cells at low abundance (12.5 x 10(3) copies/cell). In contrast to the TAR-containing mRNAs, which decay very rapidly after incubation of cells with actinomycin D (half-life of approximately 120 min) the half-life of TAR in the Tat.TAR complex is > 180 min. Alignment studies revealed that TAR-RNA (positive strand) has a potential binding ability to the U5 region within the long terminal repeat (DNA negative strand; nucleotides +107 to +147); a complementary binding with a continuous homology of 16 nucleotides was identified. It is proposed that the Tat. TAR complex functions as a small ribonucleoprotein particle during transcription initiation of HIV mRNA.	UNIV MAINZ, INST PHYSIOL CHEM, ANGEW MOLEK BIOL ABT, DUESBERGWEG 6, W-6500 MAINZ, GERMANY; RUDJER BOSKOVIC INST, DEPT ORGAN CHEM & BIOCHEM, YU-41001 ZAGREB, CROATIA; NATL CANC CTR, RES INST, DIV VIROL, CHUO KU, TOKYO 104, JAPAN	Johannes Gutenberg University of Mainz; Rudjer Boskovic Institute; National Cancer Center - Japan			Müller, W. E. G./AAR-8651-2020; Bachmann, Michael/AAA-5153-2020; Bachmann, Michael P/E-8850-2010	Müller, W. E. G./0000-0002-8223-3689; Bachmann, Michael/0000-0002-8029-5755; Bachmann, Michael P/0000-0002-8029-5755; Schroder, Heinz C./0000-0003-0992-6427				ALDOVINI A, 1986, P NATL ACAD SCI USA, V83, P6672, DOI 10.1073/pnas.83.18.6672; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; ARYA SK, 1984, SCIENCE, V225, P927, DOI 10.1126/science.6089333; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BACHMANN M, 1986, J GEN VIROL, V67, P2587, DOI 10.1099/0022-1317-67-12-2587; BACHMANN M, 1990, CELL, V60, P85, DOI 10.1016/0092-8674(90)90718-T; BACHMANN M, 1984, BIOCHIM BIOPHYS ACTA, V783, P89, DOI 10.1016/0167-4781(84)90082-4; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BRUNI JE, 1985, BRAIN RES REV, V9, P1, DOI 10.1016/0165-0173(85)90016-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMENS MJ, 1984, TRANSCRIPTION TRANSL, P211; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DAVIS LG, 1986, BASIC METHODS MOL BI, P45; DINGERMANN T, 1987, EUR J BIOCHEM, V170, P217, DOI 10.1111/j.1432-1033.1987.tb13689.x; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; England T E, 1980, Methods Enzymol, V65, P65; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; IKEDA H, 1988, GENE, V71, P19, DOI 10.1016/0378-1119(88)90073-X; KINLAW CS, 1982, MOL CELL BIOL, V2, P1159, DOI 10.1128/MCB.2.10.1159; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MICHAELI S, 1990, J BIOL CHEM, V265, P10582; MULLER WEG, 1988, ANTIVIR RES, V9, P191, DOI 10.1016/0166-3542(88)90003-4; MULLER WEG, 1990, J BIOL CHEM, V265, P3803; MULLER WEG, 1989, BIOCHIM BIOPHYS ACTA, V1008, P208, DOI 10.1016/0167-4781(80)90011-1; OKAMOTO T, 1986, CELL, V47, P29, DOI 10.1016/0092-8674(86)90363-6; PALACIOS R, 1972, J BIOL CHEM, V247, P2316; PEDERSON T, 1974, J MOL BIOL, V83, P163, DOI 10.1016/0022-2836(74)90386-6; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; ROSEN CA, 1990, AIDS, V4, P499, DOI 10.1097/00002030-199006000-00002; ROY S, 1990, J VIROL, V64, P1402, DOI 10.1128/JVI.64.3.1402-1406.1990; RUBEN S, 1989, J VIROL, V63, P1; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIN PS, 1987, J NATL CANCER I, V78, P663; SCHRODER HC, 1990, AIDS RES HUM RETROV, V6, P659, DOI 10.1089/aid.1990.6.659; SCHRODER HC, 1988, BIOL CHEM H-S, V369, P985, DOI 10.1515/bchm3.1988.369.2.985; SCHRODER HC, 1989, J BIOL CHEM, V264, P5669; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; STLAURENT G, 1983, CELL, V33, P95; TOOHEY MG, 1989, GENE DEV, V3, P265, DOI 10.1101/gad.3.3.265; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARMUS H, 1988, SCIENCE, V240, P1427, DOI 10.1126/science.3287617; VARMUS H, 1988, GENE DEV, V2, P1055, DOI 10.1101/gad.2.9.1055; WRIGHT CM, 1986, SCIENCE, V234, P988, DOI 10.1126/science.3490693	50	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14620	14626						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1830589				2022-12-25	WOS:A1991FZ35100079
J	COELHOSAMPAIO, T; TEIXEIRAFERREIRA, A; VIEYRA, A				COELHOSAMPAIO, T; TEIXEIRAFERREIRA, A; VIEYRA, A			NOVEL EFFECTS OF CALMODULIN AND CALMODULIN ANTAGONISTS ON THE PLASMA-MEMBRANE (CA2+ + MG2+)-ATPASE FROM RABBIT KIDNEY PROXIMAL TUBULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(CA-2+ + MG-2+)-ATPASE; RED-CELL MEMBRANES; SARCOPLASMIC-RETICULUM; KIDNEY CORTEX; CALCIUM-PUMP; ERYTHROCYTE CA-2+-ATPASE; ADENOSINE-TRIPHOSPHATASE; REGULATED FUNCTIONS; POWERFUL INHIBITOR; HIGH-AFFINITY	In this work we report an unusual pattern of activation by calmodulin on the (Ca2+ + Mg2+)-ATPase from basolateral membranes of kidney proximal tubule cells. The activity of the ATPase depleted to calmodulin is characterized by a high Ca2+ affinity (K(m) = 2.2-3.4-mu-M) and a biphasic dependence on ATP concentration. The preparation responded to the addition of calmodulin by giving rise to a new Ca2+ site of very high affinity (K(m) < 0.05-mu-M). Calmodulin antagonists had diverse effects on ATPase activity. Compound 48/80 inhibited calmodulin-stimulated activity by 70%, whereas calmidazolium did not modify this component. In the absence of calmodulin, 48/80 still acted as an antagonist, increasing the K(m) for Ca2+ to 5.7-mu-M and reducing enzyme turnover by competing with ATP at the low affinity regulatory site. Calmidazolium did not affect Ca2+ affinity, but it did displace ATP from the regulatory site. At fixed Ca2+ (30-mu-M) and ATP (5 mM) concentrations, P(i) protected against 48/80 and potentiated inhibition by calmidazolium. At 25-mu-M ATP, P(i) protected against calmidazolium inhibition. We propose that the effects of ATP and P(i) arise because binding of the drugs to the ATPase occurs mainly on the E2 forms.			COELHOSAMPAIO, T (corresponding author), UNIV FED RIO DE JANEIRO,ICB,DEPT BIOQUIM,BR-21910 RIO DE JANEIRO,BRAZIL.							ADAMO HP, 1988, J BIOL CHEM, V263, P17548; ADUNYAH ES, 1982, FEBS LETT, V143, P65, DOI 10.1016/0014-5793(82)80274-3; ALVES EW, 1986, J BIOL CHEM, V261, P6854; CHIESI M, 1982, J BIOL CHEM, V257, P984; CROUCH TH, 1980, BIOCHEMISTRY-US, V19, P3692, DOI 10.1021/bi00557a009; DESMEDT H, 1981, FEBS LETT, V131, P60, DOI 10.1016/0014-5793(81)80887-3; DIXON DA, 1989, J BIOL CHEM, V264, P13612; ENYEDI A, 1987, J BIOL CHEM, V262, P6425; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GIETZEN K, 1983, BIOCHIM BIOPHYS ACTA, V736, P109, DOI 10.1016/0005-2736(83)90175-X; GIETZEN K, 1981, BIOCHEM BIOPH RES CO, V101, P418, DOI 10.1016/0006-291X(81)91276-6; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GMAJ P, 1982, FEBS LETT, V144, P226, DOI 10.1016/0014-5793(82)80643-1; GMAJ P, 1983, EUR J BIOCHEM, V136, P71, DOI 10.1111/j.1432-1033.1983.tb07706.x; GMAJ P, 1979, BIOCHEM J, V178, P549, DOI 10.1042/bj1780549; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; KLEE CB, 1980, ANNU REV BIOCHEM, V49, P489, DOI 10.1146/annurev.bi.49.070180.002421; KOSKKOSICKA D, 1990, BIOCHEMISTRY-US, V29, P1875, DOI 10.1021/bi00459a030; MUALEM S, 1979, NATURE, V277, P238, DOI 10.1038/277238a0; NIGGLI V, 1981, J BIOL CHEM, V256, P395; RICHARDS DE, 1978, BIOCHIM BIOPHYS ACTA, V511, P194, DOI 10.1016/0005-2736(78)90313-9; ROSSI JPFC, 1989, BIOCHIM BIOPHYS ACTA, V996, P153, DOI 10.1016/0167-4838(89)90241-0; ROSSI JPFC, 1985, BIOCHIM BIOPHYS ACTA, V816, P379, DOI 10.1016/0005-2736(85)90505-X; SCHATZMANN HJ, 1989, ANNU REV PHYSIOL, V51, P473, DOI 10.1146/annurev.ph.51.030189.002353; SORENSON MM, 1986, J MEMBRANE BIOL, V90, P219, DOI 10.1007/BF01870128; SUKI WN, 1979, AM J PHYSIOL, V237, pF1, DOI 10.1152/ajprenal.1979.237.1.F1; TEIXEIRAFERREIR.A, 1989, ARQ BIOL TECNOL, V32, P13; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VIEYRA A, 1986, J BIOL CHEM, V261, P4247; ZOT HG, 1989, J BIOL CHEM, V264, P15552	30	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10249	10253						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1828069				2022-12-25	WOS:A1991FP08600041
J	VIEYRA, A; CARUSONEVES, C; MEYERFERNANDES, JR				VIEYRA, A; CARUSONEVES, C; MEYERFERNANDES, JR			ATP-REVERSIBLE-P-32(I) EXCHANGE CATALYZED BY PLASMA-MEMBRANE CA2+-ATPASE FROM KIDNEY PROXIMAL TUBULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM VESICLES; (CA-2+ + MG-2+)-ATPASE; ACTIVE ORGANIC SOLUTES; RENAL INNER MEDULLA; ADENOSINE-TRIPHOSPHATASE; CALCIUM-PUMP; ATP SYNTHESIS; ION-TRANSPORT; CONCENTRATION GRADIENT; PROTEIN STABILIZATION	The Ca2+-stimulated adenosine 5'-triphosphate-or-thophosphate (ATP arrow point right over arrow pointing left P-32i) exchange reaction was studied using a vesicular preparation derived from plasma membrane of kidney proximal tubules. With native inside-out vesicles, ATP arrow pointing right over arrow pointing left P-32i was stimulated by micromolar Ca2+ concentrations. Treatment of the vesicles with the Ca2+ ionophore A23187 that abolished Ca2+ accumulation, strongly inhibited ATP arrow pointing right over arrow pointing left P-32i. When Ca2+-ATPase was solubilized with the nonionic detergent octaethylene glycol mono n-dodecyl ether, maximal activation of ATP arrow pointing right over arrow pointing left P-32i required millimolar Ca2+ concentrations. These Ca2+ concentrations inhibited ATP hydrolysis. ATP arrow pointing right over arrow pointing left P-32i exhibited a Michaelian dependence on Pi and Mg2+, was stimulated by ATP, and depended on the ATP/ADP ratio. ATP arrow pointing right over arrow pointing left P-32i was modified by the osmolytes urea, trimethylamine-N-oxide, and sucrose, which are representative of the methylamines and polyols that normally accumulate in renal tissue. These compounds did not modify the apparent affinity for Pi; they affected the response to ADP in the same fashion as the overall rate of ATP arrow pointing right over arrow pointing left P-32i, and their effects depended on medium pH. These data show that theCa2+-ATPase from plasma membrane kidney proximal tubules can operate simultaneously in forward and backward directions. They also show that ATP arrow pointing right over arrow pointing left P-32i is modulated by the ligands Ca2+, ATP, ADP, P(i), Mg2+, and H+, and by organic solutes found in renal tissue.	UNIV ESTADO RIO DE JANEIRO,DEPT BIOL CELULAR & GENET,RIO DE JANEIRO,BRAZIL	Universidade do Estado do Rio de Janeiro	VIEYRA, A (corresponding author), UNIV FED RIO DE JANEIRO,INST CIENCIAS BIOMED,DEPT BIOQUIM MED,POB 68041,BR-21910 RIO DE JANEIRO,BRAZIL.		Caruso-Neves, Celso/C-4014-2013	Caruso-Neves, Celso/0000-0002-2415-7753				BAGNASCO S, 1986, J BIOL CHEM, V261, P5872; BALABAN RS, 1987, KIDNEY INT, V31, P562, DOI 10.1038/ki.1987.36; BALABAN RS, 1983, AM J PHYSIOL, V245, pC439, DOI 10.1152/ajpcell.1983.245.5.C439; BALABAN RS, 1982, BIOCH KIDNEY FUNCTIO, P337; BOYER PD, 1967, METHOD ENZYMOL, V10, P60; CHIESI M, 1984, BIOCHEMISTRY-US, V23, P2595, DOI 10.1021/bi00307a009; de Meis L, 1974, Biochemistry, V13, P5032, DOI 10.1021/bi00721a026; DEMEIS L, 1989, BIOCHIM BIOPHYS ACTA, V973, P333, DOI 10.1016/S0005-2728(89)80440-2; DEMEIS L, 1988, J BIOL CHEM, V263, P157; DEMEIS L, 1975, BIOCHEMISTRY-US, V14, P2739, DOI 10.1021/bi00683a028; DEMEIS L, 1982, J BIOL CHEM, V257, P1289; DEMORAES VLG, 1982, BIOCHIM BIOPHYS ACTA, V688, P131, DOI 10.1016/0005-2736(82)90587-9; DESMEDT H, 1981, FEBS LETT, V131, P60, DOI 10.1016/0014-5793(81)80887-3; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FELDHAUS P, 1975, EUR J BIOCHEM, V57, P197, DOI 10.1111/j.1432-1033.1975.tb02291.x; FRIEDMAN PA, 1981, AM J PHYSIOL, V240, pF558, DOI 10.1152/ajprenal.1981.240.6.F558; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4667, DOI 10.1021/bi00519a023; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4677, DOI 10.1021/bi00519a024; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GMAJ P, 1982, FEBS LETT, V144, P226, DOI 10.1016/0014-5793(82)80643-1; GMAJ P, 1983, EUR J BIOCHEM, V136, P71, DOI 10.1111/j.1432-1033.1983.tb07706.x; GMAJ P, 1979, BIOCHEM J, V178, P549, DOI 10.1042/bj1780549; GULLANS SR, 1988, AM J PHYSIOL, V255, pF626, DOI 10.1152/ajprenal.1988.255.4.F626; INESI G, 1980, J BIOL CHEM, V255, P3025; JOHNSON EA, 1985, P NATL ACAD SCI USA, V82, P5352, DOI 10.1073/pnas.82.16.5352; JORGEGARCIA I, 1988, ARCH BIOCHEM BIOPHYS, V265, P82, DOI 10.1016/0003-9861(88)90373-6; KHANANSHVILI D, 1988, BIOCHEMISTRY-US, V27, P2943, DOI 10.1021/bi00408a041; KINNESAF.E, 1974, J MEMBRANE BIOL, V17, P263, DOI 10.1007/BF01870187; LOWENSTEIN JM, 1958, BIOCHEM J, V70, P222, DOI 10.1042/bj0700222; MAKINOSE M, 1971, FEBS LETT, V12, P271, DOI 10.1016/0014-5793(71)80196-5; MASHINO T, 1987, ARCH BIOCHEM BIOPHYS, V258, P356, DOI 10.1016/0003-9861(87)90355-9; MASOLIVA J, 1983, BIOCHEMISTRY-US, V22, P5822; MORGADO E, 1981, BRAZ J MED BIOL RES, V15, P85; NOZAKI Y, 1963, J BIOL CHEM, V238, P4074; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PITTS RF, 1974, PHYSL KIDNEY BODY FL, P71; POST RL, 1975, J BIOL CHEM, V250, P691; RACKER E, 1972, J BIOL CHEM, V247, P8198; RATKJE SK, 1980, BIOPHYS J, V30, P523, DOI 10.1016/S0006-3495(80)85112-5; ROBINSON DR, 1963, J BIOL CHEM, V238, P1558; SCHATZMANN HJ, 1989, ANNU REV PHYSIOL, V51, P473, DOI 10.1146/annurev.ph.51.030189.002353; SCOFANO HM, 1981, J BIOL CHEM, V256, P4282; Somero G. N., 1986, NEWS PHYSIOL SCI, V1, P9; SOMERO GN, 1986, AM J PHYSIOL, V251, pR197, DOI 10.1152/ajpregu.1986.251.2.R197; SORENSON MM, 1980, J MEMBRANE BIOL, V53, P1, DOI 10.1007/BF01871168; STAHL N, 1987, BIOCHEMISTRY-US, V26, P7654, DOI 10.1021/bi00398a019; SUKI WN, 1979, AM J PHYSIOL, V237, pF1, DOI 10.1152/ajprenal.1979.237.1.F1; TANFORD C, 1984, CRC CR REV BIOCH MOL, V17, P123, DOI 10.3109/10409238409113603; TANFORD C, 1983, ANNU REV BIOCHEM, V52, P379, DOI 10.1146/annurev.bi.52.070183.002115; TAYLOR A, 1979, AM J PHYSIOL, V236, pF505, DOI 10.1152/ajprenal.1979.236.6.F505; TROTTA EE, 1978, J BIOL CHEM, V253, P7821; VIEYRA A, 1985, ARCH BIOCHEM BIOPHYS, V238, P574, DOI 10.1016/0003-9861(85)90202-4; VIEYRA A, 1986, J BIOL CHEM, V261, P4247; VIEYRA A, 1989, METH SURV I, V19, P31; WUTHRICH A, 1979, EXPERIENTIA, V35, P1589; YANCEY PH, 1980, J EXP ZOOL, V212, P205, DOI 10.1002/jez.1402120207; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	57	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10324	10330						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1828070				2022-12-25	WOS:A1991FP08600053
J	SPIRO, MJ; SPIRO, RG				SPIRO, MJ; SPIRO, RG			POTENTIAL REGULATION OF N-GLYCOSYLATION PRECURSOR THROUGH OLIGOSACCHARIDE-LIPID HYDROLASE ACTION AND GLUCOSYLTRANSFERASE-GLUCOSIDASE SHUTTLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; THYROID ENDOPLASMIC-RETICULUM; GLYCOPROTEIN-BIOSYNTHESIS; CARBOHYDRATE UNITS; PROTEIN-SYNTHESIS; INHIBITORS; RELEASE; SLICES; CHAINS	The potential role of degradative mechanisms in controlling the level of the dolichyl pyrophosphate-linked Glc3Man9GlcNAc2 required for protein N-glycosylation has been explored in thyroid slices and endoplasmic reticulum (ER) vesicles, focusing on cleavage of the oligosaccharide from its lipid attachment and on the enzymatic removal of peripheral monosaccharide residues. Vesicle incubations demonstrated a substantial release of free Glc3Man9GlcNAc2 (at 30 min approximately 35% of that transferred to protein) which was inhibited in the presence of exogenous peptide acceptor and was sensitive to disruption of membrane integrity by detergent. In thyroid slices glucosylated oligosaccharides terminating in the di-N-acetylchitobiose sequence were also noted and these continued to be formed even during inhibition by puromycin of both protein synthesis and the attendant N-glycosylation. These observations indicated that the oligosaccharide originated from the lipid donor and suggested, together with previously reported similarities in substrate specificity and cofactor requirements, that the oligosaccharyltransferase can carry out in vivo both the hydrolytic and transfer functions. In addition to the release of the intact Glc3Man9GlcNAc2, we also obtained evidence that the lipid-linked oligosaccharide can be modified by the in vivo action of ER glycosidases. Since radiolabeling of the oligosaccharide-lipid in thyroid slices indicated a preferential turnover of the glucose residues, the possible existence of a glucosyltransferase-glucosidase shuttle was explored with the use of castanospermine. In the presence of this glucosidase inhibitor, the formation of underglucosylated and nonglucosylated oligosaccharides was not observed, even under conditions of energy deprivation in which they accumulate. Glucosidase inhibition in ER vesicle incubations likewise prevented the appearance of incompletely glucosylated oligosaccharide-lipids. Studies employing the mannosidase inhibitor 1-deoxymannojirimycin in thyroid slices furthermore indicated that in vivo removal of at least one mannose residue from the dolichyl pyrophosphate-linked oligosaccharide can occur.	ELLIOTT P JOSLIN RES LAB, 1 JOSLIN PL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM, BOSTON, MA 02115 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK 17477] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017477] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANUMULA KR, 1983, J BIOL CHEM, V258, P5274; CHALIFOUR RJ, 1988, J BIOL CHEM, V263, P15673; CHALIFOUR RJ, 1984, ARCH BIOCHEM BIOPHYS, V229, P386, DOI 10.1016/0003-9861(84)90166-8; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ELTING JJ, 1980, J BIOL CHEM, V255, P2325; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; GRANT SR, 1983, EUR J BIOCHEM, V134, P575, DOI 10.1111/j.1432-1033.1983.tb07605.x; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; Segrest J P, 1971, Biochem Biophys Res Commun, V44, P390; SCHMITT JW, 1979, J BIOL CHEM, V254, P2291; SPIRO MJ, 1986, J BIOL CHEM, V261, P4725; SPIRO MJ, 1985, J BIOL CHEM, V260, P5808; SPIRO MJ, 1976, J BIOL CHEM, V251, P6400; SPIRO RG, 1982, PHILOS T ROY SOC B, V300, P117, DOI 10.1098/rstb.1982.0160; SPIRO RG, 1983, J BIOL CHEM, V258, P9469; SPIRO RG, 1979, J BIOL CHEM, V254, P7659	19	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					5311	5317						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1825831				2022-12-25	WOS:A1991FC21700092
J	NHIEU, GTV; ISBERG, RR				NHIEU, GTV; ISBERG, RR			THE YERSINIA-PSEUDOTUBERCULOSIS INVASIN PROTEIN AND HUMAN FIBRONECTIN BIND TO MUTUALLY EXCLUSIVE SITES ON THE ALPHA-5-BETA-1 INTEGRIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; EPITHELIAL-CELLS; MAMMALIAN-CELLS; BETA-SUBUNIT; SURFACE; IDENTIFICATION; FAMILY; HETERODIMERS; VITRONECTIN; MOLECULES	The Yersinia pseudotuberculosis invasin protein promotes bacterial penetration into mammalian cells by binding to several beta-1 chain integrins. We show here that proteins containing the cell-binding domain of invasin bind to the fibronectin receptor alpha-5-beta-1 isolated from human placenta and immobilized on a filter membrane. Two forms of the receptor, each having a molecular weight of about 290,000, were immunodepleted by monoclonal antibodies specific for the beta-1 subunit or the alpha-5-beta-1 heterodimer. The binding of invasin to the receptor immobilized on the filter, or to whole JAR cells, reaches saturation after 90 min and has an apparent dissociation constant (K(d)) of 5.0 x 10(-9) M. Invasin binding to alpha-5-beta-1 is inhibited by the 120-kDa chymotryptic fragment of fibronectin in a competitive manner with an inhibition constant (K(i)) of 7.5 x 10(-7) M. Furthermore, invasin-receptor binding is also inhibited by the hexapeptide GRGDSP, and monoclonal antibodies that block cell attachment to invasin-coated surfaces also block cell attachment to fibronectin-coated surfaces. These results indicate that invasin and fibronectin bind to the same, or closely located sites on alpha-5-beta-1, although invasin binds with a much higher affinity than does fibronectin.	TUFTS UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02111	Howard Hughes Medical Institute; Tufts University	NHIEU, GTV (corresponding author), TUFTS UNIV,SCH MED,DEPT MICROBIOL & MOLEC BIOL,BOSTON,MA 02111, USA.		Van Nhieu, Guy Tran/Y-6359-2018	Van Nhieu, Guy Tran/0000-0002-3901-2186	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023538] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI23538] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BODARY SC, 1990, J BIOL CHEM, V265, P5938; BRASAEMLE DL, 1988, BIOTECHNIQUES, V6, P418; BRYAN JK, 1977, ANAL BIOCHEM, V78, P513, DOI 10.1016/0003-2697(77)90111-7; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FINLAY BB, 1988, MOL MICROBIOL, V2, P757, DOI 10.1111/j.1365-2958.1988.tb00087.x; FLOCK JI, 1987, EMBO J, V6, P2351, DOI 10.1002/j.1460-2075.1987.tb02511.x; FORMAL SB, 1983, REV INFECT DIS, V5, pS702; FRELINGER AL, 1990, J CELL BIOL, V110, P2175; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1989, J BIOL CHEM, V264, P6529; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; ISBERG RR, 1985, NATURE, V317, P262, DOI 10.1038/317262a0; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; LARJAVA H, 1990, J CELL BIOL, V110, P803, DOI 10.1083/jcb.110.3.803; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MILLER VL, 1988, INFECT IMMUN, V56, P1242, DOI 10.1128/IAI.56.5.1242-1248.1988; MOULDER JW, 1985, MICROBIOL REV, V49, P298, DOI 10.1128/MMBR.49.3.298-337.1985; PAYNE NR, 1987, J EXP MED, V166, P1377, DOI 10.1084/jem.166.5.1377; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; RELMAN D, 1990, CELL, V61, P1375, DOI 10.1016/0092-8674(90)90701-F; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RUSSELL DG, 1988, J EXP MED, V168, P279, DOI 10.1084/jem.168.1.279; SANSONETTI PJ, 1986, INFECT IMMUN, V51, P461, DOI 10.1128/IAI.51.2.461-469.1986; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; TAKADA Y, 1987, P NATL ACAD SCI USA, V84, P3239, DOI 10.1073/pnas.84.10.3239; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDEWATER L, 1983, SCIENCE, V220, P201, DOI 10.1126/science.6338594; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881	38	93	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24367	24375						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1837020				2022-12-25	WOS:A1991GW84500023
J	CARLES, C; TREICH, I; BOUET, F; RIVA, M; SENTENAC, A				CARLES, C; TREICH, I; BOUET, F; RIVA, M; SENTENAC, A			2 ADDITIONAL COMMON SUBUNITS, ABC10-ALPHA AND ABC10-BETA, ARE SHARED BY YEAST RNA-POLYMERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBODIES; PROTEINS; GENE	Yeast nuclear RNA polymerases are multisubunit enzymes that contain in common some small subunits. We show that the smallest, a 10-kDa component of three enzymes (A10, B10, and C10), is heterogeneous. In each case, it can be resolved into two distinct polypeptides (alpha and beta) by reverse-phase chromatography. A10-alpha, B10-alpha, and C10-alpha were indistinguishable on the basis of their electrophoretic and chromatographic behaviors, characteristic silver staining, and tryptic peptide analysis. All three polypeptides are blocked at their amino termini. By the same criteria, A10-beta, B10-beta, and C10-beta were also indistinguishable. The amino-terminal sequence of A10-beta and C10-beta corresponded to that of subunit B10 recently cloned by Woychik and Young (Woychik, N. A., and Young, R. A. (1990) J. Biol. Chem. 265, 17816-17819). Thus, the three forms of RNA polymerase share two additional and distinct polypeptides, ABC10-alpha and ABC10-beta, that therefore can be considered bona fide subunits of these enzymes. Interestingly, these two subunits bind zinc.	CENS,INGN PROT LAB,F-91191 GIF SUR YVETTE,FRANCE	CEA	CARLES, C (corresponding author), CENS,SERV BIOCHIM & GENET MOLEC,F-91191 GIF SUR YVETTE,FRANCE.							BREANT B, 1983, J BIOL CHEM, V258, P1968; BUHLER JM, 1976, J BIOL CHEM, V251, P1712; BUHLER JM, 1974, J BIOL CHEM, V249, P5963; DEQUARDCHABLAT M, 1991, J BIOL CHEM, V266, P15300; DEZELEE S, 1982, FEBS LETT, V257, P2613; HUET J, 1985, J BIOL CHEM, V260, P5304; JAMES P, 1991, J BIOL CHEM, V266, P5616; KOLODZIEJ P, 1989, MOL CELL BIOL, V9, P5387, DOI 10.1128/MCB.9.12.5387; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANN C, 1987, CELL, V48, P627, DOI 10.1016/0092-8674(87)90241-8; MEMET S, 1988, J BIOL CHEM, V263, P2830; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PATI UK, 1989, J BIOL CHEM, V264, P13114; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; SWENDSEN PJ, 1980, J BIOCHEM BIOPH METH, V3, P97; TREICH I, 1991, J BIOL CHEM, V266, P21971; TREICH I, UNPUB; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313; WOYCHIK NA, 1990, J BIOL CHEM, V265, P17818; YANO R, 1991, MOL CELL BIOL, V11, P754, DOI 10.1128/MCB.11.2.754	21	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					24092	24096						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748681				2022-12-25	WOS:A1991GV31900087
J	PREISER, PR; LEVINGER, LF				PREISER, PR; LEVINGER, LF			DROSOPHILA 5-S RNA PROCESSING REQUIRES THE 1-118 BASE PAIR AND ADDITIONAL SEQUENCE PROXIMAL TO THE PROCESSING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5S RIBOSOMAL-RNA; DNA; POLYMERASE; TRANSCRIPTION; PRECURSOR; YEAST; ENDONUCLEASE; MUTAGENESIS; TEMPLATES; BINDING	Using an in vitro processing system, we have identified a required sequence surrounding the Drosophila melanogaster 5 S RNA processing site at nucleotide 120. Mutations in this region vary the processing rate from complete inhibition to a level equal to or greater than wild type. Analysis of mutants at +1 and in the region 118-122 separates the inhibitory effect into two parts. 1) Nucleotide 118 C, the base-paired nucleotide in helix I proximal to the processing site, plays an essential role. Changing it to a purine inhibits processing. The +1-118 base pair must be intact, but this alone is not sufficient for processing, since compensatory changes at +1 do not restore down-processing mutants at 118 to the wild type level. 2) The processing site has to be pyrimidine rich; multiple contiguous purines inhibit processing. On the other hand, multiple pyrimidines can largely negate the inhibitory effect of a mutation at position 118. Thus a base-paired C at 118 followed by a stretch of pyrimidines is the processing signal, which may be recognized by the processing enzyme and/or a required accessory factor.	UNIV DELAWARE, SCH LIFE & HLTH SCI, NEWARK, DE 19716 USA	University of Delaware	LEVINGER, LF (corresponding author), WORCESTER FDN EXPTL BIOL INC, SHREWSBURY, MA 01545 USA.		Preiser, Peter R/A-2201-2011	, Peter/0000-0003-4331-7000	NIGMS NIH HHS [GM08153] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOROS I, 1984, GENE, V30, P257, DOI 10.1016/0378-1119(84)90130-6; BROW DA, 1987, J BIOL CHEM, V262, P13959; DINGERMANN T, 1981, NUCLEIC ACIDS RES, V9, P3907, DOI 10.1093/nar/9.16.3907; ENGELKE DR, 1990, ANAL BIOCHEM, V191, P396, DOI 10.1016/0003-2697(90)90238-5; ESCHALIER G, 1970, IN VITRO, V6, P162; GARRETT RA, 1981, TRENDS BIOCHEM SCI, V6, P137, DOI 10.1016/0968-0004(81)90051-7; HAMADA H, 1979, CELL, V17, P163, DOI 10.1016/0092-8674(79)90304-0; Hardesty B., 1986, STRUCTURE FUNCTION G; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; JACQ B, 1977, J MOL BIOL, V117, P785, DOI 10.1016/0022-2836(77)90069-9; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIM HM, 1988, GENE ANAL TECH, V5, P32, DOI 10.1016/0735-0651(88)90024-6; Maniatis T., 1982, MOL CLONING; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PIPER PW, 1983, EMBO J, V2, P353, DOI 10.1002/j.1460-2075.1983.tb01430.x; PIPER PW, 1984, EUR J BIOCHEM, V141, P115, DOI 10.1111/j.1432-1033.1984.tb08165.x; PREISER PR, 1991, J BIOL CHEM, V266, P7509; PRICE DH, 1987, J BIOL CHEM, V262, P3244; RINKE J, 1982, CELL, V29, P149, DOI 10.1016/0092-8674(82)90099-X; RUBIN GM, 1975, CELL, V6, P207, DOI 10.1016/0092-8674(75)90011-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMMONS DT, 1990, J VIROL, V64, P1973, DOI 10.1128/JVI.64.5.1973-1983.1990; STAHL DA, 1980, P NATL ACAD SCI-BIOL, V77, P5644, DOI 10.1073/pnas.77.10.5644; STAHL DA, 1984, J BIOL CHEM, V259, P1448; TEKAMP PA, 1980, J BIOL CHEM, V255, P9501; XING YY, 1989, GENE DEV, V3, P1008, DOI 10.1101/gad.3.7.1008	27	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23602	23605						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748637				2022-12-25	WOS:A1991GV31900015
J	SNOUWAERT, JN; LEEBEEK, FWG; FOWLKES, DM				SNOUWAERT, JN; LEEBEEK, FWG; FOWLKES, DM			ROLE OF DISULFIDE BONDS IN BIOLOGIC ACTIVITY OF HUMAN INTERLEUKIN-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY STIMULATING FACTOR; HUMAN IL-6; RECEPTORS; RADIOACTIVITIES; DIFFERENTIATION; MUTAGENESIS; DELETION; PROTEIN; MUTANTS; CELLS	We have examined the functional importance of the two disulfide bonds formed by the four conserved cysteines of human interleukin (IL-6). Using a bacterial expression system, we have synthesized a series of recombinant IL-6 mutants in which the constituent cysteines of the first (Cys45-Cys51), second (Cys74-Cys84), or both disulfide bonds of recombinant human interleukin-6 were replaced by other amino acids. Each mutant was partially purified and tested in four representative bioassays. While mutants lacking Cys45 and Cys51 retained activity similar to nonmutated recombinant IL-6, the activity of mutants lacking Cys74 and Cys84 was significantly reduced, especially in assays involving human cell lines. These results indicate that the first disulfide bond of human interleukin-6 is not required for maintenance of normal biologic activity. However, the fact that mutants lacking CyS45 and Cys51 were more active than corresponding cysteine-free mutants indicates that the disulfide bond formed by these residues contributes to biologic activity in the absence of the second disulfide bond. Competition binding studies with representative mutants indicate that their affinity for the human IL-6 receptor parallels their biologic activities on human cells.	UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NHLBI NIH HHS [HL31012] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031012, R23HL031012] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; BRAKENHOFF JPJ, 1987, J IMMUNOL, V139, P4116; BRAKENHOFF JPJ, 1989, J IMMUNOL, V143, P1175; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CLOGSTON CL, 1989, ARCH BIOCHEM BIOPHYS, V272, P144, DOI 10.1016/0003-9861(89)90205-1; COULIE PG, 1989, EUR J IMMUNOL, V19, P2107, DOI 10.1002/eji.1830191121; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; GEIGER T, 1988, EUR J BIOCHEM, V175, P181, DOI 10.1111/j.1432-1033.1988.tb14181.x; GREENSTEIN D, 1989, CURRENT PROTOCOLS MO; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; JAMBOU RC, 1988, P NATL ACAD SCI USA, V139, P4116; JONES DH, 1990, BIOTECHNIQUES, V8, P178; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KOEFFLER HP, 1983, BLOOD, V62, P709; KRUTTGEN A, 1990, FEBS LETT, V262, P323, DOI 10.1016/0014-5793(90)80219-9; KRUTTGEN A, 1990, FEBS LETT, V273, P93; LIN SH, 1984, BIOCHEMISTRY-US, V23, P5504, DOI 10.1021/bi00318a019; LU HS, 1989, ARCH BIOCHEM BIOPHYS, V268, P81, DOI 10.1016/0003-9861(89)90567-5; MATSUDA T, 1989, J IMMUNOL, V142, P148; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ONOZAKI K, 1989, CANCER RES, V49, P3602; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P14; SEHGAL PB, 1990, MOL BIOL MED, V7, P117; SIMPSON RJ, 1988, BIOCHEM BIOPH RES CO, V157, P364, DOI 10.1016/S0006-291X(88)80056-1; SNOUWAERT JN, 1991, J IMMUNOL, V146, P585; TAGA T, 1987, J EXP MED, V166, P967, DOI 10.1084/jem.166.4.967; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WOLVEKAMP MCJ, 1990, IMMUNOL LETT, V24, P1, DOI 10.1016/0165-2478(90)90028-O	31	29	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23097	23102						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744107				2022-12-25	WOS:A1991GT48300051
J	HOYT, DW; CYR, DM; GIERASCH, LM; DOUGLAS, MG				HOYT, DW; CYR, DM; GIERASCH, LM; DOUGLAS, MG			INTERACTION OF PEPTIDES CORRESPONDING TO MITOCHONDRIAL PRESEQUENCES WITH MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F1-ATPASE BETA-SUBUNIT; PROTEIN IMPORT; PRECURSOR PROTEINS; YEAST MITOCHONDRIA; SIGNAL PEPTIDES; TARGETING FUNCTION; ESCHERICHIA-COLI; INNER MEMBRANE; BLOCKS IMPORT; SEQUENCES	The transport of the F1-ATPase beta-subunit precursor into mitochondria is dependent upon a presequence at its amino terminus. Within the mitochondrial membrane translocation site the potential amphiphilic character of the presequence region may be necessary to stabilize binding to the mitochondrial inner membrane. To better understand its role in protein import, the interaction of the F1-beta-presequence with lipid membranes was measured using circular dichroism and surface tensiometry. These studies reveal that a 20-residue peptide containing the F1-beta-presequence binds to phospholipid vesicles (K(d) = 4.5-6.0 x 10(-8) M) and adopts a predominantly alpha-helical structure. Although the presequence peptide binds avidly to lipids, it does not appear to penetrate deeply into the bilayer to perturb a reporter probe in the membrane interior. Compared with the effect of the peptides with demonstrated membrane insertion and lytic properties, the F1-beta-presequence appears to displace phospholipid head groups but not insert deeply into the bilayer. High concentrations (> 50-mu-M) of presequence peptides are required to noticibly perturb import of the full length F1-alpha- or F1-beta-subunit precursors. Thus, the F1-beta-presequence alone is not sufficient to efficiently compete for import but may require a protein context or a minimal length to assist insertion into the transport site. These observations are discussed in light of the different requirements for import of various presequence containing precursors into mitochondria.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Hoyt, David/H-6295-2013; Gierasch, Lila M/D-1494-2009	Hoyt, David/0000-0002-2857-719X; Cyr, Douglas/0000-0002-4928-3414	NIGMS NIH HHS [GM36537, GM26713, GM34962] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026713, R01GM036537, R01GM034962] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON AW, 1976, PHYSICAL CHEM SURFAC, P176; ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; AMES BN, 1960, J BIOL CHEM, V235, P769; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BEDWELL DM, 1989, MOL CELL BIOL, V9, P1014, DOI 10.1128/MCB.9.3.1014; BEDWELL DM, 1987, MOL CELL BIOL, V7, P4038, DOI 10.1128/MCB.7.11.4038; BILBUS C, 1988, J BIOL CHEM, V263, P13097; BRIGGS MS, 1985, SCIENCE, V228, P1096, DOI 10.1126/science.3158076; BRIGGS MS, 1986, SCIENCE, V233, P206, DOI 10.1126/science.2941862; BRIGGS MS, 1984, BIOCHEMISTRY-US, V23, P3111, DOI 10.1021/bi00309a001; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHEN WJ, 1987, J BIOL CHEM, V262, P15598; CHEN WJ, 1987, CELL, V49, P651, DOI 10.1016/0092-8674(87)90541-1; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CYR DM, 1991, J BIOL CHEM, V266, P21700; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DOUGLAS MG, 1991, INTRACELLULAR TRAFFI, P658; EILERS M, 1987, EMBO J, V6, P1073, DOI 10.1002/j.1460-2075.1987.tb04860.x; EILERS M, 1989, J BIOL CHEM, V264, P2945; ENDO T, 1988, EMBO J, V7, P1153, DOI 10.1002/j.1460-2075.1988.tb02925.x; GASSER SM, 1982, J BIOL CHEM, V257, P3034; GILLESPIE LL, 1985, J BIOL CHEM, V260, P6045; GLASER SM, 1990, J BIOL CHEM, V265, P8808; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HOYT DW, 1987, PEPTIDES 1986, P373; HUANG CH, 1969, BIOCHEMISTRY-US, V8, P344, DOI 10.1021/bi00829a048; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; ITO A, 1985, J BIOCHEM-TOKYO, V98, P1571, DOI 10.1093/oxfordjournals.jbchem.a135426; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; LEMIRE BD, 1989, J BIOL CHEM, V264, P20206; LENTZ BR, 1989, CHEM PHYS LIPIDS, V50, P171, DOI 10.1016/0009-3084(89)90049-2; Maniatis T., 1982, MOL CLONING; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MCKNIGHT CJ, 1989, J BIOL CHEM, V264, P17293; Miller JH., 1972, EXPT MOL GENETICS; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; MURAKAMI K, 1990, EMBO J, V9, P3201, DOI 10.1002/j.1460-2075.1990.tb07518.x; MYERS M, 1987, BIOCHEMISTRY-US, V26, P4309, DOI 10.1021/bi00388a019; OHTA S, 1984, EMBO J, V4, P1129; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; SALTZGABERMULLER J, 1983, J BIOL CHEM, V258, P1465; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SEGRIST J, 1990, PROTEIN-STRUCT FUNCT, V8, P108; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SPERKAGOTTLIEB C, 1989, ARCH BIOCHEM BIOPHYS, V271, P471; Stewart JM, 1984, SOLID PHASE PEPTIDE; TAKEDA M, 1986, J BIOL CHEM, V261, P1516; TAMM LK, 1986, BIOCHEMISTRY-US, V25, P7470, DOI 10.1021/bi00371a032; TZAGOLOFF A, 1982, MITOCHONDRIA, P30; VASSAROTTI A, 1987, J BIOL CHEM, V261, P411; VERNER K, 1989, EMBO J, V8, P1491, DOI 10.1002/j.1460-2075.1989.tb03533.x; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WALKER ME, 1990, BIOCHEM J, V266, P227, DOI 10.1042/bj2660227	63	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21693	21699						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1834660				2022-12-25	WOS:A1991GP80400057
J	TRUGNAN, G; OGIERDENIS, E; SAPIN, C; DARMOUL, D; BAUVY, C; AUBERY, M; CODOGNO, P				TRUGNAN, G; OGIERDENIS, E; SAPIN, C; DARMOUL, D; BAUVY, C; AUBERY, M; CODOGNO, P			THE N-GLYCAN PROCESSING IN HT-29 CELLS IS A FUNCTION OF THEIR STATE OF ENTEROCYTIC DIFFERENTIATION - EVIDENCE FOR AN ATYPICAL TRAFFIC ASSOCIATED WITH CHANGE IN POLYPEPTIDE STABILITY IN UNDIFFERENTIATED HT-29 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; COLON CANCER-CELLS; GLYCOPROTEIN-BIOSYNTHESIS; ENDOPLASMIC-RETICULUM; ALPHA-MANNOSIDASE; GOLGI-COMPLEX; LINE HT-29; PROTEIN; DEGRADATION; INHIBITION	When the human colon cancer cells HT-29 undergo enterocytic differentiation, they correctly process their N-glycans, whereas their undifferentiated counterpart are unable to process Man9-8-GlcNAc2 species, the natural substrate of alpha-mannosidase I. As this enzyme is fully active in both HT-29 cell populations, we hypothesize that N-glycoproteins are unable to reach the cis Golgi, the site where alpha-mannosidase I has been localized. We have demonstrated this point by using 1-deoxymannojirimycin, leupeptin, and monensin. In the presence of 1-deoxymannojirimycin, a specific inhibitor of alpha-mannosidase I, differentiated HT-29 cells, as expected, accumulate Man9-8-GlcNAC2 species, whereas in undifferentiated HT-29 cells these compounds continue to be rapidly degraded. In contrast, the use of leupeptin, a specific inhibitor of thiol and serine proteases, leads to the accumulation of these oligosaccharides in undifferentiated HT-29 cells. Monensin, a carboxylic ionophore that perturbs distal Golgi functions, is unable to stabilize these compounds. Therefore, we conclude that N-linked glycoproteins in undifferentiated HT-29 cells rapidly egress from the exocytic pathway to a leupeptin-sensitive degradative compartment without entering a monensin-sensitive compartment. These results favor the hypothesis that a direct pathway should exist between the rough endoplasmic reticulum and a leupeptin-sensitive degradative compartment in undifferentiated HT-29 cells. The emergence of this new pathway could explain why protein stability and N-glycan processing may vary as a function of the state of cell differentiation.	UFR BIOMED ST PERES,INSERM,U180,UNITE RECH BIOL & PATHOL MOLEC GLYOPROT,45 RUE ST PERES,F-75006 PARIS,FRANCE; INSERM,U178,UNITE RECH DIFFERENCIAT & NEUROENDOCRINOL CELLULES DIGEST,F-94807 VILLEJUIF,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			Darmoul, Dalila/M-5812-2018; Ogier-Denis, Eric/E-5030-2016; Codogno, Patrice/G-1384-2013	Darmoul, Dalila/0000-0002-1206-0655; Codogno, Patrice/0000-0002-5492-3180; Ogier-Denis, Eric/0000-0002-0057-7593				AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BAINTON D, 1981, J CELL BIOL, V91, P66; BISCHOFF J, 1984, BIOCHEM BIOPH RES CO, V125, P324, DOI 10.1016/S0006-291X(84)80371-X; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; DANIELSEN EM, 1989, J BIOL CHEM, V264, P13726; DORLING PR, 1980, BIOCHEM J, V191, P649, DOI 10.1042/bj1910649; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; HERSCOVICS A, 1987, ANAL BIOCHEM, V166, P85, DOI 10.1016/0003-2697(87)90550-1; KOCOUREK J, 1969, J BACTERIOL, V100, P1175, DOI 10.1128/JB.100.3.1175-1181.1969; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LIBBY P, 1978, SCIENCE, V199, P534, DOI 10.1126/science.622552; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; OGIERDENIS E, 1989, J CELL BIOCHEM, V41, P13, DOI 10.1002/jcb.240410103; OGIERDENIS E, 1988, J BIOL CHEM, V263, P6031; OGIERDENIS E, 1990, J BIOL CHEM, V265, P5366; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PINTO M, 1982, BIOL CELL, V44, P193; REITZER LJ, 1979, J BIOL CHEM, V254, P2669; ROMERO PA, 1985, BIOCHEM J, V226, P733, DOI 10.1042/bj2260733; ROMERO PA, 1986, J BIOL CHEM, V261, P5936; ROTHMAN JE, 1984, J CELL BIOL, V99, P248, DOI 10.1083/jcb.99.1.248; ROTHMAN JE, 1984, J CELL BIOL, V99, P260, DOI 10.1083/jcb.99.1.260; SPIRO RG, 1983, J BIOL CHEM, V258, P9469; TABAS I, 1979, J BIOL CHEM, V254, P1655; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TARTAKOFF AM, 1977, J EXP MED, V146, P1332, DOI 10.1084/jem.146.5.1332; TRUGNAN G, 1987, J CELL BIOL, V104, P1199, DOI 10.1083/jcb.104.5.1199; TRUGNAN G, 1990, GLYCOBIOLOGY, P127; TULSIANI DRP, 1982, J BIOL CHEM, V257, P3660; TULSIANI DRP, 1982, J BIOL CHEM, V257, P7936; UMEZAWA H, 1977, PROTEINASES MAMMALIA, P637; WICE BM, 1985, J BIOL CHEM, V260, P139; ZWEIBAUM A, 1985, J CELL PHYSIOL, V122, P21, DOI 10.1002/jcp.1041220105	40	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20849	20855						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1834650				2022-12-25	WOS:A1991GN00100042
J	NORAIS, N; PROME, D; VELOURS, J				NORAIS, N; PROME, D; VELOURS, J			ATP SYNTHASE OF YEAST MITOCHONDRIA - CHARACTERIZATION OF SUBUNIT-D AND SEQUENCE-ANALYSIS OF THE STRUCTURAL GENE ATP7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ADENOSINE-TRIPHOSPHATASE COMPLEX; SENSITIVITY-CONFERRING PROTEIN; SACCHAROMYCES-CEREVISIAE; DEFICIENT MUTANTS; ESCHERICHIA-COLI; H+-ATPASE; MEMBRANE; DNA; TRANSFORMATION	The subunit analogous to the d-subunit of ATP synthase from bovine heart mitochondria was isolated from the purified yeast enzyme. Partial protein sequences were determined by direct methods. From this information, two oligonucleotide probes were constructed and used for screening a DNA genomic bank of Saccharomyces cerevisiae. The sequence of yeast subunit d was deduced from the DNA sequence of ATP7 gene. Mature yeast subunit d is 173 amino acids long. Its NH2-terminal serine is blocked by an N-acetyl group, and the protein has no processed NH2-terminal sequence other than the removal of the initiator methionine. The protein is predominantly hydrophilic. The amino acid sequence is 22% identical and 44% homologous to bovine subunit d. A null mutant was constructed. The mutant strain was unable to grow on glycerol medium. The mutant mitochondria had no detectable oligomycin-sensitive ATPase activity, and the catalytic sector F1 was loosely bound to the membranous part. The mutant mitochondria did not contain subunit d, and the mitochondrially encoded hydrophobic subunit 6 was not present.	UNIV BORDEAUX 2,CNRS,INST BIOCHIM CELLULAIRE & NEUROCHIM,1 RUE CAMILLE ST SAENS,F-33077 BORDEAUX,FRANCE; CNRS,CTR RECH BIOCHIM & GENET CELLULAIRES,F-31062 TOULOUSE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS)								ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626; AGGELER R, 1990, J BIOL CHEM, V265, P16389; ANSORGE W, 1983, ELECTROPHORESIS, V82, P235; ARENDS H, 1984, EMBO J, V3, P377, DOI 10.1002/j.1460-2075.1984.tb01815.x; ARSELIN G, 1991, J BIOL CHEM, V266, P723; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; BOUILLAUD F, 1986, J BIOL CHEM, V261, P1487; DAYOFF MO, 1983, METHOD ENZYMOL, V91, P524; DECHATEAUBODEAU GA, 1976, BIOCHIMIE PARIS, V58, P601; EBNER E, 1973, J BIOL CHEM, V248, P5379; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; GAROFF H, 1981, ANAL BIOCHEM, V115, P450, DOI 10.1016/0003-2697(81)90031-2; HADIKUSUMO RG, 1984, BIOCHIM BIOPHYS ACTA, V765, P258, DOI 10.1016/0005-2728(84)90164-6; HADIKUSUMO RG, 1988, BIOCHIM BIOPHYS ACTA, V933, P212, DOI 10.1016/0005-2728(88)90072-2; HARE PE, 1988, METHODS PROTEIN SEQU, P2; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HIGUTI T, 1988, J BIOL CHEM, V263, P6772; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOPPE J, 1980, EUR J BIOCHEM, V107, P57, DOI 10.1111/j.1432-1033.1980.tb04624.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANEHISA M, 1982, NUCLEIC ACIDS RES, V10, P183, DOI 10.1093/nar/10.1.183; LANG B, 1977, ANAL BIOCHEM, V77, P110, DOI 10.1016/0003-2697(77)90295-0; LARDY HA, 1953, J BIOL CHEM, V210, P357; LEE MS, 1988, NUCLEIC ACIDS RES, V16, P8181, DOI 10.1093/nar/16.16.8181; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MATSUBARA H, 1981, J BIOCHEM-TOKYO, V90, P1159, DOI 10.1093/oxfordjournals.jbchem.a133568; MCEWEN JE, 1985, J BACTERIOL, V161, P831, DOI 10.1128/JB.161.3.831-835.1985; NAGLEY P, 1988, TRENDS GENET, V4, P46, DOI 10.1016/0168-9525(88)90066-2; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; ROSE M, 1984, GENE, V29, P113, DOI 10.1016/0378-1119(84)90172-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RYRIE IJ, 1979, BIOCHIM BIOPHYS ACTA, V545, P1, DOI 10.1016/0005-2728(79)90108-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMPSON RJ, 1988, EUR J BIOCHEM, V176, P187, DOI 10.1111/j.1432-1033.1988.tb14267.x; STECK G, 1980, ANAL BIOCHEM, V107, P21, DOI 10.1016/0003-2697(80)90486-8; STONE KL, 1989, TECHNIQUES PROTEIN C, P377; TAKEDA M, 1985, J BIOL CHEM, V260, P5458; TODD RD, 1981, J BIOL CHEM, V256, P6984; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1970, J BIOL CHEM, V245, P1545; UH M, 1990, J BIOL CHEM, V265, P19047; VELOURS J, 1987, EUR J BIOCHEM, V164, P579, DOI 10.1111/j.1432-1033.1987.tb11166.x; VELOURS J, 1984, EMBO J, V3, P207, DOI 10.1002/j.1460-2075.1984.tb01785.x; VELOURS J, 1988, EUR J BIOCHEM, V170, P634; WALKER JE, 1987, J MOL BIOL, V197, P89, DOI 10.1016/0022-2836(87)90611-5; WEBER J, 1984, 3RD EUR BIOEN C A, V3, P377; WRIGHT RM, 1986, J BIOL CHEM, V261, P7183	51	66	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16541	16549						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1832157				2022-12-25	WOS:A1991GD63500051
J	FOSKETT, JK; WONG, D				FOSKETT, JK; WONG, D			FREE CYTOPLASMIC CA2+ CONCENTRATION OSCILLATIONS IN THAPSIGARGIN-TREATED PAROTID ACINAR-CELLS ARE CAFFEINE-SENSITIVE AND RYANODINE-SENSITIVE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CALCIUM-RELEASE CHANNEL; CARDIAC SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; CA-2+ RELEASE; TRISPHOSPHATE RECEPTOR; PLASMA-MEMBRANE; TUMOR PROMOTER; ACTIVATION; INHIBITION	The microsomal Ca-ATPase inhibitor thapsigargin induces in rat salivary acinar cells [Ca2+]i oscillations which, though similar to those activated by agonists, are independent of inositol phosphates or inositol 1,4,5-trisphosphate (IP3)-sensitive intracellular Ca2+ stores (Foskett, J. K., Roifman, C., and Wong, D. (1991) J. Biol. Chem. 266, 2778-2782). To examine whether the oscillation mechanism resides in another, thapsigargin- and IP3-insensitive intracellular store, we examined the effects of caffeine and ryanodine, known modulators of Ca2+ release from sarcoplasmic reticulum in excitable cells. Oscillations were induced by caffeine (1-20 mM) in nonoscillating thapsigargin-treated acinar cells, which required the continued presence of caffeine, whereas caffeine was without effect or reduced oscillation amplitude in oscillating cells. Ryanodine (10-50-mu-M) inhibited oscillations in most of the cells. These results suggest that Ca2+ oscillations in parotid acinar cells are driven by periodic Ca2+ release from an IP3-insensitive Ca2+ store with properties similar to sarcoplasmic reticulum of excitable cells.			FOSKETT, JK (corresponding author), HOSP SICK CHILDREN,RES INST,DIV CELL BIOL,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA.		Foskett, Kevin/R-2549-2019	Foskett, J. Kevin/0000-0002-8854-0268				BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; CANNELL MB, 1985, FED PROC, V44, P2964; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FABIATO A, 1985, FED PROC, V44, P2970; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; Foskett J.K., 1990, NONINVASIVE TECHNIQU, P237; FOSKETT JK, 1988, AM J PHYSIOL, V255, pC566, DOI 10.1152/ajpcell.1988.255.4.C566; FOSKETT JK, 1989, P NATL ACAD SCI USA, V86, P167, DOI 10.1073/pnas.86.1.167; FOSKETT JK, 1989, SCIENCE, V244, P1582, DOI 10.1126/science.2500708; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GLITSCH HG, 1975, PFLUG ARCH EUR J PHY, V358, P11, DOI 10.1007/BF00584566; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HAWORTH RA, 1989, CELL CALCIUM, V10, P263, DOI 10.1016/0143-4160(89)90009-2; HERRMANNFRANK A, 1989, J MUSCLE RES CELL M, V10, P437, DOI 10.1007/BF01771819; HOLMBERG SRM, 1990, BIOCHIM BIOPHYS ACTA, V1022, P187, DOI 10.1016/0005-2736(90)90113-3; IINO M, 1988, J GEN PHYSIOL, V152, P417; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P15637; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; KORT AA, 1985, CIRC RES, V57, P844, DOI 10.1161/01.RES.57.6.844; KUBA K, 1980, J PHYSIOL-LONDON, V298, P251, DOI 10.1113/jphysiol.1980.sp013079; KUBA K, 1976, J NEUROPHYSIOL, V39, P547, DOI 10.1152/jn.1976.39.3.547; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LAKATTA EG, 1985, FED PROC, V44, P2977; LIPSCOMBE D, 1988, P NATL ACAD SCI USA, V85, P2398, DOI 10.1073/pnas.85.7.2398; MA J, 1988, SCIENCE, V242, P99, DOI 10.1126/science.2459777; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MARTONOSI AN, 1984, PHYSIOL REV, V64, P1240, DOI 10.1152/physrev.1984.64.4.1240; MARTY A, 1989, J PHYSIOL-LONDON, V419, P665, DOI 10.1113/jphysiol.1989.sp017892; MERRITT JE, 1987, J BIOL CHEM, V262, P17362; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; NELSON TE, 1990, FEBS LETT, V263, P292, DOI 10.1016/0014-5793(90)81396-6; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PAYNE R, 1990, NEURON, V4, P547, DOI 10.1016/0896-6273(90)90112-S; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; PUTNEY JW, 1989, FASEB J, V3, P1899, DOI 10.1096/fasebj.3.8.2542110; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; RASMUSSEN H, 1990, BIOL CHEM H-S, V371, P191; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; ROUSSEAU E, 1988, ARCH BIOCHEM BIOPHYS, V267, P75, DOI 10.1016/0003-9861(88)90010-0; SANCHEZBUENO A, 1990, BIOCHEM J, V268, P627, DOI 10.1042/bj2680627; SCHMID A, 1990, NATURE, V346, P374, DOI 10.1038/346374a0; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WAKUI M, 1990, FEBS LETT, V263, P206, DOI 10.1016/0014-5793(90)81374-W; WIER WG, 1985, FED PROC, V44, P2989; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; ZHAO H, 1990, J BIOL CHEM, V265, P21419	62	95	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14535	14538						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1830587				2022-12-25	WOS:A1991FZ35100067
J	MCGAVIN, MJ; RAUCCI, G; GURUSIDDAPPA, S; HOOK, M				MCGAVIN, MJ; RAUCCI, G; GURUSIDDAPPA, S; HOOK, M			FIBRONECTIN BINDING DETERMINANTS OF THE STAPHYLOCOCCUS-AUREUS FIBRONECTIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; PROTEIN; COLLAGEN; PEPTIDES; GENE	Synthetic peptide analogs mimicking a repeated motif within the Staphylococcus aureus fibronectin receptor inhibit binding of the bacteria to fibronectin (Signas, C., Raucci, G., Jonsson, K., Lindgren, P. E., Anantharamaiah, G. M., Hook, M., and Lindberg, M. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 699-703). In this study, we have further localized the fibronectin-binding determinant within the 37 amino acid D3 peptide. Chemical modification of the carboxyl side chains of the glutamic and aspartic residues in D3 abolished fibronectin-binding activity, whereas modifications of lysine or tyrosine residues had little effect. An active peptide encompassing residues 15-36 was isolated from a trypsin digest of D3, and a synthetic peptide S16-36 had activity comparable with that of intact D3. Scrambling the amino acid sequence of S16-36 or replacing the aspartic and glutamic residues with asparagine and glutamine resulted in loss of activity. Therefore, one or more of the acidic residues are essential for activity. However, additional sequence is required. Reduction in the size of S16-36 from either the N- or C-terminal end resulted in peptides with greatly diminished activity. These data suggest that the amino acids essential for binding fibronectin are contained within residues 21-33 of the D3 peptide and that the flanking N- and C-terminal amino acids are necessary for the peptide to acquire a conformation that is favorable for fibronectin binding.	UNIV ALABAMA,DEPT BIOCHEM,1918 UNIV BLVD,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham				McGavin, Martin/0000-0001-5955-0689	NIAID NIH HHS [AI020624] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020624] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHARYA AS, 1984, J CHROMATOGR, V297, P37, DOI 10.1016/S0021-9673(01)89027-0; AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; CLARK RAF, 1982, J INVEST DERMATOL, V79, P269, DOI 10.1111/1523-1747.ep12500076; DSOUZA SE, 1988, J BIOL CHEM, V263, P3943; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FLOCK JI, 1987, EMBO J, V6, P697; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FROMAN G, 1987, J BIOL CHEM, V262, P6564; GRINNELL F, 1981, J INVEST DERMATOL, V76, P181, DOI 10.1111/1523-1747.ep12525694; Hook M, 1989, FIBRONECTIN, P295; HUNTER W, 1978, HDB EXPT IMMUNOLOGY; KURKINEN M, 1980, LAB INVEST, V43, P47; LOFDAHL S, 1983, P NATL ACAD SCI-BIOL, V80, P697, DOI 10.1073/pnas.80.3.697; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LUNDBLAD RL, 1984, CHEM REAGENTS PROTEI, P105; MOSHER DF, 1980, SCIENCE, V209, P927, DOI 10.1126/science.7403857; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PROCTOR RA, 1982, J BIOL CHEM, V257, P4788; RAJA RH, 1990, INFECT IMMUN, V58, P2593, DOI 10.1128/IAI.58.8.2593-2598.1990; RYDEN C, 1983, J BIOL CHEM, V258, P3396; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; SPEZIALE P, 1984, J BACTERIOL, V157, P420, DOI 10.1128/JB.157.2.420-427.1984	23	56	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8343	8347						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1827119				2022-12-25	WOS:A1991FK44100060
J	MULLINS, LS; LUSTY, CJ; RAUSHEL, FM				MULLINS, LS; LUSTY, CJ; RAUSHEL, FM			ALTERATIONS IN THE ENERGETICS OF THE CARBAMOYL PHOSPHATE SYNTHETASE REACTION BY SITE-DIRECTED MODIFICATION OF THE ESSENTIAL SULFHYDRYL-GROUP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; REVERSIBLE DISSOCIATION; SUBUNIT	The change in reaction energetics of the bicarbonate-dependent ATPase reaction of Escherichia coli carbamoyl phosphate synthetase has been investigated for two site-directed mutations of the essential cysteine in the small subunit. Cysteine 269 has been proposed to facilitate the hydrolysis of glutamine by the formation of a glutamyl-thioester intermediate. The two mutant enzymes, C269S and C269G, along with the isolated large subunit, exhibit a 2-2.6-fold increase in the bicarbonate-dependent ATPase reaction relative to that observed for the wild type enzyme. In the presence of glutamine the overall enhancement is 3.7 and 9.0 for the C269G and C269S mutant enzymes, respectively. Carboxyphosphate is an intermediate in the bicarbonate-dependent ATPase reaction. The cause of the rate enhancements was investigated by measuring the positional isotope exchange rate in [gamma-(O4)-18]ATP relative to the net rate of ATP hydrolysis. This ratio (V(ex)/V(chem)) is a measure of the partitioning of the enzyme-carboxyphosphate-ADP complex. The partitioning ratio for the mutants is identical within experimental error to that observed for the wild type enzyme. This observation is consistent with the conclusion that the ground state for the enzyme-carboxyphosphate-ADP complex in the mutants is destabilized relative to the same complex in the wild type enzyme. If the increase in the absolute rate of ATP hydrolysis was due to a stabilization of the transition state for carboxyphosphate hydrolysis then the positional isotope exchange rate relative to the chemical hydrolysis rate would have been expected to decrease in the mutants.	TEXAS A&M UNIV SYST,DEPT CHEM,COLLEGE STN,TX 77843; PUBL HLTH RES INST CITY NEW YORK INC,DEPT MOLEC GENET,NEW YORK,NY 10016	Texas A&M University System; Texas A&M University College Station			Raushel, Frank/B-7125-2015	Raushel, Frank/0000-0002-5918-3089	NIDDK NIH HHS [DK 30343] Funding Source: Medline; NIGMS NIH HHS [GM 25846, GM 33894] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030343, R56DK030343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025846, R01GM033894] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON PM, 1973, BIOCHEM BIOPH RES CO, V55, P246, DOI 10.1016/S0006-291X(73)80086-5; ANDERSON PM, 1975, BIOCHEMISTRY-US, V14, P3688, DOI 10.1021/bi00687a027; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3157, DOI 10.1021/bi00874a012; BURBAUM JJ, 1989, BIOCHEMISTRY-US, V28, P9293, DOI 10.1021/bi00450a009; KASEMAN DS, 1985, METHOD ENZYMOL, V113, P305; KHEDOURI E, 1966, BIOCHEMISTRY-US, V5, P3552, DOI 10.1021/bi00875a024; MATTHEWS SL, 1972, BIOCHEMISTRY-US, V11, P1176, DOI 10.1021/bi00757a010; MEISTER A, 1989, ADV ENZYMOL, V62, P322; MERGEAY M, 1974, MOL GEN GENET, V133, P299, DOI 10.1007/BF00332706; PIERARD A, 1964, BIOCHEM BIOPH RES CO, V15, P76, DOI 10.1016/0006-291X(64)90106-8; PINKUS LM, 1972, J BIOL CHEM, V247, P6119; POWERS SG, 1978, J BIOL CHEM, V253, P1258; RAUSHEL GM, 1979, BIOCHEMISTRY-US, V18, P3424; RAUSHEL GM, 1980, BIOCHEMISTRY-US, V19, P3170; RISLEY JM, 1978, J LABELLED COMPD RAD, V15, P533, DOI 10.1002/jlcr.2580150162; RUBINO SD, 1987, J BIOL CHEM, V262, P4382; RUBINO SD, 1986, J BIOL CHEM, V261, P1320; SNODGRASS PJ, 1969, J LAB CLIN MED, V73, P940; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599; TROTTA PP, 1974, J BIOL CHEM, V249, P492; WIMMER MJ, 1979, J BIOL CHEM, V254, P1854	21	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8236	8240						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1827118				2022-12-25	WOS:A1991FK44100046
J	ALMAHROUQ, HA; KEMPSON, SA				ALMAHROUQ, HA; KEMPSON, SA			PHOTOAFFINITY-LABELING OF BRUSH-BORDER MEMBRANE-PROTEINS WHICH BIND PHOSPHONOFORMIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE-TRANSPORT; ADP-RIBOSYLTRANSFERASE; IDENTIFICATION; NAD+; COTRANSPORTER; KIDNEY	Identification and characterization of the Na+/P(i) co-transporter in the renal brush-border membrane (BBM) has proved to be difficult in part because of the lack of a specific covalent label. NAD is a competitive inhibitor of Na+/P(i) co-transport, and we have explored its potential use as a specific label. We describe the synthesis and use of a highly reactive azido derivative of NAD. This derivative (AB-NAD), like the parent NAD molecule, acts as a competitive inhibitor of Na+/P(i) co-transport by isolated BBM vesicles. After photoirradiation, the inhibition changes to noncompetitive, as would be expected if the label was bound covalently. This was confirmed by use of [H-3]AB-NAD. Photoirradiation produced a 4-fold increase in acid-stable incorporation of H-3 into BBM vesicles compared to controls which were not exposed to light. Polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate revealed that photoirradiation with [P-32]AB-NAD produced labeling of several different protein bands, but almost one-half of the P-32 was recovered in two bands corresponding to molecular masses of 97 and 70 kDa. Labeling of these bands was markedly reduced in the presence of Na+ and phosphonoformic acid, a specific inhibitor of Na+/P(i) co-transport. Chromatography of solubilized BBM proteins indicated that the protein fraction which is photolabeled by AB-NAD is co-eluted with the protein fraction which exhibits Na+-dependent binding of phosphonoformic acid. The 97- and 70-kDa polypeptide bands may contain components of the intact Na+/P(i) co-transport system.			ALMAHROUQ, HA (corresponding author), INDIANA UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,INDIANAPOLIS,IN 46202, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032148] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32148] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AL-MAHROUQ H A, 1989, FASEB Journal, V3, pA555; ALMAHROUQ HA, 1989, BIOCHIM BIOPHYS ACTA, V981, P200, DOI 10.1016/0005-2736(89)90029-1; BELIVEAU R, 1988, BIOCHEM J, V252, P807, DOI 10.1042/bj2520807; CHEN S, 1977, J BIOL CHEM, V252, P8990; DEBIEC H, 1988, BIOCHEM J, V255, P185, DOI 10.1042/bj2550185; GMAJ P, 1986, PHYSIOL REV, V66, P36, DOI 10.1152/physrev.1986.66.1.36; KEMPSON SA, 1985, AM J PHYSIOL, V249, pF948, DOI 10.1152/ajprenal.1985.249.6.F948; KEMPSON SA, 1983, AM J PHYSIOL, V245, pC449, DOI 10.1152/ajpcell.1983.245.5.C449; KEMPSON SA, 1986, BIOCHEM PHARMACOL, V35, P721, DOI 10.1016/0006-2952(86)90237-6; KEMPSON SA, 1984, BIOCHIM BIOPHYS ACTA, V770, P101, DOI 10.1016/0005-2736(84)90079-8; KESSLER RJ, 1982, J BIOL CHEM, V257, P4311; Klingenberg M., 1974, METHOD ENZYMAT AN, V4, P2045, DOI [10. 1016/B978-0-12-091304-6. 50060-4, DOI 10.1016/B978-0-12-091304-6.50060-4]; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIZGALA CL, 1985, PHYSIOL REV, V65, P431, DOI 10.1152/physrev.1985.65.2.431; PEERCE BE, 1989, AM J PHYSIOL, V256, pG645, DOI 10.1152/ajpgi.1989.256.4.G645; SZCZEPANSKAKONKEL M, 1987, J BIOL CHEM, V262, P8000; SZCZEPANSKAKONKEL M, 1986, J BIOL CHEM, V261, P6375; Wu K I, 1988, Am J Physiol, V255, pF15; WUARIN F, 1989, BIOCHIM BIOPHYS ACTA, V981, P185, DOI 10.1016/0005-2736(89)90027-8	19	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1422	1427						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1824842				2022-12-25	WOS:A1991EU49700014
J	GUO, QB; AKINS, RA; GARRIGA, G; LAMBOWITZ, AM				GUO, QB; AKINS, RA; GARRIGA, G; LAMBOWITZ, AM			STRUCTURAL-ANALYSIS OF THE NEUROSPORA MITOCHONDRIAL LARGE RIBOSOMAL-RNA INTRON AND CONSTRUCTION OF A MINI-INTRON THAT SHOWS PROTEIN-DEPENDENT SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-I INTRONS; LARGE RIBOSOMAL-RNA; SITE-SPECIFIC MUTAGENESIS; CRASSA MITOCHONDRIA; PHENOTYPIC SELECTION; NUCLEOTIDE-SEQUENCE; SECONDARY STRUCTURE; GENETIC ELEMENTS; NUCLEAR MUTANTS; CODING REGIONS	The gene encoding the Neurospora mitochondrial large rRNA contains a single group I intron of 2.3 kilobases that is not self-splicing in vitro. We showed previously that the splicing of this intron in vivo and in vitro is dependent on the Neurospora cyt-18 protein, mitochondrial tyrosyl-tRNA synthetase. In the present work, we carried out further structural analysis of the intron and constructed mutant derivatives of it in order to identify features that are either required for splicing or prevent it from self-splicing. Previous studies showed that the intron contains a large hairpin structure near the 5' splice site. By mapping RNase III cleavage sites, we identified this hairpin structure as an extended P2 stem. We constructed a mini-intron of 388 nucleotides by deleting the 426-amino acid intron open reading frame, most of the 5' intron hairpin, and all of L8. This mini-intron shows the same protein-dependent splicing as the full length intron, but is still not self-splicing. Further deletions, which remove all of P2 or all or part of P4, P6, P7, or P9, inactivate splicing, suggesting that an intact group I intron core structure is required. Strengthening the P1, P10, or P9.0 pairings did not enable the mini-intron to self-splice. Our findings indicate that the inability of the mitochondrial large rRNA intron to self-splice reflects deficiency of a structure or activity required for cleavage at the 5' splice site, either in the intron core itself or in the interaction between the core and the P1 stem.	OHIO STATE UNIV,DEPT MOLEC GENET,484 W 12TH AVE,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,CTR BIOTECHNOL,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NIGMS NIH HHS [GM37951] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037951, R01GM037951] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; BERTRAND H, 1982, CELL, V29, P517, DOI 10.1016/0092-8674(82)90168-4; BURKE JM, 1982, CELL, V31, P509, DOI 10.1016/0092-8674(82)90307-5; BURKE JM, 1989, FEBS LETT, V250, P129, DOI 10.1016/0014-5793(89)80704-5; BURKE JM, 1987, NUCLEIC ACIDS RES, V15, P7217, DOI 10.1093/nar/15.18.7217; BURKE JM, 1988, GENE, V73, P273, DOI 10.1016/0378-1119(88)90493-3; BURKE JM, 1990, NATURE, V344, P80, DOI 10.1038/344080a0; BURKE JM, 1983, THESIS MIT CAMBRIDGE; CECH TR, 1988, GENE, V73, P259, DOI 10.1016/0378-1119(88)90492-1; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; COLLINS RA, 1985, J MOL BIOL, V184, P413, DOI 10.1016/0022-2836(85)90291-8; CUMMINGS DJ, 1989, J MOL EVOL, V28, P242, DOI 10.1007/BF02102482; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; DOUDNA JA, 1989, P NATL ACAD SCI USA, V86, P7402, DOI 10.1073/pnas.86.19.7402; DUJON B, 1989, GENE, V82, P91, DOI 10.1016/0378-1119(89)90034-6; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; Favaloro J, 1980, Methods Enzymol, V65, P718; GARRIGA G, 1983, J BIOL CHEM, V258, P4745; GARRIGA G, 1986, CELL, V46, P669, DOI 10.1016/0092-8674(86)90342-9; GARRIGA G, 1984, CELL, V36, P623, DOI 10.1016/0092-8674(84)90342-8; GRIMM MF, 1981, BIOCHEMISTRY-US, V20, P2836, DOI 10.1021/bi00513a020; HECKMAN JE, 1979, CELL, V17, P583, DOI 10.1016/0092-8674(79)90266-6; JACOBSON AB, 1984, NUCLEIC ACIDS RES, V12, P45, DOI 10.1093/nar/12.1Part1.45; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lambowitz A M, 1979, Methods Enzymol, V59, P421; LAMBOWITZ AM, 1979, J CELL BIOL, V82, P17, DOI 10.1083/jcb.82.1.17; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; LAMBOWITZ AM, 1985, ACHIEVEMENTS PERSPEC, V2, P237; LAPOLLA RJ, 1979, J BIOL CHEM, V254, P1746; MAJUMDER AL, 1989, MOL CELL BIOL, V9, P2089, DOI 10.1128/MCB.9.5.2089; Maxam A M, 1980, Methods Enzymol, V65, P499; MICHEL F, 1990, GENE DEV, V4, P777, DOI 10.1101/gad.4.5.777; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MOTA EM, 1988, NATURE, V332, P654, DOI 10.1038/332654a0; NETZKER R, 1982, NUCLEIC ACIDS RES, V10, P4783, DOI 10.1093/nar/10.15.4783; PRICE JV, 1985, NUCLEIC ACIDS RES, V13, P1871, DOI 10.1093/nar/13.6.1871; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TU CPD, 1980, GENE, V10, P177, DOI 10.1016/0378-1119(80)90135-3; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9; WARING RB, 1984, GENE, V28, P277, DOI 10.1016/0378-1119(84)90145-8; WOLLENZIEN PL, 1983, CELL, V32, P397, DOI 10.1016/0092-8674(83)90459-2	42	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1809	1819						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1824845				2022-12-25	WOS:A1991EU49700070
J	MUENCH, KA; BRYANT, FR				MUENCH, KA; BRYANT, FR			DISRUPTION OF AN ATP-DEPENDENT ISOMERIZATION OF THE RECA PROTEIN BY MUTATION OF HISTIDINE 163	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; BINDING-SITE; RECOMBINATION; GENE; 5'-TRIPHOSPHATE; IDENTIFICATION; COMPLEXES; EXCHANGE; REGIONS	We have used site-directed mutagenesis to replace histidine 163 of the recA polypeptide with an alanine residue. The new [Ala-163]recA protein catalyzes single-stranded (ss) DNA-dependent ATP hydrolysis with a turnover number that is similar to that of the wild-type recA protein. Despite being proficient in ssDNA-dependent ATP hydrolysis, the [Ala-163]recA protein is unable to promote the ATP-dependent three-strand exchange reaction under standard reaction conditions, pH 7.5. The [Ala-163]recA protein does exhibit three-strand exchange activity at pH 6.0-7.0, however, and the induction of strand exchange activity at low pH correlates directly with the activation of an ATP-dependent isomerization of the mutant protein. Thus, the [Ala-163]recA protein is functionally similar to our previously described mutant [Asn-160]recA protein (Bryant, F. R. (1988) J. Biol. Chem. 263, 8716-8723; Muench, K. A., and Bryant, F.R. (1990) J. Biol. Chem. 265, 11560-11566). Trypsin proteolysis studies indicate that the [Ala-163]recA and [Asn-160]recA proteins, like the wild-type recA protein, are organized into carboxyl-terminal and amino-terminal domains of nearly equal size. According to this structural model, the [Ala-163]recA and [Asn-160]recA mutations may lie in a linker region joining these two domains. We speculate that the [Ala-163]recA and [Asn-160]recA mutations interfere with an ATP-dependent conformational change of the recA protein that perhaps involves a change in the relative orientation of the carboxyl-terminal and amino-terminal domains.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21205	Johns Hopkins University					NIGMS NIH HHS [GM 36516] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036516] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANKS GR, 1986, BIOCHEMISTRY-US, V25, P5882, DOI 10.1021/bi00368a007; BRYANT FR, 1988, J BIOL CHEM, V263, P8716; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; COTTERILL SM, 1982, BIOCHEMISTRY-US, V21, P4332, DOI 10.1021/bi00261a023; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; ELLEDGE SJ, 1987, MOL CELL BIOL, V7, P2783, DOI 10.1128/MCB.7.8.2783; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GRIFFITH JD, 1988, CRC CR REV BIOCH MOL, V23, pS43, DOI 10.3109/10409238809083375; HORII T, 1980, P NATL ACAD SCI-BIOL, V77, P313, DOI 10.1073/pnas.77.1.313; KNIGHT KL, 1985, J BIOL CHEM, V260, P177; KNIGHT KL, 1985, J BIOL CHEM, V260, P185; KOBAYASHI N, 1987, BIOCHEMISTRY-US, V26, P6801, DOI 10.1021/bi00395a033; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; MENGE KL, 1988, BIOCHEMISTRY-US, V27, P2635, DOI 10.1021/bi00407a055; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; MUENCH KA, 1990, J BIOL CHEM, V265, P11560; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; RADDING CM, 1982, ANNU REV GENET, V16, P405, DOI 10.1146/annurev.ge.16.120182.002201; SANCAR A, 1980, P NATL ACAD SCI-BIOL, V77, P2611, DOI 10.1073/pnas.77.5.2611; THRESHER RJ, 1988, J MOL BIOL, V201, P101, DOI 10.1016/0022-2836(88)90442-1; TSANG SS, 1985, J MOL BIOL, V185, P295, DOI 10.1016/0022-2836(85)90405-X; WANG WB, 1986, J BACTERIOL, V168, P901, DOI 10.1128/jb.168.2.901-910.1986; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126; YANCEY SD, 1984, MOL GEN GENET, V193, P53, DOI 10.1007/BF00327413	27	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					844	850						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1824702				2022-12-25	WOS:A1991ET17700029
J	SWANLJUNGCOLLINS, H; COLLINS, JH				SWANLJUNGCOLLINS, H; COLLINS, JH			CA2+ STIMULATES THE MG2+-ATPASE ACTIVITY OF BRUSH-BORDER MYOSIN-I WITH 3 OR 4 CALMODULIN LIGHT-CHAINS BUT INHIBITS WITH LESS THAN 2 BOUND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVILLAR 110K-CALMODULIN COMPLEX; ACANTHAMOEBA-CASTELLANII; BINDING PROTEIN; ACTIN-BINDING; CALCIUM; HEAD; PHOSPHORYLATION; MECHANOENZYME; PURIFICATION; CONTRACTION	Brush border myosin I from chicken intestinal microvilli is a membrane-associated, single-headed myosin composed of a 119-kDa heavy chain and several calmodulin light chains. We first describe in detail a new procedure for the rapid purification of brush border myosin I in greater than 99% purity with a yield of 40%, significantly higher than for previous methods. The subunit stoichiometry was determined to be 4 calmodulin light chains/myosin I heavy chain by amino acid compositional analysis of the separated subunits. We have studied the effects of Ca2+ and temperature on dissociation of calmodulin from myosin I and on myosin I Mg2+-ATPase and contractile activities. At 30-degrees-C the actin-activable ATPase activity is stimulated 2-fold at 10-700-mu-M Ca2+. Dissociation of 1 calmodulin occurs at 25-50-mu-M Ca2+, but this has no effect on actin activation. The contractile activity of myosin I, expressed as superprecipitation, is greatly enhanced by Ca2+ under conditions in which 1 calmodulin is dissociated. This calmodulin is thus not essential for actin activation or superprecipitation. Myosin I was found to be highly temperature-sensitive, with an increase to 37-degrees-C resulting in dissociation of 1 calmodulin at below 10(-7) M Ca2+ and an additional 1.5 calmodulins at 1-10 mu-M Ca2+. A complete loss of actin activation accompanies the Ca2+-induced calmodulin dissociation at 37-degrees-C. Our conclusion is that physiological levels of Ca2+ can either stimulate or inhibit the mechanoenzyme activities of brush border myosin I in vitro, with the mode of regulation determined by the number of associated calmodulin light chains.	EASTERN VIRGINIA MED SCH, DEPT BIOCHEM, POB 1980, 700 OLNEY RD, NORFOLK, VA 23501 USA	Eastern Virginia Medical School					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032567, R01GM035448] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35448, GM 32567] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS RJ, 1989, CELL MOTIL CYTOSKEL, V14, P178, DOI 10.1002/cm.970140203; ALBANESI JP, 1985, J BIOL CHEM, V260, P1174; BAGSHAW CR, 1979, J MOL BIOL, V130, P317, DOI 10.1016/0022-2836(79)90544-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS WH, 1980, BIOCHIM BIOPHYS ACTA, V623, P257, DOI 10.1016/0005-2795(80)90254-8; CARBONI JM, 1988, J CELL BIOL, V107, P1749, DOI 10.1083/jcb.107.5.1749; COLCA JR, 1987, J BIOL CHEM, V262, P11399; COLLINS JH, 1984, J BIOL CHEM, V259, P4128; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; COLUCCIO LM, 1987, J CELL BIOL, V105, P325, DOI 10.1083/jcb.105.1.325; CONZELMAN KA, 1987, J CELL BIOL, V105, P314; COOKE R, 1989, CELL MOTIL CYTOSKEL, V14, P183, DOI 10.1002/cm.970140204; COTE GP, 1985, J BIOL CHEM, V260, P4543; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; GARCIA A, 1989, J CELL BIOL, V109, P2895, DOI 10.1083/jcb.109.6.2895; HALSALL DJ, 1990, FEBS LETT, V267, P126, DOI 10.1016/0014-5793(90)80305-3; HARDWICKE PMD, 1983, NATURE, V301, P478, DOI 10.1038/301478a0; HIROKAWA N, 1983, J CELL BIOL, V96, P1325, DOI 10.1083/jcb.96.5.1325; HOSHIMARU M, 1987, J BIOL CHEM, V262, P14625; HOWE CL, 1983, J CELL BIOL, V97, P974, DOI 10.1083/jcb.97.4.974; KELLER TCS, 1985, J CELL BIOL, V100, P1647, DOI 10.1083/jcb.100.5.1647; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; Kohama K., 1987, Advances in Biophysics, V23, P149; Korn ED, 1990, CURR OPIN CELL BIOL, V2, P57, DOI 10.1016/S0955-0674(05)80031-6; KORN ED, 1988, ANNU REV BIOPHYS BIO, V17, P23; KORN ED, 1982, METHOD ENZYMOL, V85, P357; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Louvard D, 1989, CURR OPIN CELL BIOL, V1, P51, DOI 10.1016/S0955-0674(89)80036-5; MADARA JL, 1987, AM J PHYSIOL, V253, pC854, DOI 10.1152/ajpcell.1987.253.6.C854; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; MOOSEKER MS, 1989, J CELL BIOL, V109, P1153, DOI 10.1083/jcb.109.3.1153; MOOSEKER MS, 1989, J CELL BIOL, V108, P2395, DOI 10.1083/jcb.108.6.2395; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; PUTKEY JA, 1983, J BIOL CHEM, V258, P1864; RIEKER JP, 1987, FEBS LETT, V223, P262, DOI 10.1016/0014-5793(87)80301-0; SIMMONS RM, 1985, J PHYSIOL-LONDON, V358, P47, DOI 10.1113/jphysiol.1985.sp015539; SIMPSON RJ, 1976, J BIOL CHEM, V251, P1936; SPUDICH JA, 1989, CELL REGUL, V1, P1; STEIN JP, 1983, P NATL ACAD SCI-BIOL, V80, P6485, DOI 10.1073/pnas.80.21.6485; SWANLJUNGCOLLINS H, 1987, METHOD ENZYMOL, V139, P137; VANAMAN TC, 1983, METHOD ENZYMOL, V102, P296; WATTERSON DM, 1980, J BIOL CHEM, V255, P962	45	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					1312	1319						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1824700				2022-12-25	WOS:A1991ET17700096
J	AKKARAJU, GR; HANSEN, LJ; JAGUS, R				AKKARAJU, GR; HANSEN, LJ; JAGUS, R			INCREASE IN EUKARYOTIC INITIATION FACTOR-2B ACTIVITY FOLLOWING FERTILIZATION REFLECTS CHANGES IN REDOX POTENTIAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; POLYPEPTIDE-CHAIN INITIATION; SEA-URCHIN EGGS; PROTEIN-SYNTHESIS INITIATION; RABBIT-RETICULOCYTE LYSATE; GDP GTP EXCHANGE; FACTOR-II; STRONGYLOCENTROTUS-PURPURATUS; TRANSLATIONAL CONTROL; OXIDATION-REDUCTION	One of the factors involved in the postfertilization activation of protein synthesis in the sea urchin, Strongylocentrotus purpuratus, is the activation of eIF-2B, the initiation factor responsible for guanine nucleotide exchange on eIF-2. Cell-free translation systems from unfertilized eggs are stimulated by added eIF-2B, although this dependency is rapidly lost in translation systems prepared at various times following fertilization. Cell-free translation systems prepared from unfertilized eggs show significantly lower eIF-2B activities than those prepared from 2-h embryos. However, the provision of an NADPH regeneration system significantly stimulates eIF-2B activity in egg extracts and, in addition, stimulates both binding of initiator tRNA to the small ribosomal subunit and protein synthetic activity. These data suggest that the activation of eIF-2B following fertilization reflects the fertilization-induced increase in NADPH levels.	CTR MARINE BIOTECHNOL, BALTIMORE, MD 21202 USA; UNIV PITTSBURGH, SCH MED, DEPT MICROBIOL BIOCHEM & MOLEC BIOL, PITTSBURGH, PA 15261 USA; US EPA, OFF PESTICIDES PROGRAM, DIV TOXICOL HLTH EFFECTS, WASHINGTON, DC 20460 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; United States Environmental Protection Agency					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033631] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33631] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUNE TM, 1978, J CELL BIOL, V79, pA164; CAPPEL RE, 1988, J BIOL CHEM, V263, P12204; CLEMENS M, 1987, NATURE, V330, P699, DOI 10.1038/330699a0; COLIN AM, 1987, DEV BIOL, V123, P354, DOI 10.1016/0012-1606(87)90394-0; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P546; DHOLAKIA JN, 1988, P NATL ACAD SCI USA, V85, P51, DOI 10.1073/pnas.85.1.51; DHOLAKIA JN, 1986, P NATL ACAD SCI USA, V83, P6746, DOI 10.1073/pnas.83.18.6746; EPEL D, 1981, CELL, V23, P543, DOI 10.1016/0092-8674(81)90150-1; EPEL D, 1964, BIOCHEM BIOPH RES CO, V17, P62, DOI 10.1016/0006-291X(64)90301-8; EPEL D, 1967, P NATL ACAD SCI USA, V57, P899, DOI 10.1073/pnas.57.4.899; ERNST V, 1978, J BIOL CHEM, V253, P7163; FAHEY RC, 1976, BIOCHIM BIOPHYS ACTA, V437, P445, DOI 10.1016/0304-4165(76)90013-1; GOUSTIN AS, 1981, DEV BIOL, V82, P32, DOI 10.1016/0012-1606(81)90426-7; GOUSTIN AS, 1981, DEV BIOL, V87, P163, DOI 10.1016/0012-1606(81)90069-5; GROSS DJ, 1984, J BIOL CHEM, V259, P7374; GROSS M, 1988, J BIOL CHEM, V263, P12486; HANSEN LJ, 1987, J BIOL CHEM, V262, P6114; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HUANG WI, 1987, P NATL ACAD SCI USA, V84, P6359, DOI 10.1073/pnas.84.18.6359; HUNT T, 1983, EUR J BIOCHEM, V131, P303, DOI 10.1111/j.1432-1033.1983.tb07263.x; ISONO N, 1968, EXP CELL RES, V50, P616, DOI 10.1016/0014-4827(68)90423-0; Isono N., 1963, Journal of the Faculty of Science Tokyo University Zoology, V10, P37; JACKSON RJ, 1983, EUR J BIOCHEM, V131, P289, DOI 10.1111/j.1432-1033.1983.tb07262.x; JACKSON RJ, 1983, EUR J BIOCHEM, V131, P313, DOI 10.1111/j.1432-1033.1983.tb07264.x; JAGUS R, 1981, J BIOL CHEM, V256, P1317; JAGUS R, 1981, J BIOL CHEM, V256, P1324; KAN B, 1988, J BIOL CHEM, V263, P15652; KONIECZNY A, 1983, J BIOL CHEM, V258, P3402; LOPO AC, 1988, BIOCHEMISTRY-US, V27, P351, DOI 10.1021/bi00401a053; LOPO AC, 1989, BIOCHEM J, V258, P553, DOI 10.1042/bj2580553; LOWRY OH, 1972, FLEXIBLE SYSTEM ENZY, pCH7; MATTS RL, 1983, P NATL ACAD SCI-BIOL, V80, P2559, DOI 10.1073/pnas.80.9.2559; MERRICK WC, 1979, J BIOL CHEM, V254, P3708; PANNIERS R, 1983, J BIOL CHEM, V258, P7928; PETERSON DT, 1979, J BIOL CHEM, V254, P7730; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2140; REGIER JC, 1977, DEV BIOL, V57, P270, DOI 10.1016/0012-1606(77)90214-7; ROMANIUK PJ, 1985, BIOCHEMISTRY-US, V24, P4239, DOI 10.1021/bi00336a064; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; ROWLANDS AG, 1988, EUR J BIOCHEM, V175, P93, DOI 10.1111/j.1432-1033.1988.tb14170.x; Safer B, 1979, Methods Enzymol, V60, P61; SAFER B, 1975, J BIOL CHEM, V250, P9076; SAFER B, 1983, CELL, V33, P7, DOI 10.1016/0092-8674(83)90326-4; SAFER B, 1989, EUR J BIOCHEM, V89, P696; SALIMANS M, 1984, EUR J BIOCHEM, V145, P91, DOI 10.1111/j.1432-1033.1984.tb08526.x; SIEKIERKA J, 1982, P NATL ACAD SCI-BIOL, V79, P2537, DOI 10.1073/pnas.79.8.2537; SIEKIERKA J, 1984, P NATL ACAD SCI-BIOL, V81, P352, DOI 10.1073/pnas.81.2.352; STARZYK RM, 1982, NATURE, V298, P136, DOI 10.1038/298136a0; WINKLER MM, 1985, DEV BIOL, V107, P290, DOI 10.1016/0012-1606(85)90312-4; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	50	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24451	24459						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761545				2022-12-25	WOS:A1991GW84500035
J	BASSLER, BL; GIBBONS, PJ; YU, C; ROSEMAN, S				BASSLER, BL; GIBBONS, PJ; YU, C; ROSEMAN, S			CHITIN UTILIZATION BY MARINE-BACTERIA - CHEMOTAXIS TO CHITIN OLIGOSACCHARIDES BY VIBRIO-FURNISSII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTRANSFERASE-SYSTEM ENZYMES; 2-COMPONENT REGULATORY SYSTEMS; PROTEIN-PHOSPHORYLATION; ENVIRONMENTAL STIMULI; CONSERVED DOMAINS; ESCHERICHIA-COLI; PARAHAEMOLYTICUS; CHEMORECEPTORS; METHYLATION; BEHAVIOR	The adhesion/deadhesion apparatus of the marine bacterium Vibrio furnissii (Yu, C., Lee, A., Bassler, B. L., and Roseman, S. (1991) J. Biol. Chem. 266, 24260-24267) probably catalyzes the first step in colonizing chitin. Evidence is presented here for a second step, chemotaxis to chitin hydrolysis products. V. furnissii swarms toward chitin oligomers (GlcNAc)n, n = 1-6, at initial concentrations as low as 10-mu-M. A modified capillary assay was used for quantitation; the cells exhibit low level constitutive taxis to GlcNAc but not to the oligosaccharides. A mutant defective in the GlcNAc receptor (II(Nag) of the phosphotransferase system) showed inducible taxis to the oligosaccharides. Two (or more) independently inducible receptors with overlapping specificities recognize (GlcNAc)n, n = 24. (GlcNAc)5, and (GlcNAc)6 were inactive in the capillary assay; expression of this receptor(s) apparently require special induction conditions. The (GlcNAc)n, n = 1-4, chemoreceptors of V. furnissii may be the most potent reported for bacteria. L-Amino acids were weak, constitutive attractants; glutamine, not known to be an attractant in other bacteria, was the most effective amino acid. The most potent receptor in Escherichia coli, Tar (aspartate), is not expressed in V. furnissii. The chemotactic responses were greatly affected by growth and induction conditions and the presence of nutrients in the assay media. Taxis to GlcNAc and GlcNAc oligomers was optimally induced by growth in lactate medium containing 0.6 mM sugar, while growth on the sugar per se resulted in poor taxis. Chemotaxis to the sugars increased 2- to 3-fold when the cells were starved. Nutrients in the assay medium, especially compounds that feed into or are part of the Krebs cycle were potent inhibitors of taxis to the sugars and Gln With the exception of isocitrate, inhibition of taxis correlated with the rate of oxidation of these compounds. The results suggest a link between catabolism and taxis in this organism, i.e. interactions or "cross-talk" between systems that are regulated by protein phosphorylation (Stock, J. A., Ninfa, A. J., and Stock, A. M. (1989) Microbiol. Rev. 53, 450-490).	JOHNS HOPKINS UNIV, MCCOLLUM PRATT INST, BALTIMORE, MD 21218 USA; JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	Johns Hopkins University; Johns Hopkins University				Bassler, Bonnie/0000-0002-0043-746X	NIGMS NIH HHS [5T32GM07321] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1974, P NATL ACAD SCI USA, V71, P2895, DOI 10.1073/pnas.71.7.2895; ADLER J, 1973, J GEN MICROBIOL, V74, P77, DOI 10.1099/00221287-74-1-77; ALAM M, 1982, FEBS LETT, V143, P144, DOI 10.1016/0014-5793(82)80292-5; BASSLER B, 1989, BIOCHEM BIOPH RES CO, V161, P1172, DOI 10.1016/0006-291X(89)91365-X; BASSLER BL, 1991, J BIOL CHEM, V266, P24276; BASSLER BL, 1990, THESIS J HOPKINS U, P65; BINSTOCK J, 1984, METHOD ENZYMOL, V106, P310; BOURRET RB, 1989, J BIOL CHEM, V264, P7085; CHET I, 1976, ANNU REV MICROBIOL, V30, P221, DOI 10.1146/annurev.mi.30.100176.001253; GOLDBERG ED, 1974, SEA, V5; HAZEN TC, 1984, CURR MICROBIOL, V10, P13, DOI 10.1007/BF01576041; HOROWITZ ST, 1957, J AM CHEM SOC, V79, P5046, DOI 10.1021/ja01575a059; KORT EN, 1975, P NATL ACAD SCI USA, V72, P3939, DOI 10.1073/pnas.72.10.3939; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENGELER J, 1981, MOL GEN GENET, V183, P163, DOI 10.1007/BF00270156; MACNAB RM, 1987, ESCHERICHIA COLI SAL, V1, P732; MCCARTER L, 1988, CELL, V54, P345, DOI 10.1016/0092-8674(88)90197-3; MITCHELL R, 1976, GOV REP ANNOUNCE, V76, P110; NIXON BT, 1986, P NATL ACAD SCI USA, V83, P7850, DOI 10.1073/pnas.83.20.7850; Parson T. R., 1977, BIOL OCEANOGRAPHIC P; RONSON CW, 1987, CELL, V49, P579, DOI 10.1016/0092-8674(87)90530-7; SAR N, 1990, J BACTERIOL, V172, P334, DOI 10.1128/JB.172.1.334-341.1990; SMITH FGW, 1974, HDB MARINE SCI, V1; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; YU C, 1991, J BIOL CHEM, V266, P24260	26	70	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24268	24275						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761532				2022-12-25	WOS:A1991GW84500009
J	LOPEZCORCUERA, B; VAZQUEZ, J; ARAGON, C				LOPEZCORCUERA, B; VAZQUEZ, J; ARAGON, C			PURIFICATION OF THE SODIUM-COUPLED AND CHLORIDE-COUPLED GLYCINE TRANSPORTER FROM CENTRAL-NERVOUS-SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC ACID; RAT SPINAL-CORD; MEMBRANE-VESICLES; BRAIN; RECONSTITUTION; GLYCOPROTEIN; CARRIER; SITE	We have recently developed a reconstitution assay which allows the rapid determination of sodium- and chloride-dependent glycine transport activity of many fractions (Lopez-Corcuera, B., and Aragon, C. (1989) Eur. J. Biochem. 181, 519-524). In this paper we report the purification of the sodium- and chloride-coupled glycine transporter from pig brain stem. Transporter is solubilized from plasma membrane vesicles with 2% cholate and purified by sequential chromatography on phenyl-Sepharose, wheat germ agglutinin-Sepharose, and hydroxylapatite columns, followed by a 5-20% sucrose density gradient fractionation. Taking into account the inactivation suffered by the transporter, a final increase in specific activity of about 450-fold is achieved. Although two polypeptides with apparent molecular masses of 100 and 37 kDa are progressively enriched during the chromatographic steps, only the 100-kDa band comigrates with transport activity along the density gradient. This band is finally isolated to apparent homogeneity in the active fractions. We conclude that the 100-kDa band represents the glycine transporter. Finally, the pure transporter can be reconstituted into liposomes, retaining the absolute dependence on sodium and chloride gradients, the electrogenicity, the glycine affinity, the substrate specificity, and the sensitivity to group-selective modifiers characteristic of the native transporter.	UNIV AUTONOMA MADRID,FAC CIENCIAS,CTR BIOL MOLEC,DEPT BIOL MOLEC,E-28049 MADRID,SPAIN	Autonomous University of Madrid			Corcuera, Beatriz López/D-5188-2009; Vazquez, Jesus/B-7697-2015; Aragon, Carmen/K-9783-2014	Corcuera, Beatriz López/0000-0002-0383-4241; Vazquez, Jesus/0000-0003-1461-5092; Aragon, Carmen/0000-0001-8287-9386				ALCANTARA R, 1991, BIOCHIM BIOPHYS ACTA, V1067, P64, DOI 10.1016/0005-2736(91)90026-5; ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; ARAGON MC, 1987, FEBS LETT, V212, P87, DOI 10.1016/0014-5793(87)81562-4; BEDNAR RA, 1989, J BIOL CHEM, V264, P14272; CHRISTENSEN HN, 1981, BIOCHEM BIOPH RES CO, V98, P102, DOI 10.1016/0006-291X(81)91875-1; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; DUDECK KL, 1987, J BIOL CHEM, V262, P12565; FOLCH J, 1957, J BIOL CHEM, V226, P497; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HUTHER FJ, 1984, EUR J BIOCHEM, V143, P79, DOI 10.1111/j.1432-1033.1984.tb08343.x; IGARASHI P, 1987, J BIOL CHEM, V262, P860; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KANNER BI, 1983, BIOCHIM BIOPHYS ACTA, V726, P293, DOI 10.1016/0304-4173(83)90013-7; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P1207, DOI 10.1021/bi00600a011; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KERWIN RW, 1979, EUR J PHARMACOL, V54, P93, DOI 10.1016/0014-2999(79)90411-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZCORCUERA B, 1989, BIOCHIM BIOPHYS ACTA, V983, P247, DOI 10.1016/0005-2736(89)90240-X; LOPEZCORCUERA B, 1989, EUR J BIOCHEM, V181, P519, DOI 10.1111/j.1432-1033.1989.tb14754.x; MAYOR F, 1981, BIOCHEM J, V198, P535, DOI 10.1042/bj1980535; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PEERCE BE, 1985, J BIOL CHEM, V260, P6026; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RADIAN R, 1986, J BIOL CHEM, V261, P5437; RADIAN R, 1985, J BIOL CHEM, V260, P1859; RICCIO P, 1989, ANION CARRIERS OF MITOCHONDRIAL MEMBRANES, P35; Riordan J F, 1972, Methods Enzymol, V25, P449, DOI 10.1016/S0076-6879(72)25040-6; Stein W., 2012, TRANSPORT DIFFUSION; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289	29	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24809	24814						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761575				2022-12-25	WOS:A1991GW84500086
J	VANVELDHOVEN, PP; VANHOVE, G; VANHOUTTE, F; DACREMONT, G; PARMENTIER, G; EYSSEN, HJ; MANNAERTS, GP				VANVELDHOVEN, PP; VANHOVE, G; VANHOUTTE, F; DACREMONT, G; PARMENTIER, G; EYSSEN, HJ; MANNAERTS, GP			IDENTIFICATION AND PURIFICATION OF A PEROXISOMAL BRANCHED-CHAIN FATTY ACYL-COA OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; BETA-OXIDATION; TRIHYDROXYCOPROSTANOYL-COA; ACID; ENZYMES	Isoprenoid (branched) fatty acids such as pristanic acid can be degraded via beta-oxidation in peroxisomes. We synthesized 2-methylpalmitoyl-CoA as a model substrate in order to study the first step of the peroxisomal beta-oxidation of branched fatty acids, catalyzed by an acyl-CoA oxidase. 2-Methylpalmitoyl-CoA oxidase activity was found in rat liver homogenates. Subcellular fractionation demonstrated that the oxidase was confined to peroxisomes. 2-Methylpalmitoyl-CoA oxidase was also present in kidney and intestine. It was not induced in liver or in the extrahepatic tissues by treatment of rats with peroxisome proliferators or by feeding diets containing excess isoprenoids. The enzyme was partially purified together with palmitoyl-CoA oxidase and trihydroxycoprostanoyl-CoA oxidase by heat treatment and ammonium sulfate fractionation of liver extracts. The partially purified preparation was chromatographed on various columns. 2-Methylpalmitoyl-CoA oxidase could be separated from the inducible (by peroxisome proliferators) palmitoyl-CoA oxidase and from trihydroxycoprostanoyl-CoA oxidase, but it always coeluted with the noninducible palmitoyl-CoA oxidase, recently described by us (Schepers, L., Van Veldhoven, P. P., Casteels, M., Eyssen, H. J., and Mannaerts, G. P. (1990) J. Biol. Chem. 265, 5242-5246). 2-Methylpalmitoyl-CoA oxidase was purified to near homogeneity in three chromatographic steps (anion exchange, hydroxylapatite, and gel filtration). Its apparent molecular mass is approximately 415 kDa, and it consists of identical subunits of approximately 70 kDa. The enzyme oxidized 2-methylpalmitoyl-CoA twice as rapidly as palmitoyl-CoA and pristanoyl-CoA as rapidly as palmitoyl-CoA, so that it can be considered as a branched fatty acyl-CoA oxidase. Since pristanoyl-CoA is one of its naturally occurring substrates we propose to name this enzyme pristanoyl-CoA oxidase.	REGA INST, B-3000 LOUVAIN, BELGIUM; STATE UNIV GHENT HOSP, DEPT PEDIAT, B-9000 GHENT, BELGIUM	KU Leuven; Ghent University; Ghent University Hospital			, Van Veldhoven Paul/U-6359-2019	, Van Veldhoven Paul/0000-0002-4478-2564				CARLSEN PHJ, 1981, J ORG CHEM, V46, P3936, DOI 10.1021/jo00332a045; CASON J, 1965, TETRAHEDRON, V21, P471, DOI 10.1016/S0040-4020(01)82217-1; CASTEELS M, 1988, J BIOL CHEM, V263, P4654; CASTEELS M, 1990, J LIPID RES, V31, P1865; CHEN RF, 1967, J BIOL CHEM, V242, P173; DECLERCQ PE, 1984, J BIOL CHEM, V259, P9064; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; FIESER LF, 1967, REAGENTS ORGANIC SYN, P1088; GUEVARA J, 1982, ELECTROPHORESIS, V3, P197, DOI 10.1002/elps.1150030404; INESTROSA NC, 1980, BIOCHEM BIOPH RES CO, V95, P7, DOI 10.1016/0006-291X(80)90696-8; KAWAGUCHI A, 1981, J BIOCHEM-TOKYO, V89, P337, DOI 10.1093/oxfordjournals.jbchem.a133207; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; MANNAERTS GP, 1990, BIOCHEM SOC T, V18, P87, DOI 10.1042/bst0180087; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; OSMUNDSEN H, 1982, ANN NY ACAD SCI, V386, P13, DOI 10.1111/j.1749-6632.1982.tb21404.x; OSUMI T, 1980, J BIOCHEM, V87, P1735, DOI 10.1093/oxfordjournals.jbchem.a132918; OSUMI T, 1987, J BIOL CHEM, V262, P8138; POULOS A, 1988, EUR J PEDIATR, V147, P143, DOI 10.1007/BF00442211; SCHEPERS L, 1990, J BIOL CHEM, V265, P5242; STEEN L, 1984, BIOCHIM BIOPHYS ACTA, V796, P294, DOI 10.1016/0005-2760(84)90130-9; SUMEGI B, 1984, J BIOL CHEM, V259, P8748; VANHOVE G, 1991, J BIOL CHEM, V266, P24670; VANVELDHOVEN P, 1985, BIOCHEM J, V227, P737, DOI 10.1042/bj2270737; VANVELDHOVEN PP, 1991, BIOCHIM BIOPHYS ACTA, V1073, P203, DOI 10.1016/0304-4165(91)90203-S; VEERAVAGU P, 1964, J AM CHEM SOC, V86, P3072, DOI 10.1021/ja01069a020; VOGEL AI, 1978, TXB PRACTICAL ORGANI, P654; WANDERS RJA, 1990, J INHERIT METAB DIS, V13, P4, DOI 10.1007/BF01799330; WANDERS RJA, 1990, BIOCHEM BIOPH RES CO, V172, P490, DOI 10.1016/0006-291X(90)90699-N	28	83	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24676	24683						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761563				2022-12-25	WOS:A1991GW84500068
J	BALAZY, M				BALAZY, M			METABOLISM OF 5,6-EPOXYEICOSATRIENOIC ACID BY THE HUMAN PLATELET - FORMATION OF NOVEL THROMBOXANE ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; EPOXYEICOSATRIENOIC ACIDS; PROSTAGLANDIN ENDOPEROXIDES; MONOOXYGENASE; OXYGENATION; EPOXYGENASE; EPOXIDES	Radiolabeled cis-(+/-)-5,6-epoxyeicosatrienoic acid (5(6)-EpETrE) was incubated with a suspension of isolated human platelets in order to study its metabolic fate. The epoxide slowly disappeared from the suspension and was completely metabolized within 30 min. After extraction and analysis by reverse-phase high performance liquid chromatography, seven metabolites were found. Addition of either indomethacin (0.01 mM, cyclooxygenase inhibitor) or BW755C (0.1 mM, cyclooxygenase/lipoxygenase inhibitor) to the incubations blocked the formation of four and six metabolites, respectively. 1,2-Epoxy-3,3,3-trichloropropane (inhibitor of microsomal epoxide hydrolase) failed to inhibit the formation of 5,6-dihydroxyeicosatrienoic acid (5,6-DiHETrE), a hydrolysis product of the precursor 5(6)-EpETrE. The metabolites were characterized by UV spectroscopy, negative ion chemical ionization liquid chromatography/mass spectrometry, gas chromatography/mass spectrometry and, in one instance, coelution with synthetic standard. Three primary platelet metabolites were structurally determined to be 5,6-epoxy-12-hydroxyeicosatrienoic acid, 5,6-epoxy-12-hydroxyheptadecadienoic acid, and a unique bicyclic metabolite, 5-hydroxy-6,9-epoxythromboxane B1, which originated from intramolecular hydrolysis of 5,6-epoxythromboxane-B1. This thromboxane analog was partially separated into stereoisomers and coeluted with the racemic synthetic standard in gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry. Three other metabolites were characterized as 5,6,12-trihydroxyeicosatrienoic acid, 5,6,12-trihydroxyheptadecadienoic acid, and 5,6-dihydroxythromboxane-B1, and resulted from the hydrolysis of the corresponding epoxides rather than from the metabolism of 5,6-DiHETrE. The latter was not metabolized by platelet cyclooxygenase or lipoxygenase. The biosynthesis of two cyclooxygenase metabolites indicated the formation of unstable 5,6-epoxythromboxane-A1 as an intermediate precursor. Platelet aggregation was not induced by 5(6)-EpETrE, although responsiveness to arachidonic acid was reduced following preincubation with the epoxide. The platelet metabolites of 5(6)-EpETrE might be useful in assessing its in vivo production in humans.			BALAZY, M (corresponding author), NEW YORK MED COLL, DEPT PHARMACOL, VALHALLA, NY 10595 USA.			Balazy, Ph.D., Michael/0000-0003-0218-8820	NHLBI NIH HHS [PPG P01-HL34300] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034300] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMRUTHESH S C, 1990, FASEB Journal, V4, pA993; BALAZY M, 1988, PROSTAGLANDINS, V36, P421, DOI 10.1016/0090-6980(88)90040-8; CAPDEVILA J, 1982, P NATL ACAD SCI-BIOL, V79, P767, DOI 10.1073/pnas.79.3.767; CARROLL MA, 1990, CIRC RES, V67, P1082, DOI 10.1161/01.RES.67.5.1082; CARROLL MA, 1991, IN PRESS J PHARM EXP; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; COREY EJ, 1979, J AM CHEM SOC, V101, P1586, DOI 10.1021/ja00500a035; ELLIS EF, 1990, AM J PHYSIOL, V259, pH1171, DOI 10.1152/ajpheart.1990.259.4.H1171; FINNEN M J, 1986, British Journal of Pharmacology, V88, p406P; FITZGERALD GA, 1989, ADV EXP MED BIOL, V259, P325; FITZPATRICK FA, 1988, PHARMACOL REV, V40, P229; FITZPATRICK FA, 1986, J BIOL CHEM, V261, P5334; GERRARD JM, 1982, METHOD ENZYMOL, V86, P642; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HASUNUMA K, 1991, PROSTAG LEUKOTR ESS, V42, P171, DOI 10.1016/0952-3278(91)90153-V; HIRT DL, 1989, J CLIN INVEST, V84, P1805, DOI 10.1172/JCI114365; MCGIFF JC, 1986, KIDNEY HORMONES, V3, P363; MEIJER J, 1988, CHEM-BIOL INTERACT, V64, P207, DOI 10.1016/0009-2797(88)90100-7; OLIW EH, 1984, J BIOL CHEM, V259, P2716; OLIW EH, 1984, FEBS LETT, V172, P279, DOI 10.1016/0014-5793(84)81141-2; OLIW EH, 1982, J BIOL CHEM, V257, P3771; PACEASCIAK CR, 1984, J BIOL CHEM, V259, P8332; PINTO A, 1986, J PHARMACOL EXP THER, V236, P445; PROCTOR KG, 1987, CIRC RES, V60, P50, DOI 10.1161/01.RES.60.1.50; ROMERO MF, 1991, RENAL PHYSIOL BIOCH, V14, P199; ROSSOLOVSKY M, 1990, ADV PROSTAGLANDIN A, V21, P213; SCHLONDORFF D, 1987, AM J PHYSIOL, V253, pF464, DOI 10.1152/ajprenal.1987.253.3.F464; SMITH AG, 1977, J CHROMATOGR, V142, P533, DOI 10.1016/S0021-9673(01)92066-7; SNYDER G, 1986, BIOCHEM BIOPH RES CO, V139, P1188, DOI 10.1016/S0006-291X(86)80303-5; TAKAHASHI K, 1990, AM J PHYSIOL, V258, pF781, DOI 10.1152/ajprenal.1990.258.4.F781; TOTO R, 1987, BIOCHIM BIOPHYS ACTA, V919, P132, DOI 10.1016/0005-2760(87)90199-8	31	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23561	23567						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748634				2022-12-25	WOS:A1991GV31900010
J	TSAI, SC; HAUN, RS; TSUCHIYA, M; MOSS, J; VAUGHAN, M				TSAI, SC; HAUN, RS; TSUCHIYA, M; MOSS, J; VAUGHAN, M			ISOLATION AND CHARACTERIZATION OF THE HUMAN GENE FOR ADP-RIBOSYLATION FACTOR-III, A 20-KDA GUANINE NUCLEOTIDE-BINDING PROTEIN ACTIVATOR OF CHOLERA-TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PROMOTER REGION; SEQUENCE; GTP; TRANSCRIPTION; PSEUDOGENE; CLONING; BOVINE; END	ADP-ribosylation factors (ARFs) are approximately 20-kDa guanine nucleotide-binding proteins that stimulate the ADP-ribosyltransferase activity of cholera toxin in vitro. Five different human ARFs have been identified by cDNA cloning. Northern analysis using ARF 3-specific oligonucleotides identified two mRNAs of 3.7 and 1.2 kilobases (kb). We report here the complete nucleotide sequence of the 3.7-kb ARF 3 mRNA derived from three overlapping cDNAs isolated from human hippocampus and fetal brain cDNA libraries, as well as the structure of human ARF 3 gene. Sequences of two overlapping genomic clones indicated that the ARF 3 gene spans approximately 18.3 kb and contains five exons and four introns. The conserved amino acid sequences involved in guanine nucleotide binding by ARF 3 are distributed among separate exons, as found in other GTP-binding protein genes. Translation initiates in exon 2 which includes the sequence GXXXXGK that probably participates in phosphate binding and GTP hydrolysis. The sequence DVGG in exon 3 coordinates binding of Mg2+ and the beta-phosphate of GDP. In the ARF 3 gene in contrast to those of other GTP-binding proteins, the sequence NKXD (which is thought to contribute to the specificity of interaction with the guanine ring) is divided between exons 4 and 5. The latter encodes the COOH-terminal 53 amino acids of ARF 3 and contains > 2500 base pairs of untranslated DNA. The sequence AATTAA is 19 bases 5' to the polyadenylation addition site of the 3.7-kb mRNA. Multiple transcription start sites were identified by primer extension and S1 and mung bean nuclease analyses. The 5'-flanking region of exon 1 contains neither a TATA nor a CAAT box, but is high in GC content (> 70%) and includes three potential Sp1-binding sites (GC box), consistent with the promoters described for several housekeeping genes. The 1.2-kb ARF 3 mRNA is shown to arise by use of an alternative polyadenylation signal (AACAAA) at nucleotide 1091 within the ARF 3 cDNA.			TSAI, SC (corresponding author), NHLBI,CELLULAR METAB LAB,RM 5N307,BLDG 10,BETHESDA,MD 20892, USA.							ALSIP GR, 1986, NUCLEIC ACIDS RES, V14, P2123, DOI 10.1093/nar/14.5.2123; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOBAK DA, 1990, ADP RIBOSYLATING TOX, P439; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GREEN MR, 1980, CELL, V22, P231, DOI 10.1016/0092-8674(80)90171-3; HEATH CV, 1990, J BIOL CHEM, V265, P9098; HENDERSON GS, 1991, BIOTECHNIQUES, V10, P190; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1990, ADP RIBOSYLATING TOX, P397; Sambrook J, 1989, MOL CLONING LABORATO; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TSAI SC, 1987, P NATL ACAD SCI USA, V84, P5139, DOI 10.1073/pnas.84.15.5139; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSAI SC, 1991, J BIOL CHEM, V266, P8213; TSUCHIYA M, 1989, BIOCHEMISTRY-US, V28, P9668, DOI 10.1021/bi00451a019; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; TSUKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P2974, DOI 10.1073/pnas.88.8.2974; WEINSTEIN LS, 1988, FEBS LETT, V232, P333, DOI 10.1016/0014-5793(88)80764-6; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611	28	35	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23053	23059						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744102				2022-12-25	WOS:A1991GT48300045
J	ZHOU, DX; YEN, TSB				ZHOU, DX; YEN, TSB			THE HEPATITIS-B VIRUS S PROMOTER COMPRISES A CCAAT MOTIF AND 2 INITIATION REGIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; DIHYDROFOLATE-REDUCTASE PROMOTER; SURFACE-ANTIGEN TRANSCRIPTION; HEPATOMA-CELL LINES; POL II PROMOTERS; AFFINITY PURIFICATION; NEGATIVE ELEMENTS; MAMMALIAN-CELLS; HIP1 BINDING; ACTIVATION	The hepatitis B virus S (major surface gene) promoter is embedded in two overlapping open reading frames and specifies several transcripts with heterogeneous 5' termini. We have identified the cis-elements necessary for S promoter function. A single upstream CCAAT element is essential for high level expression in both liver and non-liver cells. No TATA box is present, but two regions surrounding the initiation sites can function separately as initiating elements. These results show that the S promoter has a simple requirement for upstream activating sequences, but a complex initiation region. Therefore, it may provide a suitable model system for studying transcription initiation in non-TATA type promoters.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PATHOL,BOX 0506,SAN FRANCISCO,CA 94143; VET AFFAIRS MED CTR,DEPT PATHOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Zhou, Dao-Xiu/0000-0002-1540-0598				AYER DE, 1988, MOL CELL BIOL, V8, P2021, DOI 10.1128/MCB.8.5.2021; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BULLA GA, 1989, VIROLOGY, V170, P251, DOI 10.1016/0042-6822(89)90373-5; CATTANEO R, 1983, NATURE, V305, P336, DOI 10.1038/305336a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DEMEDINA T, 1988, MOL CELL BIOL, V8, P2449, DOI 10.1128/MCB.8.6.2449; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; FARNHAM PJ, 1990, MOL CELL BIOL, V10, P1390, DOI 10.1128/MCB.10.4.1390; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; ORITO E, 1989, P NATL ACAD SCI USA, V86, P7059, DOI 10.1073/pnas.86.18.7059; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; OU J, 1985, P NATL ACAD SCI USA, V82, P83, DOI 10.1073/pnas.82.1.83; OZER J, 1990, J BIOL CHEM, V265, P22143; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; RANEY AK, 1989, J VIROL, V63, P3919, DOI 10.1128/JVI.63.9.3919-3925.1989; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; VALENZUELA P, 1980, ANIMAL VIRUS GENETIC, P57; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VUORIO T, 1990, J BIOL CHEM, V265, P22480; ZHOU DX, 1991, MOL CELL BIOL, V11, P1353, DOI 10.1128/MCB.11.3.1353; ZHOU DX, 1990, J BIOL CHEM, V265, P20731	36	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23416	23421						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1840596				2022-12-25	WOS:A1991GT48300095
J	REDDY, ESP; RAO, VN				REDDY, ESP; RAO, VN			ERG, AN ETS-RELATED GENE, CODES FOR SEQUENCE-SPECIFIC TRANSCRIPTIONAL ACTIVATORS	ONCOGENE			English	Article							PUTATIVE ONCOGENE SPI-1; LONG TERMINAL REPEAT; AVIAN LEUKEMIA-VIRUS; PROTO-ONCOGENE; DNA-BINDING; C-ETS; V-ETS; CHROMOSOME-21; PROTEINS; CELLS	E26 is a replication-defective avian acute leukemia virus which causes erythroblastosis and myeloblastosis in chickens. It carries two distinct oncogenes, v-myb and v-ets, both of which contribute to its transforming properties. Several genes related to the ets oncogene (c-ets-1, ets-2, erg, elk-1, elk-2, PU.1/Spi-1, E74 and Fli-1) have been described. Previously we have shown that the erg gene (ets-related gene) codes for at least two proteins (erg-1 and erg-2) because of alternative splicing and alternative usage of the initiation codon. We have expressed erg-1 and erg-2 proteins in Escherichia coli and have used these recombinant proteins to show that they bind to DNA in a sequence-specific manner. erg proteins exhibited different sequence specificity and affinity for the oligonucleotides recognized by c-ets-1, ets-2, some of PU.1/Spi-1 and elk-1, suggesting that the DNA-binding specificities of erg and other members may overlap but are not necessarily identical. The erg gene was found to transactivate a reporter gene that was linked to erg target sequences. These results suggest that erg-1 and erg-2 are sequence-specific transcriptional activators like the other members of the ets oncogene superfamily which represent a distinct class of transcriptional activators.	TEMPLE UNIV,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University								ATCHISON ML, 1988, EMBO J, V7, P4213, DOI 10.1002/j.1460-2075.1988.tb03318.x; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; COQUILLAND M, 1988, ONCOGENE RES, V2, P335; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1991, IN PRESS ONCOGENE; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1986, GENE ANAL TECH, V3, P41; REDDY ESP, 1991, ERG ELK 1 ELK 2 GUID; REDDY ESP, 1990, CANCER RES, V50, P5013; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; [No title captured]	36	71	72	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2285	2289						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766675				2022-12-25	WOS:A1991GX73500016
J	LEITMAN, DC; RIBEIRO, RCJ; MACKOW, ER; BAXTER, JD; WEST, BL				LEITMAN, DC; RIBEIRO, RCJ; MACKOW, ER; BAXTER, JD; WEST, BL			IDENTIFICATION OF A TUMOR NECROSIS FACTOR-RESPONSIVE ELEMENT IN THE TUMOR-NECROSIS-FACTOR-ALPHA GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MESSENGER-RNA LEVELS; FACTOR-KAPPA-B; TRANSCRIPTION FACTORS; ENHANCER ELEMENTS; HUMAN-FIBROBLASTS; FACTOR BINDING; EXPRESSION; CACHECTIN; PROTEINS; ACTIVATION	The regulation by tumor necrosis factor-alpha (TNF) of its own promoter has been investigated by transient transfection and nuclear protein binding assays. In human K652 erythroleukemia cells TNF produced an 8 - 10-fold activation of the human TNF promoter linked to the chloramphenicol acetyltransferase gene. The TNF-responsive element was localized to the -125 to -82 region by examining the TNF activation in 5'-deletion or site-directed mutants of the TNF promoter and by demonstrating that the -125 to -82 fragment confers TNF responsiveness to the thymidine kinase promoter. This region contains a palindrome, 5' TGAGCTCA 3', that resembles the consensus binding sequences for the transcription factors, activator protein-1 (AP-1), cyclic AMP-responsive element binding protein (CREB), and activation transcription factor (ATF). An internal deletion in the palindrome abolished the TNF responsiveness, whereas known AP-1 and CREB/ATF elements were unresponsive to TNF. In band shift analyses a nuclear factor from U937 cells specifically bound to the -125 to -82 TNF-responsive fragment in or near the palindromic sequence. Oligonucleotides containing AP-1 or CREB/ATF sites did not effectively compete for the binding, indicating that the U937 cell factor is different from these factors. Anti-c-fos antiserum did not affect binding of the U937 cell factor, whereas anti-c-jun antiserum did block its binding, indicating that either c-jun or a protein antigenically related to c-jun is a component of the factor. These results suggest that the TNF-responsive element is not activated by AP-1 or CREB in U937 cells and that a novel DNA binding factor is important for constitutive and inducible TNF gene expression.	UNIV CALIF SAN FRANCISCO,METAB RES UNIT,HSE 671,SAN FRANCISCO,CA 94143; STANFORD UNIV,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	University of California System; University of California San Francisco; Stanford University				West, Brian/0000-0002-5320-3691	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041842] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41842] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENBROOK DM, 1990, ONCOGENE, V5, P295; BEUTLER B, 1988, BIOCHEMISTRY-US, V27, P7575, DOI 10.1021/bi00420a001; BEUTLER B, 1988, ANNU REV MED, V39, P75, DOI 10.1146/annurev.med.39.1.75; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; COLLINS T, 1986, P NATL ACAD SCI USA, V83, P446, DOI 10.1073/pnas.83.2.446; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; ECONOMOU JS, 1989, J EXP MED, V170, P321, DOI 10.1084/jem.170.1.321; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; Grunfeld C, 1990, Adv Intern Med, V35, P45; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HENSEL G, 1989, LYMPHOKINE RES, V8, P347; HENSEL G, 1987, LYMPHOKINE RES, V6, P119; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; JACOBSEN H, 1989, MOL CELL BIOL, V9, P3037, DOI 10.1128/MCB.9.7.3037; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN JX, 1987, J BIOL CHEM, V262, P11908; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MILLER SC, 1988, MOL CELL BIOL, V8, P2295, DOI 10.1128/MCB.8.6.2295; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; NEDWIN GE, 1985, NUCLEIC ACIDS RES, V13, P6361, DOI 10.1093/nar/13.17.6361; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; OLIFF A, 1988, CELL, V54, P141, DOI 10.1016/0092-8674(88)90543-0; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PAPE ME, 1989, MOL CELL BIOL, V9, P974, DOI 10.1128/MCB.9.3.974; PERLMUTTER DH, 1986, J CLIN INVEST, V78, P1349, DOI 10.1172/JCI112721; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SOLISHERRUZO JA, 1988, J BIOL CHEM, V263, P5841; STEPHENS KE, 1988, AM REV RESPIR DIS, V137, P1364, DOI 10.1164/ajrccm/137.6.1364; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; TORTI SV, 1988, J BIOL CHEM, V263, P12638; TRACEY KJ, 1989, LANCET, V1, P1122; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WISPE JR, 1990, J CLIN INVEST, V86, P1954, DOI 10.1172/JCI114929; WU JP, 1989, J BIOL CHEM, V264, P6472	41	92	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9343	9346						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1827793				2022-12-25	WOS:A1991FM45900002
J	SAINTRUF, C; MALFOY, B; SCHOLL, S; ZAFRANI, B; DUTRILLAUX, B				SAINTRUF, C; MALFOY, B; SCHOLL, S; ZAFRANI, B; DUTRILLAUX, B			GST-PI-GENE IS FREQUENTLY COAMPLIFIED WITH INT2 AND HSTF1 PROTOONCOGENES IN HUMAN BREAST CANCERS	ONCOGENE			English	Article							GLUTATHIONE-S-TRANSFERASE; HUMAN DESMIN GENE; TUMOR-CELL-LINES; SV40 DNA; AMPLIFICATION; EXPRESSION; ASSIGNMENT; MARKER; BCL-1	The glutathione S-transferase gene (GST-pi) is located on the same chromosome band (11q13) as proto-oncogenes INT2 and HSTF1 which are frequently amplified in breast cancer. Using the Southern blot technique, we looked for the amplification of the GST-pi gene in 17 fresh tumors from human mammary carcinoma. The tumors were preselected because either they had an amplification of the INT2 proto-oncogene detected by dot blot, or their karyotypes exhibited or did not exhibit homogeneously staining regions, a cytogenetic character indicating amplification. Coamplification of GST-pi, HSTF1 and INT2 was observed in five tumors, and coamplification of GST-pi and HSTF1 without amplification of INT2 in another tumor. We also observed coamplification of GST-pi, INT2, HSTF1 in the mammary carcinoma cell line MDA/MB134, whereas GST-pi alone was amplified in the mammary epithelial cell line HBL100. These results indicate that INT2, HSTF1 and GST-pi belong to the same large amplicon. Since GST-pi is involved in intracellular detoxication and since chemotherapeutic drugs are among its substrates, it will be of interest to study GST-pi gene expression as well as the response to chemotherapy in patients presenting this amplicon.	INST CURIE,BIOL SECT,CNRS,URA 620,26 RUE ULM,F-75231 PARIS 05,FRANCE; INST CURIE,MED SECT,F-75231 PARIS 05,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie								ADELAIDE J, 1988, ONCOGENE, V2, P413; ALI IU, 1989, ONCOGENE, V4, P89; BIEDLER JL, 1976, SCIENCE, V191, P185, DOI 10.1126/science.942798; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; COWELL IG, 1988, BIOCHEM J, V255, P79, DOI 10.1042/bj2550079; DIILIO C, 1988, CARCINOGENESIS, V9, P335; DULIK DM, 1986, BIOCHEM PHARMACOL, V35, P3405, DOI 10.1016/0006-2952(86)90444-2; DUTRILLAUX B, IN PRESS CANCER GENE; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; GERBAULTSEUREAU M, 1987, ANN GENET-PARIS, V30, P146; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HILL DL, 1976, P AM ASSOC CANC RES, V17, P52; HOWIE AF, 1990, CARCINOGENESIS, V11, P295, DOI 10.1093/carcin/11.2.295; Jakoby W B, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P383; JOLLY DJ, 1982, P NATL ACAD SCI-BIOL, V79, P5038, DOI 10.1073/pnas.79.16.5038; KANO T, 1987, CANCER RES, V47, P5626; LI YC, 1988, P NATL ACAD SCI USA, V85, P344, DOI 10.1073/pnas.85.2.344; LILIENBAUM A, 1988, CELL MOL BIOL, V34, P663; MARLHENS F, 1988, ANN GENET-PARIS, V31, P81; MOSCOW JA, 1988, P NATL ACAD SCI USA, V85, P6518, DOI 10.1073/pnas.85.17.6518; MOSCOW JA, 1989, CANCER RES, V49, P1422; NGUYEN C, 1988, ONCOGENE, V3, P703; SAINTRUF C, 1989, INT J CANCER, V44, P367, DOI 10.1002/ijc.2910440230; SAINTRUF C, IN PRESS CANCER GENE; SAINTRUF C, 1990, GENES CHROMOSOMES CA, V2, P63; SHEA TC, 1988, CANCER RES, V48, P527; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SODROSKI JG, 1984, P NATL ACAD SCI-BIOL, V81, P3039, DOI 10.1073/pnas.81.10.3039; THEILLET C, 1990, ONCOGENE, V5, P147; VIEGASPEQUIGNOT E, 1989, HUM GENET, V83, P33, DOI 10.1007/BF00274143; WADA A, 1988, BIOCHEM BIOPH RES CO, V157, P828, DOI 10.1016/S0006-291X(88)80324-3; 1981, CLASSIFICATION HISTO; 1982, TNM VICC TNM ATLAS; 1989, CYTOGENET CELL GENET, V51, P1	36	39	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					403	406						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1826346				2022-12-25	WOS:A1991FT34400008
J	HAYASHI, K; FUJIO, Y; KATO, I; SOBUE, K				HAYASHI, K; FUJIO, Y; KATO, I; SOBUE, K			STRUCTURAL AND FUNCTIONAL-RELATIONSHIPS BETWEEN H-CALDESMONS AND L-CALDESMONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING PROTEIN; CHICKEN GIZZARD CALDESMON; MUSCLE THIN-FILAMENTS; SMOOTH-MUSCLE; ATPASE ACTIVITY; F-ACTIN; CA-2+ REGULATION; TROPONIN-T; MYOSIN INTERACTION; CROSS-LINKING	Two different M(r) forms of caldesmon as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (M(r) values in the range of 120,000-150,000, h-caldesmon and 70,000-80,000, l-caldesmon) have been already identified. h-Caldesmon is predominantly expressed in smooth muscle cells, whereas l-caldesmon widely distributes in non-muscle cells. Most recently, the molecular cloning of h-caldesmon has been reported (Hayashi,K., Kanda, K., Kimizuka, F., kato, I., and Sobue, K. (1989) Biochem. Biophys. Res. Commun. 164, 503-511; Bryan, J., Imai, M., Lee, R., Moore, P., Cook, R.G., and Lin, W-G. (1989) J. Biol. Chem. 264, 13873-13879). The calculated M(r) of this protein from its primary structure is 88,743. Here, the nucleotide and deduced amino acid sequences of l-caldesmon have been determined by cloning and sequencing the cDNA from chick brain and compared with those of h-caldesmon. The l-caldesmon cDNA encodes a sequence of 517 amino acids with the calculated M(r) of 58,844. Two isoforms of caldesmon conserve the completely identical sequences in the NH2- and COOH-terminal domains except for the insertion of Ala-508 in l-caldesmon. Interestingly, the central repeating sequence of h-caldesmon (residues 201-477) is deleted in the l-caldesmon molecule. The short NH2-terminals of two caldesmons individually show the unique sequences. The results of Northern and Southern blot analyses suggest that two mRNAs (4.8 and 4.1 kilobases) coding for caldesmon isoforms may be generated from a single gene by alternative splicing. Using a series of truncated caldesmons expressed in Escherichia coli, the common calmodulin-, tropomyosin-, and acting-binding sites and the minimum regulatory domains, which are involved in the Ca2+-dependent regulation of actin-myosin interaction, have been identified within the limited consensus sequences (residues 381-433 for l-caldesmon and residues 636-688 for h-caldesmon).	OSAKA UNIV,SCH MED,BIOMED RES CTR,DEPT NEUROCHEM & NEUROPHARMACOL,4-3-57 NAKANOSHIMA,KITA KU,OSAKA 530,JAPAN; TAKARA SHUZO CO LTD,BIOTECHNOL RES LABS,OTSU,SHIGA 52021,JAPAN	Osaka University; Takara Holdings Inc.			Fujio, Yasushi/H-3421-2017	Fujio, Yasushi/0000-0003-0828-2930				BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BRETSCHER A, 1985, J CELL BIOL, V100, P1656, DOI 10.1083/jcb.100.5.1656; BRYAN J, 1989, J BIOL CHEM, V264, P13873; BRYAN J, 1990, JC SEIDEL MEMORIAL S; CHALOVICH JM, 1987, J BIOL CHEM, V262, P5711; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DINGUS J, 1986, J CELL BIOL, V102, P1748, DOI 10.1083/jcb.102.5.1748; FUJII T, 1987, J BIOL CHEM, V262, P2757; FUJII T, 1988, J BIOCHEM-TOKYO, V104, P734, DOI 10.1093/oxfordjournals.jbchem.a122542; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V164, P503, DOI 10.1016/0006-291X(89)91748-8; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V161, P38, DOI 10.1016/0006-291X(89)91556-8; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; IKEBE M, 1988, J BIOL CHEM, V263, P3055; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASH JA, 1986, J BIOL CHEM, V261, P6155; LESZYK J, 1989, BIOCHEM BIOPH RES CO, V160, P210, DOI 10.1016/0006-291X(89)91642-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MABUCHI K, 1990, JC SEIDEL MEMORIAL S; MAKI M, 1987, FEBS LETT, V223, P174, DOI 10.1016/0014-5793(87)80531-8; Maniatis T., 1982, MOL CLONING; MARSTON SB, 1985, BIOCHEM J, V231, P517, DOI 10.1042/bj2310517; MORNET D, 1988, BIOCHEM BIOPH RES CO, V154, P564, DOI 10.1016/0006-291X(88)90177-5; NGAI PK, 1984, J BIOL CHEM, V259, P3656; OWADA MK, 1984, P NATL ACAD SCI-BIOL, V81, P3133, DOI 10.1073/pnas.81.10.3133; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; PRITCHARD K, 1989, BIOCHEM J, V257, P839, DOI 10.1042/bj2570839; RISEMAN VM, 1989, J BIOL CHEM, V264, P2869; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIRINSKY VP, 1988, BIOCHEM J, V255, P203; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOBUE K, 1985, BIOMED RES-TOKYO, V6, P93; SOBUE K, 1979, FEBS LETT, V105, P105, DOI 10.1016/0014-5793(79)80896-0; SOBUE K, 1982, BIOCHEM INT, V5, P503; SOBUE K, 1988, J CELL BIOCHEM, V37, P317, DOI 10.1002/jcb.240370306; SOBUE K, 1985, P NATL ACAD SCI USA, V82, P5025, DOI 10.1073/pnas.82.15.5025; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SOBUE K, 1985, BIOCHEM BIOPH RES CO, V132, P645, DOI 10.1016/0006-291X(85)91181-7; SOBUE K, 1989, CALMODULIN, P325; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUTHERLAND C, 1989, J BIOL CHEM, V264, P578; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; TANAKA T, 1985, J BIOCHEM-TOKYO, V97, P1823, DOI 10.1093/oxfordjournals.jbchem.a135244; TANAKA T, 1990, EUR J BIOCHEM, V188, P495, DOI 10.1111/j.1432-1033.1990.tb15427.x; THOMAS PS, 1980, P NATL ACAD SCI USA, V164, P5140; UEKI N, 1987, P NATL ACAD SCI USA, V84, P9049, DOI 10.1073/pnas.84.24.9049; VELAZ L, 1990, J BIOL CHEM, V265, P2929; WANG CLA, 1988, BIOCHEM BIOPH RES CO, V156, P1033, DOI 10.1016/S0006-291X(88)80948-3; YAZAWA M, 1987, J BIOCHEM-TOKYO, V102, P1065, DOI 10.1093/oxfordjournals.jbchem.a122144	53	116	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					355	361						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1824698				2022-12-25	WOS:A1991EQ33900052
J	HARPEL, MR; LARIMER, FW; HARTMAN, FC				HARPEL, MR; LARIMER, FW; HARTMAN, FC			FUNCTIONAL-ANALYSIS OF THE PUTATIVE CATALYTIC BASES HIS-321 AND SER-368 OF RHODOSPIRILLUM-RUBRUM RIBULOSE BISPHOSPHATE CARBOXYLASE OXYGENASE BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIOSE PHOSPHATE ISOMERASE; RIBULOSEBISPHOSPHATE CARBOXYLASE; ACTIVE-SITE; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; 1,5-BISPHOSPHATE CARBOXYLASE; CARBON-DIOXIDE; PROTEIN; ANALOGS; ENZYME; PHOSPHOGLYCOLATE	Numerous candidates have been suggested according to chemical and structural criteria for the active site base of ribulose bisphosphate carboxylase/oxygenase that catalyzes substrate enolization. We evaluate the functional significance of two such candidates, His-321 and Ser-368 of the Rhodospirillum rubrum enzyme, by site-directed mutagenesis. Position 321 mutants retain 3-12% of wild-type rates of both overall carboxylation and the initial enolization, with little effect on K(m) for CO2 or ribulose bisphosphate. Position 368 mutants exhibit approximately 1% of wild-type carboxylation but 4-9% of enolization, also accompanied by little effect on K(m) values. The modest catalytic facilitations elicited by these residues are incompatible with either acting as the crucial base. The enhanced efficiency of the position 368 mutants in enolization versus carboxylation clearly indicates that Ser-368 effects catalysis preferentially beyond the point of proton abstraction. Both sets of mutants bind the reaction intermediate analogue, 2-carboxy-D-arabinitol bisphosphate, stoichiometrically. Ligand exchange from complexes with position 321 mutants is increased relative to wild type, whereas complexes with position 368 mutants are more exchange-inert. Therefore, His-321 may assist stabilization of the transition state mimicked by the analogue.	OAK RIDGE NATL LAB, DIV BIOL, PROT ENGN PROGRAM, POB 2009, OAK RIDGE, TN 37831 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory								ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; Andrews T.J., 1987, BIOCH PLANTS, P131, DOI 10.1016/B978-0-12-675410-0.50009-9; ANDREWS TJ, 1973, BIOCHEMISTRY-US, V12, P11, DOI 10.1021/bi00725a003; BENDER SL, 1989, BIOCHEMISTRY-US, V28, P7560, DOI 10.1021/bi00445a010; BOWES G, 1971, BIOCHEM BIOPH RES CO, V45, P716, DOI 10.1016/0006-291X(71)90475-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN ZX, 1989, J BIOL CHEM, V264, P3051; CLELAND WW, 1990, BIOCHEMISTRY-US, V29, P3194, DOI 10.1021/bi00465a006; COULSON AFW, 1970, NATURE, V227, P180, DOI 10.1038/227180a0; DAVENPORT RC, 1991, BIOCHEMISTRY-US, V30, P5821, DOI 10.1021/bi00238a002; GUTTERIDGE S, 1988, PLANT PHYSIOL BIOCH, V26, P675; HARTMAN FC, 1985, J BIOL CHEM, V260, P3968; HARTMAN FC, 1971, BIOCHEMISTRY-US, V10, P146, DOI 10.1021/bi00777a021; HARTMAN FC, 1987, J BIOL CHEM, V262, P3496; HARTMAN FC, 1989, J BIOL CHEM, V264, P11784; HARTMAN FC, 1990, NATO ADV SCI I C-MAT, V314, P347; Hermann V. P., 1968, HOPPESEYLERS Z PHYSL, V349, P390; Horecker B. L., 1958, BIOCHEM PREP, V6, P83; JAWOROWSKI A, 1984, J BIOL CHEM, V259, P6783; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; KULIOPULOS A, 1989, BIOCHEMISTRY-US, V28, P149, DOI 10.1021/bi00427a022; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LARIMER FW, 1990, PROTEIN ENG, V3, P227, DOI 10.1093/protein/3.3.227; LORIMER GH, 1976, BIOCHEMISTRY-US, V15, P529, DOI 10.1021/bi00648a012; LORIMER GH, 1988, J BIOL CHEM, V263, P6468; LUNDQVIST T, 1991, J BIOL CHEM, V266, P12604; MIZIORKO HM, 1980, BIOCHEMISTRY-US, V19, P1167, DOI 10.1021/bi00547a020; MURAL RJ, 1990, J BIOL CHEM, V265, P6501; NIYOGI SK, 1986, J BIOL CHEM, V261, P87; PERIANA RA, 1980, J AM CHEM SOC, V102, P3923, DOI 10.1021/ja00531a040; PIERCE J, 1980, BIOCHEMISTRY-US, V19, P934, DOI 10.1021/bi00546a018; PIERCE J, 1986, BIOCHEMISTRY-US, V25, P1636, DOI 10.1021/bi00355a029; Sambrook J., 1989, MOL CLONING LABORATO, V3, pA3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLOSS JV, 1988, J BIOL CHEM, V263, P4145; SCHLOSS JV, 1982, METHOD ENZYMOL, V90, P522; SCHLOSS JV, 1990, NATO ADV SCI I C-MAT, V314, P321; SMITH HB, 1990, J BIOL CHEM, V265, P1243; SMITH HB, 1988, J BIOL CHEM, V263, P4921; SMITH HB, 1991, BIOCHEMISTRY-US, V30, P5172, DOI 10.1021/bi00235a009; SUE JM, 1982, BIOCHEMISTRY-US, V21, P5404, DOI 10.1021/bi00265a004; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; VANDYK DE, 1986, BIOCHEMISTRY-US, V25, P5145, DOI 10.1021/bi00366a024; WALEY SG, 1970, NATURE, V227, P181, DOI 10.1038/227181a0; XUE L, 1991, BIOCHEMISTRY-US, V30, P4991, DOI 10.1021/bi00234a022	46	28	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24734	24740						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761567				2022-12-25	WOS:A1991GW84500076
J	HORTON, WE; BALAKIR, R; PRECHT, P; LIANG, CT				HORTON, WE; BALAKIR, R; PRECHT, P; LIANG, CT			1,25-DIHYDROXYVITAMIN-D3 DOWN-REGULATES AGGRECAN PROTEOGLYCAN EXPRESSION IN IMMORTALIZED RAT CHONDROCYTES THROUGH A POSTTRANSCRIPTIONAL MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D; CELLS; CARTILAGE; CULTURE; INVITRO; PROTEIN; 24R,25-DIHYDROXYCHOLECALCIFEROL; 1,25-DIHYDROXYCHOLECALCIFEROL; SEQUENCE; GENES	We have examined the effects of various analogs of vitamin D on the expression of the aggrecan proteoglycan by an immortalized rat chondrocyte cell line. The active metabolite of vitamin D, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), produced a concentration-dependent reduction in the synthesis of aggrecan as monitored by histochemical staining of the matrix, incorporation of [S-35]sulfate, and the level of aggrecan core protein. Other analogs of vitamin D were much less potent or had no activity whatsoever. The reduced expression of aggrecan was caused by a dramatic decrease in the steady-state level of the mRNA coding for the aggrecan core protein. A nuclear run-off analysis revealed that the rate of transcription of the aggrecan gene was not significantly altered by 1,25(OH)2D3 treatment, suggesting that the metabolite was acting through a post-transcriptional mechanism. Experiments using the transcriptional inhibitor actinomycin D also supported a nondirect effect of 1,25(OH)2D3 on the expression of the aggrecan gene. These results suggest that the vitamin D metabolite activates a new pattern of gene expression which results in a more rapid turnover of the aggrecan mRNA. This system should be useful for characterizing the regulation of chondrocyte gene expression by vitamin D.			HORTON, WE (corresponding author), NIA,GERONTOL RES CTR,BALTIMORE,MD 21224, USA.							CELANO P, 1989, BIOFEEDBACK, V7, P83; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DICKSON IR, 1985, J ENDOCRINOL, V105, P79, DOI 10.1677/joe.0.1050079; DOEGE K, 1986, J BIOL CHEM, V261, P8108; GERSTENFELD LC, 1990, ENDOCRINOLOGY, V126, P1599, DOI 10.1210/endo-126-3-1599; HARMAND MF, 1984, J CELL PHYSIOL, V119, P359, DOI 10.1002/jcp.1041190315; HARRISON JR, 1989, ENDOCRINOLOGY, V125, P327, DOI 10.1210/endo-125-1-327; HORTON WE, 1988, EXP CELL RES, V178, P457, DOI 10.1016/0014-4827(88)90414-4; JIBRIL AO, 1967, BIOCHIM BIOPHYS ACTA, V136, P162, DOI 10.1016/0304-4165(67)90335-2; KATO Y, 1990, P NATL ACAD SCI USA, V87, P6522, DOI 10.1073/pnas.87.17.6522; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG CT, 1986, J MEMBRANE BIOL, V90, P145, DOI 10.1007/BF01869932; MARKOSE ER, 1990, P NATL ACAD SCI USA, V87, P1701, DOI 10.1073/pnas.87.5.1701; MCDONNELL DP, 1987, SCIENCE, V235, P1214, DOI 10.1126/science.3029866; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; MUIR IHM, 1985, JOINTS SYNOUIAL FLUI, V2, P27; ORNOY A, 1983, CARTILAGE, P310; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; PRICE PA, 1980, J BIOL CHEM, V255, P1660; SIMPSON RU, 1987, J BIOL CHEM, V262, P4104; SUDW S, 1985, CALCIFIED TISSUE INT, V37, P82; SUTCLIFFE JG, 1983, CELL, V33, P671, DOI 10.1016/0092-8674(83)90010-7; SUZUKI F, 1981, P NATL ACAD SCI-BIOL, V78, P2368, DOI 10.1073/pnas.78.4.2368; TAKEUCHI Y, 1989, J BIOL CHEM, V264, P18407; TAKIGAWA M, 1988, ENDOCRINOLOGY, V122, P831, DOI 10.1210/endo-122-3-831	25	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24804	24808						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761574				2022-12-25	WOS:A1991GW84500085
J	IDO, E; HAN, HP; KEZDY, FJ; TANG, J				IDO, E; HAN, HP; KEZDY, FJ; TANG, J			KINETIC-STUDIES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEASE AND ITS ACTIVE-SITE HYDROGEN-BOND MUTANT A28S	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HIV-1 PROTEASE; ASPARTIC PROTEINASES; PORCINE PEPSIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; 2.3-A RESOLUTION; AIDS VIRUS; INHIBITORS; PEPSTATIN; SEQUENCE	Human immunodeficiency virus type 1 (HIV-1) protease optimally catalyzes in the pH range of 4-6 in contrast to nearly all of the other eukaryotic aspartic proteases, which catalyze best in the pH range of 2-4. A possible structural reason for the higher optimal pH of HIV-1 protease is the absence of a hydrogen bond to the carboxyl group of active-site Asp25, which is nearly universally present in others. To investigate this hypothesis, we have mutated residue 28 in HIV-1 protease from alanine to serine. Both the wild-type and the mutant A28S enzymes have been overexpressed in Escherichia coli using a chemically synthesized gene and purified for a comparative study in enzyme kinetics. The k(cat) and K(m) values were determined by a radiometric assay for the wild-type enzyme from pH 3.2 to 7.0, and for the mutant enzyme from pH 3.2 to 6.0. The low pK values of the active site of the free enzyme, pK(e1), are 3.3 and 3.4 for the wild-type and mutant enzymes, respectively. The low pK values of the active site of the enzyme bound to substrate, pK(es1), are 5.1 and 4.3 for the wild-type and mutant enzymes, respectively. The high pK values of the free enzyme, pK(e2), are 6.8 and 5.6, and the corresponding ones for the substrate-bound enzyme, pK(es2), are 6.9 and 6.0 for the wild-type and mutant enzymes, respectively. The lowering of pK values in mutant HIV-1 protease indicates that the hydroxyl group of Ser28 forms a new hydrogen bond to active-site Asp25 to increase its acidity.	OKLAHOMA MED RES FDN,PROT STUDIES PROGRAM,825 NE 13TH ST,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73104; UPJOHN CO,BIOPOLYMER CHEM UNIT,KALAMAZOO,MI 49001	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Pfizer					NIAID NIH HHS [AI 26762] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026762] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABADZAPATERO C, 1990, PROTEINS, V8, P62, DOI 10.1002/prot.340080109; ANDREEVA NS, 1984, J BIOL CHEM, V259, P1353; BABE LM, 1991, BIOCHEMISTRY-US, V30, P106, DOI 10.1021/bi00215a016; BLUMENSTEIN JJ, 1989, BIOCHEM BIOPH RES CO, V163, P980, DOI 10.1016/0006-291X(89)92318-8; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; CHENG YSE, 1990, GENE, V87, P243, DOI 10.1016/0378-1119(90)90308-E; CHENG YSE, 1990, P NATL ACAD SCI USA, V87, P9660, DOI 10.1073/pnas.87.24.9660; COOPER JB, 1990, J MOL BIOL, V214, P199, DOI 10.1016/0022-2836(90)90156-G; DARKE PL, 1989, J BIOL CHEM, V264, P2307; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; DEBOUCK C, 1987, P NATL ACAD SCI USA, V84, P8903, DOI 10.1073/pnas.84.24.8903; DESJARLAIS RL, 1990, P NATL ACAD SCI USA, V87, P6644, DOI 10.1073/pnas.87.17.6644; FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209; GOLDBLUM A, 1990, FEBS LETT, V261, P241, DOI 10.1016/0014-5793(90)80562-W; GRAVES MC, 1988, P NATL ACAD SCI USA, V85, P2449, DOI 10.1073/pnas.85.8.2449; GUTFREUND H, 1972, ENZYMES PHYSICAL PRI, P39; HANSEN J, 1988, EMBO J, V7, P1785, DOI 10.1002/j.1460-2075.1988.tb03009.x; HYLAND LJ, 1990, ANAL BIOCHEM, V188, P408, DOI 10.1016/0003-2697(90)90628-M; IKEMURA T, 1985, MOL BIOL EVOL, V2, P13; Inagami T., 1981, BIOCH REGULATION BLO, P39; JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023; KATOH I, 1987, NATURE, V329, P654, DOI 10.1038/329654a0; KNOWLES JR, 1976, CRC CR REV BIOCH MOL, V4, P165, DOI 10.3109/10409237609105457; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGRICE SFJ, 1988, EMBO J, V7, P2547, DOI 10.1002/j.1460-2075.1988.tb03103.x; MCQUADE TJ, 1990, SCIENCE, V247, P464; MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MILLER M, 1989, NATURE, V337, P576, DOI 10.1038/337576a0; MOORE ML, 1989, BIOCHEM BIOPH RES CO, V159, P420, DOI 10.1016/0006-291X(89)90008-9; PEARL L, 1984, FEBS LETT, V174, P96, DOI 10.1016/0014-5793(84)81085-6; POORMAN RA, 1991, J BIOL CHEM, V266, P14554; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RICHARDS AD, 1990, J BIOL CHEM, V265, P7733; RICHARDS AD, 1989, FEBS LETT, V247, P113, DOI 10.1016/0014-5793(89)81251-7; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; ROSSI JJ, 1982, J BIOL CHEM, V257, P9226; SEELMEIER S, 1988, P NATL ACAD SCI USA, V85, P6612, DOI 10.1073/pnas.85.18.6612; Segel I. H., 1975, ENZYME KINETICS, P884; SIELECKI AR, 1989, SCIENCE, V243, P1346, DOI 10.1126/science.2493678; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUGUNA K, 1987, J MOL BIOL, V196, P877, DOI 10.1016/0022-2836(87)90411-6; TANG J, 1978, NATURE, V271, P618, DOI 10.1038/271618a0; TOH H, 1985, NATURE, V315, P691, DOI 10.1038/315691a0; TOMASSELLI AG, 1990, BIOCHEMISTRY-US, V29, P264, DOI 10.1021/bi00453a036; WEBER IT, 1989, SCIENCE, V243, P928, DOI 10.1126/science.2537531; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; WONGSTAAL F, 1985, NATURE, V317, P395, DOI 10.1038/317395a0; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879, DOI 10.1248/bpb1978.4.879	50	119	123	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24359	24366						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761538				2022-12-25	WOS:A1991GW84500022
J	YU, C; LEE, AM; BASSLER, BL; ROSEMAN, S				YU, C; LEE, AM; BASSLER, BL; ROSEMAN, S			CHITIN UTILIZATION BY MARINE-BACTERIA - A PHYSIOLOGICAL-FUNCTION FOR BACTERIAL ADHESION TO IMMOBILIZED CARBOHYDRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; POLYACRYLAMIDE GELS; VIBRIO; ANTIBIOTICS; ADHERENCE; PROTEIN; CELLS	Chitin turnover is essential for recycling carbon and nitrogen in marine ecosystems. A key step in this process is the adhesion of marine bacteria to chitin-containing particulates. Vibrio species were therefore surveyed for their ability to bind to immobilized carbohydrates, and one, Vibrio furnissii, adhered to glycosides of three sugars, N-acetylglucosamine (the preferred ligand), D-Mannose, and D-glucose. A single Ca2+-requiring lectin is responsible for binding to the three sugars. Cells adhering to the chitin analogue divided at the same rate as cells in liquid culture. The first progeny of adherent cells continued to bind to the beads, but the population gradually shifted to a large fraction of free swimming cells, a process that may be necessary for colonization. Metabolic energy is required for cell adhesion to the glycosides, and transient (or no) adhesion occurred in incomplete growth media. The results were explained by studying met and pro mutants. Both the initiation and maintenance of lectin-mediated adhesion requires continuous protein synthesis; expression of lectin activity is a major priority of these cells and functions under conditions adequate for minimal protein synthesis, but insufficient to support cell growth. The adhesion/deadhesion apparatus is apparently used to continuously monitor the nutrient status of the environment, i.e. as a nutrient sensorium. In incomplete medium, cells deadhere, presumably to migrate to a more favorable environment.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	Johns Hopkins University	YU, C (corresponding author), JOHNS HOPKINS UNIV, MCCOLLUM PRATT INST, BALTIMORE, MD 21218 USA.			Bassler, Bonnie/0000-0002-0043-746X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007231] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM07231] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELBERG EA, 1965, BIOCHEM BIOPH RES CO, V18, P788, DOI 10.1016/0006-291X(65)90855-7; BASSLER BL, 1991, J BIOL CHEM, V266, P24268; BASSLER BL, 1991, J BIOL CHEM, V266, P24276; BOZZARO S, 1983, J BIOL CHEM, V258, P3890; BRINTON CC, 1965, T NEW YORK ACAD SCI, V27, P1003, DOI 10.1111/j.2164-0947.1965.tb02342.x; Carlton BC, 1981, MANUAL METHODS GENER, P222; CASTELL JV, 1979, ANAL BIOCHEM, V99, P379, DOI 10.1016/S0003-2697(79)80022-6; CHIPOWSKY S, 1973, CARBOHYD RES, V31, P339, DOI 10.1016/S0008-6215(00)86198-4; CHIPOWSKY S, 1973, P NATL ACAD SCI USA, V70, P2309, DOI 10.1073/pnas.70.8.2309; CHOPRA I, 1986, J ANTIMICROB CHEMOTH, V18, P441, DOI 10.1093/jac/18.4.441; Colwell R.R., 1984, VIBRIOS ENV; EISENSTEIN BI, 1982, SCAND J INFECT DIS, P108; FLETCHER M, 1986, APPL ENVIRON MICROB, V52, P672, DOI 10.1128/AEM.52.4.672-676.1986; FOX GE, 1980, SCIENCE, V209, P457, DOI 10.1126/science.6771870; GOLDBERY ED, 1974, SEA, V5; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; HOROWITZ ST, 1957, J AM CHEM SOC, V79, P5046, DOI 10.1021/ja01575a059; HULTGREN SJ, 1989, P NATL ACAD SCI USA, V86, P4357, DOI 10.1073/pnas.86.12.4357; Johnstone J., 1908, CONDITIONS LIFE SEA, P332; KJELLEBERG S, 1982, APPL ENVIRON MICROB, V43, P1166, DOI 10.1128/AEM.43.5.1166-1172.1982; KORHONEN TK, 1986, PROTEIN CARBOHYDRATE, P245; LINDBERG F, 1987, NATURE, V328, P84, DOI 10.1038/328084a0; LINDQUIST BL, 1987, INFECT IMMUN, V55, P3044, DOI 10.1128/IAI.55.12.3044-3050.1987; MEADOW ND, 1987, J BACTERIOL, V169, P4893, DOI 10.1128/jb.169.11.4893-4900.1987; MIRELMAN D, 1986, WILEY SERIES ECOLOGI; PALLESEN L, 1989, MOL MICROBIOL, V3, P925, DOI 10.1111/j.1365-2958.1989.tb00242.x; Parson T. R., 1977, BIOL OCEANOGRAPHIC P; PAUL JH, 1984, APPL ENVIRON MICROB, V48, P924, DOI 10.1128/AEM.48.5.924-929.1984; PLESS DD, 1983, J BIOL CHEM, V258, P2340; ROSEMAN S, 1956, ANAL CHEM, V28, P1743, DOI 10.1021/ac60119a028; SANDBERG T, 1979, REV INFECT DIS, V1, P838; SCHNAAR RL, 1978, J BIOL CHEM, V253, P7940; SMITH FGW, 1974, HDB MARINE SCI, V1; SUGARMAN B, 1979, J INFECT DIS, V140, P622, DOI 10.1093/infdis/140.4.622; WEIGEL PH, 1979, J BIOL CHEM, V254, P830; WEISS EI, 1988, J BACTERIOL, V170, P1123, DOI 10.1128/jb.170.3.1123-1128.1988; YU C, 1987, BIOCHEM BIOPH RES CO, V149, P86, DOI 10.1016/0006-291X(87)91608-1; Zobell CE, 1938, J BACTERIOL, V35, P275, DOI 10.1128/JB.35.3.275-287.1938	38	103	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24260	24267						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761531				2022-12-25	WOS:A1991GW84500008
J	BAILEY, SC; SPANGLER, R; SYTKOWSKI, AJ				BAILEY, SC; SPANGLER, R; SYTKOWSKI, AJ			ERYTHROPOIETIN INDUCES CYTOSOLIC PROTEIN-PHOSPHORYLATION AND DEPHOSPHORYLATION IN ERYTHROID-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-2 RECEPTOR-BETA; MR 100,000 SUBSTRATE; ELONGATION FACTOR-II; KINASE-C; TYROSINE PHOSPHORYLATION; EXPRESSION CLONING; MEMBRANE; IDENTIFICATION; DIFFERENTIATION; FAMILY	Erythropoietin, the prime regulator of red blood cell growth and differentiation, causes rapid changes in the phosphorylation of several integral plasma membrane proteins (Choi, H-S., Wojchowski, D. M., and Sytkowski, A. J. (1987) J. Biol. Chem. 262. 2933-2936; Choi, H-S., Bailey, S. C., Donahue, K. A., Vanasse, G. J., and Sytkowski, A. J. (1990) J. Biol. Chem. 265, 4143-4148). In the present study we have demonstrated that erythropoietin's signal is transduced rapidly to the cytosol resulting in specific phosphorylation/dephosphorylation events. Erythropoietin treatment of Rauscher murine erythroleukemia cells previously labeled with [P-32-]orthophosphate results in a rapid increase in phosphorylation of two cytosolic proteins, designated pp96 and pp80, and a decrease in phosphorylation of another protein, designated pp90. The relative molecular mass and pI of pp80 are virtually identical to those reported for the protein kinase C substrate p80, or "MARCKS protein." Treatment of the cells with 12-O-tetradecanoylphorbol-13-acetate also increases pp80 but not pp96 phosphorylation, suggesting that erythropoietin triggers a protein kinase C-dependent pathway to pp80 and a protein kinase C-independent pathway to pp96. The effect of erythropoietin on pp96 phosphorylation was also shown in nontransformed erythroid cells isolated from the spleens of phenylhydrazine-treated mice. In contrast, almost no P-32 labeling of pp80 or pp90 was detected, and pp80 and pp90 protein were nearly absent from these normal cells. These differences in expression and phosphorylation of erythropoietin-sensitive phosphoproteins may be related to the growth factor independence or dependence of the erythroid cells.	HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT MED,DIV HEMATOL & ONCOL,BOSTON,MA 02215	Harvard University; Harvard Medical School	SYTKOWSKI, AJ (corresponding author), HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT MED,DIV HEMATOL & ONCOL,BOSTON,MA 02215, USA.				NIDDK NIH HHS [DK 38841] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038841] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; AEBERSOLD R, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P71; ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; CHERN YJ, 1991, J BIOL CHEM, V266, P2009; CHOI HS, 1987, J BIOL CHEM, V262, P2933; CHOI HS, 1990, J BIOL CHEM, V265, P4143; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; de Both N J, 1978, Nature, V272, P626, DOI 10.1038/272626a0; DUNBAR BS, 1987, 2 DIMENSIONAL ELECTR, P217; EVANS SW, 1986, BLOOD, V68, P906; EVANS SW, 1987, J BIOL CHEM, V262, P4624; EVANS SW, 1987, BIOCHEM J, V244, P683, DOI 10.1042/bj2440683; FARRAR WL, 1985, NATURE, V315, P233, DOI 10.1038/315233a0; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GRABER SE, 1974, J LAB CLIN MED, V83, P288; GRABER SE, 1972, P SOC EXP BIOL MED, V141, P206; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; IMAGAWA S, 1988, BLOOD, V73, P1542; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; LEVENSON RM, 1989, J BIOL CHEM, V264, P19984; LEVENSON RM, 1989, J BIOL CHEM, V264, P11904; LINCH DC, 1987, BLOOD S, V70, pA177; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILLER BA, 1989, BLOOD, V73, P1188; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MIRE AR, 1985, BIOCHIM BIOPHYS ACTA, V847, P159, DOI 10.1016/0167-4889(85)90169-7; MISITI J, 1979, J CLIN INVEST, V64, P1151; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NAIRN AC, 1985, P NATL ACAD SCI USA, V82, P7939, DOI 10.1073/pnas.82.23.7939; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; QUELLE FW, 1991, J BIOL CHEM, V266, P609; SAWYER ST, 1984, J BIOL CHEM, V259, P2769; SIMEK SL, 1989, P NATL ACAD SCI USA, V86, P7410, DOI 10.1073/pnas.86.19.7410; SPANGLER R, 1991, J BIOL CHEM, V266, P681; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; SYTKOWSKI AJ, 1980, SCIENCE, V210, P74, DOI 10.1126/science.6932101; TAVARE JM, 1991, J BIOL CHEM, V266, P1390; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YONEKURA S, 1991, P NATL ACAD SCI USA, V88, P2535, DOI 10.1073/pnas.88.6.2535	44	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					24121	24125						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748684				2022-12-25	WOS:A1991GV31900092
J	FILUTOWICZ, M; INMAN, R				FILUTOWICZ, M; INMAN, R			A COMPACT NUCLEOPROTEIN STRUCTURE IS PRODUCED BY BINDING OF ESCHERICHIA-COLI INTEGRATION HOST FACTOR (IHF) TO THE REPLICATION ORIGIN OF PLASMID R6K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; NUCLEOTIDE-SEQUENCE; INITIATOR PROTEIN; GAMMA-ORIGIN; SITES; RECOMBINATION; MUTATIONS; ENHANCER; MUTANTS; INVITRO	Understanding the role of Escherichia coli histone-like protein integration host factor (IHF) in replication of R6K plasmid (Dellis, S., and Filutowicz, M. (1991) J. Bacteriol. 173, 1279-1286) requires detailed analyses of the interaction of IHF protein with the plasmid's replication origin (gamma-ori). We describe an electron microscopic analysis which shows that a compact structure can be formed in the presence of IHF, in which, on average, a 102-base pair (bp) ori segment is involved. IHF . gamma-ori complexes also undergo a two-step conformational change in an IHF concentration-dependent manner when analysed by band shift assay. We believe that the DNA is bent at low IHF concentrations, but folded at high IHF concentrations. This idea is supported by the fact that electrophoretic mobility of the IHF . gamma-ori complexes is faster at higher concentrations of IHF. Furthermore, it is shown that the formation of a compact nucleoprotein structure depends on the two regions flanking the AT-rich segment; the iterons to the right and the 106-bp ori domain to the left. Finally we show that IHF protects the entire AT-rich segment of the ori against nuclease cleavage. In addition to the protection, an altered cleavage pattern by DNase I, in the presence of high levels of IHF, was observed within the iterons but not within the 106-bp domain of the ori. Implications of the IHF-mediated gamma-ori folding as a possible mechanism protecting the ori from replication inhibition by R6K initiator protein-pi are discussed.	UNIV WISCONSIN, INST MOLEC VIROL, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	FILUTOWICZ, M (corresponding author), UNIV WISCONSIN, DEPT BACTERIOL, MADISON, WI 53706 USA.				NIGMS NIH HHS [GM 14711-23, GM 40314-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040314, R01GM014711] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIEK DP, 1989, J BACTERIOL, V171, P2056, DOI 10.1128/jb.171.4.2056-2065.1989; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; DELLIS S, 1991, J BACTERIOL, V173, P1279, DOI 10.1128/jb.173.3.1279-1286.1991; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FILUTOWICZ M, 1986, P NATL ACAD SCI USA, V83, P9645, DOI 10.1073/pnas.83.24.9645; FILUTOWICZ M, 1986, J MOL BIOL, V187, P225, DOI 10.1016/0022-2836(86)90230-5; FILUTOWICZ M, 1988, NUCLEIC ACIDS RES, V16, P3829, DOI 10.1093/nar/16.9.3829; FILUTOWICZ M, 1987, J CELL SCI, P15; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; GAMAS P, 1986, MOL GEN GENET, V204, P85, DOI 10.1007/BF00330192; GREENE JR, 1986, J BIOL CHEM, V261, P2820; GREENSTEIN D, 1988, P NATL ACAD SCI USA, V85, P6262, DOI 10.1073/pnas.85.17.6262; HODGESGARCIA Y, 1989, J BIOL CHEM, V264, P14621; INUZUKA M, 1978, P NATL ACAD SCI USA, V75, P5381, DOI 10.1073/pnas.75.11.5381; JOHNSON GG, 1977, BIOCHEMISTRY-US, V16, P1473, DOI 10.1021/bi00626a036; KOLTER R, 1978, J MOL BIOL, V124, P425, DOI 10.1016/0022-2836(78)90180-8; KOLTER R, 1982, J MOL BIOL, V161, P45, DOI 10.1016/0022-2836(82)90277-7; KOSTURKO LD, 1989, NUCLEIC ACIDS RES, V17, P317, DOI 10.1093/nar/17.1.317; KUR J, 1989, GENE, V81, P1, DOI 10.1016/0378-1119(89)90331-4; LEONG JM, 1985, J BIOL CHEM, V260, P4468; LEWISKITTELL B, 1991, P NATL ACAD SCI USA, V88, P1389; LITTLEWOOD RK, 1982, NUCLEIC ACIDS RES, V10, P1691, DOI 10.1093/nar/10.5.1691; Maniatis T., 1982, MOL CLONING; MCEACHERN MJ, 1985, P NATL ACAD SCI USA, V82, P1480, DOI 10.1073/pnas.82.5.1480; MCEACHERN MJ, 1989, P NATL ACAD SCI USA, V86, P7942, DOI 10.1073/pnas.86.20.7942; MCEACHERN MJ, 1987, THESIS U CALIFORNIA; MCEACHERN MJ, 1987, BANBURY C EVOLUTION; MENSAWILMOT K, 1989, EMBO J, V8, P2393, DOI 10.1002/j.1460-2075.1989.tb08369.x; MUKHERJEE S, 1988, CELL, V52, P375, DOI 10.1016/S0092-8674(88)80030-8; NASH HA, 1981, J BIOL CHEM, V256, P9246; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; PATEL I, 1986, CELL, V47, P785, DOI 10.1016/0092-8674(86)90521-0; PRENTKI P, 1987, EMBO J, V6, P2479, DOI 10.1002/j.1460-2075.1987.tb02529.x; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; ROUVIEREYANIV J, 1975, P NATL ACAD SCI USA, V72, P3428, DOI 10.1073/pnas.72.9.3428; STALKER DM, 1979, P NATL ACAD SCI USA, V76, P1150, DOI 10.1073/pnas.76.3.1150; STENZEL TT, 1987, CELL, V49, P709, DOI 10.1016/0092-8674(87)90547-2; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; WILLIAMS RC, 1977, P NATL ACAD SCI USA, V74, P2311, DOI 10.1073/pnas.74.6.2311; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	43	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					24077	24083						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1836213				2022-12-25	WOS:A1991GV31900085
J	HOFSTEENGE, J; SERVIS, C; STONE, SR				HOFSTEENGE, J; SERVIS, C; STONE, SR			STUDIES ON THE INTERACTION OF RIBONUCLEASE INHIBITOR WITH PANCREATIC RIBONUCLEASE INVOLVING DIFFERENTIAL LABELING OF CYSTEINYL RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEATS; HUMAN-PLACENTA; KINETIC CHARACTERIZATION; BINDING DOMAIN; PORCINE LIVER; PROTEIN; ANGIOGENIN; SUPERFAMILY	Ribonuclease inhibitor (RI) is a protein that forms a very tight complex with ribonucleases (RNases) of the pancreatic type. RI contains 30 thiol groups, some of which are important for the enzyme-inhibitor interaction. To examine which thiols are affected by the binding of RNase, differential labeling experiments were performed. Reaction of porcine RI with the cysteine-specific labeling reagent 4-N,N-dimethylaminoazobenzene-4'-iodoacetamido-2'-sulfonic acid resulted in labeling of an average of 7.4 of the 30 cysteinyl residues. Binding of bovine pancreatic RNase A caused a 3.2-fold reduction in the extent of modification. Peptide mapping showed that in free RI, Cys-57, -371, and -404 were labeled to the greatest extent (yield, 0.40. 6 mol/mol). RNase A did not protect Cys-57 against modification, whereas the labeling of Cys-371 and - 404 was reduced by more than 90%. A second group of residues was labeled to a lesser extent in free RI (yield, 0.04-0.2 mol/mol). Within this group 11 residues were protected by RNase A by more than 90%, 2 were not affected at all, and 7 were protected between 10 and 90%. Seven cysteinyl residues in RI that were protected in the RI.RNase A complex were no longer protected in the RI.S-protein complex. These residues were mainly present in the N-terminal region of RI. However, when the S-peptide was included to yield the RI.RNase S complex, the same pattern of labeling was obtained as with the RI.RNase A complex. Addition of the S-peptide alone had no effect on the labeling. The implications of these observations with respect to RNase binding areas of RI are discussed in relation to the results obtained from the analysis of active RI molecules that contain deletions.			HOFSTEENGE, J (corresponding author), FRIEDRICH MIESCHER INST,INST CHIM ORGAN,POB 2543,CH-4002 BASEL,SWITZERLAND.							AOKI Y, 1983, BIOCHEM J, V196, P699; BLACKBURN P, 1982, J BIOL CHEM, V257, P316; BLACKBURN P, 1977, J BIOL CHEM, V252, P5904; BLACKBURN P, 1979, J BIOL CHEM, V254, P2488; Blackburn P, 1982, ENZYMES, VXV, P317; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; GARCIASEGURA JM, 1985, BIOCHIM BIOPHYS ACTA, V826, P129, DOI 10.1016/0167-4781(85)90118-6; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P8537, DOI 10.1021/bi00423a006; HOFSTEENGE J, 1989, BIOCHEMISTRY-US, V28, P9806, DOI 10.1021/bi00451a040; HOFSTEENGE J, 1991, BIOCHEM J, V257, P541; KNECHT R, 1986, ANAL CHEM, V58, P2375, DOI 10.1021/ac00125a006; KRAFT N, 1970, AUST J BIOL SCI, V23, P175, DOI 10.1071/BI9700175; LEE FS, 1988, BIOCHEMISTRY-US, V27, P8545, DOI 10.1021/bi00423a007; LEE FS, 1989, BIOCHEMISTRY-US, V28, P225, DOI 10.1021/bi00427a031; LEE FS, 1990, P NATL ACAD SCI USA, V87, P1879, DOI 10.1073/pnas.87.5.1879; LEE FS, 1989, BIOCHEMISTRY-US, V28, P219, DOI 10.1021/bi00427a030; LEE FS, 1990, BIOCHEMISTRY-US, V29, P6633, DOI 10.1021/bi00480a012; RICHARDS FM, 1959, J BIOL CHEM, V234, P1459; RICHARDS FREDERIC M., 1955, COMPT REND TRAV LAB CARLSBERG SER CHIM, V29, P329; ROTH JS, 1958, J BIOL CHEM, V231, P1085; SCHNEIDER R, 1988, EMBO J, V7, P4151, DOI 10.1002/j.1460-2075.1988.tb03310.x; SHAPIRO R, 1986, BIOCHEMISTRY-US, V25, P7255, DOI 10.1021/bi00371a002; SHORTMAN K, 1962, BIOCHIM BIOPHYS ACTA, V55, P88; SUN XJ, 1989, J BIOL CHEM, V264, P11288; VICENTINI AM, 1990, BIOCHEMISTRY-US, V29, P8827, DOI 10.1021/bi00489a046; WELLING GW, 1974, FEBS LETT, V40, P134, DOI 10.1016/0014-5793(74)80911-7	26	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					24198	24204						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748689				2022-12-25	WOS:A1991GV31900102
J	KARGMAN, S; PRASIT, P; EVANS, JF				KARGMAN, S; PRASIT, P; EVANS, JF			TRANSLOCATION OF HL-60 CELL 5-LIPOXYGENASE - INHIBITION OF A23187-FORMYL-METHIONYL-LEUCYL-PHENYLALANINE-INDUCED OR N-FORMYL-METHIONYL-LEUCYL-PHENYLALANINE-INDUCED TRANSLOCATION BY INDOLE AND QUINOLINE LEUKOTRIENE SYNTHESIS INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATED HL60 CELLS; PROTEIN KINASE-C; LEUKEMIA-CELLS; ARACHIDONATE 5-LIPOXYGENASE; HUMAN-LEUKOCYTES; PURIFICATION; MEMBRANE; BIOSYNTHESIS; EXPRESSION; CDNA	We have demonstrated translocation of HL-60 cell 5-lipoxygenase to a membrane compartment in response to both the calcium ionophore A23187 and the receptor-mediated stimulus, N-formyl-methionyl-leucyl-phenylalanine (fMLP). In addition, we have shown inhibition of A23187- and fMLP-induced 5-lipoxygenase translocation by an indole and a quinoline leukotriene synthesis inhibitor, MK-886 and L-674,573, respectively. Selectivity of inhibition of 5-lipoxygenase translocation in both fMLP- or A23187-challenged cells is shown using the indole L-583,916 and quinoline L-671,480, which neither inhibit leukotriene synthesis nor inhibit 5-lipoxygenase translocation. The present study in HL-60 cells is the first demonstration of the selective inhibition of 5-lipoxygenase translocation by quinolone leukotriene synthesis inhibitors, exemplified by L-674,573. Also described here is the first demonstration of 5-lipoxygenase translocation and inhibition in response to a stimulus other than A23187, namely the receptor-mediated stimulus, fMLP.	MERCK FROSST CTR THERAPEUT RES,DEPT MED CHEM,POINTE CLAIRE H9R 4P8,QUEBEC,CANADA	Merck & Company	KARGMAN, S (corresponding author), MERCK FROSST CTR THERAPEUT RES,DEPT PHARMACOL,POB 1005,POINTE CLAIRE H9R 4P8,QUEBEC,CANADA.							ANTHES JC, 1986, INFLAMMATION, V10, P145, DOI 10.1007/BF00915996; BABA A, 1989, J BIOL CHEM, V264, P15790; BALCAREK JM, 1988, J BIOL CHEM, V263, P13937; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BONSER RW, 1981, BIOCHEM BIOPH RES CO, V102, P1269, DOI 10.1016/S0006-291X(81)80148-9; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1979, J EXP MED, V149, P969, DOI 10.1084/jem.149.4.969; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; DIPERSIO JF, 1988, PROSTAGLANDINS, V36, P673, DOI 10.1016/0090-6980(88)90013-5; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; EVANS J, 1990, 22ND NAT MED CHEM S; EVANS JF, 1991, MOL PHARMACOL, V40, P22; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2587, DOI 10.1073/pnas.86.8.2587; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2592, DOI 10.1073/pnas.86.8.2592; GILLARD JW, 1989, CAN J PHYSL PHARM, V67, P17; GOETZE AM, 1985, PROSTAGLANDINS, V29, P689, DOI 10.1016/0090-6980(85)90130-3; HOGABOOM GK, 1986, MOL PHARMACOL, V30, P510; HORN W, 1986, BIOCHEM BIOPH RES CO, V139, P1169, DOI 10.1016/S0006-291X(86)80300-X; KARGMAN S, 1989, J BIOL CHEM, V264, P13313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARQUEZ C, 1991, J IMMUNOL, V147, P627; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; NAGUCHI M, 1990, FEBS LETT, V247, P267; NAKAMURA M, 1990, GENE, V89, P231, DOI 10.1016/0378-1119(90)90010-O; REID GK, 1990, J BIOL CHEM, V265, P19818; ROUZER CA, 1985, P NATL ACAD SCI USA, V82, P6040, DOI 10.1073/pnas.82.18.6040; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; ROUZER CA, 1990, J BIOL CHEM, V265, P1436; ROUZER CA, 1988, J BIOL CHEM, V263, P10135; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SHIMIZU T, 1986, P NATL ACAD SCI USA, V83, P4175, DOI 10.1073/pnas.83.12.4175; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEDA N, 1986, J BIOL CHEM, V261, P7982; WONG A, 1988, BIOCHEMISTRY-US, V27, P6763, DOI 10.1021/bi00418a018	36	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23745	23752						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748650				2022-12-25	WOS:A1991GV31900036
J	NARDULLI, AM; LEW, D; ERIJMAN, L; SHAPIRO, DJ				NARDULLI, AM; LEW, D; ERIJMAN, L; SHAPIRO, DJ			PURIFIED ESTROGEN-RECEPTOR DNA-BINDING DOMAIN EXPRESSED IN ESCHERICHIA-COLI ACTIVATES TRANSCRIPTION OF AN ESTROGEN-RESPONSIVE PROMOTER IN CULTURED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN PROGESTERONE-RECEPTOR; HIGH-LEVEL EXPRESSION; HUMAN GLUCOCORTICOID RECEPTOR; GENE-EXPRESSION; INVITRO TRANSCRIPTION; NUCLEAR-LOCALIZATION; FUNCTIONAL DOMAINS; HORMONE-BINDING; MAMMALIAN-CELLS; IDENTIFICATION	The region of the Xenopus laevis estrogen receptor responsible for interaction with DNA, the DNA binding domain (DBD), has been cloned and overexpressed in Escherichia coli using a T7 RNA polymerase expression system. Extracts from cells transformed with the DBD expression vector contain a single protein which reacts with polyclonal antibodies to estrogen receptor and exhibits sequence-specific binding to a DNA fragment containing a consensus estrogen response element. The DBD protein has been purified to near homogeneity. Determination of the rotational relaxation time of the dansylated DBD by fluorescence polarization and size fractionation by Superdex column chromatography indicate that the DBD is a monomer in solution. The DBD forms a single protein-estrogen response element complex in gel mobility shift assays at DBD concentrations of 18-3,600 nM, suggesting that the DBD is bound to both halves of the palindromic estrogen response element. To investigate the ability of the DBD expressed in bacteria to activate gene expression, we have developed a simple liposome-based system for delivery of protein into cultured cells. Transfected DBD protein elicited large, concentration-dependent increases in transcription of an estrogen receptor regulated reporter gene. These data demonstrate that the bacterially expressed DNA binding domain, which represents a small portion of the Xenopus laevis estrogen receptor, retains significant ability to activate transcription of an estrogen-responsive promoter in vertebrate cells.	UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign	SHAPIRO, DJ (corresponding author), UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801, USA.		Erijman, Leonardo/AAI-1359-2020	Erijman, Leonardo/0000-0001-7525-2112	NICHD NIH HHS [HD-16720] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016720] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CHANG TC, 1990, J BIOL CHEM, V265, P8176; CHANG TC, 1990, THESIS U ILLINOIS UR; CHILDS J, 1985, UCLA S MOL CELLULAR, V30, P341; CHODOSH L, 1988, CURRENT PROTOCOLS MO, V2; CORTHESY B, 1989, MOL CELL BIOL, V9, P5548, DOI 10.1128/MCB.9.12.5548; DAHLMAN K, 1989, J BIOL CHEM, V264, P804; DEBS RJ, 1990, J BIOL CHEM, V265, P10189; DENNER LA, 1990, J BIOL CHEM, V265, P16548; ECKERT RL, 1982, J BIOL CHEM, V257, P8840; EUL J, 1989, EMBO J, V8, P83, DOI 10.1002/j.1460-2075.1989.tb03351.x; FALWELL SE, 1990, CELL, V60, P953; FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0; FREEDMAN LP, 1989, SCIENCE, V245, P298, DOI 10.1126/science.2473529; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; FUCHSYOUNG R, 1989, 71ST P ANN M END SOC, P159; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GRATTON E, 1983, BIOPHYS J, V44, P315, DOI 10.1016/S0006-3495(83)84305-7; GREEN S, 1991, NUCLEAR HORMONE RECE, P15; GUIOCHONMANTEL A, 1988, NATURE, V336, P695, DOI 10.1038/336695a0; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HIGUCHI K, 1969, J CELL PHYSL, V75, P65; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; JAMESON DM, 1978, REV SCI INSTRUM, V49, P510, DOI 10.1063/1.1135451; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LEW D, 1988, THESIS U ILLINOIS UR; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MIESFELD R, 1987, SCIENCE, V236, P423, DOI 10.1126/science.3563519; MIGLIACCIO A, 1982, BIOCHEM BIOPH RES CO, V109, P1002, DOI 10.1016/0006-291X(82)92039-3; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NOTIDES AC, 1981, P NATL ACAD SCI-BIOL, V78, P4926, DOI 10.1073/pnas.78.8.4926; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; POWER RF, 1990, J BIOL CHEM, V265, P1419; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; WAHLI W, 1982, P NATL ACAD SCI-BIOL, V79, P6832, DOI 10.1073/pnas.79.22.6832; WATERMAN ML, 1988, MOL ENDOCRINOL, V2, P14, DOI 10.1210/mend-2-1-14; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WEILER IJ, 1987, MOL ENDOCRINOL, V1, P355, DOI 10.1210/mend-1-5-355	53	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					24070	24076						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748680				2022-12-25	WOS:A1991GV31900084
J	PENMAN, M; LUX, A; FREEDMAN, NJ; ROHRER, L; EKKEL, Y; MCKINSTRY, H; RESNICK, D; KRIEGER, M				PENMAN, M; LUX, A; FREEDMAN, NJ; ROHRER, L; EKKEL, Y; MCKINSTRY, H; RESNICK, D; KRIEGER, M			THE TYPE-I AND TYPE-II BOVINE SCAVENGER RECEPTORS EXPRESSED IN CHINESE-HAMSTER OVARY CELLS ARE TRIMERIC PROTEINS WITH COLLAGENOUS TRIPLE HELICAL DOMAINS COMPRISING NONCOVALENTLY ASSOCIATED MONOMERS AND CYS83-DISULFIDE-LINKED DIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; POST-TRANSLATIONAL MODIFICATIONS; CORE-SPECIFIC LECTIN; MEDIATED ENDOCYTOSIS; 1ST COMPONENT; LDL RECEPTOR; FAMILIAL HYPERCHOLESTEROLEMIA; CHOLESTEROL DEPOSITION; SURFACTANT PROTEIN; HUMAN-COMPLEMENT	Scavenger receptors have been implicated in the development of atherosclerosis and other macrophage-associated functions. The structures and processing of type I and type II bovine macrophage scavenger receptors were examined using polyclonal anti-receptor antibodies. Pulse/chase metabolic labeling experiments showed that both types of scavenger receptors expressed in Chinese hamster ovary (CHO) cells behaved as typical cell surface membrane glycoproteins. They were synthesized as endoglycosidase H-sensitive precursors which were converted to endoglycosidase H-resistant mature forms expressed on the cell surface. The reduced precursor and mature forms were doublets on sodium dodecyl sulfate-gel electrophoresis, primarily because of heterogeneous N-glycosylation. The approximate molecular sizes were: type I precursor, 65/63 kDa; type I mature, 82/76 kDa; type II precursor, 57/53 kDa; and type II mature, 72/65 kDa. During post-translational processing, the cysteine-rich C terminus (SRCR domain) of some of the type I receptors was proteolytically removed to form a relatively stable, approximately 69-kDa degradation product. Type II receptors differ from type I receptors in that they do not have SRCR domains and an analogous proteolytic cleavage was not observed. Several experiments provided strong evidence that the Gly-X-Y-repeat domains in the scavenger receptors oligomerize into collagenous triple helices. For example, alpha,alpha'-dipyridyl, an inhibitor of the collagen-modifying enzymes prolyl and lysyl hydroxylases, interfered with both the kinetics and nature of post-translational receptor processing, and both precursor and mature forms of the receptors in intact cells could be cross-linked with difluorodinitrobenzene into reduction-resistant trimers. In intact cells, precursor receptor trimers (type I, 198 kDa; type II, 176 kDa) were assembled in the endoplasmic reticulum by the noncovalent association of monomers and Cys83-disulfide-linked dimers (type I, 129 kDa; type II, 119 kDa). When cells were lysed in the absence of the sulfhydryl trapping agent iodoacetamide, oxidation of the side chain of Cys17 in the cytoplasmic domain leads to the artifactual formation of reduction-sensitive covalently linked trimers. The approximate masses of the mature dimer and trimer forms were 162 and 237 kDa for type I receptors and 147 and 219 kDa for type II receptors. Cys83-disulfide-linked dimer formation was not required for function because mutant receptors (Cys83 --> Gly83) assembled into trimers of noncovalently associated monomers and exhibited normal receptor activity. Treatment of cells with difluorodinitrobenzene cross-linked some of the receptors into complexes larger than trimers, raising the possibility that the trimers may assemble into higher order oligomers.	MIT,DEPT BIOL,ROOM E25-236,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	KRIEGER, M (corresponding author), MIT,DEPT BIOL,ROOM E25-236,CAMBRIDGE,MA 02139, USA.		Krieger, Marco/AAE-8611-2020		NHLBI NIH HHS [HL41484] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BISCHOFF J, 1988, J CELL BIOL, V106, P1067, DOI 10.1083/jcb.106.4.1067; BOURNE HR, 1991, NATURE, V351, P188, DOI 10.1038/351188a0; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; COLLEY KJ, 1987, J BIOL CHEM, V262, P10290; COLLEY KJ, 1987, J BIOL CHEM, V262, P10296; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HASS C, 1991, EUR J BICH, V197, P799; HURYCH J, 1965, BIOCHIM BIOPHYS ACTA, V97, P361, DOI 10.1016/0304-4165(65)90108-X; JIMENEZ SA, 1973, J BIOL CHEM, V248, P720; JURGENS G, 1987, CHEM PHYS LIPIDS, V45, P315, DOI 10.1016/0009-3084(87)90070-3; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KIVIRIKKO KI, 1985, ANN NY ACAD SCI, V460, P187, DOI 10.1111/j.1749-6632.1985.tb51167.x; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; Kornfeld R., 1980, BIOCH GLYCOPROTEINS, P1; KOZARSKY KF, 1986, J CELL BIOL, V102, P1567, DOI 10.1083/jcb.102.5.1567; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; LEHRMAN MA, 1985, CELL, V41, P735, DOI 10.1016/S0092-8674(85)80054-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; MULLER W, 1978, FEBS LETT, V90, P218, DOI 10.1016/0014-5793(78)80372-X; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; OREILLY MA, 1988, BIOCHIM BIOPHYS ACTA, V969, P176, DOI 10.1016/0167-4889(88)90073-0; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; PITAS RE, 1985, J CELL BIOL, V100, P103, DOI 10.1083/jcb.100.1.103; RAETZ CRH, 1988, COLD SPRING HARB SYM, V53, P973, DOI 10.1101/SQB.1988.053.01.112; REID KBM, 1982, BIOCHEM J, V203, P559, DOI 10.1042/bj2030559; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; Sambrook J, 1989, MOL CLONING LABORATO; SCHUMAKER VN, 1981, J MOL BIOL, V148, P191, DOI 10.1016/0022-2836(81)90511-8; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; STUHLMANN H, 1989, MOL CELL BIOL, V9, P100, DOI 10.1128/MCB.9.1.100; THIEL S, 1989, FEBS LETT, V250, P78, DOI 10.1016/0014-5793(89)80689-1; TOLLESHAUG H, 1983, CELL, V32, P941, DOI 10.1016/0092-8674(83)90079-X; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2	44	52	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23985	23993						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748671				2022-12-25	WOS:A1991GV31900071
J	CASEY, ML; SMITH, JW; NAGAI, K; HERSH, LB; MACDONALD, PC				CASEY, ML; SMITH, JW; NAGAI, K; HERSH, LB; MACDONALD, PC			PROGESTERONE-REGULATED CYCLIC MODULATION OF MEMBRANE METALLOENDOPEPTIDASE (ENKEPHALINASE) IN HUMAN ENDOMETRIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEPTIDASE 24.11 ENKEPHALINASE; NEUTRAL ENDOPEPTIDASE; STROMAL CELLS; LEUKEMIA ANTIGEN; INVITRO; CULTURE; ACID; DECIDUALIZATION; BIOSYNTHESIS; ENDOTHELINS	Membrane metalloendopeptidase (MMEP; EC 3.4.24.11; enkephalinase) catalyzes the degradation of endothelins, enkephalins, atrial natriuretic factor, substance P, and other small bioactive peptides. We found that MMEP is present in human endometrium, localized primarily in stromal cells of this tissue, and that the specific activity of MMEP (and immunoreactive MMEP protein) in endometrial tissue is correlated in a highly significant positive manner with the concentration of progesterone in plasma. In estrogen-treated, human endometrial stromal cells in monolayer culture, the specific activity of MMEP increases in response to treatment with progestin; and, this increase is accompanied by increases in immunoreactive MMEP protein, newly synthesized MMEP, and MMEP mRNA.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT OBSTET & GYNECOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	CASEY, ML (corresponding author), UNIV TEXAS,SW MED CTR,CECIL H & IDA GREEN CTR REPROD BIOL SCI,DALLAS,TX 75235, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD011149] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD011149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002243] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-5-P50-11149] Funding Source: Medline; NIDA NIH HHS [DA-02243] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BATEMAN RC, 1989, J BIOL CHEM, V264, P6151; BENEDETTO MT, 1990, J CLIN ENDOCR METAB, V70, P342, DOI 10.1210/jcem-70-2-342; BORSON DB, 1991, AM J PHYSIOL, V260, pL83, DOI 10.1152/ajplung.1991.260.2.L83; CASEY ML, 1988, J BIOL CHEM, V263, P7846; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUNNINGHAM FG, 1989, WILLIAMS OBSTETRICS, P25; ECONOMOS K, 1991, IN PRESS J CLIN ENDO; HERSH LB, 1986, J BIOL CHEM, V261, P6433; HUANG JR, 1987, ENDOCRINOLOGY, V121, P2011; IRWIN JC, 1989, FERTIL STERIL, V52, P761; KORTE K, 1983, BIOCHIM BIOPHYS ACTA, V752, P423, DOI 10.1016/0005-2760(83)90272-2; LETARTE M, 1988, J EXP MED, V168, P1247, DOI 10.1084/jem.168.4.1247; LORKOWSKI G, 1987, BIOCHEM J, V248, P345, DOI 10.1042/bj2480345; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALFROY B, 1978, NATURE, V276, P523, DOI 10.1038/276523a0; MATAS R, 1983, P NATL ACAD SCI USA, V80, P3111; MILEWICH L, 1975, GYNECOL OBSTET INVES, V6, P291, DOI 10.1159/000301525; OLINS GM, 1989, MOL CELL ENDOCRINOL, V61, P201, DOI 10.1016/0303-7207(89)90131-7; POHL U, 1989, J CARDIOVASC PHAR S5, V13, P5188; SATYASWAROOP PG, 1979, J CLIN ENDOCR METAB, V48, P639, DOI 10.1210/jcem-48-4-639; SHIGENO T, 1989, J CARDIOVASC PHARM S, V13, P5174; SHIPP MA, 1988, P NATL ACAD SCI USA, V85, P4819, DOI 10.1073/pnas.85.13.4819; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOKOLOVSKY M, 1990, P NATL ACAD SCI USA, V87, P4702, DOI 10.1073/pnas.87.12.4702; STRAHLE U, 1989, NATURE, V339, P629, DOI 10.1038/339629a0; VIJAYARAGHAVAN J, 1990, J BIOL CHEM, V265, P14150; WORD RA, 1990, AM J OBSTET GYNECOL, V162, P1103; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	28	87	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23041	23047						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744100				2022-12-25	WOS:A1991GT48300043
J	DEB, S; ROBY, KF; FARIA, TN; SZPIRER, C; LEVAN, G; KWOK, SCM; SOARES, MJ				DEB, S; ROBY, KF; FARIA, TN; SZPIRER, C; LEVAN, G; KWOK, SCM; SOARES, MJ			MOLECULAR-CLONING AND CHARACTERIZATION OF PROLACTIN-LIKE PROTEIN-C COMPLEMENTARY DEOXYRIBONUCLEIC-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL LACTOGEN-II; GROWTH-HORMONE GENE; DEVELOPING RAT PLACENTA; MESSENGER-RNA; BOVINE PLACENTA; MOUSE PLACENTA; CDNA CLONE; EXPRESSION; FAMILY; IDENTIFICATION	In this report, we describe the isolation and characterization of a full length cDNA clone for rat prolactin-like protein C (PLP-C) and describe the expression of PLP-C mRNA in the developing rat placenta. Nucleotide sequence analysis of the PLP-C cDNA clone predicted a mature protein of 238 amino acids, including a 30-amino acid signal sequence. The predicted PLP-C amino acid sequence contains seven cysteine residues, three tryptophan residues, and two putative N-linked glycosylation sites. Six of the cysteine residues in PLP-C are located in positions homologous to the cysteines of pituitary prolactin (PRL). Additional sequence similarities with pituitary PRL and other members of the rat placental PRL family are evident. The PLP-C gene was localized to rat chromosome 17. Northern blot analysis showed that the PLP-C cDNA clone specifically hybridized to a 1.0-kilobase mRNA. PLP-C mRNA was first detectable between days 13 and 14 of gestation, peaked by day 18 of gestation, and remained elevated until term. In situ hybridization analysis indicated that PLP-C mRNA was specifically expressed by spongiotrophoblast cells and some trophoblast giant cells in the junctional zone region of rat chorioallantoic placenta.	UNIV KANSAS, MED CTR, DEPT PHYSIOL, KANSAS CITY, KS 66103 USA; UNIV KANSAS, MED CTR, DEPT BIOCHEM, KANSAS CITY, KS 66103 USA; UNIV LIBRE BRUXELLES, DEPT BIOL MOLEC, B-1640 RHODE ST GENESE, BELGIUM; GOTHENBURG UNIV, DEPT GENET, S-40033 GOTHENBURG, SWEDEN	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; Universite Libre de Bruxelles; University of Gothenburg				Kwok, Simon/0000-0001-6003-5350	NICHD NIH HHS [HD-20676] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD020676] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAHL OP, 1977, GLYCOCONJUGATES, P385; BARTA A, 1981, P NATL ACAD SCI-BIOL, V78, P4867, DOI 10.1073/pnas.78.8.4867; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; CAMPBELL WJ, 1989, ENDOCRINOLOGY, V125, P1565, DOI 10.1210/endo-125-3-1565; COLOSI P, 1989, MOL ENDOCRINOL, V3, P1462, DOI 10.1210/mend-3-9-1462; COLOSI P, 1987, MOL ENDOCRINOL, V1, P767, DOI 10.1210/mend-1-11-767; COOKE NE, 1986, ENDOCRINOLOGY, V119, P2451, DOI 10.1210/endo-119-6-2451; DAVIS JA, 1989, MOL ENDOCRINOL, V3, P949, DOI 10.1210/mend-3-6-949; DEB S, 1991, ENDOCRINOLOGY, V128, P3066, DOI 10.1210/endo-128-6-3066; DEB S, 1989, J BIOL CHEM, V264, P14348; DEB S, 1990, MOL CELL ENDOCRINOL, V74, P163, DOI 10.1016/0303-7207(90)90118-R; DEB S, 1991, J BIOL CHEM, V266, P1605; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DUCKWORTH ML, 1988, INT CONGR SER, V819, P79; DUCKWORTH ML, 1988, MOL ENDOCRINOL, V2, P912, DOI 10.1210/mend-2-10-912; DUCKWORTH ML, 1986, J BIOL CHEM, V261, P871; DUCKWORTH ML, 1986, J BIOL CHEM, V261, P879; DUCKWORTH ML, 1990, PLACENTA, V11, P143, DOI 10.1016/S0143-4004(05)80176-6; FARIA TN, 1990, DEV BIOL, V141, P279, DOI 10.1016/0012-1606(90)90384-U; GUBBINS EJ, 1980, J BIOL CHEM, V255, P8655; ISLAM MQ, 1987, HEREDITAS, V107, P127, DOI 10.1111/j.1601-5223.1987.tb00277.x; JACKSON LL, 1986, P NATL ACAD SCI USA, V83, P8496, DOI 10.1073/pnas.83.22.8496; JACKSONGRUSBY LL, 1988, ENDOCRINOLOGY, V122, P2462, DOI 10.1210/endo-122-6-2462; KESSLER MA, 1989, BIOCHEMISTRY-US, V28, P5154, DOI 10.1021/bi00438a036; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; Levan G., 1990, Genetic maps: locus of complex genomes.; LEVAN G, 1991, GENOMICS, V10, P699, DOI 10.1016/0888-7543(91)90455-N; LINZER DIH, 1985, EMBO J, V4, P1419, DOI 10.1002/j.1460-2075.1985.tb03796.x; LINZER DIH, 1985, P NATL ACAD SCI USA, V82, P4356, DOI 10.1073/pnas.82.13.4356; MARKOFF E, 1988, ENDOCRINOLOGY, V123, P1303, DOI 10.1210/endo-123-3-1303; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; Ogren L, 1988, Int Rev Cytol, V112, P1; OWERBACH D, 1981, SCIENCE, V212, P815, DOI 10.1126/science.7221563; PARK OK, 1991, MOL ENDOCRINOL, V5, P967, DOI 10.1210/mend-5-7-967; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; ROBERTSON MC, 1990, ENDOCRINOLOGY, V127, P702, DOI 10.1210/endo-127-2-702; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULER LA, 1987, P NATL ACAD SCI USA, V84, P5650, DOI 10.1073/pnas.84.16.5650; SCHULER LA, 1988, BIOCHEMISTRY-US, V27, P8443, DOI 10.1021/bi00422a022; SOARES MJ, 1987, J REPROD FERTIL, V79, P335, DOI 10.1530/jrf.0.0790335; SOARES MJ, 1985, DEV BIOL, V107, P520, DOI 10.1016/0012-1606(85)90332-X; SOARES MJ, 1987, DEV BIOL, V124, P134, DOI 10.1016/0012-1606(87)90466-0; SOUTHARD JN, 1989, MOL ENDOCRINOL, V3, P1710, DOI 10.1210/mend-3-11-1710; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SZPIRER J, 1984, CYTOGENET CELL GENET, V38, P142, DOI 10.1159/000132047; YAMAKAWA M, 1990, J BIOL CHEM, V265, P8915	48	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23027	23032						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744098				2022-12-25	WOS:A1991GT48300041
J	GHOSH, A; RONNER, P; CHEONG, E; KHALID, P; MATSCHINSKY, FM				GHOSH, A; RONNER, P; CHEONG, E; KHALID, P; MATSCHINSKY, FM			THE ROLE OF ATP AND FREE ADP IN METABOLIC COUPLING DURING FUEL-STIMULATED INSULIN RELEASE FROM ISLET BETA-CELLS IN THE ISOLATED PERFUSED RAT PANCREAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE K+ CHANNELS; B-CELLS; GLUCOSE; SECRETION; LANGERHANS; PHOSPHATE; SECRETAGOGUES; HYPOTHESIS	The isolated perfused rat pancreas was used to test the hypothesis that total cellular ATP or the ratio of ATP/free ADP plays the primary role in coupling intermediary metabolism to the biophysical events that are the basis of glucose-stimulated insulin release. The pancreas was preperfused for 20 min with 4.0 mM of a physiological mixture of 20 amino acids plus 4.2 mM glucose, and insulin release was then stimulated for 150 s by suddenly increasing the glucose to 8.3 mM. The pancreas was sampled at 24, 48, 72, and 150 s after the switch. The content of total ATP, ADP, AMP, P(i), phosphocreatine, and creatine were measured in beta-cell enriched cores of pancreatic islets microdissected from freeze-dried pancreas cryostat sections. Metabolites were measured by quantitative histochemical enzymatic cycling techniques. Modeling studies were carried out to assess the impact of biochemical analytical results on the membrane potential of the beta-cells. The level of free ADP was calculated using the creatine kinase equilibrium reaction and an intracellular pH of 7.2. First phase insulin release was stimulated at least 10-fold with the maximum reached 45 s after adding high glucose. The biochemical analytical data demonstrate that the total cellular level of the putative coupling factor ATP and of the ratios ATP/free ADP and ATP/free ADP x P(i) are not significantly influenced by a glucose level change that causes a more than 10-fold surge of insulin release. The strength and limitations of the present experimental strategy and the implications of the results for our understanding of metabolic coupling in glucose-stimulated insulin release are discussed.	UNIV PENN,SCH MED,DIABET RES CTR,501 MED EDUC BLDG,36TH & HAMILTON WALK,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania				Ronner, Peter/0000-0003-0071-0152	NIDDK NIH HHS [DK38430, DK19525, DK22122] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK022122, R01DK022122, R23DK038430, P30DK019525, R01DK038430] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCROFT SJ, 1973, BIOCHEM J, V132, P223, DOI 10.1042/bj1320223; ASHCROFT SJH, 1980, DIABETOLOGIA, V18, P5, DOI 10.1007/BF01228295; ASHCROFT SJH, 1979, BIOCHEM J, V184, P697, DOI 10.1042/bj1840697; BUKOWIECKI L, 1979, BIOCHIM BIOPHYS ACTA, V583, P370, DOI 10.1016/0304-4165(79)90461-6; CHAY TR, 1990, CELL BIOPHYS, V17, P11, DOI 10.1007/BF02989802; COOK DL, 1988, DIABETES, V37, P495, DOI 10.2337/diabetes.37.5.495; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; FREINKEL N, 1974, J CLIN INVEST, V54, P1179, DOI 10.1172/JCI107861; GRODSKY GM, 1984, METHODS DIABETES RES, V1, P137; GYLFE E, 1990, BIOCHIM BIOPHYS ACTA, V1055, P82, DOI 10.1016/0167-4889(90)90094-T; HELLMAN B, 1969, DIABETES, V18, P509, DOI 10.2337/diab.18.8.509; HERBERT V, 1965, J CLIN ENDOCR METAB, V25, P1375, DOI 10.1210/jcem-25-10-1375; KAKEI M, 1986, FEBS LETT, V208, P63, DOI 10.1016/0014-5793(86)81533-2; KORETSKY AP, 1990, P NATL ACAD SCI USA, V87, P3112, DOI 10.1073/pnas.87.8.3112; KRZANOWSKI JJ, 1971, DIABETES, V20, P598, DOI 10.2337/diab.20.9.598; LANDGRAF R, 1971, P NATL ACAD SCI USA, V68, P536, DOI 10.1073/pnas.68.3.536; LOWRY OH, 1972, FLEXIBLE SYSTEM ENZY, P86; MALAISSE WJ, 1982, J BIOL CHEM, V257, P8731; MALAISSE WJ, 1979, METABOLISM, V28, P373, DOI 10.1016/0026-0495(79)90111-2; MALAISSE WJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P190, DOI 10.1016/0167-4889(87)90134-0; MATSCHIN.FM, 1972, DIABETES, V21, P555, DOI 10.2337/diab.21.2.S555; MATSCHINSKY FM, 1986, J BIOL CHEM, V261, P14057; MATSCHINSKY FM, 1976, J BIOL CHEM, V251, P6053; MATSCHINSKY FM, 1971, J BIOL CHEM, V246, P1007; MATSCHINSKY FM, 1971, RECENT ADV QUANTITAT, P143; MATSCHINSKY FM, 1989, 13TH IDF P SYDN, P17; MATSCHINSKY FM, 1979, ENDOCRINOLOGY, V2, P935; Matsuzaki F, 1968, Horumon To Rinsho, V16, P29; MEGLASSON MD, 1989, METABOLISM, V38, P1188, DOI 10.1016/0026-0495(89)90158-3; MEISSNER HP, 1976, J PHYSIOL-PARIS, V72, P757; MISLER S, 1986, P NATL ACAD SCI USA, V83, P7119, DOI 10.1073/pnas.83.18.7119; ORCI L, 1982, DIABETES, V31, P538, DOI 10.2337/diab.31.6.538; SCHARFF R, 1964, NATURE, V202, P603, DOI 10.1038/202603a0; SENER A, 1978, DIABETES METAB, V4, P127; SENER A, 1978, BIOCHEM J, V176, P217, DOI 10.1042/bj1760217; TRUS M, 1980, DIABETES, V29, P1, DOI 10.2337/diabetes.29.1.1; VEECH RL, 1979, J BIOL CHEM, V254, P6538	37	112	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22887	22892						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744082				2022-12-25	WOS:A1991GT48300020
J	KHILLAN, JS; OLSEN, AS; KONTUSAARI, S; SOKOLOV, B; PROCKOP, DJ				KHILLAN, JS; OLSEN, AS; KONTUSAARI, S; SOKOLOV, B; PROCKOP, DJ			TRANSGENIC MICE THAT EXPRESS A MINI-GENE VERSION OF THE HUMAN GENE FOR TYPE-I PROCOLLAGEN (COL1A1) DEVELOP A PHENOTYPE RESEMBLING A LETHAL FORM OF OSTEOGENESIS IMPERFECTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN GENE; TRIPLE HELIX; MESSENGER-RNA; MUTATIONS; CHAIN; SEQUENCES; DELETION; CYSTEINE; VARIANT; SUBSTITUTION	A mini-gene version of the human gene for a pro-alpha-1(I) chain of type I procollagen (COL1A1) was prepared that contained -2.5 kilobases of the promoter region and the 5'- and 3'-ends of the gene but lacked a large central region containing 41 exons. The construct was modeled after a sporadic in-frame deletion of the human gene that produced a lethal variant of osteogenesis imperfecta, because it caused synthesis of shortened pro-alpha-1(I) chains that associated with normal pro-alpha-1(I) and pro-alpha-2(I) chains and caused degradation of both the shortened and normal pro-alpha chains through a process called procollagen suicide. The mini-gene was used to prepare transgenic mice. Eight of 15 transgenic mice expressed varying levels of the gene. All except one of the Fo founders were phenotypically normal, but several of the founders were apparently mosaic since they produced F1 progeny that died shortly after birth with a distinctive phenotype. The phenotype included extensive fractures of ribs and long bones similar to the fractures seen in lethal variants of osteogenesis imperfecta. Mice with the lethal phenotype expressed much higher levels of the mini-gene than transgenic mice without the lethal phenotype. Experiments with cultured skin fibroblasts from the transgenic mice demonstrated that shortened pro-alpha-1(1) chains synthesized from the mini-gene became disulfide-linked to pro-alpha-1(I) chains synthesized from the endogenous mouse gene. The results demonstrate that a mutated type I procollagen gene based on the model of procollagen suicide can be used to produce a severe phenotype of osteogenesis imperfecta that is genetically transmitted.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107	Jefferson University					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR038188, P01AR038923, P01AR039740] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR38188, AR38923, AR39740] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARSH GS, 1981, P NATL ACAD SCI-BIOL, V78, P5142, DOI 10.1073/pnas.78.8.5142; BARSH GS, 1984, J BIOL CHEM, V259, P4906; BARSH GS, 1985, P NATL ACAD SCI USA, V82, P2870, DOI 10.1073/pnas.82.9.2870; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; BYERS PH, 1990, TRENDS GENET, V6, P293, DOI 10.1016/0168-9525(90)90235-X; BYERS PH, 1988, AM J HUM GENET, V42, P237; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU ML, 1985, J BIOL CHEM, V260, P691; CHU ML, 1983, NATURE, V304, P78, DOI 10.1038/304078a0; CHU ML, 1991, IN PRESS EXTRACELLUL; COHN D H, 1989, American Journal of Human Genetics, V45, pA180; CONSTANTINOU CD, 1990, AM J HUM GENET, V47, P670; DOLZ R, 1990, ANN NY ACAD SCI, V580, P421, DOI 10.1111/j.1749-6632.1990.tb17948.x; DOLZ R, 1988, EUR J BIOCHEM, V178, P357, DOI 10.1111/j.1432-1033.1988.tb14458.x; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; KHILLAN JS, 1990, AM J HUM GENET, V47, pA224; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; KURKINEN M, 1985, NATURE, V317, P177, DOI 10.1038/317177a0; OLSEN A, 1990, J BIOL CHEM, V266, P1117; PACK M, 1989, J BIOL CHEM, V264, P19694; PAGLIA LM, 1979, BIOCHEMISTRY-US, V20, P3323; PIEZ KA, 1984, EXTRACELLULAR MATRIX, P1; PROCKOP DJ, 1990, J BIOL CHEM, V265, P15349; PROCKOP DJ, 1990, ANN NY ACAD SCI, V580, P330, DOI 10.1111/j.1749-6632.1990.tb17942.x; PROCKOP DJ, 1989, SPRINGER SERIES BIOP, V3, P81; ROLE C, 1981, STAIN TECHNOL, V56, P271; SANDMEYER S, 1979, J BIOL CHEM, V254, P4950; SCHNIEKE A, 1987, P NATL ACAD SCI USA, V84, P764, DOI 10.1073/pnas.84.3.764; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPOTILA LD, 1991, P NATL ACAD SCI USA, V88, P5423, DOI 10.1073/pnas.88.12.5423; STACEY A, 1988, NATURE, V332, P131, DOI 10.1038/332131a0; STEINMANN B, 1984, J BIOL CHEM, V259, P1129; STOLLE CA, 1985, J BIOL CHEM, V260, P1937; SYKES B, 1990, NATURE, V348, P18, DOI 10.1038/348018a0; VOGEL BE, 1988, J BIOL CHEM, V263, P19249; WALLIS G A, 1989, American Journal of Human Genetics, V45, pA228; WESTERHAUSEN A, 1990, J BIOL CHEM, V265, P13995; WILLIAMS CJ, 1983, J BIOL CHEM, V258, P5915; WU CH, 1986, J BIOL CHEM, V261, P482	39	69	79	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23373	23379						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744131				2022-12-25	WOS:A1991GT48300089
J	KOLHOUSE, JF; UTLEY, C; STABLER, SP; ALLEN, RH				KOLHOUSE, JF; UTLEY, C; STABLER, SP; ALLEN, RH			MECHANISM OF CONVERSION OF HUMAN APOMETHIONINE TO HOLOMETHIONINE SYNTHASE BY VARIOUS FORMS OF COBALAMIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLMALONYL-COA MUTASE; DEPENDENT METHIONINE SYNTHASE; HUMAN-PLACENTA; ANALOGS; METHYLTRANSFERASE; SYNTHETASE	Methionine synthase catalyzes the conversion of N5-methyltetrahydrofolate and homocysteine to tetrahydrofolate and methionine. Methylcobalamin (Me-Cbl) is tightly bound to methionine synthase and is required for enzymatic activity. When added to crude tissue homogenates, Me-Cbl stimulates methionine synthase but similar stimulation is observed with hydroxocobalamin, cyanocobalamin (CN-Cbl), and adenosyl-Cbl, although the mechanisms involved are unknown. We prepared human apomethionine synthase and studied its activation in the presence of [C-14]CN-Cbl and [(CH3)-C-14]Me-Cbl with concentrations of 2-mercaptoethanol ranging from 0.15 to 100 mM. We observed that the removal of the labeled upper axial ligands from CN-Cbl and Me-Cbl both paralleled the activation of human apomethionine synthase. Spectral studies employing CN-Cbl and Me-Cbl showed that both forms of Cbl must be converted to Cob(II)alamin before they can bind to human apomethionine synthase and convert it to its activated holoenzyme form. Studies with 14 different Cbl analogues with alterations in various portions of the corrin ring and the nucleotide showed that all of the analogues were able to fully activate human methionine synthase when they were reduced with 2-mercaptoethanol. Full activation occurred at lower concentrations of many of the Cbl analogues than occurred with Cbl itself. We conclude that Me-Cbl and other forms of Cob(III)alamin do not bind to human apomethionine synthase and that all must first be reduced to Cob(II)alamin before such binding can occur. The fact that human methionine synthase shows little absolute specificity for alterations in various portions of the Cbl molecule suggests that the potent inhibition of mammalian methionine synthase activity observed in vivo with various Cbl analogues is due to inhibition of intracellular Cbl transport or to inhibition of the enzymatic formation of Cob(II)alamin rather than to direct inhibition of mammalian methionine synthase itself.	UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	KOLHOUSE, JF (corresponding author), UNIV COLORADO,HLTH SCI CTR,DIV HEMATOL,CAMPUS BOX B170,4200 E 9TH AVE,DENVER,CO 80262, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021365, R01DK037165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026486] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK21365, DK37165] Funding Source: Medline; NIGMS NIH HHS [GM26486] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; BANERJEE RV, 1990, FASEB J, V4, P1450, DOI 10.1096/fasebj.4.5.2407589; Dolphin D., 1971, METHOD ENZYMOL, V18, P34; Hogenkamp H. P. C., 1975, COBALAMIN BIOCH PATH, P21; HOGENKAMP HP, 1966, BIOCHEMISTRY-US, V5, P417, DOI 10.1021/bi00866a005; HUENNEKENS FM, 1982, B12, V1, P145; KOLHOUSE JF, 1978, ANAL BIOCHEM, V84, P486, DOI 10.1016/0003-2697(78)90067-2; KOLHOUSE JF, 1977, J CLIN INVEST, V60, P1381, DOI 10.1172/JCI108899; KOLHOUSE JF, 1980, J BIOL CHEM, V255, P2708; KOLHOUSE JF, 1977, P NATL ACAD SCI USA, V74, P921, DOI 10.1073/pnas.74.3.921; KONDO H, 1982, J CLIN INVEST, V70, P889, DOI 10.1172/JCI110685; LEDLEY FD, 1988, P NATL ACAD SCI USA, V85, P3518, DOI 10.1073/pnas.85.10.3518; MELMAN IS, 1977, P NATL ACAD SCI USA, V74, P916; PEEL JL, 1963, BIOCHEM J, V88, P296, DOI 10.1042/bj0880296; PEYTREMANN R, 1975, J CLIN INVEST, V56, P1293, DOI 10.1172/JCI108205; Retey J., 1982, B12, VII, P357; ROSENBERG LE, 1989, METABOLIC BASIS INHE, P821; ROSENBLATT DS, 1986, PEDIATRICS, V78, P51; ROTHENBERG SP, 1972, NEW ENGL J MED, V286, P1335, DOI 10.1056/NEJM197206222862504; STALER SP, 1991, J CLIN INVEST, V87, P1422; TAYLOR RT, 1974, ARCH BIOCHEM BIOPHYS, V165, P787, DOI 10.1016/0003-9861(74)90308-7; TAYLOR RT, 1982, B12, V2, P307; UTLEY CS, 1985, J BIOL CHEM, V260, P3656; VITOLS E, 1966, J BIOL CHEM, V241, P1455; WEISSBACH H, 1965, J BIOL CHEM, V240, P856	25	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23010	23015						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744096				2022-12-25	WOS:A1991GT48300038
J	MENDELMAN, LV; RICHARDSON, CC				MENDELMAN, LV; RICHARDSON, CC			REQUIREMENTS FOR PRIMER SYNTHESIS BY BACTERIOPHAGE-T7 63-KDA GENE-4 PROTEIN - ROLES OF TEMPLATE SEQUENCE AND T7 56-KDA GENE-4 PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID REPLICATION INVITRO; NUCLEOSIDE 5'-TRIPHOSPHATASE ACTIVITY; LAGGING STRAND SYNTHESIS; DEOXYRIBONUCLEIC-ACID; DNA-POLYMERASE; ESCHERICHIA-COLI; RNA PRIMER; NUCLEOTIDE-SEQUENCE; PRIMASE-HELICASE; ZINC FINGERS	Gene 4 of bacteriophage T7 encodes two proteins, a 63-kDa protein and a colinear 56-kDa protein, that are essential for synthesis of leading and lagging strands during DNA replication. The gene 4 proteins together catalyze the synthesis of oligoribonucleotides, pppACC(C/A) or pppACAC, at the single-stranded DNA sequences 3'-CTGG(G/T)-5' or 3'-CTGTG-5', respectively. Purified 56-kDa protein has helicase activity, but no primase activity. In order to study 63-kDa gene 4 protein free of 56-kDa gene 4 protein, mutations were introduced into the internal ribosome-binding site responsible for the translation of the 56-kDa protein. The 63-kDa gene 4 protein was purified 16,000-fold from Escherichia coli cells harboring an expression vector containing the mutated gene 4. Purified 63-kDa gene 4 protein has primase, helicase, and single-stranded DNA-dependent dTTPase activities. The constraints of primase recognition sequences, nucleotide substrate requirements, and the effects of additional proteins on oligoribonucleotide synthesis by the 63-kDa gene 4 protein have been examined using templates of defined sequence. A three-base sequence, 3'-CTG-5', is necessary and sufficient to support the synthesis of pppAC dimers. dTTP hydrolysis is essential for oligoribonucleotide synthesis. Addition of a 7-fold molar excess of 56-kDa gene 4 protein to 63-kDa protein increases the number of oligoribonucleotides synthesized by 63-kDa protein 100-fold. The increase in oligonucleotides results predominantly from an increase in the synthesis of tetramers, with relatively little change in the synthesis of dimers and trimers. The presence of 56-kDa protein also causes 63-kDa protein to synthesize "pseudo-templated" pppACCCC pentamers at the recognition sequence 3'-CTGGG-5'. T7 gene 2.5 protein, a single-stranded DNA binding protein, increases the total number of oligoribonucleotides synthesized by 63-kDa gene 4 protein on single-stranded M13 DNA, but has no effect on the ratio of dimers to trimers and tetramers.			MENDELMAN, LV (corresponding author), HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA.				NIAID NIH HHS [AI-06045] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI006045, R37AI006045] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARAI K, 1979, P NATL ACAD SCI USA, V76, P4308, DOI 10.1073/pnas.76.9.4308; ARAI KI, 1981, P NATL ACAD SCI-BIOL, V78, P707, DOI 10.1073/pnas.78.2.707; BECK PJ, 1989, J MOL BIOL, V210, P687, DOI 10.1016/0022-2836(89)90102-2; BERG JM, 1990, J BIOL CHEM, V265, P6513; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN WC, 1989, J BIOL CHEM, V264, P6748; BURKE RL, 1985, J BIOL CHEM, V260, P1711; BURTON ZF, 1983, CELL, V32, P335, DOI 10.1016/0092-8674(83)90453-1; CALDER JM, 1990, NUCLEIC ACIDS RES, V18, P3573, DOI 10.1093/nar/18.12.3573; CHA TA, 1986, J BIOL CHEM, V261, P7001; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DAVEY SK, 1990, J BIOL CHEM, V265, P3611; DESMIT MH, 1990, PROG NUCLEIC ACID RE, V38, P1; DODSON MS, 1991, P NATL ACAD SCI USA, V88, P1105, DOI 10.1073/pnas.88.4.1105; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; EKLUND H, 1982, J BIOL CHEM, V257, P4349; ENGLER MJ, 1983, J BIOL CHEM, V258, P1165; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FLENSBURG J, 1987, J MOL BIOL, V195, P439, DOI 10.1016/0022-2836(87)90664-4; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUJIYAMA A, 1981, P NATL ACAD SCI-BIOL, V78, P903, DOI 10.1073/pnas.78.2.903; HILL J, 1979, ANN BOT-LONDON, V43, P449, DOI 10.1093/oxfordjournals.aob.a085655; HINTON DM, 1985, J BIOL CHEM, V260, P2851; HINTON DM, 1987, J BIOL CHEM, V262, P10873; HOUGH E, 1989, NATURE, V338, P357, DOI 10.1038/338357a0; HUBER HE, 1987, J BIOL CHEM, V262, P16224; JACQUES JP, 1991, GENE DEV, V5, P707, DOI 10.1101/gad.5.5.707; JENDRISAK J, 1987, PROTEIN PURIFICATION, P75; KITANI T, 1985, J MOL BIOL, V184, P45, DOI 10.1016/0022-2836(85)90042-7; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KOLODNER R, 1977, P NATL ACAD SCI USA, V74, P1525, DOI 10.1073/pnas.74.4.1525; KOLODNER R, 1978, J BIOL CHEM, V253, P566; KORNBERG A, 1980, DNA REPLICATION, P121; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUROSAWA Y, 1979, J MOL BIOL, V135, P841, DOI 10.1016/0022-2836(79)90515-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MESSING J, 1977, P NATL ACAD SCI USA, V74, P3642, DOI 10.1073/pnas.74.9.3642; MILLER H, 1987, METHOD ENZYMOL, V152, P145; NAKAI H, 1986, J BIOL CHEM, V261, P5217; NAKAI H, 1986, J BIOL CHEM, V261, P5208; NAKAI H, 1988, J BIOL CHEM, V263, P9831; NAKAI H, 1988, J BIOL CHEM, V263, P9818; Nakai H., 1988, DNA REPLICATION MUTA, P85; NOSSAL NG, 1987, J BIOL CHEM, V262, P10879; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PLEVANI P, 1987, NUCLEIC ACIDS RES, V15, P7975; PRUSSAK CE, 1989, J BIOL CHEM, V264, P4957; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; ROMANO LJ, 1979, J BIOL CHEM, V254, P476; ROMANO LJ, 1979, J BIOL CHEM, V254, P483; SAMBROOK J, 1989, MOL CLONING LAB MANU, pB12; SCHERZINGER E, 1977, EUR J BIOCHEM, V72, P543, DOI 10.1111/j.1432-1033.1977.tb11278.x; SCHERZINGER E, 1977, NUCLEIC ACIDS RES, V4, P4151, DOI 10.1093/nar/4.12.4151; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; SILVER LL, 1982, J BIOL CHEM, V257, P1696; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WANG LF, 1985, J BIOL CHEM, V260, P3368; YODA K, 1991, MOL GEN GENET, V227, P1, DOI 10.1007/BF00260698	72	97	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23240	23250						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744119				2022-12-25	WOS:A1991GT48300071
J	MESSING, RO; PETERSEN, PJ; HENRICH, CJ				MESSING, RO; PETERSEN, PJ; HENRICH, CJ			CHRONIC ETHANOL EXPOSURE INCREASES LEVELS OF PROTEIN KINASE-C-DELTA AND KINASE-C-EPSILON AND PROTEIN KINASE-C-MEDIATED PHOSPHORYLATION IN CULTURED NEURAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-CHANNEL ANTAGONISTS; PHORBOL ESTER; TRANSCRIPTIONAL ACTIVATION; SIGNAL TRANSDUCTION; PC12 CELLS; WITHDRAWAL; EXPRESSION; DIACYLGLYCEROL; STIMULATION; BINDING	Exposure to ethanol for several days increases the number and function of dihydropyridine-sensitive Ca2+ channels in excitable tissues. In the neural cell line PC12, this process is blocked by inhibitors of protein kinase C (PKC), suggesting that PKC mediates ethanol-induced increases in Ca2+ channels. We report that treatment with 25-200 mM ethanol for 2-8 days increased PKC activity in PC12 cells and NG108-15 neuroblastoma-glioma cells. Detailed studies in PC12 cells showed that ethanol also increased phorbol ester binding and immunoreactivity to PKC-delta and PKC-epsilon. These changes were associated with increased PKC-mediated phosphorylation. Ethanol did not activate the enzyme directly, nor did ethanol increase levels of diacylglycerol. Ethanol-induced increases in PKC levels may promote up-regulation of Ca2+ channels, and may also regulate the expression and function of other proteins involved in cellular adaptation to ethanol.	SAN FRANCISCO GEN HOSP,ERNEST GALLO CLIN & RES CTR,SAN FRANCISCO,CA 94110; LIFE TECHNOL INC,GAITHERSBURG,MD 20877	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; Thermo Fisher Scientific	MESSING, RO (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94110, USA.		Messing, Robert/D-3642-2015	Messing, Robert/0000-0002-5345-4431	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008117] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA08117] Funding Source: Medline; NINDS NIH HHS [NS01151] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMES BN, 1960, J BIOL CHEM, V235, P769; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; Bell R M, 1986, Methods Enzymol, V124, P353; BELL RM, 1991, J BIOL CHEM, V266, P4661; BONE GHA, 1989, PSYCHOPHARMACOLOGY, V99, P386, DOI 10.1007/BF00445563; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARNESS ME, 1988, BIOCHEM BIOPH RES CO, V155, P138, DOI 10.1016/S0006-291X(88)81060-X; CHARNESS ME, 1989, NEW ENGL J MED, V321, P442, DOI 10.1056/NEJM198908173210706; DATTA R, 1990, BLOOD, V76, P298; DOLIN S, 1987, NEUROPHARMACOLOGY, V26, P275, DOI 10.1016/0028-3908(87)90220-6; HATA A, 1989, FEBS LETT, V252, P144, DOI 10.1016/0014-5793(89)80907-X; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HU GY, 1987, NATURE, V328, P426, DOI 10.1038/328426a0; KOLBER MA, 1988, ALCOHOL CLIN EXP RES, V12, P820, DOI 10.1111/j.1530-0277.1988.tb01353.x; KOPPI S, 1987, NEUROPSYCHOBIOLOGY, V17, P49, DOI 10.1159/000118340; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LITTLE HJ, 1986, LIFE SCI, V39, P2059, DOI 10.1016/0024-3205(86)90356-5; LITTLETON JM, 1990, PSYCHOPHARMACOLOGY, V100, P387, DOI 10.1007/BF02244612; LIU TC, 1987, ENDOCRINOLOGY, V121, P1589, DOI 10.1210/endo-121-5-1589; MESSING RO, 1989, J NEUROSCI, V9, P507; MESSING RO, 1986, P NATL ACAD SCI USA, V83, P6213, DOI 10.1073/pnas.83.16.6213; MESSING RO, 1990, J NEUROCHEM, V55, P1383, DOI 10.1111/j.1471-4159.1990.tb03150.x; MILES MF, 1991, J BIOL CHEM, V266, P2409; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; NAVARRO J, 1987, J BIOL CHEM, V262, P4649; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OBEID LM, 1990, J BIOL CHEM, V265, P2370; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; PARENT LJ, 1987, FASEB J, V1, P469, DOI 10.1096/fasebj.1.6.3678702; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SKATTEBOL A, 1987, BIOCHEM PHARMACOL, V36, P2227, DOI 10.1016/0006-2952(87)90156-0; STRONG JA, 1987, NATURE, V325, P714, DOI 10.1038/325714a0; URSO T, 1981, LIFE SCI, V28, P1053, DOI 10.1016/0024-3205(81)90752-9; VANVELDHOVEN PP, 1988, BIOCHIM BIOPHYS ACTA, V959, P185, DOI 10.1016/0005-2760(88)90030-6	39	175	181	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23428	23432						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744136				2022-12-25	WOS:A1991GT48300097
J	RAJAGOPALAN, M; NEIDIGH, JL; MCCLAIN, DA				RAJAGOPALAN, M; NEIDIGH, JL; MCCLAIN, DA			AMINO-ACID-SEQUENCES GLY-PRO-LEU-TYR AND ASN-PRO-GLU-TYR IN THE SUBMEMBRANOUS DOMAIN OF THE INSULIN-RECEPTOR ARE REQUIRED FOR NORMAL ENDOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; DNA MISMATCH-REPAIR; MEDIATED ENDOCYTOSIS; CYTOPLASMIC DOMAIN; ESCHERICHIA-COLI; RAT ADIPOCYTES; INTERNALIZATION; BINDING; RETROENDOCYTOSIS; PHOSPHOTYROSINE	We have recently shown that the immediately submembranous domain of the human insulin receptor (hIR) is required for rapid ligand-dependent internalization (Thies, R. S., Webster, N. J., and McClain, D. A. (1990) J. Biol. Chem. 265, 10132-10137). This region contains one copy of an NPXY sequence that is required for endocytosis of the low density lipoprotein receptor. In order to dissect and analyze the specific sequences involved in endocytosis of the insulin receptor, we have mutated the NPXY sequence from NPEY (residues 957-960) to APEA (NPEY/APEA). In addition, we have mutated a similar sequence in the same region, changing GPLY (residues 950-953) to APLA (GPLY/APLA). The cDNAs encoding the normal hIR and these mutant receptors were transfected into Rat 1 fibroblasts. The expressed receptors bound insulin with high affinity and retained insulin-stimulated tyrosine kinase activity. Despite the ability of these mutant receptors to bind insulin and undergo autophosphorylation, the GPLY/APLA receptor internalized insulin at only 32% of the rate of normal hIR at low receptor occupancy. On the other hand, the NPEY/APEA receptor internalized insulin at 87% of the normal rate. These results were confirmed by measuring internalization of photoaffinity-labeled insulin receptors. Another receptor with both the NPEY/APEA and GPLY/APLA mutations internalized to a lesser degree than the GPLY/APLA receptor and at a rate equivalent to that seen for a receptor with the entire submembranous domain deleted. A receptor with the complete normal submembranous domain but with the tyrosine kinase and C-terminal region of the hIR deleted exhibited only a basal internalization rate. We conclude that the information contained in the GPLY and, to a lesser extent, the NPEY sequences are necessary but not sufficient for signaling internalization of the insulin receptor.	UNIV ALABAMA,DEPT MED,DIV ENDOCRINOL,DH 777,UAB STN,BIRMINGHAM,AL 35294; VET ADM MED CTR,BIRMINGHAM,AL 35233	University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)				McClain, Don/0000-0002-3310-2359	NIDDK NIH HHS [R29 DK 42295] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HEIDENREICH KA, 1984, J BIOL CHEM, V259, P6511; KAMPS MP, 1988, ONCOGENE, V2, P305; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEVY J, 1987, ENDOCRINOLOGY, V120, P450, DOI 10.1210/endo-120-2-450; LEVY JR, 1986, ENDOCRINOLOGY, V119, P572, DOI 10.1210/endo-119-2-572; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MCCLAIN DA, 1990, DIABETES CARE, V13, P302, DOI 10.2337/diacare.13.3.302; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MCCLAIN DA, 1988, DIABETES, V37, P806, DOI 10.2337/diabetes.37.6.806; OPRESKO LK, 1987, J BIOL CHEM, V262, P4116; PILCH PF, 1983, J CELL BIOL, V96, P133, DOI 10.1083/jcb.96.1.133; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SMITH RM, 1983, J CELL PHYSIOL, V115, P199, DOI 10.1002/jcp.1041150215; THIES RS, 1989, J BIOL CHEM, V264, P12820; THIES RS, 1990, J BIOL CHEM, V265, P10132; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WILEY HS, 1982, J BIOL CHEM, V257, P4222; ZELL R, 1987, EMBO J, V6, P1809, DOI 10.1002/j.1460-2075.1987.tb02435.x	28	95	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23068	23073						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744103				2022-12-25	WOS:A1991GT48300047
J	DEGROOT, RP; MEIJER, I; VANDENBRINK, S; MUMMERY, C; KRUIJER, W				DEGROOT, RP; MEIJER, I; VANDENBRINK, S; MUMMERY, C; KRUIJER, W			DIFFERENTIAL REGULATION OF JUNB AND JUND BY ADENOVIRUS TYPE-5 AND TYPE-12 E1A-PROTEINS	ONCOGENE			English	Note							EMBRYONAL CARCINOMA-CELLS; CELLULAR TRANSCRIPTION FACTOR; C-HA-RAS; PROTO-ONCOGENE; RESPONSE ELEMENT; TRANS-ACTIVATION; MESSENGER-RNAS; FACTOR FAMILY; E1A PRODUCTS; GENE FAMILY	The genes of the Jun family encode components of the TPA-inducible transcription factor AP-1. These genes are induced by a wide variety of extracellular stimuli, such as growth factors, phorbol esters and activators of protein kinase A. We have previously shown that the adenovirus type 5 E1A protein (E1A5) induces c-jun and junB expression in a number of different cell types. In this paper we show that the third member of the Jun family junD, is also strongly induced by E1A5. Multiple sequences in the junB and junD promoters are responsible for the effects of E1A5. By contrast, adenovirus type 12 E1A (E1A12), like retinoic acid (RA), strongly induces c-jun expression, while expression of junB and junD is not altered. Interestingly, E1A12 expression leads to complete differentiation of P19 EC cells, comparable to the effect of RA on these cells, while E1A5-expressing cells are only partially differentiated.	NETHERLANDS INST DEV BIOL,HUBRECHT LAB,3584 CT UTRECHT,NETHERLANDS; LEIDEN UNIV,SYLVIUS LABS,MOLEC CARCINOGENESIS LAB,2300 RA LEIDEN,NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Leiden University; Leiden University - Excl LUMC				Mummery, Christine/0000-0002-4549-6535				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BUCKBINDER L, 1989, EMBO J, V8, P4239, DOI 10.1002/j.1460-2075.1989.tb08609.x; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P1585, DOI 10.1093/nar/19.7.1585; DEGROOT RP, 1991, EMBO J, V10, P2523, DOI 10.1002/j.1460-2075.1991.tb07792.x; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; FRISCH SM, 1990, ONCOGENE, V5, P75; HARDY S, 1988, P NATL ACAD SCI USA, V85, P4171, DOI 10.1073/pnas.85.12.4171; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; Imler J L, 1989, Prog Growth Factor Res, V1, P69, DOI 10.1016/0955-2235(89)90001-X; JALINOT P, 1988, P NATL ACAD SCI USA, V85, P2484, DOI 10.1073/pnas.85.8.2484; JONES N, 1979, P NATL ACAD SCI USA, V79, P3655; KAO HT, 1983, MOL CELL BIOL, V3, P2058, DOI 10.1128/MCB.3.11.2058; KITABAYASHI I, 1991, NUCLEIC ACIDS RES, V19, P649, DOI 10.1093/nar/19.3.649; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAMPH WW, 1988, NATURE, V334, P592; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; LEZA MA, 1988, J VIROL, V62, P3003, DOI 10.1128/JVI.62.8.3003-3013.1988; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MEIJER I, 1991, ONCOGENE, V6, P911; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; MULLER U, 1989, GENE DEV, V3, P1991, DOI 10.1101/gad.3.12a.1991; MUMMERY CL, 1986, EXP CELL RES, V165, P229, DOI 10.1016/0014-4827(86)90547-1; MUMMERY CL, 1985, DEV BIOL, V109, P402, DOI 10.1016/0012-1606(85)90466-X; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; REES AR, 1979, NATURE, V281, P309, DOI 10.1038/281309a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1987, P NATL ACAD SCI USA, V84, P6430, DOI 10.1073/pnas.84.18.6430; SASSONECORSI P, 1988, P NATL ACAD SCI USA, V85, P7192, DOI 10.1073/pnas.85.19.7192; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VELCICH A, 1989, ONCOGENE, V4, P707; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670; YANG-YEN H-F, 1990, New Biologist, V2, P351; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	55	12	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2357	2361						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1837351				2022-12-25	WOS:A1991GX73500027
J	SCHAFER, R; NIRKKO, AC; AMBUHL, PM; GRZESCHIK, KH; SCHWARTEWALDHOFF, I				SCHAFER, R; NIRKKO, AC; AMBUHL, PM; GRZESCHIK, KH; SCHWARTEWALDHOFF, I			EVIDENCE FOR HUMAN DNA-MEDIATED TRANSFER OF THE SUPPRESSED PHENOTYPE INTO MALIGNANT CHINESE-HAMSTER CELLS	ONCOGENE			English	Article							DIPLOID MOUSE FIBROBLASTS; HA-RAS ONCOGENE; TRANSFORMED PHENOTYPE; GENETIC-ANALYSIS; RB GENE; TUMOR SUPPRESSION; PARTIAL REVERSION; CARCINOMA-CELLS; TRANSGENIC MICE; SRC GENE	Genetic suppression of the neoplastic phenotype has been demonstrated in somatic cell hybrids between tumor and normal cells. Suppression in whole-cell and microcell hybrids cannot, as yet, be attributed to specific elements defined at the molecular level. To identify a gene capable of suppressing the neoplastic phenotype, we have introduced DNA of normal human cells into tumorigenic Chinese hamster Wg3-h-o cells. Primary and secondary transfectants which exhibit the suppressed phenotype similar to Wg3-h-o x embryonic fibroblast hybrids were selected. The cells require serum growth factors and anchorage for proliferation in vitro and show a reduced tumorigenicity in nude mice. Transferred human DNA segments were molecularly cloned from a secondary transfectant. Indirect evidence suggests that the cloned human DNA is associated with the expression of the suppressed phenotype.	UNIV MARBURG,INST HUMAN GENET,W-3550 MARBURG,GERMANY	Philipps University Marburg	SCHAFER, R (corresponding author), UNIV ZURICH,INST PATHOL,DIV CANC RES,SCHMELZBERGSTR 12,CH-8091 ZURICH,SWITZERLAND.							BAKER RF, 1983, P NATL ACAD SCI-BIOL, V80, P1174, DOI 10.1073/pnas.80.5.1174; BARDWELL L, 1989, MUTAGENESIS, V4, P245, DOI 10.1093/mutage/4.4.245; BECHER R, 1983, CANCER GENET CYTOGEN, V9, P173, DOI 10.1016/0165-4608(83)90038-9; BENEDICT WF, 1984, CANCER RES, V44, P3471; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLAIR DG, 1982, SCIENCE, V218, P1122, DOI 10.1126/science.6293052; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHOMCZYNSKI P, 1984, BIOCHEM BIOPH RES CO, V122, P340, DOI 10.1016/0006-291X(84)90480-7; CRAIG RW, 1985, P NATL ACAD SCI USA, V82, P2062, DOI 10.1073/pnas.82.7.2062; CULINE S, 1989, INT J CANCER, V44, P990; DIAMANTIS ID, 1989, P NATL ACAD SCI USA, V86, P9299, DOI 10.1073/pnas.86.23.9299; DUIGOU GJ, 1990, MOL CELL BIOL, V10, P2027, DOI 10.1128/MCB.10.5.2027; DYSON PJ, 1982, CELL, V30, P491, DOI 10.1016/0092-8674(82)90246-X; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GEISER AG, 1986, P NATL ACAD SCI USA, V83, P5209, DOI 10.1073/pnas.83.14.5209; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HOHN B, 1980, GENE, V11, P291, DOI 10.1016/0378-1119(80)90069-4; HOWELL N, 1981, CYTOGENET CELL GENET, V31, P214, DOI 10.1159/000131651; HSU TC, 1964, J NATL CANCER I, V32, P857; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Iten E, 1989, Recent Results Cancer Res, V113, P78; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLINGER HP, 1983, JNCI-J NATL CANCER I, V71, P559; KOZAK CA, 1977, EXP CELL RES, V105, P109, DOI 10.1016/0014-4827(77)90156-2; KUZUMAKI N, 1989, MOL CELL BIOL, V9, P2258, DOI 10.1128/MCB.9.5.2258; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; MARSHALL CJ, 1980, EXP CELL RES, V127, P373, DOI 10.1016/0014-4827(80)90442-5; MIKKELSEN T, 1990, CELL GROWTH DIFFER, V1, P201; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; OSHIMURA M, 1989, P AM ASSOC CANC RES, V30, P786; PADMANABHAN R, 1987, MOL CELL BIOL, V7, P1894, DOI 10.1128/MCB.7.5.1894; PATERSON H, 1987, CELL, V51, P803, DOI 10.1016/0092-8674(87)90103-6; PATTENGALE PK, 1989, AM J PATHOL, V135, P39; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; PIZON V, 1988, ONCOGENE, V3, P201; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; RUSSELL WC, 1975, NATURE, V253, P461, DOI 10.1038/253461a0; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; SCHAFER R, 1981, CANCER RES, V41, P1214; SCHAFER R, 1983, CANCER RES, V43, P2240; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SRIVATSAN ES, 1986, CANCER RES, V46, P6174; STENMAN G, 1987, P NATL ACAD SCI USA, V84, P9099, DOI 10.1073/pnas.84.24.9099; STOLER A, 1985, P NATL ACAD SCI USA, V82, P570, DOI 10.1073/pnas.82.2.570; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TRENT JM, 1981, CANCER GENET CYTOGEN, V3, P279, DOI 10.1016/0165-4608(81)90037-6; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WEINBERG RA, 1989, CANCER RES, V49, P3713; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	56	5	5	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2221	2228						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766670				2022-12-25	WOS:A1991GX73500007
J	STRITTMATTER, SM; VALENZUELA, D; SUDO, Y; LINDER, ME; FISHMAN, MC				STRITTMATTER, SM; VALENZUELA, D; SUDO, Y; LINDER, ME; FISHMAN, MC			AN INTRACELLULAR GUANINE-NUCLEOTIDE RELEASE PROTEIN FOR G0 - GAP-43 STIMULATES ISOLATED ALPHA-SUBUNITS BY A NOVEL MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; HUMAN BETA-2-ADRENERGIC RECEPTOR; NEURONAL GROWTH CONE; KINASE-C SUBSTRATE; ADENYLATE-CYCLASE; BINDING-PROTEIN; ESCHERICHIA-COLI; AMINO TERMINUS; GI-ALPHA; GS-ALPHA	G protein-coupled membrane receptors activate G proteins by enhancing guanine nucleotide exchange. G(o) is a major component of the growing regions (growth cones) of neurons. GAP-43 is a neuronal protein associated with the cytosolic face of the growth cone plasma membrane and stimulates binding of guanosine 5'-3-O-(thio)triphosphate (GTP-gamma-S) to G. (Strittmatter, S. M., Valenzuela, D., Kennedy, T. E., Neer, E. J., and Fishman, M. C. (1990) Nature 344, 836-841). Here we have examined the mechanism by which GAP-43 affects G(o). Like G protein-coupled receptors, GAP-43 enhances GDP release from G(o), increases the initial rate of GTP-gamma-S binding, and increases the GTPase activity of G(o), all without altering the intrinsic k(cat) for the GTPase. Unlike the case for receptors, however, the GAP-43 effect is not blocked by pertussis toxin, nor affected by the presence or absence of beta-gamma or of phospholipids. There is specificity to the interaction, in that GAP-43 increases GTP-gamma-S binding to recombinant alpha(o) and alpha(il), but not to recombinant alpha(s). Thus, GAP-43 is a guanine nucleotide release protein with a novel mechanism of action, potentially controlling membrane-associated G proteins from within the cell.	MASSACHUSETTS GEN HOSP E, DEV BIOL LAB, 149 13TH ST, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02114 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; MASSACHUSETTS GEN HOSP E, CARDIOVASC RES CTR, BOSTON, MA 02129 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Linder, Maurine/AAU-9999-2021; Strittmatter, Stephen/F-5739-2011	Linder, Maurine/0000-0003-2202-9712; Strittmatter, Stephen/0000-0001-8188-3092				ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4615, DOI 10.1021/bi00289a001; BANKER GA, 1979, J COMP NEUROL, V187, P469, DOI 10.1002/cne.901870302; BENOWITZ LI, 1983, J NEUROSCI, V3, P2153; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; CASSEL D, 1977, J CYCLIC NUCL PROT, V3, P11; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; DOSTER SK, 1991, NEURON, V6, P635, DOI 10.1016/0896-6273(91)90066-9; EDMONDS BT, 1990, DEV BRAIN RES, V56, P131, DOI 10.1016/0165-3806(90)90172-U; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HEKMAN M, 1984, EMBO J, V3, P3339, DOI 10.1002/j.1460-2075.1984.tb02301.x; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; KATADA T, 1982, J BIOL CHEM, V257, P7210; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; LETOURNEAU PC, 1975, DEV BIOL, V44, P92, DOI 10.1016/0012-1606(75)90379-6; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LIU YC, 1991, NEURON, V6, P411, DOI 10.1016/0896-6273(91)90249-Y; LOCKERBIE RO, 1987, NEUROSCIENCE, V20, P719, DOI 10.1016/0306-4522(87)90235-1; LOVINGER DM, 1985, BRAIN RES, V343, P137, DOI 10.1016/0006-8993(85)91167-9; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MIERI K, 1986, P NATL ACAD SCI USA, V83, P3537; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PARKER EM, 1991, J BIOL CHEM, V266, P519; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SKENE JHP, 1986, SCIENCE, V233, P783, DOI 10.1126/science.3738509; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; SKENE JHP, 1981, J CELL BIOL, V89, P96, DOI 10.1083/jcb.89.1.96; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRITTMATTER SM, 1990, NATURE, V13, P127; TSAI SC, 1987, BIOCHEMISTRY-US, V26, P4728, DOI 10.1021/bi00389a020; VANDONGEN CJ, 1985, BIOCHEM BIOPH RES CO, V128, P1219, DOI 10.1016/0006-291X(85)91070-8; VANHOOFF COM, 1989, J CELL BIOL, V108, P1115, DOI 10.1083/jcb.108.3.1115; ZUBER MX, 1989, SCIENCE, V244, P1193, DOI 10.1126/science.2658062; ZUBER MX, 1989, NATURE, V341, P345, DOI 10.1038/341345a0; ZWIERS H, 1985, J NEUROCHEM, V44, P1083, DOI 10.1111/j.1471-4159.1985.tb08728.x	52	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22465	22471						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1834672				2022-12-25	WOS:A1991GR56400065
J	ISHIKAWA, R; OKAGAKI, T; HIGASHIFUJIME, S; KOHAMA, K				ISHIKAWA, R; OKAGAKI, T; HIGASHIFUJIME, S; KOHAMA, K			STIMULATION OF THE INTERACTION BETWEEN ACTIN AND MYOSIN BY PHYSARUM CALDESMON-LIKE PROTEIN AND SMOOTH-MUSCLE CALDESMON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+ REGULATION; ATPASE ACTIVITY; THIN-FILAMENTS; LIGHT CHAIN; F-ACTIN; BINDING; POLYCEPHALUM; PURIFICATION; CALMODULIN; MECHANISM	We have purified an actin-binding protein from the plasmodia of a lower eukaryote, Physarum polycephalum, with an apparent molecular mass of 210,000 daltons on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. This protein bound to actin filaments with a stoichiometry of 1:7-8 in a Ca2+-calmodulin-dependent manner. Antibody raised against caldesmon from smooth muscle cross-reacted with the 210-kDa protein. In vitro motility assay revealed that the 210-kDa protein increased the sliding velocity of actin filaments on Physarum myosin. The 210-kDa protein more than doubled the actin-activated ATPase activity of Physarum myosin under comparative conditions of in vitro motility assay. Further increases in the concentration of the 210-kDa protein decreased its stimulatory effects. Ca2+-calmodulin prevented the stimulatory effects of the 210-kDa protein. Unexpectedly, smooth muscle caldesmon also increased the sliding velocity of actin filaments on smooth muscle myosin at lower concentrations. The well-known inhibitory effect of smooth muscle caldesmon on the actin-myosin interaction was observed with this motility assay when the concentration of the caldesmon was increased further. The stimulatory and inhibitory effects were confirmed by measurements of actin-activated ATPase activity of smooth muscle myosin. From estimations of the intracellular concentrations of the 210-kDa protein and smooth muscle caldesmon in vivo, it appears that effects of the former and the latter on actin-myosin interactions in vivo are stimulatory and inhibitory, respectively.	NIHON UNIV,PHYS SCI LABS,FUNABASHI,CHIBA 274,JAPAN; NAGOYA UNIV,FAC SCI,DEPT MOLEC BIOL,NAGOYA,AICHI 464,JAPAN	Nihon University; Nagoya University	ISHIKAWA, R (corresponding author), GUNMA UNIV,SCH MED,DEPT PHARMACOL,MAEBASHI,GUNMA 371,JAPAN.							ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BRYAN J, 1989, J BIOL CHEM, V264, P13873; EBASHI S, 1976, J BIOCHEM-TOKYO, V79, P229, DOI 10.1093/oxfordjournals.jbchem.a131052; HASEGAWA T, 1980, BIOCHEMISTRY-US, V19, P2677, DOI 10.1021/bi00553a021; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HORIUCHI KY, 1988, BIOCHEMISTRY-US, V27, P8388, DOI 10.1021/bi00422a014; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; KESSLER D, 1980, CELL MOTIL CYTOSKEL, V1, P63, DOI 10.1002/cm.970010106; KOBAYASHI T, 1988, J BIOL CHEM, V263, P305; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; KOHAMA K, 1990, TRENDS PHARMACOL SCI, V11, P433; KOHAMA K, 1981, J BIOCHEM, V90, P497, DOI 10.1093/oxfordjournals.jbchem.a133497; KOHAMA K, 1986, J BIOCHEM-TOKYO, V99, P1433, DOI 10.1093/oxfordjournals.jbchem.a135613; Kohama K., 1987, Advances in Biophysics, V23, P149; KOHAMA K, 1986, J BIOL CHEM, V261, P8022; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSTON SB, 1985, J MUSCLE RES CELL M, V6, P669, DOI 10.1007/BF00712237; NGAI PK, 1984, J BIOL CHEM, V259, P3656; OKAGAKI T, 1989, J BIOCHEM-TOKYO, V106, P955, DOI 10.1093/oxfordjournals.jbchem.a122980; OKAGAKI T, 1991, J BIOCHEM, V109, P858, DOI 10.1093/oxfordjournals.jbchem.a123471; OZAKI K, 1984, J CELL BIOL, V98, P1919, DOI 10.1083/jcb.98.6.1919; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; YAMASHIRO-MATSUMURA S, 1988, Protoplasma Supplementum, V2, P9; YAMASHIROMATSUM.S, 1988, J CELL BIOL, V106, P1937	30	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21784	21790						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1834662				2022-12-25	WOS:A1991GP80400070
J	PABORSKY, LR; CARAS, IW; FISHER, KL; GORMAN, CM				PABORSKY, LR; CARAS, IW; FISHER, KL; GORMAN, CM			LIPID ASSOCIATION, BUT NOT THE TRANSMEMBRANE DOMAIN, IS REQUIRED FOR TISSUE FACTOR ACTIVITY - SUBSTITUTION OF THE TRANSMEMBRANE DOMAIN WITH A PHOSPHATIDYLINOSITOL ANCHOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPHOSPHOLIPID MEMBRANE ANCHOR; COAGULATION PROTEASE CASCADE; FACTOR-VII; CELLULAR RECEPTOR; CDNA; DNA; PURIFICATION; ATTACHMENT; BINDING; SIGNAL	Full-length tissue factor (263 rTF) and three truncated forms have been expressed in human kidney 293 cells; 1) 243 rTF, which lacks the cytoplasmic tail, is fu]IY functional in the chromogenic assay and has a specific activity comparable with that of the full-length molecule, 263 rTF; 2) 219 rTF, which lacks both the transmembrane and cytoplasmic domains, is not functional; 3) the third variant, referred to as TF-PI, is a fusion protein containing the extracellular domain of TF (amino acids 1-219) fused to the last 37 amino acids of decay-accelerating factor which contain a signal for attachment of a phosphatidylinositol membrane anchor (PI). TF-PI is a membrane-bound protein expressed on the cell surface. The PI anchor restores TF activity lost when the transmembrane domain is deleted from the 219 rTF variant. The ability of the PI anchor to restore activity to 219 rTF clearly demonstrates that while the transmembrane domain is not required for TF activity, lipid association is required.	GENENTECH INC,DEPT CELL GENET,460 PT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT IMMUNOBIOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT CARDIOVASC RES,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech				Caras, Ingrid/0000-0002-8902-808X				BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BACH R, 1988, BIOCHEMISTRY-US, V27, P4227, DOI 10.1021/bi00412a004; BACH R, 1981, J BIOL CHEM, V256, P8324; BERMAN PW, 1985, SCIENCE, V227, P1490, DOI 10.1126/science.2983428; BONA R, 1987, THROMB RES, V48, P487, DOI 10.1016/0049-3848(87)90405-1; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CARAS IW, 1989, J CELL BIOL, V108, P1387, DOI 10.1083/jcb.108.4.1387; CARAS IW, 1989, SCIENCE, V243, P1196, DOI 10.1126/science.2466338; DOWBENKO D, 1988, J VIROL, V62, P4703, DOI 10.1128/JVI.62.12.4703-4711.1988; DRAKE TA, 1989, J CELL BIOL, V109, P389, DOI 10.1083/jcb.109.1.389; FAIR DS, 1987, J BIOL CHEM, V262, P11692; FISHER KL, 1987, THROMB RES, V48, P89, DOI 10.1016/0049-3848(87)90349-5; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUHA A, 1986, P NATL ACAD SCI USA, V83, P299, DOI 10.1073/pnas.83.2.299; HVATUM M, 1969, THROMB DIATH HAEMOST, V21, P217; JACKMAN RW, 1986, P NATL ACAD SCI USA, V83, P8834, DOI 10.1073/pnas.83.23.8834; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOW MG, 1985, NATURE, V28, P61; MACKMAN N, 1989, BIOCHEMISTRY-US, V28, P1755, DOI 10.1021/bi00430a050; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; MORRISSEY JH, 1988, THROMB RES, V50, P481, DOI 10.1016/0049-3848(88)90197-1; MORRISSEY JH, 1988, THROMB RES, V52, P247, DOI 10.1016/0049-3848(88)90084-9; NEMERSON Y, 1968, J CLIN INVEST, V47, P72, DOI 10.1172/JCI105716; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; NEMERSON Y, 1988, BLOOD, V71, P1; PABORSKY LR, 1989, BIOCHEMISTRY-US, V28, P8072, DOI 10.1021/bi00446a016; PABORSKY LR, 1990, PROTEIN ENG, V6, P547; PITLICK FA, 1970, BIOCHEMISTRY-US, V9, P5105; SAKAI T, 1989, J BIOL CHEM, V264, P9980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARPATI EM, 1987, BIOCHEMISTRY-US, V26, P5234, DOI 10.1021/bi00391a004; SPICER EK, 1987, P NATL ACAD SCI USA, V84, P5148, DOI 10.1073/pnas.84.15.5148; TRAUNECKER A, 1989, NATURE, V339, P68, DOI 10.1038/339068a0; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	39	80	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21911	21916						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1834663				2022-12-25	WOS:A1991GP80400088
J	GRACEFFA, P; JANCSO, A				GRACEFFA, P; JANCSO, A			DISULFIDE CROSS-LINKING OF CALDESMON TO ACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALDESMON; RABBIT SKELETAL-MUSCLE; AMINO-ACID SEQUENCE; CALMODULIN-BINDING FRAGMENT; CHICKEN GIZZARD CALDESMON; CYANOGEN-BROMIDE PEPTIDES; F-ACTIN; THIN-FILAMENTS; ATPASE ACTIVITY; MYOSIN SUBFRAGMENT-1	Treatment of a solution of actin and smooth muscle caldesmon with 5,5'-dithiobis(2-nitrobenzoic acid) results in the formation of a disulfide cross-link between the C-terminal penultimate residue Cys-374 of actin and Cys-580 in caldesmon's C-terminal actin-binding region. Therefore, these 2 residues are close in the actin-caldesmon complex. Since myosin also binds to actin in the vicinity of Cys-374 and since caldesmon inhibits actomyosin ATPase activity by the reduction of myosin binding to actin, then the inhibition might be by caldesmon sterically hindering or blocking myosin's interaction with actin. [Ca2+]Calmodulin, which reverses the inhibition of the ATPase activity, decreases the yield of the cross-linked species, suggesting a weakening of the caldesmon-actin interaction in the cross-linked region. It is possible to maximally cross-link one caldesmon molecule/every three actin monomers, in the absence or presence of tropomyosin, clearly ruling out an elongated, end-to-end alignment of caldesmon on the actin filament in vitro, and raising the possibility that the N-terminal part of caldesmon projects out from the filament. Reaction of 5,5'-dithiobis (2-nitrobenzoic acid)-modified actin with caldesmon leads to the same disulfide cross-linked product between actin and caldesmon Cys-580, enabling the specific labeling of the other caldesmon cysteine, residue 153, in the N-terminal part of caldesmon with a spectroscopic probe.			GRACEFFA, P (corresponding author), BOSTON BIOMED RES INST,DEPT MUSCLE RES,20 STANFORD ST,BOSTON,MA 02114, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030917] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-30917] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS S, 1990, J BIOL CHEM, V265, P19652; BALL EH, 1988, BIOCHEMISTRY-US, V27, P6093, DOI 10.1021/bi00416a039; BARTEGI A, 1990, J BIOL CHEM, V265, P2231; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BENDER N, 1976, EUR J BIOCHEM, V64, P215, DOI 10.1111/j.1432-1033.1976.tb10290.x; BERTRAND R, 1989, EUR J BIOCHEM, V181, P747, DOI 10.1111/j.1432-1033.1989.tb14787.x; BERTRAND R, 1988, BIOCHEMISTRY-US, V27, P5728, DOI 10.1021/bi00415a050; BLACKHOLM H, 1981, BIOCHEM BIOPH RES CO, V103, P125, DOI 10.1016/0006-291X(81)91669-7; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; DILLON PF, 1981, SCIENCE, V211, P495, DOI 10.1126/science.6893872; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ELZINGA M, 1973, P NATL ACAD SCI USA, V70, P2687, DOI 10.1073/pnas.70.9.2687; ELZINGA M, 1975, J BIOL CHEM, V250, P5897; FAULSTICH H, 1984, BIOCHEMISTRY-US, V23, P1608, DOI 10.1021/bi00303a004; FAUST U, 1974, EUR J BIOCHEM, V43, P273, DOI 10.1111/j.1432-1033.1974.tb03410.x; FUJII T, 1987, J BIOL CHEM, V262, P2757; FURST DO, 1986, EMBO J, V5, P251, DOI 10.1002/j.1460-2075.1986.tb04206.x; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GRACEFFA P, 1990, J MUSCLE RES CELL M, V11, P439; GRACEFFA P, 1988, J BIOL CHEM, V263, P14196; GRACEFFA P, 1989, BIOCHEMISTRY-US, V28, P1282, DOI 10.1021/bi00429a050; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V164, P503, DOI 10.1016/0006-291X(89)91748-8; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HEMRIC ME, 1990, J BIOL CHEM, V265, P19672; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HORIUCHI KY, 1989, BIOCHEMISTRY-US, V28, P9111, DOI 10.1021/bi00449a023; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; IKEBE M, 1988, J BIOL CHEM, V263, P3055; JANCSO A, 1991, J BIOL CHEM, V266, P5891; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KATAYAMA E, 1989, BIOCHEM BIOPH RES CO, V160, P1316, DOI 10.1016/S0006-291X(89)80147-0; KOBASHI K, 1967, ARCH BIOCHEM BIOPHYS, V121, P178, DOI 10.1016/0003-9861(67)90022-7; KOBASHI K, 1968, BIOCHIM BIOPHYS ACTA, V158, P239, DOI 10.1016/0304-4165(68)90136-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASH JA, 1986, J BIOL CHEM, V261, P6155; LEHMAN W, 1989, J MUSCLE RES CELL M, V10, P101, DOI 10.1007/BF01739966; LEHRER SS, 1975, P NATL ACAD SCI USA, V72, P3377, DOI 10.1073/pnas.72.9.3377; LESZYK J, 1989, BIOCHEM BIOPH RES CO, V160, P1371, DOI 10.1016/S0006-291X(89)80155-X; LESZYK J, 1989, BIOCHEM BIOPH RES CO, V160, P210, DOI 10.1016/0006-291X(89)91642-2; LEVINE BA, 1990, EUR J BIOCHEM, V193, P687, DOI 10.1111/j.1432-1033.1990.tb19388.x; LUSTY CJ, 1969, BIOCHEMISTRY-US, V8, P2933, DOI 10.1021/bi00835a036; LYNCH WP, 1987, J BIOL CHEM, V262, P7429; MABUCHI K, 1991, J MUSCLE RES CELL M, V12, P145, DOI 10.1007/BF01774033; MARSTON S, 1990, BIOCHEM J, V272, P305, DOI 10.1042/bj2720305; MARSTON SB, 1985, J MUSCLE RES CELL M, V6, P669, DOI 10.1007/BF00712237; MARSTON SB, 1984, BIOCHEM SOC T, V12, P945, DOI 10.1042/bst0120945; MARSTON SB, 1989, J MUSCLE RES CELL M, V10, P97, DOI 10.1007/BF01739965; MEJEAN C, 1987, BIOCHEM J, V244, P571, DOI 10.1042/bj2440571; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MOODY C, 1990, J MUSCLE RES CELL M, V11, P176, DOI 10.1007/BF01766496; MORNET D, 1988, BIOCHEM BIOPH RES CO, V154, P564, DOI 10.1016/0006-291X(88)90177-5; NGAI PK, 1984, J BIOL CHEM, V259, P3656; NISHIDA W, 1990, FEBS LETT, V268, P165, DOI 10.1016/0014-5793(90)80999-Y; RISEMAN VM, 1989, J BIOL CHEM, V264, P2869; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SOBUE K, 1985, BIOCHEM BIOPH RES CO, V132, P645, DOI 10.1016/0006-291X(85)91181-7; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUTOH K, 1984, BIOCHEMISTRY-US, V23, P6757, DOI 10.1021/bi00321a073; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; SZILAGYI L, 1982, BIOCHIM BIOPHYS ACTA, V709, P204, DOI 10.1016/0167-4838(82)90462-9; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; TAKAGI T, 1989, J BIOCHEM-TOKYO, V106, P778, DOI 10.1093/oxfordjournals.jbchem.a122930; TRAYER IP, 1987, EUR J BIOCHEM, V164, P259, DOI 10.1111/j.1432-1033.1987.tb11019.x; VELAZ L, 1990, J BIOL CHEM, V265, P2929; VELAZ L, 1989, J BIOL CHEM, V264, P9602; WELLS JA, 1980, BIOCHEMISTRY-US, V19, P1711, DOI 10.1021/bi00549a030; WOLFF DJ, 1977, J BIOL CHEM, V252, P4108; YAMAMOTO K, 1983, J BIOCHEM-TOKYO, V94, P2075, DOI 10.1093/oxfordjournals.jbchem.a134565; YAZAWA M, 1987, J BIOCHEM-TOKYO, V102, P1065, DOI 10.1093/oxfordjournals.jbchem.a122144	77	42	42	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20305	20310						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1834643				2022-12-25	WOS:A1991GM03900064
J	LOWENSON, JD; CLARKE, S				LOWENSON, JD; CLARKE, S			STRUCTURAL ELEMENTS AFFECTING THE RECOGNITION OF L-ISOASPARTYL RESIDUES BY THE L-ISOASPARTYL D-ASPARTYL PROTEIN METHYLTRANSFERASE - IMPLICATIONS FOR THE REPAIR HYPOTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTACT HUMAN-ERYTHROCYTES; ENZYMATIC METHYL ESTERIFICATION; CARBOXYL METHYLTRANSFERASE; ASPARAGINYL RESIDUES; SEMINAL RIBONUCLEASE; MEMBRANE-PROTEINS; ALPHA-CARBOXYL; PEPTIDE-BOND; DEAMIDATION; IDENTIFICATION	We have synthesized a series Of L-isoaspartyl-containing (isoD) peptides and characterized their interaction with the human erythrocyte L-isoaspartyl/D-aspartyl protein methyltransferase (EC 2.1.1.77). Our findings indicate that this enzyme interacts with 6 residues extending from the isoD-2 to isoD+3 positions in peptide substrates. Although peptides as simple as G-isoD-G are methylated with low affinity (K(m) = 17.8 mM), a wide variety of L-isoaspartyl-containing sequences in larger peptides are recognized with high affinity (K(m) < 20-mu-M), the best yet discovered being VYP-isoD-HA, with a K(m) of 0.29-mu-M. Only two sequence elements have been found that can interfere with the high affinity binding of peptides of 4 or more residues, these being a prolyl residue in the isoD+1 position and negatively charged residues in the isoD+1, isoD+2, and/or isoD+3 positions. We investigated the effect of higher order structure on binding affinity using several L-isoaspartyl-containing proteins. Although conformation did, in some cases, lower the affinity of the methyltransferase for L-isoaspartyl residues, the range of kinetic constants for the methylation of these proteins was similar to that observed with the synthetic peptides. The L-isoaspartyl/D-aspartyl methyltransferase has been proposed to function in vivo to prevent the accumulation of L-isoaspartyl residues that arise spontaneously as proteins age. To examine whether such a mechanism is feasible given the wide range of substrate K(m) values observed in vitro, we set up a computer simulation to model the degradation and methylation reactions in aging human erythrocytes. Our results suggest that enough methyltransferase activity exists in these cells to significantly lower the expected number of L-isoaspartyl residues, even when these residues have millimolar K(m) values for methylation.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	LOWENSON, JD (corresponding author), UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024, USA.		Lowenson, Jonathan/AAN-6768-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026020, R01GM026020, T32GM007185] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-26020, GM 07185] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTIGUES A, 1990, J BIOL CHEM, V265, P4853; ASWAD DW, 1987, BIOCHEMISTRY-US, V26, P675, DOI 10.1021/bi00377a003; ASWAD DW, 1987, TRENDS BIOCHEM SCI, V12, P155, DOI 10.1016/0968-0004(87)90073-9; ASWAD DW, 1984, J BIOL CHEM, V259, P714; ASWAD DW, 1983, J NEUROCHEM, V40, P1718, DOI 10.1111/j.1471-4159.1983.tb08147.x; BARBER JR, 1983, J BIOL CHEM, V258, P1189; BLODGETT JK, 1985, J AM CHEM SOC, V107, P4305, DOI 10.1021/ja00300a039; BRUNAUER LS, 1986, J BIOL CHEM, V261, P2538; CHARACHE S, 1977, J CLIN INVEST, V59, P652, DOI 10.1172/JCI108683; CHAZIN WJ, 1989, BIOCHEMISTRY-US, V28, P8646, DOI 10.1021/bi00447a055; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; DIDONATO A, 1986, BIOCHEMISTRY-US, V25, P8361, DOI 10.1021/bi00374a005; Eisenberg D., 1982, FARADAY S CHEM SOC, V17, P109, DOI DOI 10.1039/FS9821700109; FREITAG C, 1981, J BIOL CHEM, V256, P6102; GALLETTI P, 1988, EUR J BIOCHEM, V177, P233, DOI 10.1111/j.1432-1033.1988.tb14367.x; GALLETTI P, 1988, BIOCHEMISTRY-US, V27, P1752, DOI 10.1021/bi00405a055; GALLETTI P, 1989, INT J PEPT PROT RES, V33, P397; GEIGER T, 1987, J BIOL CHEM, V262, P785; GEORGENASCIMENT.C, 1990, BIOCHEMISTRY-US, V29, P9586; GILBERT JM, 1988, BIOCHEMISTRY-US, V27, P5227, DOI 10.1021/bi00414a042; Hirs C. H. W, 1967, METHODS ENZYMOL, V11, P197; INGROSSO D, 1991, BIOCHEM BIOPH RES CO, V175, P351, DOI 10.1016/S0006-291X(05)81242-2; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; JOHNSON BA, 1991, ANAL BIOCHEM, V192, P384, DOI 10.1016/0003-2697(91)90553-6; KAHNE D, 1988, J AM CHEM SOC, V110, P7529, DOI 10.1021/ja00230a041; LADINO CA, 1990, MECH AGEING DEV, V55, P123, DOI 10.1016/0047-6374(90)90020-G; LINSE S, 1990, BIOCHEMISTRY-US, V29, P5925, DOI 10.1021/bi00477a007; LOWENSON JD, 1991, GERONTOLOGY, V37, P128; LOWENSON JD, 1990, J BIOL CHEM, V265, P3106; LURA R, 1988, BIOCHEMISTRY-US, V27, P7671, DOI 10.1021/bi00420a015; MACFARLANE DE, 1984, J BIOL CHEM, V259, P1357; MAN EH, 1987, J NEUROCHEM, V48, P510, DOI 10.1111/j.1471-4159.1987.tb04122.x; MCFADDEN PN, 1982, P NATL ACAD SCI-BIOL, V79, P2460, DOI 10.1073/pnas.79.8.2460; MCFADDEN PN, 1986, MECH AGEING DEV, V34, P91, DOI 10.1016/0047-6374(86)90107-7; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; MCFADDEN PN, 1986, J BIOL CHEM, V261, P1503; MIDELFORT CF, 1972, P NATL ACAD SCI USA, V69, P1816, DOI 10.1073/pnas.69.7.1816; MURRAY ED, 1984, J BIOL CHEM, V259, P722; OCONNOR CM, 1984, J BIOL CHEM, V259, P2570; OTA IM, 1990, ARCH BIOCHEM BIOPHYS, V279, P320, DOI 10.1016/0003-9861(90)90498-N; OTA IM, 1988, BIOCHEM BIOPH RES CO, V151, P1136, DOI 10.1016/S0006-291X(88)80484-4; OTA IM, 1989, J BIOL CHEM, V264, P54; OTA IM, 1987, J BIOL CHEM, V262, P8522; PAIK WK, 1980, PROTEIN METHYLATION, P208; PISZKIEW.D, 1970, BIOCHEM BIOPH RES CO, V40, P1173, DOI 10.1016/0006-291X(70)90918-6; Robinson A B, 1974, Curr Top Cell Regul, V8, P247; SMYTH DG, 1962, J BIOL CHEM, V237, P1845; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; STEWART JM, 1984, SOLID PHASE PEPTIDE, P119; VANDENOETELAAR PJM, 1989, EXP EYE RES, V48, P209, DOI 10.1016/S0014-4835(89)80070-3; VOORTER CEM, 1988, J BIOL CHEM, V263, P19020; YAMADA H, 1983, BIOCHEMISTRY-US, V22, P4551, DOI 10.1021/bi00288a031; YAMADA H, 1985, BIOCHEMISTRY-US, V24, P7953, DOI 10.1021/bi00348a017; YUKSEL KU, 1986, ARCH BIOCHEM BIOPHYS, V248, P452, DOI 10.1016/0003-9861(86)90498-4	56	77	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19396	19406						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1833402				2022-12-25	WOS:A1991GK66700044
J	TORNHEIM, K; ANDRES, V; SCHULTZ, V				TORNHEIM, K; ANDRES, V; SCHULTZ, V			MODULATION BY CITRATE OF GLYCOLYTIC OSCILLATIONS IN SKELETAL-MUSCLE EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURINE-NUCLEOTIDE CYCLE; FRUCTOSE 2,6-BISPHOSPHATE; GLUCOSE-METABOLISM; ACID CYCLE; FATTY-ACIDS; FREE CA-2+; RAT; PHOSPHOFRUCTOKINASE; STARVATION; OPERATION	Oscillatory behavior of glycolysis in cell-free extracts of skeletal muscle involves repeated bursts of phosphofructokinase activity and associated oscillations in the [ATP]/[ADP] ratio. Addition of citrate, a potent physiological inhibitor of phosphofructokinase, decreased the frequency of the oscillations and delayed the first burst of phosphofructokinase activity in a dose-dependent manner. Citrate decreased the trigger point [ATP]/[ADP] ratio at which bursts of phosphofructokinase activity were initiated but had a much smaller effect on the average [ATP]/[ADP] ratio and did not decrease the peak values of the ratio. When oscillations were prevented by addition of fructose-2,6-P2, the decrease in the [ATP]/[ADP] ratio caused by citrate in the steady state system was similar to the decrease in the trigger point [ATP]/[ADP] ratio in the oscillatory system. The decrease in the average [ATP]/[ADP] ratio was greater in the steady state system than in the oscillating system. These results demonstrate advantages of oscillatory behavior of glycolysis in the regulation of carbohydrate utilization and the maintenance of a high [ATP]/[ADP] ratio.	BOSTON UNIV,SCH MED,DEPT DIABET & METAB,BOSTON,MA 02118	Boston University	TORNHEIM, K (corresponding author), BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118, USA.		Andres, Vicente/I-6440-2014	Andres, Vicente/0000-0002-0125-7209; Tornheim, Keith/0000-0002-6235-5128	NIDDK NIH HHS [DK 31559] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031559] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADROUNY GA, 1969, AM J PHYSIOL, V217, P686, DOI 10.1152/ajplegacy.1969.217.3.686; ANDRES V, 1988, BIOCHEM BIOPH RES CO, V157, P664, DOI 10.1016/S0006-291X(88)80301-2; ANDRES V, 1990, J BIOL CHEM, V265, P21441; ARAGON JJ, 1980, EUR J BIOCHEM, V110, P371, DOI 10.1111/j.1432-1033.1980.tb04877.x; BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BETZ A, 1965, ARCH BIOCHEM BIOPHYS, V109, P585, DOI 10.1016/0003-9861(65)90404-2; BOQUIST L, 1987, BIOCHEM INT, V14, P531; BOWMAN RH, 1966, J BIOL CHEM, V241, P3041; CHANCE B, 1965, J BIOL CHEM, V240, P3170; CORKEY BE, 1988, J BIOL CHEM, V263, P4254; FOE LG, 1983, BIOCHEMISTRY-US, V22, P4601, DOI 10.1021/bi00288a039; FRENKEL R, 1968, ARCH BIOCHEM BIOPHYS, V125, P157, DOI 10.1016/0003-9861(68)90650-4; FRENKEL R, 1968, ARCH BIOCHEM BIOPHYS, V125, P151, DOI 10.1016/0003-9861(68)90649-8; GARLAND PB, 1963, NATURE, V200, P169, DOI 10.1038/200169a0; GARLAND PB, 1964, BIOCHEM J, V93, P678, DOI 10.1042/bj0930678; GOODMAN MN, 1974, DIABETES, V23, P881, DOI 10.2337/diab.23.11.881; Hess B, 1969, Adv Enzyme Regul, V7, P149, DOI 10.1016/0065-2571(69)90016-8; HESS B, 1971, ANNU REV BIOCHEM, V40, P237, DOI 10.1146/annurev.bi.40.070171.001321; IBSEN KH, 1967, BIOCHIM BIOPHYS ACTA, V131, P407; JANSSON E, 1984, ACTA PHYSIOL SCAND, V122, P145, DOI 10.1111/j.1748-1716.1984.tb07492.x; KITAJIMA S, 1983, J BIOL CHEM, V258, P7352; LONGO EA, 1991, J BIOL CHEM, V266, P9314; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAIZELS EZ, 1977, BIOCHEM J, V162, P557, DOI 10.1042/bj1620557; MATSCHINSKY FM, 1968, BIOCHEM BIOPH RES CO, V33, P855, DOI 10.1016/0006-291X(68)90240-4; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; PARMEGGIANI A, 1963, BIOCHEM BIOPH RES CO, V12, P268, DOI 10.1016/0006-291X(63)90294-8; PURICH DL, 1973, ADV ENZYMOL RAMB, V39, P249; RAMAIAH A, 1964, J BIOL CHEM, V239, P3619; Randle P J, 1966, Recent Prog Horm Res, V22, P1; RAPP PE, 1987, PROG NEUROBIOL, V29, P261, DOI 10.1016/0301-0082(87)90023-2; RENNIE MJ, 1976, BIOCHEM J, V156, P647, DOI 10.1042/bj1560647; RENNIE MJ, 1977, BIOCHEM J, V168, P161, DOI 10.1042/bj1680161; RITCHER PH, 1980, BIOPHYS CHEM, V12, P285; RUDERMAN NB, 1977, FED PROC, V36, P171; SCHONFELD G, 1968, AM J PHYSIOL, V215, P513, DOI 10.1152/ajplegacy.1968.215.2.513; SPYDEVOLD O, 1976, EUR J BIOCHEM, V71, P155, DOI 10.1111/j.1432-1033.1976.tb11101.x; TERMONIA Y, 1981, P NATL ACAD SCI-BIOL, V78, P2952, DOI 10.1073/pnas.78.5.2952; TORNHEIM K, 1974, J BIOL CHEM, V249, P3241; TORNHEIM K, 1979, J THEOR BIOL, V79, P491, DOI 10.1016/0022-5193(79)90240-6; TORNHEIM K, 1972, J BIOL CHEM, V247, P162; TORNHEIM K, 1988, J BIOL CHEM, V263, P2619; TORNHEIM K, 1973, J BIOL CHEM, V248, P2670; TORNHEIM K, 1975, J BIOL CHEM, V250, P6304; TORNHEIM K, 1985, J BIOL CHEM, V260, P7985; WILLIAMSON JR, 1965, J BIOL CHEM, V240, P2308; ZORZANO A, 1985, BIOCHEM J, V232, P585, DOI 10.1042/bj2320585	48	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15675	15678						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1831450				2022-12-25	WOS:A1991GB97700025
J	VILSEN, B; ANDERSEN, JP; MACLENNAN, DH				VILSEN, B; ANDERSEN, JP; MACLENNAN, DH			FUNCTIONAL CONSEQUENCES OF ALTERATIONS TO AMINO-ACIDS LOCATED IN THE HINGE DOMAIN OF THE CA2+-ATPASE OF SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING SITE; INTRAMOLECULAR CROSS-LINKING; CA-2+-TRANSPORTING ATPASE; NUCLEOTIDE-BINDING; ACTIVE-SITE; ADENOSINE TRIPHOSPHOPYRIDOXAL; MECHANISTIC IMPLICATIONS; CONFORMATIONAL CHANGE; TRANSMEMBRANE DOMAIN; TRANSPORTING ATPASES	Site-specific mutagenesis of the sarcoplasmic reticulum Ca2+-ATPase was used to investigate the functional roles of 18 amino acid residues located at or near the "hinge-domain," a highly conserved region of the cation-transporting ATPases. Mutation of Lys684 to arginine, alanine, histidine, and glutamine resulted in complete loss of calcium transport function and ATPase activity. For the Lys684 --> Ala, histidine, and glutamine mutants, this coincided with a loss of the ability to form a phosphorylated intermediate from ATP or P(i). The Lys684 --> Arg mutant retained the ability to phosphorylate from ATP with normal apparent affinity, demonstrating the importance of the positive charge. On the other hand, no phosphorylation was observed with P(i) as substrate in this mutant. Examination of the partial reactions after phosphorylation from ATP in the Lys684 --> Arg mutant demonstrated a reduction of the rate of transformation of the ADP-sensitive phosphoenzyme intermediate (E1P) to the ADP-insensitive phosphoenzyme intermediate (E2P), which could account for the loss of transport function. Once accumulated, the E2P intermediate was able to decompose rapidly in the presence of K+ at neutral pH. These results may be interpreted in terms of a preferential destabilization of protein phosphate interactions in the E2P form of this mutant. The Asp703 --> Ala and Asn-Asp707 --> Ala-Ala mutants were completely inactive and unable to form phosphoenzyme intermediates from ATP or P(i). In these mutants as well as in the Lys684 --> Ala mutant, nucleotides were found to protect with normal affinity against intramolecular cross-linking induced with glutaraldehyde, indicating that the nucleotide binding site was intact. Mutation of Glu646, Glu647, Asp659, Asp660, Glu689, Asp695, Glu696 Glu715, and Glu732 to alanine did not affect the maximum rates of calcium transport and ATP hydrolysis or the apparent affinities for calcium and ATP. Mutation of the 2 highly conserved proline residues, Pro681 and Pro709, as well as Lys728, to alanine resulted in partially inhibited Ca2+-ATPase enzymes with retention of the ability to form a phosphoenzyme intermediate from ATP or P(i) and with normal apparent affinities for ATP and calcium. The proline mutants retained the biphasic ATP concentration dependence of ATPase activity, characteristic of the wild-type, and therefore the partial inhibition of turnover could not be ascribed to a disruption of the low affinity modulatory ATP site. The data seem to exclude a critical role of the hinge domain in the formation of calcium and nucleotide binding sites but point to a role of the hinge domain in the binding and transfer of phosphate to the protein and in the transport-associated conformational changes of the phosphorylation site.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto	VILSEN, B (corresponding author), AARHUS UNIV,DANISH BIOMEMBRANE RES CTR,INST PHYSIOL,DK-8000 AARHUS,DENMARK.			Vilsen, Bente/0000-0002-4727-9382; Andersen, Jens Peter/0000-0003-0654-4300				ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; ANDERSEN JP, 1985, P NATL ACAD SCI USA, V82, P4573, DOI 10.1073/pnas.82.14.4573; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GREEN NM, 1986, CIBA F SYMP, V122, P93; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; OHTA T, 1986, P NATL ACAD SCI USA, V83, P2071, DOI 10.1073/pnas.83.7.2071; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P111, DOI 10.1016/0014-5793(87)81253-X; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7451, DOI 10.1021/bi00484a014; ROSS DC, 1987, J BIOL CHEM, V262, P12977; ROSS DC, 1987, J BIOL CHEM, V262, P2042; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SERRANO R, 1989, ANNU REV PLANT PHYS, V40, P61; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SUZUKI H, 1990, BIOCHEMISTRY-US, V29, P7040, DOI 10.1021/bi00482a013; TANFORD C, 1987, P NATL ACAD SCI USA, V84, P7094, DOI 10.1073/pnas.84.20.7094; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; VILSEN B, 1989, J BIOL CHEM, V264, P21024; YAMAMOTO H, 1988, J BIOCHEM-TOKYO, V103, P452, DOI 10.1093/oxfordjournals.jbchem.a122291; YAMAMOTO H, 1989, J BIOCHEM-TOKYO, V106, P1121, DOI 10.1093/oxfordjournals.jbchem.a122976; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	37	98	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16157	16164						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1831454				2022-12-25	WOS:A1991GB97700094
J	HEKMAN, C; TOMICH, JM; HATEFI, Y				HEKMAN, C; TOMICH, JM; HATEFI, Y			MITOCHONDRIAL ATP SYNTHASE COMPLEX - MEMBRANE TOPOGRAPHY AND STOICHIOMETRY OF THE F0 SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BEEF-HEART MITOCHONDRIA; DICYCLOHEXYLCARBODIIMIDE-BINDING PROTEIN; ADENOSINE-TRIPHOSPHATASE INHIBITOR; RAT-LIVER MITOCHONDRIA; COUPLING FACTOR-B; CHARGERIN-II A6L; OXIDATIVE-PHOSPHORYLATION; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE	The topography of the subunits of the membrane sector F0 of the ATP synthase complex in the bovine mitochondrial inner membrane was studied with the help of subunit-specific antibodies raised to the F0 subunits b, d, 6, F6, A6L, OSCP (oligomycin-sensitivity-conferring protein), and N,N'-dicyclohexylcarbodiimide (DCCD)-binding proteolipid and to the ATPase inhibitor protein (IF1) as an internal control. Exposure of F0 subunits in inverted and right-side-out inner membranes was investigated bv direct antibody binding as well as by susceptibility of these subunits to degradation by various proteases as monitored bv gel electrophoresis of the membrane digests and immunoblotting with the subunit-specific antibodies. Results show that subunits b, d, F6, A6L (including its C-terminal end) and OSCP were exposed on the matrix side. Sufficient masses of these subunits to recognize antibodies or undergo proteolysis were not exposed on the cytosolic side. This was also the case for subunit 6 and the DCCD-binding proteolipid on either side of the inner membrane. Quantitative immunoblotting in which bound radioactivity, from [I-125]protein A was employed to estimate the concentration of an antigen in a sample allowed the determination of the stoichiometry of several F0 subunits and IF1 relative to F1-ATPase. Results showed that per mol of F1 there are in bovine heart mitochondria 1 mol each of d, OSCP, and IF1, and 2 mol each of b and F6. Subunit 6 and the DCCD-binding proteolipid could not be quantitated, because the former transferred poorly to nitrocellulose and the latter's antibody did not bind [I-125]protein A.	Scripps Res Inst, RES INST,DEPT MOLEC & EXPTL MED,DIV BIOCHEM, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA; CHILDRENS HOSP, DIV MED GENET, LOS ANGELES, CA 90027 USA	Scripps Research Institute; Children's Hospital Los Angeles				TOMICH, JOHN/0000-0001-7848-8307	NIDDK NIH HHS [DK08126] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK008126, R01DK008126] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; BENOIT R, 1982, P NATL ACAD SCI-BIOL, V79, P917, DOI 10.1073/pnas.79.3.917; BISSON R, 1986, J BIOL CHEM, V261, P4373; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CHOMYN A, 1983, P NATL ACAD SCI-BIOL, V80, P5535, DOI 10.1073/pnas.80.18.5535; CROSS RL, 1982, J BIOL CHEM, V257, P2101; EBELING W, 1974, EUR J BIOCHEM, V47, P91, DOI 10.1111/j.1432-1033.1974.tb03671.x; FANG JK, 1984, P NATL ACAD SCI-BIOL, V81, P6603, DOI 10.1073/pnas.81.21.6603; FEARNLEY IM, 1986, EMBO J, V5, P2003, DOI 10.1002/j.1460-2075.1986.tb04456.x; FILLINGAME RH, 1976, J BIOL CHEM, V251, P6630; FRANGIONE B, 1981, P NATL ACAD SCI-BIOL, V78, P7403, DOI 10.1073/pnas.78.12.7403; GALANTE YM, 1981, BIOCHEMISTRY-US, V20, P2671, DOI 10.1021/bi00512a048; GIRVIN ME, 1989, BIOCHEMISTRY-US, V28, P4340, DOI 10.1021/bi00436a032; GONZALEZHALPHEN D, 1988, BIOCHEMISTRY-US, V27, P7021, DOI 10.1021/bi00418a053; GRAF T, 1978, FEBS LETT, V94, P218, DOI 10.1016/0014-5793(78)80941-7; HAN AL, 1988, ARCH BIOCHEM BIOPHYS, V267, P490, DOI 10.1016/0003-9861(88)90055-0; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HATEFI Y, 1961, ARCH BIOCHEM BIOPHYS, V94, P148, DOI 10.1016/0003-9861(61)90022-4; Hatefi Y, 1978, Methods Enzymol, V53, P35; HATEFI Y, 1985, BIOCHIM BIOPHYS ACTA, V27, P83; HEKMAN C, 1991, ARCH BIOCHEM BIOPHYS, V284, P90, DOI 10.1016/0003-9861(91)90268-N; HERMOLIN J, 1989, J BIOL CHEM, V264, P3896; HOPPE J, 1984, BIOCHIM BIOPHYS ACTA, V768, P164; HORSTMAN LL, 1970, J BIOL CHEM, V245, P1336; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; JOSHI S, 1979, J BIOL CHEM, V254, P145; JOSHI S, 1990, J BIOL CHEM, V265, P14518; KANNER BI, 1976, BIOCHEM BIOPH RES CO, V69, P1050, DOI 10.1016/0006-291X(76)90479-4; KIEHL R, 1980, BIOCHEMISTRY-US, V19, P541, DOI 10.1021/bi00544a023; KREBS JJR, 1979, J BIOL CHEM, V254, P5308; LIPPE G, 1988, J BIOL CHEM, V263, P18627; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; MACINO G, 1980, CELL, V20, P507, DOI 10.1016/0092-8674(80)90637-6; MATSUNOYAGI A, 1990, J BIOL CHEM, V265, P82; MATSUNOYAGI A, 1985, J BIOL CHEM, V260, P4424; MATSUNOYAGI A, 1988, BIOCHEMISTRY-US, V27, P335, DOI 10.1021/bi00401a050; MURAGUCHI M, 1990, BIOCHEM BIOPH RES CO, V168, P226, DOI 10.1016/0006-291X(90)91697-Q; NEWBOULD BB, 1965, IMMUNOLOGY, V9, P613; ODA T, 1989, BIOCHEM BIOPH RES CO, V165, P449, DOI 10.1016/0006-291X(89)91091-7; OVCHINNIKOV YA, 1984, FEBS LETT, V166, P19, DOI 10.1016/0014-5793(84)80036-8; PENIN F, 1985, BIOCHIM BIOPHYS ACTA, V810, P346, DOI 10.1016/0005-2728(85)90220-8; RACKER E, 1967, J BIOL CHEM, V242, P2547; SANADI DR, 1982, BIOCHIM BIOPHYS ACTA, V683, P39; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; SCHNEIDER J, 1988, CELL, V54, P363, DOI 10.1016/0092-8674(88)90199-7; SEBALD W, 1981, CURR TOP BIOENERG, V12, P1; SEBALD W, 1979, EUR J BIOCHEM, V93, P587, DOI 10.1111/j.1432-1033.1979.tb12859.x; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SENIOR AE, 1983, J MEMBRANE BIOL, V73, P105, DOI 10.1007/BF01870434; SENIOR AE, 1971, BIOENERGETICS, V2, P141; Stiggall D L, 1979, Methods Enzymol, V55, P308; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; VELOURS J, 1986, BIOCHEM BIOPH RES CO, V138, P78, DOI 10.1016/0006-291X(86)90249-4; WALKER JE, 1987, J MOL BIOL, V197, P89, DOI 10.1016/0022-2836(87)90611-5	57	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13564	13571						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1830306				2022-12-25	WOS:A1991FY02700020
J	SHI, YG; TYLER, BM				SHI, YG; TYLER, BM			ALL INTERNAL PROMOTER ELEMENTS OF NEUROSPORA-CRASSA 5-S RIBOSOMAL-RNA AND TRANSFER-RNA GENES, INCLUDING THE A-BOXES, ARE FUNCTIONALLY GENE-SPECIFIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5S RIBOSOMAL-RNA; III TRANSCRIPTION FACTOR; POLYMERASE-III; CONTROL REGION; INVITRO TRANSCRIPTION; UPSTREAM PROMOTER; SEQUENCE ELEMENTS; 5S-RNA GENE; REQUIRES; BINDING	The internal control elements of Neurospora crassa 5 S genes include an A box and a C box as in Xenopus and Saccharomyces cerevisiae, plus a novel element, the Ribo box at position +18 to +34. The Ribo box is also found in the 40 S rRNA promoter and a ribosomal protein gene but is absent from tRNA genes in N. crassa. The 5 S A box diverges from the tRNA A box consensus at two positions. We tested whether replacement of the 5 S A box with a tRNA(Leu) A box sequence would increase 5 S gene transcription in vitro or would remove the requirement for the Ribo box. The 5 S gene with the tRNA(Leu) A box was transcribed poorly, and the Ribo box and the C box are still required for transcription. We tested the function of the Ribo box and 5 S A box in a tRNA-like transcription unit by constructing hybrids between a 5 S gene and a tRNA(Leu) gene. In the tRNA-like context, the 5 S A box supported a lower level of transcription than the tRNA A box, and the Ribo box was not required at all. Therefore, in N. crassa, all of the 5 S internal control elements are gene-specific. In particular, the 5 S and tRNA A box sequences are not functionally interchangeable and may bind different transcription factors. Transcription of the hybrids was initiated at the 5 S initiation site, suggesting that the mechanism of initiation site selection is the same in the 5 S and tRNA genes. Competition experiments with the tRNA B box suggested that the N. crassa 5 S and tRNA genes require at least one common transcription factor such as TFIIIC.	UNIV CALIF DAVIS,DEPT PLANT PATHOL,DAVIS,CA 95616	University of California System; University of California Davis					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042178] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42178] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER RE, 1986, J BIOL CHEM, V261, P5275; BAKER RE, 1987, P NATL ACAD SCI USA, V84, P8768, DOI 10.1073/pnas.84.24.8768; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; CAREY MF, 1986, J BIOL CHEM, V261, P4309; CHALLICE JM, 1989, J BIOL CHEM, V264, P20060; CILIBERTO G, 1983, CELL, V32, P725, DOI 10.1016/0092-8674(83)90058-2; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; FABRIZIO P, 1987, P NATL ACAD SCI USA, V84, P8763, DOI 10.1073/pnas.84.24.8763; FAIRALL L, 1986, J MOL BIOL, V192, P577, DOI 10.1016/0022-2836(86)90278-0; FRADKIN LG, 1989, MOL CELL BIOL, V9, P4941, DOI 10.1128/MCB.9.11.4941; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; HUIET L, 1984, NUCLEIC ACIDS RES, V12, P5757, DOI 10.1093/nar/12.14.5757; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; Maxam A M, 1980, Methods Enzymol, V65, P499; MORTON DG, 1984, P NATL ACAD SCI-BIOL, V81, P5519, DOI 10.1073/pnas.81.17.5519; MURPHY S, 1987, CELL, V51, P81, DOI 10.1016/0092-8674(87)90012-2; NISBET IT, 1985, GENE ANAL TECH, V2, P23, DOI 10.1016/0735-0651(85)90001-9; OEI SL, 1990, J BIOL CHEM, V265, P7485; PALMER JM, 1990, TRENDS BIOCHEM SCI, V15, P300, DOI 10.1016/0968-0004(90)90018-7; PIELER T, 1987, CELL, V48, P91, DOI 10.1016/0092-8674(87)90359-X; SAKONJU S, 1981, CELL, V23, P665, DOI 10.1016/0092-8674(81)90429-3; SAKONJU S, 1980, CELL, V19, P13, DOI 10.1016/0092-8674(80)90384-0; SEGALL J, 1986, J BIOL CHEM, V261, P1578; SELKER EU, 1981, CELL, V24, P819, DOI 10.1016/0092-8674(81)90107-0; SHARP SJ, 1985, CRC CR REV BIOCH MOL, V19, P107, DOI 10.3109/10409238509082541; SHARP SJ, 1988, MOL CELL BIOL, V8, P1266, DOI 10.1128/MCB.8.3.1266; SHI YG, 1989, NUCLEIC ACIDS RES, V17, P3317, DOI 10.1093/nar/17.8.3317; STILLMAN DJ, 1984, EMBO J, V3, P847, DOI 10.1002/j.1460-2075.1984.tb01895.x; TYLER BM, 1984, NUCLEIC ACIDS RES, V12, P5737, DOI 10.1093/nar/12.14.5737; TYLER BM, 1987, J MOL BIOL, V196, P801, DOI 10.1016/0022-2836(87)90406-2; TYLER BM, 1990, NUCLEIC ACIDS RES, V18, P1805, DOI 10.1093/nar/18.7.1805; TYLER BM, 1990, NUCLEIC ACIDS RES, V18, P5759, DOI 10.1093/nar/18.19.5759; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3	35	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8015	8019						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1827115				2022-12-25	WOS:A1991FK44100012
J	KIMURA, E; AKITA, M; MATSUYAMA, S; MIZUSHIMA, S				KIMURA, E; AKITA, M; MATSUYAMA, S; MIZUSHIMA, S			DETERMINATION OF A REGION IN SECA THAT INTERACTS WITH PRESECRETORY PROTEINS IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; PROTON MOTIVE FORCE; MEMBRANE-VESICLES; INVITRO TRANSLOCATION; SIGNAL PEPTIDE; SECRETORY PROTEIN; EXPORT; GENE; MUTANT; ATP	SecA interacts with presecretory proteins through recognition of the positive charge at the amino terminus of the signal peptide (Akita, M., Sasaki, S., Matsuyama, S., and Mizushima, S. (1989) J. Biol. Chem. 265, 8164-8169). A large variety of amino-terminal and carboxyl-terminal fragments of SecA were prepared in 6 M guanidine hydrochloride. SecA analogues were then reconstituted from them and examined for their ability to cross-link with [S-35]proOmpF-Lpp, a presecretory protein, in the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide. The reconstituted SecA analogues were active in the cross-linking with proOmpF-Lpp when the SecA fragments used were large enough to structurally complement each other. The cross-linking was signal peptide-dependent and suppressed in the presence of other presecretory proteins. The cross-linking was enhanced in the presence of ATP. The SecA fragments that cross-linked with proOmpF-Lpp were then analyzed on sodium dodecyl sulfate-polyacrylamide gels. The cross-linking preferentially took place on fragments possessing the amino terminus of SecA. Weak cross-linking was also observed with carboxyl-terminal fragments when they were large enough. The smallest amino-terminal and carboxyl-terminal fragments with which the cross-linking was observed were 39 and 72 kDa, respectively. From these results, the region responsible for the cross-linking with presecretory proteins was deduced to be located between amino acid residues 267 and 340 from the amino terminus of SecA. These results are discussed in relation to the structure and function of SecA.	UNIV TOKYO,INST APPL MICROBIOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								AKITA M, 1990, J BIOL CHEM, V265, P8164; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CHEN LL, 1985, P NATL ACAD SCI USA, V82, P4384, DOI 10.1073/pnas.82.13.4384; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; FANDL JP, 1988, P NATL ACAD SCI USA, V85, P8953, DOI 10.1073/pnas.85.23.8953; FIKES JD, 1989, J BACTERIOL, V171, P402, DOI 10.1128/jb.171.1.402-409.1989; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; HIRASHIMA A, 1973, J BIOL CHEM, V248, P5654; ITO K, 1983, CELL, V32, P789, DOI 10.1016/0092-8674(83)90065-X; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; KAWASAKI H, 1989, FEBS LETT, V242, P431, DOI 10.1016/0014-5793(89)80516-2; KUMAMOTO CA, 1983, J BACTERIOL, V154, P253, DOI 10.1128/JB.154.1.253-260.1983; KUMAMOTO CA, 1989, J BIOL CHEM, V264, P2242; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MATSUYAMA S, 1989, J BIOL CHEM, V264, P3583; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; OZAWA Y, 1987, J BACTERIOL, V169, P1331, DOI 10.1128/jb.169.3.1331-1334.1987; RIGGS PD, 1988, GENETICS, V118, P571; SAXENA VP, 1970, BIOCHEMISTRY-US, V16, P4678; SCHATZ PJ, 1989, GENE DEV, V3, P1035, DOI 10.1101/gad.3.7.1035; SCHMIDT MG, 1988, J BACTERIOL, V170, P3404, DOI 10.1128/jb.170.8.3404-3414.1988; SHIBA K, 1984, EMBO J, V3, P631, DOI 10.1002/j.1460-2075.1984.tb01859.x; SHINKAI A, 1990, BIOCHEM BIOPH RES CO, V172, P1217, DOI 10.1016/0006-291X(90)91578-G; TANI K, 1990, J BIOL CHEM, V265, P17341; TANIUCHI H, 1971, J BIOL CHEM, V246, P2291; TANIUCHI H, 1969, J BIOL CHEM, V244, P3864; YAMADA H, 1989, J BIOL CHEM, V264, P18577; YAMANE K, 1988, J BIOL CHEM, V263, P19690; YAMANE K, 1987, J BIOL CHEM, V262, P2358; YAMANE K, 1988, J BIOL CHEM, V263, P5368	38	129	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6600	6606						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1826108				2022-12-25	WOS:A1991FE37300088
J	DHARIWAL, KR; SHIRVAN, M; LEVINE, M				DHARIWAL, KR; SHIRVAN, M; LEVINE, M			ASCORBIC-ACID REGENERATION IN CHROMAFFIN GRANULES - INSITU KINETICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ADRENAL-MEDULLA; CELL-VOLUME REGULATION; NOREPINEPHRINE BIOSYNTHESIS; ELECTRON-TRANSFER; MYCOPLASMA-GALLISEPTICUM; MEMBRANE; TRANSPORT; ENZYMES; ATP; PH	We have investigated in intact chromaffin secretory vesicles the kinetics, specificity, and mechanism of intragranular ascorbic acid regeneration by extragranular ascorbic acid. The apparent K(m) of internal ascorbic acid regeneration for external ascorbic acid was 280-mu-M by Lineweaver-Burk analysis and 287-mu-M by Eadie-Hofstee analysis. Intragranular ascorbic acid regeneration was specifically mediated by extragranular ascorbic acid or its isomer isoascorbic acid; the reducing agents glutathione, thiourea, homocysteine, NADH, and NADPH did not support regeneration. The structural analog D-glucose did not inhibit regeneration by external ascorbic acid, suggesting specificity at the membrane site of electron transfer. The driving force for regeneration of intragranular ascorbic acid was independent of membrane potential, absolute intragranular and extragranular pH, and ATPase activity, but might be coupled to the pH difference across the chromaffin granule membrane. Since the apparent K(m) of regeneration was approximately 10-fold below the cytosolic concentration of ascorbic acid, the reaction may proceed at V(max) in situ.	NIDDKD,CELL BIOL & KINET LAB,BLDG 8,ROOM 419,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BERGSTEN P, 1990, J BIOL CHEM, V265, P2584; DHARIWAL KR, 1989, J BIOL CHEM, V264, P15404; FLATMARK T, 1971, BIOCHIM BIOPHYS ACTA, V253, P487, DOI 10.1016/0005-2728(71)90052-1; FRIEDMAN S, 1965, J BIOL CHEM, V240, P4763; HARTMAN BK, 1972, PHARMACOL REV, V24, P311; KELLEY PM, 1986, J BIOL CHEM, V261, P6429; LADURON PM, 1975, FEBS LETT, V52, P132, DOI 10.1016/0014-5793(75)80654-5; LEVIN EY, 1960, J BIOL CHEM, V235, P2080; LEVINE M, 1985, J BIOL CHEM, V260, P5598; LEVINE M, 1985, J BIOL CHEM, V260, P2942; LEVINE M, 1988, J BIOL CHEM, V263, P19353; LEVINE M, 1986, J BIOL CHEM, V261, P7347; LEVINE MA, 1983, FEBS LETT, V158, P134, DOI 10.1016/0014-5793(83)80693-0; MENNITI FS, 1987, J BIOL CHEM, V262, P7651; NJUS D, 1983, J BIOL CHEM, V258, P27; PADAN E, 1973, EUR J BIOCHEM, V40, P431, DOI 10.1111/j.1432-1033.1973.tb03212.x; POLLARD HB, 1976, J BIOL CHEM, V251, P4544; POLLARD HB, 1979, J BIOL CHEM, V254, P1170; POLLARD HB, 1978, ANAL BIOCHEM, V86, P761, DOI 10.1016/0003-2697(78)90805-9; ROTTEM S, 1981, J BACTERIOL, V145, P1299, DOI 10.1128/JB.145.3.1299-1304.1981; SHIRVAN MH, 1989, J BACTERIOL, V171, P4410, DOI 10.1128/JB.171.8.4410-4416.1989; TAUGNER G, 1972, BIOCHEM J, V130, P969, DOI 10.1042/bj1300969; TERLAND O, 1975, FEBS LETT, V59, P52, DOI 10.1016/0014-5793(75)80339-5; TIRRELL JG, 1979, NEUROSCIENCE, V4, P181, DOI 10.1016/0306-4522(79)90227-6; TUCKER BW, 1984, NUTR REV, V42, P173, DOI 10.1111/j.1753-4887.1984.tb02315.x; WAKEFIELD LM, 1986, J BIOL CHEM, V261, P9746; WAKEFIELD LM, 1986, J BIOL CHEM, V261, P9739; WASHKO P, 1989, J BIOL CHEM, V264, P18996; WASHKO PW, 1989, ANAL BIOCHEM, V181, P276, DOI 10.1016/0003-2697(89)90243-1; WINKLER H, 1970, BIOCHEM J, V118, P303, DOI 10.1042/bj1180303	30	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5384	5387						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1825997				2022-12-25	WOS:A1991FD37000007
J	SHINKAI, A; MEI, LH; TOKUDA, H; MIZUSHIMA, S				SHINKAI, A; MEI, LH; TOKUDA, H; MIZUSHIMA, S			THE CONFORMATION OF SECA, AS REVEALED BY ITS PROTEASE SENSITIVITY, IS ALTERED UPON INTERACTION WITH ATP, PRESECRETORY PROTEINS, EVERTED MEMBRANE-VESICLES, AND PHOSPHOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON MOTIVE FORCE; ESCHERICHIA-COLI; INVITRO TRANSLOCATION; SECRETORY PROTEIN; TRIGGER FACTOR; EXPORT; BACTERIOPHAGE-T4; RECOGNITION; ACTIVATION; CLEAVAGE	Interactions between SecA and cellular components involved in the translocation of secretory proteins across the cytoplasmic membrane of Escherichia coli were studied by examining changes in the sensitivity of SecA to staphylococcal protease V8. In the presence of ATP, the amino-terminal 95-kDa portion of the SecA molecule became highly resistant to V8 digestion. Adenosine 5'-(gamma-thio)triphosphate (ATP-gamma-S) and ADP were as effective as ATP. For the effect, ATP could be partly replaced by CTP and UTP, but not GTP, as in the case of the protein translocation reaction. In the presence of proOmpA, a presecretory protein, on the other hand, SecA became more sensitive to V8 digestion. The signal peptide region was involved in this effect. The V8-digestion profile in the presence of both proOmpA and ATP or ADP was the same as that in the presence of proOmpA alone. Consistently, proOmpA-induced discharge of ADP or ATP-gamma-S from SecA was observed by means of flow dialysis. SecA-deprived everted membrane vesicles and an E. coli phospholipid mixture were also effective in making SecA more sensitive to V8 digestion. Among the phospholipids, phosphatidylglycerol and cardiolipin were effective, whereas phosphatidylethanolamine was not. It is suggested that SecA directly interacts with these cellular components and the interactions result in changes in the conformation of SecA. The physiological significance of such interactions in protein secretion is discussed.	UNIV TOKYO,INST APPL MICROBIOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo			Shinkai, Akeo/E-8354-2013	Shinkai, Akeo/0000-0002-9867-0832				AKITA M, 1990, J BIOL CHEM, V265, P8164; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BRICKMAN ER, 1984, MOL GEN GENET, V196, P24, DOI 10.1007/BF00334087; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CHEN LL, 1985, P NATL ACAD SCI USA, V82, P4384, DOI 10.1073/pnas.82.13.4384; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; FANDL JP, 1988, P NATL ACAD SCI USA, V85, P8953, DOI 10.1073/pnas.85.23.8953; FIKES JD, 1989, J BACTERIOL, V171, P402, DOI 10.1128/jb.171.1.402-409.1989; FURUKAWA H, 1982, J BACTERIOL, V150, P916, DOI 10.1128/JB.150.2.916-924.1982; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; KAWASAKI H, 1989, FEBS LETT, V242, P431, DOI 10.1016/0014-5793(89)80516-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUYAMA S, 1989, J BIOL CHEM, V264, P3583; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; MIZUSHIMA S, 1990, J BIOENERG BIOMEMBR, V22, P389, DOI 10.1007/BF00763174; MIZUSHIMA S, 1975, BIOCHIM BIOPHYS ACTA, V375, P44, DOI 10.1016/0005-2736(75)90071-1; OLIVER DB, 1982, J BACTERIOL, V150, P686, DOI 10.1128/JB.150.2.686-691.1982; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; OZAWA Y, 1987, J BACTERIOL, V169, P1331, DOI 10.1128/jb.169.3.1331-1334.1987; PAPAHADJ.D, 1967, BIOCHIM BIOPHYS ACTA, V135, P624, DOI 10.1016/0005-2736(67)90094-6; PAPAHADJ.D, 1967, BIOCHIM BIOPHYS ACTA, V135, P639, DOI 10.1016/0005-2736(67)90095-8; SCHMIDT MG, 1988, J BACTERIOL, V170, P3404, DOI 10.1128/jb.170.8.3404-3414.1988; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; STOLLERY JG, 1977, BIOCHIM BIOPHYS ACTA, V471, P372, DOI 10.1016/0005-2736(77)90043-8; TANI K, 1990, J BIOL CHEM, V265, P17341; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMADA H, 1989, J BIOL CHEM, V264, P18577; YAMANE K, 1987, J BIOL CHEM, V262, P2358	37	90	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5827	5833						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1826005				2022-12-25	WOS:A1991FD37000074
J	NOLAND, TA; KUO, JF				NOLAND, TA; KUO, JF			PROTEIN-KINASE-C PHOSPHORYLATION OF CARDIAC TROPONIN-I OR TROPONIN-T INHIBITS CA2+-STIMULATED ACTOMYOSIN MGATPASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBCELLULAR-DISTRIBUTION; BIOLOGICAL-ACTIVITY; PHORBOL ESTERS; RAT-HEART; TROPOMYOSIN; ACTIN; ISOPROTERENOL; MYOCYTES; SUBUNIT; BINDING	Effects of troponin phosphorylation on Ca2+-stimulated MgATPase activity of bovine cardiac actomyosin were examined. Phosphorylation by protein kinase C of troponin I and troponin T subunits in troponin or troponin-tropomyosin complex resulted in a decreased Ca2+-stimulated MgATPase activity in reconstituted actomyosin, and this effect was reversed by subsequent dephosphorylation by protein phosphatase 1. It was further observed that protein kinase C phosphorylation of either troponin I or troponin T subunits led to a similar inhibition of Ca2+-stimulated actomyosin MgATPase activity. In all cases, EC50 values (concentrations causing 50% stimulation) for Ca2+ were not appreciably affected by troponin phosphorylation by protein kinase C. Data from phosphorylation site analysis suggests that phosphorylation of threonine 144 in troponin I and possibly threonine 280 or threonine 199 in troponin T might be important for the observed decrease of Ca2+-stimulated actomyosin MgATPase. It is suggested that inhibition of actomyosin MgATPase caused by protein kinase C phosphorylation of troponin I and/or troponin T represents a new mechanism that can account for in part the reported negative inotropic effect of phorbol esters on various cardiac preparations.			NOLAND, TA (corresponding author), EMORY UNIV,SCH MED,DEPT PHARMACOL,ATLANTA,GA 30322, USA.				NCI NIH HHS [CA-36777] Funding Source: Medline; NHLBI NIH HHS [HL-15696] Funding Source: Medline; NINDS NIH HHS [NS-17608] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036777] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL015696, R37HL015696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017608] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAILIN G, 1979, AM J PHYSIOL, V236, pC41, DOI 10.1152/ajpcell.1979.236.1.C41; BUSS JE, 1977, FEBS LETT, V73, P101, DOI 10.1016/0014-5793(77)80025-2; DOBROVOLSKIJ AB, 1982, BIOCHEM INT, V5, P473; DOSEMECI A, 1988, CIRC RES, V62, P347, DOI 10.1161/01.RES.62.2.347; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GIRARD PR, 1986, J BIOL CHEM, V261, P370; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARTZELL HC, 1985, J MOL BIOL, V186, P185, DOI 10.1016/0022-2836(85)90268-2; HOLROYD J, 1979, BIOCHIM BIOPHYS ACTA, V586, P63; KATOH N, 1983, BIOCHEM J, V209, P189, DOI 10.1042/bj2090189; LEATHERMAN GF, 1987, AM J PHYSIOL, V253, pH205, DOI 10.1152/ajpheart.1987.253.1.H205; LEAVIS PC, 1984, CRC CRIT REV BIOCH, V16, P233; LIU JD, 1989, BIOCHEM BIOPH RES CO, V162, P1105, DOI 10.1016/0006-291X(89)90787-0; MAZZEI GJ, 1984, BIOCHEM J, V218, P361, DOI 10.1042/bj2180361; NOLAND TA, 1989, J BIOL CHEM, V264, P20778; OISHI K, 1990, J BIOL CHEM, V265, P70; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PHILLIPS RC, 1966, J AM CHEM SOC, V88, P2631, DOI 10.1021/ja00964a002; PINTO GF, 1984, COMPUT BIOL MED, V13, P507; POTTER JD, 1982, METHOD ENZYMOL, V85, P234; RAY KP, 1976, FEBS LETT, V70, P11, DOI 10.1016/0014-5793(76)80716-8; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; ROGERS TB, 1990, J BIOL CHEM, V265, P4302; RUBIO R, 1975, J CYCLIC NUCL PROT, V1, P143; SASAKI Y, 1988, BIOCHEM PHARMACOL, V37, P679, DOI 10.1016/0006-2952(88)90142-6; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; SOLARO RJ, 1986, PROTEIN PHOSPHORYLAT, P129; STEWART AA, 1981, EUR J BIOCHEM, V115, P197; Stull J T, 1980, Adv Cyclic Nucleotide Res, V13, P39; STULL JT, 1977, J BIOL CHEM, V252, P851; TALBOT JA, 1979, J BIOL CHEM, V254, P3720; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; YUAN SH, 1987, CIRC RES, V61, P372, DOI 10.1161/01.RES.61.3.372; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	35	109	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					4974	4978						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1825828				2022-12-25	WOS:A1991FC21700047
J	WILEMAN, T; KANE, LP; CARSON, GR; TERHORST, C				WILEMAN, T; KANE, LP; CARSON, GR; TERHORST, C			DEPLETION OF CELLULAR CALCIUM ACCELERATES PROTEIN-DEGRADATION IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR CHAINS; INTRACELLULAR-TRANSPORT; BREFELDIN-A; INFLUENZA HEMAGGLUTININ; RAPID REDISTRIBUTION; BINDING-PROTEIN; GOLGI PROTEINS; COMPLEX; CELLS; ER	In this study the effects of A23187 and thapsigargin on the degradation of T-cell antigen receptor-beta (TCR-beta) and CD3-delta in the endoplasmic reticulum have been studied. Preliminary experiments showed that these drugs had different effects on the secretory pathway. Depletion of cellular calcium pools by incubation of cells with A23187 in calcium-free medium blocked transport between the endoplasmic reticulum and the Golgi apparatus whereas thapsigargin caused a modest increase in transport. When added to cells transfected with TCR-beta or CD3-delta the drugs caused an immediate stimulation of proteolysis of presynthesized protein and at maximum effective concentrations caused a 3-fold increase in the rate of degradation. They did not affect the lag period of 1 h which precedes degradation of newly synthesized proteins. Chelation of cytosolic calcium also accelerated degradation, suggesting that depletion of calcium from the endoplasmic reticulum was the main stimulus of proteolysis and that increased degradation was not caused by a transient increase in cytosolic calcium levels. The selectivity of degradation in the endoplasmic reticulum was maintained. A23187 had no effect on the stability of CD3-gamma nor co-transfected epsilon-beta-dimers. Calcium depletion increased the overall rate of degradation in the endoplasmic reticulum and increased the rate of proteolysis of an "anchor minus" beta-chain. The results suggested that proteolysis within the endoplasmic reticulum may be regulated by the high concentrations of Ca2+ which are stored in the organelle. Ca2+ may be required for protein folding. Calcium depletion may have caused the beta and delta-chains to adopt a conformation that was more susceptible to proteolysis. Alternatively, calcium depletion may have disrupted the lumenal content of the endoplasmic reticulum and increased the access of proteases to potential substrates.	T CELL SCI INC,PROT EXPRESS GRP,CAMBRIDGE,MA 02139		WILEMAN, T (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,MOLEC IMMUNOL LAB,RM 309 JFB,44 BINNEY ST,BOSTON,MA 02115, USA.			Kane, Lawrence/0000-0001-5198-516X	NIAID NIH HHS [AI-15066] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI115066, R56AI015066, R01AI015066] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALARCON B, 1988, J BIOL CHEM, V263, P2953; AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; CHEN C, 1988, J CELL BIOL, V107, P2149, DOI 10.1083/jcb.107.6.2149; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JACONI MEE, 1990, J CELL BIOL, V110, P1555, DOI 10.1083/jcb.110.5.1555; KOCH GLE, 1990, J CELL SCI, V345, P480; KRISSANSEN GW, 1986, EMBO J, V5, P1799, DOI 10.1002/j.1460-2075.1986.tb04429.x; LAEMMLI UK, 1970, NATUR, V227, P6813; LEE C, 1988, CELL, V54, P37, DOI 10.1016/0092-8674(88)90177-8; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LODISH HF, 1990, J BIOL CHEM, V265, P10893; PESSANO S, 1985, EMBO J, V4, P337, DOI 10.1002/j.1460-2075.1985.tb03634.x; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROTUNDO RL, 1989, J BIOL CHEM, V264, P3146; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SATO R, 1990, J BIOL CHEM, V265, P11880; SHIA M, 1989, P NATL ACAD SCI USA, V84, P1158; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TREIGER BF, 1986, J IMMUNOL, V136, P4099; WILEMAN T, 1990, CELL REGUL, V1, P907, DOI 10.1091/mbc.1.12.907; WILEMAN T, 1990, INT IMMUNOL, V2, P743, DOI 10.1093/intimm/2.8.743; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973	39	92	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4500	4507						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1825655				2022-12-25	WOS:A1991FA69400075
J	CHRISTMAS, P; CALLAWAY, J; FALLON, J; JONES, J; HAIGLER, HT				CHRISTMAS, P; CALLAWAY, J; FALLON, J; JONES, J; HAIGLER, HT			SELECTIVE SECRETION OF ANNEXIN-1, A PROTEIN WITHOUT A SIGNAL SEQUENCE, BY THE HUMAN PROSTATE-GLAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR-KINASE; PLACENTAL ANTICOAGULANT PROTEIN; PHOSPHOLIPID BINDING-PROTEIN; GROWTH-FACTOR; LIPOCORTIN-I; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; ULTRASTRUCTURAL ASPECTS; EUKARYOTIC CELLS; 33-KDA PROTEIN	Annexins are primarily intracellular proteins as would be predicted from their lack of hydrophobic signal sequences. However, we now report that the human prostate gland selectively secretes high concentrations of annexin 1 (also called lipocortin 1 and p35) and a proteolytic cleavage product, des1-29-annexin 1, into seminal plasma. Secreted annexin 1 had a blocked amino terminus and was structurally indistinguishable from intracellular annexin 1. Although annexin 1 and the structurally related protein, annexin 4, co-localized to many of the same cells of the ductal epithelium of the prostate, annexin 4 was no secreted. Thus, the secretion of annexin 1 appears to involve a highly selective mechanism that does not involve targeting to the endoplasmic reticulum by a hydrophobic signal sequence.	UNIV CALIF IRVINE, DEPT PHYSIOL & BIOPHYS, IRVINE, CA 92717 USA; UNIV CALIF IRVINE, DEPT ANAT & NEUROBIOL, IRVINE, CA 92717 USA	University of California System; University of California Irvine; University of California System; University of California Irvine			Haigler, Harry/C-3788-2011		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015321] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM357844] Funding Source: Medline; NINDS NIH HHS [NS15321] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; AMBROSE MP, 1990, J APPL PHYSIOL, V68, P1668, DOI 10.1152/jappl.1990.68.4.1668; ANDO Y, 1989, J BIOL CHEM, V264, P6948; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BELLOMO G, 1988, ANN NY ACAD SCI, V551, P128, DOI 10.1111/j.1749-6632.1988.tb22327.x; BERRUTI G, 1988, EXP CELL RES, V179, P374, DOI 10.1016/0014-4827(88)90276-5; BIAGINI G, 1982, PROSTATE, V3, P99, DOI 10.1002/pros.2990030112; BIEMANN K, 1987, SCIENCE, V237, P992, DOI 10.1126/science.3303336; BLACKWOOD RA, 1990, BIOCHEM J, V266, P195, DOI 10.1042/bj2660195; BRADSHAW RA, 1989, TRENDS BIOCHEM SCI, V14, P276, DOI 10.1016/0968-0004(89)90063-7; Brandes D, 1966, Int Rev Cytol, V20, P207, DOI 10.1016/S0074-7696(08)60802-5; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; CRUMPTON MJ, 1990, NATURE, V345, P212, DOI 10.1038/345212a0; DAVIDSON FF, 1987, J BIOL CHEM, V262, P1698; DAVIDSON FF, 1990, J BIOL CHEM, V265, P5602; DIXON SJ, 1987, J CELL PHYSIOL, V132, P473, DOI 10.1002/jcp.1041320309; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; FAVA RA, 1984, J BIOL CHEM, V259, P2636; FAVA RA, 1989, J CELL PHYSIOL, V141, P284, DOI 10.1002/jcp.1041410209; FAZLEABAS AT, 1988, BIOL REPROD, V39, P729, DOI 10.1095/biolreprod39.3.729; Fisher E R, 1970, Pathol Annu, V5, P1; FUNAKOSHI T, 1987, BIOCHEMISTRY-US, V26, P5572, DOI 10.1021/bi00391a053; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; GEISOW M, 1984, EMBO J, V3, P2969, DOI 10.1002/j.1460-2075.1984.tb02242.x; GENGE BR, 1990, J BIOL CHEM, V265, P4703; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GIUGNI TD, 1985, J BIOL CHEM, V260, P5081; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; GRUNDMANN U, 1988, P NATL ACAD SCI USA, V85, P3708, DOI 10.1073/pnas.85.11.3708; HAIGLER HT, 1987, J BIOL CHEM, V262, P6921; HALE JE, 1987, J BIOL CHEM, V262, P1916; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAUPTMANN R, 1989, EUR J BIOCHEM, V185, P63, DOI 10.1111/j.1432-1033.1989.tb15082.x; HAZUDA DJ, 1988, J BIOL CHEM, V263, P8473; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; HULLIN F, 1989, J BIOL CHEM, V264, P3506; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3392; ISACKE CM, 1989, MOL CELL BIOL, V9, P232, DOI 10.1128/MCB.9.1.232; IWASAKI A, 1987, J BIOCHEM, V102, P1261, DOI 10.1093/oxfordjournals.jbchem.a122165; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KAPLAN R, 1988, J BIOL CHEM, V263, P8037; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEPINS A, 1985, EXP CELL RES, V161, P525, DOI 10.1016/0014-4827(85)90107-7; LILJA H, 1987, J CLIN INVEST, V80, P281, DOI 10.1172/JCI113070; LIZANA J, 1987, INT J FERTIL, V32, P71; LUNDWALL A, 1987, FEBS LETT, V214, P317, DOI 10.1016/0014-5793(87)80078-9; MAO P, 1965, ARCH PATHOL, V79, P270; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MATSUSHIMA K, 1986, J IMMUNOL, V136, P2883; MBIKAY M, 1987, DNA-J MOLEC CELL BIO, V6, P23, DOI 10.1089/dna.1987.6.23; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; NAKATA T, 1990, J CELL BIOL, V110, P13, DOI 10.1083/jcb.110.1.13; NORTHUP JK, 1988, J CLIN INVEST, V82, P1347, DOI 10.1172/JCI113737; PEPINSKY RB, 1988, J BIOL CHEM, V263, P10799; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; PEPINSKY RB, 1986, J BIOL CHEM, V261, P4239; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; RONQUIST G, 1990, ARCH ANDROLOGY, V24, P147, DOI 10.3109/01485019008986874; RONQUIST G, 1985, BIOCHIM BIOPHYS ACTA, V822, P203, DOI 10.1016/0304-4157(85)90008-5; ROSS TS, 1990, SCIENCE, V248, P605, DOI 10.1126/science.2159184; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SATO EF, 1989, FEBS LETT, V244, P108, DOI 10.1016/0014-5793(89)81173-1; SCHLAEPFER DD, 1988, BIOCHEMISTRY-US, V27, P4253, DOI 10.1021/bi00412a008; SCHLAEPFER DD, 1987, J BIOL CHEM, V262, P6931; SCHLAEPFER DD, 1990, J CELL BIOL, V111, P229, DOI 10.1083/jcb.111.1.229; SILVA FG, 1986, DIFFERENTIATION, V33, P175, DOI 10.1111/j.1432-0436.1986.tb00423.x; SMITH SF, 1990, J IMMUNOL METHODS, V131, P119, DOI 10.1016/0022-1759(90)90241-M; SPRINGMILLS E, 1980, HUMAN REPRODUCTION, P60; SRIGLEY JR, 1988, ULTRASTRUCT PATHOL, V12, P49, DOI 10.3109/01913128809048476; STONE MP, 1977, UROL RES, V5, P185; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P6268, DOI 10.1021/bi00417a011; TAMAKI M, 1987, NUCLEIC ACIDS RES, V15, P7637, DOI 10.1093/nar/15.18.7637; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIHKO P, 1988, FEBS LETT, V236, P275, DOI 10.1016/0014-5793(88)80037-1; WALLNER BP, 1986, NATURE, V320, P77, DOI 10.1038/320077a0; ZOKAS L, 1987, J CELL BIOL, V105, P2111, DOI 10.1083/jcb.105.5.2111	82	183	186	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2499	2507						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1824943				2022-12-25	WOS:A1991EV51500074
J	SETOYOUNG, D; PERLIN, DS				SETOYOUNG, D; PERLIN, DS			EFFECT OF MEMBRANE VOLTAGE ON THE PLASMA-MEMBRANE H+-ATPASE OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; PROTON-TRANSLOCATING ATPASE; REACTION-KINETIC ANALYSIS; RESISTANT PMA1 MUTANTS; ION-TRANSPORT SYSTEMS; RECONSTITUTED PROTEOLIPOSOMES; CONFORMATIONAL TRANSITIONS; NEUROSPORA-CRASSA; PUMPING ATPASE; K+	A novel system for generating large interior positive membrane potentials in proteoliposomes was used to examine the effects of membrane voltage on reconstituted plasma membrane H+-ATPase from Saccharomyces cerevisiae. The membrane potential-generating system was dependent upon the lipophilic electron carrier tetracyanoquinodimethane, located within the bilayer, to mediate electron flow from vesicle entrapped ascorbate to external K3Fe(CN)6. Membrane potential formation was followed by the potential-dependent probe oxonol V and was found to rapidly reach a steady-state which lasted at least 90 s. A membrane potential of approximately 254 mV was determined under optimal conditions and ATP hydrolysis by wild-type H+-ATPase was inhibited from 34 to 46% under these conditions. In contrast, membrane potential had little effect on pma1-105 mutant enzyme suggesting that it is defective in electrogenic proton translocation. Applied membrane voltage was also found to alter the sensitivity of wild-type enzyme to vanadate at concentrations less than 50 mu-M. These data suggest a coupling between the charge-transfer and ATP hydrolysis domains and establish a solid basis for future probing of the electrogenic properties of the yeast H+-ATPase.	PUBL HLTH RES INST CITY NEW YORK INC,DEPT BIOCHEM,NEW YORK,NY 10016						NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038225] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38225] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON R, 1986, J BIOL CHEM, V261, P4896; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; AMORY A, 1982, J BIOL CHEM, V257, P2509; BAHINSKI A, 1988, P NATL ACAD SCI USA, V85, P3412, DOI 10.1073/pnas.85.10.3412; Bashford C L, 1979, Methods Enzymol, V55, P569; BORSTPAUWELS GWFH, 1981, BIOCHIM BIOPHYS ACTA, V650, P88, DOI 10.1016/0304-4157(81)90002-2; BOWMAN BJ, 1981, J BIOL CHEM, V256, P2343; CALAHORRA M, 1987, BIOCHIM BIOPHYS ACTA, V899, P229, DOI 10.1016/0005-2736(87)90404-4; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CID A, 1988, J BIOL CHEM, V263, P14134; DEWEER P, 1988, ANNU REV PHYSIOL, V50, P225, DOI 10.1146/annurev.physiol.50.1.225; DIXON DA, 1989, J MEMBRANE BIOL, V112, P169, DOI 10.1007/BF01871278; DUFOUR JP, 1978, J BIOL CHEM, V253, P7026; DUFOUR JP, 1982, J BIOL CHEM, V257, P9365; GADSBY DC, 1989, MOL CELL BIOCHEM, V89, P141; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GOLDSHLEGER R, 1990, J MEMBRANE BIOL, V113, P139, DOI 10.1007/BF01872888; GRADMANN D, 1982, CURR TOP MEMBR TRANS, V16, P257; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HANSEN UP, 1981, J MEMBRANE BIOL, V63, P165, DOI 10.1007/BF01870979; HOFFMAN JF, 1974, J PHYSIOL-LONDON, V239, P519, DOI 10.1113/jphysiol.1974.sp010581; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; LAUGER P, 1987, PHYSIOL REV, V67, P1296, DOI 10.1152/physrev.1987.67.4.1296; LORENTZON P, 1988, J BIOL CHEM, V263, P10705; MALPARTIDA F, 1981, J BIOL CHEM, V256, P4175; MALPARTIDA F, 1981, EUR J BIOCHEM, V116, P413, DOI 10.1111/j.1432-1033.1981.tb05350.x; MALPARTIDA F, 1980, FEBS LETT, V111, P69, DOI 10.1016/0014-5793(80)80763-0; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; PENEFSKY HS, 1985, J BIOL CHEM, V260, P3728; PERLIN DS, 1987, J BIOL CHEM, V262, P6788; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; PERLIN DS, 1988, J BIOL CHEM, V263, P18118; PERLIN DS, 1984, J BIOL CHEM, V259, P7884; PICK U, 1982, J BIOL CHEM, V257, P6111; PORTILLO F, 1989, EUR J BIOCHEM, V186, P501, DOI 10.1111/j.1432-1033.1989.tb15235.x; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; RAMIREZ JA, 1989, P NATL ACAD SCI USA, V86, P7866, DOI 10.1073/pnas.86.20.7866; REPHAELI A, 1986, J BIOL CHEM, V261, P6248; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SERRANO R, 1984, CURR TOP CELL REGUL, V23, P87; SLAYMAN CL, 1987, J BIOENERG BIOMEMBR, V19, P1; STEIN J, 1982, TECHNIQUES LIPID M B, V403, P1; STURMER W, 1989, J MEMBRANE BIOL, V110, P67, DOI 10.1007/BF01870994; TIEN HT, 1984, BIOCHEM BIOPH RES CO, V119, P372, DOI 10.1016/0006-291X(84)91661-9; VILLALOBO A, 1981, J BIOL CHEM, V256, P2081; VILLALOBO A, 1982, J BIOL CHEM, V257, P1824; VILLALOBO A, 1984, CAN J BIOCHEM CELL B, V62, P865, DOI 10.1139/o84-111	48	41	41	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1383	1389						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1824841				2022-12-25	WOS:A1991EU49700008
J	TAYLOR, EW				TAYLOR, EW			KINETIC-STUDIES ON THE ASSOCIATION AND DISSOCIATION OF MYOSIN SUBFRAGMENT-1 AND ACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTOMYOSIN ADENOSINE-TRIPHOSPHATASE; RABBIT SKELETAL-MUSCLE; SMOOTH-MUSCLE; F-ACTIN; PHOSPHATE; BINDING; ACTO-SUBFRAGMENT-1; EXCHANGE; COMPLEX; POLYMERIZATION	The reactions of pyrene-labeled actin with myosin subfragment 1 (S1) and S1-ligand complexes at low ionic strength are described by the schemes [GRAPHICS] where M refers to a myosin head; A is actin: L is ligand; the asterisk refers to a high fluorescence state of actin; and K1 and k3 are association constants. K1 is reduced approximately 10-fold for M.ADP or M.pyrophosphate versus M alone. The rate constant of the isomerization step (k2) is 150-200 s-1 for A*M, A*M.ADP, and A*M-pyrophosphate (20-degrees-C). The interaction between the ligand the actin binding sites reduces K2 from 2,000 for A*M to 50-100 for A*M.ADP and to approximately unity for A*M-pyrophosphate. The A*M.ADP state is equated with the AM'.ADP state of Sleep and Hutton (Sleep, J., and Hutton, R. L. (1980) Biochemistry 19, 1276-1283).			TAYLOR, EW (corresponding author), UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020592] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20592] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIOSCA JA, 1986, J BIOL CHEM, V261, P9793; BOWATER R, 1988, BIOCHEMISTRY-US, V27, P5314, DOI 10.1021/bi00414a055; CARDON JW, 1978, EUR J BIOCHEM, V92, P443, DOI 10.1111/j.1432-1033.1978.tb12765.x; COATES JH, 1985, BIOCHEM J, V232, P351, DOI 10.1042/bj2320351; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; EISENBERG E, 1980, ANNU REV PHYSIOL, V42, P293, DOI 10.1146/annurev.ph.42.030180.001453; GEEVES MA, 1986, PROC R SOC SER B-BIO, V229, P85, DOI 10.1098/rspb.1986.0076; GEEVES MA, 1989, BIOCHEMISTRY-US, V28, P5864, DOI 10.1021/bi00440a024; GEEVES MA, 1984, J MUSCLE RES CELL M, V5, P351, DOI 10.1007/BF00818255; HIBBERD MG, 1986, ANNU REV BIOPHYS BIO, V15, P119; HIBBERD MG, 1985, SCIENCE, V228, P1317, DOI 10.1126/science.3159090; KASPRZAK AA, 1989, BIOCHEMISTRY-US, V28, P9230, DOI 10.1021/bi00449a040; KONRAD M, 1982, EUR J BIOCHEM, V128, P547; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; MCCAMMON JA, 1987, DYNAMICS PROTEINS NU, P151; ROSENFELD SS, 1984, J BIOL CHEM, V259, P1920; ROSENFELD SS, 1987, J BIOL CHEM, V262, P9994; ROSENFELD SS, 1984, J BIOL CHEM, V259, P1908; SHRIVER JW, 1981, BIOCHEMISTRY-US, V20, P2004, DOI 10.1021/bi00510a041; SLEEP JA, 1980, BIOCHEMISTRY-US, V19, P1276, DOI 10.1021/bi00548a002; SLEEP JA, 1978, J BIOL CHEM, V253, P5235; STEIN LA, 1984, BIOCHEMISTRY-US, V23, P1555, DOI 10.1021/bi00302a033; TRYBUS KM, 1980, P NATL ACAD SCI-BIOL, V77, P7209, DOI 10.1073/pnas.77.12.7209; TRYBUS KM, 1982, BIOCHEMISTRY-US, V21, P1284, DOI 10.1021/bi00535a028; WHITE HD, 1976, BIOCHEMISTRY-US, V15, P5818, DOI 10.1021/bi00671a020; WHITE HD, 1977, BIOPHYS J, V17, P40	27	103	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					294	302						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1845966				2022-12-25	WOS:A1991EQ33900044
J	MUNN, MM; RUPP, WD				MUNN, MM; RUPP, WD			INTERACTION OF THE UVRABC ENDONUCLEASE WITH DNA CONTAINING A PSORALEN MONOADDUCT OR CROSS-LINK - DIFFERENTIAL-EFFECTS OF SUPERHELICAL DENSITY AND COMPARISON OF PREINCISION COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION REPAIR; ESCHERICHIA-COLI UVRB; ABC EXCINUCLEASE; PROTEIN COMPLEX; POLYMERASE-I; HELICASE-II; ENZYMATIC-PROPERTIES; (A)BC EXCINUCLEASE; ACTION MECHANISM; GENE-PRODUCT	The effect of negative supercoiling on UvrABC incision of covalently closed duplex DNA circles containing either a furan-side monoadduct or a cross-link of 4'-hydroxymethyl-4,5',8-trimethylpsoralen at a unique site was examined. The rate of UvrABC incision of these DNA substrates was measured as a function of superhelical density, sigma, for values of sigma between 0 and -0.050. The monoadducted DNA substrate was incised at close to the maximum rate at all superhelical densities, with only a slight stimulation of activity between sigma = 0 and -0.035. In contrast, efficient UvrABC incision of the cross-linked DNA substrate required the DNA to be underwound, and activity showed a linear dependence on superhelical density up to sigma = -0.035. DNase I protection studies show that in the presence of both UvrA and UvrB a protein complex binds to the site of a psoralen monoadduct or crosslink in linear DNA. This UvrA-UvrB-dependent complex binds with similar affinity to both the monoadducted and the cross-linked DNA helices. However, differences in the DNase I footprint on these two DNA substrates indicate that the interaction of this protein complex is different at these two lesions. The addition of UvrC to linear DNA molecules that are saturated at the site of the lesion with the UvrA-UvrB-dependent complex resulted in efficient nicking of the monoadducted DNA, but not the cross-linked DNA. Thus, the properties of a DNA lesion site that lead to UvrAB recognition and binding are not necessarily sufficient to allow incision when all three Uvr subunits are present. We propose that after recognition and binding of a lesion site by the UvrAB complex and prior to incision, the damaged DNA helix undergoes a conformational change such as unwinding or melting that is induced by the lesion-bound Uvr complex.	YALE UNIV, SCH MED, DEPT THERAPEUT RADIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06510 USA	Yale University; Yale University					NCI NIH HHS [CA39238] Funding Source: Medline; NIGMS NIH HHS [GM31399] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA039238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031399, R01GM131399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIKAN E, 1986, NUCLEIC ACIDS RES, V14, P2637, DOI 10.1093/nar/14.6.2637; BACKENDORF C, 1986, NUCLEIC ACIDS RES, V14, P2877, DOI 10.1093/nar/14.7.2877; BACKENDORF C, 1989, NUCLEIC ACIDS RES, V17, P10337, DOI 10.1093/nar/17.24.10337; BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; BECK DJ, 1985, NUCLEIC ACIDS RES, V13, P7395, DOI 10.1093/nar/13.20.7395; BERTRANDBURGGRAF E, 1991, J MOL BIOL, V219, P27, DOI 10.1016/0022-2836(91)90854-Y; CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; CASTELL SE, 1989, NUCLEIC ACIDS RES, V17, P7045, DOI 10.1093/nar/17.17.7045; CHENG S, 1988, J BIOL CHEM, V263, P15110; CIMINO GD, 1985, ANNU REV BIOCHEM, V54, P1151, DOI 10.1146/annurev.bi.54.070185.005443; FRANKLIN WA, 1984, P NATL ACAD SCI-BIOL, V81, P3821, DOI 10.1073/pnas.81.12.3821; GAMPER H, 1984, PHOTOCHEM PHOTOBIOL, V40, P29, DOI 10.1111/j.1751-1097.1984.tb04549.x; GRUSKIN EA, 1988, J BIOL CHEM, V263, P12738; HANSSON J, 1989, J BIOL CHEM, V264, P21788; HARAN TE, 1988, BIOCHEMISTRY-US, V27, P6967, DOI 10.1021/bi00418a044; HUSAIN I, 1985, P NATL ACAD SCI USA, V82, P6774, DOI 10.1073/pnas.82.20.6774; HUSAIN I, 1986, J BIOL CHEM, V261, P4895; JOHNSON AD, 1979, P NATL ACAD SCI USA, V76, P5061, DOI 10.1073/pnas.76.10.5061; JONES BK, 1988, P NATL ACAD SCI USA, V85, P8410, DOI 10.1073/pnas.85.22.8410; JONES BK, 1990, J BIOL CHEM, V265, P3489; KACINSKI BM, 1984, CANCER RES, V44, P3489; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KODADEK T, 1988, BIOCHEMISTRY-US, V27, P3210, DOI 10.1021/bi00409a013; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; KOW YW, 1990, MUTAT RES, V235, P147, DOI 10.1016/0921-8777(90)90068-G; LAMBERT B, 1989, P NATL ACAD SCI USA, V86, P6557, DOI 10.1073/pnas.86.17.6557; LIN JJ, 1989, BIOCHEMISTRY-US, V28, P7979, DOI 10.1021/bi00446a002; Maniatis T., 1982, MOL CLONING; MATSON SW, 1986, J BIOL CHEM, V261, P169; MOOLENAAR GF, 1987, NUCLEIC ACIDS RES, V15, P4273, DOI 10.1093/nar/15.10.4273; OH EY, 1986, NUCLEIC ACIDS RES, V14, P8557, DOI 10.1093/nar/14.21.8557; OH EY, 1989, J BIOL CHEM, V264, P1336; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; PECK LJ, 1982, P NATL ACAD SCI-BIOL, V79, P4560, DOI 10.1073/pnas.79.15.4560; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; PETTIJOHN DE, 1980, P NATL ACAD SCI-BIOL, V77, P1331, DOI 10.1073/pnas.77.3.1331; PU WT, 1989, J BIOL CHEM, V264, P20697; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SANCAR GB, 1984, NUCLEIC ACIDS RES, V12, P4593, DOI 10.1093/nar/12.11.4593; SEELEY TW, 1990, J BIOL CHEM, V265, P7158; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; SHI YB, 1988, NUCLEIC ACIDS RES, V16, P8945, DOI 10.1093/nar/16.18.8945; SHI YB, 1986, BIOCHEMISTRY-US, V25, P5895, DOI 10.1021/bi00368a009; SINDEN RR, 1980, CELL, V21, P773, DOI 10.1016/0092-8674(80)90440-7; SINDEN RR, 1984, BIOCHEMISTRY-US, V23, P6299, DOI 10.1021/bi00321a002; SLADEK FM, 1989, J BIOL CHEM, V264, P6755; TANG MS, 1982, NATURE, V299, P646, DOI 10.1038/299646a0; TOMIC MT, 1987, SCIENCE, V238, P1722, DOI 10.1126/science.3686011; VANHOUTEN B, 1987, J BIOL CHEM, V262, P13180; VANHOUTEN B, 1986, P NATL ACAD SCI USA, V83, P8077; VANHOUTEN B, 1988, J BIOL CHEM, V263, P16553; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VANHOUTEN B, 1986, J BIOL CHEM, V261, P14135; VIGNY P, 1987, PHOTOCHEM PHOTOBIOL, V45, P601, DOI 10.1111/j.1751-1097.1987.tb07386.x; VISSE R, 1991, J BIOL CHEM, V266, P7609; VOIGT JM, 1989, J BIOL CHEM, V264, P5172; WALTER RB, 1988, J MOL BIOL, V203, P939, DOI 10.1016/0022-2836(88)90119-2; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P2567, DOI 10.1093/nar/14.6.2567; YEUNG AT, 1987, NUCLEIC ACIDS RES, V15, P4957, DOI 10.1093/nar/15.12.4957; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157	63	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24748	24756						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761569				2022-12-25	WOS:A1991GW84500078
J	SEGAL, DM; EICHLER, DC				SEGAL, DM; EICHLER, DC			A NUCLEOLAR 2'-O-METHYLTRANSFERASE - SPECIFICITY AND EVIDENCE FOR ITS ROLE IN THE METHYLATION OF MOUSE 28 S PRECURSOR RIBOSOMAL-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCES; XENOPUS-LAEVIS; SECONDARY STRUCTURE; RIBONUCLEIC-ACID; METHIONINE; LOCATIONS; ETHIONINE; CELLS; MODEL	Methylation of ribose moieties appears to be an essential post-transcriptional event in ribosomal RNA maturation. Although the sites of ribose methylation have been identified, the components involved in the 2'-O-methylation of precursor ribosomal RNA in mammalian cells have not yet been elucidated. To investigate the involvement of a recently isolated nucleolar 2'-O-methyltransferase in this process, an in vitro synthesized 28 S rRNA transcript containing a unique tandem triple 2'-O-methylated ribose site was used as a substrate. Activity assays demonstrated that this transcript served as a substrate for the nucleolar 2'-O-methyltransferase. The distribution of incorporated methyl groups was determined by hydrolyzing the 2'-O-methylated transcript with RNase followed by chromatography of the digested products on an anion-exchange high performance liquid chromatography column. Results showed one unique RNase-resistant 2'-O-methylated product, a tetramer. The position of the tetrameric sequence in the 28 S rRNA transcript was determined using RNase protection analysis which mapped the methylations to a 20-nucleotide region spanning the unique tandem triple 2'-O-methylated ribose site in 28 S rRNA. To confirm the absolute specificity of methylation, direct sequence analysis was carried out on the tandem triple 2'-O-methylated tetramer. The sequence determined for the tetramer, AmGmCmA, corresponded exactly with that reported from in vivo studies. These findings demonstrate that the purified nucleolar 2'-O-methyltransferase can accurately methylate at a specific site of an in vitro derived preribosomal RNA transcript and support the proposed involvement of this nucleolar enzyme in ribosomal RNA maturation.	UNIV S FLORIDA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33612	State University System of Florida; University of South Florida			Eichler, Duane/A-1906-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029162] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM29162] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNARD EA, 1969, ANN REV BIOCH, V33, P677; BRAND RC, 1977, EUR J BIOCHEM, V75, P311, DOI 10.1111/j.1432-1033.1977.tb11531.x; CLARK CG, 1984, NUCLEIC ACIDS RES, V12, P6197, DOI 10.1093/nar/12.15.6197; EICHLER DC, 1987, BIOCHEMISTRY-US, V26, P1639, DOI 10.1021/bi00380a023; EICHLER DC, 1988, BIOCHEM BIOPH RES CO, V155, P530, DOI 10.1016/S0006-291X(88)81119-7; GREENBERG H, 1966, J MOL BIOL, V21, P527, DOI 10.1016/0022-2836(66)90025-8; KHAN MSN, 1978, BIOCHEM J, V169, P531, DOI 10.1042/bj1690531; KLOOTWIJK J, 1973, EUR J BIOCHEM, V39, P325, DOI 10.1111/j.1432-1033.1973.tb03130.x; LANE BG, 1969, BIOCHIM BIOPHYS ACTA, V179, P332, DOI 10.1016/0005-2787(69)90041-0; MADEN BEH, 1986, J MOL BIOL, V189, P681, DOI 10.1016/0022-2836(86)90498-5; MADEN BEH, 1974, J MOL BIOL, V88, P133, DOI 10.1016/0022-2836(74)90299-X; MADEN BEH, 1988, J MOL BIOL, V201, P289, DOI 10.1016/0022-2836(88)90139-8; MADEN BEH, 1977, BIOCHEM J, V167, P211, DOI 10.1042/bj1670211; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MICHOT B, 1984, NUCLEIC ACIDS RES, V12, P4259, DOI 10.1093/nar/12.10.4259; MURAMATSU M, 1968, BIOCHIM BIOPHYS ACTA, V157, P476, DOI 10.1016/0005-2787(68)90147-0; SALIM M, 1981, NATURE, V291, P205, DOI 10.1038/291205a0; SEGAL DM, 1989, ARCH BIOCHEM BIOPHYS, V275, P334, DOI 10.1016/0003-9861(89)90380-9; VAUGHAN MH, 1967, P NATL ACAD SCI USA, V58, P1527, DOI 10.1073/pnas.58.4.1527; WAGNER EK, 1967, J MOL BIOL, V29, P371, DOI 10.1016/0022-2836(67)90105-2; WEN LT, 1983, BIOCHIM BIOPHYS ACTA, V741, P153, DOI 10.1016/0167-4781(83)90055-6; WOLF SF, 1977, BIOCHEMISTRY-US, V16, P2783, DOI 10.1021/bi00631a031; ZIMMERMAN EF, 1967, J MOL BIOL, V23, P149, DOI 10.1016/S0022-2836(67)80023-8	23	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24385	24389						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761539				2022-12-25	WOS:A1991GW84500025
J	HURTA, RAR; SAMUEL, SK; GREENBERG, AH; WRIGHT, JA				HURTA, RAR; SAMUEL, SK; GREENBERG, AH; WRIGHT, JA			EARLY INDUCTION OF RIBONUCLEOTIDE REDUCTASE GENE-EXPRESSION BY TRANSFORMING GROWTH FACTOR-BETA-1 IN MALIGNANT H-RAS TRANSFORMED-CELL LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METASTATIC PROGRESSION; TGF-BETA-1 INHIBITION; PROTEIN; BINDING; MUTANTS; FIBROBLASTS; RESISTANCE; ONCOGENES; PHENOTYPE; FERRITIN	Previous investigations have indicated that the suppression of proliferation by transforming growth factor (TGF) beta-1 is often lost upon cellular transformation, and that proliferation of some tumors is stimulated by TGF-beta. The present study provides the first observation of a link between TGF-beta-1 regulation of this process and alterations in the expression of ribonucleotide reductase, a highly controlled rate-limiting step in DNA synthesis. A series of radiation and T24-H-ras-transformed mouse 10T1/2 cell lines exhibiting increasing malignant potential was evaluated for TGF-beta-1 induced alterations in ribonucleotide reductase M1 and M2 gene expression. Early increases in M1 and/or M2 message and protein levels were observed only in malignant cell lines. The TGF-beta-1 induced changes in M1 and/or M2 gene expression occurred prior to any detectable changes in the rates of DNA synthesis, supporting the novel concept that ribonucleotide reductase gene expression can be elevated by TGF-beta-1 without altering the proportion of cells in S phase. T24-H-ras-transformed 10T1/2 cells were transfected with a plasmid containing the coding region of TGF-beta-1 under the control of a zinc-sensitive metallothionein promoter. When these cells were cultured in the presence of zinc, a large induction of TGF-beta-1 message was observed within 1 h. Both M1 and M2 genes were also induced, with increased mRNA levels appearing 2 h after zinc treatment, or 1 h after TGF-beta-1 message levels were clearly elevated. In total, the data suggests a mechanism of autocrine stimulation of malignant cells by TGF-beta-1, in which early alterations in the regulation of ribonucleotide reductase may play an important role.	UNIV MANITOBA,MANITOBA INST CELL BIOL,WINNIPEG R3E 0V9,MANITOBA,CANADA	University of Manitoba	WRIGHT, JA (corresponding author), UNIV MANITOBA,MANITOBA INST CELL BIOL,WINNIPEG R3E 0V9,MANITOBA,CANADA.							ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BRUNNER AM, 1989, J BIOL CHEM, V264, P13660; CHOY BK, 1989, BIOCHEM BIOPH RES CO, V162, P1417, DOI 10.1016/0006-291X(89)90832-2; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GREENBERG AH, 1989, INVAS METAST, V9, P360; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; HURTA RAR, 1990, BIOCHIM BIOPHYS ACTA, V1087, P165, DOI 10.1016/0167-4781(90)90201-C; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; MCCLARTY GA, 1987, BIOCHEMISTRY-US, V26, P8004, DOI 10.1021/bi00398a068; MCCLARTY GA, 1990, J BIOL CHEM, V265, P7539; NICOLSON GL, 1984, CANCER METAST REV, V3, P25, DOI 10.1007/BF00047691; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SCHWARZ LC, 1988, CANCER RES, V48, P6999; Schwarz LC, 1990, GROWTH FACTORS, V3, P115, DOI 10.3109/08977199009108274; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; TAKEHARA K, 1987, CELL, V49, P415, DOI 10.1016/0092-8674(87)90294-7; THELANDER L, 1980, J BIOL CHEM, V255, P7426; ULLMAN B, 1979, P NATL ACAD SCI USA, V76, P1074, DOI 10.1073/pnas.76.3.1074; WEBER G, 1983, CANCER RES, V43, P3466; WEINBERG G, 1981, P NATL ACAD SCI-BIOL, V78, P2447, DOI 10.1073/pnas.78.4.2447; WEINBERG RA, 1989, ONCOGENES MOL ORIGIN, P46; WRIGHT JA, 1990, BIOCHEM CELL BIOL, V68, P1364, DOI 10.1139/o90-199; WRIGHT JA, 1990, ANTICANCER RES, V10, P1247; WRIGHT JA, 1989, INT ENCY PHARM THERA, V128, P89	33	50	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					24097	24100						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748682				2022-12-25	WOS:A1991GV31900088
J	ZU, YL; MAEKAWA, T; MATSUDA, S; ISHII, S				ZU, YL; MAEKAWA, T; MATSUDA, S; ISHII, S			COMPLETE PUTATIVE METAL FINGER AND LEUCINE ZIPPER STRUCTURES OF CRE-BP1 ARE REQUIRED FOR THE E1A-INDUCED TRANSACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYB PROTO-ONCOGENE; ATF CDNA CLONES; CYCLIC-AMP; C-MYB; TRANSCRIPTION FACTOR; RESPONSE ELEMENT; BINDING; E1A; DNA; PROTEINS	The adenovirus E1A protein stimulates transcription of various genes. Recent experiments using a fusion protein have shown that E1A can function through a specific CRE (cyclic AMP response element)-binding protein, CRE-BP1 (also designated ATF-2), which stimulates the transcription from a CRE-containing promoter by homodimer formation or heterodimer formation with c-Jun. In this paper, the functional domains required for mediation of the E1A-induced trans-activation were analyzed using deletion and Point mutants of CRE-BP1. The mutation in the putative metal finger structure or leucine zipper structure completely abolished the ability of CRE-BP1 to mediate the E1A-induced trans-activation. Furthermore, overexpression of CRE-BP1 or c-Jun interfered with the E1A-induced trans-activation. These results suggest that the complete putative metal finger structure in the N-terminal region of CRE-BP1 plays an important role for the E1A-induced trans-activation, and the heterodimer of CRE-BP1 with the unidentified protein participates in the interaction with E1A.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC GENET LAB,3-1-1 KOYADAI,TSUKUBA,IBARAKI 305,JAPAN	RIKEN	ISHII, S (corresponding author), INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC GENET LAB,3-1-1 KOYADAI,TSUKUBA,IBARAKI 305,JAPAN.		Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; FANG L, 1990, CELL, V61, P1217; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GILARDI P, 1984, NUCLEIC ACIDS RES, V12, P7877, DOI 10.1093/nar/12.20.7877; GILARDI P, 1986, NUCLEIC ACIDS RES, V14, P9035, DOI 10.1093/nar/14.22.9035; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Higuchi R., 1989, PCR TECHNOLOGY, P61; HIRAI SI, 1990, ONCOGENE, V5, P39; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEE KAW, 1987, EMBO J, V6, P1345, DOI 10.1002/j.1460-2075.1987.tb02374.x; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MAGUIRE K, 1991, ONCOGENE, V6, P1417; MATSUDA S, 1991, J BIOL CHEM, V266, P18188; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SHI P, 1988, J CELL BIOCHEM     S, V12, P381; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	37	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					24134	24139						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1836214				2022-12-25	WOS:A1991GV31900094
J	HANNON, GJ; MARONEY, PA; NILSEN, TW				HANNON, GJ; MARONEY, PA; NILSEN, TW			U-SMALL NUCLEAR RIBONUCLEOPROTEIN REQUIREMENTS FOR NEMATODE CIS-SPLICING AND TRANSSPLICING INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CAENORHABDITIS-ELEGANS; BRUGIA-MALAYI; RNA; PARTICLES; SNRNP	In nematodes, a fraction of mRNAs acquires a common 22-nucleotide 5'-terminal spliced leader sequence via a trans-splicing reaction. The same premessenger RNAs which receive the spliced leader are also processed by conventional cis-splicing. Whole cell extracts prepared from synchronous embryos of the parasitic nematode Ascaris lumbricoides catalyze both cis- and trans-splicing. We have used this cell-free system and oligodeoxynucleotide directed RNase H digestion to assess the U small nuclear RNA requirements for nematode cis- and trans-splicing. These experiments indicated that both cis- and trans-splicing require intact U2 and U4/U6 small nuclear ribonucleoproteins (sn-RNPs). However, whereas cis-splicing displays the expected requirement for an intact U1 snRNP, trans-splicing is unaffected when approximately 90% of U1 snRNP is degraded. These results suggest that 5' splice site identification differs in nematode cis- and trans-splicing.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,10900 EUCLID AVE,CLEVELAND,OH 44106	Case Western Reserve University			Hannon, Gregory/AAB-3568-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031528] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 31528] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BARABINO SML, 1990, CELL, V63, P293, DOI 10.1016/0092-8674(90)90162-8; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BLACK DL, 1986, CELL, V46, P697, DOI 10.1016/0092-8674(86)90345-4; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BRUZIK JP, 1990, CELL, V62, P889, DOI 10.1016/0092-8674(90)90264-F; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; FRENDEWEY D, 1987, COLD SPRING HARB SYM, V52, P287, DOI 10.1101/SQB.1987.052.01.034; HANNON GJ, 1989, MOL CELL BIOL, V9, P4422, DOI 10.1128/MCB.9.10.4422; HANNON GJ, 1990, CELL, V61, P1247, DOI 10.1016/0092-8674(90)90689-C; MARONEY PA, 1990, EMBO J, V9, P3667, DOI 10.1002/j.1460-2075.1990.tb07578.x; NILSEN TW, 1989, EXP PARASITOL, V69, P413, DOI 10.1016/0014-4894(89)90191-4; PERRINE KG, 1988, MOL BIOCHEM PARASIT, V30, P97, DOI 10.1016/0166-6851(88)90137-5; RINKE J, 1985, J MOL BIOL, V185, P721, DOI 10.1016/0022-2836(85)90057-9; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; RUBY SW, 1991, TRENDS GENET, V7, P79; TAKACS AM, 1988, P NATL ACAD SCI USA, V85, P7932, DOI 10.1073/pnas.85.21.7932; THOMAS J, 1990, NUCLEIC ACIDS RES, V18, P2633, DOI 10.1093/nar/18.9.2633; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; VANDOREN K, 1988, NATURE, V335, P556; ZUKERAPRISON E, 1988, NUCLEIC ACIDS RES, V16, P7188	22	62	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22792	22795						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1835972				2022-12-25	WOS:A1991GT48300005
J	OBANION, MK; SADOWSKI, HB; WINN, V; YOUNG, DA				OBANION, MK; SADOWSKI, HB; WINN, V; YOUNG, DA			A SERUM-REGULATED AND GLUCOCORTICOID-REGULATED 4-KILOBASE MESSENGER-RNA ENCODES A CYCLOOXYGENASE-RELATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-H SYNTHASE; RIBONUCLEIC-ACID; DENOVO SYNTHESIS; SARCOMA-VIRUS; CELLS; DNA; INDUCTION; PHOSPHOLIPASE-A2; INHIBITION; CORTICOSTEROIDS	The profound influence of glucocorticoid hormones on the inflammatory response includes a rapid and significant reduction in the synthesis of cyclooxygenase (prostaglandin G/H synthase, PGHS), the key enzyme for prostaglandin biosynthesis. In analyzing the glucocorticoid effects on PGHS synthesis in C127 mouse fibroblasts, we detected a novel 4-kilobase (kb) mRNA that is related to a PGHS cDNA cloned from an ovine seminal vesicle library. This RNA is much more prevalent in cycloheximide-treated cells and, based on stringency analysis and preliminary sequence data, arises from a gene distinct from that transcribed into the previously cloned 2.8-kb PGHS cDNA. Furthermore, the 4-kb mRNA encodes a 70-kDa protein that is specifically immunoprecipitated by anti-PGHS serum. The abundance of the 4-kb mRNA is strongly decreased by dexamethasone and increased by serum within 2 h whereas the 2.8-kb PGHS mRNA, which is also seen in these cells, does not consistently change. These changes in the level of the 4-kb mRNA with serum and dexamethasone treatment parallel changes in the level of synthesized PGHS protein detected in both metabolically labeled cells and in in vitro translated mRNAs. This discovery of a cyclooxygenase-related gene that is transcriptionally regulated by serum and glucocorticoid hormones in a manner identical to that reported for cyclooxygenase activity may help clarify issues regarding cyclooxygenase regulation and suggests that two distinct and differentially regulated cyclooxygenase species exist.	UNIV ROCHESTER,SCH MED & DENT,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ENDOCRINE METAB UNIT,ROCHESTER,NY 14642	University of Rochester; University of Rochester				O'Banion, M. Kerry/0000-0003-1246-3363; Winn, Virginia/0000-0003-1136-2907	NCI NIH HHS [CA47650] Funding Source: Medline; NIDDK NIH HHS [DK1677] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047650] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARSMAN AJ, 1987, FEBS LETT, V219, P176, DOI 10.1016/0014-5793(87)81212-7; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAILEY JM, 1988, BIOCHEM BIOPH RES CO, V157, P1159, DOI 10.1016/S0006-291X(88)80995-1; BRONNEGARD M, 1988, MOL ENDOCRINOL, V2, P732, DOI 10.1210/mend-2-8-732; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; DAVIDSON FF, 1987, J BIOL CHEM, V262, P1698; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DEWITT DL, 1990, ADV PROSTAGLANDIN TH, V21, P65; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLOWER RJ, 1979, NATURE, V278, P456, DOI 10.1038/278456a0; FRASIERSCOTT K, 1988, J CLIN INVEST, V82, P1877, DOI 10.1172/JCI113805; FU JY, 1990, J BIOL CHEM, V265, P16737; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HABENICHT AJR, 1985, J CLIN INVEST, V75, P1381, DOI 10.1172/JCI111839; HAN JW, 1990, P NATL ACAD SCI USA, V87, P3373, DOI 10.1073/pnas.87.9.3373; HIRATA F, 1980, P NATL ACAD SCI-BIOL, V77, P2533, DOI 10.1073/pnas.77.5.2533; HLA T, 1986, PROSTAGLANDINS, V32, P829, DOI 10.1016/0090-6980(86)90093-6; KUSAKA M, 1988, BIOCHIM BIOPHYS ACTA, V972, P339, DOI 10.1016/0167-4889(88)90210-8; LEVENSON R, 1985, J BIOL CHEM, V260, P8056; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MASFERRER JL, 1990, J CLIN INVEST, V86, P1375, DOI 10.1172/JCI114850; PASH JM, 1988, FASEB J, V2, P2613, DOI 10.1096/fasebj.2.10.2968288; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; RAZ A, 1988, J BIOL CHEM, V263, P3022; ROSEN GD, 1989, BIOCHEM BIOPH RES CO, V164, P1358, DOI 10.1016/0006-291X(89)91819-6; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOUNG DA, 1983, METHOD ENZYMOL, V91, P190	36	581	594	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23261	23267						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744122				2022-12-25	WOS:A1991GT48300074
J	OLIVER, FJ; DELARUBIA, G; FEENER, EP; LEE, ME; LOEKEN, MR; SHIBA, T; QUERTERMOUS, T; KING, GL				OLIVER, FJ; DELARUBIA, G; FEENER, EP; LEE, ME; LOEKEN, MR; SHIBA, T; QUERTERMOUS, T; KING, GL			STIMULATION OF ENDOTHELIN-1 GENE-EXPRESSION BY INSULIN IN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE GENE; PROTEIN-KINASE-C; MESSENGER-RNA; SEQUENCE; BINDING; PROMOTER; TRANSCRIPTION; RECEPTORS	The present study characterized the regulation of the genetic expression of the vasoactive peptide endothelin-1 (ET-1) by insulin in bovine aortic endothelial cells. By RNA blot analysis, insulin (1.67 x 10(-8) M) increased ET-1 mRNA levels by 2.3-fold over the basal within 10 min and attained a maximum (5.3-fold increase) in 2 h. Dose-response studies showed that a maximum effect of insulin was reached at 1.67 x 10(-8) M although a significant increase can be observed at 1.66 x 10(-9) M. Radioligand receptor studies indicated that the affinity constant for insulin receptors on endothelial cells correlated closely with the dose response observed for ET-1 mRNA. The ET-1 mRNA half-life was estimated with actinomycin D studies to be 20 min in control cells and was not affected by insulin treatment. Moreover, the effects of phorbol 12-myristate 13-acetate (PMA) and insulin were additive in the induction of ET-1 gene expression. When protein kinase C in the bovine aortic endothelial cells was down-regulated by preincubation with 8 x 10(-7) M PMA for 24 or 48 h, insulin was still able to increase ET-1 mRNA levels whereas PMA was ineffective. Using a chloramphenicol acetyltransferase (CAT) fusion plasmid containing the CAT gene and the 5'-flanking region of the ET-1 gene (Lee, M. E., Bloch, K. D., Clifford, J. A., and Quertermous, T. (1990) J. Biol. Chem. 265, 10446-10450), we observed that 1.67 x 10(-8) M insulin increased CAT enzyme activity and mRNA levels. The insulin dose-response curve observed for CAT activity correlated with that observed for ET-1 mRNA levels. These results suggest that insulin stimulates expression of the ET-1 gene at the transcriptional level via its own receptors. This effect is mediated mostly through a protein kinase C-independent pathway, suggesting the existence of an insulin-responsive element in the ET-1 gene 5'-flanking sequence.	JOSLIN DIABET CTR,DIV RES,1 JOSLIN PL,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT MED,CARDIAC UNIT,BOSTON,MA 02114	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital			Oliver, Javier/S-1725-2018; Loeken, Mary R./AAC-2450-2022	Oliver, Javier/0000-0001-8468-1998; Loeken, Mary R./0000-0002-8056-9816; Quertermous, Thomas/0000-0002-7645-9067	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER; NEI NIH HHS [EY0-5110] Funding Source: Medline; NIDDK NIH HHS [DK36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREONE TL, 1982, J BIOL CHEM, V257, P35; BALEY PA, 1990, J CLIN INVEST, V85, P1320, DOI 10.1172/JCI114570; BLOCH KD, 1989, J BIOL CHEM, V264, P10851; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; GUNN JM, 1975, BIOCHEMISTRY-US, V14, P2350, DOI 10.1021/bi00682a012; HU KQ, 1990, J BIOL CHEM, V265, P13864; INOGUCHI T, 1985, J BIOL CHEM, V260, P14393; INOUE A, 1989, J BIOL CHEM, V264, P14954; IYEDJIAN PB, 1988, J BIOL CHEM, V263, P740; KING GL, 1983, J CLIN INVEST, V71, P974, DOI 10.1172/JCI110852; KORC M, 1981, SCIENCE, V213, P351, DOI 10.1126/science.6166044; KURIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P1435, DOI 10.1016/0006-291X(89)92270-5; LEE ME, 1990, J CLIN INVEST, V86, P141, DOI 10.1172/JCI114677; LEE ME, 1990, J BIOL CHEM, V265, P10446; LOEKEN MR, 1986, MOL CELL BIOL, V6, P2020, DOI 10.1128/MCB.6.6.2020; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OHNISHISUZAKI A, 1990, BIOCHEM BIOPH RES CO, V166, P608, DOI 10.1016/0006-291X(90)90852-E; OSBORN L, 1988, J BIOL CHEM, V263, P16519; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PROGES D, 1990, J CLIN INVEST, V85, P1680; SHIBA T, 1990, DIABETES S1, V139, P123; STOUT RW, 1987, LANCET, V1, P1077; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; YAMAUCHI T, 1990, FEBS LETT, V267, P16, DOI 10.1016/0014-5793(90)80276-O; YANAGISAWA M, 1989, J CARDIOVASC PHAR S5, V13, P513; YANAGISAWA M, 1988, NATURE, V332, P414	36	216	220	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23251	23256						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744120				2022-12-25	WOS:A1991GT48300072
J	AXELSON, H; PANDA, CK; SILVA, S; SUGIYAMA, H; WIENER, F; KLEIN, G; SUMEGI, J				AXELSON, H; PANDA, CK; SILVA, S; SUGIYAMA, H; WIENER, F; KLEIN, G; SUMEGI, J			A NEW VARIANT 15-16 TRANSLOCATION IN MOUSE PLASMACYTOMA LEADS TO THE JUXTAPOSITION OF C-MYC AND IMMUNOGLOBULIN-LAMBDA	ONCOGENE			English	Article							MURINE LEUKEMIA-VIRUS; CHROMOSOME TRANSLOCATIONS; GENE; LOCUS; ONCOGENE; LYMPHOMAS; ENHANCER; REGION; CELLS; MICE	Mouse plasmacytomas (MPCs) induced by pristane oil, or by a combination of pristane oil and Abelson virus, carry one of two chromosomal translocations. The typical 12; 15 translocation leads to the juxtaposition of c-myc and immunoglobulin heavy-chain sequences, whereas the 6; 15 translocation links the kappa light-chain locus with the pyt-1 (plasmacytoma variant translocation) locus, located al least 75 kb 3' of c-myc [Cory, S., Graham, M., Webb, E., Corcoran, L. & Adams, J. (1985). EMBO J., 4, 675-681]. Unlike the human Burkitt's lymphoma-associated translocation, the lambda/myc juxtaposed variant translocation has not been found previously in MPCs. Using unconventional MPC induction systems in which the tumor precursor cell was induced to proliferate in a secondary host, we have recently identified a 15; 16 Translocation in six of the derived MPCs [Wiener, F., Silva, S., Sugiyama, H., Babonits, M. & Klein, G. (1990). Genes Chromosomes Cancer, 2, 36-43]. Chromosome 16 harbors the lambda light-chain gene. To explore whether the 15; 16 translocation represents the lambda/myc juxtaposition, we have mapped the breakpoints on chromosomes 15 and 16 by pulsed-field gel electrophoresis (PFGE). The pvt-1 region was mapped to approximately 220 kb 3' of c-myc. The breakpoint on chromosome 15 in ABPC-Ch-163-10, one of the six 15; 16 translocation-carrying carrying MPCs, was situated approximately 80 kb 3' of c-myc and 140 kb 5' of pvt-1b, the major breakpoint cluster region of the previously analysed 6; 15 variant MPCs. The breakpoint on chromosone 16 was found to cut between the V1 and C3 regions of the lambda locus. Co-migration experiments showed that the C3 and the myc gene were juxtaposed head to tail on the 15; 16 translocation chromosome. On the reciprocal product V1 was juxtaposed to pvt-1.			AXELSON, H (corresponding author), KAROLINSKA INST,DEPT TUMOR BIOL,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN.				NCI NIH HHS [3R01CA4054] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1983, P NATL ACAD SCI-BIOL, V80, P1982, DOI 10.1073/pnas.80.7.1982; BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; CARSON S, 1989, IMMUNOGENETICS, V29, P173, DOI 10.1007/BF00373642; CAZENAVE A, 1990, EMBO J, V9, P435; CORY S, 1985, EMBO J, V4, P675, DOI 10.1002/j.1460-2075.1985.tb03682.x; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; ECCLES S, 1990, New Biologist, V2, P801; EISEN HN, 1985, ANNU REV IMMUNOL, V3, P337, DOI 10.1146/annurev.iy.03.040185.002005; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRANCKE U, 1982, CYTOGENET CELL GENET, V33, P267, DOI 10.1159/000131769; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GRAHAM M, 1985, NATURE, V314, P740, DOI 10.1038/314740a0; HAGMAN J, 1990, GENE DEV, V4, P978, DOI 10.1101/gad.4.6.978; HENGLEIN B, 1989, MOL CELL BIOL, V9, P2105, DOI 10.1128/MCB.9.5.2105; HUPPI K, 1990, CURR TOP MICROBIOL, V166, P233; KLEIN G, 1985, IMMUNOL TODAY, V6, P208, DOI 10.1016/0167-5699(85)90036-2; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MARCU KB, 1983, P NATL ACAD SCI-BIOL, V80, P519, DOI 10.1073/pnas.80.2.519; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; NADEL B, 1990, EMBO J, V9, P435, DOI 10.1002/j.1460-2075.1990.tb08128.x; OHNO S, 1979, CELL, V18, P1001, DOI 10.1016/0092-8674(79)90212-5; PEAR WS, 1988, MOL CELL BIOL, V8, P441, DOI 10.1128/MCB.8.1.441; PICARD D, 1984, NATURE, V307, P80, DOI 10.1038/307080a0; POTTER M, 1987, SCIENCE, V235, P787, DOI 10.1126/science.3810165; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; SHTIVELMAN E, 1990, MOL CELL BIOL, V10, P1835, DOI 10.1128/MCB.10.4.1835; SILVA S, 1989, INT J CANCER, V44, P337, DOI 10.1002/ijc.2910440225; STORB U, 1989, MOL CELL BIOL, V9, P711, DOI 10.1128/MCB.9.2.711; SUGIYAMA H, 1989, INT J CANCER, V44, P348, DOI 10.1002/ijc.2910440227; TSICHLIS PN, 1989, P NATL ACAD SCI USA, V86, P5487, DOI 10.1073/pnas.86.14.5487; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WIENER F, 1990, GENE CHROMOSOME CANC, V2, P36, DOI 10.1002/gcc.2870020107; WIRSCHUBSKY Z, 1986, INT J CANCER, V38, P739, DOI 10.1002/ijc.2910380518; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x	36	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2263	2270						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766673				2022-12-25	WOS:A1991GX73500013
J	FINBLOOM, DS; WAHL, LM; WINESTOCK, KD				FINBLOOM, DS; WAHL, LM; WINESTOCK, KD			THE RECEPTOR FOR INTERFERON-GAMMA ON HUMAN PERIPHERAL-BLOOD MONOCYTES CONSISTS OF MULTIPLE DISTINCT SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GEL-ELECTROPHORESIS; LIGAND-BINDING; IFN-GAMMA; EXPRESSION; GLYCOSYLATION; PROTEINS; CHROMOSOME-6; MACROPHAGES; ANTIBODIES; FRACTIONS	The interaction of interferon-gamma (IFN-gamma) (a product of activated T lymphocytes) and monocytes is essential for immune responsiveness, host defense, and chronic inflammation. In this report we define the IFN-gamma receptor (IFN-gamma-R) on human monocytes as a receptor complex consisting of at least three subunits. Solubilization and immunoprecipitation of [S-35]methionine- and [S-35]cysteine-labeled monocytes were optimized by controlling the detergent concentration during solubilization and washing of the immunoprecipitates. This enabled subunits to be coimmunoprecipitated by several different anti-IFN-gamma-R antibodies raised against the 90-kDa cloned binding protein. Immunoprecipitation under stringent (1% sodium dodecyl sulfate) conditions resulted in the visualization of only the 80-90-kDa binding protein. Under less stringent conditions at least two coimmunoprecipitated subunits (molecular mass of 200 and 38 kDa) were consistently associated with the 80-kDa (90-92 kDa reduced) binding protein. The 38-kDa subunit was shown to be distinct from the 80-kDa subunit by proteolytic fragment analysis. Cross-linking of I-125-rIFN-gamma to monocytes yielded receptor-IFN-gamma complexes consistent with the existence of multiple subunits.	NIDR, CELLULAR IMMUNOL LAB, BETHESDA, MD 20892 USA; UNIFORMED SERV UNIV HLTH SCI, DEPT CHEM, BETHESDA, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Uniformed Services University of the Health Sciences - USA	FINBLOOM, DS (corresponding author), US FDA, CTR BIOL EVALUAT & RES, DIV CYTOKINE BIOL, 8800 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.							AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; AMES GFL, 1974, J BIOL CHEM, V249, P634; BONO MR, 1989, SOMAT CELL MOLEC GEN, V15, P513, DOI 10.1007/BF01534912; CALDERON J, 1988, P NATL ACAD SCI USA, V85, P4837, DOI 10.1073/pnas.85.13.4837; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; FINBLOOM DS, 1985, J IMMUNOL, V135, P300; FISCHER DG, 1988, J BIOL CHEM, V263, P2632; FISCHER T, 1990, J BIOL CHEM, V265, P1710; FOUNTOULAKIS M, 1989, J IMMUNOL, V143, P3266; GAROTTA G, 1990, J BIOL CHEM, V265, P6908; GRAY PW, 1989, P NATL ACAD SCI USA, V86, P8497, DOI 10.1073/pnas.86.21.8497; HERSHEY GKK, 1989, J BIOL CHEM, V264, P11981; JUNG V, 1988, SOMAT CELL MOLEC GEN, V14, P583, DOI 10.1007/BF01535312; JUNG V, 1990, J BIOL CHEM, V265, P1827; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; KLEINSCHMIDT WJ, 1982, J INTERFERON RES, V2, P291, DOI 10.1089/jir.1982.2.291; LEONARD WJ, 1990, ANN NY ACAD SCI, V594, P200; MAO C, 1989, J INTERFERON RES, V9, P659, DOI 10.1089/jir.1989.9.659; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; PACE JL, 1985, J IMMUNOL, V134, P977; PURI RK, 1986, J BIOL CHEM, V261, P5651; RASHIDBAIGI A, 1986, P NATL ACAD SCI USA, V83, P384, DOI 10.1073/pnas.83.2.384; ROBERTS WK, 1982, J INTERFERON RES, V2, P519, DOI 10.1089/jir.1982.2.519; SKOGLUND C, 1988, CLIN EXP IMMUNOL, V71, P428; TETSUYA T, 1989, CELL, V58, P573; WAHL LM, 1984, CELL IMMUNOL, V85, P373, DOI 10.1016/0008-8749(84)90251-X	26	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22545	22548						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1834673				2022-12-25	WOS:A1991GR56400076
J	KALABOKIS, VN; BOZZOLA, JJ; CASTELLANI, L; HARDWICKE, PMD				KALABOKIS, VN; BOZZOLA, JJ; CASTELLANI, L; HARDWICKE, PMD			A POSSIBLE ROLE FOR THE DIMER RIBBON STATE OF SCALLOP SARCOPLASMIC-RETICULUM - DIMMER RIBBONS ARE ASSOCIATED WITH STABILIZATION OF THE CA2+-FREE CA-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; MONOMERIC CA-2+-ATPASE; CALCIUM-TRANSPORT; REACTION CYCLE; CA-2+ RELEASE; MONO-VALENT; BINDING; MEMBRANE; PROTEIN; PUMP	The Ca-ATPase activity of membranous scallop sarcoplasmic reticulum was found to be unstable when the Ca2+-binding sites on the Ca-ATPase were unoccupied. The decay in activity could be slowed or halted by inclusion in the preincubation medium of Na+, K+, nucleotides, ethylene glycol, or high concentrations of choline chloride. Stabilization of the Ca2+-free Ca-ATPase by Na+ and K+ showed a markedly different concentration dependence to that seen with activation of the Ca2+-activated ATPase activity by the two ions. Examination in the electron microscope of scallop membranes negatively stained in the presence of EGTA under conditions where the enzyme had been stabilized against lack of Ca2+ always showed vesicles containing dimer ribbon structures, whereas unstabilized membranes did not show dimer ribbons. There was an association between the effectiveness of a medium in stabilizing the enzyme in the presence of EGTA and the extent and quality of the dimer arrays seen in the microscope. Comparison of the range of Ca2+ concentration over which the Ca2+-binding sites on the scallop Ca-ATPase titrated with the range over which the dimer ribbon structural state was lost indicated that the Ca2+-binding sites on the Ca-ATPase must be empty for dimer ribbon formation to occur. Previous studies (Franzini-Armstrong, C., Ferguson, D. G., Castellani, L., and Kenney, L. J. (1987) Ann. N. Y. Acad. Sci. 483, 44-56) have found that the Ca-ATPase molecules in scallop adductor muscle freeze-fractured after fixation under relaxing conditions are arranged in dimer ribbons. Thus, the association of stabilization of the Ca2+-free Ca-ATPase with the presence of dimer ribbons implies that one function of the dimer state may be to stabilize the scallop enzyme in situ, when the Ca2+ concentration in the sarcoplasm is low and the muscle is relaxed.	SO ILLINOIS UNIV, DEPT CHEM & BIOCHEM, CARBONDALE, IL 62901 USA; SO ILLINOIS UNIV, DEPT MED BIOCHEM, CARBONDALE, IL 62901 USA; SO ILLINOIS UNIV, CTR ELECTRON MICROSCOPY, CARBONDALE, IL 62901 USA; BRANDEIS UNIV, ROSENSTIEL BASIC MED SCI RES CTR, WALTHAM, MA 02254 USA	Southern Illinois University System; Southern Illinois University; Southern Illinois University System; Southern Illinois University; Southern Illinois University System; Southern Illinois University; Brandeis University				Castellani, Loriana/0000-0002-8519-3504				ANDERSEN JP, 1985, J BIOL CHEM, V260, P371; ARAKAWA T, 1982, BIOCHEMISTRY-US, V21, P6545, DOI 10.1021/bi00268a034; BUHLE EL, 1983, J ULTRA MOL STRUCT R, V85, P186, DOI 10.1016/S0022-5320(83)90106-5; CASTELLANI L, 1985, J MOL BIOL, V185, P579, DOI 10.1016/0022-2836(85)90073-7; CASTELLANI L, 1983, J CELL BIOL, V97, P557, DOI 10.1083/jcb.97.2.557; CASTELLANI L, 1989, J CELL BIOL, V108, P511, DOI 10.1083/jcb.108.2.511; CHANTLER PD, 1980, J MOL BIOL, V138, P473, DOI 10.1016/S0022-2836(80)80013-1; COAN C, 1986, J BIOL CHEM, V261, P394; CREIGHTON TE, 1984, PROTEINS STRUCTURES, P149; DUGGAN PF, 1970, J GEN PHYSIOL, V56, P147, DOI 10.1085/jgp.56.2.147; DUGGAN PF, 1977, J BIOL CHEM, V252, P1620; DUPONT Y, 1976, BIOCHEM BIOPH RES CO, V71, P544, DOI 10.1016/0006-291X(76)90821-4; DUX L, 1983, J BIOL CHEM, V258, P1896; DUX L, 1985, J BIOL CHEM, V260, P1730; FRANZINIARMSTRONG C, 1986, ANN NY ACAD SCI, V483, P44, DOI 10.1111/j.1749-6632.1986.tb34495.x; GARCIA AM, 1984, J GEN PHYSIOL, V83, P819, DOI 10.1085/jgp.83.6.819; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4667, DOI 10.1021/bi00519a023; HARDWICKE PMD, 1989, J MUSCLE RES CELL M, V10, P245, DOI 10.1007/BF01739814; HARDWICKE PMD, 1989, J MUSCLE RES CELL M, V10, P229, DOI 10.1007/BF01739813; HEEGAARD CW, 1990, J BIOL CHEM, V265, P12020; HILL TL, 1982, P NATL ACAD SCI-BIOL, V79, P3978, DOI 10.1073/pnas.79.13.3978; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; KALABOKIS V, 1988, J BIOL CHEM, V263, P15184; MARTIN DW, 1984, P NATL ACAD SCI-BIOL, V81, P6623, DOI 10.1073/pnas.81.21.6623; MARTONOSI AN, 1984, PHYSIOL REV, V64, P1240, DOI 10.1152/physrev.1984.64.4.1240; MCINTOSH DB, 1988, J BIOL CHEM, V263, P12220; MEDDA P, 1987, EUR J BIOCHEM, V165, P251, DOI 10.1111/j.1432-1033.1987.tb11435.x; MEISSNER G, 1976, J MEMBRANE BIOL, V30, P79, DOI 10.1007/BF01869661; MELANDER W, 1977, ARCH BIOCHEM BIOPHYS, V183, P200, DOI 10.1016/0003-9861(77)90434-9; MOUTIN MJ, 1991, J BIOL CHEM, V266, P5580; MYUNG J, 1991, FEBS LETT, V278, P35, DOI 10.1016/0014-5793(91)80077-G; NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/comjnl/7.4.308; PACE CN, 1988, BIOCHEMISTRY-US, V27, P3242, DOI 10.1021/bi00409a018; SCOFANO H, 1985, BIOCHIM BIOPHYS ACTA, V819, P93, DOI 10.1016/0005-2736(85)90199-3; SELINSKY BS, 1990, BIOCHEMISTRY-US, V29, P415, DOI 10.1021/bi00454a016; SHIGEKAWA M, 1985, J BIOL CHEM, V260, P1679; SQUIER TC, 1990, J BIOL CHEM, V265, P13713; SUELTER CH, 1970, SCIENCE, V168, P789, DOI 10.1126/science.168.3933.789; TAYLOR KA, 1986, J MOL BIOL, V187, P417, DOI 10.1016/0022-2836(86)90442-0; VERJOVSKIALMEIDA S, 1981, J BIOL CHEM, V256, P2662; WATANABE T, 1981, BIOCHEMISTRY-US, V20, P6617, DOI 10.1021/bi00526a015	41	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					22044	22050						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1834665				2022-12-25	WOS:A1991GP80400107
J	DAVIS, FB; DAVIS, PJ; LAWRENCE, WD; BLAS, SD				DAVIS, FB; DAVIS, PJ; LAWRENCE, WD; BLAS, SD			SPECIFIC INOSITOL PHOSPHATES INHIBIT BASAL AND CALMODULIN-STIMULATED CA2+-ATPASE ACTIVITY IN HUMAN ERYTHROCYTE-MEMBRANES INVITRO AND INHIBIT BINDING OF CALMODULIN TO MEMBRANES	FASEB JOURNAL			English	Article						INOSITOL TRISPHOSPHATE; HEPARIN; CALMODULIN BINDING	THYROID-HORMONE; CA-2+-ATPASE ACTIVITY; CA-2+ PUMP; 1,4,5-TRISPHOSPHATE; TRISPHOSPHATE; CALCIUM; BRAIN	D-Myo-inositol 1,4,5-trisphosphate (Ins[1,4-,5]P3) inhibits rat heart sarcolemmal Ca2+-ATPase activity (T. H. Kuo, Biochem. Biophys. Res. Commun. 152: 1111, 1988). We have studied the effect and mechanism of action of Ins(1,4,5)P3 and related inositol phosphates on human red cell membrane Ca2+-ATPase (EC 3.6.1.3) activity in vitro. At 10(-6) M, Ins(1,4,5)P3 and D-myo-inositol 4,5-bisphosphate (Ins[4,5]P2) inhibited human erythrocyte membrane Ca2+-ATPase activity in vitro by 42 and 31%, respectively. D-Myo-inositol 1,3,4,5-tetrakisphosphate, D-myo-inositol 1,4-bisphosphate, and D-myo-inositol 1-phosphate were not inhibitory. Enzyme inhibition by Ins(1,4,5)P3 was blocked by heparin. Exogenous purified calmodulin also stimulated red cell membrane Ca2+-ATPase activity; this stimulation was inhibited by Ins(1,4,5)P3. Ins(4,5)P2 and Ins(1,4,5)P3, but not Ins(1,4)P2, inhibited the binding of [I-125]calmodulin to red cell membranes. Thus, specific inositol phosphates reduce plasma membrane Ca2+-ATPase activity and enhancement of the latter in vitro by purified calmodulin. The mechanism of these effects may in part relate to inhibition by inositol phosphates of binding of calmodulin to erythrocyte membranes.	UNION UNIV, DEPT MED, ALBANY, NY 12208 USA; SUNY BUFFALO, SCH MED & BIOMED SCI, DEPT MED, BUFFALO, NY 14214 USA; SAMUEL S STRATTON VET AFFAIRS MED CTR, MED SERV, ALBANY, NY 12208 USA	Union College; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								AGRE P, 1983, J BIOL CHEM, V258, P6258; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BURGESS GM, 1984, BIOCHEM J, V224, P741, DOI 10.1042/bj2240741; CATT KJ, 1989, ANNU REV MED, V40, P487; CHARBONNEAU H, 1983, METHOD ENZYMOL, V102, P17; DAVIS FB, 1983, J CLIN INVEST, V71, P579, DOI 10.1172/JCI110803; DAVIS FB, 1990, J CLIN INVEST, V85, P1999, DOI 10.1172/JCI114664; DAVIS FB, 1987, BIOCHEM J, V248, P511, DOI 10.1042/bj2480511; DAVIS PJ, 1981, BIOCHEM BIOPH RES CO, V99, P1073, DOI 10.1016/0006-291X(81)90728-2; DEZIEL MR, 1989, ARCH BIOCHEM BIOPHYS, V274, P463, DOI 10.1016/0003-9861(89)90459-1; Fiske CH, 1925, J BIOL CHEM, V66, P375; FRASER CL, 1990, J CLIN INVEST, V86, P2169, DOI 10.1172/JCI114956; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P4354, DOI 10.1073/pnas.78.7.4354; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; KUO TH, 1988, BIOCHEM BIOPH RES CO, V152, P1111, DOI 10.1016/S0006-291X(88)80399-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJERUS PW, 1988, J BIOL CHEM, V263, P3051; MAYR GW, 1989, BIOCHEM J, V259, P463, DOI 10.1042/bj2590463; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; SCHARFF O, 1981, CELL CALCIUM, V2, P1, DOI 10.1016/0143-4160(81)90043-9; SMALLWOOD JI, 1988, J BIOL CHEM, V263, P2195; TAKAZAWA K, 1989, BIOCHEM J, V261, P1059; THIELECZEK R, 1989, J BIOL CHEM, V264, P7349; WARNICK PR, 1988, BIOCHEM PHARMACOL, V37, P2619, DOI 10.1016/0006-2952(88)90255-9; Weiss B, 1978, Adv Cyclic Nucleotide Res, V9, P285; WILLIAMSON JR, 1989, ANNU REV PHYSIOL, V51, P107, DOI 10.1146/annurev.ph.51.030189.000543; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	29	20	20	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1991	5	14					2992	2995		10.1096/fasebj.5.14.1836436	http://dx.doi.org/10.1096/fasebj.5.14.1836436			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GP269	1836436				2022-12-25	WOS:A1991GP26900016
J	KHEWGOODALL, Y; GRILLO, M; GETCHELL, ML; DANHO, W; GETCHELL, TV; MARGOLIS, FL				KHEWGOODALL, Y; GRILLO, M; GETCHELL, ML; DANHO, W; GETCHELL, TV; MARGOLIS, FL			VOMEROMODULIN, A PUTATIVE PHEROMONE TRANSPORTER - CLONING, CHARACTERIZATION, AND CELLULAR-LOCALIZATION OF A NOVEL GLYCOPROTEIN OF LATERAL NASAL GLAND	FASEB JOURNAL			English	Article						OLFACTION; SECRETION; PERIRECEPTOR EVENTS; PHEROMONE; LATERAL NASAL GLAND; VOMEROMODULIN	ODORANT-BINDING PROTEIN; OLFACTORY MARKER PROTEIN; N-GLYCOSIDASE-F; CHEMOSENSORY PROCESSES; VOMERONASAL ORGAN; NERVOUS-SYSTEM; MOUSE; EVENTS; MUCOSA; CDNA	Vomeromodulin, a novel glycoprotein of lateral nasal gland, has been cloned by differential hybridization from nasal/olfactory tissue. The 2.2-kb mRNA directs the in vitro synthesis of a 60-kDa primary translation product in reticulocyte lysates. Differential sensitivity to endoglycosidases indicates that vomeromodulin is posttranslationally modified in vivo by N-glycosylation to form a 70-kDa glycoprotein of the complex type. Immunocytochemical localization with two different antipeptide antisera demonstrates that vomeromodulin is abundant in the lateral nasal glands and is also present in the posterior septal and vomeronasal glands. Most striking is the observation that it is highly concentrated in the mucus of the vomeronasal organ of Jacobson but is not detectable in the mucus of the main olfactory neuroepithelium. Evaluation of mRNA and protein distribution by Northern and Western analyses, respectively, indicates that vomeromodulin is absent from 15 other tissues. The glandular and mucosal distribution of this glycoprotein implies a transport function that may be related to the mechanisms by which pheromones of low volatility gain access to their receptors in the vomeronasal organ. These observations support our hypothesis that vomeromodulin participates in perireceptor events that facilitate the process of pheromone access and detection.	ROCHE INST MOLEC BIOL, ROCHE RES CTR, DEPT NEUROSCI, NUTLEY, NJ 07110 USA; UNIV KENTUCKY, COLL MED, DEPT SURG, DIV OTOLARYNGOL HEAD & NECK SURG, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, COLL MED, SANDERS BROWN CTR AGING, LEXINGTON, KY 40536 USA; HOFFMANN LA ROCHE INC, PEPTIDE RES DEPT, NUTLEY, NJ 07110 USA; UNIV KENTUCKY, COLL MED, DEPT PHYSIOL & BIOPHYS, LEXINGTON, KY 40536 USA; INST MED & VET SCI, HANSON CTR CANC RES, ADELAIDE, SA 5000, AUSTRALIA	Roche Holding; University of Kentucky; University of Kentucky; Roche Holding; University of Kentucky; Institute Medical & Veterinary Science Australia					NIDCD NIH HHS [DC-00159] Funding Source: Medline	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ADAMS DR, 1981, J ANAT, V132, P29; ANHOLT RRH, 1990, BIOCHEMISTRY-US, V29, P4049, DOI 10.1021/bi00469a004; BAKER H, 1989, J COMP NEUROL, V285, P246, DOI 10.1002/cne.902850207; BIFFO S, 1990, EUR J NEUROSCI, V2, P487, DOI 10.1111/j.1460-9568.1990.tb00440.x; BIFFO S, 1991, MOL BRAIN RES, V10, P13, DOI 10.1016/0169-328X(91)90051-X; BIGNETTI E, 1985, EUR J BIOCHEM, V149, P227, DOI 10.1111/j.1432-1033.1985.tb08916.x; BOJSENMOLLER F, 1964, ANAT REC, V150, P11, DOI 10.1002/ar.1091500103; CARR WES, 1990, CHEM SENSES, V15, P181, DOI 10.1093/chemse/15.2.181; CARR WES, 1990, TRENDS NEUROSCI, V13, P212, DOI 10.1016/0166-2236(90)90162-4; CARRASCO N, 1984, P NATL ACAD SCI-BIOL, V81, P4672, DOI 10.1073/pnas.81.15.4672; COBIANCHI F, 1987, METHOD ENZYMOL, V152, P94; CUSCHIERI A, 1974, HISTOCHEM J, V6, P543, DOI 10.1007/BF01003270; Dahl A.R., 1988, MOL NEUROBIOLGY OLFA, P51, DOI [10.1016/j.semcdb.2012.09.001, DOI 10.1016/J.SEMCDB.2012.09.001]; DANCIGER E, 1989, P NATL ACAD SCI USA, V86, P8565, DOI 10.1073/pnas.86.21.8565; DELONG RE, 1987, CHEM SENSES, V12, P3, DOI 10.1093/chemse/12.1.3; DING X, 1988, BIOCHEMISTRY-US, V27, P8330, DOI 10.1021/bi00422a007; EHRLICH ME, 1990, MOL BRAIN RES, V7, P115, DOI 10.1016/0169-328X(90)90088-U; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; FOSTER JD, 1991, ANAT REC, V229, P525, DOI 10.1002/ar.1092290414; FREEZE HH, 1986, BIOCHEM BIOPH RES CO, V140, P967, DOI 10.1016/0006-291X(86)90730-8; GETCHELL TV, 1990, CHEM SENSES, V15, P223, DOI 10.1093/chemse/15.2.223; GETCHELL TV, 1984, PROG NEUROBIOL, V23, P317, DOI 10.1016/0301-0082(84)90008-X; GUBLER U, 1987, GUIDE MOL CLONING TE, P325; HEMPSTEAD JL, 1983, CHEM SENSES, V8, P107, DOI 10.1093/chemse/8.1.107; HORNUNG DE, 1987, BRAIN RES, V413, P147, DOI 10.1016/0006-8993(87)90163-6; KRAEVSKAYA MA, 1987, SENSORNYE SISTEMY, V1, P127; LANCET D, 1988, COLD SPRING HARB SYM, V53, P343, DOI 10.1101/SQB.1988.053.01.041; LAZARD D, 1990, BIOCHEMISTRY-US, V29, P7433, DOI 10.1021/bi00484a012; LAZARD D, 1991, NATURE, V349, P790, DOI 10.1038/349790a0; LEE KH, 1987, SCIENCE, V235, P1053, DOI 10.1126/science.3493528; LERNER MR, 1990, CHEM SENSES, V15, P191, DOI 10.1093/chemse/15.2.191; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MARGOLIS FL, 1988, MOL NEUROBIOLOGY OLF, P237; MENDOZA AS, 1986, CHEM SENSES, V11, P541, DOI 10.1093/chemse/11.4.541; MEREDITH M, 1979, J PHYSIOL-LONDON, V286, P301, DOI 10.1113/jphysiol.1979.sp012620; MEREDITH M, 1988, CHEM SENSES, V13, P487, DOI 10.1093/chemse/13.4.487; Meredith M, 1980, CHEM SIGNALS VERTEBR, P303; MORGAN JI, 1988, MOL NEUROBIOLOGY OLF, P269; NAKASHIMA T, 1984, ARCH OTOLARYNGOL, V110, P641; NEF P, 1989, J BIOL CHEM, V264, P6780, DOI 10.1016/S0021-9258(18)83497-4; PELOSI P, 1990, CHEM SENSES, V15, P205, DOI 10.1093/chemse/15.2.205; PEVSNER J, 1990, CHEM SENSES, V15, P217, DOI 10.1093/chemse/15.2.217; PEVSNER J, 1988, P NATL ACAD SCI USA, V85, P2383, DOI 10.1073/pnas.85.7.2383; RANDALL HW, 1987, AM J ANAT, V179, P10, DOI 10.1002/aja.1001790103; REED CJ, 1988, BIOCHEM J, V253, P569, DOI 10.1042/bj2530569; ROGERS KE, 1987, P NATL ACAD SCI USA, V84, P1704, DOI 10.1073/pnas.84.6.1704; SANGER F, 1978, FEBS LETT, V87, P107, DOI 10.1016/0014-5793(78)80145-8; SINGER AG, 1987, ANN NY ACAD SCI, V519, P287; SINGER AG, 1990, CHEM SENSES, V15, P199, DOI 10.1093/chemse/15.2.199; SNYDER DA, 1991, IN PRESS BIKOCHEMIST; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; VIDIC B, 1971, AM J ANAT, V132, P491, DOI 10.1002/aja.1001320407; VOGT RG, 1988, J BIOL CHEM, V263, P3952; WIRSIG CR, 1986, BRAIN RES, V385, P10, DOI 10.1016/0006-8993(86)91541-6; WYSOCKI CJ, 1980, SCIENCE, V207, P781, DOI 10.1126/science.7352288; WYSOCKI CJ, 1979, NEUROSCI BIOBEHAV R, V3, P301, DOI 10.1016/0149-7634(79)90015-0; WYSOCKI CJ, 1979, NEUROBIOLOGY TASTE S, P125	57	51	52	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1991	5	14					2976	2982		10.1096/fasebj.5.14.1752363	http://dx.doi.org/10.1096/fasebj.5.14.1752363			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GP269	1752363				2022-12-25	WOS:A1991GP26900014
J	WEISSBORN, AC; RUMLEY, MK; KENNEDY, EP				WEISSBORN, AC; RUMLEY, MK; KENNEDY, EP			BIOSYNTHESIS OF MEMBRANE-DERIVED OLIGOSACCHARIDES - MEMBRANE-BOUND GLUCOSYLTRANSFERASE SYSTEM FROM ESCHERICHIA-COLI REQUIRES POLYPRENYL PHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGROBACTERIUM-TUMEFACIENS; O9 ANTIGEN; MECHANISM; ACCEPTOR; MANNOSE; GLUCAN	The periplasmic glucans of Gram-negative bacteria, including the membrane-derived oligosaccharides (MDO) of Escherichia coli and the cyclic glucans of the Rhizobiaceae, are now recognized to be a family of closely related substances with important functions in osmotic adaptation and cell signaling. The synthesis of the beta-1,2-glucan backbone of MDO is catalyzed by a membrane-bound glucosyltransferase system previously shown to require UDP-glucose and (surprisingly) acyl carrier protein (Therisod, H., Weissborn, A. C., and Kennedy, E. P. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 7236-7240). In the present study, no glucan intermediates bound to acyl carrier protein or to UDP could detected. The enzyme system, however, was found to be strongly inhibited by bacitracin and by amphomycin. Because the two antibiotics function by forming specific complexes with polyprenyl phosphates, their inhibitory effect suggests a prenol requirement for MDO biosynthesis. Furthermore, the activity of the glucosyltransferase was greatly stimulated by the addition of polyprenyl phosphates such as decaprenyl-P and dihydroheptaprenyl-P, but not by farnesyl-P. The same membrane preparations carry out the synthesis of polyprenyl-P-glucose, which is also stimulated by added polyprenyl-P, including farnesyl-P, the most active of those tested. Pulse chase experiments, however, indicate that the endogenous pool of polyprenyl-P-glucose cannot be an obligate intermediate in the MDO glucosyltransferase system.			WEISSBORN, AC (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115, USA.				NIGMS NIH HHS [GM22057, GM19822] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022057, R01GM019822, R37GM019822] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEE DK, 1989, J BIOL CHEM, V264, P2024; BATLEY M, 1987, BIOCHIM BIOPHYS ACTA, V901, P119, DOI 10.1016/0005-2736(87)90263-X; CLARK AF, 1973, FEBS LETT, V32, P84, DOI 10.1016/0014-5793(73)80743-4; DEDONDER RA, 1964, BIOCHIM BIOPHYS ACTA, V90, P239, DOI 10.1016/0304-4165(64)90187-4; DYLAN T, 1990, J BACTERIOL, V172, P1409, DOI 10.1128/jb.172.3.1409-1417.1990; DYLAN T, 1986, P NATL ACAD SCI USA, V83, P4403, DOI 10.1073/pnas.83.12.4403; ELBEIN AD, 1980, MECHANISMS SACCHARID, P1; FIELDER W, 1988, J BIOL CHEM, V263, P14684; GEREMIA RA, 1987, J BACTERIOL, V169, P880, DOI 10.1128/jb.169.2.880-884.1987; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; IELPI L, 1990, J BIOL CHEM, V265, P2843; JANN K, 1982, EUR J BIOCHEM, V127, P157, DOI 10.1111/j.1432-1033.1982.tb06850.x; KALINCHUK NA, 1985, BIOORG KHIM+, V11, P219; KENNEDY EP, 1982, P NATL ACAD SCI-BIOL, V79, P1092, DOI 10.1073/pnas.79.4.1092; KENNEDY EP, 1987, ESCHERICHIA COLI SAL, V1, P672; MCSWEENEY GP, 1965, J CHROMATOGR, V17, P183, DOI 10.1016/S0021-9673(00)99850-9; MILLER KJ, 1987, BIOCHIM BIOPHYS ACTA, V901, P112, DOI 10.1016/0005-2736(87)90262-8; PARK JT, 1987, ESCHERICHIA COLI SAL, V1, P663; POPJAK G, 1962, J BIOL CHEM, V237, P56; STORM DR, 1974, ANN NY ACAD SCI, V235, P387, DOI 10.1111/j.1749-6632.1974.tb43278.x; THERISOD H, 1986, P NATL ACAD SCI USA, V83, P7236, DOI 10.1073/pnas.83.19.7236; VINOPAL RT, 1975, J BACTERIOL, V122, P1172, DOI 10.1128/JB.122.3.1172-1174.1975; WEISGERBER C, 1982, EUR J BIOCHEM, V127, P165, DOI 10.1111/j.1432-1033.1982.tb06851.x; WEISSBORN AC, 1984, J BIOL CHEM, V259, P2644; ZORREGUIETA A, 1985, BIOCHEM BIOPH RES CO, V126, P352, DOI 10.1016/0006-291X(85)90613-8	25	18	18	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8062	8067						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1827116				2022-12-25	WOS:A1991FK44100019
J	BRAITHWAITE, AW; BLAIR, GE; NELSON, CC; MCGOVERN, J; BELLETT, AJD				BRAITHWAITE, AW; BLAIR, GE; NELSON, CC; MCGOVERN, J; BELLETT, AJD			ADENOVIRUS E1B-58 KD ANTIGEN BINDS TO P53 DURING INFECTION OF RODENT CELLS - EVIDENCE FOR AN N-TERMINAL BINDING-SITE ON P53	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; T-ANTIGEN; MONOCLONAL-ANTIBODIES; TRANSFORMED-CELLS; SV40-TRANSFORMED CELLS; GENE-PRODUCTS; PROTEINS BIND; ONCOGENE; DNA; MOUSE	We show using mild extraction procedures that the p53 proto-oncogene forms a complex with adenovirus 5 E1b-58 kD during infection. These complexes are detected as coimmunoprecipitates from radiolabeled extracts of adenovirus infected cells on SDS-PAGE. Furthermore, adenovirus mutants with defects in E1b-58 kD fail to form complexes, whereas mutants in other early region genes still show evidence of complex. Using a panel of monoclonal antibodies to mouse p53, we show that antibodies reacting with N-terminal epitopes on p53, displace E1b-58 KD. This result suggests that E1b-58 kD binds to an N-terminal region of mouse p53. In addition, in a transient transfection assay in monkey COS cells, we show that an N-terminal deletion mutant of mouse p53 does not bind to E1b-58 kD but wild-type mouse p53 does bind. This result again suggests that E1b-58 kD binds an N-terminal determinant on p53.	UNIV LEEDS,DEPT BIOCHEM,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,VICTORIA V8W 2Y2,BC,CANADA	University of Leeds; University of Victoria	BRAITHWAITE, AW (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL,CANBERRA,ACT 2601,AUSTRALIA.		Blair, George Eric/A-5906-2008	Blair, George Eric/0000-0003-0440-1795				BABISS LE, 1984, J VIROL, V50, P2552; BELLETT AJD, 1985, MOL CELL BIOL, V5, P1933, DOI 10.1128/MCB.5.8.1933; BRAITHWAITE A, 1990, VIROLOGY, V177, P595, DOI 10.1016/0042-6822(90)90525-V; BRAITHWAITE AW, 1989, J VIROL, V63, P1792, DOI 10.1128/JVI.63.4.1792-1799.1989; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BRIDGE E, 1989, J VIROL, V63, P631, DOI 10.1128/JVI.63.2.631-638.1989; BURGER C, 1983, VIROLOGY, V126, P19, DOI 10.1016/0042-6822(83)90459-2; CHALLBERG SS, 1981, VIROLOGY, V114, P193; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; DUTHU A, 1985, VIROLOGY, V147, P275, DOI 10.1016/0042-6822(85)90130-8; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GREAVES R, 1988, THESIS U LONDON; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, ONCOGENE HDB, P403; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; REICH NC, 1984, NATURE, V308, P188; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; Russell W C, 1967, J Gen Virol, V1, P495, DOI 10.1099/0022-1317-1-4-495; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; THOMAS R, 1983, VIROLOGY, V131, P502, DOI 10.1016/0042-6822(83)90516-0; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; ZHANG XL, 1990, VIROLOGY, V180, P199	45	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					781	787						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1828873				2022-12-25	WOS:A1991GT82500014
J	CARATTOLI, A; ROMANO, N; BALLARIO, P; MORELLI, G; MACINO, G				CARATTOLI, A; ROMANO, N; BALLARIO, P; MORELLI, G; MACINO, G			THE NEUROSPORA-CRASSA CAROTENOID BIOSYNTHETIC GENE (ALBINO-3) REVEALS HIGHLY CONSERVED REGIONS AMONG PRENYLTRANSFERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; NUCLEOTIDE-SEQUENCE; RIBONUCLEIC-ACID; EXPRESSION; PURIFICATION; PROTEIN; ENZYME; RNA; DNA	In the filamentous fungus Neurospora crassa the biosynthesis of carotenoids is regulated by blue light. Here we report the characterization of the albino-3 (al-3) gene of N. crassa, which encodes the carotenoid biosynthetic enzyme geranylgeranyl-pyrophosphate synthetase. This is the first geranylgeranyl-pyrophosphate synthetase gene isolated. Nucleotide sequence comparison of al-3 genomic and cDNA clones revealed that the al-3 gene is not interrupted by introns. Transcription of the al-3 gene has been examined in dark-grown and light-induced mycelia. The analysis revealed that the al-3 gene is not expressed in the dark and that its transcription is induced by blue light (Nelson, M. A., Morelli, G., Carattoli, A., Romano, N., and Macino, G. (1989) Mol. Cell. Biol. 9, 1271-1276). The al-3 gene encodes a polypeptide of 428 amino acids. Comparison of the deduced amino acid sequence of al-3 with the sequences of prenyltransferases of other species, from bacteria to humans, showed three highly conserved homologous regions. These homologous regions may be involved in the formation of the catalytic site of the prenyltransferases.	UNIV ROME,POLICLIN UMBERTO 1,DIPARTIMENTO BIOPATOL UMANA,SEZ BIOL CELLULARE,I-00161 ROME,ITALY; IST NAZL NUTR,UNITA NUTR SPERIMENTALE,I-00178 ROME,ITALY; UNIV ROME LA SAPIENZA,CTR STUDIO ACIDI NUCL,DIPARTIMENTO GENET & BIOL MOLECOL,I-00185 ROME,ITALY	Sapienza University Rome; University Hospital Sapienza Rome; Consiglio per la Ricerca in Agricoltura e L'analisi Dell'economia Agraria (CREA); Sapienza University Rome			Morelli, Giorgio/P-3334-2019; Carattoli, Alessandra/A-1324-2009; Morelli, Giorgio/A-5559-2016	Morelli, Giorgio/0000-0002-8994-4838; Carattoli, Alessandra/0000-0002-6120-6526; Morelli, Giorgio/0000-0002-8994-4838				ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; ANDERSON MS, 1989, J BIOL CHEM, V264, P19176; ANDERSON MS, 1989, J BIOL CHEM, V264, P19169; ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BALLANCE DJ, 1986, YEAST, V2, P229, DOI 10.1002/yea.320020404; BARNARD GF, 1980, BIOCHIM BIOPHYS ACTA, V617, P169, DOI 10.1016/0005-2760(80)90160-5; BREMS DN, 1981, BIOCHEMISTRY-US, V20, P3711, DOI 10.1021/bi00516a007; BRINKHAUS FL, 1986, ARCH BIOCHEM BIOPHYS, V266, P607; BROWN MS, 1980, J LIPID RES, V21, P505; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; COBIANCHI F, 1987, METHOD ENZYMOL, V152, P94; DAVIS RH, 1970, BIOCHEMISTRY-US, V18, P5294; DEFABO EC, 1976, PLANT PHYSIOL, V57, P440, DOI 10.1104/pp.57.3.440; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOGBO O, 1987, BIOCHIM BIOPHYS ACTA, V920, P140, DOI 10.1016/0005-2760(87)90253-0; DOGBO O, 1988, P NATL ACAD SCI USA, V85, P7054, DOI 10.1073/pnas.85.19.7054; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDIE AH, 1973, BIOCHEM GENET, V10, P275, DOI 10.1007/BF00485705; Goodwin T.W, 1980, BIOCH CAROTENOIDS, V1; HARDING RW, 1980, ANNU REV PLANT PHYS, V31, P217, DOI 10.1146/annurev.pp.31.060180.001245; HARDING RW, 1981, PLANT PHYSIOL, V68, P745, DOI 10.1104/pp.68.3.745; KING HL, 1977, BIOCHEMISTRY-US, V16, P3815, DOI 10.1021/bi00636a015; KUIPER MTR, 1988, J BIOL CHEM, V263, P2840; KUSHWAHA SC, 1978, LIPIDS, V13, P352, DOI 10.1007/BF02533727; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEGERTON TL, 1985, GENE, V39, P129, DOI 10.1016/0378-1119(85)90306-3; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Maniatis T., 1982, MOL CLONING; NAJARIAN D, 1987, MOL CELL BIOL, V7, P185, DOI 10.1128/MCB.7.1.185; NELSON MA, 1989, MOL CELL BIOL, V9, P1271, DOI 10.1128/MCB.9.3.1271; ORBACH MJ, 1986, MOL CELL BIOL, V6, P2452, DOI 10.1128/MCB.6.7.2452; POWELL GK, 1986, NUCLEIC ACIDS RES, V14, P2555, DOI 10.1093/nar/14.6.2555; RIORDAN JF, 1977, SCIENCE, V195, P884, DOI 10.1126/science.190679; ROBERTS AN, 1989, NUCLEIC ACIDS RES, V17, P197, DOI 10.1093/nar/17.1.197; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHWEIZER M, 1981, P NATL ACAD SCI-BIOL, V78, P5086, DOI 10.1073/pnas.78.8.5086; SHEARES BT, 1989, BIOCHEMISTRY-US, V28, P8129, DOI 10.1021/bi00446a025; VOGEL HJ, 1964, AM NAT, V98, P435, DOI 10.1086/282338; XIA ZG, 1990, J BIOL CHEM, V265, P6517	42	105	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5854	5859						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1826006				2022-12-25	WOS:A1991FD37000078
J	JINDAL, HK; CHANEY, WG; ANDERSON, CW; DAVIS, RG; VISHWANATHA, JK				JINDAL, HK; CHANEY, WG; ANDERSON, CW; DAVIS, RG; VISHWANATHA, JK			THE PROTEIN-TYROSINE KINASE SUBSTRATE, CALPACTIN-I HEAVY-CHAIN (P36), IS PART OF THE PRIMER RECOGNITION PROTEIN COMPLEX THAT INTERACTS WITH DNA POLYMERASE-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR-KINASE; DEPENDENT 35-KILODALTON SUBSTRATE; ROUS-SARCOMA VIRUS; REPLICATION INVITRO; PHOSPHOLIPID-BINDING; GLYCOLYTIC-ENZYMES; LIPOCORTIN-I; CELLS; CALCIUM; FORM	Primer recognition proteins (PRP) stimulate the activity of DNA polymerase-alpha on DNA substrates with long single-stranded template containing few primers. Purified PRP from HeLa cells and human placenta are composed of two subunits of 36,000 (PRP 1) and 41,000 (PRP 2) daltons. By amino acid sequence homology, we have identified PRP 2 as the glycolytic enzyme 3-phosphoglycerate kinase. Here we present data that establishes PRP 1 to be the protein-tyrosine kinase substrate, calpactin I heavy chain. Amino acid sequence analysis of six tryptic peptides of PRP 1 followed by homology search in a protein sequence data base revealed 100% identity of all six peptides with the deduced amino acid sequence of human calpactin I heavy chain. The activities of PRP and calpactin I coelute on gel filtration columns, and a high correlation of PRP and calpactin I activities was seen at different stages of purification. A rabbit polyclonal anti-chicken calpactin I antibody was shown to cross-react with PRP 1 polypeptide at various stages of PRP purification, and the homogeneous preparation of PRP exhibits 3-phosphoglycerate kinase (PRP 2) and calpactin I (PRP 1) activities. PRP activity is neutralized by a mouse monoclonal anti-calpactin II antibody although having no effect on the polymerase-alpha activity itself. Calpactin II has a 50% amino acid sequence homology with calpactin I. However, PRP 1 is not calpactin II as shown by lack of cross-reaction to a monoclonal anti-calpactin II antibody on Western blots. Calpactin I and 3-phosphoglycerate kinase, purified independently, cannot be efficiently reconstituted into the PRP complex, indicating that their association in the PRP complex involves specific protein-protein interactions that remain to be elucidated. The biochemical and immunological data presented here revealing the identity of PRP 1 as calpactin I provide evidence for one physiological role of calpactin I in the cell.	UNIV NEBRASKA,MED CTR,DEPT BIOCHEM,600 S 42ND ST,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center				Vishwanatha, Jamboor/0000-0002-0266-6020				ARRIGO AP, 1983, EMBO J, V2, P309, DOI 10.1002/j.1460-2075.1983.tb01424.x; BARIL E, 1977, NUCLEIC ACIDS RES, V4, P2641, DOI 10.1093/nar/4.8.2641; COOPER JA, 1983, NATURE, V302, P218, DOI 10.1038/302218a0; COOPER JA, 1983, J BIOL CHEM, V258, P1108; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; DE BK, 1986, J BIOL CHEM, V261, P3784; DOWNEY KM, 1988, CANCER CELL, V6, P1211; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FAIRMAN MP, 1988, CANCER CELL, V6, P143; FAVA RA, 1984, J BIOL CHEM, V259, P2636; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; GLENNEY J, 1986, P NATL ACAD SCI USA, V83, P4258, DOI 10.1073/pnas.83.12.4258; GOULD KL, 1986, MOL CELL BIOL, V6, P2738, DOI 10.1128/MCB.6.7.2738; HAIGLER HT, 1987, J BIOL CHEM, V262, P6921; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1984, CANCER CELL, V2, P61; ISACKE CM, 1989, MOL CELL BIOL, V9, P232, DOI 10.1128/MCB.9.1.232; JINDAL HK, 1990, J BIOL CHEM, V265, P6540; JINDAL HK, 1990, BIOCHEMISTRY-US, V29, P4767, DOI 10.1021/bi00472a004; KEUTZER JC, 1990, EXP CELL RES, V188, P153, DOI 10.1016/0014-4827(90)90291-H; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KORNBERG A, 1988, J BIOL CHEM, V263, P1; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MURAKAMI Y, 1986, P NATL ACAD SCI USA, V83, P2869, DOI 10.1073/pnas.83.9.2869; PEPINSKY RB, 1988, J BIOL CHEM, V263, P10799; PEPINSKY RB, 1990, FEBS LETT, V261, P247, DOI 10.1016/0014-5793(90)80564-Y; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRITCHARD CG, 1983, J BIOL CHEM, V258, P9801; SIMON M, 1987, EXP CELL RES, V169, P419, DOI 10.1016/0014-4827(87)90202-3; SIMON M, 1989, BIOCHEM CELL BIOL, V67, P740, DOI 10.1139/o89-111; SO AG, 1988, BIOCHEMISTRY-US, V27, P4591, DOI 10.1021/bi00413a001; STONE KL, 1989, TECHNIQUES PROTEIN C, P377; SUDHOF TC, 1988, P NATL ACAD SCI USA, V85, P664, DOI 10.1073/pnas.85.3.664; SYLVIA V, 1988, CELL, V54, P651, DOI 10.1016/S0092-8674(88)80009-6; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; VISHWANATHA JK, 1986, J BIOL CHEM, V261, P6619; WALLNER BP, 1986, NATURE, V320, P77, DOI 10.1038/320077a0; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; YUEN SW, 1989, BIOTECHNIQUES, V7, P74	44	91	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					5169	5176						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1825830				2022-12-25	WOS:A1991FC21700073
J	ZHAO, X; SINGH, B; BATTEN, BE				ZHAO, X; SINGH, B; BATTEN, BE			THE ROLE OF C-MOS PROTO-ONCOPROTEIN IN MAMMALIAN MEIOTIC MATURATION	ONCOGENE			English	Article							KINASE-ACTIVITY; DEVELOPMENTAL REGULATION; OOCYTE MATURATION; ONCOGENE PRODUCT; MOUSE-TISSUES; GERM-CELLS; V-MOS; EXPRESSION; EGGS; TRANSCRIPTS	The developmentally regulated expression of c-mos oncogene has led to the speculation that this gene may be involved in gametogenesis and early development. To directly test this possibility, we have used an electric field mediated transfer method to introduce an antibody against the c-mos gene product into living immature mouse oocytes. Control oocytes exposed to the electric field without antibody, non-immune IgG, or c-mos antibody pre-absorbed with the mos peptide underwent normal germinal vesicle breakdown (GVBD) (90%) and formed a polar body by 8 h. Oocytes transferred with antibody against c-mos product underwent GVBD, and chromosome condensation as judged by Hoechst 33258 staining. However, antibody transferred oocytes did not form a polar body. Confocal fluorescence microscopy using antibodies against tubulin demonstrated that 90% of the oocytes that received antibody against c-mos did not assemble a meiotic spindle. In a few instances an abnormal spindle-like structure did form. Electron microscopy confirmed that the nuclear envelope disassembled and revealed many microtubules in a disorganized manner. Western blot analysis showed the presence of p39c-mos in mouse mature oocytes, spermatocytes and granulosa cells. These results suggest a role for c-mos in regulating the assembly and/or function of the spindle during meiotic division in murine.	OHIO STATE UNIV,DEPT ANAT,COLUMBUS,OH 43210; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030	Ohio State University; University of Texas System; UTMD Anderson Cancer Center								BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; CYERT MS, 1988, CELL, V53, P185, DOI 10.1016/0092-8674(88)90380-7; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GARD DL, 1987, J CELL BIOL, V105, P2203, DOI 10.1083/jcb.105.5.2203; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; HASHIMOTO N, 1988, DEV BIOL, V126, P242, DOI 10.1016/0012-1606(88)90135-2; HERZOG NK, 1989, ONCOGENE, V4, P1307; HERZOG NK, 1988, ONCOGENE, V3, P225; HOGAN B, 1986, MANIPULATING MANIPUL; KESHET E, 1988, ONCOGENE, V2, P235; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MINSHULL J, 1989, VIROLOGY, V56, P947; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; MUTTER GL, 1988, EMBO J, V7, P683, DOI 10.1002/j.1460-2075.1988.tb02863.x; OGISO Y, 1986, BIOCHEM BIOPH RES CO, V140, P477, DOI 10.1016/0006-291X(86)90757-6; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHOLEY J M, 1985, Journal of Cell Biology, V101, p31A; SETH A, 1987, P NATL ACAD SCI USA, V84, P3560, DOI 10.1073/pnas.84.11.3560; SINGH B, 1986, VIROLOGY, V152, P502, DOI 10.1016/0042-6822(86)90156-X; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; Zhao X., 1989, TECHNIQUES J METHODS, V1, P37; ZHAO X, 1990, IN PRESS ONCOGENE	38	49	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					43	49						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1825139				2022-12-25	WOS:A1991EY03900006
J	BOHREN, KM; PAGE, JL; SHANKAR, R; HENRY, SP; GABBAY, KH				BOHREN, KM; PAGE, JL; SHANKAR, R; HENRY, SP; GABBAY, KH			EXPRESSION OF HUMAN ALDOSE AND ALDEHYDE REDUCTASES - SITE-DIRECTED MUTAGENESIS OF A CRITICAL LYSINE-262	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEXONATE DEHYDROGENASE; DIABETIC NEUROPATHY; INHIBITION; BRAIN; PURIFICATION; SORBINIL; COMPLICATIONS; ALRESTATIN; CLONING; LIVER	Human aldose reductase (EC 1.1.1.21) and aldehyde reductase (EC 1.1.1.2) are implicated in the development of diabetic complications by a variety of mechanisms, and a number of drugs to inhibit these enzymes have been proposed for the therapy and prevention of these complications. To probe the structure and function of these two enzymes, we used site-directed mutagenesis in the cDNAs of both enzymes to replace lysine 262 with methionine. Wild-type and mutant enzymes were overexpressed in Escherichia coli and purified by anion exchange and affinity chromatography. N-terminal sequence analysis, Western blots, and kinetic studies confirmed the identity of the recombinant wild-type enzymes with the native human placental and liver enzymes. Recombinant aldose reductase (hAR) and aldehyde reductase (hGR) have apparent kinetic constants virtually identical to their respective native enzymes. The mutant aldose reductase (hAR(K262 > M)) shows a 66-fold increase in K(m) for NADPH with respect to the wild type (1.9 +/- 0.4-mu-m versus 125 +/- 14-mu-M), whereas the K(m) for DL-glyceraldehyde increased 35-fold (20 +/- 2 versus 693 +/- 41 mu-M). The same constants for the mutant aldehyde reductase (hGR(K262 > M)) increased 97- and 86-fold, respectively (from 2.0 +/- 0.4 to 194 +/- 16-mu-M and from 1.6 +/- 0.4 to 137 +/- 3 mM). These results indicate that lysine 262 in aldose reductase and aldehyde reductase is crucial to their catalytic activity by affecting co-factor binding.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine	BOHREN, KM (corresponding author), BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030, USA.			Bohren, Kurt/0000-0002-3183-4118	NIDDK NIH HHS [DK-39044] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039044] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BOSRON WF, 1972, J BIOL CHEM, V247, P4480; DONS RF, 1976, BIOCHIM BIOPHYS ACTA, V452, P1, DOI 10.1016/0005-2744(76)90053-X; DOUGHTY CC, 1982, ENZYMOLOGY CARBONYL, P223; Flynn T G, 1989, Prog Clin Biol Res, V290, P251; GABBAY KH, 1979, METABOLISM, V28, P471, DOI 10.1016/0026-0495(79)90059-3; GABBAY KH, 1973, NEW ENGL J MED, V288, P831, DOI 10.1056/NEJM197304192881609; GRUNDMANN U, 1990, DNA CELL BIOL, V9, P149, DOI 10.1089/dna.1990.9.149; HAYMAN S, 1965, J BIOL CHEM, V240, P877; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOFFMAN PL, 1980, J NEUROCHEM, V35, P354, DOI 10.1111/j.1471-4159.1980.tb06272.x; JUDZEWITSCH RG, 1983, NEW ENGL J MED, V308, P119, DOI 10.1056/NEJM198301203080302; KADOR PF, 1988, MED RES REV, V8, P325, DOI 10.1002/med.2610080302; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MARTYN CN, 1987, DIABETES, V36, P987, DOI 10.2337/diabetes.36.9.987; MASSON EA, 1990, DRUGS, V39, P190, DOI 10.2165/00003495-199039020-00003; MORJANA NA, 1989, J BIOL CHEM, V264, P2912; NISHIMURA C, 1990, J BIOL CHEM, V265, P9788; OBRIEN MM, 1982, J NEUROCHEM, V39, P810, DOI 10.1111/j.1471-4159.1982.tb07964.x; OLD SE, 1990, P NATL ACAD SCI USA, V87, P4942, DOI 10.1073/pnas.87.13.4942; POULSOM R, 1986, BIOCHEM PHARMACOL, V35, P2955, DOI 10.1016/0006-2952(86)90492-2; SCHADE SZ, 1990, J BIOL CHEM, V265, P3628; Stribling D, 1989, J Diabet Complications, V3, P139, DOI 10.1016/0891-6632(89)90036-6; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TULSIANI DRP, 1977, J BIOL CHEM, V252, P2545; WERMUTH B, 1982, EUR J BIOCHEM, V127, P279, DOI 10.1111/j.1432-1033.1982.tb06867.x; Wermuth B, 1987, Prog Clin Biol Res, V232, P297; WERMUTH B, 1977, J BIOL CHEM, V252, P3821; Wermuth B, 1985, Prog Clin Biol Res, V174, P209; WERMUTH B, 1982, ENZYMOLOGY CARBONYL, P261; Windholz M, 1983, MERCK INDEX, P910	31	97	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					24031	24037						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748675				2022-12-25	WOS:A1991GV31900077
J	CORTINA, G; KRUEGER, KM; BARBIERI, JT				CORTINA, G; KRUEGER, KM; BARBIERI, JT			THE CARBOXYL TERMINUS OF THE S1-SUBUNIT OF PERTUSSIS TOXIN CONFERS HIGH-AFFINITY BINDING TO TRANSDUCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET-ACTIVATING PROTEIN; ENZYMATIC-ACTIVITIES; ADENYLATE-CYCLASE; ADP-RIBOSYLATION; S-1 SUBUNIT; IDENTIFICATION; VACCINE; GTPASE; GENE; SITE	The kinetic constants for the ADP-ribosylation of transducin were determined for the recombinant S1 subunit of pertussis toxin (rS1, composed of 235 amino acids) and two genetically derived deletion peptides, C180 and C195, which are composed of the 180 and 195 amino-terminal residues of the S1 subunit, respectively. Titration of NAD in the presence of a constant concentration of transducin (0.5-mu-M) showed that the K(m)appNAD in the ADP-ribosylation of transducin were similar, approximately 20-mu-M, for rS1, C195, and C180. In contrast, titration of transducin in the presence of a constant concentration of NAD (25 nM) showed that rS1 possessed a lower K(m)apptransducin and greater k(cat) than either C195 or C180. Previous studies (Cortina, G., and Barbieri, J. T. (1991) J. Biol. Chem. 266, 3022-3030) showed that the 16 carboxyl terminal residues of the S1 subunit did not function in the ADP-ribosylation of transducin. It thus appears that residues between 195 and 219 of the S1 subunit are required for high affinity transducin binding and may be involved in the transfer of ADP-ribose to transducin. To localize the defect in the recognition of transducin by C180, rS1 and C180 were assayed for the ability to ADP-ribosylate either transducin or the purified alpha-subunit of transducin (T-alpha). Upon saturation of the target protein, rS1 ADP-ribosylated equivalent moles of transducin or T-alpha, with the linear velocity of rS1-mediated ADP-ribosylation of transducin approximately 16-fold more rapid than the rate of ADP-ribosylation of T-alpha. In contrast, the initial linear velocity of C180-mediated ADP-ribosylation of transducin was only 1.7-fold more rapid than the rate of ADP-ribosylation of T-alpha. These data indicate that the amino-terminal 180 amino acids of S1 confer the specificity for ADP- ribosylation primarily through the interaction with T-alpha, while residues between 195 and 219 of S1 confer high affinity binding to transducin primarily through the interaction, either directly or indirectly, with T-beta-gamma.	MED COLL WISCONSIN,DEPT MICROBIOL,MILWAUKEE,WI 53226	Medical College of Wisconsin	BARBIERI, JT (corresponding author), MED COLL WISCONSIN,DEPT MICROBIOL,MILWAUKEE,WI 53226, USA.				NIAID NIH HHS [AI25079] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI025079] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBIERI JT, 1990, INFECT IMMUN, V58, P999, DOI 10.1128/IAI.58.4.999-1003.1990; BARBIERI JT, 1988, INFECT IMMUN, V56, P1934, DOI 10.1128/IAI.56.8.1934-1941.1988; BARBIERI JT, 1989, J BACTERIOL, V171, P4362, DOI 10.1128/JB.171.8.4362-4369.1989; BURNS DL, 1987, J BIOL CHEM, V262, P17677; CIEPLAK W, 1988, P NATL ACAD SCI USA, V85, P4667, DOI 10.1073/pnas.85.13.4667; CORTINA G, 1991, J BIOL CHEM, V266, P3022; KATADA T, 1982, J BIOL CHEM, V257, P3739; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LOCHT C, 1989, P NATL ACAD SCI USA, V86, P3075, DOI 10.1073/pnas.86.9.3075; LOCHT C, 1990, J BIOL CHEM, V265, P4552; LOCHT C, 1986, SCIENCE, V232, P1258, DOI 10.1126/science.3704651; LOOSMORE SM, 1990, INFECT IMMUN, V58, P3653, DOI 10.1128/IAI.58.11.3653-3662.1990; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NICOSIA A, 1986, P NATL ACAD SCI USA, V83, P4631, DOI 10.1073/pnas.83.13.4631; PIZZA M, 1989, SCIENCE, V246, P497, DOI 10.1126/science.2683073; PIZZA M, 1988, P NATL ACAD SCI USA, V85, P7521, DOI 10.1073/pnas.85.20.7521; SHINOZAWA T, 1980, P NATL ACAD SCI-BIOL, V77, P1408, DOI 10.1073/pnas.77.3.1408; TAMURA M, 1982, BIOCHEMISTRY-US, V21, P5516, DOI 10.1021/bi00265a021; UI M, 1990, ADP RIBOSYLATING TOX, P45; WATKINS PA, 1985, J BIOL CHEM, V260, P3478; WEST RE, 1985, J BIOL CHEM, V260, P4428	21	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23810	23814						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748655				2022-12-25	WOS:A1991GV31900045
J	GALLAGHER, PJ; HERRING, BP				GALLAGHER, PJ; HERRING, BP			THE CARBOXYL TERMINUS OF THE SMOOTH-MUSCLE MYOSIN LIGHT CHAIN KINASE IS EXPRESSED AS AN INDEPENDENT PROTEIN, TELOKIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; PHOSPHORYLATION; CONTRACTION; FIBROBLASTS; GIZZARD; CALMODULIN; DOMAIN; ACID; DNA; SEQUENCE	It has been proposed that the carboxyl terminus of the smooth muscle myosin light chain kinase is expressed as an independent protein. This protein has been purified from tissues and named telokin (Ito, M., Dabrowska, R., Guerriero, V., Jr., and Hartshorne, D. J. (1989) J. Biol Chem. 264, 13971-13974). In this study we have isolated and characterized cDNA and genomic clones encoding telokin. Analysis of a genomic DNA clone suggests that the mRNA encoding telokin arises from a promoter which appears to be located within an intron of the smooth muscle myosin light chain kinase (MLCK) gene. This intron interrupts exons encoding the calmodulin binding domain of the kinase. The amino acid sequence deduced from the cDNA predicts that telokin is identical to the carboxyl-terminal 155 residues of the smooth muscle MLCK. Unlike the smooth muscle MLCK which is expressed in both smooth and non-muscle tissues, telokin is expressed in some smooth muscle tissues but has not been detected in aortic smooth muscle or in any non-muscle tissues.			GALLAGHER, PJ (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007175] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026043, R01HL026043] Funding Source: NIH RePORTER; NCRR NIH HHS [2 S07 RR 07175] Funding Source: Medline; NHLBI NIH HHS [R01 HL026043-20, R37 HL026043, HL26043, R01 HL026043] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELSTEIN RS, 1978, J BIOL CHEM, V253, P8347; ADELSTEIN RS, 1975, BIOCH PHARM PLATELET, P101; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P779; BAGCHI IC, 1989, J BIOL CHEM, V264, P15843; BISSONNETTE M, 1989, BIOCHEM J, V258, P739, DOI 10.1042/bj2580739; CANDE WZ, 1986, CELL MOTIL CYTOSKEL, V6, P640, DOI 10.1002/cm.970060612; COLLINGE M, 1991, FASEB J, V54, P802; CONTI MA, 1981, J BIOL CHEM, V256, P3178; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; GOLDFINE SM, 1981, J CELL SCI, V50, P391; GUERRIERO V, 1986, BIOCHEMISTRY-US, V25, P8372, DOI 10.1021/bi00374a007; HAI CM, 1989, ANNU REV PHYSIOL, V51, P285, DOI 10.1146/annurev.physiol.51.1.285; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASHIMOTO Y, 1990, ARCH BIOCHEM BIOPHYS, V278, P41, DOI 10.1016/0003-9861(90)90228-Q; HERRING BP, 1990, J BIOL CHEM, V265, P1724; HOLZAPFEL G, 1983, EXP CELL RES, V148, P117, DOI 10.1016/0014-4827(83)90192-1; IKEBE M, 1985, J BIOL CHEM, V260, P4547; IKEBE M, 1990, J BIOL CHEM, V265, P8975; IKEBE M, 1987, J BIOL CHEM, V262, P13828; ITO M, 1989, J BIOL CHEM, V264, P13971; ITO M, 1991, BIOCHEMISTRY-US, V30, P3498, DOI 10.1021/bi00228a021; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LITTLE PFR, 1987, DNA CLONING PRACTICA, P1; MASUDA H, 1984, CELL MOTIL CYTOSKEL, V4, P315, DOI 10.1002/cm.970040503; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P556; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8808; NISHIKAWA M, 1985, J BIOL CHEM, V260, P8978; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PAYNE ME, 1986, J BIOL CHEM, V261, P6346; ROUSH CL, 1988, J BIOL CHEM, V263, P10510; RUSSO MA, 1987, MOL ENDOCRINOL, V1, P60, DOI 10.1210/mend-1-1-60; SAMBROOK J, 1989, MOL CLONING LAB MANU, P7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHATTUCK RL, 1988, J CELL BIOL, V107, P747; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STULL JT, 1990, J BIOL CHEM, V265, P16683; WYSOLMERSKI RB, 1990, P NATL ACAD SCI USA, V87, P16, DOI 10.1073/pnas.87.1.16; ZOLLER MJ, 1987, METHOD ENZYMOL, V154, P329	41	111	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23945	23952						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748667				2022-12-25	WOS:A1991GV31900066
J	SCHNETKAMP, PPM; LI, XB; BASU, DK; SZERENCSEI, RT				SCHNETKAMP, PPM; LI, XB; BASU, DK; SZERENCSEI, RT			REGULATION OF FREE CYTOSOLIC CA2+ CONCENTRATION IN THE OUTER SEGMENTS OF BOVINE RETINAL RODS BY NA-CA-K EXCHANGE MEASURED WITH FLUO-3 .1. EFFICIENCY OF TRANSPORT AND INTERACTIONS BETWEEN CATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; IONIC PERMEABILITIES; PLASMA-MEMBRANE; OPTICAL PROBE; POTASSIUM; REQUIRES	Regulation of free cytosolic Ca2+ concentration in the rod outer segments (ROS) isolated from bovine retinas was examined with the fluorescent Ca2+-indicating dye fluo-3. In situ calibration of cytosolic fluo-3 was done in the presence of the Ca2+ ionophore A23187 and yielded a dissociation constant of 500 nM for the Ca2+-fluo-3 complex. Ca2+ influx in Ca2+-depleted ROS was completely abolished when internal Na+ was removed suggesting that Ca2+ influx exclusively occurred via Na-Ca-K exchange. The most striking observation was that Na-Ca-K exchange could mediate a rapid increase in cytosolic free Ca2+ over the most of the usable indicating range of fluo-3 (from 10 nM to 2-mu-M), even when exposed to free external Ca2+ concentrations as low as 10 nM. From a comparison between changes in free Ca2+ and changes in total Ca2+, we conclude that physiologically occurring changes in cytosolic free Ca2+ are mediated by exchange fluxes < 1% of the maximal Na-Ca-K exchange flux. The Na-Ca-K exchanger could mediate both K+-dependent and K+-independent Ca2+ influx; Li+ caused a complete inhibition of K+-independent Ca2+ influx, but had no effect on K+-dependent Ca2+ influx. We examined the complex interactions of alkali cations with Ca2+ influx and discuss the results in terms of a three-site model for the Na-Ca-K exchanger (Schnetkamp, P. P. M. and Szerencsei, R. T. (1991) J. Biol. Chem. 266, 189-197). Ca2+ competed with one Mg2+ ion or two Na+ ions for binding to a common site. High K+ concentration greatly diminished the ability of Na+ and Mg2+ to compete with Ca2+ for this common site on the exchanger protein. As a result, high internal K+ induced a conformation of the exchange protein that kinetically favoured Ca2+ extrusion.			SCHNETKAMP, PPM (corresponding author), UNIV CALGARY,DEPT MED BIOCHEM,CALGARY T2N 4N1,ALBERTA,CANADA.							CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; COOK NJ, 1988, J BIOL CHEM, V263, P11382; MINTA A, 1989, J BIOL CHEM, V264, P8171; MIURA Y, 1989, J GEN PHYSIOL, V93, P1129, DOI 10.1085/jgp.93.6.1129; PHILIPSON KD, 1982, J BIOL CHEM, V257, P5111; RATTO GM, 1988, J NEUROSCI, V8, P3240; REEVES JP, 1990, INTRACELLULAR CALCIU, P305; SCHNETKAMP PPM, 1980, BIOCHIM BIOPHYS ACTA, V598, P66, DOI 10.1016/0005-2736(80)90266-7; SCHNETKAMP PPM, 1985, J MEMBRANE BIOL, V88, P263, DOI 10.1007/BF01871090; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P189; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P22983; SCHNETKAMP PPM, 1985, J MEMBRANE BIOL, V88, P249, DOI 10.1007/BF01871089; SCHNETKAMP PPM, 1989, PROG BIOPHYS MOL BIO, V54, P1, DOI 10.1016/0079-6107(89)90007-2; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P198; SCHNETKAMP PPM, 1989, AM J PHYSIOL, V257, pC153, DOI 10.1152/ajpcell.1989.257.1.C153; SCHNETKAMP PPM, 1987, BIOCHEMISTRY-US, V26, P3249, DOI 10.1021/bi00386a002; SCHNETKAMP PPM, 1986, J PHYSIOL-LONDON, V373, P25, DOI 10.1113/jphysiol.1986.sp016033; SCHNETKAMP PPM, 1988, BIOPHYS J, V53, pA389; SCHNETKAMP PPM, 1991, IN PRESS J GEN PHYSL	19	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22975	22982						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744092				2022-12-25	WOS:A1991GT48300033
J	STACEY, DW; ROUDEBUSH, M; DAY, R; MOSSER, SD; GIBBS, JB; FEIG, LA				STACEY, DW; ROUDEBUSH, M; DAY, R; MOSSER, SD; GIBBS, JB; FEIG, LA			DOMINANT INHIBITORY RAS MUTANTS DEMONSTRATE THE REQUIREMENT FOR RAS ACTIVITY IN THE ACTION OF TYROSINE KINASE ONCOGENES	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; GUANINE-NUCLEOTIDE EXCHANGE; SIGNAL TRANSDUCTION; CELL-PROLIFERATION; H-RAS; SACCHAROMYCES-CEREVISIAE; MONOCLONAL-ANTIBODIES; GENE FAMILY; PRODUCT P21; EXPRESSION	Two inhibitory Ras mutant proteins [(Asn 17) Ras and RAS(T)] were microinjected into NIH3T3 cells in order to compare their inhibitory activity with that of a neutralizing anti-ras antibody. Both mutants were able to block efficiently the mitogenic effects of serum added to quiescent NIH3T3 cells. Furthermore, each of the inhibitors blocked cell cycle progression at the same point as the injected anti-ras antibody, just prior to the initiation of a new round of DNA synthesis. Finally, as with the injected anti-ras antibody, each of the inhibitors was efficiently able to block proliferation and reverse the transformed morphology of cells transformed by tyrosine kinase oncogenes, while cells transformed by serine kinase oncogenes were unaffected. Therefore, results with all three reagents clearly indicate that cellular Ras activity is required in the late G1 phase of the cell cycle and is essential for the maintenance of the transformed phenotype induced by tyrosine but not serine kinase oncogenes. These studies demonstrate the utility of dominant inhibitory mutants as a means of interfering with the activity of cellular oncogenes.	TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111; MERCK SHARP & DOHME LTD,DEPT CANC RES,W POINT,PA 19486	Tufts University; Merck & Company	STACEY, DW (corresponding author), CLEVELAND CLIN EDUC FDN,DEPT MOLEC BIOL,9500 EUCLID AVE,CLEVELAND,OH 44106, USA.			Roudebush, Margaret/0000-0001-9005-3672				BALTUS E, 1988, P NATL ACAD SCI USA, V85, P502, DOI 10.1073/pnas.85.2.502; BOS JL, 1989, CANCER RES, V49, P4682; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FURTH ME, 1987, ONCOGENE, V1, P47; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; HATTORI S, 1987, MOL CELL BIOL, V7, P1999, DOI 10.1128/MCB.7.5.1999; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; KUNG HF, 1986, EXP CELL RES, V162, P363, DOI 10.1016/0014-4827(86)90341-1; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAPAGEORGE AG, 1986, MOL CELL BIOL, V6, P1843, DOI 10.1128/MCB.6.5.1843; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; SANTOS E, 1988, J BIOL CHEM, V263, P9853; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SRIVASTAVA SK, 1989, MOL CELL BIOL, V9, P1779, DOI 10.1128/MCB.9.4.1779; STACEY DW, 1988, COLD SPRING HARB SYM, V53, P871, DOI 10.1101/SQB.1988.053.01.100; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STACEY DW, 1987, EXP CELL RES, V171, P232, DOI 10.1016/0014-4827(87)90266-7; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028	37	106	107	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2297	2304						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766676				2022-12-25	WOS:A1991GX73500018
J	MORIYAMA, Y; IWAMOTO, A; HANADA, H; MAEDA, M; FUTAI, M				MORIYAMA, Y; IWAMOTO, A; HANADA, H; MAEDA, M; FUTAI, M			ONE-STEP PURIFICATION OF ESCHERICHIA-COLI H+-ATPASE (F0F1) AND ITS RECONSTITUTION INTO LIPOSOMES WITH NEUROTRANSMITTER TRANSPORTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; BRAIN SYNAPTIC VESICLES; OXIDATIVE-PHOSPHORYLATION; SYNTHASE F1F0; SUBUNIT; MECHANISM; SEQUENCE; PUMP	About 30% of the protein in the inner membrane of Escherichia coli strain DK8/pBWU13 is H+-ATPase (F0F1), and practically homogeneous F0F1 could be obtained by gradient centrifugation after solubilization of these membranes. The recombinant plasmid pBWU13 carries the unc operon for F0F1. When reconstituted into liposomes, F0F1 formed an ATP-dependent proton gradient and membrane potential. Proteoliposomes reconstituted with F0F1 and solubilized transporters from chromaffin granules or synaptic vesicle membranes could transport serotonin, dopamine, and norepinephrine dependent on ATP hydrolysis. F0F1 can be obtained rapidly from DK8/pBWU13, and its reconstitution into liposomes with transporters may be useful for monitoring these transporters during their purification.			MORIYAMA, Y (corresponding author), OSAKA UNIV,INST SCI & IND RES,DEPT ORGAN CHEM & BIOCHEM,IBARAKI,OSAKA 567,JAPAN.							FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FOSTER DL, 1979, J BIOL CHEM, V254, P8230; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; IWAMOTO A, 1991, J BIOL CHEM, V266, P16350; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; KANAZAWA H, 1979, P NATL ACAD SCI USA, V76, P1126, DOI 10.1073/pnas.76.3.1126; KANAZAWA H, 1980, P NATL ACAD SCI-BIOL, V77, P7005, DOI 10.1073/pnas.77.12.7005; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYCOX PR, 1990, EMBO J, V9, P1465, DOI 10.1002/j.1460-2075.1990.tb08263.x; MORIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V173, P443, DOI 10.1016/S0006-291X(05)81078-2; MORIYAMA Y, 1990, J BIOCHEM, V108, P689, DOI 10.1093/oxfordjournals.jbchem.a123264; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; NEWMAN MJ, 1980, J BIOL CHEM, V255, P583; NJUS D, 1986, BIOCHIM BIOPHYS ACTA, V853, P237, DOI 10.1016/0304-4173(87)90003-6; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; SCHNEIDER E, 1985, EMBO J, V4, P515, DOI 10.1002/j.1460-2075.1985.tb03658.x; SCHNEIDER E, 1987, MICROBIOL REV, V51, P477, DOI 10.1128/MMBR.51.4.477-497.1987; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SHAFFNER W, 1973, ANAL BIOCHEM, V56, P502; TAKEYAMA M, 1990, J BIOL CHEM, V265, P21279; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X	26	123	123	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22141	22146						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1834667				2022-12-25	WOS:A1991GR56400015
J	KOSTNER, GM; GRILLHOFER, HK				KOSTNER, GM; GRILLHOFER, HK			LIPOPROTEIN(A) MEDIATES HIGH-AFFINITY LOW-DENSITY-LIPOPROTEIN ASSOCIATION TO RECEPTOR NEGATIVE FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LP(A) LIPOPROTEIN; APOLIPOPROTEIN-B; LDL RECEPTOR; PLASMINOGEN; CHOLESTEROL; PLASMA; HYPERCHOLESTEROLEMIA; HETEROGENEITY; INHERITANCE; PHENOTYPES	Lipoprotein(a) (Lp(a)) is an acute phase protein with unknown function. Lp(a) binds to low density lipoprotein (LDL) receptors, as well as to plasminogen (Plg) receptors. Preincubation of normal human skin fibroblasts with Lp(a) or with apo(a) cause a severalfold increase of LDL binding. Plg and kringle-4 of Plg have no effect. LDL receptor-negative fibroblasts respond upon preincubation with apo(a) with high affinity binding of LDL with K(d) values that are almost identical with those of LDL binding to the LDL receptor. Incubation of apo(a)-pretreated fibroblasts with anti-apo(a) completely abolishes the increment of LDL binding. The high affinity LDL binding to LDL receptor-negative fibroblasts could be dissociated by approximately 80 and 54% with 5 mg/ml proline and 30 mg/ml NaCl, respectively, but not with dextran sulfate. The Lp(a)- and apo(a)-triggered LDL binding to fibroblasts have no effect on LDL internalization. These findings may reflect a key function in the role as an acute phase protein and may be relevant to the high atherogenicity of Lp(a).			KOSTNER, GM (corresponding author), GRAZ UNIV,INST MED BIOCHEM,HARRACHGASSE 21-III,A-8010 GRAZ,AUSTRIA.							ARMSTRONG VW, 1990, J LIPID RES, V31, P429; BIHARIVARGA M, 1988, ARTERIOSCLEROSIS, V8, P851, DOI 10.1161/01.ATV.8.6.851; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMENS P, 1986, HELV PAEDIATR ACTA, V41, P173; FLESS GM, 1986, J BIOL CHEM, V261, P8712; FLOREN CH, 1981, BIOCHEM BIOPH RES CO, V102, P636, DOI 10.1016/S0006-291X(81)80179-9; GAUBATZ JW, 1990, J LIPID RES, V31, P603; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HANDLEY DA, 1981, P NATL ACAD SCI-BIOL, V78, P368, DOI 10.1073/pnas.78.1.368; HESZ A, 1987, EXP MOL PATHOL, V46, P372, DOI 10.1016/0014-4800(87)90057-8; HOEFLER G, 1988, ARTERIOSCLEROSIS, V8, P398, DOI 10.1161/01.ATV.8.4.398; HOFMANN SL, 1990, J CLIN INVEST, V85, P1542, DOI 10.1172/JCI114602; KARADI I, 1988, BIOCHIM BIOPHYS ACTA, V960, P91, DOI 10.1016/0005-2760(88)90013-6; KLUFT C, 1989, BIOCHEM BIOPH RES CO, V161, P427, DOI 10.1016/0006-291X(89)92616-8; Kostner G. M., 1976, LOW DENSITY LIPOPROT, P229; KOSTNER GM, 1989, CIRCULATION, V80, P1313, DOI 10.1161/01.CIR.80.5.1313; KRAFT HG, 1989, J CLIN INVEST, V83, P137, DOI 10.1172/JCI113849; KREMPLER F, 1983, J CLIN INVEST, V71, P1431, DOI 10.1172/JCI110896; KREMPLER F, 1980, J CLIN INVEST, V65, P1483, DOI 10.1172/JCI109813; LISCUM L, 1987, J BIOL CHEM, V262, P17002; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAEDA S, 1989, ATHEROSCLEROSIS, V78, P145, DOI 10.1016/0021-9150(89)90218-9; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1990, THROMB HAEMOSTASIS, V63, P331; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; SALONEN EM, 1989, EMBO J, V8, P4035, DOI 10.1002/j.1460-2075.1989.tb08586.x; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCHNEIDER WJ, 1985, METHOD ENZYMOL, V109, P405; STEYRER E, 1990, J LIPID RES, V31, P1247; TRIEU VN, 1991, J BIOL CHEM, V266, P5480; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; VESSBY B, 1982, ATHEROSCLEROSIS, V44, P61, DOI 10.1016/0021-9150(82)90053-3; YE SQ, 1988, J BIOL CHEM, V263, P6337	38	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21287	21292						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1834657				2022-12-25	WOS:A1991GN00100108
J	RADICE, P; SOZZI, G; MIOZZO, M; DEBENEDETTI, V; CARIANI, T; BONGARZONE, I; SPURR, NK; PIEROTTI, MA; DELLAPORTA, G				RADICE, P; SOZZI, G; MIOZZO, M; DEBENEDETTI, V; CARIANI, T; BONGARZONE, I; SPURR, NK; PIEROTTI, MA; DELLAPORTA, G			THE HUMAN TROPOMYOSIN GENE INVOLVED IN THE GENERATION OF THE TRK ONCOGENE MAPS TO CHROMOSOME 1Q31	ONCOGENE			English	Note							THYROID PAPILLARY CARCINOMAS; SOMATIC-CELL HYBRIDS; RET PROTO-ONCOGENE; ASSIGNMENT; EXPRESSION; KINASE; MUSCLE; TISSUE; PTC	The chromosomal localization of hTMnm, a gene coding for a cytoskeletal tropomyosin non-muscle isoform involved in the activation of the TRK proto-oncogene in various human tumors, was determined by Southern blot analysis of a panel of human-rodent somatic cell hybrids. Using as a probe an Alu-free intronic fragment related to the tropomyosin sequence fused to the TRK tyrosine kinase domain, the hTMnm gene was assigned to the long arm of chromosome 1. Subsequently, in situ hybridization of the same probe to human metaphase chromosomes localized the hTMnm gene to 1q31. Since we have recently assigned the TRK locus to chromosome 1q32-q41, the generation of the hybrid transforming sequence tropomyosin-TRK may be due to an intrachromosomal rearrangement of the long arm of chromosome 1.	IST NAZL TUMORI,DIV ONCOL SPERIMENTALE A,VIA G VENEZIAN 1,I-20133 MILAN,ITALY; IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LID,HERTS,ENGLAND	Fondazione IRCCS Istituto Nazionale Tumori Milan			Radice, Paolo/O-3119-2013; Pierotti, Marco Alessandro/AAC-4728-2022; sozzi, gabriella/G-8259-2011; Miozzo, Monica Rosa/AAC-6401-2022; Bongarzone, Italia/B-9544-2017	Radice, Paolo/0000-0001-6298-4111; Pierotti, Marco Alessandro/0000-0002-7431-8332; sozzi, gabriella/0000-0001-9360-6914; Miozzo, Monica Rosa/0000-0002-6523-4575; Bongarzone, Italia/0000-0003-2530-9170				ANDREWS PW, 1985, ANN HUM GENET, V49, P31, DOI 10.1111/j.1469-1809.1985.tb01673.x; BONGARZONE I, 1989, ONCOGENE, V4, P1457; DONGHI R, 1989, ONCOGENE, V4, P521; EDWARDS YH, 1985, ANN HUM GENET, V49, P101, DOI 10.1111/j.1469-1809.1985.tb01681.x; FINE RE, 1975, J MOL BIOL, V95, P447, DOI 10.1016/0022-2836(75)90202-8; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HEISTERKAMP N, 1982, NATURE, V299, P747, DOI 10.1038/299747a0; ISHIZAKA Y, 1989, ONCOGENE, V4, P1519; JONES EA, 1976, SOMAT CELL GENET, V2, P483, DOI 10.1007/BF01542686; KIELTY CM, 1982, ANN HUM GENET, V46, P307, DOI 10.1111/j.1469-1809.1982.tb01582.x; MACLEOD AR, 1988, MOL CELL BIOL, V8, P433, DOI 10.1128/MCB.8.1.433; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MAYALL BH, 1975, AUTOMATION CYTOGENET, P113; MIOZZO M, 1990, ONCOGENE, V5, P1411; NABHOLZ M, 1969, NATURE, V223, P358, DOI 10.1038/223358a0; OLAH E, 1989, CANCER GENET CYTOGEN, V43, P179, DOI 10.1016/0165-4608(89)90029-0; PERRY P, 1974, NATURE, V251, P156, DOI 10.1038/251156a0; POVEY S, 1980, ANN HUM GENET, V43, P241, DOI 10.1111/j.1469-1809.1980.tb01557.x; PULCIANI S, 1982, NATURE, V300, P539, DOI 10.1038/300539a0; REINACH FC, 1986, NATURE, V322, P648, DOI 10.1038/322648a0; SEWELL WA, 1988, IMMUNOGENETICS, V28, P278, DOI 10.1007/BF00345506; SHABTAI F, 1986, HUM GENET, V73, P232, DOI 10.1007/BF00401234; SOLOMON E, 1979, ANN HUM GENET, V42, P273, DOI 10.1111/j.1469-1809.1979.tb00661.x; SOZZI G, 1991, ONCOGENE, V6, P339; VANHEYNINGEN V, 1975, ANN HUM GENET, V38, P295; WHITEHEAD AS, 1982, P NATL ACAD SCI-BIOL, V79, P5021, DOI 10.1073/pnas.79.16.5021	27	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2145	2148						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1834975				2022-12-25	WOS:A1991GX11900027
J	HIPSKIND, RA; NORDHEIM, A				HIPSKIND, RA; NORDHEIM, A			FUNCTIONAL DISSECTION INVITRO OF THE HUMAN C-FOS PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; RNA POLYMERASE-II; MAJOR LATE PROMOTER; EPIDERMAL GROWTH-FACTOR; MULTIPLE SEQUENCE ELEMENTS; TRANSCRIPTION FACTOR CREB; IMMEDIATE EARLY PROTEIN; DYAD SYMMETRY ELEMENT; 12-O-TETRADECANOYL PHORBOL-13-ACETATE; MEDIATE INDUCTION	Using internal and 5' deletions, the elements contributing to the in vitro activity of the human c-fos promoter have been identified. Wild type and mutant promoters were fused to the G-free cassette and tested, using HeLa nuclear and whole cell extracts, with the fos wild type promoter as the internal control. The proximal promoter domain, spanning from -124 to -58 in the fos promoter, is the primary determinant of activity. Two elements in this domain are important, the direct repeats and the -60 element, which contains overlapping MLTF/USF and CREB/ATF transcription factor binding sites. CREB/ATF appears to be dominant, since a canonical CRE functions well in place of the -60 element. Interestingly, the direct repeats appear to require the -60 element to exert their effect. Upstream elements do not Influence promoter activity in their normal position or adjacent to the TATA box, except the serum response element (SRE). Templates containing various lengths of the fos wild type SRE next to the TATA box are stimulated by adding purified serum response factor (SRF), while SRE mutants are not responsive. The stimulation is independent of small spacing differences between the SRE and TATA elements, and the CArG core of the fos SRE suffices to respond to added SRF in vitro.	HANOVER MED SCH,INST MOLEC BIOL,POSTFACH 610180,W-3000 HANNOVER 61,GERMANY	Hannover Medical School								ABMAYR SM, 1988, GENE DEV, V2, P542, DOI 10.1101/gad.2.5.542; ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; Bravo R, 1990, Semin Cancer Biol, V1, P37; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HIPSKIND RA, 1991, J BIOL CHEM, V266, P19572; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; Maniatis T., 1982, MOL CLONING; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; MILLER AD, 1984, CELL, V36, P51; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; NORMAN C, 1988, COLD SPRING HARB SYM, V53, P719, DOI 10.1101/SQB.1988.053.01.082; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PRYWES R, 1988, COLD SPRING HARB SYM, V53, P739, DOI 10.1101/SQB.1988.053.01.084; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUNKEL L, 1991, MOL CELL BIOL, V11, P1270, DOI 10.1128/MCB.11.3.1270; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHLASTA G, 1990, MOL CELL BIOL, V10, P5558; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SCHROTER H, 1987, NUCLEIC ACIDS RES, V15, P10145, DOI 10.1093/nar/15.24.10145; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHAW PE, 1989, NUCLEIC ACIDS MOL BI, V3, P120; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SIMON MC, 1990, P NATL ACAD SCI USA, V87, P513, DOI 10.1073/pnas.87.2.513; SPANGLER R, 1987, SCIENCE, V237, P1044, DOI 10.1126/science.2956686; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P9474, DOI 10.1073/pnas.85.24.9474; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WEBSTER KA, 1990, MOL CELL BIOL, V10, P2402, DOI 10.1128/MCB.10.5.2402; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	83	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19583	19592						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1833404				2022-12-25	WOS:A1991GK66700068
J	FUJII, J; ZARAINHERZBERG, A; WILLARD, HF; TADA, M; MACLENNAN, DH				FUJII, J; ZARAINHERZBERG, A; WILLARD, HF; TADA, M; MACLENNAN, DH			STRUCTURE OF THE RABBIT PHOSPHOLAMBAN GENE, CLONING OF THE HUMAN CDNA, AND ASSIGNMENT OF THE GENE TO HUMAN CHROMOSOME-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; 3'-5'-MONOPHOSPHATE-DEPENDENT PROTEIN KINASE; CA-2+ ATPASE GENES; SMOOTH-MUSCLE; SKELETAL-MUSCLE; CA-2+-ATPASE GENE; FAST-TWITCH; PHOSPHORYLATION; DNA; EXPRESSION	We have isolated and characterized genomic DNA clones encoding rabbit phospholamban. Only a single gene for phospholamban was detected in the rabbit genome. The phospholamban gene of 13.2 kilobases contains only one 10.5-kilobase intron, which separates exonic sequences located in the 5'-untranslated region. Two potential transcription initiation sites were mapped to 335 and 185 nucleotides upstream from the translation initiation site in the mRNA or 239 and 89 nucleotides upstream from the exon/intron boundary. Phospholamban gene expression in various smooth muscle tissues, as well as in cardiac and slow twitch skeletal muscle, was detected by Northern blotting. The phospholamban gene was mapped to human chromosome 6, using a human phospholamban cDNA.	UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO M5G 1L6, ONTARIO, CANADA; OSAKA UNIV, SCH MED, DEPT MED, FUKUSHIMA KU, OSAKA 553, JAPAN; UNIV VERMONT, COLL MED, DEPT PHYSIOL & BIOPHYS, BURLINGTON, VT 05405 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT GENET, STANFORD, CA 94305 USA; OSAKA UNIV, SCH MED, DEPT PATHOPHYSIOL, FUKUSHIMA KU, OSAKA 553, JAPAN	University of Toronto; Osaka University; University of Vermont; Stanford University; Osaka University								AGARWAL KL, 1981, J BIOL CHEM, V256, P1023; BERGET SM, 1984, NATURE, V309, P179, DOI 10.1038/309179a0; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREITBART RE, 1986, J MOL BIOL, V188, P313, DOI 10.1016/0022-2836(86)90157-9; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERGUSON DG, 1988, J CELL BIOL, V107, P555, DOI 10.1083/jcb.107.2.555; FUJII J, 1988, FEBS LETT, V227, P51, DOI 10.1016/0014-5793(88)81412-1; FUJII J, 1989, J BIOL CHEM, V264, P12950; FUJII J, 1987, J CLIN INVEST, V79, P301, DOI 10.1172/JCI112799; FUJII J, 1986, BIOCHEM BIOPH RES CO, V138, P1044, DOI 10.1016/S0006-291X(86)80387-4; GASSER J, 1988, EUR J BIOCHEM, V176, P535, DOI 10.1111/j.1432-1033.1988.tb14311.x; GASSER JT, 1986, BIOCHEMISTRY-US, V25, P7615, DOI 10.1021/bi00371a052; GIL A, 1987, CELL, V49, P399, DOI 10.1016/0092-8674(87)90292-3; JORGENSEN AO, 1986, J BIOL CHEM, V261, P3775; KELLER EB, 1984, P NATL ACAD SCI-BIOL, V81, P7417, DOI 10.1073/pnas.81.23.7417; KIRCHBERGER MA, 1976, J BIOL CHEM, V251, P725; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; LYTTON J, 1989, J BIOL CHEM, V264, P7059; MACLENNAN DH, 1987, SOMAT CELL MOLEC GEN, V13, P341, DOI 10.1007/BF01534928; MAHONY L, 1986, J BIOL CHEM, V261, P5257; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; Maniatis T., 1982, MOL CLONING; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAGAI R, 1989, P NATL ACAD SCI USA, V86, P2966, DOI 10.1073/pnas.86.8.2966; RAEYMAEKERS L, 1986, BIOCHIM BIOPHYS ACTA, V882, P258, DOI 10.1016/0304-4165(86)90163-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1983, NUCLEIC ACIDS RES, V11, P2427, DOI 10.1093/nar/11.8.2427; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TADA M, 1975, J BIOL CHEM, V250, P2640; TADA M, 1982, ANNU REV PHYSIOL, V44, P401, DOI 10.1146/annurev.ph.44.030182.002153; TADA M, 1988, METHOD ENZYMOL, V157, P107; VERBOOMEN H, 1989, BIOCHEM J, V262, P353, DOI 10.1042/bj2620353; WEGENER AD, 1984, J BIOL CHEM, V259, P1834; WILLARD HF, 1985, SCIENCE, V230, P940, DOI 10.1126/science.3840606; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670	43	61	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11669	11675						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1828805				2022-12-25	WOS:A1991FT76200041
J	APEL, ED; LITCHFIELD, DW; CLARK, RH; KREBS, EG; STORM, DR				APEL, ED; LITCHFIELD, DW; CLARK, RH; KREBS, EG; STORM, DR			PHOSPHORYLATION OF NEUROMODULIN (GAP-43) BY CASEIN KINASE-II - IDENTIFICATION OF PHOSPHORYLATION SITES AND REGULATION BY CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; DEPENDENT PROTEIN-KINASE; AMINO-ACID SEQUENCE; BINDING-PROTEIN; SPECIFICITY DETERMINANTS; BOVINE BRAIN; P-57; SUBSTRATE; PURIFICATION; PLASTICITY	Neuromodulin (P-57, GAP-43, B-50, F-1) is a neurospecific calmodulin-binding protein believed to play a role in regulation of neurite outgrowth and neuroplasticity. Neuromodulin is phosphorylated by protein kinase C, and this phosphorylation prevents calmodulin from binding to neuromodulin (Alexander, K. A., Cimler, B. M., Meier, K. E. & Storm, D. R. (1987) J. Biol. Chem. 262, 6108-6113). The only other protein kinase known to phosphorylate neuromodulin is casein kinase II (Pisano, M. R., Hegazy, M. G., Reimann, E. M. & Dokas, L. A. (1988) Biochem. Biophys. Res. Commun. 155, 1207-1212). Phosphoamino acid analyses revealed that casein kinase II modified serine and threonine residues in both native bovine and recombinant mouse neuromodulin. Two serines located in the C-terminal end of neuromodulin, Ser-192 and Ser-193, were identified as the major casein kinase II phosphorylation sites. Thr-88, Thr-89, or Thr-95 were identified as minor casein kinase II phosphorylation sites. Phosphorylation by casein kinase II did not affect the ability of neuromodulin to bind to calmodulin-Sepharose. However, calmodulin did inhibit the phosphorylation of neuromodulin by casein kinase II with a K(i) of 1-2-mu-M. Calmodulin inhibition of casein kinase II phosphorylation was due to calmodulin binding to neuromodulin rather than to the protein kinase. These data suggest that the minimal secondary and tertiary structure exhibited by neuromodulin may be sufficient to juxtapose its calmodulin-binding domain, located at the N-terminal end, with the neuromodulin casein kinase II phosphorylation sites at the C-terminal end of the protein. We propose that calmodulin regulates casein kinase II phosphorylation of neuromodulin by binding to neuromodulin and sterically hindering the interaction of casein kinase II with its phosphorylation sites on neuromodulin.	UNIV WASHINGTON, SCH MED, DEPT PHARMACOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Litchfield, David/E-4636-2015	Litchfield, David/0000-0002-2425-6620	NIDDK NIH HHS [DK42528] Funding Source: Medline; NIGMS NIH HHS [GM 33708, GM 07270] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033708, T32GM007270] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; ALLSOPP TE, 1989, J NEUROSCI, V9, P13; ALOYO VJ, 1983, J NEUROCHEM, V41, P649, DOI 10.1111/j.1471-4159.1983.tb04790.x; ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4615, DOI 10.1021/bi00289a001; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; AU DC, 1989, BIOCHEMISTRY-US, V28, P8142, DOI 10.1021/bi00446a027; BASI GS, 1987, CELL, V49, P785, DOI 10.1016/0092-8674(87)90616-7; BAUDIER J, 1989, J BIOL CHEM, V264, P1824; BENOWITZ LI, 1987, TRENDS NEUROSCI, V10, P527, DOI 10.1016/0166-2236(87)90135-4; CARMICHAEL DF, 1982, J BIOL CHEM, V257, P440; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHAN SY, 1986, J NEUROSCI, V6, P3618; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CIMLER BM, 1985, J BIOL CHEM, V260, P784; CIMLER BM, 1987, J BIOL CHEM, V262, P12158; COGGINS PJ, 1990, J NEUROCHEM, V54, P274, DOI 10.1111/j.1471-4159.1990.tb13311.x; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DIAZNIDO J, 1988, J CELL BIOL, V106, P2057, DOI 10.1083/jcb.106.6.2057; GOLPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; KARNS LR, 1987, SCIENCE, V236, P597, DOI 10.1126/science.2437653; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KOSIK KS, 1988, NEURON, V1, P127, DOI 10.1016/0896-6273(88)90196-1; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LABATE ME, 1989, NEURON, V3, P299, DOI 10.1016/0896-6273(89)90254-7; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MARCHIORI F, 1988, BIOCHIM BIOPHYS ACTA, V971, P332; MASURE HR, 1986, BIOCHEMISTRY-US, V25, P7553, DOI 10.1021/bi00371a044; MEGGIO F, 1988, FEBS LETT, V237, P225, DOI 10.1016/0014-5793(88)80206-0; MEGGIO F, 1988, BIOCHIM BIOPHYS ACTA, V971, P227, DOI 10.1016/S0005-2728(88)80111-7; MEIRI KF, 1990, J NEUROSCI, V10, P256; MOSS DJ, 1990, J NEUROCHEM, V54, P729, DOI 10.1111/j.1471-4159.1990.tb02312.x; NELSON RB, 1985, EXP NEUROL, V89, P213, DOI 10.1016/0014-4886(85)90277-8; PISANO MR, 1988, BIOCHEM BIOPH RES CO, V155, P1207, DOI 10.1016/S0006-291X(88)81268-3; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; TUAZON PT, 1991, ADV 2ND MESSENGER PH, V23, P123; WAKIM BT, 1987, BIOCHEMISTRY-US, V26, P7466, DOI 10.1021/bi00397a040; WESTCOTT KR, 1979, P NATL ACAD SCI USA, V76, P204, DOI 10.1073/pnas.76.1.204	44	70	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10544	10551						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1828073				2022-12-25	WOS:A1991FP08600082
J	WANG, KKW; WRIGHT, LC; MACHAN, CL; ALLEN, BG; CONIGRAVE, AD; ROUFOGALIS, BD				WANG, KKW; WRIGHT, LC; MACHAN, CL; ALLEN, BG; CONIGRAVE, AD; ROUFOGALIS, BD			PROTEIN-KINASE-C PHOSPHORYLATES THE CARBOXYL TERMINUS OF THE PLASMA-MEMBRANE CA2+-ATPASE FROM HUMAN ERYTHROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING-PROTEIN; CA-2+ PUMP; SMOOTH-MUSCLE; DEPENDENT PHOSPHORYLATION; RAT-BRAIN; SARCOLEMMAL CA-2+-ATPASE; SUBSTRATE-SPECIFICITY; CA-2+-PUMPING ATPASE; HEART SARCOLEMMA; CALCIUM-PUMP	Purified Ca2+-stimulated, Mg2+-dependent ATPase (Ca2+-ATPase) from human erythrocytes was phosphorylated with a stoichiometry of about 1 mol of phosphate/mol of ATPase at both threonine and serine residues by purified rat brain type III protein kinase C. In the presence of calmodulin, the phosphorylation was markedly reduced. Labeled phosphate from [gamma-P-32]ATP was retained on an 86-kDa calmodulin-binding tryptic fragment of Ca2+-ATPase but not on 82- and 77-kDa non-calmodulin-binding fragments. Similarly, fragmentation of the phosphorylated Ca2+-ATPase by calpain I revealed that calmodulin-binding fragments (127 and 125 kDa) retained phosphate label whereas a non-calmodulin-binding fragment (124 kDa) did not. The calmodulin-binding domain, located about 12 kDa from the carboxyl terminus of the Ca2+-ATPase, was thus located as a site of protein kinase C phosphorylation. A synthetic peptide corresponding to a segment of the calmodulin-binding domain (H-2 N-R-G-L-N-R-I-Q-T-Q-I-K-V-V-N-COOH) was indeed phosphorylated at the single threonine residue within this sequence. The additional serine phosphorylation site was carboxyl terminal to the calmodulin domain. Phosphorylation by purified type III protein kinase C (canine heart) antagonized the calmodulin activation of the Ca2+-ATPase, particularly at lower Ca2+ concentrations (0.2-1.0-mu-M). By contrast, a purified but unresolved protein kinase C isoenzyme mixture from rat brain stimulated the activity of Ca2+-ATPase prepared in asolectin, but not glycerol, by more than 2-fold in the presence of the ionophore A23187, without increasing its Ca2+ sensitivity. The results clearly indicate that human erythrocyte Ca2+-ATPase is a substrate of protein kinase C, but the effect of phosphorylation on the activity of the enzyme depends on the isoenzyme form of protein kinase C used and on the lipid associated with the Ca2+-ATPase.	UNIV SYDNEY,DEPT PHARM,SYDNEY,NSW 2006,AUSTRALIA; UNIV BRITISH COLUMBIA,FAC PHARMACEUT SCI,VANCOUVER V6T 1W5,BC,CANADA; WAYNE STATE UNIV,SCH MED,DEPT PATHOL,DETROIT,MI 48201	University of Sydney; University of British Columbia; Wayne State University			Allen, Bruce G/B-4693-2008	Allen, Bruce G/0000-0001-9000-9495; Roufogalis, Basil/0000-0001-9123-5478; Conigrave, Arthur/0000-0002-7232-3891; Wang, Kevin/0000-0002-9343-6473				ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALJOBORE A, 1981, ERYTHROCYTE MEMBRANE, V2, P57; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; AU KS, 1987, BIOCHIM BIOPHYS ACTA, V905, P273, DOI 10.1016/0005-2736(87)90455-X; BENAIM G, 1984, J BIOL CHEM, V259, P8471; BERGOT J, 1986, APPLIED BIOSYSTEMS U, V16; CARAFOLI E, 1981, CALCIUM PHOSPHATE TR, P9; CARONI P, 1981, J BIOL CHEM, V256, P9371; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; ENYEDI A, 1987, J BIOL CHEM, V262, P6425; FAQUIN WC, 1986, BIOCHIM BIOPHYS ACTA, V887, P142, DOI 10.1016/0167-4889(86)90048-0; FUKUDA T, 1990, J BIOCHEM-TOKYO, V108, P629, DOI 10.1093/oxfordjournals.jbchem.a123254; FURUKAWA KI, 1989, J BIOL CHEM, V264, P4844; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P16524; HOUSE C, 1987, J BIOL CHEM, V262, P772; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; JAMES P, 1988, J BIOL CHEM, V263, P2905; JAMES P, 1989, J BIOL CHEM, V264, P8289; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KONDO H, 1987, BIOCHEM BIOPH RES CO, V142, P155, DOI 10.1016/0006-291X(87)90464-5; KUO TH, 1991, J BIOL CHEM, V266, P2520; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LING E, 1986, J BIOL CHEM, V261, P13875; LITCHFIELD DW, 1987, J BIOL CHEM, V262, P8056; MA LD, 1990, BIOCHIM BIOPHYS ACTA, V1022, P17, DOI 10.1016/0005-2736(90)90395-5; MITCHELL KT, 1986, ANAL BIOCHEM, V158, P447, DOI 10.1016/0003-2697(86)90574-9; NEYSES L, 1985, J BIOL CHEM, V260, P283; NISHIKAWA M, 1985, J BIOL CHEM, V260, P8978; OBRIAN CA, 1984, BIOCHEM BIOPH RES CO, V124, P296, DOI 10.1016/0006-291X(84)90951-3; OGURUSU T, 1990, J BIOCHEM-TOKYO, V108, P222, DOI 10.1093/oxfordjournals.jbchem.a123184; OLORUNSOGO OO, 1988, BIOCHIM BIOPHYS ACTA, V945, P33, DOI 10.1016/0005-2736(88)90359-8; PALFREY HC, 1985, J BIOL CHEM, V260, P6021; RAESS BU, 1980, J PHARMACOL METHOD, V4, P273, DOI 10.1016/0160-5402(80)90019-4; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SMALLWOOD JI, 1988, J BIOL CHEM, V263, P2195; TAKADA A, 1987, FEBS LETT, V210, P169; UCHIDA T, 1984, J BIOL CHEM, V259, P2311; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VILLALOBO A, 1986, BIOCHIM BIOPHYS ACTA, V854, P9, DOI 10.1016/0005-2736(86)90059-3; VROLIX M, 1988, BIOCHEM J, V255, P855, DOI 10.1042/bj2550855; WANG KKW, 1988, ARCH BIOCHEM BIOPHYS, V260, P696, DOI 10.1016/0003-9861(88)90498-5; WANG KKW, 1988, ARCH BIOCHEM BIOPHYS, V267, P317, DOI 10.1016/0003-9861(88)90037-9; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; ZURINI M, 1984, J BIOL CHEM, V259, P618	47	101	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9078	9085						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1827443				2022-12-25	WOS:A1991FM03800065
J	NAKAMOTO, RK; RAO, R; SLAYMAN, CW				NAKAMOTO, RK; RAO, R; SLAYMAN, CW			EXPRESSION OF THE YEAST PLASMA-MEMBRANE [H+]ATPASE IN SECRETORY VESICLES - A NEW STRATEGY FOR DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ASPARTYL PHOSPHATE; RESISTANT PMA1 MUTANTS; SACCHAROMYCES-CEREVISIAE; H+-ATPASE; NEUROSPORA-CRASSA; SCHIZOSACCHAROMYCES-POMBE; TRANSLOCATING ATPASE; GENE; PROTEINS; PURIFICATION	Secretory vesicles that accumulate in the temperature-sensitive sec6-4 strain of yeast have been shown to contain a vanadate-sensitive ATPase, presumably en route to the plasma membrane (Walworth, N. C., and Novick, P. J. (1987) J. Cell Biol. 105, 163-174). We have now established this enzyme to be a fully functional form of the PMA1 [H+]ATPase, identical in its catalytic properties to that found in the plasma membrane. In addition, the secretory vesicles are sealed tightly enough to permit the measurement of ATP-dependent proton pumping with fluorescent probes. We have gone on to exploit the vesicles as an expression system for site-directed mutants of the ATPase. For this purpose, a sec6-4 strain has been constructed in which the chromosomal PMA1 gene is under control of the GAL1 promoter; the mutant pma1 allele to be studied is introduced on a centromeric plasmid under the control of a novel heat shock promoter. In galactose medium at 23-degrees-C, the wild-type ATPase is produced and supports normal vegetative growth. When the cells are switched to glucose medium at 37-degrees-C, however, the wild-type gene turns off, the mutant gene turns on, and secretory vesicles accumulate. The vesicles contain a substantial amount of newly synthesized, plasmid-encoded ATPase (5-10% of total vesicle protein), but only traces of residual wild-type PMA1 ATPase and no detectable mitochondrial ATPase, vacuolar ATPase, or acid or alkaline phosphatase. To test the expression strategy, we have made use of pma1-105 (Ser368 --> Phe), a vanadate-resistant mutant previously characterized by standard methods (Perlin, D. S., Harris, S. L., Seto-Young, D., and Haber, J. E. (1989) J. Biol. Chem. 264, 21857-21864). In secretory vesicles, as expected, the plasmid-borne pma1-105 allele gives rise to a mutant enzyme with a reduced rate of ATP hydrolysis and a 100-fold increase in K(i) for vanadate. Proton pumping is similarly resistant to vanadate. Thus, the vesicles appear well suited for the production and characterization of mutant forms of the PMA1 [H+]ATPase. They should also aid the study of other yeast membrane proteins that are essential for growth as well as heterologous proteins whose appearance in the plasma membrane may be toxic to the cell.	YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510	Yale University	NAKAMOTO, RK (corresponding author), YALE UNIV,SCH MED,DEPT HUMAN GENET,NEW HAVEN,CT 06510, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM011146, R01GM015761, R37GM015761] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 11146, GM 15761] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON R, 1986, J BIOL CHEM, V261, P4896; AMORY A, 1982, J BIOL CHEM, V257, P4723; BOWMAN BJ, 1979, J BIOL CHEM, V254, P2928; BOWMAN BJ, 1981, J BIOL CHEM, V256, P2343; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRADA D, 1988, J BACTERIOL, V170, P2775, DOI 10.1128/jb.170.6.2775-2783.1988; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; CID A, 1988, J BIOL CHEM, V263, P14134; DAME JB, 1981, J BIOL CHEM, V256, P724; DUFOUR JP, 1978, J BIOL CHEM, V253, P7026; Fiske CH, 1925, J BIOL CHEM, V66, P375; GEITZ RD, 1988, GENE, V74, P527; GHISLAIN M, 1987, J BIOL CHEM, V262, P17549; GOFF CG, 1984, GENE, V27, P35, DOI 10.1016/0378-1119(84)90236-1; Goldstein A, 1975, Methods Enzymol, V42, P504; GRADMANN D, 1978, J MEMBRANE BIOL, V39, P333, DOI 10.1007/BF01869898; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HENNESSEY JP, 1990, J BIOL CHEM, V265, P532; HOLCOMB CL, 1988, J CELL BIOL, V106, P641, DOI 10.1083/jcb.106.3.641; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDALA SM, 1989, J BIOL CHEM, V264, P16276; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; NAKAMOTO RK, 1989, J BIOENERG BIOMEMBR, V21, P621, DOI 10.1007/BF00808117; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; PERLIN DS, 1988, J BIOL CHEM, V263, P18118; PERLIN DS, 1984, J BIOL CHEM, V259, P7884; PORTILLO F, 1989, EUR J BIOCHEM, V186, P501, DOI 10.1111/j.1432-1033.1989.tb15235.x; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; Sambrook J, 1989, MOL CLONING LABORATO; Schekman R, 1982, MOL BIOL YEAST SACCH, VII, P361; SCHLESSER A, 1988, J BIOL CHEM, V263, P19480; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SERRANO R, 1986, FEBS LETT, V208, P143, DOI 10.1016/0014-5793(86)81549-6; SLATER MR, 1987, MOL CELL BIOL, V7, P1906, DOI 10.1128/MCB.7.5.1906; SMITH R, 1984, ANAL BIOCHEM, V138, P156, DOI 10.1016/0003-2697(84)90784-X; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; VANRIJN HJM, 1972, BIOCHIM BIOPHYS ACTA, V268, P431, DOI 10.1016/0005-2744(72)90339-7; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163	46	148	156	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7940	7949						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1826908				2022-12-25	WOS:A1991FJ34200096
J	COROMINAS, M; LEON, J; KAMINO, H; CRUZALVAREZ, M; NOVICK, SC; PELLICER, A				COROMINAS, M; LEON, J; KAMINO, H; CRUZALVAREZ, M; NOVICK, SC; PELLICER, A			ONCOGENE INVOLVEMENT IN TUMOR-REGRESSION - H-RAS ACTIVATION IN THE RABBIT KERATOACANTHOMA MODEL	ONCOGENE			English	Article							BLADDER-CARCINOMA ONCOGENE; GROWTH-FACTOR RECEPTORS; MURINE SARCOMA-VIRUS; N-RAS; PROTO-ONCOGENE; NUCLEOTIDE-SEQUENCE; K-RAS; NEURONAL DIFFERENTIATION; GENETIC MECHANISMS; CELLS	Activated H-ras genes are present in a number of skin tumors induced in animals by carcinogen treatment. The involvement of the ras oncogenes in tumorigenesis was investigated in keratoacanthomas, benign and self-regressing tumors, as well as malignant squamous cell carcinomas. Both tumors were induced in rabbit ears by repeated applications of 7,12 dimethylbenz(a)anthracene (DMBA). The rabbit H-ras gene was cloned and sequenced. PCR analysis revealed that approximately 82% of the keratoacanthoma DNAs contained an A:T to T:A transversion in codon 61. The relative levels of H-ras transcript were increased in keratoacanthomas compared to normal skin and the activated allele was expressed in tumors, even during the regressing phase. Although a G:C to A:T mutation in codon 12 of the H-ras and an activated N-ras gene were found in two squamous cell carcinomas, the frequency of H-ras activation in codon 61 was much lower (40%) in the malignant tumours induced by the same carcinogen treatment. Therefore, DMBA induced at least two types of genetic lesions in this system: H-ras activation, present in most regressing keratoacanthomas, and activation of other unidentified oncogenes which may result in the development of malignant tumors. Our observations indicate that expression of an activated H-ras gene, in this system, is neither sufficient to induce a malignant phenotype nor even capable of maintaining the growth of a benign tumor and suggest that it could be involved in tumor regression.	NYU MED CTR,DEPT PATHOL,550 1ST AVE,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University			Leon, Javier/K-4615-2014; Corominas, Montserrat/K-6528-2012	Corominas, Montserrat/0000-0002-0724-8346; Kamino, Hideko/0000-0001-9256-5284; Leon, Javier/0000-0001-5803-0112; Pellicer, Angel/0000-0002-5062-0692	NCI NIH HHS [CA 50434, CA 36327, CA 16239] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050434, R37CA036327, P01CA016239, R01CA036327] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDAZ CM, 1988, CANCER RES, V48, P3253; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CHANG EH, 1987, SCIENCE, V237, P1036, DOI 10.1126/science.3616624; CHENG JF, 1984, J MOL BIOL, V176, P1, DOI 10.1016/0022-2836(84)90379-6; COROMINAS M, 1989, P NATL ACAD SCI USA, V86, P6372, DOI 10.1073/pnas.86.16.6372; DIAMOND LE, 1988, MOL CELL BIOL, V8, P2233, DOI 10.1128/MCB.8.5.2233; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GHADIALLY FN, 1985, J PATHOLBACTERIOL, V75, P441; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; GUERRERO I, 1985, P NATL ACAD SCI USA, V82, P7810, DOI 10.1073/pnas.82.23.7810; GUERRERO I, 1988, BIOCHEM BIOPH RES CO, V150, P1185, DOI 10.1016/0006-291X(88)90754-1; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; LEON J, 1988, MOL CELL BIOL, V8, P786, DOI 10.1128/MCB.8.2.786; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; Maniatis T., 1982, MOL CLONING; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PERANTONI AO, 1987, P NATL ACAD SCI USA, V84, P6317, DOI 10.1073/pnas.84.17.6317; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; PRUTKIN L, 1966, DERMATOLOGICA, V132, P16, DOI 10.1159/000254393; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RAMSELAAR CG, 1976, ACTA DERM-VENEREOL, V56, P245; REDDY EP, 1983, SCIENCE, V220, P1061, DOI 10.1126/science.6844927; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; RUTA M, 1986, MOL CELL BIOL, V6, P1706, DOI 10.1128/MCB.6.5.1706; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHIH TY, 1979, VIROLOGY, V96, P64, DOI 10.1016/0042-6822(79)90173-9; SIGALIS, 1986, P NATL ACAD SCI USA, V83, P1986; SUKUMAR S, 1986, MOL CELL BIOL, V6, P2716, DOI 10.1128/MCB.6.7.2716; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YUSPA SH, 1983, CANCER RES, V43, P6021; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	53	26	27	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					645	651						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1840681				2022-12-25	WOS:A1991FR93900021
J	MOUTIN, MJ; DUPONT, Y				MOUTIN, MJ; DUPONT, Y			INTERACTION OF POTASSIUM AND MAGNESIUM WITH THE HIGH-AFFINITY CALCIUM-BINDING SITES OF THE SARCOPLASMIC-RETICULUM CALCIUM-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; DIRECT FLUORESCENCE; TRANSIENT KINETICS; PUMP MECHANISM; CA-2+-ATPASE; PHOSPHORYLATION; EQUILIBRIUM; TEMPERATURE; VESICLES; CA-2+	The sarcoplasmic reticulum Ca2+-ATPase of skeletal muscle has two high affinity calcium sites, one of fast access ("f" site) and one of slow access ("s" site). In addition to Ca2+ these sites are able to interact with other cations like Mg2+ or K+. We have studied with a stopped-flow method the modifications produced by Mg2+ and K+ on the kinetics of the intrinsic fluorescence changes produced by Ca2+ binding to and dissociation from the Ca2+-ATPase of sarcoplasmic reticulum. The presence of Mg2+ ions (K1/2 = 0.5 mM at pH 7.2) leads to the appearance of a rapid phase in the Ca2+ binding, which represents half of the signal amplitude at optimal Mg2+. The presence of K+ greatly accelerates both the Ca2+ binding and the Ca2+ dissociation reactions, giving, respectively, a 4- and 8-fold increase of the rate constant of the induced fluorescence change. K+ ions also increase the rate of the Ca-45/Ca-40 exchange reaction at the s site measured by rapid filtration. These results lead us to build up a model for the Ca2+-binding mechanism of the sarcoplasmic reticulum Ca2+-ATPase in which Mg2+ and K+ participate at particular steps of the reaction. Moreover, we propose that, in the absence of Ca2+, this enzyme may be the pathway for monovalent ion fluxes across the sarcoplasmic reticulum membrane.			MOUTIN, MJ (corresponding author), CEN, DEPT BIOL MOLEC & STRUCT, BIOPHYS MOLEC & CELLULAIRE LAB, CNRS, F-38041 GRENOBLE, FRANCE.		Moutin, Marie-Jo/P-7518-2017	Moutin, Marie-Jo/0000-0003-2681-9818				ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; BENNETT N, 1981, FEBS LETT, V128, P269, DOI 10.1016/0014-5793(81)80096-8; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHAMPEIL P, 1983, J BIOL CHEM, V258, P4453; DUPONT Y, 1982, FEBS LETT, V139, P237, DOI 10.1016/0014-5793(82)80860-0; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; DUPONT Y, 1984, ANAL BIOCHEM, V142, P504, DOI 10.1016/0003-2697(84)90496-2; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; DUPONT Y, 1977, EUR J BIOCHEM, V72, P185, DOI 10.1111/j.1432-1033.1977.tb11238.x; DUPONT Y, 1978, NATURE, V273, P396, DOI 10.1038/273396a0; DUPONT Y, 1985, STRUCTURE FUNCTION S, P389; DUPONT Y, 1988, METHOD ENZYMOL, V157, P206; FORBUSH B, 1988, J BIOL CHEM, V263, P7979; GUILLAIN F, 1982, J BIOL CHEM, V257, P7366; GUILLAIN F, 1980, J BIOL CHEM, V255, P2072; HASSELBACH W, 1963, BIOCHEM Z, V339, P94; HILL TL, 1982, P NATL ACAD SCI-BIOL, V79, P3978, DOI 10.1073/pnas.79.13.3978; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; INESI G, 1980, J BIOL CHEM, V255, P3025; KARLISCH SJD, 1982, J PHYSL, V328, P2954; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; NAKAMURA J, 1986, BIOCHIM BIOPHYS ACTA, V870, P495, DOI 10.1016/0167-4838(86)90258-X; NAKAMURA J, 1989, J BIOL CHEM, V264, P17029; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; TANFOR, 1984, CRC CRIT REV BIOCH, V17, P120; THORLEYL.DA, 1973, EUR J BIOCHEM, V40, P403, DOI 10.1111/j.1432-1033.1973.tb03209.x	27	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5580	5586						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1826001				2022-12-25	WOS:A1991FD37000036
J	FORREST, TM; WILSON, GE; PAN, Y; SCHAEFER, J				FORREST, TM; WILSON, GE; PAN, Y; SCHAEFER, J			CHARACTERIZATION OF CROSS-LINKING OF CELL-WALLS OF BACILLUS-SUBTILIS BY A COMBINATION OF MAGIC-ANGLE SPINNING NMR AND GAS-CHROMATOGRAPHY MASS-SPECTROMETRY OF BOTH INTACT AND HYDROLYZED C-13-LABELED AND N-15-LABELED CELL-WALL PEPTIDOGLYCAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; AEROCOCCUS-VIRIDANS GAFFKYA; SOLID-STATE C-13; N-15 NMR; METABOLISM; HOMARI	Cross-polarization magic-angle spinning C-13 and N-15 NMR, rotational-echo double resonance C-13 NMR, and delays alternating with nutation for tailored excitation-difference C-13 NMR spectra have been obtained from lyophilized cell walls of Bacillus subtilis grown on a synthetic medium containing D,L-[2-C-13,N-15]aspartate and D-[1-C-13]alanine. Label from aspartate is incorporated into D-glutamic acid and m-diaminopimelic acid of cell-wall peptidoglycan, while label from alanine appears in the C-1 positions of both D- and L-alanyl residues. The cross-link index (the fraction of peptide stems joined by an isopeptide covalent bond) is obtained directly from analysis of the results of the C-13 NMR experiments. However, specific isotopic enrichments of cell-wall components cannot be obtained from NMR data alone. The latter are determined either from a gas chromatographic-mass spectrometric analysis of the amino acids derived from hydrolysis of cell-wall peptidoglycan, or from a combination of NMR and gas chromatographic-mass spectrometric results. The combined analysis is overdetermined and so involves the least error for evaluations of both the cross-link index and the isotopic enrichments. The cross-link index is 0.33 +/- 0.03 for cell walls of B. subtilis grown in the presence of the antibiotic, cephalothin.	WASHINGTON UNIV,DEPT CHEM,ST LOUIS,MO 63130	Washington University (WUSTL)	FORREST, TM (corresponding author), UNIV AKRON,DEPT CHEM,AKRON,OH 44325, USA.							ABE I, 1983, J HIGH RES CHROMATOG, V6, P366, DOI 10.1002/jhrc.1240060704; BORK V, 1988, J MAGN RESON, V78, P348, DOI 10.1016/0022-2364(88)90281-8; CARAVATTI P, 1983, J MAGN RESON, V55, P88, DOI 10.1016/0022-2364(83)90279-2; CHIN T, 1966, ARCH BIOCHEM BIOPHYS, V116, P358, DOI 10.1016/0003-9861(66)90042-7; GHUYSEN JM, 1968, BACTERIOL REV, V32, P425, DOI 10.1128/MMBR.32.4_Pt_2.425-464.1968; GULLION T, 1989, J MAGN RESON, V81, P196, DOI 10.1016/0022-2364(89)90280-1; GULLION T, 1991, J MAGN RESON, V92, P439, DOI 10.1016/0022-2364(91)90286-3; GULLION T, 1989, ADV MAGN RESON, V13, P57; HUGHES RC, 1970, BIOCHEM J, V119, P849, DOI 10.1042/bj1190849; JACOB GS, 1985, J BIOL CHEM, V260, P2777; JACOB GS, 1983, J BIOL CHEM, V258, P824; JOHNSTON RB, 1968, PYRIDOXAL CATALYSIS, P537; LEE TA, 1990, ANAL BIOCHEM, V185, P24, DOI 10.1016/0003-2697(90)90249-9; PAN Y, 1990, J MAGN RESON, V90, P341, DOI 10.1016/0022-2364(90)90139-Z; PAN Y, 1990, J MAGN RESON, V90, P330, DOI 10.1016/0022-2364(90)90138-Y; Rogers H, 1980, MICROBIAL CELL WALLS; SCHAEFER J, 1986, BIOCHEM BIOPH RES CO, V137, P736, DOI 10.1016/0006-291X(86)91140-X; SCHAEFER J, 1976, J AM CHEM SOC, V98, P1031, DOI 10.1021/ja00420a036; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SPIZIZEN J, 1958, P NATL ACAD SCI USA, V44, P1072, DOI 10.1073/pnas.44.10.1072; TYCKO R, 1990, CHEM PHYS LETT, V173, P461, DOI 10.1016/0009-2614(90)87235-J; WARD JB, 1973, BIOCHEM J, V133, P395, DOI 10.1042/bj1330395; WARTH AD, 1971, BIOCHEMISTRY-US, V10, P4349, DOI 10.1021/bi00800a001; WILSON GE, 1985, BIOCHEM BIOPH RES CO, V126, P1006, DOI 10.1016/0006-291X(85)90285-2; [No title captured]	25	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24485	24491						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761548				2022-12-25	WOS:A1991GW84500039
J	LOPEZ, AF; VADAS, MA; WOODCOCK, JM; MILTON, SE; LEWIS, A; ELLIOTT, MJ; GILLIS, D; IRELAND, R; OLWELL, E; PARK, LS				LOPEZ, AF; VADAS, MA; WOODCOCK, JM; MILTON, SE; LEWIS, A; ELLIOTT, MJ; GILLIS, D; IRELAND, R; OLWELL, E; PARK, LS			INTERLEUKIN-5, INTERLEUKIN-3, AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR CROSS-COMPETE FOR BINDING TO CELL-SURFACE RECEPTORS ON HUMAN EOSINOPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN INTERLEUKIN-5; FACTOR GM-CSF; DIFFERENTIATION FACTOR; SCHISTOSOMA-MANSONI; 3T3 FIBROBLASTS; DENSITY; HETEROGENEITY; EXPRESSION; HYPODENSE; SURVIVAL	Human interleukin (IL)-5 receptors were characterized by means of binding studies using bioactive I-125-labeled IL-5. Of purified primary myeloid cells, eosinophils and basophils but not neutrophils or monocytes expressed surface receptors for IL-5. Binding studies showed that eosinophils expressed a single class of high affinity receptors (K(a) = 1.2 x 10(10) M-1) with the number of receptors being small (< 1000 receptors/cell) and varying between individuals. Among several cell lines examined only HL-60 cells showed detectable IL-5 receptors which were small in numbers (200 receptors/cell) and also bound I-IL-5 with high affinity. The binding of IL-5 was rapid at 37-degrees-C while requiring several hours to reach equilibrium at 4-degrees-C. Specificity studies revealed that the two other human eosinophilopoietic cytokines IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF) inhibited the binding of I-125-IL-5 to eosinophils. No competition was observed by other eosinophil activating or nonactivating cytokines. The inhibition of I-125-IL-5 binding by IL-3 and GM-CSF was partial up to a concentration of competitor of 10(-7) M with GM-CSF consistently being the stronger competitor. Converse experiments using IL-5 as a competitor revealed that this cytokine inhibited the binding of I-125-IL-3 and of I-125-GM-CSF in some but not all the individuals tested, perhaps reflecting eosinophil heterogeneity in vivo. Cross-linking experiments on HL-60 cells demonstrated two IL-5-containing complexes of M(r) 150,000 and M(r) 80,000 both of which were inhibited by GM-CSF. The competition between IL-5, IL-3, and GM-CSF on the surface of mature eosinophils may represent a unifying mechanism that may help explain the common biological effects of these three eosinophilopoietic cytokines on eosinophil function. This unique pattern of competition may also be beneficial to the host by preventing excessive eosinophil stimulation.	IMMUNEX CORP,SEATTLE,WA 98101	Immunex Corporation	LOPEZ, AF (corresponding author), INST MED & VET SCI,DIV HUMAN IMMUNOL,FROME RD,ADELAIDE,SA 5000,AUSTRALIA.		Lopez, Angel F/E-2260-2011; Vadas, Mathew/R-1378-2019	Woodcock, Joanna/0000-0001-5127-9687; Lopez, Angel F/0000-0001-7430-0135	NATIONAL CANCER INSTITUTE [R01CA045822] Funding Source: NIH RePORTER; NCI NIH HHS [1 RO1 CA45 822-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEGLEY CG, 1986, BLOOD, V68, P162; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CAMPBELL HD, 1987, P NATIONAL ACADEMY S, V84, P6627; CHIHARA J, 1990, J EXP MED, V172, P1347, DOI 10.1084/jem.172.5.1347; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; CLUTTERBUCK EJ, 1990, BLOOD, V75, P1774; CONTRERAS MA, 1983, METHOD ENZYMOL, V92, P277; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; DOWER SK, 1981, BIOCHEMISTRY-US, V20, P6335, DOI 10.1021/bi00525a008; ELLIOTT MJ, 1989, BLOOD, V74, P2349; FERNANDEZBOTRAN R, 1989, J EXP MED, V169, P379, DOI 10.1084/jem.169.2.379; FUJISAWA T, 1990, J IMMUNOL, V144, P642; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIRAI K, 1990, J EXP MED, V172, P1525, DOI 10.1084/jem.172.5.1525; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; KAJITA T, 1985, INT ARCH ALLER A IMM, V78, P406, DOI 10.1159/000233922; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZ AF, 1990, J CELL PHYSIOL, V145, P69, DOI 10.1002/jcp.1041450111; LOPEZ AF, 1987, P NATL ACAD SCI USA, V84, P2761; LOPEZ AF, 1989, P NATL ACAD SCI USA, V86, P7022, DOI 10.1073/pnas.86.18.7022; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; LOPEZ AF, 1986, J EXP MED, V163, P1085, DOI 10.1084/jem.163.5.1085; LOPEZ AF, 1988, BLOOD, V72, P1797; MITA S, 1989, P NATL ACAD SCI USA, V86, P2311, DOI 10.1073/pnas.86.7.2311; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; OWEN WF, 1989, J EXP MED, V170, P343, DOI 10.1084/jem.170.1.343; OWEN WF, 1990, P NATL ACAD SCI USA, V87, P8647, DOI 10.1073/pnas.87.21.8647; PARK LS, 1986, J BIOL CHEM, V261, P4177; PARK LS, 1989, J BIOL CHEM, V264, P5420; Parry D A, 1988, J Mol Recognit, V1, P107, DOI 10.1002/jmr.300010302; PLAETINCK G, 1990, J EXP MED, V172, P683, DOI 10.1084/jem.172.3.683; PRIN L, 1983, INT ARCH ALLER A IMM, V72, P336, DOI 10.1159/000234893; PRIN L, 1984, CLIN EXP IMMUNOL, V57, P735; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; ROTHENBERG ME, 1988, J BIOL CHEM, V263, P13901; SANDERSON CJ, 1988, IMMUNOL REV, V102, P29, DOI 10.1111/j.1600-065X.1988.tb00740.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SILBERSTEIN DS, 1986, P NATL ACAD SCI USA, V83, P1055, DOI 10.1073/pnas.83.4.1055; SONODA Y, 1989, LEUKEMIA, V3, P14; SPRY C J F, 1985, Heart and Vessels, V1, P162, DOI 10.1007/BF02066412; VADAS MA, 1979, J IMMUNOL, V122, P1228; VANLEEUWEN BH, 1989, BLOOD, V73, P1142; WANG JM, 1989, EUR J IMMUNOL, V19, P701, DOI 10.1002/eji.1830190420; YANG YC, 1988, BLOOD, V71, P958	47	126	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24741	24747						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761568				2022-12-25	WOS:A1991GW84500077
J	MURRAY, PJ; SPITHILL, TW				MURRAY, PJ; SPITHILL, TW			VARIANTS OF A LEISHMANIA SURFACE-ANTIGEN DERIVED FROM A MULTIGENIC FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-CRUZI; MEXICANA-AMAZONENSIS; GLYCOPROTEIN GP63; GENE; EXPRESSION; SEQUENCE; PROTEIN; LIPOPHOSPHOGLYCAN; PROMASTIGOTES; DONOVANI	The promastigote surface antigen-2 (PSA-2) complex comprises a group of immunogenic surface antigens linked to the surface of the Leishmania major promastigote with glycosylphosphatidylinositol anchors. The L. major genome contains at least 14 PSA-2 genes on a 950-kilobase chromosome and comprising approximately 20% of the length of this chromosome. The sequence of three independent, but incomplete, PSA-2 cDNAs and one genomic fragment encoding a complete PSA-2 coding sequence were compared. PSA-2 genes encode polypeptides exhibiting 22-25aa tandem repeat elements, threonine-rich segments which vary between genes, a conserved COOH-terminal cysteine-rich region, and a conserved GPI anchor signal sequence. PSA-2 genes appear to be transcribed in a complex manner with multiple RNAs. The complex genomic organization of PSA-2 genes is present in other members of the genus suggesting that PSA-2 function is important for the biology of Leishmania.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA; VICTORIAN INST ANIM SCI,ATTWOOD,VIC 3049,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Victorian Department of Environment & Primary Industries			Murray, Peter J/K-4725-2018	Murray, Peter J/0000-0001-6329-9802; Spithill, Terence/0000-0002-4171-1277	PHS HHS [A1-19347] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BEARD CA, 1988, MOL BIOCHEM PARASIT, V28, P227, DOI 10.1016/0166-6851(88)90007-2; BORDIER C, 1986, P NATL ACAD SCI USA, V83, P5988, DOI 10.1073/pnas.83.16.5988; BOUVIER J, 1989, MOL BIOCHEM PARASIT, V37, P235, DOI 10.1016/0166-6851(89)90155-2; BUTTON LL, 1989, MOL BIOCHEM PARASIT, V32, P271, DOI 10.1016/0166-6851(89)90076-5; CHAMPSI J, 1988, INFECT IMMUN, V56, P3272, DOI 10.1128/IAI.56.12.3272-3279.1988; CHANDHURI G, 1989, J BIOL CHEM, V264, P7483; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COWMAN AF, 1984, CELL, V37, P653, DOI 10.1016/0092-8674(84)90397-0; DONELSON JE, 1988, BIOL PARASITISM; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERGUSON MAJ, 1983, BIOCHEM J, V213, P313, DOI 10.1042/bj2130313; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROMMEL TO, 1990, MOL BIOCHEM PARASIT, V38, P25, DOI 10.1016/0166-6851(90)90201-V; GARFINKEL MD, 1983, J MOL BIOL, V168, P765, DOI 10.1016/S0022-2836(83)80074-6; HANDMAN E, 1983, MOL BIOCHEM PARASIT, V7, P111, DOI 10.1016/0166-6851(83)90039-7; HANDMAN E, 1985, EMBO J, V4, P637; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; IBANEZ CF, 1988, MOL BIOCHEM PARASIT, V30, P27, DOI 10.1016/0166-6851(88)90129-6; IOVANNISCI DM, 1989, MOL BIOCHEM PARASIT, V34, P177, DOI 10.1016/0166-6851(89)90009-1; IP HS, 1990, MOL BIOCHEM PARASIT, V40, P163, DOI 10.1016/0166-6851(90)90038-N; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; KAHL LP, 1987, J IMMUNOL, V138, P1587; KAHN S, 1990, J EXP MED, V172, P589, DOI 10.1084/jem.172.2.589; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; LANDFEAR SM, 1984, NATURE, V309, P716, DOI 10.1038/309716a0; LOHMAN KL, 1990, P NATL ACAD SCI USA, V87, P8393, DOI 10.1073/pnas.87.21.8393; Maniatis T., 1982, MOL CLONING; MCCONVILLE MJ, 1987, P NATL ACAD SCI USA, V84, P8941, DOI 10.1073/pnas.84.24.8941; MCCONVILLE MJ, 1990, MOL BIOCHEM PARASIT, V38, P57, DOI 10.1016/0166-6851(90)90205-Z; MEADE JC, 1987, MOL CELL BIOL, V7, P3937, DOI 10.1128/MCB.7.11.3937; MEDINAACOSTA E, 1989, MOL BIOCHEM PARASIT, V37, P263, DOI 10.1016/0166-6851(89)90158-8; MILLER RA, 1990, MOL BIOCHEM PARASIT, V39, P267, DOI 10.1016/0166-6851(90)90065-T; MURRAY PJ, 1989, J IMMUNOL, V143, P4221; MURRAY PJ, 1990, EXP PARASITOL, V71, P294, DOI 10.1016/0014-4894(90)90034-A; MURRAY PJ, 1989, INFECT IMMUN, V57, P2203, DOI 10.1128/IAI.57.7.2203-2209.1989; OLAFSON RW, 1990, J BIOL CHEM, V265, P12240; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; PETERSEN DS, 1989, EMBO J, V12, P3911; PETERSON DS, 1986, NATURE, V322, P566, DOI 10.1038/322566a0; RUSSELL DG, 1987, EUR J BIOCHEM, V164, P213, DOI 10.1111/j.1432-1033.1987.tb11013.x; SACKS DL, 1989, EXP PARASITOL, V69, P100, DOI 10.1016/0014-4894(89)90176-8; SAMARAS N, 1987, MOL BIOCHEM PARASIT, V25, P279, DOI 10.1016/0166-6851(87)90092-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPITHILL TW, 1987, MOL BIOCHEM PARASIT, V24, P23, DOI 10.1016/0166-6851(87)90112-5; STEIN DA, 1990, NUCLEIC ACIDS RES, V18, P1549, DOI 10.1093/nar/18.6.1549; TAKLE GB, 1989, MOL BIOCHEM PARASIT, V37, P57, DOI 10.1016/0166-6851(89)90102-3; TSCHUDI C, 1988, EMBO J, V7, P455, DOI 10.1002/j.1460-2075.1988.tb02833.x; WALLIS AE, 1987, J EXP MED, V166, P1814, DOI 10.1084/jem.166.6.1814; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WILSON ME, 1989, J IMMUNOL, V143, P678	52	56	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24477	24484						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761547				2022-12-25	WOS:A1991GW84500038
J	RICHES, DWH; UNDERWOOD, GA				RICHES, DWH; UNDERWOOD, GA			EXPRESSION OF INTERFERON-BETA DURING THE TRIGGERING PHASE OF MACROPHAGE CYTOCIDAL ACTIVATION - EVIDENCE FOR AN AUTOCRINE PARACRINE ROLE IN THE REGULATION OF THIS STATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; TUMOR NECROSIS FACTOR; FACTOR-B; MURINE MACROPHAGES; NITRIC-OXIDE; BACTERIAL LIPOPOLYSACCHARIDE; CYTO-TOXICITY; MESSENGER-RNA; INVITRO; ACID	The expression of cytocidal activity is induced by the sequential interaction of macrophages with a priming stimulus, such as interferon (IFN)alpha, -beta, or -gamma, and a triggering stimulus, such as poly(I.C) or lipopolysaccharide. However, most triggering stimuli are also capable of inducing IFN expression. This suggested to us the possibility that in addition to its role in initially priming macrophages for cytocidal activity, IFN may also be expressed during the triggering stage where it may potentially contribute to the regulation of cytocidal activity. We have explored this question by (i) attempting to dissociate IFN-inducing activity from triggering activity with a variety of structurally related and charge-related polyanions; (ii) determining if macrophages express IFN during the triggering stage; and (iii) questioning if IFN produced during the triggering stage contributes to the regulation of cytocidal activation. Exposure of unprimed macrophages to a triggering concentration of poly(I.C) alone failed to induce IFN-beta expression. However, exposure of IFN-beta-primed cells to poly(I.C) dramatically increased the expression of IFN-beta mRNA. Priming with IFN-gamma was likewise found to increase the expression of IFN-beta mRNA in response to a triggering concentration of polyribonucleotides. Three approaches were adopted to ascertain if the increased expression of IFN-beta contributed to cytocidal activation. First, macrophages derived from strains of mice which differ in their susceptibility to IFN induction by poly(I.C) were primed with IFN-beta, washed, and triggered with poly(I.C). Under these conditions, macrophages derived from stain B10.A(2R), which are hyporesponsive to poly(I.C) in terms of IFN induction, also showed a diminished capacity to express Bf, a marker of cytocidal activation. Second, exposure of IFN-primed macrophages to poly(I.C) in the presence of anti-IFN-alpha/beta antibody was found to reduce substantially the synthesis of NO2/NO3, an alternative marker of macrophage cytocidal activation. Third, exposure of IFN-primed macrophages to the calcium ionophores ionomycin or A23187, which do not induce the production of IFN-beta during triggering, led to an abbreviated expression of Bf compared with stimuli that induce IFN-beta expression such as poly(I.C). However, the capacity to synthesize Bf in response to A23187 was partially reconstituted when macrophages were triggered with the ionophore in the continuous presence of IFN-beta. Collectively, these data show that IFN-beta is expressed during the triggering stage of macrophage cytocidal activation and suggest that it plays an important and previously unsuspected role in the expression of this state.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DIV PULM SCI,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	RICHES, DWH (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DIV BASIC SCI,NEUSTADT BLDG,RM D405,DENVER,CO 80206, USA.				NCI NIH HHS [CA 50107] Funding Source: Medline; NHLBI NIH HHS [HL 27353] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050107] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL027353] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER P, 1971, NATURE-NEW BIOL, V232, P76, DOI 10.1038/newbio232076a0; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BELARDELLI F, 1987, J GEN VIROL, V68, P2203, DOI 10.1099/0022-1317-68-8-2203; BREHM G, 1986, J INTERFERON RES, V6, P21, DOI 10.1089/jir.1986.6.21; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLBY C, 1969, BIOCHEMISTRY-US, V63, P160; COLE FS, 1985, J IMMUNOL, V134, P2610; DECLERCQ E, 1974, P NATL ACAD SCI USA, V71, P182; DEMAEYER E, 1979, IMMUNOGENETICS, V8, P257, DOI 10.1007/BF01561435; DEMAEYER E, 1975, IMMUNOGENETICS, V1, P438; DEMAEYER E, 1975, IMMUNOGENETICS, V2, P151, DOI 10.1007/BF01572283; DESOMER P, 1968, J VIROL, V2, P886, DOI 10.1128/JVI.2.9.886-893.1968; DING AH, 1988, J IMMUNOL, V141, P2407; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FIELD AK, 1967, P NATL ACAD SCI USA, V58, P1004, DOI 10.1073/pnas.58.3.1004; FLEIT HB, 1981, CELL IMMUNOL, V57, P495, DOI 10.1016/0008-8749(81)90107-6; FUJITA T, 1981, VIROLOGY, V112, P62, DOI 10.1016/0042-6822(81)90612-7; GARLEPP MJ, 1989, J CLIN LAB IMMUNOL, V28, P137; GESSANI S, 1989, J VIROL, V63, P2785, DOI 10.1128/JVI.63.6.2785-2789.1989; HAVELL EA, 1983, J RETICULOENDOTH SOC, V33, P369; HEIDENREICH S, 1988, J IMMUNOL, V140, P1511; Hibbs J B, 1979, Adv Exp Med Biol, V121B, P433; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HIGASHI Y, 1983, J BIOL CHEM, V258, P9522; ISAACS A, 1958, NATURE, V182, P1073, DOI 10.1038/1821073a0; MACE KF, 1988, CANCER RES, V48, P5427; PACE JL, 1981, J RETICULOENDOTH SOC, V30, P15; PACE JL, 1988, J LEUKOCYTE BIOL, V44, P514, DOI 10.1002/jlb.44.6.514; PACE JL, 1985, J IMMUNOL, V134, P977; PAOLUCCI ES, 1983, IMMUNOGENETICS, V17, P67, DOI 10.1007/BF00364290; PUGLIESE A, 1980, ARCH VIROL, V65, P83, DOI 10.1007/BF01340545; RICHES DWH, 1986, J CELL BIOL, V102, P1606, DOI 10.1083/jcb.102.5.1606; RICHES DWH, 1988, J IMMUNOL, V141, P180; ROBERTS BE, 1973, P NATL ACAD SCI USA, V70, P2330, DOI 10.1073/pnas.70.8.2330; ROOS MH, 1982, IMMUNOGENETICS, V15, P23, DOI 10.1007/BF00375499; ROSZTOCZY I, 1976, ACTA VIROL, V20, P472; RUCO LP, 1978, J IMMUNOL, V121, P2035; RUSSELL SW, 1977, J EXP MED, V146, P1511, DOI 10.1084/jem.146.6.1511; SACKSTEIN R, 1983, J BIOL CHEM, V258, P4693; Schultz R M, 1980, Adv Pharmacol Chemother, V17, P157, DOI 10.1016/S1054-3589(08)60010-1; SCHULTZ RM, 1977, SCIENCE, V197, P674, DOI 10.1126/science.877584; SCHULTZ RM, 1978, CELL IMMUNOL, V35, P84, DOI 10.1016/0008-8749(78)90128-4; SCHULTZ RM, 1979, CELL IMMUNOL, V48, P52, DOI 10.1016/0008-8749(79)90098-4; SHAW GD, 1983, NUCLEIC ACIDS RES, V11, P555, DOI 10.1093/nar/11.3.555; STEWART CC, 1981, METHODS STUDYING MON, P5; STEWART WE, 1971, J VIROL, V7, P792, DOI 10.1128/JVI.7.6.792-801.1971; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; STUEHR DJ, 1989, J EXP MED, V169, P1011, DOI 10.1084/jem.169.3.1011; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TARAMELLI D, 1982, ADV EXP MED BIOL, V155, P487; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TORRENCE PF, 1984, ANTIVIR RES, V4, P339, DOI 10.1016/0166-3542(84)90005-6; TORRES BA, 1985, BIOCHEM BIOPH RES CO, V131, P395, DOI 10.1016/0006-291X(85)91815-7; WEINBERG JB, 1978, J IMMUNOL, V121, P72	57	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24785	24792						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761573				2022-12-25	WOS:A1991GW84500083
J	SHARMA, VS; BANDYOPADHYAY, D; BERJIS, M; RIFKIND, J; BOSS, GR				SHARMA, VS; BANDYOPADHYAY, D; BERJIS, M; RIFKIND, J; BOSS, GR			DOUBLE-MIXING KINETIC-STUDIES OF THE REACTIONS OF MONOLIGANDED SPECIES OF HEMOGLOBIN - ALPHA-2(CO)1-BETA-2 AND ALPHA-2-BETA-2(CO)1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE; LIGAND-BINDING; CARBOXYHEMOGLOBIN	The kinetics of CO association to and dissociation from the two isomers of monoliganded species alpha(I)CO-beta(I)(alpha(II)beta(II)) and alpha(I)beta(I)(alpha(II)beta(II)CO) has been studied by double-mixing stopped-flow and microperoxidase methods. The monoliganded species were generated by hybridization between excess ferric Hb and alpha-2CO-beta-2+ or alpha-2+-beta-2CO prepared by high-pressure liquid chromatography (HPLC). The results indicated that: 1) there were no significant differences in the reactivities of alpha and beta-chains in the first step of ligation; 2) in the second step of ligation there was significant cooperativity in the reaction of deoxyhemoglobin with 0.05 or 0.1 equivalent of CO. Diliganded species were therefore formed in significant amounts. The double-mixing HPLC results suggested that in the second step of ligation alpha-chains reacted faster than the beta chains, and the main diliganded species formed was alpha(I)beta(I)CO(alpha(II)CO-beta(II)) or its isomer alpha(I)CO(I)(alpha(II)beta(II)CO). These results seem to indicate that the reaction of the first CO is mostly random and in the second step of ligation CO binds more to the tetramers in which one beta-chain is already ligated: alpha(I)beta(I)(alpha(II)beta(II)) + CO --> alpha(I)CO-beta(I)(alpha(II)beta(II) and alpha(I)beta(I)CO(alpha(II)beta(II)) + CO --> alpha(I)beta(I)CO(alpha(II)CO-beta(II).	NIH, GERONTOL RES UNIT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA	SHARMA, VS (corresponding author), UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA.			Boss, Gerry/0000-0002-9758-8714	NHLBI NIH HHS [HL31159] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL031159, R01HL031159] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERS GK, 1987, ANNU REV BIOPHYS BIO, V16, P583; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BENJAMIN WT, 1981, METHOD ENZYMOL, V76, P596; BERJIS M, 1990, BIOCHEMISTRY-US, V29, P10106, DOI 10.1021/bi00495a014; CASSOLY R, 1972, J BIOL CHEM, V247, P7332; DICERA E, 1987, BIOCHEMISTRY-US, V26, P6494, DOI 10.1021/bi00394a031; GIBSON QH, 1973, J BIOL CHEM, V248, P1281; KHALEQUE MA, 1986, PHOTOBIOCH PHOTOBIOP, V13, P155; MACQUARRIE R, 1972, J BIOL CHEM, V247, P5686; MATHEWS AJ, 1991, J BIOL CHEM, V266, P21631; PERRELLA M, 1986, J BIOL CHEM, V261, P8391; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; SAMAJA M, 1987, J BIOL CHEM, V262, P4528; SHARMA VS, 1988, J BIOL CHEM, V263, P2292; SHARMA VS, 1976, J BIOL CHEM, V251, P4267; SHARMA VS, 1989, J BIOL CHEM, V264, P10582; SHARMA VS, 1983, J MOL BIOL, V166, P677, DOI 10.1016/S0022-2836(83)80292-7; SMITH FR, 1985, P NATL ACAD SCI USA, V82, P5347, DOI 10.1073/pnas.82.16.5347; VIGGIANO G, 1979, P NATL ACAD SCI USA, V76, P3673, DOI 10.1073/pnas.76.8.3673; ZAHROON IA, 1989, BIOPHYS J, V56, P947, DOI 10.1016/S0006-3495(89)82740-7	20	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24492	24497						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761549				2022-12-25	WOS:A1991GW84500040
J	OHNUMA, S; KOYAMA, T; OGURA, K				OHNUMA, S; KOYAMA, T; OGURA, K			PURIFICATION OF SOLANESYL-DIPHOSPHATE SYNTHASE FROM MICROCOCCUS-LUTEUS - A NEW CLASS OF PRENYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERANYLGERANYL PYROPHOSPHATE SYNTHETASE; RUBBER ELONGATION-FACTOR; 2 ESSENTIAL COMPONENTS; RAT-LIVER MICROSOMES; BACILLUS-SUBTILIS; LACTOBACILLUS-PLANTARUM; HEVEA-BRASILIENSIS; BIOSYNTHESIS; PROTEIN; SPECIFICITY	The activity of solanesyl-diphosphate synthase from Micrococcus luteus is stimulated by a high molecular mass fraction (HMF) which is separated from cell-free extracts of the same bacterium by DEAE-Toyopearl chromatography followed by Sephadex G-100 chromatography. By employing HMF in the assay procedure, solanesyl-diphosphate synthase was able to be purified to homogeneity and was found to be a homodimer with a monomeric molecular mass of 34 kDa. In contrast to hexaprenyl- and heptaprenyl-diphosphate synthases, which are composed of two easily dissociable components that are inactive unless combined, the homogeneously purified solanesyl-diphosphate synthase itself showed a catalytic activity, though weak, catalyzing the synthesis of both (all-E)-nonaprenyl-(solanesyl-) and (all-E)-octaprenyl diphosphate. HMF does not affect the stability of solanesyl-diphosphate synthase or K(m) values for isopentenyl diphosphate and farnesyl diphosphate, but it markedly increases V(max) values in a time-dependent manner. Several lines of evidence indicate that HMF contains a factor which binds to polyprenyl products and removes them out of the active site of enzyme to facilitate and maintain the turnover of catalysis.	TOHOKU UNIV,INST CHEM REACT SCI,SENDAI,MIYAGI 980,JAPAN	Tohoku University	OGURA, K (corresponding author), TOHOKU UNIV,INST CHEM REACT SCI,SENDAI,MIYAGI 980,JAPAN.			Ohnuma, Shin-ichi/0000-0002-3305-5126				ADAIR WL, 1984, J BIOL CHEM, V259, P4441; ALLEN CM, 1967, J BIOL CHEM, V242, P1895; ALLEN CM, 1976, ARCH BIOCHEM BIOPHYS, V175, P236, DOI 10.1016/0003-9861(76)90504-X; BABA T, 1980, ARCH BIOCHEM BIOPHYS, V200, P474, DOI 10.1016/0003-9861(80)90379-3; BABA T, 1984, BIOCHEMISTRY-US, V17, P5598; BARTLETT DL, 1985, ANAL BIOCHEM, V149, P507, DOI 10.1016/0003-2697(85)90606-2; BLACKSHEAR PJ, 1984, METHOD ENZYMOL, V104, P237; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BREMS DN, 1981, BIOCHEMISTRY-US, V20, P3711, DOI 10.1021/bi00516a007; BRINKHAUS FL, 1988, ARCH BIOCHEM BIOPHYS, V266, P607, DOI 10.1016/0003-9861(88)90293-7; DAVISSON VJ, 1986, J ORG CHEM, V51, P4768, DOI 10.1021/jo00375a005; DENNIS MS, 1989, J BIOL CHEM, V264, P18618; DENNIS MS, 1989, J BIOL CHEM, V264, P18608; EBERHARDT NL, 1975, J BIOL CHEM, V250, P863; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; FUJII H, 1980, BIOCHEM BIOPH RES CO, V96, P1648, DOI 10.1016/0006-291X(80)91363-7; FUJII H, 1983, FEBS LETT, V161, P257, DOI 10.1016/0014-5793(83)81020-5; FUJII H, 1982, J BIOL CHEM, V257, P4610; FUJISAKI S, 1986, J BIOCHEM-TOKYO, V99, P1327, DOI 10.1093/oxfordjournals.jbchem.a135600; GAVEY KL, 1981, J BIOL CHEM, V256, P2993; HEIDE L, 1989, ARCH BIOCHEM BIOPHYS, V273, P331, DOI 10.1016/0003-9861(89)90491-8; ISHII K, 1986, BIOCHEM J, V233, P733; JEFFRIES L, 1967, NATURE, V215, P257, DOI 10.1038/215257a0; KOYAMA T, 1988, J BIOCHEM-TOKYO, V103, P867, DOI 10.1093/oxfordjournals.jbchem.a122363; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOVICS FM, 1981, BIOCHEMISTRY-US, V20, P1893, DOI 10.1021/bi00510a027; LIGHT DR, 1989, J BIOL CHEM, V264, P18598; LIGHT DR, 1989, J BIOL CHEM, V264, P18589; MUTH JD, 1984, ARCH BIOCHEM BIOPHYS, V230, P49, DOI 10.1016/0003-9861(84)90085-7; NOLAND BJ, 1980, J BIOL CHEM, V255, P4282; OGURA K, 1985, METHOD ENZYMOL, V110, P167; Poulter C. D., 1981, BIOSYNTHESIS ISOPREN, V1, P161; REED BC, 1975, BIOCHEMISTRY-US, V14, P50, DOI 10.1021/bi00672a009; SAGAMI H, 1989, BIOCHIM BIOPHYS ACTA, V1002, P218, DOI 10.1016/0005-2760(89)90290-7; SAGAMI H, 1981, J BIOCHEM-TOKYO, V89, P1573, DOI 10.1093/oxfordjournals.jbchem.a133351; SAGAMI H, 1981, BIOCHEM INT, V3, P669; SAGAMI H, 1977, BIOCHEMISTRY-US, V16, P4616, DOI 10.1021/bi00640a014; SAITO A, 1979, J BIOL CHEM, V254, P8511; SAITO Y, 1981, J BIOCHEM-TOKYO, V89, P1445, DOI 10.1093/oxfordjournals.jbchem.a133337; SHINKA T, 1975, J BIOCHEM-TOKYO, V78, P1177, DOI 10.1093/oxfordjournals.jbchem.a131014; SPENER F, 1989, FEBS LETT, V244, P1, DOI 10.1016/0014-5793(89)81149-4; STORM DR, 1973, J BIOL CHEM, V248, P3940; SUGA T, 1991, PHYTOCHEMISTRY, V30, P1757, DOI 10.1016/0031-9422(91)85007-M; TAKAHASHI I, 1982, J BIOCHEM-TOKYO, V92, P1527, DOI 10.1093/oxfordjournals.jbchem.a134077; TAKAHASHI I, 1980, J BIOL CHEM, V255, P4539; TAKAHASHI I, 1981, J BIOCHEM-TOKYO, V89, P1581, DOI 10.1093/oxfordjournals.jbchem.a133352; YOSHIDA I, 1987, BIOCHEMISTRY-US, V26, P6840, DOI 10.1021/bi00395a038; YOSHIDA I, 1989, BIOCHEM BIOPH RES CO, V160, P448, DOI 10.1016/0006-291X(89)92453-4	48	59	61	3	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23706	23713						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748647				2022-12-25	WOS:A1991GV31900031
J	ROPP, PA; LITTLE, MR; CHENG, PW				ROPP, PA; LITTLE, MR; CHENG, PW			MUCIN BIOSYNTHESIS - PURIFICATION AND CHARACTERIZATION OF A MUCIN BETA-6N-ACETYLGLUCOSAMINYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE; GLYCOPROTEIN-SYNTHESIS; POLYACRYLAMIDE GELS; DYE-BINDING; BETA-6-N-ACETYLGLUCOSAMINYLTRANSFERASE; PROTEINS; CELLS; SIALOGLYCOPROTEIN; EXPRESSION; ACTIVATION	We have purified, to apparent homogeneity, a mucin beta-6N-acetylglucosaminyltransferase (beta-6GlcNAc transferase) from bovine tracheal epithelium. Golgi membranes were isolated from a 0.25 M sucrose homogenate of epithelial scrapings by discontinuous sucrose gradient centrifugation. The Golgi membranes were solubilized with 1% Triton X-100 in the presence of 1 mM Gal-beta-1-3GalNAc-alpha-benzyl (Bzl) to stabilize the beta-6GlcNAc transferase. The solubilized enzyme was bound to a UDP-hexanolamine-Actigel-ALD Superflow affinity column equilibrated with 1 mM Gal-beta-1-3GalNAc-alpha-Bzl and 5 mM Mn2+. Elution of the enzyme with 0.5 mM UDP-GlcNAc resulted in a 133,800-fold purification with a 1.3% yield and a specific activity of 70-mu-mol/min/mg protein. Radioiodination of the purified enzyme followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography revealed a single band at 69,000 Da. Kinetic analyses of the beta-6GlcNAc tranferase-catalyzed reaction showed an ordered sequential mechanism in which UDP-GlcNAc binds to the enzyme first and UDP is released last. The K(m) values for UDP-GlcNAc and Gal-beta-1-3GalNAc-alpha-Bzl were 0.36 and 0.14 mM, respectively. Acceptor competition studies showed that the purified beta-6GlcNAc transferase can use core 1 and core 3 mucin oligosaccharides as well as GlcNAc-beta-1-3Gal-beta-R as acceptor substrates. Proton NMR analyses of the three products demonstrated that GlcNAc was added in a beta-1-6 linkage to the penultimate GalNAc or Gal, suggesting that this enzyme is capable of synthesizing all beta-6GlcNAc structures found in mucin-type oligosaccharides.	UNIV N CAROLINA, DEPT PEDIAT, 635 CLIN SCI BLDG, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	CHENG, PW (corresponding author), UNIV N CAROLINA, DEPT PEDIAT, 635 CLIN SCI BLDG, CHAPEL HILL, NC 27599 USA.							AMBUDKAR SV, 1986, J BIOL CHEM, V261, P79; BASU M, 1984, J BIOL CHEM, V259, P2557; BELLEAU B, 1968, J AM CHEM SOC, V90, P1651, DOI 10.1021/ja01008a045; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BOAT TF, 1980, FED PROC, V39, P3067; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKHAUSEN I, 1986, EUR J BIOCHEM, V157, P463, DOI 10.1111/j.1432-1033.1986.tb09690.x; BROCKHAUSEN I, 1985, BIOCHEMISTRY-US, V24, P1866, DOI 10.1021/bi00329a010; BROCKHAUSEN I, 1991, CANCER RES, V51, P1257; CARLSON DM, 1968, J BIOL CHEM, V243, P616; CHENG PW, 1985, BIOCHEM J, V227, P405, DOI 10.1042/bj2270405; DALE RMK, 1975, BIOCHEMISTRY-US, V14, P2447, DOI 10.1021/bi00682a027; DAMERVAL C, 1987, ELECTROPHORESIS, V8, P158, DOI 10.1002/elps.1150080308; EVANS ME, 1972, CARBOHYD RES, V21, P473, DOI 10.1016/S0008-6215(00)84931-9; FLOWERS HM, 1965, J ORG CHEM, V30, P2041, DOI 10.1021/jo01017a078; FUKUDA M, 1989, CIBA F SYMP, V145, P257; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; GREER WL, 1989, BIOCHEM CELL BIOL, V67, P503, DOI 10.1139/o89-081; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HIGGINS EA, 1991, J BIOL CHEM, V266, P6280; HILL HD, 1977, J BIOL CHEM, V252, P3791; KOENDERMAN AHL, 1987, EUR J BIOCHEM, V166, P199, DOI 10.1111/j.1432-1033.1987.tb13502.x; KOENDERMAN AHL, 1989, RECL TRAV CHIM PAY B, V108, P369; KOHN J, 1982, BIOCHEM BIOPH RES CO, V107, P878, DOI 10.1016/0006-291X(82)90604-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPPANEN A, 1989, 10TH P INT S GLYC JE; Moss DW, 1984, METHOD ENZYMAT AN, V4, P92; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; NISHIKAWA Y, 1988, J BIOL CHEM, V263, P8270; OLDEN K, 1985, TRENDS BIOCHEM SCI, V10, P78, DOI 10.1016/0968-0004(85)90238-5; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; PILLER F, 1988, J BIOL CHEM, V263, P15146; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; RAO AK, 1978, ANAL BIOCHEM, V91, P490, DOI 10.1016/0003-2697(78)90535-3; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; ROPP PA, 1990, ANAL BIOCHEM, V187, P104, DOI 10.1016/0003-2697(90)90424-8; ROUSSEL P, 1985, 7 P INT S GLYC HOUST, V1, P99; SAHA GB, 1989, NUCL MED BIOL, V16, P431, DOI 10.1016/0883-2897(89)90112-8; SANGADALA S, 1991, MOL CELL BIOCHEM, V101, P125; SCHACHTER H, 1989, METHOD ENZYMOL, V179, P351; SEKINE M, 1990, J BIOCHEM-TOKYO, V108, P103, DOI 10.1093/oxfordjournals.jbchem.a123147; TADOLINI B, 1982, ITAL J BIOCHEM, V92, P822; TANIGUCHI N, 1991, GLYCOCONJUGATE J, V8, P261; VANDENEIJNDEN DH, 1983, J BIOL CHEM, V258, P3435; VANHALBEEK H, 1982, EUR J BIOCHEM, V127, P21; Vassault A, 1984, METHODS ENZYM ANAL, V3, P118; Wharton DC., 1967, METHOD ENZYMOL, P245; WICE BM, 1985, J BIOL CHEM, V260, P139; WILLIAMS D, 1980, J BIOL CHEM, V255, P1247; WILLIAMS D, 1980, J BIOL CHEM, V255, P1253; WINGERT WE, 1984, BIOCHEMISTRY-US, V23, P690, DOI 10.1021/bi00299a017; YAZAWA S, 1986, CARBOHYD RES, V149, P241, DOI 10.1016/S0008-6215(00)90381-1; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772; ZHIVKOV V, 1975, COMP BIOCHEM PHYS B, V51, P421, DOI 10.1016/0305-0491(75)90032-2; ZIELENSKI J, 1983, FEBS LETT, V158, P164, DOI 10.1016/0014-5793(83)80700-5; ZIELENSKI J, 1983, FEBS LETT, V163, P114, DOI 10.1016/0014-5793(83)81175-2	57	67	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23863	23871						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1836212				2022-12-25	WOS:A1991GV31900053
J	GARRISON, K; MACKRELL, AJ; FESSLER, JH				GARRISON, K; MACKRELL, AJ; FESSLER, JH			DROSOPHILA LAMININ-A CHAIN SEQUENCE, INTERSPECIES COMPARISON, AND DOMAIN-STRUCTURE OF A MAJOR CARBOXYL PORTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; B-CHAINS; MULTIDOMAIN PROTEIN; NEURITE OUTGROWTH; MEMBRANE-PROTEIN; GLOBULAR DOMAIN; ACID SEQUENCES; LONG ARM; MOUSE; CDNA	Recent studies ascribed some biological actions of cell adhesion and cell outgrowth to the carboxyl-most 1200 amino acids of vertebrate laminin A chains. Here we report a 6.1-kilobase pair nucleotide cDNA sequence encoding 1951 amino acids and the carboxyl end of a Drosophila laminin A chain. It corresponds to the mouse laminin A domains G, I, II, and III, but may represent a different type of laminin A chain. The arrangement of the cysteine-rich repeats of domain III resembles that of B2 chains. However, it has more amino acid identity with a portion of the mouse laminin A chain domain IIIb than with other laminin repeats. Domains I and II are consistent with an interrupted coiled-coil alpha-helical model of the long arm of laminin but are poorly conserved. The G domain contains five subdomains which are individually related to subdomains of vertebrate laminin A chains. The results indicate that laminin G subdomains should be considered individually, rather than merely as parts of a G-globule. A sequence of hydroxyamino acids contributes to a spacer between two of the subdomains. Stretches of hydroxyamino acids may be indicative of junctions between domains of extracellular Drosophila proteins.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,405 HILGARD AVE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG002128] Funding Source: NIH RePORTER; NIA NIH HHS [AG02128] Funding Source: Medline; NIGMS NIH HHS [GM07185] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARLOW DP, 1984, EMBO J, V3, P2355, DOI 10.1002/j.1460-2075.1984.tb02140.x; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; BOGAERT T, 1987, CELL, V51, P929, DOI 10.1016/0092-8674(87)90580-0; CHI HC, 1988, NUCLEIC ACIDS RES, V16, P7205, DOI 10.1093/nar/16.14.7205; CHI HC, 1989, J BIOL CHEM, V264, P1543; Dayhoff M. O., 1976, ATLAS PROTEIN SEQ S2, V5, P1; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEUTZMANN R, 1988, EUR J BIOCHEM, V177, P35, DOI 10.1111/j.1432-1033.1988.tb14342.x; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P513, DOI 10.1111/j.1432-1033.1990.tb19151.x; DURKIN ME, 1988, BIOCHEMISTRY-US, V27, P5198, DOI 10.1021/bi00414a038; EDGAR D, 1988, J CELL BIOL, V106, P1299, DOI 10.1083/jcb.106.4.1299; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; EKBLOM P, 1989, FASEB J, V3, P2141, DOI 10.1096/fasebj.3.10.2666230; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FESSLER JH, 1989, ANNU REV CELL BIOL, V5, P309, DOI 10.1146/annurev.cb.05.110189.001521; FESSLER JH, 1984, ROLE EXTRACELLULAR M, P207; FESSLER LI, 1987, J CELL BIOL, V105, P2383, DOI 10.1083/jcb.105.5.2383; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; GOAD WB, 1982, NUCLEIC ACIDS RES, V10, P247, DOI 10.1093/nar/10.1.247; HAAPARANTA T, 1991, MATRIX, V11, P151, DOI 10.1016/S0934-8832(11)80153-8; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; KANEHISA M, 1984, NUCLEIC ACIDS RES, V12, P417, DOI 10.1093/nar/12.1Part1.417; KLEIN G, 1990, DEVELOPMENT, V110, P823; MACKRELL AJ, 1988, P NATL ACAD SCI USA, V85, P2633, DOI 10.1073/pnas.85.8.2633; Marshall R D, 1974, Biochem Soc Symp, P17; MONTELL DJ, 1989, J CELL BIOL, V109, P2441, DOI 10.1083/jcb.109.5.2441; MONTELL DJ, 1988, CELL, V53, P463, DOI 10.1016/0092-8674(88)90166-3; NISSINEN M, 1991, BIOCHEM J, V276, P369, DOI 10.1042/bj2760369; NOONAN DM, 1988, J BIOL CHEM, V263, P16379; OLSEN D, 1989, LAB INVEST, V60, P772; OLSON PF, 1990, EMBO J, V9, P1219, DOI 10.1002/j.1460-2075.1990.tb08229.x; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PARRY DAD, 1987, FIBROUS PROTEIN STRU, P141; PAULSSON M, 1989, J BIOL CHEM, V264, P18726; PAULSSON M, 1985, EMBO J, V4, P309, DOI 10.1002/j.1460-2075.1985.tb03630.x; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SEPHEL GC, 1989, BIOCHEM BIOPH RES CO, V162, P821, DOI 10.1016/0006-291X(89)92384-X; SEPHEL GC, 1989, DEV NEUROSCI-BASEL, V11, P313, DOI 10.1159/000111909; SKUBITZ A P N, 1990, Journal of Cell Biology, V111, p143A; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P4731, DOI 10.1093/nar/10.15.4731; TERRANOVA VP, 1984, SCIENCE, V226, P982, DOI 10.1126/science.6505678; THOMAS U, 1991, DEVELOPMENT, V111, P749; TIMPL R, 1979, J BIOL CHEM, V254, P9933; TOKIDA Y, 1990, J BIOL CHEM, V265, P18123; VOLK T, 1990, CELL, V63, P525, DOI 10.1016/0092-8674(90)90449-O; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHAO DB, 1988, EMBO J, V7, P1115, DOI 10.1002/j.1460-2075.1988.tb02920.x	54	39	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22899	22904						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744083				2022-12-25	WOS:A1991GT48300022
J	PARVIN, JD; SHARP, PA				PARVIN, JD; SHARP, PA			IDENTIFICATION OF NOVEL FACTORS WHICH BIND SPECIFICALLY TO THE CORE PROMOTER OF THE IMMUNOGLOBULIN HEAVY-CHAIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; DNA-SEQUENCE ELEMENTS; YEAST TATA ELEMENT; NUCLEOTIDE-SEQUENCE; TRANSCRIPTIONAL ACTIVATION; ACCURATE TRANSCRIPTION; B-CELLS; PROTEIN; VIRUS; INITIATION	Nuclear extracts from HeLa cells and the B-cell line, BJA-B, generated two protein-DNA complexes which bound specifically to sequences in the TATA box of the immunoglobulin heavy chain gene (IgH) promoter. Complex A also bound the core promoter of a retroviral long terminal repeat but did not bind to five other promoters including the adenovirus major late promoter. Of these seven promoters, complex B bound only to the IgH promoter. Footprinting analysis revealed that both complexes A and B bound sequences which include the TATA element, and complex A additionally contacted sequences downstream to +28. Mutation of the IgH TATA element from ATTAATATA to GCTATAAAA, the optimal TATA sequence as found in the major late promoter, resulted in a 10-fold decrease in binding to complex A and a 25-fold decrease in binding complex B. Surprisingly, both transfection experiments in HeLa cells and in vitro transcription experiments with whole nuclear extract demonstrated that mutation of the TATA box in the core IgH promoter to this concensus sequence resulted in a 2-fold decrease in the level of transcription. These data suggest that the specific sequence of the TATA region is important, and factors which recognize these sequences, such as complex A and B, may modulate the level of transcription from the IgH promoter.	MIT,CTR CANC RES,40 AMES ST,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			Parvin, Jeffrey D/C-8955-2009		NATIONAL CANCER INSTITUTE [P30CA014051, P01CA042063] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA14051, P01-CA42063] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EATON S, 1987, P NATL ACAD SCI USA, V84, P7634, DOI 10.1073/pnas.84.21.7634; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; GROSSCHEDL R, 1985, BANBURY REPORT, V20, P187; GROSVELD GC, 1982, NATURE, V295, P122; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P3283, DOI 10.1073/pnas.71.8.3283; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LEBOWITZ JH, 1988, GENE DEV, V2, P1227, DOI 10.1101/gad.2.10.1227; MACKEM S, 1982, J VIROL, V44, P939, DOI 10.1128/JVI.44.3.939-949.1982; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5949, DOI 10.1093/nar/8.24.5949; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TAYLOR ICA, 1990, MOL CELL BIOL, V10, P165, DOI 10.1128/MCB.10.1.165; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0	32	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22878	22886						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744081				2022-12-25	WOS:A1991GT48300019
J	LIMPENS, J; DEJONG, D; VANKRIEKEN, JHJM; PRICE, CGA; YOUNG, BD; VANOMMEN, GJB; KLUIN, PM				LIMPENS, J; DEJONG, D; VANKRIEKEN, JHJM; PRICE, CGA; YOUNG, BD; VANOMMEN, GJB; KLUIN, PM			BCL-2/JH REARRANGEMENTS IN BENIGN LYMPHOID-TISSUES WITH FOLLICULAR HYPERPLASIA	ONCOGENE			English	Article							T(14-18) CHROMOSOMAL TRANSLOCATION; BREAKPOINT-CLUSTER REGION; NON-HODGKINS-LYMPHOMA; B-CELL NEOPLASMS; RECIPROCAL PARTNERS; HISTOLOGIC SUBTYPES; STRUCTURAL-ANALYSIS; C-MYC; GENE; ABNORMALITIES	The t(14; 18)(q32; q21) chromosomal translocation, characteristic of follicular lymphoma, couples the bcl-2 proto-oncogene on chromosome 18 to the immunoglobulin heavy-chain joining region (J(H)). This results in a deregulated transcription rate of bcl-2, suggesting a major role of the t(14; 18) translocation in lymphomagenesis. By using a sensitive polymerase chain reaction technique specific for the major breakpoint region t(14; 18), we now demonstrate the presence of bcl-2/J(H), rearrangements in lymph nodes and tonsils with follicular hyperplasia in 13 of 24 cases (54%). The approximate frequency was one translocation-positive cell in 10(5) cells. No bcl-2/J(H) rearrangements were detected in reactive lymph nodes without follicular hyperplasia or in bone marrow cells. Sequence analysis showed the amplified bcl-2/J(H) fragments to be unique to each individual sample and distinct from 24 sequenced follicular lymphoma-derived t(14; 18) junctions, thus excluding contamination artifacts. The presence of random nucleotide insertions at the breakpoint junctions suggests a pre-B-cell origin of the t(14; 18) translocation, in analogy with follicular lymphomas. We conclude that the t(14; 18) translocation can occur in non-malignant tissue and will not, on its own lead to malignancy.	LEIDEN UNIV,DEPT PATHOL,2300 RC LEIDEN,NETHERLANDS; ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND,DEPT MED ONCOL,LONDON EC1A BE,ENGLAND	Leiden University; Leiden University - Excl LUMC	LIMPENS, J (corresponding author), LEIDEN UNIV,SYLVIUS LAB,DEPT HUMAN GENET,WASSENAARSE WEG 72,2333 AL LEIDEN,NETHERLANDS.		van Krieken, Joannes H J M/D-4138-2009	van Krieken, Joannes H J M/0000-0001-6544-1040; Limpens, Jacqueline/0000-0002-7362-8574				ADACHI M, 1990, ONCOGENE, V5, P1653; ALTIOK E, 1989, P NATL ACAD SCI USA, V86, P6333, DOI 10.1073/pnas.86.16.6333; AURIAS A, 1980, MUTAT RES, V69, P369, DOI 10.1016/0027-5107(80)90101-3; BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BOEHM T, 1989, FASEB J, V3, P2344, DOI 10.1096/fasebj.3.12.2676678; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1986, J EXP MED, V164, P315, DOI 10.1084/jem.164.1.315; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COTTER F, 1990, BLOOD, V76, P131; CRESCENZI M, 1988, P NATL ACAD SCI USA, V85, P4869, DOI 10.1073/pnas.85.13.4869; DEJONG D, 1988, NEW ENGL J MED, V318, P1373, DOI 10.1056/NEJM198805263182106; DEJONG D, 1989, J EXP MED, V169, P613, DOI 10.1084/jem.169.3.613; DEWALD GW, 1986, AM J HUM GENET, V38, P520; GAUWERKY CE, 1988, P NATL ACAD SCI USA, V85, P8548, DOI 10.1073/pnas.85.22.8548; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; HECHT F, 1987, CANCER GENET CYTOGEN, V26, P95, DOI 10.1016/0165-4608(87)90137-3; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JUNEJA S, 1990, BRIT J HAEMATOL, V76, P231, DOI 10.1111/j.1365-2141.1990.tb07877.x; KLUINNELEMANS JC, 1991, LEUKEMIA, V55, P221; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; LEVINE EG, 1985, BLOOD, V66, P1414; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; NGAN BY, 1989, BLOOD, V73, P1759; NOWELL PC, 1990, AM J CLIN PATHOL, V94, P229, DOI 10.1093/ajcp/94.2.229; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PRICE CGA, 1991, LEUKEMIA, V5, P548; PRICE CGA, 1991, J CLIN ONCOL, V9, P1527, DOI 10.1200/JCO.1991.9.9.1527; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; ROWLEY JD, 1984, CANCER RES, V44, P3159; RUANO G, 1989, NUCLEIC ACIDS RES, V17, P5407, DOI 10.1093/nar/17.13.5407; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; STETLERSTEVENSON M, 1990, J NATL CANCER I, V82, P855, DOI 10.1093/jnci/82.10.855; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TSUJIMOTO Y, 1988, ONCOGENE, V2, P347; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TYCKO B, 1989, SCIENCE, V245, P1242, DOI 10.1126/science.2551037; TYCKO B, 1990, CANCER CELL-MON REV, V2, P1; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; YUNIS JJ, 1982, NEW ENGL J MED, V307, P1231, DOI 10.1056/NEJM198211113072002; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204	42	262	264	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2271	2276						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766674				2022-12-25	WOS:A1991GX73500014
J	CYR, DM; DOUGLAS, MG				CYR, DM; DOUGLAS, MG			EARLY EVENTS IN THE TRANSPORT OF PROTEINS INTO MITOCHONDRIA - IMPORT COMPETITION BY A MITOCHONDRIAL PRESEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT PRECURSOR; OUTER-MEMBRANE PROTEIN; YEAST MITOCHONDRIA; INNER MEMBRANE; ESCHERICHIA-COLI; ADP/ATP CARRIER; TRANSLOCATION; MATRIX; RECEPTOR; ATP	Studies with a synthetic presequence peptide, F1-beta-1-20, corresponding to the NH2-terminal 20 amino acids of the F1-ATPase beta-subunit precursor (pF1-beta) show that although this peptide binds avidly to phospholipid bilayers it does not efficiently compete for import of full-length precursor into mitochondria, K(i) approximately-equal-to 100-mu-M (Hoyt, D. W., Cyr, D. M., Gierasch, L. M., and Douglas, M. G. (1991) J. Biol. Chem. 266, 21693-21699). Herein we report that longer F1-beta presequence peptides F1-beta-1-32 + 2, F1-beta-1-32SQ + 2, and F1-beta-21-51 + 3 compete for mitochondrial import at 1000-, 250-, and 25-fold lower concentrations, respectively, than F1-beta-1-20. A longer peptide, F1-beta-1-51 + 3, was no more effective as an import competitor than F1-beta-1-32 + 2. Both minimal length and amphiphilic character appear required in order for F1-beta-peptides to block mitochondrial import. Import competition by longer F1-beta-peptides seems to occur at a step common to all precursors since they blocked import of precursors to F1-ATPase alpha- and beta-subunits and the ADP/ATP carrier protein. Dissipation of membrane potential (DELTA-psi) across the inner mitochondrial membrane is observed in the presence of F1-beta-peptides, but this mechanism alone does not account for the observed import inhibition. F1-beta-1-32 + 2 and 21-51 + 3 block import of pF 1-beta 100% at peptide concentrations which dissipate DELTA-psi less than 25%. In contrast, experiments with valinomycin demonstrate that when mitochondrial DELTA-psi is reduced 25% import of pF1-beta is inhibited only 25%. Therefore, at least 75% of maximal import inhibition observed in the presence of F1-beta-1-32 + 2 and F1-beta-21-51 + 3 does not result from dissipation of DELTA-psi. Import inhibition by F1-beta-peptides is reversible and can be overcome by increasing the amount of full-length precursor in import reactions. F1-beta-presequence peptides and full-length precursor are therefore likely to compete for a common import step. Presequence dependent binding of pF1-beta to trypsin-sensitive elements on the outer mitochondrial membrane is insensitive to inhibitory concentrations of F1-beta presquence peptide. We conclude that import inhibition by F1-beta-presequence peptides is competitive and occurs at a site beyond initial interaction of precursor proteins with mitochondria.	UNIV N CAROLINA, SCH MED, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27514 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Cyr, Douglas/0000-0002-4928-3414	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036537] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36537] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; BEDWELL DM, 1987, MOL CELL BIOL, V7, P4038, DOI 10.1128/MCB.7.11.4038; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHAMBERLIN JP, 1977, ANAL BIOCHEM, V98, P132; CHEN WJ, 1987, J BIOL CHEM, V262, P15598; CHEN WJ, 1987, CELL, V49, P651, DOI 10.1016/0092-8674(87)90541-1; CHENG MY, 1989, NATURE, V6, P20; DAUM G, 1982, J BIOL CHEM, V257, P3028; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; EILERS M, 1987, EMBO J, V6, P1073, DOI 10.1002/j.1460-2075.1987.tb04860.x; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; GASSER SM, 1982, J BIOL CHEM, V257, P3034; GILLESPIE LL, 1985, J BIOL CHEM, V260, P6045; GLASER SM, 1990, J BIOL CHEM, V265, P8808; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HORWICH AL, 1985, EMBO J, V4, P1129, DOI 10.1002/j.1460-2075.1985.tb03750.x; HOYT DW, 1991, J BIOL CHEM, V266, P21693; HURT EC, 1984, FEBS LETT, V178, P306, DOI 10.1016/0014-5793(84)80622-5; HWANG ST, 1989, P NATL ACAD SCI USA, V86, P8432, DOI 10.1073/pnas.86.21.8432; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANIATIS T, 1982, MOL CLONING LABORATO, P352; MILLER BR, 1991, J CELL BIOL, V112, P833, DOI 10.1083/jcb.112.5.833; Miller JH., 1972, EXPT MOL GENETICS; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; MURAKAMI K, 1990, EMBO J, V9, P3201, DOI 10.1002/j.1460-2075.1990.tb07518.x; OHTA S, 1984, EMBO J, V4, P1129; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFALLER R, 1989, J BIOL CHEM, V264, P34; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; PFANNER N, 1987, J BIOL CHEM, V262, P7528; PFANNER N, 1991, TRENDS BIOCHEM SCI, V16, P63, DOI 10.1016/0968-0004(91)90026-R; RIEZMAN H, 1983, EMBO J, V2, P1113, DOI 10.1002/j.1460-2075.1983.tb01554.x; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SCHLEYER M, 1982, EUR J BIOCHEM, V125, P109, DOI 10.1111/j.1432-1033.1982.tb06657.x; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; SMAGULA C, 1988, J BIOL CHEM, V263, P6783; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; TAKEDA M, 1986, J BIOL CHEM, V261, P5126; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WALKER ME, 1990, BIOCHEM J, V266, P227, DOI 10.1042/bj2660227	50	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21700	21708						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1834661				2022-12-25	WOS:A1991GP80400058
J	NELSON, RM; VANDUSEN, WJ; FRIEDMAN, PA; LONG, GL				NELSON, RM; VANDUSEN, WJ; FRIEDMAN, PA; LONG, GL			BETA-HYDROXYASPARTIC ACID AND BETA-HYDROXYASPARAGINE RESIDUES IN RECOMBINANT HUMAN PROTEIN-S ARE NOT REQUIRED FOR ANTICOAGULANT COFACTOR ACTIVITY OR FOR BINDING TO C4B-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN FACTOR-IX; GAMMA-CARBOXYGLUTAMIC ACID; K-DEPENDENT PROTEINS; FACTOR-LIKE DOMAINS; CALCIUM-BINDING; BLOOD-COAGULATION; FACTOR-XA; FACTOR-VA; THROMBIN; BOVINE	Among the vitamin K-dependent plasma proteins, only protein S contains the post-translationally modified amino acid erythro-beta-hydroxyasparagine (Hyn). Protein S also contains erythro-beta-hydroxyaspartic acid (Hya). The function of these unusual amino acids, located in the epidermal growth factor-like domains, is unknown. To determine if these post-translational modifications contribute to the functional integrity of human protein S (HPS), recombinant human protein S lacking Hya and Hyn (rHPSdesHya/Hyn) was purified from the medium of human kidney 293 cells that were transfected with HPS cDNA and grown in the presence of the hydroxylase inhibitor 2,2'-dipyridyl. Solution-phase equilibrium binding studies revealed that rHPSdesHya/Hyn binds C4b-binding protein (C4BP) in a manner indistinguishable from recombinant HPS and plasma-derived HPS, exhibiting a K(d) in the presence of 2 mM CaCl2 of approximately 0.7 nM and a K(d) in the presence of 4 mm EDTA approximately 10-fold higher. In a purified component system, rHPSdesHya/Hyn displayed normal anticoagulant cofactor activity in the activated protein C-catalyzed inactivation of coagulation factor Va bound in the prothrombinase complex. In addition, digestion of rHPSdesHya/Hyn with thrombin in the presence of EDTA appeared normal, and 2 mM CaCl2 prevented the cleavage. Together these results suggest that the post-translational modifications of Asn and Asp residues are not necessary for the macromolecular or Ca2+ interactions associated with the anticoagulant and C4BP binding characteristics of HPS.	UNIV VERMONT,COLL MED,DEPT BIOCHEM,GIVEN BLDG,BURLINGTON,VT 05405; MERCK SHARP & DOHME LTD,W POINT,PA 19486	University of Vermont; Merck & Company					NCI NIH HHS [CO6HL39745] Funding Source: Medline; NHLBI NIH HHS [R01HL38899] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038899] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DAHLBACK B, 1983, BIOCHEM J, V209, P837, DOI 10.1042/bj2090837; DAHLBACK B, 1986, J BIOL CHEM, V261, P5111; DAHLBACK B, 1990, J BIOL CHEM, V265, P18481; DERIAN CK, 1989, J BIOL CHEM, V264, P6615; DISCIPIO RG, 1979, BIOCHEMISTRY-US, V18, P899, DOI 10.1021/bi00572a026; FERNLUND P, 1983, J BIOL CHEM, V258, P2509; FOSTER DC, 1987, BIOCHEMISTRY-US, V26, P7003, DOI 10.1021/bi00396a022; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; GRINNELL BW, 1990, BLOOD, V76, P2546; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; LITWILLER RD, 1986, BLOOD, V67, P1583; LUNDWALL A, 1986, P NATL ACAD SCI USA, V83, P6716, DOI 10.1073/pnas.83.18.6716; MITCHELL CA, 1986, THROMB HAEMOSTASIS, V56, P151; MORITA T, 1985, BIOCHEM BIOPH RES CO, V130, P841, DOI 10.1016/0006-291X(85)90493-0; NELSON RM, 1991, BIOCHEMISTRY-US, V30, P2384, DOI 10.1021/bi00223a013; NESHEIM ME, 1982, J BIOL CHEM, V257, P1443; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PRZYSIECKI CT, 1987, P NATL ACAD SCI USA, V84, P7856, DOI 10.1073/pnas.84.22.7856; RABIET MJ, 1987, J BIOL CHEM, V262, P14895; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; STENFLO J, 1987, P NATL ACAD SCI USA, V84, P368, DOI 10.1073/pnas.84.2.368; SUGO T, 1985, J BIOL CHEM, V260, P453; SUZUKI K, 1983, J BIOCHEM-TOKYO, V94, P699, DOI 10.1093/oxfordjournals.jbchem.a134409; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1984, J BIOL CHEM, V259, P335	28	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20586	20589						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1834648				2022-12-25	WOS:A1991GN00100003
J	MARTIN, J; MAHLKE, K; PFANNER, N				MARTIN, J; MAHLKE, K; PFANNER, N			ROLE OF AN ENERGIZED INNER MEMBRANE IN MITOCHONDRIAL PROTEIN IMPORT - DELTA-PSI DRIVES THE MOVEMENT OF PRESEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED PRECURSOR PROTEIN; CHARGED AMINO-ACIDS; HEAT-SHOCK PROTEIN; ADP-ATP CARRIER; ESCHERICHIA-COLI; NUCLEOSIDE TRIPHOSPHATES; ADP/ATP CARRIER; CONTACT SITES; TRANSLATION SYSTEM; SECRETORY PROTEIN	The transport of precursor proteins into mitochondria requires an energized inner membrane. We report here that the import of various precursor proteins showed a differential sensitivity to treatment of the mitochondria with the uncoupler carbonyl cyanide m-chlorophenylhydrazone. The differential inhibition by carbonyl cyanide m-chlorophenylhydrazone was not influenced by the length of the precursor, the presence of mature protein parts, or the folding state of the precursor but was specific for the presequence. Moreover, only the membrane potential DELTA-PSI and not the total proton motive force was required for the transport of precursors, indicating that protein translocation across the inner membrane is not driven by a movement of protons. We conclude that DELTA-PSI (negative inside) is needed for the translocation of the positively charged presequences, possibly via an electrophoretic effect.	UNIV MUNICH, DEPT PHYSIOL CHEM, GOETHESTR 33, W-8000 MUNICH 2, GERMANY	University of Munich			Pfanner, Nikolaus/AAV-7878-2021					ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BAKKER EP, 1984, EMBO J, V3, P895, DOI 10.1002/j.1460-2075.1984.tb01902.x; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHEN WJ, 1988, J BIOL CHEM, V263, P4997; CHEN WJ, 1987, CELL, V49, P651, DOI 10.1016/0092-8674(87)90541-1; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; DEKROON AIP, 1991, IN PRESS BIOCH BIOPH; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DOUGLAS MG, 1986, MICROBIOL REV, V50, P166, DOI 10.1128/MMBR.50.2.166-178.1986; DRIESSEN AJM, 1991, P NATL ACAD SCI USA, V88, P2471, DOI 10.1073/pnas.88.6.2471; EILERS M, 1987, EMBO J, V6, P1073, DOI 10.1002/j.1460-2075.1987.tb04860.x; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; EILERS M, 1988, CELL, V52, P481, DOI 10.1016/0092-8674(88)90458-8; GASSER SM, 1982, J BIOL CHEM, V257, P3034; GELLER BL, 1989, J BIOL CHEM, V264, P16465; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; Horwich A, 1990, CURR OPIN CELL BIOL, V2, P625, DOI 10.1016/0955-0674(90)90103-L; HWANG ST, 1989, P NATL ACAD SCI USA, V86, P8432, DOI 10.1073/pnas.86.21.8432; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KEEGSTRA K, 1989, CELL, V56, P247, DOI 10.1016/0092-8674(89)90898-2; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KUHN A, 1990, EMBO J, V9, P2385, DOI 10.1002/j.1460-2075.1990.tb07413.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAHLKE K, 1990, EUR J BIOCHEM, V192, P551, DOI 10.1111/j.1432-1033.1990.tb19260.x; MORAN O, 1990, J BIOL CHEM, V265, P908; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; NICHOLLS DG, 1974, EUR J BIOCHEM, V50, P305, DOI 10.1111/j.1432-1033.1974.tb03899.x; NICHOLLS DG, 1982, IOENERGETICS; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; OSTERMANN J, 1990, FEBS LETT, V277, P281, DOI 10.1016/0014-5793(90)80865-G; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1986, FEBS LETT, V209, P152, DOI 10.1016/0014-5793(86)81101-2; PFANNER N, 1987, J BIOL CHEM, V262, P14851; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; PFANNER N, 1988, J BIOL CHEM, V263, P4049; PFANNER N, 1987, J BIOL CHEM, V262, P7528; PFANNER N, 1988, TRENDS BIOCHEM SCI, V13, P165, DOI 10.1016/0968-0004(88)90140-5; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; PFANNER N, 1990, J BIOL CHEM, V265, P16324; PFANNER N, 1987, EUR J BIOCHEM, V169, P289, DOI 10.1111/j.1432-1033.1987.tb13610.x; RAPOPORT TA, 1991, NATURE, V349, P107, DOI 10.1038/349107a0; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; RASSOW J, 1990, NUCLEIC ACIDS RES, V18, P4922, DOI 10.1093/nar/18.16.4922; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROISE D, 1988, J BIOL CHEM, V263, P4509; SCARPA A, 1979, MEMBRANE TRANSPORT B, V2, P263; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHLEYER M, 1982, EUR J BIOCHEM, V125, P109, DOI 10.1111/j.1432-1033.1982.tb06657.x; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHWAIGER M, 1987, J CELL BIOL, V105, P109; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; SKERJANC IS, 1987, EMBO J, V6, P3117, DOI 10.1002/j.1460-2075.1987.tb02621.x; SMAGULA CS, 1988, J CELL BIOCHEM, V36, P323, DOI 10.1002/jcb.240360402; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; VERNER K, 1987, EMBO J, V6, P2449, DOI 10.1002/j.1460-2075.1987.tb02524.x; VIEBROCK A, 1989, EUR J BIOCHEM, V180, P535; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMADA H, 1989, J BIOL CHEM, V264, P18577; ZIMMERMANN R, 1982, J BIOL CHEM, V257, P6529	76	283	283	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18051	18057						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1833391				2022-12-25	WOS:A1991GG55300054
J	OVERBERGH, L; TORREKENS, S; VANLEUVEN, F; VANDENBERGHE, H				OVERBERGH, L; TORREKENS, S; VANLEUVEN, F; VANDENBERGHE, H			MOLECULAR CHARACTERIZATION OF THE MURINOGLOBULINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-INHIBITOR-III MESSENGER-RNA; WEIGHT PROTEASE INHIBITORS; ALPHA-MACROGLOBULIN; RAT PLASMA; HUMAN ALPHA-2-MACROGLOBULIN; SEQUENCE; TRYPSIN; PROTEINASES; EVOLUTION	Proteinase inhibitors of the alpha-2-macroglobulin (alpha-2M) type, although well characterized in vitro, still evade a precise description of their actual role in vivo. The main reason for this is the absence of any clinical evidence for the malfunctioning of alpha-2M in humans. Moreover, despite their ubiquitous presence in animals of very different taxa, animal models are notoriously absent in this field. With the advent of transgenic animals an important tool became available in this respect. As a first step in this direction we are analyzing at the molecular level all the members of this proteinase inhibitor family in the mouse. To retrieve related sequences we screened a mouse liver cDNA library with human alpha-2M cDNA. The sequences from two isolated clones partially coded for a protein with a high degree of sequence identity with human alpha-2M, rat alpha-2M, and rat alpha-1I3. Protein sequence data from the large and small subunits of mouse alpha-2M and of the protein isolated from mouse plasma allowed us to designate the clones as coding for murinoglobulin (MUG), an alpha-2M-related single-chain proteinase inhibitor. Rescreening resulted in the isolation of 24 clones, of which 21 were related or identical to the original MUG clones. Restriction analysis led to three groups of clones of which representative members were sequenced. Two highly homologous cDNA sequences were derived, coding for proteins that displayed the typical features of alpha-2M-type proteinase inhibitors: the overall size, the positions of a putative bait region and of the internal thiol ester, and the positional conservation of cysteine residues and putative asparagine-glycosylation sites. A third related member for which only one incomplete cDNA clone was obtained and sequenced, proved to be aberrant: the bait region contained what appeared to be an intron which escaped proper splicing. A second apparent intron was present at the 5' end of the cDNA while a frameshift mutation near the 3' end (insertion of a G) caused premature termination of the reading frame when compared to the other MUG sequences. These features were confirmed from an isolated genomic clone and extended at the genomic level: the corresponding gene, a transcriptionally weakly active pseudogene, contained the small intron but as part of a larger intron. The presence of suitable intron/exon splice sites show that a relatively small part of the intron is being introduced as an exon in the mRNA. Although the resulting reading frame is not open, which makes this mRNA useless, the mechanism as such is highly intriguing since it occurs in the bait region, the least conserved sequence in all members of the alpha-2M family.			OVERBERGH, L (corresponding author), CATHOLIC UNIV LEUVEN, CTR HUMAN GENET, CAMPUS GASTHUISBERG, B-3000 LOUVAIN, BELGIUM.		Overbergh, Lut/AAC-3515-2020					ABE K, 1989, J BIOCHEM-TOKYO, V106, P564; AIELLO LP, 1988, J BIOL CHEM, V263, P4013; Battey, 1986, BASIC METHODS MOL BI; BRACIAK TA, 1988, J BIOL CHEM, V263, P3999; ENGHILD JJ, 1989, J BIOL CHEM, V264, P11428; ESNARD F, 1985, FEBS LETT, V182, P125, DOI 10.1016/0014-5793(85)81168-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GANROT K, 1973, BIOCHIM BIOPHYS ACTA, V322, P62, DOI 10.1016/0005-2795(73)90175-X; GORDON AH, 1976, BIOCHEM J, V159, P643, DOI 10.1042/bj1590643; HILL RE, 1987, NATURE, V326, P96, DOI 10.1038/326096a0; KAN CC, 1985, P NATL ACAD SCI USA, V82, P2282, DOI 10.1073/pnas.82.8.2282; LASKOWSKI M, 1987, COLD SPRING HARB SYM, V52, P545, DOI 10.1101/SQB.1987.052.01.062; LONBERGHOLM K, 1987, J BIOL CHEM, V262, P4844; LONBERGHOLM K, 1987, J BIOL CHEM, V262, P438; Maniatis T., 1982, MOL CLONING; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NORTHEMANN W, 1989, BIOCHEMISTRY-US, V28, P84, DOI 10.1021/bi00427a013; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; SAITO A, 1985, J BIOL CHEM, V260, P775; SAITO A, 1985, J BIOCHEM-TOKYO, V98, P501, DOI 10.1093/oxfordjournals.jbchem.a135305; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEIZER M, 1987, EUR J BIOCHEM, V164, P375, DOI 10.1111/j.1432-1033.1987.tb11068.x; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; VANLEUVEN F, 1982, BIOCHEM J, V201, P119, DOI 10.1042/bj2010119; VANLEUVEN F, 1982, TRENDS BIOCHEM SCI, V7, P185, DOI 10.1016/0968-0004(82)90135-9; VANLEUVEN F, 1982, BIOCHEM J, V101, P1181; VANLEUVEN F, 1985, SCI TOOLS, V32, P41; VANLEUVEN F, 1982, SCIENCE TOOLS, V101, P1181; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8	33	40	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16903	16910						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1840592				2022-12-25	WOS:A1991GD63500104
J	ZHAO, X; SINGH, B; ARLINGHAUS, RB				ZHAO, X; SINGH, B; ARLINGHAUS, RB			INHIBITION OF C-MOS PROTEIN-KINASE BLOCKS MOUSE ZYGOTES AT THE PRONUCLEI STAGE	ONCOGENE			English	Article							MURINE SARCOMA-VIRUS; V-MOS; MEIOTIC MATURATION; DEVELOPMENTAL REGULATION; PROTOONCOGENE PRODUCT; XENOPUS OOCYTES; GERM-CELLS; ONCOGENE; EXPRESSION; SEQUENCE	The c-mos gene product is required for activation of the maturation-promoting factor (MPF) during oocyte maturation. The c-mos protein also acts as a cytostatic factor which is responsible for meiotic metaphase arrest of vertebrate eggs via stabilization of MPF. Here we show that mouse zygotes contain the c-mos protein. Introduction of a kinase-inhibitory anti-mos antibody into mouse zygotes 12 h after fertilization prevented the first cleavage of zygotes at the pronuclei stage. A second anti-mos antibody, known to allow the mos kinase to function, did not interfere with the formation of two-cell embryos. In addition to its known role in MPF activation in oocyte maturation and meiotic metaphase arrest, our findings indicate that the c-mos protein kinase is also required for completion of pronuclei breakdown following fertilization of mouse eggs.	STANFORD UNIV,MED CTR,SCH MED,DEPT MED,STANFORD,CA 94305; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030	Stanford University; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA045125, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA45125] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; BOLD RJ, 1985, MOL CELL BIOL, V5, P3131, DOI 10.1128/MCB.5.11.3131; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GOLDMAN DS, 1988, ONCOGENE, V3, P159; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERZOG NK, 1989, ONCOGENE, V4, P1307; HERZOG NK, 1988, ONCOGENE, V3, P255; HOGAN B, 1986, MANIPULATING MOUSE E; KESHET E, 1988, ONCOGENE, V2, P235; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; MUTTER GL, 1988, EMBO J, V7, P683, DOI 10.1002/j.1460-2075.1988.tb02863.x; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SINGH B, 1990, VIROLOGY, V178, P535, DOI 10.1016/0042-6822(90)90351-Q; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SINGH B, 1988, VIROLOGY, V164, P114, DOI 10.1016/0042-6822(88)90626-5; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; ZHAO X, 1990, ONCOGENE, V5, P1727; Zhao X., 1989, TECHNIQUES J METHODS, V1, P37	31	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1423	1426						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1832216				2022-12-25	WOS:A1991GX27200019
J	OHANA, P; DELMER, DP; STEFFENS, JC; MATTHEWS, DE; MAYER, R; BENZIMAN, M				OHANA, P; DELMER, DP; STEFFENS, JC; MATTHEWS, DE; MAYER, R; BENZIMAN, M			BETA-FURFURYL-BETA-GLUCOSIDE - AN ENDOGENOUS ACTIVATOR OF HIGHER-PLANT UDP-GLUCOSE - (1-]3)-BETA-GLUCAN SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCAN SYNTHASE	We have recently established the existence of endogenous activators of higher plant UDP-glucose: (1 --> 3)-beta-glucan synthase (Callaghan, T., Ross, P., Weinberger-Ohana, P., and Benziman, M. (1988) Plant Physiol. 86, 1099-1103). Here we report the purification and chemical analysis of the most abundant and specific compound, termed Activator 1, isolated from Vigna radiata. This compound was extensively purified by a multistep procedure which yielded 0.1 mg of purified activator/g of fresh tissue. Enzyme digestion, neutral sugar analysis, GC/MS of permethylated derivatives, and NMR analysis of native Activator I indicated that the compound contains a single beta-linked glucosyl residue. High resolution FAB-MS indicated an elemental composition of C11H16O7 (M(r) = 260), with a calculated M(r) of 98 for the aglycone. C-13, DEPT, and COSY NMR spectra showed that the aglycone molecule is an oxygen heterocycle of 5 carbons, consistent with a structure of beta-furfuryl alcohol. Comparison of IR and GC/EI-MS spectra of authentic beta-furfuryl alcohol with native aglycone confirmed the conclusion that Activator I is beta-furfuryl-beta-glucoside. Chemically synthesized beta-furfuryl-beta-glucoside has identical chemical properties and biological activity when compared with the purified endogenous activator (K(a) = 50-mu-M).	HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT BOT,IL-91904 JERUSALEM,ISRAEL; CORNELL UNIV,NEW YORK STATE COLL AGR & LIFE SCI,DEPT PLANT BREEDING & BIOMETRY,ITHACA,NY 14853	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Cornell University								BENN R, 1983, ANGEW CHEM INT EDIT, V22, P350, DOI 10.1002/anie.198303501; BLAKENEY AB, 1983, CARBOHYD RES, V113, P291, DOI 10.1016/0008-6215(83)88244-5; CALLAGHAN T, 1988, PLANT PHYSIOL, V86, P1104, DOI 10.1104/pp.86.4.1104; CALLAGHAN T, 1988, PLANT PHYSIOL, V86, P1099, DOI 10.1104/pp.86.4.1099; GENSHIRT H, 1965, THIN LAYER CHROMATOG, P344; HARRIS PJ, 1984, CARBOHYD RES, V127, P59, DOI 10.1016/0008-6215(84)85106-X; HARRISON AG, 1983, CHEM IONIZATION MASS, P119; HAYASHI T, 1987, PLANT PHYSIOL, V83, P1054, DOI 10.1104/pp.83.4.1054; KAMEOKA H, 1982, NIPPON NOGEIKAGAKU K, V55, P997; KAMEOKA H, 1979, NIPPON NOGEIKAGAKU K, V52, P335; KAUSS H, 1987, ANN REV PLANT PHYSL, V65, P67; KITAGAWA I, 1983, CHEM PHARM BULL, V31, P664; KOHLE H, 1985, PLANT PHYSIOL, V77, P544, DOI 10.1104/pp.77.3.544; REINECKE MG, 1988, J NAT PROD, V51, P1236, DOI 10.1021/np50060a030; SCHROEDER LR, 1966, J CHEM SOC C, P530, DOI 10.1039/j39660000530; STOTHERS JB, 1972, CARBON 13 NMR SPECTR, P461; SYNDER CF, 1962, METHODS CARBOHYDR CH, V1, P524; TALLEY EA, 1963, METHODS CARBOHYDRATE, V2, P337	19	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13742	13745						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1830307				2022-12-25	WOS:A1991FY02700046
J	BOURGUIGNON, LYW; KALOMIRIS, EL; LOKESHWAR, VB				BOURGUIGNON, LYW; KALOMIRIS, EL; LOKESHWAR, VB			ACYLATION OF THE LYMPHOMA TRANSMEMBRANE GLYCOPROTEIN, GP85, MAY BE REQUIRED FOR GP85-ANKYRIN INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERRIN RECEPTOR; INVARIANT CHAIN; PROTEIN-KINASE; PALMITIC ACID; FATTY-ACID; ANKYRIN; CYTOSKELETON; PURIFICATION; BINDING; CELLS	The lymphoma plasma membrane glycoprotein, GP85, is a transmembrane glycoprotein that binds directly to ankyrin, a molecule known to link the plasma membrane with the underlying cytoskeleton. In this study, we have demonstrated that palmitic acid is incorporated into GP85 in vivo and that the amount of palmitic acid incorporated is greatly stimulated during lymphoma cap formation. The majority of the incorporated palmitic acid appears to be strongly linked to GP85 since it is not dissociated by strong detergents (e.g. sodium dodecyl sulfate) or by chloroform/methanol extraction, but is labile to alkaline or acid hydrolysis. Furthermore, we have established that deacylation of GP85 (i.e. removal of the palmitic acid moiety from GP85 by 1 M hydroxylamine treatment) significantly reduces the binding affinity between GP85 and ankyrin, and reacylation of GP85 restores the binding affinity. These findings suggest that fatty acid acylation of GP85 by palmitic acid may be required for the stable attachment of the cytoskeleton to the lymphoma plasma membrane.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,MIAMI,FL 33101	University of Miami					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036353] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 36353] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT V, 1980, J BIOL CHEM, V255, P2540; BOURGUIGNON LYW, 1986, J CELL BIOL, V103, P2529, DOI 10.1083/jcb.103.6.2529; BOURGUIGNON LYW, 1986, J CELL BIOL, V102, P2115, DOI 10.1083/jcb.102.6.2115; BOURGUIGNON LYW, 1984, INT REV CYTOL, V87, P195, DOI 10.1016/S0074-7696(08)62443-2; BOURGUIGNON LYW, 1988, J CELL BIOCHEM, V37, P131, DOI 10.1002/jcb.240370202; BOURGUIGNON LYW, 1985, J CELL BIOL, V101, P477, DOI 10.1083/jcb.101.2.477; BOURGUIGNON LYW, 1988, ENERGETICS SECRETORY, V1, P83; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; CHEN ZQ, 1985, J VIROL, V56, P607, DOI 10.1128/JVI.56.2.607-612.1985; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GARBER EA, 1985, MOL CELL BIOL, V5, P2781, DOI 10.1128/MCB.5.10.2781; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; HEDO JA, 1987, J BIOL CHEM, V262, P954; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; KALOMIRIS EL, 1985, BIOCHEMISTRY-US, V24, P5430, DOI 10.1021/bi00341a022; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; KALOMIRIS EL, 1988, J CELL BIOL, V106, P319, DOI 10.1083/jcb.106.2.319; KELLIE S, 1987, FEBS LETT, V213, P428, DOI 10.1016/0014-5793(87)81536-3; KOCH N, 1985, BIOCHEMISTRY-US, V24, P6185, DOI 10.1021/bi00343a023; KOCH N, 1986, J BIOL CHEM, V261, P3434; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; OMARY MB, 1981, J BIOL CHEM, V256, P4715; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; STADLER J, 1985, EMBO J, V4, P1153, DOI 10.1002/j.1460-2075.1985.tb03753.x; STAUFENBIEL M, 1986, P NATL ACAD SCI USA, V83, P318, DOI 10.1073/pnas.83.2.318; TOWLER D, 1986, BIOCHEMISTRY-US, V25, P878, DOI 10.1021/bi00352a021; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WOLFFE EJ, 1990, J BIOL CHEM, V265, P341; ZHOU DFH, 1989, J IMMUNOL, V143, P3390	32	78	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11761	11765						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1828806				2022-12-25	WOS:A1991FT76200054
J	AVITAL, S; GROMETELHANAN, Z				AVITAL, S; GROMETELHANAN, Z			EXTRACTION AND PURIFICATION OF THE BETA-SUBUNIT AND AN ACTIVE ALPHA-BETA-CORE COMPLEX FROM THE SPINACH CHLOROPLAST CF0F1-ATP SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOSPIRILLUM-RUBRUM CHROMATOPHORES; COUPLING FACTOR; ATP SYNTHESIS; ALPHA-3-BETA-3 COMPLEX; ESCHERICHIA-COLI; GAMMA-SUBUNIT; H+-ATPASE; RECONSTITUTION; HYDROLYSIS; F1-ATPASE	Incubation of Rhodospirillum rubrum chromatophores with 2 M LiCl in the presence of MgATP has been shown to remove their F1-beta-subunit leaving inactive but fully reconstitutable beta-less chromatophores (Gromet-Elhanan, Z., and Khananshvili, D. (1986) Methods Enzymol. 126, 528-538). A similar treatment of thoroughly washed spinach thylakoids has now been shown to release the CF1-beta-subunit (CF1-beta) together with a complex containing equal amounts of CF1-alpha and CF1-beta (CF1(alpha-beta)). The purified CF1(alpha-beta) complex can reconstitute an active membrane-bound hybrid F0F1-ATPase with beta-less R. rubrum chromatophores and also catalyzes a low but very reproducible soluble MgATPase. Purified CF1-beta shows none of these activities although it can bind as efficiently as CF1(alpha-beta) to the beta-less chromatophores. By subjecting the crude spinach 2 M LiCl extract to dissociating conditions an enriched CF1-beta preparation is released. It contains traces of CF1-alpha and CF1-delta, is able to reconstitute an active hybrid F0F1-ATPase but, as the pure CF1-beta, shows no soluble ATPase activity. These results indicate that trace amounts of CF1-alpha are enough for endowing CF1-beta with a reconstitutive capacity, but for exhibition of a significant soluble ATPase activity equivalent amounts of CF1-alpha and beta are required. The CF1(alpha-beta) complex isolated and purified in this report thus represents the minimal catalytic core of the CF1-ATPase.			AVITAL, S (corresponding author), WEIZMANN INST SCI, DEPT BIOCHEM, IL-76100 REHOVOT, ISRAEL.							AMZEL LM, 1983, ANNU REV BIOCHEM, V52, P801, DOI 10.1146/annurev.bi.52.070183.004101; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; AVITAL S, 1990, CURRENT RES PHOTOSYN, V3, P45; AVRON M, 1960, BIOCHIM BIOPHYS ACTA, V40, P257, DOI 10.1016/0006-3002(60)91350-0; BINDER A, 1975, 3RD P INT C PHOT, V2, P1163; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Clayton R. K., 1963, BACTERIAL PHOTOSYNTH, P495; CORTEZ N, 1983, BIOCHIM BIOPHYS ACTA, V724, P396, DOI 10.1016/0005-2728(83)90099-3; CROSS RL, 1981, ANNU REV BIOCHEM, V50, P681, DOI 10.1146/annurev.bi.50.070181.003341; FARKAS DL, 1979, PLANT PHYSIOL, V64, P942, DOI 10.1104/pp.64.6.942; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FRASCH WD, 1989, J BIOL CHEM, V264, P5064; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1977, BIOCHEM BIOPH RES CO, V79, P1231, DOI 10.1016/0006-291X(77)91138-X; GERSHONI JM, 1988, METHOD BIOCHEM ANAL, V33, P1; GROMETELHANAN Z, 1985, J BIOL CHEM, V260, P2635; GROMETELHANAN Z, 1986, METHOD ENZYMOL, V126, P528; GROMETELHANAN Z, 1974, J BIOL CHEM, V249, P2522; HARRIS DA, 1985, BIOCHEMISTRY-US, V24, P3876, DOI 10.1021/bi00336a010; KAGAWA Y, 1989, FEBS LETT, V249, P67, DOI 10.1016/0014-5793(89)80017-1; KHANANSHVILI D, 1982, J BIOL CHEM, V257, P1377; KHANANSHVILI D, 1983, J BIOL CHEM, V258, P3714; KUNO H, 1967, NATURE, V215, P974, DOI 10.1038/215974a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIWA K, 1989, P NATL ACAD SCI USA, V86, P6484, DOI 10.1073/pnas.86.17.6484; NELSON N, 1976, EUR J BIOCHEM, V69, P203, DOI 10.1111/j.1432-1033.1976.tb10874.x; NELSON N, 1980, METHOD ENZYMOL, V69, P301; OHTA S, 1990, BIOCHEM BIOPH RES CO, V171, P1258, DOI 10.1016/0006-291X(90)90821-4; PHILOSOPH S, 1977, J BIOL CHEM, V252, P8747; PHILOSOPH S, 1981, BIOCHEM BIOPH RES CO, V101, P384, DOI 10.1016/0006-291X(81)91271-7; RICHTER ML, 1986, J BIOL CHEM, V261, P2109; RICHTER ML, 1989, PHYSIOL PLANTARUM, V76, P185; ROUXFROMY M, 1987, BIOCHEM BIOPH RES CO, V144, P718, DOI 10.1016/S0006-291X(87)80024-4; SAHA S, 1970, BIOCHIM BIOPHYS ACTA, V223, P158, DOI 10.1016/0005-2728(70)90140-4; SATO MH, 1990, J BIOL CHEM, V265, P13419; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; STROTMANN H, 1973, BIOCHIM BIOPHYS ACTA, V314, P202, DOI 10.1016/0005-2728(73)90135-7; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; VIGNAIS PV, 1984, MOL CELL BIOCHEM, V60, P33; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YOSHIDA M, 1977, J BIOL CHEM, V252, P3480; YOSHIDA M, 1984, H PLUS ATPASE ATP SY, P147	42	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7067	7072						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1826683				2022-12-25	WOS:A1991FG72700066
J	IKEBE, M; HEWETT, TE; MARTIN, AF; CHEN, M; HARTSHORNE, DJ				IKEBE, M; HEWETT, TE; MARTIN, AF; CHEN, M; HARTSHORNE, DJ			CLEAVAGE OF A SMOOTH-MUSCLE MYOSIN HEAVY-CHAIN NEAR ITS C-TERMINUS BY ALPHA-CHYMOTRYPSIN - EFFECT ON THE PROPERTIES OF MYOSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED ATPASE ACTIVITY; MG-2+-ATPASE ACTIVITY; ENZYMATIC-ACTIVITY; FILAMENT FORMATION; CHICKEN GIZZARD; LIGHT-CHAINS; CONFORMATION; ACTIN; PROTEOLYSIS; MEROMYOSIN	Limited proteolysis of gizzard myosin by alpha-chymotrypsin converted the heavy chain doublet pattern, seen by gel electrophoresis, to a single band. Light chain degradation was not observed and only minor cleavage occurred at other heavy chain sites. Using a polyclonal antibody raised against a unique sequence from the slower-migrating heavy chain (SM1) it was shown that this conversion was due to the loss of a peptide approximately 4000 daltons from the C terminus of SM1. The peptide was isolated and sequenced, and the cleavage site was identified between phenylalanine 1943 and alanine 1944. Addition of antibody before protease protected SM1 from cleavage. The following changes were observed (a) the Mg2+-dependence of actin-activated ATPase of digested phosphorylated myosin was altered and activity was relatively high at low Mg2+ levels, i.e. similar to phosphorylated heavy meromyosin; (b) the KCl dependence of Mg2+-ATPase of the digested myosin, particularly the phosphorylated form, showed an altered pattern consistent with the stabilization of the 6 S conformation; (c) the tendency for aggregation was increased by proteolysis of phosphorylated myosin. These results show that the C-terminal region of a gizzard myosin heavy chain can modify some of the properties of myosin. It is suggested that the observed modifications reflect an enhanced tendency of the digested myosin to aggregate.	UNIV CINCINNATI,MED CTR,COLL MED,DEPT PHYSIOL & BIOPHYS,CINCINNATI,OH 45267; UNIV CINCINNATI,MED CTR,COLL MED,DEPT PHARMACOL & CELL BIOPHYS,CINCINNATI,OH 45267; CHINESE ACAD SCI,SHANGHAI INST PHYSIOL,SHANQHAI,PEOPLES R CHINA; UNIV ARIZONA,DEPT ANIM SCI,MUSCLE BIOL GRP,TUCSON,AZ 85721	University of Cincinnati; University of Cincinnati; Chinese Academy of Sciences; University of Arizona	IKEBE, M (corresponding author), CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106, USA.		Hewett, Timothy Edwin/GLT-1556-2022; Hewett, Timothy/G-1023-2011; Hewett, Timothy E/E-3241-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020984, R01HL023615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R23AR038431] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20984, HL23615] Funding Source: Medline; NIAMS NIH HHS [AR38431] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ATKINSON MAL, 1988, FEBS LETT, V234, P435, DOI 10.1016/0014-5793(88)80132-7; DRISKA S, 1975, ARCH BIOCHEM BIOPHYS, V167, P203, DOI 10.1016/0003-9861(75)90457-9; EDDINGER TJ, 1988, BIOCHEMISTRY-US, V27, P3807, DOI 10.1021/bi00410a043; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V1, P423; HIGASHIHARA M, 1988, BIOCHEM BIOPH RES CO, V154, P928, DOI 10.1016/0006-291X(88)90228-8; IKEBE M, 1983, J BIOL CHEM, V258, P4770; IKEBE M, 1983, BIOCHEMISTRY-US, V22, P4580, DOI 10.1021/bi00288a036; IKEBE M, 1984, J BIOL CHEM, V259, P1639; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1984, BIOCHEMISTRY-US, V23, P5062, DOI 10.1021/bi00316a036; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; IKEBE M, 1986, BIOCHEMISTRY-US, V25, P6177, DOI 10.1021/bi00368a052; IKEBE M, 1987, J BIOL CHEM, V262, P13828; IKEBE M, 1985, FED PROC, V44, P1452; KAMINSKI EA, 1984, J BIOL CHEM, V259, P9104; KAWAMOTO S, 1987, J BIOL CHEM, V262, P7282; KUZNICKI J, 1983, J BIOL CHEM, V258, P6011; KUZNICKI J, 1985, J BIOL CHEM, V260, P1967; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOHAMMAD MA, 1989, BIOCHEM J, V260, P421, DOI 10.1042/bj2600421; MOHAMMAD MA, 1988, AUST J BIOL SCI, V41, P409; NAGAI R, 1989, J BIOL CHEM, V264, P9734; NAGAI R, 1988, P NATL ACAD SCI USA, V85, P1047, DOI 10.1073/pnas.85.4.1047; OGIHARA S, 1983, J BIOCHEM, V93, P205, DOI 10.1093/oxfordjournals.jbchem.a134155; OKAMOTO Y, 1980, J BIOCHEM, V88, P361, DOI 10.1093/oxfordjournals.jbchem.a132981; OKAMOTO Y, 1981, J BIOCHEM-TOKYO, V90, P833, DOI 10.1093/oxfordjournals.jbchem.a133540; ONISHI H, 1979, J BIOCHEM, V85, P457, DOI 10.1093/oxfordjournals.jbchem.a132352; PASTERNAK C, 1989, J CELL BIOL, V109, P203, DOI 10.1083/jcb.109.1.203; ROVNER AS, 1986, AM J PHYSIOL, V250, pC861, DOI 10.1152/ajpcell.1986.250.6.C861; SATHYAMOORTHY V, 1990, BIOCHEMISTRY-US, V29, P3793, DOI 10.1021/bi00467a028; SCHILDMEYER LA, 1989, LIFE SCI, V45, P1617, DOI 10.1016/0024-3205(89)90271-3; SOMLYO AV, 1981, NATURE, V294, P567, DOI 10.1038/294567a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRYBUS KM, 1989, J CELL BIOL, V109, P2887, DOI 10.1083/jcb.109.6.2887; WALSH MP, 1982, BIOCHEMISTRY-US, V21, P6890, DOI 10.1021/bi00269a041; WALSH MP, 1983, METHOD ENZYMOL, V99, P279; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0	38	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7030	7036						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1826682				2022-12-25	WOS:A1991FG72700061
J	ETINGIN, OR; HAJJAR, DP; HAJJAR, KA; HARPEL, PC; NACHMAN, RL				ETINGIN, OR; HAJJAR, DP; HAJJAR, KA; HARPEL, PC; NACHMAN, RL			LIPOPROTEIN (A) REGULATES PLASMINOGEN-ACTIVATOR INHIBITOR-1 EXPRESSION IN ENDOTHELIAL-CELLS - A POTENTIAL MECHANISM IN THROMBOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; 3' UNTRANSLATED REGION; MESSENGER-RNA LEVELS; GROWTH-FACTOR; FIBRINOLYTIC SYSTEM; HUMAN-FIBROBLASTS; GENE-EXPRESSION; TISSUE-TYPE; PROTEIN-C; SEQUENCE	Lipoprotein (a) (Lp(a)) is a low density lipoprotein-like particle which contains the plasminogen-like apolipoprotein a. Lp(a) levels are elevated in patients with atherosclerotic coronary artery disease. Recent studies suggest that Lp(a) competitively inhibits plasminogen binding to the endothelial cell and interferes with surface-associated plasmin generation. In this study, we present evidence for the presence of Lp(a) in the microvasculature of inflamed tissue. In addition, we demonstrate that Lp(a) regulates endothelial cell synthesis of a major fibrinolytic protein, plasminogen activator inhibitor-1 (PAI-1). In cultured human endothelial cells, Lp(a) enhanced PAI-1 antigen, activity, and steady-state mRNA levels without altering tissue plasminogen activator activity or mRNA transcript levels. This effect was cell-specific. Although other lipoproteins did not coordinately raise PAI-1 mRNA levels in endothelial cells, low density lipoprotein treatment selectively raised the level of the 3.4-kilobase mRNA species of PAI-1 without a concomitant increase in PAI-1 activity or antigen. Endothelial cell exposure to Lp(a) did not cause generalized endothelial cell activation since the functional activity and mRNA levels for tissue factor, platelet-derived growth factor and interleukin-6 were no elevated following Lp(a) exposure. These data suggest a molecular mechanism whereby (Lp(a) may support a specific prothrombotic endothelial cell phenotype, namely by increasing PAI-1 expression.	CORNELL UNIV,MED CTR,COLL MED,DEPT BIOCHEM,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,DEPT PATHOL,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,DEPT PEDIAT,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,NIH,SPECIALIZED CTR THROMBOSIS RES,NEW YORK,NY 10021	Cornell University; Cornell University; Cornell University; Cornell University; National Institutes of Health (NIH) - USA	ETINGIN, OR (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT MED,NEW YORK,NY 10021, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039701, P50HL018828] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-01687, HL-39701, HL-18828] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG VW, 1985, J LIPID RES, V26, P1314; ARMSTRONG VW, 1986, ATHEROSCLEROSIS, V62, P249, DOI 10.1016/0021-9150(86)90099-7; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BEVILACQUA MP, 1986, J CLIN INVEST, V78, P587, DOI 10.1172/JCI112613; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BROWN MS, 1987, NATURE, V330, P113, DOI 10.1038/330113a0; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CARSON SD, 1986, THROMB RES, V41, P185, DOI 10.1016/0049-3848(86)90228-8; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5894; DICHEK D, 1989, BLOOD, V74, P222; DICHEK D, 1989, IN VITRO CELL DEV B, V25, P289; EATON DL, 1987, P NATL ACAD SCI USA, V84, P3224, DOI 10.1073/pnas.84.10.3224; EDLUND T, 1983, P NATL ACAD SCI-BIOL, V80, P349, DOI 10.1073/pnas.80.2.349; EMEIS JJ, 1986, J EXP MED, V163, P1260, DOI 10.1084/jem.163.5.1260; ERICKSON LA, 1985, CLIN HAEMATOL, V14, P513; ESMON NL, 1988, SEMIN THROMB HEMOST, V14, P210, DOI 10.1055/s-2007-1002779; FIENBERG AP, 1984, ANAL BIOCHEM, V137, P266; FROSTEGARD J, 1990, P NATL ACAD SCI USA, V87, P904, DOI 10.1073/pnas.87.3.904; GELEHRTER TD, 1986, J CLIN INVEST, V77, P165, DOI 10.1172/JCI112271; GONZALEZGRONOW M, 1989, BIOCHEMISTRY-US, V28, P2374, DOI 10.1021/bi00432a005; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HAJJAR KA, 1987, J CLIN INVEST, V80, P1712, DOI 10.1172/JCI113262; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HAJJAR KA, 1988, J CLIN INVEST, V82, P1769, DOI 10.1172/JCI113790; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HOFF HF, 1988, CIRCULATION, V77, P1238, DOI 10.1161/01.CIR.77.6.1238; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KNUDSEN BS, 1986, J BIOL CHEM, V261, P765; KONKLE BA, 1988, J CLIN INVEST, V82, P579, DOI 10.1172/JCI113635; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCORE CL, 1988, J BIOL CHEM, V263, P15845; MAEDA S, 1989, ATHEROSCLEROSIS, V78, P145, DOI 10.1016/0021-9150(89)90218-9; MAJESKY MW, 1988, P NATL ACAD SCI USA, V85, P1525; MARSHALL PJ, 1985, ANAL BIOCHEM, V145, P192, DOI 10.1016/0003-2697(85)90347-1; MAY LT, 1986, P NATL ACAD SCI USA, V83, P8957, DOI 10.1073/pnas.83.23.8957; MAYER M, 1988, J BIOL CHEM, V263, P15688; MEDCALF RL, 1988, J CELL BIOL, V106, P971, DOI 10.1083/jcb.106.3.971; MILES L A, 1988, Fibrinolysis, V2, P61, DOI 10.1016/0268-9499(88)90369-4; MILES LA, 1989, NATURE, V339, P303; NACHMAN RL, 1986, J EXP MED, V163, P1595, DOI 10.1084/jem.163.6.1595; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; NAWROTH PP, 1986, P NATL ACAD SCI USA, V83, P3460, DOI 10.1073/pnas.83.10.3460; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; POMERANTZ K, 1989, J LIPID RES, V30, P1385; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SCHLEEF RR, 1990, J CELL BIOL, V110, P155, DOI 10.1083/jcb.110.1.155; SCOTT J, 1989, NATURE, V341, P22, DOI 10.1038/341022a0; SEHGAL PB, 1987, SCIENCE, V235, P731, DOI 10.1126/science.3492764; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPICER E, 1987, P NATL ACAD SCI USA, V84, P8957; SPRENGERS ED, 1987, BLOOD, V69, P381; VANHINSBERGH VWM, 1985, BLOOD, V65, P444	57	256	260	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2459	2465						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1824942				2022-12-25	WOS:A1991EV51500068
J	MACFARLAND, RT; ZELUS, BD; BEAVO, JA				MACFARLAND, RT; ZELUS, BD; BEAVO, JA			HIGH-CONCENTRATIONS OF A CGMP-STIMULATED PHOSPHODIESTERASE MEDIATE ANP-INDUCED DECREASES IN CAMP AND STEROIDOGENESIS IN ADRENAL GLOMERULOSA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATRIAL NATRIURETIC FACTOR; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADENYLATE-CYCLASE ACTIVITY; ALDOSTERONE SECRETION; GMP; INHIBITION; PURIFICATION; ANGIOTENSIN; CALCIUM; AMP	An adrenal cGMP-stimulated phosphodiesterase (cGS-PDE) has been shown to mediate atrial natriuretic peptide (ANP)-induced reductions in aldosterone secretion and cAMP levels in primary bovine glomerulosa cells. High concentrations of cGS-PDE have been localized to the zona glomerulosa cell layer of the adrenal cortex using biochemical and immunological techniques. Immunoblot analysis using an affinity-purified, isozyme-specific antiserum revealed a single band that comigrated with a purified cGS-PDE (104 kDa) (1) and that was most highly concentrated in the outermost 1-2 mm of the cortex, representing the capsule and zona glomerulosa regions. Greater than 90% of the overall phosphodiesterase activity present in tissue extracts prepared from these regions was immunoprecipitated using a solid-phase monoclonal antibody reagent, indicating the cGS-PDE as the predominant phosphodiesterase isozyme. Immunohistochemical staining experiments of frozen thin sections of intact adrenal tissue revealed that the cGS-PDE present in this region was localized in the glomerulosa cells themselves. The role of this isozyme as a mediator of ANP-induced decreases in intracellular cAMP concentrations and aldosterone production was tested in primary cultures of bovine adrenal glomerulosa cells. In cells stimulated by ACTH, ANP treatment produced dose-dependent reductions in aldosterone secretion and cellular cAMP content over the same concentration range. Increases in aldosterone production elicited by three cell-permeable cAMP derivatives (8-bromo-cAMP, 8-p-chlorophenylthio-cAMP, and N6-2'-O-dibutyryl-cAMP) were antagonized by ANP, indicating a site of action distal to adenylate cyclase for this hormone. Because the relative magnitude of the ANP effect differed depending upon the derivative used, the three derivatives were compared with respect to their relative rates of in vitro hydrolysis by adrenal cGS-PDE. A positive correlation between their rates of hydrolysis and the degree to which the steroidogenic response produced by these derivatives was antagonized by ANP was demonstrated, further suggesting an ANP-induced activation of the cGS-PDE as being responsible for this effect. The possible contribution of an additional pathway mediated by an inhibitory guanine nucleotide binding regulatory protein (G(i)) acting on adenylate cyclase was tested by pretreatment of primary glomerulosa cells with pertussis toxin. Levels of pertussis toxin sufficient to inhibit subsequent in vitro ribosylation did not significantly alter the ANP effect on aldosterone production, although a partial reduction in the ANP effect on cAMP levels was observed. These findings support the proposed role of an adrenal cGS-PDE as a major mediator of ANP action in this tissue, and provide one of the first examples in intact cells of regulation of a phosphodiesterase by direct allosteric activation of the enzyme by cGMP.			MACFARLAND, RT (corresponding author), UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA.				NHLBI NIH HHS [T32-HL07312] Funding Source: Medline; NIDDK NIH HHS [DK21723] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021723] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANDSRIVASTAVA MB, 1990, J BIOL CHEM, V265, P8566; ANANDSRIVASTAVA MB, 1984, BIOCHEM BIOPH RES CO, V121, P855, DOI 10.1016/0006-291X(84)90756-3; ANANDSRIVASTAVA MB, 1987, J BIOL CHEM, V262, P4931; ANANDSRIVASTAVA MB, 1985, FEBS LETT, V181, P199, DOI 10.1016/0014-5793(85)80259-3; BARRETT PQ, 1989, ENDOCR REV, V10, P496, DOI 10.1210/edrv-10-4-496; BARRETT PQ, 1988, ENDOCRINOLOGY, V122, P799, DOI 10.1210/endo-122-3-799; BARSONY J, 1990, P NATL ACAD SCI USA, V87, P1188, DOI 10.1073/pnas.87.3.1188; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BEEBE SJ, 1985, J BIOL CHEM, V260, P5781; COUCHIE D, 1983, EUR J BIOCHEM, V136, P571, DOI 10.1111/j.1432-1033.1983.tb07778.x; ELLIOTT ME, 1986, FED PROC, V45, P2376; ERNEUX C, 1985, J CYCLIC NUCL PROT, V10, P463; ESTENSEN R D, 1983, Journal of Experimental Pathology (New York), V1, P49; FUJITA K, 1979, J BIOL CHEM, V254, P8567; GALLANT S, 1974, LIFE SCI, V14, P937, DOI 10.1016/0024-3205(74)90083-6; GANGULY A, 1989, BIOCHEM BIOPH RES CO, V159, P148, DOI 10.1016/0006-291X(89)92416-9; GILLESPIE PG, 1989, MOL PHARMACOL, V36, P773; HAMET P, 1984, BIOCHEM BIOPH RES CO, V123, P515, DOI 10.1016/0006-291X(84)90260-2; HARRISON SA, 1986, MOL PHARMACOL, V29, P506; HARTZELL HC, 1986, NATURE, V323, P273, DOI 10.1038/323273a0; HUGHES AR, 1984, P NATL ACAD SCI-BIOL, V81, P5680, DOI 10.1073/pnas.81.18.5680; HUNYADY L, 1988, BIOCHEM BIOPH RES CO, V157, P1247, DOI 10.1016/S0006-291X(88)81008-8; JAISWAL RK, 1988, FEBS LETT, V227, P47, DOI 10.1016/0014-5793(88)81411-X; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOJIMA I, 1985, J BIOL CHEM, V260, P4248; KRAMER RE, 1988, AM J PHYSIOL, V255, pE338, DOI 10.1152/ajpendo.1988.255.3.E338; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MA, 1988, J CLIN INVEST, V82, P388, DOI 10.1172/JCI113610; MACFARLAND RT, 1987, ADV CYCLIC NUCLEOTID, V23, P249; Manganiello V.C., 1990, CYCLIC NUCLEOTIDE PH, P61; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; MATSUOKA H, 1985, BIOCHEM BIOPH RES CO, V127, P1052, DOI 10.1016/S0006-291X(85)80051-6; MATSUOKA H, 1987, AM J PHYSIOL, V252, pE643, DOI 10.1152/ajpendo.1987.252.5.E643; MIOT F, 1985, EUR J BIOCHEM, V149, P59, DOI 10.1111/j.1432-1033.1985.tb08893.x; NARUSE M, 1987, J CLIN ENDOCR METAB, V64, P10, DOI 10.1210/jcem-64-1-10; OKAMOTO M, 1988, ACTA ENDOCRINOL-COP, V119, P358, DOI 10.1530/acta.0.1190358; PYNE NJ, 1986, BIOCHEM J, V234, P325, DOI 10.1042/bj2340325; RESINK TJ, 1988, EUR J BIOCHEM, V174, P531, DOI 10.1111/j.1432-1033.1988.tb14131.x; RIBEIRONETO FAP, 1985, METHOD ENZYMOL, V109, P566; SCHULICK A, 1990, LIFE SCI, V46, P671, DOI 10.1016/0024-3205(90)90071-X; SHIMA S, 1978, ENDOCRINOLOGY, V103, P1361, DOI 10.1210/endo-103-4-1361; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; STERNBER.LA, 1970, J HISTOCHEM CYTOCHEM, V18, P315, DOI 10.1177/18.5.315; STROOP SD, 1989, J BIOL CHEM, V264, P13718; TAKAYANAGI R, 1987, J BIOL CHEM, V262, P12104; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WHALIN ME, 1988, BIOCHIM BIOPHYS ACTA, V972, P79; YAMAMOTO T, 1983, J BIOL CHEM, V258, P2526; YAMAMOTO T, 1983, J BIOL CHEM, V258, P4173	49	192	201	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					136	142						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1845962				2022-12-25	WOS:A1991EQ33900023
J	CAREY, J; LEWIS, DEA; LAVOIE, TA; YANG, J				CAREY, J; LEWIS, DEA; LAVOIE, TA; YANG, J			HOW DOES TRP REPRESSOR BIND TO ITS OPERATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA-BINDING; CIRCULAR-DICHROISM; COMPLEX; RESOLUTION; TRYPTOPHAN; PROTEINS; HELIX; ACID	Three explanations have been advanced to account for the unexpected absence of direct hydrogen bonds and presence of a buried water layer in the co-crystalline complex of Escherichia coli trp repressor with DNA. We present results of physical and biochemical measurements that address the testable predictions of each model. We find that the DNA oligomer used for co-crystallization binds to the repressor with high affinity and specificity, and 1:1 stoichiometry, consistent with other evidence that this sequence represents the true operator target for a single repressor dimer. A proposed alternative DNA sequence binds weaker and with higher stoichiometry, consistent with a cooperative binding mode. The operator DNA in solution has a B-form helical structure in the presence and absence of repressor. Affinity of repressor for operator is altered under the conditions used for cocrystal growth.			CAREY, J (corresponding author), PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544, USA.				NIGMS NIH HHS [GM13650, GM07312] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM013650] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ARAKAWA T, 1990, BIOCHEMISTRY-US, V29, P1924, DOI 10.1021/bi00459a037; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; CAREY J, 1989, J BIOL CHEM, V264, P1941; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; CHOU WY, 1989, J BIOL CHEM, V264, P18309; DICKERSON RE, 1983, SCI AM, V249, P94, DOI 10.1038/scientificamerican1283-94; FAIRALL L, 1989, EMBO J, V8, P1809, DOI 10.1002/j.1460-2075.1989.tb03575.x; GUNSALUS RP, 1986, J BACTERIOL, V167, P272, DOI 10.1128/jb.167.1.272-278.1986; HARE DR, 1983, J MOL BIOL, V171, P319, DOI 10.1016/0022-2836(83)90096-7; HURLBURT BK, 1990, J BIOL CHEM, V265, P7853; IVANOV VI, 1973, BIOPOLYMERS, V12, P89, DOI 10.1002/bip.1973.360120109; JOACHIMIAK A, 1987, J BIOL CHEM, V262, P4917; JOHNSON BB, 1981, BIOCHEMISTRY-US, V20, P73, DOI 10.1021/bi00504a013; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KLIG LS, 1987, NUCLEIC ACIDS RES, V15, P5339, DOI 10.1093/nar/15.13.5339; KOPKA ML, 1983, J MOL BIOL, V163, P129, DOI 10.1016/0022-2836(83)90033-5; KUMAMOTO AA, 1987, GENE DEV, V1, P556, DOI 10.1101/gad.1.6.556; LEFEVRE JF, 1987, BIOCHEMISTRY-US, V26, P5076, DOI 10.1021/bi00390a029; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; RECORD MT, 1977, BIOCHEMISTRY-US, V16, P4791, DOI 10.1021/bi00641a005; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; STAACKE D, 1990, EMBO J, V9, P1963, DOI 10.1002/j.1460-2075.1990.tb08324.x; VONHIPPEL PH, 1986, P NATL ACAD SCI USA, V83, P1608; WOLBERGER C, 1988, NATURE, V335, P789, DOI 10.1038/335789a0; Wuthrich K., 1986, NMR PROTEINS NUCL AC	28	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24509	24513						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761550				2022-12-25	WOS:A1991GW84500043
J	KARSENTY, G; RAVAZZOLO, R; DECROMBRUGGHE, B				KARSENTY, G; RAVAZZOLO, R; DECROMBRUGGHE, B			PURIFICATION AND FUNCTIONAL-CHARACTERIZATION OF A DNA-BINDING PROTEIN THAT INTERACTS WITH A NEGATIVE ELEMENT IN THE MOUSE ALPHA-1(I) COLLAGEN PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCOLLAGEN MESSENGER-RNA; TRANSCRIPTION FACTOR; GENE-EXPRESSION; SEQUENCE; CELLS	In an effort to understand the regulation of expression of the mouse type I collagen genes, we have purified to homogeneity a transcription factor, called inhibitory factor 2 (IF-2), that binds to the mouse alpha-1(I) collagen promoter upstream of the proximal CCAAT motif. IF-2 was purified to homogeneity from mouse lymphocyte nuclear extracts by ion-exchange chromatography and two different steps of DNA affinity chromatography, one using the wild-type IF-2-binding site as affinity ligand and one using a mutated IF-2-binding site that has a higher affinity for the factor. Renaturation of active DNA-binding proteins purified through several chromatography steps from sodium dodecyl sulfate-polyacrylamide gels identified two polypeptides of 120 and 100 kDa, respectively, capable of binding specifically to an IF-2-binding site. DNA transfection experiments of NIH 3T3 fibroblasts using an alpha-1(I) promoter-CAT chimeric gene in which mutations were introduced that either improved or decreased the binding affinity of IF-2 for its recognition site, strongly suggest that IF-2 acts as a transcriptional inhibitor of the mouse alpha-1(I) collagen gene. DNA-binding studies with similar concentrations of purified IF-2 and CBF (CCAAT-binding factor) indicate that CBF inhibits binding of IF-2, whereas IF-2 inhibits CBF binding more weakly.			KARSENTY, G (corresponding author), UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT MOLEC GENET, HOUSTON, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA049515] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041264] Funding Source: NIH RePORTER; NCI NIH HHS [CA49515] Funding Source: Medline; NHLBI NIH HHS [HL41264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BORSCH AS, 1981, P NATL ACAD SCI USA, V78, P5141; BRENNER DA, 1989, NUCLEIC ACIDS RES, V17, P6055, DOI 10.1093/nar/17.15.6055; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEWET WJ, 1983, J BIOL CHEM, V258, P7721; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOLDRING MB, 1986, J BIOL CHEM, V261, P9049; GOLDRING MB, 1987, J BIOL CHEM, V262, P16724; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; KRIEG T, 1985, ANN NY ACAD SCI, V460, P375, DOI 10.1111/j.1749-6632.1985.tb51184.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAURENT GJ, 1985, CIBA F SYMP, V114, P222; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; RIPPE RA, 1989, MOL CELL BIOL, V9, P2224, DOI 10.1128/MCB.9.5.2224; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; TJIAN R, 1981, CELL, V26, P1, DOI 10.1016/0092-8674(81)90026-X; VUORIO T, 1990, J BIOL CHEM, V265, P22480; VURST J, 1985, EUR J BIOCHEM, V151, P449; WEINER FR, 1987, J BIOL CHEM, V262, P6955	31	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24842	24848						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761577				2022-12-25	WOS:A1991GW84500090
J	REXIN, M; BUSCH, W; GEHRING, U				REXIN, M; BUSCH, W; GEHRING, U			PROTEIN-COMPONENTS OF THE NONACTIVATED GLUCOCORTICOID RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; STEROID-HORMONE RECEPTORS; CHEMICAL CROSS-LINKING; MONOCLONAL-ANTIBODIES; 59-KILODALTON PROTEIN; PROGESTERONE-RECEPTOR; POLYACRYLAMIDE GELS; LYMPHOMA-CELLS; RAT-LIVER; BINDING	The nonactivated glucocorticoid receptor (M(r) approximately 350,000) of WEHI-7 mouse lymphoma cells was investigated with respect to the stoichiometry of protein subunits. Cross-linking patterns obtained by affinity labeling and denaturing gel electrophoresis revealed a heterotetramer consisting of one receptor polypeptide in association with two 90- and one approximately 50-kDa subunits. The receptor stabilized by molybdate, disulfide bond formation, or chemical cross-linking was purified roughly 6000-fold by immunoaffinity chromatography and analyzed by gel electrophoresis and immunoblotting. The 90-kDa component was consistently detected in a 2:1 ratio with respect to the receptor polypeptide and was identified as the 90-kDa heat shock protein, hSP90. A 70-kDa heat shock protein was found in both stabilized and nonstabilized receptors and bound to the immunomatrix independent of receptor. The additional receptor subunit was unequivocally identified as the 59-kDa protein previously described (Tai, P.-K. K., Maeda, Y., Nakao, K., Wakim, N. G., Duhring, J. L., and Faber, L. E. (1986) Biochemistry 25, 5269-5275). This component was found only in complexes cross-linked via amino groups. It was removed from the molybdate-stabilized receptor under our purification conditions, thus leaving behind a trimer composed of the receptor polypeptide and two molecules of hsp90. In the absence of hormone, the receptor had the same subunit composition as in its presence.	UNIV HEIDELBERG, INST BIOL CHEM, NEUENHEIMER FELD 501, W-6900 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg								ABDELLA PM, 1979, BIOCHEM BIOPH RES CO, V87, P734, DOI 10.1016/0006-291X(79)92020-5; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOURGEOIS S, 1977, CELL, V11, P423, DOI 10.1016/0092-8674(77)90060-5; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; Danielson M, 1991, NUCLEAR HORMONE RECE, P39; DENIS M, 1988, J STEROID BIOCHEM, V30, P271, DOI 10.1016/0022-4731(88)90105-7; DENIS M, 1989, CANCER RES, V49, pS2275; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GEHRING U, 1987, MOL CELL ENDOCRINOL, V53, P33, DOI 10.1016/0303-7207(87)90189-4; GEHRING U, 1985, FEBS LETT, V179, P138, DOI 10.1016/0014-5793(85)80208-8; GEHRING U, 1984, MOL CELL ENDOCRINOL, V36, P107, DOI 10.1016/0303-7207(84)90089-3; GEHRING U, 1987, TRENDS BIOCHEM SCI, V12, P399, DOI 10.1016/0968-0004(87)90195-2; GEHRING U, 1988, HORMONES THEIR ACT 1, P217; HARRIS AW, 1973, J IMMUNOL, V110, P431; HOUSLEY PR, 1984, BIOCHEM ACTION HORM, V11, P347; HOWARD KJ, 1988, J BIOL CHEM, V263, P3474; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFEBVRE P, 1989, BIOCHEM BIOPH RES CO, V159, P677, DOI 10.1016/0006-291X(89)90048-X; LITWACK G, 1988, CANCER RES, V48, P2636; MENDEL DB, 1988, J BIOL CHEM, V263, P6695; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OKRET S, 1985, BIOCHEMISTRY-US, V24, P6581, DOI 10.1021/bi00344a041; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRATT WB, 1987, J CELL BIOCHEM, V35, P51, DOI 10.1002/jcb.240350105; PRATT WB, 1990, MOL CELL ENDOCRINOL, V74, pC69, DOI 10.1016/0303-7207(90)90198-H; RATAJCZAK T, 1990, J STEROID BIOCHEM, V35, P543, DOI 10.1016/0022-4731(90)90197-Z; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; REXIN M, 1988, BIOCHEMISTRY-US, V27, P5593, DOI 10.1021/bi00415a030; REXIN M, 1988, FEBS LETT, V241, P234, DOI 10.1016/0014-5793(88)81068-8; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHAGGER H, 1988, ANAL BIOCHEM, V173, P201, DOI 10.1016/0003-2697(88)90179-0; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SEGNITZ B, 1990, J BIOL CHEM, V265, P2789; SMITH DF, 1990, J BIOL CHEM, V265, P3996; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TOFT DO, 1987, BIOCHEM ACTION HORM, V14, P293; WESTPHAL HM, 1982, EMBO J, V1, P1467, DOI 10.1002/j.1460-2075.1982.tb01339.x	44	87	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24601	24605						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761557				2022-12-25	WOS:A1991GW84500056
J	BROWN, KE; LAWRENCE, R; SONENSHEIN, GE				BROWN, KE; LAWRENCE, R; SONENSHEIN, GE			CONCERTED MODULATION OF ALPHA-1(XI) AND ALPHA-2(V) COLLAGEN MESSENGER-RNAS IN BOVINE VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V COLLAGEN; C-MYC; HUMAN ATHEROSCLEROSIS; GENE-EXPRESSION; XI COLLAGEN; CHAIN; CLONING; CDNA; TRANSFORMATION; PATHOGENESIS	We have isolated a partial cDNA for alpha-1(XI) collagen from a bovine smooth muscle cell (SMC) library. Previously, this collagen was not known to be expressed in SMCs. Comparison of the nucleotide and deduced amino acid sequence of the 2.7-kilobase bovine clone and the human alpha-1(XI) sequence indicates 92 and 98% homology, respectively. Bovine SMCs in culture were found to produce alpha-1(XI) mRNA. However, alpha-2(XI) and alpha-1(II) collagen RNA were not detectable; therefore, SMCs cannot synthesize the same type XI collagen as found in cartilage. Since type XI collagen is structurally related to type V collagen, the expression of alpha-1(XI) and alpha-2(V) collagen mRNA in SMCs was characterized. Levels of alpha-1(XI) and alpha-2(V) collagen mRNAs were low in exponentially growing SMCs and increased 3-4-fold as cells became confluent. Increased mRNA levels were also observed when exponentially growing subconfluent SMCs were incubated in medium containing 0.5% fetal bovine serum for 24 h, similar to the effects of serum deprivation on the expression of types I and III collagen genes (Kindy, M. S., Chang, C.-J., and Sonenshein, G. E. (1988) J. Biol. Chem. 263, 11426-11430). However, as cell density increased, serum deprivation resulted in very different responses for these collagen genes. Serum deprivation caused a decrease in expression of alpha-1(XI) and alpha-2(V) collagen mRNAs in cultures as they approached confluence. In contrast, at confluence alpha-1(I) and alpha-2(I) mRNA levels no longer responded to serum concentration whereas expression of alpha-1(III) mRNA remained inducible by serum deprivation. These results suggest concerted regulation of alpha-1(XI) and alpha-2(V) collagen gene expression, which is distinct from that for the chains of type I and type III collagen with respect to cell density and serum.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262, T32HL007429] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07429, HL13262] Funding Source: Medline; NIA NIH HHS [AG00115] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADACHI E, 1986, CONNECT TISSUE RES, V14, P257, DOI 10.3109/03008208609017469; ALTERMAN RBM, 1984, MOL CELL BIOL, V4, P123, DOI 10.1128/MCB.4.1.123; ANG AH, 1990, BIOCHEM J, V265, P461, DOI 10.1042/bj2650461; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BANTLE JA, 1976, ANAL BIOCHEM, V2, P413; BARNES MJ, 1985, COLLAGEN REL RES, V5, P65; BELDEKAS JC, 1981, BIOCHEMISTRY-US, V20, P2162, DOI 10.1021/bi00511a014; BELDEKAS JC, 1982, J BIOL CHEM, V257, P2252; BERK AJ, 1978, P NATL ACAD SCI USA, V75, P1274, DOI 10.1073/pnas.75.3.1274; BERNARD M, 1988, J BIOL CHEM, V263, P17159; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; BIRK DE, 1990, J CELL SCI, V95, P649; BOND JF, 1983, MOL CELL BIOL, V3, P1333, DOI 10.1128/MCB.3.8.1333; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHANG CJ, 1991, IN PRESS MATRIX; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5284; DEAN M, 1983, NATURE, V305, P443, DOI 10.1038/305443a0; Eyre D, 1987, STRUCTURE FUNCTION C, P261; FEINBERG A, 1982, ANAL BIOCHEM, V32, P6; FESSLER JH, 1987, STRUCTURE FUNCTION C, P81; FESSLER LI, 1985, J BIOL CHEM, V260, P3286; KEENE DR, 1987, J CELL BIOL, V105, P2392; KIMURA T, 1989, J BIOL CHEM, V264, P13910; KINDY MS, 1986, J BIOL CHEM, V261, P2865; KINDY MS, 1988, J BIOL CHEM, V263, P11426; LAWLER J, 1986, BLOOD, V67, P1197; LIAU G, 1989, J BIOL CHEM, V264, P10315; MAYNE R, 1978, BIOCHEMISTRY-US, V17, P446, DOI 10.1021/bi00596a011; MAYNE R, 1986, ARTERIOSCLEROSIS, V6, P585, DOI 10.1161/01.ATV.6.6.585; MCCULLAGH KA, 1975, NATURE, V258, P73, DOI 10.1038/258073a0; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MORRIS NP, 1990, J BIOL CHEM, V265, P10081; MUNRO JM, 1988, LAB INVEST, V58, P249; MURATA K, 1986, ATHEROSCLEROSIS, V60, P251, DOI 10.1016/0021-9150(86)90172-3; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; OAKES BW, 1982, EUR J CELL BIOL, V27, P34; OOSHIMA A, 1981, SCIENCE, V213, P666, DOI 10.1126/science.7256267; ROSS R, 1973, SCIENCE, V180, P1332, DOI 10.1126/science.180.4093.1332; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SANGIORGI FO, 1985, NUCLEIC ACIDS RES, V13, P2815, DOI 10.1093/nar/13.8.2815; SARGENT TD, 1987, METHOD ENZYMOL, V152, P423; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; SHEKHONIN BV, 1986, ATHEROSCLEROSIS, V60, P9; STEPP MA, 1986, J BIOL CHEM, V261, P6542; STEPP MA, 1985, ANN NY ACAD SCI, V460, P510, DOI 10.1111/j.1749-6632.1985.tb51225.x; VASIOS G, 1987, STRUCTURE FUNCTION C, P283; WEIL D, 1987, NUCLEIC ACIDS RES, V15, P181, DOI 10.1093/nar/15.1.181; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423	49	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23268	23273						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744123				2022-12-25	WOS:A1991GT48300075
J	CHANG, CP; KAO, JPY; LAZAR, CS; WALSH, BJ; WELLS, A; WILEY, HS; GILL, GN; ROSENFELD, MG				CHANG, CP; KAO, JPY; LAZAR, CS; WALSH, BJ; WELLS, A; WILEY, HS; GILL, GN; ROSENFELD, MG			LIGAND-INDUCED INTERNALIZATION AND INCREASED CELL CALCIUM ARE MEDIATED VIA DISTINCT STRUCTURAL ELEMENTS IN THE CARBOXYL TERMINUS OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; EGF-RECEPTOR; INSULIN-RECEPTOR; DOWN-REGULATION; A431 CELLS; ENDOCYTOSIS; PHOSPHORYLATION; IDENTIFICATION; SEQUENCE; BINDING	Signals that can mediate ligand-induced receptor internalization and calcium regulation are present in a 48-amino acid "calcium-internalization" domain in the C' terminus of the epidermal growth factor (EGF) receptor. The basis of calcium and internalization regulation signalled by this 48-amino acid sequence was analyzed using deletion and substitution mutant receptors. Cells expressing truncated receptors containing either the NH2- or COOH-terminal portion of the 48-residue domain displayed high affinity EGF-dependent endocytosis and receptor down-regulation. These endocytosis-competent EGF receptor mutants that lacked any autophosphorylation site were unable to increase the concentration of intracellular calcium. To investigate the role of self-phosphorylation in EGF-induced calcium mobilization, phenylalanine was substituted for the single autophosphorylated tyrosine residue in this region of an internalization-competent truncated receptor. The receptor-mediated calcium response was abolished, while ligand-dependent receptor internalization was unimpaired. These results demonstrate that EGF-dependent receptor endocytosis and calcium mobilization are separate events. Tyrosine self-phosphorylation is required for increased [Ca2+]i, while structural features distinct from autophosphorylation are required for receptor internalization.	UNIV CALIF SAN DIEGO,DEPT MED,CMM RM 345,9500 GILMAN DR,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,EUKARYOT REGULATORY BIOL PROGRAM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT PATHOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT PATHOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV MARYLAND,DEPT PHYSIOL,BALTIMORE,MD 21201; UNIV UTAH,DEPT PATHOL,SALT LAKE CITY,UT 84112	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University System of Maryland; University of Maryland Baltimore; Utah System of Higher Education; University of Utah				Wells, Alan/0000-0002-1637-8150; Wiley, Steven/0000-0003-0232-6867; Kao, Joseph/0000-0002-8875-2180				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HALEY J, 1987, ONCOGENE RES, V1, P375; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HEPLER JR, 1987, J BIOL CHEM, V262, P2951; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HSUAN JJ, 1989, BIOCHEM J, V262, P659, DOI 10.1042/bj2620659; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; LUND KA, 1990, J BIOL CHEM, V265, P15713; LUND KA, 1990, J BIOL CHEM, V265, P20517; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MOOLENAAR WH, 1984, J BIOL CHEM, V259, P8066; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; THIES RS, 1990, J BIOL CHEM, V265, P10132; TSIEN RY, 1990, CELL CALCIUM, V11, P93, DOI 10.1016/0143-4160(90)90063-Z; TSIEN RY, 1981, NATURE, V290, P527, DOI 10.1038/290527a0; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WILEY SH, 1991, J BIOL CHEM, V266, P11083	31	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23467	23470						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744139				2022-12-25	WOS:A1991GT48300103
J	DRAKE, RR; ZIMNIAK, P; HALEY, BE; LESTER, R; ELBEIN, AD; RADOMINSKA, A				DRAKE, RR; ZIMNIAK, P; HALEY, BE; LESTER, R; ELBEIN, AD; RADOMINSKA, A			SYNTHESIS AND CHARACTERIZATION OF 5-AZIDO-UDP-GLUCURONIC ACID - A NEW PHOTOAFFINITY PROBE FOR UDP-GLUCURONIC ACID-UTILIZING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							35-KDA MEMBRANE-PROTEIN; HUMAN-LIVER; ENDOPLASMIC-RETICULUM; CDNA SEQUENCE; BILE-ACIDS; GLUCURONOSYLTRANSFERASE; EXPRESSION; IDENTIFICATION; CLONING; SPECIFICITY	A new active site-directed photoaffinity analogue, [beta-P-32]5-azido-UDP-glucuronic acid (UDP-GlcA), was enzymatically synthesized from [beta-P-32] 5-N3UDP-Glc using UDP-glucose dehydrogenase. The product was characterized by its mobility on ion exchange and two thin-layer chromatographic systems, by its UV absorbance at 288 nm, and the loss of this absorbance after UV irradiation of the compound. Photoincorporation of [beta-P-32]5-N3UDP-GlcA into bovine liver UDP-Glc dehydrogenase (EC 1.1.1.22) was saturable with an apparent K(d) of 12.5-mu-M, and was inhibited by the known active-site effectors UDP-GlcA, UDP-Glc, and UDP-xylose. When human liver microsomes with known UDP-glucuronosyltransferase (EC 2.4.1.17) activities were photolabeled with [beta-P-32]5-N3UDP-GlcA, major photolabeled bands of 35-37 and 50-54 kDa were detected. When rat liver microsomes from phenobarbital-injected rats were photolabeled with [beta-P-32]5-N3UDP-GlcA, there was a marked increase in photoincorporation of a 51-kDa protein as compared with control animals. Evidence is presented which suggests that the photolabeled 51-54-kDa proteins in the liver microsomes from both tissues are UDP-glucuronosyltransferase and that [beta-P-32]5-N3UDP-GlcA represents a new alternative approach in the study of UDP-glucuronosyltransferase and other UDP-GlcA-utilizing enzymes.	UNIV ARKANSAS MED SCI HOSP,DEPT INTERNAL MED,LITTLE ROCK,AR 72205; UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205; UNIV KENTUCKY,ALBERT B CHANDLER MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Kentucky					NHLBI NIH HHS [HL-08238] Funding Source: Medline; NIDDK NIH HHS [DK-21800] Funding Source: Medline; NIGMS NIH HHS [GM-35766] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035766] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANDURSKI RS, 1951, J BIOL CHEM, V193, P405; BURCHELL B, 1989, PHARMACOL THERAPEUT, V43, P261, DOI 10.1016/0163-7258(89)90122-8; COFFMAN BL, 1990, ARCH BIOCHEM BIOPHYS, V281, P170, DOI 10.1016/0003-9861(90)90428-2; DRAKE R, 1990, BIOSCIENCE REP, V10, P61, DOI 10.1007/BF01116852; DRAKE RR, 1989, J BIOL CHEM, V264, P11928; DRAKE RR, 1991, IN PRESS PLANT PHYSL; Dutton G.F., 1980, GLUCURONIDATION DRUG; EVANS RK, 1987, BIOCHEMISTRY-US, V26, P269, DOI 10.1021/bi00375a037; Feingold D.S., 1982, PLANT CARBOHYDRATES, P3; FOURNELGIGLEUX S, 1989, FEBS LETT, V243, P119, DOI 10.1016/0014-5793(89)80111-5; FROST DJ, 1990, J BIOL CHEM, V265, P2162; GREEN MD, 1988, ARCH BIOCHEM BIOPHYS, V262, P367, DOI 10.1016/0003-9861(88)90200-7; HALEY BE, 1989, BIOSCOPE, V1, P3; HARDING D, 1988, P NATL ACAD SCI USA, V85, P8381, DOI 10.1073/pnas.85.22.8381; HAUSER SC, 1988, BIOCHIM BIOPHYS ACTA, V967, P149, DOI 10.1016/0304-4165(88)90004-9; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; IRSHAID YM, 1987, MOL PHARMACOL, V31, P27; IRSHAID YM, 1990, DRUG METAB DISPOS, V19, P173; JACKSON MR, 1987, BIOCHEM J, V242, P581, DOI 10.1042/bj2420581; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN FC, 1990, J BIOL CHEM, V265, P4782; MACKENZIE PI, 1990, J BIOL CHEM, V265, P8699; MACKENZIE PI, 1986, J BIOL CHEM, V261, P14112; MATERN H, 1990, EUR J BIOCHEM, V105, P99; NEUFELD EF, 1965, BIOCHEM BIOPH RES CO, V19, P456, DOI 10.1016/0006-291X(65)90146-4; ORDMAN AB, 1977, BIOCHIM BIOPHYS ACTA, V481, P25, DOI 10.1016/0005-2744(77)90133-4; PALAMARCZYK G, 1990, P NATL ACAD SCI USA, V87, P2666, DOI 10.1073/pnas.87.7.2666; RADOMINSKAPYREK A, 1987, J CLIN INVEST, V80, P234, DOI 10.1172/JCI113053; RADOMINSKAPYREK A, 1986, J LIPID RES, V27, P89; RITTER JK, 1991, J BIOL CHEM, V266, P1043; RITTER JK, 1990, J BIOL CHEM, V265, P7900; SHAILUBHAI K, 1990, J BIOL CHEM, V265, P14105; SHEPHERD SRP, 1989, BIOCHEM J, V259, P617, DOI 10.1042/bj2590617; TEPHLY TR, 1989, DRUG METAB REV, V20, P689, DOI 10.3109/03602538909103571	34	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23257	23260						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744121				2022-12-25	WOS:A1991GT48300073
J	GIBSON, BW; TANG, DZ; MANDRELL, R; KELLY, M; SPINDEL, ER				GIBSON, BW; TANG, DZ; MANDRELL, R; KELLY, M; SPINDEL, ER			BOMBININ-LIKE PEPTIDES WITH ANTIMICROBIAL ACTIVITY FROM SKIN SECRETIONS OF THE ASIAN TOAD, BOMBINA-ORIENTALIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS; NEISSERIA-GONORRHOEAE; CDNA SEQUENCE; FROG-SKIN; PRECURSORS; LIPOOLIGOSACCHARIDES; MAGAININS; CERULEIN; FORMS; MENINGITIDIS	The structures and hemolytic and bactericidal activities of three bombinin-like peptides, or BLP-1-3, from the skin of Bombina orientalis are described. The peptides were isolated from the skin of B. orientalis and sequenced by tandem mass spectrometry and are amphipathic, cationic peptides of 25-27 amino acids in length. The sequence of the most abundant member (BLP-1) is: Gly-Ile-Gly-Ala-Ser-Ile-Leu-Ser-Ala-Gly-Lys-Ser-Ala-Leu-Lys-Gly-Leu-Ala-Lys-Gly-Leu-Ala-Glu-His-Phe-Ala-Asn-NH2. All three peptides were found to share considerable, but not complete, homology with bombinin, an antimicrobial, hemolytic peptide first isolated by Michl and Csordas (Csordas, A., and Michl, A. (1970) Monatsh. Chem. 101, 182-189) from the skin of Bombina variegata. The BLPs have been assayed for antibiotic and hemolytic activity and found to be more potent than magainin 2 (a related antimicrobial peptide from Xenopus laevis) in their ability to kill bacteria. However, no significant hemolytic activity was found for these peptides which suggests a selectivity for prokaryotic over eukaryotic membranes. The molecular basis for antibacterial activity is presumed to be due to their predicted amphipathic alpha-helical structures which is supported by circular dichroism measurements that found significant helical content (63-69% alpha-helix) in 40% trifluoroethanol. Last, a cDNA library was constructed from the skin of B. orientalis and screened with an oligonucleotide probe complementary to the COOH terminus of BLP-1. Several clones were isolated and sequenced that encode BLP-1 and BLP-3, as well as an additional peptide (BLP-4) that differs by two amino acid substitutions from BLP-3.	VET ADM MED CTR,SAN FRANCISCO,CA 94121; OREGON REG PRIMATE RES CTR,BEAVERTON,OR 97006	US Department of Veterans Affairs; Veterans Health Administration (VHA); Oregon Health & Science University; Oregon National Primate Research Center	GIBSON, BW (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143, USA.		Mandrell, Robert E/O-9814-2018	Kelly, Michele/0000-0003-1799-055X	NATIONAL CANCER INSTITUTE [R01CA039237, R23CA039237] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NCI NIH HHS [CA39237] Funding Source: Medline; NCRR NIH HHS [RR01614] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDREU D, 1985, EUR J BIOCHEM, V149, P531, DOI 10.1111/j.1432-1033.1985.tb08957.x; AUSBEL FM, 1987, CURRENT PROTOCOLS MO; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHEN HC, 1988, FEBS LETT, V236, P462, DOI 10.1016/0014-5793(88)80077-2; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; CSORDAS A, 1970, MONATSH CHEM, V101, P182, DOI 10.1007/BF00907538; Cuervo J H, 1988, Pept Res, V1, P81; DUCLOHIER H, 1989, BIOPHYS J, V56, P1017, DOI 10.1016/S0006-3495(89)82746-8; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; GIBSON BW, 1986, J BIOL CHEM, V261, P5341; GIBSON BW, 1990, ACS SYM SER, V444, P222; GIOVANNINI MG, 1987, BIOCHEM J, V243, P113, DOI 10.1042/bj2430113; HUNT LT, 1988, FEBS LETT, V233, P282, DOI 10.1016/0014-5793(88)80443-5; JOHNSON RS, 1988, INT J MASS SPECTROM, V86, P136; KIM JJ, 1989, INFECT IMMUN, V57, P602, DOI 10.1128/IAI.57.2.602-608.1989; KUCHLER K, 1989, EUR J BIOCHEM, V179, P281, DOI 10.1111/j.1432-1033.1989.tb14552.x; KUKS PFM, 1989, J BIOL CHEM, V264, P14609; MANDRELL R, 1986, INFECT IMMUN, V54, P63, DOI 10.1128/IAI.54.1.63-69.1986; MANDRELL RE, 1988, J EXP MED, V168, P107, DOI 10.1084/jem.168.1.107; MATSUZAKI K, 1989, BIOCHIM BIOPHYS ACTA, V981, P130, DOI 10.1016/0005-2736(89)90090-4; MORRISET.JD, 1973, BIOCHEMISTRY-US, V12, P1290, DOI 10.1021/bi00731a008; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PHILLIPS NJ, 1990, BIOMED ENVIRON MASS, V19, P731, DOI 10.1002/bms.1200191112; POULTER L, 1988, J BIOL CHEM, V263, P3279; RANA FR, 1990, FEBS LETT, V261, P464, DOI 10.1016/0014-5793(90)80616-Q; RICHTER K, 1986, J BIOL CHEM, V261, P3676; SELSTED ME, 1989, J BIOL CHEM, V264, P4003; SORAVIA E, 1988, FEBS LETT, V228, P337, DOI 10.1016/0014-5793(88)80027-9; SPINDEL ER, 1987, GEN COMP ENDOCR, V67, P67, DOI 10.1016/0016-6480(87)90206-1; SPINDEL ER, 1990, P NATL ACAD SCI USA, V87, P9813, DOI 10.1073/pnas.87.24.9813; STANFIELD RL, 1988, J BIOL CHEM, V263, P5933; TERRY AS, 1988, J BIOL CHEM, V263, P5745; WALLS FC, 1990, BIOLOGICAL MASS SPECTROMETRY /, P197; WESTERHOFF HV, 1989, P NATL ACAD SCI USA, V86, P6597, DOI 10.1073/pnas.86.17.6597; WHITE LA, 1965, APPL MICROBIOL, V13, P171, DOI 10.1128/AEM.13.2.171-174.1965; WILLIAMS RW, 1990, BIOCHEMISTRY-US, V29, P4490, DOI 10.1021/bi00470a031; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; ZASLOFF M, 1988, P NATL ACAD SCI USA, V85, P910, DOI 10.1073/pnas.85.3.910; [No title captured]	41	143	154	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23103	23111						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744108				2022-12-25	WOS:A1991GT48300052
J	KLER, RS; JACKSON, S; BARTLETT, K; BINDOFF, LA; EATON, S; POURFARZAM, M; FRERMAN, FE; GOODMAN, SI; WATMOUGH, NJ; TURNBULL, DM				KLER, RS; JACKSON, S; BARTLETT, K; BINDOFF, LA; EATON, S; POURFARZAM, M; FRERMAN, FE; GOODMAN, SI; WATMOUGH, NJ; TURNBULL, DM			QUANTITATION OF ACYL-COA AND ACYLCARNITINE ESTERS ACCUMULATED DURING ABNORMAL MITOCHONDRIAL FATTY-ACID OXIDATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE MITOCHONDRIA; NON-KETOTIC HYPOGLYCEMIA; DEHYDROGENASE-DEFICIENCY; BETA-OXIDATION; CULTURED FIBROBLASTS; CHAIN; COMPLEX; PATIENT; DEFECTS; ASSAY	We have used radio-high pressure liquid chromatography to study the acyl-CoA ester intermediates and the acylcarnitines formed during mitochondrial fatty acid oxidation. During oxidation of [U-C-14]hexadecanoate by normal human fibroblast mitochondria, only the saturated acyl-CoA and acylcarnitine esters can be detected, supporting the concept that the acyl-CoA dehydrogenase step is rate-limiting in mitochondrial beta-oxidation. Incubations of fibroblast mitochondria from patients with defects of beta-oxidation show an entirely different profile of intermediates. Mitochondria from patients with defects in electron transfer flavoprotein and electron transfer flavoprotein:ubiquinone oxidoreductase are associated with slow flux through beta-oxidation and accumulation of long chain acyl-CoA and acylcarnitine esters. Increased amounts of saturated medium chain acyl-CoA and acylcarnitine esters are detected in the incubations of mitochondria with medium chain acyl-CoA dehydrogenase deficiency, whereas long chain 3-hydroxyacyl-CoA dehydrogenase deficiency is associated with accumulation of long chain 3-hydroxyacyl- and 2-enoyl-CoA and carnitine esters. These studies show that the control strength at the site of the defective enzyme has increased. Radio-high pressure liquid chromatography analysis of intermediates of mitochondrial fatty acid oxidation is an important new technique to study the control, organization and defects of the enzymes of beta-oxidation.	UNIV NEWCASTLE UPON TYNE, SCH MED, DIV CLIN NEUROSCI, FRAMLINGTON PL, NEWCASTLE UPON TYNE NE2 4HH, ENGLAND; UNIV NEWCASTLE UPON TYNE, SCH MED, DEPT CHILD HLTH, NEWCASTLE UPON TYNE NE2 4HH, ENGLAND; UNIV COLORADO, HLTH SCI CTR, DEPT PEDIAT, BF STOLINSKY RES LABS, DENVER, CO 80262 USA	Newcastle University - UK; Newcastle University - UK; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Watmough, Nicholas J/A-6643-2010; Eaton, Simon/C-4942-2008; pourfarzam, morteza/A-8211-2017	Watmough, Nicholas J/0000-0001-5901-6750; Eaton, Simon/0000-0003-0892-9204; pourfarzam, morteza/0000-0002-9563-8044; Bindoff, Laurence/0000-0003-0988-276X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD004024] Funding Source: NIH RePORTER; NICHD NIH HHS [HD08315, HD04024] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARTLETT K, 1991, NESTLE NUTR WORKS SE, V24, P19; BHUIYAN AKMJ, 1988, BIOCHEM SOC T, V16, P796, DOI 10.1042/bst0160796; COUDE FX, 1981, HUM GENET, V59, P263; FRERMAN FE, 1985, BIOCHEM MED METAB B, V33, P38, DOI 10.1016/0006-2944(85)90124-3; FUKUSHIMA T, 1989, J BIOL CHEM, V264, P16483; HALE DE, 1985, PEDIATR RES, V19, P666, DOI 10.1203/00006450-198507000-00006; JACKSON S, 1991, PEDIATR RES, V29, P406, DOI 10.1203/00006450-199104000-00016; JACKSON S, 1991, IN PRESS MOL GENETIC; KERNER J, 1990, BIOCHEMISTRY-US, V29, P4326, DOI 10.1021/bi00470a010; KOLVRAA S, 1982, CLIN CHIM ACTA, V126, P53, DOI 10.1016/0009-8981(82)90361-8; LOEHR JP, 1990, PEDIATR RES, V27, P311, DOI 10.1203/00006450-199003000-00024; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNING NJ, 1990, J INHERIT METAB DIS, V13, P58, DOI 10.1007/BF01799333; MCCARRY JD, 1980, ANNU REV BIOCHEM, V49, P395; MELDE K, 1991, BIOCHEM J, V274, P395, DOI 10.1042/bj2740395; MOON A, 1987, J CLIN INVEST, V79, P59, DOI 10.1172/JCI112808; NIEDERWIESER A, 1983, HELV PAEDIATR ACTA, V38, P9; RHEAD WJ, 1983, SCIENCE, V221, P73, DOI 10.1126/science.6857268; SAUDUBRAY JM, 1982, PEDIATR RES, V16, P877, DOI 10.1203/00006450-198210000-00015; SCHULZ H, 1990, PROG CLIN BIOL RES, V321, P23; SCHULZ H, 1985, BIOCH LIPIDS MEMBRAN, P116; Shepherd D., 1969, METHODS ENZYMOL, V13, P11, DOI [10.1016/0076-6879(69)13006-2, DOI 10.1016/0076-6879(69)13006-2]; STANLEY CA, 1983, PEDIATR RES, V17, P877, DOI 10.1203/00006450-198311000-00008; STANLEY KK, 1975, BIOCHEM J, V150, P77, DOI 10.1042/bj1500077; STEWART HB, 1973, BIOCHEM J, V132, P61, DOI 10.1042/bj1320061; TURNBULL DM, 1982, BIOCHEM J, V206, P511, DOI 10.1042/bj2060511; TURNBULL DM, 1984, NEW ENGL J MED, V311, P1232, DOI 10.1056/NEJM198411083111906; VERJEE ZH, 1985, J INHERIT METAB DIS, V8, P137, DOI 10.1007/BF01811497; VERKAMP JH, 1986, BIOCHEM MED METAB B, V35, P248; WATMOUGH NJ, 1990, J CLIN INVEST, V85, P177, DOI 10.1172/JCI114409; WATMOUGH NJ, 1989, BIOCHEM J, V262, P261, DOI 10.1042/bj2620261; YANG SY, 1987, J BIOL CHEM, V262, P13027; [No title captured]	33	85	88	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22932	22938						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744086				2022-12-25	WOS:A1991GT48300027
J	SPOTTS, RO; CHAKERIAN, AE; MATTHEWS, KS				SPOTTS, RO; CHAKERIAN, AE; MATTHEWS, KS			ARGININE 197 OF LAC REPRESSOR CONTRIBUTES SIGNIFICANT ENERGY TO INDUCER BINDING - CONFIRMATION OF HOMOLOGY TO PERIPLASMIC SUGAR BINDING-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; LACTOSE REPRESSOR; ESCHERICHIA-COLI; OPERATOR DNA; GENE; MUTATIONS; SITES; MUTAGENESIS; COMPLEXES; CLONING	Based on primary sequence homology between the lactose repressor protein and periplasmic sugar-binding proteins (Muller-Hill, B. (1983) Nature 302, 163-164), a hypothetical sugar-binding site for the lac repressor was proposed using the solved x-ray crystallographic structure of the arabinose-binding protein (ABP) (Sams, C. F., Vyas, N. K., Quiocho, F. A., and Matthews, K. S. (1984) Nature 310, 429-430). By analogy to Arg151 in the ABP sugar site, Arg197 is predicted to play an important role in lac repressor binding to inducer sugars. Hydrogen bonding occurs between Arg151 and the ring oxygen and 4-hydroxyl of the sugar ligand, two backbone carbonyls, and a side chain in ABP, and similar interactions in the lac repressor would be anticipated. To test this hypothesis, Arg197 in the lac repressor protein was altered by oligonucleotide-directed site-specific mutagenesis to substitute Gly, Leu, or Lys. Introduction of these substitutions at position 197 had no effect on operator binding parameters of the isolated mutant proteins, whereas the affinity for inducer was dramatically decreased, consistent with in vivo phenotypic behavior obtained by suppression of nonsense mutations at this site (Kleina, L. G., and Miller, J. H. (1990) J. Mol. Biol. 212, 295-318). Inducer binding affinity was reduced approximately 3 orders of magnitude for Leu, Gly, or Lys substitutions, corresponding to a loss of 50% of the free energy of binding. The pH shift characteristic of wild-type repressor is conserved in these mutants. Circular dichroic spectra demonstrated no significant alterations in secondary structure for these mutants. Thus, the primary effect of substitution for Arg197 is a very significant decrease in the affinity for inducer sugars. Arginine is uniquely able to make the multiple contacts found in the ABP sugar site, and we conclude that this residue plays a similar role in sugar binding for lactose repressor protein. These results provide experimental validation for the proposed homology between ABP and the lac repressor and suggest that homology with ABP may be employed to generate additional insight into the structure and function of this regulatory protein.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Rice University					NIGMS NIH HHS [GM35133, GM22441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035133, R01GM022441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTI S, 1991, NEW BIOL, V3, P57; BARKLEY MD, 1975, BIOCHEMISTRY-US, V14, P1700, DOI 10.1021/bi00679a024; BETZ JL, 1986, GENE, V42, P283, DOI 10.1016/0378-1119(86)90232-5; BEYREUTHER K, 1978, NATURE, V274, P767, DOI 10.1038/274767a0; BEYREUTHER K, 1975, EUR J BIOCHEM, V59, P491, DOI 10.1111/j.1432-1033.1975.tb02477.x; BEYREUTHER K, 1973, P NATL ACAD SCI USA, V70, P3576, DOI 10.1073/pnas.70.12.3576; BOELENS R, 1987, J MOL BIOL, V193, P213, DOI 10.1016/0022-2836(87)90638-3; BOURGEOIS S, 1971, METHODS ENZYMOLOGY D, V21, P491; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BRENOWITZ M, 1991, J BIOL CHEM, V266, P1281; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P1371; COULONDRE C, 1977, J MOL BIOL, V117, P525, DOI 10.1016/0022-2836(77)90056-0; COULONDRE C, 1977, J MOL BIOL, V117, P568; COULONDRE C, 1977, J MOL BIOL, V117, P572; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5479, DOI 10.1021/bi00367a020; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5468, DOI 10.1021/bi00367a018; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5474, DOI 10.1021/bi00367a019; FARABAUGH PJ, 1978, NATURE, V274, P765, DOI 10.1038/274765a0; GILBERT W, 1966, P NATL ACAD SCI USA, V56, P1891, DOI 10.1073/pnas.56.6.1891; GORDON AJE, 1988, J MOL BIOL, V200, P239, DOI 10.1016/0022-2836(88)90237-9; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMERICHS RMJN, 1989, BIOCHEMISTRY-US, V28, P2985, DOI 10.1021/bi00433a037; LAMERICHS RMJN, 1990, EUR J BIOCHEM, V194, P629, DOI 10.1111/j.1432-1033.1990.tb15662.x; LECLERC JE, 1988, J MOL BIOL, V203, P619, DOI 10.1016/0022-2836(88)90197-0; LIN SY, 1975, CELL, V4, P107, DOI 10.1016/0092-8674(75)90116-6; MATTHEWS BW, 1982, P NATL ACAD SCI-BIOL, V79, P1428, DOI 10.1073/pnas.79.5.1428; MATTHEWS KS, 1979, J BIOL CHEM, V254, P3348; MATTHEWS KS, 1987, DNA PROTEIN INTERACT, P13; Miller J. H., 1980, OPERON; MILLER JH, 1979, J MOL BIOL, V131, P223, DOI 10.1016/0022-2836(79)90074-3; MILLER JH, 1979, J MOL BIOL, V131, P249, DOI 10.1016/0022-2836(79)90075-5; MILLER JH, 1979, J MOL BIOL, V131, P191, DOI 10.1016/0022-2836(79)90073-1; Muller-Hill B, 1975, Prog Biophys Mol Biol, V30, P227; MULLERHILL B, 1971, ANGEW CHEM INT EDIT, V10, P160, DOI 10.1002/anie.197101601; MULLERHILL B, 1983, NATURE, V302, P163, DOI 10.1038/302163a0; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; OGORMAN RB, 1980, J BIOL CHEM, V255, P107; OGORMAN RB, 1980, J BIOL CHEM, V255, P100; PACE HC, 1990, P NATL ACAD SCI USA, V87, P1870, DOI 10.1073/pnas.87.5.1870; PFAHL M, 1974, GENETICS, V76, P669; QUIOCHO FA, 1984, NATURE, V310, P381, DOI 10.1038/310381a0; RIGGS AD, 1968, J MOL BIOL, V34, P361, DOI 10.1016/0022-2836(68)90260-X; ROSENBERG JM, 1977, NUCLEIC ACIDS RES, V4, P567, DOI 10.1093/nar/4.3.567; SAMS CF, 1985, J BIOL CHEM, V260, P1185; SAMS CF, 1984, NATURE, V310, P429, DOI 10.1038/310429a0; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SAUER RT, 1982, NATURE, V298, P447, DOI 10.1038/298447a0; SCHMITZ A, 1976, J BIOL CHEM, V251, P3359; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; VYAS NK, 1991, J BIOL CHEM, V266, P5226; WEBER IT, 1982, NUCLEIC ACIDS RES, V10, P5085, DOI 10.1093/nar/10.16.5085; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	55	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22998	23002						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744095				2022-12-25	WOS:A1991GT48300036
J	BIANCHET, M; YSERN, X; HULLIHEN, J; PEDERSEN, PL; AMZEL, LM				BIANCHET, M; YSERN, X; HULLIHEN, J; PEDERSEN, PL; AMZEL, LM			MITOCHONDRIAL ATP SYNTHASE - QUATERNARY STRUCTURE OF THE F1 MOIETY AT 3.6 A DETERMINED BY X-RAY-DIFFRACTION ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; ELECTRON-MICROSCOPY; LIVER MITOCHONDRIA; ESCHERICHIA-COLI; MONOCLONAL-ANTIBODIES; ANOMALOUS SCATTERING; F1-ATPASE; RESOLUTION; MECHANISM; SUBUNITS	The F1 moiety of the mitochondrial ATP synthase is composed of five different subunits with stoichiometry alpha-3-beta-3-gamma-delta-epsilon and exhibits the capacity to synthesize ATP from ADP and P(i). We have previously crystallized rat liver F1 and described its structure at 9-angstrom resolution (Amzel, L. M., McKinney, M., Narayanan, P., and Pedersen, P. L. (1982) Proc. Natl. Acad. Sci. U. S. A. 79, 5852-5856). Here we present an x-ray map of this complex enzyme at 3.6 angstrom, which provides a much more informative description of its quaternary structure. The overall dimensions of the F1 molecule are 120 angstrom x 120 angstrom x 74 angstrom. The enzyme exhibits 3-fold symmetry relating the three copies of each of the two major subunits, alpha and beta. As the alpha-subunits (but not the beta-subunits) contain cysteine residues, it has been possible to identify the alpha-subunits by heavy atom labeling with mersalyl and to relate their positions in the F1 molecule to the beta-subunits. Significantly, the alpha and beta-subunits each exist as trimeric arrays which are organized in two slightly offset, interdigitated layers along the 3-fold axis. In one trimeric layer the alpha-subunits are located close to the axis with homologous subunits interacting with each other; in the other trimeric layer the beta-subunits are far from the axis, and they interact only with alpha-subunits and not with one another. At one end of the structure, part of the interface between each a and beta-subunit encloses a space or "pocket" that is accessible to the solvent; at the other end the interfaces between the subunits are more open and exposed. The present work represents the highest resolution map reported to date for the F1 moiety of an ATP synthase complex.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,MOLEC & CELLULAR BIOENERGET LAB,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University			; Bianchet, Mario/K-2131-2015	Amzel, L. Mario/0000-0002-0129-9572; Bianchet, Mario/0000-0001-9032-7549	NCI NIH HHS [CA 10951] Funding Source: Medline; NIGMS NIH HHS [GM 25432] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA010951, R37CA010951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025432] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMZEL LM, 1983, ANNU REV BIOCHEM, V52, P801, DOI 10.1146/annurev.bi.52.070183.004101; AMZEL LM, 1982, P NATL ACAD SCI-BIOL, V79, P5852, DOI 10.1073/pnas.79.19.5852; AMZEL LM, 1978, J BIOL CHEM, V253, P2067; BLOW DM, 1959, ACTA CRYSTALLOGR, V12, P794, DOI 10.1107/S0365110X59002274; BLUNDELL TL, 1976, PROTEIN CRYSTALLOGRA, P212; BOEKEMA EJ, 1986, BIOCHIM BIOPHYS ACTA, V851, P353, DOI 10.1016/0005-2728(86)90071-X; BRYANT SH, 1985, ACTA CRYSTALLOGR B, V41, P362, DOI 10.1107/S0108768185002270; Catterall W. A., 1974, BIOCHEM SOC SPEC PUB, V4, P63; CATTERALL WA, 1971, J BIOL CHEM, V246, P4987; COZENS AL, 1987, J MOL BIOL, V194, P359, DOI 10.1016/0022-2836(87)90667-X; CRAWFORD JL, 1977, THESIS HARVARD U; CROSS RL, 1981, ANNU REV BIOCHEM, V50, P681, DOI 10.1146/annurev.bi.50.070181.003341; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; GUINIER A, 1952, XRAY CRYSTALLOGRAPHI, P74; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HENDRICKSON WA, 1981, NATURE, V290, P107, DOI 10.1038/290107a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; LUNSDORF H, 1984, J MOL BIOL, V173, P131, DOI 10.1016/0022-2836(84)90408-X; MATTHEWS BW, 1975, ACTA CRYSTALLOGR A, V31, P480, DOI 10.1107/S0567739475001040; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; PEDERSEN PL, 1976, BIOCHEM BIOPH RES CO, V71, P1182, DOI 10.1016/0006-291X(76)90778-6; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; THIAGALINGAM S, 1991, J BIOL CHEM, V266, P11395; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; TIEDGE H, 1983, EUR J BIOCHEM, V132, P37, DOI 10.1111/j.1432-1033.1983.tb07322.x; TSUPRUN VL, 1984, FEBS LETT, V167, P285, DOI 10.1016/0014-5793(84)80144-1; VERBURG JG, 1990, J BIOL CHEM, V265, P8065; WAKABAYASHI T, 1977, J MOL BIOL, V117, P515, DOI 10.1016/0022-2836(77)90140-1; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WILLIAMS N, 1982, J BIOL CHEM, V263, P5569; WINKLER FK, 1979, ACTA CRYSTALLOGR A, V35, P901, DOI 10.1107/S0567739479002035; YOSHIMURA H, 1989, J BIOCHEM-TOKYO, V106, P958, DOI 10.1093/oxfordjournals.jbchem.a122981; YSERN X, 1988, J BIOENERG BIOMEMBR, V20, P423, DOI 10.1007/BF00762202	39	111	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21197	21201						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1834656				2022-12-25	WOS:A1991GN00100095
J	VILSEN, B; ANDERSEN, JP; MACLENNAN, DH				VILSEN, B; ANDERSEN, JP; MACLENNAN, DH			FUNCTIONAL CONSEQUENCES OF ALTERATIONS TO HYDROPHOBIC AMINO-ACIDS LOCATED AT THE M4S4 BOUNDARY OF THE CA2+-ATPASE OF SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; TRANSMEMBRANE DOMAIN; NUCLEOTIDE-BINDING; COMPLEMENTARY-DNA; MOLECULAR-CLONING; CA-ATPASE; CA-2+-ATPASE; MUTATIONS; TRANSPORT; SITE	Site-specific mutagenesis was used to investigate the functional roles of amino acids in the relatively hydrophobic sequence Ile-Thr-Thr-Cys-Leu-Ala-320, located at the M4S4 boundary of the sarcoplasmic reticulum Ca2+-ATPase. Each of the residues was replaced with either a less hydrophobic, a polar, or a charged residue. Mutants Ile-315 --> Arg and Leu-319 --> Arg were devoid of any Ca2+ transport function or ATPase activity, while the mutant Thr-317 --> Asp retained about 5 and 7% of the wild-type Ca2+ transport and ATPase activities, respectively. These three mutants were able to form the ADP-sensitive phosphoenzyme intermediate (E1P) by reaction with ATP, but this intermediate decayed very slowly to the ADP-insensitive phosphoenzyme intermediate (E2P). In the mutants Ile-315 --> Arg and Leu-319 --> Arg, the level of E2P formed in the backward reaction with inorganic phosphate was extremely low, but hydrolysis of E2P occurred at a normal rate. These mutants, in addition, displayed a higher apparent affinity for Ca2+ than the wild-type enzyme. In the mutants Ile-315 --> Ser and Ile-315 --> Asp, the Ca2+ transport and ATPase activities were moderately reduced to 30-40% of the wild-type activities, but normal affinities for Ca2+, P(i), and ATP were retained, as was the low affinity modulatory effect of ATP. Mutation of Thr-316 to Asp, Thr-317 to Ala, Cys-318 to Ala and Ala-320 to Arg had little or no effect on Ca2+ transport or ATPase activities. Introduction of two negative and one positive charge by triple mutation of the Ile-Thr-Thr-317 sequence created a mutant enzyme that, although completely inactive, was inserted into the membrane, consistent with a location of these residues on the cytoplasmic side of the M4S4 interface. Our findings suggest that the amphipathic character of the S4 helix and/or the distribution of charges in S4 is important for the stability of the E2P intermediate.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto	VILSEN, B (corresponding author), AARHUS UNIV,INST PHYSIOL,DANISH BIOMEMBRANE RES CTR,DK-8000 AARHUS,DENMARK.			Vilsen, Bente/0000-0002-4727-9382; Andersen, Jens Peter/0000-0003-0654-4300				ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; ANDERSEN JP, 1986, J MEMBRANE BIOL, V93, P85, DOI 10.1007/BF01871021; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1989, BIOCHIM BIOPHYS ACTA, V973, P333, DOI 10.1016/S0005-2728(89)80440-2; DEMEIS L, 1991, SARCOPLASMIC RETICUL, V2; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; ROSS DC, 1987, J BIOL CHEM, V262, P12977; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; TAYLOR KA, 1986, J MOL BIOL, V187, P417, DOI 10.1016/0022-2836(86)90442-0; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1989, J BIOL CHEM, V264, P21024; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	35	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18839	18845						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1833400				2022-12-25	WOS:A1991GJ47200068
J	RESCIGNO, J; MANSUKHANI, A; BASILICO, C				RESCIGNO, J; MANSUKHANI, A; BASILICO, C			A PUTATIVE RECEPTOR TYROSINE KINASE WITH UNIQUE STRUCTURAL TOPOLOGY	ONCOGENE			English	Note							ADHESION MOLECULE L1; IMMUNOGLOBULIN SUPERFAMILY; HUMAN CHROMOSOME-19Q; HOMOLOGY; MEMBER; SIGNAL; FAMILY; RECOGNITION; FIBRONECTIN; SEQUENCE	We have cloned a murine cDNA on the basis of homology to the tyrosine kinase domain of the bek fibroblast growth factor receptor. This cDNA encodes a putative tyrosine kinase receptor with a unique structural pattern in its extracellular domain. It is a new member of the immunoglobulin superfamily with two immunoglobulin-like domains. It also contains two fibronectin type III domains which are found on diverse proteins such as receptor tyrosine phosphatases and neural cell adhesion molecules. This protein tyrosine kinase called ark (adhesion-related kinase) is likely to represent a new class of receptor tyrosine kinase. Ark mRNA appears to be expressed in most cell lines and adult tissues examined except those of hematopoietic lineage. It is undetectable in undifferentiated teratocarcinoma cells, F9 and N Tera 2.	NYU, SCH MED, DEPT MICROBIOL, NEW YORK, NY 10016 USA; NYU, SCH MED, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	New York University; New York University				Mansukhani, Alka/0000-0003-1020-3242	NCI NIH HHS [CA 42568] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042568] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASTIANI MJ, 1986, J NEUROSCI, V6, P3542; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURRIDGE K, 1987, J CELL SCI, P211; CAVANNA JS, 1990, GENOMICS, V7, P12, DOI 10.1016/0888-7543(90)90513-T; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DEUSTACHIO P, 1988, J NEUROCHEM, V50, P589, DOI 10.1111/j.1471-4159.1988.tb02951.x; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; GENNARINI G, 1989, J CELL BIOL, V109, P775, DOI 10.1083/jcb.109.2.775; GRIBSKOV M, 1990, METHOD ENZYMOL, V183, P146; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JENKINS RB, 1989, CANCER GENET CYTOGEN, V39, P253, DOI 10.1016/0165-4608(89)90192-1; JONES FS, 1989, P NATL ACAD SCI USA, V86, P1905, DOI 10.1073/pnas.86.6.1905; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NORTON PA, 1990, CELL, V61, P15, DOI 10.1016/0092-8674(90)90209-W; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; RINDLER MJ, 1982, J CELL BIOL, V95, pA262; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHONK D, 1990, CYTOGENET CELL GENET, V54, P15; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	35	100	126	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1991	6	10					1909	1913						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1840679				2022-12-25	WOS:A1991GX11800027
J	GALINA, A; DEMEIS, L				GALINA, A; DEMEIS, L			CA2+ TRANSLOCATION AND CATALYTIC ACTIVITY OF THE SARCOPLASMIC-RETICULUM ATPASE - MODULATION BY ATP, CA2+, AND PI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP; CA-2+ EFFLUX; ADENOSINE-TRIPHOSPHATASE; MOLECULAR MECHANISM; SKELETAL-MUSCLE; ENERGIZED STATE; VESICLES; TRANSPORT; RELEASE; PERMEABILITY	The ratio between Ca2+ uptake and Ca2+-dependent ATP hydrolysis measured in sarcoplasmic reticulum vesicles of rabbit skeletal muscle was found to vary greatly depending on the concentrations of oxalate or P(i) used. In the presence of 5 mM oxalate, 20 mM P(i), and 1 mM P(i), the ratios found were in the range of 1.4-2.3, 0.6-0.8, and 0.01-0.10, respectively. The rates of Ca2+ exchange and ATP synthesis were measured at the steady state by adding trace amounts of Ca-45 and P-32(i), after the vesicles had been loaded with Ca2+. In the presence of 1 mM P(i), 10 mM MgCl2, and 0.2 mM CaCl2, the ratio between Ca2+ exchange and ATP synthesis varied from 9 to 14. This ratio approached two when Ca2+ in the medium was reduced to a very low level, or when in the presence of Ca2+, dimethyl sulfoxide was added to the assay medium, or when the P(i) concentration was raised from 1 to 20 mM. A ratio of two was also measured when the steady state was attained using ITP instead of ATP. In all the conditions that led to a ratio close to two, there was an increase in the fraction of enzyme phosphorylated by P(i). It is proposed that the coupling between Ca2+ translocation and ATP hydrolysis or synthesis is modulated by the phosphorylation of the ATPase by P(i).			GALINA, A (corresponding author), UNIV FED RIO DE JANEIRO, INST CIENCIAS BIOMED, DEPT BIOQUIM, ILHA FUNDAO, BR-21910 RIO DE JANEIRO, BRAZIL.		Galina, Antonio/A-9292-2008					ALVES EW, 1987, EUR J BIOCHEM, V166, P647, DOI 10.1111/j.1432-1033.1987.tb13562.x; BENECH JC, 1991, BIOCHEM J, V274, P427, DOI 10.1042/bj2740427; CHIESI M, 1979, J BIOL CHEM, V254, P370; DAGLORIA M, 1976, J BIOL CHEM, V251, P3629; De Meis L, 1971, J Biol Chem, V246, P4764; de Meis L, 1974, Biochemistry, V13, P5032, DOI 10.1021/bi00721a026; de Meis L, 1974, Biochemistry, V13, P2057, DOI 10.1021/bi00707a009; DEAMER DW, 1972, ARCH BIOCHEM BIOPHYS, V153, P47, DOI 10.1016/0003-9861(72)90418-3; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1990, J BIOL CHEM, V265, P18848; DEMEIS L, 1991, J BIOL CHEM, V266, P5736; DEMEIS L, 1988, METHOD ENZYMOL, V157, P190; DEMEIS L, 1981, TRANSPORT LIFE SCI, V2; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FIEHN W, 1970, EUR J BIOCHEM, V13, P510, DOI 10.1111/j.1432-1033.1970.tb00954.x; GERDES U, 1983, BIOCHIM BIOPHYS ACTA, V734, P191, DOI 10.1016/0005-2736(83)90117-7; GERDES U, 1983, BIOCHIM BIOPHYS ACTA, V734, P180, DOI 10.1016/0005-2736(83)90116-5; GOULD GW, 1987, BIOCHEM J, V245, P739, DOI 10.1042/bj2450739; GOULD GW, 1987, BIOCHIM BIOPHYS ACTA, V904, P45, DOI 10.1016/0005-2736(87)90085-X; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HASSELBACH W, 1963, BIOCHEM Z, V339, P94; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; HASSELBACH W, 1978, BIOCHIM BIOPHYS ACTA, V515, P23, DOI 10.1016/0304-4157(78)90007-2; HASSELBACH W, 1983, ANNU REV PHYSIOL, V45, P325, DOI 10.1146/annurev.ph.45.030183.001545; HASSELBACH W, 1972, FEBS LETT, V20, P311, DOI 10.1016/0014-5793(72)80094-2; HASSELBACH W, 1964, PROGR BIOPHYS MOL BI, V14, P169; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INESI G, 1989, J BIOL CHEM, V264, P5929; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; JILKA RL, 1977, BIOCHIM BIOPHYS ACTA, V466, P57, DOI 10.1016/0005-2736(77)90208-5; KANAZAWA T, 1975, J BIOL CHEM, V250, P113; KURZMACK M, 1977, FEBS LETT, V74, P35, DOI 10.1016/0014-5793(77)80746-1; MAKINOSE M, 1971, FEBS LETT, V12, P271, DOI 10.1016/0014-5793(71)80196-5; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MCWHIRTER JM, 1987, BIOCHEM J, V245, P713, DOI 10.1042/bj2450713; MEISSNER G, 1975, BIOCHIM BIOPHYS ACTA, V389, P51, DOI 10.1016/0005-2736(75)90385-5; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; PANET R, 1972, BIOCHIM BIOPHYS ACTA, V255, P34, DOI 10.1016/0005-2736(72)90005-3; PICK U, 1983, EUR J BIOCHEM, V131, P393, DOI 10.1111/j.1432-1033.1983.tb07276.x; SANDELEMOS MP, 1988, EUR J BIOCHEM, V171, P273, DOI 10.1111/j.1432-1033.1988.tb13786.x; TADA M, 1978, PHYSIOL REV, V58, P1; THE R, 1977, EUR J BIOCHEM, V74, P611, DOI 10.1111/j.1432-1033.1977.tb11430.x; WAGENKNECHT T, 1989, NATURE, V338, P167, DOI 10.1038/338167a0; YAMADA S, 1972, J BIOCHEM, V72, P1537, DOI 10.1093/oxfordjournals.jbchem.a130045	44	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17978	17982						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1833389				2022-12-25	WOS:A1991GG55300044
J	MOCHLYROSEN, D; KHANER, H; LOPEZ, J; SMITH, BL				MOCHLYROSEN, D; KHANER, H; LOPEZ, J; SMITH, BL			INTRACELLULAR RECEPTORS FOR ACTIVATED PROTEIN-KINASE-C - IDENTIFICATION OF A BINDING-SITE FOR THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT-LIVER NUCLEI; IMMUNOCHEMICAL CHARACTERIZATION; PHORBOL ESTERS; 14-3-3 PROTEIN; ASSOCIATION; TRANSLOCATION; CELLS; BRAIN; PURIFICATION; FIBROBLASTS	Protein kinase C (PKC) isozymes comprise a family of cytosolic enzymes that translocate to different intracellular sites on activation. We have recently characterized at least two intracellular receptor proteins for PKC (termed RACKs for receptors for activated C-kinase) in the Triton-insoluble material of the particulate fraction from neonatal rat heart. Here, we identify a sequence that appears to resemble the PKC binding site on these RACKs. A peptide (peptide I) with the sequence KGDYEKILVALCGGN bound PKC, and binding was markedly increased in the presence of PKC activators. Furthermore, peptide I inhibited PKC binding to RACKs in a dose-dependent manner. These data suggest that these RACKs have a common PKC binding sequence. Since peptide I inhibited PKC binding to RACKs in vitro, it may be a useful tool to inhibit PKC translocation and subsequent function in vivo.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT NEUROL,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT PHARMACOL,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,RES CTR,SAN FRANCISCO,CA 94110	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	MOCHLYROSEN, D (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,ERNEST GALLO CLIN,BLDG 1,RM 101,SAN FRANCISCO,CA 94110, USA.			Mochly-Rosen, Daria/0000-0002-6691-8733				AITKEN A, 1990, NATURE, V344, P594; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; CAPITANI S, 1987, BIOCHEM BIOPH RES CO, V142, P367, DOI 10.1016/0006-291X(87)90283-X; CHEN ZZ, 1987, J IMMUNOL, V138, P2345; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; ERNST JD, 1989, BIOCHEM BIOPH RES CO, V161, P959, DOI 10.1016/0006-291X(89)91336-3; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P6438; HALSEY DL, 1987, J BIOL CHEM, V262, P2234; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; ITO M, 1989, BIOCHEM BIOPH RES CO, V160, P1344, DOI 10.1016/S0006-291X(89)80151-2; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; MASMOUDI A, 1989, J BIOL CHEM, V264, P1172; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PAPADOPOULOS V, 1989, J CELL BIOL, V108, P553, DOI 10.1083/jcb.108.2.553; SAITO N, 1989, P NATL ACAD SCI USA, V86, P3409, DOI 10.1073/pnas.86.9.3409; TAMAKI M, 1987, NUCLEIC ACIDS RES, V15, P7637, DOI 10.1093/nar/15.18.7637; THOMAS TP, 1988, CANCER RES, V48, P1910; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ZALEWSKI PD, 1988, BIOCHEM PHARMACOL, V37, P1415, DOI 10.1016/0006-2952(88)90802-7	27	203	206	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14866	14868						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1831196				2022-12-25	WOS:A1991GB09700010
J	WIECZOREK, H; PUTZENLECHNER, M; ZEISKE, W; KLEIN, U				WIECZOREK, H; PUTZENLECHNER, M; ZEISKE, W; KLEIN, U			A VACUOLAR-TYPE PROTON PUMP ENERGIZES K+/H+ ANTIPORT IN AN ANIMAL PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; TOBACCO HORNWORM MIDGUT; LEPIDOPTERAN INSECT LARVAE; K+-TRANSPORT; MANDUCA-SEXTA; H+-ATPASE; DEPENDENT TRANSPORT; ESCHERICHIA-COLI; NA+/H+ ANTIPORT; ION-TRANSPORT	In this paper we demonstrate that a vacuolar-type H+-ATPase energizes secondary active transport in an insect plasma membrane and thus we provide an alternative to the classical concept of plasma membrane energization in animal cells by the Na+/K+-ATPase. We investigated ATP-dependent and -independent vesicle acidification, monitored with fluorescent acridine orange, in a highly purified K+-transporting goblet cell apical membrane preparation of tobacco hornworm (Manduca sexta) midgut. ATP-dependent proton transport was shown to be catalyzed by a vacuolar-type ATPase as deduced from its sensitivity to submicromolar concentrations of bafilomycin A1. ATP-independent amiloride-sensitive proton transport into the vesicle interior was dependent on an outward-directed K+ gradient across the vesicle membrane. This K+-dependent proton transport may be interpreted as K+/H+ antiport because it exhibited the same sensitivity to amiloride and the same cation specificity as the K+-dependent dissipation of a pH gradient generated by the vacuolar-type proton pump. The vacuolar-type ATPase is exclusively a proton pump because it could acidify vesicles independent of the extravesicular K+ concentration, provided that the antiport was inhibited by amiloride. Polyclonal antibodies against the purified vacuolar-type ATPase inhibited ATPase activity and ATP-dependent proton transport, but not K+/H+ antiport, suggesting that the antiporter and the ATPase are two different molecular entities. Experiments in which fluorescent oxonol V was used as an indicator of a vesicle-interior positive membrane potential provided evidence for the electrogenicity of K+/H+ antiport and suggested that more than one H+ is exchanged for one K+ during a reaction cycle. Both the generation of the K+ gradient-dependent membrane potential and the vesicle acidification were sensitive to harmaline, a typical inhibitor of Na+-dependent transport processes including Na+/H+ antiport. Our results led to the hypothesis that active and electrogenic K+ secretion in the tobacco hornworm midgut results from electrogenic K+/nH+ antiport which is energized by the electrical component of the proton-motive force generated by the electrogenic vacuolar-type proton pump.			WIECZOREK, H (corresponding author), UNIV MUNICH,INST ZOOL,LUISENSTR 14,W-8000 MUNICH 2,GERMANY.							AHEARN GA, 1989, AM J PHYSIOL, V257, pR484, DOI 10.1152/ajpregu.1989.257.3.R484; ARONSON PS, 1980, AM J PHYSIOL, V238, pF210, DOI 10.1152/ajprenal.1980.238.3.F210; ATKINSON MM, 1989, PLANT PHYSIOL, V91, P298, DOI 10.1104/pp.91.1.298; BASSET G, 1988, J PHYSIOL-LONDON, V400, P529, DOI 10.1113/jphysiol.1988.sp017135; BELL RA, 1976, ANN ENTOMOL SOC AM, V69, P365, DOI 10.1093/aesa/69.2.365; Bertram G., 1989, Verhandlungen der Deutschen Zoologischen Gesellschaft, V82, P203; BERTRAM G, 1991, J INSECT PHYSL, V37, P207; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BREY RN, 1980, J BIOL CHEM, V255, P39; BREY RN, 1979, J BIOL CHEM, V254, P1957; BRIERLEY GP, 1989, BIOCHEMISTRY-US, V28, P4347, DOI 10.1021/bi00436a034; BRIERLEY GP, 1988, J BIOENERG BIOMEMBR, V20, P193, DOI 10.1007/BF00768394; CHAO AC, 1991, J EXP BIOL, V155, P403; CIOFFI M, 1983, TISSUE CELL, V15, P781, DOI 10.1016/0040-8166(83)90050-2; DOW JAT, 1988, J EXP BIOL, V140, P455; DOW JAT, 1984, J MEMBRANE BIOL, V77, P223, DOI 10.1007/BF01870571; DOW JAT, 1990, J EXP BIOL, V150, P247; DUBINSKY WP, 1983, AM J PHYSIOL, V245, pC157, DOI 10.1152/ajpcell.1983.245.1.C157; EHRENFELD J, 1989, PFLUG ARCH EUR J PHY, V414, P59, DOI 10.1007/BF00585627; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GANAPATHY V, 1985, AM J PHYSIOL, V249, pG153, DOI 10.1152/ajpgi.1985.249.2.G153; GANAPATHY V, 1988, J BIOL CHEM, V263, P4561; GIORDANA B, 1989, AM J PHYSIOL, V257, pR494, DOI 10.1152/ajpregu.1989.257.3.R494; GLUCK S, 1987, J BIOL CHEM, V262, P15780; GRAVES JS, 1989, CELL TISSUE RES, V258, P137; GULTEKIN H, 1988, ANAL BIOCHEM, V172, P320, DOI 10.1016/0003-2697(88)90451-4; Harold F. M., 1986, VITAL FORCE STUDY BI; HARVEY BJ, 1986, PFLUG ARCH EUR J PHY, V406, P362, DOI 10.1007/BF00590937; HARVEY WR, 1983, J EXP BIOL, V106, P91; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; KANE PM, 1989, J BIOL CHEM, V264, P19236; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; KRULWICH TA, 1983, BIOCHIM BIOPHYS ACTA, V726, P245, DOI 10.1016/0304-4173(83)90011-3; KULANTHAIVEL P, 1990, J BIOL CHEM, V265, P1249; LOHDENBENDINGER U, 1990, Z NATURFORSCH C, V45, P229; MARTIN WH, 1984, J BIOL CHEM, V259, P2062; MOFFETT DF, 1988, J EXP BIOL, V135, P25; MOFFETT DF, 1988, J EXP BIOL, V135, P39; MORIYAMA Y, 1988, BIOCHEM BIOPH RES CO, V156, P211, DOI 10.1016/S0006-291X(88)80826-X; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NG LL, 1989, BIOCHEM J, V259, P311, DOI 10.1042/bj2590311; RABON E, 1985, J BIOL CHEM, V260, P200; RAJENDRAN VM, 1987, J BIOL CHEM, V262, P14974; SCHERER GGFE, 1985, PLANT SCI, V41, P161, DOI 10.1016/0168-9452(85)90083-4; SCHUMAKER KS, 1986, J BIOL CHEM, V261, P2172; SCHWEIKL H, 1989, J BIOL CHEM, V264, P11136; SHETLAR RE, 1989, AM J PHYSIOL, V257, pR924, DOI 10.1152/ajpregu.1989.257.4.R924; SOKOL PP, 1988, BIOCHIM BIOPHYS ACTA, V940, P209, DOI 10.1016/0005-2736(88)90196-4; SOLTOFF SP, 1983, SCIENCE, V220, P957, DOI 10.1126/science.6302840; STONE DK, 1989, J BIOENERG BIOMEMBR, V21, P605, DOI 10.1007/BF00808116; SZE H, 1983, BIOCHIM BIOPHYS ACTA, V732, P586, DOI 10.1016/0005-2736(83)90235-3; Thurm U., 1980, P735; TIRUPPATHI C, 1988, BIOCHEM J, V256, P219, DOI 10.1042/bj2560219; TURRINI F, 1989, J MEMBRANE BIOL, V107, P1, DOI 10.1007/BF01871078; VANADELSBERG J, 1986, J CELL BIOL, V102, P1638, DOI 10.1083/jcb.102.5.1638; VILLALOBO A, 1982, J BIOL CHEM, V257, P1824; WIECZOREK H, 1989, J BIOL CHEM, V264, P11143; WIECZOREK H, 1986, BIOCHIM BIOPHYS ACTA, V857, P271, DOI 10.1016/0005-2736(86)90356-1; WIECZOREK H, 1990, METHOD ENZYMOL, V192, P608; WIECZOREK H, 1985, 19TH P JAP S TAST SM, P42; ZEISKE W, 1986, PFLUG ARCH EUR J PHY, V407, P657, DOI 10.1007/BF00582648	64	262	267	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15340	15347						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1831202				2022-12-25	WOS:A1991GB09700077
J	PAPP, B; ENYEDI, A; KOVACS, T; SARKADI, B; WUYTACK, F; THASTRUP, O; GARDOS, G; BREDOUX, R; LEVYTOLEDANO, S; ENOUF, J				PAPP, B; ENYEDI, A; KOVACS, T; SARKADI, B; WUYTACK, F; THASTRUP, O; GARDOS, G; BREDOUX, R; LEVYTOLEDANO, S; ENOUF, J			DEMONSTRATION OF 2 FORMS OF CALCIUM PUMPS BY THAPSIGARGIN INHIBITION AND RADIOIMMUNOBLOTTING IN PLATELET MEMBRANE-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCO(ENDO)PLASMIC RETICULUM CA-2+-ATPASE; CA-2+ TRANSPORT-SYSTEMS; PLASMA-MEMBRANE; MOLECULAR-CLONING; SKELETAL-MUSCLE; CA-2+-TRANSPORTING ATPASE; FUNCTIONAL DOMAINS; TUMOR PROMOTER; PROTEOLYSIS; ANTIBODIES	In mixed membrane vesicles prepared from human platelets, the presence of two distinct calcium pump enzymes (molecular mass 100 and 97 kDa) was demonstrated by P-32 autoradiography, immunoblotting, and thapsigargin inhibition. Both the 100- and 97-kDa membrane proteins showed calcium-dependent phosphoenzyme formation and reacted with a polyclonal anti-sarcoplasmic reticulum calcium pump antiserum, while only the 100-kDa protein reacted with the antiserum specific for the sarco-endoplasmic reticulum-type calcium transport ATPase 2b isoform. Thapsigargin, inhibiting active calcium transport in platelet membrane vesicles, predominantly blocked the phosphoenzyme formation of the 100-kDa isoform and of the tryptic calcium pump fragments of 55 and 35 kDa, while lanthanum specifically increased the phosphoenzyme formation of the 97-kDa enzyme and of the tryptic fragment of 80 kDa. These results indicate the presence of the sarco-endoplasmic reticulum-type calcium transport ATPase 2b isoform and of a yet unidentified, 97-kDa calcium pump protein in human platelet membranes.	NATL INST HAEMATOL & BLOOD TRANSFUS,H-1113 BUDAPEST,HUNGARY; CATHOLIC UNIV LEUVEN,FYSIOL LAB,B-3000 LOUVAIN,BELGIUM; UNIV COPENHAGEN HOSP,DEPT CLIN CHEM,DK-2100 COPENHAGEN,DENMARK	KU Leuven; University of Copenhagen	PAPP, B (corresponding author), HOP LARIBOISIERE,INSERM,U150,8 RUE GUY PATIN,F-75475 PARIS 10,FRANCE.		Sarkadi, Balazs/I-5024-2013; Kovács, Tünde/O-6020-2017; Enyedi, Agnes/N-9742-2013	Kovács, Tünde/0000-0003-1064-2616; Enyedi, Agnes/0000-0002-7366-9376; Papp, Bela/0000-0002-5025-3087				BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BRAYDEN DJ, 1989, BRIT J PHARMACOL, V98, P809, DOI 10.1111/j.1476-5381.1989.tb14609.x; BURK SE, 1989, J BIOL CHEM, V264, P18561; DEAN WL, 1982, J BIOL CHEM, V257, P4390; ENOUF J, 1988, J BIOL CHEM, V263, P13922; ENOUF J, 1989, BIOCHEM J, V263, P547, DOI 10.1042/bj2630547; ENOUF J, 1987, J BIOL CHEM, V262, P9293; ENYEDI A, 1986, J BIOL CHEM, V261, P9558; FODER B, 1989, CELL CALCIUM, V10, P477, DOI 10.1016/0143-4160(89)90025-0; GREEB J, 1989, J BIOL CHEM, V264, P18569; KASERGLANZMANN R, 1978, BIOCHIM BIOPHYS ACTA, V512, P1, DOI 10.1016/0005-2736(78)90213-4; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; LYTTON J, 1989, J BIOL CHEM, V264, P7059; PAPP B, 1989, J BIOL CHEM, V264, P4577; RASMUSSEN U, 1978, ACTA PHARM SUEC, V15, P133; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SARKADI B, 1988, BIOCHIM BIOPHYS ACTA, V939, P40, DOI 10.1016/0005-2736(88)90044-2; SARKADI B, 1980, BIOCHIM BIOPHYS ACTA, V598, P326, DOI 10.1016/0005-2736(80)90010-3; SCHARFF O, 1988, BIOCHIM BIOPHYS ACTA, V972, P257, DOI 10.1016/S0005-2728(88)80056-2; SHULL GE, 1988, J BIOL CHEM, V263, P8646; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1987, BIOCHEM BIOPH RES CO, V142, P654, DOI 10.1016/0006-291X(87)91464-1; THASTRUP O, 1989, AGENTS ACTIONS, V27, P1; THASTRUP O, 1990, AGENTS ACTIONS, V29, P1; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WUYTACK F, 1989, BIOCHEM J, V264, P765, DOI 10.1042/bj2640765; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670	29	141	141	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14593	14596						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1830588				2022-12-25	WOS:A1991FZ35100075
J	DESMEDT, H; EGGERMONT, JA; WUYTACK, F; PARYS, JB; VANDENBOSCH, L; MISSIAEN, L; VERBIST, J; CASTEELS, R				DESMEDT, H; EGGERMONT, JA; WUYTACK, F; PARYS, JB; VANDENBOSCH, L; MISSIAEN, L; VERBIST, J; CASTEELS, R			ISOFORM SWITCHING OF THE SARCO(ENDO)PLASMIC RETICULUM CA2+ PUMP DURING DIFFERENTIATION OF BC3H1 MYOBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; ENDOPLASMIC-RETICULUM; SKELETAL-MUSCLE; SMOOTH-MUSCLE; CA-2+ PUMP; CA-2+-ATPASE GENE; MOLECULAR-CLONING; THYROID-HORMONE; TWITCH MUSCLE; ATPASE	We have studied the expression of the gene 2 for the sarco(endo)plasmic reticulum Ca2+ pump (SERCA2) in BC3H1 cells. Myogenic differentiation not only activated the SERCA2 expression but it also induced an isoform switch. Undifferentiated myoblasts only expressed the SERCA2b isoform (non-muscle) whereas differentiated myocytes predominantly contained the SERCA2a isoform (cardiac/slow skeletal muscle). The isoform switch was documented by immunoblot analysis with isoform-specific antibodies. This observation was confirmed at the mRNA level by using antisense RNA probes specific for class 1 (SERCA2a) or class 2 (SERCA2b) messengers. The expression of the SERCA2a isoform after differentiation was accompanied by a decreased sensitivity of the Ca2+ uptake in permeabilized cells to the Ca2+ pump inhibitor thapsigargin.			DESMEDT, H (corresponding author), CATHOLIC UNIV LEUVEN, FYSIOL LAB, CAMPUS GASTHUISBERG O-N, HERESTR 49, B-3000 LOUVAIN, BELGIUM.		Van Den Bosch, Ludo/B-7258-2012	Eggermont, Jan/0000-0002-8497-1159; Parys, Jan/0000-0002-3591-4967; Van Den Bosch, Ludo/0000-0003-0104-4067				AMBLER SK, 1988, J BIOL CHEM, V263, P1952; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BRENNAN TJ, 1990, J CELL BIOL, V110, P929, DOI 10.1083/jcb.110.4.929; BRUNETTI A, 1990, J BIOL CHEM, V265, P5960; BURK SE, 1989, J BIOL CHEM, V264, P18561; CAFFREY JM, 1987, SCIENCE, V236, P570, DOI 10.1126/science.2437651; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DELABASTIE D, 1988, FEBS LETT, V229, P45, DOI 10.1016/0014-5793(88)80794-4; DESMEDT H, 1991, BIOCHEM J, V273, P219, DOI 10.1042/bj2730219; DESMEDT H, 1987, BIOCHIM BIOPHYS ACTA, V929, P103, DOI 10.1016/0167-4889(87)90245-X; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EGGERMONT JA, 1990, BIOCHEM J, V271, P649, DOI 10.1042/bj2710649; EGGERMONT JA, 1989, BIOCHEM J, V260, P757, DOI 10.1042/bj2600757; EGGERMONT JA, 1990, BIOCHEM J, V266, P901; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HEIRWEGH KPM, 1988, BIOCHEM J, V254, P101, DOI 10.1042/bj2540101; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; LEBERER E, 1989, EUR J BIOCHEM, V185, P51, DOI 10.1111/j.1432-1033.1989.tb15080.x; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; NAGAI R, 1989, P NATL ACAD SCI USA, V86, P2966, DOI 10.1073/pnas.86.8.2966; PLESSERS L, 1991, IN PRESS J NEUROSCI; RAEYMAEKERS L, 1985, BIOCHIM BIOPHYS ACTA, V815, P441, DOI 10.1016/0005-2736(85)90372-4; ROHRER D, 1988, J BIOL CHEM, V263, P6941; SIMONIDES WS, 1990, FEBS LETT, V274, P73, DOI 10.1016/0014-5793(90)81332-I; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAUBMAN MB, 1989, J CELL BIOL, V108, P1799, DOI 10.1083/jcb.108.5.1799; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WUYTACK F, 1989, BIOCHEM J, V257, P117, DOI 10.1042/bj2570117; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670	33	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7092	7095						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1826684				2022-12-25	WOS:A1991FG72700070
J	HOCEVAR, BA; FIELDS, AP				HOCEVAR, BA; FIELDS, AP			SELECTIVE TRANSLOCATION OF BETA-II-PROTEIN KINASE-C TO THE NUCLEUS OF HUMAN PROMYELOCYTIC (HL60) LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; 3 DISTINCT FORMS; PHORBOL ESTER; RAT-BRAIN; IMMUNOCYTOCHEMICAL LOCALIZATION; ISOZYMIC FORMS; NIH-3T3 CELLS; LAMIN-B; ACTIVATION; DIFFERENTIATION	The promyelocytic leukemia (HL60) cell line differentiates into monocyte-like cells after treatment with phorbol dibutyrate (PBt2). In contrast, bryostatin 1 (bryo), a structurally distinct protein kinase C (PKC) activator, does not induce differentiation and blocks the cytostatic effect of PBt2. The divergent responses to these agents correlate with activation of a PKC-like activity at the nucleus in response to bryo but not PBt2 (Fields, A.P., Pettit, G.R., and May, W.W. (1988) J. Biol. Chem. 263, 8253-8260). In the present study, this nuclear PKC-like activity (termed PKC(n)) was isolated from HL60 cells and shown to phosphorylate its known nuclear substrate, lamin B. PKC(n)-mediated phosphorylation of nuclear envelope-associated lamin B in vitro is calcium-dependent and is stimulated by bryo and 1,2-dicotanoylglycerol (DiC8), but not PBT2. In contrast, PKC(n)-mediated phosphorylation of histone IIIS is stimulated equally by all three activators. PKC(n) mediates calcium- and phosphatidylserine-dependent phosphorylation of both histone IIIS and partially purified lamin B. PKC(n) activity can be inhibited by ann anti-PKC monoclonal antibody which specifically inhibits PKC. Isotype-specific PKC antibodies identify PKC(n) as beta-II-PKC. Immunoblot analysis indicates that HL60 cells express both alpha- and beta-II-PKc but no Beta-I- or gamma-PKC. Treatment of intact cells with bryo for 30 min leads to complete translocation of both alpha- and beta-II-PKc from the cytosol to the membrane fractions. Approximately 8-10% of the total beta-II-PKC (and < 0.3% of the alpha-PKC) is found associated with the nuclear membrane of bryo-treated cells. In contrast, PBt2 treatment leads to complete translocation of alpha-PKC, but only partial translocation of beta-II-PKC to the plasma membrane fraction. Neither PKC isotype is found associated with the nuclear membrane of PBt2-treated cells. These data demonstrate that alpha- and beta-II-PKc differ with respect to activator responsiveness, intracellular distribution, and substrate specificity and indicate that their selective activation at distinct intracellular sites, including the nucleus, can have a dramatic effect on resulting cellular responses.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHARMACOL,CLEVELAND,OH 44106	Case Western Reserve University								ABDELGHANY M, 1989, P NATL ACAD SCI USA, V86, P1761, DOI 10.1073/pnas.86.6.1761; AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; ASAOKA Y, 1988, FEBS LETT, V231, P221, DOI 10.1016/0014-5793(88)80735-X; BEH I, 1989, FEBS LETT, V249, P264, DOI 10.1016/0014-5793(89)80637-4; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; COOPER DR, 1989, BIOCHEM BIOPH RES CO, V161, P327, DOI 10.1016/0006-291X(89)91600-8; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DELLAQUILA ML, 1987, CANCER RES, V47, P6006; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; FIELDS AP, 1990, J CELL SCI, V96, P107; FOURNIER A, 1989, BIOCHEM BIOPH RES CO, V161, P556, DOI 10.1016/0006-291X(89)92635-1; GERACE L, 1978, J CELL BIOL, V79, P546, DOI 10.1083/jcb.79.2.546; HARLOW E, 1988, ANTIBODIES LABORATOR, P82; HOUWELING M, 1989, FEBS LETT, V247, P487, DOI 10.1016/0014-5793(89)81397-3; HUANG FL, 1987, BIOCHEM BIOPH RES CO, V149, P946, DOI 10.1016/0006-291X(87)90500-6; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; ISAKOV N, 1990, J BIOL CHEM, V265, P2091; JAKEN S, 1987, P NATL ACAD SCI USA, V84, P4418, DOI 10.1073/pnas.84.13.4418; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KISS Z, 1988, FEBS LETT, V231, P41, DOI 10.1016/0014-5793(88)80698-7; Kitano T, 1986, Methods Enzymol, V124, P349; KOSAKA Y, 1988, BIOCHEM BIOPH RES CO, V151, P973, DOI 10.1016/S0006-291X(88)80461-3; KRAFT AS, 1986, P NATL ACAD SCI USA, V83, P1334, DOI 10.1073/pnas.83.5.1334; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MARIAS RM, 1989, EUR J BIOCHEM, V182, P129; MCBAIN JA, 1988, CARCINOGENESIS, V9, P123, DOI 10.1093/carcin/9.1.123; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; MOCHLYROSEN D, 1988, ANAL BIOCHEM, V170, P31, DOI 10.1016/0003-2697(88)90085-1; NAOR Z, 1988, MOL ENDOCRINOL, V2, P1043, DOI 10.1210/mend-2-11-1043; NISHIKAWA M, 1990, CANCER RES, V50, P621; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHNO S, 1988, BIOCHEMISTRY-US, V27, P2083, DOI 10.1021/bi00406a040; ROGUE P, 1990, J BIOL CHEM, V265, P4161; SAWAMURA S, 1989, FEBS LETT, V247, P353, DOI 10.1016/0014-5793(89)81369-9; SEKIGUCHI K, 1988, J BIOCHEM-TOKYO, V103, P759, DOI 10.1093/oxfordjournals.jbchem.a122343; SEKIGUCHI K, 1987, BIOCHEM BIOPH RES CO, V145, P797, DOI 10.1016/0006-291X(87)91035-7; SHEARMAN MS, 1987, BIOCHEM BIOPH RES CO, V147, P911, DOI 10.1016/S0006-291X(87)80157-2; STRULOVICI B, 1989, BIOCHEMISTRY-US, V28, P3569, DOI 10.1021/bi00434a063; TAKAI Y, 1979, BIOCHEM BIOPH RES CO, V91, P1218, DOI 10.1016/0006-291X(79)91197-5; THOMAS TP, 1988, CANCER RES, V48, P1910; WOLF M, 1985, NATURE, V317, P546, DOI 10.1038/317546a0; WOOD JG, 1986, J NEUROSCI, V6, P2571	45	260	260	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					28	33						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1845965				2022-12-25	WOS:A1991EQ33900006
J	VORHERR, T; KESSLER, T; HOFMANN, F; CARAFOLI, E				VORHERR, T; KESSLER, T; HOFMANN, F; CARAFOLI, E			THE CALMODULIN-BINDING DOMAIN MEDIATES THE SELF-ASSOCIATION OF THE PLASMA-MEMBRANE CA2+ PUMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED ERYTHROCYTE CA-2+-ATPASE; ION MOTIVE ATPASES; RED-CELL GHOSTS; SARCOPLASMIC-RETICULUM; CA-2+ PUMP; MONOMERIC CA-2+-ATPASE; CA-2+-PUMPING ATPASE; HEART SARCOLEMMA; PROTEIN-KINASE; CALCIUM-PUMP	Dimerization (oligomerization) of the plasma membrane Ca2+ pump increases its activity (Kosk-Kosicka, d., Bzdega, T., and Wawrzynow, A. (1989) J. Biol. Chem. 264, 19495-19499). Fluorescence titration preparations of the purified eosin-labeled human erythrocyte ATPase has been used to monitor the oligomerization process. Calmodulin inhibits oligomerization, although it can bind to the oligomerized enzyme. Synthetic peptides corresponding to the calmodulin-binding domain of the pump stimulate its ATPase activity, indicating the formation of heterooligomers of the peptides with the pump. The oligomerization is prevented by the preincubation of the ATPase with calmodulin. Polyclonal antibodies against the synthetic calmodulin-binding domain inhibit its basal and its calmodulin-stimulated ATPase activity and prevent the formation of the oligomers. ATPase preparations truncated at the COOH terminus with calpain to a fragment of 124 kDa which does not contain the calmodulin-binding domain fail to oligomerize with the intact ATPase. The results show that the calmodulin-binding domain mediates the oligomerization of the Ca2+ pump.	SWISS FED INST TECHNOL,BIOCHEM LAB,UNIV STR 16,CH-8092 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich			Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; ANDERSEN JP, 1985, P NATL ACAD SCI USA, V82, P4573, DOI 10.1073/pnas.82.14.4573; ANDERSEN JP, 1985, J BIOL CHEM, V260, P371; BENAIM G, 1984, J BIOL CHEM, V259, P8471; BOYLE JM, 1985, EMBO J, V4, P3093, DOI 10.1002/j.1460-2075.1985.tb04050.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARONI P, 1981, J BIOL CHEM, V256, P3263; CAVIERES JD, 1984, BIOCHIM BIOPHYS ACTA, V771, P241, DOI 10.1016/0005-2736(84)90539-X; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FINDLAY SBC, 1989, PROTEIN SEQUENCING, P14; GOORMAGHTIGH E, 1986, J BIOL CHEM, V261, P7466; GRAF E, 1981, ARCH BIOCHEM BIOPHYS, V210, P257, DOI 10.1016/0003-9861(81)90187-9; GUERINI D, 1984, J BIOL CHEM, V259, P5172; HYMEL L, 1984, J BIOL CHEM, V259, P4890; JAMES P, 1988, J BIOL CHEM, V263, P2905; JAMES P, 1989, J BIOL CHEM, V264, P8289; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KNAUF PA, 1974, J GEN PHYSIOL, V63, P324, DOI 10.1085/jgp.63.3.324; KOSKKOSICKA D, 1988, J BIOL CHEM, V263, P18184; KOSKKOSICKA D, 1989, J BIOL CHEM, V264, P19495; KOSKKOSICKA D, 1990, BIOCHEMISTRY-US, V29, P1875, DOI 10.1021/bi00459a030; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; NEYSES L, 1985, J BIOL CHEM, V260, P283; NIGGLI V, 1981, J BIOL CHEM, V256, P395; NIGGLI V, 1979, J BIOL CHEM, V254, P9955; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; SMALLWOOD JI, 1988, J BIOL CHEM, V263, P2195; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; WANG KKW, 1988, ARCH BIOCHEM BIOPHYS, V260, P696, DOI 10.1016/0003-9861(88)90498-5; ZURINI M, 1984, J BIOL CHEM, V259, P618; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012	37	80	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					22	27						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1824694				2022-12-25	WOS:A1991EQ33900005
J	KOSFELD, MD; PAVLOPOULOS, TV; FRAZIER, WA				KOSFELD, MD; PAVLOPOULOS, TV; FRAZIER, WA			CELL ATTACHMENT ACTIVITY OF THE CARBOXYL-TERMINAL DOMAIN OF HUMAN THROMBOSPONDIN EXPRESSED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PLATELET THROMBOSPONDIN; ANGIOGENESIS; RECEPTOR; GROWTH	Thrombospondin (TS) is a multidomain, adhesive glycoprotein that associates with cells through multiple cell attachment sites. One of these has been located in or near the globular COOH-terminal region of TS by the monoclonal antibody (mAb) C6.7, which inhibits the attachment of human melanoma cells (G361) to TS. The epitope for C6.7 lies within the last 122 residues of the COOH-terminal domain of TS. This domain is distant from two known cell attachment sites in TS, namely the NH2-terminal heparin-binding domain and the CSVTCG sequences in the type I repeats, but is close to the RGDA sequence, an integrin-dependent cell attachment site. In order to separate the adhesive activity of the TS COOH-terminal domain from that of the RGD sequence, we have expressed the COOH-terminal 212 amino acids (residues 941-1152) of TS in Escherichia coli using the expression vector pRIT2T. The resultant fusion protein is effective in supporting G361 cell attachment even though it lacks the RGD sequence. In addition, the expressed protein inhibits adhesion of G361 cells to intact TS. mAb C6.7 blocks adhesion to the expressed TS COOH-terminal domain whereas GRGDSP and VTCG peptides are not inhibitory. These results show that the TS COOH-terminal domain contains a separate cell adhesion site, defined by mAb C6.7, that is distinct from the other adhesion sites of TS.	WASHINGTON UNIV, SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS, 660 S EUCLID AVE,BOX 8231, ST LOUIS, MO 63110 USA	Washington University (WUSTL)					NIH HHS [NH14147] Funding Source: Medline; NINDS NIH HHS [NS13269] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013269] Funding Source: NIH RePORTER	NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; DIXIT VM, 1985, P NATL ACAD SCI USA, V82, P3472, DOI 10.1073/pnas.82.10.3472; FRAZIER WA, 1987, J CELL BIOL, V105, P625, DOI 10.1083/jcb.105.2.625; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GALVIN NJ, 1985, J CELL BIOL, V101, P1434, DOI 10.1083/jcb.101.4.1434; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; HENNESSY SW, 1989, J CELL BIOL, V108, P729, DOI 10.1083/jcb.108.2.729; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LEUNG LLK, 1984, J CLIN INVEST, V74, P1764, DOI 10.1172/JCI111595; MAJACK RA, 1985, J CELL BIOL, V101, P1059, DOI 10.1083/jcb.101.3.1059; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MURPHYULLRICH JE, 1987, J CELL BIOL, V105, P1603, DOI 10.1083/jcb.105.4.1603; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; ROBERTS DD, 1987, J CELL BIOL, V104, P131, DOI 10.1083/jcb.104.1.131; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TUSZYNSKI GP, 1987, CANCER RES, V47, P4130; VARANI J, 1986, EXP CELL RES, V167, P376, DOI 10.1016/0014-4827(86)90178-3	19	31	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24257	24259						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761530				2022-12-25	WOS:A1991GW84500007
J	BOURDAIS, J; PIEROTTI, AR; BOUSSETTA, H; BARRE, N; DEVILLIERS, G; COHEN, P				BOURDAIS, J; PIEROTTI, AR; BOUSSETTA, H; BARRE, N; DEVILLIERS, G; COHEN, P			ISOLATION AND FUNCTIONAL-PROPERTIES OF AN ARGININE-SELECTIVE ENDOPROTEASE FROM RAT INTESTINAL-MUCOSA - A PUTATIVE PROSOMATOSTATIN CONVERTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCESSING ENZYME; HORMONE PRECURSORS; SECRETORY GRANULES; SINGLE ARGININE; THIOL PROTEASE; XENOPUS-LAEVIS; GOLGI-COMPLEX; PROHORMONE; CLEAVAGE; KEX2	The endoproteolytic activity previously detected in rat intestinal mucosal extracts (Beinfeld M., Bourdais, J., Kuks, P., Morel, A., and Cohen, P. (1989) J. Biol. Chem. 264, 4460-4465), was purified to homogeneity as a 65-kDa molecular species. This putative proprotein-processing enzyme cleaves the peptide bond on the carboxyl side of a single arginine residue in hepta-[Leu62-Gln-Arg-Ser-Ala-Asn-Ser68] or trideca-[Asp56-Glu-Met-Arg-Leu-Glu-Leu-Gln-Arg-Ser-Ala-Asn-Ser68] peptides, reproducing the prosomatostatin sequence around Arg64, the locus for endoproteolytic release of either somatostatin-28 or its NH2-terminal fragment, somatostatin-28-(1-12), from their common precursor. This enzyme exhibits a strict selectivity for arginyl residues, as demonstrated with related substrates, and did not cleave at lysyl residues. Moreover, only arginyl residues belonging to peptides of the prosomatostatin family were cleaved, since no hydrolysis of peptides from other prohormones was detected. In addition, the arginine residue situated at position -5 on the NH2-terminal side of Arg64 not only did not function as a cleavage locus, but had no effect on the overall cleavage kinetics of the prosomatostatin-(56-68) peptide substrate. This enzyme also cleaved, but with much less efficiency, the peptide bond on the carboxyl side of an arginine in peptides containing either an Arg-Lys or a Lys-Arg doublet corresponding to prohormone cleavage sites. This enzyme was insensitive to divalent cation chelators, was completely inhibited by aprotinin and leupeptin, and was somewhat inhibited by other serine-protease inhibitors. It is concluded that this endoprotease is a serine protease and could be involved in prohormone or proprotein post-translational processing at single arginine cleavage sites.	UNIV PARIS 06,NEUROBIOCHIM CELLULAIRE & MOLEC GRP,CNRS,URA 554,96 BLVD RASPAIL,F-75006 PARIS,FRANCE; CNRS,INST JACQUES MONOD,F-75005 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite								BEINFELD MC, 1989, J BIOL CHEM, V264, P4460; BENOIT R, 1987, SCIENCE, V238, P1126, DOI 10.1126/science.2891188; BOURDAIS J, 1990, BIOCHEM BIOPH RES CO, V170, P1263, DOI 10.1016/0006-291X(90)90530-Z; BRAKCH N, 1989, J BIOL CHEM, V264, P15912; CHANG JY, 1983, METHOD ENZYMOL, V91, P455; CLAMAGIRAND C, 1987, BIOCHEMISTRY-US, V26, P6018, DOI 10.1021/bi00393a011; COHEN P, 1987, BIOCHIMIE, V69, P87, DOI 10.1016/0300-9084(87)90239-2; CONLON JM, 1990, FEBS LETT, V266, P37, DOI 10.1016/0014-5793(90)81500-N; DARBY NJ, 1988, BIOCHEM BIOPH RES CO, V153, P1193, DOI 10.1016/S0006-291X(88)81354-8; DARBY NJ, 1990, BIOSCIENCE REP, V10, P1, DOI 10.1007/BF01116845; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; DEVI L, 1986, J NEUROCHEM, V47, P154; DEVI L, 1991, J NEUROCHEM, V56, P320, DOI 10.1111/j.1471-4159.1991.tb02598.x; DOCHERTY K, 1982, P NATL ACAD SCI-BIOL, V79, P4613, DOI 10.1073/pnas.79.15.4613; ERICKSON BW, 1976, PROTEINS, P255; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; FUNCKES CL, 1983, J BIOL CHEM, V258, P8781; GERMAIN D, 1990, MOL ENDOCRINOL, V4, P1572, DOI 10.1210/mend-4-10-1572; GOMEZ S, 1989, EMBO J, V8, P2911, DOI 10.1002/j.1460-2075.1989.tb08440.x; GOMEZ S, 1988, P NATL ACAD SCI USA, V85, P5468, DOI 10.1073/pnas.85.15.5468; HOPSU VK, 1966, ARCH BIOCHEM BIOPHYS, V114, P557, DOI 10.1016/0003-9861(66)90380-8; KUKS P, 1990, THESIS U P M CURIE P; KUKS PFM, 1989, J BIOL CHEM, V264, P14609; LEPAGELEZIN A, 1991, J BIOL CHEM, V266, P1679; LINDHARDT K, 1963, METHOD ENZYMAT AN, P783; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; MORITA T, 1977, J BIOCHEM-TOKYO, V82, P1495, DOI 10.1093/oxfordjournals.jbchem.a131840; NICOLAS P, 1986, BIOCHEM BIOPH RES CO, V140, P565, DOI 10.1016/0006-291X(86)90769-2; PATEL YC, 1981, ENDOCRINOLOGY, V109, P1943, DOI 10.1210/endo-109-6-1943; PLEVRAKIS I, 1989, BIOCHEMISTRY-US, V28, P2705, DOI 10.1021/bi00432a051; RHOLAM M, 1986, FEBS LETT, V207, P1, DOI 10.1016/0014-5793(86)80002-3; RHOLAM M, 1991, CONSENSUS; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; SCHWARTZ TW, 1986, FEBS LETT, V200, P1, DOI 10.1016/0014-5793(86)80500-2; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; THOMAS G, 1988, SCIENCE, V241, P226, DOI 10.1126/science.3291117; VALLON O, 1985, FEBS LETT, V183, P245, DOI 10.1016/0014-5793(85)80786-9; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; ZOLLINGER L, 1990, BIOCHEM CELL BIOL, V68, P635, DOI 10.1139/o90-090	44	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23386	23391						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744132				2022-12-25	WOS:A1991GT48300091
J	FAUTSCH, MP; WIEBEN, ED				FAUTSCH, MP; WIEBEN, ED			TRANSCRIPTIONAL REGULATION OF THE SMALL NUCLEAR RIBONUCLEOPROTEIN-E PROTEIN GENE - IDENTIFICATION OF CIS-ACTING SEQUENCES WITH HOMOLOGY TO GENES ENCODING RIBOSOMAL-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER REGION; HOUSEKEEPING GENE; EXPRESSION; ELEMENTS; BINDING; ONCOGENE; ENHANCER; MOTIFS; EGF	The 5'-upstream region of the small nuclear ribonucleoprotein E protein (snRNP E) gene has multiple sequence similarities to elements found to be integral in the transcriptional regulation of some mouse ribosomal protein genes (G + C block, CTTCCG motifs) as well as U1 snRNA genes (U1 "B," U1 "D," and SPH enhancers). Furthermore, the immediate upstream region of the snRNP E protein gene lacks typical TATA and CAAT sequence motifs but contains one copy of a GC box characteristic of a housekeeping promoter. By transfection of constructs containing various amounts of the 5'-upstream region of the snRNP E protein gene linked to the bacterial gene for chloramphenicol acetyl transferase (CAT), we determined that the 5' boundary of sequence needed for transcription was within the first 153 nucleotides upstream of the transcription start site. Further deletions to within 51 base pairs reduced CAT expression by 2.5-fold. Mutational analysis within this 51-base pair region revealed that direct repeats of the hexamer CTTCCG were essential for CAT expression. Gel shift assays and DNase I foot-printing experiments confirmed this conclusion by demonstrating specific binding of proteins to the CTTCCG motifs. This suggests that the direct repeats of the CTTCCG hexamer sequence play a key role in transcriptional regulation of the snRNP E protein gene.			FAUTSCH, MP (corresponding author), MAYO CLIN & MAYO FDN,200 1ST ST SW,ROCHESTER,MN 55905, USA.							ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ATCHISON ML, 1989, MOL CELL BIOL, V9, P2067, DOI 10.1128/MCB.9.5.2067; BOYER TG, 1989, J BIOL CHEM, V264, P5177; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHAMBERS JC, 1988, J BIOL CHEM, V263, P18043; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; ETZERODT M, 1988, EMBO J, V7, P4311, DOI 10.1002/j.1460-2075.1988.tb03330.x; FARMHAM PJ, 1986, MOL CELL BIOL, V6, P2392; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; KARIN M, 1990, MOL ASPECTS CELLULAR, V6, P143; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MANIATIS T, 1982, MOL CLONING LABORATO, P113; MELTON DW, 1986, CELL, V44, P319, DOI 10.1016/0092-8674(86)90766-X; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MURPHY JT, 1987, J BIOL CHEM, V262, P1795; PATEL PI, 1986, MOL CELL BIOL, V6, P393, DOI 10.1128/MCB.6.2.393; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; RHOADS DD, 1986, MOL CELL BIOL, V6, P2774, DOI 10.1128/MCB.6.8.2774; ROEBUCK KA, 1987, MOL CELL BIOL, V7, P4185, DOI 10.1128/MCB.7.12.4185; ROEBUCK KA, 1990, MOL CELL BIOL, V10, P341, DOI 10.1128/MCB.10.1.341; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SINGERSAM J, 1984, GENE, V32, P409, DOI 10.1016/0378-1119(84)90016-7; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STANFORD DR, 1988, NUCLEIC ACIDS RES, V16, P10593, DOI 10.1093/nar/16.22.10593; STANFORD DR, 1988, J BIOL CHEM, V263, P17772; STANFORD DS, 1991, J DNA SEQUENCE, V1, P357; STEERS E, 1971, J BIOL CHEM, V246, P196; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; WINGENDER E, 1990, Critical Reviews in Eukaryotic Gene Expression, V1, P11	38	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23288	23295						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1835977				2022-12-25	WOS:A1991GT48300078
J	HUANG, CH; BLUMENFELD, OO				HUANG, CH; BLUMENFELD, OO			MULTIPLE ORIGINS OF THE HUMAN GLYCOPHORIN-STA GENE - IDENTIFICATION OF HOT-SPOTS FOR INDEPENDENT UNEQUAL HOMOLOGOUS RECOMBINATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANE; COMPLETE STRUCTURAL-ANALYSIS; MOLECULAR ANALYSIS; CDNA CLONES; NUCLEOTIDE-SEQUENCE; HYBRID GLYCOPHORINS; DNA-POLYMERASE; RED-CELLS; DELTA; SIALOGLYCOPROTEIN	Human glycophorin St(a) (HGpSt(a)), one of the structural variants of erythrocyte membrane sialoglycoproteins, is encoded by a delta-alpha hybrid gene that arose from a single unequal crossover between the parent HGpB(delta) and HGpA(alpha) genes. We report here the identification of two new HGpSt(a) genes (type A and type B) in four unrelated St(a) heterozygotes from two ethnic groups. These St(a) genes represent distinct genetic isoforms that differ from the previously reported St(a) gene (type C) in the location of crossing-over sites. Comparison of nucleotide sequences among HGpB(delta), HGpA(alpha), and HGpSt(a) type A genes revealed that the delta-alpha unequal crossover for the St(a) type A gene occurred 110-246 base pairs downstream from pseudoexon III. In the crossing-over site of this St(a) gene, an AT-rich sequence lying 3' to a nonameric palindrome was found to be highly similar to the lambda-phage attachment site, att B, in inverted orientation. In the St(a) type B gene, the delta-alpha crossing-over point was localized to an AG-rich sequence that is 302-490 base pairs downstream from pseudoexon III. Multiple lambda-chi-like elements were identified at the crossover boundaries and within the breakpoint of this St(a) gene. These results suggest strongly that recurrent and independent unequal recombination events have occurred in the formation of multiple St(a) genes and that particular genomic sequences are important in defining the recombination sites for these homology-driven processes.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM016389] Funding Source: NIH RePORTER; NCI NIH HHS [5P30CA13330] Funding Source: Medline; NIGMS NIH HHS [R01 GM 16389] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANCHARD D, 1987, EUR J BIOCHEM, V167, P361, DOI 10.1111/j.1432-1033.1987.tb13345.x; BLUMENFELD OO, 1987, J BIOL CHEM, V262, P11864; BLUMENFELD OO, 1978, P NATL ACAD SCI USA, V75, P2727, DOI 10.1073/pnas.75.6.2727; BONNER TI, 1973, J MOL BIOL, V81, P123, DOI 10.1016/0022-2836(73)90184-8; Bothwell A., 1990, METHODS CLONING ANAL; DAHR W, 1987, EUR J BIOCHEM, V166, P31, DOI 10.1111/j.1432-1033.1987.tb13479.x; DAHR W, 1980, H-S Z PHYSIOL CHEM, V361, P895, DOI 10.1515/bchm2.1980.361.1.895; DAHR W, 1990, BIOL CHEM H-S, V371, P403, DOI 10.1515/bchm3.1990.371.1.403; DAHR W, 1986, RECENT ADV BLOOD GRO, P23; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GYLLENSTEN UB, 1991, P NATL ACAD SCI USA, V88, P3686, DOI 10.1073/pnas.88.9.3686; HUANG CH, 1988, P NATL ACAD SCI USA, V85, P9640, DOI 10.1073/pnas.85.24.9640; HUANG CH, 1987, BLOOD, V70, P1830; HUANG CH, 1991, BLOOD, V77, P381; HUANG CH, 1989, BLOOD, V74, P836; HUANG CH, 1991, BLOOD, V77, P1813; HUANG CH, 1991, J BIOL CHEM, V266, P7248; HUANG CH, 1986, CHIN BIOCH J, V2, P9; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; JOHE KK, 1989, J BIOL CHEM, V264, P17486; JOHE KK, 1991, J BIOL CHEM, V266, P7256; KITTS PA, 1987, NATURE, V329, P346, DOI 10.1038/329346a0; KOBORI JA, 1986, SCIENCE, V234, P173, DOI 10.1126/science.3018929; KUDO S, 1990, J BIOL CHEM, V265, P13825; KUDO S, 1990, J BIOL CHEM, V265, P1102; KUDO S, 1989, P NATL ACAD SCI USA, V86, P4619, DOI 10.1073/pnas.86.12.4619; LANDY A, 1977, SCIENCE, V197, P1147, DOI 10.1126/science.331474; MAEDA N, 1986, P NATL ACAD SCI USA, V83, P7395, DOI 10.1073/pnas.83.19.7395; Maniatis T., 1982, MOL CLONING; RACE RR, 1975, BLOOD GROUPS MAN, P92; RAHUEL C, 1988, EUR J BIOCHEM, V177, P605, DOI 10.1111/j.1432-1033.1988.tb14413.x; RAHUEL C, 1988, EUR J BIOCHEM, V172, P147, DOI 10.1111/j.1432-1033.1988.tb13866.x; REARDEN A, 1990, J BIOL CHEM, V265, P9259; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIEBERT PD, 1987, P NATL ACAD SCI USA, V84, P6735, DOI 10.1073/pnas.84.19.6735; SIEBERT PD, 1986, P NATL ACAD SCI USA, V83, P1665, DOI 10.1073/pnas.83.6.1665; SMITH GR, 1981, CELL, V24, P429, DOI 10.1016/0092-8674(81)90333-0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TATE CG, 1988, BIOCHEM J, V254, P743, DOI 10.1042/bj2540743; VIGNAL A, 1989, EUR J BIOCHEM, V184, P337, DOI 10.1111/j.1432-1033.1989.tb15024.x; VIGNAL A, 1990, EUR J BIOCHEM, V191, P619, DOI 10.1111/j.1432-1033.1990.tb19166.x; VNENCAKJONES CL, 1990, SCIENCE, V250, P1745, DOI 10.1126/science.1980158; WEATHERALL DJ, 1979, CELL, V16, P467, DOI 10.1016/0092-8674(79)90022-9; WEINREB A, 1988, P NATL ACAD SCI USA, V85, P529, DOI 10.1073/pnas.85.2.529	46	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23306	23314						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744126				2022-12-25	WOS:A1991GT48300080
J	LI, Y; CAMP, S; RACHINSKY, TL; GETMAN, D; TAYLOR, P				LI, Y; CAMP, S; RACHINSKY, TL; GETMAN, D; TAYLOR, P			GENE STRUCTURE OF MAMMALIAN ACETYLCHOLINESTERASE - ALTERNATIVE EXONS DICTATE TISSUE-SPECIFIC EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; MOLECULAR-FORMS; PHOSPHOLIPASE-C; SKELETAL-MUSCLE; ELECTRIC ORGAN; MESSENGER-RNA; DIMERIC FORM; SINGLE GENE; MEMBRANE; BOVINE	The genes encoding mouse and human acetylcholinesterases have been cloned from genomic and cosmid libraries. Restriction analysis and a comparison of sequence with the cDNAs have defined the exon-intron boundaries. In mammals, three invariant exons encode the signal peptide and the amino-terminal 535 amino acids common to all forms of the enzyme whereas alternative exon usage of the next exon accounts for the structural divergence in the carboxyl termini of the catalytic subunits. mRNA protection studies show that the cDNA encoding the hydrophilic catalytic subunits represents the dominant mRNA species in mammalian brain and muscle whereas divergent mRNA species are evident in cells of hematopoietic origin (bone marrow cells and a erythroleukemia cell line). Analyses of mRNA species in these cells and the genomic sequence have enabled us to define two alternative exons in addition to the one found in the cDNAs; they encode unique carboxyl-terminal sequences. One mRNA consists of a direct extension through the intervening sequence between the common exon and the 3' exon deduced from the cDNA. This sequence encodes a subunit lacking the cysteine critical to oligomer formation. Another mRNA results from a splice that encodes a stretch of hydrophobic amino acids immediately upstream of a stop codon. This exon, when spliced to the upstream invariant exons, should encode glycophospholipid-linked species of the enzyme. Homologous sequence, identity of exon-intron junctions, and identity of position of the stop codon are seen for this region in mouse and human. Polymerase chain reactions carried out across the expected intron region and mRNA protection studies show that this splice occurs in mouse bone marrow and erythroleukemia cells yielding the appropriate cDNA.			LI, Y (corresponding author), UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093, USA.				NIGMS NIH HHS [GM18360] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018360, R37GM018360] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGLISTER L, 1978, J MOL BIOL, V125, P293, DOI 10.1016/0022-2836(78)90404-7; ARPAGAUS M, 1990, BIOCHEMISTRY-US, V29, P124, DOI 10.1021/bi00453a015; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BON S, 1991, CELL MOL NEUROBIOL, V11, P157, DOI 10.1007/BF00712807; BON S, 1988, J NEUROCHEM, V51, P776, DOI 10.1111/j.1471-4159.1988.tb01812.x; BURSTEIN SA, 1985, J CELL PHYSIOL, V122, P159, DOI 10.1002/jcp.1041220124; CARTAUD J, 1978, J CELL BIOL, V77, P315, DOI 10.1083/jcb.77.2.315; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERGUSON MAS, 1988, ANNU REV BIOCHEM, V67, P285; FUENTES ME, 1988, MOL CELL BIOCHEM, V81, P53; GANOVASMUNOZ MD, 1990, BIOCHIM BIOPHYS ACTA, V1039, P323; GARCIA L, 1988, NEUROCHEM INT, V13, P327, DOI 10.1016/0197-0186(88)90005-8; GIBNEY G, 1990, J BIOL CHEM, V265, P12576; GIBNEY G, 1988, J BIOL CHEM, V263, P1140; HAAS R, 1986, BIOCHEMISTRY-US, V25, P3098, DOI 10.1021/bi00359a005; INESTROSA NC, 1988, NEUROSCI LETT, V90, P186, DOI 10.1016/0304-3940(88)90809-9; INESTROSA NC, 1987, J BIOL CHEM, V262, P4441; KAWASAKI E, 1989, AMPLIFICATIONS, V3, P406; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAYER PG, 1988, CELL TISSUE RES, V251, P587, DOI 10.1007/BF00214007; LAYER PG, 1987, J NEUROCHEM, V49, P175, DOI 10.1111/j.1471-4159.1987.tb03411.x; LOW MG, 1987, BIOCHEM J, V244, P1; LWEBUGAMUKASA J, 1975, BIOCHEMISTRY-US, V15, P1425; MACDONALD ME, 1978, J CELL PHYSIOL, V96, P291, DOI 10.1002/jcp.1040960304; MANIATIS T, 1982, MOL CLONING LABORATO, P122; MASSOULIE J, 1988, HDB EXP PHARM, V86, P167; MAULET Y, 1990, NEURON, V4, P289, DOI 10.1016/0896-6273(90)90103-M; PAULUS JM, 1981, BLOOD, V58, P1100; PRIETO AL, 1989, J NEUROSCI RES, V24, P169, DOI 10.1002/jnr.490240207; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; ROBERTS WL, 1987, P NATL ACAD SCI USA, V84, P7817, DOI 10.1073/pnas.84.22.7817; ROTUNDO RL, 1988, J BIOL CHEM, V263, P19398; ROTUNDO RL, 1988, P NATL ACAD SCI USA, V85, P7805, DOI 10.1073/pnas.85.20.7805; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIKORAV JL, 1988, EMBO J, V7, P2983, DOI 10.1002/j.1460-2075.1988.tb03161.x; SILMAN I, 1987, EUR J BIOCHEM, V170, P11, DOI 10.1111/j.1432-1033.1987.tb13662.x; SOREQ H, 1990, P NATL ACAD SCI USA, V87, P9688, DOI 10.1073/pnas.87.24.9688; STEIGER S, 1989, EUR J BIOCHEM, V181, P633; TAYLOR P, 1991, J BIOL CHEM, V266, P4025; TOUTANT JP, 1989, EUR J BIOCHEM, V180, P503, DOI 10.1111/j.1432-1033.1989.tb14674.x; TOUTANT JP, 1990, EUR J BIOCHEM, V187, P31, DOI 10.1111/j.1432-1033.1990.tb15274.x; TSIM KWK, 1988, P NATL ACAD SCI USA, V85, P1262, DOI 10.1073/pnas.85.4.1262; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585	46	179	187	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23083	23090						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744105				2022-12-25	WOS:A1991GT48300049
J	VOSS, A; REINHART, M; SANKARAPPA, S; SPRECHER, H				VOSS, A; REINHART, M; SANKARAPPA, S; SPRECHER, H			THE METABOLISM OF 7,10,13,16,19-DOCOSAPENTAENOIC ACID TO 4,7,10,13,16,19-DOCOSAHEXAENOIC ACID IN RAT-LIVER IS INDEPENDENT OF A 4-DESATURASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; PEROXISOMAL BETA-OXIDATION; CHAIN ELONGATION; CULTURED-CELLS; MICROSOMES; DESATURATION	The hypothesis that the last step in the biosynthesis of 4,7,10,13,16,19-22:6 from linolenate is catalyzed by an acyl-CoA-dependent 4-desaturase has never been evaluated by direct experimentation. When rat liver microsomes were incubated with [1-C-14]7,10,13,16,19-22:5, under conditions where linoleate was readily desaturated to 6,9,12-18:3, it was never possible to detect the product of the putative 4-desaturase. In the presence of malonyl-CoA, 7,10,13,16,19-22:5 was sequentially chain-elongated to 9,12,15,18,21-24:5, followed by its desaturation at position 6 to give 6,9,12,15,18,21-24:6. Microsomes desaturated 9,12,15,18,21-24:5 at rates similar to those observed for metabolizing linoleate to 6,9,12-18:3. Rat hepatocytes metabolize [1-C-14]7,10,13,16,19-22:5 to 22:6(n-3), but in addition, it was possible to detect small amounts of esterified 24:5(n-3) and 24:6(n-3) in phospholipids, which is a finding consistent with their role as obligatory intermediates in 22:6(n-3) biosynthesis. When 3-C-14-labeled 24:5(n-3) or 24:6(n-3) were incubated with hepatocytes, only a small amount of either substrate was esterified. [3-C-14] 24:5(n-3) was metabolized both by beta-oxidation to 22:5(n-3) and by serving as a precursor for the biosynthesis of 24:6(n-3) and 22:6(n-3). The primary metabolic fate of [3-C-14]24:6(n-3) was beta-oxidation to 22:6(n-3), followed by its acylation into membrane lipids. Our results thus document that 22:5(n-3) is the precursor for 22:6(n-3) but via a pathway that is independent of a 4-desaturase. This pathway involves the microsomal chain elongation of 22:5(n-3) to 24:5(n-3), followed by its desaturation to 24:6(n-3). This microsomal product is then metabolized, via beta-oxidation, to 22:6(n-3).	OHIO STATE UNIV,DEPT MED BIOCHEM,337 HAMILTON HALL,1645 NEIL AVE,COLUMBUS,OH 43210	University System of Ohio; Ohio State University					NIDDK NIH HHS [DK-20387, DK-18844] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020387, R01DK018844] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYALA S, 1973, J LIPID RES, V14, P296; BAUMANN WJ, 1968, J LIPID RES, V9, P287; BERNERT JT, 1977, J BIOL CHEM, V252, P6736; BERNERT JT, 1975, BIOCHIM BIOPHYS ACTA, V398, P354, DOI 10.1016/0005-2760(75)90186-1; BRENNER R R, 1981, Progress in Lipid Research, V20, P41, DOI 10.1016/0163-7827(81)90012-6; CARPENTER MP, 1971, BIOCHIM BIOPHYS ACTA, V231, P52, DOI 10.1016/0005-2760(71)90255-4; CROSSLAN.RK, 1970, J ORG CHEM, V35, P3195, DOI 10.1021/jo00834a087; DUNBAR LM, 1975, J BIOL CHEM, V250, P1152; FISCHER S, 1987, PROSTAGLANDINS, V34, P367, DOI 10.1016/0090-6980(87)90082-7; GRONN M, 1991, BIOCHIM BIOPHYS ACTA, V1081, P85, DOI 10.1016/0005-2760(91)90254-F; HILTUNEN JK, 1986, J BIOL CHEM, V261, P6484; HOVIK R, 1987, BIOCHEM J, V247, P531, DOI 10.1042/bj2470531; KLENK E, 1960, H-S Z PHYSIOL CHEM, V320, P218, DOI 10.1515/bchm2.1960.320.1.218; KUNAU WH, 1974, EUR J BIOCHEM, V48, P311, DOI 10.1111/j.1432-1033.1974.tb03770.x; LUDWIG SA, 1979, ARCH BIOCHEM BIOPHYS, V197, P331; MAEDA M, 1978, BIOCHIM BIOPHYS ACTA, V530, P153; MARTINEZ M, 1989, LIPIDS, V24, P261, DOI 10.1007/BF02535160; Mead JF, 1968, PROGRESS CHEMISTRY F, V9, P161; MOHAMMED BS, 1990, LIPIDS, V25, P854, DOI 10.1007/BF02535909; OKAYASU T, 1981, ARCH BIOCHEM BIOPHYS, V206, P21, DOI 10.1016/0003-9861(81)90061-8; OSBOND JM, 1961, J CHEM SOC, P2779, DOI 10.1039/jr9610002779; POLLARD MR, 1980, LIPIDS, V15, P690, DOI 10.1007/BF02534021; PRASAD MR, 1986, J BIOL CHEM, V261, P8213; PUGH EL, 1977, J BIOL CHEM, V252, P68; ROSENTHAL MD, 1991, BIOCHIM BIOPHYS ACTA, V1083, P29, DOI 10.1016/0005-2760(91)90121-W; SCHULZ H, 1987, TRENDS BIOCHEM SCI, V12, P403, DOI 10.1016/0968-0004(87)90196-4; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SPRECHER H, 1968, BIOCHIM BIOPHYS ACTA, V152, P519, DOI 10.1016/0005-2760(68)90092-1; SPRECHER H, 1967, BIOCHIM BIOPHYS ACTA, V144, P296, DOI 10.1016/0005-2760(67)90159-2; SPRECHER H, 1982, METHOD ENZYMOL, V86, P357; SPRECHER H, 1975, BIOCHIM BIOPHYS ACTA, V388, P113, DOI 10.1016/0005-2760(75)90067-3; STOFFEL W, 1970, H-S Z PHYSIOL CHEM, V351, P1545, DOI 10.1515/bchm2.1970.351.2.1545; STOFFEL W, 1963, H-S Z PHYSIOL CHEM, V333, P71, DOI 10.1515/bchm2.1963.333.1.71; VERDINO B, 1964, J NUTR, V83, P234, DOI 10.1093/jn/83.3.234; VOSS AC, 1988, BIOCHIM BIOPHYS ACTA, V958, P153, DOI 10.1016/0005-2760(88)90172-5	35	551	561	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					19995	20000						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1834642				2022-12-25	WOS:A1991GM03900023
J	GAO, BC; BIOSCA, J; CRAIG, EA; GREENE, LE; EISENBERG, E				GAO, BC; BIOSCA, J; CRAIG, EA; GREENE, LE; EISENBERG, E			UNCOATING OF COATED VESICLES BY YEAST HSP70 PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK RESPONSE; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; STRESS PROTEINS; PEPTIDE BINDING; CLATHRIN; ATPASE; GENES; TRANSLOCATION; REPLICATION	The ability of hsp70 isoenzymes from wild-type and mutant yeast strains to uncoat bovine brain coated vesicles was analyzed and compared with that of the brain uncoating ATPase. Results show that, among the four major cytoplasmic isoenzymes produced in wild-type yeast, almost all of the activity is associated with the SSA1 and SSA2 isoenzymes. The SSB1 and SSB2 isoenzymes have almost no uncoating activity and are not found in the clathrin-hsp70 complexes formed during the uncoating reaction. Using hsp70 mutant yeast strains we find a marked difference in uncoating activity between the SSA1 and SSA2 isoenzymes, although there is only a 3% difference between their amino acid sequences. The SSA4 isoenzyme, which is produced only under stress conditions, has an uncoating activity intermediate between SSA1 and SSA2. These results suggest that the ability of hsp70 isoenzymes to uncoat clathrin-coated vesicles is restricted to certain members of the hsp70 family and can be affected by subtle changes in amino acid sequence. We also investigated the uncoating activity of mixtures of isoenzymes and find that the isoenzyme with lower uncoating activity reduces the activity of the isoenzyme with higher uncoating activity possibly by occupying binding sites on coated vesicles.	UNIV AUTONOMA BARCELONA,DEPT BIOQUIM,BARCELONA,SPAIN; UNIV WISCONSIN,DEPT PHYSIOL CHEM,MADISON,WI 53706	Autonomous University of Barcelona; University of Wisconsin System; University of Wisconsin Madison	GAO, BC (corresponding author), HLBI,CELL BIOL LAB,BETHESDA,MD 20892, USA.		Biosca, Josep/G-3137-2013	Biosca, Josep/0000-0003-2794-3124				BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CRAIG EA, 1984, CELL, V38, P841, DOI 10.1016/0092-8674(84)90279-4; CRAIG EA, 1985, MOL CELL BIOL, V5, P3517, DOI 10.1128/MCB.5.12.3517; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GREENE LE, 1990, J BIOL CHEM, V265, P6682; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NANDI PK, 1982, P NATL ACAD SCI-BIOL, V79, P5881, DOI 10.1073/pnas.79.19.5881; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID SL, 1985, J BIOL CHEM, V260, P10050; SCHMID SL, 1985, J BIOL CHEM, V260, P1057; SLATER MR, 1989, NUCLEIC ACIDS RES, V17, P4891, DOI 10.1093/nar/17.12.4891; SLATER MR, 1989, NUCLEIC ACIDS RES, V17, P805, DOI 10.1093/nar/17.2.805; TILLY K, 1989, J BACTERIOL, V171, P6025, DOI 10.1128/jb.171.11.6025-6029.1989; UNGEWICKELL E, 1985, EMBO J, V4, P3385, DOI 10.1002/j.1460-2075.1985.tb04094.x; VANBUSKIRK A, 1989, J EXP MED, V170, P1799, DOI 10.1084/jem.170.6.1799; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	29	66	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19565	19571						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1833403				2022-12-25	WOS:A1991GK66700066
J	LIND, SE; SMITH, CJ				LIND, SE; SMITH, CJ			ACTIN ACCELERATES PLASMIN GENERATION BY TISSUE PLASMINOGEN-ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-BINDING-PROTEIN; SKELETAL-MUSCLE ACTIN; FIBRIN CLOTS; HUMAN-SERUM; DENATURED PROTEINS; LYSINE RESIDUES; GLU-PLASMINOGEN; DEGRADED FIBRIN; GELSOLIN LEVELS; LUNG INJURY	Actin has been found to bind to plasmin's kringle regions, thereby inhibiting its enzymatic activity in a noncompetitive manner. We, therefore, examined its effect upon the conversion of plasminogen to plasmin by tissue plasminogen activator. Actin stimulated plasmin generation from both Glu- and Lys-plasminogen, lowering the K(m) for activation of Glu-plasminogen into the low micromolar range. Accelerated plasmin generation did not occur in the presence of epsilon-amino caproic acid or if actin was exposed to acetic anhydride, an agent known to acetylate lysine residues. Actin binds to tissue plasminogen activator (t-Pa) (K(d) = 0.55-mu-M), at least partially via lysine-binding sites. Actin's stimulation of plasmin generation from Glu-plasminogen was inhibited by the addition of aprotinin and was restored by the substitution of plasmin-treated actin, indicating the operation of a plasmin-dependent positive feedback mechanism. Native actin binds to Lys-plasminogen, and promotes its conversion to plasmin even in the presence of aprotinin, indicating that plasmin's cleavage of either actin or plasminogen leads to further plasmin generation. Plasmin-treated actin binds Glu-plasminogen and t-PA simultaneously, thereby raising the local concentration of t-PA and plasminogen. Together, but not separately, actin and t-PA prolong the thrombin time of plasma through the generation of plasmin and fibrinogen degradation products. Actin-stimulated plasmin generation may be responsible for some of the changes found in peripheral blood following tissue injury and sepsis.	MASSACHUSETTS GEN HOSP,HEMATOL UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					NHLBI NIH HHS [HL 42457] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN RA, 1982, THROMB HAEMOSTASIS, V47, P41; BICSAK TA, 1989, J BIOL CHEM, V264, P630; BOK RA, 1985, BIOCHEMISTRY-US, V24, P3279, DOI 10.1021/bi00334a031; CAMIOLO SM, 1971, P SOC EXP BIOL MED, V138, P277; CHRISTENSEN U, 1985, FEBS LETT, V182, P43, DOI 10.1016/0014-5793(85)81150-9; CHRISTENSEN U, 1984, BIOCHEM J, V223, P413, DOI 10.1042/bj2230413; DEVRIES C, 1989, J BIOL CHEM, V264, P12604; EMERSON DL, 1983, AM J REPROD IMMUNOL, V4, P185, DOI 10.1111/j.1600-0897.1983.tb00276.x; GOLDSCHMIDTCLERMONT PJ, 1988, GASTROENTEROLOGY, V94, P1454, DOI 10.1016/0016-5085(88)90686-5; GOLDSCHMIDTCLERMONT PJ, 1988, J CLIN INVEST, V81, P1519, DOI 10.1172/JCI113484; HADDAD JG, 1990, P NATL ACAD SCI USA, V87, P1381, DOI 10.1073/pnas.87.4.1381; HARPEL PC, 1985, J BIOL CHEM, V260, P4432; HARPER KD, 1987, J CLIN INVEST, V79, P1365, DOI 10.1172/JCI112963; HIGGINS DL, 1987, BIOCHEMISTRY-US, V26, P7786, DOI 10.1021/bi00398a038; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; JANMEY PA, 1987, BLOOD, V70, P524; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WM, 1989, CIRC SHOCK, V28, P249; LIND SE, 1986, J CLIN INVEST, V78, P736, DOI 10.1172/JCI112634; LIND SE, 1988, AM REV RESPIR DIS, V138, P429, DOI 10.1164/ajrccm/138.2.429; LIND SE, 1991, J BIOL CHEM, V266, P5273; MEJEAN C, 1987, J IMMUNOL METHODS, V99, P129; MORNET D, 1984, P NATL ACAD SCI-BIOL, V81, P3680, DOI 10.1073/pnas.81.12.3680; OHSAWA M, 1989, BIOCHIM BIOPHYS ACTA, V992, P195, DOI 10.1016/0304-4165(89)90010-X; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; PETERSEN TE, 1990, J BIOL CHEM, V265, P6104; RADCLIFFE R, 1983, BIOCHIM BIOPHYS ACTA, V743, P422, DOI 10.1016/0167-4838(83)90401-6; RADCLIFFE R, 1981, ARCH BIOCHEM BIOPHYS, V211, P750, DOI 10.1016/0003-9861(81)90512-9; RANBY M, 1982, BIOCHIM BIOPHYS ACTA, V704, P461, DOI 10.1016/0167-4838(82)90068-1; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; RUBENSTEIN P, 1982, J CELL BIOL, V92, P164, DOI 10.1083/jcb.92.1.164; SILVERSTEIN RL, 1985, J BIOL CHEM, V260, P346; SILVERSTEIN RL, 1986, J BIOL CHEM, V261, P9959; SMITH DB, 1988, BLOOD, V72, P214; SMITH DB, 1988, AM J PATHOL, V130, P261; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, P191; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; THEWES T, 1990, J BIOL CHEM, V265, P3906; THORSTENSSON R, 1982, EUR J BIOCHEM, V126, P11, DOI 10.1111/j.1432-1033.1982.tb06738.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRANTHANG C, 1984, J CLIN INVEST, V74, P2009, DOI 10.1172/JCI111623; VERHEIJEN JH, 1982, THROMB HAEMOSTASIS, V48, P266; VOSKUILEN M, 1987, J BIOL CHEM, V262, P5944; WATT GH, 1989, CIRC SHOCK, V28, P279	45	38	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17673	17678						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1832675				2022-12-25	WOS:A1991GF44500102
J	AZROLAN, N; GAVISH, D; BRESLOW, JL				AZROLAN, N; GAVISH, D; BRESLOW, JL			PLASMA LIPOPROTEIN(A) CONCENTRATION IS CONTROLLED BY APOLIPOPROTEIN(A) (APO(A)) PROTEIN SIZE AND THE ABUNDANCE OF HEPATIC APO(A) MESSENGER-RNA IN A CYNOMOLGUS MONKEY MODEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; LP(A); SEQUENCE; ISOFORMS; LP<A>; DNA; ATHEROSCLEROSIS; HETEROGENEITY; BABOONS; SITES	The cynomolgus macaque was used as a model to study lipoprotein(a) (Lp(a)). Antibodies to Lp(a) were used in Ouchterlony and Western blot analysis to show that cynomolgus monkey and human Lp(a) were similar immunochemically. Monkey Lp(a) levels were measured by a quantitative sandwich enzyme-linked immunosorbent assay in 117 animals, and Lp(a) varied in concentration from 1 to 64 mg/dl. Individual monkeys had apo(a) glycoprotein sizes as either single- or double-band phenotypes that ranged from 400 to 750 kDa. Monkey apo(a) transcript lengths varied from 8.5 to 13.6 kilobases. The Lp(a) concentration, apo(a) glycoprotein size, and apo(a) transcript length distributions were similar to those in humans. In the monkeys, there was a very high correlation between apo(a) transcript size and apo(a) protein size (R = 0.93, p = 0.0001). This variation in apo(a) transcript and protein size was shown to be due to the number of kringle IV repeats in apo(a) mRNA and DNA. Monkey plasma Lp(a) concentrations correlated inversely with apo(a) glycoprotein size (R = -0.43, p = 0.0016) and directly with hepatic apo(a) mRNA abundance (R = 0.54, p = 0.004). Apo(a) transcript lengths did not correlate with hepatic apo(a) mRNA levels. This suggests that apo(a) size and mRNA levels have major independent effects on plasma Lp(a) concentration. In multivariate analysis, they account for up to 58% of the variability in Lp(a) concentration. In summary, these data provide insight into the regulation of Lp(a) levels and suggest that the cynomolgus monkey is a suitable model in which to study the role of Lp(a) in the pathogenesis of atherosclerosis.			AZROLAN, N (corresponding author), ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,NEW YORK,NY 10021, USA.		Breslow, Jan L/B-7544-2008		NHLBI NIH HHS [HL32435, HL36461, HL33714] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033714, R01HL032435, R37HL036461] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG VW, 1985, J LIPID RES, V26, P1314; AZROLAN N, 1990, J LIPID RES, V31, P1141; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; EHRLICH KC, 1990, MOL CELL BIOL, V10, P4957, DOI 10.1128/MCB.10.9.4957; FLESS GM, 1989, J LIPID RES, V30, P651; GAUBATZ JW, 1990, J LIPID RES, V31, P603; GAVISH D, 1989, J CLIN INVEST, V84, P2021, DOI 10.1172/JCI114395; HIXSON JE, 1989, J BIOL CHEM, V264, P6013; KONDO I, 1990, CLIN GENET, V37, P132; KOSCHINSKY ML, 1990, BIOCHEMISTRY-US, V29, P640, DOI 10.1021/bi00455a007; LAPLAUD PM, 1988, J LIPID RES, V29, P1157; LINDAHL G, 1990, HUM GENET, V84, P563; MAKINO K, 1989, ATHEROSCLEROSIS, V78, P81, DOI 10.1016/0021-9150(89)90161-5; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; NACHMAN RL, 1991, ARTERIOSCLER THROMB, V11, P32, DOI 10.1161/01.ATV.11.1.32; NEVEN L, 1990, J LIPID RES, V31, P633; Ouchterlony O., 1964, IMMUNOLOGICAL METHOD, P55; RAINWATER DL, 1989, J LIPID RES, V30, P549; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SILVER G, 1988, J BIOL CHEM, V263, P11802; TALL AR, 1978, J CLIN INVEST, V62, P1354, DOI 10.1172/JCI109256; TOMLINSON JE, 1989, J BIOL CHEM, V264, P5957; UTERMANN G, 1989, P NATL ACAD SCI USA, V86, P4171, DOI 10.1073/pnas.86.11.4171; UTERMANN G, 1988, HUM GENET, V78, P41, DOI 10.1007/BF00291232; VESSELINOVITCH D, 1988, ARCH PATHOL LAB MED, V112, P1011; WINGAND K, 1989, EXP MOL PATHOL, V50, P1	28	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13866	13872						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1830309				2022-12-25	WOS:A1991FY02700066
J	HARADA, M; ITO, Y; SATO, M; AONO, O; OHTA, S; KAGAWA, Y				HARADA, M; ITO, Y; SATO, M; AONO, O; OHTA, S; KAGAWA, Y			SMALL-ANGLE X-RAY-SCATTERING STUDIES OF MG.AT(D)P-INDUCED HEXAMER TO DIMER DISSOCIATION IN THE RECONSTITUTED ALPHA-3-BETA-3-COMPLEX OF ATP SYNTHASE FROM THERMOPHILIC BACTERIUM PS3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; SUBUNITS; KINETICS; EXCHANGE; COMPLEX	The alpha-3-beta-3 complex of ATP synthase obtained from a thermophilic bacterium PS3 was isolated and found to show the ATPase activity (Kagawa, Y., Ohta, S., and Otawara-Hamamoto, Y. (1989) FEBS Lett. 249, 67-69). The structure and the nucleotide binding effects of the alpha-3-beta-3 complex were investigated by means of small-angle x-ray scattering and high performance liquid chromatography. The scattering profile from the alpha-3-beta-3 complex was explained with a model in which the complex is made of an ellipsoid of revolution with the axes of 121.8, 121.8, and 72.0 angstrom having an elliptical hollow cavity with the axes of 35.4, 35.4, and 72.0 angstrom. By the addition of Mg.AT(D)P, significant changes in the scattering profile were observed, in which the radius of gyration decreased from 44 to 35 angstrom. This change was found by gel filtration to be caused by the dissociation reaction from the alpha-3-beta-3 hexamer to the alpha-beta dimer. The dissociation of the alpha-3-beta-3 complex was not induced by unhydrolyzable ATP analogue, nor by Pi, Mg2+, and Pi + Mg2+. The structure of the dimer was well explained by the triaxial ellipsoidal model with the axes of 105.2, 39.4, and 108.2 angstrom. The dissociation into the dimer is considered to be related to the ATPase activity because the AT(D)P-induced dissociation is observed only in the presence of Mg2+ ions.	UNIV TOKYO,INST SOLID STATE PHYS,MINATO KU,TOKYO 106,JAPAN; OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN; JICHI MED SCH,DEPT PHYS,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; JICHI MED SCH,DEPT BIOCHEM,MINAMI KAWACHI,TOCHIGI 32904,JAPAN	University of Tokyo; Osaka University; Jichi Medical University; Jichi Medical University								FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GLATTER O, 1974, J APPL CRYSTALLOGR, V7, P147, DOI 10.1107/S0021889874008983; Glatter O., 1982, ACTA PHY AUSTRIACA; Guinier A., 1955, SMALL ANGLE SCATTERI, P126; Guinier A., 1939, ANN PHYS-LEIPZIG, DOI DOI 10.1051/ANPHYS/193911120161; HIRAGI Y, 1981, ACTA CRYSTALLOGR A, V37, P378, DOI 10.1107/S0567739481000831; ITO Y, 1990, J MOL BIOL, V213, P289, DOI 10.1016/S0022-2836(05)80191-3; KAGAWA Y, 1972, BIOCHIM BIOPHYS ACTA, V265, P297, DOI 10.1016/0304-4157(72)90012-3; KAGAWA Y, 1989, FEBS LETT, V249, P67, DOI 10.1016/0014-5793(89)80017-1; KAGAWA Y, 1984, BIOENERGETICS, P149; MITCHELL P, 1979, SCIENCE, V206, P1148, DOI 10.1126/science.388618; MITTELBACH P, 1962, ACTA PHYS AUSTRIACA, V15, P122; OHTA S, 1990, BIOCHEM BIOPH RES CO, V171, P1258, DOI 10.1016/0006-291X(90)90821-4; OHTA S, 1978, BIOCHEM BIOPH RES CO, V80, P929, DOI 10.1016/0006-291X(78)91334-7; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; OHTA S, 1980, BIOCHEMISTRY-US, V19, P2160, DOI 10.1021/bi00551a025; PENEFSKY HS, 1965, J BIOL CHEM, V240, P4694; Pilz I, 1979, Methods Enzymol, V61, P148; Sholer I., 1976, Soviet Physics - Crystallography, V20, P713; WAKABAYASHI T, 1977, J MOL BIOL, V117, P515, DOI 10.1016/0022-2836(77)90140-1; YOSHIDA M, 1990, J BIOL CHEM, V265, P2483; YOSHIDA M, 1977, J BIOL CHEM, V252, P3480; YOSHIMURA H, 1989, J BIOCHEM-TOKYO, V106, P958, DOI 10.1093/oxfordjournals.jbchem.a122981	23	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11455	11460						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1828800				2022-12-25	WOS:A1991FT76200012
J	HARTWIG, R; DANISHEFSKY, KJ				HARTWIG, R; DANISHEFSKY, KJ			STUDIES ON THE ASSEMBLY AND SECRETION OF FIBRINOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; COMPLEMENTARY DEOXYRIBONUCLEIC-ACID; ROUGH ENDOPLASMIC-RETICULUM; CHAIN BINDING-PROTEIN; ALPHA-CHAIN; CALCIUM-BINDING; GAMMA-CHAIN; BETA-CHAIN; HEAVY-CHAINS; GENES	cDNAs of fibrinogen A-alpha and gamma-chains were individually subcloned into a eukaryotic expression vector by using the polymerase chain reaction. Triple cotransfection into COS cells of the two plasmids together with a B-beta chain expression plasmid, constructed as described previously (Danishefsky, K. J., Hartwig, R., Banerjee, D., and Redman, C. (1990) Biochim. Biophys. Acta 1048, 202-208), resulted in the secretion of complete fibrinogen into the media and the formation of four additional intracellular complexes which we also showed to be present in the hepatocyte cell line Hep 3B. The complexes, which have M(r) = 232, 150, 135, and 128 (x 10(-3) conform with the M(r) expected for A-alpha-B-beta-gamma-2, A-alpha-gamma-2, B-beta-gamma-2 and gamma-3, respectively. A mechanism of assembly is proposed based on the assumption that all these complexes are precursors of complete fibrinogen. Each of the expressed fibrinogen chains in transfected COS cells interacts noncovalently with binding protein (BiP, GRP 78), but not to the same extent; gamma-chain binds less BiP than the A-alpha and B-beta chains. Assembly of fibrinogen is not absolutely required for its secretion. In addition to complete fibrinogen, the conditioned media of hepatocytes and of transfected COS cells contained free A-alpha, free-gamma, and two of the above-mentioned complexes, A-alpha-gamma-2 and A-alpha-B-beta-gamma-2.	NEW YORK MED COLL,DEPT MED,LUCY & ISHMAEL HERMAN LAB CARDIOVASC MOLEC BIOL,VALHALLA,NY 10595	New York Medical College					NHLBI NIH HHS [HL 37457] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037457] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALVING BM, 1982, ARCH BIOCHEM BIOPHYS, V217, P1, DOI 10.1016/0003-9861(82)90472-6; AMRANI DL, 1983, BIOCHIM BIOPHYS ACTA, V743, P394, DOI 10.1016/0167-4838(83)90398-9; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3244, DOI 10.1021/bi00282a032; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3250, DOI 10.1021/bi00282a033; CRABTREE GR, 1981, J BIOL CHEM, V256, P9718; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DANG CV, 1985, J BIOL CHEM, V260, P9713; DANISHEFSKY K, 1990, BIOCHIM BIOPHYS ACTA, V1048, P202, DOI 10.1016/0167-4781(90)90057-9; DOOLITTLE RF, 1978, J MOL BIOL, V120, P311, DOI 10.1016/0022-2836(78)90070-0; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; DOOLITTLE RF, 1979, NATURE, V280, P464, DOI 10.1038/280464a0; FERGUSON EW, 1975, J BIOL CHEM, V250, P7210; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; Hantgan RR, 1987, HEMOSTASIS THROMBOSI, P269; HAVERKATE F, 1977, THROMB RES, V10, P575; HENSCHEN A, 1977, H-S Z PHYSIOL CHEM, V358, P1643; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KANT JA, 1983, P NATL ACAD SCI-BIOL, V80, P3953, DOI 10.1073/pnas.80.13.3953; KUDRYK B, 1982, EUR J BIOCHEM, V125, P673, DOI 10.1111/j.1432-1033.1982.tb06735.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; LOTTSPEICH F, 1977, H-S Z PHYSIOL CHEM, V358, P935; LUCAS MA, 1983, ANN NY ACAD SCI, V408, P78; MALISSEN B, 1984, CELL, V36, P319, DOI 10.1016/0092-8674(84)90225-3; Maniatis T., 1982, MOL CLONING; MARDER VJ, 1969, J BIOL CHEM, V244, P2111; NIEUWENHUIZEN W, 1983, ANN NY ACAD SCI, V408, P92, DOI 10.1111/j.1749-6632.1983.tb23236.x; NIKERSON JM, 1981, P NATL ACAD SCI USA, V78, P303; NUSSENZWEIG V, 1960, ANN I PASTEUR, V100, P377; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; RIXON MW, 1983, BIOCHEMISTRY-US, V22, P3237, DOI 10.1021/bi00282a031; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SEVERINSSON L, 1984, J CELL BIOL, V99, P226, DOI 10.1083/jcb.99.1.226; STOOFLET ES, 1988, SCIENCE, V239, P491; TOWNSEND RR, 1982, J BIOL CHEM, V257, P9704; VARADI A, 1986, BIOCHEMISTRY-US, V25, P519, DOI 10.1021/bi00351a001; WATT KWK, 1979, BIOCHEMISTRY-US, V18, P5410, DOI 10.1021/bi00591a024; WEINSTEI.MJ, 1972, BIOCHIM BIOPHYS ACTA, V258, P577, DOI 10.1016/0005-2744(72)90250-1; YU S, 1984, J BIOL CHEM, V259, P574; YU S, 1983, J BIOL CHEM, V258, P3407; YU S, 1980, BIOCHEM BIOPH RES CO, V96, P1030	46	46	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6578	6585						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1826107				2022-12-25	WOS:A1991FE37300085
J	TKESHELASHVILI, LK; MCBRIDE, T; SPENCE, K; LOEB, LA				TKESHELASHVILI, LK; MCBRIDE, T; SPENCE, K; LOEB, LA			MUTATION SPECTRUM OF COPPER-INDUCED DNA DAMAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC SITES; HYDROGEN-PEROXIDE; INTRACELLULAR IRON; BASE SUBSTITUTION; MUTAGENESIS; INVITRO; SPECIFICITY; POLYMERASE; FIDELITY; SEQUENCE	The ability of metal ions to damage DNA and cause mutagenesis has been analyzed with reversion and forward mutation assays using single-stranded DNA templates. We previously reported that incubation of phi-X174 am3 DNA with Fe2+ in vitro results in mutagenesis when the treated DNA is transfected into Escherichia coli spheroplasts (Loeb, L. A., James, E. A., Waltersdorph, A. M., and Klebanoff, S. J. (1988) Proc. Natl. Acad. Sci. U.S.A. 85, 3918-3922, 1988). We now extend these studies to other metal ions. Of the metal ions tested, copper ions were the most mutagenic; the frequency of mutants produced was equal to or greater than that produced by Fe2+. Mutagenesis by Cu+ was diminished by catalase, mannitol, and superoxide dismutase suggesting the involvement of H2O2, hydroxyl ions, and superoxide, respectively. However, the findings that Cu+ and Cu2+ are nearly equally mutagenic and that the mutagenic activities are not completely inhibited by oxygen free radical scavengers make it unlikely that the mechanism for mutagenesis is simply the production of hydroxyl free radicals. The spectra of mutations produced by either copper ion using the lacZ gene as a target are very similar and differ from those reported with other agents. The predominant mutagenic sequence changes are single-base substitutions, the most frequent being replacement of a template C by a T. This transition presumably results from mispairing of an altered C with deoxyadenosine. Copper-induced mutations are not randomly distributed. Instead, they are found predominantly in clusters suggesting direct interaction of copper ions with specific nucleotide sequences in DNA. Evidence is considered that the high frequency of C --> T transitions may be a common manifestation of DNA damage by oxygen radicals.	UNIV WASHINGTON,SCH MED,DEPT PATHOL,JOSEPH GOTTSTEIN MEM CANC RES LAB,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NCI NIH HHS [R35-CA-39903] Funding Source: Medline; NIA NIH HHS [AG-00757] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039903] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARUOMA OI, 1989, J BIOL CHEM, V264, P20509; AYAKI H, 1986, NUCLEIC ACIDS RES, V14, P5013, DOI 10.1093/nar/14.12.5013; BECKMAN RA, 1985, BIOCHEMISTRY-US, V24, P5810, DOI 10.1021/bi00342a019; BOORSTEIN RJ, 1989, BIOCHEMISTRY-US, V28, P6164, DOI 10.1021/bi00441a007; CADET J, 1985, INT J RADIAT BIOL, V47, P127, DOI 10.1080/09553008514550201; CICCARELLI RB, 1982, CANCER RES, V42, P3544; COSTA M, 1981, CANCER RES, V41, P2868; DIPAOLO JA, 1979, CANCER RES, V39, P1008; DREYER GB, 1985, P NATL ACAD SCI USA, V82, P968, DOI 10.1073/pnas.82.4.968; EICHHORN GL, 1965, P NATL ACAD SCI USA, V53, P586, DOI 10.1073/pnas.53.3.586; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; FORNACE AJ, 1981, CHEM-BIOL INTERACT, V36, P345, DOI 10.1016/0009-2797(81)90077-6; FORSTER W, 1979, BIOPOLYMERS, V18, P625, DOI 10.1002/bip.1979.360180311; HUTCHINSON F, 1981, PROG NUCLEIC ACID RE, V32, P414; INOUE S, 1987, CANCER RES, V47, P6522; KANE CM, 1981, J BIOL CHEM, V256, P3405; KAWANISHI S, 1986, J BIOL CHEM, V261, P5952; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1989, BIOCHEMISTRY-US, V28, P988, DOI 10.1021/bi00429a011; KUNKEL TA, 1984, P NATL ACAD SCI-BIOL, V81, P1494, DOI 10.1073/pnas.81.5.1494; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LECLERC JE, 1984, J MOL BIOL, V180, P217, DOI 10.1016/S0022-2836(84)80001-7; Loeb L.A., 1980, NUCL ACID METAL ION, P115; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; LOEB LA, 1988, P NATL ACAD SCI USA, V85, P3918, DOI 10.1073/pnas.85.11.3918; LOEB LA, 1985, CELL, V40, P483, DOI 10.1016/0092-8674(85)90191-6; MCBRIDE TJ, 1991, BIOCHEMISTRY-US, V30, P207, DOI 10.1021/bi00215a030; MELLO AC, 1984, BIOCHEM J, V218, P273, DOI 10.1042/bj2180273; NAQUI A, 1986, ANNU REV BIOCHEM, V55, P137, DOI 10.1146/annurev.biochem.55.1.137; PARK J, 1987, CARCINOGENESIS, V10, P827; PEZZANO H, 1980, CHEM REV, V80, P365, DOI 10.1021/cr60327a001; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; SAGRIPANTI JL, 1989, J BIOL CHEM, V264, P1729; SANGER F, 1978, J MOL BIOL, V125, P225, DOI 10.1016/0022-2836(78)90346-7; SCHAAPER RM, 1983, P NATL ACAD SCI-BIOL, V80, P487, DOI 10.1073/pnas.80.2.487; SCHAAPER RM, 1987, MUTAT RES, V177, P179, DOI 10.1016/0027-5107(87)90001-7; Singer B., 1983, MOL BIOL MUTAGENS CA; SIROVER MA, 1976, SCIENCE, V194, P1434, DOI 10.1126/science.1006310; SIROVER MA, 1977, J BIOL CHEM, V252, P3605; SUNDERMAN FW, 1986, ENV CARCINOGENS SELE, V8, P17; TINDALL KR, 1988, GENETICS, V118, P551; WACKER WEC, 1959, J BIOL CHEM, V234, P3257; WEYMOUTH LA, 1978, P NATL ACAD SCI USA, V75, P1924, DOI 10.1073/pnas.75.4.1924; YAMAMOTO K, 1989, J BIOL CHEM, V264, P15435; YAMAMOTO K, 1989, CHEM RES TOXICOL, V2, P234, DOI 10.1021/tx00010a004	47	190	192	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6401	6406						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1826106				2022-12-25	WOS:A1991FE37300061
J	SCHONBRUNNER, ER; MAYER, S; TROPSCHUG, M; FISCHER, G; TAKAHASHI, N; SCHMID, FX				SCHONBRUNNER, ER; MAYER, S; TROPSCHUG, M; FISCHER, G; TAKAHASHI, N; SCHMID, FX			CATALYSIS OF PROTEIN FOLDING BY CYCLOPHILINS FROM DIFFERENT SPECIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BINDING-PROTEIN; CIS-TRANS-ISOMERASE; AMINO-ACID SEQUENCE; PEPTIDYL-PROLYL ISOMERASE; T-CELL ACTIVATION; CYCLOSPORIN-A; IMMUNOSUPPRESSANT FK506; PROLINE ISOMERIZATION; ESCHERICHIA-COLI; GENE	Cyclophilins are a class of ubiquitous proteins with yet unknown function. They were originally discovered as the major binding proteins for the immunosuppressant cyclosporin A. The only known catalytic function of these proteins in vitro is the cis/trans isomerization of Xaa-Pro bonds in oligopeptides. This became clear after the discovery that bovine cyclophilin is identical with porcine prolyl isomerase. This enzyme accelerates slow, proline-limited steps in the refolding of several proteins. Here we demonstrate that the cyclophilins from man, pig, Neurospora crassa, Saccharomyces cerevisiae, and Escherichia coli are all active as prolyl isomerases and as catalysts of protein folding. This evolutionary conservation suggests that catalysis of prolyl peptide bond isomerization may be an important function of the cyclophilins. It could be related with de novo protein folding or be involved in regulatory processes. Catalysis of folding is very efficient in the presence of the high cellular concentrations of prolyl isomerase.	UNIV BAYREUTH,BIOCHEM LAB,POSTFACH 101251,W-8580 BAYREUTH,GERMANY; UNIV MUNICH,INST PHYSIOL CHEM,W-8000 MUNICH 2,GERMANY; MARTIN LUTHER UNIV,SEKT BIOWISSENSCH,WISSENSCH BEREICH BIOCHEM,O-4020 HALLE,GERMANY; TONEN CORP,RES & DEV LAB,IRUMA,SAITAMA 354,JAPAN	University of Bayreuth; University of Munich; Martin Luther University Halle Wittenberg			TAKAHASHI, Nobuhiro/G-1129-2013					BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DAVIS JM, 1989, J BIOL CHEM, V264, P8956; DIETMEIER K, 1990, NUCLEIC ACIDS RES, V18, P373, DOI 10.1093/nar/18.2.373; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLUBINOFF P, 1989, NATURE, V342, P884; HAENDLER B, 1989, GENE, V83, P39, DOI 10.1016/0378-1119(89)90401-0; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; HEINEMANN U, 1982, NATURE, V299, P27, DOI 10.1038/299027a0; KAWAMUKAI M, 1989, J BACTERIOL, V171, P4525, DOI 10.1128/JB.171.8.4525-4529.1989; KIEFHABER T, 1990, BIOCHEMISTRY-US, V29, P6475, DOI 10.1021/bi00479a020; KIEFHABER T, 1990, BIOCHEMISTRY-US, V29, P3053, DOI 10.1021/bi00464a023; KIEFHABER T, 1990, BIOCHEMISTRY-US, V29, P3062; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; LANG K, 1988, NATURE, V331, P453, DOI 10.1038/331453a0; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LIGHTOWLERS MW, 1989, MOL BIOCHEM PARASIT, V36, P287, DOI 10.1016/0166-6851(89)90177-1; LIN LN, 1988, BIOCHIM BIOPHYS ACTA, V956, P256, DOI 10.1016/0167-4838(88)90142-2; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; Pace C N, 1986, Methods Enzymol, V131, P266; QUAAS R, 1988, EUR J BIOCHEM, V173, P617, DOI 10.1111/j.1432-1033.1988.tb14043.x; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; SAWADA S, 1987, J IMMUNOL, V139, P1797; SCHMID FX, 1978, P NATL ACAD SCI USA, V75, P4764, DOI 10.1073/pnas.75.10.4764; SCHMID FX, 1986, P NATL ACAD SCI USA, V83, P872, DOI 10.1073/pnas.83.4.872; SCHMID FX, 1991, IN PRESS P AAAS SEMI; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0; TROPSCHUG M, 1988, J BIOL CHEM, V263, P14433; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007	41	177	178	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3630	3635						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1825312				2022-12-25	WOS:A1991EY68200045
J	MAGENDZO, K; SHIRVAN, A; CULTRARO, C; SRIVASTAVA, M; POLLARD, HB; BURNS, AL				MAGENDZO, K; SHIRVAN, A; CULTRARO, C; SRIVASTAVA, M; POLLARD, HB; BURNS, AL			ALTERNATIVE SPLICING OF HUMAN SYNEXIN MESSENGER-RNA IN BRAIN, CARDIAC, AND SKELETAL-MUSCLE ALTERS THE UNIQUE N-TERMINAL DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMAFFIN GRANULES; MEMBRANE-FUSION; PHOSPHOLIPID-BINDING; SHAKER LOCUS; CALCIUM; PROTEIN; GENE; DIVERSITY; FAMILY; POLYADENYLATION	Several synexin (annexin VII) mRNAs have been identified by screening a human fibroblast cDNA library. One type of message contained an alternatively spliced cassette exon, predicting two isoforms of synexin differing in the N-terminal domain. Polymerase chain reaction analysis of synexin mRNA from various fetal and adult tissues, from human and monkey, revealed that the alternative splicing event is tissue-regulated; synexin mRNA containing the cassette exon is prevalent in brain, heart, and skeletal muscle. This is supported by Western blot analysis showing that muscle synexin (annexin VIIb) is larger than synexin from lung (annexin VIIa). The muscle and lung isoforms have the same molecular mass as the recombinant synexins expressed in Escherichia coli using cDNAs containing or lacking the cassette exon, respectively. The difference in size is consistent with the molecular masses predicted from the proteins encoded by the alternatively spliced synexin mRNAs. Another type of synexin mRNA contained a longer 3'-noncoding region generated by the selection of an alternate poly(A) signal. Northern analysis of human fibroblast RNA showed the presence of two bands (2.0- and 2.4-kilobase) when hybridized to a cDNA fragment of the coding region of synexin, but only the 2.4-kilobase band hybridized to a probe made from the longer 3' end.	NIDDK,CELL BIOL & GENET LAB,BLDG 8,RM 403,9000 ROCKVILLE PIKE,BETHESDA,MD 20892; US FDA,DIV CARDIORENAL,BETHESDA,MD 20014	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); US Food & Drug Administration (FDA)								AMMAN E, 1988, GENE, V69, P301; ANDREADIS A, 1987, ANNU REV CELL BIOL, V3, P207, DOI 10.1146/annurev.cellbio.3.1.207; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BURGOYNE RD, 1989, CELL CALCIUM, V10, P1, DOI 10.1016/0143-4160(89)90038-9; BURNS AL, 1989, P NATL ACAD SCI USA, V86, P3798, DOI 10.1073/pnas.86.10.3798; CREUTZ CE, 1988, BIOCHEM BIOPH RES CO, V152, P1298, DOI 10.1016/S0006-291X(88)80426-1; CREUTZ CE, 1979, J BIOL CHEM, V254, P553; CREUTZ CE, 1981, J CELL BIOL, V91, P247, DOI 10.1083/jcb.91.1.247; CREUTZ CE, 1978, J BIOL CHEM, V253, P2858; CREUTZ CE, 1982, J CELL BIOCHEM, V18, P87, DOI 10.1002/jcb.1982.240180108; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; DEDMAN JR, 1990, NATURE, V345, P212; DOWLING LG, 1985, BIOCHEM BIOPH RES CO, V132, P382, DOI 10.1016/0006-291X(85)91033-2; GALLWITZ D, 1981, NUCLEIC ACIDS RES, V9, P6339, DOI 10.1093/nar/9.23.6339; HAUPTMANN R, 1989, EUR J BIOCHEM, V185, P63, DOI 10.1111/j.1432-1033.1989.tb15082.x; HONG K, 1981, J BIOL CHEM, V256, P3641; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; MANIATIS T, 1982, MOL CLONING LABORATO, P196; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; MATSUSHIMA N, 1990, PROTEINS, V7, P125, DOI 10.1002/prot.340070204; MOSS SE, 1990, FEBS LETT, V261, P299, DOI 10.1016/0014-5793(90)80576-5; NORBURY CJ, 1987, J VIROL, V61, P3754, DOI 10.1128/JVI.61.12.3754-3758.1987; POLLARD HB, 1988, J EXP BIOL, V139, P267; POLLARD HB, 1988, P NATL ACAD SCI USA, V85, P2974, DOI 10.1073/pnas.85.9.2974; POLLARD HB, 1990, J MEMBRANE BIOL, V117, P101, DOI 10.1007/BF01868677; SASAVAGE NL, 1982, P NATL ACAD SCI-BIOL, V79, P223, DOI 10.1073/pnas.79.2.223; SIMONSEN CC, 1983, MOL CELL BIOL, V3, P2250, DOI 10.1128/MCB.3.12.2250; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TIMPE LC, 1988, NEURON, V1, P659, DOI 10.1016/0896-6273(88)90165-1; WEIS JH, 1987, CURRENT PROTOCOLS MO; WIEDEMANN LM, 1984, MOL CELL BIOL, V4, P2518, DOI 10.1128/MCB.4.11.2518	34	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1991	266	5					3228	3232						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EX600	1825209				2022-12-25	WOS:A1991EX60000084
J	PISONI, RL				PISONI, RL			CHARACTERIZATION OF A PHOSPHATE-TRANSPORT SYSTEM IN HUMAN FIBROBLAST LYSOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER-MEDIATED TRANSPORT; RAT-LIVER MITOCHONDRIA; AMINO-ACID TRANSPORT; SIALIC-ACID; SALLA DISEASE; PROTON PUMP; INORGANIC POLYPHOSPHATES; MEMBRANE; METABOLISM; ACCUMULATION	The uptake of [P-32]KH2PO4 by Percoll-purified human fibroblast lysosomes at pH 7.0 was investigated to determine if lysosomes contain a transport system recognizing phosphate. Lysosomal phosphate uptake was linear for the first 2 min, attained a steady state by 8-10 min at 37-degrees-C, and was not Na+ or K+ dependent. Upon entering lysosomes, [P-32]phosphate was rapidly metabolized to trichloroacetic acid-soluble and trichloroacetic acid-insoluble products. After 1-min incubations, 50% of the radioactivity recovered from lysosomes was in the form of inorganic phosphate; and after a 2.5-min incubation, 27% of the radioactivity was recovered as inorganic phosphate. When lysosomes are loaded with radioactivity by incubation with 0.03 mM [P-32]KH2PO4 for 25 min and then washed at 4-degrees-C, lysosomes fail to release the accumulated radio-activity during a subsequent incubation at 37-degrees-C. Lysosomal phosphate uptake gave linear Arrhenius plots (Q10 = 1.8) and was inversely proportional to medium osmolarity. Phosphate uptake was maximal at pH 5-6, half-maximal at pH 7.1, with little transport activity at pH > 8, suggesting that the transport system recognizes the monobasic form of phosphate. Lysosomal phosphate uptake is saturable, displaying a K(m) of 5-mu-M at pH 7.0 and 37-degrees-C. High specificity for phosphate is demonstrated since large concentrations of Na2SO4, NaHCO3, KCl, NaCl, 5'-AMP, or the anion transport inhibitor, 4,4'-diisothiocyanatostilbene-2,2'-disulfonate, have no effect on lysosomal phosphate transport. In contrast, the phosphate analog, arsenate, strongly inhibits lysosomal phosphate uptake in a competitive manner with a K(i) of 7-mu-M. Pyridoxal phosphate, CTP, adenosine 5'-(beta,gamma-imino)triphosphate (AMP-PNP), and glucose 6-phosphate were found to be noncompetitive inhibitors of lysosomal phosphate uptake displaying K(i) values of 80-250-mu-M. When lysosomes are incubated with [gamma-P-32]ATP, the lysosomal membrane ATPase hydrolyzes the ATP to form inorganic phosphate which then enters lysosomes by this lysosomal phosphate transport route.			PISONI, RL (corresponding author), UNIV MICHIGAN,SCH MED,DEPT PEDIAT & COMMUN DIS,ANN ARBOR,MI 48109, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040323] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40323] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON HC, 1990, J BIOL CHEM, V265, P10950; ARSENIS C, 1970, J BIOL CHEM, V245, P205; ARSENIS C, 1968, J BIOL CHEM, V243, P5702; BARRETT AJ, 1972, LYSOSOMES LABORATORY, P63; BERNAR J, 1986, J BIOL CHEM, V261, P7107; BREWER JM, 1974, EXPT TECHNIQUES BIOC, P324; CASEY RP, 1978, BIOCHIM BIOPHYS ACTA, V508, P15, DOI 10.1016/0005-2736(78)90185-2; CLARK JE, 1986, J BACTERIOL, V168, P1212, DOI 10.1128/jb.168.3.1212-1219.1986; Cleland W W, 1979, Methods Enzymol, V63, P103; COLLARINI EJ, 1989, BIOCHIM BIOPHYS ACTA, V987, P139, DOI 10.1016/0005-2736(89)90536-1; COON HG, 1966, P NATL ACAD SCI USA, V55, P66, DOI 10.1073/pnas.55.1.66; COTY WA, 1974, J BIOL CHEM, V249, P2593; CRAMER CL, 1980, J BACTERIOL, V142, P945, DOI 10.1128/JB.142.3.945-952.1980; CUPPOLETTI J, 1987, BIOCHIM BIOPHYS ACTA, V899, P276, DOI 10.1016/0005-2736(87)90409-3; DSOUZA MP, 1987, P NATL ACAD SCI USA, V84, P6980, DOI 10.1073/pnas.84.20.6980; FREITAG H, 1978, EUR J BIOCHEM, V83, P53, DOI 10.1111/j.1432-1033.1978.tb12067.x; GAHL W, 1983, PEDIATR RES, V17, P210; GAHL WA, 1982, J BIOL CHEM, V257, P9570; GAHL WA, 1982, SCIENCE, V217, P1263, DOI 10.1126/science.7112129; HARIKUMAR P, 1983, J BIOL CHEM, V258, P403; HIRATA R, 1990, J BIOL CHEM, V265, P6726; JAY D, 1986, ANNU REV BIOCHEM, V55, P511, DOI 10.1146/annurev.bi.55.070186.002455; JONAS AJ, 1986, BIOCHEM BIOPH RES CO, V137, P175, DOI 10.1016/0006-291X(86)91192-7; JONAS AJ, 1982, P NATL ACAD SCI-BIOL, V79, P4442, DOI 10.1073/pnas.79.14.4442; JONAS AJ, 1989, J BIOL CHEM, V264, P4953; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KULAEV IS, 1983, ADV MICROB PHYSIOL, V24, P83, DOI 10.1016/S0065-2911(08)60385-9; LARDEUX BR, 1987, J BIOL CHEM, V262, P14507; LARDEUX BR, 1987, J BIOL CHEM, V262, P14514; MANCINI GMS, 1989, J BIOL CHEM, V264, P15247; MANCINI GMS, 1990, J BIOL CHEM, V265, P12380; OHKUMA S, 1982, P NATL ACAD SCI-BIOL, V79, P2758, DOI 10.1073/pnas.79.9.2758; PISONI RL, 1989, J BIOL CHEM, V264, P4850; PISONI RL, 1990, J CELL BIOL, V110, P327, DOI 10.1083/jcb.110.2.327; PISONI RL, 1987, J BIOL CHEM, V262, P15011; PISONI RL, 1987, J BIOL CHEM, V262, P6010; PISONI RL, 1985, J BIOL CHEM, V260, P4791; RENLUND M, 1986, SCIENCE, V232, P759, DOI 10.1126/science.3961501; RENLUND M, 1986, J CLIN INVEST, V77, P568, DOI 10.1172/JCI112338; ROSENBLATT DS, 1985, SCIENCE, V228, P1319, DOI 10.1126/science.4001945; SCHNEIDER DL, 1983, J BIOL CHEM, V258, P1833; SHACTER E, 1984, ANAL BIOCHEM, V138, P416, DOI 10.1016/0003-2697(84)90831-5; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; TIETZE F, 1989, J BIOL CHEM, V264, P15316; TIETZE F, 1989, J BIOL CHEM, V264, P4762; VAES FG, 1973, LYSOSOMES STORAGE DI, P70; WOHLRAB H, 1986, BIOCHIM BIOPHYS ACTA, V853, P115, DOI 10.1016/0304-4173(86)90007-8; WOOD HG, 1988, ANNU REV BIOCHEM, V57, P235, DOI 10.1146/annurev.bi.57.070188.001315	48	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					979	985						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1824704				2022-12-25	WOS:A1991ET17700049
J	SNAVELY, MD; MILLER, CG; MAGUIRE, ME				SNAVELY, MD; MILLER, CG; MAGUIRE, ME			THE MGTB MG2+ TRANSPORT LOCUS OF SALMONELLA-TYPHIMURIUM ENCODES A P-TYPE ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE H+-ATPASE; SARCOPLASMIC-RETICULUM MEMBRANE; NA,K-ATPASE BETA-SUBUNIT; AMINO-ACID-SEQUENCE; ION MOTIVE ATPASES; X-RAY-DIFFRACTION; FUNCTIONAL CONSEQUENCES; MAGNESIUM TRANSPORT; MOLECULAR-CLONING; ESCHERICHIA-COLI	The mgtB locus codes for one of three distinct Mg2+ transport systems of Salmonella typhimurium. The system encoded by the mgtB locus mediates Mg2+ influx only. The nucleotide sequence of a 4.6-kilobase fragment of DNA carrying mgtB has been determined. Two open reading frames were apparent. The most 5' (mgtC) could encode a hydrophobic protein of up to 25 kDa depending on which translation starts are used. A plasmid carrying this region downstream from a phage T7 promoter expresses a 22.5-kDa protein. The second open reading frame encoded a 101-kDa polypeptide (MgtB) consistent with our previous observation that a plasmid carrying the mgtB locus expresses a 102-kDa protein in maxicells. Insertions into either open reading frame abolished the ability of the plasmid to relieve the requirement for added Mg2+ and to restore Mg2+ uptake to a Mg2+ transport-deficient strain of S. typhimurium. The predicted amino acid sequence of MgtC showed no similarity to any other known protein. In contrast, the predicted sequence of MgtB indicated that it is a member of the family of cation transport P-type ATPases. Strikingly, however, MgtB was significantly more similar to eukaryotic Ca2+-ATPases than to prokaryotic P-type ATPases or other classes of eukaryotic P-type ATPases such as the Na+,K+-ATPase. MgtB is most closely related to Ca2+-ATPases of mammalian sarcoplasmic reticulum and yeast. A number of features of the Ca2+-ATPases thought to be important for cation transduction across the membrane are present in MgtB but not in other prokaryotic members of this enzyme family. Unlike the Ca2+-ATPases, however, which mediate efflux of cation from the cytosol, MgtB mediates influx of cation into the cytosol.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHARMACOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University					NIGMS NIH HHS [GM26340] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026340] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON R, 1986, J BIOL CHEM, V261, P4896; ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; BLASIE JK, 1985, BIOPHYS J, V48, P9, DOI 10.1016/S0006-3495(85)83756-5; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BROUDE NE, 1989, FEBS LETT, V257, P1, DOI 10.1016/0014-5793(89)81773-9; BUCHET R, 1989, BIOCHIM BIOPHYS ACTA, V983, P167, DOI 10.1016/0005-2736(89)90230-7; BURK SE, 1989, J BIOL CHEM, V264, P18561; CASTILHO BA, 1984, J BACTERIOL, V158, P488, DOI 10.1128/JB.158.2.488-495.1984; CID A, 1988, J BIOL CHEM, V263, P14134; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; EPSTEIN W, 1990, IN PRESS BACTERIA; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GANGOLA P, 1987, J BIOL CHEM, V262, P12570; GHISLAIN M, 1987, J BIOL CHEM, V262, P17549; GREEB J, 1989, J BIOL CHEM, V264, P18569; GREEN NM, 1989, BIOCHEM SOC T, V17, P970; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HESSE JE, 1984, P NATL ACAD SCI-BIOL, V81, P4746, DOI 10.1073/pnas.81.15.4746; HMIEL SP, 1989, J BACTERIOL, V171, P4742, DOI 10.1128/jb.171.9.4742-4751.1989; HMIEL SP, 1986, J BACTERIOL, V168, P1444, DOI 10.1128/jb.168.3.1444-1450.1986; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; KAUAKAMI K, 1988, J BIOCH, V103, P54; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANE LK, 1989, GENOMICS, V5, P445, DOI 10.1016/0888-7543(89)90008-6; LEMAIRE M, 1990, J BIOL CHEM, V265, P1111; Lynn A.R., 1987, ION TRANSPORT PROKAR, P181; LYTTON J, 1989, J BIOL CHEM, V264, P7059; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; Martonosi A, 1985, Soc Gen Physiol Ser, V39, P57; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; MEADE JC, 1987, MOL CELL BIOL, V7, P3937, DOI 10.1128/MCB.7.11.3937; MEADE JC, 1989, MOL BIOCHEM PARASIT, V33, P81, DOI 10.1016/0166-6851(89)90045-5; MOLLER JV, 1988, METHOD ENZYMOL, V157, P261; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; OKAMOTO CT, 1990, BIOCHIM BIOPHYS ACTA, V1037, P360, DOI 10.1016/0167-4838(90)90038-H; PALMERO I, 1989, J MOL BIOL, V210, P737, DOI 10.1016/0022-2836(89)90106-X; PASCOLINI D, 1988, BIOPHYS J, V54, P679, DOI 10.1016/S0006-3495(88)83003-0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; POLAREK JW, 1988, METHOD ENZYMOL, V157, P655; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; PORTILLO F, 1989, FEBS LETT, V247, P381, DOI 10.1016/0014-5793(89)81375-4; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SALON J, 1989, J MEMBRANE BIOL, V108, P177, DOI 10.1007/BF01871028; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSER A, 1988, J BIOL CHEM, V263, P19480; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SHULL GE, 1986, J BIOL CHEM, V261, P6788; Silhavy T.J., 1984, EXPT GENE FUSIONS; SNAVELY MD, 1989, J BACTERIOL, V171, P4761, DOI 10.1128/jb.171.9.4761-4766.1989; SNAVELY MD, 1991, J BIOL CHEM, V266, P824; SNAVELY MD, 1989, J BACTERIOL, V171, P4752, DOI 10.1128/jb.171.9.4752-4760.1989; SOLIOZ M, 1987, J BIOL CHEM, V262, P7358; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VILSEN B, 1989, J BIOL CHEM, V264, P21024; Walderhaug M.O., 1987, ION TRANSPORT PROKAR, P85	67	183	187	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					815	823						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1824701				2022-12-25	WOS:A1991ET17700025
J	BULET, P; COCIANCICH, S; DIMARCQ, JL; LAMBERT, J; REICHHART, JM; HOFFMANN, D; HETRU, C; HOFFMANN, JA				BULET, P; COCIANCICH, S; DIMARCQ, JL; LAMBERT, J; REICHHART, JM; HOFFMANN, D; HETRU, C; HOFFMANN, JA			INSECT IMMUNITY - ISOLATION FROM A COLEOPTERAN INSECT OF A NOVEL INDUCIBLE ANTIBACTERIAL PEPTIDE AND OF NEW MEMBERS OF THE INSECT DEFENSIN FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEREGRINA FLESH FLY; DIPTERAN PHORMIA-TERRANOVAE; ANTI-BACTERIAL PROTEINS; SARCOPHAGA-PEREGRINA; HYALOPHORA-CECROPIA; DISULFIDE ARRAY; MANDUCA-SEXTA; AMINO-ACID; LARVAE; PURIFICATION	Injection of heat-killed bacteria into larvae of the large tenebrionid beetle Zophobas atratus (Insecta, Endopterygota, Coleoptera) results in the appearance in the hemolymph of a potent antibacterial activity as evidenced by a plate growth inhibition assay. We have isolated three peptides (A-C) from this immune hemolymph which probably account for most of this activity. Their primary structures were established by a combination of peptide sequencing and molecular mass determination by mass spectrometry. Peptide A, which is bactericidal against Gram-negative cells, is a 74-residue glycine-rich molecule with no sequence homology to known peptides. We propose the name coleoptericin for this novel inducible antibacterial peptide. Peptides B and C are isoforms of a 43-residue peptide which contains 6 cysteines and shows significant sequence homology to insect defensins, initially reported from dipteran insects. This peptide is active against Gram-positive bacteria. The results are discussed in connection with recent studies on inducible antibacterial peptides present in the three other major orders of the endopterygote clade of insects: the Lepidoptera, Diptera, and Hymenoptera.	UNIV STRASBOURG 1,BIOL GEN LAB,CNRS,UNITE RECH ASSOCIEE ENDOCRINOL & IMMUNOL INSECTES,F-67070 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			COCIANCICH, Stéphane/C-4267-2014; BULET, Philippe/C-8557-2014	COCIANCICH, Stéphane/0000-0001-8601-3598; BULET, Philippe/0000-0001-9016-265X				ANDO K, 1987, BIOCHEMISTRY-US, V26, P226, DOI 10.1021/bi00375a030; BREHELIN M, 1975, CELL TISSUE RES, V160, P283; CASTEELS P, 1989, EMBO J, V8, P2387, DOI 10.1002/j.1460-2075.1989.tb08368.x; CASTEELS P, 1990, EUR J BIOCHEM, V187, P381, DOI 10.1111/j.1432-1033.1990.tb15315.x; CASTEELS P, 1990, RES IMMUNOL, V141, P957; DAI W, 1988, THESIS PURDUE U W LA; DICKINSON L, 1988, J BIOL CHEM, V263, P19424; DIMARCQ JL, 1988, EUR J BIOCHEM, V171, P17, DOI 10.1111/j.1432-1033.1988.tb13752.x; DUNN PE, 1985, DEV COMP IMMUNOL, V9, P559, DOI 10.1016/0145-305X(85)90019-9; ENGSTROM A, 1985, EMBO J, V4, P2119, DOI 10.1002/j.1460-2075.1985.tb03901.x; FUJIWARA S, 1990, J BIOL CHEM, V265, P11333; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; GLASER RW, 1918, PSYCHE, V5, P38; HOFFMANN D, 1981, INSECT BIOCHEM, V11, P537, DOI 10.1016/0020-1790(81)90022-6; Hoffmann J.A., 1979, P29, DOI 10.1017/CBO9780511759987.003; HULTMARK D, 1982, EUR J BIOCHEM, V127, P207, DOI 10.1111/j.1432-1033.1982.tb06857.x; HULTMARK D, 1983, EMBO J, V2, P571, DOI 10.1002/j.1460-2075.1983.tb01465.x; KUZUHARA T, 1990, J BIOCHEM-TOKYO, V107, P514, DOI 10.1093/oxfordjournals.jbchem.a123077; KYLSTEN P, 1990, EMBO J, V9, P217, DOI 10.1002/j.1460-2075.1990.tb08098.x; LAMBERT J, 1989, P NATL ACAD SCI USA, V86, P262, DOI 10.1073/pnas.86.1.262; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; LEPAGE P, 1991, EUR J BIOCHEM, V196, P735, DOI 10.1111/j.1432-1033.1991.tb15872.x; MATSUYAMA K, 1988, J BIOL CHEM, V263, P17117; METALNIKOV S, 1933, C ENTOMOL PARIS, V1, P209; Metalnikow S, 1920, CR SOC BIOL, V83, P817; OKADA M, 1985, J BIOL CHEM, V260, P7174; Paillot A, 1920, CR SOC BIOL, V83, P278; POWNING RF, 1976, COMP BIOCHEM PHYS B, V55, P221, DOI 10.1016/0305-0491(76)90234-0; REICHHART JM, 1990, RES IMMUNOL, V141, P943, DOI 10.1016/0923-2494(90)90200-I; SELSTED ME, 1989, J BIOL CHEM, V264, P4003; SPIES AG, 1986, J INVERTEBR PATHOL, V47, P234, DOI 10.1016/0022-2011(86)90052-2; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; TAKAHASHI H, 1986, J INSECT PHYSIOL, V32, P771, DOI 10.1016/0022-1910(86)90080-6; WICKER C, 1990, J BIOL CHEM, V265, P22493	34	160	175	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24520	24525						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761552				2022-12-25	WOS:A1991GW84500045
J	ZHANG, L; LEVY, A; RIFKIND, JM				ZHANG, L; LEVY, A; RIFKIND, JM			AUTOXIDATION OF HEMOGLOBIN ENHANCED BY DISSOCIATION INTO DIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; BIS(3,5-DIBROMOSALICYL) FUMARATE; NUCLEOPHILIC DISPLACEMENT; QUATERNARY ENHANCEMENT; SUBUNIT DISSOCIATION; DISTAL HISTIDINE; OXYGEN BINDING; ALPHA-CHAINS; MECHANISM; SUPEROXIDE	Autoxidation as a function of hemoglobin concentration indicates a 17-fold increase in the rate of autoxidation from 0.25 (%/h) to 4.3 (%/h) when tetrameric oxyhemoglobin dissociates into dimers. As a result of this large enhancement, a contribution of dissociation to the autoxidation is evident even at relatively high concentrations of hemoglobin for which it is usually considered that dissociation can be neglected. The mechanism for this phenomenon is attributed to alterations in the ligand pocket which occur when constraints due to subunit contacts within the R-state are eliminated.			ZHANG, L (corresponding author), NIA,GERONTOL RES CTR,CELLULAR & MOLEC BIOL LAB,BALTIMORE,MD 21224, USA.							ACKERS GK, 1974, P NATL ACAD SCI USA, V71, P4312, DOI 10.1073/pnas.71.11.4312; ATHA DH, 1976, J BIOL CHEM, V251, P5537; BANERJEE R, 1970, BIOCHIM BIOPHYS ACTA, V221, P636, DOI 10.1016/0005-2795(70)90235-7; BARKSDALE AD, 1978, J BIOL CHEM, V253, P4881; CHATTERJEE R, 1986, J BIOL CHEM, V261, P9929; CHU AH, 1984, BIOCHEMISTRY-US, V23, P604, DOI 10.1021/bi00299a004; GIBSON QH, 1987, J BIOL CHEM, V262, P516; IMAI K, 1977, BIOCHIM BIOPHYS ACTA, V490, P164, DOI 10.1016/0005-2795(77)90116-7; JOHNSON ML, 1984, P NATL ACAD SCI-BIOL, V81, P1093, DOI 10.1073/pnas.81.4.1093; LEVY A, 1990, BIOCHEMISTRY-US, V29, P9311, DOI 10.1021/bi00492a002; LEVY A, 1984, J BIOMOL STRUCT DYN, V1, P1299, DOI 10.1080/07391102.1984.10507518; LEVY A, 1988, OXY RADICALS MOL BIO, P11; MANSOURI A, 1973, BIOCHEMISTRY-US, V12, P4946, DOI 10.1021/bi00748a020; MILLS FC, 1979, P NATL ACAD SCI USA, V76, P273, DOI 10.1073/pnas.76.1.273; MILLS FC, 1976, BIOCHEMISTRY-US, V15, P5350, DOI 10.1021/bi00669a023; MILLS FC, 1979, J BIOL CHEM, V254, P2875; MISRA HP, 1972, J BIOL CHEM, V247, P6960; PHILO JS, 1990, J BIOL CHEM, V265, P139; RIFKIND JM, 1976, BIOCHEMISTRY-US, V15, P5337, DOI 10.1021/bi00669a021; RIFKIND JM, 1974, BIOCHEMISTRY-US, V13, P2475, DOI 10.1021/bi00709a003; RIFKIND JM, 1981, MET IONS BIOL SYST, V12, P191; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; ROMEROHERRERA AE, 1981, J MOL EVOL, V17, P140, DOI 10.1007/BF01733907; SATOH Y, 1981, J BIOL CHEM, V256, P272; SHIKAMA K, 1984, BIOCHEM J, V223, P279, DOI 10.1042/bj2230279; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; SUTTON HC, 1976, BIOCHEM J, V155, P503, DOI 10.1042/bj1550503; TSUBAMOTO Y, 1990, EUR J BIOCHEM, V193, P55, DOI 10.1111/j.1432-1033.1990.tb19303.x; TUCKER PW, 1978, P NATL ACAD SCI USA, V75, P1076, DOI 10.1073/pnas.75.3.1076; VANDEGRIFF KD, 1989, J BIOL CHEM, V264, P17824; WALLACE WJ, 1982, J BIOL CHEM, V257, P4966; WALLACE WJ, 1974, FEBS LETT, V43, P33, DOI 10.1016/0014-5793(74)81099-9; WALLACE WJ, 1975, BIOCHEM BIOPH RES CO, V62, P561, DOI 10.1016/0006-291X(75)90435-0; WALLACE WJ, 1974, BIOCHEM BIOPH RES CO, V57, P1104, DOI 10.1016/0006-291X(74)90810-9; WANG JH, 1958, J AM CHEM SOC, V80, P1109, DOI 10.1021/ja01538a024; WEVER R, 1973, BIOCHIM BIOPHYS ACTA, V302, P475, DOI 10.1016/0005-2744(73)90180-0; YANG T, 1989, BIOCHEM BIOPH RES CO, V163, P733, DOI 10.1016/0006-291X(89)92284-5; YUSA K, 1987, BIOCHEMISTRY-US, V26, P6684, DOI 10.1021/bi00395a018	38	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24698	24701						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761565				2022-12-25	WOS:A1991GW84500071
J	ANDRES, JL; RONNSTRAND, L; CHEIFETZ, S; MASSAGUE, J				ANDRES, JL; RONNSTRAND, L; CHEIFETZ, S; MASSAGUE, J			PURIFICATION OF THE TRANSFORMING GROWTH-FACTOR-BETA (TGF-BETA) BINDING PROTEOGLYCAN BETAGLYCAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; CORE PROTEIN; GLYCOSAMINOGLYCAN CHAINS; MEMBRANE PROTEOGLYCAN; LIGAND-BINDING; 2 FORMS; RECEPTORS; CELLS; EXPRESSION; CLONING	We report the purification of betaglycan, a low-abundance membrane proteoglycan with high affinity for transforming growth factor-beta (TGF-beta). Betaglycan solubilized from rat embryo membrane preparations was purified to near-homogeneity by sequential chromatography through DEAE-Trisacryl, wheat germ lectin-Sepharose, and TGF-beta-1-agarose. Purified betaglycan has properties similar to betaglycan affinity-labeled in intact cells: it binds TGF-beta-1 and TGF-beta-2 with K(D) approximately 0.2 nM, contains heparan sulfate and chondroitin sulfate glycosaminoglycan (GAG) chains and N-linked glycans attached to a 110-kDa core protein, and can spontaneously associate with phosphatidylcholine liposomes. The betaglycan core obtained by enzymatic removal of the GAG chains has high affinity for TGF-beta and associates with artificial liposomes, indicating that the core protein binds TGF-beta and anchors to membranes independently of the GAG chains present on the native protein or of any ancillary protein.	MEM SLOAN KETTERING CANC CTR, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	ANDRES, JL (corresponding author), MEM SLOAN KETTERING CANC CTR, CELL BIOL & GENET PROGRAM, NEW YORK, NY 10021 USA.		Ronnstrand, Lars/A-2429-2011	Ronnstrand, Lars/0000-0003-1275-5809; Massague, Joan/0000-0001-9324-8408	NATIONAL CANCER INSTITUTE [R37CA034610, R01CA034610] Funding Source: NIH RePORTER; NCI NIH HHS [CA 34610] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEIFETZ S, 1988, J BIOL CHEM, V263, P10783; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1989, J BIOL CHEM, V264, P12025; CHEIFETZ S, 1986, J BIOL CHEM, V261, P9972; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DEBOECK H, 1987, BIOCHEM J, V247, P765, DOI 10.1042/bj2470765; ECAROTCHARRIER B, 1987, J BIOL CHEM, V262, P5345; FISHER LW, 1989, J BIOL CHEM, V264, P4571; HEREMANS A, 1988, J BIOL CHEM, V263, P4731; JALKANEN M, 1988, J CELL BIOL, V106, P953, DOI 10.1083/jcb.106.3.953; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIHO M, 1990, J BIOL CHEM, V265, P18518; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MASSAGUE J, 1984, J BIOL CHEM, V259, P9756; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MULLER G, 1987, P NATL ACAD SCI USA, V84, P5600, DOI 10.1073/pnas.84.16.5600; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SANT AJ, 1985, J EXP MED, V162, P1916, DOI 10.1084/jem.162.6.1916; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SCHMIDT A, 1988, EXP CELL RES, V178, P242, DOI 10.1016/0014-4827(88)90395-3; SEGARINI PR, 1988, J BIOL CHEM, V263, P8366; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SEGARINI PR, 1987, J BIOL CHEM, V262, P14655; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	34	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23282	23287						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744125				2022-12-25	WOS:A1991GT48300077
J	LEE, SC; KOH, H; YU, MH				LEE, SC; KOH, H; YU, MH			MOLECULAR-PROPERTIES OF GLOBAL SUPPRESSORS OF TEMPERATURE-SENSITIVE FOLDING MUTATIONS IN P22 TAILSPIKE ENDORHAMNOSIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAIL-SPIKE PROTEIN; AMINO-ACID SUBSTITUTIONS; ESCHERICHIA-COLI; SALMONELLA PHAGE-P22; POLYPEPTIDE-CHAIN; LAMBDA-REPRESSOR; GENETIC-ANALYSIS; SUBUNIT; BACTERIOPHAGE-P22; MUTANTS	Two global suppressors (Val-331 > Ala and Ala-334 > Val) have been identified for temperature-sensitive folding (tsf) mutations in gene 9 of bacteriophage P22 (Mitraki, A., Fane, B., Haase-Pettingell, C., Sturtevant, J., and King, J. (1991) Science 253, 54-58). We have introduced 19 different single amino acid substitutions at the two global suppressor sites independently and examined the effects on the tailspike formation in Escherichia coli. Folding and maturation patterns of the various substitutions at the two global suppressor sites in the wild-type background suggest that Val-331 is located on the protein surface and Ala-334 is in the hydrophobic region. In combination with a tsf mutation, tsfH304 (Gly-244 > Arg), only Gly at 331 and Ile at 334, the substitutions that have similar side chain properties to the original suppressor sequences, were active as tsf suppressors. The newly identified suppressors of tsfH304 could also alleviate the tsf defect of three other mutations. The mutant carrying both Val-331 > Ala and Ala-334 > Val substitutions was also a global suppressor and was more active in suppressing the tsf defect than mutants carrying only one substitution. The suppressors may act by increasing the stability of an intermediate in the productive pathway of folding and maturation of the mutant polypeptides.	KOREA ADV INST SCI & TECHNOL,GENET ENGN RES INST,DAEDUCK SCI TOWN,TAEJON 305333,SOUTH KOREA	Korea Advanced Institute of Science & Technology (KAIST)								ALBER T, 1987, BIOCHEMISTRY-US, V26, P3754, DOI 10.1021/bi00387a002; BERGET PB, 1980, J VIROL, V34, P234, DOI 10.1128/JVI.34.1.234-243.1980; BOTSTEIN D, 1973, J MOL BIOL, V80, P669, DOI 10.1016/0022-2836(73)90204-0; BUSHMAN FD, 1989, CELL, V58, P1163, DOI 10.1016/0092-8674(89)90514-X; FANE B, 1987, GENETICS, V117, P157; FANE B, 1991, GENETICS, V127, P263; FANE B, 1991, J BIOL CHEM, V261, P11640; FUCHS A, 1991, BIOCHEMISTRY-US, V30, P6598, DOI 10.1021/bi00240a032; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; GOLDENBERG DP, 1981, J MOL BIOL, V145, P633, DOI 10.1016/0022-2836(81)90307-7; GOLDENBERG DP, 1983, P NATL ACAD SCI-BIOL, V80, P7060, DOI 10.1073/pnas.80.23.7060; GOLDENBERG DP, 1982, J BIOL CHEM, V257, P7864; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; HECHT MH, 1984, P NATL ACAD SCI-BIOL, V81, P5685, DOI 10.1073/pnas.81.18.5685; ISRAEL JV, 1967, P NATL ACAD SCI USA, V57, P284, DOI 10.1073/pnas.57.2.284; IWASHITA S, 1976, EUR J BIOCHEM, V65, P87, DOI 10.1111/j.1432-1033.1976.tb10392.x; KIM J, 1990, Korean Biochemical Journal, V23, P75; KLIG LS, 1988, GENETICS, V120, P651; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; PAKULA AA, 1990, NATURE, V344, P363, DOI 10.1038/344363a0; REIDHAAROLSON JF, 1988, SCIENCE, V241, P53, DOI 10.1126/science.3388019; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGENT D, 1988, J MOL BIOL, V199, P491, DOI 10.1016/0022-2836(88)90620-1; SAUER RT, 1982, BIOCHEMISTRY-US, V21, P5811, DOI 10.1021/bi00266a014; SCHULTZ SC, 1986, P NATL ACAD SCI USA, V83, P1588, DOI 10.1073/pnas.83.6.1588; SECKLER R, 1989, J BIOL CHEM, V264, P11750; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SHORTLE D, 1985, GENETICS, V110, P539; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SMITH DH, 1981, J MOL BIOL, V145, P653, DOI 10.1016/0022-2836(81)90308-9; SMITH DH, 1980, GENETICS, V96, P331; STROUP AN, 1990, BIOCHEMISTRY-US, V29, P9765, DOI 10.1021/bi00494a002; STURTEVANT JM, 1989, J BIOL CHEM, V264, P10693; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; VILLAFANE R, 1988, J MOL BIOL, V204, P607, DOI 10.1016/0022-2836(88)90359-2; YU MH, 1988, J BIOL CHEM, V263, P1424; YU MH, 1984, P NATL ACAD SCI-BIOL, V81, P6584, DOI 10.1073/pnas.81.21.6584; YUTANI K, 1987, P NATL ACAD SCI USA, V84, P4441, DOI 10.1073/pnas.84.13.4441	41	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23191	23196						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1835976				2022-12-25	WOS:A1991GT48300065
J	PALMGREN, MG; SOMMARIN, M; SERRANO, R; LARSSON, C				PALMGREN, MG; SOMMARIN, M; SERRANO, R; LARSSON, C			IDENTIFICATION OF AN AUTOINHIBITORY DOMAIN IN THE C-TERMINAL REGION OF THE PLANT PLASMA-MEMBRANE H+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; REGULATORY DOMAIN; NEUROSPORA-CRASSA; INSIDE-OUT; YEAST; VESICLES; ACTIVATION; PROTEINS; OAT; LYSOPHOSPHATIDYLCHOLINE	Proteolytic (trypsin) treatment removes a small terminal segment from the 100-kDa plant plasma membrane H+-ATPase. This results in activation of H+ pumping across the plasma membrane, suggesting that an inhibitory domain is located in one of the terminal regions of the enzyme (Palmgren, M.G., Larsson, C., and Sommarin, M. (1990) J. Biol. Chem. 265,13423-13426). In order to identify the origin of the fragment released by trypsin, polyclonal antibodies were raised against the first 55 amino acids (N-terminal region), the last 99 amino acids (C-terminal region), and a portion of 150 amino acids in the central part of the enzyme as deduced from one of the H+-ATPase genes (PMA2) of Arabidopsis thaliana. The native, 100-kDa H+-ATPase was recognized by all three antisera in Western blots. By contrast, the approximately 90-kDa polypeptide appearing after trypsin treatment was only recognized by the antisera against the N-terminal and central region, but not by the antiserum against the C-terminal region, suggesting that the inhibitory domain is located in this part of the enzyme. To more closely determine the position of the inhibitory domain, three peptides representing conserved parts of the C-terminal region were synthesized (residues 861-888, 912-943, and 936-949 of the Arabidopsis (PMA2) sequence). Only one of the peptides (residues 861-888) affected H+ pumping by the trypsin-activated (approximately 90-kDa) enzyme. This peptide of 28 amino acids inhibited H+ pumping with an IC50 of about 15-mu-M, suggesting that the autoinhibitory domain is located within the corresponding part of the C-terminal region.	UNIV LUND,DEPT PLANT BIOCHEM,S-22007 LUND 7,SWEDEN	Lund University	PALMGREN, MG (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,POSTFACH 10-2209,W-6900 HEIDELBERG,GERMANY.		Palmgren, Michael/A-9808-2013	Palmgren, Michael/0000-0002-9982-6114				ADDISON R, 1982, J BIOL CHEM, V257, P421; BEARDEN JC, 1978, BIOCHIM BIOPHYS ACTA, V533, P525, DOI 10.1016/0005-2795(78)90398-7; BOUTRY M, 1989, BIOCHEM BIOPH RES CO, V162, P567, DOI 10.1016/0006-291X(89)92348-6; BRANDT P, 1988, P NATL ACAD SCI USA, V85, P2914, DOI 10.1073/pnas.85.9.2914; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CID A, 1988, J BIOL CHEM, V263, P14134; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; EWING NN, 1990, PLANT PHYSIOL, V94, P1874, DOI 10.1104/pp.94.4.1874; GISLAIN M, 1987, J BIOL CHEM, V262, P17549; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HALL TG, 1987, J BIOL CHEM, V262, P10537; HEIDEMAN W, 1987, J BIOL CHEM, V262, P7087; HENNESSEY JP, 1990, J BIOL CHEM, V265, P532; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON C, 1987, METHOD ENZYMOL, V148, P558; LARSSON C, 1984, FEBS LETT, V171, P271, DOI 10.1016/0014-5793(84)80502-5; MANDALA SM, 1988, J BIOL CHEM, V263, P15122; PALMGREN MG, 1990, BIOCHIM BIOPHYS ACTA, V1021, P133, DOI 10.1016/0005-2736(90)90025-J; PALMGREN MG, 1990, PLANT PHYSIOL, V92, P871, DOI 10.1104/pp.92.4.871; PALMGREN MG, 1988, PHYSIOL PLANTARUM, V74, P11, DOI 10.1111/j.1399-3054.1988.tb04934.x; PALMGREN MG, 1989, PLANT PHYSIOL, V90, P1009, DOI 10.1104/pp.90.3.1009; PALMGREN MG, 1990, PLANT PHYSIOL, V94, P882, DOI 10.1104/pp.94.3.882; PALMGREN MG, 1990, J BIOL CHEM, V265, P13423; PARDO JM, 1989, J BIOL CHEM, V264, P8557; PARDO JM, 1989, PLANT MEMBRANE TRANS, P499; PARETSSOLER A, 1990, PLANT PHYSIOL, V93, P1654, DOI 10.1104/pp.93.4.1654; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PERLIN DS, 1987, J BIOL CHEM, V262, P6788; PORTILLO F, 1989, FEBS LETT, V247, P381, DOI 10.1016/0014-5793(89)81375-4; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERRANO R, 1989, ANNU REV PLANT PHYS, V40, P61; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; Serrano R., 1990, The plant plasma membrane., P127; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; SOMMARIN M, 1985, PHYSIOL PLANTARUM, V65, P27, DOI 10.1111/j.1399-3054.1985.tb02354.x; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P188	39	226	236	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20470	20475						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1834646				2022-12-25	WOS:A1991GM03900089
J	LAI, S; WATSON, JC; HANSEN, JN; SZE, H				LAI, S; WATSON, JC; HANSEN, JN; SZE, H			MOLECULAR-CLONING AND SEQUENCING OF CDNAS ENCODING THE PROTEOLIPID SUBUNIT OF THE VACUOLAR H+-ATPASE FROM A HIGHER-PLANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; SULFOLOBUS-ACIDOCALDARIUS; OAT ROOTS; ACIDOTHERMOPHILIC ARCHAEBACTERIUM; PURIFICATION; POLYPEPTIDE; MEMBRANE; HOMOLOGY; COMPLEX; DICYCLOHEXYLCARBODIIMIDE	To understand the molecular structure of the vacuolar H+-translocating ATPase from plants, cDNAs encoding the N,N'-dicyclohexylcarbodiimide-binding 16-kDa proteolipid from oat (Avena sativa L. var. Lang) have been obtained. A synthetic oligonucleotide corresponding to a region of the bovine proteolipid cDNA (Mandel, M., Moriyama, Y., Hulmes, J. D., Pan, Y.-C. E., Nelson, H., and Nelson, N. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 5521-5524) was used to screen an oat cDNA library constructed in lambda-gt11. The nucleotide sequences of several positive clones (VATP-P1, clones 12, 54, 93) demonstrated the presence of a small multigene family. The four clones showed extensive divergence in their codon usage and their 3'-untranslated regions; however, the deduced amino acid sequences of the proteins were 97-99% identical. These clones encoded the proteolipid subunit as one of them (clone 12) expressed a fusion protein that reacted with an antibody to the 16-kDa proteolipid. The open reading frame of one cDNA clone (VATP-P1) predicted a polypeptide of 165 amino acids with a molecular mass of 16,641. Based on hydropathy plots, a molecule with four membrane-spanning domains was predicted, in which domain IV was especially conserved among different species. This domain showed 80% identity in nucleotide or amino acid sequences between the oat and the bovine proteolipids and contained a glutamate residue that is the putative N,N'-dicyclohexylcarbodiimide-binding residue. The presence of a small multigene family of the 16-kDa proteolipid was confirmed by Southern blot analysis showing that several distinct restriction fragments of oat nuclear DNA hybridized with the VATP-PI cDNA.	UNIV MARYLAND,DEPT BOT,COLLEGE PK,MD 20742; UNIV MARYLAND,DEPT CHEM & BIOCHEM,COLLEGE PK,MD 20742; UNIV MARYLAND,CTR AGR BIOTECHNOL,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park								ARAI H, 1987, J BIOL CHEM, V262, P11006; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1988, J BIOL CHEM, V263, P8796; BIRMAN S, 1990, FEBS LETT, V261, P303, DOI 10.1016/0014-5793(90)80577-6; BOLLER T, 1986, ANNU REV PLANT PHYS, V37, P137, DOI 10.1146/annurev.pp.37.060186.001033; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; DENDA K, 1990, J BIOL CHEM, V265, P21509; DENDA K, 1989, J BIOL CHEM, V264, P7119; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GLUCK S, 1987, J BIOL CHEM, V262, P15780; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; HURLEY D, 1989, PLANT PHYSIOL, V89, P391, DOI 10.1104/pp.89.2.391; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KAESTNER KH, 1988, J BIOL CHEM, V263, P1282; KANE PM, 1989, J BIOL CHEM, V264, P19236; KONISHI J, 1987, J BIOCHEM, V102, P1379, DOI 10.1093/oxfordjournals.jbchem.a122184; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAI SP, 1988, J BIOL CHEM, V263, P16731; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; PARRY RV, 1989, J BIOL CHEM, V264, P20025; RANDALL SK, 1989, PLANT PHYSIOL, V89, P1292, DOI 10.1104/pp.89.4.1292; RANDALL SK, 1986, J BIOL CHEM, V261, P1364; RANDALL SK, 1987, J BIOL CHEM, V262, P7135; REA PA, 1987, J BIOL CHEM, V262, P14745; REA PA, 1987, PHYSIOL PLANTARUM, V71, P131, DOI 10.1111/j.1399-3054.1987.tb04630.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEBALD W, 1981, CURR TOP BIOENERG, V12, P1; SOLIOZ M, 1984, TRENDS BIOCHEM SCI, V9, P309, DOI 10.1016/0968-0004(84)90298-6; SUN SZ, 1987, J BIOL CHEM, V262, P14790; SZE H, 1985, ANNU REV PLANT PHYS, V36, P175, DOI 10.1146/annurev.pp.36.060185.001135; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; WATSON CJ, 1985, DNA CLONING PRACTICA, V1, P79; Watson JC, 1988, METHODS PLANT MOL BI, P57; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	43	67	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16078	16084						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1831453				2022-12-25	WOS:A1991GB97700083
J	SIMARD, J; DELAUNOIT, Y; LABRIE, F				SIMARD, J; DELAUNOIT, Y; LABRIE, F			CHARACTERIZATION OF THE STRUCTURE-ACTIVITY-RELATIONSHIPS OF RAT TYPE-I AND TYPE-II 3-BETA-HYDROXYSTEROID DEHYDROGENASE DELTA-5-DELTA-4 ISOMERASE BY SITE-DIRECTED MUTAGENESIS AND EXPRESSION IN HELA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN SEQUENCES; PURIFICATION; LOCALIZATION; MEMBRANE; BIOSYNTHESIS; METABOLISM; ANDROGENS; HORMONE; GENE	The membrane-bound enzyme 3-beta-hydroxysteroid dehydrogenase/DELTA-5-DELTA-4 isomerase (3-beta-HSD) catalyzes the conversion of DELTA-5-3-beta-hydroxysteroid precursors into DELTA-4-ketosteroids, thus representing an essential step in the biosynthesis of all classes of hormonal steroids. We have recently characterized two types of cDNA clones encoding rat 3-beta-HSD proteins, the rat type I protein being much more active than type II. In order to characterize further the functional difference between these two 3-beta-HSD types, transient expression of type I and type II 3-beta-HSD cDNAs was performed in HeLa human cervical carcinoma cells. The present study demonstrates that the type I 3-beta-HSD protein has a relative specificity 64- and 46-fold higher than type II protein for pregnenolone (PREG) and dehydroepiandrosterone (DHEA) as substrates, respectively. The K(m) values of type I and type II enzymes were calculated at 0.74 and 14.3-mu-M, respectively, using PREG as substrate whereas the respective K(m) values were 0.68 and 12.9-mu-M when DHEA was used, thus showing that their different relative specificity results largely from a different affinity for substrates. Since the change of 4 amino acid residues in type II could prevent the formation of a putative membrane-spanning domain (MSD) predicted between amino acid residues 75 and 91, chimeric cDNAs containing either type I MSD in type II (II + MSD) or an absence of this MSD in type I (I - MSD) were constructed and transiently expressed. The addition of MSD in type II 3-beta-HSD markedly increased the affinity leading to K(m) values similar to those found in type I 3-beta-HSD, namely 0.36 and 0.40 -mu-M for PREG and DHEA, respectively. 11 + MSD chimera thus encodes a protein having a relative specificity for PREG and DHEA of 58 and 73%, respectively, to that of native type I 3-beta-HSD. Moreover, removal of MSD in the type I protein (I - MSD chimera) decreased the relative specificity of type I 3-beta-HSD protein for PREG and DHEA to only 0.37 and 0.48%, with respective K(m) values of 11.7 and 11.0-mu-M, thus strongly indicating the functional importance of this putative MSD which is predicted in wild type rat type I as well as in macaque and human 3-beta-HSD proteins.	UNIV LAVAL,QUEBEC CITY G1V 4G2,QUEBEC,CANADA	Laval University	SIMARD, J (corresponding author), CHU LAVAL,RES CTR,MRC,MOLEC ENDOCRINOL GRP,QUEBEC CITY G1V 4G2,QUEBEC,CANADA.			Simard, Jacques/0000-0001-6906-3390				ABALAIN JH, 1989, J STEROID BIOCHEM, V34, P467, DOI 10.1016/0022-4731(89)90129-5; ABULHAJJ YJ, 1975, STEROIDS, V26, P488, DOI 10.1016/0039-128X(75)90068-9; BERUBE D, 1989, CYTOGENET CELL GENET, V52, P199, DOI 10.1159/000132878; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cameron EDH, 1966, J ENDOCRINOL, V35, P19; CHAPMAN JC, 1979, J BIOL CHEM, V254, P6624; DUPONT E, 1990, ENDOCRINOLOGY, V127, P1394, DOI 10.1210/endo-127-3-1394; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FASMAN GD, 1990, TRENDS BIOCHEM SCI, V15, P89, DOI 10.1016/0968-0004(90)90187-G; FORD HC, 1974, J BIOL CHEM, V249, P1363; ISHIIOHBA H, 1986, J STEROID BIOCHEM, V24, P753; JUNGTESTAS I, 1989, ENDOCRINOLOGY, V125, P2083; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; LABRIE F, 1991, MOL CELL ENDOCRINOL, V78, pC113, DOI 10.1016/0303-7207(91)90116-A; LACHANCE Y, 1990, J BIOL CHEM, V265, P20469; LACOSTE D, 1990, ANN NY ACAD SCI, V595, P389, DOI 10.1111/j.1749-6632.1990.tb34313.x; LUU TV, 1989, MOL ENDOCRINOL, V3, P1310; LUUTHE V, 1990, ANN NY ACAD SCI, V595, P386, DOI 10.1111/j.1749-6632.1990.tb34312.x; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; Sambrook J, 1989, MOL CLONING LABORATO; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SIMARD J, 1991, MOL CELL ENDOCRINOL, V75, P101, DOI 10.1016/0303-7207(91)90224-G; TAKAHASHI M, 1990, J STEROID BIOCHEM, V37, P231, DOI 10.1016/0960-0760(90)90331-E; ZHAO HF, 1991, J BIOL CHEM, V266, P583; ZHAO HF, 1990, ENDOCRINOLOGY, V127, P3237, DOI 10.1210/endo-127-6-3237; ZHAO HF, 1989, FEBS LETT, V259, P153, DOI 10.1016/0014-5793(89)81516-9	27	59	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14842	14845						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1831194				2022-12-25	WOS:A1991GB09700004
J	GRANOWITZ, EV; CLARK, BD; MANCILLA, J; DINARELLO, CA				GRANOWITZ, EV; CLARK, BD; MANCILLA, J; DINARELLO, CA			INTERLEUKIN-1 RECEPTOR ANTAGONIST COMPETITIVELY INHIBITS THE BINDING OF INTERLEUKIN-1 TO THE TYPE-II INTERLEUKIN-1 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; LEUKEMIA-CELLS; AUTOCRINE GROWTH; T-CELLS; B-CELLS; EXPRESSION; ACTIVATION; PROLIFERATION; PROTEIN; RELEASE	The interleukin-1 receptor antagonist (IL-1ra) inhibits the binding of interleukin-1 (IL-1) to T-cell lines possessing the type I IL-1 receptor; evidence has been published (Carter, D. B., Deibel, M. R. J., Dunn, C. J., Tomich, C. S., Laborde, A. L., Slightom, J. L., Berger, A. E., Bienkowski, M. J., Sun, F. F., McEwan, R. N., Harris, P. K. W., Yem, A. W., Waszak, G. A., Chosay, J. G., Sieu, L. C., Hardee, M. M., Zurcher-Neely, H. A., Reardon, I. M., Heinrickson, R. L., Truesdell, S. E., Shelly, J. A., Eessalu, T. E., Taylor, B. M., and Tracey, D. E. (1990) Nature 344, 633-638; Hannum, C. H., Wilcox, C. J., Arend, W. P., Joslin, F. G., Dripps, D. J., Heimdal, P. L., Armes, L. G., Sommer, A., Eisenberg, S. P., and Thompson, R. C. (1990) Nature 343, 336-340) that IL-Ira does not bind to the type II IL-1 receptor (IL-1RtII). In this study we examined the ability of human recombinant IL-1ra to block the binding of IL-1 to the IL-1RtII on human polymorphonuclear leukocytes (PMN) and Raji human B-lymphoma cells. The binding of I-125-IL-1-beta to PMN was competitively inhibited by IL-1ra. IL-1-beta was more potent in inhibiting the binding of I-125-IL-1-beta than IL-1ra. Incubating PMN with I-125-IL-1ra in the presence of increasing concentrations of IL-1-beta or IL-1ra showed that IL-1-beta was an approximately 40-fold more potent inhibitor of binding of I-125-IL-1ra than unlabeled IL-1ra. The IL-1ra was approximately 500-fold less potent in inhibiting the binding of I-125-IL-1-alpha than IL-1-alpha. IL-1ra was also able to competitively inhibit binding of I-125-IL-1-beta to Raji cells. PMN or Raji cells were also incubated with I-125-IL-1 in the absence or presence of IL-1 or IL-1ra. After cross-linking of IL-1 to cells followed by specific immunoprecipitation, sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed a band at 85 kDa corresponding to the 68-kDa IL-1RtII. However, in the presence of an excess of either unlabeled IL-1 or IL-1ra, the 85-kDa IL-1.IL-1RtII complex was not present. These findings demonstrate that the IL-1ra recognizes and blocks IL-1 binding to the IL-1RtII.	NEW ENGLAND MED CTR HOSP, DEPT MED, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University			Mancilla Ramírez, Javier/GSJ-0934-2022	Mancilla Ramirez, Javier/0000-0002-9236-8149				BAGBY GC, 1988, J CLIN INVEST, V82, P1430, DOI 10.1172/JCI113748; BENDTZEN K, 1989, LYMPHOKINE RES, V8, P335; BORISH L, 1990, INFLAMMATION, V14, P151, DOI 10.1007/BF00917454; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CLARK BD, 1989, CYTOKINE, V1, P90; COZZOLINO F, 1989, P NATL ACAD SCI USA, V86, P2369, DOI 10.1073/pnas.86.7.2369; DELWEL R, 1989, BLOOD, V74, P586; DINARELLO CA, 1991, BLOOD, V77, P1627; DOWER SK, 1986, P NATL ACAD SCI USA, V83, P1060, DOI 10.1073/pnas.83.4.1060; DULARAY B, 1990, J LEUKOCYTE BIOL, V47, P158, DOI 10.1002/jlb.47.2.158; EASTGATE JA, 1988, LANCET, V2, P706; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FALKOFF RJM, 1983, J IMMUNOL, V131, P801; FERRANTE A, 1988, INT ARCH ALLER A IMM, V86, P82, DOI 10.1159/000234610; GASPARETTO C, 1989, BLOOD, V74, P547; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HORUK R, 1987, J BIOL CHEM, V262, P16275; HORUK R, 1989, BIOCHEM J, V260, P657, DOI 10.1042/bj2600657; KAWANO M, 1989, BLOOD, V73, P2145; KILIAN PL, 1986, J IMMUNOL, V136, P4509; KOYAMA N, 1988, IMMUNOLOGY, V63, P277; KUPPER TS, 1988, J CLIN INVEST, V82, P1787, DOI 10.1172/JCI113792; NETA R, 1987, J IMMUNOL, V139, P1861; RAMBALDI A, 1990, BLOOD, V76, P2565; RANGNEKAR VM, 1988, J BIOL CHEM, V263, P16408; RHYNE JA, 1988, CLIN IMMUNOL IMMUNOP, V48, P354, DOI 10.1016/0090-1229(88)90029-3; SAKAI K, 1987, J EXP MED, V166, P1597, DOI 10.1084/jem.166.5.1597; SCAPIGLIATI G, 1989, FEBS LETT, V243, P394, DOI 10.1016/0014-5793(89)80169-3; SECKINGER P, 1987, J IMMUNOL, V139, P1546; SIMS J, 1990, LYMPHOKINE RES, V9, P555; SULLIVAN GW, 1989, J LEUKOCYTE BIOL, V45, P389, DOI 10.1002/jlb.45.5.389; TANAKA Y, 1989, J IMMUNOL, V143, P1584; UCKUN FM, 1989, BLOOD, V74, P761	34	262	268	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14147	14150						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1830582				2022-12-25	WOS:A1991FZ35100003
J	JAULT, JM; DIPIETRO, A; FALSON, P; GAUTHERON, DC				JAULT, JM; DIPIETRO, A; FALSON, P; GAUTHERON, DC			ALTERATION OF APPARENT NEGATIVE COOPERATIVITY OF ATPASE ACTIVITY BY ALPHA-SUBUNIT GLUTAMINE 173 MUTATION IN YEAST MITOCHONDRIAL-F1 - CORRELATION WITH IMPAIRED NUCLEOTIDE INTERACTION AT A REGULATORY SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; HYSTERETIC INHIBITION; SCHIZOSACCHAROMYCES-POMBE; DIRECTED MUTAGENESIS; PROTEIN INHIBITOR; ESCHERICHIA-COLI; CATALYTIC SITES; BINDING-SITES; H+-ATPASE	The first described alpha-subunit mutation of yeast mitochondrial F1 has been recently identified as a single Gln173 --> Leu substitution in a strongly conserved sequence (Falson, P., Maffey, L., Conrath, K., and Boutry, M. (1991) J. Biol. Chem. 266, 287-293). This mutation is shown here to greatly modify the biphasic pattern of ATPase activity as a function of pH: (i) the shoulder observed at acidic pH is significantly increased; (ii) the main peak, at alkaline pH, is markedly lowered; (iii) the optimal pH is shifted from 8.8 to 7.7. The mutation lowers both apparent negative cooperativity and sensitivity to azide inhibition which concomitantly increase when the assay pH decreases. Azide partial inhibition produces apparent negative cooperativity which can be further abolished by bicarbonate. The mutation increases both activation energies determined from biphasic Arrhenius plots. The mutation decreases the inactivation rate by 5'-p-fluorosulfonylbenzoyladenosine and abolishes the protection by nucleotide binding at the adenine-specific regulatory site. On the contrary, it does not modify the reactivity of 5'-p-fluorosulfonylbenzoylguanosine at the less-selective catalytic site. In addition, partial inactivation by 5'-p-fluorosulfonylbenzoyladenosine, as opposed to 5'-p-fluorosulfonylbenzoylguanosine, produces apparent negative cooperativity under conditions where unmodified-enzyme kinetics are noncooperative. The results show that alpha-Gln173 participates in nucleotide interaction at a regulatory site which controls the negative cooperativity of F1-ATPase activity.	UNIV LYON 1,BIOL & TECHNOL MEMBRANES & SYST INTEGRES LAB,CNRS,UMR 24,F-69622 VILLEURBANNE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1			jault, jean-michel/G-2086-2012	jault, jean-michel/0000-0003-1743-2777; Falson, Pierre/0000-0002-9760-4577				BARACCA A, 1986, BIOCHEM BIOPH RES CO, V136, P891, DOI 10.1016/0006-291X(86)90416-X; BAUBICHON H, 1981, BIOCHEM BIOPH RES CO, V100, P1032, DOI 10.1016/0006-291X(81)91927-6; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BITAR KG, 1982, BIOCHEM BIOPH RES CO, V109, P30, DOI 10.1016/0006-291X(82)91561-3; BULLOUGH DA, 1986, J BIOL CHEM, V261, P5722; BULLOUGH DA, 1988, J BIOL CHEM, V263, P14053; BULLOUGH DA, 1986, J BIOL CHEM, V261, P14171; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; CROSS RL, 1982, J BIOL CHEM, V257, P2101; DAGGETT SG, 1985, ARCH BIOCHEM BIOPHYS, V236, P815, DOI 10.1016/0003-9861(85)90688-5; DIPIETRO A, 1980, BIOCHEMISTRY-US, V19, P5671, DOI 10.1021/bi00566a002; DIPIETRO A, 1989, BIOCHIMIE, V71, P931, DOI 10.1016/0300-9084(89)90075-8; DIPIETRO A, 1981, BIOCHEMISTRY-US, V20, P6312, DOI 10.1021/bi00525a005; DIPIETRO A, 1979, BIOCHEMISTRY-US, V18, P1738, DOI 10.1021/bi00576a016; DIPIETRO A, 1986, BIOCHIM BIOPHYS ACTA, V851, P283, DOI 10.1016/0005-2728(86)90136-2; DORGAN LJ, 1984, J BIOL CHEM, V259, P2816; EBEL RE, 1975, J BIOL CHEM, V250, P191; FALSON P, 1989, BIOCHIM BIOPHYS ACTA, V975, P119, DOI 10.1016/S0005-2728(89)80209-9; FALSON P, 1987, BIOCHEM BIOPH RES CO, V148, P1182, DOI 10.1016/S0006-291X(87)80257-7; FALSON P, 1991, J BIOL CHEM, V266, P287; FALSON P, 1986, J BIOL CHEM, V261, P7151; FALSON P, 1988, EUR BIOENERG C, V5, P266; FELLOUS G, 1984, BIOCHEMISTRY-US, V23, P5294, DOI 10.1021/bi00317a030; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GAUTHERON DC, 1988, J BIOENERG BIOMEMBR, V20, P451, DOI 10.1007/BF00762203; GODINOT C, 1986, BIOCHIMIE, V68, P367, DOI 10.1016/S0300-9084(86)80003-7; GODINOT C, 1975, FEBS LETT, V60, P250, DOI 10.1016/0014-5793(75)80724-1; GODINOT C, 1981, BIOCHEM INT, V2, P595; GODINOT C, 1979, ARCH BIOCHEM BIOPHYS, V192, P225, DOI 10.1016/0003-9861(79)90087-0; GRESSER MJ, 1982, J BIOL CHEM, V257, P2030; HARRIS DA, 1981, BIOCHIM BIOPHYS ACTA, V635, P412, DOI 10.1016/0005-2728(81)90039-6; JAULT JM, 1989, BIOCHEM BIOPH RES CO, V158, P392, DOI 10.1016/S0006-291X(89)80060-9; LARSON EM, 1989, BIOCHIM BIOPHYS ACTA, V973, P78, DOI 10.1016/S0005-2728(89)80405-0; MORADIAMELI M, 1989, J BIOL CHEM, V264, P1361; MUELLER DM, 1989, BIOCHEM BIOPH RES CO, V164, P381, DOI 10.1016/0006-291X(89)91730-0; MUELLER DM, 1989, J BIOL CHEM, V264, P16552; NOUMI T, 1987, FEBS LETT, V213, P381, DOI 10.1016/0014-5793(87)81526-0; PAGAN J, 1990, ARCH BIOCHEM BIOPHYS, V277, P283, DOI 10.1016/0003-9861(90)90580-R; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PENIN F, 1988, BIOCHEMISTRY-US, V27, P8969, DOI 10.1021/bi00425a014; RAO R, 1988, J BIOL CHEM, V263, P15957; RECKTENWALD D, 1977, FEBS LETT, V76, P25, DOI 10.1016/0014-5793(77)80113-0; SCHUSTER SM, 1975, J BIOL CHEM, V250, P7848; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; STUTTERHEIM E, 1980, BIOCHIM BIOPHYS ACTA, V592, P415, DOI 10.1016/0005-2728(80)90089-4; TAKEDA M, 1986, J BIOL CHEM, V261, P5126; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; VIGNAIS PV, 1985, ANNU REV BIOCHEM, V54, P977, DOI 10.1146/annurev.biochem.54.1.977; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5	52	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8073	8078						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1827117				2022-12-25	WOS:A1991FK44100021
J	NALDINI, L; VIGNA, E; NARSIMHAN, RP; GAUDINO, G; ZARNEGAR, R; MICHALOPOULOS, GK; COMOGLIO, PM				NALDINI, L; VIGNA, E; NARSIMHAN, RP; GAUDINO, G; ZARNEGAR, R; MICHALOPOULOS, GK; COMOGLIO, PM			HEPATOCYTE GROWTH-FACTOR (HGF) STIMULATES THE TYROSINE KINASE-ACTIVITY OF THE RECEPTOR ENCODED BY THE PROTOONCOGENE C-MET	ONCOGENE			English	Article							FULMINANT HEPATIC-FAILURE; CARCINOMA CELL-LINE; HEPATOPOIETIN-A; MOLECULAR-CLONING; SCATTER FACTOR; MESSENGER-RNA; PURIFICATION; EXPRESSION; SEQUENCE; PROTOONCOGENE	The human proto-oncogene c-MET encodes a heterodimeric 190 KDa transmembrane protein (p190c-met) with structural features of a tyrosine kinase receptor. The ligand for this putative receptor has not yet been identified. By Northern blot hybridization we found that, among a restricted number of human tissues, c-MET is highly expressed in the liver. This prompted us to test the hypothesis of a functional interaction between the c-MET receptor and Hepatocyte Growth Factor (HGF), a heparin-binding polypeptide consisting of heavy and light chains of 65 and 35 kDa. Nanomolar concentrations of highly purified HGF added to GTL-16 cells, which overexpress the c-MET receptor, enhanced the phosphorylation on tyrosine of the p190c-met kinase. Addition of other known growth factors or serum was ineffective. The kinase activity of the c-MET receptor was also stimulated by HGF in an in vitro assay, after detergent solubilization and partial purification of p190c-met. Moreover, elution of immunoprecipitates obtained with anti-MET antibodies from GTL-16 cell lysates yielded an HGF-responsive kinase activity. These results suggest that HGF, or a growth factor structurally related to HGF, is a candidate ligand for the receptor encoded by c-MET.	UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,I-10126 TURIN,ITALY; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710	University of Turin; Duke University			Naldini, Luigi/E-9083-2012	NALDINI, Luigi/0000-0002-7835-527X; Comoglio, Paolo/0000-0002-7056-5328; Vigna, Elisa/0000-0001-9787-5732				CHAN AML, 1988, ONCOGENE, V2, P593; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GIORDANO S, 1988, J CELL BIOCHEM, V38, P229, DOI 10.1002/jcb.240380402; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KINOSHITA T, 1989, BIOCHEM BIOPH RES CO, V165, P1229, DOI 10.1016/0006-291X(89)92733-2; LINDROOS PM, 1990, IN PRESS HEPATOLOGY; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NAKAYAMA H, 1985, BIOMED RES-TOKYO, V6, P231; NALDINI L, 1990, IN PRESS MOL CELL BI; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1990, IN PRESS ONCOGENE; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; THALER FJ, 1985, CANCER RES, V45, P2545; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; ZARNEGAR R, 1989, BIOCHEM BIOPH RES CO, V163, P1370, DOI 10.1016/0006-291X(89)91130-3; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252; ZARNEGAR R, 1989, CANCER RES, V49, P3314; ZARNEGAR R, 1990, IN PRESS BIOCH BIOPH	30	744	783	0	20	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					501	504						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1827664				2022-12-25	WOS:A1991FR93900002
J	RYSECK, RP; BRAVO, R				RYSECK, RP; BRAVO, R			C-JUN, JUN-B, AND JUN-D DIFFER IN THEIR BINDING AFFINITIES TO AP-1 AND CRE CONSENSUS SEQUENCES - EFFECT OF FOS PROTEINS	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; DNA-BINDING; LEUCINE ZIPPER; PROTO-ONCOGENE; GROWTH-FACTORS; BASIC REGION; GENE FAMILY; CYCLIC-AMP; EXPRESSION; ACTIVATION	We have compared the binding properties of c-JUN, JUN B, and JUN D in the absence or in the presence of c-FOS, FOS B, and FRA-1 to different AP-1 and CRE-containing oligonucleotides. The results demonstrate that for a given AP-1-containing oligonucleotide the binding affinities of the different JUN proteins are always c-JUN > JUN D > JUN B. The three JUN proteins have the capacity to bind to a CRE consensus sequence with very high affinity. We have found that c-JUN, JUN B, and JUN D bind with different affinities to different oligonucleotides containing an identical AP-1 or CRE binding site, implying that the adjacent sequences influence the stability of the JUN/DNA complexes. Interestingly, an AP-1-containing oligonucleotide which binds the JUN proteins with high affinity can be converted to a CRE-containing oligonucleotide which will also bind the different JUNs very efficiently. The heterodimers formed between the different JUN and FOS proteins have an enhanced binding activity compared to the JUN:JUN homodimers. In all cases the half-lives of the JUN:FOS/DNA complexes are longer than those of the JUN:JUN/DNA complexes. The most stable complexes were obtained in the presence of FOS B, followed by FRA-1 and c-FOS.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,POB 4000,PRINCETON,NJ 08543	Bristol-Myers Squibb								ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENBROOK DM, 1990, ONCOGENE, V5, P295; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COHEN DR, 1990, ONCOGENE, V5, P929; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAI T, 1989, GENE DEV, V3, P2082; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HIRAI S-I, 1989, New Biologist, V1, P181; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JANSSENTIMMEN U, 1989, GENE, V80, P325, DOI 10.1016/0378-1119(89)90296-5; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUI M, 1990, ONCOGENE, V5, P249; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; QUANTIN B, 1988, NATURE, V334, P530; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	49	595	602	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					533	542						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1827665				2022-12-25	WOS:A1991FR93900006
J	BASSLER, BL; YU, C; LEE, YC; ROSEMAN, S				BASSLER, BL; YU, C; LEE, YC; ROSEMAN, S			CHITIN UTILIZATION BY MARINE-BACTERIA - DEGRADATION AND CATABOLISM OF CHITIN OLIGOSACCHARIDES BY VIBRIO-FURNISSII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINIDASE-H; ESCHERICHIA-COLI; PHOSPHOTRANSFERASE SYSTEM; STREPTOMYCES-ERYTHRAEUS; CLONING; PURIFICATION; EXPRESSION; CHEMOTAXIS; GENES; DNA	Chemotaxis of the marine bacterium Vibrio furnissii to chitin oligosaccharides has been described (Bassler, B. L., Gibbons, P. J., Yu, C., and Roseman, S. (1991) J. Biol. Chem. 266, 24268-24275). Some steps in catabolism of the oligosaccharides are reported here. GlcNAc, (GlcNAc)2, and (GlcNAc)3 are very rapidly consumed by intact cells, about 320 nmol of GlcNAc equivalents/min/mg of protein. (GlcNAc)4 is utilized somewhat more slowly. During these processes, there is virtually no release of hydrolysis products by the cells. The oligosaccharides enter the periplasmic space (via specific porins?) and are hydrolyzed by a unique membrane-bound endoenzyme (chitodextrinase) and an exoenzyme (N-acetyl-beta-glucosaminidase; beta-GlcNAcidase). The genes encoding these enzymes have been cloned and expressed in Escherichia coli. The chitodextrinase cleaves soluble oligomers, but not chitin, to the di- and trisaccharides, while the periplasmic beta-GlcNAcidase hydrolyzes the GlcNAc termini from the oligomers. The end products in the periplasm, GlcNAc and (GlcNAc)2 (possibly (GlcNAc)3) are catabolized as follows. (a) Disaccharide pathway, A (Glc NAc)2 permease is apparently expressed by Vibrio furnissii. Translocated (GlcNAc)2 is rapidly hydrolyzed by a soluble, cytosolic beta-GlcNAcidase, and the GlcNAc is phosphorylated by an ATP-dependent, constitutive kinase to GlcNAc-6-P. (b) Monosaccharide pathway, Periplasmic GlcNAc is taken up by Enzyme II(Nag) of the phosphoenolpyruvate:glycose phosphotransferase system, yielding GlcNAc-6-P, the common intermediate for both pathways. Finally, GlcNAc-6-P --> Ac- + GlcNH2-6-P --> Fru-6-P + NH3. (GlcNAc)2 is probably the "true" inducer of the chitin degradative enzymes described in this report and, depending on its concentration in the growth medium, differentially induces the periplasmic and cytosolic beta-GlcNAcidases. The disaccharide pathway appears to be the most important when the cells are confronted with low concentrations of the oligomers (e.g. in chemotaxis swarm plates). The relative activities of the induced enzymes suggest that the rate-limiting steps in oligosaccharide catabolism are the glycosidase activities in the periplasm.	JOHNS HOPKINS UNIV,MCCOLLUM PRATT INST,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University				Bassler, Bonnie/0000-0002-0043-746X	NIGMS NIH HHS [5T32GM07321] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1973, J BACTERIOL, V115, P824, DOI 10.1128/JB.115.3.824-847.1973; ANTHONY R, 1971, J BIOL CHEM, V247, P2120; Asensio C., 1966, METHODS ENZYMOL, V9, P421; BASSLER B, 1989, BIOCHEM BIOPH RES CO, V161, P1172, DOI 10.1016/0006-291X(89)91365-X; BASSLER B, 1988, Journal of Cell Biology, V107, p535A; BASSLER BL, 1991, J BIOL CHEM, V266, P24268; BROGLIE KE, 1986, P NATL ACAD SCI USA, V83, P6820, DOI 10.1073/pnas.83.18.6820; COLOWICK SP, 1988, METHOD ENZYMOL, V161, P403; Colwell R.R., 1984, VIBRIOS ENV; COMB DG, 1958, J BIOL CHEM, V232, P807; FISCHER EH, 1960, ENZYMES, V4, P301; FUCHS RL, 1986, APPL ENVIRON MICROB, V51, P504, DOI 10.1128/AEM.51.3.504-509.1986; HARA S, 1989, J BIOCHEM, V105, P484, DOI 10.1093/oxfordjournals.jbchem.a122691; Horwitz M., 1984, CHITIN CHITOSAN RELA, P191; JANNATIPOUR M, 1987, J BACTERIOL, V169, P3785, DOI 10.1128/jb.169.8.3785-3791.1987; JEUNIAUX C, 1959, ARCH INT PHYS BIOCH, V67, P115; Johnstone J., 1908, CONDITIONS LIFE SEA; JOSHI S, 1988, J BACTERIOL, V170, P2984, DOI 10.1128/jb.170.7.2984-2988.1988; KAMEI K, 1989, J BIOCHEM-TOKYO, V105, P979, DOI 10.1093/oxfordjournals.jbchem.a122791; KINOSHITA K, 1988, J BIOCHEM-TOKYO, V104, P827, DOI 10.1093/oxfordjournals.jbchem.a122557; KORNELUK RG, 1986, J BIOL CHEM, V261, P8407; KURANDA MJ, 1987, P NATL ACAD SCI USA, V84, P2585, DOI 10.1073/pnas.84.9.2585; LENGELER J, 1981, MOL GEN GENET, V183, P163, DOI 10.1007/BF00270156; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACNAB RM, 1987, ESCHERICHIA COLI SAL, V1, P732; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; Maniatis T., 1982, MOL CLONING; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; Morgan WTJ, 1934, BIOCHEM J, V28, P988, DOI 10.1042/bj0280988; OBRIEN M, 1987, APPL ENVIRON MICROB, V53, P1718, DOI 10.1128/AEM.53.7.1718-1720.1987; PEDRAZAREYES M, 1989, J GEN MICROBIOL, V135, P211; PULLEYBLANK D, 1983, MOL BIOL REP, V9, P191, DOI 10.1007/BF00775367; REISSIG JL, 1955, J BIOL CHEM, V217, P959; ROBBINS PW, 1988, J BIOL CHEM, V263, P443; ROBBINS PW, 1984, J BIOL CHEM, V259, P7577; ROSEMAN S, 1957, J BIOL CHEM, V226, P115; SCHULZE KL, 1964, ARCH MIKROBIOL, V48, P1, DOI 10.1007/BF00406595; Soto-Gil RW, 1984, CHITIN CHITOSAN RELA, P209; SOTOGIL RW, 1989, J BIOL CHEM, V264, P14778; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STOCK JB, 1977, J BIOL CHEM, V252, P7850; TRACEY MV, 1955, BIOCHEM J, V61, P579, DOI 10.1042/bj0610579; TRUMBLY RJ, 1985, J BIOL CHEM, V260, P5683; WORTMAN AT, 1986, APPL ENVIRON MICROB, V52, P142, DOI 10.1128/AEM.52.1.142-145.1986; YU C, 1991, J BIOL CHEM, V266, P24260; YU C, 1987, BIOCHEM BIOPH RES CO, V149, P86, DOI 10.1016/0006-291X(87)91608-1; Zechmeister L, 1939, ENZYMOLOGIA, V7, P165; Zechmeister L, 1939, ENZYMOLOGIA, V7, P170; ZOBELL CE, 1937, J BACTERIOL, V35, P275	50	135	140	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24276	24286						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761533				2022-12-25	WOS:A1991GW84500010
J	JEDLITSCHKY, G; HUBER, M; VOLKL, A; MULLER, M; LEIER, I; MULLER, J; LEHMANN, WD; FAHIMI, HD; KEPPLER, D				JEDLITSCHKY, G; HUBER, M; VOLKL, A; MULLER, M; LEIER, I; MULLER, J; LEHMANN, WD; FAHIMI, HD; KEPPLER, D			PEROXISOMAL DEGRADATION OF LEUKOTRIENES BY BETA-OXIDATION FROM THE OMEGA-END	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; UNSATURATED FATTY-ACIDS; POLYMORPHONUCLEAR LEUKOCYTES; 3-ALPHA,7-ALPHA,12-ALPHA-TRIHYDROXY-5-BETA-CHOLESTANOIC ACID; 3-HYDROXYACYL-COA DEHYDROGENASE; HYPOLIPIDEMIC DRUG; PALMITOYL-COENZYME; CHOLIC-ACID; METABOLISM; IDENTIFICATION	Chain shortening via beta-oxidation from the omega-end has been recognized as the major pathway for the degradation of cysteinyl leukotrienes as well as leukotriene B4 (LTB4). The metabolic compartmentation of this pathway was studied using peroxisomes purified from normal and clofibrate-treated rat liver. Beta-oxidation products of omega-carboxy-LTB4, including omega-carboxy-dinor-LTB4 identified by gas chromatography-mass spectrometry, were formed by the isolated peroxisomes. The reaction was dependent on CoA, ATP, and NAD and was stimulated by FAD. NADPH was necessary for the further metabolism of omega-carboxy-dinor-LTB4. Together with microsomes a degradation of omega-carboxy-LTB4 also proceeded in isolated mitochondria in the presence of CoA, ATP, and carnitine. Beta-oxidation of the cysteinyl leukotriene omega-carboxy-N-acetyl-leukotriene E4 was observed only with isolated peroxisomes in combination with lipid-depleted microsomes. Direct photoaffinity labeling using omega-carboxy-[H-3]LTB4 and omega-carboxy-N-[H-3]acetyl-LTE4 served to identify peroxisomal leukotriene-binding proteins. The bifunctional protein (EC 4.2.1.17 and 1.1.1.35) and 3-ketoacyl-CoA thiolase (EC 2.3.1.16) of the peroxisomal beta-oxidation system were the predominantly labeled polypeptides as revealed by precipitation with monospecific antibodies. In vivo studies with N-acetyl-[H-3(2)]LTE4, N-acetyl-[H-3(8)]LTE4, and N-[C-14]acetyl-LTE4 after treatment with the peroxisome proliferator clofibrate indicated formation and biliary excretion of large amounts of metabolites more polar than omega-carboxy-tetranor-N-acetyl-LTE3, including omega-carboxy-tetranor-DELTA-13-N-acetyl-LTE4 and omega-carboxy-hexanor-N-acetyl-LTE3. Increased formation of beta-oxidized catabolites of N-acetyl-LTE4 and LTB4 was also observed in hepatocytes isolated after clofibrate treatment. Our results indicate that peroxisomes play a major role in the beta-oxidation of leukotrienes from the omega-end. Whereas omega-carboxy-LTB4 was beta-oxidized both in isolated peroxisomes and mitochondria, the cysteinyl leukotriene omega-carboxy-N-acetyl-LTE4 was exclusively degraded in peroxisomes.	UNIV HEIDELBERG,DEPT ANAT & CELL BIOL 2,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg	JEDLITSCHKY, G (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM,W-6900 HEIDELBERG,GERMANY.		Keppler, Dietrich/A-5528-2013; Muller, Michael/B-5795-2008; Muller, Michael/M-5724-2019	Keppler, Dietrich/0000-0003-2964-2333; Muller, Michael/0000-0002-5930-9905; Muller, Michael/0000-0002-5930-9905				AOYAMA T, 1990, J LIPID RES, V31, P1477; APPELGREN LE, 1982, J BIOL CHEM, V257, P531; BARTANA J, 1971, BIOCHEM J, V122, P353, DOI 10.1042/bj1220353; BAUMERT T, 1989, EUR J BIOCHEM, V182, P223, DOI 10.1111/j.1432-1033.1989.tb14821.x; BEIER K, 1988, EUR J CELL BIOL, V46, P383; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; DENZLINGER C, 1985, SCIENCE, V230, P330, DOI 10.1126/science.4048937; DICZFALUSY U, 1988, J LIPID RES, V29, P1629; DICZFALUSY U, 1987, BIOCHEM BIOPH RES CO, V144, P1206, DOI 10.1016/0006-291X(87)91439-2; DOMMES V, 1981, J BIOL CHEM, V256, P8259; FALK E, 1989, EUR J BIOCHEM, V186, P741, DOI 10.1111/j.1432-1033.1989.tb15268.x; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FORDHUTCHINSON AW, 1985, FED PROC, V44, P25; GIBSON GG, 1982, BIOCHEM J, V203, P161, DOI 10.1042/bj2030161; GOESER T, 1990, J CLIN INVEST, V86, P220, DOI 10.1172/JCI114687; GOLDFISCHER S, 1988, LIVER BIOL PATHOBIOL, P255; HAGMANN W, 1984, CIRC SHOCK, V14, P223; HAGMANN W, 1986, PROSTAGLANDINS, V31, P239, DOI 10.1016/0090-6980(86)90050-X; HAMMARSTROM S, 1983, ANNU REV BIOCHEM, V52, P355, DOI 10.1146/annurev.bi.52.070183.002035; HANSSON G, 1981, FEBS LETT, V130, P107, DOI 10.1016/0014-5793(81)80676-X; HARPER TW, 1986, J BIOL CHEM, V261, P5414; HASHIMOTO T, 1982, ANN NY ACAD SCI, V286, P5; HUBER M, 1990, EUR J BIOCHEM, V194, P309, DOI 10.1111/j.1432-1033.1990.tb19458.x; HUBER M, 1987, HEPATOLOGY, V7, P224, DOI 10.1002/hep.1840070204; JEDLITSCHKY G, 1990, ARCH BIOCHEM BIOPHYS, V282, P333, DOI 10.1016/0003-9861(90)90125-I; KASE F, 1983, J LIPID RES, V24, P1560; KEPPLER D, 1985, HEPATOLOGY, V5, P883, DOI 10.1002/hep.1840050530; LAZAROW PB, 1978, J BIOL CHEM, V253, P1522; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LAZAROW PB, 1977, SCIENCE, V197, P580, DOI 10.1126/science.195342; LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312; LUNDBERG U, 1981, FEBS LETT, V126, P127, DOI 10.1016/0014-5793(81)81050-2; ORNING L, 1987, EUR J BIOCHEM, V170, P77, DOI 10.1111/j.1432-1033.1987.tb13669.x; ORNING L, 1986, J BIOL CHEM, V261, P766; OSUMI T, 1978, BIOCHEM BIOPH RES CO, V83, P479, DOI 10.1016/0006-291X(78)91015-X; OSUMI T, 1979, BIOCHEM BIOPH RES CO, V89, P580, DOI 10.1016/0006-291X(79)90669-7; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; PEDERSEN JI, 1980, FEBS LETT, V121, P345, DOI 10.1016/0014-5793(80)80377-2; POWELL WS, 1984, J BIOL CHEM, V259, P3082; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; SALA A, 1990, J BIOL CHEM, V265, P21771; SAMHOUN MN, 1989, BRIT J PHARMACOL, V98, P1406; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHEPERS L, 1988, J BIOL CHEM, V263, P2724; SCHULZ H, 1987, TRENDS BIOCHEM SCI, V12, P403, DOI 10.1016/0968-0004(87)90196-4; SCHUTGENS RBH, 1986, EUR J PEDIATR, V144, P430, DOI 10.1007/BF00441734; SHAK S, 1984, J BIOL CHEM, V259, P181; SHIRLEY MA, 1990, J BIOL CHEM, V265, P16288; SINGH I, 1981, BIOCHEM BIOPH RES CO, V102, P1223, DOI 10.1016/S0006-291X(81)80142-8; SINGH I, 1984, P NATL ACAD SCI-BIOL, V81, P4203, DOI 10.1073/pnas.81.13.4203; SOBERMAN RJ, 1988, J BIOL CHEM, V263, P7996; STENE DO, 1988, J BIOL CHEM, V263, P2773; SUMIMOTO H, 1984, BIOCHEM BIOPH RES CO, V125, P615, DOI 10.1016/0006-291X(84)90583-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAMECQ J, 1987, J BIOCHEM-TOKYO, V102, P225, DOI 10.1093/oxfordjournals.jbchem.a122035; VAMECQ J, 1985, BIOCHEM J, V230, P683, DOI 10.1042/bj2300683; VAMECQ J, 1989, J BIOCHEM-TOKYO, V106, P216, DOI 10.1093/oxfordjournals.jbchem.a122835; VAMECQ J, 1988, ANN BIOL CLIN-PARIS, V46, P233; VOLKL A, 1985, EUR J BIOCHEM, V149, P257, DOI 10.1111/j.1432-1033.1985.tb08920.x	60	95	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24763	24772						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761571				2022-12-25	WOS:A1991GW84500080
J	WATANABE, K; CHISHIRO, K; KITAMURA, K; SUZUKI, Y				WATANABE, K; CHISHIRO, K; KITAMURA, K; SUZUKI, Y			PROLINE RESIDUES RESPONSIBLE FOR THERMOSTABILITY OCCUR WITH HIGH-FREQUENCY IN THE LOOP REGIONS OF AN EXTREMELY THERMOSTABLE OLIGO-1,6-GLUCOSIDASE FROM BACILLUS-THERMOGLUCOSIDASIUS KP1006	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SECONDARY-STRUCTURE; PROTEIN THERMOSTABILITY; NUCLEOTIDE-SEQUENCES; THERMAL-STABILITY; GLOBULAR PROTEINS; ALPHA-GLUCOSIDASE; ESCHERICHIA-COLI; GENE; DEHYDROGENASE	The gene encoding for an extremely thermostable oligo-1,6-glucosidase from Bacillus thermoglucosidasius KP1006 (DSM2542, obligate thermophile) was sequenced. The amino acid sequence deduced from the nucleotide sequence of the gene (1686 base pairs) corresponded to a protein of 562 amino acid residues with a M(r) of 66,502. Its predicted amino acid composition, M(r), and N-terminal sequence of 12 residues were consistent with those determined for B. thermoglucosidasius oligo-1,6-glucosidase. The deduced sequence of the enzyme was 72% homologous to that of a thermolabile oligo-1,6-glucosidase (558 residues) from Bacillus cereus ATCC7064 (mesophile). B. cereus oligo-1,6-glucosidase contained 19 prolines. Eighteen of these were conserved at the equivalent positions of B. thermoglucosidasius oligo-1,6-glucosidase. This enzyme contained 14 extra prolines besides the conservative prolines. The majority of extra prolines was replaced by polar or charged residues (Glu, Thr, or Lys) in B. cereus oligo-1,6-glucosidase. The extra prolines were responsible for the difference in thermostability between these two enzymes. We suggested that 11 of the extra prolines in B. thermoglucosidasius oligo-1,6-glucosidase occur in beta-turns or in coils within the loops binding adjacent secondary structures.	KYOTO PREFECTURAL UNIV,DEPT AGR CHEM,SAKYO KU,KYOTO 606,JAPAN	Kyoto Prefectural University								ADHYA S, 1978, ANNU REV BIOCHEM, V47, P967, DOI 10.1146/annurev.bi.47.070178.004535; ALBER T, 1989, ANNU REV BIOCHEM, V58, P765, DOI 10.1146/annurev.biochem.58.1.765; ALBER T, 1987, BIOCHEMISTRY-US, V26, P3754, DOI 10.1021/bi00387a002; AMEMURA A, 1988, J BIOL CHEM, V263, P9271; ARGOS P, 1979, BIOCHEMISTRY-US, V18, P5698, DOI 10.1021/bi00592a028; BIBB MJ, 1984, GENE, V30, P157, DOI 10.1016/0378-1119(84)90116-1; BUISSON G, 1987, EMBO J, V6, P3909, DOI 10.1002/j.1460-2075.1987.tb02731.x; BUNCHEL BE, 1980, NATURE, V283, P541; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; CID H, 1982, FEBS LETT, V150, P247, DOI 10.1016/0014-5793(82)81344-6; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HECHT M H, 1986, Proteins Structure Function and Genetics, V1, P43, DOI 10.1002/prot.340010108; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; HONG SH, 1986, GENE, V41, P75; ITO Y, 1990, J BIOCHEM-TOKYO, V107, P236, DOI 10.1093/oxfordjournals.jbchem.a123032; KAGAWA Y, 1984, J BIOL CHEM, V259, P2956; KARST U, 1989, J GEN MICROBIOL, V135, P1305; KATSURAGI N, 1987, J BACTERIOL, V169, P2301, DOI 10.1128/jb.169.5.2301-2306.1987; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVITT M, 1978, BIOCHEMISTRY-US, V17, P4277, DOI 10.1021/bi00613a026; LEWIS PN, 1973, BIOCHIM BIOPHYS ACTA, V303, P211, DOI 10.1016/0005-2795(73)90350-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MACGREGOR EA, 1989, BIOCHEM J, V259, P145, DOI 10.1042/bj2590145; MACGREGOR EA, 1988, J PROTEIN CHEM, V7, P399, DOI 10.1007/BF01024888; Maniatis T., 1982, MOL CLONING; MATSUMURA M, 1986, NATURE, V323, P356, DOI 10.1038/323356a0; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MATTHEWS BW, 1987, BIOCHEMISTRY-US, V26, P6885, DOI 10.1021/bi00396a001; MENENDEZARIAS L, 1989, J MOL BIOL, V206, P397, DOI 10.1016/0022-2836(89)90488-9; NEMETHY G, 1966, J PHYS CHEM-US, V70, P998, DOI 10.1021/j100876a008; PAONI NF, 1984, APPL ENVIRON MICROB, V47, P208, DOI 10.1128/AEM.47.1.208-209.1984; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; SALSER W, 1977, COLD SPRING HARB SYM, V42, P985; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SCHIMMEL PR, 1968, J MOL BIOL, V34, P105, DOI 10.1016/0022-2836(68)90237-4; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; STERMAN RS, 1988, BIOCHEMISTRY-US, V27, P7571; STRICKLER JE, 1984, ANAL BIOCHEM, V140, P553, DOI 10.1016/0003-2697(84)90207-0; SUZUKI Y, 1991, APPL MICROBIOL BIOT, V34, P707; SUZUKI Y, 1983, SYST APPL MICROBIOL, V4, P487, DOI 10.1016/S0723-2020(83)80006-X; SUZUKI Y, 1976, APPL ENVIRON MICROB, V31, P807, DOI 10.1128/AEM.31.6.807-812.1976; SUZUKI Y, 1989, P JPN ACAD B-PHYS, V65, P146, DOI 10.2183/pjab.65.146; SUZUKI Y, 1987, APPL MICROBIOL BIOT, V26, P546, DOI 10.1007/BF00253030; SUZUKI Y, 1979, BIOCHIM BIOPHYS ACTA, V566, P62, DOI 10.1016/0005-2744(79)90248-1; SUZUKI Y, 1989, APPL MICROBIOL BIOT, V31, P32, DOI 10.1007/BF00252522; SUZUKI Y, 1976, BIOCHIM BIOPHYS ACTA, V445, P386, DOI 10.1016/0005-2744(76)90092-9; SVENSSON B, 1988, FEBS LETT, V230, P72, DOI 10.1016/0014-5793(88)80644-6; TAGAYA M, 1989, J BIOL CHEM, V264, P990; TESFAY HS, 1989, GENE, V82, P237, DOI 10.1016/0378-1119(89)90049-8; TSUZAKI K, 1989, OCT P ANN M SOC FERM, P224; VIERA J, 1987, METHOD ENZYMOL, V153, P3; WATANABE K, 1989, J BACTERIOL, V171, P1219, DOI 10.1128/jb.171.2.1219-1222.1989; WATANABE K, 1990, EUR J BIOCHEM, V192, P609, DOI 10.1111/j.1432-1033.1990.tb19267.x; WATANABE K, 1986, NUCLEIC ACIDS RES, V14, P4393, DOI 10.1093/nar/14.11.4393; WATANABE K, 1990, NOV P ANN M MOL BIOL, P298; WATANABE K, 1989, OCT P ANN M SOC FERM, P222; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YUTANI K, 1991, PROTEINS, V9, P90, DOI 10.1002/prot.340090203; ZUBER H, 1988, BIOPHYS CHEM, V29, P171, DOI 10.1016/0301-4622(88)87037-6	64	140	147	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24287	24294						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761534				2022-12-25	WOS:A1991GW84500011
J	DIAZGUERRA, MJM; JUNCO, M; BOSCA, L				DIAZGUERRA, MJM; JUNCO, M; BOSCA, L			OLEIC-ACID PROMOTES CHANGES IN THE SUBCELLULAR-DISTRIBUTION OF PROTEIN-KINASE-C IN ISOLATED HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; ISOLATED RAT HEPATOCYTES; PHORBOL ESTER BINDING; PHOSPHATIDATE PHOSPHOHYDROLASE; PLASMA-MEMBRANE; DISTINCT FORMS; MIXED MICELLES; ACTIVATION; LIVER; TRANSLOCATION	The effect of oleate on the subcellular distribution of protein kinase C (PKC) was studied in isolated hepatocytes and in perfused rat liver in the presence of physiological concentrations of serum albumin. A time- and dose-dependent translocation of PKC from the cytosol towards the membranes was observed at oleate concentrations that fell within the range of concentrations reached under several physiological conditions. Analysis of the membrane-bound isoenzymes of PKC by hydroxylapatite chromatography revealed that the beta-isoenzyme was preferentially translocated to this compartment in hepatocytes incubated with oleate. Activation of PKC after incubation of hepatocytes with oleate involved at least three different effectors of the enzyme: the fatty acid itself, the diacylglycerol synthesized from oleate, and the rise in the cytosolic calcium concentration elicited by oleate. As a result of PKC activation, protein phosphorylation of intact hepatocytes in response to oleate exhibited an enhancement in the phosphate content of a protein of 82 kDa, similar to that phosphorylated in the presence of phorbol dibutyrate.	UNIV COMPLUTENSE MADRID,FAC FARM,INST BIOQUIM,E-28040 MADRID,SPAIN	Complutense University of Madrid	BOSCA, L (corresponding author), UNIV COMPLUTENSE MADRID,FAC FARM,INST BIOQUIM,E-28040 MADRID,SPAIN.		Bosca, Lisardo/A-2059-2008; Díaz-Guerra, María José M/M-2855-2014	Bosca, Lisardo/0000-0002-0253-5469; Díaz-Guerra, María José M/0000-0003-3843-3912				AUGERT G, 1989, J BIOL CHEM, V264, P21689; AZHAR S, 1987, BIOCHEMISTRY-US, V26, P7047, DOI 10.1021/bi00396a029; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIJLEVELD C, 1988, BIOCHEM BIOPH RES CO, V151, P193, DOI 10.1016/0006-291X(88)90578-5; BOSCA L, 1989, BIOCHEM BIOPH RES CO, V160, P1243, DOI 10.1016/S0006-291X(89)80137-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGOYNE RD, 1989, TRENDS BIOCHEM SCI, V14, P87; CASCALES C, 1984, BIOCHEM J, V219, P911, DOI 10.1042/bj2190911; CRAVEN PA, 1988, GASTROENTEROLOGY, V95, P676, DOI 10.1016/S0016-5085(88)80014-3; DELL KR, 1989, BIOCHEM J, V258, P171, DOI 10.1042/bj2580171; DIAZGUERRA MJM, 1990, BIOCHEM J, V269, P163, DOI 10.1042/bj2690163; DIAZGUERRA MJM, 1988, BIOCHIM BIOPHYS ACTA, V970, P157, DOI 10.1016/0167-4889(88)90174-7; ELTOUNY S, 1990, J BIOL CHEM, V265, P16437; EMMISON N, 1988, FEBS LETT, V236, P83, DOI 10.1016/0014-5793(88)80289-8; FERRANNINI E, 1983, J CLIN INVEST, V72, P1737, DOI 10.1172/JCI111133; Fleischer S, 1974, Methods Enzymol, V31, P6; FOLCH J, 1957, J BIOL CHEM, V226, P497; GIRARD PR, 1986, J BIOL CHEM, V261, P370; HANNUN YA, 1986, J BIOL CHEM, V261, P9341; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; HOPEWELL R, 1985, BIOCHEM J, V232, P485, DOI 10.1042/bj2320485; HOUWELING M, 1989, BIOCHEM BIOPH RES CO, V158, P294, DOI 10.1016/S0006-291X(89)80211-6; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; HUE L, 1978, BIOCHEM J, V176, P791, DOI 10.1042/bj1760791; JUNCO M, 1990, FEBS LETT, V263, P169, DOI 10.1016/0014-5793(90)80731-W; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KODA Y, 1989, NEUROSCIENCE, V29, P495, DOI 10.1016/0306-4522(89)90076-6; KOHOUT M, 1971, J BIOL CHEM, V246, P5067; KRUG E, 1987, J BIOL CHEM, V262, P11852; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDEN DJ, 1986, BRAIN RES, V379, P358, DOI 10.1016/0006-8993(86)90790-0; MARTIN A, 1986, BIOCHIM BIOPHYS ACTA, V876, P581, DOI 10.1016/0005-2760(86)90047-0; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; METZ SA, 1988, DIABETES, V37, P1453, DOI 10.2337/diabetes.37.11.1453; MURAKAMI K, 1986, J BIOL CHEM, V261, P5424; NAKADATE T, 1988, BIOCHEM PHARMACOL, V37, P1541, DOI 10.1016/0006-2952(88)90016-0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOY N, 1986, BIOCHEMISTRY-US, V25, P2013, DOI 10.1021/bi00356a027; NUNEZ D, 1990, J BIOL CHEM, V265, P18330; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; PONTREMOLI S, 1990, P NATL ACAD SCI USA, V87, P3705, DOI 10.1073/pnas.87.10.3705; PREISS J, 1986, J BIOL CHEM, V261, P8597; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SCHOLZ R, 1973, EUR J BIOCHEM, V38, P64, DOI 10.1111/j.1432-1033.1973.tb03034.x; SEIFERT R, 1987, BIOCHEM BIOPH RES CO, V149, P762, DOI 10.1016/0006-291X(87)90433-5; SEKIGUCHI K, 1987, BIOCHEM BIOPH RES CO, V145, P797, DOI 10.1016/0006-291X(87)91035-7; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; STALMANS W, 1975, EUR J BIOCHEM, V54, P341, DOI 10.1111/j.1432-1033.1975.tb04144.x; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3584, DOI 10.1073/pnas.83.11.3584; STREMMEL W, 1987, J BIOL CHEM, V262, P6284; SUNDLER R, 1974, J BIOL CHEM, V249, P5102; WINTER NS, 1990, J BIOL CHEM, V265, P10955; WOLF M, 1988, BIOCHEM BIOPH RES CO, V154, P1273, DOI 10.1016/0006-291X(88)90277-X; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836	58	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23568	23576						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748635				2022-12-25	WOS:A1991GV31900011
J	EISENREICH, W; BACHER, A				EISENREICH, W; BACHER, A			BIOSYNTHESIS OF 5-HYDROXYBENZIMIDAZOLYLCOBAMID (FACTOR-III) IN METHANOBACTERIUM-THERMOAUTOTROPHICUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; EUBACTERIUM-LIMOSUM; GUANOSINE TRIPHOSPHATE; METHANOSARCINA-BARKERI; ANAEROBIC-BACTERIA; SPOROMUSA-OVATA; CORRIN RING; 5,6-DIMETHYLBENZIMIDAZOLE MOIETY; VITAMIN-B12 BIOSYNTHESIS; METHANOGENIC BACTERIA	Cultures of Methanobacterium thermoautotrophicum ere supplemented with C-13-labeled acetate or pyruvate, and the labeling pattern of the corrinoid, factor III, was established by C-13 NMR spectroscopy. Complete C-13 signal assignments were obtained by two-dimensional NMR experiments. The labeling pattern of factor III was analyzed by comparison with those of amino acids and nucleosides. The corrin ring system is derived from eight molecules of glutamate. The aminopropanol moiety is derived in a hitherto unknown pathway from pyruvate by reductive amination. The heterocyclic ring of hydroxybenzimidazole shares the labeling pattern of the imidazole ring of purines. The remaining four carbon atoms of the carbocyclic ring show the labeling signature of a carbohydrate with two of the carbons introduced from acetate and two from C-1 of pyruvate. However, erythrose can be ruled out as the specific precursor on the basis of a detailed investigation of aromatic amino acids indicating that erythrose 4-phosphate is obtained by reductive carboxylation of a triose precursor and not by the pentose phosphate cycle.			EISENREICH, W (corresponding author), TECH UNIV MUNICH,LEHRSTUHL ORGAN CHEM & BIOCHEM,LICHTENBERGSTR 4,W-8046 GARCHING,GERMANY.		Eisenreich, Wolfgang/A-1258-2013	Eisenreich, Wolfgang/0000-0002-9832-8279				ALWORTH WL, 1977, BIOCHEMISTRY-US, V16, P526, DOI 10.1021/bi00622a029; ALWORTH WL, 1971, BIOCHEMISTRY-US, V10, P1421, DOI 10.1021/bi00784a023; ANTON DL, 1982, BIOCHEMISTRY-US, V21, P2372, DOI 10.1021/bi00539a015; BATTERSBY AR, 1988, J NAT PROD, V51, P643, DOI 10.1021/np50058a002; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRATT GT, 1984, BIOCHEMISTRY-US, V23, P5653, DOI 10.1021/bi00318a041; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BROWN CE, 1973, J BIOL CHEM, V248, P8015; BROWN GM, 1987, ESCHERICHIA COLI SAL, P521; EISENREICH W, 1991, J BIOL CHEM, V266, P9622; EKIEL I, 1983, J BACTERIOL, V156, P316, DOI 10.1128/JB.156.1.316-326.1983; ELSTNER EF, 1971, J BIOL CHEM, V246, P6973; FOOR F, 1975, J BIOL CHEM, V250, P3545; FORD SH, 1985, BIOCHIM BIOPHYS ACTA, V841, P306, DOI 10.1016/0304-4165(85)90073-X; FORD SH, 1976, ARCH BIOCHEM BIOPHYS, V175, P121, DOI 10.1016/0003-9861(76)90490-2; FORD SH, 1977, BIOCHIM BIOPHYS ACTA, V500, P217, DOI 10.1016/0304-4165(77)90062-9; FRIEDMAN.HC, 1965, J BIOL CHEM, V240, P406; FRIEDMANN HC, 1986, FEBS LETT, V207, P84, DOI 10.1016/0014-5793(86)80017-5; FRIEDMANN HC, 1970, ANNU REV MICROBIOL, V24, P159, DOI 10.1146/annurev.mi.24.100170.001111; FRIEDRICH W, 1954, Z NATURFORSCH B, V9, P685; FUCHS G, 1980, ARCH MICROBIOL, V127, P267, DOI 10.1007/BF00427203; FUCHS G, 1978, ARCH MICROBIOL, V118, P121, DOI 10.1007/BF00406084; GILLES H, 1983, ARCH MICROBIOL, V135, P237, DOI 10.1007/BF00414486; GRUESORENSEN G, 1986, J AM CHEM SOC, V108, P146, DOI 10.1021/ja00261a024; HOLLRIEGL V, 1982, ARCH MICROBIOL, V132, P155, DOI 10.1007/BF00508722; HORIG JA, 1978, J BIOL CHEM, V253, P7410; HORIG JA, 1980, EUR J BIOCHEM, V105, P587, DOI 10.1111/j.1432-1033.1980.tb04536.x; KRASNA AI, 1957, J BIOL CHEM, V225, P745; KRAUTLER B, 1987, EUR J BIOCHEM, V162, P275, DOI 10.1111/j.1432-1033.1987.tb10596.x; LAMM L, 1980, EUR J BIOCHEM, V109, P115, DOI 10.1111/j.1432-1033.1980.tb04775.x; LAMM L, 1982, EUR J BIOCHEM, V122, P569; PFALTZ A, 1982, HELV CHIM ACTA, V65, P828, DOI 10.1002/hlca.19820650320; POL A, 1982, BIOCHEM BIOPH RES CO, V108, P731, DOI 10.1016/0006-291X(82)90890-7; RENZ P, 1970, FEBS LETT, V6, P187, DOI 10.1016/0014-5793(70)80053-9; RENZ P, 1987, EUR J BIOCHEM, V163, P175, DOI 10.1111/j.1432-1033.1987.tb10752.x; SCHERER P, 1984, ARCH MICROBIOL, V138, P354, DOI 10.1007/BF00410903; SCOTT AI, 1972, J AM CHEM SOC, V94, P8267, DOI 10.1021/ja00778a076; SCOTT AI, 1990, ACCOUNTS CHEM RES, V23, P308, DOI 10.1021/ar00177a007; STUPPERICH E, 1989, ARCH MICROBIOL, V151, P372, DOI 10.1007/BF00406567; STUPPERICH E, 1988, ARCH MICROBIOL, V149, P268, DOI 10.1007/BF00422016; STUPPERICH E, 1989, EUR J BIOCHEM, V186, P657, DOI 10.1111/j.1432-1033.1989.tb15256.x; STUPPERICH E, 1988, EUR J BIOCHEM, V172, P459, DOI 10.1111/j.1432-1033.1988.tb13910.x; SUMMERS MF, 1986, J AM CHEM SOC, V108, P4285, DOI 10.1021/ja00275a008; TAYLOR GT, 1977, ARCH MICROBIOL, V113, P17, DOI 10.1007/BF00428574; THAUER RK, 1967, EUR J BIOCHEM, V1, P482, DOI 10.1111/j.1432-1033.1967.tb00096.x; VOGT JRA, 1988, EUR J BIOCHEM, V171, P655, DOI 10.1111/j.1432-1033.1988.tb13836.x; VOGT JRA, 1988, EUR J BIOCHEM, V174, P637, DOI 10.1111/j.1432-1033.1988.tb14145.x; VOLK R, 1990, J BIOL CHEM, V265, P19479; WARREN MJ, 1990, TRENDS BIOCHEM SCI, V15, P486, DOI 10.1016/0968-0004(90)90304-T; YAMADA K, 1983, BIOCHIM BIOPHYS ACTA, V756, P41, DOI 10.1016/0304-4165(83)90022-3; YIM JJ, 1976, J BIOL CHEM, V251, P5087; [No title captured]	54	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23840	23849						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748658				2022-12-25	WOS:A1991GV31900050
J	MORTON, TA; RUNQUIST, JA; RAGSDALE, SW; SHANMUGASUNDARAM, T; WOOD, HG; LJUNGDAHL, LG				MORTON, TA; RUNQUIST, JA; RAGSDALE, SW; SHANMUGASUNDARAM, T; WOOD, HG; LJUNGDAHL, LG			THE PRIMARY STRUCTURE OF THE SUBUNITS OF CARBON-MONOXIDE DEHYDROGENASE/ACETYL-COA SYNTHASE FROM CLOSTRIDIUM-THERMOACETICUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; ACETYL COENZYME-A; ACETOGENIC BACTERIA; ESCHERICHIA-COLI; CITRATE SYNTHASE; NICKEL; RESOLUTION; MOSSBAUER; SEQUENCE; PATHWAY	CO dehydrogenase/acetyl-coenzyme A synthase (CODH) is the central enzyme in the pathway of acetyl-coenzyme A biosynthesis in Clostridium thermoaceticum. It catalyzes the interconversion of CO and CO2 and the synthesis of acetyl-coenzyme A from the methylated corrinoid/iron sulfur protein, CO, and coenzyme A. It is a nickel-iron-sulfur protein and contains two subunits in the form (alpha-beta)3. Reported here is the cloning and sequencing of the genes for both subunits of CODH. The gene for the alpha-subunit codes for a protein with 729 amino acids and a molecular weight of 81,730, and the beta-gene for a protein with 674 amino acids and a molecular weight of 72,928. The alpha-subunit follows the beta-subunit by 23 bases and the genes for both subunits are preceded by a sequence which is similar to the Shine-Dalgarno sequence of Escherichia coli. No significant amino acid sequence homology has been found to any known sequence. Labeling CODH with 2,4-dinitrophenylsulfenyl chloride and isolating labeled peptide fragments demonstrated that a tryptophan, residue 418 of the alpha-subunit, is protected by coenzyme A and thus may be considered a potential part of the coenzyme A site.	UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602; UNIV GEORGIA,CTR BIOL RESOURCE RECOVERY,ATHENS,GA 30602; UNIV WISCONSIN,DEPT CHEM,MILWAUKEE,WI 53201; CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,CLEVELAND,OH 44106	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University of Wisconsin System; University of Wisconsin Milwaukee; Case Western Reserve University	LJUNGDAHL, LG (corresponding author), UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024913, R37GM024913] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-27332] Funding Source: Medline; NIGMS NIH HHS [GM24913] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSORGE W, 1984, J BIOCHEM BIOPH METH, V10, P237, DOI 10.1016/0165-022X(84)90043-5; Barton, 1991, VARIATIONS AUTOTROPH, P201; BASTIAN NR, 1988, J AM CHEM SOC, V110, P5581, DOI 10.1021/ja00224a058; BUCK D, 1985, BIOCHEMISTRY-US, V24, P6245, DOI 10.1021/bi00343a031; BURTON JW, 1970, J MOL BIOL, V52, P165; CRAMER SP, 1987, INORG CHEM, V26, P2477, DOI 10.1021/ic00262a027; DALE RMK, 1985, PLASMID, V13, P31, DOI 10.1016/0147-619X(85)90053-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EGGEN RIL, 1991, J BIOL CHEM, V266, P6883; ELLIOTT JI, 1982, BIOCHEMISTRY-US, V21, P3294, DOI 10.1021/bi00257a007; FAN CL, 1991, BIOCHEMISTRY-US, V30, P431, DOI 10.1021/bi00216a018; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUCHS G, 1986, FEMS MICROBIOL LETT, V39, P181, DOI 10.1111/j.1574-6968.1986.tb01859.x; Hirs CHW, 1967, METHOD ENZYMOL, P59, DOI [10.1016/S0076-6879(67)11008-2, DOI 10.1016/S0076-6879(67)11008-2]; Kushner SR, 1978, GENET ENG N Y, P17; LAURSEN RA, 1981, J BIOL CHEM, V256, P8102; LINDAHL PA, 1990, J BIOL CHEM, V265, P3880; LINDAHL PA, 1990, J BIOL CHEM, V265, P3873; Ljungdahl L G, 1978, Methods Enzymol, V53, P360; LU WP, 1991, J BIOL CHEM, V266, P3554; LU WP, 1990, J BIOL CHEM, V265, P3124; Maniatis T., 1982, MOL CLONING; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; NEIDHARDT FC, 1987, CELLULAR MOL BIOL, V2, P1231; PADJAK W, 1973, CLIN CHIM ACTA, V48, P113; PEZACKA E, 1986, J BIOL CHEM, V261, P1609; POSTON JM, 1966, J BIOL CHEM, V241, P4209; RAGSDALE SW, 1987, J BIOL CHEM, V262, P14289; RAGSDALE SW, 1985, J BIOL CHEM, V260, P3970; RAGSDALE SW, 1985, P NATL ACAD SCI USA, V82, P6811, DOI 10.1073/pnas.82.20.6811; RAGSDALE SW, 1983, J BIOL CHEM, V258, P2364; RAMER SE, 1989, BIOCHEMISTRY-US, V28, P4675, DOI 10.1021/bi00437a025; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; ROBERTS DL, 1989, P NATL ACAD SCI USA, V86, P32, DOI 10.1073/pnas.86.1.32; SCOFFONE E, 1968, BIOCHEMISTRY-US, V7, P971, DOI 10.1021/bi00843a014; SHANMUGASUNDARA.T, 1989, BIOCHEMISTRY-US, V28, P7212; SHANMUGASUNDARAM T, 1988, Biofactors, V1, P147; SHANMUGASUNDARAM T, 1988, BIOCHEMISTRY-US, V27, P6499, DOI 10.1021/bi00417a045; SOBER HA, 1970, CRC HDB BIOCH, pC281; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P141, DOI 10.1093/nar/10.1.141; SUISSA M, 1984, EMBO J, V3, P1773, DOI 10.1002/j.1460-2075.1984.tb02045.x; WOOD HG, 1986, TRENDS BIOCHEM SCI, V11, P14, DOI 10.1016/0968-0004(86)90223-9; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0	44	59	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23824	23828						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748656				2022-12-25	WOS:A1991GV31900047
J	TURRINI, F; ARESE, P; JIE, Y; LOW, PS				TURRINI, F; ARESE, P; JIE, Y; LOW, PS			CLUSTERING OF INTEGRAL MEMBRANE-PROTEINS OF THE HUMAN ERYTHROCYTE-MEMBRANE STIMULATES AUTOLOGOUS IGG BINDING, COMPLEMENT DEPOSITION, AND PHAGOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; OCCURRING ANTI-BAND-3 ANTIBODIES; PARTICLE AGGREGATION; SICKLE ERYTHROCYTES; BAND-3 PROTEIN; CROSS-LINKING; HEINZ BODIES; MACROPHAGES; LOCALIZATION; RECOGNITION	Damaged or old erythrocytes are cleared rapidly from circulation. Because several common biochemical lesions can induce the clustering of integral membrane proteins, we have proposed that formation of microscopic protein aggregates in the membrane might constitute a cell surface marker that promotes removal of the defective/senescent cells. We demonstrate here that treatments that cluster integral membrane proteins in erythrocytes (1 mM ZnCl2, 1 mM acridine orange, and 0.35-mu-M melittin) induce autologous IgG binding, complement fixation, and phagocytosis by human monocytes in vitro. Removal of the clustering agents prior to incubation in autologous serum or cross-linking of cell surface proteins before addition of clustering agents prohibited the above response, while cross-linking after treatment with the clustering agents preserved the response even if the clustering agents were later removed. Furthermore, subsequent reversal of the chemical cross-link maintaining the clustered distribution also reversed the induction of IgG binding, complement deposition, and phagocytosis. Finally, by deleting or inactivating different steps in the phagocytosis pathway, the chronology of steps was shown to be: (i) integral protein clustering, (ii) IgG binding, (iii) complement deposition, and (iv) phagocytosis.	UNIV TURIN, DIPARTIMENTO GENET BIOL & CHIM MED, I-10126 TURIN, ITALY; PURDUE UNIV, DEPT CHEM, W LAFAYETTE, IN 47907 USA	University of Turin; Purdue University System; Purdue University; Purdue University West Lafayette Campus	LOW, PS (corresponding author), UNIV TURIN, DIPARTIMENTO GENET BIOL & CHIM MED, I-10126 TURIN, ITALY.			Low, Philip/0000-0001-9042-5528	NIGMS NIH HHS [GM24417] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024417, R01GM024417] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMINOFF D, 1988, BLOOD CELLS, V14, P229; ARESE P, 1990, SEMIN HEMATOL, V27, P1; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BEPPU M, 1990, J BIOL CHEM, V265, P3226; BRANDTS JF, 1983, SURV SYN PATHOL RES, V2, P107; BROVELLI A, 1987, BIOMED BIOCHIM ACTA, V46, pS72; CAMPWALA HQ, 1982, J LAB CLIN MED, V99, P25; CARRELL RW, 1977, HEMOGLOBIN, V1, P815, DOI 10.3109/03630267709003909; CLAGUE MJ, 1989, BIOCHIM BIOPHYS ACTA, V980, P93, DOI 10.1016/0005-2736(89)90204-6; CLARK MR, 1988, PHYSIOL REV, V68, P503, DOI 10.1152/physrev.1988.68.2.503; DACIE JV, 1975, PRACTICAL HAEMATOLOG, P42; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; ELGSAETER A, 1976, BIOCHIM BIOPHYS ACTA, V426, P101, DOI 10.1016/0005-2736(76)90433-8; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FREEDMAN J, 1984, TRANSFUSION, V24, P477, DOI 10.1046/j.1537-2995.1984.24685066804.x; GALILI U, 1986, BRIT J HAEMATOL, V62, P317, DOI 10.1111/j.1365-2141.1986.tb02935.x; HEBBEL RP, 1985, CLIN HAEMATOL, V14, P129; HEBBEL RP, 1985, CLIN HAEMATOL, V14, P141; HERMANOWSKIVOSATKA A, 1988, J BIOL CHEM, V263, P17822; HUI SW, 1990, BIOCHIM BIOPHYS ACTA, V1023, P335, DOI 10.1016/0005-2736(90)90124-7; JAIN SK, 1983, BRIT J HAEMATOL, V53, P247, DOI 10.1111/j.1365-2141.1983.tb02018.x; JENNINGS ML, 1985, J BIOL CHEM, V260, P5472; KANNAN R, 1991, BIOCHEM J, V278, P57, DOI 10.1042/bj2780057; KANNAN R, 1988, J BIOL CHEM, V263, P13766; KANNAN R, 1990, THESIS PURDUE U; KAY MMB, 1984, P NATL ACAD SCI-BIOL, V81, P5753, DOI 10.1073/pnas.81.18.5753; KAY MMB, 1975, P NATL ACAD SCI USA, V72, P3521, DOI 10.1073/pnas.72.9.3521; KURANTSINMILLS J, 1981, BIOCHIM BIOPHYS ACTA, V641, P129, DOI 10.1016/0005-2736(81)90576-9; LAW SKA, 1988, COMPLEMENT, P9; LELKES G, 1986, J CELL SCI, V86, P57; LESSIN LS, 1972, ARCH INTERN MED, V129, P306, DOI 10.1001/archinte.129.2.306; LOW PS, 1989, RED BLOOD CELL MEMBR, P237; LOW PS, 1985, SCIENCE, V227, P532; LOW PS, 1989, RED CELL, P525; LUTZ HU, 1988, BLOOD CELLS, V14, P175; LUTZ HU, 1987, P NATL ACAD SCI USA, V84, P7368, DOI 10.1073/pnas.84.21.7368; LUTZ HU, 1984, J IMMUNOL, V133, P2610; Lutz HU, 1990, BLOOD CELL BIOCH, V1, P81; MCCURDY PR, 1978, AM J MED, V64, P253, DOI 10.1016/0002-9343(78)90053-0; MCEVOY L, 1986, P NATL ACAD SCI USA, V83, P3311, DOI 10.1073/pnas.83.10.3311; MORRISON M, 1983, BIOMED BIOCHIM ACTA, V42, P5107; MULLER H, 1983, BIOCHIM BIOPHYS ACTA, V729, P249, DOI 10.1016/0005-2736(83)90491-1; NEUFELD HA, 1965, ANAL BIOCHEM, V12, P303, DOI 10.1016/0003-2697(65)90095-3; OLSSON T, 1982, CLIN CHIM ACTA, V122, P125, DOI 10.1016/0009-8981(82)90272-8; ORRINGER EP, 1977, BLOOD, V50, P1013; PIOMELLI S, 1967, J LAB CLIN MED, V69, P659; PLATT OS, 1986, J CLIN INVEST, V75, P266; SALHANY JM, 1990, J BIOL CHEM, V265, P17688; SCHROIT AJ, 1985, J BIOL CHEM, V260, P5131; SHINAR E, 1990, SEMIN HEMATOL, V27, P70; SINGER JA, 1986, P NATL ACAD SCI USA, V83, P5498, DOI 10.1073/pnas.83.15.5498; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURRINI F, 1985, BLOOD, V66, P302; VERKLEIJ AJ, 1978, BIOCHIM BIOPHYS ACTA, V515, P303, DOI 10.1016/0304-4157(78)90017-5; VLASSARA H, 1987, J EXP MED, V166, P539, DOI 10.1084/jem.166.2.539; WAUGH SM, 1985, BIOCHEMISTRY-US, V24, P34, DOI 10.1021/bi00322a006; WAUGH SM, 1986, J CLIN INVEST, V78, P1155, DOI 10.1172/JCI112696; WILEY JS, 1981, J CLIN INVEST, V67, P917, DOI 10.1172/JCI110140; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893	60	164	167	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23611	23617						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748639				2022-12-25	WOS:A1991GV31900017
J	JARVELAINEN, HT; KINSELLA, MG; WIGHT, TN; SANDELL, LJ				JARVELAINEN, HT; KINSELLA, MG; WIGHT, TN; SANDELL, LJ			DIFFERENTIAL EXPRESSION OF SMALL CHONDROITIN DERMATAN SULFATE PROTEOGLYCANS, PG-I BIGLYCAN AND PG-II DECORIN, BY VASCULAR SMOOTH-MUSCLE AND ENDOTHELIAL-CELLS IN CULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ARTICULAR-CARTILAGE; CORE PROTEIN; CONNECTIVE TISSUES; SKIN FIBROBLASTS; FREE TRANSLATION; ARTERIAL TISSUE; MESSENGER-RNA; COLLAGEN; BONE; BIOSYNTHESIS	Cultured bovine aortic smooth muscle (BASM) and endothelial (BAE) cells, like articular chondrocytes, synthesize two populations of small chondroitin/dermatan sulfate (CS/DS) proteoglycans (PGs) of similar size as PG-I/biglycan and PG-II/decorin. However, Northern blot analyses demonstrated that BAE cells express detectable amounts of mRNA transcripts only for PG-I/biglycan, whereas BASM cells and articular chondrocytes express mRNA transcripts for both PG-I/biglycan and PG-II/decorin. Endothelial cells from human umbilical vein also expressed detectable amounts of mRNA transcripts only for PG-I/biglycan, and not PG-II/decorin. Antiserum raised against bovine PG-II/decorin immunoprecipitated an apparent single PG species with relative molecular mass (M(r)) of approximately 120,000-180,000 from BASM cell and articular chondrocyte cultures but failed to immunoprecipitate an equivalent PG species from BAE cell cultures, consistent with the results from Northern blot analysis. In contrast, immunoprecipitations by antisera to PG-I/biglycan indicated that cultured endothelial cells synthesize two forms of PG-I/biglycan with M(r) values slightly larger than 200,000 and 120,000-140,000. It is likely, based on the magnitude of the size difference, that these two forms of PG-I/biglycan differ in the number of glycosaminoglycan chains. Additionally, BASM but not BAE cells were found to express detectable amounts of mRNA transcripts for type I collagen. The above results indicate that the two main cell types of the vascular wall, endothelial and smooth muscle cells, express different sets of small interstitial CS/DS PGs and that the synthesis of PG-II/decorin by these cells correlates with the expression of type I collagen, a collagen known to interact specifically with this PG. These differences in the expression of extracellular matrix molecules may be important in regulating the cell type-specific functions of endothelial and smooth muscle cells within the vascular tissue.	UNIV WASHINGTON, SCH MED, DEPT ORTHOPAED, RK-10, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT PATHOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT BIOCHEM, SEATTLE, WA 98195 USA; VET ADM MED CTR, SEATTLE, WA 98108 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA)					FOGARTY INTERNATIONAL CENTER [F05TW004222] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036994] Funding Source: NIH RePORTER; FIC NIH HHS [F05TW04222] Funding Source: Medline; NHLBI NIH HHS [HL18645] Funding Source: Medline; NIAMS NIH HHS [AR36994] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ASUNDI V, 1990, EUR J CELL BIOL, V52, P98; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; CHOI HU, 1989, J BIOL CHEM, V264, P2876; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOPRA RK, 1985, BIOCHEM J, V232, P277, DOI 10.1042/bj2320277; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; CHU ML, 1985, J BIOL CHEM, V260, P4357; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; DAY AA, 1986, NUCLEIC ACIDS RES, V14, P9861, DOI 10.1093/nar/14.24.9861; DREHER KL, 1990, EUR J CELL BIOL, V53, P296; ELSDALE T, 1973, BIOL FIBROBLAST, P41; FISHER LW, 1987, J BIOL CHEM, V262, P9702; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GLIMELIUS B, 1981, CELL DIFFER DEV, V10, P173, DOI 10.1016/0045-6039(81)90038-5; HASSELL JR, 1986, ANNU REV BIOCHEM, V55, P539, DOI 10.1146/annurev.bi.55.070186.002543; HEINEGARD D, 1985, BIOCHEM J, V230, P181, DOI 10.1042/bj2300181; HERING TM, 1988, J BIOL CHEM, V263, P1030; IRUELAARISPE ML, 1991, LAB INVEST, V64, P174; JARVELAINEN H T, 1990, Journal of Cell Biology, V111, p151A; KAPOOR R, 1981, BIOCHEM J, V197, P259, DOI 10.1042/bj1970259; KIMURA JH, 1987, METHOD ENZYMOL, V144, P372; KINSELLA MG, 1986, J CELL BIOL, V102, P679, DOI 10.1083/jcb.102.3.679; KINSELLA MG, 1988, J BIOL CHEM, V263, P19222; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; KUETTNER KE, 1982, J CELL BIOL, V93, P743, DOI 10.1083/jcb.93.3.743; KURKINEN M, 1987, J BIOL CHEM, V262, P8496; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARJAVA H, 1988, BIOCHEM J, V256, P35, DOI 10.1042/bj2560035; LARK MW, 1986, ARTERIOSCLEROSIS, V6, P638, DOI 10.1161/01.ATV.6.6.638; LINDAHL U, 1973, J BIOL CHEM, V248, P7234; LINDBLOM A, 1989, BIOCHEM J, V261, P145, DOI 10.1042/bj2610145; Maniatis T, 1982, MOL CLONING LABORATO, P433; MANN DM, 1990, J BIOL CHEM, V265, P5317; MAR H, 1988, J HISTOCHEM CYTOCHEM, V36, P1387, DOI 10.1177/36.11.2844888; MAYNE R, 1986, ARTERIOSCLEROSIS, V6, P585, DOI 10.1161/01.ATV.6.6.585; MCBRIDE OW, 1990, GENOMICS, V6, P219, DOI 10.1016/0888-7543(90)90560-H; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; POOLE AR, 1986, BIOCHEM J, V236, P1; RAUCH U, 1986, BIOCHEM J, V238, P465, DOI 10.1042/bj2380465; REGISTER TC, 1990, CONNECT TISSUE RES, V25, P35, DOI 10.3109/03008209009009811; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; ROUGHLEY PJ, 1989, BIOCHEM J, V262, P823, DOI 10.1042/bj2620823; ROWE HA, 1985, ARTERIOSCLEROSIS, V5, P101, DOI 10.1161/01.ATV.5.1.101; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAGE H, 1986, VASCULAR ENDOTHELIUM, P187; Sage H., 1984, BIOL ENDOTHELIAL CEL, P161, DOI [10.1007/978-1-4613-2825-4_16, DOI 10.1007/978-1-4613-2825-4_16]; SAITO H, 1968, J BIOL CHEM, V243, P1536; SANDELL LJ, 1988, EUR J CELL BIOL, V46, P253; SAWHNEY RS, 1991, J BIOL CHEM, V266, P9231; SCHMIDT A, 1984, H-S Z PHYSIOL CHEM, V365, P445, DOI 10.1515/bchm2.1984.365.1.445; SCHMIDT A, 1982, EUR J BIOCHEM, V125, P95, DOI 10.1111/j.1432-1033.1982.tb06655.x; SCHMIDT A, 1989, BIOCHEM SOC T, V17, P19, DOI 10.1042/bst0170019; SCHONBERR E, 1990, Journal of Cell Biology, V111, p151A; SCHWARTZ SM, 1978, IN VITRO CELL DEV B, V14, P966, DOI 10.1007/BF02616210; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VOGEL KG, 1989, EUR J CELL BIOL, V49, P236; VOGEL KG, 1986, J BIOL CHEM, V261, P1334; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VOLKER W, 1987, EUR J CELL BIOL, V45, P72; VOLKER W, 1986, J HISTOCHEM CYTOCHEM, V34, P1293, DOI 10.1177/34.10.2427568; WASTESON A, 1973, BIOCHEM J, V136, P1069, DOI 10.1042/bj1361069; WIGHT TN, 1989, ARTERIOSCLEROSIS, V9, P1, DOI 10.1161/01.ATV.9.1.1	65	147	153	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23274	23281						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744124				2022-12-25	WOS:A1991GT48300076
J	ANDRISANI, OM; DIXON, JE				ANDRISANI, OM; DIXON, JE			INVOLVEMENT OF LYSINE RESIDUE-289 AND RESIDUE-291 OF THE CAMP-RESPONSIVE ELEMENT-BINDING PROTEIN IN THE RECOGNITION OF THE CAMP-RESPONSIVE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SOMATOSTATIN GENE; TRANSCRIPTIONAL ACTIVATOR PROTEIN; DNA-BINDING; CYCLIC-AMP; LEUCINE ZIPPER; JUN ENCODES; PROMOTER; SEQUENCE; EXPRESSION; IDENTIFICATION	The molecular interactions resulting in specific binding of trans-acting factors to distinct cis-acting elements is not well understood. Here we report our attempt to understand the involvement of distinct amino acid residues of the basic domain of cAMP-responsive element-binding protein (DELTA-CREB) in the determination of binding toward the cAMP-responsive element (CRE). Using in vitro mutagenesis, we constructed site-directed mutants of distinct amino acid residues within the DNA contact region of DELTA-CREB. The activities of the mutant proteins were analyzed by gel retardation, methylation interference, and CRE competition analyses. We demonstrate that a single lysine to glutamine substitution at positions 289 and 291 of DELTA-CREB alters the methylation interference pattern of the mutant protein for the CRE site. Additional mutants constructed at these positions demonstrate that only identical basic residues at both positions 289 and 291 of DELTA-CREB can restore the wild type methylation interference pattern of the mutant DELTA-CREB protein for the CRE site. These observations point to the importance of the lysine residues at positions 289 and 291 in the process of CRE binding. In addition, this observation suggests that the symmetrical nature of the CRE site is reflected in the DNA contact region of the protein.	PURDUE UNIV,WALTHER CANC INST,W LAFAYETTE,IN 47907; PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Walther Cancer Institute; Purdue University System; Purdue University; Purdue University West Lafayette Campus	ANDRISANI, OM (corresponding author), PURDUE UNIV,DEPT VET PHYSIOL & PHARMACOL,W LAFAYETTE,IN 47907, USA.			Andrisani, Ourania/0000-0002-6230-0303	PHS HHS [18024] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABATE C, 1990, SCIENCE, V249, P1077; ANDRISANI O, 1990, J BIOL CHEM, V265, P3212; ANDRISANI OM, 1989, P NATL ACAD SCI USA, V86, P2181, DOI 10.1073/pnas.86.7.2181; ANDRISANI OM, 1988, MOL CELL BIOL, V8, P1947, DOI 10.1128/MCB.8.5.1947; ANDRISANI OM, 1987, NUCLEIC ACIDS RES, V15, P5715, DOI 10.1093/nar/15.14.5715; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ARON DC, 1981, ENDOCRINOLOGY, V109, P1830, DOI 10.1210/endo-109-6-1830; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CORTES P, 1988, GENE DEV, V2, P975, DOI 10.1101/gad.2.8.975; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HARDY S, 1988, P NATL ACAD SCI USA, V85, P4171, DOI 10.1073/pnas.85.12.4171; HOCHSCHILD A, 1986, CELL, V44, P925, DOI 10.1016/0092-8674(86)90015-2; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; JACOBS KA, 1988, NUCLEIC ACIDS RES, V16, P4637, DOI 10.1093/nar/16.10.4637; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; Maxam A M, 1980, Methods Enzymol, V65, P499; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; ZHU Z, 1989, J BIOL CHEM, V264, P6550	32	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21444	21450						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1834659				2022-12-25	WOS:A1991GP80400024
J	IZANT, JG; BRYSON, LJ				IZANT, JG; BRYSON, LJ			XENOPUS ANNEXIN-II (CALPACTIN-I) HEAVY-CHAIN HAS A DISTINCT AMINO TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; ROUS-SARCOMA VIRUS; NON-ERYTHROID SPECTRIN; FACTOR RECEPTOR-KINASE; PROTEIN-KINASE; CELLULAR SUBSTRATE; BINDING PROTEINS; CDNA SEQUENCE; PHOSPHOLIPASE-A2 INHIBITOR; DROSOPHILA-MELANOGASTER	We have isolated cDNAs encoding annexin II (calpactin I) heavy chain homologues from a Xenopus oocyte cDNA library. Two of the clones are full length, while two appear to be derived from incompletely spliced mRNAs. The 1230- and 1240-base pair full length clones are 99% identical, and both have 84 bases of 5'-untranslated sequence, 1020-base open reading frames, and either 126- or 136-base 3' - untranslated domains. Northern blots show a 1.4-kilobase (kb) annexin II heavy chain transcript throughout oogenesis and in mature eggs. Xenopus annexin II mRNA levels are constant during early embryogenesis, but decrease at 8 h. After midblastula transition, the steady state level of the 1.4-kb transcript increases substantially, and a 3.3-kb transcript appears. Adult brain, heart, striated muscle, and liver contain moderate amounts of the 1.4-kb transcript, while skin has the 3.3-kb transcript and very high levels of the 1.4-kb transcript. Synthetic mRNA derived from the Xenopus annexin II cDNAs directs the synthesis of an apparent M(r) = 36,500 polypeptide when microinjected into Xenopus oocytes. The predicted 339-amino acid protein products are 80% identical with murine annexin II heavy chain. Most of the differences are concentrated in the amino end from residues 15 to 24. The Xenopus annexin II heavy chain lacks the highly conserved tyrosine at position 23 which is the site of src oncogene tyrosine kinase phosphorylation in the murine protein. These results demonstrate that Xenopus oocytes contain an annexin II (calpactin I) heavy chain mRNA with a distinct amino terminus and suggest that multiple annexin II isoforms may be expressed during amphibian embryogenesis and development.			IZANT, JG (corresponding author), YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510, USA.							ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; AMIGUET P, 1990, BIOCHEMISTRY-US, V29, P1226, DOI 10.1021/bi00457a019; BEMENT WM, 1989, J CELL BIOL, V108, P885, DOI 10.1083/jcb.108.3.885; BILOFSKY HS, 1986, NUCLEIC ACIDS RES, V14, P1, DOI 10.1093/nar/14.1.1; BURGOYNE RD, 1988, NATURE, V331, P20, DOI 10.1038/331020a0; CARTER VC, 1986, J CELL BIOL, V103, P2017, DOI 10.1083/jcb.103.5.2017; CHENEY RE, 1989, J BIOL CHEM, V264, P18068; CREUTZ CE, 1987, J BIOL CHEM, V262, P1860; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; CROMPTON MR, 1988, EMBO J, V7, P21, DOI 10.1002/j.1460-2075.1988.tb02779.x; CRUMPTON MJ, 1990, NATURE, V345, P212, DOI 10.1038/345212a0; DE BK, 1986, J BIOL CHEM, V261, P3784; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; ELINSON RP, 1980, S SOC DEV BIOL, V38, P217; ERICKSON E, 1984, MOL CELL BIOL, V4, P77; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; GEISOW MJ, 1986, NATURE, V320, P636, DOI 10.1038/320636a0; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GERKE V, 1985, J BIOL CHEM, V260, P1688; GERKE V, 1990, NUCLEIC ACIDS RES, V18, P4246, DOI 10.1093/nar/18.14.4246; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; GLENNEY J, 1986, P NATL ACAD SCI USA, V83, P4258, DOI 10.1073/pnas.83.12.4258; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; GLENNEY JR, 1986, J BIOL CHEM, V261, P485; GOULD KL, 1984, J CELL BIOL, V98, P487, DOI 10.1083/jcb.98.2.487; GOULD KL, 1986, MOL CELL BIOL, V6, P2738, DOI 10.1128/MCB.6.7.2738; GREENBERG ME, 1983, CELL, V33, P767, DOI 10.1016/0092-8674(83)90019-3; GREENBERG ME, 1984, J CELL BIOL, V98, P473, DOI 10.1083/jcb.98.2.473; HORSEMAN ND, 1989, MOL ENDOCRINOL, V3, P773, DOI 10.1210/mend-3-5-773; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; JOHNSSON N, 1988, EMBO J, V7, P2435, DOI 10.1002/j.1460-2075.1988.tb03089.x; JOHNSSON N, 1986, EMBO J, V5, P3455, DOI 10.1002/j.1460-2075.1986.tb04669.x; JOHNSTON PA, 1990, J BIOL CHEM, V265, P11382; KEUTZER JC, 1990, EXP CELL RES, V188, P153, DOI 10.1016/0014-4827(90)90291-H; KRISTENSEN T, 1986, BIOCHEMISTRY-US, V25, P4497, DOI 10.1021/bi00364a007; MARK GE, 1987, MOL CELL BIOL, V7, P2134, DOI 10.1128/MCB.7.6.2134; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; RADKE K, 1980, CELL, V21, P821, DOI 10.1016/0092-8674(80)90445-6; RADKE K, 1979, P NATL ACAD SCI USA, V76, P5612; ROBITZKI A, 1990, BIOCHEM J, V271, P415, DOI 10.1042/bj2710415; ROSENTHAL ET, 1987, DEV BIOL, V121, P237, DOI 10.1016/0012-1606(87)90155-2; RUDERMAN JV, 1979, DEV BIOL, V71, P71, DOI 10.1016/0012-1606(79)90083-6; SARIS CJM, 1986, CELL, V46, P201, DOI 10.1016/0092-8674(86)90737-3; SCHLAEPFER DD, 1990, J CELL BIOL, V111, P229, DOI 10.1083/jcb.111.1.229; TAKEICHI T, 1984, J EMBRYOL EXP MORPH, V81, P1; TURNER PR, 1984, NATURE, V310, P414, DOI 10.1038/310414a0; VINCENT JP, 1987, DEV BIOL, V123, P526, DOI 10.1016/0012-1606(87)90411-8; WALLNER BP, 1986, NATURE, V320, P77, DOI 10.1038/320077a0; WEBER K, 1987, EMBO J, V6, P1599, DOI 10.1002/j.1460-2075.1987.tb02406.x; YISRAELI JK, 1990, DEVELOPMENT, V108, P289; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	55	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18560	18566						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1833398				2022-12-25	WOS:A1991GJ47200027
J	WU, YJ; NOGUCHI, CT				WU, YJ; NOGUCHI, CT			ACTIVATION OF GLOBIN GENE-EXPRESSION BY CDNAS FROM INDUCED K562 CELLS - EVIDENCE FOR INVOLVEMENT OF FERRITIN IN GLOBIN GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-RESPONSIVE ELEMENT; MAMMALIAN-CELLS; MESSENGER-RNA; ERYTHROLEUKEMIA-CELLS; MOLECULAR-CLONING; BINDING PROTEINS; LEUKEMIC-CELL; HEAVY-CHAIN; TRANSCRIPTION; DNA	We have isolated non-globin cDNA clones specific for erythroid differentiation from K562 human erythroleukemia cells and have identified those that may regulate globin gene transcription. A cDNA library was constructed from K562 cells induced by hemin for production of embryonic and fetal hemoglobins and screened against cDNA from uninduced K562 cells. Full-length clones specific for induced K562 cells were ligated into a eukaryotic expression vector and transfected into HeLa cells to allow for production of the corresponding coded polypeptide. The ability to increase epsilon- or gamma-globin promoter activity was identified using cotransfection with a second vector containing a globin gene promoter fused to a reporter gene. Six of the induced K562-specific clones exhibited the ability to increase the levels of the reporter genes, bacterial chloramphenicol acetyltransferase and human growth hormone. Sequencing analyses of these clones indicated that five were homologous to ferritin heavy and light chains and one had no homology with known DNA or protein sequences. The ferritin light chain cDNA had the greatest effect on globin gene promoter activation, increasing the gamma-globin promoter activity by 6-8-fold. The activation of the globin gene promoter in the absence of globin gene translation suggests that ferritin (or iron) may have a direct role in globin gene transcription. The subtractive library cloning strategy has enabled us to isolate cDNA clones that activate specific gene promoters without the requirement of direct DNA binding. This approach may allow further identification of the genes encoding proteins that are involved in the control of erythropoiesis.	NIDDKD,CHEM BIOL LAB,BLDG 10,RM 9N307,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BARON MH, 1986, CELL, V46, P591, DOI 10.1016/0092-8674(86)90885-8; BAZETTJONES DP, 1985, NATURE, V371, P824; BENZ EJ, 1980, P NATL ACAD SCI-BIOL, V77, P3509, DOI 10.1073/pnas.77.6.3509; BODINE DM, 1987, EMBO J, V6, P2997, DOI 10.1002/j.1460-2075.1987.tb02605.x; BOYD D, 1985, J BIOL CHEM, V260, P1755; CHARNAY P, 1985, MOL CELL BIOL, V5, P1498, DOI 10.1128/MCB.5.6.1498; CHOU CC, 1986, MOL CELL BIOL, V6, P566, DOI 10.1128/MCB.6.2.566; COLLINS FS, 1985, NATURE, V313, P323; COSTANZO F, 1986, NUCLEIC ACIDS RES, V14, P721, DOI 10.1093/nar/14.2.721; DEAN A, 1985, EXPT APPROACHES STUD, P205; DICKEY LF, 1987, J BIOL CHEM, V262, P7901; DRYSDALE JW, 1988, PROG NUCLEIC ACID RE, V35, P127, DOI 10.1016/S0079-6603(08)60612-1; EMERSON BM, 1989, CELL, V57, P1189, DOI 10.1016/0092-8674(89)90056-1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORDIS CM, 1984, P NATL ACAD SCI-BIOL, V81, P4485, DOI 10.1073/pnas.81.14.4485; FORNACE AJ, 1986, NUCLEIC ACIDS RES, V14, P5793, DOI 10.1093/nar/14.14.5793; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSS M, 1971, J BIOL CHEM, V246, P2480; GROUDINE M, 1983, P NATL ACAD SCI-BIOL, V80, P7551, DOI 10.1073/pnas.80.24.7551; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; HENTZE MW, 1986, P NATL ACAD SCI USA, V83, P7226, DOI 10.1073/pnas.83.19.7226; HESSE JE, 1986, P NATL ACAD SCI USA, V83, P4312, DOI 10.1073/pnas.83.12.4312; HRINDA ME, 1969, BIOCHIM BIOPHYS ACTA, V195, P165, DOI 10.1016/0005-2787(69)90613-3; KAVATHAS P, 1984, P NATL ACAD SCI-BIOL, V81, P7688, DOI 10.1073/pnas.81.24.7688; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MATTIA E, 1986, J BIOL CHEM, V261, P4587; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUSHINSKI JF, 1980, P NATL ACAD SCI-BIOL, V77, P7405, DOI 10.1073/pnas.77.12.7405; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROUAULT TA, 1987, P NATL ACAD SCI USA, V84, P6335, DOI 10.1073/pnas.84.18.6335; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; STAMATOYANNOPOU.G, 1987, MOL BASIS BLOOD DISE, P66; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; THIEL EC, 1990, ADV ENZYMOL RELAT AR, V63, P421; TORTI SV, 1988, J BIOL CHEM, V263, P12638; TRAINOR CD, 1990, NATURE, V343, P92, DOI 10.1038/343092a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; URSINI MV, 1988, BIOCHEM BIOPH RES CO, V150, P287, DOI 10.1016/0006-291X(88)90518-9; WADA Y, 1988, J BIOL CHEM, V263, P12142; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; WRIGHTON N, 1988, MOL CELL BIOL, V8, P130, DOI 10.1128/MCB.8.1.130; YOUNG K, 1985, NUCLEIC ACIDS RES, V13, P5203, DOI 10.1093/nar/13.14.5203	49	17	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17566	17572						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1840594				2022-12-25	WOS:A1991GF44500087
J	GERARDYSCHAHN, R; MITTRUCKER, HW; SCHULTZE, U; FLEISCHER, B				GERARDYSCHAHN, R; MITTRUCKER, HW; SCHULTZE, U; FLEISCHER, B			SELECTIVE LOSS OF PERTUSSIS TOXIN-SENSITIVE G-PROTEINS FROM THE PLASMA-MEMBRANE AFTER ANTIBODY-INDUCED INTERNALIZATION OF T-CELL SURFACE MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR CD3 COMPLEX; HUMAN LYMPHOCYTES-T; MONOCLONAL-ANTIBODIES; CHOLERA-TOXIN; INDUCED MODULATION; ANTIGENIC MODULATION; ACTIVATION; PATHWAY; EXPRESSION; BINDING	Antibody-induced antigenic modulation occurs after binding of antibodies to a variety of cell surface proteins. It is characterized by aggregation and subsequent loss of the molecules from the cell surface, usually by internalization. In this study we have investigated the effect of modulation of the T-cell antigen receptor complex (TCR) and the transferrin receptor (TFR) on the distribution of cholera toxin (CTx)- and pertussis toxin (PTx)-sensitive GTP binding proteins in human T-lymphocytes. Modulation of both the TCR and the TFR induced a selective shift of PTx-sensitive G-proteins from the plasma membrane to a high density membrane fraction enriched for lysosomal membranes. The distribution of CTx-sensitive G-proteins was unaffected. This shift was found in both the T-cell leukemia line Jurkat and in normal T-cells. The loss of PTx-sensitive G-proteins from the plasma membrane required approximately 15 h to be complete and was not inhibited by cycloheximide. It had no influence on T-cell triggering via anti-T-cell receptor antibodies and is unrelated to the inactivating effect of TCR-modulation on T-cell signalling. The loss of PTx-sensitive G-proteins was not accompanied by greater sensitivity to stimuli raising cAMP concentration. These results show that PTx-sensitive G-proteins can be selectively depleted from the plasma membrane by antibody treatment of T-cells.	UNIV MAINZ,DEPT MED 1,PATHOPHYSIOL SECT,W-6500 MAINZ,GERMANY	Johannes Gutenberg University of Mainz								ANDERSON DL, 1989, J IMMUNOL, V143, P3647; AUSSEL C, 1988, J IMMUNOL, V140, P215; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL M, 1986, J IMMUNOL, V136, P2983; CASS CE, 1977, CANCER RES, V37, P3314; CATT KJ, 1979, NATURE, V280, P109, DOI 10.1038/280109a0; DEAN MF, 1982, BIOCHIM BIOPHYS ACTA, V721, P441, DOI 10.1016/0167-4889(82)90100-8; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; Fiske CH, 1925, J BIOL CHEM, V66, P375; FLEISCHER B, 1986, J IMMUNOL, V136, P1625; FLEISCHER B, 1988, J IMMUNOL, V141, P1103; FUJINAMI RS, 1984, J IMMUNOL, V132, P2618; GREEN A, 1990, J BIOL CHEM, V265, P5206; GUNTER KC, 1987, NATURE, V326, P505, DOI 10.1038/326505a0; HARAGUCHI K, 1990, P NATL ACAD SCI USA, V87, P1208, DOI 10.1073/pnas.87.3.1208; HOLTER W, 1988, J IMMUNOL, V140, P1043; IMBODEN JB, 1986, P NATL ACAD SCI USA, V83, P5673, DOI 10.1073/pnas.83.15.5673; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KAHN CR, 1977, J CLIN INVEST, V60, P1094, DOI 10.1172/JCI108861; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; KIM DK, 1988, J IMMUNOL, V141, P3429; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANNERON A, 1978, J CELL BIOL, V77, P211; MEUER SC, 1984, P NATL ACAD SCI-BIOL, V81, P1509, DOI 10.1073/pnas.81.5.1509; MORETTA A, 1986, EUR J IMMUNOL, V16, P1427, DOI 10.1002/eji.1830161118; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUSTELIN T, 1986, EMBO J, V5, P3287, DOI 10.1002/j.1460-2075.1986.tb04641.x; OLD LJ, 1968, J EXP MED, V127, P523, DOI 10.1084/jem.127.3.523; OROURKE EJ, 1983, MOL CELL BIOL, V3, P1580, DOI 10.1128/MCB.3.9.1580; PANTALEO G, 1987, J EXP MED, V166, P619, DOI 10.1084/jem.166.2.619; PESANDO JM, 1986, J IMMUNOL, V137, P3689; REINHERZ EL, 1982, CELL, V30, P735, DOI 10.1016/0092-8674(82)90278-1; RIBEIRONETO F, 1987, MOL ENDOCRINOL, V1, P472, DOI 10.1210/mend-1-7-472; ROSENBERG SA, 1984, SCIENCE, V223, P1412, DOI 10.1126/science.6367046; SCHREIBER AB, 1981, P NATL ACAD SCI-BIOL, V78, P7535, DOI 10.1073/pnas.78.12.7535; SCHREZENMEIER H, 1988, J EXP MED, V168, P817, DOI 10.1084/jem.168.2.817; SOMMERMEYER H, 1990, EUR J IMMUNOL, V20, P1881, DOI 10.1002/eji.1830200902; TAKAYAMA H, 1988, J BIOL CHEM, V263, P2330	38	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6942	6947						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1826680				2022-12-25	WOS:A1991FG72700049
J	LEBWOHL, DE; NUNEZ, I; CHAN, M; ROSEN, OM				LEBWOHL, DE; NUNEZ, I; CHAN, M; ROSEN, OM			EXPRESSION OF INDUCIBLE MEMBRANE-ANCHORED INSULIN-RECEPTOR KINASE ENHANCES DEOXYGLUCOSE UPTAKE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; ANTIBODY; FAMILY; VIRUS; GENE	We have transfected mouse L cells with a recombinant membrane-anchored insulin receptor kinase (called MARK), under the transcriptional control of a glucocorticoid-responsive element. The transfected construct includes only 15 extracellular residues, with the transmembrane in intracellular kinase domains of the human insulin receptor cDNA (amino acid residues -27 to 12 and 915 to 1343 (see Ullrich, A., Bell, J. R., Chen, E. Y., Herrera, R., Petruzzelli, L. M., Dull, T.J., Gray, A., Coussens, L., Liao, Y.C., Tsubokawa, M. Mason, A., Seeburg, P. H., Grunfeld, C., Rosen, O. M., and Ramachandran, J. (1985) Nature 313, 756-761), predicted M(r) = 56,000 with signal sequence, 53,000 without). Transfected cells which are exposed to dexamethasone express two proteins of approximate M(r) = 54,000 which (a) react with anti-peptide antisera raised to human insulin receptor sequences, (b) localize to the membrane fraction, and (c) possess ligand (insulin)-independent tyrosine kinase activity. In extracts of steroid-treated MARK cells, a phosphotyrosine-containing protein of M(r) = 185,000 is detected, which corresponds in size to a known endogenous substrate for the insulin receptor. Control studies were performed with the nontransfected parent line, and with L cells transfected with an inactive human insulin receptor protein tyrosine kinase. Dexamethasone induced no change in the proteins detected by an antiphosphotyrosine antibody in the two control lines. In studies of deoxyglucose uptake, dexamethasone stimulated increase in deoxyglucose uptake 2-fold in the MARK cells compared to the same cell studied in the absence of dexamethasone. Dexamethasone had no effect in the control cell lines. These studies demonstrate that a membrane-anchored insulin receptor kinase, devoid of virtually the entire extracellular domain of the insulin receptor, is sufficient to induce enhanced deoxyglucose uptake.	MEM SLOAN KETTERING CANC CTR,DIV SOLID TUMOR ONCOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	LEBWOHL, DE (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NIDDK NIH HHS [B1 K11DK01799] Funding Source: Medline; NIGMS NIH HHS [GM 35158] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK001799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035158] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHOU CK, 1987, J BIOL CHEM, V262, P1842; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1987, MOL ENDOCRINOL, V1, P15, DOI 10.1210/mend-1-1-15; HERRERA R, 1988, J BIOL CHEM, V263, P5560; HERRERA R, 1985, P NATL ACAD SCI USA, V82, P7899, DOI 10.1073/pnas.82.23.7899; MAJORS JE, 1981, NATURE, V289, P253, DOI 10.1038/289253a0; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG LH, 1987, P NATL ACAD SCI USA, V84, P5725, DOI 10.1073/pnas.84.16.5725; WHITE MF, 1987, J BIOL CHEM, V262, P9769; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X	13	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					386	390						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1845969				2022-12-25	WOS:A1991EQ33900056
J	STRAKA, JG; BLOOMER, JR; KEMPNER, ES				STRAKA, JG; BLOOMER, JR; KEMPNER, ES			THE FUNCTIONAL SIZE OF FERROCHELATASE DETERMINED INSITU BY RADIATION INACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PROTOPORPHYRIA; LIVER-FERROCHELATASE; MOUSE FERROCHELATASE; BICINCHONINIC ACID; MOLECULAR-CLONING; TARGET ANALYSIS; PURIFICATION; HEME; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; EXPRESSION	Ferrochelatase (EC 4.99.1.1) catalyzes the final step of heme biosynthesis, the insertion of iron(II) into protoporphyrin. It is an integral protein of the inner mitochondrial membrane. The functional size of bovine hepatic ferrochelatase has been studied in situ using radiation inactivation analysis. The functional unit required for enzymic activity in intact mitochondria was found to have a mass of 82 +/- 13 kDa. In contrast, the structural unit (evaluated in immunoblots following sodium dodecyl sulfate-polyacrylamide gel electrophoresis) has a mass of 40 +/- 10 kDa. Similar results were obtained when irradiation was performed on sodium cholate-solubilized mitochondria. The presence or absence of dithiothreitol during irradiation had no effect on target sizes obtained from either intact or solubilized mitochondria. Pairwise comparison of the functional and structural target sizes from each set of irradiated samples yielded a ratio of 2.0 +/- 0.4. Previous studies using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and gel filtration chromatography have shown that a M(r) 40,000 peptide is associated with ferrochelatase activity. This study shows that the functional size of bovine ferrochelatase is approximately 80 kDa; the data are most consistent with a model for active ferrochelatase composed of two structural subunits of about 40 kDa each.	NIAMSD, PHYS BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	STRAKA, JG (corresponding author), UNIV MINNESOTA, SCH MED, DEPT MED, DIGHT LABS, 400 CHURCH ST SE, MINNEAPOLIS, MN 55455 USA.				NIDDK NIH HHS [DK-26466] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026466, R37DK026466] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLOOMER JR, 1982, AM J HUM GENET, V34, P322; BLOOMER JR, 1987, J BIOL CHEM, V262, P667; BONKOWSKY HL, 1975, J CLIN INVEST, V56, P1139, DOI 10.1172/JCI108189; BRENNER DA, 1991, P NATL ACAD SCI USA, V88, P849, DOI 10.1073/pnas.88.3.849; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CODDINGTON A, 1966, J MOL BIOL, V17, P503, DOI 10.1016/S0022-2836(66)80160-2; DAILEY HA, 1989, BIOCHIM BIOPHYS ACTA, V999, P7, DOI 10.1016/0167-4838(89)90021-6; DAILEY HA, 1983, J BIOL CHEM, V258, P1453; DAILEY HA, 1984, J BIOL CHEM, V259, P2711; FARMER EE, 1984, ANAL BIOCHEM, V141, P79, DOI 10.1016/0003-2697(84)90428-7; HANSON JW, 1984, BIOCHEM J, V222, P695, DOI 10.1042/bj2220695; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; HARMON JT, 1985, METHOD ENZYMOL, V117, P65; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; JONES MS, 1969, BIOCHEM J, V113, P507, DOI 10.1042/bj1130507; KEMPNER ES, 1979, ANAL BIOCHEM, V92, P2, DOI 10.1016/0003-2697(79)90617-1; KEMPNER ES, 1988, ADV ENZYMOL RAMB, V61, P107; KEMPNER ES, 1986, ANAL BIOCHEM, V156, P140, DOI 10.1016/0003-2697(86)90165-X; KEMPNER ES, 1989, METHOD ENZYMOL, V172, P410; KOOLS AM, 1989, HEPATOLOGY, V9, P557, DOI 10.1002/hep.1840090409; LABBEBOIS R, 1990, J BIOL CHEM, V265, P7278; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATHEWSROTH MM, 1987, ARCH DERMATOL, V123, P429, DOI 10.1001/archderm.123.4.429; MCINTYRE JO, 1985, ANAL BIOCHEM, V147, P468, DOI 10.1016/0003-2697(85)90300-8; NAKAHASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P748, DOI 10.1016/S0006-291X(05)80099-3; RUTH GR, 1977, SCIENCE, V198, P199, DOI 10.1126/science.905823; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRAKA JG, 1991, AM J HUM GENET, V48, P72; TAKETANI S, 1982, EUR J BIOCHEM, V127, P443; TAKETANI S, 1990, J BIOL CHEM, V265, P19377; TAKETANI S, 1981, J BIOL CHEM, V256, P2748; TANAKA S, 1976, J BIOCHEM-TOKYO, V80, P1067, DOI 10.1093/oxfordjournals.jbchem.a131362	32	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24637	24641						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761561				2022-12-25	WOS:A1991GW84500062
J	KILEY, SC; PARKER, PJ; FABBRO, D; JAKEN, S				KILEY, SC; PARKER, PJ; FABBRO, D; JAKEN, S			DIFFERENTIAL REGULATION OF PROTEIN-KINASE-C ISOZYMES BY THYROTROPIN-RELEASING-HORMONE IN GH4C1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PITUITARY-CELLS; PHORBOL ESTER RECEPTOR; PLATELET-ACTIVATING FACTOR; DOWN-REGULATION; GH3 CELLS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; INDEPENDENT ACTIVATION; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; FOCAL CONTACTS	GH4C1 cells, which express Ca+-dependent alpha- and beta- as well as Ca2+-independent gamma-, epsilon- and zeta-protein kinase C (PKC) isozymes, provide a cell culture model for studying isozyme-specific properties and functions. Hormonal activation of PKCs regulates the differentiated functions of these cells, namely secretion and synthesis of prolactin (PRL). We previously reported that thyrotropin-releasing hormone (TRH) selectively down-modulates epsilon-PKC with no effect on alpha- or beta-PKCs (Kiley, S. C., Schaap, D., Parker, P., Hsieh, L.-L., and Jaken, S. (1990) J. Biol. Chem. 265, 15704-15712). We now extend those studies to explore the relationship between TRH-stimulated diacylglycerol (DAG) levels and epsilon-PKC down-modulation. TRH stimulates three distinct DAG phases in GH cells. Phase 1 DAG peaks at 15 s, is accompanied by a 6-fold increase in intracellular Ca2+, and causes the redistribution of alpha-, beta-, delta, and epsilon-PKC isozymes from a soluble to a detergent-insoluble particulate compartment. Phase 2 DAG peaks at 10 min, is not associated with a Ca2+ signal, and does not activate PKC by any criteria tested. Phase 3 DAG peaks at 6 h and is sustained through 12 h. This novel DAG phase is not associated with increased intracellular Ca2+. The time course of phase 3 DAG formation corresponds to the time course of TRH-stimulated epsilon-PKC down-regulation; maximal effects are observed at 6-12 h for both events. Unlike alpha-, beta-, and delta-PKCs which are preferentially distributed in the soluble fraction of resting GH cells, epsilon-PKC is also distributed in the detergent-insoluble particulate fraction. The selective compartmentilization of epsilon-PKC in the particulate fraction may render this pool uniquely susceptible to proteolytic degradation. The time course of phase 3 DAG formation and epsilon-PKC down-modulation corresponds to the time course of decreasing PRL message synthesis in GH4 cells. The data suggests that loss of epsilon-PKC may be associated with the down-regulation of prolactin synthesis and that regulation of PRL gene transcription may be an epsilon-PKC-specific function in GH cells.	W ALTON JONES CELL SCI CTR,10 OLD BARN RD,LAKE PLACID,NY 12946; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; CIBA GEIGY AG,DIV PHARMACEUT,CH-4002 BASEL,SWITZERLAND	Cancer Research UK; Novartis	JAKEN, S (corresponding author), W ALTON JONES CELL SCI CTR,10 OLD BARN RD,LAKE PLACID,NY 12946, USA.		Parker, Peter j/D-5192-2013	parker, peter/0000-0002-6218-2933	NCI NIH HHS [CA-37589, CA-53841] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053841, P01CA037589] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKITA Y, 1990, BIOCHEM BIOPH RES CO, V172, P184, DOI 10.1016/S0006-291X(05)80191-3; ALBERT PR, 1984, J BIOL CHEM, V259, P5827; ASE K, 1988, FEBS LETT, V236, P396, DOI 10.1016/0014-5793(88)80064-4; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORNER C, 1989, J BIOL CHEM, V264, P13902; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIDA K, 1986, J BIOL CHEM, V261, P3013; COOPER DR, 1987, J BIOL CHEM, V262, P3633; DANNIES PS, 1976, NATURE, V261, P707, DOI 10.1038/261707a0; DIAZGUERRA MJM, 1990, BIOCHEM J, V269, P163, DOI 10.1042/bj2690163; DRUMMOND AH, 1984, MOL PHARMACOL, V25, P201; DRUST DS, 1985, BIOCHEM BIOPH RES CO, V128, P531, DOI 10.1016/0006-291X(85)90079-8; FEARON CW, 1987, J BIOL CHEM, V262, P9515; FEARON CW, 1985, J BIOL CHEM, V260, P8366; FOURNIER A, 1987, NATURE, V330, P767, DOI 10.1038/330767a0; GERSHENGORN MC, 1986, ANNU REV PHYSIOL, V48, P515; GERSHENGORN MC, 1985, ENDOCRINOLOGY, V116, P591, DOI 10.1210/endo-116-2-591; HUANG FL, 1989, J BIOL CHEM, V264, P4238; HUANG KP, 1988, J BIOL CHEM, V263, P14839; HUANG KP, 1986, J BIOL CHEM, V261, P2134; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; IMAI A, 1986, P NATL ACAD SCI USA, V83, P8540, DOI 10.1073/pnas.83.22.8540; JAKEN S, 1985, ENDOCRINOLOGY, V117, P2293, DOI 10.1210/endo-117-6-2293; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JAKEN S, 1985, ENDOCRINOLOGY, V117, P2301, DOI 10.1210/endo-117-6-2301; JAKEN S, 1987, P NATL ACAD SCI USA, V84, P4418, DOI 10.1073/pnas.84.13.4418; KENNERLY DA, 1979, ANAL BIOCHEM, V98, P23; KILEY S, 1990, J BIOL CHEM, V265, P15704; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; KING WG, 1989, J BIOL CHEM, V264, P6070; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KONNO Y, 1989, J BIOCHEM-TOKYO, V106, P673, DOI 10.1093/oxfordjournals.jbchem.a122915; KOSHIYAMA H, 1991, BIOCHEM BIOPH RES CO, V177, P551, DOI 10.1016/0006-291X(91)92019-G; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LEACH KL, 1988, J BIOL CHEM, V263, P13223; MACPHEE CH, 1984, MOL PHARMACOL, V25, P193; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; MARTIN TFJ, 1990, J BIOL CHEM, V265, P7623; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; MITCHELL FE, 1989, BIOCHEM J, V261, P131, DOI 10.1042/bj2610131; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; MURDOCH GH, 1983, J BIOL CHEM, V258, P5329; NAOR Z, 1988, MOL ENDOCRINOL, V2, P1043, DOI 10.1210/mend-2-11-1043; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1990, J BIOL CHEM, V265, P22434; OSBORNE R, 1981, ENDOCRINOLOGY, V108, P1164, DOI 10.1210/endo-108-4-1164; PELECH SL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P100, DOI 10.1016/0167-4889(90)90179-H; POTTER E, 1981, P NATL ACAD SCI-BIOL, V78, P6662, DOI 10.1073/pnas.78.11.6662; PREISS J, 1986, J BIOL CHEM, V261, P8597; REBECCHI MJ, 1983, BIOCHEM J, V216, P287, DOI 10.1042/bj2160287; REBECCHI MJ, 1983, J BIOL CHEM, V258, P227; SAITO N, 1989, P NATL ACAD SCI USA, V86, P3409, DOI 10.1073/pnas.86.9.3409; SALARI H, 1990, BIOCHEM J, V267, P689, DOI 10.1042/bj2670689; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SEKIGUCHI K, 1988, J BIOCHEM-TOKYO, V103, P759, DOI 10.1093/oxfordjournals.jbchem.a122343; STRULOVICI B, 1991, J BIOL CHEM, V266, P168; TASHJIAN AH, 1971, BIOCHEM BIOPH RES CO, V43, P516, DOI 10.1016/0006-291X(71)90644-9; USUDA N, 1991, J CELL BIOL, V112, P1241, DOI 10.1083/jcb.112.6.1241; VANDEMOORTELE S, 1991, J CELL SCI, V99, P79; WEINBERG JM, 1989, AM J PHYSIOL, V256, pC967, DOI 10.1152/ajpcell.1989.256.5.C967; WELSH CJ, 1991, ANAL BIOCHEM, V192, P281, DOI 10.1016/0003-2697(91)90537-4; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YANG HC, 1989, EXP CELL RES, V183, P36, DOI 10.1016/0014-4827(89)90416-3; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	71	131	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23761	23768						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748652				2022-12-25	WOS:A1991GV31900038
J	NAGAI, K; HECHT, SM				NAGAI, K; HECHT, SM			SITE-SPECIFIC DNA CLEAVAGE BY ANTISENSE OLIGONUCLEOTIDES COVALENTLY LINKED TO PHENAZINE DI-N-OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; SEQUENCE-SPECIFIC CLEAVAGE; HUMAN IMMUNODEFICIENCY VIRUS; TARGETED IRREVERSIBLE INHIBITORS; CHRONICALLY INFECTED-CELLS; NUCLEOSIDE H-PHOSPHONATES; 1,10-PHENANTHROLINE COPPER; NUCLEIC-ACIDS; OLIGODEOXYRIBONUCLEOSIDE METHYLPHOSPHONATES; HYDROGENPHOSPHONATE APPROACH	Site-specific degradation of DNA was achieved by the use of DNA oligonucleotides covalently tethered to phenazine 5,10-di-N-oxide. When annealed to a complementary DNA target strand, the antisense oligonucleotide effected alkylation of guanosine residues in proximity to the phenazine di-N-oxide prosthetic group. Admixture of dithiothreitol to the formed duplex resulted in reductive activation of the phenazine di-N-oxide moiety with concomitant generation of diffusible oxygen radicals; the latter effected strand scission of the target DNA oligonucleotide. Several parameters of DNA degradation were studied, including the effect on DNA degradation of chain length in the tether connecting the oligonucleotides and prosthetic group, the relative efficiencies of DNA cleavage when the prosthetic group was in the middle or at the end of the antisense oligonucleotide, and the effect of O2 on DNA degradation. Also studied was the actual chemistry of DNA oligonucleotide degradation and the ability of individual diastereomers of the modified oligonucleotides to mediate degradation of the target DNA.	UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22901; UNIV VIRGINIA,DEPT BIOL,CHARLOTTESVILLE,VA 22901	University of Virginia; University of Virginia	HECHT, SM (corresponding author), UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22901, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027185] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 27185] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGRAWAL S, 1989, P NATL ACAD SCI USA, V86, P7790, DOI 10.1073/pnas.86.20.7790; AGRAWAL S, 1990, TETRAHEDRON LETT, V31, P1543, DOI 10.1016/0040-4039(90)80011-A; AGRIS CH, 1986, BIOCHEMISTRY-US, V25, P6268, DOI 10.1021/bi00368a065; ASSELINE U, 1984, EMBO J, V3, P795, DOI 10.1002/j.1460-2075.1984.tb01887.x; ATHERTON FA, 1944, J CHEM SOC, V76, P660; BAKER BF, 1989, J AM CHEM SOC, V111, P2700, DOI 10.1021/ja00189a054; BOIDOTFORGET M, 1988, GENE, V72, P361, DOI 10.1016/0378-1119(88)90163-1; BUCK HM, 1990, SCIENCE, V248, P208, DOI 10.1126/science.2326635; CARTER BJ, 1991, J AM CHEM SOC, V113, P5099; CHEN CHB, 1988, J AM CHEM SOC, V110, P6570, DOI 10.1021/ja00227a052; CHEN CHB, 1986, P NATL ACAD SCI USA, V83, P7147, DOI 10.1073/pnas.83.19.7147; CHU BCF, 1985, P NATL ACAD SCI USA, V82, P963, DOI 10.1073/pnas.82.4.963; DERVAN PB, 1986, SCIENCE, V232, P464, DOI 10.1126/science.2421408; DREYER GB, 1985, P NATL ACAD SCI USA, V82, P968, DOI 10.1073/pnas.82.4.968; ESSIGMANN JM, 1977, P NATL ACAD SCI USA, V74, P1870, DOI 10.1073/pnas.74.5.1870; FRANCOIS JC, 1988, BIOCHEMISTRY-US, V27, P2272, DOI 10.1021/bi00407a004; FROEHLER BC, 1986, NUCLEIC ACIDS RES, V14, P5399, DOI 10.1093/nar/14.13.5399; GAREGG PJ, 1986, TETRAHEDRON LETT, V27, P4055, DOI 10.1016/S0040-4039(00)84909-6; GAREGG PJ, 1986, TETRAHEDRON LETT, V27, P4051, DOI 10.1016/S0040-4039(00)84908-4; HELENE C, 1985, BIOCHIMIE, V67, P777, DOI 10.1016/S0300-9084(85)80167-X; HENNER WD, 1983, J BIOL CHEM, V258, P711; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HOGREFE HH, 1990, J BIOL CHEM, V265, P5561; ITAKURA K, 1984, ANNU REV BIOCHEM, V53, P323; IVERSON BL, 1988, P NATL ACAD SCI USA, V85, P4615, DOI 10.1073/pnas.85.13.4615; IVERSON BL, 1987, J AM CHEM SOC, V109, P1241, DOI 10.1021/ja00238a041; JAGER A, 1988, BIOCHEMISTRY-US, V27, P7237, DOI 10.1021/bi00419a010; JAYARAMAN K, 1981, P NATL ACAD SCI-BIOL, V78, P1537, DOI 10.1073/pnas.78.3.1537; JOHNSON MT, 1986, BIOTECHNIQUES, V4, P46; KNORRE DG, 1985, ADV ENZYME REGUL, V24, P277, DOI 10.1016/0065-2571(85)90082-2; KNORRE DG, 1985, PROG NUCLEIC ACID RE, V32, P291, DOI 10.1016/S0079-6603(08)60352-9; LEE BL, 1988, BIOCHEMISTRY-US, V27, P3197, DOI 10.1021/bi00409a011; LEE M, 1988, NUCLEIC ACIDS RES, V16, P665, DOI 10.1093/nar/16.2.665; LESKO SA, 1980, BIOCHEMISTRY-US, V19, P3023, DOI 10.1021/bi00554a029; LETSINGER RL, 1988, J AM CHEM SOC, V110, P4470, DOI 10.1021/ja00221a089; LETSINGER RL, 1981, J AM CHEM SOC, V103, P7394, DOI 10.1021/ja00414a086; LIN SB, 1989, BIOCHEMISTRY-US, V28, P1045; MARUGG JE, 1986, TETRAHEDRON LETT, V27, P2661, DOI 10.1016/S0040-4039(00)84611-0; MATSUKURA M, 1989, P NATL ACAD SCI USA, V86, P4244, DOI 10.1073/pnas.86.11.4244; Maxam A M, 1980, Methods Enzymol, V65, P499; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MEYER RB, 1989, J AM CHEM SOC, V111, P8517, DOI 10.1021/ja00204a034; NISHIKAWA K, 1982, J AM CHEM SOC, V104, P326, DOI 10.1021/ja00365a076; PACHTER IJ, 1952, J AM CHEM SOC, V74, P971, DOI 10.1021/ja01124a030; POVSIC TJ, 1990, J AM CHEM SOC, V112, P9428, DOI 10.1021/ja00181a075; REESE CB, 1978, TETRAHEDRON, V34, P3143, DOI 10.1016/0040-4020(78)87013-6; SANGER F, 1977, NATURE, V265, P687, DOI 10.1038/265687a0; SANKAR S, 1989, EUR J BIOCHEM, V184, P39, DOI 10.1111/j.1432-1033.1989.tb14987.x; SMITH CC, 1986, P NATL ACAD SCI USA, V83, P2787, DOI 10.1073/pnas.83.9.2787; STEIN CA, 1988, CANCER RES, V48, P2659; STILL WC, 1978, J ORG CHEM, V43, P2923, DOI 10.1021/jo00408a041; STILL WC, 1988, MACROMODEL VERSION 2; SUGIYAMA H, 1988, BIOCHEMISTRY-US, V27, P58, DOI 10.1021/bi00401a011; SUN JS, 1988, BIOCHEMISTRY-US, V27, P6039, DOI 10.1021/bi00416a032; THUONG NT, 1987, P NATL ACAD SCI USA, V84, P5129, DOI 10.1073/pnas.84.15.5129; TOULME JJ, 1988, GENE, V72, P51, DOI 10.1016/0378-1119(88)90127-8; UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001; VERSPIEREN P, 1987, GENE, V61, P307, DOI 10.1016/0378-1119(87)90194-6; VIVIAN DL, 1951, J AM CHEM SOC, V73, P457, DOI 10.1021/ja01145a146; VLASSOV VV, 1985, ADV ENZYME REGUL, V24, P301, DOI 10.1016/0065-2571(85)90083-4; WALLING C, 1975, ACCOUNTS CHEM RES, V8, P125, DOI 10.1021/ar50088a003; YOUNGQUIST RS, 1985, P NATL ACAD SCI USA, V82, P2565, DOI 10.1073/pnas.82.9.2565; ZAIA JA, 1988, J VIROL, V62, P3914, DOI 10.1128/JVI.62.10.3914-3917.1988; ZARYTOVA VF, 1986, BIOORG KHIM+, V12, P911; ZERIAL A, 1987, NUCLEIC ACIDS RES, V15, P9909, DOI 10.1093/nar/15.23.9909	65	32	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23994	24002						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748672				2022-12-25	WOS:A1991GV31900072
J	REMALEY, AT; UGORSKI, M; WU, N; LITZKY, L; BURGER, SR; MOORE, JS; FUKUDA, M; SPITALNIK, SL				REMALEY, AT; UGORSKI, M; WU, N; LITZKY, L; BURGER, SR; MOORE, JS; FUKUDA, M; SPITALNIK, SL			EXPRESSION OF HUMAN GLYCOPHORIN-A IN WILD-TYPE AND GLYCOSYLATION-DEFICIENT CHINESE-HAMSTER OVARY CELLS - ROLE OF NORMAL-LINKED AND ORTHO-LINKED GLYCOSYLATION IN CELL-SURFACE EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; HUMAN-ERYTHROCYTE-MEMBRANE; GOLGI VESICLE MEMBRANES; GDP-L-FUCOSE; PLASMODIUM-FALCIPARUM; BLOOD-GROUP; O-GLYCOSYLATION; MONOCLONAL-ANTIBODIES; SIALIC-ACID; G-PROTEIN	Glycophorin A, the most abundant sialoglycoprotein on human red blood cells, carries several medically important blood group antigens. To study the role of glycosylation in surface expression and antigenicity of this highly glycosylated protein (1 N-linked and 15 O-linked oligosaccharides), glycophorin A cDNA (M-allele) was expressed in Chinese hamster ovary (CHO) cells. Both wild type CHO cells and mutant CHO cells with well defined glycosylation defects were used. Glycophorin A was well expressed on the surface of transfected wild type CHO cells. On immunoblots, the CHO cells expressed monomer (approximately 38 kDa) and dimer forms of glycophorin A which co-migrated with human red blood cell glycophorin A. The transfected cells specificially expressed the M blood group antigen when tested with mouse monoclonal antibodies. Tunicamycin treatment of these CHO cells did not block surface expression of glycophorin A, indicating that, in the presence of normal O-linked glycosylation, the N-linked oligosaccharide is not required for surface expression. To study O-linked glycosylation, glycophorin A cDNA was transfected into the Lec 2, Lec 8, and ldlD glycosylation-deficient CHO cell lines. Glycophorin A with truncated O-linked oligosaccharides was well expressed on the surface of ldlD cells (cultured in the presence of N-acetylgalactosamine alone), Lec 2 cells, and Lec 8 cells with monomers of approximately 25 kDa, approximately 33 kDa, and approximately 25 kDa, respectively. In contrast, non-O-glycosylated glycophorin A (approximately 19-kDa monomers) was poorly expressed on the surface of ldlD cells cultured in the absence of both galactose and N-acetylgalactosamine. Thus, under these conditions, in the absence of O-linked glycosylation, the N-linked oligosaccharide itself is not able to support appropriate surface expression of glycophorin A in transfected CHO cells.	UNIV PENN,DEPT PATHOL & LAB MED,220 JOHN MORGAN BLDG,PHILADELPHIA,PA 19104; LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	University of Pennsylvania; Sanford Burnham Prebys Medical Discovery Institute	SPITALNIK, SL (corresponding author), UNIV PENN,DEPT PATHOL & LAB MED,220 JOHN MORGAN BLDG,PHILADELPHIA,PA 19104, USA.		Ugorsku, Maciej/AAJ-1050-2020	Ugorski, Maciej/0000-0003-0299-8372; Spitalnik, Steven/0000-0002-8528-4561	NCI NIH HHS [CA 45690, 5T32 CA09140-15, CA 33000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033000, R37CA033000, R29CA045690, T32CA009140] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANSTEE DJ, 1981, SEMIN HEMATOL, V18, P13; BASAK S, 1983, VIROLOGY, V128, P77, DOI 10.1016/0042-6822(83)90320-3; BIGBEE WL, 1984, J IMMUNOL, V133, P3149; BIGBEE WL, 1983, MOL IMMUNOL, V20, P1353, DOI 10.1016/0161-5890(83)90166-9; BLUMENFELD OO, 1978, P NATL ACAD SCI USA, V75, P2727, DOI 10.1073/pnas.75.6.2727; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRAY J, 1981, J IMMUNOL, V126, P1966; BREUER WV, 1983, INFECT IMMUN, V42, P133, DOI 10.1128/IAI.42.1.133-140.1983; BURGER SR, 1991, J GEN VIROL, V72, P359, DOI 10.1099/0022-1317-72-2-359; CARRAWAY KL, 1989, BIOESSAYS, V10, P117, DOI 10.1002/bies.950100406; DAHR W, 1975, VOX SANG, V29, P36, DOI 10.1111/j.1423-0410.1975.tb00475.x; DAHR W, 1984, EUR J BIOCHEM, V138, P259, DOI 10.1111/j.1432-1033.1984.tb07910.x; DAVIS CG, 1986, J BIOL CHEM, V261, P2828; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; ERNST LK, 1989, J BIOL CHEM, V264, P3436; FURTH HP, 1981, FUSION A, V1, P123; GAHMBERG CG, 1980, J BIOL CHEM, V255, P2169; GIBSON R, 1978, CELL, V13, P671, DOI 10.1016/0092-8674(78)90217-9; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HADLEY TJ, 1986, ANNU REV MICROBIOL, V40, P451, DOI 10.1146/annurev.mi.40.100186.002315; HOLT EH, 1989, AM J TROP MED HYG, V40, P245, DOI 10.4269/ajtmh.1989.40.245; JASKIEWICZ E, 1990, GLYCOCONJUGATE J, V7, P255, DOI 10.1007/BF01050609; JOKINEN M, 1985, J BIOL CHEM, V260, P1314; KIM YD, 1980, VOX SANG, V39, P162, DOI 10.1111/j.1423-0410.1980.tb01852.x; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZARSKY K, 1988, P NATL ACAD SCI USA, V85, P4335, DOI 10.1073/pnas.85.12.4335; KOZARSKY KF, 1988, MOL CELL BIOL, V8, P3357, DOI 10.1128/MCB.8.8.3357; KRIEGER M, 1989, METHODS CELL BIOL B, V32, P58; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LEAVITT R, 1977, J BIOL CHEM, V252, P9018; LISOWSKA E, 1978, EUR J BIOCHEM, V88, P247, DOI 10.1111/j.1432-1033.1978.tb12444.x; LOZZIO BB, 1981, P SOC EXP BIOL MED, V166, P546; LU YQ, 1987, BLOOD, V69, P618; LUBLIN DM, 1991, J CLIN INVEST, V87, P1945, DOI 10.1172/JCI115220; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MACHAMER CE, 1985, MOL CELL BIOL, V5, P3074, DOI 10.1128/MCB.5.11.3074; MACHAMER CE, 1988, J BIOL CHEM, V263, P5948; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; MITCHELL GH, 1986, BLOOD, V67, P1519; MORROW B, 1987, J BIOL CHEM, V262, P13812; PASVOL G, 1982, LANCET, V2, P947; PERKINS M, 1981, J CELL BIOL, V90, P563, DOI 10.1083/jcb.90.3.563; PERKINS ME, 1988, MOL BIOCHEM PARASIT, V27, P23, DOI 10.1016/0166-6851(88)90021-7; PERKINS ME, 1989, EXP PARASITOL, V69, P94, DOI 10.1016/0014-4894(89)90175-6; PILLER V, 1990, J BIOL CHEM, V265, P9264; REARDEN A, 1987, VOX SANG, V52, P318, DOI 10.1111/j.1423-0410.1987.tb04900.x; REDDY P, 1989, J BIOL CHEM, V264, P17329; SADLER JE, 1979, J BIOL CHEM, V254, P2112; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SCHWARZ RT, 1982, METHOD ENZYMOL, V83, P432; SHIROISHI T, 1985, J IMMUNOL, V134, P623; SIEBERT PD, 1986, P NATL ACAD SCI USA, V83, P1665, DOI 10.1073/pnas.83.6.1665; SILBERSTEIN LE, 1988, ARCH BIOCHEM BIOPHYS, V264, P244, DOI 10.1016/0003-9861(88)90591-7; SILVER RE, 1987, ARCH BIOCHEM BIOPHYS, V256, P285, DOI 10.1016/0003-9861(87)90448-6; SNIDER MD, 1986, J CELL BIOL, V103, P265, DOI 10.1083/jcb.103.1.265; SODORA DL, 1989, J VIROL, V63, P5184, DOI 10.1128/JVI.63.12.5184-5193.1989; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; THOMAS DB, 1969, J BIOL CHEM, V244, P5943; TOMITA M, 1975, P NATL ACAD SCI USA, V72, P2964, DOI 10.1073/pnas.72.8.2964; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIGATA Y, 1987, J EXP MED, V165, P124, DOI 10.1084/jem.165.1.124; WALKER RH, 1990, TECHNICAL MANUAL; WERTZ GW, 1989, J VIROL, V63, P4767, DOI 10.1128/JVI.63.11.4767-4776.1989; WUNNER WH, 1980, J VIROL, V36, P133, DOI 10.1128/JVI.36.1.133-142.1980; YOSHIMA H, 1980, J BIOL CHEM, V255, P9713; ZANNI EE, 1989, J BIOL CHEM, V264, P9137	72	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					24176	24183						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748686				2022-12-25	WOS:A1991GV31900099
J	ELSHOLTZ, HP; LEW, AM; ALBERT, PR; SUNDMARK, VC				ELSHOLTZ, HP; LEW, AM; ALBERT, PR; SUNDMARK, VC			INHIBITORY CONTROL OF PROLACTIN AND PIT-1 GENE PROMOTERS BY DOPAMINE - DUAL SIGNALING PATHWAYS REQUIRED FOR D2 RECEPTOR-REGULATED EXPRESSION OF THE PROLACTIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; INOSITOL PHOSPHATE PRODUCTION; TRANSCRIPTION FACTORS; GROWTH-HORMONE; CYCLIC-AMP; MOLECULAR-CLONING; PITUITARY-CELLS; CA-2+ CHANNELS; POU-DOMAIN; RAT	Transcription of the prolactin gene is suppressed by dopaminergic activation of D2 receptors in pituitary lactotrophs. The mechanism of signal transduction at the nuclear level and the cell surface was examined in the dopamine-responsive GH4ZR7 cell line. Dopamine treatment caused a 40-50% decrease in endogenous prolactin mRNA that was specifically blocked by addition of (-)-sulpiride. To define dopamine-responsive elements, plasmids containing 5'-regulatory regions of the prolactin gene fused to the coding sequences for luciferase were transiently or stably transfected into GH4ZR7 cells. Chimeric transcripts initiated at the authentic transcription start site were regulated in a promoter-selective manner; dopamine or the agonist bromocryptine inhibited prolactin promoter (position -422) activity by 70%, but had no regulatory effects on other cellular or viral promoters. A shorter prolactin promoter (position -78) or a prolactin TATAA box linked to heterologous binding sites for transcription factor Pit-1 was sufficient to confer dopamine inhibition (40%). In addition to the prolactin promoter, we found that dopamine inhibited transcriptional activity of the Pit-1 promoter (positions -258 to +8) by 60%. Surprisingly, deletion of two cAMP response elements in the Pit-1 promoter only partially eliminated dopamine responsiveness. These data suggest that sequences in the Pit-1 promoter between positions -92 and +8, which include an autoregulatory Pit-1-binding site and the TATAA box, are sufficient for negative regulation. In this study, we also examined the signal transduction pathways that link D2 receptor activation and the inhibition of prolactin gene transcription. We found, as suggested in earlier studies, that a dopamine-dependent decrease in cAMP may be important for mediating negative regulation of transcription. However, high extracellular K+ concentrations that prevent dopamine effects on membrane potential and [Ca+]i, but not cAMP levels, completely blocked dopamine regulation of the prolactin promoter. This suggests that two distinct signaling pathways initiated at D2 receptors may be required for transcriptional regulation of the prolactin gene.	UNIV TORONTO, BANTING & BEST DIABET CTR, TORONTO M5G 1L5, ONTARIO, CANADA; MCGILL UNIV, DEPT PHARMACOL & THERAPEUT, MONTREAL H3G 1Y6, QUEBEC, CANADA	University of Toronto; McGill University	ELSHOLTZ, HP (corresponding author), UNIV TORONTO, DEPT CLIN BIOCHEM, 100 COLL ST, TORONTO M5G 1L5, ONTARIO, CANADA.		Albert, Paul/E-4804-2010	Albert, Paul/0000-0002-1809-3554				ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; ALBERT PR, 1990, J BIOL CHEM, V265, P2098; BANDYOPADHYAY SK, 1989, J BIOL CHEM, V264, P14216; BENJONATHAN N, 1985, ENDOCR REV, V6, P564, DOI 10.1210/edrv-6-4-564; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CAMPER SA, 1985, J BIOL CHEM, V260, P2246; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; CHIO CL, 1990, NATURE, V343, P266, DOI 10.1038/343266a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; DAVIS JRE, 1991, MOL ENDOCRINOL, V5, P8, DOI 10.1210/mend-5-1-8; DAVIS JRE, 1990, J ENDOCRINOL, V125, P171, DOI 10.1677/joe.0.1250171; DAY RN, 1990, MOL ENDOCRINOL, V4, P736, DOI 10.1210/mend-4-5-736; DAY RN, 1989, MOL ENDOCRINOL, V3, P3, DOI 10.1210/mend-3-1-3; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; DAY RN, 1989, J BIOL CHEM, V264, P431; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; ELSHOLTZ HP, 1990, GENE DEV, V4, P43, DOI 10.1101/gad.4.1.43; ENJALBERT A, 1990, J BIOL CHEM, V265, P18816; ENYEART JJ, 1990, J BIOL CHEM, V265, P16373; FOX SR, 1990, MOL ENDOCRINOL, V4, P1069, DOI 10.1210/mend-4-7-1069; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; INGRAHAM HA, 1990, ANNU REV PHYSIOL, V52, P773; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JACKSON AE, 1988, MOL ENDOCRINOL, V2, P1139, DOI 10.1210/mend-2-11-1139; KEECH CA, 1989, MOL ENDOCRINOL, V3, P832, DOI 10.1210/mend-3-5-832; LAVERRIERE JN, 1988, ENDOCRINOLOGY, V122, P333, DOI 10.1210/endo-122-1-333; LOGIN IS, 1986, AM J PHYSIOL, V250, pE731, DOI 10.1152/ajpendo.1986.250.6.E731; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MAURER RA, 1981, NATURE, V294, P94, DOI 10.1038/294094a0; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MONSMA FJ, 1989, NATURE, V342, P926, DOI 10.1038/342926a0; MUELLER SG, 1989, MOL ENDOCRINOL, V3, P976, DOI 10.1210/mend-3-6-976; MURDOCH GH, 1982, SCIENCE, V218, P1315, DOI 10.1126/science.6293056; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; PRITCHETT DB, 1987, P NATL ACAD SCI USA, V84, P5545, DOI 10.1073/pnas.84.16.5545; RAMPYRAI HR, 1991, MOL ENDOCRINOL, V5, P514; ROSENFELD MG, 1988, COLD SPRING HARB SYM, V53, P545, DOI 10.1101/SQB.1988.053.01.063; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SHARP ZD, 1989, NUCLEIC ACIDS RES, V17, P2705, DOI 10.1093/nar/17.7.2705; SHULL JD, 1986, VITAM HORM, V43, P197; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; Tashjian A H Jr, 1979, Methods Enzymol, V58, P527; VALLAR L, 1988, J BIOL CHEM, V263, P10127; VALLAR L, 1990, J BIOL CHEM, V265, P10320; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; WHITE BA, 1981, J BIOL CHEM, V256, P5942; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0; ZHOU XM, 1990, EUR J PHARM-MOLEC PH, V189, P327, DOI 10.1016/0922-4106(90)90126-I	59	111	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22919	22925						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1835974				2022-12-25	WOS:A1991GT48300025
J	BRUNE, B; ULLRICH, V				BRUNE, B; ULLRICH, V			DIFFERENT CALCIUM POOLS IN HUMAN PLATELETS AND THEIR ROLE IN THROMBOXANE-A2 FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILIZED HUMAN-PLATELETS; PROTEIN KINASE-C; RECEPTOR DESENSITIZATION; INOSITOL TRISPHOSPHATE; SIGNAL TRANSDUCTION; CA-2+ CONCENTRATION; TUMOR PROMOTION; THAPSIGARGIN; ACTIVATION; MECHANISMS	Activation of human platelets by diverse receptor-transduced signals is followed by an intracellular calcium increase. Calcium liberation from an inositol 1,4,5-trisphosphate-sensitive compartment is recognized to be one of the prime events, followed by further mechanisms to amplify the signal. Among these, the formation of prostaglandin endoperoxides and thromboxane A2 are part of the self-amplificating activation system. Two inhibitors of intracellular Ca2+-ATPases, thapsigargin and 2,5-di-(tert-butyl)-1,4-benzohydroquinone have been reported to deplete the intracellular inositol 1,4,5-trisphosphate-responsive stores. In human platelets with EGTA present, we found that these inhibitors of the microsomal Ca2+ sequestration generate quite different Ca2+ transients due to an inherent cyclooxygenase inhibition by the benzohydroquinone derivative compared to thapsigargin, and, therefore, only one-half of the fura-2 signal is generated. For a maximal calcium release, Ca2+-ATPase inhibitors depend on the self-amplification system involving thromboxane formation. Following the thapsigargin-induced [Ca2+]i transient, thrombin was unable to raise [Ca2+]i, indicating that thapsigargin mobilizes calcium from the thrombin-responsive store, as long as the self-amplifying system of platelets is intact. With the thromboxane receptor blocked, thapsigargin releases only one-half of the calcium, and, hence, thrombin was able to release additional calcium. Interestingly, in the converse experiment, thrombin did not prevent a raise of [Ca2+]i by thapsigargin at all, although applying thrombin a second time was without any effect. Therefore, we propose two calcium pools in human platelets: receptor activation transiently releases calcium from an inositol-sensitive pool including the thapsigargin-sensitive compartment, followed by reuptake within minutes. Sequestration occurs into the thapsigargin-sensitive compartment from where it can be released even when the endoperoxide/thromboxane receptor is blocked. Calcium release from both compartments allows the formation of thromboxane B2, but not if only the Ca2+-ATPase inhibitor-sensitive pool is emptied. In the presence of a protonophor, a calcium accumulation in the Ca2+-ATPase-sensitive pool could be observed.			BRUNE, B (corresponding author), UNIV CONSTANCE,FAC BIOL,UNIV STR 8-10,POSTFACH 5560,W-7750 CONSTANCE,GERMANY.							AUTHI KS, 1987, FEBS LETT, V213, P95, DOI 10.1016/0014-5793(87)81471-0; BERRIDGE MJ, 1991, CELL CALCIUM, V12, P63, DOI 10.1016/0143-4160(91)90009-4; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BRASS LF, 1985, J BIOL CHEM, V260, P5172; BRUNE B, 1991, FEBS LETT, V284, P1, DOI 10.1016/0014-5793(91)80747-Q; BRUNE B, 1987, MOL PHARMACOL, V32, P497; CROUCH MF, 1989, J BIOL CHEM, V264, P584; ENOUF J, 1984, BIOCHIM BIOPHYS ACTA, V772, P251, DOI 10.1016/0005-2736(84)90141-X; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; KASS GEN, 1989, J BIOL CHEM, V264, P15192; LAPETINA E G, 1986, P271; LAPETINA EG, 1983, LIFE SCI, V32, P2069, DOI 10.1016/0024-3205(83)90094-2; LAPETINA EG, 1984, P NATL ACAD SCI-BIOL, V81, P7431, DOI 10.1073/pnas.81.23.7431; MISSIAEN L, 1991, BIOCHEM BIOPH RES CO, V174, P1183, DOI 10.1016/0006-291X(91)91546-O; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; MURRAY R, 1990, J BIOL CHEM, V265, P21670; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OLDERSHAW KA, 1990, FEBS LETT, V274, P214, DOI 10.1016/0014-5793(90)81366-V; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; SCHULZ I, 1989, CELL CALCIUM, V10, P325, DOI 10.1016/0143-4160(89)90058-4; SIESS W, 1983, J BIOL CHEM, V258, P4683; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; THASTRUP O, 1987, BIOCHEM BIOPH RES CO, V142, P654, DOI 10.1016/0006-291X(87)91464-1; THEVENOD F, 1988, AM J PHYSIOL, V255, pG429, DOI 10.1152/ajpgi.1988.255.4.G429; TSUNODA Y, 1991, EXP CELL RES, V193, P356, DOI 10.1016/0014-4827(91)90107-6; VERMA A, 1990, BIOCHEM BIOPH RES CO, V172, P811, DOI 10.1016/0006-291X(90)90747-B; VOLPE P, 1988, P NATL ACAD SCI USA, V85, P1091, DOI 10.1073/pnas.85.4.1091	29	79	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19232	19237						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1833401				2022-12-25	WOS:A1991GK66700021
J	BUSBY, SJ; MULVIHILL, E; RAO, D; KUMAR, AA; LIOUBIN, P; HEIPEL, M; SPRECHER, C; HALFPAP, L; PRUNKARD, D; GAMBEE, J; FOSTER, DC				BUSBY, SJ; MULVIHILL, E; RAO, D; KUMAR, AA; LIOUBIN, P; HEIPEL, M; SPRECHER, C; HALFPAP, L; PRUNKARD, D; GAMBEE, J; FOSTER, DC			EXPRESSION OF RECOMBINANT HUMAN PLASMINOGEN IN MAMMALIAN-CELLS IS AUGMENTED BY SUPPRESSION OF PLASMIN ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRINOLYTIC COMPONENTS; LYS-PLASMINOGEN; BINDING; ACTIVATOR; UROKINASE; SURFACE; SYSTEM; DNA; INHIBITOR; PROTEINS	We present evidence that over-expression of human plasminogen, the precursor to the serine protease plasmin, can be cytotoxic to mammalian cells. When an expression vector containing plasminogen cDNA is transfected into baby hamster kidney cells, the number of drug-resistant colonies as well as the levels of plasminogen secreted by those colonies is lower than observed in similar transfections of other protease precursor genes. The recombinant plasminogen accumulates intracellularly as degraded NH2-terminal fragments. In contrast, a mutant of plasminogen that produces inactive plasmin (active site Ser740 changed to Ala) is synthesized by these cells as a full-length plasminogen molecule, and the colony numbers and expression levels are normal. Thus, the generation of plasmin activity is responsible for the cytotoxic phenomena and the degradation associated with plasminogen expression. In addition, experiments using a plasminogen mutant that cannot be activated to plasmin (activation cleavage site Arg560 to Gly) or using coexpression of antisense urokinase RNA indicate that an endogenous plasminogen activator is responsible for converting newly synthesized plasminogen to plasmin. Finally, coexpression of plasminogen with alpha-2-plasmin inhibitor, a serpin which is the physiologic inhibitor of plasmin, prevents the toxic effects of intracellular plasmin activity and allows the synthesis and secretion of native human plasminogen.	ZYMOGENET CORP,SEATTLE,WA 98105	Zymogenet Inc.								BENZEEV A, 1979, CELL, V17, P859, DOI 10.1016/0092-8674(79)90326-X; BERKNER K, 1986, COLD SPRING HARB SYM, V51, P531, DOI 10.1101/SQB.1986.051.01.065; BUSBY S, 1985, NATURE, V316, P271, DOI 10.1038/316271a0; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; DANO K, 1985, ADV CANCER RES, V44, P140; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P3585, DOI 10.1021/bi00466a023; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P5584, DOI 10.1021/bi00475a024; EDELBERG JM, 1990, J CLIN INVEST, V86, P107, DOI 10.1172/JCI114671; FOSTER DC, 1987, BIOCHEMISTRY-US, V26, P7003, DOI 10.1021/bi00396a022; FRANCIS CW, 1986, ANNU REV MED, V37, P187; GONZALEZGRONOW M, 1989, BIOCHEMISTRY-US, V28, P2374, DOI 10.1021/bi00432a005; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAJJAR KA, 1988, J CLIN INVEST, V82, P1769, DOI 10.1172/JCI113790; HOLMES WE, 1987, J BIOL CHEM, V262, P1659; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LIJNEN HR, 1982, SEMIN THROMB HEMOST, V8, P2, DOI 10.1055/s-2007-1005038; MALINOWSKI DP, 1984, BIOCHEMISTRY-US, V23, P4243, DOI 10.1021/bi00313a035; MCCRACKEN A A, 1984, Biotechniques, V2, P82; MILES LA, 1989, BIOCHEMISTRY-US, V28, P9337, DOI 10.1021/bi00450a014; MILES LA, 1988, J BIOL CHEM, V263, P11928; MILES LA, 1987, THROMB HAEMOSTASIS, V58, P936; NAGAMINE Y, 1984, NUCLEIC ACIDS RES, V12, P9525, DOI 10.1093/nar/12.24.9525; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; REICH E, 1978, MOL BASIS BIOL DEGRA, P155; SILVERSTEIN RL, 1988, J CLIN INVEST, V82, P1948, DOI 10.1172/JCI113814; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VALINSKY JE, 1981, CELL, V25, P471, DOI 10.1016/0092-8674(81)90065-9; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914; VIRJI MAG, 1980, P NATL ACAD SCI-BIOL, V77, P875, DOI 10.1073/pnas.77.2.875; ZAWORSKI PG, 1990, GENE AMST, V85, P545; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	33	51	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15286	15292						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1831201				2022-12-25	WOS:A1991GB09700070
J	SUGIYAMA, E; DEGASPERI, R; URAKAZE, M; CHANG, HM; THOMAS, LJ; HYMAN, R; WARREN, CD; YEH, ETH				SUGIYAMA, E; DEGASPERI, R; URAKAZE, M; CHANG, HM; THOMAS, LJ; HYMAN, R; WARREN, CD; YEH, ETH			IDENTIFICATION OF DEFECTS IN GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR BIOSYNTHESIS IN THE THY-1 EXPRESSION MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							VARIANT SURFACE GLYCOPROTEINS; PHOSPHATIDYLINOSITOL MEMBRANE ANCHORS; GLYCOLIPID PRECURSORS; RESISTANT GLYCOLIPIDS; LYMPHOMA MUTANTS; T-LYMPHOMA; DEFICIENT; CELLS; PROTEINS	A number of eukaryotic proteins are anchored to the membrane by glycosylphosphatidylinositol (GPI), of which the core structure is conserved from protozoan to mammalian cells. Here, we used a panel of thymoma mutants, which synthesize Thy-1 but cannot express it on the cell surface, to study the GPI biosynthetic pathway in mammalian cells. These mutants have been assigned into six complementation classes (A, B, C, E, F, H) by the technique of somatic cell hybridization. Using a combination of metabolic labeling and chemical/enzymatic tests, the biosynthetic defects were mapped to four different steps. Class A, C, and H mutants cannot transfer N-acetylglucosamine (GlcNAc) to a phosphatidylinositol acceptor, suggesting that the first step of GPI synthesis is regulated by at least three genes. The Class E mutant does not synthesize dolichol-phosphate-mannose, the donor for the first mannose residue transferred to the GPI core, and thus cannot form any mannose-containing GPI precursors. Class B and F mutants are defective in the addition of the third mannose residue or ethanolamine phosphate, respectively, to the elongating GPI core. Our findings have implications for the biosynthesis and attachment of the mammalian GPI anchor.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT MED,ARTRITIS UNIT,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT ANESTHESIA,PAIN CONTROL UNIT,BOSTON,MA 02114; SALK INST BIOL STUDIES,DEPT CANC BIOL,SAN DIEGO,CA 92138	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Salk Institute				Chang, Hui-Ming/0000-0002-5856-3397	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021087] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR003564] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45851] Funding Source: Medline; NIAMS NIH HHS [AR-03564] Funding Source: Medline; NICHD NIH HHS [HD-21087] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BUTIKOFER P, 1990, J BIOL CHEM, V265, P18983; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CONZELMANN A, 1986, EMBO J, V5, P3291, DOI 10.1002/j.1460-2075.1986.tb04642.x; CONZELMANN A, 1988, MOL CELL BIOL, V8, P674, DOI 10.1128/MCB.8.2.674; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; DOERING TL, 1990, J BIOL CHEM, V265, P611; FATEMI SH, 1987, J BIOL CHEM, V262, P4728; FATEMI SH, 1986, CELL, V46, P653, DOI 10.1016/0092-8674(86)90340-5; FATEMI SH, 1988, J BIOL CHEM, V263, P1288; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GUPTA D, 1988, SCIENCE, V242, P1446, DOI 10.1126/science.2904699; HYMAN R, 1988, TRENDS GENET, V4, P5, DOI 10.1016/0168-9525(88)90120-5; LOW MG, 1985, NATURE, V318, P62, DOI 10.1038/318062a0; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; STEVENS VL, 1990, J BIOL CHEM, V265, P15653; WANECK GL, 1988, SCIENCE, V241, P697, DOI 10.1126/science.3399901; WARREN CD, 1981, CARBOHYD RES, V92, P85, DOI 10.1016/S0008-6215(00)85984-4; WARREN CD, 1983, CARBOHYD RES, V116, P171, DOI 10.1016/0008-6215(83)88107-5; YEH ETH, 1988, CELL, V52, P665, DOI 10.1016/0092-8674(88)90404-7	24	139	140	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12119	12122						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1829456				2022-12-25	WOS:A1991FV18000002
J	KING, SM; WILKERSON, CG; WITMAN, GB				KING, SM; WILKERSON, CG; WITMAN, GB			THE MR 78,000 INTERMEDIATE CHAIN OF CHLAMYDOMONAS OUTER ARM DYNEIN INTERACTS WITH ALPHA-TUBULIN INSITU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URCHIN SPERM FLAGELLA; ACTIN-MYOSIN COMPLEX; BETA-HEAVY-CHAINS; BINDING-SITES; CROSS-LINKING; 8-AZIDOADENOSINE 5'-TRIPHOSPHATE; ADENOSINE-TRIPHOSPHATASE; POLYPEPTIDE COMPOSITION; MICROTUBULES INVITRO; BRAIN MICROTUBULES	We have used the zero-length cross-linker 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) to examine protein-protein associations within purified outer arm dynein and axonemes from Chlamydomonas flagella. When axonemes were treated with 0.5-1 mM EDC in either the presence or absence of ATP/vanadate, a polypeptide band of M(r) 127,000 recognized by monoclonal antibody 1878A (specific for the M(r) 78,000 intermediate chain (IC78) of outer arm dynein) was generated. This conjugate was not obtained when purified dynein was treated with EDC. Further immunological analysis demonstrated that this complex also contained alpha- (but not beta-) tubulin. These results indicate that IC78 interacts with alpha-tubulin in situ in an ATP-insensitive manner. Identification of this interface between dynein and tubulin suggests that IC78, which probably is located at the base of the dynein particle (King, S. M., and Witman, G. B. (1990) J. Biol. Chem. 265, 19807-19811), contributes to the structural attachment of the dynein arms to the A-tubules of the outer doublet microtubules. Analysis of the cross-linked products from the purified dynein revealed several additional interactions involving the intermediate chains; these adducts provide further evidence for an intermediate chain/light chain complex within dynein and confirm that IC78 and IC69 associate directly.	WORCESTER FDN EXPTL BIOL INC, CELL BIOL GRP, SHREWSBURY, MA 01545 USA	Worcester Foundation for Biomedical Research				Witman, George/0000-0002-9497-9218	NATIONAL CANCER INSTITUTE [P30CA012708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030626, R01GM030626] Funding Source: NIH RePORTER; NCI NIH HHS [CA12708] Funding Source: Medline; NIGMS NIH HHS [GM30626] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPLEGATE D, 1987, J BIOL CHEM, V262, P6856; ARATA T, 1986, J MOL BIOL, V191, P107, DOI 10.1016/0022-2836(86)90426-2; BELL CW, 1982, J BIOL CHEM, V257, P516; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brokaw C.J., 1989, CELL MOVEMENT, V1, P267; CHEN T, 1985, BIOCHEMISTRY-US, V24, P137, DOI 10.1021/bi00322a019; CRAIG R, 1985, P NATL ACAD SCI USA, V82, P3247, DOI 10.1073/pnas.82.10.3247; FAY RB, 1977, J CELL BIOL, V75, pA286; GATTI JL, 1989, J BIOL CHEM, V264, P11450; GIBBONS IR, 1988, J BIOL CHEM, V263, P15837; GOODENOUGH U, 1984, J MOL BIOL, V180, P1083, DOI 10.1016/0022-2836(84)90272-9; GOODENOUGH UW, 1987, J MOL BIOL, V194, P481, DOI 10.1016/0022-2836(87)90676-0; GREENE LE, 1984, J BIOL CHEM, V259, P7363; HAIMO LT, 1984, CELL MOTIL CYTOSKEL, V4, P371, DOI 10.1002/cm.970040506; HAIMO LT, 1988, CELL MOTIL CYTOSKEL, V9, P129, DOI 10.1002/cm.970090205; HEAPHY S, 1984, BIOCHEMISTRY-US, V23, P2211, DOI 10.1021/bi00305a017; HEAPHY S, 1970, BIOCHEMISTRY-US, V92, P6568; HOARE DG, 1967, J BIOL CHEM, V242, P2447; HOARE DG, 1966, J AM CHEM SOC, V88, P2057, DOI 10.1021/ja00961a045; JOHNSON KA, 1985, ANNU REV BIOPHYS BIO, V14, P161, DOI 10.1146/annurev.bb.14.060185.001113; KING SM, 1986, METHOD ENZYMOL, V134, P291; KING SM, 1990, J BIOL CHEM, V265, P19807; KING SM, 1990, CELL MOTIL CYTOSKEL, V16, P266, DOI 10.1002/cm.970160406; KING SM, 1987, J BIOL CHEM, V262, P17596; KING SM, 1988, J CELL BIOL, V107, P1799, DOI 10.1083/jcb.107.5.1799; KING SM, 1985, P NATL ACAD SCI USA, V82, P4717, DOI 10.1073/pnas.82.14.4717; KING SM, 1989, J BIOL CHEM, V264, P10210; King SM, 1989, CELL MOVEMENT DYNEIN, V1, P61; LEEEIFORD A, 1986, J BIOL CHEM, V261, P2337; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; LITTAUER UZ, 1986, P NATL ACAD SCI USA, V83, P7162, DOI 10.1073/pnas.83.19.7162; MITCHELL D R, 1989, Journal of Cell Biology, V109, p158A; MITCHELL DR, 1986, CELL MOTIL CYTOSKEL, V6, P510, DOI 10.1002/cm.970060510; MORNET D, 1981, NATURE, V292, P301, DOI 10.1038/292301a0; OMOTO CK, 1986, BIOCHEMISTRY-US, V25, P419, DOI 10.1021/bi00350a022; ONISHI H, 1990, BIOCHEMISTRY-US, V29, P3013, DOI 10.1021/bi00464a018; ONISHI H, 1990, J BIOL CHEM, V265, P19362; OTTER T, 1987, ANAL BIOCHEM, V162, P370, DOI 10.1016/0003-2697(87)90406-4; PASCHAL BM, 1987, NATURE, V330, P672, DOI 10.1038/330672a0; PFISTER KK, 1985, J BIOL CHEM, V260, P2844; PFISTER KK, 1984, J BIOL CHEM, V259, P8499; PFISTER KK, 1982, CELL MOTIL CYTOSKEL, V2, P525, DOI 10.1002/cm.970020604; PFISTER KK, 1984, J BIOL CHEM, V259, P2072; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; PIPERNO G, 1979, J BIOL CHEM, V254, P3084; PORTER ME, 1989, ANNU REV CELL BIOL, V5, P119; PORTER ME, 1983, J BIOL CHEM, V258, P6575; SALE WS, 1988, J CELL BIOL, V107, P1793, DOI 10.1083/jcb.107.5.1793; SALE WS, 1985, J CELL BIOL, V101, P1400, DOI 10.1083/jcb.101.4.1400; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024; SHIMIZU T, 1989, BIOCHEMISTRY-US, V28, P7016, DOI 10.1021/bi00443a035; SHIMIZU T, 1983, J BIOL CHEM, V258, P3841; SILFLOW CD, 1986, ANN NY ACAD SCI, V466, P18, DOI 10.1111/j.1749-6632.1986.tb38381.x; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; SUTOH K, 1983, BIOCHEMISTRY-US, V22, P1579, DOI 10.1021/bi00276a009; TAKAHASHI M, 1978, J BIOCHEM-TOKYO, V84, P1339, DOI 10.1093/oxfordjournals.jbchem.a132256; TANG WJY, 1982, J BIOL CHEM, V257, P508; TANG WJY, 1987, J BIOL CHEM, V262, P17728; VALE RD, 1989, J CELL BIOL, V108, P2327, DOI 10.1083/jcb.108.6.2327; WARNER FD, 1982, CELL MOTIL CYTOSKEL, V2, P429, DOI 10.1002/cm.970020503; WARNER FD, 1989, CELL MOVEMENT KINESI, V2; WARNER FD, 1989, CELL MOVEMENT DYNEIN, V1; WITMAN GB, 1986, METHOD ENZYMOL, V134, P280; WITMAN GB, 1982, SYM SOC EXP BIOL, P203; WITMAN GB, 1983, J SUBMICR CYTOL PATH, V15, P193; WITMAN GB, 1989, CELL MOVEMENT, V1, P25; WITMAN GB, 1991, IN PRESS COMP SPERMA	67	137	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8401	8407						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1827120				2022-12-25	WOS:A1991FK44100068
J	SCHOBERT, B				SCHOBERT, B			F1-LIKE PROPERTIES OF AN ATPASE FROM THE ARCHAEBACTERIUM HALOBACTERIUM-SACCHAROVORUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUB-MITOCHONDRIAL PARTICLES; AFFINITY BINDING-SITE; VACUOLAR H+-ATPASE; TIGHTLY BOUND ADP; SULFOLOBUS-ACIDOCALDARIUS; ADENOSINE-TRIPHOSPHATASE; ACIDOTHERMOPHILIC ARCHAEBACTERIUM; OXIDATIVE-PHOSPHORYLATION; CHLOROPLAST ATPASE; NUCLEOTIDE-BINDING	For F1-ATPases from mitochondria and chloroplasts, tight binding of Mg2+ and ADP without P(i) at a catalytic site had been reported as a cause of enzyme inhibition. The time dependence of this inhibition and the effect of various agents on this process have been described (Du, Z., and Boyer, P. D. (1990) Biochemistry 29, 402-407, and references therein). Similar results are now reported for the ATPase from Halobacterium saccharovorum. The nonlinear hydrolysis kinetics were modulated by nitrate, azide, sulfite, GTP, ADP in the absence of ATP, or P(i) in characteristic ways, in good analogy with the effects of these agents on F1 enzymes. The similarity to the F1 systems suggests that it is tight ADP binding that is affected. Although these reactions of the H. saccharovorum ATPase occurred on different time and concentration scales than those of F1-ATPases, the two systems do not appear to be fundamentally different. The hydrolytic mechanism of the H. saccharovorum ATPase thus identifies this enzyme as a member of the F0F1-ATPase family.			SCHOBERT, B (corresponding author), UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717, USA.							ABBOTT MS, 1984, J BIOL CHEM, V259, P2271; ADOLFSEN R, 1976, ARCH BIOCHEM BIOPHYS, V172, P425, DOI 10.1016/0003-9861(76)90094-1; BARZVI D, 1982, BIOCHIM BIOPHYS ACTA, V681, P451, DOI 10.1016/0005-2728(82)90187-6; BOWMAN BJ, 1986, J MEMBRANE BIOL, V94, P83, DOI 10.1007/BF01871190; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; CANTLEY LC, 1975, BIOCHEMISTRY-US, V14, P2968, DOI 10.1021/bi00684a027; CARMELI C, 1972, BIOCHIM BIOPHYS ACTA, V267, P86, DOI 10.1016/0005-2728(72)90140-5; CHERNYAK BV, 1986, TRENDS BIOCHEM SCI, V11, P32, DOI 10.1016/0968-0004(86)90229-X; CHERNYAK BV, 1988, FEBS LETT, V230, P159, DOI 10.1016/0014-5793(88)80662-8; DENDA K, 1988, J BIOL CHEM, V263, P17251; DROBINSKAYA IY, 1985, FEBS LETT, V182, P419, DOI 10.1016/0014-5793(85)80346-X; DU ZY, 1990, BIOCHEMISTRY-US, V29, P402, DOI 10.1021/bi00454a014; FELDMAN RI, 1985, J BIOL CHEM, V260, P3088; FITIN AF, 1979, BIOCHEM BIOPH RES CO, V86, P434, DOI 10.1016/0006-291X(79)90884-2; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; GRESSER MJ, 1982, J BIOL CHEM, V257, P2030; GUERRERO KJ, 1990, J BIOL CHEM, V265, P16280; HARRIS DA, 1978, BIOCHIM BIOPHYS ACTA, V504, P364, DOI 10.1016/0005-2728(78)90060-9; INATOMI KI, 1989, J BIOL CHEM, V264, P10954; KAKINUMA Y, 1990, FEBS LETT, V271, P97, DOI 10.1016/0014-5793(90)80381-R; KALASHNIKOVA TY, 1988, EUR J BIOCHEM, V177, P213, DOI 10.1111/j.1432-1033.1988.tb14364.x; KASHO VN, 1989, P NATL ACAD SCI USA, V86, P8708, DOI 10.1073/pnas.86.22.8708; KONISHI J, 1987, J BIOCHEM, V102, P1379, DOI 10.1093/oxfordjournals.jbchem.a122184; KRISTJANSSON H, 1985, ARCH BIOCHEM BIOPHYS, V241, P590, DOI 10.1016/0003-9861(85)90584-3; LUBBEN M, 1987, EUR J BIOCHEM, V164, P533, DOI 10.1111/j.1432-1033.1987.tb11159.x; LUBBEN M, 1988, BIOL CHEM H-S, V369, P1259, DOI 10.1515/bchm3.1988.369.2.1259; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MILGROM YM, 1990, J BIOL CHEM, V265, P18725; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; MOYLE J, 1975, FEBS LETT, V56, P55, DOI 10.1016/0014-5793(75)80110-4; MUKOHATA Y, 1987, ARCH BIOCHEM BIOPHYS, V259, P650, DOI 10.1016/0003-9861(87)90532-7; MUKOHATA Y, 1987, J BIOCHEM-TOKYO, V102, P792; NANBA T, 1987, J BIOCHEM-TOKYO, V102, P591, DOI 10.1093/oxfordjournals.jbchem.a122092; NELSON N, 1972, J BIOL CHEM, V247, P7657; SCHOBERT B, 1989, J BIOL CHEM, V264, P12805; STANLOTTER H, 1989, EUR J BIOCHEM, V179, P155, DOI 10.1111/j.1432-1033.1989.tb14533.x; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; VASILYEVA EA, 1982, BIOCHEM J, V202, P9, DOI 10.1042/bj2020009; VASILYEVA EA, 1980, BIOCHEM J, V188, P807, DOI 10.1042/bj1880807; VULFSON EN, 1984, BIOL MEMBRANY, V1, P696; ZHOU JM, 1988, BIOCHEMISTRY-US, V27, P5129, DOI 10.1021/bi00414a027; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	45	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8008	8014						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1827114				2022-12-25	WOS:A1991FK44100011
J	INOHARA, N; IWAMOTO, A; MORIYAMA, Y; SHIMOMURA, S; MAEDA, M; FUTAI, M				INOHARA, N; IWAMOTO, A; MORIYAMA, Y; SHIMOMURA, S; MAEDA, M; FUTAI, M			2 GENES, ATPC1 AND ATPC2, FOR THE GAMMA-SUBUNIT OF ARABIDOPSIS-THALIANA CHLOROPLAST ATP SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; PROTON-TRANSLOCATING ATPASE; NUCLEOTIDE-SEQUENCE; CHLAMYDOMONAS-REINHARDTII; BOVINE MITOCHONDRIA; ALPHA-SUBUNITS; CDNA SEQUENCE; RBCS-3A GENE; H+-ATPASE; PROTEIN	Arabidopsis thaliana has two genes (atpC1, atpC2) coding for gamma-subunits of chloroplast ATP synthase. The atpC1 and atpC2 were cloned and sequenced. They had no introns within the reading frames and coded for proteins of 373 and 386 amino acid residues, respectively, including putative transit sequences (50 and 60 amino acid residues, respectively). In contrast, the spinach gamma-subunit gene had two introns within the reading frame. The mature sequences coded by the two genes of A. thaliana (atpC1, 323 residues; atpC2, 326 residues) were homologous with that of spinach (J. Miki, M. Maeda, Y. Mukohata, and M. Futai (1988) FEBS Lett. 232, 221-226): the homologies of gamma-subunits coded by atpC1 and atpC2 were 72%, those of the subunits coded by atpC1 and spinach cDNA were 84%, and those of the proteins coded by atpC2 and spinach cDNA were 71%. Like the spinach subunit, the gamma-subunits coded by the two genes had unique regulatory domains not found in mitochondrial or bacterial subunits. Poly(A)+ mRNAs corresponding to atpC1 (1.5 kilobases) and atpC2 (2.5 kilobases) were detected in illuminated plants, the amount of the former being at least 140 times that of the latter. The atpC1 mRNA was not found in dark-adapted plants. Nuclear protein(s) specifically bound to the upstream region of atpC1 was detected by gel shift assay and its binding was shown to be inhibited by the GT-1 element of the gene encoding the ribulose-1,5-bisphosphate carboxylase small subunit, which is expressed under illumination (P. J. Green, S. A. Kay, and N. H. Chau (1987) EMBO J. 6, 2543-2549). Consistent with these findings, an increased amount of the gamma-subunit was detected immunochemically in illuminated plants.			INOHARA, N (corresponding author), OSAKA UNIV,INST SCI & IND RES,DEPT INFECT DIS,IBARAKI,OSAKA 567,JAPAN.							BRUSILOW WSA, 1989, J BIOL CHEM, V264, P1528; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHRISTOFFERSEN RE, 1982, P NATL ACAD SCI-BIOL, V79, P4060, DOI 10.1073/pnas.79.13.4060; COZENS AL, 1987, J MOL BIOL, V194, P359, DOI 10.1016/0022-2836(87)90667-X; DEHEIJ HT, 1984, EUR J BIOCHEM, V138, P161; DIETRICH G, 1987, PLANTA, V172, P393, DOI 10.1007/BF00398669; DYER MR, 1989, BIOCHEMISTRY-US, V28, P3670, DOI 10.1021/bi00435a008; FALK G, 1985, BIOCHEM J, V228, P391, DOI 10.1042/bj2280391; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GIULIANO G, 1988, P NATL ACAD SCI USA, V85, P7089, DOI 10.1073/pnas.85.19.7089; GREEN PJ, 1988, EMBO J, V7, P4035, DOI 10.1002/j.1460-2075.1988.tb03297.x; GREEN PJ, 1987, EMBO J, V6, P2543, DOI 10.1002/j.1460-2075.1987.tb02542.x; HARTMAN H, 1990, MOL BIOL EVOL, V7, P247; IWAMOTO A, 1990, J BIOL CHEM, V265, P5043; JAGENDORF AT, 1958, J BIOL CHEM, V231, P277; KANAZAWA H, 1981, BIOCHEM BIOPH RES CO, V103, P604, DOI 10.1016/0006-291X(81)90494-0; KAY SA, 1989, PLANT CELL, V1, P351, DOI 10.1105/tpc.1.3.351; KETCHAM SR, 1984, J BIOL CHEM, V259, P7286; KIMURA T, 1989, J BIOL CHEM, V264, P3183; KRUMHOLZ LR, 1989, NUCLEIC ACIDS RES, V17, P7993, DOI 10.1093/nar/17.19.7993; Maniatis T., 1982, MOL CLONING; MASON JG, 1990, PLANT MOL BIOL, V14, P1007, DOI 10.1007/BF00019397; MCCARN DF, 1988, J BACTERIOL, V170, P3448, DOI 10.1128/jb.170.8.3448-3458.1988; MCCARTY RE, 1982, ANN NY ACAD SCI, V402, P84, DOI 10.1111/j.1749-6632.1982.tb25733.x; MCCARTY RE, 1985, ENZYMES BIOL MEMBR, P383; Messing J., 1983, GENETIC ENG PLANTS A, P211; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MORONEY JV, 1984, J BIOL CHEM, V259, P7281; NALIN CM, 1984, J BIOL CHEM, V259, P7275; NECHUSHTAI R, 1985, PLANT MOL BIOL, V4, P377, DOI 10.1007/BF02418259; NELSON N, 1983, METHOD ENZYMOL, V97, P510; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; TYBULEWICZ VLJ, 1984, J MOL BIOL, V179, P185, DOI 10.1016/0022-2836(84)90465-0; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WERNER S, 1990, FEBS LETT, V261, P204, DOI 10.1016/0014-5793(90)80671-5; YU LM, 1988, P NATL ACAD SCI USA, V85, P1369, DOI 10.1073/pnas.85.5.1369; YU LM, 1988, J BIOL CHEM, V263, P19342	41	38	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7333	7338						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1826905				2022-12-25	WOS:A1991FJ34200006
J	MOHAGHEGHPOUR, N; CHAKRABARTI, R; STEIN, BS; GOWDA, SD; ENGLEMAN, EG				MOHAGHEGHPOUR, N; CHAKRABARTI, R; STEIN, BS; GOWDA, SD; ENGLEMAN, EG			EARLY ACTIVATION EVENTS RENDER T-CELLS SUSCEPTIBLE TO HIV-1-INDUCED SYNCYTIA FORMATION - ROLE OF PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; HTLV-III/LAV ENVELOPE; POTENT INHIBITORS; AIDS RETROVIRUS; LYMPHOCYTES-T; RECEPTOR; ANTIGEN; CD4; PROLIFERATION; STAUROSPORINE	In human immunodeficiency virus-1 (HIV-1)-infected cell cultures, cell-to-cell fusion and the formation of multinucleated giant cells (syncytia) are induced as a consequence of interactions between the viral envelope glycoprotein on infected cells and cell surface CD4 molecules on uninfected cells. Although activated CD4+ T cells rapidly form syncytia when cultured with HIV-1 envelope glycoprotein expressing (env+) cells, freshly isolated, unstimulated CD4+ T cells do so more slowly. In these studies, we sought to explore the role of T cell activation in rendering CD4+ T cells susceptible to HIV-1-mediated syncytia formation. Our results indicate that within 2 h of exposure to immunologic stimuli, CD4+ T cells acquire the ability to form syncytia with HIV-1 env+ cells. Both cholera toxin, an inhibitor of protein kinase C (PKC) through its effects on inositol triphosphate and diacylglycerol production, and 1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride, a noncompetitive inhibitor (with respect to ATP) of PKC, prevented unstimulated but not previously stimulated CD4+ T cells from forming syncytia with HIV-1 env+ cells. 1-Oleoyl-2-acetyl glycerol, an analog of the PKC activator, diacylglycerol, enhanced syncytia formation whereas ionomycin, a calcium ionophore, had no effect. These results suggest that activation of PKC is essential for previously unstimulated CD4+ T cells to become fusogenic.	STANFORD UNIV,DEPT PATHOL,STANFORD,CA 94305	Stanford University	MOHAGHEGHPOUR, N (corresponding author), STANFORD BLOOD CTR,800 WELCH RD,PALO ALTO,CA 94304, USA.				NIAID NIH HHS [AI25922, AI72657] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI072657, U01AI025922] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; CLARK RB, 1987, BIOCHEM BIOPH RES CO, V145, P666, DOI 10.1016/0006-291X(87)91016-3; COLOMBANI PM, 1985, SCIENCE, V228, P337, DOI 10.1126/science.3885394; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DAVID JD, 1990, DEV BIOL, V139, P89, DOI 10.1016/0012-1606(90)90281-M; ENGLEMAN EG, 1981, J IMMUNOL, V127, P2124; FIELDS AP, 1988, NATURE, V333, P278, DOI 10.1038/333278a0; GOWDA SD, 1989, J IMMUNOL, V142, P773; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; IMBODEN JB, 1986, P NATL ACAD SCI USA, V83, P5673, DOI 10.1073/pnas.83.15.5673; ISAKOV N, 1987, IMMUNOL REV, V95, P89, DOI 10.1111/j.1600-065X.1987.tb00501.x; KANEOKA H, 1983, J IMMUNOL, V131, P158; KAPLAN ME, 1974, J IMMUNOL METHODS, V5, P131, DOI 10.1016/0022-1759(74)90003-9; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KORNFELD H, 1988, NATURE, V335, P445, DOI 10.1038/335445a0; LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0; LIFSON JD, 1989, IMMUNOL REV, V109, P93, DOI 10.1111/j.1600-065X.1989.tb00021.x; LIFSON JD, 1986, SCIENCE, V232, P1123, DOI 10.1126/science.3010463; LIN S, 1978, P NATL ACAD SCI USA, V75, P329, DOI 10.1073/pnas.75.1.329; MARGOLICK JB, 1987, J IMMUNOL, V138, P1719; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MONTAGNIER Luc, 1984, HUMAN T CELL LEUKEMI, P363; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PAPOVIC M, 1984, SCIENCE, V224, P497; PHATAK PD, 1988, J IMMUNOL, V141, P2929; ROTMAN B, 1966, P NATL ACAD SCI USA, V55, P134, DOI 10.1073/pnas.55.1.134; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SASAKI DT, 1987, CYTOMETRY, V8, P413, DOI 10.1002/cyto.990080411; SECRIST JP, 1990, J BIOL CHEM, V265, P20394; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; SOMMERMEYER H, 1990, EUR J IMMUNOL, V20, P1881, DOI 10.1002/eji.1830200902; STEIN BS, 1987, CELL, V49, P659, DOI 10.1016/0092-8674(87)90542-3; STOSSEL TP, 1984, FED PROC, V43, P2760; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; VANNOESEL C, 1988, NATURE, V333, P850, DOI 10.1038/333850a0; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	39	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7233	7238						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1826686				2022-12-25	WOS:A1991FG72700091
J	CIDON, S; TAMIR, H; NUNEZ, EA; GERSHON, MD				CIDON, S; TAMIR, H; NUNEZ, EA; GERSHON, MD			ATP-DEPENDENT UPTAKE OF 5-HYDROXYTRYPTAMINE BY SECRETORY GRANULES ISOLATED FROM THYROID PARAFOLLICULAR CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN GRANULES; BRAIN SYNAPTIC VESICLES; NEURAL CREST ORIGIN; MEMBRANE-VESICLES; SEROTONIN TRANSPORT; PROTONMOTIVE FORCE; CALCIUM-TRANSPORT; SUBUNIT STRUCTURE; H+-ATPASES; ACETYLCHOLINE	The current study was done to test the hypotheses that parafollicular granules contain a vacuolar ATPase (V-ATPase) similar to that found in chromaffin granules, that the transport of H+ into granules mediated by this enzyme drives the granular uptake of 5-hydroxytryptamine (5-HT, serotonin), and that secretogogues stimulate both the acidification of parafollicular granules and their ability to take up 5-HT by opening an anion channel in the granular membrane. Our studies indicate that parafollicular granules contain a V-ATPase that is antigenically similar to that of the V-ATPase of adrenal chromaffin granules; however, the parafollicular granular membrane differs from that of chromaffin granules in permeability to Cl- and K+. The membranes of granules derived from resting parafollicular cells appear to be relatively impermeable to Cl- but permeable to K+. Parafollicular granules (and ghosts derived from them) manifest ATP-dependent transmembrane transport of 5-HT. This transport is more dependent on the pH difference (DELTA-pH) than on the membrane potential component of the proton electrochemical gradient across the granular membrane. Transport of 5-HT is thus inhibited more by exposure of parafollicular granules to agents, such as nigericin, that collapse DELTA-pH than by those, such as valinomycin, that decrease transmembrane difference in potential. ATP-dependent uptake of 5-HT by granules isolated from secretogogue-stimulated parafollicular cells is greater than that into granules isolated from unstimulated cells. Since secretogogues open a Cl- channel in parafollicular granule membranes, which enhances acidification of the granules, the facilitation of 5-HT uptake by secretogogues is probably due to an increase in DELTA-pH.	COLUMBIA UNIV COLL PHYS & SURG,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032; NEW YORK STATE PSYCHIAT INST & HOSP,NEW YORK,NY 10032	Columbia University; New York State Psychiatry Institute					NIADDK NIH HHS [AM19743] Funding Source: Medline; NINDS NIH HHS [NS 12969] Funding Source: Medline; PHS HHS [37575] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM019743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS012969] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAHR BA, 1986, J NEUROCHEM, V46, P1214, DOI 10.1111/j.1471-4159.1986.tb00640.x; BARASCH J, 1988, J CELL BIOL, V107, P2137, DOI 10.1083/jcb.107.6.2137; BARASCH JM, 1987, J NEUROSCI, V7, P2874; BARASCH JM, 1987, J NEUROSCI, V7, P4017; BASHFORD CL, 1976, NEUROSCIENCE, V1, P399, DOI 10.1016/0306-4522(76)90133-0; BLUMWALD E, 1985, PLANT PHYSIOL, V78, P163, DOI 10.1104/pp.78.1.163; BRODIE BB, 1964, COMPARATIVE NEUROCHE, P367; BUSH DR, 1986, PLANT PHYSIOL, V80, P549, DOI 10.1104/pp.80.2.549; CASEY RP, 1976, BIOCHEM J, V158, P583, DOI 10.1042/bj1580583; CIDON S, 1989, J BIOL CHEM, V264, P8281; CIDON S, 1986, J BIOL CHEM, V261, P9222; DEUPREE JD, 1984, J BIOL CHEM, V259, P10906; ERSPAMER V, 1952, NATURE, V169, P800, DOI 10.1038/169800b0; FISHKES H, 1982, J BIOL CHEM, V257, P5671; FUJITA T, 1977, ARCH HISTOL JAPON, V40, P1; GERSHON MD, 1976, J PHARMACOL EXP THER, V198, P548; GERSHON MD, 1984, BIOCHEM PHARMACOL, V33, P3115, DOI 10.1016/0006-2952(84)90065-0; GERSHON MD, 1989, PERIPHERAL ACTIONS 5, P247; GRONBERG M, 1987, EUR J BIOCHEM, V164, P1, DOI 10.1111/j.1432-1033.1987.tb10983.x; JOHNSON RG, 1979, J BIOL CHEM, V254, P3750; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; KANNER BI, 1985, BIOCHIM BIOPHYS ACTA, V816, P403, DOI 10.1016/0005-2736(85)90508-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDOUARIN N, 1974, HISTOCHEMISTRY, V38, P297, DOI 10.1007/BF00496718; MANDALA S, 1986, J BIOL CHEM, V261, P2850; MANOLSON MF, 1987, P MEMBRANE PROTEIN S, P627; MICHAELSON DM, 1986, J BIOL CHEM, V261, P6831; MORIYAMA Y, 1988, BIOCHEM BIOPH RES CO, V156, P211, DOI 10.1016/S0006-291X(88)80826-X; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; MORIYAMA Y, 1989, BIOCHIM BIOPHYS ACTA, V980, P241, DOI 10.1016/0005-2736(89)90405-7; NELSON N, 1989, J BIOENERG BIOMEMBR, V21, P553, DOI 10.1007/BF00808113; NELSON N, 1988, PLANT PHYSIOL, V86, P1, DOI 10.1104/pp.86.1.1; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NELSON N, 1987, METHOD ENZYMOL, V157, P619; Njus D, 1981, CURR TOP BIOENERG, V11, P107; Nunez E A, 1978, Int Rev Cytol, V52, P1, DOI 10.1016/S0074-7696(08)60753-6; NUNEZ EA, 1988, ANAT RECORD, V221, P707, DOI 10.1002/ar.1092210305; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; PHILLIPS JH, 1974, BIOCHEM J, V144, P311, DOI 10.1042/bj1440311; POLAK JM, 1974, HISTOCHEMISTRY, V40, P209, DOI 10.1007/BF00501955; ROSS SB, 1982, BIOL SEROTONERGIC TR, P160; RUDNICK G, 1980, J BIOL CHEM, V255, P3638; RUDNICK G, 1986, PLATELET FUNCTION ME, V2, P119; SCHERMAN D, 1986, J NEUROCHEM, V47, P331; SCHWEIKL H, 1989, J BIOL CHEM, V264, P11136; SLOTKIN TA, 1978, J NEUROCHEM, V31, P961, DOI 10.1111/j.1471-4159.1978.tb00134.x; SLOTKIN TA, 1971, MOL PHARMACOL, V7, P581; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Steinbusch H W, 1981, Adv Exp Med Biol, V133, P7; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TAWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350; TOLL L, 1980, J BIOL CHEM, V255, P1787; WIECZOREK H, 1989, J BIOL CHEM, V264, P11143	54	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4392	4400						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1825654				2022-12-25	WOS:A1991FA69400059
J	SEITHER, RL; TRENT, DF; MIKULECKY, DC; RAPE, TJ; GOLDMAN, ID				SEITHER, RL; TRENT, DF; MIKULECKY, DC; RAPE, TJ; GOLDMAN, ID			EFFECT OF DIRECT SUPPRESSION OF THYMIDYLATE SYNTHASE AT THE 5,10-METHYLENETETRAHYDROFOLATE BINDING-SITE ON THE INTERCONVERSION OF TETRAHYDROFOLATE COFACTORS TO DIHYDROFOLATE BY ANTIFOLATES - INFLUENCE OF DEGREE OF DIHYDROFOLATE-REDUCTASE INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NETWORK THERMODYNAMIC ANALYSES; FOLATE-POOL INTERCONVERSIONS; NORMAL MEMBRANE-TRANSPORT; L1210 LEUKEMIA-CELLS; METHOTREXATE RESISTANCE; BIOSYNTHETIC PROCESSES; SYNTHETASE-ACTIVITY; POLYGLUTAMATES; DERIVATIVES; TRANSFORMYLASE	An important unresolved issue in antifolate pharmacology is the basis for the observation that the major portion of cellular tetrahydrofolate cofactors is preserved after dihydrofolate reductase activity is abolished by antifolates despite the fact that tetrahydrofolate cofactor-dependent purine and pyrimidine biosynthesis ceases. This has been attributed to feedback inhibition of thymidylate synthase by dihydrofolate polyglutamates that accumulate in the presence of antifolates. This report combines network thermodynamic modeling and experimental observations to evaluate the effects of direct inhibition of thymidylate synthase at the 5,10-methylenetetrahydrofolate binding site with a potent lipophilic quinazoline antifolate PD130883 on folate oxidation in cells. Computer simulations predict and the data indicate that marked PD130883 suppression of thymidylate synthase only slows the rate but not the extent of tetrahydrofolate cofactor interconversion to dihydrofolate upon complete suppression of dihydrofolate reductase with trimetrexate. These observations are consistent with earlier studies from this laboratory with fluorodeoxyuridine inhibition at the deoxyuridylate binding site. Hence, the much weaker inhibition by dihydrofolate polyglutamates at the level of thymidylate synthase cannot account for the apparent preservation of tetrahydrofolate cofactor pools in cells and has virtually no pharmacologic significance under conditions in which antifolates completely suppress dihydrofolate reductase. The extent of interconversion of tetrahydrofolate cofactors to dihydrofolate is strongly influenced by residual dihydrofolate reductase catalytic activity. Exposure of cells to 0.1-mu-M trimetrexate results in only approximately 60% of maximum dihydrofolate levels achieved when dihydrofolate reductase activity is abolished. Network thermodynamic simulations predict, and experiments verify, that inhibition of thymidylate synthase at the 5,10-methylenetetrahydrofolate site by PD130883, when dihydrofolate reductase is only partially suppressed (approximately 85%) with 0.1-mu-M trimetrexate, substantially decreases (31-47%) the net level of interconversion of tetrahydrofolate cofactors to dihydrofolate. Further computer simulations predict that under conditions in which residual dihydrofolate reductase activity persists within the cells (more than about 5%), feedback inhibitory effects of dihydrofolate polyglutamates as well as other weak inhibitors of thymidylate synthase can significantly limit the extent of net interconversion of tetrahydrofolate cofactors to dihydrofolate and produce an apparent "compartmentation phenomenon" in which tetrahydrofolate cofactor pools are preserved within the cell in the presence of antifolates. Residual dihydrofolate reductase activity cannot, however, account for the partial interconversion of tetrahydrofolate cofactors to dihydrofolate after exposure to high trimetrexate or methotrexate levels. This is more likely attributed to tetrahydrofolate cofactors in a fraction of the cell population (i.e. in some cells out of S-phase) and a physical compartment (i.e. mitochondrial) and in a physical state within the cytosol which makes them unavailable for oxidation to dihydrofolate when dihydrofolate reductase is blocked by antifolates.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,BOX 230,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHYSIOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT BIOMED ENGN,RICHMOND,VA 23298	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University					NCI NIH HHS [CA-39807, CA-09340] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039807] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEGRA CJ, 1985, P NATL ACAD SCI USA, V82, P4881, DOI 10.1073/pnas.82.15.4881; ALLEGRA CJ, 1986, J BIOL CHEM, V261, P6478; ALLEGRA CJ, 1985, J BIOL CHEM, V260, P9720; ALLEGRA CJ, 1985, 2ND P WORKSH FOL ANT, P348; BAGGOTT JE, 1986, BIOCHEM J, V236, P193, DOI 10.1042/bj2360193; BARAM J, 1988, J BIOL CHEM, V263, P7105; CHU E, 1990, J BIOL CHEM, V265, P8470; DOLNICK BJ, 1978, J BIOL CHEM, V253, P3563; FRY DW, 1983, CANCER RES, V43, P1087; FRY DW, 1989, P AM ASSOC CANC RES, V30, P479; GOLDMAN ID, 1968, J BIOL CHEM, V243, P5007; JACKSON RC, 1984, PHARMACOL THERAPEUT, V25, P61, DOI 10.1016/0163-7258(84)90024-X; JACKSON RC, 1984, ADV ENZYME REGUL, V22, P187, DOI 10.1016/0065-2571(84)90014-1; KISLIUK RL, 1974, J BIOL CHEM, V249, P4100; MATHERLY LH, 1987, J BIOL CHEM, V262, P710; MATHERLY LH, 1990, BIOCHEM PHARMACOL, V39, P2005, DOI 10.1016/0006-2952(90)90622-R; MCMARTIN KE, 1981, ARCH BIOCHEM BIOPHYS, V209, P127, DOI 10.1016/0003-9861(81)90264-2; MCNAMARA DJ, 1990, J MED CHEM, V33, P2045, DOI 10.1021/jm00169a040; MIKULECKY DC, 1983, AM J PHYSIOL, V245, pR1, DOI 10.1152/ajpregu.1983.245.1.R1; MORAN RG, 1976, J BIOL CHEM, V251, P3569; MORAN RG, 1982, P AM ASSOC CANC RES, V23, P698; SEITHER RL, 1989, J BIOL CHEM, V264, P17016; SEITHER RL, 1990, COMPUT MATH APPL, V200, P87; STRONG WB, 1990, J BIOL CHEM, V265, P12149; TRENT D F, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P342; TRENT D F, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P338; WHITE JC, 1981, J BIOL CHEM, V256, P5722; WHITE JC, 1981, PHARMACOL THERAPEUT, V15, P251; WHITE JC, 1979, J BIOL CHEM, V254, P889	29	10	10	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4112	4118						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1825652				2022-12-25	WOS:A1991FA69400017
J	BERKICH, DA; WILLIAMS, GD; MASIAKOS, PT; SMITH, MB; BOYER, PD; LANOUE, KF				BERKICH, DA; WILLIAMS, GD; MASIAKOS, PT; SMITH, MB; BOYER, PD; LANOUE, KF			RATES OF VARIOUS REACTIONS CATALYZED BY ATP SYNTHASE AS RELATED TO THE MECHANISM OF ATP SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERNATING SITE COOPERATIVITY; OXYGEN-EXCHANGE REACTIONS; OXIDATIVE-PHOSPHORYLATION; SUBUNIT INTERACTION; O-18 EXCHANGE; ADP RATIO; MITOCHONDRIA; TRANSPORT; PHOSPHATE; MEMBRANE	The forward and reverse rates of the overall reaction catalyzed by the ATP synthase in intact rat heart mitochondria, as measured with P-31, were compared with the rates of two partial steps, as measured with O-18. Such rates have been measured previously, but their relationship to one another has not been determined, nor have the partial reactions been measured in intact mitochondria. The partial steps measured were the rate of medium P(i) formation from bound ATP (in state 4 this also equals the rate of medium P(i) into bound ATP) and the rate of formation of bound ATP from bound P(i) within the catalytic site. The rates of both partial reactions can be measured by P-31 NMR analysis of the O-18 distribution in P(i) and ATP released from the enzyme during incubation of intact mitochondria with highly labeled ]O-18[P(i). Data were obtained in state 3 and 4 conditions with variation in substrate concentrations, temperature, and mitochondrial membrane electrical potential gradient (DELTA-PSI-m). Although neither binding nor release of ATP is necessary for phosphate/H2O exchange, in state 4 the rate of incorporation of at least one water oxygen atom into phosphate is approximately twice the rate of the overall reaction rate under a variety of conditions. This can be explained if the release of P(i) or ATP at one catalytic site does not occur, unless ATP or P(i) is bound at another catalytic site. Such coupling provides strong support for the previously proposed alternating site mechanism. In state 3 slow reversal of ATP synthesis occurs within the mitochondrial matrix and can be detected as incorporation of water oxygen atoms into medium P(i) even though medium [P-32]ATP does not give rise to P-32(i) in state 3. These data can be explained by lack of translocation of ATP from the medium to the mitochondrial matrix. The rate of bound ATP formation from bound P(i) at catalytic sites was over twice the rate of the overall reaction in both state 4 and 3. The rate of reaction at the catalytic site is considerably less sensitive to the decrease in membrane potential and the concentration of medium ADP than is the rate of medium ATP formation. This supports the view that the active catalytic site is occluded and proceeds at a rapid rate which is relatively independent of DELTA-PSI-m and of media substrates.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,DEPT CELLULAR & MOLEC PHYSIOL,POB 850,HERSHEY,PA 17033; PENN STATE UNIV,MILTON S HERSHEY MED CTR,DIV NUCL MAGNET RESONANCE RES,HERSHEY,PA 17033; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; PENN STATE UNIV,MILTON S HERSHEY MED CTR,DEPT RADIOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of California System; University of California Los Angeles; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NHLBI NIH HHS [5P01-HL18708] Funding Source: Medline; NIGMS NIH HHS [GM11094] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011094] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGINSKI ES, 1967, CLIN CHEM, V13, P326; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; CHANCE B, 1960, BIOCHEM BIOPH RES CO, V3, P1, DOI 10.1016/0006-291X(60)90091-7; CLELAND KW, 1953, BIOCHEM J, V53, P547, DOI 10.1042/bj0530547; COTY WA, 1974, J BIOL CHEM, V249, P2593; DAVIS EJ, 1978, BIOCHEM BIOPH RES CO, V83, P1260, DOI 10.1016/0006-291X(78)91357-8; ERICINSKA M, 1982, J MEMBRANE BIOL, V70, P1; Hackney D D, 1980, Methods Enzymol, V64, P60; HACKNEY DD, 1984, CURR TOP CELL REGUL, V24, P379; HACKNEY DD, 1978, J BIOL CHEM, V253, P3164; HACKNEY DD, 1978, P NATL ACAD SCI USA, V75, P3133, DOI 10.1073/pnas.75.7.3133; HACKNEY DD, 1979, P NATL ACAD SCI USA, V76, P3646, DOI 10.1073/pnas.76.8.3646; KLINGENBERG M, 1977, EUR J BIOCHEM, V73, P125, DOI 10.1111/j.1432-1033.1977.tb11298.x; Klingenberg M, 1976, ENZYMES BIOLOGICAL M, V3, P383; LANOUE KF, 1986, J BIOL CHEM, V261, P298; LANOUE KF, 1986, BIOCHEMISTRY-US, V25, P7667, DOI 10.1021/bi00371a058; LANOUE KF, 1979, ANNU REV BIOCHEM, V48, P871, DOI 10.1146/annurev.bi.48.070179.004255; LANOUE KF, 1989, 8TH SOC MAGN RES MED; MITCHELL RA, 1984, CURR TOP BIOENERG, V13, P203; ONEAL CC, 1984, J BIOL CHEM, V259, P5761; ROTTENBERG H, 1984, J MEMBRANE BIOL, V81, P127, DOI 10.1007/BF01868977; SAKS VA, 1975, EUR J BIOCHEM, V57, P273, DOI 10.1111/j.1432-1033.1975.tb02299.x; SINES JJ, 1986, BIOCHEMISTRY-US, V25, P6144, DOI 10.1021/bi00368a047; VERHOEVEN AJ, 1985, BIOCHEM J, V226, P183, DOI 10.1042/bj2260183; Williamson J.R., 1969, METHOD ENZYMOL, V13, P434, DOI 10.1016/0076-687913072-4	25	24	24	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					123	129						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1824691				2022-12-25	WOS:A1991EQ33900021
J	CHENG, L; QIAN, SJ; ROTHSCHILD, C; DAVIGNON, A; LEFKOWITH, JB; GORDON, JI; LI, E				CHENG, L; QIAN, SJ; ROTHSCHILD, C; DAVIGNON, A; LEFKOWITH, JB; GORDON, JI; LI, E			ALTERATION OF THE BINDING-SPECIFICITY OF CELLULAR RETINOL-BINDING PROTEIN-II BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID-BINDING; PERIPHERAL-NERVE MYELIN; ESCHERICHIA-COLI; P2 PROTEIN; RAT; SEQUENCE; GASTROTROPIN; EXPRESSION	Rat cellular retinol-binding protein II (CRBP II) is an abundant 134-residue intestinal protein that binds all-trans-retinol and all-trans-retinal. It belongs to a family of homologous, 15-kDa cytoplasmic proteins that bind hydrophobic ligands in a noncovalent fashion. These binding proteins include a number of proteins that bind long chain fatty acids. X-ray analyses of the structure of two family members, rat intestinal fatty acid-binding protein and bovine myelin P2 protein, indicate that they have a high degree of conformational similarity and that the carboxylate group of their bound fatty acid interacts with a delta-guanidium group of at least 1 of 2 "buried" arginine residues. These 2 Arg residues are conserved in other family members that bind long chain fatty acids and in cellular retinoic acid-binding protein, but are replaced by Gln109 and Gln129 in CRBP II. We have genetically engineered two amino acid substitutions in CRBP II: 1) Gln109 to Arg and 2) Gln129 to Arg. The purified Escherichia coli-derived CRBP II mutant proteins were analyzed by fluorescence and nuclear magnetic resonance spectroscopy. Both mutants exhibit markedly decreased binding of all-trans-retinol and all-trans-retinaldehyde, but no increased binding of all-trans-retinoic acid. Arg substitution for Gln109 but not for Gln129 produces a dramatic increase in palmitate binding activity. Analysis of the endogenous fatty acids associated with the purified E. coli-derived proteins revealed that E. coli-derived intestinal fatty acid binding protein and the Arg109 CRBP II mutant are complexed with endogenous fatty acids in a qualitatively and quantitatively similar manner. These results provide evidence that this internal Arg may play an important role in the binding of long chain fatty acids by members of this protein family.	WASHINGTON UNIV,SCH MED,DEPT MED,660 S EUCLID AVE,BOX 8051,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT CHEM,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040172, R01DK037879, R01DK030292, R37DK030292, R29DK040172] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37879, DK30292, DK40172] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERS DH, 1984, P NATL ACAD SCI-BIOL, V81, P313, DOI 10.1073/pnas.81.2.313; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOHMER FD, 1987, J BIOL CHEM, V262, P15137; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; CRONAN JE, 1975, BACTERIOL REV, V39, P232, DOI 10.1128/MMBR.39.3.232-256.1975; CROW JA, 1985, P NATL ACAD SCI USA, V82, P4707, DOI 10.1073/pnas.82.14.4707; DRAPEAU GR, 1968, J MOL BIOL, V35, P357, DOI 10.1016/S0022-2836(68)80030-0; GANTZ I, 1989, J BIOL CHEM, V264, P20248; GORDON JI, 1991, CURR OPIN LIPIDOL, V2, P125; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; KANESHIRO T, 1961, J BIOL CHEM, V236, P2615; KITAMURA K, 1980, FEBS LETT, V115, P27, DOI 10.1016/0014-5793(80)80719-8; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; LI E, 1991, J BIOL CHEM, V266, P3622; LI E, 1990, J BIOL CHEM, V265, P11549; LI E, 1989, J BIOL CHEM, V264, P17041; LI E, 1988, J BIOL CHEM, V262, P7118; LI E, 1986, P NATL ACAD SCI USA, V83, P8102; LOWE JB, 1987, J BIOL CHEM, V262, P5931; MACDONALD PN, 1987, J BIOL CHEM, V262, P10550; OLINS PO, 1990, METHOD ENZYMOL, V185, P115; ROPSON IJ, 1990, BIOCHEMISTRY-US, V29, P9591, DOI 10.1021/bi00493a013; SACCHETTINI JC, 1987, J BIOL CHEM, V262, P15756; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1986, J BIOL CHEM, V261, P8218; SACCHETTINI JC, 1988, J BIOL CHEM, V263, P5815; SACCHETTINI JC, 1990, MOL CELL BIOCHEM, V98, P81; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILBERT DF, 1968, J BACTERIOL, V95, P1658, DOI 10.1128/JB.95.5.1658-1665.1968; STUMP DG, 1991, J BIOL CHEM, V266, P4622; SUNDELIN J, 1985, J BIOL CHEM, V260, P6494; SUNDELIN J, 1985, J BIOL CHEM, V260, P6488; TAKAHASHI K, 1982, BIOCHEM BIOPH RES CO, V106, P1099, DOI 10.1016/0006-291X(82)91225-6; WALZ DA, 1988, J BIOL CHEM, V263, P14189; ZHANG J, 1989, J CELL BIOL, V109, P289	36	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24404	24412						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761542				2022-12-25	WOS:A1991GW84500028
J	BOTTALICO, LA; WAGER, RE; AGELLON, LB; ASSOIAN, RK; TABAS, I				BOTTALICO, LA; WAGER, RE; AGELLON, LB; ASSOIAN, RK; TABAS, I			TRANSFORMING GROWTH FACTOR-BETA-1 INHIBITS SCAVENGER RECEPTOR ACTIVITY IN THP-1 HUMAN MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; HUMAN MONOCYTE-MACROPHAGES; FATTY STREAK FORMATION; NONHUMAN PRIMATE; FACTOR-BETA; CELLS; HYPERCHOLESTEROLEMIA; CHOLESTEROL; METABOLISM; EXPRESSION	The macrophage scavenger receptor, a 220-kDa trimeric membrane glycoprotein, mediates the internalization of modified forms of low density lipoprotein (LDL) such as acetyl-LDL and oxidized-LDL and thus is likely to play a key role in atheroma macrophage foam cell formation. In addition, recent evidence suggests that the scavenger receptor may be an important macrophage binding site for lipopolysaccharide involved in lipopolysaccharide scavenging by macrophages. However, little is known about the regulation of this important receptor. We now report that the induction of scavenger receptor activity (as measured by acetyl-LDL stimulation of intracellular cholesterol esterification) seen in phorbol ester-differentiated THP-1 human macrophages was completely suppressed to the level seen in undifferentiated THP-1 monocytes by picomolar concentrations of transforming growth factor-beta-1 (TGF-beta-1). I-125-Acetyl-LDL degradation was inhibited in a dose-dependent manner by TGF-beta-1, with maximal inhibition (approximately 70%) occurring at 24 pm TGF-beta-1. Scatchard analysis revealed that TGF-beta-1 treatment resulted in a approximately 2-fold decrease in receptor number, and Northern blot analysis of RNA isolated from differentiated THP-1 macrophages demonstrated approximately 2-fold less scavenger receptor mRNA in TGF-beta-1-treated cells compared with that in macrophages not treated with TGF-beta-1. Since TGF-beta-1 is thought to be present in both atherosclerotic and inflammatory lesions, the above findings may have physiological relevance regarding the regulation of atheroma foam cell formation and/or the regulation of lipopolysaccharide clearance by macrophages.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, 630 W 168TH ST, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT ANAT & CELL BIOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, CTR REPROD SCI, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039703, R01HL038884, P50HL021006] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-21006, HL-38884, HL-39703] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; AVIRAM M, 1989, METABOLISM, V38, P425, DOI 10.1016/0026-0495(89)90192-3; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BROWN MS, 1990, NATURE, V343, P508, DOI 10.1038/343508a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FOGELMAN AM, 1981, J LIPID RES, V22, P1131; GERRITY RG, 1981, AM J PATHOL, V103, P181; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HABERLAND ME, 1986, J CLIN INVEST, V77, P681, DOI 10.1172/JCI112362; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HARA H, 1987, BIOCHEM BIOPH RES CO, V146, P802, DOI 10.1016/0006-291X(87)90601-2; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASUDA J, 1990, ARTERIOSCLEROSIS, V10, P164, DOI 10.1161/01.ATV.10.2.164; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; NATHAN CF, 1980, NEW ENGL J MED, V303, P622, DOI 10.1056/NEJM198009113031106; PHILLIPS DR, 1985, NATURE, V316, P746, DOI 10.1038/316746a0; ROBERTS AB, 1988, RECENT PROG HORM RES, V44, P157; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; SCHAFFNER T, 1980, AM J PATHOL, V100, P57; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TSUCHIYA S, 1982, CANCER RES, V42, P1530; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; VANLENTEN BJ, 1985, J IMMUNOL, V134, P3718; WAGER RE, 1990, MOL CELL BIOL, V10, P5983, DOI 10.1128/MCB.10.11.5983; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; XU XX, 1991, J BIOL CHEM, V266, P17040; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111	33	99	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22866	22871						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744079				2022-12-25	WOS:A1991GT48300017
J	KRABBE, M; CARLSON, K				KRABBE, M; CARLSON, K			INVIVO RESTRICTION - SEQUENCE AND STRUCTURE OF ENDONUCLEASE II-DEPENDENT CLEAVAGE SITES IN BACTERIOPHAGE-T4 DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSINE-CONTAINING DNA; ESCHERICHIA-COLI CTR5X; B-DNA; DEOXYRIBONUCLEIC ACID; TOPOISOMERASE-II; CRITHIDIA-FASCICULATA; MICROCOCCAL NUCLEASE; CRYSTAL-STRUCTURE; GENE-EXPRESSION; HELIX STRUCTURE	Endonuclease II of bacteriophage T4 is required for in vivo restriction of cytosine-containing DNA from its host, Escherichia coli, (as well as from phage mutants lacking cytosine modification), normally the first step in the reutilization of host DNA nucleotides for synthesis of phage DNA in infected cells. The phage cytosine-DNA is fragmented incompletely to yield genetically defined fragments. This restriction is different from that of type I, II, or III restriction enzymes. We have located seven major endonuclease II-dependent restriction sites in the T4 genome, of which three were analyzed in detail; in addition, abundant sites were cleaved in less-than-or-equal-to 5% of all molecules. Sites I, II, and III shared the sequence 5'-CCGNNTTGGC-3' and were cleaved in about 25% (I and III) and 65% (II) of all molecules, predominantly staggered around the first or second of the central unspecified base pairs to yield fragments with one 5' base. The less frequently cleaved sites I and III deviated from site II in predicted helical structure when viewed from the consensus strand, and in sequence when viewed from the opposite strand. Thus, interaction with a particular helical structure as well as recognition of the bases in DNA appears important for efficient cleavage.	UNIV UPPSALA,CTR BIOCHEM,DEPT MICROBIOL,S-75123 UPPSALA,SWEDEN	Uppsala University								AMITSUR M, 1989, EMBO J, V8, P2411, DOI 10.1002/j.1460-2075.1989.tb08371.x; ANDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P6237, DOI 10.1021/bi00441a015; ANSEVIN AT, 1990, NUCLEIC ACIDS RES, V18, P6119, DOI 10.1093/nar/18.20.6119; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; BROKER TR, 1975, ANNU REV GENET, V9, P213, DOI 10.1146/annurev.ge.09.120175.001241; CALLADINE CR, 1982, J MOL BIOL, V161, P343, DOI 10.1016/0022-2836(82)90157-7; CARLSON K, 1983, J VIROL, V48, P18, DOI 10.1128/JVI.48.1.18-30.1983; CARLSON K, 1986, GENETICS, V114, P669; CARLSON K, 1980, J VIROL, V36, P1; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICKERSON RE, 1983, J MOL BIOL, V166, P419, DOI 10.1016/S0022-2836(83)80093-X; DINGWALL C, 1981, NUCLEIC ACIDS RES, V9, P2659, DOI 10.1093/nar/9.12.2659; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; FISCHER LM, 1981, P NATL ACAD SCI USA, V78, P4165; FRASER D, 1953, J BIOL CHEM, V205, P291; FRATINI AV, 1982, J BIOL CHEM, V257, P4686; FRAZIER MW, 1990, GENE, V88, P7, DOI 10.1016/0378-1119(90)90053-T; FREDERICK CA, 1984, NATURE, V309, P327, DOI 10.1038/309327a0; GRALLA JD, 1989, CELL, V57, P193, DOI 10.1016/0092-8674(89)90955-0; HERCULES K, 1971, J VIROL, V7, P95, DOI 10.1128/JVI.7.1.95-105.1971; HOMYK T, 1974, VIROLOGY, V61, P505, DOI 10.1016/0042-6822(74)90286-4; HORZ W, 1981, NUCLEIC ACIDS RES, V9, P2643, DOI 10.1093/nar/9.12.2643; HOSODA J, 1971, J VIROL, V8, P372, DOI 10.1128/JVI.8.4.372-387.1971; HOSODA J, 1976, J MOL BIOL, V106, P277, DOI 10.1016/0022-2836(76)90085-1; KAUFMANN G, 1986, J MOL BIOL, V188, P15, DOI 10.1016/0022-2836(86)90476-6; KEENE MA, 1984, CELL, V36, P121, DOI 10.1016/0092-8674(84)90080-1; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KOLATA G, 1983, SCIENCE, V222, P495, DOI 10.1126/science.6623088; KREUZER KN, 1984, J BIOL CHEM, V259, P5339; KREUZER KN, 1983, BACTERIOPHAGE T, V4, P90; KUTTER EM, 1968, J MOL BIOL, V38, P395, DOI 10.1016/0022-2836(68)90394-X; KUTTER EM, 1990, GENETIC MAPS; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LINIAL M, 1987, P NATL ACAD SCI USA, V84, P8205, DOI 10.1073/pnas.84.23.8205; LINIAL M, 1988, J BIOL CHEM, V263, P290; LOCKSHON D, 1985, J MOL BIOL, V181, P63, DOI 10.1016/0022-2836(85)90324-9; LOMONOSSOFF GP, 1981, J MOL BIOL, V149, P745, DOI 10.1016/0022-2836(81)90356-9; LUDER A, 1982, P NATL ACAD SCI-BIOL, V79, P1101, DOI 10.1073/pnas.79.4.1101; MACDONALD PM, 1984, GENETICS, V106, P1; MACDONALD PM, 1984, EMBO J, V3, P2863, DOI 10.1002/j.1460-2075.1984.tb02221.x; Maniatis T., 1982, MOL CLONING; MARMUR J, 1962, J MOL BIOL, V5, P109, DOI 10.1016/S0022-2836(62)80066-7; MARSH RC, 1981, J VIROL, V38, P104, DOI 10.1128/JVI.38.1.104-114.1981; MARX JL, 1985, SCIENCE, V230, P794, DOI 10.1126/science.2997919; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MOSIG G, 1975, J VIROL, V17, P756; MOSIG G, 1988, BACTERIOPHAGES, V2, P521; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PATEL DJ, 1983, P NATL ACAD SCI-BIOL, V80, P3908, DOI 10.1073/pnas.80.13.3908; PRUSS GJ, 1989, CELL, V56, P521, DOI 10.1016/0092-8674(89)90574-6; REZNIKOFF WS, 1985, ANNU REV GENET, V19, P355, DOI 10.1146/annurev.genet.19.1.355; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; SADOWSKI PD, 1972, J BIOL CHEM, V247, P405; SADOWSKI PD, 1969, J BIOL CHEM, V244, P6182; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; SHEN CC, 1990, J MOL BIOL, V212, P67, DOI 10.1016/0022-2836(90)90305-6; SINDEN RR, 1982, J MOL BIOL, V162, P659, DOI 10.1016/0022-2836(82)90394-1; SNYDER L, 1976, P NATL ACAD SCI USA, V73, P3098, DOI 10.1073/pnas.73.9.3098; SPICER EK, 1988, J BIOL CHEM, V263, P7478; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; TANNER D, 1971, BIOCHIM BIOPHYS ACTA, V228, P767, DOI 10.1016/0005-2787(71)90747-7; TUNG CS, 1987, NUCLEIC ACIDS RES, V15, P4973, DOI 10.1093/nar/15.12.4973; TUNG CS, 1984, NUCLEIC ACIDS RES, V12, P3343, DOI 10.1093/nar/12.7.3343; TUNG CS, 1986, J BIOL CHEM, V261, P3700; TUNG CS, 1986, NUCLEIC ACIDS RES, V14, P381, DOI 10.1093/nar/14.1.381; WARNER HR, 1971, J VIROL, V7, P534, DOI 10.1128/JVI.7.4.534-536.1971; WARNER HR, 1970, J VIROL, V5, P700, DOI 10.1128/JVI.5.6.700-708.1970; WARNER HR, 1983, BACTERIOPHAGE T, V4, P103; WIBERG JS, 1966, P NATL ACAD SCI USA, V55, P614, DOI 10.1073/pnas.55.3.614; WOOD WB, 1966, BACTERIOL REV, V40, P847; YOON C, 1988, P NATL ACAD SCI USA, V85, P6332, DOI 10.1073/pnas.85.17.6332; ZAHN K, 1987, SCIENCE, V236, P416, DOI 10.1126/science.2951850; 1989, EMBO J, V8, P1	77	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23407	23415						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744134				2022-12-25	WOS:A1991GT48300094
J	WANG, WC; LEE, N; AOKI, D; FUKUDA, MN; FUKUDA, M				WANG, WC; LEE, N; AOKI, D; FUKUDA, MN; FUKUDA, M			THE POLY-N-ACETYLLACTOSAMINES ATTACHED TO LYSOSOMAL MEMBRANE-GLYCOPROTEINS ARE INCREASED BY THE PROLONGED ASSOCIATION WITH THE GOLGI-COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASN-LINKED OLIGOSACCHARIDES; HAMSTER OVARY CELLS; ANEMIA TYPE-II; PLASMA-MEMBRANE; HUMAN-GRANULOCYTES; SIALYL-LEX; CARBOHYDRATE; PROTEINS; ADHESION; LACTOSAMINOGLYCAN	The poly-N-acetyllactosamines on neutrophils and monocytes have been shown to serve as ligands for various selectins present on endothelial cells and platelets. We have previously shown that only a limited number of glycoproteins contain poly-N-acetyllactosamine and found that lysosomal membrane glycoproteins (lamps) are the major glycoproteins carrying poly-N-acetyllactosamine. In order to understand the reason why only certain glycoproteins can be modified by poly-N-acetyllactosamine, we have utilized 21-degrees-C incubation conditions, which were previously shown to cause the accumulation of glycoproteins at the trans-Golgi. HL-60 cells were labeled with [H-3]galactose at 21 or 37-degrees-C for 6 or 24 h, and lamp-1 and lamp-2 were immunoprecipitated. Upon examination by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, each lamp from HL-60 cells incubated at 21-degrees-C exhibited a much broader, slower migrating band than that isolated from the cells incubated at 37-degrees-C. The number of N-glycans containing poly-N-acetyllactosamine, estimated by their binding to tomato lectin column, increased approximately 30-50% after incubation at 21-degrees-C than incubation at 37-degrees-C. The analysis of oligosaccharides released by endo-beta-galactosidase digestion demonstrates that the amount of side chains containing three or more N-acetyllactosamine repeats increased about 100% after incubation at 21-degrees-C, and methylation analysis confirmed these results. The same analysis and the results obtained by ion-exchange chromatography also provided evidence that the N-glycans of lamps are sialylated at 21-degrees-C as much as at 37-degrees-C. Pulse-chase experiments using [S-35]methionine labeling indicated that the time necessary for processing of lamps is much longer at 21-degrees-C than at 37-degrees-C. These results therefore indicate that incubation at 21-degrees-C causes the lamps to reside longer within the Golgi complex, and such longer residence allows lamps to acquire more polylactosaminoglycan. These results also suggest that the time necessary for moving through the Golgi complex is a critical factor for poly-N-acetyllactosamine formation.			WANG, WC (corresponding author), LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037, USA.		Aoki, Daisuke/E-6650-2014		NATIONAL CANCER INSTITUTE [R01CA048737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037016] Funding Source: NIH RePORTER; NCI NIH HHS [CA48737] Funding Source: Medline; NIDDK NIH HHS [DK37016] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; DUNN WA, 1980, J BIOL CHEM, V255, P5971; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FUKUDA M, 1988, J BIOL CHEM, V263, P5314; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA M, 1984, BIOL GLYCOPROTEINS, P183; FUKUDA MN, 1986, BLOOD, V68, P521; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; FUKUDA MN, 1987, J BIOL CHEM, V262, P7195; FULLER SD, 1985, EMBO J, V4, P297, DOI 10.1002/j.1460-2075.1985.tb03629.x; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LEE N, 1990, J BIOL CHEM, V265, P20476; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MANE SM, 1989, ARCH BIOCHEM BIOPHYS, V268, P360, DOI 10.1016/0003-9861(89)90597-3; MARSH M, 1983, CELL, V32, P931, DOI 10.1016/0092-8674(83)90078-8; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MERKLE RK, 1988, J BIOL CHEM, V263, P16143; NOVIKOFF AB, 1977, HISTOCHEM J, V9, P525, DOI 10.1007/BF01002901; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PILLER F, 1983, J BIOL CHEM, V258, P2293; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; SASAKI H, 1987, J BIOL CHEM, V262, P12059; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SPOONCER E, 1984, J BIOL CHEM, V259, P4792; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WANG WC, 1988, J BIOL CHEM, V263, P4576; WATTENBERG BW, 1990, J CELL PHYSIOL, V143, P287, DOI 10.1002/jcp.1041430212; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476	38	63	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23185	23190						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744116				2022-12-25	WOS:A1991GT48300064
J	ZON, LI; GURISH, MF; STEVENS, RL; MATHER, C; REYNOLDS, DS; AUSTEN, KF; ORKIN, SH				ZON, LI; GURISH, MF; STEVENS, RL; MATHER, C; REYNOLDS, DS; AUSTEN, KF; ORKIN, SH			GATA-BINDING TRANSCRIPTION FACTORS IN MAST-CELLS REGULATE THE PROMOTER OF THE MAST-CELL CARBOXYPEPTIDASE-A GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE BONE-MARROW; CONNECTIVE-TISSUE-TYPE; MOLECULAR-CLONING; DNA-POLYMERASE; GROWTH-FACTOR; EXPRESSION; DIFFERENTIATION; PROTEIN; RNA; IDENTIFICATION	The transcription factors GATA-1, GATA-2, and GATA-3 were found to be expressed in several mouse and rat mast cell lines that contain mast cell carboxypeptidase A (MC-CPA) and other proteases in their cytoplasmic granules. GATA-1 mRNA was not detected in P815 cells, an immature mouse mastocytoma-derived cell line that lacks electron-dense granules and has low levels of secretory granule proteases. Because the 5'-flanking regions of the mouse and human MC-CPA genes contained a conserved GATA-binding motif 51 base pairs upstream of their translation initiation sites, the ability of GATA-binding proteins to regulate the promoter activity of the MC-CPA gene was examined in rat basophilic leukemia cells, mouse P815 cells, and transfected mouse P815 cells that expressed GATA-1. In all three mast cell lines, the promoter activity of the MC-CPA gene depended on the GATA binding site. GATA-1, GATA-2, and GATA-3 are thus the first DNA-binding proteins identified in mast cells which regulate the promoter activity of a gene that encodes a secretory granule protease.	HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL & IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HOWARD HUGES MED INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	ZON, LI (corresponding author), CHILDRENS HOSP MED CTR,DEPT PEDIAT,DIV HEMATOL ONCOL,300 LONGWOOD AVE,ENDERS 761,BOSTON,MA 02115, USA.				NHLBI NIH HHS [HL-02347] Funding Source: Medline; NIAID NIH HHS [AI-22531, AI-23483] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023483, R01AI022531, R37AI022531] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUBUSKE L, 1984, J IMMUNOL, V133, P1535; DUNN TB, 1957, J NATL CANCER I, V18, P587; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; LEE JJ, 1986, J MOL BIOL, V188, P173, DOI 10.1016/0022-2836(86)90302-5; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MCNEIL HP, IN PRESS J BIOL CHEM; NABEL G, 1981, NATURE, V291, P332, DOI 10.1038/291332a0; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; PERKINS ND, 1989, NUCLEIC ACIDS RES, V17, P1299, DOI 10.1093/nar/17.4.1299; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RAZIN E, 1981, P NATL ACAD SCI-BIOL, V78, P2559, DOI 10.1073/pnas.78.4.2559; RAZIN E, 1984, J IMMUNOL, V132, P1479; RAZIN E, 1982, J BIOL CHEM, V257, P7229; REYNOLDS DS, 1989, P NATL ACAD SCI USA, V86, P9480, DOI 10.1073/pnas.86.23.9480; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1988, J BIOL CHEM, V263, P12783; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SCHRADER JW, 1981, P NATL ACAD SCI-BIOL, V78, P323, DOI 10.1073/pnas.78.1.323; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SELDIN DC, 1985, P NATL ACAD SCI USA, V82, P3871, DOI 10.1073/pnas.82.11.3871; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SERAFIN WE, 1987, J IMMUNOL, V139, P3771; SERAFIN WE, 1986, J BIOL CHEM, V261, P5017; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; TERTIAN G, 1981, J IMMUNOL, V127, P788; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON HL, 1990, J CLIN INVEST, V85, P1227, DOI 10.1172/JCI114557; Trong H Le, 1989, BIOCHEMISTRY-US, V28, P391, DOI 10.1021/BI00427A054; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZON L I, 1991, Journal of Allergy and Clinical Immunology, V87, P350, DOI 10.1016/0091-6749(91)92125-K; ZON LI, 1990, P NATL ACAD SCI USA, V87, P668, DOI 10.1073/pnas.87.2.668	48	148	152	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22948	22953						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744088				2022-12-25	WOS:A1991GT48300029
J	TRINCHERA, M; FABBRI, M; GHIDONI, R				TRINCHERA, M; FABBRI, M; GHIDONI, R			TOPOGRAPHY OF GLYCOSYLTRANSFERASES INVOLVED IN THE INITIAL GLYCOSYLATIONS OF GANGLIOSIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL MUTANT DEFICIENT; RAT-LIVER; GOLGI-APPARATUS; GM1 GANGLIOSIDE; UDP-GALACTOSE; TUBULAR CELLS; BREFELDIN-A; BIOSYNTHESIS; LOCALIZATION; LACTOSYLCERAMIDE	We attempted to establish within which organelle UDP-Glc:ceramide beta-1 --> 1'glucosyltransferase (GlcT) is located and moreover to obtain information about its orientation on intracellular membranes as well as that of UDP-Gal:glucosylceramide beta-1 --> 4galactosyltransferase (GalT-2) and CMP-NeuAc:lactosylceramide alpha-2 --> 3sialyltransferase (SAT-1). An extremely purified Golgi apparatus fraction was the only liver fraction where a ceramide-dependent formation of glucosylceramide could be demonstrated. This Golgi fraction, mainly constituted by stacks of intact cisternae which retained the same topographical orientation as in vivo, was then incubated with liposomal dispersions of glycosphingolipid-glycosyltransferase acceptors in reaction mixtures containing all the requirements for enzyme activity but no detergent. Under such conditions, SAT-1 and other late acting glycosyltransferases were over 90% latent, while both GlcT and GalT-2 were just as active as in the detergent-containing assay; they were still inhibited by EDTA. Sepharose-immobilized ceramide and Sepharose-immobilized glucosylceramide were found to be suitable acceptors for GlcT and GalT-2, respectively, still using intact Golgi cisternae as the enzyme source. Moreover, a part of GlcT and GalT-2 activity was released from intact Golgi cisternae upon cathepsin D treatment. These results provide strong evidence that GlcT and GalT-2 face the cytoplasmic side of the Golgi apparatus, whereas SAT-1 and the other late acting enzymes face the luminal side.			TRINCHERA, M (corresponding author), UNIV MILAN,DEPT MED CHEM & BIOCHEM,VIA SALDINI 50,I-20133 MILAN,ITALY.			GHIDONI, RICCARDO/0000-0002-6300-5867				ABEIJON C, 1990, J BIOL CHEM, V265, P14691; BRANDLI AW, 1988, J BIOL CHEM, V263, P16283; BRILES EB, 1977, J BIOL CHEM, V252, P1107; CAHAN LD, 1982, P NATL ACAD SCI-BIOL, V79, P7629, DOI 10.1073/pnas.79.24.7629; CAPASSO JM, 1988, J BIOL CHEM, V263, P19778; CHATTERJEE S, 1988, J BIOL CHEM, V263, P13017; CHATTERJEE S, 1983, P NATL ACAD SCI-BIOL, V80, P1313, DOI 10.1073/pnas.80.5.1313; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DUBOIS G, 1980, ANAL BIOCHEM, V102, P313, DOI 10.1016/0003-2697(80)90159-1; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; GHIDONI R, 1980, J BIOL CHEM, V255, P6990; GHIDONI R, 1986, BIOCHEM J, V237, P147, DOI 10.1042/bj2370147; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; KEENAN TW, 1974, J BIOL CHEM, V249, P310; LAMMERS G, 1988, BIOCHEM J, V256, P623, DOI 10.1042/bj2560623; MAKITA A, 1985, NEW COMPREHENSIVE BI, V10, P1; MASSERINI M, 1985, CHEM PHYS LIPIDS, V37, P83, DOI 10.1016/0009-3084(85)90076-3; MCMASTER MC, 1976, J LABELLED COMPD RAD, V23, P353; MORRE DM, 1988, EUR J CELL BIOL, V46, P307; Pagano RE, 1990, CURR OPIN CELL BIOL, V2, P652, DOI 10.1016/0955-0674(90)90107-P; PILLER V, 1990, J BIOL CHEM, V265, P9264; ROTH J, 1986, J BIOL CHEM, V261, P14307; SASAKI T, 1990, EXPERIENTIA, V46, P611, DOI 10.1007/BF01939700; SONNINO S, 1985, J LIPID RES, V26, P248; SONNINO S, 1990, CHEM PHYS LIPIDS, V52, P231, DOI 10.1016/0009-3084(90)90119-C; SONNINO S, 1989, BIOCHEMISTRY-US, V28, P77, DOI 10.1021/bi00427a012; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; SYMINGTON FW, 1987, J BIOL CHEM, V262, P11356; TAATJES DJ, 1988, J BIOL CHEM, V263, P6302; TETTAMAN.G, 1973, BIOCHIM BIOPHYS ACTA, V296, P160, DOI 10.1016/0005-2760(73)90055-6; TRINCHERA M, 1991, J BIOL CHEM, V266, P9093; TRINCHERA M, 1989, J BIOL CHEM, V264, P15766; TRINCHERA M, 1990, BIOCHEM J, V266, P363, DOI 10.1042/bj2660363; TRINCHERA M, 1991, BIOCHEMISTRY-US, V30, P2719, DOI 10.1021/bi00224a021; TRINCHERA M, 1990, BIOCHEM J, V270, P815, DOI 10.1042/bj2700815; TRINCHERA M, 1987, J IBOL CHEM, V138, P5575; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; WALTER VP, 1983, BIOCHIM BIOPHYS ACTA, V750, P346, DOI 10.1016/0005-2760(83)90039-5; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838; YUSUF HKM, 1983, P NATL ACAD SCI-BIOL, V80, P7075, DOI 10.1073/pnas.80.23.7075; 1977, LIPIDS, V12, P455	42	89	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20907	20912						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1834652				2022-12-25	WOS:A1991GN00100051
J	GHISLAIN, M; GOFFEAU, A				GHISLAIN, M; GOFFEAU, A			THE PMA1 AND PMA2 H+-ATPASES FROM SCHIZOSACCHAROMYCES-POMBE ARE FUNCTIONALLY INTERCHANGEABLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE ATPASE; SACCHAROMYCES-CEREVISIAE; YEAST; SEQUENCE; GENE; PROTEINS; ACTIVATION; HOMOLOGY; MUTATION; GROWTH	The pma2 gene of Schizosaccharomyces pombe codes for a polypeptide having a predicted M(r) of 110,126 and which is 79% identical to the plasma membrane H+-ATPase encoded by the pma1 gene. The pma2 gene, unlike pma1, is weakly expressed and not essential to mitotic growth. By constructing yeast strains in which the chromosomal pma2 gene is under control of the adh promoter, it has been possible to identify the over-produced ATPase in plasma membrane via formation of a phosphoenzyme. In a pma1-1 mutant strain whose ATPase activity is insensitive to vanadate, the over-expressed pma2 gene restores vanadate sensitivity. It also rescues a pma1 null mutant from lethality. These results demonstrate that the two H+-ATPases are functionally interchangeable in vivo but differently expressed.	CATHOLIC UNIV LOUVAIN, UNITE BIOCHIM PHYSIOL, PL CROIX SUD 2, B-1348 LOUVAIN, BELGIUM	Universite Catholique Louvain								ADDISON R, 1986, J BIOL CHEM, V261, P4896; AMORY A, 1980, J BIOL CHEM, V255, P9353; BARNES WM, 1983, METHOD ENZYMOL, V101, P98; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; CLEMENT JD, 1986, PLANT SCI, V5, P43; DUFOUR JP, 1988, METHOD ENZYMOL, V157, P513; ERASO P, 1987, FEBS LETT, V224, P193, DOI 10.1016/0014-5793(87)80446-5; GHISLAIN M, 1987, J BIOL CHEM, V262, P17549; GOFFEAU A, 1990, MONOVALENT CATIONS B, P155; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; ITOH H, 1983, J BACTERIOL, V153, P163; Johnson B.F, 1989, MOL BIOL FISSION YEA, P243; KOHLI J, 1987, CURR GENET, V11, P575, DOI 10.1007/BF00393919; KOLAROV J, 1988, J BIOL CHEM, V263, P10613; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; MCDONOUGH JP, 1982, J BIOL CHEM, V257, P4579; NAKAMOTO RK, 1989, J BIOENERG BIOMEMBR, V21, P621, DOI 10.1007/BF00808117; PORTILLO F, 1985, FEBS LETT, V192, P95, DOI 10.1016/0014-5793(85)80050-8; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSER A, 1988, J BIOL CHEM, V263, P19480; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUISSA M, 1983, ANAL BIOCHEM, V133, P511, DOI 10.1016/0003-2697(83)90117-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULASZEWSKI S, 1987, J BIOL CHEM, V262, P223; ULASZEWSKI S, 1983, EUR J BIOCHEM, V130, P235, DOI 10.1111/j.1432-1033.1983.tb07141.x; YANAGITA Y, 1987, P NATL ACAD SCI USA, V84, P925, DOI 10.1073/pnas.84.4.925	33	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18276	18279						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1833395				2022-12-25	WOS:A1991GG55300084
J	MATSUDA, S; MAEKAWA, T; ISHII, S				MATSUDA, S; MAEKAWA, T; ISHII, S			IDENTIFICATION OF THE FUNCTIONAL DOMAINS OF THE TRANSCRIPTIONAL REGULATOR CRE-BP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER STRUCTURE; AMP-RESPONSIVE ELEMENT; ATF CDNA CLONES; CYCLIC-AMP; FACTOR CREB; SOMATOSTATIN GENE; BINDING; PHOSPHORYLATION; PROTEINS; CELLS	We present evidence that CRE-BP1 binding to the cyclic AMP (cAMP) response element (CRE) is a transcriptional activator. Transcriptional activation was assayed by cotransfection into CV-1 cells of a CRE-BP1 expression plasmid together with a reporter plasmid in which the thymidine kinase promoter and four tandem repeats of CRE were linked to the chloramphenicol acetyltransferase (CAT) gene. Cotransfection with the CRE-BP1 expression plasmid caused an 8-fold stimulation of CAT activity, while cotransfection with the plasmids to express CRE-BP1 and c-Jun induced a 32-fold stimulation of CAT activity, suggesting that a heterodimer of CRE-BP1 with c-Jun is a stronger trans-activator than a homodimer of CRE-BP1. By using a series of deletion and point mutants of CRE-BP1 in this cotransfection assay, two functional domains of CRE-BP1 were identified: the putative metal finger structure in the amino-terminal region and the leucine zipper motif linked to a cluster of basic amino acids in the carboxyl-terminal region. The former was a transcriptional activation domain in the absence of c-Jun. The latter was a DNA-binding domain, and was essential in both the presence and absence of c-Jun.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC GENET LAB,TSUKUBA,IBARAKI 305,JAPAN	RIKEN			Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; FRIEDMAN DL, 1984, HDB EXP PHARM, V58, P151; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Higuchi R., 1989, PCR TECHNOLOGY, P61; HIRAI SI, 1990, ONCOGENE, V5, P39; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KANEIISHII C, 1989, NUCLEIC ACIDS RES, V17, P1521, DOI 10.1093/nar/17.4.1521; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; TAKEDA J, 1991, IN PRESS ONCOGENE, V6; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	26	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18188	18193						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1833393				2022-12-25	WOS:A1991GG55300072
J	HALL, FL; BRAUN, RK; MIHARA, K; FUNG, YKT; BERNDT, N; CARBONAROHALL, DA; VULLIET, PR				HALL, FL; BRAUN, RK; MIHARA, K; FUNG, YKT; BERNDT, N; CARBONAROHALL, DA; VULLIET, PR			CHARACTERIZATION OF THE CYTOPLASMIC PROLINE-DIRECTED PROTEIN-KINASE IN PROLIFERATIVE CELLS AND TISSUES AS A HETERODIMER COMPRISED OF P34CDC2 AND P58CYCLIN A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATURATION-PROMOTING FACTOR; CYCLE CONTROL GENE; YEAST SCHIZOSACCHAROMYCES-POMBE; GROWTH-FACTOR RECEPTOR; HISTONE H-1 KINASE; HUMAN CDC2 PROTEIN; FISSION YEAST; M-PHASE; TYROSINE-HYDROXYLASE; MITOTIC CONTROL	Site-specific analysis of tyrosine hydroxylase phosphorylation in rat pheochromocytoma led previously to the identification of a novel growth factor-sensitive serine/threonine protein kinase, designated proline-directed protein kinase (PDPK). In this article we describe further the activation, purification, subunit configuration, and biochemical characteristics of this cytoplasmic enzyme system. In human A431 epidermoid carcinoma cells PDPK activity was found to be stimulated by epidermal growth factor in a dose-dependent, time-dependent manner. The PDPK purified from the cytosol of mouse FM3A mammary carcinoma cells exhibited the same chromatographic behavior and biochemical properties as the tyrosine hydroxylase-associated enzyme purified originally from rat pheochromocytoma. The presence of p34cdc2 was ultimately detected in all active fractions of highly purified PDPK by Western blotting and immunoprecipitation; however, it was determined that this catalytic subunit is complexed with a 58-kDa regulatory subunit that is clearly distinct from that of the "growth-associated" M phase-specific histone H1 kinase (i.e. cyclin B). The 58-kDa regulatory subunit of PDPK was identified by direct immunoblotting as a mammalian A-type cyclin. Furthermore, the p58cyclinA subunit of PDPK was found to be phosphorylated on tyrosine residues in vivo and in vitro, the latter of which resulted in a significant increase in PDPK activity. Additional distinctions between this growth factor-sensitive PDPK (p34cdc2-p58cyclinA) and the M phase-specific histone H1 kinase (p34cdc2-p62cyclinB-p13suc1) are identified on the basis of chromatographic behavior, enzyme kinetics, and physicochemical properties. Based on these findings, it is proposed that PDPK represents a unique complex of the p34cdc2 protein kinase which is active in the cytoplasm of proliferative cells, is regulated differently from the M phase-specific histone H1 kinase by phosphorylation reactions, and is modualted selectively growth factors.	UNIV SO CALIF,CHILDRENS HOSP LOS ANGELES,SCH MED,DIV HEMATOL ONCOL & OPHTHALMOL,LOS ANGELES,CA 90054; UNIV SO CALIF,CHILDRENS HOSP LOS ANGELES,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90054; UNIV SO CALIF,SCH PHARM,LOS ANGELES,CA 90054; UNIV CALIF DAVIS,SCH VET MED,DEPT VET PHARMACOL & TOXICOL,DAVIS,CA 95616	Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California; University of Southern California; University of California System; University of California Davis	HALL, FL (corresponding author), UNIV SO CALIF,CHILDRENS HOSP LOS ANGELES,SCH MED,DIV ORTHOPAED SURG,4650 SUNSET BLVD,POB 54700,LOS ANGELES,CA 90054, USA.			Braun, Rudolf/0000-0002-1778-9613	NCI NIH HHS [CA44754] Funding Source: Medline; NEI NIH HHS [EY07846] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044754, R29CA044754] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY007846] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANANTHANARAYANAN VS, 1984, ARCH BIOCHEM BIOPHYS, V232, P482, DOI 10.1016/0003-9861(84)90565-4; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; Braun R K, 1989, Proc West Pharmacol Soc, V32, P15; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; CAMPBELL DG, 1986, J BIOL CHEM, V261, P489; CHAMBERS TC, 1990, J BIOL CHEM, V265, P16940; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ERIKSON E, 1989, J BIOL CHEM, V264, P19577; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAGAN I, 1988, J CELL SCI, V91, P587; Hall F L, 1989, Proc West Pharmacol Soc, V32, P1; HALL FL, 1990, J BIOL CHEM, V265, P6944; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; Kulp K S, 1990, Proc West Pharmacol Soc, V33, P219; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LANGAN TA, 1980, PROTEIN PHOSPHORYLAT, P70; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; Nestler E. J., 1984, PROTEIN PHOSPHORYLAT; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PARDEE AB, 1987, CANCER RES, V47, P1488; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; ROMANO C, 1987, J NEUROSCI, V7, P1300; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; Vulliet P R, 1988, Proc West Pharmacol Soc, V31, P255; VULLIET PR, 1985, FEBS LETT, V182, P335, DOI 10.1016/0014-5793(85)80328-8; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0	60	74	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17430	17440						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1832672				2022-12-25	WOS:A1991GF44500069
J	PAUDEL, HK; CARLSON, GM				PAUDEL, HK; CARLSON, GM			THE ATPASE ACTIVITY OF PHOSPHORYLASE-KINASE IS REGULATED IN PARALLEL WITH ITS PROTEIN-KINASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT-SKELETAL-MUSCLE; GAMMA-SUBUNIT; CATALYTIC SUBUNIT; ALPHA-SUBUNIT; B KINASE; ACTIVATION; BINDING; AUTOPHOSPHORYLATION; MECHANISM; ASSAYS	Phosphorylase kinase from rabbit skeletal muscle has been found to have an intrinsic ATPase activity that occurs at a rate approximately 0.2% of that of its phosphorylase conversion activity and about three times that of its autophosphorylation activity. The characteristics of this ATPase activity were in all aspects tested essentially the same as the kinase's phosphorylase conversion activity. The ATPase requires Mg2+ and is dramatically stimulated by Ca2+ ions. At neutral pH there is a pronounced lag in the rate of product formation that is not present at alkaline pH, a condition that greatly stimulates both the phosphorylase conversion and ATPase activities. ATP is preferentially hydrolyzed over GTP and the K(m) for MgATP determined in the ATPase assay is 0.14 mM. ADP, an allosteric activator of phosphorylase conversion, also stimulates the ATPase activity, whereas beta-glycerophosphate, an inhibitor of phosphorylase conversion, is an inhibitor of the ATPase activity. Phosphorylation or partial proteolysis of the kinase, which are known to activate phosphorylase conversion, also activate the ATPase activity. Because the phosphorylase conversion and ATPase activities are regulated in parallel, we conclude that activation of the two catalytic activities must share a common underlying basis, namely an enhanced phosphotransferase activity that is independent of the phosphoryl acceptor.	UNIV TENNESSEE,CTR HLTH SCI,COLL MED,DEPT BIOCHEM,800 MADISON AVE,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032953] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 32953] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARMSTRONG RN, 1979, P NATL ACAD SCI USA, V76, P722, DOI 10.1073/pnas.76.2.722; BROSTROM CO, 1971, J BIOL CHEM, V246, P1961; CHENG A, 1988, J BIOL CHEM, V263, P5543; CHENG A, 1985, J BIOL CHEM, V260, P2535; Cleland W W, 1979, Methods Enzymol, V63, P103; CLERCH LB, 1972, BIOCHIM BIOPHYS ACTA, V268, P654, DOI 10.1016/0005-2744(72)90269-0; COHEN P, 1973, EUR J BIOCHEM, V34, P1, DOI 10.1111/j.1432-1033.1973.tb02721.x; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1978, FEBS LETT, V92, P287, DOI 10.1016/0014-5793(78)80772-8; FISCHER EDMOND H., 1958, JOUR BIOL CHEM, V231, P65; FITZGERALD TJ, 1984, J BIOL CHEM, V259, P3266; Gulyaeva N. V., 1977, BIOKHIMIYA, V43, P373; HALLENBECK PC, 1983, J BIOL CHEM, V258, P3493; HAYAKAWA T, 1973, BIOCHEMISTRY-US, V12, P574, DOI 10.1021/bi00728a002; Johnson R A, 1979, Adv Cyclic Nucleotide Res, V10, P135; KASTENSCHMIDT LL, 1968, BIOCHEMISTRY-US, V7, P3590, DOI 10.1021/bi00850a037; KEE SM, 1986, J BIOL CHEM, V261, P4732; KIM G, 1973, BIOCHEMISTRY-US, V12, P2090, DOI 10.1021/bi00735a011; KING MM, 1982, J BIOL CHEM, V257, P4058; KING MM, 1983, J BIOL CHEM, V258, P9925; KING MM, 1981, J BIOL CHEM, V256, P1058; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KREBS EG, 1959, J BIOL CHEM, V234, P2867; KREBS EG, 1964, BIOCHEMISTRY-US, V3, P1022, DOI 10.1021/bi00896a003; MOLL GW, 1976, J BIOL CHEM, V251, P3993; OIKONOMAKOS NG, 1989, ARCH BIOCHEM BIOPHYS, V270, P62, DOI 10.1016/0003-9861(89)90007-6; PAUDEL HK, 1987, J BIOL CHEM, V262, P11912; PAUDEL HK, 1990, FASEB J, V4, pA2313; Pickett-Gies CA., 1986, ENZYMES, V17, P395; POLLARD TD, 1982, METHOD ENZYMOL, V85, P123; REIMANN EM, 1984, BIOCHEMISTRY-US, V23, P4185, DOI 10.1021/bi00313a027; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SALERNO A, 1990, J BIOL CHEM, V265, P18079; SILBERMAN SR, 1984, J BIOL CHEM, V259, P2913; SKUSTER JR, 1980, J BIOL CHEM, V255, P2203; SUGDEN PH, 1976, BIOCHEM J, V159, P409, DOI 10.1042/bj1590409; TABATABAI LB, 1978, J BIOL CHEM, V253, P2196; TREMPE MR, 1987, J BIOL CHEM, V262, P4333; WALSH DA, 1971, J BIOL CHEM, V246, P1968; WANG JH, 1976, J BIOL CHEM, V251, P4521; YOON MY, 1987, BIOCHEMISTRY-US, V26, P4118, DOI 10.1021/bi00387a056; ZAMAN N, 1989, EUR J BIOCHEM, V182, P577, DOI 10.1111/j.1432-1033.1989.tb14866.x	42	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16524	16529						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1832156				2022-12-25	WOS:A1991GD63500048
J	CLAASSEN, LA; GROSSMAN, L				CLAASSEN, LA; GROSSMAN, L			DELETION MUTAGENESIS OF THE ESCHERICHIA-COLI UVRA PROTEIN LOCALIZES DOMAINS FOR DNA-BINDING, DAMAGE RECOGNITION, AND PROTEIN-PROTEIN INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION REPAIR; NUCLEASE INVITRO; COMPLEX; ENDONUCLEASE; PURIFICATION; EXCINUCLEASE; SITES	The UvrA protein is the DNA binding and damage recognition subunit of the damage-specific UvrABC endonuclease. In addition, it is an ATPase/GTPase, and the binding energy of ATP is linked to dimerization of the UvrA protein. Furthermore, the UvrA protein interacts with the UvrB protein to modulate its activities, both in solution and in association with DNA, where the UvrAB complex possesses a helicase activity. The domains of the UvrA protein that sponsor each of these activities were localized within the protein by studying the in vitro properties of a set of purified deletion mutants of the UvrA protein. A region located within the first 230 amino acids was found to contain the minimal region necessary for interactions with UvrB, the UvrA dimerization interface was localized to within the first 680 amino acids, and the DNA binding domain lies within the first 900 amino acids of the 940-amino acid UvrA protein. Two damage recognition domains were detected. The first domain, which coincides with the DNA binding region, is required to detect the damage. The second domain, located on or near the C-terminal 40 amino acids, stabilizes the protein-DNA complex when damage is encountered.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21205	Johns Hopkins University					NIGMS NIH HHS [GM 31110, GM 22846] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031110, R01GM022846, R37GM022846] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARON PR, 1988, NUCLEIC ACIDS RES, V16, P9651, DOI 10.1093/nar/16.20.9651; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11380; DOOLITTLE RF, 1986, NATURE, V323, P451, DOI 10.1038/323451a0; FREDERICK CA, 1984, NATURE, V309, P327, DOI 10.1038/309327a0; HUSAIN I, 1986, J BIOL CHEM, V261, P4895; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; Maniatis T., 1982, MOL CLONING; MAZUR S, 1991, IN PRESS BIOCHEMISTR; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MILMAN G, 1987, METHOD ENZYMOL, V153, P482; OH EY, 1989, NUCLEIC ACIDS RES, V17, P4145, DOI 10.1093/nar/17.11.4145; OH EY, 1986, NUCLEIC ACIDS RES, V14, P8557, DOI 10.1093/nar/14.21.8557; OH EY, 1989, J BIOL CHEM, V264, P1336; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PEARLMAN DA, 1985, SCIENCE, V227, P1304, DOI 10.1126/science.3975615; PU WT, 1989, J BIOL CHEM, V264; RAMACHANDRAN GN, 1966, BIOPHYS J, V6, P849, DOI 10.1016/S0006-3495(66)86699-7; RAMSTEIN J, 1988, P NATL ACAD SCI USA, V85, P7231, DOI 10.1073/pnas.85.19.7231; SANCAR A, 1984, P NATL ACAD SCI-BIOL, V81, P7397, DOI 10.1073/pnas.81.23.7397; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SCHWARTZ A, 1989, J MOL BIOL, V207, P445, DOI 10.1016/0022-2836(89)90266-0; SEEBERG E, 1982, P NATL ACAD SCI-BIOL, V79, P988, DOI 10.1073/pnas.79.4.988; SEELEY TW, 1990, J BIOL CHEM, V265, P7158; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P87; VANHOUTEN B, 1987, J BIOL CHEM, V262, P13180; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157	31	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11388	11394						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1828248				2022-12-25	WOS:A1991FQ77400104
J	VOGEL, PD; CROSS, RL				VOGEL, PD; CROSS, RL			ADENINE NUCLEOTIDE-BINDING SITES ON MITOCHONDRIAL F1-ATPASE - EVIDENCE FOR AN ADENYLATE KINASE-LIKE ORIENTATION OF CATALYTIC AND NONCATALYTIC SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND ADENOSINE-DIPHOSPHATE; BEEF-HEART F1-ATPASE; BETA-SUBUNIT; ESCHERICHIA-COLI; ATP HYDROLYSIS; OXIDATIVE-PHOSPHORYLATION; COUPLING FACTOR; F1 ATPASE; TRIPHOSPHATASE; MECHANISM	Nucleotide-depleted mitochondrial F1-ATPase (F1[0,0]) is inhibited by the diadenosine oligophosphate compounds, AP4A, AP5A, and AP6A (where AP(x)A stands for 5',5'-diadenosine oligophosphates having a chain of x phosphoryl groups linking the two adenosine moieties). When F1[0,0] is preincubated with these compounds and then assayed for ATP hydrolysis activity under conditions that normally allow turnover at all three catalytic sites, the maximal level of inhibition observed is 80%. However, when assayed at lower ATP concentrations under conditions that allow simultaneous turnover at only two of the three sites, no inhibition is observed. A decrease in the number of phosphoryl groups that links the adenosine moieties to less than 4 (AP3A, AP2A) converts the compound to an activator of ATP hydrolysis, similar in effect to that obtained when one mol of ADP or 2-azido-ADP binds at a catalytic site on F1[0,0]. Inhibition by the compounds requires the presence of at least one vacant noncatalytic site. Evidence is provided that the probes also interact with a catalytic site. The stoichiometry for maximal inhibition by AP4A is 0.94 mol/mol of F1. The data presented support a model for the structure of nucleotide-binding sites on F1 that places catalytic and noncatalytic sites in close proximity in an orientation analogous to the ATP and AMP binding sites on adenylate kinase. Inhibition of the enzyme by the dinucleotide compounds can be explained by the crossbridging of one of the catalytic sites to a noncatalytic site in analogy to the inhibition of adenylate kinase by AP5A. The residual capacity for bi-site catalysis indicates that the second and third catalytic sites remain catalytically active.			VOGEL, PD (corresponding author), SUNY HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, SYRACUSE, NY 13210 USA.			Vogel, Pia/0000-0002-8135-4649	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023152, R01GM023152] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 23152] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BULLOUGH DA, 1986, J BIOL CHEM, V261, P14171; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; CROSS RL, 1982, J BIOL CHEM, V257, P2101; CROSS RL, 1982, J BIOL CHEM, V257, P2874; CUNNINGHAM D, 1988, J BIOL CHEM, V263, P18850; CZARNECKI JJ, 1984, BIOCHIM BIOPHYS ACTA, V800, P41, DOI 10.1016/0304-4165(84)90092-8; DIEDERICHS K, 1990, BIOCHEMISTRY-US, V29, P8138, DOI 10.1021/bi00487a022; DIPIETRO A, 1980, BIOCHEMISTRY-US, V19, P5671, DOI 10.1021/bi00566a002; DROBINSKAYA IY, 1985, FEBS LETT, V182, P419, DOI 10.1016/0014-5793(85)80346-X; DUNCAN TM, 1986, FEBS LETT, V208, P1, DOI 10.1016/0014-5793(86)81519-8; EGNER U, 1987, J MOL BIOL, V195, P649, DOI 10.1016/0022-2836(87)90188-4; ESCH FS, 1978, J BIOL CHEM, V253, P6100; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GARIN J, 1986, BIOCHEMISTRY-US, V25, P4431, DOI 10.1021/bi00363a039; GARRETT NE, 1975, J BIOL CHEM, V250, P6640; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; GUERRERO KJ, 1989, BIOCHEM BIOPH RES CO, V154, P854; HARRIS DA, 1978, BIOCHIM BIOPHYS ACTA, V463, P245, DOI 10.1016/0304-4173(78)90002-2; HOLLER E, 1983, BIOCHEMISTRY-US, V22, P4924, DOI 10.1021/bi00290a008; HORNER RD, 1983, J BIOL CHEM, V258, P5618; KAYALAR C, 1977, J BIOL CHEM, V252, P2486; KIM HJ, 1990, BIOCHEMISTRY-US, V29, P1107, DOI 10.1021/bi00457a002; KIRONDE FAS, 1986, J BIOL CHEM, V261, P2544; KRAUSPE R, 1988, FEBS LETT, V235, P275, DOI 10.1016/0014-5793(88)81278-X; LIENHARD GE, 1973, J BIOL CHEM, V248, P1121; LUNARDI J, 1986, J BIOL CHEM, V261, P5350; MCCARTY RE, 1978, FEBS LETT, V95, P299, DOI 10.1016/0014-5793(78)81015-1; MELESE T, 1988, J BIOL CHEM, V263, P5833; MELESE T, 1985, J BIOL CHEM, V260, P5398; MOUDRIANAKIS EN, 1976, J BIOL CHEM, V251, P7796; Penefsky H S, 1979, Methods Enzymol, V55, P304; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PENEFSKY HS, 1975, ELECTRON TRANSFER CH, P135; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROY H, 1971, P NATL ACAD SCI USA, V68, P464, DOI 10.1073/pnas.68.2.464; SANDERS CR, 1989, BIOCHEMISTRY-US, V28, P9028, DOI 10.1021/bi00449a011; VETTER IR, 1990, BIOCHEMISTRY-US, V29, P7459, DOI 10.1021/bi00484a015; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; VOGELCLAUDE P, 1988, FEBS LETT, V227, P107, DOI 10.1016/0014-5793(88)80878-0; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WEBB MR, 1980, J BIOL CHEM, V255, P1637; WISE JG, 1987, FEBS LETT, V223, P395, DOI 10.1016/0014-5793(87)80326-5; WISE JG, 1983, BIOCHEM J, V215, P343, DOI 10.1042/bj2150343; WISE JG, 1985, BIOCHEMISTRY-US, V24, P6949, DOI 10.1021/bi00345a030; XUE ZX, 1988, J BIOL CHEM, V263, P16880; XUE ZX, 1987, FEBS LETT, V223, P391, DOI 10.1016/0014-5793(87)80325-3; YAN HG, 1990, BIOCHEMISTRY-US, V29, P6385, DOI 10.1021/bi00479a007; [No title captured]	48	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6101	6105						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1826104				2022-12-25	WOS:A1991FE37300018
J	GIORDANO, A; MCCALL, C; WHYTE, P; FRANZA, BR				GIORDANO, A; MCCALL, C; WHYTE, P; FRANZA, BR			HUMAN CYCLIN-A AND THE RETINOBLASTOMA PROTEIN INTERACT WITH SIMILAR BUT DISTINGUISHABLE SEQUENCES IN THE ADENOVIRUS E1A-GENE PRODUCT	ONCOGENE			English	Note							LARGE T-ANTIGEN; E1A PROTEINS; FUNCTIONAL DOMAINS; SEPARATE DOMAINS; TERMINAL REGION; DNA-SYNTHESIS; CELL-CYCLE; M-PHASE; TRANSFORMATION; GROWTH	The adenovirus early region 1A (E1A) proteins associate with several cellular proteins in adenovirus infected or transformed cells. Recently, two of the cellular proteins that bind to E1A encoded proteins have been identified. p105 has been shown to be the product of the retinoblastoma tumor suppressing gene. p60 has been shown to be a human cyclin A. Previously studies have shown that E1A protein sequences encoded by conserved domains 1 and 2 are required for interactions with the retinoblastoma protein (pRB). We have demonstrated here that amino acids 30 to 60 and 121 to 127 within the E1A proteins are required for interaction with p60/cyclin A. These are the same sites within conserved domains 1 and 2 that are required for E1A protein association with pRB. However, the association of p60/cyclin A does not appear to require pRB. We also demonstrate that another cellular protein, 130K, interacts with E1A at essentially the same sites. It is interesting that mutations in these regions destroy the ability of E1A to function as an oncogene, thereby raising the possibility that interaction with several different cellular proteins may be needed for transformation by E1A.	FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA	Fred Hutchinson Cancer Center	GIORDANO, A (corresponding author), COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA.		Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; JELSMA TN, 1988, VIROLOGY, V163, P494, DOI 10.1016/0042-6822(88)90290-5; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LEWIS JB, 1980, CELL, V21, P303, DOI 10.1016/0092-8674(80)90138-5; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; NEVINS JR, 1979, J VIROL, V32, P727, DOI 10.1128/JVI.32.3.727-733.1979; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; QUINLAN MP, 1987, P NATL ACAD SCI USA, V84, P3283, DOI 10.1073/pnas.84.10.3283; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; SPECTOR DJ, 1978, J MOL BIOL, V126, P395, DOI 10.1016/0022-2836(78)90048-7; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; VANDENELSEN P, 1983, VIROLOGY, V128, P377; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	54	135	136	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1991	6	3					481	485						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1826347				2022-12-25	WOS:A1991FT34400021
J	SCHWARZ, FP; PURI, K; SUROLIA, A				SCHWARZ, FP; PURI, K; SUROLIA, A			THERMODYNAMICS OF THE BINDING OF GALACTOPYRANOSIDE DERIVATIVES TO THE BASIC LECTIN FROM WINGED BEAN (PSOPHOCARPUS-TETRAGONOLOBUS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL SCANNING CALORIMETERS; CARBOHYDRATE BINDING; ESCHERICHIA-COLI; CONCANAVALIN-A; PROTEIN; TETRAGONOLOBUS; RIBONUCLEASE; DENATURATION; CALIBRATION	The thermodynamics of the binding of D-galactopyranoside (Gal), 2-acetamido-2-deoxygalactopyranoside (GalNAc), methyl-alpha-D-galactopyranoside, and methyl-beta-D-galactopyranoside to the basic agglutinin from winged bean (WBAI) in 0.02 M sodium phosphate and 0.15 M sodium chloride buffer have been investigated from 298.15 to 333.15 K by titration calorimetry and at the denaturation temperature by differential scanning calorimetry (DSC). WBAI is a dimer with two binding sites. The titration calorimetry yielded single-site binding constants ranging from 0.56 +/- 0.14 x 10(3) M-1 for Gal at 323.15 K to 7.2 +/- 0.5 x 10(3) M-1 for GalNAc at 298.15 K and binding enthalpies ranging from -28.0 +/- 2.0 kJ mol-1 for GalNAc at 298.15 K to -14.3 +/- 0.1 kJ mol-1 for methyl-beta-D-galactopyranoside at 322.65 K. The denaturation transition consisted of two overlapping peaks over the pH range 5.6-7.4. Fits of the differential scanning calorimetry data to a two-state transition model showed that the low temperature transition (341.6 +/- 0.4 K at pH 7.4) consisted of two domains unfolding as a single entity while the higher temperature transition (347.8 +/- 0.6 K at pH 7.4) is of the remaining WBAI dimer unfolding into two monomers. Both transitions shift to higher temperatures and higher calorimetric enthalpies with increase in added ligand concentration at pH 7.4. Analysis of the temperature increase as a function of added ligand concentration suggests that one ligand binds to the two domains unfolding at 341.6 +/- 0.6 K and one ligand binds to the domain unfolding at 347.8 +/- 0.6 K.	INDIAN INST SCI,MOLEC BIOPHYS UNIT,BANGALORE 560012,KARNATAKA,INDIA	Indian Institute of Science (IISC) - Bangalore	SCHWARZ, FP (corresponding author), NATL INST STAND & TECHNOL,CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850, USA.		SUROLIA, AVADESHA/C-5442-2009					AMBROSINO R, 1987, BIOCHEMISTRY-US, V26, P3971, DOI 10.1021/bi00387a034; APPUKUTTAN PS, 1981, ANAL BIOCHEM, V113, P253, DOI 10.1016/0003-2697(81)90074-9; BESSLER W, 1974, J BIOL CHEM, V249, P2819; BORREBAECK C, 1980, EUR J BIOCHEM, V107, P67, DOI 10.1111/j.1432-1033.1980.tb04625.x; BRANDTS JF, 1989, BIOCHEMISTRY-US, V28, P8588, DOI 10.1021/bi00447a048; FUKADA H, 1983, J BIOL CHEM, V258, P3193; GHOSAINI LR, 1988, BIOCHEMISTRY-US, V27, P5257, DOI 10.1021/bi00414a046; KALB AJ, 1968, BIOCHIM BIOPHYS ACTA, V168, P366, DOI 10.1016/0005-2795(68)90161-X; KHAN MI, 1986, J BIOL CHEM, V261, P3013; KORTT AA, 1985, ARCH BIOCHEM BIOPHYS, V236, P544, DOI 10.1016/0003-9861(85)90657-5; MANLY SP, 1985, BIOCHEMISTRY-US, V24, P3842, DOI 10.1021/bi00336a004; MATSUDA T, 1989, MOL IMMUNOL, V26, P189, DOI 10.1016/0161-5890(89)90101-6; ROSS PD, 1988, J BIOL CHEM, V263, P11196; SCHELLMAN JA, 1975, BIOPOLYMERS, V14, P999, DOI 10.1002/bip.1975.360140509; SCHWARZ FP, 1986, THERMOCHIM ACTA, V107, P37, DOI 10.1016/0040-6031(86)85033-X; SCHWARZ FP, 1988, BIOCHEMISTRY-US, V27, P8429, DOI 10.1021/bi00422a020; SCHWARZ FP, 1988, THERMOCHIM ACTA, V128, P267, DOI 10.1016/0040-6031(88)85371-1; SHARON N, 1977, SCI AM, V236, P108, DOI 10.1038/scientificamerican0677-108; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	19	75	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24344	24350						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761537				2022-12-25	WOS:A1991GW84500020
J	TODD, MJ; HAUSINGER, RP				TODD, MJ; HAUSINGER, RP			IDENTIFICATION OF THE ESSENTIAL CYSTEINE RESIDUE IN KLEBSIELLA-AEROGENES UREASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JACK BEAN UREASE; AMINO-ACID-SEQUENCE; NUCLEOTIDE-SEQUENCE; GENES; PURIFICATION	During reaction with [C-14]iodoacetamide at pH 6.3, radioactivity was incorporated primarily into a single Klebsiella aerogenes urease peptide concomitant with activity loss. This peptide was protected from modification at pH 6.3 by inclusion of phosphate, a competitive inhibitor of urease, which also protected the enzyme from inactivation. At pH 8.5, several peptides were alkylated; however, modification of one peptide, identical to that modified at pH 6.3, paralleled activity loss. The N-terminal amino acid sequence and composition of the peptide containing the essential thiol was determined. Previous enzyme inactivation studies of K. aerogenes urease could not distinguish whether one or two essential thiols were present per active site (Todd, M. J., and Hausinger, R. P. (1991) J. Biol. Chem. 266, 10260-10267); we conclude that there is a single essential thiol present and identify this residue as Cys319 in the large subunit of the heteropolymeric enzyme.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT MICROBIOL,E LANSING,MI 48824	Michigan State University; Michigan State University				Hausinger, Robert/0000-0002-3643-2054				ALLEN G, 1981, LABORATORY TECHNIQUE, P52; Andrews R. K., 1988, BIOINORGANIC CHEM NI, P141; BLANCHARD A, 1990, MOL MICROBIOL, V4, P669, DOI 10.1111/j.1365-2958.1990.tb00636.x; CLAYTON CL, 1990, NUCLEIC ACIDS RES, V18, P362, DOI 10.1093/nar/18.2.362; JONES BD, 1989, J BACTERIOL, V171, P6414, DOI 10.1128/jb.171.12.6414-6422.1989; LABIGNE A, 1991, J BACTERIOL, V173, P1920, DOI 10.1128/jb.173.6.1920-1931.1991; LEE MH, 1990, J BACTERIOL, V172, P4427, DOI 10.1128/jb.172.8.4427-4431.1990; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOBLEY HLT, 1989, MICROBIOL REV, V53, P85, DOI 10.1128/MMBR.53.1.85-108.1989; MORSDORF G, 1990, FEMS MICROBIOL LETT, V66, P67, DOI 10.1016/0378-1097(90)90260-W; MULROONEY SB, 1989, J GEN MICROBIOL, V135, P1769; MULROONEY SB, 1990, J BACTERIOL, V172, P5837, DOI 10.1128/jb.172.10.5837-5843.1990; NORRIS R, 1976, BIOCHEM J, V159, P245, DOI 10.1042/bj1590245; SAKAGUCHI K, 1984, J BIOCHEM-TOKYO, V96, P73, DOI 10.1093/oxfordjournals.jbchem.a134831; SAKAGUCHI K, 1983, J BIOCHEM-TOKYO, V93, P681, DOI 10.1093/jb/93.3.681; TAKISHIMA K, 1988, EUR J BIOCHEM, V175, P151, DOI 10.1111/j.1432-1033.1988.tb14177.x; TAKISHIMA K, 1983, FRONTIERS BIOCH BIOP, P193; TODD MJ, 1989, J BIOL CHEM, V264, P15835; TODD MJ, 1987, J BIOL CHEM, V262, P5963; TODD MJ, 1991, J BIOL CHEM, V266, P10260; WINKLER RG, 1988, TRENDS BIOCHEM SCI, V13, P97, DOI 10.1016/0968-0004(88)90049-7	21	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24327	24331						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761535				2022-12-25	WOS:A1991GW84500017
J	XU, XX; TABAS, I				XU, XX; TABAS, I			SPHINGOMYELINASE ENHANCES LOW-DENSITY-LIPOPROTEIN UPTAKE AND ABILITY TO INDUCE CHOLESTERYL ESTER ACCUMULATION IN MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; ACYL COENZYME-A; ATHEROSCLEROTIC LESIONS; TRANSFERASE-ACTIVITY; J774 MACROPHAGES; RECEPTOR; METABOLISM; CELLS; LDL; HYPERCHOLESTEROLEMIA	Cholesteryl ester-loaded macrophages, or foam cells, are a prominent feature of atherosclerotic lesions. Low density lipoprotein (LDL) receptor-mediated endocytosis of native LDL is a relatively poor inducer of macrophage cholesteryl ester accumulation. However, the data herein show that in the presence of a very small amount of sphingomyelinase, LDL receptor-mediated endocytosis of I-125-LDL was enhanced and led to a 2-6-fold increase in I-125-LDL degradation and up to a 10-fold increase in cholesteryl ester accumulation in macrophages. The enhanced lipoprotein uptake and cholesterol esterification was seen after only approximately 12% hydrolysis of LDL phospholipids, was specific for sphingomyelin hydrolysis, and appeared to be related to the formation of fused or aggregated spherical particles up to 100 nm in diameter. Sphingomyelinase-treated LDL was bound by the macrophage LDL receptor. However, when unlabeled acetyl-LDL, a scavenger receptor ligand, was present during or after sphingomyelinase treatment of I-125-LDL, I-125-LDL binding and degradation were enhanced further through the formation of LDL-acetyl-LDL mixed aggregates. Experiments with cytochalasin D suggested that endocytosis, not phagocytosis, was involved in internalization of sphingomyelinase-treated LDL. Nonetheless, the sphingomyelinase effect on LDL uptake was macrophage-specific. These data illustrate that LDL receptor-mediated endocytosis of fused LDL particles can lead to foam cell formation in cultured macrophages. Furthermore, since both LDL and sphingomyelinase are present in atherosclerotic lesions and since some lesion LDL probably is fused or aggregated, there is a possibility that sphingomyelinase-treated LDL is a physiologically important atherogenic lipoprotein.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,630 W 168TH ST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032	Columbia University; Columbia University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006, R01HL039703] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-39703, HL-21006] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASSOIAN RK, 1986, J CELL BIOL, V102, P1217, DOI 10.1083/jcb.102.4.1217; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BROWN MS, 1975, P NATL ACAD SCI USA, V72, P2925, DOI 10.1073/pnas.72.8.2925; CLEVIDENCE BA, 1984, ARTERIOSCLEROSIS, V4, P196, DOI 10.1161/01.ATV.4.3.196; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DAS DVM, 1984, BIOCHIM BIOPHYS ACTA, V777, P339; DAUGHERTY A, 1988, ARTERIOSCLEROSIS, V8, P768, DOI 10.1161/01.ATV.8.6.768; ELLSWORTH JL, 1987, J BIOL CHEM, V262, P2316; FOGELMAN AM, 1980, P NATL ACAD SCI-BIOL, V77, P2214, DOI 10.1073/pnas.77.4.2214; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; GERRITY RG, 1981, AM J PATHOL, V103, P181; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOFF HF, 1978, EXP MOL PATHOL, V28, P290, DOI 10.1016/0014-4800(78)90003-5; HOFF HF, 1991, J LIPID RES, V32, P115; HOFF HF, 1989, ARTERIOSCLEROSIS, V9, P538, DOI 10.1161/01.ATV.9.4.538; HOFF HF, 1990, EUR HEART J, V11, P105, DOI 10.1093/eurheartj/11.suppl_E.105; HOFF HF, 1983, HDB ELECTROPHORESIS, V3, P133; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KLAUS GG, 1973, EXP CELL RES, V79, P73, DOI 10.1016/0014-4827(73)90490-4; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KOO C, 1986, J BIOL CHEM, V261, P1194; MAHLEY RW, 1980, J LIPID RES, V21, P970; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MORTON RE, 1986, J LIPID RES, V27, P1124; PORTMAN OW, 1970, J LIPID RES, V11, P23; PORTMAN OW, 1969, BIOCHIM BIOPHYS ACTA, V87, P435; RACHMILEWITZ D, 1967, BIOCHIM BIOPHYS ACTA, V144, P624, DOI 10.1016/0005-2760(67)90051-3; SCHAFFNER T, 1980, AM J PATHOL, V100, P57; SCHWARTZ S, 1978, IN VITRO, V14, P14966; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TABAS I, 1987, J BIOL CHEM, V262, P12175; TABAS I, 1988, J BIOL CHEM, V263, P1266; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; TABAS I, 1987, J CLIN INVEST, V79, P418, DOI 10.1172/JCI112828; TABAS I, 1985, P NATL ACAD SCI USA, V82, P416, DOI 10.1073/pnas.82.2.416; XU XX, 1991, J BIOL CHEM, V266, P17040; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	43	137	139	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24849	24858						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761578				2022-12-25	WOS:A1991GW84500091
J	SCHNETKAMP, PPM; BASU, DK; LI, XB; SZERENCSEI, RT				SCHNETKAMP, PPM; BASU, DK; LI, XB; SZERENCSEI, RT			REGULATION OF INTRACELLULAR FREE CA2+ CONCENTRATION IN THE OUTER SEGMENTS OF BOVINE RETINAL RODS BY NA-CA-K EXCHANGE MEASURED WITH FLUO-3 .2. THERMODYNAMIC COMPETENCE OF TRANSMEMBRANE NA+ AND K+ GRADIENTS AND INACTIVATION OF NA+-DEPENDENT CA2+ EXTRUSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; NA+-CA-2+ EXCHANGE; PLASMA-MEMBRANE; NA/CA EXCHANGE; SQUID AXONS; KINETICS; ATP	Regulation of cytosolic free Ca2+ in the physiologically relevant submicromolar range was measured in isolated intact bovine rod outer segments (ROS) with the intracellular Ca2+-indicating dye fluo-3. Changes in free Ca2+ were compared with changes in total Ca2+ measured with Ca-45 fluxes and a good qualitative correlation was observed. Ca2+ homeostasis in isolated bovine ROS was exclusively mediated via the Na-Ca-K exchanger. Free cytosolic Ca2+ concentration was lowered by an increase in the inward Na+ gradient, was raised by an increase in external K+, and was raised by depolarization of the plasma membrane. The simplest stoichiometry consistent with these qualitative observations is 4Na:(1Ca + 1K). The individual K:Ca, Na:Ca, and K:Na coupling ratios were deduced from quantitative changes in cytosolic free Ca2+ upon changes in the transmembrane Na+ and K+ gradients. The observed changes in free Ca2+ did not agree with changes in free Ca2+ calculated on the basis of the above fixed stoichiometry which may reflect the flexibility in the Ca:K coupling ratio observed before in flux experiments (Schnetkamp, P. P. M., Szerencsei, R. T., and Basu, D. K. (1991) J. Biol. Chem. 266,198-206). The most dramatic discrepancy was observed for the Na:Ca coupling ratio: the expected very large changes in cytosolic free Ca2+ upon changes in the transmembrane Na+ gradient were not observed. Rapid Na+-induced Ca2+ extrusion was unable to lower cytosolic free Ca2+ below 100 nM, even under nonequilibrium conditions and despite the observation that Ca2+ influx via reverse Na-Ca-K exchange readily occurred at a free external Ca2+ concentration of 20 nM. We conclude that the Na+-dependent extrusion mode of the Na-Ca-K exchanger occurs in a brief (20-s) burst of high maximal velocity transport followed by a nearly complete inactivation of transport. The importance of our findings for Ca2+ homeostasis in functioning rod photoreceptors is discussed.			SCHNETKAMP, PPM (corresponding author), UNIV CALGARY,DEPT MED BIOCHEM,CALGARY T2N 4N1,ALBERTA,CANADA.							ALLEN TJA, 1985, NATURE, V315, P755, DOI 10.1038/315755a0; CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; DIPOLO R, 1987, J GEN PHYSIOL, V90, P505, DOI 10.1085/jgp.90.4.505; DIPOLO R, 1987, BIOCHIM BIOPHYS ACTA, V897, P347, DOI 10.1016/0005-2736(87)90432-9; GOLD GH, 1980, P NATL ACAD SCI-BIOL, V77, P5557, DOI 10.1073/pnas.77.9.5557; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; MILLER DL, 1987, J GEN PHYSIOL, V90, P397, DOI 10.1085/jgp.90.3.397; MIURA Y, 1989, J GEN PHYSIOL, V93, P1129, DOI 10.1085/jgp.93.6.1129; RASGADOFLORES H, 1989, J GEN PHYSIOL, V93, P1219, DOI 10.1085/jgp.93.6.1219; RATTO GM, 1988, J NEUROSCI, V8, P3240; SCHNETKAMP PPM, 1980, BIOCHIM BIOPHYS ACTA, V598, P66, DOI 10.1016/0005-2736(80)90266-7; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P189; SCHNETKAMP PPM, 1985, J MEMBRANE BIOL, V88, P249, DOI 10.1007/BF01871089; SCHNETKAMP PPM, 1989, PROG BIOPHYS MOL BIO, V54, P1, DOI 10.1016/0079-6107(89)90007-2; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P198; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P22975; SCHNETKAMP PPM, 1989, AM J PHYSIOL, V257, pC153, DOI 10.1152/ajpcell.1989.257.1.C153; SCHNETKAMP PPM, 1986, J PHYSIOL-LONDON, V373, P25, DOI 10.1113/jphysiol.1986.sp016033; SCHNETKAMP PPM, 1991, IN PRESS ANN NY ACAD; YAU KW, 1985, NATURE, V313, P579, DOI 10.1038/313579a0	20	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22983	22990						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744093				2022-12-25	WOS:A1991GT48300034
J	BAI, WL; SINGH, B; KARSHIN, WL; SHONK, RA; ARLINGHAUS, RB				BAI, WL; SINGH, B; KARSHIN, WL; SHONK, RA; ARLINGHAUS, RB			PHOSPHORYLATION OF V-MOS SER 47 BY THE MITOTIC FORM OF P34CDC2	ONCOGENE			English	Article							PROTEIN-KINASE ACTIVITY; MURINE SARCOMA-VIRUS; MATURATION-PROMOTING FACTOR; CELL-CYCLE CONTROL; ONCOGENE PRODUCT; NUCLEOTIDE-SEQUENCE; MEIOTIC MATURATION; XENOPUS HOMOLOG; GENE; OOCYTES	P85gag-mos is hyperphosphorylated during mitosis in normal rat kidney (NRK) cells transformed by Moloney murine sarcoma virus ts110. We now report that P85gag-mos is phosphorylated in vitro by the mitotic form of the cdc2 kinase (p34cdc2, known as M-phase kinase) derived from virus-transformed cells. The major site of P85gag-mos phosphorylation by the M-phase kinase in vitro lies within the amino-terminal portion of the viral mos protein sequence spanning residues 45-53, as determined by tryptic peptide mapping. A synthetic peptide corresponding to amino acids 37-55 of v-mos was specifically phosphorylated by the M-phase kinase, whereas v-mos peptides either lacking Ser 47 or substituted with Ala at residue 47 were not phosphorylated. Protein sequencing analyses established that the M-phase kinase specifically phosphorylates Ser 47. Tryptic phosphopeptide mapping of the in vivo-phosphorylated gag-mos protein from mitotic cells indicated that the 45-53 v-mos region was also phosphorylated within mitotic cells. These findings demonstrate that the M-phase kinase phosphorylates the viral mos protein at Ser 47. These results were unexpected in view of earlier reports regarding cdc2 kinase activation/stabilization by the c-mos kinase in maturing oocytes.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOLEC PATHOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556	NCI NIH HHS [CA16672, CA45125] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045125, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBAGDADI F, 1990, ONCOGENE, V5, P1251; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BLAIR DG, 1979, VIROLOGY, V95, P303, DOI 10.1016/0042-6822(79)90486-0; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; HARLOW E, 1988, ANTIBODIES LABORATOR; HERZOG NK, 1988, ONCOGENE, V3, P225; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KROHNE G, 1982, J CELL BIOL, V94, P749, DOI 10.1083/jcb.94.3.749; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIU JX, 1990, ONCOGENE, V5, P171; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MAXWELL SA, 1985, J GEN VIROL, V66, P2135, DOI 10.1099/0022-1317-66-10-2135; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; PANTAZIS P, 1981, J BIOL CHEM, V256, P4669; PAULES RS, 1988, ONCOGENE, V3, P59; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SINGH B, 1986, VIROLOGY, V152, P502, DOI 10.1016/0042-6822(86)90156-X; SINGH B, 1990, VIROLOGY, V178, P535, DOI 10.1016/0042-6822(90)90351-Q; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SINGH B, 1988, VIROLOGY, V164, P114, DOI 10.1016/0042-6822(88)90626-5; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; VANDERHOORN FA, 1984, NUCLEIC ACIDS RES, V12, P2147, DOI 10.1093/nar/12.4.2147; WANG YH, 1988, ANAL BIOCHEM, V174, P537, DOI 10.1016/0003-2697(88)90053-X; WARDELL MR, 1989, J BIOL CHEM, V264, P15656; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; WEINMASTER G, 1983, J VIROL, V46, P29, DOI 10.1128/JVI.46.1.29-41.1983; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; ZHAO X, 1990, ONCOGENE, V5, P1727	48	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1715	1723						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1833715				2022-12-25	WOS:A1991GX11800001
J	ELLIS, V; BEHRENDT, N; DANO, K				ELLIS, V; BEHRENDT, N; DANO, K			PLASMINOGEN ACTIVATION BY RECEPTOR-BOUND UROKINASE - A KINETIC-STUDY WITH BOTH CELL-ASSOCIATED AND ISOLATED RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN UROKINASE; HUMAN SARCOMA-CELLS; BINDING-SITE; MONOCLONAL-ANTIBODIES; HUMAN ANTIPLASMIN; LYS-PLASMINOGEN; U937 MONOCYTES; SURFACE; INHIBITORS; PROENZYME	The specific cellular receptor for urokinase-type plasminogen activator (uPA) is found on a variety of cell types and has been postulated to play a central role in the mediation of pericellular proteolytic activity. We have studied the kinetics of plasminogen (Plg) activation catalyzed by uPA specifically bound to its receptor on the human monocytoid cell-line U937 and demonstrate this process to have properties differing widely from those observed for uPA in solution. The solution-phase reaction was characterized by a K(m) of 25-mu-M and for the cell-associated reaction this fell 40-fold to 0.67-mu-M, below the physiological Plg concentration of 2-mu-M. A concomitant 6-fold reduction in k(cat) resulted in an increase in the overall catalytic efficiency, k(cat)/K(m) of 5.7-fold. This high affinity Plg activation was abolished in the presence of a Plg-binding antagonist. In contrast to intact cells, purified uPA receptor (isolated from phorbol 12-myristate 13-acetate-stimulated U937 cells) was observed to partially inhibit uPA-catalyzed Plg activation, although activity against low molecular weight substrates was retained. Therefore, the cellular binding of Plg appears to be of critical importance for the efficient activation of Plg by receptor-bound uPA. Plasmin generated in the cell-surface Plg activation system described here was also observed to be protected from its principal physiological inhibitor alpha-2-antiplasmin. Together, these data demonstrate that the cell surface constitutes the preferential site for Plg activation when uPA is bound to its specific cellular receptor, which therefore has the necessary characteristics to play an efficient role in the generation of pericellular proteolytic activity.			ELLIS, V (corresponding author), RIGSHOSP,FINSEN INST,STRANDBOULEVARDEN 49,DK-2100 COPENHAGEN,DENMARK.		Ellis, Vincent/D-1860-2009	Ellis, Vincent/0000-0003-1956-073X; Behrendt, Niels/0000-0003-1833-3922				APPELLA E, 1987, J BIOL CHEM, V262, P4437; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; DANO K, 1979, BIOCHIM BIOPHYS ACTA, V566, P138, DOI 10.1016/0005-2744(79)90256-0; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; ELLIS V, 1987, J BIOL CHEM, V262, P14998; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; GONZALEZGRONOW M, 1989, BIOCHEMISTRY-US, V28, P2374, DOI 10.1021/bi00432a005; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HAJJAR KA, 1988, J CLIN INVEST, V82, P1769, DOI 10.1172/JCI113790; HANSEN SH, 1990, EXP CELL RES, V187, P255, DOI 10.1016/0014-4827(90)90089-S; HEBERT CA, 1988, J CELL BIOL, V106, P1241, DOI 10.1083/jcb.106.4.1241; LIJNEN HR, 1990, J BIOL CHEM, V265, P5232; MILES L A, 1988, Fibrinolysis, V2, P61, DOI 10.1016/0268-9499(88)90369-4; MILES LA, 1985, J BIOL CHEM, V260, P4303; MILES LA, 1989, BIOCHEMISTRY-US, V28, P9337, DOI 10.1021/bi00450a014; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; NIELSEN LS, 1986, THROMB HAEMOSTASIS, V55, P206; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; PICONE R, 1989, J CELL BIOL, V108, P693, DOI 10.1083/jcb.108.2.693; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; POLLANEN J, 1987, J CELL BIOL, V104, P1085, DOI 10.1083/jcb.104.4.1085; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; REICH E, 1978, MOL BASIS BIOL DEGRA, P155; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SILVERSTEIN RL, 1988, J CLIN INVEST, V82, P1948, DOI 10.1172/JCI113814; SIM PS, 1986, EUR J BIOCHEM, V158, P537, DOI 10.1111/j.1432-1033.1986.tb09787.x; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STOPPELLI MP, 1986, CELL, V45, P657; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WIMAN B, 1978, EUR J BIOCHEM, V87, P143, DOI 10.1111/j.1432-1033.1978.tb12360.x; WIMAN B, 1978, EUR J BIOCHEM, V84, P573, DOI 10.1111/j.1432-1033.1978.tb12200.x	35	495	507	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12752	12758						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1829461				2022-12-25	WOS:A1991FV18000100
J	LAUDER, SD; KOWALCZYKOWSKI, SC				LAUDER, SD; KOWALCZYKOWSKI, SC			ASYMMETRY IN THE RECA PROTEIN-DNA FILAMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; DUPLEX DNA; ADENOSINE 5'-TRIPHOSPHATE; STABLE COMPLEXES; BINDING-PROTEIN; ATP HYDROLYSIS; EXCHANGE; PURIFICATION	The apparent DNA site size obtained from an assay monitoring the ATPase activity of Escherichia coli recA protein (n = 3.5) differs from that determined from a direct DNA binding assay (n = 7) done under identical conditions. Investigation of this discrepancy indicates that at a DNA:protein ratio of 3.5:1, one-half of the recA protein population is less sensitive to ATPase activity inhibition by the nonhydrolyzable ATP analogue adenosine 5'-O-(3-thiotriphosphate) (ATP-gamma-S), suggesting that the recA protein filament is asymmetric with respect to NTP affinity. This asymmetry does not depend on the presence of ATP-gamma-S since the apparent K(m) for ATP derived from single-stranded DNA-dependent ATP hydrolysis activity is dependent on the DNA:protein ratio. Three models are proposed to account for the observed site size discrepancy and the NTP binding affinity asymmetry. They differ mainly in the intrinsic site size for each recA protein monomer and in the number of DNA-binding sites/recA molecule. Gel filtration of recA-single-stranded DNA complexes at different DNA:protein ratios complements the enzymological data and provides an additional method of distinguishing among the proposed models. The phenomenon of subunit nonequivalence within the recA protein presynaptic filament may provide a molecular basis for understanding how recA protein can discriminate between different DNA molecules during homologous pairing.	NORTHWESTERN UNIV,SCH MED,DEPT MOLEC BIOL,CHICAGO,IL 60611	Northwestern University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018987] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-18987] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRENNER SL, 1988, J MOL BIOL, V204, P959, DOI 10.1016/0022-2836(88)90055-1; BRYANT FR, 1985, P NATL ACAD SCI USA, V82, P297, DOI 10.1073/pnas.82.2.297; CONWAY A, 1972, BIOCHEMISTRY-US, V11, P241; COTTERILL SM, 1982, BIOCHEMISTRY-US, V21, P4332, DOI 10.1021/bi00261a023; COTTERILL SM, 1983, BIOCHEMISTRY-US, V22, P3525, DOI 10.1021/bi00283a034; COX MM, 1982, J BIOL CHEM, V257, P8523; DICAPUA E, 1982, J MOL BIOL, V157, P87, DOI 10.1016/0022-2836(82)90514-9; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; FLORY J, 1984, P NATL ACAD SCI-BIOL, V81, P7026, DOI 10.1073/pnas.81.22.7026; FREITAG N, 1988, J BIOL CHEM, V263, P19525; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; HUANG CY, 1982, ANNU REV BIOCHEM, V51, P935, DOI 10.1146/annurev.bi.51.070182.004443; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P5872, DOI 10.1021/bi00368a006; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MENETSKI JP, 1989, BIOCHEMISTRY-US, V28, P5871, DOI 10.1021/bi00440a025; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MENETSKI JP, 1987, J BIOL CHEM, V262, P2085; MENGE KL, 1988, BIOCHEMISTRY-US, V27, P2635, DOI 10.1021/bi00407a055; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; NEET KE, 1983, CONT ENZYME KINETICS, P267; PUGH BF, 1988, J BIOL CHEM, V263, P76; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; SCHUTTE BC, 1987, BIOCHEMISTRY-US, V26, P5616, DOI 10.1021/bi00392a006; Segel I. H., 1975, BIOCH CALCULATIONS, P246; SHANER SL, 1987, J BIOL CHEM, V262, P9211; SHIBATA T, 1981, J BIOL CHEM, V256, P7565; TAKAHASHI M, 1989, J MOL BIOL, V205, P137, DOI 10.1016/0022-2836(89)90371-9; UHLIN BE, 1981, J BACTERIOL, V148, P386, DOI 10.1128/JB.148.1.386-390.1981; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8829; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P2100, DOI 10.1073/pnas.78.4.2100; ZLOTNICK A, 1990, J BIOL CHEM, V265, P17050	34	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5450	5458						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1826000				2022-12-25	WOS:A1991FD37000018
J	SELMANREIMER, S; DUHE, RJ; STOCKMAN, BJ; SELMAN, BR				SELMANREIMER, S; DUHE, RJ; STOCKMAN, BJ; SELMAN, BR			L-1-N-METHYL-4-MERCAPTOHISTIDINE DISULFIDE, A POTENTIAL ENDOGENOUS REGULATOR IN THE REDOX CONTROL OF CHLOROPLAST COUPLING FACTOR-I IN DUNALIELLA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; FACTOR ATPASE ACTIVITY; FACTOR-I CF1; INTACT CHLOROPLASTS; THIOL MODULATION; GAMMA-SUBUNIT; CONFORMATIONAL CHANGE; PARTIAL-PURIFICATION; ENERGY TRANSDUCTION; ADENINE-NUCLEOTIDES	A water-soluble, highly polar, heat-stable, small molecule has been isolated from cell-free extracts of the halotolerant green alga Dunaliella salina. This compound, soluble inhibitory factor (SIF), when added to in vivo light-activated, thylakoid membrane-bound preparations of the D. salina coupling factor 1 (CF1), causes a rapid inactivation of the ATPase activity. SIF must be in its oxidized form to inactivate the CF1 ATPase and probably functions by oxidizing the reduced form of the light-activated enzyme. SIF has been purified to homogeneity and characterized by UV-visible and IR absorption spectroscopy, H-1 and C-13 NMR spectroscopy, and mass spectrometry. SIF has different kinds of nonexchangeable protons and seven different kinds of carbon atoms. Three of the carbon atoms and one proton are part of a heterocyclic (imidazole) ring. One carbon atom is a carbonyl (carboxylic acid). One carbon atom and three protons form a methyl group attached to the aromatic ring. one carbon atom and two protons are a methylene group, and one carbon atom (an alpha-amino carbon) is attached to a single proton. In addition, in its reduced form, SIF contains a thiol group attached to the heterocyclic ring. From high resolution mass spectrometry, the molecular weight of SIF was determined to be 401 (M + H+) and is consistent with the composition being C-14-H21N6O4S2. The UV absorption of SIF shows a large increase at 240 nm upon reduction. An effective difference extinction coefficient for this absorbance change has been calculated to be 6.84 meq/cm. A comparison of SIF with the oxidized form of ovothiol A (1-N-methyl-4-mercaptohistidine disulfide) shows the two compounds to be identical in all respects. In addition, ovothiol A disulfide is as effective as SIF in inhibiting the light-triggered, CF1 ATPase activity. It is concluded, therefore, that SIF and L-1-N-methyl-4-mercaptohistidine disulfide are identical.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Stockman, Brian/0000-0002-8520-9588	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002301, S10RR002781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031384] Funding Source: NIH RePORTER; NCRR NIH HHS [RR02781, RR02301] Funding Source: Medline; NIGMS NIH HHS [GM 31384] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; AVRON M, 1977, ANNU REV BIOCHEM, V46, P143, DOI 10.1146/annurev.bi.46.070177.001043; BENAMOTZ A, 1974, PLANT PHYSIOL, V53, P628, DOI 10.1104/pp.53.4.628; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRAWFORD NA, 1989, ARCH BIOCHEM BIOPHYS, V271, P223, DOI 10.1016/0003-9861(89)90273-7; DUHE RJ, 1989, BIOCHIM BIOPHYS ACTA, V974, P294, DOI 10.1016/S0005-2728(89)80247-6; DUHE RJ, 1990, BIOCHIM BIOPHYS ACTA, V1017, P70, DOI 10.1016/0005-2728(90)90180-C; FEIGL F, 1966, SPOT TESTS ORGANIC A, P370; GENGHOF DS, 1970, J BACTERIOL, V103, P475, DOI 10.1128/JB.103.2.475-478.1970; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HOLLER TP, 1987, J ORG CHEM, V52, P4420, DOI 10.1021/jo00228a060; JOCELYN PC, 1972, BIOCH SH GROUP, P7; KETCHAM SR, 1984, J BIOL CHEM, V259, P7286; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGNUSSON RP, 1976, ANAL BIOCHEM, V72, P653, DOI 10.1016/0003-2697(76)90580-7; MCCARTY RE, 1972, J BIOL CHEM, V247, P3048; MCCARTY RE, 1979, ANNU REV PLANT PHYS, V30, P79, DOI 10.1146/annurev.pp.30.060179.000455; MCCARTY RE, 1973, BIOCHEMISTRY-US, V12, P1503, DOI 10.1021/bi00732a006; MERCHANT S, 1985, PHOTOSYNTH RES, V6, P3, DOI 10.1007/BF00029044; MILLS JD, 1980, FEBS LETT, V112, P173, DOI 10.1016/0014-5793(80)80173-6; MILLS JD, 1984, BIOCHIM BIOPHYS ACTA, V764, P93, DOI 10.1016/0005-2728(84)90145-2; MILLS JD, 1982, BIOCHIM BIOPHYS ACTA, V679, P75, DOI 10.1016/0005-2728(82)90257-2; MORONEY JV, 1980, J BIOL CHEM, V255, P6670; MORONEY JV, 1984, J BIOL CHEM, V259, P7281; MORONEY JV, 1979, J BIOL CHEM, V254, P8951; NALIN CM, 1984, J BIOL CHEM, V259, P7275; NOCTOR G, 1987, BIOCHIM BIOPHYS ACTA, V894, P295, DOI 10.1016/0005-2728(87)90199-X; PALUMBO A, 1982, TETRAHEDRON LETT, V23, P3207, DOI 10.1016/S0040-4039(00)88597-4; PALUMBO A, 1984, COMP BIOCHEM PHYS B, V78, P81, DOI 10.1016/0305-0491(84)90149-4; PEI FK, 1982, J MAGN RESON, V48, P318, DOI 10.1016/0022-2364(82)90285-2; PICK U, 1982, BIOCHEMISTRY-US, V21, P6144, DOI 10.1021/bi00267a019; PRETSCH E, 1983, TABLES SPECTRAL DATA, pB65; QUICK WP, 1986, BIOCHIM BIOPHYS ACTA, V851, P166, DOI 10.1016/0005-2728(86)90122-2; Racker E., 1971, METHOD ENZYMOL, V23, P547; RYRIE IJ, 1972, J BIOL CHEM, V247, P4453; RYRIE IJ, 1971, J BIOL CHEM, V246, P3771; SELMAN BR, 1981, J BIOL CHEM, V256, P1722; SELMANREIMER S, 1988, FEBS LETT, V230, P21, DOI 10.1016/0014-5793(88)80633-1; SELMANREIMER S, 1988, FEBS LETT, V230, P17, DOI 10.1016/0014-5793(88)80632-X; SELMANREIMER S, 1984, BIOCHIM BIOPHYS ACTA, V764, P138, DOI 10.1016/0005-2728(84)90023-9; SELMANREIMER S, 1990, 8TH P INT C PHOT, V3, P165; SHAHAK Y, 1985, J BIOL CHEM, V260, P1459; SHAPIRO BM, 1990, IN PRESS ADV ENZYMOL; SHAVIT N, 1980, ANNU REV BIOCHEM, V49, P111, DOI 10.1146/annurev.bi.49.070180.000551; STROTMANN H, 1977, BIOCHIM BIOPHYS ACTA, V460, P126, DOI 10.1016/0005-2728(77)90158-X; TURNER E, 1986, J BIOL CHEM, V261, P3056; TURNER E, 1988, SCIENCE, V242, P939, DOI 10.1126/science.3187533; TURNER E, 1987, BIOCHEMISTRY-US, V26, P4028, DOI 10.1021/bi00387a043	48	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					182	188						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1824692				2022-12-25	WOS:A1991EQ33900029
J	STEINKUHLER, C; SAPORA, O; CARRI, MT; NAGEL, W; MARCOCCI, L; CIRIOLO, MR; WESER, U; ROTILIO, G				STEINKUHLER, C; SAPORA, O; CARRI, MT; NAGEL, W; MARCOCCI, L; CIRIOLO, MR; WESER, U; ROTILIO, G			INCREASE OF CU,ZN-SUPEROXIDE DISMUTASE ACTIVITY DURING DIFFERENTIATION OF HUMAN K562 CELLS INVOLVES ACTIVATION BY COPPER OF A CONSTANTLY EXPRESSED COPPER-DEFICIENT PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUZN-SUPEROXIDE-DISMUTASE; ERYTHROLEUKEMIA-CELLS; MESSENGER-RNA; RAT; GLUTATHIONE; ENZYME; METALLOTHIONEIN; METABOLISM; INDUCTION; TOXICITY	Cu,Zn-superoxide dismutase activity, expressed on the basis of cell number, increased by 50% during sodium butyrate-induced differentiation of human K562 erythroleukemia cells. The increased enzyme activity was found to be concomitant with constant Cu,Zn-superoxide dismutase mRNA and immunoreactive protein levels and was accompanied by a rise in intracellular copper and glutathione. Incubation of K562 cell homogenates with copper caused an increase of Cu,Zn-superoxide dismutase activity which reached the levels observed after differentiation in the presence of sodium butyrate. The same treatment led to no significant activity increase in homogenates derived from differentiated cells. Externally added ceruloplasmin increased both intracellular copper levels and Cu,Zn-superoxide dismutase activity in undifferentiated cells to a level comparable with that observed after induction of differentiation. Both increments were abolished by depletion of cell glutathione. Cu,Zn-superoxide dismutase purified from control cells had both a lower k(cat) and a lower copper content than the enzyme purified from differentiated cells. From these data we conclude that: 1) Cu,Zn-superoxide dismutase is present in K562 cells also under the form of a less active copper-deficient enzyme, 2) the extent of enzyme activation is regulated post-translationally by differential delivery of copper as a function of differentiation stage, and 3) glutathione is likely to play a role in delivering copper to the copper-deficient protein in intact K562 cells.	UNIV ROME TOR VERGATA, DEPT BIOL, VIA E CARNEVALE, I-00173 ROME, ITALY; CNR, CTR MOLEC BIOL, I-00173 ROME, ITALY; UNIV ROME LA SAPIENZA, DEPT BIOCHEM SCI, I-00162 ROME, ITALY; UNIV ROME LA SAPIENZA, CNR, CTR MOLEC BIOL, I-00162 ROME, ITALY; UNIV TUBINGEN, INST PHYSIOL CHEM, W-7400 TUBINGEN 1, GERMANY; IST SUPER SANITA, COMPARAT TOXICOL & ECOTOXICOL LAB, I-00162 ROME, ITALY	University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Eberhard Karls University of Tubingen; Istituto Superiore di Sanita (ISS)			Ciriolo, Maria Rosa/K-6572-2016; Carri, Maria Teresa/K-5480-2016	Ciriolo, Maria Rosa/0000-0002-7863-9029; Marcocci, Lucia/0000-0003-2301-7166; Carri, Maria Teresa/0000-0002-1789-1546				AUWERX JH, 1989, BLOOD, V74, P1807; BANNISTER JV, 1987, CRC CR REV BIOCH MOL, V22, P111, DOI 10.3109/10409238709083738; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BECKMAN BS, 1989, J CELL PHYSIOL, V139, P370, DOI 10.1002/jcp.1041390220; BEYER WF, 1991, J BIOL CHEM, V266, P303; BOHNENKAMP W, 1976, BIOCHIM BIOPHYS ACTA, V444, P396, DOI 10.1016/0304-4165(76)90383-4; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CALABRESE L, 1989, J BIOL CHEM, V264, P6183; CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIRIOLO MR, 1990, J BIOL CHEM, V265, P11030; CIVALLERI L, 1982, MOL CELL BIOCHEM, V47, P3; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; DAMERON CT, 1987, BIOCHEM J, V248, P669, DOI 10.1042/bj2480669; DANCIGER E, 1986, P NATL ACAD SCI USA, V83, P3619, DOI 10.1073/pnas.83.11.3619; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DELABAR JM, 1987, EUR J BIOCHEM, V166, P181, DOI 10.1111/j.1432-1033.1987.tb13500.x; Di Iorio E E, 1981, Methods Enzymol, V76, P57; DISILVESTRO RA, 1989, ARCH BIOCHEM BIOPHYS, V274, P298, DOI 10.1016/0003-9861(89)90442-6; Felix K, 1990, Biol Met, V3, P141, DOI 10.1007/BF01179524; FREEDMAN JH, 1989, J BIOL CHEM, V264, P5598; FREEDMAN JH, 1986, J BIOL CHEM, V261, P1840; FREEDMAN JH, 1989, BIOCHIM BIOPHYS ACTA, V992, P145, DOI 10.1016/0304-4165(89)90003-2; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GALEOTTI T, 1989, BIOCHEM BIOPH RES CO, V165, P581, DOI 10.1016/S0006-291X(89)80006-3; GALIAZZO F, 1988, BIOCHIM BIOPHYS ACTA, V965, P46, DOI 10.1016/0304-4165(88)90149-3; GALIAZZO F, 1991, EUR J BIOCHEM, V196, P545, DOI 10.1111/j.1432-1033.1991.tb15848.x; Griffith O.W., 1985, METHODS ENZYMATIC AN, V7, P521; HASS MA, 1988, J BIOL CHEM, V263, P776; KEYHANI E, 1975, ARCH BIOCHEM BIOPHYS, V167, P596, DOI 10.1016/0003-9861(75)90503-2; KRAUTER B, 1989, BIOCHIM BIOPHYS ACTA, V1013, P212, DOI 10.1016/0167-4889(89)90137-7; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luck H, 1963, METHODS ENZYMATIC AN, P885; MEISTER A, 1984, FED PROC, V43, P3031; MONTESANO L, 1989, EUR J BIOCHEM, V186, P421, DOI 10.1111/j.1432-1033.1989.tb15226.x; NAGEL W, 1991, THESIS U TUBINGEN FE; PAOLETTI F, 1988, CANCER RES, V48, P6674; PERCIVAL SS, 1991, BIOCHEM J, V274, P153, DOI 10.1042/bj2740153; PERCIVAL SS, 1990, AM J PHYSIOL, V258, pC140, DOI 10.1152/ajpcell.1990.258.1.C140; PERCIVAL SS, 1988, J TRACE ELEM EXP MED, V1, P63; PRIVALLE CT, 1989, J BIOL CHEM, V264, P2758; RIGO A, 1975, ANAL BIOCHEM, V68, P1, DOI 10.1016/0003-2697(75)90672-7; RIGO A, 1977, ANAL BIOCHEM, V81, P157, DOI 10.1016/0003-2697(77)90609-1; ROE JA, 1990, J AM CHEM SOC, V112, P1538, DOI 10.1021/ja00160a037; SADHU C, 1988, J BIOL CHEM, V263, P2679; SONE T, 1987, J BIOL CHEM, V262, P5878; SPEIER C, 1986, ARCH BIOCHEM BIOPHYS, V251, P551, DOI 10.1016/0003-9861(86)90363-2; STEINKUHLER C, 1990, BIOCHEM PHARMACOL, V39, P1473, DOI 10.1016/0006-2952(90)90429-O; WESTERBEEKMARRES CAM, 1988, EUR J BIOCHEM, V174, P611, DOI 10.1111/j.1432-1033.1988.tb14142.x	52	76	78	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24580	24587						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761555				2022-12-25	WOS:A1991GW84500053
J	DEMARCO, L; MAZZUCATO, M; MASOTTI, A; FENTON, JW; RUGGERI, ZM				DEMARCO, L; MAZZUCATO, M; MASOTTI, A; FENTON, JW; RUGGERI, ZM			FUNCTION OF GLYCOPROTEIN IB-ALPHA IN PLATELET ACTIVATION INDUCED BY ALPHA-THROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BERNARD-SOULIER SYNDROME; ENDOTHELIAL-CELL COFACTOR; RECEPTOR-MEDIATED EVENT; FACTOR-BINDING DOMAIN; AMINO-ACID SEQUENCE; VONWILLEBRAND-FACTOR; MEMBRANE-GLYCOPROTEINS; MONOCLONAL-ANTIBODIES; PROTEIN-C; CATALYZED ACTIVATION	We have obtained evidence that selective inhibition of high affinity thrombin-binding sites located in the amino-terminal domain of the membrane glycoprotein (GP) Ib-alpha results in impaired platelet activation, as shown by abrogation or reduction of the following responses induced in normal platelets by exposure to < 1 nM alpha-thrombin: (i) increase in intracellular ionized calcium concentration ([Ca2+]i), (ii) release of dense granule content, (iii) binding of fibrinogen, (iv) aggregation. An anti-GP Ib monoclonal antibody, LJ-Ib10, which does not inhibit von Willebrand factor binding to platelets, obliterated the high affinity alpha-thrombin-binding sites on normal platelets. Isotherms of alpha-thrombin binding to normal platelets treated with saturating amounts of the antibody were virtually identical to those obtained with platelets from a patient with classical Bernard-Soulier syndrome. In parallel with decreased binding of the agonist, this antibody caused 50% inhibition of the maximal extent of platelet aggregation and 90% inhibition of ATP release induced by 0.3 nM alpha-thrombin. By inhibiting alpha-thrombin binding to GP Ib, the antibody prevented the activation of platelets exposed to low concentrations of the agonist, as demonstrated by abrogation of the increase in intraplatelet ionized calcium concentration induced in control platelets by 0.18 nM alpha-thrombin; under these conditions, fibrinogen binding was inhibited by 84%. Therefore, there is a correlation between occupancy of the high affinity sites for alpha-thrombin on GP Ib-alpha and platelet activation, secretion, and aggregation, suggesting that GP Ib-alpha is part of an alpha-thrombin receptor relevant for platelet function.	SCRIPPS RES INST, ROON RES CTR ARTERIOSCLEROSIS & THROMBOSIS, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA; CTR RIFERIMENTO ONCOL, SERV IMMUNOTRASFUS & ANAL CLIN, I-33081 AVIANO, ITALY; NEW YORK STATE DEPT HLTH, WADSWORTH CTR LAB & RES, ALBANY, NY 12201 USA; UNION UNIV, DEPT PHYSIOL, ALBANY, NY 12208 USA; UNION UNIV, DEPT BIOCHEM, ALBANY, NY 12208 USA	Scripps Research Institute; Scripps Research Institute; IRCCS Aviano (CRO); State University of New York (SUNY) System; Wadsworth Center; Union College; Union College	RUGGERI, ZM (corresponding author), SCRIPPS RES INST, ROON RES CTR ARTERIOSCLEROSIS & THROMBOSIS, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA.		Mazzucato, Mario/ABF-5472-2020	Mazzucato, Mario/0000-0001-8319-053X	NHLBI NIH HHS [HL-42846, HL-13160, R01 HL042846] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL013160, R01HL042846, R37HL042846] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOLIN RB, 1977, AM J HEMATOL, V3, P63, DOI 10.1002/ajh.2830030108; CLEMETSON KJ, 1982, J CLIN INVEST, V70, P304, DOI 10.1172/JCI110618; COLLER BS, 1983, BLOOD, V61, P99; COMP PC, 1982, J CLIN INVEST, V70, P127, DOI 10.1172/JCI110584; DAVEY MG, 1967, NATURE, V216, P857, DOI 10.1038/216857a0; DEMARCO L, 1986, ACTA HAEMATOL-BASEL, V75, P203; DEMARCO L, 1990, J CLIN INVEST, V86, P25, DOI 10.1172/JCI114692; DODT J, 1984, FEBS LETT, V165, P180, DOI 10.1016/0014-5793(84)80165-9; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; ESMON NL, 1983, J BIOL CHEM, V258, P2238; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GANGULY P, 1978, BRIT J HAEMATOL, V39, P599, DOI 10.1111/j.1365-2141.1978.tb03630.x; HANDA M, 1986, J BIOL CHEM, V261, P2579; HANSON SR, 1988, P NATL ACAD SCI USA, V85, P3184, DOI 10.1073/pnas.85.9.3184; HARMON JT, 1986, J BIOL CHEM, V261, P5928; HARMON JT, 1986, ANN NY ACAD SCI, V485, P387, DOI 10.1111/j.1749-6632.1986.tb34599.x; HARMON JT, 1986, J BIOL CHEM, V261, P3224; HARMON JT, 1985, BIOCHEMISTRY-US, V24, P58, DOI 10.1021/bi00322a010; JAMIESON GA, 1978, J CLIN INVEST, V61, P861, DOI 10.1172/JCI109000; JANDROTPERRUS M, 1988, EUR J BIOCHEM, V174, P359, DOI 10.1111/j.1432-1033.1988.tb14106.x; JENKINS CSP, 1983, BRIT J HAEMATOL, V53, P491, DOI 10.1111/j.1365-2141.1983.tb02051.x; JUNG SM, 1983, BIOCHIM BIOPHYS ACTA, V761, P152, DOI 10.1016/0304-4165(83)90224-6; KATAGIRI Y, 1990, THROMB HAEMOSTASIS, V63, P122; KNUPP CL, 1985, BLOOD, V65, P578; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KONKLE BA, 1990, J BIOL CHEM, V265, P19833; KUROSAWA S, 1987, J BIOL CHEM, V262, P2206; LARSEN NE, 1981, BIOCHEMISTRY-US, V20, P4141, DOI 10.1021/bi00517a030; MACHIN SJ, 1988, J CLIN PATHOL, V41, P1322; MARTIN BM, 1975, BIOCHEMISTRY-US, V14, P1308, DOI 10.1021/bi00677a032; MAZUROV AV, 1991, THROMB RES, V62, P673, DOI 10.1016/0049-3848(91)90371-3; MCGOWAN EB, 1983, J BIOL CHEM, V258, P1243; MCGOWAN EB, 1986, J BIOL CHEM, V261, P739; MCGREGOR JL, 1983, EUR J BIOCHEM, V131, P427, DOI 10.1111/j.1432-1033.1983.tb07281.x; MOSHER DF, 1979, BLOOD, V53, P437; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; NIIYA K, 1987, BLOOD, V70, P475; NISONOFF A, 1964, BIOCHEMISTRY-US, V3, P1338, DOI 10.1021/bi00897a025; OKUMURA T, 1976, THROMB RES, V8, P701, DOI 10.1016/0049-3848(76)90250-4; OKUMURA T, 1978, J BIOL CHEM, V253, P3435; OWEN WG, 1981, J BIOL CHEM, V256, P5532; PARHAM P, 1983, J IMMUNOL, V131, P2895; PHILLIPS DR, 1977, BIOCHEM BIOPH RES CO, V75, P940, DOI 10.1016/0006-291X(77)91473-5; PHILLIPS DR, 1974, THROMB DIATH HAEMOST, V32, P207, DOI 10.1055/s-0038-1647686; PURI RN, 1989, BIOCHEM BIOPH RES CO, V162, P1017, DOI 10.1016/0006-291X(89)90775-4; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SIXMA JJ, 1977, SEMIN HEMATOL, V14, P265; TAKAMATSU J, 1986, J CLIN INVEST, V77, P362, DOI 10.1172/JCI112313; TAM SW, 1980, J BIOL CHEM, V255, P6626; TITANI K, 1987, P NATL ACAD SCI USA, V84, P5610, DOI 10.1073/pnas.84.16.5610; TOLLEFSEN DM, 1974, J BIOL CHEM, V249, P2646; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALSH PN, 1977, BRIT J HAEMATOL, V36, P281, DOI 10.1111/j.1365-2141.1977.tb00649.x; WEISS HJ, 1975, NEW ENGL J MED, V293, P531, DOI 10.1056/NEJM197509112931105; WICKI AN, 1985, EUR J BIOCHEM, V153, P1, DOI 10.1111/j.1432-1033.1985.tb09259.x; WORKMAN EF, 1977, J BIOL CHEM, V252, P7118; YAMAGUCHI A, 1986, THROMB RES, V44, P165, DOI 10.1016/0049-3848(86)90132-5; YAMAMOTO N, 1991, BLOOD, V77, P1740; YAMAMOTO N, 1985, THROMB RES, V39, P751, DOI 10.1016/0049-3848(85)90259-2; [No title captured]	64	135	136	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23776	23783						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748654				2022-12-25	WOS:A1991GV31900040
J	COHEN, JB; SHARP, SD; LIU, WS				COHEN, JB; SHARP, SD; LIU, WS			STRUCTURE OF THE AGONIST-BINDING SITE OF THE NICOTINIC ACETYLCHOLINE-RECEPTOR - [H-3] ACETYLCHOLINE MUSTARD IDENTIFIES RESIDUES IN THE CATION-BINDING SUBSITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TORPEDO POSTSYNAPTIC MEMBRANES; ALPHA-SUBUNIT PRECURSOR; SODIUM DODECYL-SULFATE; DELTA-SUBUNIT; CDNA SEQUENCE; BETA-SUBUNIT; GUINEA-PIG; MUSCLE; CALIFORNICA; LIGAND	To characterize the structure of the agonist-binding site of the Torpedo nicotinic acetylcholine receptor (AChR), we have used [H-3]acetylcholine mustard ([H-3]AChM), a reactive analog of acetylcholine, to identify residues contributing to the cation-binding subsite. Reaction of [H-3]AChM, in its aziridinium form, with AChR-rich membrane suspensions, resulted initially in reversible, high affinity binding (K approximately 0.3-mu-M) followed by slow alkylation of the acetylcholine-binding site. Incorporation of label into AChR alpha-subunit was inhibited by agonists and competitive antagonists, but not by noncompetitive antagonists, and reaction with 3-mu-M [H-3]AChM for 2 h resulted in specific alkylation of 0.6% of alpha-subunits. Within the alpha-subunit, > 90% of specific incorporation was contained within an 18-kDa Staphylococcus aureus V8 proteolytic fragment beginning at Val-46 and containing N-linked carbohydrate. To identify sites of specific alkylation, [H-3]AChM-labeled alpha-subunit was digested with trypsin, and the digests were fractionated by reverse phase high pressure liquid chromatography. Specifically labeled material was recovered within a single peak containing a peptide extending from Leu-80 to Lys-107. NH2-terminal amino acid sequencing revealed specific release of H-3 in cycle 14 corresponding to alpha-subunit Tyr-93. Identification of Tyr-93 as the site of alkylation was confirmed by radiosequence analysis utilizing o-phthalaldehyde to establish that the released H-3 originated from a peptide containing prolines at residues 2 and 9. Because [H-3]AChM contains as its reactive group a positively charged quaternary aziridinium, alpha-subunit Tyr-93 is identified as contributing to the cation-binding domain of the AChR agonist-binding site. The selective reaction of [H-3]AChM with tyrosyl rather than acidic side chains indicates the importance of aromatic interactions for the binding of the quaternary ammonium group, and the lack of reaction with the tyrosyl or acidic side chains within alpha-190-200 emphasizes the selective orientation of acetylcholine within its binding site.			COHEN, JB (corresponding author), WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS022828, R01NS019522] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 22828, NS 19522] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; ALEXANDER P, 1958, BIOCHEM PHARMACOL, V1, P25, DOI 10.1016/0006-2952(58)90005-4; ALLEN G, 1989, SEQUENCING PROTEINS, P232; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BOSSY B, 1988, EMBO J, V7, P611, DOI 10.1002/j.1460-2075.1988.tb02854.x; BOULTER J, 1990, J BIOL CHEM, V265, P4472; BOYD ND, 1980, BIOCHEMISTRY-US, V19, P5344, DOI 10.1021/bi00564a031; BRAUER AW, 1984, ANAL BIOCHEM, V137, P134, DOI 10.1016/0003-2697(84)90359-2; BULLOUGH DA, 1989, J BIOL CHEM, V264, P9155; BUONANNO A, 1986, J BIOL CHEM, V261, P6451; CARR C, 1987, BIOCHEMISTRY-US, V26, P7090, DOI 10.1021/bi00396a034; CLAUDIO T, 1989, FRONTIERS MOL BIOL M, P63; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CONTITRONCONI BM, 1990, BIOCHEMISTRY-US, V29, P6221, DOI 10.1021/bi00478a016; COUTURIER S, 1990, J BIOL CHEM, V265, P17560; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DERMER DC, 1969, ETHLENIMINE OTHER AR, P205; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; DREYER EB, 1986, J BIOL CHEM, V261, P3727; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; GLOCKSHUBER R, 1991, BIOCHEMISTRY-US, V30, P3049, DOI 10.1021/bi00226a010; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HARTMAN DS, 1990, NATURE, V343, P372, DOI 10.1038/343372a0; HARVEY SC, 1954, J PHARMACOL EXP THER, V112, P274; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; HUDGINS PM, 1972, J PHARMACOL EXP THER, V182, P303; HUDGINS PM, 1975, J PHARM SCI, V64, P1419, DOI 10.1002/jps.2600640839; ISENBERG KE, 1986, NUCLEIC ACIDS RES, V14, P5111, DOI 10.1093/nar/14.12.5111; JACKSON CH, 1972, J MED CHEM, V15, P1183, DOI 10.1021/jm00281a026; Jeng A Y, 1980, Ann N Y Acad Sci, V358, P370, DOI 10.1111/j.1749-6632.1980.tb15425.x; JOHNSON BA, 1989, J BIOL CHEM, V264, P14262; KAO PN, 1984, J BIOL CHEM, V259, P1662; KAO PN, 1986, J BIOL CHEM, V261, P8085; KELLARIS KV, 1989, BIOCHEMISTRY-US, V28, P3469, DOI 10.1021/bi00434a048; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPOLLA RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7970, DOI 10.1073/pnas.81.24.7970; LENTZ TL, 1988, INT REV NEUROBIOL, V29, P117, DOI 10.1016/S0074-7742(08)60085-9; Michelson M.J., 1973, ACETYLCHOLINE, P73; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; MITRA AK, 1989, J CELL BIOL, V109, P755, DOI 10.1083/jcb.109.2.755; NEF P, 1988, EMBO J, V7, P595, DOI 10.1002/j.1460-2075.1988.tb02852.x; NEUBIG RR, 1979, BIOCHEMISTRY-US, V18, P5464, DOI 10.1021/bi00591a032; NEUBIG RR, 1982, BIOCHEMISTRY-US, V21, P3460, DOI 10.1021/bi00257a032; NEUBIG RR, 1980, BIOCHEMISTRY-US, V19, P2770, DOI 10.1021/bi00553a036; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; NODA M, 1983, NATURE, V305, P818, DOI 10.1038/305818a0; NODA M, 1983, NATURE, V301, P251, DOI 10.1038/301251a0; PADLAN EA, 1985, ANN INST PASTEUR IMM, VC136, P271, DOI 10.1016/S0769-2625(85)80058-1; PEDERSEN SE, 1990, BIOPHYS J, V57, pA126; PEDERSEN SE, 1986, J BIOL CHEM, V261, P3735; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; PODLESKI TR, 1969, BIOCHEM PHARMACOL, V18, P211, DOI 10.1016/0006-2952(69)90026-4; RAFTERY MA, 1980, SCIENCE, V208, P1454, DOI 10.1126/science.7384786; REYNOLDS JA, 1978, BIOCHEMISTRY-US, V17, P2035, DOI 10.1021/bi00604a001; ROBINSON DA, 1975, BRIT J PHARMACOL, V53, P363, DOI 10.1111/j.1476-5381.1975.tb07372.x; RYLETT RJ, 1980, THESIS U W ONTARIO; SHIVERS BD, 1989, NEURON, V3, P327, DOI 10.1016/0896-6273(89)90257-2; STROU DRM, 1990, BIOCHEMISTRY-US, V29, P11009; TOYOSHIMA C, 1990, J CELL BIOL, V111, P2623, DOI 10.1083/jcb.111.6.2623; TRIGGLE DJ, 1971, NEUROTRANSMITTER REC, P236; WHITE BH, 1988, BIOCHEMISTRY-US, V27, P8741, DOI 10.1021/bi00424a009; YU L, 1986, NUCLEIC ACIDS RES, V14, P3539, DOI 10.1093/nar/14.8.3539	68	123	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23354	23364						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744130				2022-12-25	WOS:A1991GT48300087
J	LEE, C; FISHER, SK; AGRANOFF, BW; HAJRA, AK				LEE, C; FISHER, SK; AGRANOFF, BW; HAJRA, AK			QUANTITATIVE-ANALYSIS OF MOLECULAR-SPECIES OF DIACYLGLYCEROL AND PHOSPHATIDATE FORMED UPON MUSCARINIC RECEPTOR ACTIVATION OF HUMAN SK-N-SH NEUROBLASTOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; PROTEIN KINASE-C; PHOSPHATIDYLCHOLINE HYDROLYSIS; INOSITOL 1,4,5-TRISPHOSPHATE; MAST-CELLS; PHOSPHOLIPIDS; 1,2-DIACYLGLYCEROL; STIMULATION; HEPATOCYTES; BREAKDOWN	Quantitative changes in the total mass and the molecular species of 1,2-diacyl-sn-glycerol (DAG) and phosphatidic acid (PA) formed upon muscarinic receptor activation were studied in cultured human SK-N-SH neuroblastoma cells. DAG was isolated from the total lipid extracts of carbachol (CCh)-stimulated and unstimulated cells and after benzoylation, was subjected to reverse phase high performance liquid chromatography to separate the component species. The molecular species of DAG were identified by analyzing the fatty acid composition of each separated fraction by gas chromatography, and their total and individual masses were quantified from the known amount of an internal standard, 1,2-distearoyl-sn-glycerol, added during the extraction of the lipid. Relatively high basal levels of DAG (1.5 nmol/mg protein) are present in these cells, and addition of CCh elicited a 50-60% increase in the total amounts of DAG within 5 min. The increase was biphasic: an initial major peak at 5 min was followed by a sustained increase that persisted for at least 30 min. An increase in DAG was elicited by both full and partial muscarinic agonists and was blocked by atropine. The presence of extracellular Ca2+ was necessary for muscarinic receptor-activated formation of DAG. To determine the source of the DAG, the molecular species of the major phospholipids present in SK-N-SH cells were also analyzed. The phospholipids were first enzymatically hydrolyzed to DAGs which were then analyzed as described above. A number of unusual fatty acids, the major one being 20:3 (n-9), were present in these lipids especially in the phosphoinositides and also in the DAG formed after CCh stimulation. Within 5 s of CCh stimulation there were transient increases in the DAG species representative of phosphoinositides. By 5 min the newly formed molecular species of DAG resembled a mixture of phosphoinositides and phosphatidylcholine (PC). Quantitative comparison of the molecular species compositions of phosphoinositides, PC, and newly formed DAGs indicated that at time periods up to 10 min, approximately 30% of the DAG originated from the phosphoinositides and the rest from PC. At longer intervals (> 20 min), most (85%) of DAGs originated from PC. Activation of muscarinic receptors in SK-N-SH cells also elicited an increase in PA (200% in 5 min). A quantitative molecular species analysis, using 1,2-distearoyl-sn-glycerol-3-P as internal standard, was performed by enzymatic (alkaline phosphatase) hydrolysis of PA to DAG and subsequent analysis. The molecular species composition of PAs in the quiescent cells was similar to that of PCs whereas in CCh-stimulated cells the newly formed PA resembled the phosphoinositides. Labeling studies with P-32(i) indicated that the PA formed by enzymatic phosphorylation of DAG is then converted to PI. These results indicate that DAG is formed in these cells by phospholipase C-catalyzed hydrolysis of PC and phosphoinositides but that only the DAGs from phosphoinositides are phosphorylated to PA.	UNIV MICHIGAN,MENTAL HLTH RES INST,NEUROSCI LAB,1103 E HURON ST,ANN ARBOR,MI 48104; UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48104; UNIV MICHIGAN,DEPT PHARMACOL,ANN ARBOR,MI 48104	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					PHS HHS [08841, 42652] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AUGERT G, 1989, J BIOL CHEM, V264, P21689; BATLEY M, 1980, J CHROMATOGR, V198, P520, DOI 10.1016/S0021-9673(00)80524-5; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLANK ML, 1984, J CHROMATOGR, V298, P473, DOI 10.1016/S0021-9673(01)92744-X; BOCCKINO SB, 1985, J BIOL CHEM, V260, P4201; COOK SJ, 1990, BIOCHEM J, V265, P617, DOI 10.1042/bj2650617; DANIEL LW, 1986, J BIOL CHEM, V261, P9128; Ehle H, 1985, FEBS Lett, V183, P413; EXTON JH, 1990, J BIOL CHEM, V265, P1; FISHER SK, 1989, MOL PHARMACOL, V35, P195; FISHER SK, 1990, MOL PHARMACOL, V38, P54; FISHER SK, 1987, MOL PHARMACOL, V32, P81; FUKAMI K, 1989, J BIOL CHEM, V264, P14985; HAJRA AK, 1988, LIPIDS RELATED COMPO, P211; HONEGGER P, 1976, BRAIN RES, V109, P335, DOI 10.1016/0006-8993(76)90534-5; KARMIOL S, 1988, LIPIDS, V23, P891, DOI 10.1007/BF02536211; KENNEDY EUGENE P., 1962, HARVEY LECTURES, V57, P143; KENNERLY DA, 1990, J IMMUNOL, V144, P3912; KENNERLY DA, 1987, J BIOL CHEM, V262, P16305; KRUEGER J, 1984, Journal of Chromatography Biomedical Applications, V307, P387; LEE CH, 1991, J NEUROCHEM, V56, P370, DOI 10.1111/j.1471-4159.1991.tb08161.x; MACDONALD ML, 1988, J BIOL CHEM, V263, P1584; MARTINSON EA, 1989, J BIOL CHEM, V264, P14748; NAKAGAWA Y, 1983, J LIPID RES, V24, P1268; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PATTON GM, 1982, J LIPID RES, V23, P190; PESSIN MS, 1989, J BIOL CHEM, V264, P8729; PREISS J, 1986, J BIOL CHEM, V261, P8597; ROGUE P, 1990, J BIOL CHEM, V265, P4161; TAKAMURA H, 1986, LIPIDS, V21, P356, DOI 10.1007/BF02535701; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10337	32	81	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22837	22846						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744076				2022-12-25	WOS:A1991GT48300013
J	THOMAS, LJ; DEGASPERI, R; SUGIYAMA, E; CHANG, HM; BECK, PJ; ORLEAN, P; URAKAZE, M; KAMITANI, T; SAMBROOK, JF; WARREN, CD; YEH, ETH				THOMAS, LJ; DEGASPERI, R; SUGIYAMA, E; CHANG, HM; BECK, PJ; ORLEAN, P; URAKAZE, M; KAMITANI, T; SAMBROOK, JF; WARREN, CD; YEH, ETH			FUNCTIONAL-ANALYSIS OF T-CELL MUTANTS DEFECTIVE IN THE BIOSYNTHESIS OF GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR - RELATIVE IMPORTANCE OF GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR VERSUS N-LINKED GLYCOSYLATION IN T-CELL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE LYMPHOMA-CELLS; HAMSTER OVARY CELLS; ANTIGEN RECEPTOR; PHOSPHATIDYLINOSITOL ANCHOR; GLUCOSE STARVATION; LYMPHOCYTES-T; GROWTH-FACTOR; OLIGOSACCHARIDES; PROTEINS; COMPLEX	The glycosylphosphatidylinositol (GPI) anchor, potentially capable of generating a number of second messengers, such as diacylglycerol, phosphatidic acid, and inositol phosphate glycan, has been postulated to be involved in signal transduction in various cell types, including T-cells. We have identified a panel of T-cell hybridoma mutants that are defective at various steps of GPI anchor biosynthesis. Since they were derived from a functional T-T hybridoma, we were able to determine the precise role of the GPI anchor in T-cell activation. Two mutants were chosen for this analysis. The first mutant is defective at the first step of GPI anchor biosynthesis, i.e. in the transfer of N-acetylglucosamine to a phosphatidylinositol acceptor. Thus, it cannot form any GPI precursors or GPI-like compounds. Interestingly, this mutant can be activated by antigen, superantigen, and concanavalin A in a manner comparable to the wild-type hybridoma. These data strongly suggest that the GPI anchor, its precursor, or its potential cleavage product, inositol phosphate glycan, is not required for the early phase of T-cell activation. The second mutant is able to synthesize the first two GPI precursors, but is not able to add mannose residues to them due to a deficiency in dolichol-phosphate-mannose (Dol-P-Man) biosynthesis. Unexpectedly, all of the Dol-P-Man mutants are defective in activation by antigen, superantigen, and concanavalin A despite normal T-cell receptor expression. Here, we show that the activation defect was due to a pleiotropic glycosylation abnormality because Dol-P-Man is required for both GPI anchor and N-linked oligosaccharide biosynthesis. When the yeast Dol-P-Man synthase gene was stably transfected into the mutants, full expression of surface GPI-anchored proteins was restored. However, N-linked glycosylation was either partially or completely corrected in different transfectants. Reconstitution of activation defects correlates well with the status of N-linked glycosylation, but not with the expression of GPI-anchored proteins. These results thus reveal an unexpected role of N-linked glycosylation in T-cell activation.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT MED,ARTHRITIS UNIT,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT ANESTHESIA,PAIN CONTROL UNIT,BOSTON,MA 02114; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Illinois System; University of Illinois Urbana-Champaign				Chang, Hui-Ming/0000-0002-5856-3397; Kamitani, Tetsu/0000-0002-3257-9630	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021087] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR003564] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45851] Funding Source: Medline; NIAMS NIH HHS [AR-03564] Funding Source: Medline; NICHD NIH HHS [HD-21087] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BECK PJ, 1990, MOL CELL BIOL, V10, P4612, DOI 10.1128/MCB.10.9.4612; BLUMBERG RS, 1990, P NATL ACAD SCI USA, V87, P7220, DOI 10.1073/pnas.87.18.7220; CHAN BL, 1988, SCIENCE, V241, P1670, DOI 10.1126/science.2843987; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; CHAPMAN A, 1980, J BIOL CHEM, V255, P4441; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; CRISPE IN, 1985, NATURE, V317, P627, DOI 10.1038/317627a0; DAVIGNON D, 1981, P NATL ACAD SCI-BIOL, V78, P4535, DOI 10.1073/pnas.78.7.4535; DAVIS LS, 1988, J IMMUNOL, V141, P2246; DEGASPERI R, 1991, J BIOL CHEM, V266, P16556; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; DOERING TL, 1990, J BIOL CHEM, V265, P611; EARDLEY DD, 1991, SCIENCE, V251, P78, DOI 10.1126/science.1824727; FARESE RV, 1988, BIOCHEM BIOPH RES CO, V156, P1346, DOI 10.1016/S0006-291X(88)80780-0; FLOOD PM, 1990, J EXP MED, V172, P115, DOI 10.1084/jem.172.1.115; GERSHMAN H, 1981, J BIOL CHEM, V256, P7774; HAHN AB, 1989, J IMMUNOL, V143, P407; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HUBBARD SC, 1986, P NATL ACAD SCI USA, V83, P1852, DOI 10.1073/pnas.83.6.1852; KOCH N, 1980, H-S Z PHYSIOL CHEM, V361, P885, DOI 10.1515/bchm2.1980.361.1.885; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1979, J BIOL CHEM, V254, P1649; KROCZEK RA, 1986, NATURE, V322, P181, DOI 10.1038/322181a0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MALEK TR, 1986, J EXP MED, V164, P709, DOI 10.1084/jem.164.3.709; MARCHALONIS JJ, 1971, BIOCHEM J, V124, P921, DOI 10.1042/bj1240921; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARRACK P, 1987, SCIENCE, V238, P1073, DOI 10.1126/science.3317824; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MCINTYRE BW, 1984, CELL, V38, P659, DOI 10.1016/0092-8674(84)90260-5; MENON AK, 1990, J BIOL CHEM, V265, P9033; MERIDA I, 1990, P NATL ACAD SCI USA, V87, P9421, DOI 10.1073/pnas.87.23.9421; MERKLE RK, 1987, METHOD ENZYMOL, V138, P232; OETTGEN HC, 1986, NATURE, V320, P272, DOI 10.1038/320272a0; PINTER A, 1988, J VIROL, V62, P1016, DOI 10.1128/JVI.62.3.1016-1021.1988; PRESKY DH, 1990, J IMMUNOL, V144, P860; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; REARICK JI, 1981, J BIOL CHEM, V256, P6255; ROCK KL, 1986, J EXP MED, V163, P315, DOI 10.1084/jem.163.2.315; SALTIEL AR, 1986, SCIENCE, V233, P967, DOI 10.1126/science.3016898; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SPIRO MJ, 1979, J BIOL CHEM, V254, P7668; STAERZ UD, 1985, J IMMUNOL, V134, P3994; STIERNBERG J, 1987, J IMMUNOL, V138, P3877; STOLL J, 1982, P NATL ACAD SCI-BIOL, V79, P2296, DOI 10.1073/pnas.79.7.2296; SUGIYAMA E, 1990, CELL IMMUNOL, V130, P271, DOI 10.1016/0008-8749(90)90270-2; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; SUSSMAN JJ, 1988, J IMMUNOL, V140, P2520; THOMPSON LF, 1989, J IMMUNOL, V143, P1815; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; WARREN CD, 1988, J BIOL CHEM, V263, P15041; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; YEH ETH, 1984, J EXP MED, V160, P799, DOI 10.1084/jem.160.3.799; YEH ETH, 1988, CELL, V52, P665, DOI 10.1016/0092-8674(88)90404-7; YEH ETH, 1987, J IMMUNOL, V138, P91	60	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23175	23184						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1835975				2022-12-25	WOS:A1991GT48300063
J	WEBSTER, C; GAUT, RL; BROWNING, KS; RAVEL, JM; ROBERTS, JKM				WEBSTER, C; GAUT, RL; BROWNING, KS; RAVEL, JM; ROBERTS, JKM			HYPOXIA ENHANCES PHOSPHORYLATION OF EUKARYOTIC INITIATION FACTOR-4A IN MAIZE ROOT-TIPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; MESSENGER-RNA TRANSLATION; WHEAT-GERM; ELONGATION-FACTORS; CAP RECOGNITION; BINDING-PROTEIN; EIF-4F; KINASES; CELLS; YEAST	We have identified two isoforms of initiation factor 4A (eIF-4A) in maize root tips, with distinct isoelectric points and similar molecular mass (approximately 50 kDa). Both isoforms of maize eIF-4A cross-react with antibodies raised against wheat germ eIF-4A, and one of the maize proteins (higher pI isoform) comigrates with purified wheat germ eIF-4A on two-dimensional gels. The two maize eIF-4As were indistinguishable by comparative peptide fingerprint analysis, which also showed a very strong similarity between eIF-4A in maize roots and wheat germ. Maize eIF-4As copurify with eIF-4F and eIF-(iso)4F on a 7-methyl-GTP-Sepharose affinity column, indicating that they are part of the 5'-cap-binding complex. Two-dimensional gel electrophoresis and immunoblotting of proteins from P-32-labeled maize root tips revealed that the lower pI isoform of eIF-4A is phosphorylated. Two-dimensional phosphopeptide maps of trypsin-digested eIF-4A contained one principal phosphorylated fragment; phosphoamino acid analysis indicated phosphorylation of threonine. In oxygenated maize root tips, the ratio of phosphorylated to nonphosphorylated eIF-4A is approximately 0.2. This ratio increases to approximately 1 within 20 min following the onset of hypoxia, due to interconversion between the two maize eIF-4A isoforms. The hypoxia-induced phosphorylation of eIF-4A is discussed with respect to metabolic responses, and the translational control of gene expression, in hypoxic plant tissues.	UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521; UNIV TEXAS,CLAYTON FDN,INST BIOCHEM,AUSTIN,TX 78712; UNIV TEXAS,DEPT CHEM,AUSTIN,TX 78712; UNIV TEXAS,DEPT BIOCHEM,AUSTIN,TX 78712	University of California System; University of California Riverside; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018775] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-18775] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; ABRAMSON RD, 1988, J BIOL CHEM, V263, P5462; BAILEYSERRES J, 1990, PLANT PHYSIOL, V94, P1237, DOI 10.1104/pp.94.3.1237; BROWNING KS, 1989, J BIOL CHEM, V264, P8491; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BROWNING KS, 1990, J BIOL CHEM, V265, P17967; CARBERRY SE, 1991, BIOCHEMISTRY-US, V30, P1624, DOI 10.1021/bi00220a026; CARBERRY SE, 1991, BIOCHEMISTRY-US, V30, P4542, DOI 10.1021/bi00232a025; DUNCAN R, 1985, J BIOL CHEM, V260, P5493; EDERY I, 1983, J BIOL CHEM, V258, P1398; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; JARAMILLO M, 1990, BIOCHIM BIOPHYS ACTA, V1050, P134, DOI 10.1016/0167-4781(90)90154-T; LAX S, 1985, P NATL ACAD SCI USA, V82, P330, DOI 10.1073/pnas.82.2.330; LAX SR, 1986, METHOD ENZYMOL, V118, P109; LAX SR, 1986, J BIOL CHEM, V261, P5632; LIN CY, 1967, J MOL BIOL, V26, P237, DOI 10.1016/0022-2836(67)90294-X; LINDER P, 1989, P NATL ACAD SCI USA, V86, P2286, DOI 10.1073/pnas.86.7.2286; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; MORLEY SJ, 1991, IN PRESS INT ENCY PH; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NIELSEN PJ, 1988, EMBO J, V7, P2097, DOI 10.1002/j.1460-2075.1988.tb03049.x; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; ROBERTS JKM, 1984, P NATL ACAD SCI-BIOL, V81, P3379, DOI 10.1073/pnas.81.11.3379; ROBERTS JKM, 1985, ARCH BIOCHEM BIOPHYS, V240, P712, DOI 10.1016/0003-9861(85)90080-3; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SACHS MM, 1980, CELL, V20, P761, DOI 10.1016/0092-8674(80)90322-0; SAFER B, 1989, EUR J BIOCHEM, V186, P1, DOI 10.1111/j.1432-1033.1989.tb15169.x; SEAL SN, 1986, ARCH BIOCHEM BIOPHYS, V246, P710, DOI 10.1016/0003-9861(86)90327-9; TAHARA SM, 1981, J BIOL CHEM, V256, P7691; TUAZON PT, 1979, EUR J BIOCHEM, V94, P497, DOI 10.1111/j.1432-1033.1979.tb12918.x; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; TUAZON PT, 1990, J BIOL CHEM, V265, P10617; WEBSTER C, 1991, PLANT PHYSIOL, V96, P418, DOI 10.1104/pp.96.2.418	34	71	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23341	23346						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744128				2022-12-25	WOS:A1991GT48300085
J	FUJII, M; TSUCHIYA, H; SEIKI, M				FUJII, M; TSUCHIYA, H; SEIKI, M			HTLV-1 TAX HAS DISTINCT BUT OVERLAPPING DOMAINS FOR TRANSCRIPTIONAL ACTIVATION AND FOR ENHANCER SPECIFICITY	ONCOGENE			English	Note							CELL LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; LEUCINE ZIPPER STRUCTURE; C-FOS; TRANS-ACTIVATION; MAMMALIAN-CELLS; GENE-EXPRESSION; DNA-BINDING; PROTEIN; INTERLEUKIN-2	Tax1 of human T-cell leukemia virus type 1 (HTLV-1) activates viral transcription dependent upon three 21-bp enhancer elements in the long terminal repeat. Difficulties in detecting any association of Tax1 with the viral enhancer have hampered elucidation of the molecular mechanisms of Tax1-mediated transcriptional activation. By constructing a fusion protein with the heterologous DNA-binding domain of yeast GAL4, Tax1 was shown to be a potent transcriptional activator dependent on the presence of GAL4-binding sites. Deletions of the Tax1 portion of the fusion protein revealed that almost the entire region of Tax1 (amino acids 2-337) is required for activation, and the activity correlated well with that of the viral enhancer. The GAL/Tax1 mutant lacking 41 residues of the C-terminus of Tax1. GAL/Tax1(2-312). was inactive for the viral enhancer, but activity was recovered by adding the heterologous activation domain of herpes simplex virus VP16. These results indicate that Tax1 has two distinct but overlapping functional domains for transcriptional activation and for enhancer specificity. Thus, Tax1 is thought to be a transcription factor acting in the enhancer complex rather than as a catalytic or allosteric modifier of pre-existing cellular transcription factors.	KANAZAWA UNIV,SCH MED,DEPT INTERNAL MED 3,KANAZAWA,ISHIKAWA 920,JAPAN	Kanazawa University	FUJII, M (corresponding author), KANAZAWA UNIV,SCH MED,CANC RES INST,DEPT VIROL,13-1 TAKARA MACHI,KANAZAWA,ISHIKAWA 920,JAPAN.		Seiki, Motoharu/K-9443-2015					ALTMAN R, 1988, J VIROL, V62, P1339, DOI 10.1128/JVI.62.4.1339-1346.1988; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BEIMLING P, 1989, ONCOGENE, V4, P511; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SADOWSKI I, 1986, NATURE, V332, P853; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; WILLEMS L, 1991, ONCOGENE, V6, P159; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	37	44	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2349	2352						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766679				2022-12-25	WOS:A1991GX73500025
J	MASON, MJ; GARCIARODRIGUEZ, C; GRINSTEIN, S				MASON, MJ; GARCIARODRIGUEZ, C; GRINSTEIN, S			COUPLING BETWEEN INTRACELLULAR CA2+ STORES AND THE CA2+ PERMEABILITY OF THE PLASMA-MEMBRANE - COMPARISON OF THE EFFECTS OF THAPSIGARGIN, 2,5-DI-(TERT-BUTYL)-1,4-HYDROQUINONE, AND CYCLOPIAZONIC ACID IN RAT THYMIC LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL PHOSPHATE PRODUCTION; TUMOR PROMOTER; CALCIUM INFLUX; HUMAN-NEUTROPHILS; ION CHANNELS; CELL-LINE; CA-2+; MOBILIZATION; ENTRY; POOL	The regulation of Ca2+ uptake by receptors is incompletely understood. It has been proposed that the Ca2+ permeability of the plasma membrane increases in response to depletion of a critical intracellular Ca2+ storage compartment (Takemura, H., Hughes, A. R., Thastrup, O., and Putney, J. W. (1989) J. Biol. Chem. 264, 12266-12271). This hypothesis is based largely on the effect of thapsigargin, an inhibitor of endomembrane Ca2+-ATPases. Due to the existence of an endogenous leak, inhibition of Ca2+ uptake by thapsigargin induces depletion of the stores. This is accompanied by increased plasmalemmal Ca2+ permeability, without change in the level of inositol phosphates. On the other hand, depletion of the intracellular stores by 2,5-di(tert-butyl)-1,4-hydroquinone (BHQ), a chemically unrelated inhibitor of the Ca2+-ATPases, fails to induce Ca2+ influx (Kass, G. E., Duddy, S. K., Moore, G. A., and Orrenius, S. (1989) J. Biol. Chem. 264, 15192-15198). In an attempt to reconcile these observations, we analyzed in lymphocytes the mode of action of thapsigargin and BHQ. In addition, we tested the effects of cyclopiazonic acid (CPA), a blocker of the skeletal muscle sarcoplasmic reticulum Ca2+-ATPase. All three compounds released Ca2+ from a common intracellular compartment. Thapsigargin and low concentrations of BHQ and CPA concomitantly elevated the plasmalemmal Ca2+ permeability. Higher concentrations of BHQ and CPA produced a secondary inhibition of the Ca2+ entry pathway, by a mechanism seemingly unrelated to their effects on the internal stores. This inhibitory side effect can account for the reported discrepancies between the effects of thapsigargin and BHQ. The data provide further support for the notion that endomembrane Ca2+ stores are functionally coupled to the plasma membrane Ca2+ permeability pathway.	LAB NEFROL,E-28040 MADRID,SPAIN		MASON, MJ (corresponding author), HOSP SICK CHILDREN,DIV CELL BIOL,TORONTO M5G 1X8,ONTARIO,CANADA.		Garcia, Carmen/L-9961-2017	Garcia, Carmen/0000-0002-7205-4572				BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; GOUY H, 1990, EUR J IMMUNOL, V20, P2269, DOI 10.1002/eji.1830201016; GRINSTEIN S, 1984, J GEN PHYSIOL, V83, P341, DOI 10.1085/jgp.83.3.341; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALLAM TJ, 1989, BIOCHEM J, V259, P125, DOI 10.1042/bj2590125; HALLAM TJ, 1985, FEBS LETT, V186, P175, DOI 10.1016/0014-5793(85)80703-1; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KELLEY LL, 1990, J BIOL CHEM, V265, P17657; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; MACDOUGALL SL, 1988, CELL, V54, P229, DOI 10.1016/0092-8674(88)90555-7; MASON MJ, 1991, J BIOL CHEM, V266, P10872; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; NG J, 1990, BIOCHIM BIOPHYS ACTA, V1053, P97, DOI 10.1016/0167-4889(90)90031-8; NG J, 1988, BIOCHIM BIOPHYS ACTA, V971, P207, DOI 10.1016/S0005-2728(88)80108-7; PANDOL SJ, 1990, J BIOL CHEM, V265, P12846; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; SCHARFF O, 1988, BIOCHIM BIOPHYS ACTA, V972, P257, DOI 10.1016/S0005-2728(88)80056-2; SIEDLER NW, 1989, J BIOL CHEM, V264, P17816; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1987, BIOCHIM BIOPHYS ACTA, V927, P65, DOI 10.1016/0167-4889(87)90066-8; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0	25	265	267	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20856	20862						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1834651				2022-12-25	WOS:A1991GN00100043
J	CASTRONOVO, V; TARABOLETTI, G; SOBEL, ME				CASTRONOVO, V; TARABOLETTI, G; SOBEL, ME			FUNCTIONAL DOMAINS OF THE 67-KDA LAMININ RECEPTOR PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; MESSENGER-RNA; BINDING PROTEIN; CARCINOMA-CELLS; TUMOR CELLS; SEQUENCE; GLYCOPROTEIN; POLYPEPTIDES; FIBRONECTIN; ATTACHMENT	We report the characterization of two functional domains of the metastasis-associated 67-kDa laminin receptor (67-LR). Using synthetic peptides deduced from the cDNA sequence of the 37-kDa precursor of the laminin receptor (37-LRP) as well as their corresponding affinity-purified polyclonal antibodies, we identified a unique laminin binding site as well as a membrane-associated domain of the receptor. In laminin dot blot and solid phase radioligand assays, a 20 amino acid synthetic peptide (IPCNNKGAHSVGLMWWMLAR, amino acid residues 161-180, designated peptide G) specifically bound to laminin with high affinity (K(d) = 5 x 10(-8) M). Peptide G also specifically eluted the 67-LR from a laminin affinity column. Peptide G and laminin reacted with a 1:1 stoichiometry, suggesting that there is one recognition site on laminin for the peptide G domain. Immunofluorescence studies, performed on permeabilized and nonpermeabilized human A2058 melanoma cells using 10 different affinity-purified antibodies to distinct regions of the 37-LRP, identified an unusually short membrane-associated domain that was consistent with a computer predicted transmembrane domain (residues 86-101). Our data demonstrate for the first time that the 37-LRP has two functional domains consistent with the characteristics of the mature 67-LR. Furthermore, we propose peptide G as a potential inhibitor of tumor cell interactions with laminin.			CASTRONOVO, V (corresponding author), NCI,PATHOL LAB,TUMOR INVAS & METASTASIS SECT,BLDG 10,RM 2A33,BETHESDA,MD 20892, USA.		Taraboletti, Giulia/J-4089-2018	Taraboletti, Giulia/0000-0001-8780-5001				ADAMS GA, 1985, CELL, V41, P1007, DOI 10.1016/S0092-8674(85)80081-7; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; CASTRONOVO V, 1989, J NATL CANCER I, V81, P781, DOI 10.1093/jnci/81.10.781; CASTRONOVO V, 1991, BIOCHEM BIOPH RES CO, V177, P177, DOI 10.1016/0006-291X(91)91965-F; CASTRONOVO V, 1990, AM J PATHOL, V137, P1373; CASTRONOVO V, 1989, FASEB J, V3, pA1052; CIOCE V, 1991, J NATL CANCER I, V83, P29, DOI 10.1093/jnci/83.1.29; CLEMENT B, 1990, J CELL BIOL, V110, P185, DOI 10.1083/jcb.110.1.185; DAVIS CM, 1991, EXP CELL RES, V193, P262, DOI 10.1016/0014-4827(91)90095-C; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; FERNANDEZ MT, 1991, BIOCHEM BIOPH RES CO, V165, P84; GEHLSEN KR, 1988, SCIENCE, V241, P1228, DOI 10.1126/science.2970671; GRAF J, 1987, BIOCHEMISTRY-US, V26, P6896, DOI 10.1021/bi00396a004; GROSSO LE, 1991, BIOCHEMISTRY-US, V30, P3346, DOI 10.1021/bi00227a026; HADLEY MA, 1990, DEV BIOL, V140, P318, DOI 10.1016/0012-1606(90)90082-T; HEDRICK SM, 1984, NATURE, V308, P153, DOI 10.1038/308153a0; HORANHAND P, 1985, CANCER RES, V45, P2713; HORWITZ A, 1985, J CELL BIOL, V101, P2134, DOI 10.1083/jcb.101.6.2134; KLEINMAN HK, 1985, J CELL BIOCHEM, V27, P317, DOI 10.1002/jcb.240270402; KLEINMAN HK, 1988, P NATL ACAD SCI USA, V83, P8182; KRAMER RH, 1989, J BIOL CHEM, V264, P15642; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESOT H, 1983, EMBO J, V2, P861, DOI 10.1002/j.1460-2075.1983.tb01514.x; LIOTTA LA, 1986, CANCER RES, V46, P1; MAFUNE K, 1990, CANCER RES, V50, P3888; MAKRIDES S, 1988, NUCLEIC ACIDS RES, V16, P2349, DOI 10.1093/nar/16.5.2349; MALINOFF HL, 1983, J CELL BIOL, V96, P1475, DOI 10.1083/jcb.96.5.1475; MCCARTHY JB, 1988, J NATL CANCER I, V80, P108, DOI 10.1093/jnci/80.2.108; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; RAHMAN A, 1989, J NATL CANCER I, V81, P1794, DOI 10.1093/jnci/81.23.1794; RAO CN, 1989, BIOCHEMISTRY-US, V28, P7476, DOI 10.1021/bi00444a047; RAO CN, 1983, BIOCHEM BIOPH RES CO, V111, P804; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; RUNYAN RB, 1988, J CELL BIOL, V107, P1863, DOI 10.1083/jcb.107.5.1863; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; TANDON NN, 1991, BIOCHEM J, V271, P535; TERRANOVA VP, 1983, P NATL ACAD SCI-BIOL, V80, P444, DOI 10.1073/pnas.80.2.444; TIMPL R, 1979, J BIOL CHEM, V254, P9933; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; WEWER UM, 1987, CANCER RES, V47, P5691; WEWER UM, 1986, P NATL ACAD SCI USA, V83, P7137, DOI 10.1073/pnas.83.19.7137; WILLINGHAM MC, 1985, ATLAS IMMUNOFLUORESC; YANAGI Y, 1984, NATURE, V308, P146; YOW HK, 1988, P NATL ACAD SCI USA, V85, P6394, DOI 10.1073/pnas.85.17.6394	45	134	141	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20440	20446						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1834645				2022-12-25	WOS:A1991GM03900084
J	VANDEWINKEL, JGJ; ERNST, LK; ANDERSON, CL; CHIU, IM				VANDEWINKEL, JGJ; ERNST, LK; ANDERSON, CL; CHIU, IM			GENE ORGANIZATION OF THE HUMAN HIGH-AFFINITY RECEPTOR FOR IGG, FC-GAMMA-RI (CD64) - CHARACTERIZATION AND EVIDENCE FOR A 2ND GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE CLEAVAGE SITES; MONOCYTE CELL-LINE; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; MESSENGER-RNA; EXPRESSION; BINDING; CD32; DNA; NEUTROPHILS	We have isolated, characterized, and sequenced the gene coding for the 72-kDa human high affinity IgG FcR, hFc-gamma-RI. It consists of six exons and spans 9.4 kilobase pairs. The leader sequence is encoded by two exons, the second of which is 21 base pairs long and contains the predicted site of peptidase cleavage. The third, fourth, and fifth exons each encode homologous Ig-like extracellular domains. The hydrophobic transmembrane region and a highly charged cytoplasmic tail are encoded by a single final exon. The sequence of the 5'-flanking region was determined. Two major transcription initiation sites were identified by RNase protection. The first, more downstream site was confirmed by primer extension studies; canonical CAAT and TATA boxes are located in appropriate positions upstream from this site. The second transcription initiation site was utilized only in RNA from cells incubated with gamma-interferon. This site initiates transcription upstream from the first major site. These data are consistent with the finding of two species of mRNA for hFc-gamma-RI in myeloid cells that are upregulated when cultured with gamma-interferon. Southern analysis of genomic DNA confirms the restriction map generated from the cloned DNA. One additional HindIII fragment was observed in genomic DNA from 13 randomly selected individuals that was not present in the phage clone used to characterize the gene. This observation suggests the existence of a second hFc-gamma-RI gene which lacks one of the two internal HindIII sites rather than a restriction fragment length polymorphism.	OHIO STATE UNIV,DAVIS MED RES CTR,DEPT INTERNAL MED,480 W 9TH AVE,COLUMBUS,OH 43210; OHIO STATE UNIV,CTR COMPREHENS CANC,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University			Chiu, Ing-Ming/B-1534-2008		NATIONAL CANCER INSTITUTE [K04CA001369, R01CA045611, R01CA044983] Funding Source: NIH RePORTER; NCI NIH HHS [KO4-CA01369, R01-CA45611, R01-CA44983] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN JM, 1989, SCIENCE, V243, P378, DOI 10.1126/science.2911749; ANDERSON CL, 1986, J BIOL CHEM, V261, P2856; ANDERSON CL, 1982, J EXP MED, V156, P1794, DOI 10.1084/jem.156.6.1794; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; DOUGHERTY GJ, 1987, EUR J IMMUNOL, V17, P1453, DOI 10.1002/eji.1830171011; ERNST LK, 1989, J BIOL CHEM, V264, P3436; GRUNDY HO, 1989, IMMUNOGENETICS, V29, P331, DOI 10.1007/BF00352843; GUYRE PM, 1989, J IMMUNOL, V143, P1650; HIBBS ML, 1988, P NATL ACAD SCI USA, V85, P2240, DOI 10.1073/pnas.85.7.2240; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KINDT GC, 1991, IN PRESS AM J PHYSL; KINET JP, 1989, CELL, V57, P351, DOI 10.1016/0092-8674(89)90910-0; KULCZYCKI A, 1990, P NATL ACAD SCI USA, V87, P2856, DOI 10.1073/pnas.87.7.2856; Maniatis T., 1982, MOL CLONING; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PAN L, 1990, J IMMUNOL, V145, P267; PELTZ GA, 1989, P NATL ACAD SCI USA, V86, P1013, DOI 10.1073/pnas.86.3.1013; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; QIU WQ, 1990, SCIENCE, V248, P732, DOI 10.1126/science.2139735; Ravetch J.V., 1990, FC RECEPTORS ACTION, P211; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; SAMMARTINO L, 1988, IMMUNOGENETICS, V28, P380, DOI 10.1007/BF00364238; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCALLON BJ, 1989, P NATL ACAD SCI USA, V86, P5079, DOI 10.1073/pnas.86.13.5079; SEARS DW, 1990, J IMMUNOL, V144, P371; STENGELIN S, 1988, EMBO J, V7, P1053, DOI 10.1002/j.1460-2075.1988.tb02913.x; STUART SG, 1989, EMBO J, V8, P3657, DOI 10.1002/j.1460-2075.1989.tb08540.x; TEPLER I, 1989, J BIOL CHEM, V264, P5912; VANDEWINKEL JGJ, 1991, J LEUKOCYTE BIOL, V49, P511, DOI 10.1002/jlb.49.5.511; VANDEWINKEL JGJ, 1990, J IMMUNOL, V145, P1890; VANDEWINKEL JGJ, 1989, J IMMUNOL, V143, P571; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; WARMERDAM PAM, 1990, J EXP MED, V172, P19, DOI 10.1084/jem.172.1.19; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YANG Z, 1990, P NATL ACAD SCI USA, V87, P9226, DOI 10.1073/pnas.87.23.9226	39	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13449	13455						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1830050				2022-12-25	WOS:A1991FX13200100
J	HOPPE, A; LIN, JT; ONSGARD, M; KNOX, FG; DOUSA, TP				HOPPE, A; LIN, JT; ONSGARD, M; KNOX, FG; DOUSA, TP			QUANTITATION OF THE NA+-PI COTRANSPORTER IN RENAL CORTICAL BRUSH-BORDER MEMBRANES - [C-14] PHOSPHONOFORMIC ACID AS A USEFUL PROBE TO DETERMINE THE DENSITY AND ITS CHANGE IN RESPONSE TO PARATHYROID-HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE-TRANSPORT; PHOSPHONOFORMIC ACID; DEPENDENT TRANSPORT; ADAPTIVE INCREASE; PHLORIZIN BINDING; PROXIMAL TUBULES; KIDNEY; ENDOCYTOSIS; INHIBITORS; MECHANISMS	To determine the density of Na+-P(i) symporters in brush border membranes (BBM) from rat renal cortex, [C-14]phosphonoformic acid ([C-14]PFA), a competitive inhibitor of Na+-P(i) cotransport, was employed as a probe. The [C-14]PFA binding was measured in BBM vesicles (BBMV) under equilibrated conditions (extravesicular Na+, K+, and H+ = intravesicular Na+, K+, and H+) to avoid modulatory effects of these solutes. BBMV were preincubated in media without or with addition of molar excess of P(i) (> 20 times) to determine the P(i)-protectable PFA-binding sites, and then [C-14] PFA binding was determined. Only the [C-14]PFA binding in the presence of Na+ displaceable by an excess of P(i) was saturated and was independent of intravesicular volume of BBMV. This value denoted as "P(i)-protectable Na+-[C-14]PFA binding," was analyzed by Scatchard plot showing B(maxPFA) = 375 +/- 129 pmol of PFA/mg protein, K(DPFA) = 158 +/- 18-mu-m; the Hill coefficient was congruent-to 1. For Na+-dependent binding of [H-3]phlorizin, in the same BBMV, B(max) = 310 +/- 37 pmol/mg protein and K(D) = 2.2 +/- 0.5-mu-m. BBMV prepared from cortex of thyroparathyroidectomized rats infused with phosphaturic doses of parathyroid hormone (PTH) were compared with vehicle-infused controls. Administration of PTH resulted in decrease of B(maxPFA) (-38%) and of Na+-gradient-dependent uptake of P-32i (-35%), but K(DPFA) was not changed. Neither B(maxPhl) and K(DPHl) for Na+-phlorizin binding, nor the Na+-gradient-dependent uptake of [H-3]D-glucose differed between PTH-treated and control rats. We conclude: (a) measurement of P(i)-protectable Na+-[C-14]PFA binding determines numbers and affinity of Na+-P(i) symporters in renal BBMV; (b) the affinity of PFA for Na+-P(i) symporter is similar to apparent affinity for P(i) (K(mPi), as determined from measurements of Na+-gradient-dependent P-32i uptake by BBMV; (c) both Na+-P(i) symporter and [Na+]D-glucose symporters are present within renal BBM in a similar range of density; (d) PTH decreases the number of Na+-P(i) cotransporters in BBMV commensurate with the parallel decrease of Na+-gradient-dependent P(i) transport, whereas the affinity of Na+-P(i) symporters for P(i) is not changed. These observations support the hypothesis that PTH decreases capacity for Na+-dependent P(i) reabsorption by internalization of Na+-P(i) symporters in BBM of renal proximal tubules.	MAYO CLIN & MAYO FDN,MAYO MED SCH,DIV NEPHROL & INTERNAL MED,NEPHROL RES UNIT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,MAYO CLIN,DEPT PHYSIOL & BIOPHYS,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030759, R01DK019715] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-19715, R37-DK30759] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1978, J MEMBRANE BIOL, V42, P81, DOI 10.1007/BF01870395; BELIVEAU R, 1988, AM J PHYSIOL, V254, pF329, DOI 10.1152/ajprenal.1988.254.3.F329; BROTLAROCHE E, 1983, INTESTINAL TRANSPORT, P147; CHAMNESS GC, 1975, STEROIDS, V26, P538, DOI 10.1016/0039-128X(75)90073-2; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; COUDRIER E, 1988, KIDNEY INT, V34, P309, DOI 10.1038/ki.1988.183; DOUSA TP, 1990, KIDNEY INT, V37, P465; DUNLAY R, 1990, AM J PHYSIOL, V258, pF223, DOI 10.1152/ajprenal.1990.258.2.F223; FUHR J, 1955, KLIN WOCHENSCHR, V33, P729, DOI 10.1007/BF01473295; GMAJ P, 1986, PHYSIOL REV, V66, P36, DOI 10.1152/physrev.1986.66.1.36; HAMMERMAN MR, 1980, BIOCHIM BIOPHYS ACTA, V603, P322, DOI 10.1016/0005-2736(80)90378-8; HAMMOND TG, 1985, J CLIN INVEST, V75, P1983, DOI 10.1172/JCI111916; HOFFMANN N, 1976, PFLUG ARCH EUR J PHY, V362, P147, DOI 10.1007/BF00583641; KEMPSON SA, 1988, NEWS PHYSIOL SCI, V3, P154; KEMPSON SA, 1985, AM J PHYSIOL, V249, pF948, DOI 10.1152/ajprenal.1985.249.6.F948; KEMPSON SA, 1990, AM J PHYSIOL, V258, pF1336, DOI 10.1152/ajprenal.1990.258.5.F1336; KEMPSON SA, 1986, BIOCHEM PHARMACOL, V35, P721, DOI 10.1016/0006-2952(86)90237-6; KEMPSON SA, 1989, J BIOL CHEM, V264, P18451; LIN JT, 1979, BIOCHIM BIOPHYS ACTA, V557, P179, DOI 10.1016/0005-2736(79)90100-7; LIN JT, 1984, BIOCHIM BIOPHYS ACTA, V777, P201, DOI 10.1016/0005-2736(84)90421-8; LIN JT, 1983, ANAL BIOCHEM, V129, P337, DOI 10.1016/0003-2697(83)90559-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MURER H, 1985, ANN NY ACAD SCI, V456, P139, DOI 10.1111/j.1749-6632.1985.tb14859.x; MURER H, 1978, BIOCH NEPHROLOGY, P455; OBERG B, 1989, PHARMACOL THERAPEUT, V40, P213, DOI 10.1016/0163-7258(89)90097-1; Sacktor B., 1977, Current Topics in Bioenergetics, V6, P39; SARAVIS CA, 1984, ELECTROPHORESIS, V5, P54, DOI 10.1002/elps.1150050110; SZCZEPANSKAKONKEL M, 1989, BIOCHEM PHARMACOL, V38, P4191; SZCZEPANSKAKONKEL M, 1987, J BIOL CHEM, V262, P8000; SZCZEPANSKAKONKEL M, 1986, J BIOL CHEM, V261, P6375; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; TSUJI A, 1989, BIOCHEM PHARMACOL, V38, P1019; VANDEURS B, 1984, EUR J CELL BIOL, V33, P163; VANSCOY M, 1988, AM J PHYSIOL, V255, pF984, DOI 10.1152/ajprenal.1988.255.5.F984; WRIGHT EM, 1985, ANNU REV PHYSIOL, V47, P127; YUSUFI ANK, 1989, AM J PHYSIOL, V256, pF852, DOI 10.1152/ajprenal.1989.256.5.F852; YUSUFI ANK, 1986, BIOCHEM BIOPH RES CO, V139, P679, DOI 10.1016/S0006-291X(86)80044-4; YUSUFI ANK, 1987, AM J PHYSIOL, V252, pF598, DOI 10.1152/ajprenal.1987.252.4.F598; YUSUFI ANK, 1989, BIOCHEM BIOPH RES CO, V161, P1160, DOI 10.1016/0006-291X(89)91363-6	39	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11528	11536						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1828801				2022-12-25	WOS:A1991FT76200021
J	INGRAHAM, CA; COOKE, MP; CHUANG, YN; PERLMUTTER, RM; MANESS, PF				INGRAHAM, CA; COOKE, MP; CHUANG, YN; PERLMUTTER, RM; MANESS, PF			CELL TYPE AND DEVELOPMENTAL REGULATION OF THE FYN PROTOONCOGENE IN NEURAL RETINA	ONCOGENE			English	Article								The product of the proto-oncogene c-fyn (p59fyn) is a non-receptor tyrosine kinase of unknown function. The expression of the p59fyn tyrosine kinase was analysed by immunoperoxidase staining of the different neuronal cell types in the developing chick neural retina. p59fyn was primarily localized in the cell bodies of mature retinal neurons. p59fyn immunoreactivity was most abundant in cell bodies of differentiated ganglion, amacrine and photoreceptor cells. The onset of p59fyn expression in developing photoreceptors occurred coordinately with terminal neuronal differentiation. p59fyn was also found within the outer plexiform layer, which contains synaptic terminals of the photoreceptors. At embryonic stages prior to photoreceptor differentiation, p59fyn was most highly concentrated in the cell bodies of differentiating ganglion and amacrine cells. p59fyn autokinase activity in retinal extracts decreased concomitant with the final stages of maturation of retinal neurons, suggesting that the p59fyn kinase is developmentally regulated. Thus, the expression of p59fyn is regulated in both a developmental and cell type-specific manner. The existence of p59fyn in some of the same neuronal cells as p60c-src suggests the possibility of functional redundancy of these non-receptor tyrosine kinases.	UNIV N CAROLINA, SCH MED, DEPT BIOCHEM, CHAPEL HILL, NC 27599 USA; UNIV WASHINGTON, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT IMMUNOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED, DIV MED GENET, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NCI NIH HHS [CA45682] Funding Source: Medline; NEI NIH HHS [EY08975] Funding Source: Medline; NINDS NIH HHS [NS26620] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045682] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY008975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026620] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARCLAY AN, 1981, IMMUNOLOGY, V44, P727; BUSS JE, 1984, MOL CELL BIOL, V4, P2697, DOI 10.1128/MCB.4.12.2697; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, IN PRESS CELL; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1987, PEPTIDES PHOSPHORYLA; Dowling J. E., 1987, RETINA APPROACHABLE; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUGHES WF, 1974, ANAT REC, V179, P297, DOI 10.1002/ar.1091790302; KAHN AJ, 1974, DEV BIOL, V38, P30, DOI 10.1016/0012-1606(74)90256-5; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; LEMMON V, 1986, J NEUROSCI, V6, P2987; LINSER P, 1979, P NATL ACAD SCI USA, V76, P6476, DOI 10.1073/pnas.76.12.6476; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MARTH JD, 1989, J IMMUNOL, V142, P2430; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; PEARSON R, 1972, AVIAN BRAIN; PERRY VH, 1981, NEUROSCIENCE, V6, P931, DOI 10.1016/0306-4522(81)90174-3; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SHORES CG, 1989, J NEUROSCI RES, V24, P59, DOI 10.1002/jnr.490240109; SINCLAIR CM, 1986, BRAIN RES, V398, P91, DOI 10.1016/0006-8993(86)91254-0; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SUDOL M, 1988, ONCOGENE RES, V2, P345; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; TOWLE AC, 1984, J HISTOCHEM CYTOCHEM, V32, P766, DOI 10.1177/32.7.6145741; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEBB M, 1984, J NEUROCHEM, V43, P1061, DOI 10.1111/j.1471-4159.1984.tb12844.x; WONG ROL, 1987, J COMP NEUROL, V255, P159, DOI 10.1002/cne.902550202	39	28	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1992	7	1					95	100						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741169				2022-12-25	WOS:A1992HC22700013
J	SHULL, S; HEINTZ, NH; PERIASAMY, M; MANOHAR, M; JANSSEN, YMW; MARSH, JP; MOSSMAN, BT				SHULL, S; HEINTZ, NH; PERIASAMY, M; MANOHAR, M; JANSSEN, YMW; MARSH, JP; MOSSMAN, BT			DIFFERENTIAL REGULATION OF ANTIOXIDANT ENZYMES IN RESPONSE TO OXIDANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; CONTAINING SUPEROXIDE-DISMUTASE; TRACHEAL EPITHELIAL-CELLS; XANTHINE-OXIDASE; INTERLEUKIN-1; EXPRESSION; INDUCTION; TOXICITY; CDNA; RNA	We have demonstrated the selective induction of manganese superoxide dismutase (MnSOD) or catalase mRNA after exposure of tracheobronchial epithelial cells in vitro to different oxidant stresses. Addition of H2O2 caused a dose-dependent increase in catalase mRNA in both exponentially growing and confluent cells. A 3-fold induction of catalase mRNA was seen at a nontoxic dose of 250-mu-M H2O2. Increase in the steady-state mRNA levels of glutathione peroxidase (GPX) and MnSOD were less striking. Expression of catalase, MnSOD, and GPX mRNA was highest in confluent cells. In contrast, constitutive expression of copper and zinc SOD (CuZnSOD) mRNA was greatest in dividing cells and was unaffected by H2O2 in both exponentially growing and confluent cells. MnSOD mRNA was selectively induced in confluent epithelial cells exposed to the reactive oxygen species-generating system, xanthine/xanthine oxidase, while steady-state levels of GPX, catalase, and CuZnSOD mRNA remained unchanged. The 3-fold induction of MnSOD mRNA was dose-dependent, reaching a peak at 0.2 unit/ml xanthine oxidase. MnSOD mRNA increases were seen as early as 2 h and reached maximal induction at 24 h. Immunoreactive MnSOD protein was produced in a corresponding dose- and time-dependent manner. Induction of MnSOD gene expression was prevented by addition of actinomycin D and cycloheximide. These data indicate that epithelial cells of the respiratory tract respond to different oxidant insults by selective induction of certain antioxidant enzymes. Hence, gene expression of antioxidant enzymes does not appear to be coordinately regulated in these cell types.	UNIV VERMONT,SCH MED,DEPT PATHOL,BURLINGTON,VT 05405; UNIV VERMONT,SCH MED,DEPT PHYSIOL & BIOPHYS,BURLINGTON,VT 05405; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,MOLEC IMMUNOL LAB,BOSTON,MA 02115	University of Vermont; University of Vermont; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	SHULL, S (corresponding author), UNIV VERMONT,SCH MED,DEPT BIOCHEM,BURLINGTON,VT 05405, USA.			Periasamy, Muthu/0000-0001-8834-5975	NHLBI NIH HHS [HL-39469] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039469] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGGIOLINI M, 1990, TRENDS BIOCHEM SCI, V15, P69, DOI 10.1016/0968-0004(90)90179-F; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EDMONDSON SW, 1990, J CELL PHYSIOL, V142, P21, DOI 10.1002/jcp.1041420104; FANTONE JC, 1982, AM J PATHOL, V107, P397; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FREEMAN BA, 1982, LLAB INVEST, V47, P5; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; GREENBERG JT, 1990, P NATL ACAD SCI USA, V87, P6181, DOI 10.1073/pnas.87.16.6181; Grisham MB, 1986, PHYSL OXYGEN RADICAL, P01; HEFFNER JE, 1989, AM REV RESPIR DIS, V140, P531, DOI 10.1164/ajrccm/140.2.531; HO YS, 1987, NUCLEIC ACIDS RES, V15, P10070, DOI 10.1093/nar/15.23.10070; HO YS, 1987, NUCLEIC ACIDS RES, V15, P6746, DOI 10.1093/nar/15.16.6746; HO YS, 1991, AM J RESP CELL MOL, V4, P278, DOI 10.1165/ajrcmb/4.3.278; IQBAL J, 1989, AM J PHYSIOL, V257, pL61, DOI 10.1152/ajplung.1989.257.2.L61; KUPPUSAMY P, 1989, J BIOL CHEM, V264, P9880; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANIATIS T, 1980, MOL CLONING LABORATO, P201; MARSH JP, 1991, CANCER RES, V51, P167; MASUDA A, 1988, FASEB J, V2, P3087, DOI 10.1096/fasebj.2.15.3263930; MOSSMAN BT, 1980, CANCER RES, V40, P4403; MOSSMAN BT, 1989, ENVIRON HEALTH PERSP, V81, P91, DOI 10.2307/3430811; MULLENBACH GT, 1988, OXYRADICALS MOL BIOL, P313; OBERLEY TD, 1990, AM J PATHOL, V137, P199; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; SHAFFER JB, 1987, J BIOL CHEM, V262, P12908; SIBELLE Y, 1990, AM REV RESPIR DIS, V141, P471; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; VISNER GA, 1990, J BIOL CHEM, V265, P2856; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6	30	370	378	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24398	24403						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761541				2022-12-25	WOS:A1991GW84500027
J	SHENNAN, KIJ; SEAL, AJ; SMEEKENS, SP; STEINER, DF; DOCHERTY, K				SHENNAN, KIJ; SEAL, AJ; SMEEKENS, SP; STEINER, DF; DOCHERTY, K			SITE-DIRECTED MUTAGENESIS AND EXPRESSION OF PC2 IN MICROINJECTED XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYPEPTIDASE-E; SERINE PROTEASES; SUBTILISIN; KEX2; SECRETION; PROTEINS; HORMONE; IDENTIFICATION; POLYPEPTIDE; PROINSULIN	The biosynthesis and post-translational maturation of PC2, a neuroendocrine-specific Kex2-like endoprotease, following expression in Xenopus oocytes is described. The initial translation product was a 75-kDa membrane-associated protein which was released from the oocytes as a glycosylated 71-kDa protein. During extended chase periods, the extracellular 71-kDa protein was converted to a mature 68-kDa product. A deletion mutant lacking a putative COOH-terminal amphipathic helix was still membrane-associated, suggesting that this domain was not essential for attachment of PC2 to membranes. Two putative proregion cleavage site mutants were also constructed. Conversion of the 75-kDa peptide to the 71-kDa peptide involved cleavage at the sequence Lys-Arg-Arg-Arg (amino acids 78-81), since mutation of this sequence to Lys-Val-Arg-Leu resulted in the secretion of the 75-kDa peptide. Extracellular conversion of the 71-kDa peptide to the 68-kDa peptide involved cleavage at the sequence Arg-Lys-Lys-Arg (amino acids 106-109), since deletion of this tetrabasic sequence resulted in secretion of the 71-kDa peptide without further conversion to the 68-kDa form. Finally, a mutation which changed a catalytically important Asp to Asn did not affect processing of proPC2. These results may be relevant to our understanding of mechanisms in the intracellular sorting and maturation of proPC2 in neuroendocrine cells.	UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, CHICAGO, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago	SHENNAN, KIJ (corresponding author), UNIV BIRMINGHAM, QUEEN ELIZABETH HOSP, DEPT MED, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND.		Seal, Andrew/C-8550-2014	Seal, Andrew/0000-0003-3656-4054; Docherty, Kevin/0000-0001-6765-2060				BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRENNER C, 1991, IN PRESS P NATL ACAD; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DARBY NJ, 1990, BIOSCIENCE REP, V10, P1, DOI 10.1007/BF01116845; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DOCHERTY K, 1989, J BIOL CHEM, V264, P18335; FOREMAN RC, 1987, FEBS LETT, V219, P75, DOI 10.1016/0014-5793(87)81193-6; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; HUEZ G, 1986, MICROINJECTION ORGAN, P327; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; IKEDA K, 1989, MOL ENDOCRINOL, V3, P1084, DOI 10.1210/mend-3-7-1084; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; JULIUS D, 1983, CELL, V32, P839, DOI 10.1016/0092-8674(83)90070-3; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE CD, 1981, EUR J BIOCHEM, V113, P273, DOI 10.1111/j.1432-1033.1981.tb05063.x; Markland F. S., 1971, ENZYMES, V3, P561, DOI 10.1016/S1874-6047(08)60407-2; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; MOEHLE CM, 1987, MOL CELL BIOL, V7, P4390, DOI 10.1128/MCB.7.12.4390; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; RAPOPORT TA, 1981, EUR J BIOCHEM, V115, P665; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1988, BIOCHIMIE, V70, P99, DOI 10.1016/0300-9084(88)90164-2; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297	34	41	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					24011	24017						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748673				2022-12-25	WOS:A1991GV31900074
J	BRAUN, C; ZUMFT, WG				BRAUN, C; ZUMFT, WG			MARKER EXCHANGE OF THE STRUCTURAL GENES FOR NITRIC-OXIDE REDUCTASE BLOCKS THE DENITRIFICATION PATHWAY OF PSEUDOMONAS-STUTZERI AT NITRIC-OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSPOSON TN5-INDUCED MUTANTS; NITROUS-OXIDE; PARACOCCUS-DENITRIFICANS; INTERMEDIATE; PERFECTOMARINUS; RESPIRATION; AERUGINOSA; EXPRESSION; MECHANISM; BACTERIA	Bacterial denitrification reverses nitrogen fixation in the global N-cycle by transforming nitrate or nitrite to dinitrogen. Both nitrite and nitric oxide (NO) are considered as the chemical species within the denitrification pathway, that precede nitrous oxide (N2O), the first recognized intermediate with N,N-bonds antecedent to N2. Molecular cloning of the structural genes for NO reductase from Pseudomonas stutzeri has allowed us to generate the first mutants defective in NO utilization (Nor- phenotype) by marker exchange of the norCB genes with a gene cassette for gentamicin resistance. Nitric oxide reductase was found to be an indispensable component for denitrification; its loss constituted a conditionally lethal mutation. NO as the sole product accumulated from nitrite by mutant cells induced for nitrite respiration (denitrification). The Nor- mutant lost the capability to reduce NO and did not grow anymore anaerobically on nitrate. A Nir-Nor- double mutation, that inactivated also the respiratory nitrite reductase cytochrome cd1 rendered the bacterium again viable under anaerobiosis. Our observations provide evidence for a denitrification pathway in vivo of NO2- --> NO --> N2O, and N,N-bond formation catalyzed by NO reductase and not by cytochrome cd1.	UNIV KARLSRUHE, LEHRSTUHL MIKROBIOL, DEPT MICROBIOL, KAISERSTR 12, W-7500 KARLSRUHE 1, GERMANY	Helmholtz Association; Karlsruhe Institute of Technology								BESSIERES P, 1984, BIOCHIMIE, V66, P313, DOI 10.1016/0300-9084(84)90008-7; CARR GJ, 1989, EUR J BIOCHEM, V179, P683, DOI 10.1111/j.1432-1033.1989.tb14601.x; CARR GJ, 1990, BIOCHEM J, V269, P423, DOI 10.1042/bj2690423; Cole JA., 1988, NITROGEN SULPHUR CYC; DERMASTIA M, 1991, J BIOL CHEM, V266, P10899; FIRESTONE MK, 1979, BIOCHEM BIOPH RES CO, V91, P10, DOI 10.1016/0006-291X(79)90575-8; GARBER EAE, 1982, J BIOL CHEM, V257, P4705; GORETSKI J, 1988, J BIOL CHEM, V263, P2316; GORETSKI J, 1990, J BIOL CHEM, V265, P889; GORETSKI J, 1990, J BIOL CHEM, V265, P11535; HEISS B, 1989, J BACTERIOL, V123, P1345; HOCHSTEIN LI, 1988, ANNU REV MICROBIOL, V42, P231, DOI 10.1146/annurev.mi.42.100188.001311; JUNGST A, 1991, FEBS LETT, V279, P205, DOI 10.1016/0014-5793(91)80150-2; JUNGST A, 1991, MOL GEN GENET, V225, P241, DOI 10.1007/BF00269855; KIM CH, 1983, J BIOL CHEM, V258, P4861; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDENMAIER W, 1985, MOL ZELLBIOLOGIE, P65; Maniatis T., 1982, MOL CLONING; MATSUBARA T, 1968, J BIOCHEM, V64, P863, DOI 10.1093/oxfordjournals.jbchem.a128968; PAYNE WJ, 1971, J BACTERIOL, V106, P356, DOI 10.1128/JB.106.2.356-361.1971; SHEARER G, 1988, J BIOL CHEM, V263, P13231; SILVESTRINI MC, 1990, J BIOL CHEM, V265, P11783; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; VIEBROCK A, 1988, J BACTERIOL, V170, P4658, DOI 10.1128/jb.170.10.4658-4668.1988; WEEGAERSSENS E, 1988, J AM CHEM SOC, V110, P6851, DOI 10.1021/ja00228a039; WHARTON DC, 1980, BIOCHEM BIOPH RES CO, V97, P236, DOI 10.1016/S0006-291X(80)80159-8; WOHLLEBEN W, 1989, MOL GEN GENET, V217, P202, DOI 10.1007/BF02464882; YE RW, 1991, J BIOL CHEM, V266, P12848; YOSHIMURA T, 1988, J BIOCHEM, V103, P1016, DOI 10.1093/oxfordjournals.jbchem.a122372; ZAFIRIOU OC, 1989, J BIOL CHEM, V264, P5694; ZUMFT WG, 1985, J BACTERIOL, V163, P918, DOI 10.1128/JB.163.3.918-924.1985; ZUMFT WG, 1982, BIOCHIM BIOPHYS ACTA, V681, P459, DOI 10.1016/0005-2728(82)90188-8; ZUMFT WG, 1988, ARCH MICROBIOL, V149, P492, DOI 10.1007/BF00446750; ZUMFT WG, 1990, EUR J BIOCHEM, V192, P591, DOI 10.1111/j.1432-1033.1990.tb19265.x; ZUMFT WG, 1979, NATURWISSENSCHAFTEN, V66, P81, DOI 10.1007/BF00373498; ZUMFT WG, 1990, FEMS S, V56, P37	36	67	69	0	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22785	22788						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744072				2022-12-25	WOS:A1991GT48300003
J	DEREWENDA, ZS; CAMBILLAU, C				DEREWENDA, ZS; CAMBILLAU, C			EFFECTS OF GENE-MUTATIONS IN LIPOPROTEIN AND HEPATIC LIPASES AS INTERPRETED BY A MOLECULAR-MODEL OF THE PANCREATIC TRIGLYCERIDE LIPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFICIENCY; SEQUENCE; TRIPROPIONIN; SIMILARITIES; MUTAGENESIS; FEATURES; BINDING; FAMILY	A molecular model of human pancreatic lipase (Winkler, F. K., D'Arcy, A., and Hunziker, W. (1990) Nature 343, 771-774) is used to explain the possible structural effects of the amino acid mutations identified to date in the human lipoprotein and hepatic lipase genes. A sequence homology profile was used to evaluate the alignment of the amino acid sequences of all three lipolytic enzymes (Kirchgessner, T. G., Chuat, J.-C., Heinzmann, C., Etienne, J., Guilhot, S., Svenson, K., Ameis, D., Pilon, C., D'Auriol, L., Andalibi, A., Schotz, M. C., Galibert, F., and Lusis, A. J. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 9647-965 1) with respect to the secondary structure elements identified in the pancreatic lipase. As expected, maximum homology is observed in internal regions namely the hydrophobic strands of the central, beta-pleated sheet. This observation strongly supports the hypothesis that all three molecules exhibit a very similar three-dimensional structure, particularly in the N-terminal catalytic domain. There is considerable variation in some of the surface loops connecting the individual strands, whereas others are conserved. It is hypothesized that the most conserved loops located around the active site are responsible for the catalytic function (similar for all three enzymes), whereas those that markedly differ are involved in the regulation at the molecular level, namely the binding of colipase (pancreatic enzyme) and apolipoprotein CII (lipoprotein lipase). The currently available library of hepatic and lipoprotein gene mutations seems to indicate that the majority of mutants disrupt the folding of the polypeptide chain, rather than affect specific constellations in and around the catalytic site or regulatory loops.	FAC MED MARSEILLE, CNRS, CRISTALLOG & CRISTALLISAT MACROMOLEC BIOL LAB, F-13385 MARSEILLE 5, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	DEREWENDA, ZS (corresponding author), UNIV ALBERTA, DEPT BIOCHEM, MED RES COUNCIL CANADA, PROT STRUCT & FUNCT GRP, 474 MED SCI BLDG, EDMONTON T6G 2H7, ALBERTA, CANADA.							AMEIS D, 1990, J BIOL CHEM, V265, P6552; AMEIS D, 1991, J CLIN INVEST, V87, P1165, DOI 10.1172/JCI115114; BEG OU, 1990, P NATL ACAD SCI USA, V87, P3474, DOI 10.1073/pnas.87.9.3474; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BRECKENRIDGE WC, 1982, ATHEROSCLEROSIS, V45, P161, DOI 10.1016/0021-9150(82)90136-8; BROCKERHOFF H, 1968, BIOCHIM BIOPHYS ACTA, V159, P296, DOI 10.1016/0005-2744(68)90078-8; BROCKMAN HL, 1973, J BIOL CHEM, V248, P4965; BRUIN T, 1990, 55TH M EUR ATH SOC B, P91; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; BUVINGER WE, 1989, J BIOL CHEM, V264, P1195; CAI SJ, 1989, BIOCHEMISTRY-US, V28, P8966, DOI 10.1021/bi00449a002; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CONNELLY PW, 1990, ARTERIOSCLEROSIS, V10, P40, DOI 10.1161/01.ATV.10.1.40; DATTA S, 1988, J BIOL CHEM, V263, P1107; DAVIS RC, 1990, J BIOL CHEM, V265, P6291; DEEB SS, 1989, BIOCHEMISTRY-US, V28, P4132, DOI 10.1021/bi00436a001; DEREWENDA ZS, 1991, IN PRESS BIOCH CELL; DICHEK HL, 1991, J BIOL CHEM, V266, P473; ENTRESSANGLES B, 1974, BIOCHIM BIOPHYS ACTA, V341, P437, DOI 10.1016/0005-2744(74)90236-8; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P9481; HEGELE RA, 1991, J CLIN ENDOCR METAB, V72, P730, DOI 10.1210/jcem-72-3-730; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KINNUNEN PKJ, 1983, ATHER REV, V11, P65; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; MONSALVE MV, 1990, J CLIN INVEST, V86, P728, DOI 10.1172/JCI114769; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PAULWEBER B, 1991, ATHEROSCLEROSIS, V86, P239, DOI 10.1016/0021-9150(91)90220-W; PERSSON B, 1989, EUR J BIOCHEM, V179, P39, DOI 10.1111/j.1432-1033.1989.tb14518.x; ROUSSEL A, 1990, SILICON GRAPHICS GEO, P109; SARDA L, 1958, BIOCHIM BIOPHYS ACTA, V30, P513, DOI 10.1016/0006-3002(58)90097-0; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SEMENKOVICH CF, 1990, J BIOL CHEM, V265, P5429; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WELLS MA, 1974, BIOCHEMISTRY-US, V13, P2248, DOI 10.1021/bi00708a002; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907	41	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23112	23119						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744109				2022-12-25	WOS:A1991GT48300053
J	NOONAN, DM; FULLE, A; VALENTE, P; CAI, S; HORIGAN, E; SASAKI, M; YAMADA, Y; HASSELL, JR				NOONAN, DM; FULLE, A; VALENTE, P; CAI, S; HORIGAN, E; SASAKI, M; YAMADA, Y; HASSELL, JR			THE COMPLETE SEQUENCE OF PERLECAN, A BASEMENT-MEMBRANE HEPARAN-SULFATE PROTEOGLYCAN, REVEALS EXTENSIVE SIMILARITY WITH LAMININ-A CHAIN, LOW-DENSITY LIPOPROTEIN-RECEPTOR, AND THE NEURAL CELL-ADHESION MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; CYSTEINE-RICH REPEATS; HUMAN LDL RECEPTOR; MULTIDOMAIN PROTEIN; CORE PROTEIN; DOMAIN-STRUCTURE; PROMOTING FACTOR; COLLAGEN-IV; BINDING; CDNA	A heparan sulfate proteoglycan is a component of all basement membranes. This molecule consists of three heparan sulfate side chains linked to a large core protein of approximately 400 kDa. We have isolated seven overlapping murine cDNA clones that encode the entire mRNA sequence of 12.685 kilobases of this molecule. This sequence has a single open reading frame of 3,707 amino acids that encodes for a protein of 396 kDa. Identical or near identical matchups with nine peptide sequences derived from the core protein of the molecule isolated from the Engelbreth-Holm-Swarm tumor were found with the deduced sequence. Sequence analysis and data base comparison of the deduced sequence show the protein to consist of five different domains, most of which contain internal repeats. Domain I contains a start methionine followed by a typical signal transfer sequence and a unique segment of 172 amino acids that contains the three probable sites of heparan sulfate attachment, SGD. Domain II contains four cysteine- and acidic amino acid-rich repeats that are very similar to those found in the LDL receptor and proteins such as GP330. Domain III consists of cysteine-rich and globular regions, both of which show similarity to those in the short arm of the laminin A chain. Domain IV contains 14 repeats of the immunoglobulin superfamily that are most highly similar to the immunoglobulin-like repeats in the neural cell adhesion molecule. Domain V contains three repeats with similarity to the laminin A chain G domain that are separated by epidermal growth factor-like regions not found in the laminin A chain. As the primary structural data agree with the appearance of the molecule in the electron microscope as a series of globules separated by rods, or "beads on a string," we have adopted the name perlecan for this molecule. The variety of domains in perlecan suggest multiple interactions with other molecules.	EYE & EAR INST PITTSBURGH,PITTSBURGH,PA; NIDR,BETHESDA,MD 20892; UNIV PITTSBURGH,PITTSBURGH,PA 15260	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	NOONAN, DM (corresponding author), IST NAZL RIC CANC,I-16132 GENOA,ITALY.		Noonan, Douglas M/A-8620-2010	Noonan, Douglas M/0000-0001-8058-0719	NEI NIH HHS [EY08098] Funding Source: Medline; NIDCR NIH HHS [F32 DE05417-02] Funding Source: Medline; NIGMS NIH HHS [GM 45389] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY008098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [F32DE005417] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADAMS SL, 1977, P NATL ACAD SCI USA, V74, P3399, DOI 10.1073/pnas.74.8.3399; ALBINI A, 1989, CLIN EXP METASTAS, V7, P437, DOI 10.1007/BF01753664; BARTHELS D, 1987, EMBO J, V6, P907, DOI 10.1002/j.1460-2075.1987.tb04837.x; BRAUER PR, 1989, ANAT REC, V223, P376, DOI 10.1002/ar.1092230405; CAPLAN MJ, 1987, NATURE, V329, P632, DOI 10.1038/329632a0; CHAKRAVARTI S, 1991, MAMM GENOME, V1, P270, DOI 10.1007/BF00352338; CHIU AY, 1986, J CELL BIOL, V103, P1383, DOI 10.1083/jcb.103.4.1383; CLEMENT B, 1990, EXP CELL RES, V187, P320, DOI 10.1016/0014-4827(90)90098-U; CLEMENT B, 1989, J BIOL CHEM, V264, P12467; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DAVIS GE, 1987, NEUROCHEM RES, V12, P909, DOI 10.1007/BF00966313; DEININGER PL, 1983, ANAL BIOCHEM, V129, P216, DOI 10.1016/0003-2697(83)90072-6; DODGE GR, 1991, GENOMICS, V10, P673, DOI 10.1016/0888-7543(91)90451-J; DOEGE K, 1986, P NATL ACAD SCI USA, V83, P3761, DOI 10.1073/pnas.83.11.3761; DURKIN ME, 1988, J CELL BIOL, V107, P2749, DOI 10.1083/jcb.107.6.2749; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; Farquhar M. G., 1981, CELL BIOL EXTRACELLU, V1981, P335; GABRIEL G, 1991, COMMENTS, V17, P21; GRANT DS, 1989, J CELL BIOL, V108, P1567, DOI 10.1083/jcb.108.4.1567; HANTAZAMBROISE D, 1987, J NEUROSCI, V7, P2293; HAYASHI K, 1990, Journal of Cell Biology, V111, p11A; HEREMANS A, 1990, J BIOL CHEM, V265, P8716; HEREMANS A, 1989, J CELL BIOL, V109, P3199, DOI 10.1083/jcb.109.6.3199; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; INOUE S, 1989, J HISTOCHEM CYTOCHEM, V37, P597, DOI 10.1177/37.5.2522961; KLEIN DJ, 1988, J CELL BIOL, V106, P963, DOI 10.1083/jcb.106.3.963; KOHNO K, 1985, J BIOL CHEM, V260, P4441; LAURIE GW, 1986, J MOL BIOL, V189, P205, DOI 10.1016/0022-2836(86)90391-8; LAURIE GW, 1988, AM J ANAT, V181, P320, DOI 10.1002/aja.1001810308; LEDBETTER SR, 1985, J BIOL CHEM, V260, P8106; LEDBETTER SR, 1987, BIOCHEMISTRY-US, V26, P988, DOI 10.1021/bi00378a003; MANIATIS T, 1982, MOL CLONING LABORATO, P320; MANN K, 1989, EMBO J, V8, P65, DOI 10.1002/j.1460-2075.1989.tb03349.x; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; NOONAN DM, 1988, J BIOL CHEM, V263, P16379; PATHAK RK, 1990, J CELL BIOL, V111, P347, DOI 10.1083/jcb.111.2.347; PAULSSON M, 1987, J MOL BIOL, V197, P297, DOI 10.1016/0022-2836(87)90125-2; PIKKARAINEN T, 1987, J BIOL CHEM, V262, P10454; PIKKARAINEN T, 1988, J BIOL CHEM, V263, P6751; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SCHITTNY JC, 1988, J CELL BIOL, V107, P1599, DOI 10.1083/jcb.107.4.1599; SINGER II, 1987, EXP CELL RES, V173, P558, DOI 10.1016/0014-4827(87)90295-3; STEELE JG, 1987, J NEUROSCI RES, V17, P119, DOI 10.1002/jnr.490170205; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WINTLE RF, 1990, CYTOGENET CELL GENET, V54, P60, DOI 10.1159/000132956; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636; YURCHENCO PD, 1987, J BIOL CHEM, V262, P17668; ZAGURSKY RJ, 1985, GENE ANAL TECH, V2, P89, DOI 10.1016/0735-0651(85)90011-1; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	60	389	403	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22939	22947						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744087				2022-12-25	WOS:A1991GT48300028
J	OTTEN, AD; PARENTEAU, LA; DOSKELAND, S; MCKNIGHT, GS				OTTEN, AD; PARENTEAU, LA; DOSKELAND, S; MCKNIGHT, GS			HORMONAL ACTIVATION OF GENE-TRANSCRIPTION IN RAS-TRANSFORMED NIH3T3 CELLS OVEREXPRESSING RII-ALPHA AND RII-BETA SUBUNITS OF THE CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II REGULATORY SUBUNIT; CYCLIC-NUCLEOTIDE ANALOGS; CATALYTIC SUBUNIT; MOLECULAR-CLONING; SKELETAL-MUSCLE; MESSENGER-RNA; ADENOSINE 3'-5'-MONOPHOSPHATE; SOMATOSTATIN GENE; GOLGI-COMPLEX; MOUSE-BRAIN	ras-Transformed NIH3T3 (R3T3) cells were transfected with expression vectors for the RII-alpha and RII-beta regulatory subunits of the type II isozyme of cAMP-dependent protein kinase, and the effects on gene activation by corticotropin-releasing factor (CRF) and prostaglandin E1 (PGE1) were analyzed. In RII-alpha and RII-beta-overexpressing cells, type II isozyme levels were increased, and type I isozyme levels were eliminated, demonstrating that both RII regulatory subunits compete efficiently with RI for catalytic subunit. The type II isozyme separated into three peaks on high performance liquid chromatography, referred to as A, B, and C. Western blot analysis strongly suggests that peak A and peak C correspond to holoenzymes containing RII-beta and RII-alpha, respectively. Overexpression of RII-alpha resulted in the loss of peak A and a dramatic reduction in RII-beta protein with no change in RII-beta mRNA, indicating that the level of RII-beta protein is controlled post-transcriptionally and that RII-beta protein may become unstable when displaced from C. The role of type I and II kinases in transcriptional activation was investigated by comparing the response of control and RII expressing clones to site-selective cAMP analogs and the hormones, CRF and PGE1. The site-selective analogs demonstrated that either type I or type II kinase could activate the cAMP-responsive alpha-subunit promoter. The response to various concentrations of CRF or PGE1 was identical in control cells and transfected clones containing very little type I kinase. These experiments suggest that in the CRF and PGE1 response pathways leading to gene induction, the magnitude and sensitivity of the response are not influenced by the presence or absence of type I cAMP-dependent protein kinase.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; UNIV BERGEN,INST ANAT,N-5009 BERGEN,NORWAY	University of Washington; University of Washington Seattle; University of Bergen				Doskeland, Stein Ove/0000-0002-4009-4756	NIGMS NIH HHS [GM32875] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032875] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEEBE SJ, 1984, MOL CELL ENDOCRINOL, V36, P67, DOI 10.1016/0303-7207(84)90086-8; BEEBE SJ, 1988, METHOD ENZYMOL, V159, P118; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BEEBE SJ, 1986, ENZYMES, V17, P43; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BUILDER SE, 1980, J BIOL CHEM, V255, P3514; BUXTON ILO, 1983, J BIOL CHEM, V258, P233; BYUS CV, 1979, MOL PHARMACOL, V16, P941; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; CADD GG, 1990, J BIOL CHEM, V265, P19502; CLEGG CH, 1989, J BIOL CHEM, V264, P20140; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; COBB CE, 1987, J BIOL CHEM, V262, P16566; CONNELLY PA, 1986, J BIOL CHEM, V261, P2325; Corbin J D, 1975, Adv Cyclic Nucleotide Res, V5, P265; CORBIN JD, 1977, J BIOL CHEM, V252, P3854; DARBON JM, 1984, J BIOL CHEM, V259, P4778; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; EKANGER R, 1985, J BIOL CHEM, V260, P3393; ERLICHMAN J, 1980, J BIOL CHEM, V255, P8179; EWALD DA, 1985, NATURE, V315, P503, DOI 10.1038/315503a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HOFFMAN LM, 1981, J BIOL CHEM, V256, P2597; HOFMANN F, 1980, J BIOL CHEM, V255, P1559; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; JUNGMANN RA, 1983, J BIOL CHEM, V258, P5312; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANOTTE M, 1991, IN PRESS J CELL PHYS; LITVIN Y, 1984, J BIOL CHEM, V259, P296; LIU AYC, 1982, J BIOL CHEM, V257, P289; LIVESEY SA, 1982, J BIOL CHEM, V257, P4983; LIVESEY SA, 1984, BIOCHEM J, V224, P361, DOI 10.1042/bj2240361; LORIMER IAJ, 1989, BIOCHEM J, V264, P305, DOI 10.1042/bj2640305; LUO ZJ, 1990, J BIOL CHEM, V265, P21804; MAGGOFFIN DA, 1989, ENDOCRINOLOGY, V125, P1464; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MAURER RA, 1981, NATURE, V294, P94, DOI 10.1038/294094a0; MCKNIGHT GS, 1980, J BIOL CHEM, V255, P144; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; OGREID D, 1989, EUR J BIOCHEM, V181, P19; OGREID D, 1985, EUR J BIOCHEM, V150, P219, DOI 10.1111/j.1432-1033.1985.tb09010.x; OTTEN AD, 1989, J BIOL CHEM, V264, P20255; OYEN O, 1988, FEBS LETT, V229, P391, DOI 10.1016/0014-5793(88)81163-3; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RANGELALDAO R, 1977, J BIOL CHEM, V252, P7140; REIMANN EM, 1971, J BIOL CHEM, V246, P1986; RICHARDSON JM, 1990, J BIOL CHEM, V265, P13635; RUBIN CS, 1972, J BIOL CHEM, V247, P6135; SCHUSTER MJ, 1985, NATURE, V313, P392; SCHWARTZ DA, 1983, J BIOL CHEM, V258, P777; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; SHOWERS MO, 1986, J BIOL CHEM, V261, P6288; SHUNTOH H, 1991, J CELL PHYSIOL, V146, P86, DOI 10.1002/jcp.1041460112; STEINBERG RA, 1981, J BIOL CHEM, V256, P731; THEURKAUF WE, 1982, J BIOL CHEM, V257, P3284; UHLER MD, 1987, J BIOL CHEM, V262, P15202; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; WEISS A, 1988, MOL ENDOCRINOL, V2, P412, DOI 10.1210/mend-2-5-412	68	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23074	23082						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744104				2022-12-25	WOS:A1991GT48300048
J	MITRA, G				MITRA, G			MUTATIONAL ANALYSIS OF CONSERVED RESIDUES IN THE TYROSINE KINASE DOMAIN OF THE HUMAN TRK-ONCOGENE	ONCOGENE			English	Article							BIOCHEMICAL-CHARACTERIZATION; ACTIVATION; SEQUENCES; RECOMBINATION; PROTOONCOGENE; MUTAGENESIS	The human trk oncogene (originally identified in a colon carcinoma) was activated by a genetic rearrangement which resulted in replacement of the extracellular ligand-binding domain of the proto-trk transmembrane receptor by non-muscle tropomyosin sequences. The product of the trk oncogene, a protein of 70 kDa (p70trk), possesses tyrosine-specific protein kinase activity, is autophosphorylated in vitro on tyrosine and is phosphorylated on serine, threonine and tyrosine residues in trk-transformed cells. By site-directed mutagenesis of trk oncogene cDNA, the codon for lysine (367) at the putative ATP-binding site was changed to that for methionine and the codons for tyrosines (503 and 504) at the putative autophosphorylation sites were changed to those for phenylalanine. Replacement of Lys-367 by methionine results in a biologically inactive, kinase-negative mutant. Phe-ala mutants of trk showed drastically reduced ability to induce morphologic transformation, anchorage-independent growth and tumorigenicity in mouse NIH3T3 cells and showed reduced in vitro tyrosine kinase activity when assayed by autophosphorylation and phosphorylation of histone as exogenous substrate. The present study indicates the role of these specific conserved residues in regulating the biochemical and biological properties of p70trk oncoprotein.			MITRA, G (corresponding author), CLEVELAND CLIN FDN,RES INST,DEPT MOLEC BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.							BONGARZONE I, 1989, ONCOGENE, V4, P1457; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; GEER PV, 1990, MOL CELL BIOL, V10, P2991; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MITRA G, 1989, P NATL ACAD SCI USA, V86, P8650, DOI 10.1073/pnas.86.22.8650; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; ULRICH A, 1990, CELL, V61, P203; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	25	26	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2237	2241						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1837350				2022-12-25	WOS:A1991GX73500009
J	DHUGGA, KS; ULVSKOV, P; GALLAGHER, SR; RAY, PM				DHUGGA, KS; ULVSKOV, P; GALLAGHER, SR; RAY, PM			PLANT POLYPEPTIDES REVERSIBLY GLYCOSYLATED BY UDP-GLUCOSE - POSSIBLE COMPONENTS OF GOLGI BETA-GLUCAN SYNTHASE IN PEA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAUCUS-CAROTA L; CALLOSE SYNTHASE; PROTEIN PRIMER; ALPHA-GLUCAN; RED BEET; MEMBRANES; GLYCOGEN; POLYSACCHARIDE; SOLUBILIZATION; IDENTIFICATION	In pea membranes, UDP[C-14]Glc glycosylates a approximately 40-kDa polypeptide doublet. This label rapidly disappears if excess unlabeled UDP-Glc, or UDP, is added, indicating that the glycosylation is reversible, and suggesting that the glycosylated polypeptides might be intermediates in a glycosyl transfer reaction. Glycosylation of the doublet requires a divalent cation, the effective ions being the same (except for Zn2+) as those that activate Golgi-localized beta-glucan synthase (GS-I) activity. Treatments that inhibit GS-I also inhibit doublet glycosylation. The doublet is associated with Golgi (and to a minor extent with plasma) membranes and occurs also in the soluble fraction. The Golgi-bound doublet may be a component of the GS-I system. Immunological, inactivation, and fractionation evidence indicates that at least one other polypeptide is required in GS-I activity.	STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA	Stanford University			Ulvskov, Peter/I-1228-2014	Ulvskov, Peter/0000-0003-3776-818X; Dhugga, Kanwarpal/0000-0003-2477-3422				BOLWELL GP, 1988, PHYTOCHEMISTRY, V27, P1235, DOI 10.1016/0031-9422(88)80173-0; CAPUTTO R, 1950, J BIOL CHEM, V184, P333; DELMER DP, 1985, J CELL SCI, P33; DELMER DP, 1991, PLANT PHYSIOL, V95, P556, DOI 10.1104/pp.95.2.556; DELMER DP, 1988, BIOCH PLANTS, V14, P373; DHUGGA KS, 1991, FEBS LETT, V278, P283, DOI 10.1016/0014-5793(91)80136-Q; DHUGGA KS, 1991, PLANT PHYSIOL, V95, P1302, DOI 10.1104/pp.95.4.1302; DUPONT FM, 1985, PLANT PHYSIOL, V77, P857, DOI 10.1104/pp.77.4.857; FROST DJ, 1990, J BIOL CHEM, V265, P2162; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTMANNBOUILLO.MA, 1979, BIOL CELL, V53, P183; HASSID WZ, 1972, BIOCH GLYCOSIDIC LIN, P315; HAYASHI T, 1987, PLANT PHYSIOL, V83, P1054, DOI 10.1104/pp.83.4.1054; INGOLD E, 1986, Z NATURFORSCH C, V41, P409; KAUSS H, 1987, PLANT SCI, V48, P63, DOI 10.1016/0168-9452(87)90132-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LAWSON SG, 1989, PLANT PHYSIOL, V90, P101, DOI 10.1104/pp.90.1.101; LEEGOOD RC, 1983, ISOLATION MEMBRANES, P185; LIN FC, 1990, J BIOL CHEM, V265, P4782; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; MASON TL, 1990, PHYSIOL PLANTARUM, V79, P439, DOI 10.1111/j.1399-3054.1990.tb02100.x; MAYER R, 1991, P NATL ACAD SCI USA, V88, P5472, DOI 10.1073/pnas.88.12.5472; MORENO S, 1987, EUR J BIOCHEM, V162, P609, DOI 10.1111/j.1432-1033.1987.tb10682.x; MORENO S, 1986, EUR J BIOCHEM, V157, P539, DOI 10.1111/j.1432-1033.1986.tb09700.x; MULLINS JT, 1990, PHYSIOL PLANTARUM, V78, P309, DOI [10.1111/j.1399-3054.1990.tb02096.x, 10.1034/j.1399-3054.1990.780221.x]; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PALMGREN MG, 1990, BIOCHIM BIOPHYS ACTA, V1021, P133, DOI 10.1016/0005-2736(90)90025-J; PEREZ M, 1986, BIOCHIM BIOPHYS ACTA, V864, P213, DOI 10.1016/0304-4157(86)90012-2; PONTLEZICA R, 1976, PLANT PHYSIOL, V58, P675; QUAIL PH, 1979, ANNU REV PLANT PHYS, V30, P425, DOI 10.1146/annurev.pp.30.060179.002233; QUENTMEIER H, 1987, PLANTA, V171, P483, DOI 10.1007/BF00392295; RAY PM, 1976, BER DEUT BOT GES, V89, P121; RAY PM, 1980, BIOCHIM BIOPHYS ACTA, V629, P431, DOI 10.1016/0304-4165(80)90149-X; RAY PM, 1979, PLANT ORGANELLES, P135; READ SM, 1987, PLANT PHYSIOL, V85, P1008, DOI 10.1104/pp.85.4.1008; READ SM, 1986, CELL WALLS 86, P308; RODRIGUEZ IR, 1988, ARCH BIOCHEM BIOPHYS, V260, P628, DOI 10.1016/0003-9861(88)90491-2; SMITH CA, 1977, J BIOL CHEM, V252, P7294; SMYTHE C, 1989, EUR J BIOCHEM, V183, P205, DOI 10.1111/j.1432-1033.1989.tb14914.x; TAKAHARA H, 1977, J BIOCHEM-TOKYO, V81, P1587, DOI 10.1093/oxfordjournals.jbchem.a131617; TANDECARZ JS, 1978, BIOCHIM BIOPHYS ACTA, V543, P423, DOI 10.1016/0304-4165(78)90297-0; THOM M, 1986, PLANTA, V167, P410, DOI 10.1007/BF00391347; WIDELL S, 1987, BLUE LIGHT RESPONSE, P99	44	53	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21977	21984						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1834664				2022-12-25	WOS:A1991GP80400098
J	DRIPPS, DJ; VERDERBER, E; NG, RK; THOMPSON, RC; EISENBERG, SP				DRIPPS, DJ; VERDERBER, E; NG, RK; THOMPSON, RC; EISENBERG, SP			INTERLEUKIN-1 RECEPTOR ANTAGONIST BINDS TO THE TYPE-II INTERLEUKIN-1 RECEPTOR ON B-CELLS AND NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOLOGICAL CHARACTERIZATION; MOLECULAR-PROPERTIES; IL-1 RECEPTORS; PURIFICATION; EXPRESSION; INHIBITOR; LINES; INDUCTION; PROTEIN; INVIVO	We have examined the binding of human and rodent interleukin-1 receptor antagonist (IL-1ra) to the type II IL-1 receptor on the human B cell line, Raji, on the mouse pre-B cell line, 70Z/3, and on human polymorphonuclear leukocytes (PMNs). Human IL-1ra binds to the receptors on the human B cells with an affinity (K(D) = 15 +/- 3 nM) equal to that of IL-1-alpha and only 15-fold lower than that of IL-1-beta and, likewise, binds to human PMNs with an affinity (K(D) = 8 +/- 4 nM) 15-fold lower than that of IL-1-beta. Mouse and rat IL-1ra bind to these two human cell types with an affinity similar to that of the human protein. Human IL-1ra binds very weakly to the type II receptor on the mouse pre-B cells with an affinity (K(D) = 1.4 +/- 0.2-mu-M) about 1500-fold lower than human IL-1-beta. Mouse and rat IL-1ra also bind to the mouse pre-B cells with low affinity. The weak binding of the three IL-1ra proteins to these mouse cells appears to be more a consequence of the cell type rather than species specificity. There may be a population of cells for which the actions of IL-1 cannot be effectively opposed by IL-1ra, although this group does not include mature B cells and PMNs.	SYNERGEN INC,1885 33RD ST,BOULDER,CO 80301									AREND WP, 1990, J CLIN INVEST, V85, P1694, DOI 10.1172/JCI114622; BENJAMIN D, 1990, BLOOD, V75, P2017; BENJAMIN D, 1990, J BIOL CHEM, V265, P9943; BENSIMON C, 1989, J IMMUNOL, V143, P1168; BOMSZTYK K, 1989, P NATL ACAD SCI USA, V86, P8034, DOI 10.1073/pnas.86.20.8034; BOMSZTYK K, 1989, J BIOL CHEM, V264, P6052; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; COMINELLI F, 1990, J CLIN INVEST, V86, P972, DOI 10.1172/JCI114799; DINARELLO CA, 1987, J IMMUNOL, V139, P1902; DOKOVICH M, 1986, CLIN IMMUNOL IMMUNOP, V38, P381; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; EISENBERG SP, 1990, J BIOL CHEM, V265, P7976; EISENBERG SP, 1991, P NATL ACAD SCI USA, V88, P5232, DOI 10.1073/pnas.88.12.5232; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; EISENBERG SP, 1989, CYTOKINE, V1, P90; GIRI JG, 1990, J BIOL CHEM, V265, P17416; GRANOWITZ EV, 1991, J BIOL CHEM, V266, P14147; GRANOWITZ EV, 1991, CLIN RES, V39, P462; GRANSTEIN RD, 1986, J CLIN INVEST, V77, P1020, DOI 10.1172/JCI112354; GUBLER U, 1986, J IMMUNOL, V136, P2492; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HORUK R, 1987, J BIOL CHEM, V262, P16275; KASTELEIN RA, 1986, GENE PROTEIN STEPS D, P225; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KRONHEIM SR, 1986, BIO-TECHNOL, V4, P1078, DOI 10.1038/nbt1286-1078; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P82; MCINTYRE KW, 1991, J EXP MED, V173, P931, DOI 10.1084/jem.173.4.931; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; OZAKI Y, 1987, J LEUKOCYTE BIOL, V42, P621, DOI 10.1002/jlb.42.6.621; PARKER KP, 1989, J IMMUNOL, V142, P537; SAMPLEE AK, 1990, C RES WORKERS ANIMAL, P18; SAYERS TJ, 1988, J IMMUNOL, V141, P1670; SLACK J, 1989, BIOTECHNIQUES, V7, P1132; SPRIGGS MK, 1990, J BIOL CHEM, V265, P22499; SYMONS J A, 1990, Cytokine, V2, P190, DOI 10.1016/1043-4666(90)90015-L; VENDENABEELE P, 1988, EUR J IMMUNOL, V18, P1027	39	104	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20311	20315						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1834644				2022-12-25	WOS:A1991GM03900065
J	COLYER, J; WANG, JH				COLYER, J; WANG, JH			DEPENDENCE OF CARDIAC SARCOPLASMIC-RETICULUM CALCIUM-PUMP ACTIVITY ON THE PHOSPHORYLATION STATUS OF PHOSPHOLAMBAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MEDIATED STIMULATION; POLYACRYLAMIDE GELS; MONOCLONAL-ANTIBODY; CA-2+ PUMP; TRANSPORT; MUSCLE; ATPASE; CHROMATOGRAPHY; PURIFICATION	The application of electrophoretic resolution of the different phosphorylation species of pentameric phospholamban as a measure of phosphorylation stoichiometry was examined and verified. This enabled a critical evaluation of a number of issues central to current models of calcium pump regulation in cardiac sarcoplasmic reticulum. The phospholamban content of numerous preparations was calculated from P-32 incorporation at a given stoichiometry, and compared with the respective calcium pump concentration (derived by comparison with a Coomassie-stained calibration curve of the fast-twitch skeletal muscle isozyme). A relationship of 2 mol of phospholamban:1 mol of ATPase resulted (phospholamban monomer:ATPase monomer), which was maintained throughout all vesicle subpopulations. The precise mechanism of coupling of phospholamban phosphorylation to calcium pump stimulation was probed, with particular emphasis on the individual contributions of each phosphorylated species (P1 to P5). This relationship could be adequately explained in three ways: (i) each phosphorylation event contributed equally to calcium pump stimulation; (ii) P1 and P2 were incapable of stimulating calcium pump activity, but full stimulation occurred upon generation of species P3; or (iii) the phosphospecies P1 was without effect on basal calcium pump activity, but successive phosphorylations contributed equally to stimulation. Finally, the functional implication of dual site phosphorylation of phospholamban (cAMP- and the endogenous calmodulin-dependent kinases) was examined. No change in calcium pump activity accompanied the second tier of phosphorylation over that achieved by the first.	UNIV CALGARY,DEPT MED BIOCHEM,MRC,SIGNAL TRANSDUCT GRP,CALGARY T2N 4N1,ALBERTA,CANADA	University of Calgary								BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P6602; CHENG HC, 1986, J BIOL CHEM, V261, P989; DELABASTIE D, 1990, CIRC RES, V66, P554, DOI 10.1161/01.RES.66.2.554; EAST JM, 1982, BIOCHEMISTRY-US, V21, P4144, DOI 10.1021/bi00260a035; FLEISCHER S, 1986, PROGR CLIN BIOL RES, V273, P435; FUJII J, 1989, J BIOL CHEM, V264, P12950; FUJII J, 1987, J CLIN INVEST, V79, P301, DOI 10.1172/JCI112799; FUJII J, 1986, BIOCHEM BIOPH RES CO, V138, P1044, DOI 10.1016/S0006-291X(86)80387-4; GOULD GW, 1986, BIOCHEM J, V237, P217, DOI 10.1042/bj2370217; IMAGAWA T, 1986, J BIOCHEM-TOKYO, V99, P41, DOI 10.1093/oxfordjournals.jbchem.a135478; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JORGENSEN AO, 1987, J CELL BIOL, V104, P1343, DOI 10.1083/jcb.104.5.1343; KASINATHAN C, 1988, BIOCHEM BIOPH RES CO, V157, P1296, DOI 10.1016/S0006-291X(88)81015-5; KIM HW, 1990, J BIOL CHEM, V265, P1702; KIRCHBERGER MA, 1974, J BIOL CHEM, V249, P6166; KIRCHBERGER MA, 1976, BIOCHIM BIOPHYS ACTA, V419, P559, DOI 10.1016/0005-2736(76)90269-8; KRANIAS EG, 1985, J BIOL CHEM, V260, P1006; KRANIAS EG, 1986, J BIOL CHEM, V261, P29; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPEUCH CJ, 1979, BIOCHEMISTRY-US, V18, P5150, DOI 10.1021/bi00590a019; LI CF, 1990, BIOCHEMISTRY-US, V29, P4535, DOI 10.1021/bi00471a005; LINDEMANN JP, 1985, J BIOL CHEM, V260, P4516; LOUIS CF, 1987, NEUROCHEM RES, V12, P937, DOI 10.1007/BF00966316; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MICHELANGELI F, 1990, BIOCHEM J, V267, P423, DOI 10.1042/bj2670423; MOVSESIAN MA, 1990, J CLIN INVEST, V85, P1698, DOI 10.1172/JCI114623; PETERS KA, 1977, BIOCHEMISTRY-US, V16, P5691, DOI 10.1021/bi00645a007; PLANK B, 1983, BIOCHIM BIOPHYS ACTA, V732, P99, DOI 10.1016/0005-2736(83)90191-8; RAEYMAEKERS L, 1988, BIOCHEM J, V252, P269, DOI 10.1042/bj2520269; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; SHARMA RK, 1990, J BIOL CHEM, V265, P1152; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P1333; STANKER LH, 1985, J IMMUNOL METHODS, V76, P157, DOI 10.1016/0022-1759(85)90488-0; SUZUKI T, 1987, BIOCHEM CELL BIOL, V65, P302, DOI 10.1139/o87-039; SUZUKI T, 1986, J BIOL CHEM, V261, P7018; Tada M, 1978, Adv Cyclic Nucleotide Res, V9, P355; TADA M, 1983, J MOL CELL CARDIOL, V15, P335, DOI 10.1016/0022-2828(83)91345-7; TADA M, 1982, ANNU REV PHYSIOL, V44, P401, DOI 10.1146/annurev.ph.44.030182.002153; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGENER AD, 1989, J BIOL CHEM, V264, P11468; WEGENER AD, 1984, J BIOL CHEM, V259, P1834; WIER WG, 1990, ANNU REV PHYSIOL, V52, P467; YOUNG EF, 1989, MEMBRANE BIOCHEM, V8, P95, DOI 10.3109/09687688909082263	46	77	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17486	17493						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1832673				2022-12-25	WOS:A1991GF44500076
J	LIBEREK, K; SKOWYRA, D; ZYLICZ, M; JOHNSON, C; GEORGOPOULOS, C				LIBEREK, K; SKOWYRA, D; ZYLICZ, M; JOHNSON, C; GEORGOPOULOS, C			THE ESCHERICHIA-COLI DNAK CHAPERONE, THE 70-KDA HEAT-SHOCK PROTEIN EUKARYOTIC EQUIVALENT, CHANGES CONFORMATION UPON ATP HYDROLYSIS, THUS TRIGGERING ITS DISSOCIATION FROM A BOUND TARGET PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-LAMBDA; NUCLEOPROTEIN STRUCTURES; POLYPEPTIDE-CHAIN; REPLICATION; INITIATION; PURIFICATION; NUCLEOTIDES; ASSOCIATION	The DnaK protein of Escherichia coli and its eukaryotic hsp70 analogues are known to bind some polypeptides and to release or dissociate from them following ATP hydrolysis. Here we demonstrate that hydrolysis (and not simply binding) of nucleotide triphosphates leads to a change in the DnaK protein, from the "closed" to the "open" conformation. A conformational change is not observed with the mutant DnaK756 protein, which is always found in the open conformation. Although ATP is the preferred substrate, the hydrolysis of CTP, GTP, UTP, and dATP also results in DnaK's conversion from a closed to an open conformation. The ability of DnaK to hydrolyze various triphosphates correlates perfectly with its ability to release the bound denatured bovine pancreatic trypsin inhibitor polypeptide.	UNIV UTAH,SCH MED,DEPT CELLULAR VIRAL & MOLEC BIOL,SALT LAKE CITY,UT 84132; UNIV GDANSK,DEPT MOLEC BIOL,DIV BIOPHYS,PL-80822 GDANSK,POLAND	Utah System of Higher Education; University of Utah; Fahrenheit Universities; University of Gdansk			Liberek, Krzysztof/F-5812-2011	Liberek, Krzysztof/0000-0002-7532-9279	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023917, R37GM023917] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21029] Funding Source: Medline; NIGMS NIH HHS [GM23917] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFANO C, 1989, J BIOL CHEM, V264, P10709; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; CREIGHTON TE, 1980, NATURE, V284, P487, DOI 10.1038/284487a0; DODSON M, 1989, J BIOL CHEM, V264, P10719; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GAITANARIS GA, 1990, CELL, V61, P1013, DOI 10.1016/0092-8674(90)90066-N; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GEORGOPOULOS CP, 1982, J BACTERIOL, V49, P1175; Gross C. A., 1990, STRESS PROTEINS BIOL, P166; HWANG DS, 1990, J BIOL CHEM, V265, P19244; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1990, J BIOL CHEM, V265, P3022; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MORIMOTO R I, 1990, P1; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WILEY HS, 1982, J BIOL CHEM, V257, P4222; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437	29	221	222	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14491	14496						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1830586				2022-12-25	WOS:A1991FZ35100061
J	OHYA, Y; UMEMOTO, N; TANIDA, I; OHTA, A; IIDA, H; ANRAKU, Y				OHYA, Y; UMEMOTO, N; TANIDA, I; OHTA, A; IIDA, H; ANRAKU, Y			CALCIUM-SENSITIVE CLS MUTANTS OF SACCHAROMYCES-CEREVISIAE SHOWING A PET- PHENOTYPE ARE ASCRIBABLE TO DEFECTS OF VACUOLAR MEMBRANE H+-ATPASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; PHEROMONE RESPONSE; CELL-CYCLE; YEAST; GENE; SUBUNIT; TRIPHOSPHATASE; PURIFICATION; BIOGENESIS; DISRUPTION	Ca2+-sensitive mutants of the yeast Saccharomyces cerevisiae showing a Pet- phenotype (cls7-cls11) have lesions in a system for maintaining intracellular Ca2+ homeostasis (Ohya, Y., Ohsumi, Y., and Anraku, Y. (1986) J. Gen. Microbiol. 132, 979-988). Genetic and biochemical studies have demonstrated that these Pet- cls mutants are related to defects in vacuolar membrane H+-ATPase. CLS7 and CLS8 were found to be identical with the structural genes encoding subunit c (VMA3) and subunit a (VMA1), respectively, of the enzyme. In addition, these five mutants all had vma defects; no vacuolar membrane ATPase activity was detected in the cls cells, and the cls mutants showed a loss of ability to acidify the vacuole in vivo. Measurements of the cytosolic free Ca2+ concentration ([Ca2+]i) in individual cells showed that the average [Ca2+]i in wild-type cells was 150 +/- 80 nm, whereas that in five Pet- cls cells was 900 +/- 100 nm. These data are consistent with the observation that vacuolar membrane vesicles prepared from the Pet- cls cells have lost ATP-dependent Ca2+ uptake activities. The cls defects of vacuolar membrane H+-ATPase resulted in pleiotropic effects on several cellular activities, including Ca2+ homeostasis, glycerol metabolism, and phospholipid metabolism. The mutants showed an inositol-dependent phenotype, possibly due to alteration in regulation of phospholipid biosynthesis; the phosphatidylserine decarboxylase activities of the mutants were 15-50% of that of the wild-type cells and were not repressed by the addition of inositol. In contrast to the majority of previously isolated pet mutants (Tzagoloff, A., and Dieckmann, C. L. (1990) Microbiol. Rev. 54, 211-225), the Pet- cls mutants showed no detectable mitochondrial defects. Taking all these findings into account, we suggest that at least six genes, VMA1 (CLS8, subunit a), VMA2 (subunit b), VMA3 (CLS7, subunit c), VMA11 (CLS9), VMA12 (CLS10), and VMA13 (CLS11), are required for expression of the vacuolar membrane H+-ATPase activity.	UNIV TOKYO,FAC SCI,DEPT BIOL,BUNKYO KU,TOKYO 113,JAPAN; SAITAMA UNIV,DEPT BIOCHEM,URAWA,SAITAMA 338,JAPAN; NATL INST BASIC BIOL,DIV CELL PROLIFERAT,OKAZAKI,AICHI 444,JAPAN	University of Tokyo; Saitama University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)			Umemoto, Naoyuki/C-9712-2017; Tanida, Isei/C-8277-2009	Umemoto, Naoyuki/0000-0001-5507-0848; Tanida, Isei/0000-0001-8999-3990				BAUM P, 1986, P NATL ACAD SCI USA, V83, P5512, DOI 10.1073/pnas.83.15.5512; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CHVATCHKO Y, 1986, CELL, V46, P355, DOI 10.1016/0092-8674(86)90656-2; FOURY F, 1990, J BIOL CHEM, V265, P18554; GALONS JP, 1990, EUR J BIOCHEM, V193, P111, DOI 10.1111/j.1432-1033.1990.tb19311.x; GERLACH E, 1963, BIOCHEM Z, V337, P477; HIKIJI T, 1988, J BIOCHEM-TOKYO, V104, P894, DOI 10.1093/oxfordjournals.jbchem.a122579; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; IIDA H, 1990, J BIOL CHEM, V265, P21216; IIDA H, 1990, J BIOL CHEM, V265, P13391; JONES EW, 1977, GENETICS, V85, P23; KASAHARA M, 1974, J BIOCHEM-TOKYO, V76, P959; KITA K, 1984, J BIOL CHEM, V259, P3368; KITAMOTO K, 1988, J BACTERIOL, V170, P2687, DOI 10.1128/jb.170.6.2687-2691.1988; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTOON JR, 1966, J BIOL CHEM, V241, P4330; MIYAMOTO S, 1987, GENE, V54, P125, DOI 10.1016/0378-1119(87)90354-4; Mortimer R K, 1975, Methods Cell Biol, V11, P221, DOI 10.1016/S0091-679X(08)60325-8; NELSON H, 1989, J BIOL CHEM, V264, P5313; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; OHNISHI T, 1975, ANAL BIOCHEM, V69, P261, DOI 10.1016/0003-2697(75)90585-0; OHSUMI Y, 1988, J BACTERIOL, V170, P2676, DOI 10.1128/jb.170.6.2676-2682.1988; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OHYA Y, 1989, CURR GENET, V15, P113, DOI 10.1007/BF00435457; OHYA Y, 1984, MOL GEN GENET, V193, P389, DOI 10.1007/BF00382073; OHYA Y, 1986, J GEN MICROBIOL, V132, P979; OHYA Y, 1986, J BACTERIOL, V165, P28, DOI 10.1128/jb.165.1.28-33.1986; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; SHERMAN F, 1963, GENETICS, V48, P375; SHERMAN F, 1983, METHODS YEAST GENETI, P31; SIKORSKI RS, 1989, GENETICS, V122, P19; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; YOSHIHISA T, 1989, BIOCHEM BIOPH RES CO, V163, P908, DOI 10.1016/0006-291X(89)92308-5	42	170	175	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13971	13977						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1830311				2022-12-25	WOS:A1991FY02700082
J	SAGARA, Y; INESI, G				SAGARA, Y; INESI, G			INHIBITION OF THE SARCOPLASMIC-RETICULUM CA2+ TRANSPORT ATPASE BY THAPSIGARGIN AT SUBNANOMOLAR CONCENTRATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RABBIT SKELETAL-MUSCLE; ERYTHROCYTE-MEMBRANES; CALCIUM-BINDING; VESICLES; CA-2+	ATP-dependent calcium uptake by isolated sarcoplasmic reticulum vesicles is inhibited by concentrations of free thapsigargin as low as 10(-10) M. This effect is due to primary inhibition of the Ca2+-dependent ATPase which is coupled to active transport. When binding of calcium to the activating sites of the enzyme is measured under equilibrium conditions in the absence of ATP, addition of thapsigargin produces strong inhibition. On the other hand, if [tau-P-32]ATP is added to ATPase preincubated with Ca+ under favorable conditions, significant levels of P-32 phosphorylated intermediate are still formed transiently, even in the presence of thapsigargin. The phosphoenzyme, however, decays rapidly as the calcium-enzyme complex is destabilized as a consequence of ATP utilization, and formation of the thapsigargin-enzyme complex is favored. Formation of the thapsigargin-enzyme complex is also favored by Ca2+ chelation with EGTA, with consequent inhibition of the enzyme reactivity to P(i) (i.e. reverse of the ATPase hydrolytic reaction). Neither the Ca2+- and ATP-induced Ca2+ release from junctional sarcoplasmic reticulum nor the Ca2+- and calmodulin-dependent ATPase of plasma membranes (erythrocyte ghosts) were found to be altered by thapsigargin at such low concentrations.			SAGARA, Y (corresponding author), UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201, USA.				NHLBI NIH HHS [P01 HL27867] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHEVALLIER J, 1971, BIOCHEMISTRY-US, V10, P2733; CHU A, 1988, BIOCHEMISTRY-US, V27, P2827, DOI 10.1021/bi00408a025; DEMEIS L, 1969, BIOCHIM BIOPHYS ACTA, V172, P343; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; HASSELBACH W, 1964, PROGR BIOPHYS MOL BI, V14, P169; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1980, J BIOL CHEM, V255, P3025; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; KOSKOSICKA D, 1986, J BIOL CHEM, V261, P3333; LIN TI, 1977, ANAL BIOCHEM, V77, P10, DOI 10.1016/0003-2697(77)90284-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; NIGGLI V, 1979, J BIOL CHEM, V254, P9955; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SCHARFF O, 1988, BIOCHIM BIOPHYS ACTA, V972, P257, DOI 10.1016/S0005-2728(88)80056-2; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P21024	17	431	437	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13503	13506						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1830305				2022-12-25	WOS:A1991FY02700010
J	BIAN, JH; GHOSH, TK; WANG, JC; GILL, DL				BIAN, JH; GHOSH, TK; WANG, JC; GILL, DL			IDENTIFICATION OF INTRACELLULAR CALCIUM POOLS - SELECTIVE MODIFICATION BY THAPSIGARGIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CELL-LINE; ENDOPLASMIC-RETICULUM; INOSITOL 1,4,5-TRISPHOSPHATE; REGULATORY MECHANISM; GUANINE-NUCLEOTIDES; PLASMA-MEMBRANE; TUMOR PROMOTER; ACINAR-CELLS; RELEASE; GTP	Recent studies have identified inositol 1,4,5-trisphosphate(InsP3)-sensitive and -insensitive Ca2+ pools and a GTP-dependent mechanism that transfers Ca2+ between them. Here, the Ca2+ pump-inhibitory sesquiterpene lactone, thapsigargin, is shown to distinguish these two Ca2+ pools and identify a third Ca2+ pumping pool unresponsive to InsP3 or GTP. Using saponinpermeabilized DDT1MF-2 smooth muscle cells, approximately 75% of total intracellular ATP-dependent Ca2+ accumulation is blocked by thapsigargin with an IC50 of 30 nM. In contrast, 1 mM vanadate or 5-mu-M A23187 block 100% of Ca2+ accumulation. The thapsigargin-responsive Ca2+ pool corresponds exactly to that released by 10-mu-M InsP3 in the presence of 10-mu-M GTP. Indeed, addition of InsP3 with GTP has no effect on Ca2+ accumulated in the presence of 3-mu-M thapsigargin whereas A23187 releases all the remaining Ca2+. Added after maximal Ca2+ uptake, thapsigargin induces only slow Ca2+ release consistent with blockade of pumping activity. Unlike InsP3, the action of thapsigargin is entirely heparin insensitive. The large increment in Ca2+ uptake caused by 12 mM oxalate is completely reversed by thapsigargin, indicating that thapsigargin functions on an oxalate-permeable pool. Moreover, the still larger uptake induced by GTP in the presence of oxalate is also completely reversed by either thapsigargin or InsP3. The results indicate that thapsigargin blocks Ca2+ uptake into two discrete pools: the InsP3-sensitive, oxalate-permeable Ca2+ pool and the InsP3-insensitive, oxalate-impermeable Ca2+ pool that can be "recruited" into the InsP3-sensitive pool by GTP-dependent Ca2+ translocation (Ghosh, T. K., Mullaney, J. M., Tarazi, F. I., and Gill, D. L. (1989) Nature 340, 236-239). Additionally, a third Ca2+ pool is defined, unreleasable by InsP3 or GTP, and containing a thapsigargin-insensitive Ca2+ pump.			BIAN, JH (corresponding author), UNIV MARYLAND, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21201 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019304] Funding Source: NIH RePORTER; NINDS NIH HHS [NS19304] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BURTON PR, 1985, J NEUROSCI, V5, P3047; CARONI P, 1981, J BIOL CHEM, V256, P3263; CHUEH SH, 1987, J BIOL CHEM, V262, P13857; CHUEH SH, 1986, J BIOL CHEM, V261, P13883; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GILL DL, 1989, CELL CALCIUM, V10, P363, DOI 10.1016/0143-4160(89)90062-6; GILL DL, 1985, J BIOL CHEM, V260, P9289; GILL DL, 1986, NATURE, V320, P461, DOI 10.1038/320461a0; GILL DL, 1984, J BIOL CHEM, V259, P807; HENKART MP, 1978, SCIENCE, V202, P1300, DOI 10.1126/science.725607; INESI G, 1984, J BIOL CHEM, V259, P996; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; MARTONOSI A, 1982, CALCIUM CELL FUNCTIO, V3, P37; MCGRAW CF, 1980, J CELL BIOL, V85, P228, DOI 10.1083/jcb.85.2.228; MULLANEY JM, 1987, J BIOL CHEM, V262, P13865; MULLANEY JM, 1988, P NATL ACAD SCI USA, V85, P2499, DOI 10.1073/pnas.85.8.2499; NORRIS JS, 1974, NATURE, V248, P422, DOI 10.1038/248422a0; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; UEDA T, 1986, J BIOL CHEM, V261, P3184; VERMA A, 1990, BIOCHEM BIOPH RES CO, V172, P811, DOI 10.1016/0006-291X(90)90747-B; WAKASUGI H, 1982, J MEMBRANE BIOL, V65, P205, DOI 10.1007/BF01869964	29	262	263	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8801	8806						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1827436				2022-12-25	WOS:A1991FM03800029
J	ADAMS, DS; GRIFFIN, LA; NACHAJKO, WR; REDDY, VB; WEI, CM				ADAMS, DS; GRIFFIN, LA; NACHAJKO, WR; REDDY, VB; WEI, CM			A SYNTHETIC DNA ENCODING A MODIFIED HUMAN UROKINASE RESISTANT TO INHIBITION BY SERUM PLASMINOGEN-ACTIVATOR INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN; CELLS; EXPRESSION; THROMBIN; CLONING; PLASMA; INACTIVATION; PURIFICATION; SEQUENCE; COMPLEX	Using DNA synthesis technology we constructed two synthetic DNAs, designated syn-uPA-DNA and mutuPA-DNA. Syn-uPA-DNA contains the complete coding sequence of human presecretion form of single-chain u-PA. Mut-uPA-DNA was derived from syn-uPA-DNA by deleting 18 base pairs coding for amino acids Arg179-Ser184. Each synthetic DNA was inserted into a bovine papilloma viral genome-based expression vector to obtain expression in mouse cells. The results indicate that both syn-uPA and mut-uPA proteins are secreted predominantly in single-chain form. The single-chain form of both enzymes can be completely converted to two-chain form by treatment with plasmin. Both enzymes are as active as natural urokinase (std-uPA) isolated from urine. Analysis of enzymatic activity indicates that under conditions where syn-uPA and std-uPA are completely inhibited by endothelial-type plasminogen activator inhibitor (PAI-1), mut-uPA retains 90% activity. In identical experiments with placental-type PAI (PAAI-2), mut-uPA retains 80% activity. Syn-uPA is capable of forming a almost-equal-to 100-kDa complex with PAI, whereas mut-uPA can not. PAI-treated mut-uPA has kinetic properties similar to untreated syn-uPA or std-uPA. Overall, the data indicate that amino acids Arg179-Ser184 function at least in part as a binding site for PAI. Resistance to PAI inhibition may increase the potency of mut-uPA as a thrombolytic agent.	TRANSGEN SCI INC,WORCESTER,MA 01608		ADAMS, DS (corresponding author), WORCESTER POLYTECH INST,DEPT BIOL BIOTECHNOL,WORCESTER,MA 01609, USA.				NIGMS NIH HHS [GM41954-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM041954] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTALIS TM, 1988, P NATL ACAD SCI USA, V85, P985, DOI 10.1073/pnas.85.4.985; APPELLA E, 1987, J BIOL CHEM, V262, P4437; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BODE C, 1990, CIRCULATION, V81, P1974, DOI 10.1161/01.CIR.81.6.1974; COLLEN D, 1989, DRUGS, V38, P346, DOI 10.2165/00003495-198938030-00003; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; EGUCHI Y, 1990, J BIOCHEM-TOKYO, V108, P72, DOI 10.1093/oxfordjournals.jbchem.a123166; ERICKSON LA, 1990, NATURE, V346, P74, DOI 10.1038/346074a0; FEARS R, 1990, BIOCHEM J, V266, P693, DOI 10.1042/bj2660693; FLETCHER AP, 1965, J LAB CLIN MED, V65, P713; HABER E, 1989, SCIENCE, V243, P51, DOI 10.1126/science.2492113; HIGGINS DL, 1990, ANNU REV PHARMACOL, V30, P91; HOLDEN RW, 1990, RADIOLOGY, V174, P993, DOI 10.1148/radiology.174.3.174-3-993; HOMANDBERG GA, 1990, THROMB RES, V58, P403, DOI 10.1016/0049-3848(90)90211-T; HUBER R, 1974, J MOL BIOL, V89, P73, DOI 10.1016/0022-2836(74)90163-6; ICHINOSE A, 1986, J BIOL CHEM, V261, P3486; JESPERSEN J, 1983, HAEMOSTASIS, V13, P301; KAWANO T, 1968, NATURE, V217, P253, DOI 10.1038/217253a0; KRAUSE J, 1990, BIOCHEM J, V267, P647, DOI 10.1042/bj2670647; LIJNEN HR, 1990, FIBRINOLYSIS, V4, P211, DOI 10.1016/0268-9499(90)90016-D; LIJNEN HR, 1987, EUR J BIOCHEM, V169, P359, DOI 10.1111/j.1432-1033.1987.tb13620.x; LIJNEN HR, 1988, J BIOL CHEM, V263, P5594; LOSKUTOFF DJ, 1981, J BIOL CHEM, V256, P4142; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MAYER M, 1990, CLIN BIOCHEM, V23, P197, DOI 10.1016/0009-9120(90)90601-P; MEADE H, 1990, BIO-TECHNOL, V8, P443, DOI 10.1038/nbt0590-443; MIYAKE T, 1988, J BIOCHEM-TOKYO, V104, P643, DOI 10.1093/oxfordjournals.jbchem.a122526; NAGAI M, 1985, GENE, V36, P183; NAGAMINE Y, 1983, CELL, V32, P1181, DOI 10.1016/0092-8674(83)90301-X; NELLES L, 1990, THROMB HAEMOSTASIS, V64, P53; REDDY VB, 1987, DNA-J MOLEC CELL BIO, V6, P461, DOI 10.1089/dna.1987.6.461; RUNGE MS, 1989, CIRCULATION, V79, P217, DOI 10.1161/01.CIR.79.2.217; RYDZEWSKI A, 1989, THROMB HAEMOSTASIS, V62, P752; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEUNING WD, 1987, MOL CELL BIOL, V7, P4564, DOI 10.1128/MCB.7.12.4564; STRASSBURGER W, 1983, FEBS LETT, V157, P219, DOI 10.1016/0014-5793(83)80551-1; STUMP DC, 1986, J BIOL CHEM, V261, P2759; THERIAULT NY, 1988, BIOTECHNIQUES, V6, P470; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERDE P, 1984, P NATL ACAD SCI-BIOL, V81, P4727, DOI 10.1073/pnas.81.15.4727; VERSTRAETE M, 1986, THROMB HAEMOSTASIS, V56, P1; WAGNER OF, 1986, J BIOL CHEM, V261, P4474; WIMAN B, 1984, J BIOL CHEM, V259, P3644; YE RD, 1987, J BIOL CHEM, V262, P3718	45	53	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8476	8482						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1827121				2022-12-25	WOS:A1991FK44100078
J	CELIS, JE; RASMUSSEN, HH; LEFFERS, H; MADSEN, P; HONORE, B; GESSER, B; DEJGAARD, K; VANDEKERCKHOVE, J				CELIS, JE; RASMUSSEN, HH; LEFFERS, H; MADSEN, P; HONORE, B; GESSER, B; DEJGAARD, K; VANDEKERCKHOVE, J			HUMAN CELLULAR PROTEIN-PATTERNS AND THEIR LINK TO GENOME DNA-SEQUENCE DATA - USEFULNESS OF 2-DIMENSIONAL GEL-ELECTROPHORESIS AND MICROSEQUENCING	FASEB JOURNAL			English	Article						HUMAN PROTEIN PATTERNS; 2-DIMENSIONAL GEL PROTEIN DATABASES; GENE EXPRESSION; MICROSEQUENCING; CDNA CLONING; LINKING PROTEIN AND DNA INFORMATION; GENOME MAPPING AND SEQUENCING	POLYVINYLIDENE DIFLUORIDE MEMBRANES; TWO-DIMENSIONAL GELS; COATED GLASS-FIBER; POLYACRYLAMIDE GELS; PICOMOLE QUANTITIES; DATABASES; DIGESTION	Analysis of cellular protein patterns by computer-aided 2-dimensional gel electrophoresis together with recent advances in protein sequence analysis have made possible the establishment of comprehensive 2-dimensional gel protein database that may link protein and DNA information and that offer a global approach to the study of the cell. Using the integrated approach offered by 2-dimensional gel protein databases it is now possible to reveal phenotype specific protein (or proteins), to microsequence them, to search for homology with previously identified proteins, to clone the cDNAs, to assign partial protein sequence to genes for which the full DNA sequence and the chromosome location is known, and to study the regulatory properties and function of groups of proteins that are coordinately expressed in a given biological process. Human 2-dimensional gel protein databases are becoming increasingly important in view of the concerted effort to map and sequence the entire genome.	AARHUS UNIV, HUMAN GENOME RES CTR, DK-8000 AARHUS, DENMARK	Aarhus University	CELIS, JE (corresponding author), AARHUS UNIV, INST MED BIOCHEM, OLE WORMS ALLE, BLDG 170, UNIV PK, DK-8000 AARHUS, DENMARK.		Honoré, Bent/ABF-3650-2021	Madsen, Peder Sondergaard/0000-0002-8845-4802; Honore, Bent/0000-0002-3459-7429				AEBERSOLD R, 1990, ELECTROPHORESIS, V11, P517, DOI 10.1002/elps.1150110702; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AEBERSOLD RH, 1986, J BIOL CHEM, V261, P4229; ANDERSON NG, 1982, CLIN CHEM, V28, P739; ANDERSON NL, 1984, CLIN CHEM, V30, P2031; APPEL R, 1988, ELECTROPHORESIS, V9, P136, DOI 10.1002/elps.1150090307; BAUW G, 1987, P NATL ACAD SCI USA, V84, P4806, DOI 10.1073/pnas.84.14.4806; BAUW G, 1988, J PROTEIN CHEM, V7, P194; BAUW G, 1990, ELECTROPHORESIS, V11, P528, DOI 10.1002/elps.1150110703; BAUW G, 1989, P NATL ACAD SCI USA, V86, P7701, DOI 10.1073/pnas.86.20.7701; Celis J, 1984, 2 DIMENSIONAL GEL EL; CELIS JE, 1989, FEBS LETT, V244, P247, DOI 10.1016/0014-5793(89)80538-1; CELIS JE, 1990, BIOESSAYS, V12, P93, DOI 10.1002/bies.950120209; CELIS JE, 1990, ELECTROPHORESIS, V11, P1072, DOI 10.1002/elps.1150111203; CELIS JE, 1988, LEUKEMIA, V2, P561; CELIS JE, 1990, ELECTROPHORESIS, V11, P242, DOI 10.1002/elps.1150110308; CELIS JE, 1990, ELECTROPHORESIS, V11, P989, DOI 10.1002/elps.1150111202; CELIS JE, 1989, ELECTROPHORESIS, V10, P76, DOI 10.1002/elps.1150100204; CELIS JE, 1987, FEBS LETT, V220, P1, DOI 10.1016/0014-5793(87)80865-7; CELIS JE, 1989, ELECTROPHORESIS, V2; CELIS JE, 1989, ADV ELECTROPHORESIS; Celis JE, 1990, ELECTROPHORESIS, V11; ECKERSKORN C, 1990, ELECTROPHORESIS, V11, P554, DOI 10.1002/elps.1150110705; ECKERSKORN C, 1988, EUR J BIOCHEM, V176, P509, DOI 10.1111/j.1432-1033.1988.tb14308.x; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GARRELS JI, 1989, J BIOL CHEM, V264, P5283; GARRELS JI, 1990, ELECTROPHORESIS, V11, P1114, DOI 10.1002/elps.1150111204; GARRELS JI, 1984, 2 DIMENSIONAL GEL EL, P37; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KENNEDY TE, 1988, P NATL ACAD SCI USA, V85, P7008, DOI 10.1073/pnas.85.18.7008; LEMKIN PF, 1989, ELECTROPHORESIS, V10, P122, DOI 10.1002/elps.1150100207; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILLER MJ, 1989, ADV ELECTROPHORESIS, V3, P182; MOOS M, 1988, J BIOL CHEM, V263, P6005; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLSON AD, 1988, ANAL BIOCHEM, V169, P49, DOI 10.1016/0003-2697(88)90255-2; RASMUSSEN HH, 1991, ADV LIF SCI, P103; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; VANBOGELEN RA, 1990, ELECTROPHORESIS, V11, P1131, DOI 10.1002/elps.1150111205; VANDEKERCKHOVE J, 1985, EUR J BIOCHEM, V152, P9, DOI 10.1111/j.1432-1033.1985.tb09157.x; VINCENS P, 1988, INT J BIOCHEM, V20, P499, DOI 10.1016/0020-711X(88)90498-3; VINCENS P, 1986, ELECTROPHORESIS, V7, P347, DOI 10.1002/elps.1150070802; Weber K., 1975, PROTEINS, VI, P179; 1982, CLIN CHEM, V28; [No title captured]	46	51	52	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1991	5	8					2200	2208		10.1096/fasebj.5.8.1827083	http://dx.doi.org/10.1096/fasebj.5.8.1827083			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FK111	1827083				2022-12-25	WOS:A1991FK11100013
J	MORAN, P; RAAB, H; KOHR, WJ; CARAS, IW				MORAN, P; RAAB, H; KOHR, WJ; CARAS, IW			GLYCOPHOSPHOLIPID MEMBRANE ANCHOR ATTACHMENT - MOLECULAR ANALYSIS OF THE CLEAVAGE ATTACHMENT SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECAY-ACCELERATING FACTOR; VARIANT SURFACE GLYCOPROTEIN; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; GLYCOSYL-PHOSPHATIDYLINOSITOL; TRYPANOSOMA-BRUCEI; CARBOXYL TERMINUS; FACTOR DAF; THY-1 GLYCOPROTEIN; PROTEINS; SIGNAL	The COOH terminus of decay accelerating factor (DAF) contains a signal that directs attachment of a glycophosphatidylinositol (GPI) membrane anchor in a process involving proteolytic removal of 17-31 COOH-terminal residues. Previous work suggested that two elements are required for anchor addition, a COOH-terminal hydrophobic domain (the GPI signal) and an element located NH2-terminal to it, postulated to be the cleavage/attachment site. Using [H-3]ethanolamine (a component of the anchor) to tag the COOH terminus, we isolated and sequenced a COOH-terminal tryptic peptide, thereby identifying Ser-319 as the COOH-terminal residue attached to the GPI anchor. This indicates that a 28-residue peptide is removed during processing and localizes the cleavage/attachment site precisely to the region previously shown to be required for anchor attachment (between 10 and 20 residues NH2-terminal to the hydrophobic domain). Since DAF contains multiple cryptic cleavage/attachment sites, we used a GPI-linked human growth hormone-DAF fusion to study the structural requirements for cleavage/attachment. Our results show that while sequences immediately NH2-terminal to the attachment site are not required for anchor addition, deletion of Ser-319 abolishes both anchor attachment and transport to the cell surface. Systematic replacement of the attachment site serine with all possible amino acids indicated that alanine, aspartate, asparagine, glycine, or serine efficiently support GPI anchor attachment while valine and glutamate are partially effective. All other substitutions including cysteine (permitted at the attachment site in other GPI-anchored proteins) abolish both GPI anchor attachment and transport to the cell surface, resulting in accumulation of uncleaved fusion protein in internal compartments (endoplasmic reticulum and Golgi). These results support the general rule that the residue at the cleavage/attachment site must be small. Further, addition of a GPI anchor appears to be necessary for transport to the cell surface in transfected COS cells.	GENENTECH INC,DEPT IMMUNOBIOL,SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PROT CHEM,SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech				Caras, Ingrid/0000-0002-8902-808X				BANGS JD, 1986, J CELL BIOL, V103, P255, DOI 10.1083/jcb.103.1.255; BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BOOTHROYD JC, 1981, NUCLEIC ACIDS RES, V9, P4735, DOI 10.1093/nar/9.18.4735; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CARAS IW, 1987, NATURE, V325, P545, DOI 10.1038/325545a0; CARAS IW, 1989, J CELL BIOL, V108, P1387, DOI 10.1083/jcb.108.4.1387; CARAS IW, 1989, SCIENCE, V243, P1196, DOI 10.1126/science.2466338; DAVITZ MA, 1987, J IMMUNOL METHODS, V97, P71, DOI 10.1016/0022-1759(87)90107-4; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HAAS R, 1986, BIOCHEMISTRY-US, V25, P3098, DOI 10.1021/bi00359a005; HEFTA SA, 1988, P NATL ACAD SCI USA, V85, P4648, DOI 10.1073/pnas.85.13.4648; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; KINOSHITA T, 1986, J IMMUNOL, V136, P3390; KNOX JH, 1986, J CHROMATOGR, V352, P3, DOI 10.1016/S0021-9673(01)83368-9; LANIER LL, 1989, SCIENCE, V246, P1611, DOI 10.1126/science.2531919; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MAJUMDER HK, 1981, NUCLEIC ACIDS RES, V9, P4745, DOI 10.1093/nar/9.18.4745; MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558; MICANOVIC R, 1988, P NATL ACAD SCI USA, V85, P1398, DOI 10.1073/pnas.85.5.1398; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P157, DOI 10.1073/pnas.87.1.157; NICHOLSONWELLER A, 1982, J IMMUNOL, V129, P184; RAVETCH JV, 1989, NATURE, V342, P805; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SELDEN RF, 1987, CURRENT PROTOCOLS MO, V1; TSE AGD, 1985, SCIENCE, V230, P1003, DOI 10.1126/science.2865810; TYKOCINSKI ML, 1988, P NATL ACAD SCI USA, V85, P3555, DOI 10.1073/pnas.85.10.3555; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	32	152	160	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					1250	1257						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1824699				2022-12-25	WOS:A1991ET17700087
J	RAO, VN; REDDY, ESP				RAO, VN; REDDY, ESP			A DIVERGENT ETS-RELATED PROTEIN, ELK-1, RECOGNIZES SIMILAR C-ETS-1 PROTOONCOGENE TARGET SEQUENCES AND ACTS AS A TRANSCRIPTIONAL ACTIVATOR	ONCOGENE			English	Article							LONG TERMINAL REPEAT; AVIAN LEUKEMIA-VIRUS; DNA-BINDING; V-ETS; ERG GENE; C-ETS; CELLS; E26; TRANSLOCATION; LOCALIZATION	The ets oncogene superfamily consists of a family of sequence-specific DNA-binding proteins that activate transcription. We have previously identified two new members of the ets oncogene superfamily, namely elk-1 and elk-2. In this report we show that the recombinant elk-1 protein expressed in bacteria, like the c-ets-1 proto-oncogene, binds in a sequence-specific manner to Moloney murine sarcoma virus long terminal repeat, E74 target sequences and the PEA3 motif (polyoma enhancer), but does not bind to PU box sequences. Thus analysis of the DNA-binding specificity of ets-related proteins supports the view that different members show similar DNA-binding specificity, which is a general feature of the homeobox proteins. Our data using the chloramphenicol acetyltransferase gene linked to a thymidine kinase promoter containing multimers of the elk-1 target sequence indicates that elk-1 functions as a transcriptional activator. Interestingly, although elk-1 is the most divergent of all the members of the ets gene family, it shows very close similarities with c-ets-1 in some of its sequence-specific DNA-binding specificities. Here, we propose a new function for the elk-1 gene to act as a transcriptional activator of retroviruses and DNA tumor viruses.	TEMPLE UNIV,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University								ATCHISON ML, 1988, EMBO J, V7, P4213, DOI 10.1002/j.1460-2075.1988.tb03318.x; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; CLARK SP, 1983, P NATL ACAD SCI-BIOL, V80, P5037, DOI 10.1073/pnas.80.16.5037; COQUILLAND M, 1988, ONCOGENE RES, V2, P335; DIAZ MO, 1986, SCIENCE, V231, P265, DOI 10.1126/science.3455787; FUJIWARA S, 1988, ONCOGENE, V2, P99; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GRAF T, 1979, VIROLOGY, V99, P431, DOI 10.1016/0042-6822(79)90024-2; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HOLLAND CA, 1987, P NATL ACAD SCI USA, V84, P8662, DOI 10.1073/pnas.84.23.8662; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, IN PRESS ONCOGENE, V6; REDDY ESP, 1991, ERG ELK 1 ELK 2 GUID; REDDY ESP, 1990, CANCER RES, V50, P5013; Sambrook J, 1989, MOL CLONING LABORATO; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK D, 1990, NATURE, V3346, P191; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862	43	77	78	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					65	70						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741166				2022-12-25	WOS:A1992HC22700009
J	KROMER, WJ; ARNDT, E				KROMER, WJ; ARNDT, E			HALOBACTERIAL S9 OPERON - 3 RIBOSOMAL-PROTEIN GENES ARE COTRANSCRIBED WITH GENES ENCODING A TRANSFER RNALEU, THE ENOLASE, AND A PUTATIVE MEMBRANE-PROTEIN IN THE ARCHAEBACTERIUM HALOARCULA (HALOBACTERIUM) MARISMORTUI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; ACID; TRANSCRIPTION; CLONING; ORGANIZATION; TERMINATION; EXPRESSION; HOMOLOGY; REGION	In the eubacterium Escherichia coli the genes for the ribosomal proteins L13 and S9 form an operon consisting of two genes. The corresponding operon of the archaebacterium Haloarcula marismortui (Halobacterium marismortui was recently reassigned to the genus Haloarcula [Oren, A., Ginzburg, M., Ginzburg, B. Z., Hochstein, L. I., and Volcani, B. E. (1990) Int. J. Syst. Bacteriol. 40, 209-210] and is now called Haloarcula marismortui) which is presented here, is much larger encoding three ribosomal proteins (HL29, HmaL13, HmaS9), a tRNA(Leu), the glycolytic enzyme enolase (HmaEno), a putative membrane protein (OrfMSG), and two not yet identified open reading frames (OrfMMV, OrfMNA). The nucleotide sequence of 3931 base pairs has been established. Northern analysis revealed the existence of a polycistronic mRNA (3.7 kilobases) demonstrating that the transcription of a gene of the glycolytic pathway is coupled to the transcription of ribosomal protein genes. Upstream of the first gene of the operon (tRNA(Leu)) a promoter structure typical for the extreme halophilic archaebacteria was detected and downstream of the last gene (OrfMSG) a terminator structure was present. As shown by S1-nuclease mapping, a tRNA-mRNA transcript as well as the mRNA alone was present in vivo. The transcriptional start point and the tRNA-mRNA cleavage point are shown to be almost identical to the 5' and 3' ends, respectively, of the putative mature tRNA. The C-terminal part of the OrfMSG protein shows a significant similarity to the vertebrate laminin receptor protein.			KROMER, WJ (corresponding author), MAX PLANCK INST MOLEC GENET,WITTMANN ABT,W-1000 BERLIN 33,GERMANY.							AIBA H, 1981, J BIOL CHEM, V256, P1905; ARNDT E, 1988, J BIOL CHEM, V263, P16063; ARNDT E, 1990, FEBS LETT, V267, P193, DOI 10.1016/0014-5793(90)80923-7; ARNDT E, 1990, J BIOL CHEM, V265, P3034; ARNDT E, 1990, NUCLEIC ACIDS RES, V18, P1285, DOI 10.1093/nar/18.5.1285; ARNDT E, 1991, BIOCHIMIE, V73, P657, DOI 10.1016/0300-9084(91)90045-3; BILOFSKY HS, 1986, NUCLEIC ACIDS RES, V14, P1, DOI 10.1093/nar/14.1.1; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BROMBACH M, 1989, NUCLEIC ACIDS RES, V17, P3293, DOI 10.1093/nar/17.8.3293; BROWN JW, 1989, CRIT REV MICROBIOL, V16, P287, DOI 10.3109/10408418909105479; Carmichael G G, 1980, Methods Enzymol, V65, P380; CHAN YL, 1990, FEBS LETT, V263, P85, DOI 10.1016/0014-5793(90)80711-Q; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COBIANCHI F, 1987, METHOD ENZYMOL, V152, P94; Deutscher M. P., 1983, ENZYMES NUCLEIC ACID, V2, P159; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GROSSO LE, 1991, BIOCHEMISTRY-US, V30, P3346, DOI 10.1021/bi00227a026; GUPTA R, 1986, SYST APPL MICROBIOL, V7, P102, DOI 10.1016/S0723-2020(86)80131-X; HAMM GH, 1986, NUCLEIC ACIDS RES, V14, P5, DOI 10.1093/nar/14.1.5; HATAKEYAMA T, 1988, EUR J BIOCHEM, V172, P703, DOI 10.1111/j.1432-1033.1988.tb13945.x; HOLLAND MJ, 1981, J BIOL CHEM, V256, P1385; HUDSON L, 1981, NATURE, V294, P422, DOI 10.1038/294422a0; ISHII S, 1984, P NATL ACAD SCI-BIOL, V81, P409, DOI 10.1073/pnas.81.2.409; ISONO S, 1985, MOL GEN GENET, V198, P279, DOI 10.1007/BF00383007; KIMURA M, 1984, FEBS LETT, V175, P213, DOI 10.1016/0014-5793(84)80739-5; KIMURA M, 1989, CAN J MICROBIOL, V35, P195, DOI 10.1139/m89-030; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEBIODA L, 1988, NATURE, V333, P683, DOI 10.1038/333683a0; Maniatis T., 1982, MOL CLONING; MATHESON AT, 1990, RIBOSOME, P617; MENDE L, 1978, FEBS LETT, V96, P313, DOI 10.1016/0014-5793(78)80425-6; MESSING J, 1983, METHOD ENZYMOL, V101, P20; ORCUTT BC, 1982, NBR82050108710 NAT B; OREN A, 1990, INT J SYST BACTERIOL, V40, P209, DOI 10.1099/00207713-40-2-209; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PHUA SH, 1989, J BIOL CHEM, V264, P1968; PONCZ M, 1982, P NATL ACAD SCI-BIOL, V79, P4298, DOI 10.1073/pnas.79.14.4298; RAO CN, 1989, BIOCHEMISTRY-US, V28, P7476, DOI 10.1021/bi00444a047; REZNIKOFF WS, 1985, ANNU REV GENET, V19, P355, DOI 10.1146/annurev.genet.19.1.355; SCHOLZEN T, 1991, MOL GEN GENET, V228, P70, DOI 10.1007/BF00282450; SEGIL N, 1988, BIOCHEM J, V251, P31, DOI 10.1042/bj2510031; SPECHT T, 1986, NUCLEIC ACIDS RES, V14, P4693, DOI 10.1093/nar/14.11.4693; THOMM M, 1988, NUCLEIC ACIDS RES, V16, P151, DOI 10.1093/nar/16.1.151; THOMM M, 1989, CAN J MICROBIOL, V35, P30, DOI 10.1139/m89-005; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WENG M, 1986, J BIOL CHEM, V261, P5568; WITTMANN HG, 1986, STRUCTURE FUNCTION G, P1; WITTMANNLIEBOLD B, 1990, RIBOSOME, P598; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088; YONATH A, 1989, TRENDS BIOCHEM SCI, V14, P329, DOI 10.1016/0968-0004(89)90166-7; ZILLIG W, 1988, EUR J BIOCHEM, V173, P473, DOI 10.1111/j.1432-1033.1988.tb14023.x	53	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24573	24579						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1840597				2022-12-25	WOS:A1991GW84500052
J	WARSHAW, DM; DESROSIERS, JM; WORK, SS; TRYBUS, KM				WARSHAW, DM; DESROSIERS, JM; WORK, SS; TRYBUS, KM			EFFECTS OF MGATP, MGADP, AND PI ON ACTIN MOVEMENT BY SMOOTH-MUSCLE MYOSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN PHOSPHORYLATION; ADENOSINE-TRIPHOSPHATASE; ACTOMYOSIN ATPASE; HEAVY-MEROMYOSIN; FLASH-PHOTOLYSIS; GUINEA-PIG; FIBERS; CONTRACTION; FILAMENTS; MECHANISM	To test the idea that the in vitro motility assay is a simplified model system for muscle contraction, the MgATP-dependent movement of actin filaments by thiophosphorylated smooth muscle myosin was characterized in the presence of the products MgADP and inorganic phosphate. The dependence of actin filament velocity on MgATP concentration was hyperbolic with a maximum velocity of 0.6-mu-m/s and an apparent K(m) = 40-mu-M (30-degrees-C). MgADP competitively inhibited actin movement by MgATP with a K(i) = 0.24 mM. Inorganic phosphate did not affect actin filament velocity in the presence of 1 mM MgATP, but competitively inhibited movement in the presence of 50-mu-M MgATP with a K(i) = 9.5 mM. The effects of ADP and P(i) on velocity agree with fiber mechanical studies, confirming that the motility assay is an excellent system to investigate the molecular mechanism of force generation and shortening in smooth muscle. The rate at which rigor cross-bridges can be recruited to move actin filaments was observed by initiating cross-bridge cycling from rigor by flash photolysis of caged MgATP. Following the flash, which results in a rapid increase in MgATP concentration, actin filaments experienced a MgATP-dependent delay prior to achieving steady state velocity. The delay at low MgATP concentrations was interpreted as evidence that motion generating cross-bridges are slowed by a load due to a transiently high percentage of rigor cross-bridges immediately following MgATP release.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254	Brandeis University	WARSHAW, DM (corresponding author), UNIV VERMONT,DEPT PHYSIOL & BIOPHYS,BURLINGTON,VT 05405, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038113, R01HL045161, R01HL038113] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45161, HL38113] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNER A, 1987, J MUSCLE RES CELL M, V8, P377, DOI 10.1007/BF01578427; ARNER A, 1985, J PHYSIOL-LONDON, V360, P347, DOI 10.1113/jphysiol.1985.sp015621; ARNER A, 1987, REGULATION CONTRACTI, P43; BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; COOKE R, 1979, BIOPHYS J, V28, P241, DOI 10.1016/S0006-3495(79)85174-7; COOKE R, 1985, BIOPHYS J, V48, P789, DOI 10.1016/S0006-3495(85)83837-6; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P637, DOI 10.1146/annurev.ph.49.030187.003225; GOLDMAN YE, 1984, J PHYSIOL-LONDON, V354, P577, DOI 10.1113/jphysiol.1984.sp015394; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HARADA Y, 1987, NATURE, V326, P805, DOI 10.1038/326805a0; HOMSHER E, 1990, ANNU REV PHYSIOL, V52, P875, DOI 10.1146/annurev.ph.52.030190.004303; HORIUTI K, 1989, J GEN PHYSIOL, V94, P769, DOI 10.1085/jgp.94.4.769; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1990, J BIOL CHEM, V265, P8347; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; MARSTON SB, 1980, J MOL BIOL, V139, P573, DOI 10.1016/0022-2836(80)90050-9; MCELROY WD, 1949, ARCH BIOCHEM, V22, P420; MOOS C, 1973, COLD SPRING HARB SYM, V37, P137, DOI 10.1101/SQB.1973.037.01.021; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PATE E, 1989, PFLUG ARCH EUR J PHY, V414, P73, DOI 10.1007/BF00585629; SELLERS JR, 1985, J CELL BIOL, V101, P1897, DOI 10.1083/jcb.101.5.1897; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; SELLERS JR, 1985, J BIOL CHEM, V260, P5815; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; SLEEP J, 1986, BIOCHEMISTRY-US, V25, P1149, DOI 10.1021/bi00353a030; SOMLYO AV, 1988, J GEN PHYSIOL, V91, P165, DOI 10.1085/jgp.91.2.165; TAYLOR EW, 1979, CRC CR REV BIOCH MOL, V6, P103, DOI 10.3109/10409237909102562; TOYOSHIMA YY, 1990, P NATL ACAD SCI USA, V87, P7130, DOI 10.1073/pnas.87.18.7130; TRYBUS KM, 1989, J CELL BIOL, V109, P2887, DOI 10.1083/jcb.109.6.2887; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; UYEDA TQP, 1990, J MOL BIOL, V214, P599; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WARSHAW DM, 1983, SCIENCE, V219, P1438, DOI 10.1126/science.6828870; WHITE HD, 1976, BIOCHEMISTRY-US, V15, P5818, DOI 10.1021/bi00671a020; WOLEDGE RC, 1985, ENERGETIC ASPECTS MU, P107	37	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24339	24343						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761536				2022-12-25	WOS:A1991GW84500019
J	BRICKGHANNAM, C; HUANG, FL; TEMIME, N; CHARRON, D				BRICKGHANNAM, C; HUANG, FL; TEMIME, N; CHARRON, D			PROTEIN-KINASE-C (PKC) ACTIVATION VIA HUMAN-LEUKOCYTE ANTIGEN CLASS-II MOLECULES - A NOVEL REGULATION OF PKC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL ACTIVATION; RAT-BRAIN; MONOCLONAL-ANTIBODIES; IMMUNOCHEMICAL CHARACTERIZATION; RIBONUCLEIC-ACID; LYMPHOCYTES-B; T-CELLS; HLA; TRANSLOCATION; BINDING	Analysis of intracellular localization of protein kinase C (PKC) in a lymphoblastoid B cell line shows that anti-human leucocyte antigen (HLA) class II antibodies induce an increase of cytosolic and membrane PKC activities. This phenomenon is both time- and dose-dependent. The maximal PKC activation was observed after exposure to 12.5-mu-g/ml antibody for 30 to 45 min. Unlike TPA, no translocation of the cytosolic PKC was observed at any time following exposure to the anti-HLA class II antibodies. We observed a good correlation between the [H-3]phorbol dibutyrate binding activity and the enzymatic activity of PKC. Using a panel of antibodies specific for the HLA class II isotypes (DP, DQ, DR), we demonstrated that PKC activation via HLA class II molecules is not restricted to one isotype. We also showed by Western blot analysis that the increased PKC activity correlates with a quantitative increase of PKC. The increase of PKC activity induced by anti-HLA class II antibodies was completly abolished by the treatment with actinomycin D, a transcriptional inhibitor, or cycloheximide, a translational inhibitor. Finally, Northern blot analysis revealed that anti-HLA class II antibodies induce an increase of the PKC-alpha and PKC-beta mRNAs levels which are significant after 20 min of stimulation and rose to a maximum after 60 min. In summary, our results show that increased PKC activity induced by HLA class II antibody is regulated at the transcriptional level.	NICHHD,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	BRICKGHANNAM, C (corresponding author), INST BIOMED CORDELIERS,IMMUNOGENET MOLEC LAB,15 RUE ECOLE MED,F-75006 PARIS,FRANCE.			BRICK, CHEHRAZADE/0000-0002-7017-6533				BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BERRY N, 1990, P NATL ACAD SCI USA, V87, P2294, DOI 10.1073/pnas.87.6.2294; BERRY N, 1989, J IMMUNOL, V143, P1407; BERZOFSKY JA, 1989, FUNDAMENTAL IMMUNOLO, V12, P315; BOSCA L, 1989, IMMUNOL TODAY, V10, P223, DOI 10.1016/0167-5699(89)90256-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT SJ, 1987, CELL, V49, P57, DOI 10.1016/0092-8674(87)90755-0; BRICKGHANNAM C, 1991, HUM IMMUNOL, V30, P202, DOI 10.1016/0198-8859(91)90035-8; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CARREL S, 1981, MOL IMMUNOL, V18, P403, DOI 10.1016/0161-5890(81)90102-4; CHARRON DJ, 1980, J EXP MED, V152, pS18; CHARRON DJ, 1979, P NATL ACAD SCI USA, V76, P6567, DOI 10.1073/pnas.76.12.6567; CHARRON DJ, 1984, NATURE, V312, P157, DOI 10.1038/312157a0; CHEN ZZ, 1987, J IMMUNOL, V138, P2345; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMENT LT, 1986, J IMMUNOL, V136, P2375; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERMAND JP, 1985, EUR J IMMUNOL, V15, P1183, DOI 10.1002/eji.1830151208; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HORNBECK P, 1989, MOL CELL BIOL, V9, P3727, DOI 10.1128/MCB.9.9.3727; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; HUANG KP, 1986, J BIOL CHEM, V261, P4781; HUANG KP, 1988, J BIOL CHEM, V263, P14839; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KUMARARATNE DS, 1981, EUR J IMMUNOL, V11, P858, DOI 10.1002/eji.1830111103; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LEPEUCH CJ, 1983, P NATL ACAD SCI-BIOL, V80, P6858; MOONEY N, 1989, J AUTOIMMUN, V2, P215, DOI 10.1016/0896-8411(89)90133-9; MOONEY NA, 1990, J IMMUNOL, V145, P2070; MURAYAMA S, 1985, J IMMUNOL, V135, P192; NABAVI N, 1989, J IMMUNOL, V142, P1444; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OGAWA Y, 1981, J IMMUNOL, V127, P1369; PALACIOS R, 1983, P NATL ACAD SCI-BIOL, V80, P3456, DOI 10.1073/pnas.80.11.3456; RUBINSTEIN D, 1986, J IMMUNOL, V137, P1803; SCOTT DW, 1985, CELL IMMUNOL, V93, P124, DOI 10.1016/0008-8749(85)90393-4; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIDA T, 1984, J BIOL CHEM, V259, P2311; WARNER JA, 1989, J IMMUNOL, V142, P1669; WITT JJ, 1975, ANAL BIOCHEM, V66, P253, DOI 10.1016/0003-2697(75)90743-5	43	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					24169	24175						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748685				2022-12-25	WOS:A1991GV31900098
J	BUSSE, SC; LAMAR, GN; HOWARD, JB				BUSSE, SC; LAMAR, GN; HOWARD, JB			2-DIMENSIONAL NMR INVESTIGATION OF IRON-SULFUR CLUSTER ELECTRONIC AND MOLECULAR-STRUCTURE OF OXIDIZED CLOSTRIDIUM-PASTEURIANUM FERREDOXIN - INTERPRETABILITY OF CONTACT SHIFTS IN TERMS OF CYSTEINE ORIENTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE; PARAMAGNETIC PROTEINS; 2-IRON FERREDOXINS; REDOX POTENTIALS; H-1-NMR; ASSIGNMENT; ANALOGS; HISTIDINE; RESIDUES; STATE	A two-dimensional NMR study has been carried out on the four-iron clusters of a bacterial oxidized ferredoxin for the purpose of investigating the relationship between contact shift patterns and the orientation of the individual coordinated cysteines. The ferredoxin from Clostridium pasteurianum, CpFd(ox), was selected because of its extensive sequence homology, and likely close structural similarity, to the crystallographically characterized ferredoxin from Peptococcus aerogenes, Pa Fd(ox) (Adman, E. T., Sieker, L. C., and Jensen, L. H. (1973) J. Biol. Chem. 249, 3987-3996). Rapid data collection rates with minimal but adequate acquisition time allowed the detection of numerous CpFd(ox) cross-peaks from the contact-shifted and strongly relaxed coordinated cysteinyl C(beta)H protons in the resolved 10-20 ppm window. Relatively strong magnitude COSY cross peaks from the resolved eight cysteinyl C(beta)H resonance unambiguously locate the geminal C(beta)H partner for each residue; weaker cross-peaks locate the C(alpha)Hs from three of the residues. The geminal nature of the magnitude-COSY detected partners to the resolved C(beta)H peaks is confirmed by strong NOESY cross-peaks. The NOESY spectra, moreover, assign an additional two cysteinyl C(alpha)H resonances. The present results confirm some previous one-dimensional NOE assignments, revise others, and locate resonances previously undetected (Bertini, I., Briganti, F., Luchinat, C., and Scozzafara, A. (1990) Inorg. Chem. 29, 1874-1880). A striking pairwise pseudo-symmetry in cysteinyl contact shift patterns is observed which is attributed to the previously recognized pseudo-symmetry in the crystal of PaFd(ox). A detailed analysis of the structural/electronic determinants of the coordinated cysteine C(beta)H contact shift pattern is made, and the NMR data necessary for unique interpretation are identified. It is shown that analysis of the relaxation properties of cysteine beta-methylene protons provides the stereospecific assignments necessary for comparison of shift ratios with crystallographic structural data. The available structural data on PaFd(ox) (Backes, G., Mino, Y., Loehr, T., Meyer, T., Cusanovich, M., Sweeney, W., Adman, E., and Sanders-Loehr, J. (1991) J. Am. Chem. Soc. 13, 2055-2064) are qualitatively but not quantitatively consistent with the observed cysteinyl contact shift pattern, with the NMR data reflecting more asymmetry than previous studies. A tentative assignment of a single pair of symmetry-related cysteines is proposed. It is concluded that the angular variation in cysteinyl, beta-methylene contact shift patterns can provide information on the orientation of the cysteine, the mechanism of Fe-S spin transmission, the asymmetry in the spin magnetization within a cluster, and possibly hydrogen-bonding to the coordinated sulfur. However, several of these mechanisms manifest themselves in a manner that make separation of their contributions difficult.	UNIV CALIF DAVIS,DEPT CHEM,DAVIS,CA 95616; UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455	University of California System; University of California Davis; University of Minnesota System; University of Minnesota Twin Cities	LAMAR, GN (corresponding author), UNIV CALIF DAVIS,DEPT CHEM,DAVIS,CA 95616, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034321] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-34321] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADMAN ET, 1976, J BIOL CHEM, V251, P3801; ADMAN ET, 1973, J BIOL CHEM, V248, P3987; AVERILL BA, 1978, MET IONS BIOL SYST, V7, P127; BACKES G, 1991, J AM CHEM SOC, V113, P2055, DOI 10.1021/ja00006a027; BANCI L, 1990, STRUCT BOND, V72, P113; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; BERTINI I, 1990, INORG CHEM, V29, P1874, DOI 10.1021/ic00335a023; BERTINI I, 1991, J AM CHEM SOC, V113, P1237, DOI 10.1021/ja00004a025; BERTINI I, 1986, NMR PARAMAGNETIC MOL; CAMMACK R, 1977, IRON SULFUR PROTEINS, V3, P283; CARTER CW, 1977, J BIOL CHEM, V252, P7802; CHAN TM, 1983, BIOCHEMISTRY-US, V22, P5982, DOI 10.1021/bi00294a044; CHENG H, 1990, J BIOL CHEM, V265, P12388; CIURLI S, 1990, J AM CHEM SOC, V112, P2654, DOI 10.1021/ja00163a028; COWAN JA, 1990, BIOCHEMISTRY-US, V29, P5633, DOI 10.1021/bi00475a031; CZERNUSZEWICZ RS, 1987, J AM CHEM SOC, V109, P7178, DOI 10.1021/ja00257a045; DEROPP JS, 1991, J AM CHEM SOC, V113, P4348, DOI 10.1021/ja00011a058; DUGAD LB, 1990, J AM CHEM SOC, V112, P1386, DOI 10.1021/ja00160a015; DUGAD LB, 1990, BIOCHEMISTRY-US, V29, P2263, DOI 10.1021/bi00461a009; DUNHAM WR, 1971, BIOCHIM BIOPHYS ACTA, V253, P373, DOI 10.1016/0005-2728(71)90041-7; EMERSON SD, 1990, BIOCHEMISTRY-US, V29, P1545, DOI 10.1021/bi00458a028; HELLER C, 1960, J CHEM PHYS, V32, P1535, DOI 10.1063/1.1730955; HILL CL, 1977, J AM CHEM SOC, V99, P2549, DOI 10.1021/ja00450a024; HO FFL, 1969, ANAL CHEM, V41, P1835, DOI 10.1021/ac60282a008; HOWARD JB, 1991, ADV PROTEIN CHEM, V42, P99199; KARPLUS M, 1963, J AM CHEM SOC, V85, P2870, DOI 10.1021/ja00901a059; KASSNER RJ, 1977, J AM CHEM SOC, V99, P4351, DOI 10.1021/ja00455a024; La Mar G. N., 1973, NMR PARAMAGNETIC MOL, P86; MARION D, 1989, BIOCHEM BIOPH RES CO, V159, P592, DOI 10.1016/0006-291X(89)90035-1; MARKLEY JL, 1986, IRON SULFUR PROTEIN, P167; MARTIN GE, 1988, 2 DIMENSIONAL NMR ME, P58; NAGAYAMA K, 1986, IRON SULFUR PROTEIN, P125; NEUHAUS D, 1989, NUCL OVERHAUSER EFFE, P103; OH BH, 1990, BIOCHEMISTRY-US, V29, P3993, DOI 10.1021/bi00468a029; ORMEJOHNSON NR, 1983, BIOCHIM BIOPHYS ACTA, V748, P68, DOI 10.1016/0167-4838(83)90028-6; OTAKA E, 1987, J MOL EVOL, V26, P257, DOI 10.1007/BF02099857; PACKER EL, 1977, J BIOL CHEM, V252, P2245; PHILLIPS WD, 1973, NMR PARAMAGNETIC MOL, P421; PHILLIPS WD, 1977, IRON SULFUR PROTEINS, VB, P255; POE M, 1970, P NATL ACAD SCI USA, V65, P797, DOI 10.1073/pnas.65.4.797; Rees D. C., 1990, ENZYMES, V19, P38; THANABAL V, 1988, BIOCHEMISTRY-US, V27, P5400, DOI 10.1021/bi00415a003; UNGER SW, 1985, J MAGN RESON, V64, P521, DOI 10.1016/0022-2364(85)90117-9; UNGER SW, 1985, J MAGN RESON, V61, P448, DOI 10.1016/0022-2364(85)90185-4; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P13; YU LPP, 1990, J AM CHEM SOC, V112, P9527, DOI 10.1021/ja00182a012	47	43	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23714	23723						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748648				2022-12-25	WOS:A1991GV31900032
J	GORCZYNSKA, E; HANDELSMAN, DJ				GORCZYNSKA, E; HANDELSMAN, DJ			THE ROLE OF CALCIUM IN FOLLICLE-STIMULATING-HORMONE SIGNAL TRANSDUCTION IN SERTOLI CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR FREE CALCIUM; RECEPTOR-MEDIATED UPTAKE; FUNCTIONAL EXPRESSION; CYCLIC-AMP; FREE CA-2+; RAT-BRAIN; CHANNELS; TESTIS; MODULATION; BINDING	Sertoli cells are hormonally regulated by follicle-stimulating hormone (FSH) acting upon a G-protein-linked cell surface FSH receptor. FSH increases intracellular cyclic AMP but the involvement of other signal transduction mechanisms including intracellular calcium in FSH action are not proven. Using freshly isolated rat Sertoli cells we measured cytosolic free ionized calcium levels by dual-wavelength fluorescence spectrophotometry using the calcium-sensitive fluorescent dye Fura2-AM. The cytosolic calcium concentration in unstimulated Sertoli cells was 89 +/- 2 nm (n = 151 experiments) and was markedly increased by either calcium channel ionophores (ionomycin, Bay K8644) or plasma membrane depolarization consistent with the presence of voltage-sensitive and -independent calcium channel in Sertoli cell membranes. Ovine FSH stimulated a specific, sensitive (ED50, 5.0 ng of S-16/ml), and dose-dependent (maximal at 20 ng/ml) rise in cytosolic calcium commencing within 60 s to reach levels of 192 +/- 31 nm after 180 s and lasting for at least 10 min. The effect of FSH was replicated by forskokin, cholera toxin, and dibutyryl cyclic AMP, suggesting that cyclic AMP may mediate the FSH-induced rise in cytosolic calcium. The FSH-induced rise in cytosolic calcium required extracellular calcium and was abolished by calcium channel blockers specific for dihydropyridine (verapamil, nicardipine), nonvoltage-gated (ruthenium red) or all calcium channels (cobalt). Thus FSH action on Sertoli cells involves a specific, rapid, and sustained increase in cytosolic calcium which requires extracellular calcium and involves both dihydropyridine-sensitive, voltage-gated calcium channels and voltage-independent, receptor-gated calcium channels in the plasma membranes of rat Sertoli cells. The replication by cyclic AMP of the effects of FSH suggests that calcium may be a signal-amplification or -modulating mechanism rather than an alternate primary signal transduction system for FSH in Sertoli cells.	UNIV SYDNEY,DEPT MED,SYDNEY,NSW 2006,AUSTRALIA	University of Sydney	GORCZYNSKA, E (corresponding author), UNIV SYDNEY,DEPT OBSTET & GYNECOL,SYDNEY,NSW 2006,AUSTRALIA.		Handelsman, David/AAR-9580-2021	Handelsman, David/0000-0002-4200-7476				ANDERSEN TT, 1982, J BIOL CHEM, V257, P1551; APFELDORF WJ, 1988, CELL CALCIUM, V9, P71, DOI 10.1016/0143-4160(88)90026-7; Bardin C.W., 1988, P933; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; COOKE BA, 1990, MOL CELL ENDOCRINOL, V69, pC11, DOI 10.1016/0303-7207(90)90081-I; DAGONI F, 1990, BRAIN RES, V530, P261; DAVIDSON J, 1991, MOL CELL ENDOCRINOL, V76, pC33, DOI 10.1016/0303-7207(91)90278-Z; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FLORES JA, 1990, ENDOCRINOLOGY, V127, P3172, DOI 10.1210/endo-127-6-3172; GLOSSMANN H, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1917; GLOSSMANN H, 1985, METHOD ENZYMOL, V109, P513; GODFRAIND T, 1986, PHARMACOL REV, V38, P321; GRASSO P, 1988, MOL ENDOCRINOL, V2, P420, DOI 10.1210/mend-2-5-420; GRASSO P, 1990, ENDOCRINOLOGY, V127, P949, DOI 10.1210/endo-127-2-949; GRASSO P, 1989, ENDOCRINOLOGY, V125, P3029, DOI 10.1210/endo-125-6-3029; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; JOFFRE M, 1988, REPROD NUTR DEV, V28, P1019, DOI 10.1051/rnd:19880703; JOFFRE M, 1988, J PHYSIOL-LONDON, V400, P481, DOI 10.1113/jphysiol.1988.sp017133; KIM HS, 1990, J BIOL CHEM, V265, P11858; KOCH WJ, 1989, FEBS LETT, V250, P386, DOI 10.1016/0014-5793(89)80761-6; LAVOIE PA, 1990, CAN J PHYSIOL PHARM, V68, P1414, DOI 10.1139/y90-215; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MEANS AR, 1980, ANNU REV PHYSIOL, V42, P59, DOI 10.1146/annurev.ph.42.030180.000423; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; MONACO L, 1988, ENDOCRINOLOGY, V123, P2032, DOI 10.1210/endo-123-4-2032; MONACO L, 1989, J STEROID BIOCHEM, V32, P129, DOI 10.1016/0022-4731(89)90153-2; PEONIE M, 1985, NATURE, V315, P147; Pierce J.G., 1988, P1335; QUIRK SM, 1988, ENDOCRINOLOGY, V123, P230, DOI 10.1210/endo-123-1-230; REICHERT LE, 1989, BIOL REPROD, V40, P13, DOI 10.1095/biolreprod40.1.13; ROCHE A, 1989, J REPROD FERTIL, V85, P343, DOI 10.1530/jrf.0.0850343; ROSENBERG RL, 1986, SCIENCE, V231, P1564, DOI 10.1126/science.2420007; SACHS G, 1989, CELL CALCIUM, V10, P265, DOI 10.1016/0143-4160(89)90053-5; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; SULLIVAN MHF, 1986, BIOCHEM J, V236, P45, DOI 10.1042/bj2360045; TERRIAN DM, 1990, NEUROSCI LETT, V119, P211, DOI 10.1016/0304-3940(90)90836-X; TSIEN RY, 1985, CELL CALCIUM, V6, P145, DOI 10.1016/0143-4160(85)90041-7; TUCK RR, 1970, PFLUG ARCH EUR J PHY, V318, P225, DOI 10.1007/BF00593663; WASSERMANN G F, 1990, Medical Science Research, V18, P175	40	80	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23739	23744						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748649				2022-12-25	WOS:A1991GV31900035
J	SHEMER, R; EISENBERG, S; BRESLOW, JL; RAZIN, A				SHEMER, R; EISENBERG, S; BRESLOW, JL; RAZIN, A			METHYLATION PATTERNS OF THE HUMAN APOA-I/C-III/A-IV GENE-CLUSTER IN ADULT AND EMBRYONIC-TISSUES SUGGEST DYNAMIC CHANGES IN METHYLATION DURING DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; ISLANDS	We describe here a detailed analysis of the methylation patterns of the apoC-III and apoA-IV genes in adult and embryonic tissues. Together with previously reported data on the human apoA-I gene (4), the results presented here constitute a comprehensive study on the methylation pattern of the apoA-I/C-III/A-IV gene cluster. The two genes (apoC-III and apoA-IV) display tissue-specific methylation patterns that correlate with their activity. This gene-specific methylation pattern indicates that the apoA-I/C-III/A-IV gene cluster is not one entity with respect to methylation. The cluster is almost entirely methylated in tissues that do not express any of the genes; however, individual gene regions are unmethylated in the tissue of expression. A comparison of the observed methylation patterns in adult tissues with those in embryonic tissues suggests that the mature tissue-specific methylation patterns are a result of an interplay between demethylation and de novo methylation events in the embryo. These changes in DNA methylation include demethylation in the early embryo followed by de novo methylation at later stages. A second round of tissue-specific demethylation and methylation de novo occurs in the late embryo as well. Evidence presented here supports the idea that CpG islands are protected in general from methylation de novo by a built-in signal and not by CpG density per se.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT CELLULAR BIOCHEM,IL-91010 JERUSALEM,ISRAEL; ROCKEFELLER UNIV,DEPT BIOCHEM GENET & METAB,NEW YORK,NY 10021; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT INTERNAL MED B,IL-91010 JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Rockefeller University; Hebrew University of Jerusalem	RAZIN, A (corresponding author), HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT CELLULAR BIOCHEM,IL-91010 JERUSALEM,ISRAEL.		Breslow, Jan L/B-7544-2008		NIGMS NIH HHS [GM 20483] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRESLOW JL, 1988, PHYSIOL REV, V68, P85, DOI 10.1152/physrev.1988.68.1.85; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CEDAR H, 1990, BIOCHIM BIOPHYS ACTA, V1049, P1, DOI 10.1016/0167-4781(90)90076-E; FRANK D, 1991, NATURE, V351, P239, DOI 10.1038/351239a0; KARATHANASIS SK, 1983, P NATL ACAD SCI-BIOL, V80, P6147, DOI 10.1073/pnas.80.20.6147; KARATHANASIS SK, 1986, BIOCHEMISTRY-US, V25, P3962, DOI 10.1021/bi00361a034; KOLSTO AB, 1986, NUCLEIC ACIDS RES, V14, P9667; LEVYWILSON B, 1989, J BIOL CHEM, V264, P9891; LOYD J, 1987, GENE DEV, V1, P594; MONK M, 1987, DEVELOPMENT, V99, P371; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; SHEMER R, 1990, J BIOL CHEM, V265, P1010; SHEMER R, 1991, IN PRESS P NATL ACAD; SZYF M, 1990, MOL CELL BIOL, V10, P4396, DOI 10.1128/MCB.10.8.4396; YISRAELI J, 1984, DNA METHYLATION BIOC, P353; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028	18	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23676	23681						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748645				2022-12-25	WOS:A1991GV31900027
J	ZINN, SA; EBERT, KM; MEHTA, ND; JOSHI, J; KILPATRICK, DL				ZINN, SA; EBERT, KM; MEHTA, ND; JOSHI, J; KILPATRICK, DL			SELECTIVE TRANSCRIPTION OF RAT PROENKEPHALIN FUSION GENES FROM THE SPERMATOGENIC CELL-SPECIFIC PROMOTER IN TESTIS OF TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE PROMOTER; TISSUE-SPECIFIC EXPRESSION; BETA-GLOBIN GENES; MESSENGER-RNA; SOMATIC-CELLS; GERM-CELLS; KINASE; INITIATION; SEQUENCE; ELEMENT	The rat and mouse proenkephalin genes each contains two distinct promoters, one of which is utilized exclusively by spermatogenic cells. The germ cell-specific promoter lacks TATA sequences, is G+C rich, and contains multiple initiation sites. To investigate the nature of the cis-acting elements that determine selective transcription of the proenkephalin gene in male germ cells, two rat proenkephalin-chloramphenicol acetyltransferase fusion genes containing the two different promoter regions as well as 1.6 or 0.3 kilobases, respectively, of 5'-flanking sequence were expressed in transgenic mice. Multiple transgenic lines were developed which expressed the fusion genes in testis, brain, and heart but not in tissues that do not normally express the proenkephalin gene. Fusion gene transcripts in transgenic mouse testes were localized to those spermatogenic cell types that utilize the spermatogenic cell promoter and were selectively and accurately initiated from the multiple rat germ cell start sites. Transgenic mice thus provide a useful model for the localization and characterization of cis-acting elements mediating transcription of the proenkephalin gene from its germ cell-specific promoter.	WORCESTER FDN EXPTL BIOL INC,NEUROBIOL GRP,222 MAPLE AVE,SHREWSBURY,MA 01545; NIH,BIOCHEM GENET LAB,BETHESDA,MD 20205; TUFTS UNIV,SCH VET MED,DEPT ANAT & CELL BIOL,N GRAFTON,MA 01536; TUFTS UNIV,SCH MED & DENT MED,DEPT ANAT & CELL BIOL,N GRAFTON,MA 01536	Worcester Foundation for Biomedical Research; National Institutes of Health (NIH) - USA; Tufts University; Tufts University	KILPATRICK, DL (corresponding author), WORCESTER FDN EXPTL BIOL INC,NEUROBIOL GRP,222 MAPLE AVE,SHREWSBURY,MA 01545, USA.				NIDDK NIH HHS [DK-36468] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036468] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOER PH, 1987, MOL CELL BIOL, V7, P3107, DOI 10.1128/MCB.7.9.3107; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; GARRETT JE, 1989, MOL ENDOCRINOL, V3, P2093, DOI 10.1210/mend-3-12-2093; GARRITY PA, 1990, MOL CELL BIOL, V10, P5646, DOI 10.1128/MCB.10.11.5646; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; Hecht NB., 1986, EXPT APPROACHES MAMM, P151; HOGAN B, 1986, MANIPULATING MOUSE E, P174; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; HOWELLS RD, 1986, P NATL ACAD SCI USA, V83, P1960, DOI 10.1073/pnas.83.6.1960; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INGRAHAM HA, 1986, MOL CELL BIOL, V6, P2923, DOI 10.1128/MCB.6.8.2923; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KEIME S, 1990, EUR J BIOCHEM, V190, P195, DOI 10.1111/j.1432-1033.1990.tb15564.x; KEW D, 1990, P NATL ACAD SCI USA, V87, P1943; KHILLAN JS, 1986, P NATL ACAD SCI USA, V83, P725, DOI 10.1073/pnas.83.3.725; KILPATRICK DL, 1990, MOL CELL BIOL, V10, P3717, DOI 10.1128/MCB.10.7.3717; KILPATRICK DL, 1987, P NATL ACAD SCI USA, V84, P5695, DOI 10.1073/pnas.84.16.5695; KILPATRICK DL, 1985, P NATL ACAD SCI USA, V82, P7467, DOI 10.1073/pnas.82.21.7467; KILPATRICK DL, 1986, P NATL ACAD SCI USA, V83, P5015, DOI 10.1073/pnas.83.14.5015; KOLLIAS G, 1986, CELL, V46, P89, DOI 10.1016/0092-8674(86)90862-7; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGRAM J, 1985, NATURE, V315, P338, DOI 10.1038/315338a0; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MEEKER TC, 1990, MOL CELL BIOL, V10, P1680, DOI 10.1128/MCB.10.4.1680; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PESCHON JJ, 1987, P NATL ACAD SCI USA, V84, P5316, DOI 10.1073/pnas.84.15.5316; ROBINSON MO, 1989, P NATL ACAD SCI USA, V86, P8437, DOI 10.1073/pnas.86.21.8437; SAKIMURA K, 1987, GENE, V60, P103, DOI 10.1016/0378-1119(87)90218-6; SCHIBLER U, 1987, ANNU REV GENET, V21, P237, DOI 10.1146/annurev.ge.21.120187.001321; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STEWART TA, 1988, MOL CELL BIOL, V8, P1748, DOI 10.1128/MCB.8.4.1748; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; TOWNES TM, 1985, EMBO J, V4, P1715, DOI 10.1002/j.1460-2075.1985.tb03841.x; VIBERT M, 1989, EUR J BIOCHEM, V181, P33, DOI 10.1111/j.1432-1033.1989.tb14690.x; VIRBASIUS JV, 1988, J BIOL CHEM, V263, P6791; WANG XM, 1990, EMBO J, V9, P783, DOI 10.1002/j.1460-2075.1990.tb08174.x; WILKIE TM, 1986, DEV BIOL, V118, P9, DOI 10.1016/0012-1606(86)90068-0; WILLISON K, 1987, TRENDS GENET, V3, P351, DOI 10.1016/0168-9525(87)90296-4; YOSHIKAWA K, 1988, BIOCHEM BIOPH RES CO, V151, P664, DOI 10.1016/S0006-291X(88)80332-2	43	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23850	23855						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748659				2022-12-25	WOS:A1991GV31900051
J	NAH, HD; UPHOLT, WB				NAH, HD; UPHOLT, WB			TYPE-II COLLAGEN MESSENGER-RNA CONTAINING AN ALTERNATIVELY SPLICED EXON PREDOMINATES IN THE CHICK LIMB PRIOR TO CHONDROGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL PROPEPTIDE; PROCOLLAGEN GENE; CARTILAGE DIFFERENTIATION; INSITU HYBRIDIZATION; PROMOTER REGION; CDNA CLONES; V COLLAGEN; 1ST INTRON; EXPRESSION; DOMAIN	A series of cDNA clones corresponding to the 5' end of the chicken type II collagen mRNA were generated using a single-sided polymerase chain reaction technique. Analysis of these cDNAs showed that the second exon of the gene is alternatively spliced such that it is either present or absent in the mRNA. This exon encodes a 70-amino acid cysteine-rich globular domain which is present in the amino-terminal propeptides of alpha-1(I), alpha-1(III), and alpha-2(V) procollagen chains but which was previously thought to be absent from type II procollagen. Analysis of the expression of the two alternatively spliced forms of the chicken type II collagen mRNA showed that the mRNA without the second exon was the predominant form (approximately 90%) in sternal cartilage from 14-day embryos, but in pre-cartilage limb mesenchyme only the form including the second exon was detected. This later form was also present in a number of non-cartilage tissues including embryonic calvaria, skin, heart, skeletal muscle, and brain; no type II collagen mRNA was detected in liver. Studies of developing limbs from progressive embryonic stages suggest that the appearance of the mRNA lacking the second exon is a relatively late event during chondrogenesis.	UNIV CONNECTICUT,CTR HLTH,SCH DENT MED,DEPT BIOSTRUCT & FUNCT,FARMINGTON,CT 06030	University of Connecticut					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD022610, R55HD022896, R01HD022896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007131] Funding Source: NIH RePORTER; NICHD NIH HHS [HD22896, HD22610] Funding Source: Medline; NIDCR NIH HHS [DE07131] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BALDWIN CT, 1989, BIOCHEM J, V262, P521, DOI 10.1042/bj2620521; BENNETT VD, 1991, J BIOL CHEM, V266, P5918; BENSONCHANDA V, 1989, GENE, V78, P255, DOI 10.1016/0378-1119(89)90228-X; BERNARD M, 1988, J BIOL CHEM, V263, P17159; BURGESON RE, 1982, J BIOL CHEM, V257, P7852; CHEAH KSE, 1991, DEVELOPMENT, V111, P945; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU ML, 1984, NATURE, V310, P337, DOI 10.1038/310337a0; CURRAN S, 1982, BIOCHEMISTRY-US, V21, P1482, DOI 10.1021/bi00536a003; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINER MH, 1987, J BIOL CHEM, V262, P13323; FITCH JM, 1989, DEVELOPMENT, V105, P85; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUROTO DK, 1983, ARCH BIOCHEM BIOPHYS, P604; GILMAN M, 1987, CURRENT PROTOCOLS MO; KIMURA T, 1988, BIOMED RES-TOKYO, V9, P319, DOI 10.2220/biomedres.9.319; KOHNO K, 1985, J BIOL CHEM, V260, P4441; KOHNO K, 1984, J BIOL CHEM, V259, P3668; KOSHER RA, 1989, DEV BIOL, V131, P558, DOI 10.1016/S0012-1606(89)80026-0; KOSHER RA, 1986, DEV BIOL, V118, P112, DOI 10.1016/0012-1606(86)90078-3; KOSHER RA, 1986, J CELL BIOL, V102, P1151, DOI 10.1083/jcb.102.4.1151; KRAVIS D, 1985, DEV BIOL, V108, P164, DOI 10.1016/0012-1606(85)90018-1; KUHN K, 1982, CONNECT TISSUE RES, V10, P43, DOI 10.3109/03008208209034405; KULYK WM, 1991, MATRIX, V11, P282, DOI 10.1016/S0934-8832(11)80236-2; LIAU G, 1985, J BIOL CHEM, V260, P531; LOVELLBADGE RH, 1987, P NATL ACAD SCI USA, V84, P2803, DOI 10.1073/pnas.84.9.2803; MALLEINGERIN F, 1990, ROUX ARCH DEV BIOL, V198, P363, DOI 10.1007/BF00383774; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCDONALD SA, 1989, DEV BIOL, V133, P221, DOI 10.1016/0012-1606(89)90313-8; MINA M, 1991, IN PRESS DIFFERENTIA; NAH HD, 1988, COLLAGEN REL RES, V8, P277; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; NUNEZ AM, 1986, GENE, V44, P11, DOI 10.1016/0378-1119(86)90037-5; PAGLIA LM, 1981, BIOCHEMISTRY-US, V20, P3523, DOI 10.1021/bi00515a034; ROWE DW, 1978, BIOCHEMISTRY-US, V17, P1581, DOI 10.1021/bi00602a001; RYAN MC, 1990, J BIOL CHEM, V265, P10334; RYAN MC, 1990, GENOMICS, V8, P41, DOI 10.1016/0888-7543(90)90224-I; Sambrook J, 1989, MOL CLONING LABORATO; SANDELL LJ, 1984, J BIOL CHEM, V259, P7826; SANDELL LJ, 1990, EXTRACELLULAR MATRIX, P1; SANGIORGI FO, 1985, NUCLEIC ACIDS RES, V13, P2207, DOI 10.1093/nar/13.7.2207; SU MW, 1989, GENOMICS, V4, P438, DOI 10.1016/0888-7543(89)90353-4; SWALLA BJ, 1988, DEV BIOL, V125, P51, DOI 10.1016/0012-1606(88)90057-7; THOM JR, 1991, J BIOL CHEM, V266, P7262; THOROGOOD P, 1986, DEV BIOL, V116, P497, DOI 10.1016/0012-1606(86)90150-8; TIMPL R, 1981, CLIN ORTHOP RELAT R, V158, P224; UPHOLT WB, 1986, P NATL ACAD SCI USA, V83, P2325, DOI 10.1073/pnas.83.8.2325; VERTEL BM, 1976, SCANNING ELECTRON MI, P291; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; VUORIO E, 1982, NUCLEIC ACIDS RES, V10, P1175, DOI 10.1093/nar/10.4.1175; WIESTNER M, 1979, J BIOL CHEM, V254, P7016; WOOD A, 1991, DEVELOPMENT, V111, P955; WOODBURY D, 1989, J BIOL CHEM, V264, P2735; YAMADA Y, 1984, NATURE, V310, P333, DOI 10.1038/310333a0; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423	56	81	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23446	23452						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744138				2022-12-25	WOS:A1991GT48300100
J	TRIMBLE, RB; ATKINSON, PH; TSCHOPP, JF; TOWNSEND, RR; MALEY, F				TRIMBLE, RB; ATKINSON, PH; TSCHOPP, JF; TOWNSEND, RR; MALEY, F			STRUCTURE OF OLIGOSACCHARIDES ON SACCHAROMYCES SUC2 INVERTASE SECRETED BY THE METHYLOTROPHIC YEAST PICHIA-PASTORIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-EXCHANGE CHROMATOGRAPHY; PULSED-AMPEROMETRIC DETECTION; N-LINKED OLIGOSACCHARIDES; EXTERNAL INVERTASE; ALPHA-MANNOSIDASE; CEREVISIAE; GLYCOSYLATION; SPECTROSCOPY; EXPRESSION; SEPARATION	Saccharomyces SUC2 invertase, secreted by the methylotrophic yeast Pichia pastoris and purified to homogeneity from the growth medium by DE-52 chromatography, appeared on sodium dodecyl sulfate-polyacrylamide gel electrophoresis as a diffuse ladder of species at 85-90 kDa, while the secreted Saccharomyces form migrated as a broad band from 100 to 150 kDa. Endo-beta-N-acetylglucosaminidase H released the Pichia invertase carbohydrate generating a 60-kDa protein with residual Asn-linked GlcNAcs and oligosaccharides separated on Bio-Gel P-4 into Man8-11GlcNAc. Nearly 75% of the oligosaccharides were equally distributed between Man8,9GlcNAc, while 17% were Man10GlcNAc and 8% were Man11GlcNAc. Oligosaccharide pools were analyzed for homogeneity by high-pH anion-exchange chromatography, and structures were assigned using 500 MHz one- and two-dimensional H-1 NMR spectroscopy. Pichia Man8GlcNAc was the same isomer as found in Saccharomyces, which arises by removing the alpha-1,2-linked terminal mannose from the middle arm of the lipid-oligosaccharide Man9GlcNAc (Byrd, J. C., Tarentino, A. L., Maley, F., Atkinson, P. H., and Trimble, R. B. (1982) J. Biol. Chem. 257, 14657-14666). The Man9GlcNAc pool was 5% lipid-oligosaccharide precursor and 95% Man8GlcNAc isomer with a terminal alpha-1,6-linked mannose on the lower-arm alpha-1,3-core-linked residue (Hernandez, L. M., Ballou, L., Alvarado, E., Gillece-Castro, B. L., Burlingame, A. L., and Ballou, C. E. (1989) J. Biol. Chem. 264, 11849-11856). An alpha-1,2-linked mannose on the new alpha-1,6-linked branch in Man9GlcNAc provided 80% of the Man10GlcNAc, which is the structure on Saccharomyces invertase (Trimble, R. B., and Atkinson, P. H. (1986) J. Biol. Chem. 261, 9815-9824). A minor Man10GlcNAc (12%) and the principal Man11GlcNAc (82%) were the major Man9,10GlcNAc with novel alpha-1,2-linked mannoses on the preexisting alpha-1,2-linked termini. Although Pichia glycans did not have terminal alpha-1,3-linked mannoses as found on Saccharomyces core oligosaccharides, over 60% of the structures were isometric configurations unique to lower eukaryotes.	SUNY ALBANY, SCH PUBL HLTH, ALBANY, NY 12201 USA; SIBIA CORP, LA JOLLA, CA 92037 USA; MINIST AGR & FISHERIES, WALLACEVILLE ANIM RES CTR, UPPER HUTT, NEW ZEALAND; UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany; AgResearch - New Zealand; University of California System; University of California San Francisco	TRIMBLE, RB (corresponding author), NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, POB 509, ALBANY, NY 12201 USA.				NATIONAL CANCER INSTITUTE [R01CA013402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031376] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023900] Funding Source: NIH RePORTER; NCI NIH HHS [CA13402] Funding Source: Medline; NIDDK NIH HHS [DK31376] Funding Source: Medline; NIGMS NIH HHS [GM23900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVARADO E, 1990, BIOCHEMISTRY-US, V29, P2471, DOI 10.1021/bi00462a006; BYRD JC, 1982, J BIOL CHEM, V257, P4657; COHEN RE, 1980, BIOCHEMISTRY-US, V19, P4345, DOI 10.1021/bi00559a031; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; ESMON B, 1984, J BIOL CHEM, V259, P322; GRINNA LS, 1989, YEAST, V5, P107, DOI 10.1002/yea.320050206; HARDY MR, 1989, CARBOHYD RES, V188, P1, DOI 10.1016/0008-6215(89)84052-2; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HERNANDEZ LM, 1990, CARBOHYD RES, V203, P1, DOI 10.1016/0008-6215(90)80040-A; HERNANDEZ LM, 1989, J BIOL CHEM, V264, P13648; JELINEKKELLY S, 1988, J BIOL CHEM, V263, P14757; JELINEKKELLY S, 1985, J BIOL CHEM, V260, P2253; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NEUMANN NP, 1967, BIOCHEMISTRY-US, V6, P468, DOI 10.1021/bi00854a015; REDDY VA, 1988, J BIOL CHEM, V263, P6978; Rendlema J., 1973, ADV CHEM SER, V117, P51; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; TOWNSEND RR, 1991, CARBOHYD RES, V215, P211, DOI 10.1016/0008-6215(91)84021-6; TRIMBLE RB, 1980, J BIOL CHEM, V255, P232; TRIMBLE RB, 1986, J BIOL CHEM, V261, P9815; TRIMBLE RB, 1977, J BIOL CHEM, V252, P4409; TRUMBLY RJ, 1985, J BIOL CHEM, V260, P5683; TSCHOPP JF, 1987, NUCLEIC ACIDS RES, V15, P3859, DOI 10.1093/nar/15.9.3859; TSCHOPP JF, 1987, BIO-TECHNOL, V5, P1305, DOI 10.1038/nbt1287-1305; VEROSTEK MF, 1991, J BIOL CHEM, V266, P5547; WANG WT, 1990, ANAL BIOCHEM, V190, P182, DOI 10.1016/0003-2697(90)90178-C; WILLIAMS RS, 1985, J BIOL CHEM, V260, P3334; ZIEGLER FD, 1988, J BIOL CHEM, V263, P6986	29	139	162	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22807	22817						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744075				2022-12-25	WOS:A1991GT48300009
J	PEAKE, P; BASTEN, A; BRITTON, WJ				PEAKE, P; BASTEN, A; BRITTON, WJ			CHARACTERIZATION OF THE FUNCTIONAL-PROPERTIES OF THE 70-KDA PROTEIN OF MYCOBACTERIUM-BOVIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAK; T-CELL RESPONSES; LEPRAE; ANTIGEN; TUBERCULOSIS; ATPASE; HSP70; MITOCHONDRIA; REPLICATION; NUCLEOTIDE	A number of mycobacterial proteins have been shown to induce strong humoral and cellular immune responses, including the 70-kDa antigen (p70) of Mycobacterium leprae and Mycobacterium bovis. On the basis of sequence homology and an ATP binding ability, p70 has previously been tentatively allocated to the 70-kDa family of heat shock proteins (hsp70). We have purified the M. bovis p70 antigen and described ATPase and Ca2+-dependent autophosphorylating activities. These co-purified with p70 on gel chromatography and were up-regulated by native proteins and down-regulated by peptides. Inhibitory peptides were shown to bind p70. These data imply close functional similarities of mycobacterial p70 to other members of the hsp70 family, the Escherichia coli homologue dnaK in particular.			PEAKE, P (corresponding author), UNIV SYDNEY,CENTENARY INST,SYDNEY,NSW 2006,AUSTRALIA.							ADAMS E, 1989, CLIN EXP IMMUNOL, V80, P206; AMIRSHAPIRA D, 1990, P NATL ACAD SCI USA, V87, P1749, DOI 10.1073/pnas.87.5.1749; ANDERSEN AB, 1990, J GEN MICROBIOL, V136, P477, DOI 10.1099/00221287-136-3-477; BRITTON WJ, 1986, J EXP MED, V164, P695, DOI 10.1084/jem.164.3.695; BRITTON WJ, 1985, J IMMUNOL, V135, P4171; CEGIELSKA A, 1989, J BIOL CHEM, V264, P21122; ENGERS HD, 1985, INFECT IMMUN, V48, P603; ENGERS HD, 1986, INFECT IMMUN, V51, P718; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GARSIA RJ, 1989, INFECT IMMUN, V57, P204, DOI 10.1128/IAI.57.1.204-212.1989; GRAY PW, 1983, NATURE, V298, P8859; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; LAMB FI, 1988, INFECT IMMUN, V56, P1237, DOI 10.1128/IAI.56.5.1237-1241.1988; LEUSTEK T, 1989, P NATL ACAD SCI USA, V86, P7805, DOI 10.1073/pnas.86.20.7805; MCKENZIE KR, 1991, J IMMUNOL, V147, P312; MUNK ME, 1988, EUR J IMMUNOL, V18, P1835, DOI 10.1002/eji.1830181128; OFTUNG F, 1990, J IMMUNOL, V144, P1478; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SHENOLIKAR S, 1988, FASEB J, V2, P2753, DOI 10.1096/fasebj.2.12.2842213; THANGARAJ HS, 1989, NUCLEIC ACIDS RES, V17, P8378, DOI 10.1093/nar/17.20.8378; YOUNG D, 1988, P NATL ACAD SCI USA, V85, P4267, DOI 10.1073/pnas.85.12.4267; YOUNG DB, 1987, IMMUNOL TODAY, V8, P215, DOI 10.1016/0167-5699(87)90168-X; YOUNG RA, 1985, NATURE, V316, P450, DOI 10.1038/316450a0; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	27	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20828	20832						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1834649				2022-12-25	WOS:A1991GN00100039
J	DORING, V; SCHLEICHER, M; NOEGEL, AA				DORING, V; SCHLEICHER, M; NOEGEL, AA			DICTYOSTELIUM ANNEXIN-VII (SYNEXIN) - CDNA SEQUENCE AND ISOLATION OF A GENE DISRUPTION MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE PROTEIN; CALCIUM-CHANNEL ACTIVITY; MONOCLONAL-ANTIBODIES; ANTICOAGULANT PROTEIN; OCTOPUS RHODOPSIN; MEMBRANE-BINDING; RECEPTOR KINASE; MESSENGER-RNA; DISCOIDEUM; DNA	By cloning the cDNA coding for the membrane associated actin-binding protein p24, we identified a repetitive sequence motif consisting of the amino acids Gly, Tyr, Pro, Gln which is characteristic for a gene family in Dictyostelium discoideum. Using a cDNA probe corresponding to this motif, we isolated cDNA clones coding for a protein of the annexin family. On the basis of a long NH2-terminal sequence encompassing the Gly/Tyr/Pro/Gln motifs, the Dictyostelium annexin was identified as a homolog of vertebrate annexin VII (synexin). The mRNA coding for the Dictyostelium annexin VII has a size of 1.6 kilobases and is present during all developmental stages. Annexin VII is coded for by a single gene in Dictyostelium. A mutant deficient in annexin VII was isolated using a vector which carried the amino-terminal third of the Dictyostelium annexin VII cDNA followed by a viral epitope specific for a monoclonal antibody and a stop codon. Using this approach, homologous recombination in the annexin VII gene led to an expression of the viral epitope under the control of the endogenous annexin VII promoter. Lack of annexin VII is not a lethal event for D. discoideum, and the cells are able to undergo development on agar plates.	MAX PLANCK INST BIOCHEM,KLOPFERSPITZ 18A,W-8033 MARTINSRIED,GERMANY	Max Planck Society								BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BUCKLEY KM, 1987, J CELL BIOL, V105, P2447, DOI 10.1083/jcb.105.6.2447; BURNS AL, 1989, P NATL ACAD SCI USA, V86, P3798, DOI 10.1073/pnas.86.10.3798; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CIRINO G, 1989, P NATL ACAD SCI USA, V86, P3428, DOI 10.1073/pnas.86.9.3428; CIRINO G, 1987, NATURE, V328, P270, DOI 10.1038/328270a0; CLAVIEZ M, 1982, EMBO J, V1, P1017, DOI 10.1002/j.1460-2075.1982.tb01287.x; CREUTZ CE, 1978, J BIOL CHEM, V253, P2858; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; CRUMPTON MJ, 1990, NATURE, V345, P212, DOI 10.1038/345212a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORING V, 1990, J CELL BIOL, V111, P77; DOWLING LG, 1985, BIOCHEM BIOPH RES CO, V132, P382, DOI 10.1016/0006-291X(85)91033-2; EINBERGER H, 1990, J VIROL, V64, P4274, DOI 10.1128/JVI.64.9.4274-4280.1990; FAVA RA, 1984, J BIOL CHEM, V259, P2636; GEISOW MJ, 1986, TRENDS BIOCHEM SCI, V11, P420, DOI 10.1016/0968-0004(86)90176-3; GERKE V, 1991, J BIOL CHEM, V266, P1697; GERKE V, 1990, STIMULUS RESPONSE CO, P311; GLENNEY J, 1986, P NATL ACAD SCI USA, V83, P4258, DOI 10.1073/pnas.83.12.4258; GRUNDMANN U, 1988, P NATL ACAD SCI USA, V85, P3708, DOI 10.1073/pnas.85.11.3708; HARLOFF C, 1989, GENE DEV, V3, P2011, DOI 10.1101/gad.3.12a.2011; HONG K, 1982, P NATL ACAD SCI-BIOL, V79, P4642, DOI 10.1073/pnas.79.15.4642; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; HUBER R, 1990, FEBS LETT, V275, P15, DOI 10.1016/0014-5793(90)81428-Q; IWASAKI A, 1987, J BIOCHEM, V102, P1261, DOI 10.1093/oxfordjournals.jbchem.a122165; JOHNSTON PA, 1990, J BIOL CHEM, V265, P11382; KARASIK A, 1988, J BIOL CHEM, V263, P11862; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; LACOMBE ML, 1986, J BIOL CHEM, V261, P6811; LEUBE RE, 1987, EMBO J, V6, P3261, DOI 10.1002/j.1460-2075.1987.tb02644.x; LIN HC, 1985, ANAL BIOCHEM, V147, P114, DOI 10.1016/0003-2697(85)90016-8; MANIATIS T, 1982, MOL CLONING LAB MANU; MATSUSHIMA N, 1990, PROTEINS, V7, P125, DOI 10.1002/prot.340070204; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; NEWELL PC, 1969, J BACTERIOL, V100, P763, DOI 10.1128/JB.100.2.763-768.1969; NOEGEL A, 1985, EMBO J, V4, P3805, DOI 10.1002/j.1460-2075.1985.tb04151.x; NOEGEL AA, 1990, FEBS LETT, V266, P118, DOI 10.1016/0014-5793(90)81521-O; OVCHINNIKOV YA, 1988, FEBS LETT, V232, P69, DOI 10.1016/0014-5793(88)80388-0; POLLARD HB, 1988, P NATL ACAD SCI USA, V85, P2974, DOI 10.1073/pnas.85.9.2974; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH VL, 1990, CELL REGUL, V1, P165, DOI 10.1091/mbc.1.2.165; SPUDICH JA, 1989, CELL REGUL, V1, P1; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; WHITBREAD JA, 1991, DEV GENET, V12, P78, DOI 10.1002/dvg.1020120114; WILLIAMS KL, 1976, GENETICS, V82, P287; WITKE W, 1987, EMBO J, V6, P4143, DOI 10.1002/j.1460-2075.1987.tb02760.x	47	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17509	17515						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1832674				2022-12-25	WOS:A1991GF44500079
J	RAO, US; HENNESSEY, JP; SCARBOROUGH, GA				RAO, US; HENNESSEY, JP; SCARBOROUGH, GA			IDENTIFICATION OF THE MEMBRANE-EMBEDDED REGIONS OF THE NEUROSPORA-CRASSA PLASMA-MEMBRANE H+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYVINYLIDENE DIFLUORIDE MEMBRANES; CARBENE-GENERATING REAGENT; AMINO-ACID RESIDUES; PROTEIN; SEQUENCE; 3-(TRIFLUOROMETHYL)-3-(META-<I-125>IODOPHENYL)DIAZIRINE; 3-(TRIFLUOROMETHYL)-3-(M-<I-125>IODOPHENYL)DIAZIRINE; TOPOLOGY	Reconstituted proteoliposomes containing functional Neurospora crassa plasma membrane H+-ATPase molecules oriented predominantly with their cytoplasmic surface exposed were treated with trypsin and then subjected to Sepharose CL-6B column chromatography to remove the liberated peptides. The peptides remaining associated with the liposomes were then separated from the phospholipid by Sephadex LH-60 column chromatography and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Six H+-ATPase peptides with approximate molecular masses of 7, 7.5, 8, 10, 14, and 21 kDa were found to be tightly associated with the liposomal membrane. Amino acid sequencing of the 7-, 7.5-, and 21-kDa peptides in the LH-60 eluate identified them as H+-ATPase fragments beginning at residues 99 or 100, 272, and 660, respectively. After further purification, the approximately 10- and 14-kDa peptides were also similarly identified as beginning at residues 272 and 660. The approximately 8-kDa fragment was purified further but could not be sequenced, presumably indicating NH2-terminal blockage. To identify which of the liposome-associated peptides are embedded in the membrane, H+-ATPase molecules in the proteoliposomes were labeled from the hydrophobic membrane interior with 3-(trifluoromethyl)3-(m-[I-125] iodophenyl)diazirine and cleaved with trypsin, after which the membrane-associated peptides were purified and assessed for the presence of label. The results indicate that the approximately 7-, 7.5-, and 21-kDa peptides are in contact with the lipid bilayer whereas the approximately 8-kDa peptide is not. Taken together with the results of our recent analyses of the peptides released from the proteoliposomes, this information establishes the transmembrane topography of nearly all of the 919 residues in the H+-ATPase molecule.	UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Hennessey, John/0000-0003-2252-0421	NIGMS NIH HHS [GM24784, GM32166] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024784, R55GM024784, R01GM032166] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON R, 1986, J BIOL CHEM, V261, P4896; Andersen JP, 1990, CURR OPIN CELL BIOL, V2, P722, DOI 10.1016/0955-0674(90)90116-V; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRUNNER J, 1980, J BIOL CHEM, V255, P3313; BRUNNER J, 1985, BIOCHEMISTRY-US, V24, P5422, DOI 10.1021/bi00341a021; BRUNNER J, 1981, BIOCHEMISTRY-US, V20, P7174, DOI 10.1021/bi00528a019; BRUNNER J, 1983, METHOD ENZYMOL, V96, P386; FRIELLE T, 1982, J BIOL CHEM, V257, P4979; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HENNESSEY JP, 1989, ANAL BIOCHEM, V176, P284, DOI 10.1016/0003-2697(89)90310-2; HENNESSEY JP, 1990, J BIOL CHEM, V265, P532; HENNESSEY JP, 1988, J CELL BIOL, V107, P124; HOPPE J, 1984, BIOCHEMISTRY-US, V23, P5610, DOI 10.1021/bi00318a035; KRATZIN HD, 1989, ANAL BIOCHEM, V183, P1, DOI 10.1016/0003-2697(89)90161-9; KREBS J, 1984, BIOCHEMISTRY-US, V23, P400, DOI 10.1021/bi00298a002; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEISTER H, 1985, J BIOL CHEM, V260, P6326; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; PATTERSON MS, 1965, ANAL CHEM, V37, P854, DOI 10.1021/ac60226a017; RAO US, 1990, J BIOL CHEM, V265, P7227; RAO US, 1988, ANAL BIOCHEM, V173, P251, DOI 10.1016/0003-2697(88)90187-X; SCARBOROUGH GA, 1990, J BIOL CHEM, V265, P16145; SCARBOROUGH GA, 1988, METHOD ENZYMOL, V157, P574; Schulz G. E., 1979, PRINCIPLES PROTEIN S; SILVER S, 1989, TRENDS BIOCHEM SCI, V14, P76, DOI 10.1016/0968-0004(89)90048-0; SMITH R, 1984, ANAL BIOCHEM, V138, P156, DOI 10.1016/0003-2697(84)90784-X	26	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14740	14746						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1830591				2022-12-25	WOS:A1991FZ35100097
J	TAGUCHI, H; OHTA, T				TAGUCHI, H; OHTA, T			D-LACTATE DEHYDROGENASE IS A MEMBER OF THE D-ISOMER-SPECIFIC 2-HYDROXYACID DEHYDROGENASE FAMILY - CLONING, SEQUENCING, AND EXPRESSION IN ESCHERICHIA-COLI OF THE D-LACTATE DEHYDROGENASE GENE OF LACTOBACILLUS-PLANTARUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; D-2-HYDROXYISOCAPROATE DEHYDROGENASE; LACTIC DEHYDROGENASES; LIMULUS-POLYPHEMUS; CASEI; ACID; DNA; PROTEINS; BINDING	The gene encoding D-lactate dehydrogenase (D-lactate: NAD+ oxidoreductase, EC 1.1.1.28) of Lactobacillus plantarum has been sequenced, and expressed in Escherichia coli cells with an inducible expression plasmid, in which the 5'-noncoding region of the gene was replaced with the tac promoter. Comparison of the sequence Of D-lactate dehydrogenase with L-lactate dehydrogenases, including the L. plantarum L-lactate dehydrogenase, showed no significant homology. In contrast, the D-lactate dehydrogenase is homologous to E. coli D-3-phosphoglycerate dehydrogenase and Lactobacillus casei D-2-hydroxyisocaproate dehydrogenase. This indicates that D-lactate dehydrogenase is a member of a new family of 2-hydroxyacid dehydrogenases recently proposed, being distinct from L-lactate dehydrogenase and L-malate dehydrogenase, and strongly suggests that the new family consists Of D-iSomer-stereospecific enzymes. In the reductive reaction, the enzyme showed a broad substrate specificity, although pyruvate was the most favorable of all 2-ketocarboxylic acids tested. In particular, hydroxypyruvate is effectively reduced by the enzyme, the reaction rate, and K(m) value being comparable to those in the case of pyruvate, indicating that the enzyme has not only D-lactate dehydrogenase activity but also D-glycerate dehydrogenase activity. The conserved residues in this family appear to be the residues involved in the substrate binding and the catalytic reaction, and thus to be targets for site-directed mutagenesis.			TAGUCHI, H (corresponding author), UNIV TOKYO,DEPT AGR CHEM,BUNKYO KU,TOKYO 113,JAPAN.			Taguchi, Hayao/0000-0001-5270-581X				BIRKTOFT JJ, 1983, J BIOL CHEM, V258, P472; BIRSTOFT JJ, 1982, P NATL ACAD SCI USA, V79, P6166; CLARKE AR, 1988, BIOCHEMISTRY-US, V27, P1617, DOI 10.1021/bi00405a034; DE MAN J. C., 1960, JOUR APPL BACT, V23, P130, DOI 10.1111/j.1365-2672.1960.tb00188.x; DENNIS D, 1960, J BIOL CHEM, V235, P810; DENNIS D, 1965, ANN NY ACAD SCI, V119, P868, DOI 10.1111/j.1749-6632.1965.tb47448.x; EVENTOFF W, 1977, P NATL ACAD SCI USA, V74, P2677, DOI 10.1073/pnas.74.7.2677; EVERSE J, 1973, ADV ENZYMOL RAMB, V37, P61; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GARVIE EI, 1980, MICROBIOL REV, V44, P106, DOI 10.1128/MMBR.44.1.106-139.1980; GASSER F, 1970, J GEN MICROBIOL, V62, P223, DOI 10.1099/00221287-62-2-223; GASSER F, 1970, J GEN MICROBIOL, V62, P241, DOI 10.1099/00221287-62-2-241; GASSER F, 1970, J BACTERIOL, V106, P113; GLEASON FH, 1966, SCIENCE, V152, P1272, DOI 10.1126/science.152.3726.1272; GRANT GA, 1989, BIOCHEM BIOPH RES CO, V165, P1371, DOI 10.1016/0006-291X(89)92755-1; GREENLER JM, 1989, PLANT MOL BIOL, V13, P139, DOI 10.1007/BF00016133; HART KW, 1987, BIOCHIM BIOPHYS ACTA, V914, P294, DOI 10.1016/0167-4838(87)90289-5; HENSEL R, 1977, EUR J BIOCHEM, V80, P83, DOI 10.1111/j.1432-1033.1977.tb11859.x; HENSEL R, 1983, EUR J BIOCHEM, V134, P503, DOI 10.1111/j.1432-1033.1983.tb07595.x; Holbrook JJ., 1975, ENZYMES, P191; HUMMEL W, 1985, APPL MICROBIOL BIOT, V21, P7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERCH HP, 1989, GENE, V78, P47, DOI 10.1016/0378-1119(89)90313-2; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LONG GL, 1973, ARCH BIOCHEM BIOPHYS, V154, P711, DOI 10.1016/0003-9861(73)90026-X; LONG GL, 1968, SCIENCE, V162, P685, DOI 10.1126/science.162.3854.685; Maniatis T, 1989, DECONTAMINATION DILU; MEZES PSF, 1985, J BIOL CHEM, V260, P1218; SAITO H, 1963, BIOCHIM BIOPHYS ACTA, V72, P619, DOI 10.1016/0926-6550(63)90386-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOENLEIN PV, 1989, J BACTERIOL, V171, P6084, DOI 10.1128/jb.171.11.6084-6092.1989; SIEBENALLER JF, 1983, BIOCHIM BIOPHYS ACTA, V749, P153, DOI 10.1016/0167-4838(83)90247-9; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TERADA I, 1990, J BIOL CHEM, V265, P6576; TOBEY KL, 1986, J BIOL CHEM, V261, P2179; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	39	163	169	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12588	12594						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1840590				2022-12-25	WOS:A1991FV18000076
J	ALEXANDRE, C; VERRIER, B				ALEXANDRE, C; VERRIER, B			4 REGULATORY ELEMENTS IN THE HUMAN C-FOS PROMOTER MEDIATE TRANSACTIVATION BY HTLV-1 TAX PROTEIN	ONCOGENE			English	Article							CELL LEUKEMIA-VIRUS; SERUM RESPONSE ELEMENT; MULTIPLE SEQUENCE ELEMENTS; CYCLIC-AMP; GROWTH-FACTOR; RAPID INDUCTION; AUTO-REGULATION; ONCOGENE FOS; ACTIN GENES; T-CELLS	Expression of the human c-fos proto-oncogene is activated in trans by the Tax protein encoded by human T-cell leukemia virus type-1 (HTLV-1). Indeed, we show here that a HeLa clone stably transfected by Tax expresses Fos at a high level. We also show that multiple elements of the human c-fos promoter, i.e. the v-sis conditioned medium inducible element (SIE), the dyad symmetry element (DSE) necessary for growth factor induction, the octanucleotide direct repeat element (DR), and the cyclic AMP response element (CRE) centred at -60, can all mediate Tax transactivation. In the DSE, the 10 bp central core that binds the serum response factor (SRF) is, by itself, sufficient to mediate Tax transactivation. Moreover, a CRE-binding protein is involved in Tax activation through the CRE-60 element. Since Fos is a transregulator of cellular genes, our results suggest that the oncoprotein plays a crucial role in T-cell transformation by HTLV-1 in conjunction with other Tax-inducible genes.	ECOLE NORMALE SUPER LYON,CNRS,UNITE BIOMERIEUX 103,46 ALLEE ITALIE,F-69364 LYONS 07,FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)			verrier, bernard/J-4094-2017	verrier, bernard/0000-0002-8478-7095				ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; BALLARD D W, 1989, New Biologist, V1, P83; BEIMLING P, 1990, ONCOGENE, V5, P361; BENBROOK DM, 1990, ONCOGENE, V5, P295; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BOHNLEIN E, 1989, J VIROL, V63, P1578; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; Curran T, 1988, ONCOGENE HDB, P307; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1212; GREENE WC, 1989, IMMUNOL TODAY, V10, P272, DOI 10.1016/0167-5699(89)90141-2; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; JACOBSON S, 1988, NATURE, V331, P540, DOI 10.1038/331540a0; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LILIENBAUM A, 1990, J VIROL, V64, P256, DOI 10.1128/JVI.64.1.256-263.1990; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MARRIOTT SJ, 1989, MOL CELL BIOL, V9, P4152, DOI 10.1128/MCB.9.10.4152; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; PRYWES R, 1987, MOL CELL BIOL, V7, P3482, DOI 10.1128/MCB.7.10.3482; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; RUBEN S M, 1989, New Biologist, V1, P275; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SEIKI M, 1985, GANN, V76, P1127; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; TAN TH, 1989, J VIROL, V63, P3761, DOI 10.1128/JVI.63.9.3761-3768.1989; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOSHIDA M, 1989, GENOME, V31, P662, DOI 10.1139/g89-121; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	60	81	82	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					543	551						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1827666				2022-12-25	WOS:A1991FR93900007
J	CHAPMAN, ER; AU, D; ALEXANDER, KA; NICOLSON, TA; STORM, DR				CHAPMAN, ER; AU, D; ALEXANDER, KA; NICOLSON, TA; STORM, DR			CHARACTERIZATION OF THE CALMODULIN BINDING DOMAIN OF NEUROMODULIN - FUNCTIONAL-SIGNIFICANCE OF SERINE-41 AND PHENYLALANINE-42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; KINASE-C; PROTEIN F1; PHOSPHORYLATION; P-57; B-50; PHOSPHOPROTEINS; PURIFICATION; PERSISTENCE; MEMBRANES	Neuromodulin (also designated P-57, GAP-43, B-50) is a major presynaptic substrate for protein kinase C. Phosphorylation of neuromodulin decreases its affinity for calmodulin, suggesting that neuromodulin may function to bind and concentrate calmodulin at specific sites within neurons, releasing calmodulin locally in response to phosphorylation by protein kinase C (Alexander, K. A., Cimler, B. M., meier, K. E., and Storm, D. R. (1987) J. biol. Chem. 262, 6108-6113). In the present study, we have constructed and characterized several mutant neuromodulins to demonstrate that the amino acid sequence 39-56 is required for calmodulin binding, and that this domain contains the sole in vitro protein kinase C phosphorylation site at serine 41. We also demonstrate that the adjacent phenylalanine 42, interacts hydrophobically with calmodulin. These hydrophobic interactions may be disrupted by the introduction of negative charge at a serine 41, and thereby regulate the neuromodulin/calmodulin binding interaction. The sensitivity of the neuromodulin/calmodulin binding interaction to negative charge at serine 41 was determined by substitution of serine 41 with an aspartate or an asparagine residue. The asparagine mutant retained its affinity for calmodulin-Sepharose while the aspartate mutant did not adsorb to calmodulin-Sepharose. We conclude that protein kinase C phosphorylation of neuromodulin abolishes calmodulin binding by introducing negative charges within the calmodulin binding domain at a position adjacent to the phenylalanine.			CHAPMAN, ER (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195, USA.			Chapman, Edwin/0000-0001-9787-8140	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023606] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270, R01GM033708] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-23606] Funding Source: Medline; NIGMS NIH HHS [GM-07270, GM-33708] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adair GS, 1925, J BIOL CHEM, V63, P529; AKERS RF, 1985, BRAIN RES, V334, P147, DOI 10.1016/0006-8993(85)90576-1; ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; ANDREASEN TJ, 1981, P NATL ACAD SCI-BIOL, V78, P2782, DOI 10.1073/pnas.78.5.2782; ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4615, DOI 10.1021/bi00289a001; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; AU DC, 1989, BIOCHEMISTRY-US, V28, P8142, DOI 10.1021/bi00446a027; BENOWITZ LI, 1987, TRENDS NEUROSCI, V10, P527, DOI 10.1016/0166-2236(87)90135-4; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CIMLER BM, 1985, J BIOL CHEM, V260, P784; COGGINS PJ, 1989, J NEUROCHEM, V53, P1895, DOI 10.1111/j.1471-4159.1989.tb09259.x; COGGINS PJ, 1990, J NEUROCHEM, V54, P274, DOI 10.1111/j.1471-4159.1990.tb13311.x; DEKKER LV, 1989, NATURE, V342, P74, DOI 10.1038/342074a0; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; FONG YL, 1989, J BIOL CHEM, V264, P16759; KREIG PA, 1984, NUCLEIC ACIDS RES, V12, P7057; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LABATE ME, 1989, NEURON, V3, P299, DOI 10.1016/0896-6273(89)90254-7; LAPORTE DC, 1980, BIOCHEMISTRY-US, V19, P3814, DOI 10.1021/bi00557a025; LIU Y, 1989, J BIOL CHEM, V264, P12800; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LOVINGER DM, 1986, BRAIN RES, V399, P205, DOI 10.1016/0006-8993(86)91510-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASURE HR, 1986, BIOCHEMISTRY-US, V25, P7553, DOI 10.1021/bi00371a044; MOLYNEUX P, 1961, J AM CHEM SOC, V83, P3169, DOI 10.1021/ja01476a001; NELSON RB, 1989, BRAIN RES, V497, P30, DOI 10.1016/0006-8993(89)90966-9; NELSON RB, 1989, J NEUROSCI, V9, P381; OLWIN BB, 1983, BIOCHEMISTRY-US, V22, P5390, DOI 10.1021/bi00292a021; ONEIL KT, 1987, SCIENCE, V236, P1454, DOI 10.1126/science.3589665; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; ROUTTENBERG A, 1985, BEHAV NEURAL BIOL, V43, P3, DOI 10.1016/S0163-1047(85)91426-8; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; VANDONGEN CJ, 1985, BIOCHEM BIOPH RES CO, V128, P1219, DOI 10.1016/0006-291X(85)91070-8; VANHOOFF COM, 1988, J NEUROSCI, V8, P1789; Weber G, 1975, Adv Protein Chem, V29, P1, DOI 10.1016/S0065-3233(08)60410-6; WILLARD M, 1987, AXONAL TRANSPORT, P407	37	164	170	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					207	213						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1824693				2022-12-25	WOS:A1991EQ33900032
J	RIGHI, M; SASSANO, M; VALSASNINI, P; SHAMMAH, S; RICCIARDICASTAGNOLI, P				RIGHI, M; SASSANO, M; VALSASNINI, P; SHAMMAH, S; RICCIARDICASTAGNOLI, P			ACTIVATION OF THE M-CSF GENE IN MOUSE MACROPHAGES IMMORTALIZED BY RETROVIRUSES CARRYING A V-MYC ONCOGENE	ONCOGENE			English	Article							AVIAN LEUKEMIA VIRUSES; C-MYC; NUCLEOTIDE-SEQUENCE; MURINE RETROVIRUSES; MESSENGER-RNA; GROWTH-FACTOR; CELL-LINES; MONOCLONAL-ANTIBODY; TUMORS INVIVO; TRANSFORMATION	We have recently immortalized murine brain macrophages (microglial cells) with a complex of retroviruses (3RV) transducing separately the myc and mil oncogenes. Surprisingly, the immortalized cells harboured an exogenous v-myc oncogene, but no v-mil sequences. The transformed macrophage cell lines grew in vitro without the addition of exogenous growth factors and were also able to grow in vivo in nude mice. In addition, they released oncogenic retroviruses able to immortalize mouse macrophages from primary splenic or thymic cultures. Molecular cloning of the provirus (VN-11) harboured in a microglial clone demonstrated that no cell-derived sequences apart from an avian v-myc gene were transduced by the recombinant retrovirus. When cells were tested for production of myeloid growth factors, they were found to transcribe and synthesize the Macrophage-Colony Stimulating Factor (M-CSF). The correlation between viral infection and activation of the M-CSF gene was tested using a M-CSF dependent cells line from which growth factor independent clones could be readily obtained after infection. The synthesis of M-CSF was detected only in cells expressing the avian v-myc protein. These data support the hypothesis that, in our conditions, macrophages can be immortalized by the expression of v-myc and the concomitant establishment of an autocrine loop triggered by viral infection.			RIGHI, M (corresponding author), UNIV MILAN,DEPT PHARMACOL,CNR,CTR CYTOPHARMACOL,VIA VANVITELLI 32,I-20129 MILAN,ITALY.		Righi, Marco/P-4332-2019; Righi, Marco Giovanni Enea/M-9003-2019; Righi, Marco Giovanni Enea/G-5171-2011	Righi, Marco Giovanni Enea/0000-0003-1181-0327; Righi, Marco Giovanni Enea/0000-0003-1181-0327				AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BAUMBACH WR, 1987, MOL CELL BIOL, V7, P664, DOI 10.1128/MCB.7.2.664; BIRCHENALLROBERTS MC, 1989, ONCOGENE, V4, P731; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; CAMPBELL HD, 1985, EUR J BIOCHEM, V150, P297, DOI 10.1111/j.1432-1033.1985.tb09020.x; CELANDER D, 1984, NATURE, V312, P159, DOI 10.1038/312159a0; COLL J, 1983, EMBO J, V2, P2189, DOI 10.1002/j.1460-2075.1983.tb01722.x; CORY S, 1987, ONCOGENE RES, V1, P61; DEAN M, 1987, ONCOGENE RES, V1, P279; DONNER L, 1982, J VIROL, V41, P489, DOI 10.1128/JVI.41.2.489-500.1982; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GOUGH NM, 1985, EMBO J, V4, P645, DOI 10.1002/j.1460-2075.1985.tb03678.x; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1982, BIOCHIM BIOPHYS ACTA, V651, P245, DOI 10.1016/0304-419X(82)90014-2; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GREEN SM, 1989, ONCOGENE, V4, P737; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HERR W, 1984, J VIROL, V49, P471, DOI 10.1128/JVI.49.2.471-478.1984; HOLLON T, 1989, J VIROL, V63, P3353, DOI 10.1128/JVI.63.8.3353-3361.1989; JANSEN HW, 1985, VIROLOGY, V142, P248, DOI 10.1016/0042-6822(85)90333-2; JANSEN HW, 1983, EMBO J, V2, P1969, DOI 10.1002/j.1460-2075.1983.tb01686.x; KAN NC, 1983, P NATL ACAD SCI USA, V81, P3004; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; METCALF D, 1982, INT J CANCER, V30, P773, DOI 10.1002/ijc.2910300616; METCALF D, 1984, HEMOPOIETIC COLONIES; MORI L, 1985, EMBO J, V4, P2025, DOI 10.1002/j.1460-2075.1985.tb03887.x; NEDOSPASOV SA, 1986, NUCLEIC ACIDS RES, V14, P7713, DOI 10.1093/nar/14.19.7713; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RIGHI M, 1989, ONCOGENE, V4, P223; RIGHI M, 1989, EUR J IMMUNOL, V19, P1443, DOI 10.1002/eji.1830190815; SAULE S, 1982, J VIROL, V42, P71, DOI 10.1128/JVI.42.1.71-82.1982; SAULE S, 1984, EXP CELL RES, V155, P496, DOI 10.1016/0014-4827(84)90209-X; SHER E, 1989, J CELL BIOL, V108, P2291, DOI 10.1083/jcb.108.6.2291; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; SYMONDS G, 1989, ONCOGENE, V4, P285; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; VOGT M, 1989, ONCOGENE RES, V4, P19; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7	44	23	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					103	111						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1825138				2022-12-25	WOS:A1991EY03900014
J	CABELLI, RJ; DOLAN, KM; QIAN, LP; OLIVER, DB				CABELLI, RJ; DOLAN, KM; QIAN, LP; OLIVER, DB			CHARACTERIZATION OF MEMBRANE-ASSOCIATED AND SOLUBLE STATES OF SECA PROTEIN FROM WILD-TYPE AND SECA51(TS) MUTANT STRAINS OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATION ATPASE; PLASMA-MEMBRANE; PRECURSOR PROTEINS; EXPORT; BINDING; SECRETION; COMPONENT; VESICLES; LEADER; PEPTIDE	The subcellular localization of SecA, a protein essential for the catalysis of general protein export, was studied to better understand its state(s) and function(s) within Escherichia coli cells. In a wild-type strain approximately half of the cellular SecA content was found to be associated with the inner membrane, while the remainder was soluble. Association of SecA protein with the inner membrane required the presence of anionic phospholipids and was modulated by ATP. A fraction of the membrane-bound SecA was found to be integrally associated with the membrane. In the secA51(Ts) mutant 75-95% of SecA protein was found to be membrane associated, independent of the protein export status of the cell, implying that the partitioning of this protein between the cell membrane and cytoplasm may play an important role in its function. secA-lacZ fusions were used to map a membrane association determinant to the amino-terminal quarter of SecA protein sequence. When this portion of SecA protein was expressed within cells, it was found solely in membrane fractions and complemented the growth and protein secretion defect of the secA51(Ts) mutant. This indicates that the membrane is the site of the limiting defect in this mutant and suggests that either SecA functions can be divided into at least two separable activities or that productive interaction between SecA and the amino-terminal fragment can occur in vivo.	SUNY STONY BROOK, DEPT MICROBIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL CANCER INSTITUTE [T32CA009176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042033] Funding Source: NIH RePORTER; NCI NIH HHS [CA09176] Funding Source: Medline; NIGMS NIH HHS [GM42033] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKITA M, 1990, J BIOL CHEM, V265, P8164; AKITA M, 1991, BIOCHEM BIOPH RES CO, V174, P211, DOI 10.1016/0006-291X(91)90507-4; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; Cabelli RJ, 1991, THESIS STATE U NEW Y; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DOLAN K, 1991, IN PRESS J BIOL CHEM; FANDL JP, 1988, P NATL ACAD SCI USA, V85, P8953, DOI 10.1073/pnas.85.23.8953; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HEACOCK PN, 1989, J BIOL CHEM, V264, P14972; KAWASAKI H, 1989, FEBS LETT, V242, P431, DOI 10.1016/0014-5793(89)80516-2; KIMURA E, 1991, J BIOL CHEM, V266, P6600; KUSTERS R, 1989, J BIOL CHEM, V264, P20827; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBKE HH, 1987, J BACTERIOL, V169, P1174, DOI 10.1128/jb.169.3.1174-1181.1987; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; RHOADS DB, 1984, J BACTERIOL, V159, P63, DOI 10.1128/JB.159.1.63-70.1984; SAIER MH, 1989, MICROBIOL REV, V53, P333, DOI 10.1128/MMBR.53.3.333-366.1989; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHMIDT MG, 1988, J BACTERIOL, V170, P3404, DOI 10.1128/jb.170.8.3404-3414.1988; SCHMIDT MG, 1989, J BACTERIOL, V171, P643, DOI 10.1128/jb.171.2.643-649.1989; SWIDERSKY UE, 1990, EMBO J, V9, P1777, DOI 10.1002/j.1460-2075.1990.tb08302.x; THOM JR, 1988, J BACTERIOL, V170, P5654, DOI 10.1128/jb.170.12.5654-5661.1988	30	186	188	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24420	24427						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1837021				2022-12-25	WOS:A1991GW84500030
J	UMEMOTO, N; OHYA, Y; ANRAKU, Y				UMEMOTO, N; OHYA, Y; ANRAKU, Y			VMA11, A NOVEL GENE THAT ENCODES A PUTATIVE PROTEOLIPID, IS INDISPENSABLE FOR EXPRESSION OF YEAST VACUOLAR MEMBRANE H+-ATPASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; PROTON MOTIVE FORCE; SACCHAROMYCES-CEREVISIAE; TRIFLUOPERAZINE RESISTANCE; CATALYTIC SUBUNIT; ALPHA-MANNOSIDASE; AMINO-ACIDS; TRANSPORT; SEQUENCE; PURIFICATION	A gene, VMA11, is indispensable for expression of the vacuolar membrane H+-ATPase activity in the yeast Saccharomyces cerevisiae (Ohya, Y., Umemoto, N., Tanida, I., Ohta, A., Iida, H., and Anraku, Y. (1991) J. Biol. Chem. 266, 13971-13977). The VMA11 gene was isolated from a yeast genomic DNA library by complementation of the vma11 mutation. The nucleotide sequence of the gene predicts a hydrophobic proteolipid of 164 amino acids with a calculated molecular mass of 17,037 daltons. The deduced amino acid sequence shows 56.7% identity, and significant coincidence in amino acid composition with the 16-kDa subunit c (a VMA3 gene product) of the yeast vacuolar membrane H+-ATPase. VMA11 and VMA3 on a multicopy plasmid did not suppress the vma3 and vma11 mutation, respectively, suggesting functional independence of the two gene products. Biochemical detection of the VMA11 gene product was unsuccessful, but vacuoles in the VMA11-disrupted cells were not assembled with either subunit c or subunits a and b of the H+-ATPase, resulting in defects of the activity and in vivo vacuolar acidification.	UNIV TOKYO,FAC SCI,DEPT BIOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo			Umemoto, Naoyuki/C-9712-2017	Umemoto, Naoyuki/0000-0001-5507-0848				Albert B, 1989, MOL BIOL CELL; ANRAKU Y, 1989, J BIOENERG BIOMEMBR, V21, P589, DOI 10.1007/BF00808115; ANRAKU Y, 1991, NEW ERA BIOENERGETIC, P135; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BIRMAN S, 1990, FEBS LETT, V261, P303, DOI 10.1016/0014-5793(90)80577-6; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FOURY F, 1990, J BIOL CHEM, V265, P18554; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HIRATA R, 1989, FEBS LETT, V244, P397, DOI 10.1016/0014-5793(89)80571-X; KAKINUMA Y, 1981, J BIOL CHEM, V256, P859; KANE PM, 1989, J BIOL CHEM, V264, P19236; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MEAGHER L, 1990, NUCLEIC ACIDS RES, V18, P6712, DOI 10.1093/nar/18.22.6712; NELSON H, 1989, J BIOL CHEM, V264, P5313; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1989, J BIOENERG BIOMEMBR, V21, P553, DOI 10.1007/BF00808113; NISHIKAWA S, 1990, J BIOL CHEM, V265, P7440; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OHYA Y, 1986, J GEN MICROBIOL, V132, P979; OHYA Y, 1991, J BIOL CHEM, V266, P12356; OHYA Y, 1991, J BIOL CHEM, V266, P13971; Rodriguez R.L., 1983, RECOMBINANT DNA TECH; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO T, 1984, J BIOL CHEM, V259, P1505; SCHNEIDER E, 1987, MICROBIOL REV, V51, P477, DOI 10.1128/MMBR.51.4.477-497.1987; SHERMAN S, 1986, LABORATORY COURSE MA; SHIH CK, 1990, MOL CELL BIOL, V10, P3397, DOI 10.1128/MCB.10.7.3397; SHIH CK, 1988, MOL CELL BIOL, V8, P3094, DOI 10.1128/MCB.8.8.3094; SIKORSKI RS, 1989, GENETICS, V122, P19; UCHIDA E, 1988, J BIOL CHEM, V263, P45; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; YOSHIHISA T, 1989, BIOCHEM BIOPH RES CO, V163, P908, DOI 10.1016/0006-291X(89)92308-5; YOSHIHISA T, 1988, J BIOL CHEM, V263, P5158	44	89	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24526	24532						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1837023				2022-12-25	WOS:A1991GW84500046
J	AITCHISON, JD; MURRAY, WW; RACHUBINSKI, RA				AITCHISON, JD; MURRAY, WW; RACHUBINSKI, RA			THE CARBOXYL-TERMINAL TRIPEPTIDE ALA-LYS-ILE IS ESSENTIAL FOR TARGETING CANDIDA-TROPICALIS TRIFUNCTIONAL ENZYME TO YEAST PEROXISOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDRATASE-DEHYDROGENASE-EPIMERASE; SACCHAROMYCES-CEREVISIAE; FIREFLY LUCIFERASE; PROTEIN IMPORT; DNA; GENE; ALBICANS; IDENTIFICATION; SEQUENCE; TRANSFORMATION	The gene encoding Candida tropicalis peroxisomal trifunctional enzyme, hydratase-dehydrogenase-epimerase (HDE), was expressed in both Candida albicans and Saccharomyces cerevisiae. The cellular location of HDE was determined by subcellular fractionation followed by Western blot analysis of peroxisomal and cytosolic fractions using antiserum specific for HDE. HDE was found to be exclusively targeted to and imported into peroxisomes in both heterologous expression systems. Deletion and mutational analyses were used to determine the regions within HDE which are essential for its targeting to peroxisomes. Deletion of a carboxyl-terminal tripeptide Ala-Lys-Ile completely abolished targeting of HDE to peroxisomes, whereas large internal deletions of HDE (amino acids 38-353 or 395-731) had no effect on HDE targeting to peroxisomes in either yeast. This tripeptide is similar to, but distinct from, other tripeptide peroxisomal targeting sequences (PTSs) as identified in peroxisomal firefly luciferase and four mammalian peroxisomal proteins. Substitutions within the carboxyl-terminal tripeptide (Ala --> Gly and Lys --> Gln) supported targeting of HDE to peroxisomes of C. albicans but not of S. cerevisiae. This is the first detailed analysis of the peroxisomal targeting signal in a yeast peroxisomal protein.			AITCHISON, JD (corresponding author), MCMASTER UNIV, DEPT BIOCHEM, HAMILTON L8N 3Z5, ONTARIO, CANADA.							ADOLPHUS, 1983, EMBO J, V2, P1765, DOI 10.1002/j.1460-2075.1983.tb01655.x; AITCHISON JD, 1990, CURR GENET, V17, P481, DOI 10.1007/BF00313075; ALEXSON SEH, 1985, J CELL BIOL, V101, P294, DOI 10.1083/jcb.101.1.294; BARNS SM, 1991, J BACTERIOL, V173, P2250, DOI 10.1128/JB.173.7.2250-2255.1991; BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; BORST P, 1989, BIOCHIM BIOPHYS ACTA, V1008, P1, DOI 10.1016/0167-4781(89)90163-2; BORST P, 1986, BIOCHIM BIOPHYS ACTA, V866, P179, DOI 10.1016/0167-4781(86)90044-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DELAGARZA MM, 1985, EUR J BIOCHEM, V148, P285, DOI 10.1111/j.1432-1033.1985.tb08837.x; DELORME E, 1989, APPL ENVIRON MICROB, V55, P2242, DOI 10.1128/AEM.55.9.2242-2246.1989; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; FUJIKI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7127, DOI 10.1073/pnas.81.22.7127; FUJIKI Y, 1986, J BIOL CHEM, V261, P5787; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; GOULD SJ, 1988, J CELL BIOL, V107, P897, DOI 10.1083/jcb.107.3.897; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; JANOWICZ ZA, 1985, NUCLEIC ACIDS RES, V13, P3043, DOI 10.1093/nar/13.9.3043; KAMIRYO T, 1982, J BACTERIOL, V152, P269; KELLER G-A, 1990, Journal of Cell Biology, V111, p454A; KELLY R, 1987, MOL CELL BIOL, V7, P199, DOI 10.1128/MCB.7.1.199; KURTZ MB, 1986, MOL CELL BIOL, V6, P142, DOI 10.1128/MCB.6.1.142; KURTZ MB, 1987, MOL CELL BIOL, V7, P209, DOI 10.1128/MCB.7.1.209; KWIATOWSKI J, 1989, NUCLEIC ACIDS RES, V17, P2133, DOI 10.1093/nar/17.5.2133; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LEWIN AS, 1990, MOL CELL BIOL, V10, P1399, DOI 10.1128/MCB.10.4.1399; Maniatis T., 1982, MOL CLONING; NUTTLEY WM, 1988, GENE, V69, P171, DOI 10.1016/0378-1119(88)90428-3; NUTTLEY WM, 1990, J CELL SCI, V95, P463; NYE SH, 1990, MOL CELL BIOL, V10, P5753, DOI 10.1128/MCB.10.11.5753; ORR EC, 1990, NUCLEIC ACIDS RES, V18, P3663, DOI 10.1093/nar/18.12.3663; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1986, METHODS YEAST GENETI; SLOOTS JA, 1991, GENE, V105, P129, DOI 10.1016/0378-1119(91)90524-F; SMALL GM, 1988, EMBO J, V7, P1167, DOI 10.1002/j.1460-2075.1988.tb02927.x; SWINKELS B W, 1990, Journal of Cell Biology, V111, p195A; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TANABE I, 1966, AGR BIOL CHEM TOKYO, V30, P1175, DOI 10.1080/00021369.1966.10858755; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220	45	93	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23197	23203						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744117				2022-12-25	WOS:A1991GT48300066
J	BLACKBURN, NJ; HASNAIN, SS; PETTINGILL, TM; STRANGE, RW				BLACKBURN, NJ; HASNAIN, SS; PETTINGILL, TM; STRANGE, RW			COPPER K-EXTENDED X-RAY ABSORPTION FINE-STRUCTURE STUDIES OF OXIDIZED AND REDUCED DOPAMINE BETA-HYDROXYLASE - CONFIRMATION OF A SULFUR LIGAND TO COPPER(I) IN THE REDUCED ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE SUPEROXIDE-DISMUTASE; MULTIPLE-SCATTERING APPROACH; ELECTRON-PARAMAGNETIC-RES; CURVED-WAVE THEORY; EXAFS CALCULATIONS; CRYSTAL-STRUCTURE; CARBON-MONOXIDE; MONOOXYGENASE; SITES; SPECTROSCOPY	The structure of the copper sites in oxidized and reduced dopamine beta-hydroxylase has been studied by extended x-ray absorption fine structure spectroscopy using a restrained refinement approach to data analysis. An histidine-rich active site has been found to be present with an average histidine coordination of between two and three histidine ligands per copper. In the oxidized protein, the data support four-coordination, involving two to three imidazole groups at 1.99 angstrom with additional ligands derived from water or exogenous O-donor groups at an average distance of 1.94 angstrom. Studies on the reduced enzyme have focused on resolving the controversy in the literature (Scott, R. A., Sullivan, R. J., De Wolfe, W. E., Dolle, R. E., and Kruse, L. I. (1988) Biochemistry 27, 5411-5417; Blumberg, W. E., Desai, P. R., Powers, L., Freedman, J. H., and Villafranca, J. J. (1989) J. Biol. Chem. 264, 6029-6032) as to whether a S/Cl scatterer is a ligand to Cu(I). Five independent samples of reduced enzyme prepared under conditions designed to probe the Cu(I) ligand environment have been measured and analyzed. All five samples gave identical spectra and could be simulated by two to three imidazoles (1.93 angstrom) and 0.5 S/Cl (2.25 angstrom) per Cu(I). The spectra were insensitive to the presence of added bromide or to exclusion of chloride during preparation. The results establish that the heavy atom scatterer is derived from a sulfur donor. Some evidence was found for an additional O/N scatterer at 2.6 angstrom in the reduced enzyme. A hypothesis for the structure of the copper sites has been proposed involving inequivalent Cu(A)(His)3(H2O)...Cu(B)(His)2X(H2O) coordination in the oxidized enzyme, which upon reduction loses coordinated water and coordinates a sulfur probably from a methionine.	SERC,DARESBURY LAB,WARRINGTON WA4 4AD,CHESHIRE,ENGLAND	STFC Daresbury Laboratory	BLACKBURN, NJ (corresponding author), OREGON GRAD INST SCI & TECHNOL,DEPT CHEM & BIOL SCI,BEAVERTON,OR 97006, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027583] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS27583] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADMAN ET, 1991, IN PRESS ADV PROTEIN; ASH DE, 1984, J BIOL CHEM, V259, P3395; BINSTED N, 1988, SERC DARESBURY LABOR; BLACKBURN NJ, 1989, INORG CHEM, V28, P1349, DOI 10.1021/ic00306a027; BLACKBURN NJ, 1984, BIOCHEM J, V219, P985, DOI 10.1042/bj2190985; BLACKBURN NJ, 1988, BIOCHEMISTRY-US, V27, P6001, DOI 10.1021/bi00416a026; BLACKBURN NJ, 1988, J AM CHEM SOC, V110, P4263, DOI 10.1021/ja00221a027; BLACKBURN NJ, 1984, BIOCHEM J, V220, P447, DOI 10.1042/bj2200447; BLACKBURN NJ, 1987, J AM CHEM SOC, V109, P7162, DOI 10.1021/ja00257a043; BLACKBURN NJ, 1990, J BIOL CHEM, V265, P15383; BLACKBURN NJ, 1985, BIOL INORGANIC COPPE, P33; BLACKBURN NJ, 1989, SYNCHROTRON RAD BIOP, P63; BLUMBERG WE, 1989, J BIOL CHEM, V264, P6029; BRENNER MC, 1989, BIOCHEMISTRY-US, V28, P4664, DOI 10.1021/bi00437a023; BRENNER MC, 1989, BIOCHEMISTRY-US, V28, P4656, DOI 10.1021/bi00437a022; CLEGG W, 1984, ACTA CRYSTALLOGR C, V40, P768, DOI 10.1107/S0108270184005667; COLOMBO G, 1987, ARCH BIOCHEM BIOPHYS, V252, P71, DOI 10.1016/0003-9861(87)90009-9; Cotton F. A., 1988, ADV INORGANIC CHEM; GURMAN SJ, 1984, J PHYS C SOLID STATE, V17, P143, DOI 10.1088/0022-3719/17/1/019; GURMAN SJ, 1986, J PHYS C SOLID STATE, V19, P1845, DOI 10.1088/0022-3719/19/11/021; GURMAN SJ, 1989, SYNCHROTON RAD BIOPH, P9; GUSS JM, 1983, J MOL BIOL, V169, P521; HASNAIN SS, 1984, BIOCHEM J, V221, P545, DOI 10.1042/bj2210545; HODGMAN CD, 1963, HDB CHEM PHYSICS; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; KARLIN KD, 1987, INORG CHEM, V26, P1271, DOI 10.1021/ic00255a017; KLINMAN JP, 1984, J BIOL CHEM, V259, P3399; KNOWLES PF, 1989, J AM CHEM SOC, V111, P102, DOI 10.1021/ja00183a018; MCCRACKEN J, 1988, BIOCHEMISTRY-US, V27, P4133, DOI 10.1021/bi00411a034; MESSERSCHMIDT A, 1989, J MOL BIOL, V206, P513, DOI 10.1016/0022-2836(89)90498-1; OBATA A, 1987, BIOCHEMISTRY-US, V26, P4962, DOI 10.1021/bi00390a012; ORPEN AG, 1989, J CHEM SOC DALTON, pS1, DOI 10.1039/dt98900000s1; PETTINGILL TM, 1991, J BIOL CHEM, V266, P18996; SAYERS DE, 1988, XRAY ABSORPTION PRIN, P211; Scott R A., 1988, COMMENTS INORG CHEM, V7, P235; SCOTT RA, 1988, BIOCHEMISTRY-US, V27, P5411, DOI 10.1021/bi00415a005; SILLEN LG, 1964, SPECIAL PUBLICATION, V17; SOUTHAN C, 1989, FEBS LETT, V255, P116, DOI 10.1016/0014-5793(89)81072-5; STEWART LC, 1987, BIOCHEMISTRY-US, V26, P5302, DOI 10.1021/bi00391a013; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; STRANGE RW, 1987, J AM CHEM SOC, V109, P7157, DOI 10.1021/ja00257a042; STRANGE RW, 1989, SYNCHROTRON RAD BIOP, P105; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; TAN GO, 1990, ACTA CRYSTALLOGR C, V46, P1773, DOI 10.1107/S0108270189013922; Teo BK., 1986, EXAFS BASIC PRINCIPL, P114, DOI DOI 10.1007/978-3-642-50031-2; VILLAFRANCA JJ, 1981, METAL IONS BIOL, V3, P263; VOLBEDA A, 1989, J MOL BIOL, V209, P249, DOI 10.1016/0022-2836(89)90276-3; WALKER GA, 1977, BIOCHIM BIOPHYS ACTA, V482, P309, DOI 10.1016/0005-2744(77)90244-3	48	92	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23120	23127						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744110				2022-12-25	WOS:A1991GT48300054
J	FUJII, J; TANIGUCHI, N				FUJII, J; TANIGUCHI, N			PHORBOL ESTER INDUCES MANGANESE-SUPEROXIDE DISMUTASE IN TUMOR NECROSIS FACTOR-RESISTANT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; NF-KAPPA-B; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; FACTOR-ALPHA; EXPRESSION; INTERLEUKIN-1; ENHANCER; INDUCTION; MECHANISM	The effects of phorbol ester (TPA) and other known stimulators such as tumor necrosis factor (TNF), interleukin-1, and lipopolysaccharide on induction of mRNA for manganese-superoxide dismutase (Mn-SOD) were investigated in various cell lines. TPA enhanced Mn-SOD mRNA expression in TNF-resistant cell lines including HeLa cells, in which the other reagents also induced expression of the gene, but did not affect TNF-sensitive cells, in which the other stimulators did not alter expression of the gene. HeLa cells which had been desensitized to TPA by pretreatment with TPA for 24 h expressed Mn-SOD mRNA at a slightly higher level than the cells without TPA treatment. TPA-pretreated cells stimulated with TNF, however, expressed Mn-SOD mRNA at about twice the level of TNF-stimulated, TPA-untreated cells. When protein synthesis was inhibited by cycloheximide during TPA pretreatment, TNF no more enhanced the Mn-SOD mRNA accumulation. These data suggest that at least two separate signal-transducing pathways are involved in expression of this gene. One is triggered by protein kinase C activation itself in the absence of new protein synthesis. The other can be activated by stimulation with TNF, interleukin-1, or lipopolysaccharide and in which a protein factor that can be induced by TPA treatment is involved.	OSAKA UNIV,SCH MED,DEPT BIOCHEM,2-2 YAMADAOKA,SUITA,OSAKA 565,JAPAN	Osaka University			Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; APPLEGATE LA, 1991, CANCER RES, V51, P974; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BANNISTER JV, 1987, CRC CR REV BIOCH MOL, V22, P111, DOI 10.3109/10409238709083738; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGUISEPPI J, 1984, CRC CR REV TOXICOL, V12, P315, DOI 10.3109/10408448409044213; HALLEWELL RA, 1985, NUCLEIC ACIDS RES, V13, P2017, DOI 10.1093/nar/13.6.2017; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; HO YS, 1991, AM J RESP CELL MOL, V4, P278, DOI 10.1165/ajrcmb/4.3.278; KAWAGUCHI T, 1990, BIOCHEM BIOPH RES CO, V171, P1378, DOI 10.1016/0006-291X(90)90838-E; KAWAGUCHI T, 1989, J BIOL CHEM, V264, P5762; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KRONKE M, 1991, TUMOR NECROSIS FACTO, P189; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Maniatis T., 1982, MOL CLONING; MASUDA A, 1988, FASEB J, V2, P3087, DOI 10.1096/fasebj.2.15.3263930; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; TSAN MF, 1990, AM J PHYSIOL, V259, pL506, DOI 10.1152/ajplung.1990.259.6.L506; VILCEK J, 1991, J BIOL CHEM, V266, P7313; VISNER GA, 1990, J BIOL CHEM, V265, P2856; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; YAMAZAKI S, 1986, JPN J MED SCI BIOL, V39, P105, DOI 10.7883/yoken1952.39.105; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	30	106	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23142	23146						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744113				2022-12-25	WOS:A1991GT48300057
J	KEETON, MR; CURRIDEN, SA; VANZONNEVELD, AJ; LOSKUTOFF, DJ				KEETON, MR; CURRIDEN, SA; VANZONNEVELD, AJ; LOSKUTOFF, DJ			IDENTIFICATION OF REGULATORY SEQUENCES IN THE TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR GENE RESPONSIVE TO TRANSFORMING GROWTH-FACTOR-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; ENDOTHELIAL-CELLS; GEL-ELECTROPHORESIS; MAMMALIAN-CELLS; BINDING-SITE; INDUCTION; PROMOTER; TRANSCRIPTION; EXPRESSION; LIPOPOLYSACCHARIDE	Regulation of the human type 1 plasminogen activator inhibitor (PAI-1) promoter by transforming growth factor-beta (TGF-beta) was studied. An 800-base pair fragment from the PAI-1 promoter and 5'-flanking region was fused to the firefly luciferase reporter gene and transfected into Hep3B human hepatoma cells. Treatment of the cells with TGF-beta induced luciferase activity by more than 50-fold. Transfection studies using constructs with 5' or 3' deletions through this region revealed that two sequences were important in the TGF-beta response. The first sequence was located in the proximal promoter (-49 to -87) and mediated an 11-fold induction with TGF-beta, while the second more distal region (-636 to -740) contained two sequences which together mediated a 50-fold or greater response. Sequence comparison indicated that both of the responsive regions contained sequences with high homology to the AP-1 consensus binding site. Moreover, gel retardation analysis experiments demonstrated that both sequences bound a common nuclear protein, and that an oligonucleotide containing a consensus AP-1 sequence was able to compete for the binding of this common protein. Thus, the response of the PAI-1 gene to TGF-beta is mediated by at least two separate regions, and both of these regions contain DNA sequences homologous to the AP-1 binding site.			KEETON, MR (corresponding author), Scripps Res Inst, RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA.		van Zonneveld, Anton Jan/D-8060-2018	van Zonneveld, Anton Jan/0000-0002-1676-7738	NHLBI NIH HHS [HL16411] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI MC, 1988, THROMB HAEMOSTASIS, V60, P491; ALMER LO, 1987, THROMB RES, V47, P335, DOI 10.1016/0049-3848(87)90147-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BASSOLS A, 1988, J BIOL CHEM, V263, P3039; BRUZDZINSKI CJ, 1990, J BIOL CHEM, V265, P2078; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; COLUCCI M, 1985, J CLIN INVEST, V75, P818, DOI 10.1172/JCI111777; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EMEIS JJ, 1986, J EXP MED, V163, P1260, DOI 10.1084/jem.163.5.1260; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUJII S, 1990, CIRCULATION, V82, P1485, DOI 10.1161/01.CIR.82.4.1485; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEKMAN CM, 1988, ARCH BIOCHEM BIOPHYS, V262, P199, DOI 10.1016/0003-9861(88)90182-8; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KRUITHOF EKO, 1987, BLOOD, V69, P460; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOSKUTOFF DJ, 1991, IN PRESS FIBRINOLYSI; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; MIMURO J, 1987, THROMB HAEMOSTASIS, V58, P1647; PARAMO JA, 1985, THROMB HAEMOSTASIS, V54, P725; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SAKSELA O, 1987, J CELL BIOL, V105, P957, DOI 10.1083/jcb.105.2.957; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SHAUL Y, 1986, EMBO J, V5, P1967, DOI 10.1002/j.1460-2075.1986.tb04451.x; SIPPEL AE, 1991, CANCER CELLS, V4, P155; SLIVKA SR, 1991, BLOOD, V77, P1013; THALACKER FW, 1987, J BIOL CHEM, V262, P2283; TOMOSUGI N, 1990, KIDNEY INT, V37, P435; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092	38	293	302	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23048	23052						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744101				2022-12-25	WOS:A1991GT48300044
J	NEBES, VL; JONES, EW				NEBES, VL; JONES, EW			ACTIVATION OF THE PROTEINASE-B PRECURSOR OF THE YEAST SACCHAROMYCES-CEREVISIAE BY AUTOCATALYSIS AND BY AN INTERNAL SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; ESCHERICHIA-COLI; PROTEASE-B; ENDOPLASMIC-RETICULUM; PHENOTYPIC SELECTION; PRO-SEQUENCE; SUBTILISIN; GENE; MUTANTS; EXPRESSION	Proteinase B (PrB) is a subtilisin-like serine protease found in the vacuole of the yeast Saccharomyces cerevisiae. It is first made as a large precursor that consists of a putative signal sequence, a 260-amino acid pro region, the serine protease domain, and two small COOH-terminal post regions (Moehle, C. M., Dixon, C. K., and Jones, E. W. (1989) J. Cell Biol. 108, 309-324). This precursor is glycosylated and proteolytically processed at least three times before mature enzyme is formed. To determine whether an intact PrB catalytic site is required for proteolytic processing of the precursor, point mutations were generated at the codons for the active site serine or aspartate residues by site-directed mutagenesis. The effect of these mutations on PrB processing suggests that the large pro region may be cleaved by an intramolecular, autocatalytic mechanism. The properties of a prb1 mutant that accumulates a 37-kDa precursor in addition to mature sized mutant PrB antigen suggests that the final proteolytic cleavage step is also autocatalytic. A prb1 deletion that lacks codons for the large pro region was made to test whether this part of the precursor is required for formation of mature PrB. Analysis of this mutant revealed two functions for this region: it prevents N-linked glycosylation of the serine protease domain and it allows the PrB precursor to be processed by proteinase A. The pro region can fulfill this latter function if added as a separate molecule, so long as glycosylation of the catalytic domain is prevented by other means.	CARNEGIE MELLON UNIV, DEPT BIOL SCI, 207 MELLON INST, 4400 5TH AVE, PITTSBURGH, PA 15213 USA	Carnegie Mellon University					NIDDK NIH HHS [DK18090] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018090, R01DK018090] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BETZ H, 1974, J BIOL CHEM, V249, P4515; BRYAN P, 1986, P NATL ACAD SCI USA, V83, P3743, DOI 10.1073/pnas.83.11.3743; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DAVIDOW LS, 1987, J BACTERIOL, V169, P4621, DOI 10.1128/jb.169.10.4621-4629.1987; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; FABRE E, 1991, J BIOL CHEM, V266, P3782; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; GUNKEL FA, 1989, EUR J BIOCHEM, V179, P185, DOI 10.1111/j.1432-1033.1989.tb14539.x; HAWTHORNE DC, 1960, GENETICS, V45, P1085; HOLM C, 1986, GENE, V42, P169, DOI 10.1016/0378-1119(86)90293-3; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; JONES E, 1986, UCLA S YEAST CELL BI, P505; JONES EW, 1991, METHOD ENZYMOL, V194, P428; JONES EW, 1991, J BIOL CHEM, V266, P7963; JONES EW, 1982, GENETICS, V102, P665; JONES EW, 1977, GENETICS, V85, P23; JONES EW, 1989, UCLA S CELLULAR PROT, P141; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KOMINAMI E, 1981, BIOCHIM BIOPHYS ACTA, V661, P136, DOI 10.1016/0005-2744(81)90092-9; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MAIER K, 1979, J BIOL CHEM, V254, P2555; Maniatis T., 1982, MOL CLONING; MECHLER B, 1988, EMBO J, V7, P1705, DOI 10.1002/j.1460-2075.1988.tb02999.x; MECHLER B, 1982, BIOCHEM BIOPH RES CO, V107, P770, DOI 10.1016/0006-291X(82)90590-3; MOEHLE CM, 1990, GENETICS, V124, P39; MOEHLE CM, 1987, MOL CELL BIOL, V7, P4390, DOI 10.1128/MCB.7.12.4390; MOEHLE CM, 1989, J CELL BIOL, V108, P309, DOI 10.1083/jcb.108.2.309; MOEHLE CM, 1987, GENETICS, V115, P255; MOEHLE CM, 1988, THESIS CARNEGIE MELL; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; ROTHBLATT J, 1989, METHOD CELL BIOL, V32, P3; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SAHEKI T, 1975, BIOCHIM BIOPHYS ACTA, V384, P203, DOI 10.1016/0005-2744(75)90109-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIFFER HH, 1990, 15TH INT C YEAST GEN; SCHULEIN R, 1991, MOL GEN GENET, V227, P137, DOI 10.1007/BF00260718; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; TOMKINSON B, 1991, BIOCHEMISTRY-US, V30, P168, DOI 10.1021/bi00215a025; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; WELLS JA, 1986, PHILOS T R SOC A, V317, P415, DOI 10.1098/rsta.1986.0051; WICKERHAM LJ, 1946, J BACTERIOL, V52, P293, DOI 10.1128/JB.52.3.293-301.1946; WOLF DH, 1979, EUR J BIOCHEM, V98, P375, DOI 10.1111/j.1432-1033.1979.tb13197.x; WONG SL, 1986, J BIOL CHEM, V261, P176; WOOLFORD CA, 1990, GENETICS, V125, P739; WRIGHT CS, 1969, NATURE, V221, P235, DOI 10.1038/221235a0; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0; ZUBENKO GS, 1979, P NATL ACAD SCI USA, V76, P2395, DOI 10.1073/pnas.76.5.2395; ZUBENKO GS, 1981, GENETICS, V97, P45	60	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22851	22857						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744078				2022-12-25	WOS:A1991GT48300015
J	FLORES, I; MARIANO, TM; PESTKA, S				FLORES, I; MARIANO, TM; PESTKA, S			HUMAN INTERFERON-OMEGA (OMEGA) BINDS TO THE ALPHA/BETA-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN IMMUNE INTERFERON; PURIFICATION; PHOSPHORYLATION; PROTEINS; GAMMA	It was proposed that human interferon omega (omega) binds to the interferon alpha/beta-receptor but not to the interferon gamma-receptor. However, since no studies were performed to provide direct evidence for this hypothesis, we carried out cross-linking experiments and saturation binding assays between a P-32-labeled human interferon-alpha (Hu-IFN-alpha) and unlabeled Hu-IFN-alpha-A, -beta, -gamma, and -omega. These assays demonstrated that Hu-IFN-alpha-A, -beta, and -omega, but not Hu-IFN-gamma, were able to block binding of P-32-labeled Hu-IFN-alpha-A to human cells. These results indicate that Hu-IFN-omega binds to the alpha/beta-receptor.			FLORES, I (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MOLEC GENET & MICROBIOL,PISCATAWAY,NJ 08854, USA.				NCI NIH HHS [CA-46465] Funding Source: Medline; NIAID NIH HHS [AI-25914] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025914] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADOLF GR, 1987, J GEN VIROL, V68, P1669, DOI 10.1099/0022-1317-68-6-1669; CAPON DJ, 1985, MOL CELL BIOL, V5, P768, DOI 10.1128/MCB.5.4.768; Familletti P C, 1981, Methods Enzymol, V78, P387; FEINSTEIN SI, 1985, MOL CELL BIOL, V5, P510, DOI 10.1128/MCB.5.3.510; HAUPTMANN R, 1985, NUCLEIC ACIDS RES, V13, P4739, DOI 10.1093/nar/13.13.4739; KUMAR CS, 1988, J BIOL CHEM, V263, P13493; KUNG HF, 1986, METHOD ENZYMOL, V119, P204; KUNG HF, 1986, METHOD ENZYMOL, V119, P296; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI BL, 1989, P NATL ACAD SCI USA, V86, P558, DOI 10.1073/pnas.86.2.558; MARIANO TM, 1987, J BIOL CHEM, V262, P5812; MARIANO TM, 1991, CYTOKINES PRACTICAL, P95; MOSCHERA JA, 1986, METHOD ENZYMOL, V119, P177; Pestka S, 1981, Methods Enzymol, V78, P3; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PESTKA S, 1986, METHOD ENZYMOL, V119, P3; PITHAROWE PM, 1990, J INTERFERON RES, V10, P353; RASHIDBAIGI A, 1985, J BIOL CHEM, V260, P8514; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHIRONO H, 1990, BIOCHEM BIOPH RES CO, V168, P16, DOI 10.1016/0006-291X(90)91668-I; TARNOWSKI SJ, 1986, METHOD ENZYMOL, V119, P153	21	67	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					19875	19877						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1834641				2022-12-25	WOS:A1991GM03900003
J	BLACKMORE, PF; NEULEN, J; LATTANZIO, F; BEEBE, SJ				BLACKMORE, PF; NEULEN, J; LATTANZIO, F; BEEBE, SJ			CELL SURFACE-BINDING SITES FOR PROGESTERONE MEDIATE CALCIUM-UPTAKE IN HUMAN SPERM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACROSOME REACTION; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PHOSPHOLIPASE-D; RAT-BRAIN; MECHANISM; RECEPTOR; MEMBRANE; INFLUX; SPERMATOZOA; HYDROLYSIS	Recent studies (e.g. Blackmore, P. F., Beebe, S. J., Danforth, D. R., and Alexander, N.) (1990) J. Biol. Chem. 265, 1376-1380) have shown that in human sperm, progesterone produces a rapid increase in intracellular free calcium ([Ca2+]i) and an induction of the acrosome reaction (e.g. Osman, R. A., Andria, M. L., Jones, A. D., and Meizel, S. (1989) Biochem. Biophys. Res. Commun. 160, 828-833). In this study, the location of progesterone receptors on the cell surface of human sperm was identified using progesterone immobilized on bovine serum albumin (BSA) (progesterone 3-(O-carboxymethyl)oxime:BSA) as well as progesterone and its 3-O-carboxymethyloxime derivative. Using fluorescence microscopy, BSA-fluorescein isothiocyanate was shown to be excluded from intact sperm, thus validating the use of progesterone 3-(O-carboxymethyl)oxime:BSA to identify cell surface-binding sites for progesterone. The immobilized progesterone and the 3-O-carboxymethyloxime derivative rapidly increased [Ca2+]i and were full agonists, although they were approximately 1.5 orders of magnitude less potent than progesterone. They also displayed an identical time course to increase [Ca2+]i as free progesterone, and the entire increase in [Ca2+]i was due to the influx of Ca2+. This progesterone-mediated response displayed different steroid receptor characteristics since the very potent inhibitors of genomic progesterone responses, RU38486 and ZK98.299, were very ineffective at inhibiting the progesterone-mediated increase in [Ca2+]i. Also the synthetic progestins megestrol, medroxyprogesterone acetate, norgestrel, norethynodrel, norethindrone, R5020, and cyproterone acetate did not mimic the effects of progesterone to increase [Ca2+]i. It is proposed that a distinct nongenomic cell surface receptor for progesterone exists in human sperm.	EASTERN VIRGINIA MED SCH, DEPT OBSTET & GYNECOL, NORFOLK, VA 23501 USA; EASTERN VIRGINIA MED SCH, JONES INST REPROD MED, NORFOLK, VA 23501 USA	Eastern Virginia Medical School; Eastern Virginia Medical School	BLACKMORE, PF (corresponding author), EASTERN VIRGINIA MED SCH, DEPT PHARMACOL, POB 1980, NORFOLK, VA 23501 USA.							BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLACKMORE PF, 1990, J BIOL CHEM, V265, P1376; BLACKMORE PF, 1985, J BIOL CHEM, V260, P4477; BLACKMORE PF, 1991, FASEB J, V5, pA7050; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; DEHAYE JP, 1980, J BIOL CHEM, V255, P3905; DEJONGE CJ, 1989, GAMETE RES, V23, P387, DOI 10.1002/mrd.1120230404; DOMINO SE, 1989, J BIOL CHEM, V264, P9412; GEE KW, 1987, EUR J PHARMACOL, V136, P419, DOI 10.1016/0014-2999(87)90317-7; GILMAN AG, 1990, GOODMAN GILMANS PHAR, P1397; GODEAU JF, 1978, P NATL ACAD SCI USA, V75, P2353, DOI 10.1073/pnas.75.5.2353; HALLAM TJ, 1985, FEBS LETT, V186, P175, DOI 10.1016/0014-5793(85)80703-1; ISHIKAWA K, 1977, MOL CELL ENDOCRINOL, V9, P91, DOI 10.1016/0303-7207(77)90049-1; KE FC, 1990, J NEUROCHEM, V54, P467, DOI 10.1111/j.1471-4159.1990.tb01895.x; KE FC, 1987, NEUROENDOCRINOLOGY, V45, P514, DOI 10.1159/000124784; LAN NC, 1990, EUR J PHARM-MOLEC PH, V188, P403, DOI 10.1016/0922-4106(90)90201-8; MCEWEN BS, 1991, TRENDS PHARMACOL SCI, V12, P141, DOI 10.1016/0165-6147(91)90531-V; MEIZEL S, 1991, MOL CELL ENDOCRINOL, V11, pR1; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; NERI RO, 1976, CELLULAR MECHANISMS, V2, P233; OSMAN RA, 1989, BIOCHEM BIOPH RES CO, V160, P828, DOI 10.1016/0006-291X(89)92508-4; RINK TJ, 1990, FEBS LETT, V268, P381, DOI 10.1016/0014-5793(90)81290-5; ROLDAN ERS, 1989, BIOCHEM J, V259, P397, DOI 10.1042/bj2590397; SADLER SE, 1985, ADV CYCLIC NUCL PROT, V19, P179; SCHUMACHER M, 1990, TRENDS NEUROSCI, V13, P359, DOI 10.1016/0166-2236(90)90016-4; SIDHU KS, 1989, INT REV CYTOL, V118, P231; THOMAS P, 1989, BIOCHEM J, V264, P539, DOI 10.1042/bj2640539; TOUCHETTE N, 1990, J NIH RES, V2, P71; WU FS, 1990, MOL PHARMACOL, V37, P597; Yanagimachi R., 1988, PHYSL REPRODUCTION, V1, P135	31	274	284	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18655	18659						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1833399				2022-12-25	WOS:A1991GJ47200041
J	HOPPNER, W; BECKERT, L; BUCK, F; SEITZ, HJ				HOPPNER, W; BECKERT, L; BUCK, F; SEITZ, HJ			IS THE P-29 PROTEIN INVOLVED IN THE RAPID REGULATION OF PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CYTOSOL; MN-2+-INSENSITIVE FORMS; PHOSPHOGLYCERATE MUTASE; GUANOSINE TRIPHOSPHATE; TRANSCRIPTION; MN-2+; GENE; GLUCONEOGENESIS; FERROACTIVATOR; PURIFICATION	It has been postulated that a protein with a molecular mass of 29,000 daltons (p29), which copurifies with hepatic phosphoenolpyruvate (P-enolpyruvate) carboxykinase, forms a complex with the enzyme and stabilizes its sensitivity to Mn2+ activation by protecting critical sulfhydryl groups from oxidation (Brinkworth, R. I., Hanson, R. W., Fullin, F. A., and Schramm, V. L. (1981) J. Biol. Chem. 256, 10795-10802). In this paper we demonstrate that p29 is not only expressed in tissues which contain high amounts of P-enolpyruvate carboxykinase, such as liver and kidney, but also in brain and muscle, which have no gluconeogenic function. Furthermore, p29 is expressed in rat liver prenatally, whereas P-enolpyruvate carboxykinase is induced only after birth. The effect of p29 to protect P-enolpyruvate carboxykinase against aerobic oxidation during in vitro incubation was also observed for ovalbumin and bovine albumin. Peptide sequencing of the p29 and search in a protein data bank revealed a high homology to the muscle-specific subunit of human phosphoglycerate mutase (EC 2.7.5.3). Determination of the enzyme activity confirms the identification of the p29 as the rat liver isoform of phosphoglycerate mutase. Taking all these findings together, it is concluded that this protein has no specific effect on P-enolpyruvate carboxykinase.			HOPPNER, W (corresponding author), UNIV HAMBURG,KRANKENHAUS EPPENDORF,INST PHYSIOL CHEM,BIOCHEM ENDOKRINOL ABT,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY.							BALLARD FJ, 1967, BIOCHEM J, V104, P866, DOI 10.1042/bj1040866; BARTRONS R, 1982, BIOCHIM BIOPHYS ACTA, V708, P167, DOI 10.1016/0167-4838(82)90217-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINKWORTH RI, 1981, J BIOL CHEM, V256, P795; CARLSON GM, 1978, BIOCHEMISTRY-US, V17, P5329, DOI 10.1021/bi00618a002; COLOMBO G, 1981, BIOCHEMISTRY-US, V20, P2758, DOI 10.1021/bi00513a009; COLOMBO G, 1978, BIOCHEMISTRY-US, V17, P5321, DOI 10.1021/bi00618a001; DRAPEAU GR, 1980, J BIOL CHEM, V255, P1127; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; Grisolia S, 1975, Methods Enzymol, V42, P435; HEBDA CA, 1982, J BIOL CHEM, V257, P5515; KARCZMAREWICZ E, 1985, EUR J BIOCHEM, V151, P561, DOI 10.1111/j.1432-1033.1985.tb09140.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; Lardy H A, 1981, Curr Top Cell Regul, V18, P243; LOOSE DS, 1985, MOL BASIS INSULIN AC, P347; MAKINEN AL, 1989, J BIOL CHEM, V264, P12148; MERRYFIELD ML, 1982, J BIOL CHEM, V257, P4646; PHILIPPI.H, 1972, BIOCHEM J, V126, P1127, DOI 10.1042/bj1261127; PUNEKAR NS, 1987, J BIOL CHEM, V262, P6714; ROGNSTAD R, 1981, J BIOL CHEM, V256, P1608; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SCHRAMM VL, 1982, TRENDS BIOCHEM SCI, V7, P369, DOI 10.1016/0968-0004(82)90117-7; SCHRAMM VL, 1981, J BIOL CHEM, V256, P803; SEUBERT W, 1965, BIOCHEM Z, V343, P176; SHANSKE S, 1987, J BIOL CHEM, V262, P14612; SHORT JM, 1986, J BIOL CHEM, V261, P9721	27	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17257	17260						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1832670				2022-12-25	WOS:A1991GF44500045
J	MAGUIRE, K; SHI, XP; HORIKOSHI, N; RAPPAPORT, J; ROSENBERG, M; WEINMANN, R				MAGUIRE, K; SHI, XP; HORIKOSHI, N; RAPPAPORT, J; ROSENBERG, M; WEINMANN, R			INTERACTIONS BETWEEN ADENOVIRUS-E1A AND MEMBERS OF THE AP-1 FAMILY OF CELLULAR TRANSCRIPTION FACTORS	ONCOGENE			English	Note							RNA POLYMERASE-II; ESCHERICHIA-COLI; GENE-PRODUCT; CYCLIC-AMP; LEUCINE ZIPPER; E1A PROTEIN; BINDING; DNA; ACTIVATION; PROMOTER	We have studied interactions between bacterially produced E1A linked to Sepharose and the various DNA-binding proteins present in HeLa cell nuclear extracts (NE). DNA-binding activities and cross-reactive polypeptides recognizing the cAMP-responsive element (CRE) and the activator protein 1 (AP1) sites were bound to the E1A column, whereas nuclear factor 1 (NF1) and the activator protein 2 (AP2) DNA-binding activities were not retained by E1A. The binding activities that were retained belonged to the CRE and JUN protein family, as judged by Western blot analysis. Authentic CRE-BP1, c-Jun and c-Fos proteins produced by in-vitro translation also bound to the E1A column. However, efficient binding of in-vitro-translated CRE-BP1 and c-Fos proteins to E1A required preincubation with NE. We show here that immobilized E1A sequesters several cellular upstream transcription activators, and suggest a role for members of the AP1 family of transcription factors in E1A-mediated gene regulation.	WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104; SMITHKLINE BEECHAM CORP,KING OF PRUSSIA,PA 19406	The Wistar Institute; GlaxoSmithKline			Horikoshi, Nobuo/Y-8245-2019	Horikoshi, Nobuo/0000-0001-8464-8178	NCI NIH HHS [F32 CA08338, CA44466, CA10815] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815, R01CA044466, F32CA008338] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERK AJ, 1990, GENE DEV, V4, P151; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1987, ONCOGENE, V2, P80; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; EGAN C, 1987, VIROLOGY, V160, P292, DOI 10.1016/0042-6822(87)90077-8; FERGUSON B, 1984, SCIENCE, V224, P1343, DOI 10.1126/science.6374895; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARCIA J, 1987, NUCLEIC ACIDS RES, V15, P8367, DOI 10.1093/nar/15.20.8367; GREEN M, 1988, CELL, V53, P921, DOI 10.1016/S0092-8674(88)90429-1; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KAW, 1987, EMBO J, V6, P1345, DOI 10.1002/j.1460-2075.1987.tb02374.x; LEFF T, 1985, NUCLEIC ACIDS RES, V13, P1209, DOI 10.1093/nar/13.4.1209; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SHI XP, 1986, NUCLEIC ACIDS RES, V14, P3729, DOI 10.1093/nar/14.9.3729; SIVARAMAN L, 1987, P NATL ACAD SCI USA, V84, P6112, DOI 10.1073/pnas.84.17.6112; SOPTA M, 1985, J BIOL CHEM, V260, P353; SPANGLER R, 1987, SCIENCE, V237, P1044, DOI 10.1126/science.2956686; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; WEBSTER LC, 1991, IN PRESS MOL CELL BI; WEEKS DL, 1985, NUCLEIC ACIDS RES, V13, P5389, DOI 10.1093/nar/13.14.5389; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YACIUK P, 1990, J VIROL, V64, P4421; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G; ZOPF D, 1990, NATURE, V346, P87, DOI 10.1038/346087a0	40	30	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1417	1422						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1832215				2022-12-25	WOS:A1991GX27200018
J	MAYEUX, PR; MORINELLI, TA; WILLIAMS, TC; HAZARD, ES; MAIS, DE; OATIS, JE; BARON, DA; HALUSHKA, PV				MAYEUX, PR; MORINELLI, TA; WILLIAMS, TC; HAZARD, ES; MAIS, DE; OATIS, JE; BARON, DA; HALUSHKA, PV			DIFFERENTIAL EFFECT OF PH ON THROMBOXANE-A2 PROSTAGLANDIN-H2 RECEPTOR AGONIST AND ANTAGONIST BINDING IN HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WASHED HUMAN-PLATELETS; DIETHYL PYROCARBONATE; CHEMICAL MODIFICATION; HISTIDINE RESIDUE; SITE; LIGAND; INACTIVATION; MEMBRANES; AFFINITY; U-46619	The effects of changes in pH on the binding of agonists and antagonists to the human platelet thromboxane A2/prostaglandin H-2 (TXA2/PGH2) receptor were determined. Competition binding studies were performed with the TXA2/PGH2 mimetic [1S-1-alpha, 2-beta(5Z), 3-alpha(1E,3R*), 4-alpha)]-7-[13-(3-(3-hydroxy-4'-iodophenoxy)-1-buteny)7-oxabicyclo-[2.2.1]-heptan-2-yl]-5-heptenoic acid ([I-125]BOP). The pH optimum for binding of [I-125] BOP to washed human platelets was broad with a range of pH 4-6 in contrast to that of the TXA2/PGH2 receptor antagonist 9,11-dimethyl-methano-11,12-methano-16-(3-iodo-4-hydroxyl)-13-aza-15-alpha, beta-omega-tetranorthromboxane A2([I-125]PTA-OH) which was 7.4. Scatchard analysis of [I-125]BOP binding in washed platelets at pH 7.4, 6.0, and 5.0 revealed an increase in affinity (K(d) = 1.16 +/- 0.06, 0.6 +/- 0.09, and 0.48 +/- 0.05 nM, respectively) and an increase in the number of receptors (B(max) = 2807 +/- 415, 5397 +/- 636, and 7265 +/- 753 sites/platelet, respectively). The potency of I-BOP to induce shape change in washed platelets at pH 6.0 was also significantly increased from an EC50 value of 0.34 +/- 0.016 nm at pH 7.4 to 0.174 +/- 0.014 nM at pH 6.0 (n = 6, p < 0.05). In contrast, the EC50 value for thrombin was unaffected by the change in pH. In competition binding studies with [I-125]BOP, the affinity of the agonists U46619 and ONO11113 were increased at pH 6.0 compared to 7.4. In contrast, the affinity of the TXA2/PGH2 receptor antagonists I-PTA-OH, SQ29548, and L657925 were either decreased or unchanged at pH 6.0 compared to 7.4. Diethyl pyrocarbonate and N-bromosuccinimide, reagents used to modify histidine residues, reversed the increase in affinity of [I-125]BOP at pH 6.0 to values equivalent to those at pH 7.4. In solubilized platelet membranes, the effects of NBS were blocked by coincubation with the TXA2/PGH2 mimetic U46619. The results suggest that agonist and antagonist binding characteristics are different for the TXA2/PGH2 receptor and that histidine residue(s) may play an important role in the binding of TXA2/PGH2 ligands to the receptor.	UNIV ARKANSAS MED SCI HOSP, DEPT PHARMACOL, LITTLE ROCK, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	MAYEUX, PR (corresponding author), MED UNIV S CAROLINA, DEPT CELL & MOLEC PHARMACOL & EXPTL THERAPEUT, CHARLESTON, SC 29425 USA.							ABDULWAJID AW, 1986, BIOCHEMISTRY-US, V25, P8167, DOI 10.1021/bi00373a007; BAME KJ, 1986, J BIOL CHEM, V261, P127; BATTAGLIA G, 1983, LIFE SCI, V33, P2011, DOI 10.1016/0024-3205(83)90740-3; BHATNAGAR A, 1987, BIOCHIM BIOPHYS ACTA, V916, P179, DOI 10.1016/0167-4838(87)90106-3; BURCH RM, 1985, P NATL ACAD SCI USA, V82, P7434, DOI 10.1073/pnas.82.21.7434; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COLEMAN RA, 1981, BRIT J PHARMACOL, V73, P773, DOI 10.1111/j.1476-5381.1981.tb16814.x; DECLERCK F, 1985, THROMB RES, V40, P581, DOI 10.1016/0049-3848(85)90297-X; DIPAOLA M, 1984, J BIOL CHEM, V259, P9163; DORN GW, 1990, J BIOL CHEM, V265, P4240; DORN GW, 1990, CIRCULATION, V81, P212, DOI 10.1161/01.CIR.81.1.212; DORN GW, 1989, J CLIN INVEST, V84, P1883, DOI 10.1172/JCI114375; FRASER CM, 1988, P NATL ACAD SCI USA, V85, P5478, DOI 10.1073/pnas.85.15.5478; HALLAM TJ, 1983, J PHYSIOL-LONDON, V343, pP97; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HOLME S, 1983, J LAB CLIN MED, V101, P161; KATSURA M, 1983, ADV PROSTAG THROMB L, V11, P351; KHANANSHVILI D, 1983, FEBS LETT, V159, P271, DOI 10.1016/0014-5793(83)80462-1; KLOTZ KN, 1988, J BIOL CHEM, V263, P17522; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LAMBOLEZ B, 1987, FEBS LETT, V219, P301, DOI 10.1016/0014-5793(87)80240-5; LEVEN RM, 1983, THROMB HAEMOSTASIS, V49, P230; MAIS D, 1984, TETRAHEDRON LETT, V25, P4207, DOI 10.1016/S0040-4039(01)81396-4; MAIS DE, 1985, J PHARMACOL EXP THER, V235, P729; MAIS DE, 1989, BIOCHIM BIOPHYS ACTA, V1012, P184, DOI 10.1016/0167-4889(89)90094-3; MAYEUX PR, 1988, BIOCHEM BIOPH RES CO, V157, P733, DOI 10.1016/S0006-291X(88)80311-5; Miles E W, 1977, Methods Enzymol, V47, P431; MONCADA S, 1978, PHARMACOL REV, V30, P293; MORINELLI TA, 1989, J PHARMACOL EXP THER, V251, P557; MORINELLI TA, 1987, AM J PHYSIOL, V253, pH1035, DOI 10.1152/ajpheart.1987.253.5.H1035; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURER EH, 1977, THROMB HAEMOSTASIS, V38, P1018; OGLETREE ML, 1985, J PHARMACOL EXP THER, V234, P435; PATSCHEKE H, 1981, HAEMOSTASIS, V10, P14; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SMITH JB, 1989, J BIOL CHEM, V264, P8723; STRADER CD, 1988, J BIOL CHEM, V263, P10267; SUZUKI H, 1988, BLOOD, V71, P1310; TAKAHARA K, 1990, J BIOL CHEM, V265, P6836; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P16309; VANKOPPEN CJ, 1988, BIOCHEM BIOPH RES CO, V151, P1069, DOI 10.1016/S0006-291X(88)80474-1; WITKOP B, 1961, ADV PROTEIN CHEM, V16, P221	43	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13752	13758						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1830308				2022-12-25	WOS:A1991FY02700048
J	MILGROM, YM; EHLER, LL; BOYER, PD				MILGROM, YM; EHLER, LL; BOYER, PD			THE CHARACTERISTICS AND EFFECT ON CATALYSIS OF NUCLEOTIDE BINDING TO NONCATALYTIC SITES OF CHLOROPLAST F1-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; ADENOSINE-TRIPHOSPHATASE; ATP HYDROLYSIS; MODULATION	The recent finding that the presence of ATP at noncatalytic sites of chloroplast F1-ATPase (CF1) is necessary for ATPase activity (Milgrom, Y. M., Ehler, L. L., and Boyer, P. D. (1990) J. Biol. Chem. 265,18725-18728) prompted more detailed studies of the effect of noncatalytic site nucleotides on catalysis. CF1 containing at noncatalytic sites less than one ADP or about two ATP was prepared by heat activation in the absence of Mg2+ and in the presence of ADP or ATP, respectively. After removal of medium nucleotides, the CF, preparations were used for measurement of the time course of nucleotide binding from 10 to 100-mu-M concentrations of H-3-labeled ADP, ATP, or GTP. The presence of Mg2+ strongly promotes the tight binding of ADP and ATP at noncatalytic sites. For example, the ADP-heat-activated enzyme in presence of 1 mm Mg2+ binds ADP with a rate constant of 0.5 x 10(6) M-1 min-1 to give an enzyme with two ADP at noncatalytic sites with a K(d) of about 0.1-mu-m. Upon exposure to Mg2+ and ATP the vacant noncatalytic site binds an ATP rapidly and, as an ADP slowly dissociates, a second ATP binds. The binding correlates with an increase in the ATPase activity. In contrast the tight binding of [H-3]GTP to noncatalytic sites gives an enzyme with no ATPase activity. The three noncatalytic sites differ in their binding properties. The noncatalytic site that remains vacant after the ADP-heat-activated CF1 is exposed to Mg2+ and ADP and that can bind ATP rapidly is designated as site A; the site that fills with ATP as ADP dissociates when this enzyme is exposed to Mg2+ and ATP is called site B, and the site to which ADP remains bound is called site C. Procedures are given for attaining CF1 with ADP at sites B and C, with GTP at sites A and/or B, and with ATP at sites A, B, and/or C, and catalytic activities of such preparations are measured. For example, little or no ATPase activity is found unless ATP is at site A, but ADP can remain at site C with no effect on ATPase. Maximal GTPase activity requires ATP at site A but about one-fifth of maximal GTPase is attained when GTP is at sites A and B and ATP at site C. Noncatalytic site occupancy can thus have profound effects on the ATPase and GTPase activities of CF1.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NIGMS NIH HHS [GM-11094] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011094] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUIST MF, 1981, BIOCHEMISTRY-US, V20, P6298, DOI 10.1021/bi00525a003; CARMELI C, 1981, BIOCHEMISTRY-US, V20, P3940, DOI 10.1021/bi00516a042; CROSS RL, 1981, ANNU REV BIOCHEM, V50, P681, DOI 10.1146/annurev.bi.50.070181.003341; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GUERRERO KJ, 1990, FEBS LETT, V270, P187, DOI 10.1016/0014-5793(90)81264-O; GUERRERO KJ, 1990, J BIOL CHEM, V265, P16280; KIRONDE FAS, 1987, J BIOL CHEM, V262, P3488; LECKBAND D, 1987, BIOCHEMISTRY-US, V26, P2306, DOI 10.1021/bi00382a035; MCCARTY RE, 1987, TRENDS BIOCHEM SCI, V12, P234, DOI 10.1016/0968-0004(87)90116-2; MILGROM YM, 1990, J BIOL CHEM, V265, P18725; MILGROM YM, 1986, BIOL MEMBRANY, V3, P981; MORONEY JV, 1983, FEBS LETT, V158, P58, DOI 10.1016/0014-5793(83)80676-0; MOUDRIANAKIS EN, 1976, J BIOL CHEM, V251, P7796; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; Racker E., 1971, METHOD ENZYMOL, V23, P547; WISE JG, 1985, BIOCHEMISTRY-US, V24, P6949, DOI 10.1021/bi00345a030; XUE ZX, 1989, EUR J BIOCHEM, V179, P677, DOI 10.1111/j.1432-1033.1989.tb14600.x; YOSHIDA M, 1986, J BIOL CHEM, V261, P5714	18	54	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11551	11558						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1828802				2022-12-25	WOS:A1991FT76200024
J	MORRIS, CM; HAO, QL; HEISTERKAMP, N; FITZGERALD, PH; GROFFEN, J				MORRIS, CM; HAO, QL; HEISTERKAMP, N; FITZGERALD, PH; GROFFEN, J			LOCALIZATION OF THE TRK PROTOONCOGENE TO HUMAN-CHROMOSOME BANDS 1Q23-1Q24	ONCOGENE			English	Note							DIFFERENT CELLULAR SEQUENCES; RECEPTOR KINASE DOMAIN; BIOCHEMICAL-CHARACTERIZATION; ACTIVATION; RECOMBINATION; GENE; MAPS	A FER-related sequence isolated from a human genomic library was found to be homologous to TRK. In situ hybridization of a 0.92 kb probe, isolated from this sequence, localized the TRK gene to the long arm of chromosome 1 within bands 1q23-1q24. This is a significantly more proximal location of TRK than the 1q32-1q41 site published recently (Miozzo et al., 1990).	CHILDRENS HOSP LOS ANGELES,DEPT PATHOL,MOLEC DIAG SECT,LOS ANGELES,CA	Children's Hospital Los Angeles	MORRIS, CM (corresponding author), CHRISTCHURCH HOSP,CYTOGENET & MOLEC ONCOL UNIT,CHRISTCHURCH,NEW ZEALAND.		Heisterkamp, Nora/C-1698-2012; Morris, Christine/G-1690-2011	Heisterkamp, Nora/0000-0003-2769-2273; 	NCI NIH HHS [1RO-CA47456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047456, R55CA047456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BONGARZONE I, 1989, ONCOGENE, V4, P1457; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MIOZZO M, 1990, ONCOGENE, V5, P1411; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; MORRIS C, 1990, CYTOGENET CELL GENET, V53, P196, DOI 10.1159/000132929; MORRIS CM, 1987, LEUKEMIA RES, V11, P163, DOI 10.1016/0145-2126(87)90022-1; OLAH E, 1989, CANCER GENET CYTOGEN, V43, P179, DOI 10.1016/0165-4608(89)90029-0; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807	13	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1093	1095						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1829807				2022-12-25	WOS:A1991GU62200030
J	MORABITO, MA; YU, X; BARNSTABLE, CJ				MORABITO, MA; YU, X; BARNSTABLE, CJ			CHARACTERIZATION OF DEVELOPMENTALLY REGULATED AND RETINA-SPECIFIC NUCLEAR-PROTEIN BINDING TO A SITE IN THE UPSTREAM REGION OF THE RAT OPSIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GEL-ELECTROPHORESIS; DNA; EXPRESSION; MOUSE; RHODOPSIN; RNA	DNase I protection and gel retardation assays have identified a sequence 5' to the transcription start site of the rat opsin gene that interacts with nuclear proteins from mammalian retinas but not from a variety of other neural and non-neural tissues. Following sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transfer to nitrocellulose the protein(s) responsible for this binding were identified with an oligonucleotide probe and were found to migrate with an apparent molecular size of 40 kilodaltons. The binding complex eluted from fast protein liquid chromatography gel filtration as a peak centered at 100 kilodaltons, suggesting the presence of more than one subunit. Binding activity could be detected in postnatal day 1 retinal extracts and increased over the next 2 weeks of development, a time course coincident with opsin gene expression and maturation of rod photoreceptors. Synthetic oligonucleotides with altered sequences showed that the binding was dependent upon residues in a CTAAT motif and was facilitated by surrounding GGCCCC sequences. The specificity of the binding interaction was measured by inhibition of complex formation in a gel retardation assay. The unaltered sequence was over 2 orders of magnitude more effective at inhibiting complex formation than either an unrelated DNA sequence or a concensus sequence corresponding to a known CCAAT box binding protein NF1.	YALE UNIV,SCH MED,DEPT OPHTHALMOL & VISUAL SCI,330 CEDAR ST,NEW HAVEN,CT 06510	Yale University			Barnstable, Colin/ABB-4822-2021; Barnstable, Colin/GLU-9219-2022	Barnstable, Colin/0000-0002-7011-4068	NATIONAL EYE INSTITUTE [P30EY000785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020483] Funding Source: NIH RePORTER; NEI NIH HHS [EY00785, EY05206] Funding Source: Medline; NINDS NIH HHS [NS 20483] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHMAD I, 1990, BIOCHEM BIOPH RES CO, V173, P463, DOI 10.1016/S0006-291X(05)81081-2; BAEHR W, 1988, FEBS LETT, V238, P253, DOI 10.1016/0014-5793(88)80490-3; BARNSTABLE CJ, 1987, MOL NEUROBIOL, V1, P9, DOI 10.1007/BF02935263; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P263, DOI 10.1002/cne.901880205; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HICKS D, 1987, J HISTOCHEM CYTOCHEM, V35, P1317, DOI 10.1177/35.11.3655327; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MORABITO M A, 1989, Society for Neuroscience Abstracts, V15, P1269; NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sidman RL, 1961, STRUCTURE EYE, P487; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P1318; TREISMAN JE, 1988, MOL CELL BIOL, V8, P1570, DOI 10.1128/MCB.8.4.1570; WATANABE T, 1990, NEURON, V4, P461, DOI 10.1016/0896-6273(90)90058-N; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215; ZACK D, 1990, Investigative Ophthalmology and Visual Science, V31, P76	27	94	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9667	9672						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1827795				2022-12-25	WOS:A1991FM45900052
J	PETTEPHER, CC; LEDOUX, SP; BOHR, VA; WILSON, GL				PETTEPHER, CC; LEDOUX, SP; BOHR, VA; WILSON, GL			REPAIR OF ALKALI-LABILE SITES WITHIN THE MITOCHONDRIAL-DNA OF RINR-38 CELLS AFTER EXPOSURE TO THE NITROSOUREA STREPTOZOTOCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENT BINDING; RAT-LIVER; ALKYLATION; MECHANISMS; NUCLEAR; DAMAGE; GENE; METABOLITES; CARCINOGENS; GLYCOSYLASE	Studies were initiated to investigate whether mechanisms exist within mitochondria to repair damage incurred by mitochondrial DNA after exposure to alkylating toxins. A clonal isolate from a rat insulinoma cell line was utilized to measure the formation and repair of alkali-labile sites within the mitochondrial genome after exposure to the alkylating antibiotic streptozotocin. Alkali-labile sites were formed in mitochondrial DNA in a dose-dependent fashion. Eight hours after exposure to the toxin, 55% of the lesions were removed. The level of repair increased to 70% after 24 h. In comparison, only 46% of N7-methylguanines were removed across the entire cellular genome. These studies demonstrate that streptozotocin causes appreciable mitochondrial DNA damage in a dose-dependent manner and provide the first evidence that a repair mechanism for alkali-labile sites is present within the mitochondrion.	NCI,MOLEC PHARMACOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	PETTEPHER, CC (corresponding author), UNIV SO ALABAMA,DEPT STRUCT & CELLULAR BIOL,MOBILE,AL 36688, USA.		Bohr, Vilhelm/AAP-5931-2020		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K04ES000150, R01ES003456] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES03456, ES00150] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLEN JA, 1980, NATURE, V287, P244, DOI 10.1038/287244a0; ANDERSON CTM, 1980, NUCLEIC ACIDS RES, V8, P875; BACKER JM, 1982, CANCER RES, V42, P2764; BACKER JM, 1980, SCIENCE, V209, P297, DOI 10.1126/science.6770466; BENNETT RA, 1981, CANCER RES, V41, P2786; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1986, P NATL ACAD SCI USA, V83, P3830, DOI 10.1073/pnas.83.11.3830; Bohr VA, 1988, DNA REPAIR LABORATOR, V3, P347; CLAYTON DA, 1974, P NATL ACAD SCI USA, V71, P2777, DOI 10.1073/pnas.71.7.2777; DOMENA JD, 1988, BIOCHEMISTRY-US, V27, P6742, DOI 10.1021/bi00418a015; FRANCISCO JF, 1979, PLASMID, V2, P426, DOI 10.1016/0147-619X(79)90026-X; GAZDAR AF, 1980, P NATL ACAD SCI-BIOL, V77, P3519, DOI 10.1073/pnas.77.6.3519; LEDOUX SP, 1984, BIOCHIM BIOPHYS ACTA, V804, P387, DOI 10.1016/0167-4889(84)90064-8; LEDOUX SP, 1986, DIABETES, V35, P866, DOI 10.2337/diabetes.35.8.866; LEDOUX SP, 1990, J BIOL CHEM, V265, P14875; LEVY GN, 1984, TOXICOL LETT, V22, P229, DOI 10.1016/0378-4274(84)90071-7; MEYERS KA, 1988, CARCINOGENESIS, V9, P285; MIYAKI M, 1977, CHEM-BIOL INTERACT, V17, P321, DOI 10.1016/0009-2797(77)90095-3; NIRANJAN BG, 1982, SCIENCE, V215, P73, DOI 10.1126/science.6797067; REDDY MV, 1984, CARCINOGENESIS, V5, P231, DOI 10.1093/carcin/5.2.231; RUSHMORE T, 1984, CHEM-BIOL INTERACT, V49, P133; SAFFHILL R, 1985, BIOCHIM BIOPHYS ACTA, V823, P111, DOI 10.1016/0304-419X(85)90009-5; SCICCHITANO DA, 1989, P NATL ACAD SCI USA, V86, P3050, DOI 10.1073/pnas.86.9.3050; TEEBOR GW, 1981, DNA REPAIR, V1, P203; TOMKINSON AE, 1988, J BIOL CHEM, V263, P12532; TOMKINSON AE, 1990, NUCLEIC ACIDS RES, V18, P929, DOI 10.1093/nar/18.4.929; WANI AA, 1986, ARCH BIOCHEM BIOPHYS, V246, P690, DOI 10.1016/0003-9861(86)90325-5; WILSON GL, 1988, DIABETES, V37, P213, DOI 10.2337/diabetes.37.2.213; WUNDERLI.V, 1970, BIOCHEM J, V118, P99, DOI 10.1042/bj1180099; WUNDERLICH V, 1971, CHEM-BIOL INTERACT, V4, P81, DOI 10.1016/0009-2797(72)90001-4	30	132	144	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1991	266	5					3113	3117						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EX600	1825207				2022-12-25	WOS:A1991EX60000067
J	BECKMANN, R; GEIGER, M; DEVRIES, C; PANNEKOEK, H; BINDER, BR				BECKMANN, R; GEIGER, M; DEVRIES, C; PANNEKOEK, H; BINDER, BR			FIBRONECTIN DECREASES THE STIMULATORY EFFECT OF FIBRIN AND FIBRINOGEN FRAGMENT FCB-2 ON PLASMIN FORMATION BY TISSUE PLASMINOGEN-ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMBINED ASSAY SYSTEM; AFFINITY CHROMATOGRAPHY; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; ESCHERICHIA-COLI; KRINGLE-2 DOMAIN; KINETIC-ANALYSIS; BINDING DOMAINS; GLU-PLASMINOGEN; FINGER-DOMAIN	Fibronectin is a dimeric glycoprotein (M(r) 440,000) involved in many adhesive processes. During blood coagulation it is bound and cross-linked to fibrin. Fibrin binding is achieved by structures (type I repeats) which are homologous to the "finger" domain of tissue plasminogen activator. Tissue plasminogen activator also binds to fibrin via the finger domain and additionally via the "kringle 2" domain. Fibrin binding of tissue plasminogen activator results in stimulation of its activity and plays a crucial role in fibrinolysis. Since fibronectin might interfere with this binding, we studied the effect of fibronectin on plasmin formation by tissue plasminogen activator. In the absence of fibrin, fibronectin had no effect on plasminogen activation. In the presence of stimulating fibrinogen fragment FCB-2, fibronectin increased the duration of the initial lag phase (= time period until maximally stimulated plasmin formation occurs) and decreased the rate of maximal plasmin formation which occurs after that lag phase mainly by increasing the Michaelis constant (K(m)). These effects of fibronectin were dose-dependent and were similar with single- and two-chain tissue plasminogen activator. They were also observed with plasmin-pretreated FCB-2. An apparent K(i) of 43-mu-g/ml was calculated for the inhibitory effect of fibronectin when plasminogen activation by recombinant single-chain tissue plasminogen activator was studied in the presence of 91-mu-g/ml FCB-2. When a recombinant tissue plasminogen activator mutant lacking the finger domain was used in a system containing FCB-2, no effect of fibronectin was seen, indicating that the inhibitory effect of fibronectin might in fact be due to competition of fibronectin and tissue plasminogen activator for binding to fibrin(ogen) via the finger domain.	UNIV VIENNA,DEPT MED PHYSIOL,CLIN & EXPTL PHYSIOL LAB,SCHWARZSPANIERSTR 17,A-1090 VIENNA,AUSTRIA; NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,AMSTERDAM,NETHERLANDS	University of Vienna				Geiger, Margarethe/0000-0003-2021-5319				BACHMANN F, 1987, THROMB DIATH HAEMO, P227; BASTIDA E, 1989, INT J CANCER, V43, P1174, DOI 10.1002/ijc.2910430635; BECKMANN R, 1988, J BIOL CHEM, V263, P7176; BINDER BR, 1979, J BIOL CHEM, V254, P1998; BLOMBACK B, 1968, NATURE, V218, P130, DOI 10.1038/218130a0; CARDARELLI PM, 1986, P NATL ACAD SCI USA, V83, P2647, DOI 10.1073/pnas.83.8.2647; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DEVRIES C, 1989, J BIOL CHEM, V264, P12604; GEIGER M, 1984, J BIOL CHEM, V259, P2976; GILBOA N, 1985, THROMB HAEMOSTASIS, V54, P639; GRINNELL F, 1980, CELL, V19, P516; HARPEL PC, 1985, J BIOL CHEM, V260, P4432; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; HEDIN U, 1987, DIFFERENTIATION, V33, P239, DOI 10.1111/j.1432-0436.1987.tb01563.x; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; INGHAM KC, 1989, J BIOL CHEM, V264, P16977; KAGITANI H, 1985, FEBS LETT, V189, P145, DOI 10.1016/0014-5793(85)80860-7; KNOX P, 1986, J CELL BIOL, V102, P2318, DOI 10.1083/jcb.102.6.2318; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKI K, 1951, ARCH BIOCHEM BIOPHYS, V32, P317, DOI 10.1016/0003-9861(51)90277-9; LIAO NS, 1989, EXP CELL RES, V181, P348, DOI 10.1016/0014-4827(89)90093-1; LUNDBLAD RL, 1971, BIOCHEMISTRY-US, V10, P2501, DOI 10.1021/bi00789a012; MCDONALD JA, 1980, J BIOL CHEM, V255, P8848; MOSHER DF, 1975, J BIOL CHEM, V250, P6614; NIEUWENHUIZEN W, 1983, BIOCHIM BIOPHYS ACTA, V755, P531, DOI 10.1016/0304-4165(83)90261-1; NORRMAN B, 1985, EUR J BIOCHEM, V149, P193, DOI 10.1111/j.1432-1033.1985.tb08911.x; PATEL RS, 1987, EMBO J, V6, P2565, DOI 10.1002/j.1460-2075.1987.tb02545.x; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; PIERSCHBACHER MD, 1981, CELL, V26, P259, DOI 10.1016/0092-8674(81)90308-1; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; RANBY M, 1982, BIOCHIM BIOPHYS ACTA, V704, P461, DOI 10.1016/0167-4838(82)90068-1; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1982, METHOD ENZYMOL, V82, P803; SALONEN EM, 1985, J BIOL CHEM, V260, P2302; SAVAGNER P, 1986, J CELL BIOL, V103, P2715, DOI 10.1083/jcb.103.6.2715; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SKUBITZ APN, 1989, INVAS METAST, V9, P89; SUENSON E, 1986, BIOCHIM BIOPHYS ACTA, V870, P510, DOI 10.1016/0167-4838(86)90260-8; TRANTHANG C, 1986, EUR J BIOCHEM, V160, P599, DOI 10.1111/j.1432-1033.1986.tb10080.x; VANZONNEVELD AJ, 1986, P NATL ACAD SCI USA, V83, P4670; VANZONNEVELD AJ, 1986, J BIOL CHEM, V261, P14214; VERHEIJEN JH, 1986, EMBO J, V5, P3525, DOI 10.1002/j.1460-2075.1986.tb04678.x; VUENTO M, 1979, BIOCHEM J, V183, P331, DOI 10.1042/bj1830331; WALTHER PJ, 1975, J BIOL CHEM, V250, P5926; WOJTA J, 1989, J BIOL CHEM, V264, P7957; WOJTA J, 1989, THROMB HAEMOSTASIS, V61, P289; WOJTA J, 1987, J LAB CLIN MED, V109, P665	48	7	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2227	2232						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1824940				2022-12-25	WOS:A1991EV51500034
J	YOUSEFI, S; HIGGINS, E; ZHUANG, DL; POLLEXKRUGER, A; HINDSGAUL, O; DENNIS, JW				YOUSEFI, S; HIGGINS, E; ZHUANG, DL; POLLEXKRUGER, A; HINDSGAUL, O; DENNIS, JW			INCREASED UDP-GLCNAC-GAL-BETA-1-3GALNAC-R (GLCNAC TO GALNAC)BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE ACTIVITY IN METASTATIC MURINE TUMOR-CELL LINES - CONTROL OF POLYLACTOSAMINE SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; HAMSTER-KIDNEY CELLS; MAMMARY ADENOCARCINOMA CELLS; BLOOD-GROUP-I; MUCIN SYNTHESIS; MEMBRANE-GLYCOPROTEINS; N-ACETYLGLUCOSAMINYLTRANSFERASE; GLYCOSYLATION; EXPRESSION; ANTIGENS	Malignant transformation of rodent cell lines by polyoma virus and by activated ras genes is associated with increased UDP-GlcNAc: Man-alpha-R beta-1, 6-N-acetylglucosaminyltransferase V (GlcNAc-transferase V) activity and its product -GlcNAc-beta-1-6Man-alpha-1-6Man-beta-1-branched Asn-linked oligosaccharides. In this report, we have compared beta-1-6GlcNAc branching of core O-and N-linked oligosaccharides in three experimental models of malignancy, namely (a) rat2 fibroblasts and their malignant T24H-ras-transfected counterpart; (b) benign SP1 mammary carcinoma cells and two metastatic sublines of SP1; and (c) the metastatic MDAY-D2 lymphoma cell line and its poorly metastatic glycosylation mutant KBL-1. In addition to the previously reported increase in GlcNAc-transferase V activity, UDP-GlcNAc: Gal-beta-1-3GalNAc-alpha-R (GlcNAc to GalNAc) beta-1, 6-N-acetylglucosaminyltransferase (core 2 GlcNAc-transferase, EC 2.4.1.102) activity was found to be elevated by 70% in the malignant rat2 and SP1 cell lines while several other glycosyltransferase activities were not significantly different. The action of core 2 GlcNAc-transferase followed by beta-1-4Gal-transferase provides an N-acetyllactosamine antenna that can be extended with polylactosamine (i.e. repeating Gal-beta-1-4GlcNAc-beta-1-3) provided UDP-GlcNAc: Gal-beta-R beta-1-3GlcNAc-transferase (GlcNAc-transferase (i)) activity is present. Polylactosamine content in microsomal membrane glycoproteins was quantitated by labeling the GlcNAc termini resulting from the action of Escherichia freundii endo-beta-galactosidase with bovine galactosyltransferase/UDP-[H-3] Gal. Glycopeptidase F- sensitive and -insensitive fractions were measured to assess the N- and O-linked components. In the SP1 tumor model, the metastatic sublines showed increased core 2 GlcNAc-transferase and GlcNAc-transferase V activities but no change in GlcNAc-transferase (i) activity, yet polylactosamine was increased in both O- and N-linked oligosaccharides. In rat2 cells, down-regulation of GlcNAc-transferase (i) following transformation was associated with decreased polylactosamine even though core 2 GlcNAc-transferase and GlcNAc-transferase V were elevated in the cells. Finally, a 3-fold decrease in GlcNAc-transferase V in KBL-1, the glycosylation mutant of MDAY-D2 cells, resulted in complete loss of polylactosamine in N-linked but no change in O-linked polylactosamine content. These results suggest that, provided GlcNAc-transferase (i) is not limiting, the beta-1-6-branching enzymes core 2 GlcNAc-transferase and GlcNAc-transferase V regulate the levels of polylactosamine in O- and N-linked oligosaccharides, respectively. In addition, malignant transformation in the rat2 and SP1 tumor models is associated with increased beta-1-6GlcNAc branching of O-linked as well as N-linked oligosaccharides.	UNIV TORONTO, DEPT MED GENET, TORONTO M5S 1A1, ONTARIO, CANADA; UNIV ALBERTA, FAC SCI, DEPT CHEM, EDMONTON T6G 2G2, ALBERTA, CANADA	University of Toronto; University of Alberta	YOUSEFI, S (corresponding author), MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO M5G 1X5, ONTARIO, CANADA.		Yousefi, Shida/AAU-7986-2020; Dennis, James/E-7268-2013; Yousefi, Shida/L-9689-2016	Yousefi, Shida/0000-0002-9855-4305; Yousefi, Shida/0000-0002-9855-4305				BENDIAK B, 1989, BIOCHEMISTRY-US, V28, P6491, DOI 10.1021/bi00441a050; BROCKHAUSEN I, 1983, CAN J BIOCHEM CELL B, V61, P1322, DOI 10.1139/o83-169; BROCKHAUSEN I, 1985, BIOCHEMISTRY-US, V24, P1866, DOI 10.1021/bi00329a010; CARLOW DA, 1985, J NATL CANCER I, V75, P291; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; CHEN JW, 1988, J BIOL CHEM, V263, P8754; COLE LA, 1987, J CLIN ENDOCR METAB, V65, P811, DOI 10.1210/jcem-65-4-811; CUMMINGS RD, 1988, J BIOL CHEM, V263, P511; CUMMINGS RD, 1982, J BIOL CHEM, V257, P13421; DEBRAY H, 1986, INT J CANCER, V37, P607, DOI 10.1002/ijc.2910370421; DENNIS JW, 1988, CANCER SURV, V7, P573; DENNIS JW, 1989, ONCOGENE, V4, P853; DENNIS JW, 1989, CANCER RES, V49, P945; DENNIS JW, 1986, EUR J BIOCHEM, V161, P359, DOI 10.1111/j.1432-1033.1986.tb10455.x; DENNIS JW, 1984, J CELL BIOL, V99, P1034, DOI 10.1083/jcb.99.3.1034; DENNIS JW, 1986, CANCER RES, V46, P5131; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; DUTT A, 1988, J BIOL CHEM, V263, P2270; FUKUDA M, 1984, BIOL GLYCOPROTEINS, P183; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HEFFERNAN M, 1989, CANCER RES, V49, P6077; HOLMES EH, 1987, J BIOL CHEM, V262, P15649; HUMPHRIES MJ, 1986, P NATL ACAD SCI USA, V83, P1752, DOI 10.1073/pnas.83.6.1752; ITZKOWITZ SH, 1986, CANCER RES, V46, P2627; KAPADIA A, 1981, EXP CELL RES, V131, P185, DOI 10.1016/0014-4827(81)90418-3; KORCZAK B, 1989, CANCER RES, V49, P2597; LAFERTE S, 1989, BIOCHEM J, V259, P569, DOI 10.1042/bj2590569; LAFERTE S, 1988, CANCER RES, V48, P4743; MERKLE RK, 1988, J BIOL CHEM, V263, P16143; NARASIMHAN S, 1989, 32ND ANN M CAN FED B; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PIERCE M, 1986, J BIOL CHEM, V261, P772; PILLER F, 1983, J BIOL CHEM, V258, P2293; PILLER F, 1988, J BIOL CHEM, V263, P15146; SANTER UV, 1979, BIOCHEMISTRY-US, V18, P2533, DOI 10.1021/bi00579a016; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SINGHAL AK, 1990, CANCER RES, V50, P1375; SMETS LA, 1983, BIOCHIM BIOPHYS ACTA, V738, P237, DOI 10.1016/0304-419X(83)90006-9; SPOONCER E, 1984, J BIOL CHEM, V259, P4792; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450; TAKASAKI S, 1980, BIOCHEM BIOPH RES CO, V92, P735, DOI 10.1016/0006-291X(80)90765-2; TORRES CR, 1984, J BIOL CHEM, V259, P3308; TURCO SJ, 1980, J BIOL CHEM, V255, P3266; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; VANHALBEEK H, 1981, FEBS LETT, V133, P45, DOI 10.1016/0014-5793(81)80467-X; VIITALA J, 1984, EUR J BIOCHEM, V138, P393, DOI 10.1111/j.1432-1033.1984.tb07928.x; WAGHORNE C, 1987, ONCOGENE, V1, P149; WARREN L, 1978, BIOCHIM BIOPHYS ACTA, V516, P97, DOI 10.1016/0304-419X(78)90005-7; WILLIAMS D, 1980, J BIOL CHEM, V255, P1247; WILLIAMS D, 1980, J BIOL CHEM, V255, P1253; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; YAMASHITA K, 1984, J BIOL CHEM, V259, P834; ZHU BCR, 1985, J BIOL CHEM, V260, P4041	53	212	219	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1772	1782						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1824844				2022-12-25	WOS:A1991EU49700065
J	GUNTHER, R; BRAUER, C; JANETZKY, B; FORSTER, HH; EHBRECHT, IM; LEHLE, L; KUNTZEL, H				GUNTHER, R; BRAUER, C; JANETZKY, B; FORSTER, HH; EHBRECHT, IM; LEHLE, L; KUNTZEL, H			THE SACCHAROMYCES-CEREVISIAE TRG1 GENE IS ESSENTIAL FOR GROWTH AND ENCODES A LUMENAL ENDOPLASMIC-RETICULUM GLYCOPROTEIN INVOLVED IN THE MATURATION OF VACUOLAR CARBOXYPEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DISULFIDE ISOMERASE; HORMONE-BINDING-PROTEIN; PROLYL 4-HYDROXYLASE; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; PHOSPHOLIPASE-C; BETA-SUBUNIT; YEAST; GLYCOSYLATION; EXPRESSION	We have isolated and mapped to the left end of chromosome III a single-copy gene (TRG1) encoding a 72-kDa glycoprotein, by screening a yeast genomic library with a DNA probe specifying the catalytic center (APWCGHCK) of thioredoxin-related proteins. The TRG1 gene sequence predicts an amino-terminal leader peptide, two thioredoxin-like domains, five N-glycosylation sites and a carboxyl-terminal HDEL retention signal. The TRG1 protein shows about equal sequence similarity to a mammalian multifunctional protein family residing in the lumen of the endoplasmic reticulum (ER), and to a putative cytosolic alpha-form of phosphoinositide-specific phospholipase C. Haploid cells do not survive TRG1 gene disruptions, unless an additional wild-type copy is generated by interchromosomal transposition. Antibodies raised against synthetic amino- and carboxyl-terminal epitopes recognize a pair of lumenl ER glycoproteins (gp70/72) and a cytosolic 48-kDa protein. A 1.8-kilobase TRG1 transcript was translated by a reticulocyte lysate into a 60-kDa protein, which was translocated and processed to a 72-kDa glycoprotein in the presence of ER membrane vesicles. The TRG1 gene was placed under the control of the galactose-inducible and glucose-repressible GAL1 promoter, leading to growth arrest in glucose media. Glucose repression of the TRG1 gene caused the disappearance of gp72 and the accumulation of procarboxypeptidase. Our data indicate that the TRG1 gene encodes a growth essential lumenal ER glycoprotein involved the maturation of vacuolar carboxypeptidase.	MAX PLANCK INST EXPTL MED,CHEM ABT,HERMANN REIN STR 3,W-3400 GOTTINGEN,GERMANY; UNIV REGENSBURG,INST ZELLBIOL,W-8400 REGENSBURG,GERMANY	Max Planck Society; University of Regensburg								ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; ALBIG W, 1988, GENE, V73, P141, DOI 10.1016/0378-1119(88)90320-4; AMMERER G, 1983, METHOD ENZYMOL, V101, P192; BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BULLEID NJ, 1990, EMBO J, V9, P3527, DOI 10.1002/j.1460-2075.1990.tb07561.x; CARLE GF, 1986, SCIENCE, V232, P65, DOI 10.1126/science.3952500; CHENG SY, 1987, J BIOL CHEM, V262, P11221; CHEVALLIER MR, 1980, GENE, V11, P11, DOI 10.1016/0378-1119(80)90082-7; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; EMMELOT P, 1964, BIOCHIM BIOPHYS ACTA, V90, P126, DOI 10.1016/0304-4165(64)90125-4; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; HOLMGREN A, 1968, EUR J BIOCHEM, V6, P475, DOI 10.1111/j.1432-1033.1968.tb00470.x; HSU MP, 1989, BIOCHEMISTRY-US, V28, P6440, DOI 10.1021/bi00441a042; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KESZENMANPEREYRA D, 1988, CURR GENET, V13, P21, DOI 10.1007/BF00365751; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; LEHLE L, 1980, EUR J BIOCHEM, V109, P589, DOI 10.1111/j.1432-1033.1980.tb04832.x; LISZIEWICZ J, 1987, J BIOL CHEM, V262, P2549; MARRIOTT M, 1979, J BACTERIOL, V139, P565, DOI 10.1128/JB.139.2.566-572.1979; Maxam A M, 1980, Methods Enzymol, V65, P499; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MIZUNAGA T, 1990, J BIOCHEM, V108, P846, DOI 10.1093/oxfordjournals.jbchem.a123291; MORTIMER RK, 1989, YEAST, V5, P321, DOI 10.1002/yea.320050503; MUNDER T, 1988, MOL GEN GENET, V214, P271, DOI 10.1007/BF00337721; PARKKONEN T, 1988, BIOCHEM J, V256, P1005, DOI 10.1042/bj2561005; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; ROITSCH T, 1989, BIOCHIM BIOPHYS ACTA, V1009, P19, DOI 10.1016/0167-4781(89)90073-0; Sambrook J, 1989, MOL CLONING LABORATO; Sherman F., 1982, METHODS YEAST GENETI; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; TASANEN K, 1988, J BIOL CHEM, V263, P16218; VONHEIJNE G, 1989, FEBS LETT, V244, P439, DOI 10.1016/0014-5793(89)80579-4; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800	38	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24557	24563						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761554				2022-12-25	WOS:A1991GW84500050
J	BAGLIA, FA; JAMESON, BA; WALSH, PN				BAGLIA, FA; JAMESON, BA; WALSH, PN			IDENTIFICATION AND CHEMICAL SYNTHESIS OF A SUBSTRATE-BINDING SITE FOR FACTOR-IX ON COAGULATION FACTOR-XIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; HEAVY-CHAIN; FACTOR-XIIA; FACTOR-X; FUNCTIONAL-CHARACTERIZATION; KINETIC-BEHAVIOR; HAGEMAN-FACTOR; HUMAN-PLASMA; ACTIVATION; MECHANISM	We have previously used monoclonal antibodies to identify an epitope on the heavy chain of factor XIa that is a substrate-binding site for factor IX (Sinha, D., Seaman, F. S., and Walsh, P. N. (1987) Biochemistry 26, 3768-3775; Baglia, F. A., Sinha, D., and Walsh, P. N. (1989) Blood 74, 244-251). To define the factor XIa domain that binds factor IX, we have now screened a panel of factor XI heavy chain-derived synthetic peptides for their capacity to inhibit the formation of an activation peptide reflecting factor IX activation by factor Xla. Peptide Asn145-Ala176 (which is located in the second tandem repeat or A2 domain of the factor XI heavy chain) is a competitive inhibitor of factor IX activation by factor XIa with a K(i) of 30 nm, whereas structurally similar peptides in the A1, A3, and A4 domains were required at 10-1000-fold higher concentrations for similar effects, and a synthetic peptide identical with a highly homologous region of the heavy chain A2 domain of prekallikrein (Tyr143-Ala176) had no effect on factor IX activation by factor XIa. Because detailed structural information is lacking, a potential three-dimensional structure for the factor XI A2 domain was calculated based on its sequence information in conjunction with previously determined structural constraints. The resulting structure depicted three juxtaposed beta-stranded stem-loops that, based on biological information, constitute a candidate surface for contact with factor IX. The A2 model was therefore used as a template in the rational design of three synthetic peptides (Ala134-Ile146 (peptide a), Leu148-Arg159 (peptide b), and Ile160-Leu172 (peptide c)). When peptides a and b or a and c were added together and the activation of factor IX by factor XIa was examined, a synergistic inhibitory effect was observed, compared with each peptide added individually, whereas peptides b and c showed additive effects. Our data suggest that the sequence of amino acids from Ala134 through Leu172 of the heavy chain of factor XI contains three antiparallel beta-strands connected by-beta-turns that together comprise a continuous surface utilized for the binding of factor IX.	TEMPLE UNIV, HLTH SCI CTR,SCH MED,THROMBOSIS RES CTR, 3400 N BROAD ST, PHILADELPHIA, PA 19140 USA; THOMAS JEFFERSON UNIV, PHILADELPHIA, PA 19107 USA; TEMPLE UNIV, HLTH SCI CTR, SCH MED, DEPT MED, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, HLTH SCI CTR, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	WALSH, PN (corresponding author), TEMPLE UNIV, HLTH SCI CTR, SCH MED, THROMBOSIS RES CTR, 3400 N BROAD ST, PHILADELPHIA, PA 19140 USA.				NHLBI NIH HHS [HL36579, HL46213, HL45486] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036579, P50HL045486, R01HL046213] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA H, 1986, J CLIN INVEST, V78, P1631, DOI 10.1172/JCI112756; BAGLIA FA, 1990, J BIOL CHEM, V265, P4149; BAGLIA FA, 1989, BLOOD, V74, P244; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; Davie E W, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P277; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GRIFFIN JH, 1976, P NATL ACAD SCI USA, V73, P2554, DOI 10.1073/pnas.73.8.2554; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; JAMESON BA, 1989, NATURE, V341, P465, DOI 10.1038/341465a0; KENT SBH, 1985, SYNTHETIC PEPTIDES B, P29; KURACHI K, 1980, BIOCHEMISTRY-US, V19, P1330, DOI 10.1021/bi00548a011; KURACHI K, 1977, BIOCHEMISTRY-US, V16, P5831, DOI 10.1021/bi00645a030; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; MILETICH JP, 1980, ANAL BIOCHEM, V105, P304, DOI 10.1016/0003-2697(80)90462-5; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; SCOTT CF, 1984, BLOOD, V63, P42; SEGAL IH, 1974, ENZYME KINETICS, P100; SILVERBERG SA, 1977, J BIOL CHEM, V252, P8481; SINHA D, 1985, J BIOL CHEM, V260, P714; SINHA D, 1987, BIOCHEMISTRY-US, V26, P3768, DOI 10.1021/bi00387a005; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; WALSH PN, 1984, J CLIN INVEST, V73, P1392, DOI 10.1172/JCI111343	25	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					24190	24197						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748688				2022-12-25	WOS:A1991GV31900101
J	RUBIN, D; LAPOSATA, M				RUBIN, D; LAPOSATA, M			REGULATION OF AGONIST-INDUCED PROSTAGLANDIN-E1 VERSUS PROSTAGLANDIN-E2 PRODUCTION - A MASS ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-LINOLENIC ACID; UNSATURATED FATTY-ACIDS; RAT-LIVER MICROSOMES; CANINE KIDNEY-CELLS; ARACHIDONIC-ACID; HUMAN-PLATELETS; PROLONGED SURVIVAL; ENDOTHELIAL-CELLS; MAMMALIAN-CELLS; COA SYNTHETASE	Prostaglandin E1 (PGE1) and prostaglandin E2 (PGE2), derived by enzymatic oxidation of cellular dihomogammalinolenic acid (DHLA) and arachidonic acid (AA), respectively, have diverse and, at times, distinct biological actions. It has been suggested that PGE, specifically inhibits a variety of inflammatory processes, and, in light of the potential therapeutic benefit of PGE1 and its fatty acid precursor in inflammatory disorders, there is growing interest in the biochemical mechanisms which determine the balance between PGE1 and PGE2 synthesis. Metabolic studies in this area have been hampered by the difficulties in measuring the extremely small masses of these prostaglandins which are generated in cell culture systems. We studied the regulation of PGE1 versus PGE2 synthesis using an essential fatty acid-deficient, PGE-producing, mouse fibrosarcoma cell line, EFD-1. Because EFD-1 cells contain no endogenous AA or DHLA, we were able to replete the cells with AA and DHLA of known specific activities; thus, the mass of both cellular AA and DHLA, and synthesized PGE1 and PGE2, could be accurately determined. The major finding of this study is that production of PGE2 was highly favored over production of PGE1 due to preferential incorporation of AA versus DHLA into, and release from, the total cellular phospholipid pool. Further, we correlated the selective release of AA versus DHLA from total cellular phospholipids with the selective incorporation of AA versus DHLA into specific phospholipid pools. In addition, we showed that conversion of DHLA to AA by DELTA-5 desaturase was enhanced by increasing the cellular mass of n - 6 fatty acids and by increasing the cell proliferative activity. Together, these results indicate that the relative abundance of PGE2 versus PGE1 in vivo is not merely a function of the relative abundance of AA versus DHLA in tissues, but also relates to markedly different cellular metabolism of these two fatty acids.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	RUBIN, D (corresponding author), MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043159] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43159] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUTHI KS, 1985, FEBS LETT, V180, P95, DOI 10.1016/0014-5793(85)80239-8; BAKER DG, 1989, ARTHRITIS RHEUM, V32, P1273, DOI 10.1002/anr.1780321013; BAKER RR, 1973, J BIOL CHEM, V248, P7060; BANERJEE N, 1986, BIOCHIM BIOPHYS ACTA, V878, P404, DOI 10.1016/0005-2760(86)90249-3; BEAUDRY GA, 1982, J BIOL CHEM, V257, P973; BELL RL, 1980, PROSTAGLANDINS, V20, P269, DOI 10.1016/S0090-6980(80)80045-1; BILLS TK, 1977, J CLIN INVEST, V60, P1, DOI 10.1172/JCI108745; Capriotti A, 1986, J TISSUE CULTURE MET, V10, P219, DOI 10.1007/BF01404480; CHAPKIN RS, 1989, CANCER RES, V49, P4724; CHILTON FH, 1988, J BIOL CHEM, V263, P5260; CHRIST EJ, 1972, BIOCHIM BIOPHYS ACTA, V270, P537, DOI 10.1016/0005-2760(72)90119-1; COHEN P, 1971, J CLIN INVEST, V50, P762, DOI 10.1172/JCI106547; DANIEL LW, 1981, J BIOL CHEM, V256, P2830; DUMM INTD, 1983, LIPIDS, V18, P781, DOI 10.1007/BF02534636; Fantone J. C., 1985, PROSTAGLANDINS IMMUN, P123; GOSWAMI S, 1981, PROSTAGLANDINS, V22, P693, DOI 10.1016/0090-6980(81)90208-2; HERMAN CA, 1987, J CHROMATOGR, V394, P353, DOI 10.1016/S0021-9673(01)94187-1; HOFMANN SL, 1982, J BIOL CHEM, V257, P6461; HONG SL, 1979, J BIOL CHEM, V254, P1463; HURD ER, 1981, J CLIN INVEST, V67, P476, DOI 10.1172/JCI110056; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; KERNOFF PBA, 1977, BRIT MED J, V2, P1441, DOI 10.1136/bmj.2.6100.1441; KIRTLAND SJ, 1988, PROSTAG LEUKOTR ESS, V32, P165, DOI 10.1016/0952-3278(88)90168-8; KLOEZE J, 1969, BIOCHIM BIOPHYS ACTA, V187, P285, DOI 10.1016/0005-2760(69)90001-0; KRAKAUER KA, 1986, PROSTAGLANDINS, V32, P301, DOI 10.1016/0090-6980(86)90133-4; KRAMER RM, 1984, J BIOL CHEM, V259, P2403; KRAMER RM, 1983, J BIOL CHEM, V258, P3806; LAGARDE M, 1982, Biochemical Society Transactions, V10, P241; LANDS WEM, 1982, J BIOL CHEM, V257, P4968; LAPOSATA M, 1982, P NATL ACAD SCI-BIOL, V79, P7654, DOI 10.1073/pnas.79.24.7654; LEVINE L, 1972, BIOCHEM BIOPH RES CO, V47, P888, DOI 10.1016/0006-291X(72)90576-1; MAJERUS PW, 1985, INOSITOL PHOSPHOINOS, P443; MCKEAN ML, 1982, J BIOL CHEM, V257, P1278; MILLER CC, 1988, BIOCHEM BIOPH RES CO, V154, P967, DOI 10.1016/0006-291X(88)90234-3; NEEDLEMAN P, 1985, BIOCHIM BIOPHYS ACTA, V836, P267, DOI 10.1016/0005-2760(85)90075-X; NELSON GJ, 1986, LIPIDS, V21, P454, DOI 10.1007/BF02536403; NEUFELD EJ, 1984, J BIOL CHEM, V259, P1986; NEUFELD EJ, 1984, J LIPID RES, V25, P288; NEWCOMBE DS, 1975, P NATL ACAD SCI USA, V72, P3124, DOI 10.1073/pnas.72.8.3124; POWELL WS, 1987, PROG LIPID RES, V26, P183, DOI 10.1016/0163-7827(87)90003-8; PULLMANMOOAR S, 1990, ARTHRITIS RHEUM, V33, P1526, DOI 10.1002/art.1780331010; ROBINSON M, 1985, J BIOL CHEM, V260, P7889; ROSENTHAL MD, 1987, BIOCHIM BIOPHYS ACTA, V917, P279, DOI 10.1016/0005-2760(87)90132-9; ROSENTHAL MD, 1987, PROG LIPID RES, V26, P87, DOI 10.1016/0163-7827(87)90009-9; ROSENTHAL MD, 1988, LIPIDS, V23, P1089, DOI 10.1007/BF02535658; SAMUELSSON B, 1981, HARVEY LECT, V75, P1; SCHARSCHMIDT LA, 1989, AM J PHYSIOL, V256, pC101, DOI 10.1152/ajpcell.1989.256.1.C101; SPECTOR AA, 1981, J CLIN INVEST, V68, P1003, DOI 10.1172/JCI110322; STONE KJ, 1979, LIPIDS, V14, P174, DOI 10.1007/BF02533869; TAKAYAMA H, 1989, BIOCHEM J, V258, P427, DOI 10.1042/bj2580427; TESSNER TG, 1990, J BIOL CHEM, V265, P21032; TROTTER J, 1982, J BIOL CHEM, V257, P1816; TURK J, 1986, BIOCHIM BIOPHYS ACTA, V879, P399, DOI 10.1016/0005-2760(86)90232-8; WILSON DB, 1982, J BIOL CHEM, V257, P3510; ZURIER RB, 1977, ARTHRITIS RHEUM, V20, P1449, DOI 10.1002/art.1780200802; ZURIER RB, 1977, ARTHRITIS RHEUM, V20, P723, DOI 10.1002/art.1780200213; ZURIER RB, 1990, OMEGA 6 ESSENTIAL FA, P203	57	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23618	23623						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748640				2022-12-25	WOS:A1991GV31900018
J	SMELAND, TE; CUEBAS, D; SCHULZ, H				SMELAND, TE; CUEBAS, D; SCHULZ, H			EPIMERIZATION OF 3-HYDROXY-4-TRANS-DECENOYL COENZYME-A BY A DEHYDRATION HYDRATION MECHANISM CATALYZED BY THE MULTIENZYME COMPLEX OF FATTY-ACID OXIDATION FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; NUCLEOTIDE-SEQUENCE; LARGE SUBUNIT; FADAB OPERON; ENZYME; PURIFICATION; SPECIFICITY; THIOLASE; GENE	The mechanism of 3-hydroxyacyl-CoA epimerase (EC 5.1.2.3), which is associated with the multienzyme complex of fatty acid oxidation from Escherichia coli, was studied with D-3-hydroxy-4-trans-decenoyl-CoA as a substrate. The E. coli complex catalyzes the rapid and direct dehydration Of D-3-hydroxy-4-trans-decenoyl-CoA to 2-trans,4-trans-decadienoyl-CoA, which is slowly hydrated to L-3-hydroxy-4-trans-decenoyl-CoA. A kinetic analysis of the epimerase and its partial reactions established that epimerization of 3-hydroxyacyl-CoAs occurs solely by a dehydration/hydration mechanism. The results of a substrate competition study with L-3-hydroxy-4-trans-decenoyl-CoA and its D-isomer, together with the conclusion from a sequence analysis of the large subunit of the E. coli complex (Yang, X.-Y., Schulz, H., Elzinga, M., and Yang, S.-Y. (1991) Biochemistry 30, 6788-6795), prompt the suggestion that a single active site is responsible for the dehydration of the D- and L-isomers of 3-hydroxyacyl-CoAs.			SMELAND, TE (corresponding author), CUNY CITY COLL,DEPT CHEM,NEW YORK,NY 10031, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030847, R01HL018089] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30847, HL 18089] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CUEBAS D, 1982, J BIOL CHEM, V257, P4140; DIRUSSO CC, 1990, J BACTERIOL, V172, P6459, DOI 10.1128/jb.172.11.6459-6468.1990; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GOLDMAN P, 1961, J BIOL CHEM, V236, P2620; HILTUNEN JK, 1989, J BIOL CHEM, V264, P13536; KNAUS WH, 1987, TRENDS BIOCHEM SCI, V12, P403; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI JX, 1990, J BIOL CHEM, V265, P13629; NAKAHIGASHI K, 1990, NUCLEIC ACIDS RES, V18, P4937, DOI 10.1093/nar/18.16.4937; PAWAR S, 1981, J BIOL CHEM, V256, P3894; ROCK CO, 1985, BIOCH LIPIDS MEMBRAN, P73; SMELAND TE, 1989, BIOCHEM BIOPH RES CO, V160, P988, DOI 10.1016/S0006-291X(89)80098-1; STAACK H, 1978, J BIOL CHEM, V253, P1827; WAKIL SJ, 1956, BIOCHIM BIOPHYS ACTA, V19, P497, DOI 10.1016/0006-3002(56)90473-5; WHITE H, 1976, J BIOL CHEM, V251, P1688; YANG SY, 1983, J BIOL CHEM, V258, P9780; YANG SY, 1988, J BACTERIOL, V170, P2543, DOI 10.1128/jb.170.6.2543-2548.1988; YANG SY, 1986, J BIOL CHEM, V261, P5390; YANG SY, 1990, J BIOL CHEM, V265, P10424; YANG XYH, 1991, BIOCHEMISTRY-US, V30, P6788, DOI 10.1021/bi00241a023	21	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23904	23908						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748662				2022-12-25	WOS:A1991GV31900059
J	KIJIMA, Y; OGUNBUNMI, E; FLEISCHER, S				KIJIMA, Y; OGUNBUNMI, E; FLEISCHER, S			DRUG-ACTION OF THAPSIGARGIN ON THE CA2+ PUMP PROTEIN OF SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; TUMOR PROMOTER; CA-2+ PUMP; LONGITUDINAL TUBULES; TERMINAL CISTERNAE; ATPASE; CALCIUM; BINDING; CA-2+-ATPASE; TRANSPORT	Thapsigargin is found to be a potent inhibitor of the intracellular Ca2+ pump proteins from skeletal muscle sarcoplasmic reticulum (SR), cardiac SR, and brain microsomes. For skeletal muscle SR, the molar ratio of thapsigargin to Ca2+ pump protein for complete inhibition (MR(c)) of the CA2+ loading rate, Ca2+-dependent ATPase activity, and formation of phosphorylated intermediate (EP) was approximately 1. When the Ca2+ pump protein of low affinity to Ca2+ (E2 state) was pretreated with thapsigargin, ATP and Ca2+ binding to the Ca2+ pump protein was completely inhibited. In the presence of Ca2+ (E1 state), Ca2+ pump protein was protected from inactivation by thapsigargin with respect to Ca2+ binding and EP formation. The MR(c) for brain microsomes, which mediate Ca2+ uptake into intracellular (inositol 1,4,5-trisphosphate-releasable) Ca2+ pools, is likewise stoichiometric. Approximately 30% of Ca2+ loading activity of brain microsomes was insensitive to thapsigargin, indicating the presence of other Ca2+ pumping system(s). The MR(c) for heart is 3.8, indicating that the Ca2+ pump of cardiac SR is less sensitive to thapsigargin. Phosphorylation of cardiac SR with protein kinase A increased the sensitivity to thapsigargin to MR(c) of 2.8. In summary, we find that: 1) thapsigargin is the most effective inhibitor of the Ca2+ pump protein of intracellular membranes (SR and endoplasmic reticulum); 2) its primary inhibitory action appears to inactivate the E2 form of the enzyme preferentially; 3) cardiac SR shows lesser sensitivity to thapsigargin than skeletal muscle SR and brain microsomes; protein kinase A treatment of cardiac SR enhances the sensitivity to the drug.			KIJIMA, Y (corresponding author), VANDERBILT UNIV, DEPT MOLEC BIOL, NASHVILLE, TN 37235 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032711] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32711] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BURK SE, 1989, J BIOL CHEM, V264, P18561; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P6602; CHU A, 1987, ARCH BIOCHEM BIOPHYS, V258, P13, DOI 10.1016/0003-9861(87)90317-1; CHU A, 1988, METHOD ENZYMOL, V157, P36; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DUPONT Y, 1984, ANAL BIOCHEM, V142, P504, DOI 10.1016/0003-2697(84)90496-2; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HAKII H, 1986, J CANCER RES CLIN, V111, P177, DOI 10.1007/BF00389230; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INUI M, 1986, J BIOL CHEM, V261, P1794; INUI M, 1988, J BIOL CHEM, V263, P10843; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; KANAZAWA T, 1971, J BIOCHEM-TOKYO, V70, P95, DOI 10.1093/oxfordjournals.jbchem.a129631; KIJIMA Y, 1990, BIOCHIM BIOPHYS ACTA, V1041, P1, DOI 10.1016/0167-4838(90)90114-U; KIMURA Y, 1991, IN PRESS J MOL CELL; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1991, BIOPHYS J, V59, P249; MARTIN JB, 1949, ANAL CHEM, V21, P965, DOI 10.1021/ac60032a024; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; Meissner G, 1974, Methods Enzymol, V31, P238; OHUCHI K, 1988, BRIT J PHARMACOL, V94, P917, DOI 10.1111/j.1476-5381.1988.tb11604.x; PALADE P, 1989, MOL PHARMACOL, V36, P664; PALADE P, 1983, J BIOL CHEM, V258, P8098; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; TADA M, 1989, BIOESSAYS, V10, P157, DOI 10.1002/bies.950100505; TADA M, 1978, PHYSIOL REV, V58, P1; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VERMA A, 1990, BIOCHEM BIOPH RES CO, V172, P811, DOI 10.1016/0006-291X(90)90747-B	35	153	153	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22912	22918						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1835973				2022-12-25	WOS:A1991GT48300024
J	SEVERINI, M; SPURIO, R; LATEANA, A; PON, CL; GUALERZI, CO				SEVERINI, M; SPURIO, R; LATEANA, A; PON, CL; GUALERZI, CO			RIBOSOME-INDEPENDENT GTPASE ACTIVITY OF TRANSLATION INITIATION FACTOR-IF2 AND OF ITS G-DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ELONGATION; SEQUENCE; GENE; TU	In the absence of ribosomes, Bacillus stearothermophilus translation initiation factor IF2 (M(r) = 82 kDa) and its GTP-binding domain (i.e. the G-domain, M(r) = 41 kDa) promote barely detectable hydrolysis of GTP. Upon addition of some aliphatic alcohols, however, the rate of nucleotide cleavage is substantially increased with both IF2 and G-domain, the highest stimulation being observed with 20% (v/v) ethanol. Under these conditions, the rates of ribosome-independent GTP hydrolysis with both IF2 and G-domain are approximately 30-fold lower than the corresponding rates obtained in the presence of ribosomes, while the K(m) for GTP is approximately the same in all cases. These results indicate that, as with the other two prokaryotic G proteins involved in translation (i.e. elongation factors EF-Tu and EF-G), also in the case of IF2, the GTPase catalytic center resides in the factor and, more specifically, in its G-domain.	UNIV CAMERINO,DIPARTMENTO BIOL,GENET LAB,I-62032 CAMERINO,ITALY; MAX PLANCK INST MOLEC GENET,W-1000 BERLIN 33,GERMANY	University of Camerino; Max Planck Society				Spurio, Roberto/0000-0002-7611-4341				BROMBACH M, 1986, MOL GEN GENET, V205, P97, DOI 10.1007/BF02428037; DEVENDITTIS E, 1986, J BIOL CHEM, V261, P4445; GUALERZI CO, 1991, J BIOL CHEM, V266, P16356; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; HERSHEY JWB, 1987, ESCHERICHIA COLI SAL, V1, P613; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; LILJAS A, 1990, RIBOSOME, P309; Miller DL, 1977, MOL MECH PROTEIN BIO, P323; PARMEGGIANI A, 1981, MOL CELL BIOCHEM, V35, P129, DOI 10.1007/BF02357085; PARMEGGIANI A, 1985, ANNU REV MICROBIOL, V39, P5577; PAWLIK RT, 1981, BIOCHEM INT, V2, P421; REMAUT E, 1983, GENE, V22, P103, DOI 10.1016/0378-1119(83)90069-0; SACERDOT C, 1984, P NATL ACAD SCI-BIOL, V81, P7787, DOI 10.1073/pnas.81.24.7787; Timasheff S.N., 1989, PROTEIN STRUCTURE PR, P331	15	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22800	22802						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744073				2022-12-25	WOS:A1991GT48300007
J	YRUELA, I; MONTOYA, G; ALONSO, PJ; PICOREL, R				YRUELA, I; MONTOYA, G; ALONSO, PJ; PICOREL, R			IDENTIFICATION OF THE PHEOPHYTIN-QA-FE DOMAIN OF THE REDUCING SIDE OF THE PHOTOSYSTEM-II AS THE CU(II)-INHIBITORY BINDING-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINACH THYLAKOID MEMBRANES; ELECTRON-TRANSPORT; QUINONE ACCEPTOR; COPPER; SILICOMOLYBDATE; CHLOROPLASTS; COMPLEX; INHIBITION	Oxygen evolution by photosystem II membranes was inhibited by Cu(II) when 2,6-dichlorobenzoquinone or ferricyanide, but not silicomolybdate, was used as electron acceptor. This indicated that Cu(II) affected the reducing side of the photosystem II. The inhibition curves of Cu(II), o-phenanthroline and 3-(3,4-dichlorophenyl)-1,1-dimethylurea (DCMU), were compared; the inhibitory patterns of Cu(II) and o-phenanthroline were very similar and different in turn from that of DCMU. Cu(II) did not eliminate or modify the electron paramagnetic resonance signal at g = 8.1 ascribed to the non-heme iron of the photosystem II reaction center, indicating that the inhibition by Cu(II) was not the result of the replacement of the iron by Cu(II). Controlled trypsin digestion of thylakoid membranes inhibited oxygen evolution using 2,6-dichlorobenzoquinone, but had no effect when using ferricyanide or silicomolybdate. Using ferricyanide, oxygen evolution of trypsin-treated thylakoids was insensitive to DCMU but became even more sensitive to Cu(II) and o-phenanthroline than nontreated thylakoids; however, trypsinized thylakoids were insensitive to inhibitors in the presence of silicomolybdate. We conclude that Cu(II) impaired the photosystem II electron transfer before the Q(B) niche, most probably at the pheophytin-Q(A)-Fe domain.	CSIC,ESTAC EXPTL AULA DEI,APARTADO 202,E-50080 ZARAGOZA,SPAIN; UNIV ZARAGOZA,CSIC,INST CIENCIA MAT ARAGON,E-50009 ZARAGOZA,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental de Aula Dei (EEAD); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Quimica y Materiales de Aragon (CEQMA); CSIC - Instituto de Ciencia de Materiales de Aragon (ICMA); University of Zaragoza			PICOREL, RAFAEL/K-7930-2014; Yruela, Inmaculada/A-9330-2015; Yruela, Inmaculada/T-1239-2019; Alonso, Pablo J/L-2759-2014	PICOREL, RAFAEL/0000-0003-3791-129X; Yruela, Inmaculada/0000-0003-3608-4720; Yruela, Inmaculada/0000-0003-3608-4720; Alonso, Pablo J/0000-0003-3449-4929				ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BARBER J, 1987, FEBS LETT, V220, P67, DOI 10.1016/0014-5793(87)80877-3; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x; DINER BA, 1987, BIOCHIM BIOPHYS ACTA, V895, P107, DOI 10.1016/S0304-4173(87)80010-1; DINER BA, 1991, PHYSIOL PLANTARUM, V81, P423; DRECHSLER Z, 1989, PHOTOSYNTH RES, V21, P187, DOI 10.1007/BF00037183; DUNAHAY TG, 1984, BIOCHIM BIOPHYS ACTA, V764, P179, DOI 10.1016/0005-2728(84)90027-6; EATONRYE JJ, 1988, BIOCHIM BIOPHYS ACTA, V935, P248, DOI 10.1016/0005-2728(88)90221-6; GIAQUINTA RT, 1975, BIOCHIM BIOPHYS ACTA, V387, P288, DOI 10.1016/0005-2728(75)90111-5; GRAAN T, 1986, FEBS LETT, V206, P9, DOI 10.1016/0014-5793(86)81330-8; HSU BD, 1988, PLANT PHYSIOL, V87, P116, DOI 10.1104/pp.87.1.116; MCTAVISH H, 1989, PLANT PHYSIOL, V89, P452, DOI 10.1104/pp.89.2.452; MOHANTY N, 1989, PLANT PHYSIOL, V90, P175, DOI 10.1104/pp.90.1.175; NELSON N, 1970, J BIOL CHEM, V245, P143; REGANATHAN M, 1990, PHOTOSYNTH RES, V23, P95; RENGER G, 1976, BIOCHIM BIOPHYS ACTA, V440, P287, DOI 10.1016/0005-2728(76)90063-3; SAMSON G, 1988, PHOTOCHEM PHOTOBIOL, V48, P329, DOI 10.1111/j.1751-1097.1988.tb02829.x; SHIOI Y, 1978, PLANT CELL PHYSIOL, V19, P203; SIINGH D, 1987, PLANT PHYSIOL, V83, P12; TAKAHASHI Y, 1989, FEBS LETT, V255, P133, DOI 10.1016/0014-5793(89)81076-2; TELFER A, 1990, BIOCHIM BIOPHYS ACTA, V1018, P168, DOI 10.1016/0005-2728(90)90241-U; TREBST A, 1987, Z NATURFORSCH C, V42, P742; YAMASHITA MM, 1990, P NATL ACAD SCI USA, V87, P5648, DOI 10.1073/pnas.87.15.5648	24	72	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22847	22850						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744077				2022-12-25	WOS:A1991GT48300014
J	JONVEAUX, P; FENAUX, P; QUIQUANDON, I; PIGNON, JM; LAI, JL; LOUCHEUXLEFEBVRE, MH; GOOSSENS, M; BAUTERS, F; BERGER, R				JONVEAUX, P; FENAUX, P; QUIQUANDON, I; PIGNON, JM; LAI, JL; LOUCHEUXLEFEBVRE, MH; GOOSSENS, M; BAUTERS, F; BERGER, R			MUTATIONS IN THE P53-GENE IN MYELODYSPLASTIC SYNDROMES	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; CHRONIC MYELOGENOUS LEUKEMIA; P53 GENE-MUTATIONS; TUMOR-ANTIGEN; POINT MUTATIONS; CDNA SEQUENCE; RAS ONCOGENES; BLAST CRISIS; DNA; EXPRESSION	We have examined p53 alleles in 151 DNAs from patients with myelodysplastic syndrome using single-strand conformation polymorphism analysis of polymerase chain reaction products. We focused our study on the four highly conserved regions of the p53 gene and detected five patients with aberrantly migrating fragments. We confirmed the putative mutation in each case by direct sequencing analysis. Of these five patients, three had chromosome 17 monosomy associated with p53 mutation, one patient showed one mutated p53 allele and one wild-type allele, and the last patient demonstrated only the mutant allele, suggesting a homozygous state. Unlike many other types of human cancers, point mutations in the p53 tumor-suppressor gene appear to be a rare event in myelodysplastic syndromes.	INSERM,U124,INST RECH CANC,F-59045 LILLE,FRANCE; HOP HENRI MONDOR,INSERM,U91,F-94010 CRETEIL,FRANCE; CHU LILLE,SERV HEMATOL & CYTOGENET,F-59037 LILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille	JONVEAUX, P (corresponding author), INSERM,U301,INST GENET MOLEC,27 RUE JULIETTE DODU,F-75010 PARIS,FRANCE.							AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; AINSWORTH PJ, 1991, NUCLEIC ACIDS RES, V19, P405, DOI 10.1093/nar/19.2.405; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HARNDEN DG, 1985, CYTOGENET CELL GENET; HARNDEN DG, 1985, ISCN 1985 INT SYSTEM; HATA A, 1990, NUCLEIC ACIDS RES, V18, P5407, DOI 10.1093/nar/18.18.5407; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; KELMAN Z, 1989, BLOOD, V74, P2318; KOEFFLER HP, 1986, SEMIN HEMATOL, V23, P284; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LYONS J, 1988, BLOOD, V71, P1707; Maniatis T., 1982, MOL CLONING; MASHAL R, 1990, BLOOD, V75, P180; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MITRA G, 1989, P NATL ACAD SCI USA, V86, P8650, DOI 10.1073/pnas.86.22.8650; MURAKAMI Y, 1991, ONCOGENE, V6, P37; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1990, GENOMICS, V8, P271, DOI 10.1016/0888-7543(90)90282-Y; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PADUA RA, 1988, LEUKEMIA, V2, P503; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; RIDGE SA, 1990, P NATL ACAD SCI USA, V87, P1377, DOI 10.1073/pnas.87.4.1377; ROMANO JW, 1989, ONCOGENE, V4, P1483; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SLINGERLAND JM, 1991, BLOOD, V77, P1500; SOUSSI T, 1990, ONCOGENE, V5, P945; SUGIMOTO K, 1991, BLOOD, V77, P1153; SUZUKI Y, 1990, ONCOGENE, V5, P1037; VARLEY JM, 1991, ONCOGENE, V6, P413; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	42	139	142	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2243	2247						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766671				2022-12-25	WOS:A1991GX73500010
J	SCHNEPPE, B; DECKERSHEBESTREIT, G; MCCARTHY, JEG; ALTENDORF, K				SCHNEPPE, B; DECKERSHEBESTREIT, G; MCCARTHY, JEG; ALTENDORF, K			TRANSLATION OF THE 1ST GENE OF THE ESCHERICHIA-COLI UNC OPERON - SELECTION OF THE START CODON AND CONTROL OF INITIATION EFFICIENCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; RIBOSOME-BINDING-SITES; AMINOACYL-TRANSFER-RNA; MESSENGER-RNA; H+-ATPASE; NUCLEOTIDE-SEQUENCES; LACZ FUSIONS; EXPRESSION; SYNTHASE; INVIVO	The uncI gene is the most poorly expressed gene of the unc operon of Escherichia coli. We examined how the structural features of the translational initiation region (TIR) of this gene relate to the efficiency of its expression. A set of various TIR sequences was created for the uncI gene by coupling synthetic oligodeoxynucleotides to the 5' part of the plasmid-borne gene. Analyses of transcription and translation of the resulting constructs revealed that weak translational initiation efficiency of the uncI TIR sequence is a rate-controlling factor for expression. Moreover, the identification of an endonucleolytic cleavage site within the 5' part of the uncI mRNA by Northern blotting lends further support to the notion that instability of the uncI cistron within the polycistronic unc mRNA represents a further mode of control. The analysis of the roles of the different Shine-Dalgarno regions and putative start codons within the translational initiation region of the uncI gene revealed that the Shine-Dalgarno region III and the GUG codon (codon 4 of the uncI coding sequence described by Walker, J. E., Saraste, M., and Gay, N. J. (1984) Biochim. Biophys. Acta 768, 164-200) define the main site of initiation. However, manipulations of the translational initiation region led to selection of an initiation codon further upstream. The relationship between mRNA sequence and higher order structure on the one hand, and initiation site selection and initiation efficiency on the other, was analyzed.	UNIV OSNABRUCK, FACHBEREICH BIOL CHEM, ARBEITSGRP MIKROBIOL, BARBARASTR 11, W-4500 OSNABRUCK, GERMANY; GESELL BIOTECHNOL FORSCH GMBH, DEPT MICROBIOL, W-3300 BRAUNSCHWEIG, GERMANY	University Osnabruck; Gesellschaft fur Biotechnologische Forschung mbH								ANDERSSON SGE, 1990, MICROBIOL REV, V54, P198, DOI 10.1128/MMBR.54.2.198-210.1990; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BELASCO JG, 1988, GENE, V72, P15, DOI 10.1016/0378-1119(88)90123-0; BLASI U, 1989, EMBO J, V8, P3501, DOI 10.1002/j.1460-2075.1989.tb08515.x; BRUSILOW WSA, 1982, J BACTERIOL, V151, P1363, DOI 10.1128/JB.151.3.1363-1371.1982; BRUSILOW WSA, 1983, J BACTERIOL, V155, P1265, DOI 10.1128/JB.155.3.1265-1270.1983; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GERSTEL B, 1989, MOL MICROBIOL, V3, P851, DOI 10.1111/j.1365-2958.1989.tb00234.x; GOINS W, 1988, DNA PROTEIN ENG TECH, V1, P23; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GREN EJ, 1984, BIOCHIMIE, V66, P1, DOI 10.1016/0300-9084(84)90188-3; GROSS G, 1990, J BIOL CHEM, V265, P17627; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; HELLMUTH K, 1991, MOL MICROBIOL, V5, P813, DOI 10.1111/j.1365-2958.1991.tb00754.x; HERMOLIN J, 1989, J BIOL CHEM, V264, P3896; HOPPE J, 1984, BIOCHIM BIOPHYS ACTA, V768, P1, DOI 10.1016/0304-4173(84)90005-3; JONES HM, 1983, J BACTERIOL, V155, P1279, DOI 10.1128/JB.155.3.1279-1287.1983; KANAZAWA H, 1982, ANN NY ACAD SCI, V402, P45, DOI 10.1111/j.1749-6632.1982.tb25731.x; Kennell D, 1986, MAXIMIZING GENE EXPR, P101; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KLIONSKY DJ, 1986, J BIOL CHEM, V261, P8096; KOZAK M, 1983, MICROBIOL REV, V47, P1; LANG V, 1989, J MOL BIOL, V210, P659, DOI 10.1016/0022-2836(89)90140-X; Maniatis T., 1982, MOL CLONING; MCCARTHY JEG, 1988, MOL MICROBIOL, V2, P455, DOI 10.1111/j.1365-2958.1988.tb00051.x; MCCARTHY JEG, 1990, TRENDS GENET, V6, P78, DOI 10.1016/0168-9525(90)90098-Q; MCCARTHY JEG, 1986, GENE, V41, P201, DOI 10.1016/0378-1119(86)90099-5; MCCARTHY JEG, 1990, MOL MICROBIOL, V4, P1233, DOI 10.1111/j.1365-2958.1990.tb00702.x; MCCARTHY JEG, 1985, EMBO J, V4, P519, DOI 10.1002/j.1460-2075.1985.tb03659.x; MCCARTHY JEG, 1988, GENE, V72, P131, DOI 10.1016/0378-1119(88)90135-7; MCCARTHY JEG, 1988, J BIOENERG BIOMEMBR, V20, P19, DOI 10.1007/BF00762136; MCPHEETERS DS, 1988, J MOL BIOL, V201, P517, DOI 10.1016/0022-2836(88)90634-1; MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X; NIELSEN J, 1984, MOL GEN GENET, V193, P64, DOI 10.1007/BF00327415; OHSAWA H, 1983, J BIOL CHEM, V258, P150; PORTER ACG, 1983, J BACTERIOL, V155, P1271, DOI 10.1128/JB.155.3.1271-1278.1983; REDDY P, 1985, P NATL ACAD SCI USA, V82, P5656, DOI 10.1073/pnas.82.17.5656; RISULEO G, 1976, EUR J BIOCHEM, V67, P603, DOI 10.1111/j.1432-1033.1976.tb10726.x; SCHAEFER EM, 1989, J BACTERIOL, V171, P3901, DOI 10.1128/jb.171.7.3901-3908.1989; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAUDER B, 1989, GENE, V78, P59, DOI 10.1016/0378-1119(89)90314-4; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; SCHERER GFE, 1980, NUCLEIC ACIDS RES, V8, P3895, DOI 10.1093/nar/8.17.3895; SCHNEIDER E, 1984, TRENDS BIOCHEM SCI, V9, P51, DOI 10.1016/0968-0004(84)90181-6; SCHNEIDER E, 1987, MICROBIOL REV, V51, P477, DOI 10.1128/MMBR.51.4.477-497.1987; SCHNEIDER TD, 1986, J MOL BIOL, V188, P415, DOI 10.1016/0022-2836(86)90165-8; SCHNEPPE B, 1990, J BIOL CHEM, V265, P389; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SOLOMON KA, 1989, J BACTERIOL, V171, P3039, DOI 10.1128/jb.171.6.3039-3045.1989; STORMO GD, 1986, MAXIMIZING GENE EXPR, P195; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; VIGNAIS PV, 1984, MOL CELL BIOCHEM, V60, P33; von Meyenburg K, 1982, Tokai J Exp Clin Med, V7 Suppl, P23; VONMEYENBURG K, 1982, MOL GEN GENET, V188, P240, DOI 10.1007/BF00332682; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WILSON DB, 1969, J BIOL CHEM, V244, P2137; WINTER RB, 1987, P NATL ACAD SCI USA, V84, P7822, DOI 10.1073/pnas.84.22.7822; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133; 1989, PROMEGA PROTOCOLS AP	63	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21090	21098						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1834655				2022-12-25	WOS:A1991GN00100079
J	ATODA, H; HYUGA, M; MORITA, T				ATODA, H; HYUGA, M; MORITA, T			THE PRIMARY STRUCTURE OF COAGULATION FACTOR-IX FACTOR-X-BINDING PROTEIN ISOLATED FROM THE VENOM OF TRIMERESURUS-FLAVOVIRIDIS - HOMOLOGY WITH ASIALOGLYCOPROTEIN RECEPTORS, PROTEOGLYCAN CORE PROTEIN, TETRANECTIN, AND LYMPHOCYTE FC-EPSILON-RECEPTOR FOR IMMUNOGLOBULIN-E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; VONWILLEBRAND-FACTOR; PURIFICATION; COMPLEX; SUBUNIT; SNAKE; GEL	An anticoagulant protein, factor IX/factor X-binding protein (IX/X-bp), isolated from the venom of Trimeresurus flavoviridis, binds with factor IX and factor X in the presence of Ca2+ With a 1 to 1 stoichiometry (Atoda, H., and Morita, T. (1989) J. Biochem. (Tokyo) 106, 808-813). Analysis of S-pyridylethylated IX/X-bp by sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed a 16.0-kDa band (designated the A chain) and a 15.5-kDa band (designated the B chain). These two chains were separated by reversed-phase high performance liquid chromatography, and their complete amino acid sequences were determined by sequencing of the peptides obtained after digestion with lysyl endopeptidase, chymotrypsin, and V8 protease from Staphylococcus aureus and after chemical cleavage with cyanogen bromide. The A chain had an amino-terminal sequence of Asp-Cys-Leu-Ser-Gly- and consisted of 129 residues with M(r) 14,830. The B chain has an amino-terminal sequence of Asp-Cys-Pro-Ser-Asp- and consists of 123 residues of M(r) 14,440. There was 47% identity between the A and the B chain. The sequence of IX/X-bp showed 25-37% identity with that of the C-type carbohydrate recognition domain-like structure of acorn barnacle lectin, human and rat asialoglycoprotein receptors, the human lymphocyte Fc-epsilon receptor for immunoglobulin E, proteoglycan core protein, pancreatic stone protein, and tetranectin. The sequences of the first 18 amino acid residues of both the A and B chains were also, to a certain extent, homologous to the partial amino acid sequence of the b subunit of factor XIII, a member of the beta-2-glycoprotein I-like family. In this region, some similarity with the amino-terminal amino acid sequence of botrocetin was also observed.	MEIJI COLL PHARM, DEPT BIOCHEM, 1-22-1 YATO CHO, TANASHI, TOKYO 188, JAPAN	Meiji Pharmaceutical University								ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8317, DOI 10.1021/bi00447a009; ATODA H, 1989, J BIOCHEM, V106, P808, DOI 10.1093/oxfordjournals.jbchem.a122935; BURR FA, 1983, METHOD ENZYMOL, V96, P239; CLEMMENSEN I, 1986, EUR J BIOCHEM, V156, P327, DOI 10.1111/j.1432-1033.1986.tb09586.x; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; FUHLENDORFF J, 1987, BIOCHEMISTRY-US, V26, P6757, DOI 10.1021/bi00395a027; GIORGI D, 1989, J CLIN INVEST, V84, P100, DOI 10.1172/JCI114128; HIRANO H, 1989, J PROTEIN CHEM, V8, P115, DOI 10.1007/BF01025083; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P4633, DOI 10.1021/bi00364a027; KIKUTANI H, 1986, CELL, V47, P657, DOI 10.1016/0092-8674(86)90508-8; MURAMOTO K, 1986, BIOCHIM BIOPHYS ACTA, V874, P285, DOI 10.1016/0167-4838(86)90027-0; ROUIMI P, 1988, FEBS LETT, V229, P171, DOI 10.1016/0014-5793(88)80820-2; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; TENG CM, 1981, THROMB RES, V23, P255, DOI 10.1016/0049-3848(81)90015-3; VERCELLI D, 1989, NATURE, V338, P649, DOI 10.1038/338649a0; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x	19	120	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14903	14911						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1831197				2022-12-25	WOS:A1991GB09700019
J	FOUNTOULAKIS, M; LAHM, HW; MARIS, A; FRIEDLEIN, A; MANNEBERG, M; STUEBER, D; GAROTTA, G				FOUNTOULAKIS, M; LAHM, HW; MARIS, A; FRIEDLEIN, A; MANNEBERG, M; STUEBER, D; GAROTTA, G			A 25-KDA STRETCH OF THE EXTRACELLULAR DOMAIN OF THE HUMAN INTERFERON-GAMMA RECEPTOR IS REQUIRED FOR FULL LIGAND-BINDING CAPACITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYE-BINDING; PROTEINS; PURIFICATION; ANTIBODIES; QUANTITIES; TERMINUS	We investigated which is the shortest fragment of the interferon-gamma-receptor with ligand binding capacity. A recombinant soluble interferon-gamma-receptor produced in Escherichia coli was subjected to controlled digestion with several proteolytic enzymes. The fragments generated were assayed by four approaches for interferon-gamma-binding. A 25-kDa polypeptide comprising residues 6-227 of the mature protein was produced by sequential digestion with trypsin and proteinase K. It was identified as the shortest receptor domain with full interferon-gamma-binding capacity as judged by ligand blots. The proteolytic fragments were further tested for ligand binding by interferon-gamma-affinity chromatography. A 15-kDa polypeptide comprising amino acids 94-227 produced by digestion with endoproteinase Glu-C was found to bind with low affinity to immobilized interferon-gamma. This fragment, which does not show ligand binding capacity on protein blots, was immunoprecipitated as a complex with interferon-gamma by anti-interferon-gamma-antibodies. It also competed for the binding of radiolabeled interferon-gamma to the cell surface receptor when it was assayed as a mixture of the proteolytic products, but not after separation from the cleaved rest of the molecule. The 15-kDa polypeptide probably carries the ligand-binding domain or part of it, but it lacks sequences essential for full interferon-gamma-binding capacity. The stretch between amino acids 6 and 21 which does not include any disulfide bonds seems to be essential for the receptor to show full activity. The digestion with endoproteinase Glu-C revealed that cysteine residues 60 and 68 of the interferon-gamma-receptor form a disulfide bond.			FOUNTOULAKIS, M (corresponding author), HOFFMANN LA ROCHE LTD,PHARMA RES NEW TECHNOL,BLDG 15-16,CH-4002 BASEL,SWITZERLAND.							AGUET M, 1987, J EXP MED, V165, P988, DOI 10.1084/jem.165.4.988; AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALDERON J, 1988, P NATL ACAD SCI USA, V85, P4837, DOI 10.1073/pnas.85.13.4837; DOEBELI H, 1988, J BIOTECHNOL, V7, P199; FOUNTOULAKIS M, 1989, J IMMUNOL, V143, P3266; FOUNTOULAKIS M, 1991, EUR J BIOCHEM, V198, P441, DOI 10.1111/j.1432-1033.1991.tb16034.x; FOUNTOULAKIS M, 1990, J BIOL CHEM, V265, P13268; FOUNTOULAKIS M, 1990, J BIOL CHEM, V265, P19758; GAROTTA G, 1989, PHARMACOL RES, V21, P5, DOI 10.1016/S1043-6618(89)80013-1; GAROTTA G, 1990, J BIOL CHEM, V265, P6908; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; ICHIMORI Y, 1987, HYBRIDOMA, V6, P173, DOI 10.1089/hyb.1987.6.173; LANDOLFO S, 1991, J IMMUNOL RES, V3, P81; LUK SKS, 1990, J BIOL CHEM, V265, P13314; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIEDEL MC, 1989, J BIOL CHEM, V264, P21097; OZMEN L, 1990, DEV BIOTHER, V1, P283; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; VANLOON APGM, 1991, J LEUKOCYTE BIOL, V49, P462, DOI 10.1002/jlb.49.5.462; WETZEL R, 1990, PROTEIN ENG, V3, P611, DOI 10.1093/protein/3.7.611	25	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					14970	14977						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1831199				2022-12-25	WOS:A1991GB09700029
J	LEMONS, RM; THOENE, JG				LEMONS, RM; THOENE, JG			MEDIATED CALCIUM-TRANSPORT BY ISOLATED HUMAN FIBROBLAST LYSOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORT; RAT-LIVER LYSOSOMES; CYSTINE TRANSPORT; SYSTEM; CARRIER; FRACTIONS; MEMBRANES; ATPASE; CELLS	Lysosomes purified by Percoll gradient from normal human fibroblasts (GM0010A) show uptake of Ca2+ in a mediated manner. The uptake is linear over the first 1.5 min and approaches a steady state by 10 min. Uptake is saturable, displaying a V(max) of about 10 pmol/min/unit hexosaminidase at 20 mm Ca2+ (7 nmol/min/mg protein), and a K(m) of 5.7 mm. Ca2+ uptake increases with increasing extralysosomal pH from 5.0 to 8.5. The Q10 is 1.6, and E(a) 8.7 kcal/mol. Uptake of 0.1 mM Ca2+ was inhibited to the extent indicated by 1.0 mM of the following: Cd2+, 100%; Hg2+, 100%; Zn2+, 89%; Mg2+, 77%; Ba2+, 60%; Sr2+, 37%; Fe2+, 20%; Cu2+, 0%. Mono- and trivalent cations had no effect. ATP (1.0 mM) inhibited uptake by 80%, and chloroquine (0.1 mM) inhibited by 60%, as did 1.0 mM L-cystine. Cysteamine, N-ethylmaleimide, and the anions Cl-, SO4(2-), and acetate had no effect. The calcium ionophore A23187 augmented uptake by 10-fold at 10-mu-M. Surprisingly, Pb2+ greatly augmented lysosomal Ca2+ uptake in a concentration-dependent manner. Pb2+, however, adversely affected lysosomal latency. Lysosomal calcium uptake was not affected by inositol 1,4,5-triphosphate, and calcium-induced calcium release from lysosomes was not observed. A role for lysosomes in cellular calcium homeostasis has not been previously suggested. This work shows that Ca2+ can be transported into and out of lysosomes and could assist in lysosomal proteolysis. The extent of further lysosomal participation in cellular calcium regulation is unclear.	UNIV MICHIGAN, DEPT PEDIAT, 2612 SPH I-109 OBSERV, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Thoene, Jess/AAF-5305-2020		NIDDK NIH HHS [DK25548] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025548] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNAR J, 1986, J BIOL CHEM, V261, P7107; BLITZER BL, 1989, J CLIN INVEST, V83, P1319, DOI 10.1172/JCI114018; BRUN A, 1974, ACTA PATH MICRO IM A, VA 82, P311; CAMMER W, 1980, EXPT CLIN NEUROTOXIC, P239; CHRISTENSEN HN, 1975, BIOL TRANSPORT, P150; Cleland W W, 1979, Methods Enzymol, V63, P103; CORIA F, 1986, J SUBMICR CYTOL PATH, V18, P153; EECKHOUT Y, 1990, BIOCHEM J, V272, P529, DOI 10.1042/bj2720529; GAHL WA, 1983, BIOCHEM J, V216, P393, DOI 10.1042/bj2160393; GAHL WA, 1982, J BIOL CHEM, V257, P9570; GAHL WA, 1982, SCIENCE, V217, P1263, DOI 10.1126/science.7112129; GAHL WA, 1989, METABOLIC BASIS INHE, P2619; GREENE AA, 1990, J BIOL CHEM, V265, P9888; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HODGMAN CD, 1962, HDB CHEM PHYSICS, P2586; HODGMAN CD, 1962, HDB CHEM PHYSICS, P3431; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; JONAS AJ, 1990, J BIOL CHEM, V265, P17545; JONAS AJ, 1983, J BIOL CHEM, V258, P1727; JONAS AJ, 1982, J BIOL CHEM, V257, P13185; JONAS AJ, 1989, J BIOL CHEM, V264, P4953; MANCINI GMS, 1990, J BIOL CHEM, V265, P12380; MUALLEM S, 1989, AM J PHYSIOL, V257, pG917, DOI 10.1152/ajpgi.1989.257.6.G917; NEMERE I, 1986, J BIOL CHEM, V261, P6106; OHKUMA S, 1982, P NATL ACAD SCI-BIOL, V79, P2758, DOI 10.1073/pnas.79.9.2758; ORSI E, 1987, ADV AEROBIOL, V51, P243; PISONI RL, 1989, J BIOL CHEM, V264, P4850; PISONI RL, 1991, J BIOL CHEM, V266, P979; PISONI RL, 1990, J CELL BIOL, V110, P327, DOI 10.1083/jcb.110.2.327; PISONI RL, 1987, J BIOL CHEM, V262, P15011; PISONI RL, 1987, J BIOL CHEM, V262, P6010; PISONI RL, 1985, J BIOL CHEM, V260, P4791; RENLUND M, 1986, SCIENCE, V232, P759, DOI 10.1126/science.3961501; ROSENBLATT DS, 1985, SCIENCE, V228, P1319, DOI 10.1126/science.4001945; SUN HT, 1990, J BIOCHEM-TOKYO, V108, P730, DOI 10.1093/oxfordjournals.jbchem.a123273	35	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14378	14382						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1830585				2022-12-25	WOS:A1991FZ35100043
J	SCHUCHMAN, EH; SUCHI, M; TAKAHASHI, T; SANDHOFF, K; DESNICK, RJ				SCHUCHMAN, EH; SUCHI, M; TAKAHASHI, T; SANDHOFF, K; DESNICK, RJ			HUMAN ACID SPHINGOMYELINASE - ISOLATION, NUCLEOTIDE-SEQUENCE, AND EXPRESSION OF THE FULL-LENGTH AND ALTERNATIVELY SPLICED CDNAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIEMANN-PICK DISEASE; BETA-GLUCURONIDASE; HUMAN-URINE; PURIFICATION; GENE; RNA; DNA; ENZYME; MODEL; HYBRIDIZATION	Two types of partial cDNAs encoding human acid sphingomyelinase (EC 3.1.4.12; ASM) were recently isolated from fibroblast and placental cDNA libraries (Quintern, L. E., Schuchman, E. H., Levran, O., Suchi, M., Ferlinz, K., Reinke, H., Sandhoff, K., and Desnick, R. J. (1989) EMBO J. 8, 2469-2473). The cDNA inserts had identical sequences with the exception of an internal region; type 1 cDNAs (representing approximately 90% of the ASM cDNAs isolated) had 172 in-frame base pairs (bp), which were replaced in the type 2 cDNAs by a 40-bp in-frame sequence. Northern hybridization and RNase protection studies indicated that both type 1 and 2 transcripts were approximately 2.5 kilobases; therefore, efforts were directed to isolate full-length type 1 and 2 cDNAs by screening human placental, testis, hepatoma, and retinal cDNA libraries. In addition to type 1 and 2 cDNAs, a new type of ASM cDNA (type 3), which did not contain the type 1- or 2-specific regions, was isolated and sequenced. The full-length type 1 and the reconstructed full-length type 2 and 3 cDNAs were transiently expressed in COS-1 cells. Only the full-length type 1 transcript encoded catalytically active human ASM, demonstrating its functional integrity. The 2347-bp full-length type 1 placental cDNA (pASM-1 FL) had an 87-bp 5'-untranslated region, an 1890-bp open reading frame encoding 629 amino acids, and a 370-bp 3'-untranslated sequence. The predicted location of the signal peptide cleavage site was after alanine 46. Two base differences were identified in codons 322 and 506 and shown to be polymorphisms with the common alleles having frequencies of 0.6 and 0.7, respectively. To determine the genomic organization of the type 1, 2, and 3 sequences, a 1665-bp genomic region containing both the unique type 1 (172 bp) and type 2 (40 bp) sequences was amplified by the polymerase chain reaction and sequenced. The 172-bp sequence was exonic, flanked by 5'- and 3'-intronic sequences of 1052 and 229 bp, respectively. The 40-bp type 2 sequence was intronic, occurring at the 5' end of the 1052-bp intron due to the use of a cryptic 5' donor splice site, which deleted the entire 172-bp exon and both flanking intronic sequences. The type 3 cDNA resulted from an alternative splicing event, which excised the 172-bp exon. These studies demonstrate the occurrence of alternative splicing of the ASM transcript, but the existence of only one functional mRNA.	UNIV BONN,INST ORGAN CHEM & BIOCHEM,BONN 1,GERMANY	University of Bonn	SCHUCHMAN, EH (corresponding author), CUNY MT SINAI SCH MED,DIV MED & MOLEC GENET,100TH ST & 5TH AVE,NEW YORK,NY 10029, USA.				NIDDK NIH HHS [5 RO1 DK34045] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034045] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BESLEY GTN, 1980, HUM GENET, V54, P409, DOI 10.1007/BF00291589; BISHOP DF, 1981, J BIOL CHEM, V256, P1307; BRADY RO, 1966, P NATL ACAD SCI USA, V55, P366, DOI 10.1073/pnas.55.2.366; BROT FE, 1978, BIOCHEMISTRY-US, V17, P385, DOI 10.1021/bi00596a001; BUNZA A, 1979, VET PATHOL, V16, P530; CHATTERJEE S, 1989, J BIOL CHEM, V264, P12554; CHEN C, 1987, MOL CELL BIOL, V7, P2747; CHRIGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294; GATT S, 1978, J NEUROCHEM, V31, P547, DOI 10.1111/j.1471-4159.1978.tb02671.x; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; ITAKURA K, 1984, ANNU REV BIOCHEM, V53, P323; KAUFMAN RJ, 1982, MOL CELL BIOL, V2, P1304, DOI 10.1128/MCB.2.11.1304; KITAGAWA T, 1987, JPN J HUM GENET, V32, P55, DOI 10.1007/BF01893159; KLAR R, 1988, CLIN CHIM ACTA, V176, P259, DOI 10.1016/0009-8981(88)90185-4; KOLESNICK RN, 1988, J BIOL CHEM, V263, P6534; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8126; LEVADE T, 1986, J CLIN CHEM CLIN BIO, V24, P205; MIYAWAKI S, 1986, J HERED, V77, P379, DOI 10.1093/oxfordjournals.jhered.a110265; MORREAU H, 1989, J BIOL CHEM, V264, P20655; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OSHIMA A, 1987, P NATL ACAD SCI USA, V84, P685, DOI 10.1073/pnas.84.3.685; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PEREIRA LD, 1991, GENOMICS, V9, P229, DOI 10.1016/0888-7543(91)90246-B; QUINTERN LE, 1989, EMBO J, V8, P2469, DOI 10.1002/j.1460-2075.1989.tb08382.x; QUINTERN LE, 1987, BIOCHIM BIOPHYS ACTA, V922, P323, DOI 10.1016/0005-2760(87)90055-5; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKIYAMA T, 1986, J INHERIT METAB DIS, V9, P305, DOI 10.1007/BF01799671; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER PB, 1967, J LIPID RES, V8, P202; SORGE J, 1987, P NATL ACAD SCI USA, V84, P906, DOI 10.1073/pnas.84.4.906; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; SPENCE MW, 1989, METABOLIC BASIS INHE, P1655; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEIL D, 1989, EMBO J, V8, P1705, DOI 10.1002/j.1460-2075.1989.tb03562.x; WENGER DA, 1980, SCIENCE, V208, P1471, DOI 10.1126/science.7189903; YAMANAKA T, 1982, J NEUROCHEM, V38, P1753, DOI 10.1111/j.1471-4159.1982.tb06659.x; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	41	194	214	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8531	8539						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1840600				2022-12-25	WOS:A1991FK44100086
J	MILLS, DA; RICHTER, ML				MILLS, DA; RICHTER, ML			NUCLEOTIDE BINDING TO THE ISOLATED BETA-SUBUNIT OF THE CHLOROPLAST ATP SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; DEFECTIVE PROTON-ATPASE; ESCHERICHIA-COLI; ALPHA-3-BETA-3 COMPLEX; RHODOSPIRILLUM-RUBRUM; UNCA MUTANTS; H+-ATPASE; SITES; HYDROLYSIS	The beta-subunit isolated from the chloroplast ATP synthase F1 (CF1) has a single dissociable nucleotide binding site, consistent with the proposed function of this subunit in nucleotide binding and catalysis. The beta-subunit bound the nucleotide analogs trinitrophenyl-ATP (TNP-ATP) or trinitrophenyl-ADP (TNP-ADP) with nearly equal affinities (K(d) = 1-2-mu-M) but did not bind trinitrophenyl-AMP. Both ATP and ADP effectively competed with TNP-ATP for binding. Other nucleoside triphosphates were also able to compete with TNP-ATP for binding to beta; their order of effectiveness (ATP > GTP, ITP > CTP) mimicked the normal substrate specificity of CF1. The single nucleotide binding site on the isolated beta-subunit very closely resembles the low affinity catalytic site (site 3) of CF1 (Bruist, M. F., and Hammes, G. G. (1981) Biochemistry 20, 6298-6305), suggesting that tight nucleotide binding by other sites on the enzyme involves other CF1 subunits in addition to the beta-subunit. The results are inconsistent with an earlier report (Frasch, W. D., Green, J., Caguil, J., and Mejia, A. (1989) J. Biol. Chem. 264, 5064-5069), which suggested more than one nucleotide binding site per beta-subunit. Binding of nucleotides to the isolated beta-subunit was eliminated by a brief heat treatment (40-degrees-C for 10 min) of the protein. A small change in the circular dichroism spectrum of beta-accompanied the heat treatment indicating that a localized (rather than global) change in the folding of beta, involving at least part of the nucleotide binding domain, had occurred. Also accompanying the loss of nucleotide binding was a loss of the reconstitutive capacity of the beta-subunit. ATP protected against the effects of the heattreatment.			MILLS, DA (corresponding author), UNIV KANSAS,DEPT BIOCHEM,LAWRENCE,KS 66045, USA.							ADMON A, 1987, BIOCHEMISTRY-US, V26, P3193, DOI 10.1021/bi00385a038; ALSHAWI MK, 1990, J BIOL CHEM, V265, P5595; Boyer P.D., 1981, PRESENT STATUS BINDI, P231; BOYER PD, 1987, BIOCHEMISTRY-US, V26, P8503, DOI 10.1021/bi00400a001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUIST MF, 1981, BIOCHEMISTRY-US, V20, P6298, DOI 10.1021/bi00525a003; CARLIER MF, 1979, BIOCHEMISTRY-US, V18, P3446, DOI 10.1021/bi00583a002; FRASCH WD, 1989, J BIOL CHEM, V264, P5064; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GARBOCZI DN, 1990, J BIOL CHEM, V265, P14632; GIRAULT G, 1988, J BIOL CHEM, V263, P14690; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GROMETELHANAN Z, 1984, BIOCHEMISTRY-US, V23, P1022, DOI 10.1021/bi00300a034; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HANANSHVILI D, 1983, J BIOL CHEM, V257, P3714; HARRIS DA, 1985, BIOCHEMISTRY-US, V24, P3876, DOI 10.1021/bi00336a010; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; KAGAWA Y, 1989, FEBS LETT, V249, P67, DOI 10.1016/0014-5793(89)80017-1; LECKBAND D, 1987, BIOCHEMISTRY-US, V26, P2306, DOI 10.1021/bi00382a035; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGGIO MB, 1987, J BIOL CHEM, V262, P8981; MCCARTY RE, 1985, ENZYMES BIOL MEMBR, P383; MILLS DA, 1991, PROGR PHOTOSYNTHESIS, V4; MITRA B, 1988, BIOCHEMISTRY-US, V27, P245, DOI 10.1021/bi00401a037; MIWA K, 1989, P NATL ACAD SCI USA, V86, P6484, DOI 10.1073/pnas.86.17.6484; NELSON N, 1972, J BIOL CHEM, V247, P6506; OHTA S, 1980, J BIOCHEM-TOKYO, V87, P1609, DOI 10.1093/oxfordjournals.jbchem.a132904; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RAO R, 1988, J BIOL CHEM, V263, P5569; RICHTER ML, 1986, J BIOL CHEM, V261, P2109; RICHTER ML, 1985, BIOCHEMISTRY-US, V24, P5755, DOI 10.1021/bi00342a011; RICHTER ML, 1987, PROGR PHOTOSYNTHESIS, V3, P53; ROUXFROMY M, 1987, BIOCHEM BIOPH RES CO, V144, P718, DOI 10.1016/S0006-291X(87)80024-4; SATO MH, 1990, J BIOL CHEM, V265, P13419; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SHAPIRO AB, 1988, J BIOL CHEM, V263, P14160; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; WISE JG, 1984, BIOCHEMISTRY-US, V23, P1426, DOI 10.1021/bi00302a014	38	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7440	7444						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1826906				2022-12-25	WOS:A1991FJ34200022
J	CHING, MH; KAUR, P; KARKARIA, CE; STEINER, RF; ROSEN, BP				CHING, MH; KAUR, P; KARKARIA, CE; STEINER, RF; ROSEN, BP			SUBSTRATE-INDUCED DIMERIZATION OF THE ARSA PROTEIN, THE CATALYTIC COMPONENT OF AN ANION-TRANSLOCATING ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARSENICAL RESISTANCE OPERON; HEART MITOCHONDRIAL F1-ATPASE; R-FACTOR R773; BETA-SUBUNIT; ESCHERICHIA-COLI; CROSS-LINKING; PUMP; IDENTIFICATION; SITES; 5'-PARA-FLUOROSULFONYLBENZOYLADENOSINE	The ArsA protein, the catalytic component of the plasmid-encoded resistance system for removal of the toxic oxyanions arsenite, antimonite and arsenate from bacterial cells, catalyzes oxyanion-stimulated ATP hydrolysis. Three lines of evidence suggest that the ArsA protein functions as a homodimer. First, the ArsA protein was modified with 5'-p-fluorosulfonylbenzoyladenosine (FSBA). Antimonite potentiated FSBA inhibition, while ATP or ADP afforded partial protection. ATP and antimonite together provided complete protection, indicating interaction of the anion- and nucleotide-binding sites. The estimated K(i) values for FSBA were 0.4 mM in the absence of antimonite and 0.1 mM in the presence of antimonite suggesting that the binding of antimonite increased the affinity of ArsA protein for FSBA. Incorporation of [C-14]FSBA was examined. Extrapolation of the amount of FSBA required to inactivate the protein indicated that 1 mol of FSBA was sufficient to inhibit the activity of 1 mol of ArsA protein in the absence of substrates, while only 0.5 mol was required in the presence of the anionic substrate antimonite. Second, chemical cross-linking of the 63-kDa ArsA protein with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline resulted in formation of a species approximately twice the size of the monomer in the presence of antimonite but not ATP. Third, determination of the average mass of the ArsA protein in solution by light scattering demonstrated that the average species was 66 kDa in the absence of substrates. In the presence of antimonite the weight average molecular mass increased to a mass in excess of 100 kDA. These results are consistent with the ArsA protein existing in an equilibrium between monomer and dimer, with the equilibrium favoring dimerization upon binding of the anionic substrate. Moreover, total loss of ATPase activity in the half-modified enzyme suggests that the catalytic sites on each monomer must interact.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM, DETROIT, MI 48201 USA; UNIV MARYLAND, DEPT CHEM, CATONSVILLE, MD 21228 USA	Wayne State University				Rosen, Barry P./0000-0002-5230-4271	NIAID NIH HHS [AI19793] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019793] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALSHAWI MK, 1990, J BIOL CHEM, V265, P5595; BAUMERT HG, 1989, METHOD ENZYMOL, V172, P584; BELLEAU B, 1968, J AM CHEM SOC, V90, P1651, DOI 10.1021/ja01008a045; BULLOUGH DA, 1986, J BIOL CHEM, V261, P5722; BULLOUGH DA, 1986, J BIOL CHEM, V261, P14171; CHEN CM, 1986, J BIOL CHEM, V261, P5030; CHEN CM, 1985, J BACTERIOL, V161, P758, DOI 10.1128/JB.161.2.758-763.1985; Colman R F, 1977, Methods Enzymol, V46, P240; COLMAN RF, 1983, ANNU REV BIOCHEM, V52, P67, DOI 10.1146/annurev.bi.52.070183.000435; DIPIETRO A, 1980, BIOCHEMISTRY-US, V19, P5671, DOI 10.1021/bi00566a002; DIPIETRO A, 1979, BIOCHEMISTRY-US, V18, P1738, DOI 10.1021/bi00576a016; DUNN SD, 1980, J BIOL CHEM, V255, P113; DUPUIS A, 1985, BIOCHEMISTRY-US, V24, P734, DOI 10.1021/bi00324a030; ESCH FS, 1978, J BIOL CHEM, V253, P6100; FRANCISCO MJDS, 1989, MOL MICROBIOL, V3, P15, DOI 10.1111/j.1365-2958.1989.tb00098.x; HSU CM, 1989, J BIOL CHEM, V264, P17349; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOBLEY HLT, 1983, MOL GEN GENET, V191, P421, DOI 10.1007/BF00425757; MOYLE J, 1975, FEBS LETT, V56, P55, DOI 10.1016/0014-5793(75)80110-4; PAL PK, 1975, J BIOL CHEM, V250, P8140; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; Pittz E P, 1973, Methods Enzymol, V27, P209; ROSEN BP, 1984, BIOCHEM BIOPH RES CO, V124, P760, DOI 10.1016/0006-291X(84)91023-4; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; ROSEN BP, 1988, ION PUMPS STRUCTURE, P105; TISA LS, 1990, J BIOL CHEM, V265, P190; TSIA LS, 1990, J BIOENERG BIOMEMBR, V22, P493; VANHOLDE KE, 1985, PHYSICAL BIOCH; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WYATT JL, 1977, BIOCHEMISTRY-US, V16, P1333, DOI 10.1021/bi00626a015	33	3	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2327	2332						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1824941				2022-12-25	WOS:A1991EV51500049
J	FUNDERBURGH, JL; FUNDERBURGH, ML; MANN, MM; CONRAD, GW				FUNDERBURGH, JL; FUNDERBURGH, ML; MANN, MM; CONRAD, GW			ARTERIAL LUMICAN - PROPERTIES OF A CORNEAL-TYPE KERATAN SULFATE PROTEOGLYCAN FROM BOVINE AORTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKAGE-REGION; CORE PROTEIN	A glycoprotein reactive with antibodies against corneal keratan sulfate proteoglycan (KSPG) was purified 300-fold from extracts of bovine aorta using DEAE ion-exchange, gel-filtration, hydrophobic interaction, and reverse-phase chromatographic separations. The intact glycoprotein was 70-80 kDa on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Deglycosylation with endo-beta-galactosidase and N-glycanase reduced the size to 48 and 37 kDa, respectively, similar to the large isoforms of corneal KSPG. N-terminal amino acid sequence of the arterial KSPG was identical with lumican, the 37B isoform of corneal KSPG, and the arterial KSPG reacted with an antibody to synthetic peptide duplicating this sequence. Arterial KSPG and corneal lumican displayed identical tryptic maps. Arterial lumican contains fucose and mannose in amounts similar to corneal KSPG, but galactose, glucosamine, and sulfate were reduced compared to KSPG from cornea. Treatment of arterial lumican with endo-beta-galactosidase released 8-9 mol of glucosamine and galactose per mol of protein as oligosaccharides. These eluted as neutral, nonsulfated oligosaccharides on high pH anion-exchange chromatography. The size of arterial lumican was not altered by glycosidases having specificity for sulfated keratan sulfate, nor was the charge of the lumican molecule altered by digestion with endo-beta-galactosidase. These data show arterial lumican to be a glycoprotein containing unsulfated lactosaminoglycan chains. Abundance of low sulfate lumican in many tissues indicates that this protein occurs predominantly as a glycoprotein rather than as the more widely studied, highly sulfated proteoglycan present in the cornea.			FUNDERBURGH, JL (corresponding author), KANSAS STATE UNIV AGR & APPL SCI,DIV BIOL,MANHATTAN,KS 66506, USA.				NEI NIH HHS [EY00952] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY000952] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AXELSSON I, 1978, BIOCHEM J, V169, P517, DOI 10.1042/bj1690517; BLOCHBERGER TC, 1991, INVEST OPHTH VIS SCI, V32, P966; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONRAD GW, 1982, J BIOL CHEM, V257, P464; FUNDERBURGH JL, 1989, INVEST OPHTH VIS SCI, V30, P2278; FUNDERBURGH JL, 1986, DEV BIOL, V116, P267, DOI 10.1016/0012-1606(86)90130-2; FUNDERBURGH JL, 1987, J BIOL CHEM, V262, P11634; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P14226; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; FUNDERBURGH JL, 1989, KERATAN SULPHATE CHE, P39; JOST CJ, 1991, J BIOL CHEM, V266, P13336; Nakazawa K., 1989, KERATAN SULPHATE CHE, P99; NILSSON B, 1983, J BIOL CHEM, V258, P6056; OBEN M, 1987, BIOCHEM J, V248, P85; RADA JA, 1991, INVEST OPHTH VIS SCI, V32, P1010; SCOTT JE, 1985, BIOSCIENCE REP, V5, P765, DOI 10.1007/BF01119875; STEIN T, 1982, H-S Z PHYSIOL CHEM, V363, P825, DOI 10.1515/bchm2.1982.363.2.825	17	88	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24773	24777						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761572				2022-12-25	WOS:A1991GW84500081
J	PEREZVILAR, J; HIDALGO, J; VELASCO, A				PEREZVILAR, J; HIDALGO, J; VELASCO, A			PRESENCE OF TERMINAL N-ACETYLGALACTOSAMINE RESIDUES IN SUBREGIONS OF THE ENDOPLASMIC-RETICULUM IS INFLUENCED BY CELL-DIFFERENTIATION IN CULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; O-LINKED OLIGOSACCHARIDES; GOLGI-APPARATUS; TEMPORAL ASPECTS; CORE PROTEIN; GLYCOPROTEIN BIOSYNTHESIS; SUBCELLULAR-LOCALIZATION; ERYTHROLEUKEMIA-CELLS; RAT CHONDROSARCOMA; GOBLET CELLS	Using Helix pomatia lectin as a specific probe for terminal, nonreducing N-acetylgalactosamine residues, glycoprotein precursors bearing newly initiated O-linked oligosaccharides have been localized in the lumen of the endoplasmic reticulum and cis-Golgi cisternae. This pattern contrasts with the detection of the terminal disaccharide galactose beta-1,3-N-acetylgalactosamine by Arachis hypogaea lectin in middle and trans-Golgi compartments, which are considered elongation sites for O-glycosylation. Distribution of H. pomatia ligands in the endoplasmic reticulum is confined to specialized regions or subcompartments in both human colonic adenocarcinoma cells and cultured chicken chondrocytes. Since in cartilage, chondrocytes contain H. pomatia-binding sites exclusively concentrated in cis-Golgi cisternae, primary cultures of this cell type have been used to study those conditions that promote initiation of O-glycosylation in the endoplasmic reticulum. A correlation has been found between the age of the culture and the extent of reactivity of the endoplasmic reticulum with either H. pomatia lectin or antibody against the sequence GalNAc-alpha-serine/threonine (Tn antigen). Cells showing an extensive reaction are not hindered in their secretory activity and still maintain the chondrocyte phenotype. Taken together the results suggest that the intracellular distribution of the glycosylation enzymes is not only cell type-specific as previously shown (Roth, J., Taatjes, D. J., Weinstein, J., Paulson, J. C., Greenwell, P., and Watkins, W. M. (1986) J. Biol. Chem. 261, 14307-14312) but it might also vary depending on the stage of cell differentiation.	UNIV SEVILLE,FAC BIOL,DEPT CELL BIOL,AVD REINA MERCEDES S-N,E-4101 SEVILLE,SPAIN	University of Sevilla	VELASCO, A (corresponding author), UNIV SEVILLE,FAC BIOL,DEPT CELL BIOL,AVD REINA MERCEDES S-N,E-4101 SEVILLE,SPAIN.							ABEIJON C, 1987, J BIOL CHEM, V262, P4153; BRADA D, 1990, J CELL BIOL, V110, P309, DOI 10.1083/jcb.110.2.309; BRUCKNER P, 1989, J CELL BIOL, V109, P2537, DOI 10.1083/jcb.109.5.2537; CARRAWAY KL, 1989, BIOESSAYS, V10, P117, DOI 10.1002/bies.950100406; CASTAGNOLA P, 1988, J CELL BIOL, V106, P461, DOI 10.1083/jcb.106.2.461; CHANEY W, 1989, J CELL BIOL, V109, P2089, DOI 10.1083/jcb.109.5.2089; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DEKKER J, 1990, J BIOL CHEM, V265, P18116; DESCHUYTENEER M, 1988, J BIOL CHEM, V263, P2452; ELHAMMER A, 1984, J CELL BIOL, V98, P327; GEETHAHABIB M, 1984, J BIOL CHEM, V259, P7300; HAMMARSTROM S, 1977, BIOCHEMISTRY-US, V16, P2750, DOI 10.1021/bi00631a025; HANOVER JA, 1980, J BIOL CHEM, V255, P6713; HANOVER JA, 1982, J BIOL CHEM, V257, P172; HOFFMANN HP, 1984, CONNECT TISSUE RES, V12, P151, DOI 10.3109/03008208408992780; JOHNSON DC, 1983, CELL, V32, P987, DOI 10.1016/0092-8674(83)90083-1; KIM YS, 1971, J BIOL CHEM, V246, P5466; KIMURA JH, 1984, J CELL BIOCHEM, V26, P261, DOI 10.1002/jcb.240260406; KO GKW, 1972, BIOCHIM BIOPHYS ACTA, V264, P129, DOI 10.1016/0304-4165(72)90124-9; Kornfeld R., 1980, BIOCH GLYCOPROTEINS, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHMANDER LS, 1986, ARCH BIOCHEM BIOPHYS, V250, P211, DOI 10.1016/0003-9861(86)90719-8; LOHMANDER LS, 1989, J BIOL CHEM, V264, P18775; LOTAN R, 1975, J BIOL CHEM, V250, P8518; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MAYNE R, 1976, P NATL ACAD SCI USA, V73, P1674, DOI 10.1073/pnas.73.5.1674; MCCOOL DJ, 1990, BIOCHEM J, V267, P491, DOI 10.1042/bj2670491; MORROW B, 1987, J BIOL CHEM, V262, P13812; NAKADA H, 1991, J BIOL CHEM, V266, P12402; NIEMANN H, 1982, EMBO J, V1, P1499, DOI 10.1002/j.1460-2075.1982.tb01346.x; OHANLON T, 1989, J BIOL CHEM, V2614, P17389; PACIFICI M, 1988, J BIOL CHEM, V263, P2483; PATHAK RK, 1988, J CELL BIOL, V106, P1831, DOI 10.1083/jcb.106.6.1831; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PILLER V, 1990, J BIOL CHEM, V265, P9264; PILLER V, 1989, EUR J BIOCHEM, V183, P123, DOI 10.1111/j.1432-1033.1989.tb14904.x; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTH J, 1984, J CELL BIOL, V98, P399, DOI 10.1083/jcb.98.2.399; ROTH J, 1983, J HISTOCHEM CYTOCHEM, V31, P987, DOI 10.1177/31.8.6190857; ROTH J, 1981, J HISTOCHEM CYTOCHEM, V29, P663, DOI 10.1177/29.5.6166664; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SERAFINICESSI F, 1989, BIOCHEM J, V262, P479, DOI 10.1042/bj2620479; SHAILUBHAI K, 1990, J BIOL CHEM, V265, P9701; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SPIELMAN J, 1987, J BIOL CHEM, V262, P269; STROUS GJAM, 1979, P NATL ACAD SCI USA, V76, P2694, DOI 10.1073/pnas.76.6.2694; TARTAKOFF AM, 1983, J CELL BIOL, V97, P1243, DOI 10.1083/jcb.97.4.1243; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; VERTEL BM, 1989, J CELL BIOL, V109, P1827, DOI 10.1083/jcb.109.4.1827; WHITE DA, 1980, BIOCHEM J, V192, P297, DOI 10.1042/bj1920297	56	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23967	23976						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748669				2022-12-25	WOS:A1991GV31900069
J	PETROPOULOS, I; AUGEGOUILLOU, C; ZAKIN, MM				PETROPOULOS, I; AUGEGOUILLOU, C; ZAKIN, MM			CHARACTERIZATION OF THE ACTIVE PART OF THE HUMAN TRANSFERRIN GENE ENHANCER AND PURIFICATION OF 2 LIVER NUCLEAR FACTORS INTERACTING WITH THE TGTTTGC MOTIF PRESENT IN THIS REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; B VIRUS ENHANCER; ALBUMIN GENE; PROMOTER; TRANSCRIPTION; INVITRO; ELEMENTS; SITES	The human transferrin gene enhancer is composed of two functional domains (A and B). We have previously shown that domain A is able to mediate enhancer activity in transient expression experiments. Here, we show that multimers of the domain A single enhanson coupled to a canonical TATA box are sufficient to promote transcription in vitro with liver nuclear extracts. Gel mobility shift assays reveal the binding of two liver nuclear factors to this enhanson, and methylation interference experiments show that the motif 5'-TGTTTGCTTT-3' is the target site for these factors. This was confirmed by the use of mutants in gel retardation assays and transient expression experiments. The two proteins interacting with the decanucleotide have been purified from rat liver nuclear extracts by DNA affinity chromatography. The purified proteins named enhancer-binding protein (EBP)-45 and EBP-40 appear as single polypeptide bands with respective molecular masses of 45 and 40 kDa on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The TGTTTGC motif was found to be important for the hepatocyte-specific expression of several genes; and in some cases, it was demonstrated that the transcription factor CCAAT/enhancer-binding protein (C/EBP) is able to bind to this sequence. In vitro experiments show that EBP-45 and EBP-40 are different from C/EBP; they also show that the two proteins interact with the TGTTTGC motif present in control regions of other hepatic genes, such as the mouse albumin enhancer eH and hepatitis B virus enhancer E elements.	INST PASTEUR,EXPRESS GENES EUCARYOTES LAB,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	ZAKIN, MM (corresponding author), INST PASTEUR,EXPRESS GENES EUCARYOTES LAB,F-75724 PARIS 15,FRANCE.		GOUILLOU, Corinne AUGE/T-2346-2018	GOUILLOU, Corinne AUGE/0000-0002-3340-5560; Petropoulos, Isabelle/0000-0001-9205-7458				BENLEVY R, 1989, MOL CELL BIOL, V9, P1804, DOI 10.1128/MCB.9.4.1804; BOISSIER F, 1991, J BIOL CHEM, V266, P9822; BRUNEL F, 1988, J BIOL CHEM, V263, P10180; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P3683, DOI 10.1128/MCB.10.7.3683; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; GRAYSON DR, 1988, MOL CELL BIOL, V8, P1055, DOI 10.1128/MCB.8.3.1055; GUILLOU F, 1991, J BIOL CHEM, V266, P9876; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MENDELZON D, 1990, NUCLEIC ACIDS RES, V18, P5717, DOI 10.1093/nar/18.19.5717; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; OCHOA A, 1989, NUCLEIC ACIDS RES, V17, P119, DOI 10.1093/nar/17.1.119; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHAEFFER E, 1989, J BIOL CHEM, V264, P7153; SCHORPP M, 1988, J MOL BIOL, V202, P307, DOI 10.1016/0022-2836(88)90460-3; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; ZHANG DE, 1990, J BIOL CHEM, V265, P3382	21	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					24220	24225						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748690				2022-12-25	WOS:A1991GV31900105
J	LIN, SC; MORRISONBOGORAD, M				LIN, SC; MORRISONBOGORAD, M			CLONING AND CHARACTERIZATION OF A TESTIS-SPECIFIC THYMOSIN-BETA-10 CDNA - EXPRESSION IN POSTMEIOTIC MALE GERM-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FERRITIN EXPRESSION; AMINO-ACID-SEQUENCE; MESSENGER-RNAS; TRANSLATIONAL REGULATION; HAPLOID EXPRESSION; MOUSE; ACTIN; RAT; GENE; IRON	Thymosin beta-10 is one of a small family of proteins closely related in sequence to thymosin beta-4, recently identified as an actin-sequestering protein. A single molecular weight species of thymosin beta-10 mRNA is present in a number of rat tissues. In adult rat testis, an additional thymosin beta-10 mRNA of higher molecular weight was identified. Nucleotide sequencing of cDNA clones complementary to the testis-specific thymosin mRNA indicated that this mRNA differed from the ubiquitous thymosin beta-10 mRNA only in its 5'-untranslated region, beginning 14 nucleotides upstream of the translation initiation codon. These results, together with primer extension experiments, suggest that the two thymosin beta-10 mRNAs are transcribed from the same gene through a combination of differential promoter utilization and alternative splicing. The novel thymosin beta-10 mRNA could be detected only in RNA isolated from sexually mature rat testis. Both mRNAs were present in pachytene spermatocytes; only the testis-specific mRNA was detected in postmeiotic haploid spermatids. Immunoblot analysis using specific antibodies showed that the thymosin beta-10 protein synthesized in adult testis was identical in size to that synthesized in brain. Immunohistochemical analysis showed that the protein was present in differentiating spermatids, suggesting that the testis-specific thymosin beta-10 mRNA is translated in haploid male germ cells.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT NEUROL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NICHD NIH HHS [HD-14886, HD-07025] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD007025, R01HD014886] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; AZIZ N, 1986, NUCLEIC ACIDS RES, V14, P915, DOI 10.1093/nar/14.2.915; BENYAJATI C, 1983, CELL, V33, P125, DOI 10.1016/0092-8674(83)90341-0; BORDER B, 1990, SOC NEUR ABSTR, V16, P146; BORDER BG, 1985, EXP BRAIN RES, V59, P600; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAUGHMAN SW, 1988, J BIOL CHEM, V263, P19048; CLERMONT Y, 1957, AM J ANAT, V100, P241, DOI 10.1002/aja.1001000205; DALAKAS MC, 1986, ANN NEUROL, V19, P349, DOI 10.1002/ana.410190407; DANOFF A, 1988, J BIOL CHEM, V263, P16461; DISTEL RJ, 1984, SCIENCE, V224, P68, DOI 10.1126/science.6701535; ERICKSONVIITANEN S, 1983, ARCH BIOCHEM BIOPHYS, V225, P407, DOI 10.1016/0003-9861(83)90047-4; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; GONDO H, 1987, J IMMUNOL, V139, P3840; GOODALL GJ, 1983, J IMMUNOL, V131, P821; GOODALL GJ, 1987, ARCH BIOCHEM BIOPHYS, V256, P402, DOI 10.1016/0003-9861(87)90461-9; HANNAPPEL E, 1985, ARCH BIOCHEM BIOPHYS, V240, P236, DOI 10.1016/0003-9861(85)90028-1; HARITOS AA, 1987, FEBS LETT, V218, P107, DOI 10.1016/0014-5793(87)81028-1; HARLOW E, 1988, ANTIBODIES LABORATOR; HECHT NB, 1990, CELL MOL BIOL TESTIS; HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730; HORECKER BL, 1984, LYMPHOKINES, V9, P15; ILARIA R, 1985, J NEUROSCI METH, V15, P165, DOI 10.1016/0165-0270(85)90053-6; KIM E, 1989, MOL CELL BIOL, V9, P1875, DOI 10.1128/MCB.9.5.1875; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN SC, 1990, J MOL NEUROSCI, V2, P34; LOW TLK, 1981, P NATL ACAD SCI-BIOL, V78, P1162, DOI 10.1073/pnas.78.2.1162; LOW TLK, 1982, J BIOL CHEM, V257, P1000; MCCREARY V, 1988, BIOCHEM BIOPH RES CO, V152, P862, DOI 10.1016/S0006-291X(88)80118-9; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; MEIJER D, 1987, EMBO J, V6, P4041, DOI 10.1002/j.1460-2075.1987.tb02749.x; MEISTRICH ML, 1973, EXP CELL RES, V79, P213, DOI 10.1016/0014-4827(73)90507-7; MORRISON MR, 1977, BIOCHIM BIOPHYS ACTA, V476, P228, DOI 10.1016/0005-2787(77)90006-5; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PERIASAMY M, 1984, J BIOL CHEM, V259, P3595; PETERSON RN, 1990, J EXP ZOOL, V253, P202, DOI 10.1002/jez.1402530210; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; ROMRELL LJ, 1976, DEV BIOL, V49, P119, DOI 10.1016/0012-1606(76)90262-1; ROUAULT TA, 1987, P NATL ACAD SCI USA, V84, P6335, DOI 10.1073/pnas.84.18.6335; RUDIN CM, 1990, J IMMUNOL, V144, P4857; SAFER D, 1991, J BIOL CHEM, V266, P4029; SAFER D, 1990, P NATL ACAD SCI USA, V87, P2536, DOI 10.1073/pnas.87.7.2536; SAKIYAMA S, 1989, CELL TISSUE RES, V258, P225; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN SJ, 1988, P NATL ACAD SCI USA, V85, P1947, DOI 10.1073/pnas.85.6.1947; SLAUGHTER GR, 1987, BIOL REPROD, V37, P1259, DOI 10.1095/biolreprod37.5.1259; SLAUGHTER GR, 1989, BIOL REPROD, V40, P395, DOI 10.1095/biolreprod40.2.395; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; SOUTHWICK FS, 1990, J CELL BIOL, V110, P1965, DOI 10.1083/jcb.110.6.1965; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; WELLER FE, 1988, J BIOL RESP MODIF, V7, P91; WODNARFILIPOWIC.A, 1983, P NATL ACAD SCI USA, V80, P1811; WODNARFILIPOWICZ A, 1984, P NATL ACAD SCI-BIOL, V81, P2295, DOI 10.1073/pnas.81.8.2295; YOUNG RA, 1981, CELL, V23, P451, DOI 10.1016/0092-8674(81)90140-9	58	44	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23347	23353						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744129				2022-12-25	WOS:A1991GT48300086
J	ZHANG, YH; ROSS, EM; SNELL, WJ				ZHANG, YH; ROSS, EM; SNELL, WJ			ATP-DEPENDENT REGULATION OF FLAGELLAR ADENYLYLCYCLASE IN GAMETES OF CHLAMYDOMONAS-REINHARDTII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; ADENYLATE-CYCLASE; CYCLIC-AMP; INTRACELLULAR SIGNALS; CROSS-TALK; ACTIVATION; SYSTEM; PHOSPHORYLATION; INHIBITORS; MEMBRANES	Adenylylcyclase activity in the flagella of gametes of Chlamydomonas reinhardtii was inhibited by prior incubation at or below 30-degrees-C in the presence of ATP. This decrease did not occur in the absence of ATP, in the presence of the ATP analog 5'-adenylylimidodiphosphate (App(NH)p), or in the presence of ATP plus the protein kinase inhibitor staurosporine (2-mu-M). If ATP treatment was performed in the absence of an ATP-regenerating system, activity initially declined and subsequently recovered. Incubation of flagella at 45-degrees-C in the absence of ATP or incubation at lower temperatures in the presence of either App(NH)p or staurosporine both increased adenylylcyclase activity (over 10-fold) and blocked subsequent ATP-dependent loss of activity at 30-degrees-C. This heat-induced activation was prevented by the presence of ATP plus an ATP-regenerating system. Incubation of flagella with [gamma-P-32] ATP followed by gel electrophoresis in sodium dodecyl sulfate indicated the presence of endogenous protein kinase and protein phosphatase activities. These data suggest that the flagellar adenylylcyclase in Chlamydomonas gametes is inhibited by phosphorylation and stimulated by dephosphorylation. This mechanism for regulating adenylylcyclase may underlie the rapid increase in cyclic AMP that is induced by flagellar adhesion during fertilization in Chlamydomonas.	UNIV TEXAS, SW MED SCH, DEPT CELL BIOL & NEUROSCI, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED SCH, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Zhang, Yuhua/0000-0003-0901-935X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025661] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM025661, GM-25661] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAIR WS, 1985, J CELL SCI, P233; ANANDSRIVASTAVA MB, 1990, MOL CELL BIOCHEM, V92, P91; BECKNER SK, 1987, BIOCHEM BIOPH RES CO, V145, P176, DOI 10.1016/0006-291X(87)91303-9; BLOODGOOD R A, 1989, Journal of Cell Biology, V109, p178A; BOOKBINDER LH, 1990, J CELL BIOL, V111, P1859, DOI 10.1083/jcb.111.5.1859; BUCHANAN MJ, 1989, J CELL BIOL, V108, P199, DOI 10.1083/jcb.108.1.199; DETMERS PA, 1983, J CELL BIOL, V97, P522, DOI 10.1083/jcb.97.2.522; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GOODENOUGH UW, 1989, J CELL BIOL, V109, P247, DOI 10.1083/jcb.109.1.247; GOODENOUGH UW, 1975, J CELL BIOL, V67, P623, DOI 10.1083/jcb.67.3.623; HASEGAWA E, 1987, CELL MOTIL CYTOSKEL, V8, P302, DOI 10.1002/cm.970080403; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIDAKA H, 1980, MOL PHARMACOL, V17, P66; HILDEBRANDT JD, 1985, ENDOCRINOLOGY, V116, P1357, DOI 10.1210/endo-116-4-1357; HUNNICUTT GR, 1990, J CELL BIOL, V111, P1605, DOI 10.1083/jcb.111.4.1605; KOOIJMAN R, 1990, PLANTA, V181, P529, DOI 10.1007/BF00193006; KOPF GS, 1988, MEIOTIC INHIBITION M, P357; KOROLKOV SN, 1990, FEBS LETT, V270, P132, DOI 10.1016/0014-5793(90)81251-I; OTTE AP, 1989, CELL, V58, P641, DOI 10.1016/0092-8674(89)90099-8; PASQUALE SM, 1988, BOT ACTA, V101, P118, DOI 10.1111/j.1438-8677.1988.tb00021.x; PASQUALE SM, 1987, J CELL BIOL, V105, P2279, DOI 10.1083/jcb.105.5.2279; PIJST HLA, 1984, FEBS LETT, V174, P132, DOI 10.1016/0014-5793(84)81091-1; RODBELL M, 1971, J BIOL CHEM, V246, P1877; ROSS EM, 1977, J BIOL CHEM, V252, P5761; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SAGER R, 1954, J GEN PHYSIOL, V37, P729, DOI 10.1085/jgp.37.6.729; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHLOSS JA, 1990, MOL GEN GENET, V221, P443, DOI 10.1007/BF00259410; SEGAL RA, 1985, J CELL BIOL, V101, P1702, DOI 10.1083/jcb.101.5.1702; SNELL WJ, 1989, J CELL BIOL, V109, P1689, DOI 10.1083/jcb.109.4.1689; SNELL WJ, 1976, J CELL BIOL, V68, P48, DOI 10.1083/jcb.68.1.48; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TOMSON AM, 1990, J CELL SCI, V95, P293; WIENER E, 1989, J BIOL CHEM, V264, P4324; WITMAN GB, 1972, J CELL BIOL, V54, P507, DOI 10.1083/jcb.54.3.507; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0	36	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22954	22959						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744089				2022-12-25	WOS:A1991GT48300030
J	BROWN, CA; MAHURAN, DJ				BROWN, CA; MAHURAN, DJ			ACTIVE ARGININE RESIDUES IN BETA-HEXOSAMINIDASE - IDENTIFICATION THROUGH STUDIES OF THE B1-VARIANT OF TAY-SACHS DISEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTENSIVE HOMOLOGY; LYSOSOMAL-ENZYME; ALPHA-SUBUNITS; PRO-ALPHA; CARBOXYPEPTIDASE; ISOZYMES; FIBROBLASTS; PRECURSORS; MUTATION; PROTEIN	Lysosomal beta-hexosaminidase (EC 3.2.1.52) occurs as two major isoenzymes, hexosaminidases A (alpha-beta) and B (beta-beta). The alpha- and beta-subunits are encoded by the HEXA and HEXB genes, respectively. Extensive homology in both the gene structures and deduced primary sequences demonstrate their common evolutionary origin. Defects in the alpha- or beta-subunits lead to Tay-Sachs or Sandhoff disease, respectively. The B1 variant of Tay-Sachs disease is characterized by an unusual phenotype. Patient samples contain both isoenzymes; however, hexosaminidase A lacks activity toward alpha-specific substrates. In a previous report, we analyzed the biochemical consequences of an Arg178 --> His substitution in the alpha-subunit, causing the B1 phenotype, by in vitro mutagenesis of the homologous codon for Arg211 in the beta-subunit to produce His. We found that the substitution did not affect dimer formation or cellular targeting but caused a near total loss of activity toward a common alpha- and/or beta-substrate. Additional effects were also noted that suggested a perturbation had occurred to the protein's secondary structure. In this report, we investigate further the role of Arg in the catalysis of hexosaminidase substrates. The introduction of more or less conservative amino acid substitutions at the beta-Arg211 site were evaluated in terms of their effects on the protein's catalytic activity and susceptibility to the arginine-specific reagents and on its stability and rate of maturation in the cell's lysosome. These data demonstrate that the changes in the in vivo stability and rate of maturation, previously noted with the Arg211 --> His substitution, are independent of the loss in enzymatic activity. Whereas treatment of purified normal human placental hexosaminidases A and B with arginine-specific modifying reagents produced a time-dependent loss of enzymatic activity toward both alpha-specific and common substrates, these reagents failed to significantly decrease the residual activities of mutant proteins lacking Arg at position 211. Kinetic analysis of the residual enzyme activity from our most conservative construct, Arg211 --> Lys, determined an apparent V(max) approximately 400-fold reduced from that of the wild type enzyme but detected no change in the apparent K(m). Additionally, the pH optimum of this mutant enzyme was narrower and slightly more basic than that of the normal enzyme. Thus, Arg211 in the beta-subunit and, by extrapolation, the Arg178 in the alpha-subunit of beta-hexosaminidase are "active" residues, i.e. part of the catalytic sites, but do not participate in substrate binding.	HOSP SICK CHILDREN,RES INST,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5G 2C4,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								BERGER SA, 1990, NATURE, V343, P575, DOI 10.1038/343575a0; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BJERRUM PJ, 1983, J GEN PHYSIOL, V81, P453, DOI 10.1085/jgp.81.4.453; BROWN CA, 1989, J BIOL CHEM, V264, P21705; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; GRANTHAM R, 1974, SCIENCE, V185, P862, DOI 10.1126/science.185.4154.862; HART KW, 1987, BIOCHEM BIOPH RES CO, V146, P346, DOI 10.1016/0006-291X(87)90731-5; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HUBBES M, 1989, FEBS LETT, V249, P316, DOI 10.1016/0014-5793(89)80649-0; KABACK MM, 1977, TAY SACHS DISEASE SC, P197; KORNELUK RG, 1986, J BIOL CHEM, V261, P8407; KYTZIA HJ, 1985, J BIOL CHEM, V260, P7568; LUNDBLAD RL, 1984, CHEM REAGENTS PROTEI, V2, P1; MAHURAN D, 1985, ISOZYMES-CURR T BIOL, V12, P229; MAHURAN D, 1980, CAN J BIOCHEM CELL B, V58, P287, DOI 10.1139/o80-038; MAHURAN DJ, 1988, J BIOL CHEM, V263, P4612; MAHURAN DJ, 1990, J BIOL CHEM, V265, P6794; MAHURAN DJ, 1982, P NATL ACAD SCI-BIOL, V79, P1602, DOI 10.1073/pnas.79.5.1602; MALFROY B, 1985, BIOCHEM BIOPH RES CO, V130, P372, DOI 10.1016/0006-291X(85)90427-9; MCILVAINE, 1959, DATA BIOCH RES, P196; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; ODOWD BF, 1988, BIOCHEMISTRY-US, V27, P5216, DOI 10.1021/bi00414a041; OHNO K, 1988, J NEUROCHEM, V50, P316, DOI 10.1111/j.1471-4159.1988.tb13266.x; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; PHILLIPS MA, 1990, J BIOL CHEM, V265, P20692; PROIA RL, 1988, P NATL ACAD SCI USA, V85, P1883, DOI 10.1073/pnas.85.6.1883; QUON DVK, 1989, J BIOL CHEM, V264, P3380; RIORDAN JF, 1977, SCIENCE, V195, P884, DOI 10.1126/science.190679; RIORDAN JF, 1973, BIOCHEMISTRY-US, V12, P3915, DOI 10.1021/bi00744a020; Sambrook J, 1989, MOL CLONING LABORATO; Sandhoff KCE, 1989, METABOLIC BASIS INHE, V2, P1807; SODERLING E, 1983, ARCH BIOCHEM BIOPHYS, V220, P11, DOI 10.1016/0003-9861(83)90381-8; SONDERFELDFRESKO S, 1989, J BIOL CHEM, V264, P7692; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; TAYLOR WR, 1986, J THEOR BIOL, V119, P205, DOI 10.1016/S0022-5193(86)80075-3; TOMMASINI R, 1985, CAN J BIOCHEM CELL B, V63, P219, DOI 10.1139/o85-031; VANDIGGELEN OP, 1982, BIOCHIM BIOPHYS ACTA, V703, P69, DOI 10.1016/0167-4838(82)90012-7; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	38	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15855	15862						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1831451				2022-12-25	WOS:A1991GB97700052
J	PAN, BS; GORDON, AM; POTTER, JD				PAN, BS; GORDON, AM; POTTER, JD			DELETION OF THE 1ST 45 NH2-TERMINAL RESIDUES OF RABBIT SKELETAL TROPONIN-T STRENGTHENS BINDING OF TROPONIN TO IMMOBILIZED TROPOMYOSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE ALPHA-TROPOMYOSIN; BETA-TROPOMYOSIN; STRIATED-MUSCLE; IONIC-STRENGTH; THIN FILAMENT; FRAGMENTS; ACTIN; SENSITIVITY; PROTEINS; OVERLAP	The binding of the NH2-terminal region of troponin T (TnT) to the COOH-terminal region of tropomyosin (Tm) and the head-to-tail overlap between Tm molecules is thought to provide a pivotal link between troponin (Tn) and Tm (White, S. P., Cohen, C., and Phillips, G. N., Jr. (1987) Nature 325, 826-828). To further explore the structure-function relationship of the NH2-terminal region of TnT, we studied the binding of a 26,000-dalton TnT fragment (26K-TnT, Ohtsuki, I., Shiraishi, F., Suenaga, N., Miyata, T., and Tanokura, M. J. (1984) J. Biochem. (Tokyo) 95, 1337-1342) which corresponds to residues 46-259 of TnT2f, the major isoform of TnT in rabbit fast twitch muscle, to immobilized alpha-Tm. Both 26K-TnT and TnT2f were retained by the alpha-Tm affinity column in the presence of 150 mM NaCl. However, upon increasing the NaCl concentration 26K-TnT was eluted from the column at a higher ionic strength than was TnT. When applied alone, the binary complex of TnI and TnC (TnC.TnI) was not retained by the alpha-Tm affinity column. When applied subsequently to prebound TnT2f or 26K-TnT, TnI.TnC was retained by the alpha-Tm affinity column and eluted together with TnT2f or 26K-TnT as ternary troponin complexes. Whether Ca2+ was present or not, Tn containing 26K-TnT was eluted at a higher ionic strength than was Tn containing TnT2f, indicating that removal of the first 45 residues of TnT2f strengthens the binding of Tn to Tm. In the presence of Tm, reconstituted Tn containing 26K-TnT conferred Ca2+ sensitivity on actomyosin-S1 MgATPase, and the steepness of the pCa-ATPase relation was unchanged with respect to the actoS1 ATPase regulated by TnT2f. It is concluded that the first 45 residues of TnT2f are not essential for anchoring the troponin complex to the thin filament and do not play a crucial role in the cooperative response of regulated actoS1 ATPase to Ca2+.	UNIV MIAMI,SCH MED,DEPT MOLEC & CELLULAR PHARMACOL,POB 016189,MIAMI,FL 33101; UNIV WASHINGTON,DEPT PHYSIOL & BIOPHYS,SEATTLE,WA 98195	University of Miami; University of Washington; University of Washington Seattle					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031962] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS008384] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31962] Funding Source: Medline; NIAMS NIH HHS [AR37701] Funding Source: Medline; NINDS NIH HHS [NS08384] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BRIGGS MM, 1989, J MOL BIOL, V206, P245, DOI 10.1016/0022-2836(89)90538-X; BRISSON JR, 1986, BIOCHEMISTRY-US, V25, P4548, DOI 10.1021/bi00364a014; CARTER SG, 1982, J BIOCHEM BIOPH METH, V7, P7, DOI 10.1016/0165-022X(82)90031-8; CHO YJ, 1990, J BIOL CHEM, V265, P538; CLARKE FM, 1976, BIOCHIM BIOPHYS ACTA, V427, P617, DOI 10.1016/0005-2795(76)90205-1; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FLICKER PF, 1982, J MOL BIOL, V162, P495, DOI 10.1016/0022-2836(82)90540-X; HEELEY DH, 1988, BIOCHEMISTRY-US, V27, P8227, DOI 10.1021/bi00421a036; HEELEY DH, 1989, BIOCHEM J, V258, P831, DOI 10.1042/bj2580831; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAK AS, 1980, J BIOL CHEM, V255, P3647; MARTYN DA, 1988, J MUSCLE RES CELL M, V9, P428, DOI 10.1007/BF01774069; MORRIS EP, 1984, BIOCHEMISTRY-US, V23, P2214, DOI 10.1021/bi00305a018; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OHTSUKI I, 1979, J BIOCHEM, V86, P491, DOI 10.1093/oxfordjournals.jbchem.a132549; OHTSUKI I, 1984, J BIOCHEM, V95, P1337, DOI 10.1093/oxfordjournals.jbchem.a134740; PAN BS, 1989, J BIOL CHEM, V264, P8495; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PATO MD, 1981, J BIOL CHEM, V256, P602; PEARLSTONE JR, 1980, CAN J BIOCHEM CELL B, V58, P649, DOI 10.1139/o80-090; PEARLSTONE JR, 1976, P NATL ACAD SCI USA, V73, P1902, DOI 10.1073/pnas.73.6.1902; PEARLSTONE JR, 1978, CAN J BIOCHEM CELL B, V56, P521, DOI 10.1139/o78-080; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; PEARLSTONE JR, 1983, J BIOL CHEM, V258, P2534; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; POTTER JD, 1974, BIOCHEMISTRY-US, V13, P2697, DOI 10.1021/bi00710a007; SCHACHAT FH, 1987, J MOL BIOL, V198, P551, DOI 10.1016/0022-2836(87)90300-7; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; STEIN LA, 1979, BIOCHEMISTRY-US, V18, P3895, DOI 10.1021/bi00585a009; TOBACMAN LS, 1988, J BIOL CHEM, V263, P2668; WALSH TP, 1984, J MOL BIOL, V182, P265; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WILKINSON JM, 1974, BIOCHIM BIOPHYS ACTA, V359, P379, DOI 10.1016/0005-2795(74)90238-4; WILLIAMS DL, 1988, BIOCHEMISTRY-US, V27, P6987, DOI 10.1021/bi00418a048	35	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12432	12438						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1829457				2022-12-25	WOS:A1991FV18000053
J	GALIEN, R; MERCIER, G; GARCETTE, M; EMANOILRAVIER, R				GALIEN, R; MERCIER, G; GARCETTE, M; EMANOILRAVIER, R			RAS ONCOGENE ACTIVATES THE INTRACISTERNAL A PARTICLE LONG TERMINAL REPEAT PROMOTER THROUGH A CAMP RESPONSE ELEMENT	ONCOGENE			English	Article							LEUCINE ZIPPER PROTEINS; CYCLIC-AMP; ADENYLATE-CYCLASE; DIACYLGLYCEROL PRODUCTION; TRANSCRIPTION FACTOR; POSSIBLE INVOLVEMENT; GENE-TRANSCRIPTION; JUN PROTEINS; DNA ELEMENTS; CROSS-TALK	To understand the mechanism responsible for the high expression of Intracisternal A Particles (IAP) in murine cells transformed by the Kirsten Mouse Sarcoma Virus (Ki-MSV), we have investigated the effect of p21ras on IAP transcription. By transient cotransfections of IAP LTR-CAT plasmids with v-Ki-ras and c-Ki-ras expression vectors, we have found that p21v-Ki-ras, and the p21c-Ki-ras to a lesser extent, stimulate the promoter activity of the 5' IAP LTR. We constructed several plasmids containing the CAT gene under control of IAP LTRs deleted in different regions. CAT assays demonstrate that the ras responsive sequence is a 16 bp oligonucleotide containing an effective c-AMP Response Element (CRE) TGACGTCA, which is located in the U3 region, 20 bp upstream of the CAAT box.	HOP ST LOUIS,RETROVIRUS & RETROTRANSPOSONS VERTEBRES LAB,CNRS,UPR 0043,F-75010 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	EMANOILRAVIER, R (corresponding author), HOP ST LOUIS,RETROVIRUS & RETROTRANSPOSONS VERTEBRES LAB,CNRS,UPR 0043,F-75010 PARIS,FRANCE.							ARENZANASEISDEDOS F, 1989, ONCOGENE, V4, P1359; BAEUERLE PA, 1988, COLD SPRING HARB SYM, V53, P789, DOI 10.1101/SQB.1988.053.01.089; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECKNER SK, 1985, NATURE, V317, P71, DOI 10.1038/317071a0; BENBROOK DM, 1990, ONCOGENE, V5, P295; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLUNDELL MC, 1989, J VIROL, V63, P4814, DOI 10.1128/JVI.63.11.4814-4823.1989; CHAPON D, 1983, NATURE, V302, P33; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DOTTO GP, 1985, NATURE, V318, P472; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FALZON M, 1989, J BIOL CHEM, V264, P21915; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GATTONICELLI S, 1983, NATURE, V306, P795, DOI 10.1038/306795a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARRICH D, 1989, J VIROL, V63, P2585, DOI 10.1128/JVI.63.6.2585-2591.1989; HAWLEY RG, 1982, P NATL ACAD SCI-BIOL, V79, P7425, DOI 10.1073/pnas.79.23.7425; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KEDAR PS, 1990, MOL CELL BIOL, V10, P3852, DOI 10.1128/MCB.10.7.3852; Kuff E. L., 1988, Eukaryotic transposable elements as mutagenic agents.., P79; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; KUFF EL, 1985, MOL CELL BIOL, V5, P474, DOI 10.1128/MCB.5.3.474; LACAL JC, 1987, SCIENCE, V238, P533, DOI 10.1126/science.2821623; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LILLIE JW, 1989, NATURE, V341, P279, DOI 10.1038/341279a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUEDERS KK, 1984, MOL CELL BIOL, V4, P2128, DOI 10.1128/MCB.4.10.2128; LURIA S, 1986, J VIROL, V57, P998, DOI 10.1128/JVI.57.3.998-1003.1986; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; MERCIER G, 1987, CANCER J, V1, P314; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NICOLAS JF, 1983, TERATOCARCINOMA STEM, P469; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OWEN RD, 1990, MOL CELL BIOL, V10, P1; Pace-Asciak CR, 1983, ENZYMES LIPID ENZYMO, VXVI, P543; RECHAVI G, 1982, NATURE, V300, P607, DOI 10.1038/300607a0; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SATAKE M, 1988, ONCOGENE, V3, P69; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; TREPEL JB, 1987, MOL CELL BIOL, V7, P2644, DOI 10.1128/MCB.7.7.2644; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WIEVEL NA, 1971, INT J CANCER, V7, P165; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; YOTSUYANAGI Y, 1984, ULTRASTRUCTURE REPRO, P218	54	20	20	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					849	855						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1828874				2022-12-25	WOS:A1991GT82500022
J	MEIER, EM; SCHWARZMANN, G; FURST, W; SANDHOFF, K				MEIER, EM; SCHWARZMANN, G; FURST, W; SANDHOFF, K			THE HUMAN GM2 ACTIVATOR PROTEIN - A SUBSTRATE SPECIFIC COFACTOR OF BETA-HEXOSAMINIDASE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOMBARDMENT MASS-SPECTROMETRY; TAY-SACHS; GANGLIOSIDE GM2; CEREBROSIDE-SULFATASE; ENZYMIC-HYDROLYSIS; HUMAN LIVER; GM2-GANGLIOSIDOSIS-B1 VARIANT; ENZYMATIC-HYDROLYSIS; NEUTRON-DIFFRACTION; GLUCOSYL-CERAMIDE	Ganglioside G(D1a)-Ga1NAc was isolated from Tay-Sachs brain, tritium-labeled in its sphingosine moiety, and its enzymic degradation studied in vitro and in cultured fibroblasts. When offered as micelles, G(D1a)-Ga1NAc was almost not hydrolyzed by Hex A or Hex B, while after incorporation of the ganglioside into the outer leaflet of liposomes, the terminal Ga1NAc residue was rapidly split off by Hex A. In striking contrast to ganglioside G(M2), the major glycolipid substrate of Hex A, the enzymic hydrolysis of G(D1a)-Ga1NAc was not promoted by the G(M2) activator protein, although the activator protein did bind G(D1a)-Ga1NAc to form a water-soluble complex. Pathobiochemical studies corroborate these results. After incorporation of [H-3]G(D1a)-Ga1NAc into cultured skin fibroblasts from healthy subjects and from patients with different variants of G(M2) gangliosidosis, its degradation was found to be strongly attenuated in mutant cells with Hex A deficiencies such as variant B (Tay-Sachs disease), variant B1 and variant 0 (Sandhoff disease), while in cells with variant AB (G(M2) activator deficiency), its catabolism was blocked only at the level of G(M2). In line with these metabolic studies, a normal content of G(D1a)-Ga1NAc was found in brains of patients who had succumbed to variant AB of G(M2) gangliosidosis whereas in brains from variants B, B1, and 0, its concentration was considerably elevated (up to 19-fold). Together with studies on the enzymic degradation of G(M2) derivatives with modifications in the ceramide portion, these results indicate that mainly steric hindrance by adjacent lipid molecules impedes the access of Hex A to membrane-bound G(M2) (whose degradation therefore depends on solubilization by the G(M2) activator) and in addition that the interaction between the G(M2).G(M2) activator complex and the enzyme must be highly specific.	UNIV BONN,INST ORGAN CHEM & BIOCHEM,W-5300 BONN,GERMANY	University of Bonn								BASU A, 1984, BIOCHEM J, V224, P515, DOI 10.1042/bj2240515; BEARPARK TM, 1978, BIOCHEM J, V173, P997, DOI 10.1042/bj1730997; BEUTLER E, 1975, NATURE, V258, P262, DOI 10.1038/258262a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURG J, 1983, H-S Z PHYSIOL CHEM, V364, P821, DOI 10.1515/bchm2.1983.364.2.821; CHRISTOMANOU H, 1985, BIOL CHEM H-S, V366, P245, DOI 10.1515/bchm3.1985.366.1.245; CONZELMANN E, 1978, P NATL ACAD SCI USA, V75, P3979, DOI 10.1073/pnas.75.8.3979; CONZELMANN E, 1979, H-S Z PHYSIOL CHEM, V360, P1837, DOI 10.1515/bchm2.1979.360.2.1837; CONZELMANN E, 1982, EUR J BIOCHEM, V123, P455, DOI 10.1111/j.1432-1033.1982.tb19789.x; CONZELMANN E, 1983, AM J HUM GENET, V35, P900; DEGASPERI R, 1987, J BIOL CHEM, V262, P17149; EGGE H, 1985, CHEM PHYS LIPIDS, V37, P127, DOI 10.1016/0009-3084(85)90080-5; EGGE H, 1987, MASS SPECTROM REV, V6, P331, DOI 10.1002/mas.1280060302; FISCHER G, 1978, BIOCHIM BIOPHYS ACTA, V528, P69, DOI 10.1016/0005-2760(78)90053-X; FISCHER G, 1975, H-S Z PHYSIOL CHEM, V356, P605, DOI 10.1515/bchm2.1975.356.1.605; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRANKS NP, 1979, J MOL BIOL, V133, P469, DOI 10.1016/0022-2836(79)90403-0; GEIGER B, 1975, EUR J BIOCHEM, V56, P311, DOI 10.1111/j.1432-1033.1975.tb02235.x; GLOSSL J, 1982, BIOCHEM J, V203, P335, DOI 10.1042/bj2030335; HO MW, 1971, P NATL ACAD SCI USA, V68, P2810, DOI 10.1073/pnas.68.11.2810; INUI K, 1983, P NATL ACAD SCI-BIOL, V80, P3074, DOI 10.1073/pnas.80.10.3074; ITOH T, 1981, J BIOL CHEM, V256, P165; IWAMORI M, 1979, J NEUROCHEM, V32, P767, DOI 10.1111/j.1471-4159.1979.tb04560.x; IYER SS, 1983, BIOCHIM BIOPHYS ACTA, V748, P1, DOI 10.1016/0167-4838(83)90020-1; KRESSE H, 1981, J BIOL CHEM, V256, P2926; KYTZIA HJ, 1983, EMBO J, V2, P1201, DOI 10.1002/j.1460-2075.1983.tb01567.x; KYTZIA HJ, 1985, J BIOL CHEM, V260, P7568; LEVINE YK, 1968, NATURE, V220, P577, DOI 10.1038/220577a0; LI SC, 1984, J BIOL CHEM, V259, P5409; LI SC, 1981, BIOCHEM BIOPH RES CO, V101, P479, DOI 10.1016/0006-291X(81)91285-7; LI SC, 1988, J BIOL CHEM, V263, P6588; LI SC, 1985, J BIOL CHEM, V260, P1867; LI SC, 1979, J BIOL CHEM, V254, P592; LI SC, 1981, J BIOL CHEM, V256, P6234; Li SC, 1986, ENZYMES LIPID METABO, P307; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mehl E, 1964, Hoppe Seylers Z Physiol Chem, V339, P260, DOI 10.1515/bchm2.1964.339.1.260; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; NEUENHOFER S, 1985, FEBS LETT, V185, P112, DOI 10.1016/0014-5793(85)80751-1; OHNO K, 1988, J NEUROCHEM, V50, P316, DOI 10.1111/j.1471-4159.1988.tb13266.x; OKADA S, 1969, SCIENCE, V165, P698, DOI 10.1126/science.165.3894.698; PETERS SP, 1977, J BIOL CHEM, V252, P563; RANDERATH K, 1970, ANAL BIOCHEM, V34, P188, DOI 10.1016/0003-2697(70)90100-4; ROSENGREN B, 1987, J NEUROCHEM, V49, P834, DOI 10.1111/j.1471-4159.1987.tb00969.x; SANDHOFF K, 1977, H-S Z PHYSIOL CHEM, V358, P779, DOI 10.1515/bchm2.1977.358.2.779; SANDHOFF K, 1971, J NEUROCHEM, V18, P2469, DOI 10.1111/j.1471-4159.1971.tb00204.x; SANDHOFF K, 1968, Pathologia Europaea, V3, P278; SANDHOFF K, 1969, FEBS LETT, V4, P351, DOI 10.1016/0014-5793(69)80274-7; Sandhoff K., 1989, METABOLIC BASIS INHE; SCHWARZMANN G, 1983, BIOCHEMISTRY-US, V22, P5041, DOI 10.1021/bi00290a025; SCHWARZMANN G, 1978, BIOCHIM BIOPHYS ACTA, V529, P106, DOI 10.1016/0005-2760(78)90108-X; SCHWARZMANN G, 1987, METHOD ENZYMOL, V138, P319; SONDERFELD S, 1985, EUR J BIOCHEM, V149, P247, DOI 10.1111/j.1432-1033.1985.tb08919.x; SONDERFELD S, 1985, HUM GENET, V71, P196, DOI 10.1007/BF00284572; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; SVENNERHOLM L, 1973, J BIOL CHEM, V248, P740; TANAKA A, 1990, AM J HUM GENET, V46, P329; TANAKA A, 1988, BIOCHEM BIOPH RES CO, V156, P1015, DOI 10.1016/S0006-291X(88)80945-8; TANFORD C, 1980, HYDROPHOBIC EFFECT; THOMPSON JN, 1973, SCIENCE, V181, P866, DOI 10.1126/science.181.4102.866; WEITZ G, 1983, H-S Z PHYSIOL CHEM, V364, P863, DOI 10.1515/bchm2.1983.364.2.863; WYNN CH, 1986, J THEOR BIOL, V123, P221, DOI 10.1016/S0022-5193(86)80156-4; WYNN CH, 1986, J THEOR BIOL, V119, P81, DOI 10.1016/S0022-5193(86)80052-2; YU RK, 1983, BRAIN RES, V275, P47, DOI 10.1016/0006-8993(83)90415-8; ZACCAI G, 1979, J MOL BIOL, V134, P693, DOI 10.1016/0022-2836(79)90480-7	65	110	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1879	1887						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1824846				2022-12-25	WOS:A1991EU49700078
J	LUKACS, GL; ROTSTEIN, OD; GRINSTEIN, S				LUKACS, GL; ROTSTEIN, OD; GRINSTEIN, S			DETERMINANTS OF THE PHAGOSOMAL PH IN MACROPHAGES - INSITU ASSESSMENT OF VACUOLAR H+-ATPASE ACTIVITY, COUNTERION CONDUCTANCE, AND H+ LEAK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTON PUMP; CLATHRIN-COATED VESICLES; CHLORIDE CONDUCTANCE; ENDOCYTIC VESICLES; TRANSLOCATING ATPASES; MURINE MACROPHAGES; ACIDIFICATION; MEMBRANES; CHANNELS; CELLS	We studied the factors that determine the intraphagosomal pH (pH(p)) in elicited murine peritoneal macrophages. pH(p) was measured in situ by recording the fluorescence of covalently fluoresceinated Staphylococcus aureus ingested by the macrophages. Following spontaneous acidification of the phagosomes, passive (leak) H+ permeability was determined measuring the rate of change of pH(p) upon complete inhibition of the H+ pump with bafilomycin A1. A significant, but comparatively low passive H+ permeability was detected. The existence of a passive H+ leak implies that continuous energy expenditure is required for the maintenance of an acidic pH(p). In combination with ionophores, bafilomycin was also used to estimate the counterion permeability. The counterion conductance was found to be severalfold higher than the H+ leak. Ion substitution experiments in electropermeabilized cells and the inhibitory effects of quinine and 5-nitro-2-(3-phenylpropylamino)benzoic acid suggest that both monovalent anions and cations permeate the phagosomal membrane. The activity of the H+ pump was measured at various pH(p) levels. In the steady state, the rate of H+ pumping was considerably lower than counterion permeation. These findings suggest that the phagosomal membrane potential is insignificant. Consistent with this notion, increasing phagosomal conductance with ionophores failed to accelerate the rate of H+ pumping. Thus, the transmembrane DELTA-pH is the predominant component of the proton-motive force across the phagosomal membrane in the steady state. The rate of H+ pumping was found to decrease steeply as the phagosomal lumen became acidified. Therefore, the pH sensitivity of the H+ pump, which possibly reflects a kinetic or allosteric effect, is the primary determinant of pH(p).	HOSP SICK CHILDREN,RES INST,DIV CELL BIOL,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA; SEMMELWEIS UNIV MED,DEPT PHYSIOL,H-1444 BUDAPEST,HUNGARY; TORONTO GEN HOSP,DEPT SURG,TORONTO M5G 2C4,ONTARIO,CANADA; UNIV TORONTO,INST MED SCI,TORONTO M5S 2Z9,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Semmelweis University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto				Lukacs, Gergely/0000-0003-0900-0675				AKESON MA, 1989, BIOCHEMISTRY-US, V28, P5120, DOI 10.1021/bi00438a032; al-Awqati Q, 1989, Soc Gen Physiol Ser, V44, P283; ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; BAE HR, 1990, NATURE, V348, P637, DOI 10.1038/348637a0; BARASCH J, 1988, J CELL BIOL, V107, P2137, DOI 10.1083/jcb.107.6.2137; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; CIDON S, 1983, J BIOL CHEM, V258, P1684; CIDON S, 1989, J BIOL CHEM, V264, P8281; COOK DL, 1984, NATURE, V311, P269, DOI 10.1038/311269a0; FORGAC M, 1983, P NATL ACAD SCI-BIOL, V80, P1300, DOI 10.1073/pnas.80.5.1300; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FUCHS R, 1989, J BIOL CHEM, V264, P2212; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; GALLIN EK, 1990, CURR TOP MEMBR TRANS, V35, P127; GALLOWAY CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3334, DOI 10.1073/pnas.80.11.3334; GLICKMAN J, 1983, J CELL BIOL, V97, P1303, DOI 10.1083/jcb.97.4.1303; GREGER R, 1990, METHOD ENZYMOL, V191, P793; GRINSTEIN S, 1984, J GEN PHYSIOL, V84, P565, DOI 10.1085/jgp.84.4.565; GRINSTEIN S, 1988, AM J PHYSIOL, V254, pC272, DOI 10.1152/ajpcell.1988.254.2.C272; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; HILDEN SA, 1988, AM J PHYSIOL, V255, pF885, DOI 10.1152/ajprenal.1988.255.5.F885; INCE C, 1987, BIOCHIM BIOPHYS ACTA, V905, P195, DOI 10.1016/0005-2736(87)90023-X; JOHNSON RG, 1979, J BIOL CHEM, V254, P963; KOLB HA, 1987, BIOCHIM BIOPHYS ACTA, V899, P239, DOI 10.1016/0005-2736(87)90405-6; LANDRY DW, 1987, J GEN PHYSIOL, V90, P779, DOI 10.1085/jgp.90.6.779; LUKACS GL, 1990, J BIOL CHEM, V265, P21099; LUKACS GL, 1991, FEBS LETT, V288, P17, DOI 10.1016/0014-5793(91)80992-C; MAYORGA LS, 1991, J BIOL CHEM, V266, P6511; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; MORIYAMA Y, 1988, ION PUMPS STRUCTURE, P387; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; RANDRIAMAMPITA C, 1987, J CELL BIOL, V105, P761, DOI 10.1083/jcb.105.2.761; RODMAN JS, 1991, EXP CELL RES, V192, P445, DOI 10.1016/0014-4827(91)90063-Z; SABOLIC I, 1990, AM J PHYSIOL, V258, pF1245, DOI 10.1152/ajprenal.1990.258.5.F1245; SCHMID A, 1989, J MEMBRANE BIOL, V111, P265, DOI 10.1007/BF01871011; SCHNEIDER DL, 1981, J BIOL CHEM, V256, P3858; SCHNEIDER DL, 1987, BIOCHIM BIOPHYS ACTA, V895, P1, DOI 10.1016/S0304-4173(87)80013-7; STONE DK, 1989, J BIOENERG BIOMEMBR, V21, P605, DOI 10.1007/BF00808116; SZE H, 1985, ANNU REV PLANT PHYS, V36, P175, DOI 10.1146/annurev.pp.36.060185.001135; VANDYKE RW, 1988, J BIOL CHEM, V263, P2603; WANG ZQ, 1990, J BIOL CHEM, V265, P21957; XIE XS, 1989, J BIOL CHEM, V264, P18870; XIE XS, 1983, J BIOL CHEM, V258, P4834; YAMASHIRO DJ, 1983, J CELL BIOL, V97, P929, DOI 10.1083/jcb.97.3.929	47	115	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24540	24548						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1837024				2022-12-25	WOS:A1991GW84500048
J	VARSHNEY, U; LEE, CP; RAJBHANDARY, UL				VARSHNEY, U; LEE, CP; RAJBHANDARY, UL			DIRECT ANALYSIS OF AMINOACYLATION LEVELS OF TRANSFER-RNAS INVIVO - APPLICATION TO STUDYING RECOGNITION OF ESCHERICHIA-COLI INITIATOR TRANSFER-RNA MUTANTS BY GLUTAMINYL-TRANSFER RNA-SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPRESSOR TRANSFER-RNA; FORMYLMETHIONINE TRANSFER-RNA; SITE-SPECIFIC MUTAGENESIS; PROTEIN-SYNTHESIS; ANTICODON ARM; IDENTITY; NUCLEOTIDES; METHIONINE; SEQUENCE; INVITRO	We describe the use of a gel electrophoretic method for measuring the levels of aminoacylation in vivo of mutant Escherichia coli initiator tRNAs, which are substrates for E. coli glutaminyl-tRNA synthetase (GlnRS) due to an anticodon sequence change. Using this method, we have compared the effects of introducing further mutations in the acceptor stem, at base pairs 1:72, 2:71, and 3:70 and discriminator base 73, on the recognition of these tRNAs by E. coli GlnRS in vitro and in vivo. The effects of the acceptor stem mutations on the kinetic parameters for aminoacylation of the mutant tRNAs in vitro are consistent with interactions seen between this region of tRNA and GlnRS in the crystal structure of tRNA(Gln).GlnRS complex. Except for one mutant, the observed levels of aminoacylation of the mutant tRNAs in vivo agree with those expected on the basis of the kinetic parameters obtained in vitro. We have also measured the relative amounts of aminoacyl-tRNAs for the various mutants and their activities in suppression of an amber codon in vivo. We find that there is, in general, a good correlation between the relative amounts of aminoacyl-tRNAs and their activities in suppression.			VARSHNEY, U (corresponding author), MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA.		Varshney, Umesh/A-8062-2009; Varshney, Umesh/Q-6914-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017151, F32GM017151, R01GM017151] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17151] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHATTAPADHYAY R, 1990, BIOCHEMISTRY-US, V29, P4263, DOI 10.1021/bi00470a001; FISCHER W, 1985, FEBS LETT, V192, P151, DOI 10.1016/0014-5793(85)80062-4; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; GOODMAN HM, 1968, NATURE, V217, P1019, DOI 10.1038/2171019a0; HIMENO H, 1990, NUCLEIC ACIDS RES, V18, P6815, DOI 10.1093/nar/18.23.6815; HO YS, 1987, P NATL ACAD SCI USA, V84, P2185, DOI 10.1073/pnas.84.8.2185; HOOPER ML, 1972, FEBS LETT, V22, P149, DOI 10.1016/0014-5793(72)80241-2; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; JAKUBOWSKI H, 1984, J BACTERIOL, V158, P769, DOI 10.1128/JB.158.3.769-776.1984; KHORANA HG, 1979, SCIENCE, V203, P614, DOI 10.1126/science.366749; KLEINA LG, 1990, J MOL BIOL, V213, P705, DOI 10.1016/S0022-2836(05)80257-8; KUDO I, 1981, P NATL ACAD SCI-BIOL, V78, P4753, DOI 10.1073/pnas.78.8.4753; LEE BJ, 1989, J BIOL CHEM, V264, P9724; LEE CP, 1991, J BIOL CHEM, V266, P18012; LEINFELDER W, 1989, J BIOL CHEM, V264, P9720; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; MCCLAIN WH, 1988, SCIENCE, V241, P1804, DOI 10.1126/science.2459773; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; NORMANLY J, 1990, J MOL BIOL, V213, P719, DOI 10.1016/S0022-2836(05)80258-X; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; PERRET V, 1990, NATURE, V344, P787, DOI 10.1038/344787a0; RAFTERY LA, 1987, EMBO J, V6, P1499, DOI 10.1002/j.1460-2075.1987.tb02392.x; RAJBHANDARY UL, 1969, J BIOL CHEM, V244, P1104; ROGERS MJ, 1988, P NATL ACAD SCI USA, V85, P6627, DOI 10.1073/pnas.85.18.6627; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; SAMPSON JR, 1989, SCIENCE, V243, P1363; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHIMMEL P, 1989, BIOCHEMISTRY-US, V28, P2747, DOI 10.1021/bi00433a001; SCHON A, 1988, NATURE, V331, P187, DOI 10.1038/331187a0; SCHULMAN LH, 1985, BIOCHEMISTRY-US, V24, P7309, DOI 10.1021/bi00346a043; SCHULMAN LH, 1988, SCIENCE, V242, P765, DOI 10.1126/science.3055296; SCHULMAN LH, 1974, J BIOL CHEM, V249, P7102; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SEONG BL, 1989, J BIOL CHEM, V264, P6504; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P8859, DOI 10.1073/pnas.84.24.8859; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P334, DOI 10.1073/pnas.84.2.334; SHIMURA Y, 1972, FEBS LETT, V22, P144, DOI 10.1016/0014-5793(72)80240-0; VARSHNEY U, 1991, J BIOL CHEM, V266, P18018; VARSHNEY U, 1990, P NATL ACAD SCI USA, V87, P1586, DOI 10.1073/pnas.87.4.1586; WAKAO H, 1989, J BIOL CHEM, V264, P20363; YARUS M, 1980, P NATL ACAD SCI-BIOL, V77, P5092, DOI 10.1073/pnas.77.9.5092; YARUS M, 1986, J MOL BIOL, V192, P235, DOI 10.1016/0022-2836(86)90362-1; YARUS M, 1977, NUCLEIC ACID PROTEIN, P391	46	382	387	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24712	24718						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761566				2022-12-25	WOS:A1991GW84500073
J	KOLODZIEJ, MA; VILAIRE, G; GONDER, D; PONCZ, M; BENNETT, JS				KOLODZIEJ, MA; VILAIRE, G; GONDER, D; PONCZ, M; BENNETT, JS			STUDY OF THE ENDOPROTEOLYTIC CLEAVAGE OF PLATELET GLYCOPROTEIN-IIB USING OLIGONUCLEOTIDE-MEDIATED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLYCOPROTEIN; MAMMALIAN-CELLS; INFLUENZA-VIRUS; BINDING DOMAIN; IIIA COMPLEX; RECEPTORS; FIBRONECTIN; FIBRINOGEN; INTEGRIN; VITRONECTIN	The precursor of platelet membrane glycoprotein IIb (GPIIb) undergoes endoproteolytic cleavage into heavy and light chains post-translation. Endoproteolysis occurs within a 17-amino acid stretch of the precursor that contains 4 arginine residues, 3 in dibasic sequences [Lys-Arg (855-856) and Arg-Arg (858-859)] and a single arginine at 871. To determine the site of GPIIb cleavage and its role in the function of the glycoprotein IIb/IIIa heterodimer, we mutated arginine 856, the di-arginine sequence 858-859, and arginine 871 and coexpressed the mutants with glycoprotein IIIa (GPIIIa) in COS-1 cells. Each GPIIb mutant formed recombinant GPIIb-IIIa heterodimers, but mutants lacking arginine at 856 or 858-859 failed to undergo cleavage. Nevertheless, heterodimers containing the uncleaved GPIIb were expressed on the cell surface. Because endoproteolysis most often occurs after arginines in dibasic sequences, we next expressed GPIIb mutants containing lysine at 856 or aspartic acid at 855 with GPIIIa. Both mutants were cleaved and surface-expressed, indicating that the dibasic sequence at 858-859, but not at 855-856, is required for GPIIb cleavage. Lastly, we tested the function of GPIIb-IIIa containing uncleaved GPIIb by measuring adhesion of transfected cells to immobilized fibrinogen. We found no difference in the adhesion of cells expressing either wild-type or mutant GPIIb, indicating GPIIb-IIIa heterodimers containing uncleaved GPIIb maintain their ability to interact with fibrinogen.	HOSP UNIV PENN,HEMATOL ONCOL SECT,3400 SPRUCE ST,PHILADELPHIA,PA 19104; CHILDRENS HOSP PHILADELPHIA,DIV HEMATOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania					NHLBI NIH HHS [HL08038, HL40387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008038, P01HL040387] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BODARY SC, 1989, J BIOL CHEM, V264, P18859; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CALVETE JJ, 1990, FEBS LETT, V272, P37, DOI 10.1016/0014-5793(90)80443-M; CHARO IF, 1986, P NATL ACAD SCI USA, V83, P8351, DOI 10.1073/pnas.83.21.8351; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; HAVERSTICK DM, 1985, BLOOD, V66, P946; HOMMA M, 1973, J VIROL, V12, P1457, DOI 10.1128/JVI.12.6.1457-1465.1973; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KAWAOKA Y, 1988, P NATL ACAD SCI USA, V85, P324, DOI 10.1073/pnas.85.2.324; KEIFFER N, 1991, J CELL BIOL, V113, P451; KOLODZIEJ MA, 1991, IN PRESS BLOOD; KUNICKI TJ, 1985, P NATL ACAD SCI USA, V82, P7319, DOI 10.1073/pnas.82.21.7319; LAM SCT, 1989, BLOOD, V73, P1513; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LOFTUS JC, 1988, J BIOL CHEM, V263, P11025; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; NEURATH H, 1989, TRENDS BIOCHEM SCI, V14, P268, DOI 10.1016/0968-0004(89)90061-3; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OZAWA M, 1990, J CELL BIOL, V111, P1645, DOI 10.1083/jcb.111.4.1645; PHILLIPS DR, 1988, BLOOD, V71, P831; PONCZ M, 1987, J BIOL CHEM, V262, P8476; PONCZ M, 1990, BLOOD, V75, P1282; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILVER SM, 1987, BLOOD, V69, P1031; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; STEWART JM, 1984, SOLID PHASE PEPTIDE, P83; SUZUKI S, 1986, P NATL ACAD SCI USA, V83, P8614, DOI 10.1073/pnas.83.22.8614; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053	36	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23499	23504						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744141				2022-12-25	WOS:A1991GT48300108
J	SHAPIRO, AB; GIBSON, KD; SCHERAGA, HA; MCCARTY, RE				SHAPIRO, AB; GIBSON, KD; SCHERAGA, HA; MCCARTY, RE			FLUORESCENCE RESONANCE ENERGY-TRANSFER MAPPING OF THE 4TH OF 6 NUCLEOTIDE-BINDING SITES OF CHLOROPLAST COUPLING FACTOR-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I; GAMMA-SUBUNIT; ATP SYNTHASE; BETA-SUBUNIT; ADENOSINE 5'-TRIPHOSPHATE; NONCATALYTIC SITES; EPSILON-SUBUNIT; HYDROLYSIS; SURFACE; CF1	Equilibrium dialysis measurements of adenine nucleotide binding to chloroplast coupling factor 1 suggest that the enzyme has six binding sites for ADP, adenylyl-beta, gamma-imidodiphosphate (AMP-PNP), and 2'(3')-O-2,4,6-trinitrophenyl-ATP (TNP-ATP). High affinity binding at all six sites requires the divalent cation, Mg2+. Three of the nucleotide-binding sites, sites 1, 2, and 3, have been mapped by fluorescence resonance energy transfer distance measurements (see McCarty, R. E., and Hammes, G. G. (1987) Trends Biochem. Sci. 12, 234-237). Using the same technique, we mapped the location of nucleotide-binding site 4, a tight, exchangeable site (Shapiro, A. B., Huber, A. H., and McCarty, R. E. (1991) J. Biol. Chem. 266, 4194-4200). Two arrangements of the energy transfer map of coupling factor 1 were found which are compatible with the available data. The two arrangements make different predictions about which sites interact in cooperative catalysis.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL,ITHACA,NY 14853; CORNELL UNIV,BAKER LAB CHEM,ITHACA,NY 14853	Cornell University; Cornell University					NIGMS NIH HHS [GM-14312] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRALOJC PJ, 1990, BIOCHIM BIOPHYS ACTA, V1016, P55, DOI 10.1016/0005-2728(90)90006-P; BOEKEMA EJ, 1990, BIOCHIM BIOPHYS ACTA, V1017, P49, DOI 10.1016/0005-2728(90)90177-6; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BRAUN W, 1987, Q REV BIOPHYS, V19, P115, DOI 10.1017/S0033583500004108; BRUIST MF, 1981, BIOCHEMISTRY-US, V20, P6298, DOI 10.1021/bi00525a003; BRUIST MF, 1982, BIOCHEMISTRY-US, V21, P3370, DOI 10.1021/bi00257a019; CERIONE RA, 1983, BIOCHEMISTRY-US, V22, P769, DOI 10.1021/bi00273a010; CERIONE RA, 1982, BIOCHEMISTRY-US, V21, P745, DOI 10.1021/bi00533a026; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CRIPPEN GM, 1988, DISTANCE GEOMETRY CO; CROSS RL, 1988, J BIOENERG BIOMEMBR, V20, P395, DOI 10.1007/BF00762200; DENNIS JE, 1981, ACM T MATH SOFTWARE, V7, P348, DOI 10.1145/355958.355965; DU ZY, 1989, BIOCHEMISTRY-US, V28, P873, DOI 10.1021/bi00428a070; GIRAULT G, 1988, J BIOL CHEM, V263, P14690; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GUERRERO KJ, 1990, FEBS LETT, V270, P187, DOI 10.1016/0014-5793(90)81264-O; HADWIGER MA, 1989, J BIOMOL STRUCT DYN, V7, P749, DOI 10.1080/07391102.1989.10508518; HAMMES GG, 1981, PROTEIN PROTEIN INTE, P257; HENDRICKSON B, 1990, THESIS CORNELL U; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; JAGENDORF AT, 1981, PHOTOSYNTHESIS, V2, P719; KETCHAM SR, 1984, J BIOL CHEM, V259, P7286; LECKBAND D, 1987, BIOCHEMISTRY-US, V26, P2306, DOI 10.1021/bi00382a035; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCARTY RE, 1987, TRENDS BIOCHEM SCI, V12, P234, DOI 10.1016/0968-0004(87)90116-2; McCarty RE, 1988, LIGHT ENERGY TRANSDU, P290; MCCARTY RE, 1985, ENZYMES BIOL MEMBR, P383; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MITRA B, 1988, BIOCHEMISTRY-US, V27, P245, DOI 10.1021/bi00401a037; MORONEY JV, 1984, J BIOL CHEM, V259, P7281; NALIN CM, 1984, J BIOL CHEM, V259, P7275; NALIN CM, 1985, BIOCHEMISTRY-US, V24, P2318, DOI 10.1021/bi00330a029; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PERROT G, 1991, IN PRESS J COMP CHEM; RICHMOND TJ, 1984, J MOL BIOL, V178, P63, DOI 10.1016/0022-2836(84)90231-6; RICHTER ML, 1987, J BIOL CHEM, V262, P15037; RICHTER ML, 1985, BIOCHEMISTRY-US, V24, P5755, DOI 10.1021/bi00342a011; SCHUMANN J, 1985, J BIOL CHEM, V260, P1817; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SHAPIRO AB, 1990, J BIOL CHEM, V265, P4340; SHAPIRO AB, 1991, J BIOL CHEM, V266, P4194; SHAPIRO AB, 1988, J BIOL CHEM, V263, P14160; SNYDER B, 1985, BIOCHEMISTRY-US, V24, P2324, DOI 10.1021/bi00330a030; SNYDER B, 1984, BIOCHEMISTRY-US, V23, P5787, DOI 10.1021/bi00319a018; STROTMANN H, 1984, ANNU REV PLANT PHYS, V35, P97; STROTMANN H, 1977, BIOCHIM BIOPHYS ACTA, V460, P126, DOI 10.1016/0005-2728(77)90158-X; WAKO H, 1981, MACROMOLECULES, V314, P961; WATTRICH K, 1989, ACCOUNTS CHEM RES, V22, P36; XIAO JP, 1989, BIOCHIM BIOPHYS ACTA, V976, P203, DOI 10.1016/S0005-2728(89)80231-2; XUE ZX, 1987, BIOCHEMISTRY-US, V26, P3749, DOI 10.1021/bi00387a001; XUE ZX, 1989, EUR J BIOCHEM, V179, P677, DOI 10.1111/j.1432-1033.1989.tb14600.x; ZURAWSKI G, 1982, P NATL ACAD SCI-BIOL, V79, P6260, DOI 10.1073/pnas.79.20.6260	52	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17276	17285						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1832671				2022-12-25	WOS:A1991GF44500048
J	OSTROWSKI, J; SIMS, JE; SIBLEY, CH; VALENTINE, MA; DOWER, SK; MEIER, KE; BOMSZTYK, K				OSTROWSKI, J; SIMS, JE; SIBLEY, CH; VALENTINE, MA; DOWER, SK; MEIER, KE; BOMSZTYK, K			A SERINE THREONINE KINASE-ACTIVITY IS CLOSELY ASSOCIATED WITH A 65-KDA PHOSPHOPROTEIN SPECIFICALLY RECOGNIZED BY THE KAPPA-B ENHANCER ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DNA-BINDING PROTEINS; CHAIN GENE-EXPRESSION; NUCLEAR FACTOR CREB; CELL-LINE; TRANSCRIPTION FACTOR; IMMUNOGLOBULIN GENES; FACTOR-ALPHA; NF-KB; INTERLEUKIN-1	The immunoglobulin kappa light chain enhancer, kappa-B, is an important cis-acting transcriptional element. Kappa-B binds a number of proteins including the members of the ubiquitous NF-kappa-B family of transcription factors. Agarose beads coupled to a double-stranded oligonucleotide containing the kappa-B motif were used to isolate a 65-kDa predominantly nuclear phosphoprotein. Southwestern blot analysis demonstrated that this phosphoprotein can bind the kappa-B element directly and specifically. This kappa-B-associated protein was phosphorylated in vivo and in vitro by a nuclear serine/threonine kinase(s) which, in a number of different cell lines, appeared to be stimulated in response to interleukin-1-alpha and lipopolysaccharide treatment. In the B cell lines 70Z/3 and CH12 LX2B, and the T cell line EL-4 6.1 C10 the activity of the kappa-B-associated kinase(s) correlated with the binding activity of nuclear NF-kappa-B displayed in a gel shift assay. In vitro, the 65-kDa protein was phosphorylated in the absence of exogenously added kinase. The 65-kDa phosphoprotein and the kinase activity remained associated following sequential anion-exchange and hydrophobic interaction chromatography. These results suggest that the kappa-B-associated phosphoprotein is either autophosphorylated or is phosphorylated by a closely associated kinase(s). Stimulation of a nuclear protein kinase which is closely associated with a sequence-specific DNA may reflect a novel mechanism by which growth factors regulate gene expression.	UNIV WASHINGTON,DEPT MED,RM-11,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; IMMUNEX CORP,SEATTLE,WA 98101; MED CTR POSTGRAD EDUC,DEPT GASTROENTEROL & METAB,PL-02606 WARSAW,POLAND	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Immunex Corporation; Centre of Postgraduate Medical Education - Poland				Sims, John/0000-0002-5667-9185; dower, steve/0000-0002-4675-4225; Ostrowski, Jerzy/0000-0003-1363-3766	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01-GM42508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALDWIN AS, 1990, MOL CELL BIOL, V10, P1406, DOI 10.1128/MCB.10.4.1406; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BIRD TA, 1989, J IMMUNOL, V142, P126; BOHNLEIN E, 1989, J BIOL CHEM, V264, P8475; BOMSZTYK K, 1989, P NATL ACAD SCI USA, V86, P8034, DOI 10.1073/pnas.86.20.8034; BOMSZTYK K, 1990, J BIOL CHEM, V265, P9413; BOMSZTYK K, 1991, ELL REGUL, V2, P329; BOSH S, 1990, CELL, V62, P1019; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; CALALB MB, 1987, J BIOL CHEM, V262, P3680; CHEDID M, 1990, MOL CELL BIOL, V10, P3824, DOI 10.1128/MCB.10.7.3824; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COSTACASNELLIE MR, 1987, J BIOL CHEM, V262, P9093; DAYER JM, 1986, J CLIN INVEST, V77, P645, DOI 10.1172/JCI112350; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ESPEL E, 1990, EMBO J, V9, P929, DOI 10.1002/j.1460-2075.1990.tb08191.x; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; GALLIS B, 1989, J IMMUNOL, V143, P3235; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GRUMONT RJ, 1989, ONCOGENE RES, V4, P1; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HAUGHTON G, 1986, IMMUNOL REV, V93, P35, DOI 10.1111/j.1600-065X.1986.tb01501.x; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAUR P, 1988, FEBS LETT, V241, P6, DOI 10.1016/0014-5793(88)81019-6; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOWENTHAL JW, 1986, J EXP MED, V164, P1060, DOI 10.1084/jem.164.4.1060; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MATSUSHIMA K, 1988, BIOCHEMISTRY-US, V27, P3765, DOI 10.1021/bi00410a037; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MERINO A, 1989, J BIOL CHEM, V264, P21266; MUNOZ E, 1990, J IMMUNOL, V141, P3078; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; OSTROWSKI J, 1988, J BIOL CHEM, V263, P13786; PAIGE CJ, 1978, J IMMUNOL, V121, P641; QUIGG RJ, 1988, KIDNEY INT, V34, P43, DOI 10.1038/ki.1988.143; ROONEY JW, 1990, IMMUNOGENETICS, V31, P83; ROONEY JW, 1990, IMMUNOGENETICS, V31, P75; RUSTGI AK, 1990, P NATL ACAD SCI USA, V87, P8707, DOI 10.1073/pnas.87.22.8707; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P959, DOI 10.1128/MCB.9.3.959; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; VALENTINE MA, 1989, J BIOL CHEM, V264, P11282; WARLO DS, 1987, VIROLOGY, V160, P433; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	60	64	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12722	12733						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1829460				2022-12-25	WOS:A1991FV18000096
J	SUBRAMANIAN, T; MALSTROM, SE; CHINNADURAI, G				SUBRAMANIAN, T; MALSTROM, SE; CHINNADURAI, G			REQUIREMENT OF THE C-TERMINAL REGION OF ADENOVIRUS-E1A FOR CELL-TRANSFORMATION IN COOPERATION WITH E1B	ONCOGENE			English	Note							GROWTH-FACTOR; PROTEINS; ONCOGENE; IMMORTALIZATION; INDUCTION; GENES; POLYPEPTIDES; ASSOCIATION; ANTIGEN; DOMAINS	We have previously reported that adenovirus E1a mutants lacking the C-terminal 61 or 67 amino acids were severely defective in immortalization, but cooperated more efficiently (than wt E1a) with activated T24 ras oncogene in transformation of primary rat kidney (BRK) cells (Subramanian et al., 1989; Oncogene, 4:415-420). Here, we show that in contrast to these previous results, transformation of BRK cells in cooperation with the Ad2 E1b region is dependent on the C-terminal region of E1a. Mutational analysis of the C-terminal region has revealed that a region located between residues 266 and 276 may be important for E1a/E1b cooperative transformation. Like E1a/T24 ras cooperative transformation, E1a/E1b cooperative transformation also requires two essential domains involved in the binding of two cellular proteins (300K and 105K) within the N-terminal half of E1a. E1a/E1b cooperative transformation therefore requires an additional E1a activity encoded within the C-terminal region of E1a.	ST LOUIS UNIV,INST MOLEC VIROL,3681 PK AVE,ST LOUIS,MO 63110	Saint Louis University	CHINNADURAI, G (corresponding author), ST LOUIS UNIV,INST MOLEC VIROL,3681 PK AVE,ST LOUIS,MO 63110, USA.				NCI NIH HHS [CA-31719, CA-33616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031719, R01CA033616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BRUSCA JS, 1981, J VIROL, V39, P300, DOI 10.1128/JVI.39.1.300-305.1981; CHINNADURAI G, 1983, CELL, V33, P759, DOI 10.1016/0092-8674(83)90018-1; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KUPPUSWAMY M, 1988, ONCOGENE, V2, P613; KUPPUSWAMY MN, 1987, VIROLOGY, V159, P31, DOI 10.1016/0042-6822(87)90344-8; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	20	30	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1171	1173						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1830644				2022-12-25	WOS:A1991GV26000011
J	YUAN, G; OTT, RJ; SALGADO, C; GIACOMINI, KM				YUAN, G; OTT, RJ; SALGADO, C; GIACOMINI, KM			TRANSPORT OF ORGANIC CATIONS BY A RENAL EPITHELIAL-CELL LINE (OK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; RABBIT KIDNEY; CIMETIDINE TRANSPORT; INTRACELLULAR PH; LLC-PK1 CELLS; VESICLES; TETRAETHYLAMMONIUM; N-1-METHYLNICOTINAMIDE; SENSITIVITY; MECHANISMS	The goal of this study was to determine the mechanisms involved in the transport of the organic cation, tetraethylammonium (TEA), across the apical membrane of OK cells. [C-14]TEA accumulated in OK cell monolayers reaching equilibrium in 2 h. The uptake of [C-14]TEA at equilibrium was dependent upon temperature and was inhibited by sodium azide and by various organic cations, including N1-methylnicotinamide (NMN), mepiperphenidol, and cimetidine but not by the organic anion, p-aminohippuric acid. The initial uptake of [C-14]TEA was characterized by a saturable process. The mean +/- S.D. K(m) was 27.8 +/- 2.6-mu-M and the V(max) was 414 +/- 26.5 pmol/mg protein/min. Both an accelerated efflux and influx of [C-14]TEA in the presence of a trans-gradient of unlabeled TEA and NMN was observed, whereas a deaccelerated influx and efflux was observed in the presence of a trans-gradient of mepiperphenidol. The mechanism of interaction between NMN and TEA was examined. NMN significantly increased the apparent K(m) (mean +/- S.D.) of TEA to 82.8 +/- 16.4-mu-M (p < 0.001), whereas the V(max) (mean +/- S.D.) was only slightly affected (478 +/- 72 pmol/mg protein/min) suggesting a competitive inhibition. The stimulatory effect of trans-gradients of NMN on TEA transport was due to an increase in the V(max) of TEA suggesting that NMN trans-stimulates TEA transport by increasing the turnover rate of the exchanger. In the presence of an inwardly directed proton gradient, the efflux at 30 s of [C-14]TEA from the OK cell monolayers was significantly accelerated (p < 0.05). Studies with the pH-sensitive fluorescent probe, 2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein, suggested that TEA could drive the countertransport of protons. In apical membrane vesicles prepared from OK cells, the uptake of [H-3]NMN exhibited an apparent "overshoot phenomenon" in the presence of an initial outwardly directed proton gradient. Protons competitively inhibited TEA uptake suggesting that the proton/organic cation and the organic cation/organic cation self exchange mechanism are the same mechanism. This is the first report describing both TEA self-exchange and proton/TEA exchange in the apical membrane of a continuous cell line. OK cells are an excellent model for the study of organic cation transport across the apical membrane.	UNIV CALIF SAN FRANCISCO,SCH PHARM,S-926,BOX 0446,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Giacomini, Kathleen/AEF-2452-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036780] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-36780] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BESSEGHIR K, 1990, J PHARMACOL EXP THER, V53, P452; Booth A G, 1974, Biochem J, V142, P575; BOSCH LV, 1989, BIOCHIM BIOPHYS ACTA, V979, P91; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DANTZLER WH, 1986, AM J PHYSIOL, V250, pF407, DOI 10.1152/ajprenal.1986.250.3.F407; DANTZLER WH, 1988, AM J PHYSIOL, V255, pF167, DOI 10.1152/ajprenal.1988.255.1.F167; DANTZLER WH, 1988, AM J PHYSIOL, V256, pF351; FOUDA AK, 1990, J PHARMACOL EXP THER, V252, P286; GISCLON L, 1987, AM J PHYSIOL, V253, pF141, DOI 10.1152/ajprenal.1987.253.1.F141; HANDLER JS, 1986, KIDNEY INT, V30, P208, DOI 10.1038/ki.1986.173; HOLOHAN PD, 1981, J PHARMACOL EXP THER, V216, P294; HOLOHAN PD, 1980, J PHARMACOL EXP THER, V215, P191; HSYU PH, 1987, AM J PHYSIOL, V252, pF1065, DOI 10.1152/ajprenal.1987.252.6.F1065; HSYU PH, 1987, J BIOL CHEM, V262, P3964; INUI K, 1985, BIOCHEM J, V227, P199, DOI 10.1042/bj2270199; JANS AWH, 1987, BIOCHIM BIOPHYS ACTA, V927, P203, DOI 10.1016/0167-4889(87)90136-4; KINSELLA JL, 1979, J PHARMACOL EXP THER, V209, P443; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAEGAWA H, 1988, J BIOL CHEM, V263, P11150; MALSTROM K, 1987, BIOCHIM BIOPHYS ACTA, V902, P269, DOI 10.1016/0005-2736(87)90305-1; MALSTROM K, 1986, AM J PHYSIOL, V251, pC23; MCKINNEY TD, 1988, J CELL PHYSIOL, V137, P513, DOI 10.1002/jcp.1041370317; MCKINNEY TD, 1985, AM J PHYSIOL, V249, pF532, DOI 10.1152/ajprenal.1985.249.4.F532; MILLER RT, 1987, J BIOL CHEM, V262, P9115; MIYAMOTO Y, 1989, AM J PHYSIOL, V256, pF540, DOI 10.1152/ajprenal.1989.256.4.F540; MONTROSE MH, 1986, J MEMBRANE BIOL, V93, P33, DOI 10.1007/BF01871016; MONTROSERAFIZADEH C, 1987, BIOCHIM BIOPHYS ACTA, V904, P175, DOI 10.1016/0005-2736(87)90102-7; RAFIZADEH C, 1987, J PHARMACOL EXP THER, V240, P308; RAFIZADEH C, 1986, PFLUG ARCH EUR J PHY, V407, P404, DOI 10.1007/BF00652625; RENNICK BR, 1981, AM J PHYSIOL, V240, pF83, DOI 10.1152/ajprenal.1981.240.2.F83; SCHALI C, 1983, AM J PHYSIOL, V245, pF238, DOI 10.1152/ajprenal.1983.245.2.F238; SCHONER W, 1967, EUR J BIOCHEM, V1, P334, DOI 10.1111/j.1432-1033.1967.tb00078.x; SCHWEGLER JS, 1989, PFLUG ARCH EUR J PHY, V415, P183, DOI 10.1007/BF00370590; SOKOL PP, 1988, BIOCHIM BIOPHYS ACTA, V940, P209, DOI 10.1016/0005-2736(88)90196-4; TAKANO M, 1984, BIOCHIM BIOPHYS ACTA, V773, P113, DOI 10.1016/0005-2736(84)90556-X; TAKANO M, 1985, LIFE SCI, V37, P1579, DOI 10.1016/0024-3205(85)90476-X; WRIGHT SH, 1988, J BIOL CHEM, V263, P19494; WRIGHT SH, 1985, AM J PHYSIOL, V249, pF903, DOI 10.1152/ajprenal.1985.249.6.F903	38	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8978	8986						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1827442				2022-12-25	WOS:A1991FM03800051
J	TRENT, DF; SEITHER, RL; GOLDMAN, ID				TRENT, DF; SEITHER, RL; GOLDMAN, ID			RATE AND EXTENT OF INTERCONVERSION OF TETRAHYDROFOLATE COFACTORS TO DIHYDROFOLATE AFTER CESSATION OF DIHYDROFOLATE-REDUCTASE ACTIVITY IN STATIONARY VERSUS LOG PHASE L1210 LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMIDYLATE SYNTHETASE-ACTIVITY; INTRACELLULAR FOLATE POOLS; S-PHASE; NETWORK THERMODYNAMICS; METHOTREXATE BINDING; MONOCLONAL-ANTIBODY; MEMBRANE-TRANSPORT; KREBS ASCITES; FOLYLPOLYGLUTAMATES; INHIBITION	Previous studies from this laboratory established that the rapid but partial interconversion of tetrahydrofolate cofactors to dihydrofolate after exposure of L1210 leukemia cells to antifolates cannot be due to direct feedback inhibition of thymidylate synthase by dihydrofolate or any other endogenous folylpolyglutamates when dihydrofolate reductase activity is abolished by antifolates. Rather, the data suggested this preservation of tetrahydrofolate cofactor pools is likely due to a fraction of cellular folates unavailable for oxidation to dihydrofolate. This paper explores the role of cell cycle phase in L1210 leukemia cells in logarithmic versus stationary phase growth as a factor in the rate and extent of tetrahydrofolate cofactor interconversion to dihydrofolate after exposure of cells to the dihydrofolate reductase inhibitor trimetrexate. The S phase fraction was reduced by inoculating L1210 leukemia cells at high density to achieve a stationary state. Flow cytometric analysis of DNA content indicated that log phase cultures were 53.0% S phase; this decreased to 42.1% at 24 h and 24.1% at 48 h in stationary phase cultures. 5-Bromo-2'-deoxyuridine incorporation into DNA decreased 80 and 96%, while [H-3]dUrd incorporation into DNA declined 70 and 95% for stationary cultures at 24 and 48 h, respectively, as compared with the log phase rates. Log phase cells interconverted 28.0% of the total pool of radiolabeled folates to dihydrofolate with a half-time of approximately 30 s. Stationary cells at 24 h interconverted 20.4% of the total folate pool with a t1/2 of approximately 3 min, and at 48 h, net interconversion to dihydrofolate decreased further to 12.1% with a t1/2 of approximately 6 min. The decrease in the extent of tetrahydrofolate cofactor interconversion to dihydrofolate in stationary phase cells was directly proportional to the decrease in the S phase fraction determined by total DNA content. This suggests that tetrahydrofolate cofactor depletion occurs only in S phase cells. The much larger drop in [H-3]dUrd and 5-bromo-2'-deoxyuridine incorporation into DNA in comparison with the decline in the S phase fraction measured by DNA content along with the reduced rate of tetrahydrofolate cofactor interconversion to dihydrofolate indicates that the rate of DNA synthesis is decreased in S phase cells in stationary cultures. Network thermodynamic simulations suggest that a reduction in the number of S phase cells and their thymidylate synthase catalytic activity would account for the observed decrease in the rate and extent of interconversion of tetrahydrofolate cofactors to dihydrofolate after trimetrexate in stationary phase cultures. These observations suggest that the failure to quantitatively interconvert tetrahydrofolate cofactors to dihydrofolate in mammalian cells after antifolates is due in part to a component of non-S phase cells that have essentially no thymidylate synthase catalytic activity.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,MCV BOX 230,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL,RICHMOND,VA 23298	Virginia Commonwealth University; Virginia Commonwealth University					NATIONAL CANCER INSTITUTE [R35CA039807] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39807, CA-09340] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEGRA CJ, 1986, J BIOL CHEM, V261, P6478; ALLISON DC, 1989, CANCER RES, V49, P1456; ALLISON DC, 1986, CANCER RES, V46, P3951; ALLISON DC, 1985, CANCER RES, V45, P6010; BARAM J, 1987, J CLIN INVEST, V79, P692, DOI 10.1172/JCI112872; CADMAN E, 1986, CANCER RES, V46, P1195; CHABNER BA, 1982, PHARM PRINCIPLES CAN, P229; COLLINS JM, 1978, J BIOL CHEM, V253, P8570; CONRAD AH, 1971, J BIOL CHEM, V246, P1318; COOK RJ, 1979, BIOCHEM J, V178, P651, DOI 10.1042/bj1780651; DEAN PN, 1984, CELL TISSUE KINET, V17, P427, DOI 10.1111/j.1365-2184.1984.tb00601.x; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; FRIED J, 1977, J HISTOCHEM CYTOCHEM, V25, P942, DOI 10.1177/25.7.894010; FRY DW, 1983, CANCER RES, V43, P1087; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; HRYNIUK WM, 1969, MOL PHARMACOL, V5, P557; JACKSON RC, 1984, PHARMACOL THERAPEUT, V25, P61, DOI 10.1016/0163-7258(84)90024-X; JOLIVET J, 1983, NEW ENGL J MED, V309, P1094, DOI 10.1056/NEJM198311033091805; KESAVAN V, 1986, CANCER LETT, V30, P55, DOI 10.1016/0304-3835(86)90132-1; MATHERLY LH, 1986, CANCER RES, V46, P588; MATHERLY LH, 1984, CANCER RES, V44, P2325; MATHERLY LH, 1990, CANCER RES, V50, P3262; MATHERLY LH, 1987, J BIOL CHEM, V262, P710; MATHERLY LH, 1990, BIOCHEM PHARMACOL, V39, P2005, DOI 10.1016/0006-2952(90)90622-R; MCGUIRE JJ, 1981, MOL CELL BIOCHEM, V38, P19, DOI 10.1007/BF00235686; MORAN RG, 1982, P AM ASSOC CANC RES, V23, P178; NAVALGUND LG, 1980, J BIOL CHEM, V255, P7386; RODE W, 1980, J BIOL CHEM, V255, P1305; SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3; SEITHER RL, 1989, J BIOL CHEM, V264, P17016; SEITHER RL, 1990, COMPUT MATH APPL, V200, P87; STRONG WB, 1990, J BIOL CHEM, V265, P12149; SUR P, 1983, BIOCHEM J, V216, P295, DOI 10.1042/bj2160295; TRENT D F, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P338; WHITE JC, 1981, J BIOL CHEM, V256, P5722; WHITE JC, 1979, J BIOL CHEM, V254, P889; ZAMIEROWSKI MM, 1977, J BIOL CHEM, V252, P933	37	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5445	5449						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1825999				2022-12-25	WOS:A1991FD37000017
J	BLANK, U; RA, C; KINET, JP				BLANK, U; RA, C; KINET, JP			CHARACTERIZATION OF TRUNCATED ALPHA-CHAIN PRODUCTS FROM HUMAN, RAT, AND MOUSE HIGH-AFFINITY RECEPTOR FOR IMMUNOGLOBULIN-E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFECTED CELLS; IGE RECEPTOR; MAST-CELLS; SUBUNIT; EXPRESSION; BINDING; DNA	The high affinity receptor for immunoglobulin E (IgE) is a tetrameric structure (alpha-beta-gamma-2) consisting of noncovalently associated subunits: one IgE-binding alpha-chain, one 4-fold membrane spanning beta-chain, and two disulfide-linked gamma-chains. Here, we have engineered alpha-cDNA constructs (alpha-trunc) encoding exclusively the leader peptide and the extracellular domain of the alpha-subunit. Transfection of human alpha-trunc into COS-7 cells resulted in the secretion of soluble IgE-binding polypeptides. By contrast, the polypeptides generated from rat and mouse alpha-trunc transfections were sequestered in the endoplasmic reticulum and degraded even though they appeared to fold properly as judged by their capacity to bind IgE. Stable transfectants with human alpha-trunc were obtained from a dihydrofolate reductase-deficient Chinese hamster ovary cell line. Several clones secreted substantial amounts (0.1-mu-g/ml/10(6) cells) of IgE-binding polypeptides. The dissociation rate of bound IgE from this soluble truncated-alpha (k-1 = 4.9 x 10(-6) s-1 at 25-degrees-C) was characteristic of receptors on intact cells. After treatment with tunicamycin, the transfectants secreted unglycosylated 18-kDa polypeptides which could also bind IgE. These unglycosylated products had a tendency to form dimers and higher oligomers which were resistant to treatment by sodium dodecyl sulfate and reducing agents. These data demonstrate unequivocally that the extracellular domain of the alpha-subunit is sufficient to mediate high affinity binding of IgE. Furthermore, posttranslational addition of carbohydrates is not required for proper folding and function of the receptor binding site. The truncated human-alpha should be a suitable reagent for crystallographic analysis and for detailed analysis of the receptor binding site.	NIAID,MOLEC ALLERGY & IMMUNOL SECT,TWINBROOK II BLDG,12441 PARKLAWN DR,ROCKVILLE,MD 20852	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Blank, Ulrich/0000-0002-2661-2983				ALCARAZ G, 1987, BIOCHEMISTRY-US, V26, P2569, DOI 10.1021/bi00383a024; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CHEN C, 1988, J CELL BIOL, V107, P2149, DOI 10.1083/jcb.107.6.2149; ENNIS PD, 1990, P NATL ACAD SCI USA, V87, P2833, DOI 10.1073/pnas.87.7.2833; GOETZE A, 1981, BIOCHEMISTRY-US, V20, P6341, DOI 10.1021/bi00525a009; HAMPSTEAD BL, 1981, J BIOL CHEM, V265, P10717; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; ISHIZAKA T, 1985, J IMMUNOL, V134, P532; KANELLOPOULOS JM, 1980, J BIOL CHEM, V255, P9060; KINET JP, 1988, P NATL ACAD SCI USA, V85, P6483, DOI 10.1073/pnas.85.17.6483; KINET JP, 1987, BIOCHEMISTRY-US, V26, P4605, DOI 10.1021/bi00389a002; KINET JP, 1990, CURR OPIN IMMUNOL, V2, P499, DOI 10.1016/0952-7915(90)90002-X; KINET JP, 1990, FC RECEPTORS ACTION, P239; KOCHAN J, 1988, NUCLEIC ACIDS RES, V16, P3584, DOI 10.1093/nar/16.8.3584; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KULCZYCK.A, 1974, J EXP MED, V140, P1676, DOI 10.1084/jem.140.6.1676; KUSTER H, 1990, J BIOL CHEM, V265, P6448; LIU FT, 1980, J IMMUNOL, V124, P2728; MENDOZA G, 1976, NATURE, V264, P548, DOI 10.1038/264548a0; MILLER L, 1989, SCIENCE, V244, P334, DOI 10.1126/science.2523561; PEREZMONTFORT R, 1983, BIOCHEMISTRY-US, V22, P5722, DOI 10.1021/bi00294a007; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; QU ZX, 1988, J EXP MED, V167, P1195, DOI 10.1084/jem.167.3.1195; RA C, 1989, J BIOL CHEM, V264, P15323; ROSSI G, 1977, J BIOL CHEM, V252, P704; SHIMIZU A, 1988, P NATL ACAD SCI USA, V85, P1907, DOI 10.1073/pnas.85.6.1907; STRUCK DK, 1980, BIOCH GLYCOPROTEINS, P35; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; WANK SA, 1983, BIOCHEMISTRY-US, V22, P954, DOI 10.1021/bi00273a038; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0	34	113	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2639	2646						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1824944				2022-12-25	WOS:A1991EV51500094
J	FOSTER, SA; CERNY, J; CHENG, YC				FOSTER, SA; CERNY, J; CHENG, YC			HERPES-SIMPLEX VIRUS-SPECIFIED DNA-POLYMERASE IS THE TARGET FOR THE ANTIVIRAL ACTION OF 9-(2-PHOSPHONYLMETHOXYETHYL)ADENINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYCLIC NUCLEOTIDE ANALOGS; PHOSPHONYLMETHOXYALKYL DERIVATIVES; PHOSPHONOFORMIC ACID; TYPE-1; PROTEINS; CELLS; INFECTIONS; VARIANTS; TEMPLATE; INVITRO	9-(2-Phosphonylmethoxyethyl)adenine (PMEA) is a new antiviral compound with activity against herpes simplex virus (HSV) and retroviruses including human immunodeficiency virus. Although it has been suggested that the anti-HSV action of PMEA is through inhibition of the viral DNa polymerase via the diphosphorylated metabolite of PMEA (PMEApp), no conclusive evidence for this has been presented. We report that in cross-resistance studies, a PMEA-resistant HSV variant (PMEA(r)-1) was resistant to phosphonoformic acid, a compound which directly inhibits the HSV DNA polymerase. In addition, phosphonoformic acid-resistant HSV variants with defined drug resistance mutations within the HSV DNA polymerase gene were resistant to PMEA. Furthermore, the HSV DNA polymerase purified from PMEA(r)-1 was resistant to PMEApp in comparison with the enzyme from the parental virus. Moreover, PMEA inhibited HSV DNA synthesis in cell culture. These results provide strong evidence that HSV DNA polymerase is the major target for the antiviral action of PMEA. Further studies showed that HSV DNA polymerase incorporated PMEApp into DNA in vitro, while the HSV polymerase-associated 3'-5' exonuclease was able to remove the incorporated PMEA. Thus, the inhibition of HSV DNA polymerase by PMEApp appears to involve chain termination after its incorporation into DNA.	YALE UNIV,SCH MED,DEPT PHARMACOL,333 CEDAR ST,NEW HAVEN,CT 06510	Yale University					NCI NIH HHS [CA-44358] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044358] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALZARINI J, 1989, P NATL ACAD SCI USA, V86, P332, DOI 10.1073/pnas.86.1.332; BARIL E, 1977, NUCLEIC ACIDS RES, V4, P2641, DOI 10.1093/nar/4.8.2641; BASTOW KF, 1983, ANTIMICROB AGENTS CH, V23, P914, DOI 10.1128/AAC.23.6.914; BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; CERNY J, 1990, ANTIVIR RES, V13, P253, DOI 10.1016/0166-3542(90)90070-N; CHEN CH, 1989, J BIOL CHEM, V264, P11934; CHENG YC, 1981, BIOCHIM BIOPHYS ACTA, V652, P90, DOI 10.1016/0005-2787(81)90212-4; CHENG YC, 1983, P NATL ACAD SCI-BIOL, V80, P2767, DOI 10.1073/pnas.80.9.2767; COEN DM, 1980, P NATL ACAD SCI-BIOL, V77, P2265, DOI 10.1073/pnas.77.4.2265; DECLERCQ E, 1989, ANTIMICROB AGENTS CH, V33, P185, DOI 10.1128/AAC.33.2.185; DECLERCQ E, 1987, ANTIVIR RES, V8, P261; DERSE D, 1982, J BIOL CHEM, V257, P251; DERSE D, 1981, J BIOL CHEM, V256, P8525; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GANGEMI JD, 1989, ANTIMICROB AGENTS CH, V33, P1864, DOI 10.1128/AAC.33.11.1864; GARDELLA T, 1984, J VIROL, V50, P248, DOI 10.1128/JVI.50.1.248-254.1984; GIBBS JS, 1988, P NATL ACAD SCI USA, V85, P6672, DOI 10.1073/pnas.85.18.6672; GOLDIN AL, 1981, J VIROL, V38, P50, DOI 10.1128/JVI.38.1.50-58.1981; HOFFMANN PJ, 1978, J BIOL CHEM, V253, P3557; HOLY A, 1987, COLLECT CZECH CHEM C, V52, P2801, DOI 10.1135/cccc19872801; HOLY A, 1987, COLLECT CZECH CHEM C, V52, P2775, DOI 10.1135/cccc19872775; HONESS RW, 1974, J VIROL, V14, P8, DOI 10.1128/JVI.14.1.8-19.1974; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN JC, 1987, ANTIMICROB AGENTS CH, V31, P1431, DOI 10.1128/AAC.31.9.1431; MERTA A, 1990, ANTIVIR RES, V13, P209, DOI 10.1016/0166-3542(90)90066-G; MERTA A, 1990, NEOPLASMA, V37, P111; NUTTER LM, 1987, ANTIMICROB AGENTS CH, V31, P369; PAUWELS R, 1988, ANTIMICROB AGENTS CH, V32, P1025, DOI 10.1128/AAC.32.7.1025; ROSENBERG I, 1987, COLLECT CZECH CHEM C, V52, P2792, DOI 10.1135/cccc19872792; Sambrook J, 1989, MOL CLONING LABORATO; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330; VAZQUEZPADUA MA, 1990, CANCER COMMUN, V2, P55, DOI 10.3727/095535490820874740; VONKA V, 1990, ANTIVIR RES, V14, P117, DOI 10.1016/0166-3542(90)90049-D	33	41	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					238	244						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1845964				2022-12-25	WOS:A1991EQ33900036
J	HANSON, RD; SCLAR, GM; KANAGAWA, O; LEY, TJ				HANSON, RD; SCLAR, GM; KANAGAWA, O; LEY, TJ			THE 5'-FLANKING REGION OF THE HUMAN CGL-1/GRANZYME-B GENE TARGETS EXPRESSION OF A REPORTER GENE TO ACTIVATED LYMPHOCYTES-T IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTO-TOXIC LYMPHOCYTES; CELL ANTIGEN RECEPTOR; SERINE PROTEASE GENES; CATHEPSIN-G GENE; INTRAEPITHELIAL LYMPHOCYTES; GENOMIC ORGANIZATION; CYTOLYTIC ACTIVITY; NATURAL-KILLER; GRANZYME-A; INTERLEUKIN-2	The human CSP-B/CGL-1 gene is the homologue of the mouse granzyme B/CCPI gene and encodes a cytotoxic T-lymphocyte-specific serine protease. We have used regulatory sequences upstream from the CSP-B gene to drive human growth hormone gene expression in transgenic mice. Eleven founder mice were screened for transgene expression in activated T-cells. Expression was detected in 10 mice; levels of expression were integration site-dependent. The transgene was not expressed in resting lymphocytes but could be activated by treatment with concanavalin A or interleukin-2, indicating that CSP-B regulatory sequences are responsive to signals originating at either the T-cell receptor or the interleukin-2 receptor. Transgene expression was detected at the whole organ level only in lymph nodes and small intestine, where endogenous mouse CCPI mRNA was also present. The time course of transgene activation in T-lymphocytes was similar to that of the mouse CCPI gene. No differences in levels of expression of the transgene were observed in activated lymphocyte populations that had been depleted of either CD4+ or CD8+ cells; in contrast, the mouse CCPI gene was expressed primarily in CD8+ cells. Six CD4+ T-cell clones with Th0, Th1, or Th2 phenotypes were generated from a transgenic animal. All clones expressed moderate to high levels of the transgene, but only three clones expressed mouse CCPI, indicating that the transgene is disregulated in CD4+ T-cell subsets. The CSP-B regulatory unit represents a novel reagent for targeting gene expression to activated T-lymphocytes.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,DIV HEMATOL ONCOL,216 S KINGSHIGHWAY BLVD,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT GENET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL)					NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK038682, R01DK038682] Funding Source: NIH RePORTER; NCI NIH HHS [CA 49712] Funding Source: Medline; NIDDK NIH HHS [DK 38682] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRUNET JF, 1986, NATURE, V322, P268, DOI 10.1038/322268a0; CAPUTO A, 1988, J BIOL CHEM, V263, P6363; CARPEN O, 1982, J IMMUNOL, V128, P2691; CHEN EY, 1989, GENOMICS, V4, P479, DOI 10.1016/0888-7543(89)90271-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DEGRAVE W, 1983, EMBO J, V2, P2349, DOI 10.1002/j.1460-2075.1983.tb01745.x; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FIRESTEIN GS, 1989, J IMMUNOL, V143, P518; FUJITA T, 1983, P NATL ACAD SCI-BIOL, V80, P7437, DOI 10.1073/pnas.80.24.7437; GARCIASANZ JA, 1990, J IMMUNOL, V145, P3111; GARCIASANZ JA, 1987, EMBO J, V6, P933, DOI 10.1002/j.1460-2075.1987.tb04841.x; GOODMAN T, 1988, NATURE, V333, P855, DOI 10.1038/333855a0; HADDAD P, 1991, INT IMMUNOL, V3, P57, DOI 10.1093/intimm/3.1.57; HANSON RD, 1990, MOL CELL BIOL, V10, P5655, DOI 10.1128/MCB.10.11.5655; HANSON RD, 1990, J BIOL CHEM, V265, P1524; HANSON RD, 1990, P NATL ACAD SCI USA, V87, P960, DOI 10.1073/pnas.87.3.960; HEUSEL JW, 1991, J BIOL CHEM, V266, P6152; HOGAN B, 1986, MANIPULATION MOUSE E; HOHN PA, 1989, J BIOL CHEM, V264, P13412; HOLBROOK NJ, 1984, P NATL ACAD SCI-BIOL, V81, P1634, DOI 10.1073/pnas.81.6.1634; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KLEIN JL, 1989, GENOMICS, V5, P110, DOI 10.1016/0888-7543(89)90093-1; KOLLIAS G, 1987, P NATL ACAD SCI USA, V84, P1492, DOI 10.1073/pnas.84.6.1492; KRAHENBUHL O, 1988, J IMMUNOL, V141, P3471; LANCKI DW, 1991, J IMMUNOL, V146, P3242; LANG G, 1988, EMBO J, V7, P1675, DOI 10.1002/j.1460-2075.1988.tb02995.x; LEFRANCOIS L, 1989, SCIENCE, V243, P1716, DOI 10.1126/science.2564701; LEY TJ, 1991, BLOOD, V77, P1146; LEY TJ, 1989, J CLIN INVEST, V83, P1032, DOI 10.1172/JCI113944; LOBE CG, 1989, NUCLEIC ACIDS RES, V17, P5765, DOI 10.1093/nar/17.14.5765; LOBE CG, 1986, SCIENCE, V232, P858, DOI 10.1126/science.3518058; LOBE CG, 1986, P NATL ACAD SCI USA, V83, P1448, DOI 10.1073/pnas.83.5.1448; MANYAK CL, 1989, J IMMUNOL, V142, P3707; MASSON D, 1985, EMBO J, V4, P2533, DOI 10.1002/j.1460-2075.1985.tb03967.x; MASSON D, 1987, CELL, V49, P679, DOI 10.1016/0092-8674(87)90544-7; MEIER M, 1990, BIOCHEMISTRY-US, V29, P4042, DOI 10.1021/bi00469a003; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; OSTERGAARD HL, 1987, NATURE, V330, P71, DOI 10.1038/330071a0; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; REINHERZ EL, 1982, CELL, V30, P735, DOI 10.1016/0092-8674(82)90278-1; ROTTEVEEL FTM, 1988, J EXP MED, V168, P1659, DOI 10.1084/jem.168.5.1659; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID J, 1987, J IMMUNOL, V139, P250; SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.immunol.2.1.319; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; YUI K, 1990, P NATL ACAD SCI USA, V87, P7135, DOI 10.1073/pnas.87.18.7135	49	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24433	24438						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761544				2022-12-25	WOS:A1991GW84500032
J	ZHANG, FM; KOBE, B; STEWART, CB; RUTTER, WJ; GOLDSMITH, EJ				ZHANG, FM; KOBE, B; STEWART, CB; RUTTER, WJ; GOLDSMITH, EJ			STRUCTURAL EVOLUTION OF AN ENZYME SPECIFICITY - THE STRUCTURE OF RAT CARBOXYPEPTIDASE A2 AT 1.9-A RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-GRISEUS TRYPSIN; REFINED CRYSTAL-STRUCTURE; PROTEIN STRUCTURES; TRANSITION-STATE; GENE FAMILY; SEQUENCE; DYNAMICS; ACCESSIBILITY; PHOSPHONATE; DIFFRACTION	The structure of rat carboxypeptidase A2 (CPA2), which has a unique specificity for tryptophan-containing COOH-terminal peptides, has been determined in an unliganded state at 1.9-angstrom resolution and refined to a crystallographic R-factor of 18.3%. Comparison of the structure of CPA2 with that of bovine carboxypeptidase A (referred to here as CPA1) reveals that the specificity of the former for larger amino acids probably arises from two amino acid replacements within the binding cavity (Thr268 --> Ala and Leu203 --> Met), coupled with differences in the positions of conserved residues in a surface loop on one face of the specificity pocket. The position of the reactive-site surface loop may be affected also by a disulfide bridge between Cys210 and Cys244. In this unliganded form of the enzyme, Tyr248 takes up a position interior to the specificity pocket and is distinct from that observed in bovine CPA1. The structural differences between CPA1 and CPA2 correlate strongly with crystallographically determined temperature factors and thus appear to be largest where the enzyme is flexible.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Francisco			Kobe, Bostjan/D-1292-2009	Kobe, Bostjan/0000-0001-9413-9166				ABADZAPATERO C, 1990, PROTEINS, V8, P62, DOI 10.1002/prot.340080109; BEVINGTON PR, 1969, DATA REDUCTION ERROR, P119; BRADSHAW RA, 1969, P NATL ACAD SCI USA, V63, P1389, DOI 10.1073/pnas.63.4.1389; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHAMBERS JL, 1979, ACTA CRYSTALLOGR B, V35, P1861, DOI 10.1107/S0567740879007925; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; CHRISTIANSON DW, 1987, P NATL ACAD SCI USA, V84, P1512, DOI 10.1073/pnas.84.6.1512; CLAUSER E, 1988, J BIOL CHEM, V263, P17837; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; CROWTHER RA, 1969, ACTA CRYSTALL B-STRU, VB 25, P2571, DOI 10.1107/S0567740869006091; CUENI LB, 1980, ANAL BIOCHEM, V107, P341, DOI 10.1016/0003-2697(80)90394-2; DAYRINGER HE, 1986, J MOL GRAPHICS, V4, P82; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRAUENFELDER H, 1979, NATURE, V280, P558, DOI 10.1038/280558a0; GARAVITO RM, 1977, BIOCHEMISTRY-US, V16, P5065, DOI 10.1021/bi00642a019; GARDELL SJ, 1985, NATURE, V317, P551, DOI 10.1038/317551a0; GARDELL SJ, 1988, J BIOL CHEM, V263, P17828; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; HANSON JE, 1989, BIOCHEMISTRY-US, V28, P6294, DOI 10.1021/bi00441a022; HENDRICKSON WA, 1979, ACTA CRYSTALLOGR A, V34, P931; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1990, O VERSION 5 4; KARPUSAS M, 1989, P NATL ACAD SCI USA, V86, P8237, DOI 10.1073/pnas.86.21.8237; KIM H, 1990, BIOCHEMISTRY-US, V29, P5546, DOI 10.1021/bi00475a019; KURIYAN J, 1991, P NATL ACAD SCI USA, V88, P2773, DOI 10.1073/pnas.88.7.2773; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lipscomb W N, 1968, Brookhaven Symp Biol, V21, P24; LIPSCOMB WN, 1969, P NATL ACAD SCI USA, V64, P28, DOI 10.1073/pnas.64.1.28; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MCPHERSON A, 1982, PREPARATION ANAL PRO, P127; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PERRY KM, 1990, PROTEINS, V8, P315, DOI 10.1002/prot.340080406; PHILLIPS MA, 1990, J BIOL CHEM, V265, P20692; QUINTO C, 1982, P NATL ACAD SCI-BIOL, V79, P31, DOI 10.1073/pnas.79.1.31; READ RJ, 1990, ACTA CRYSTALLOGR A, V46, P900, DOI 10.1107/S0108767390005529; READ RJ, 1988, J MOL BIOL, V200, P523, DOI 10.1016/0022-2836(88)90541-4; READ RJ, 1984, BIOCHEMISTRY-US, V23, P6570, DOI 10.1021/bi00321a045; REES DC, 1981, P NATL ACAD SCI-BIOL, V78, P5455, DOI 10.1073/pnas.78.9.5455; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; RINGE D, 1985, PROG BIOPHYS MOL BIO, V45, P197, DOI 10.1016/0079-6107(85)90002-1; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SAWYER L, 1978, J MOL BIOL, V118, P137, DOI 10.1016/0022-2836(78)90412-6; SCHMID MF, 1976, J MOL BIOL, V103, P175, DOI 10.1016/0022-2836(76)90058-9; SHERIFF S, 1985, P NATL ACAD SCI USA, V82, P1104, DOI 10.1073/pnas.82.4.1104; SIELECKI AR, 1989, SCIENCE, V243, P1346, DOI 10.1126/science.2493678; TITANI K, 1975, P NATL ACAD SCI USA, V72, P1666, DOI 10.1073/pnas.72.5.1666	48	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24606	24612						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761558				2022-12-25	WOS:A1991GW84500057
J	MALMSTROM, K; KRIEGER, M				MALMSTROM, K; KRIEGER, M			USE OF RADIATION SUICIDE TO ISOLATE CONSTITUTIVE AND TEMPERATURE-SENSITIVE CONDITIONAL CHINESE-HAMSTER OVARY CELL MUTANTS WITH DEFECTS IN THE ENDOCYTOSIS OF LOW-DENSITY-LIPOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; O-LINKED GLYCOSYLATION; DEFICIENT MUTANT; EXPRESSION; CHOLESTEROL; INVITRO; PATHWAY; COMPLEMENTATION; GLYCOPROTEINS; ACIDIFICATION	A radiation suicide procedure was used to isolate cells with either constitutive or temperature-sensitive (ts) defects in the receptor-mediated endocytosis of low density lipoprotein (LDL). Mutagen-treated Chinese hamster ovary cells maintained at 34-degrees-C (permissive temperature) were shifted to 39.5-degrees-C (nonpermissive temperature) for 14-26 h and incubated at 39.5-degrees-C for an additional 6-8 h with [H-3]cholesteryl linoleate LDL. Wild-type cells internalized this lipoprotein via LDL receptors and accumulated [H-3]cholesteryl linoleate (1.5-2 dpm/cell). Radiolysis during 80 days of frozen storage killed most of these cells (radiation suicide). Receptor-deficient cells were identified by screening the surviving cells for their inability to internalize and accumulate I-125-LDL using a replica plating assay. From 3.6 x 10(7) tritium-labeled cells, two clones fell into previously defined constitutive and ts complementation groups (ldlA and ldlG, respectively). Another constitutive and two other ts mutants defined two new complementation groups, ldlI (constitutive) and ldlH (ts). This increases to nine the current number of recessive, LDL receptor-deficient, Chinese hamster ovary complementation groups. All of the mutants with ts defects in LDL endocytosis exhibited ts conditional-lethal phenotypes. At the nonpermissive temperature, the rates of loss of LDL receptor activity (t1/2 = 10-14 h) were significantly faster than the rates of loss of protein synthesis (t1/2 > 24 h), suggesting that the temperature sensitivity of receptor activity was not simply due to the metabolic collapse of dying cells. Detailed analysis of these new classes of mutants should help define gene products and functions required for LDL receptor activity.	MIT, DEPT BIOL, E25-236, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	KRIEGER, M (corresponding author), MIT, DEPT BIOL, E25-236, CAMBRIDGE, MA 02139 USA.				NIGMS NIH HHS [GM30243] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH WE, 1989, J BIOL CHEM, V264, P16965; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; COLBAUGH PA, 1989, J CELL BIOL, V108, P2211, DOI 10.1083/jcb.108.6.2211; COLBAUGH PA, 1988, SOMAT CELL MOLEC GEN, V14, P499, DOI 10.1007/BF01534715; CRONAN JE, 1970, P NATL ACAD SCI USA, V65, P737, DOI 10.1073/pnas.65.3.737; DANTZIG AH, 1982, SOMAT CELL GENET, V8, P509, DOI 10.1007/BF01538711; DAVIS CG, 1986, J BIOL CHEM, V261, P2828; DRAPER RK, 1990, SCIENCE, V248, P1539, DOI 10.1126/science.2163108; Esko J D, 1986, Methods Enzymol, V129, P237; FAUST JR, 1977, J BIOL CHEM, V252, P4861; FINKELSTEIN MC, 1977, P NATL ACAD SCI USA, V74, P4549, DOI 10.1073/pnas.74.10.4549; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GOLDSTEIN JL, 1979, J BIOL CHEM, V254, P5403; GOODMAN DWS, 1969, METHOD ENZYMOL, V15, P522; HAROLD FM, 1965, J BIOL CHEM, V240, P3145; HEARING J, 1989, J CELL BIOL, V108, P339, DOI 10.1083/jcb.108.2.339; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KINGSLEY DM, 1986, J CELL BIOL, V102, P1576, DOI 10.1083/jcb.102.5.1576; KLAUSNER RD, 1984, J CELL BIOL, V98, P1098, DOI 10.1083/jcb.98.3.1098; KOZARSKY K, 1988, P NATL ACAD SCI USA, V85, P4335, DOI 10.1073/pnas.85.12.4335; KOZARSKY K, 1989, J ACQ IMMUN DEF SYND, V2, P163; KOZARSKY KF, 1986, J CELL BIOL, V102, P1567, DOI 10.1083/jcb.102.5.1567; KOZARSKY KF, 1988, MOL CELL BIOL, V8, P3357, DOI 10.1128/MCB.8.8.3357; KRIEGER M, 1985, TRENDS BIOCHEM SCI, V10, P447, DOI 10.1016/0968-0004(85)90029-5; KRIEGER M, 1978, J BIOL CHEM, V253, P4093; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; KRIEGER M, 1981, J MOL BIOL, V150, P167, DOI 10.1016/0022-2836(81)90447-2; Krieger M, 1986, Methods Enzymol, V129, P227; KRIEGER M, 1983, P NATL ACAD SCI-BIOL, V80, P5607, DOI 10.1073/pnas.80.18.5607; KRIEGER M, 1979, J BIOL CHEM, V254, P3845; KRIEGER M, 1989, METHOD CELL BIOL, V32, P57; MARNELL MH, 1984, J CELL BIOL, V99, P1907, DOI 10.1083/jcb.99.6.1907; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MERION M, 1983, P NATL ACAD SCI-BIOL, V80, P5315, DOI 10.1073/pnas.80.17.5315; NAKANO A, 1985, BIOCHIM BIOPHYS ACTA, V845, P324, DOI 10.1016/0167-4889(85)90195-8; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; POUYSSEGUR J, 1987, P NATL ACAD SCI USA, V151, P131; RAETZ CRH, 1982, P NATL ACAD SCI-BIOL, V79, P3223, DOI 10.1073/pnas.79.10.3223; REDDY P, 1989, MOL CELL BIOL, V9, P4799, DOI 10.1128/MCB.9.11.4799; ROBBINS AR, 1984, J CELL BIOL, V99, P1296, DOI 10.1083/jcb.99.4.1296; ROFF CF, 1990, J CELL BIOL, V110, P1023, DOI 10.1083/jcb.110.4.1023; ROFF CF, 1986, J CELL BIOL, V103, P2283, DOI 10.1083/jcb.103.6.2283; RYSER HJP, 1988, J CELL PHYSIOL, V135, P277, DOI 10.1002/jcp.1041350215; SEGE RD, 1984, NATURE, V307, P742, DOI 10.1038/307742a0; STANLEY P, 1985, MOL CELL GENETICS CH, P745; WANG RH, 1990, J BIOL CHEM, V265, P20179; WESSLINGRESNICK M, 1990, J BIOL CHEM, V265, P690	49	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					24025	24030						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748674				2022-12-25	WOS:A1991GV31900076
J	VELAN, B; GROSFELD, H; KRONMAN, C; LEITNER, M; GOZES, Y; LAZAR, A; FLASHNER, Y; MARCUS, D; COHEN, S; SHAFFERMAN, A				VELAN, B; GROSFELD, H; KRONMAN, C; LEITNER, M; GOZES, Y; LAZAR, A; FLASHNER, Y; MARCUS, D; COHEN, S; SHAFFERMAN, A			THE EFFECT OF ELIMINATION OF INTERSUBUNIT DISULFIDE BONDS ON THE ACTIVITY, ASSEMBLY, AND SECRETION OF RECOMBINANT HUMAN ACETYLCHOLINESTERASE - EXPRESSION OF ACETYLCHOLINESTERASE CYS-580-]ALA MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SERUM CHOLINESTERASE; AMINO-ACID-SEQUENCE; HYBRID CELL-LINE; MOLECULAR-FORMS; MONOMERIC ACETYLCHOLINESTERASE; ENDOPLASMIC-RETICULUM; TORPEDO-MARMORATA; GOLGI-APPARATUS; ELECTRIC ORGAN; HUMAN-PLASMA	Site-directed mutagenesis was used to study the cysteine residue involved in the assembly of human acetyleholinesterase (HuAChE) catalytic subunits. Substitution of the cysteine at position 580 by alanine resulted in impairment of interchain disulfide bridge formation; the mutagenized enzyme (C580A) was secreted from recombinant cells in the monomeric form and failed to assemble into dimers. The mutant monomeric HuAChE did not differ from the native oligomeric enzyme neither in rate of catalysis nor in affinity to acetylthiocholine. Mutant monomers were also shown to retain the acetylcholinesterase characteristic sensitivity to high substrate concentrations. The mutation did not seem to affect the efficiencies of either synthesis or secretion of recombinant HuAChE polypeptides, as was demonstrated in cell lines derived from human embryonic kidney (293 cells) as well as from a human neuroblastoma (SK-N-SH). Furthermore, the mutation did not lead to an increase in accumulation of intracellular HuAChE polypeptides, suggesting that export of acetylcholinesterase from cells may not be coupled to subunit assembly.	ISRAEL INST BIOL RES,DEPT BIOCHEM,POB 19,IL-70450 NESS ZIONA,ISRAEL; ISRAEL INST BIOL RES,DEPT BIOTECHNOL,IL-70450 NESS ZIONA,ISRAEL		SHAFFERMAN, A (corresponding author), ISRAEL INST BIOL RES,DEPT BIOCHEM,POB 19,IL-70450 NESS ZIONA,ISRAEL.							ALLMAND P, 1981, J NEUROCHEM, V36, P860; ALWINE JC, 1985, MOL CELL BIOL, V5, P1034, DOI 10.1128/MCB.5.5.1034; ATACK JR, 1987, J NEUROCHEM, V48, P1845, DOI 10.1111/j.1471-4159.1987.tb05746.x; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BIEDLER JL, 1973, CANCER RES, V33, P2643; BROCKMAN SK, 1986, J BIOL CHEM, V261, P1201; CAUET G, 1987, BIOCHIM BIOPHYS ACTA, V912, P338, DOI 10.1016/0167-4838(87)90037-9; CHATONNET A, 1989, BIOCHEM J, V260, P625, DOI 10.1042/bj2600625; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; DOCTOR BP, 1990, FEBS LETT, V266, P123, DOI 10.1016/0014-5793(90)81522-P; EDWARDS JA, 1983, BIOCHIM BIOPHYS ACTA, V742, P509, DOI 10.1016/0167-4838(83)90268-6; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; EVANS GA, 1982, NATURE, V300, P755, DOI 10.1038/300755a0; FOECKING MK, 1986, GENE, V45, P101, DOI 10.1016/0378-1119(86)90137-X; GROSFELD H, 1989, J VIROL, V63, P3416, DOI 10.1128/JVI.63.8.3416-3422.1989; HALL LMC, 1986, EMBO J, V5, P2949, DOI 10.1002/j.1460-2075.1986.tb04591.x; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KOELLE GB, 1987, P NATL ACAD SCI USA, V84, P7749, DOI 10.1073/pnas.84.21.7749; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAR M, 1980, J NEUROCHEM, V35, P1067, DOI 10.1111/j.1471-4159.1980.tb07860.x; LAZAR M, 1984, J BIOL CHEM, V259, P3703; LEITNER M, 1991, BIOLOGICALS FROM RECOMBINANT MICROORGANISMS AND ANIMAL CELLS, P83; LEVY D, 1986, BIOCHEM PHARMACOL, V35, P1079, DOI 10.1016/0006-2952(86)90142-5; LEWIS ED, 1985, MOL CELL BIOL, V5, P2433, DOI 10.1128/MCB.5.9.2433; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LOCKRIDGE O, 1987, J BIOL CHEM, V262, P12945; LOCKRIDGE O, 1979, J BIOL CHEM, V254, P8324; LOCKRIDGE O, 1987, J BIOL CHEM, V262, P549; LOCKRIDGE O, 1982, J BIOL CHEM, V257, P2012; LUCAS CA, 1985, NEUROSCIENCE, V14, P349, DOI 10.1016/0306-4522(85)90184-8; MACPHEEQUIGLEY K, 1986, J BIOL CHEM, V261, P3565; MASSON P, 1989, BIOCHIM BIOPHYS ACTA, V998, P258, DOI 10.1016/0167-4838(89)90282-3; MASSOULIE J, 1982, ANNU REV NEUROSCI, V5, P57, DOI 10.1146/annurev.ne.05.030182.000421; PRODY CA, 1987, P NATL ACAD SCI USA, V84, P3555, DOI 10.1073/pnas.84.11.3555; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; RALSTON JS, 1985, J BIOL CHEM, V260, P432; ROBERTS WL, 1991, J BIOL CHEM, V266, P7481; ROTUNDO RL, 1988, J BIOL CHEM, V263, P19398; ROTUNDO RL, 1984, P NATL ACAD SCI-BIOL, V81, P479, DOI 10.1073/pnas.81.2.479; ROTUNDO RL, 1989, J BIOL CHEM, V264, P3146; ROTUNDO RL, 1979, J BIOL CHEM, V254, P4790; SCHUMACHER M, 1986, NATURE, V319, P407, DOI 10.1038/319407a0; SCHUMACHER M, 1988, J BIOL CHEM, V263, P18979; SCOTT EM, 1974, AM J HUM GENET, V26, P189; SHAFFERMAN A, 1990, VACCINES 90, P115; SHAFFERMAN A, 1987, J BIOL CHEM, V262, P6227; SIKORAV JL, 1988, EMBO J, V7, P2983, DOI 10.1002/j.1460-2075.1988.tb03161.x; SIKORAV JL, 1987, EMBO J, V6, P1865, DOI 10.1002/j.1460-2075.1987.tb02445.x; SILMAN I, 1987, EUR J BIOCHEM, V170, P11, DOI 10.1111/j.1432-1033.1987.tb13662.x; SOREQ H, 1990, P NATL ACAD SCI USA, V87, P9688, DOI 10.1073/pnas.87.24.9688; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STIEGER S, 1987, J NEUROCHEM, V49, P460, DOI 10.1111/j.1471-4159.1987.tb02887.x; STIEGER S, 1989, J NEUROCHEM, V52, P1188, DOI 10.1111/j.1471-4159.1989.tb01865.x; TAYLOR PB, 1981, J BIOL CHEM, V256, P3827; VELAN B, 1991, CELL MOL NEUROBIOL, V11, P143, DOI 10.1007/BF00712806; VIGNY M, 1979, J NEUROCHEM, V33, P559, DOI 10.1111/j.1471-4159.1979.tb05188.x; VOGEL J, 1986, MOL CELL BIOL, V6, P3550, DOI 10.1128/MCB.6.10.3550; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YOUNKIN SG, 1982, J BIOL CHEM, V257, P13630	60	97	99	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23977	23984						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748670				2022-12-25	WOS:A1991GV31900070
J	DYER, CA; CURTISS, LK				DYER, CA; CURTISS, LK			A SYNTHETIC PEPTIDE MIMIC OF PLASMA APOLIPOPROTEIN-E THAT BINDS THE LDL RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LOW-DENSITY LIPOPROTEIN; CHOLESTEROL; PROTEIN; FIBROBLASTS; APOPROTEIN; CLEARANCE; RABBITS; CELLS	Human plasma apolipoprotein E (apoE) is a low density lipoprotein (LDL) receptor ligand. It targets cholesterol-rich lipoproteins to LDL receptors on both hepatic and peripheral cells. The region of apoE responsible for its binding to the LDL receptor has been localized to amino acids 140-160. An apoE 141-155 monomeric peptide and a dimeric 141-155 tandem peptide were synthesized and tested for their inhibition of I-125-LDL degradation by human fibroblasts and human monocytic-like cells, THP-1. The monomer had no activity at 250-mu-M, but the dimer inhibited I-125-LDL degradation by 50% at 5-mu-M. The inhibition was specific for the LDL receptor because the dimer did not inhibit the degradation of I-125-acetylated LDL by scavenger receptors expressed by phorbol ester-stimulated THP-1 cells. As reported for native apoE, amino acid substitutions of Lys-143 --> Ala, Leu-144 --> Pro, and Arg-150 --> Ala decreased the inhibitory effectiveness of the dimer. Furthermore, a trimer of the 141-155 sequence had a 20-fold greater inhibitory activity than the dimer. Studies with a radioiodinated dimer indicated that some of the inhibitory activity could be a result of the interaction of the dimer with LDL. However, direct binding of the I-125-dimeric peptide to THP-1 cells was observed as well. This binding was time-dependent, linear with increasing cell number, Ca2+- but not Mg2+-dependent, saturable, inhibited by lipoproteins, and increased by preculture of the cells in lipoprotein-depleted medium. Therefore, a synthetically prepared dimeric repeat of amino acid residues 141-155 of apoE binds the LDL receptor.			DYER, CA (corresponding author), Scripps Clinic, DEPT IMMUNOL, IMM-17, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NHLBI NIH HHS [HL-35297] Funding Source: Medline; NICHD NIH HHS [HD-27167] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027167] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035297] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; BANKA CL, 1991, J LIPID RES, V32, P35; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BRADLEY WA, 1984, J BIOL CHEM, V259, P4728; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; DYER CA, 1991, J BIOL CHEM, V266, P15009; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; HARA H, 1987, BIOCHEM BIOPH RES CO, V146, P802, DOI 10.1016/0006-291X(87)90601-2; HOFMANN SL, 1988, SCIENCE, V239, P1277, DOI 10.1126/science.3344433; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; LALAZAR A, 1988, J BIOL CHEM, V263, P3542; MAHLEY RW, 1989, J CLIN INVEST, V83, P2125, DOI 10.1172/JCI114126; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; SEMENKOVICH CF, 1986, J CLIN ENDOCR METAB, V62, P1279, DOI 10.1210/jcem-62-6-1279; SOLTYS PA, 1988, J LIPID RES, V29, P191; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; YAMADA N, 1989, P NATL ACAD SCI USA, V86, P665, DOI 10.1073/pnas.86.2.665	20	48	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22803	22806						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744074				2022-12-25	WOS:A1991GT48300008
J	NARHI, LO; ARAKAWA, T; AOKI, KH; ELMORE, R; ROHDE, MF; BOONE, T; STRICKLAND, TW				NARHI, LO; ARAKAWA, T; AOKI, KH; ELMORE, R; ROHDE, MF; BOONE, T; STRICKLAND, TW			THE EFFECT OF CARBOHYDRATE ON THE STRUCTURE AND STABILITY OF ERYTHROPOIETIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN ERYTHROPOIETIN; HAMSTER OVARY CELLS; BIOLOGICAL-ACTIVITY; SUGAR CHAINS; GLYCOSYLATION; MECHANISM; RIBONUCLEASES; GLYCEROL; PROTEIN	Erythropoietin is a glycoprotein hormone that stimulates the maturation of late erythroid progenitor cells. It has three N-linked and one O-linked carbohydrates which play an important role in the biosynthesis and biological activities of the protein. To determine the role the carbohydrate might have in maintaining the conformational stability of the protein, the protein expressed in mammalian cells (fully glycosylated), the asialo mammalian-expressed protein, and the protein expressed in Escherichia coli (no carbohydrate) were compared for their stability to guanidine HCl, pH, and temperature. Circular dichroism was used to follow protein unfolding. Both the intact and asialo mammalian-expressed proteins unfolded with a cooperative transition in guanidine HCl, with a midpoint at 1.75 M guanidine HCl. The E. coli-expressed material unfolded with a midpoint of 1.2 M guanidine HCl, and a DELTA-G of unfolding which was 1.4 kcal/mol less than that of the two glycosylated molecules. The E. coli-derived protein was also significantly less stable to pH-induced conformational changes, showing a cooperative transition in 35% glycerol with a midpoint at pH 4.4, while both the intact and asialo mammalian-expressed molecules had a transition midpoint of pH 3.75 in the absence of glycerol, and approximately pH 3 in the presence of 35% glycerol. The E. coli-expressed molecule unfolded and precipitated upon heating to 44-degrees-C, while the asialo and intact mammalian-expressed proteins remained soluble, with a T(m) of 56-degrees-C. From these experiments, the carbohydrate appears to play a critical role in stabilizing the erythropoietin molecule to denaturing conditions, and this increased stability does not depend on the presence of sialic acid.			NARHI, LO (corresponding author), AMGEN INC,THOUSAND OAKS,CA 91320, USA.							DAVIS JM, 1987, BIOCHEMISTRY-US, V26, P2633, DOI 10.1021/bi00383a034; DORDAL MS, 1985, ENDOCRINOLOGY, V116, P2293, DOI 10.1210/endo-116-6-2293; DUBE S, 1988, J BIOL CHEM, V263, P17516; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4667, DOI 10.1021/bi00519a023; GOLDWASSER E, 1974, J BIOL CHEM, V249, P4202; GOTO M, 1988, BIO-TECHNOL, V6, P67, DOI 10.1038/nbt0188-67; GRABER SE, 1978, ANNU REV MED, V29, P51, DOI 10.1146/annurev.me.29.020178.000411; GRAFL R, 1987, J BIOL CHEM, V262, P10624; IMAI N, 1990, J BIOCHEM, V107, P352, DOI 10.1093/oxfordjournals.jbchem.a123050; JOURDIAN GW, 1971, J BIOL CHEM, V246, P430; KRANTZ SB, 1984, P NATL ACAD SCI-BIOL, V81, P7574, DOI 10.1073/pnas.81.23.7574; KREBS H, 1983, J MOL BIOL, V169, P619, DOI 10.1016/S0022-2836(83)80067-9; LAI PH, 1986, J BIOL CHEM, V261, P3116; NA GC, 1981, J MOL BIOL, V151, P165, DOI 10.1016/0022-2836(81)90226-6; OHEDA M, 1990, J BIOL CHEM, V265, P11432; SASAKI H, 1987, J BIOL CHEM, V262, P12059; SCHULKE N, 1988, J BIOL CHEM, V263, P8827; TAKEUCHI M, 1990, J BIOL CHEM, V265, P12127; TAKEUCHI M, 1989, P NATL ACAD SCI USA, V86, P7819, DOI 10.1073/pnas.86.20.7819; TAKEUCHI M, 1988, J BIOL CHEM, V263, P3657; TSUDA E, 1990, EUR J BIOCHEM, V188, P405, DOI 10.1111/j.1432-1033.1990.tb15417.x; WANG FFC, 1977, J BIOL CHEM, V252, P8358	22	173	177	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23022	23026						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744097				2022-12-25	WOS:A1991GT48300040
J	CAIRNS, P; PROCTOR, AJ; KNOWLES, MA				CAIRNS, P; PROCTOR, AJ; KNOWLES, MA			LOSS OF HETEROZYGOSITY AT THE RB-LOCUS IS FREQUENT AND CORRELATES WITH MUSCLE INVASION IN BLADDER-CARCINOMA	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; NON-OCULAR CANCER; HEREDITARY RETINOBLASTOMA; SOMATIC MUTATIONS; TUMORS; EXPRESSION; RELATIVES; SEQUENCE; IDENTIFICATION; CHROMOSOME-11	Studies of second, non-ocular tumours in surviving retinoblastoma patients and their families have reported a higher than expected incidence and lower age at diagnosis of bladder tumors. This suggests that RB mutations may predispose to bladder cancer. To determine whether this gene is involved in the development of sporadic bladder tumours we have examined 162 bladder tumours for evidence of structural alterations to the RB gene. Ninety-four patients were informative with one or more intragenic RB probes, and 28 of these (29%) showed loss of heterozygosity (LOH). Of these, two tumours showed homozygous deletions with the 5' intragenic probe p123M1.8. The probe p68RS2.0, which recognizes a variable number of tandem repeats site in intron 17 of the RB gene, detected new alleles in 5 of 162 tumours, one of which also showed LOH at another polymorphic site within the gene. The 28 tumours with RB LOH were screened with the RB cDNA probes pR3.8 and pR0.9, which revealed two homozygous deletions and one rearrangement. The tumours with RB LOH were also screened for loss of three markers which flank RB, D13S1 which maps proximal and D13S2 and D13S3 which map distal to RB on chromosome 13q. Two tumours showed retention of heterozygosity for flanking markers on one side of RB and another for markers on both sides. These results suggest that RB is the target gene on 13q in these bladder tumours. When RB loss was compared with tumour grade and stage, an association between high tumour grade and RB loss (0.005 > P > 0.001) and between muscle invasion and RB loss (P < 0.001) was found. Twenty-six of the 28 tumours with LOH were muscle-invasive. This represents 56% of invasive tumours. Only 2/48 (4%) superficial tumours showed RB allele loss, and one of these has progressed rapidly to invasive disease. These results show that LOH at the RB locus is a frequent genetic event in bladder tumours and may identify a subset of more aggressive tumours.			CAIRNS, P (corresponding author), MARIE SKLODOWSKA CURIE MEM INST,THE CHART,OXTED RH8 0TL,SURREY,ENGLAND.			Knowles, Margaret/0000-0002-9363-8657				AHERNE G, 1974, T OPHTHAL SOC UK, V94, P938; ARMOUR JAL, 1989, GENOMICS, V4, P328, DOI 10.1016/0888-7543(89)90338-8; CAVENEE W, 1984, AM J HUM GENET, V36, P10; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHAN H, 1977, J NATL CANCER I, V58, P205, DOI 10.1093/jnci/58.2.205; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CUTLER SJ, 1982, AUA MONOGRAPHS BLADD, V1, P35; DERKINDEREN DJ, 1988, INT J CANCER, V41, P499, DOI 10.1002/ijc.2910410405; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; KAYE KW, 1982, J UROLOGY, V128, P31, DOI 10.1016/S0022-5347(17)52738-X; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEPPERT M, 1986, AM J HUM GENET, V39, P425; LI SB, 1991, J NATL CANCER I, V83, P637, DOI 10.1093/jnci/83.9.637; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; PROCTOR AJ, 1991, ONCOGENE, V6, P789; SANDERS BM, 1989, BRIT J CANCER, V60, P358, DOI 10.1038/bjc.1989.285; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TARKKANEN A, 1984, OPHTHALMOLOGICA, V189, P143, DOI 10.1159/000309401; VARLEY JM, 1989, ONCOGENE, V4, P725; WADEY RB, 1990, ONCOGENE, V5, P901; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; YANDELL DW, 1991, CANCER RES, V32, P459; ZHU XP, 1989, NATURE, V340, P312, DOI 10.1038/340312a0; 1978, UNION INT CANCER	32	173	176	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2305	2309						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766677				2022-12-25	WOS:A1991GX73500019
J	FISHER, RJ; MAVROTHALASSITIS, G; KONDOH, A; PAPAS, TS				FISHER, RJ; MAVROTHALASSITIS, G; KONDOH, A; PAPAS, TS			HIGH-AFFINITY DNA PROTEIN INTERACTIONS OF THE CELLULAR ETS1 PROTEIN - THE DETERMINATION OF THE ETS BINDING MOTIF	ONCOGENE			English	Article							LONG TERMINAL REPEAT; GEL-ELECTROPHORESIS; SEQUENCE; PHOSPHORYLATION; OPERATOR; COMPLEX; DOMAIN; VIRUS; GENE	ETS1 protein purified from CEM cells was used to select its optimum DNA-binding sequence (pu) G/CC(a)GGA-AGT(c) (py). The sequence CCGGAAGT (ETS1-3) was preferred 5:1 over CAGGAAGT (PEA3). Quantitative electrophoretic mobility-shift assays (EMSA) indicated that the purified ETS1 protein binds to either ETS1-3 or PEA3 oligonucleotide probes with high affinity (K(a) = 0.5-4.0 x 10(10) M-1) and that the purified ETS1 has different binding capacities for ETFS1-3 and PEA3 oligonucleotide probes. The ETS1 protein binds 2-5 times more ETS1-3 than PEA3. Competitive binding experiments showed that the ETS1-3 and PEA3 probes effectively compete for the binding of ETS1-3. However, changing the core DNA-binding sequence from GGAA to AGAA eliminates competition. Since the human ETS1 protein selected the same DNA sequence from a mixture of random oligonucleotides as did the Drosophila E74A protein (one of the most divergent members of the ETS family), this strongly suggests that all proteins containing the ETS 85 amino acid domain (sequences which define the ETS family) will bind to the same sequence.	NCI,FREDERICK CANC RES & DEV CTR,MOLEC ONCOL LAB,POB B,FREDERICK,MD 21702; DYNCORP,PROGRAM RESOURCES INC,FREDERICK CANC RES & DEV CTR,CELLULAR BIOCHEM LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Fisher, Robert/B-1431-2009					BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CANN JR, 1989, J BIOL CHEM, V264, P17032; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HUBBARD AJ, 1990, BIOCHEMISTRY-US, V29, P9241, DOI 10.1021/bi00491a019; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOIZUMI S, 1990, ONCOGENE, V5, P675; LABARCA C, 1980, ANAL BIOCHEM, V100, P188; LIN S, 1972, J MOL BIOL, V72, P71; MAVROTHALASSITIS G, 1990, DNA CELL BIOL, V9, P783, DOI 10.1089/dna.1990.9.783; MEISTERERNST M, 1988, NUCLEIC ACIDS RES, V16, P4419, DOI 10.1093/nar/16.10.4419; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; SETH A, 1991, IN PRESS TRENDS GENE; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; ZABEL U, 1991, J BIOL CHEM, V266, P252	23	94	95	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2249	2254						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766672				2022-12-25	WOS:A1991GX73500011
J	TAHIRA, T; ISHIZAKA, Y; ITOH, F; NAKAYASU, M; SUGIMURA, T; NAGAO, M				TAHIRA, T; ISHIZAKA, Y; ITOH, F; NAKAYASU, M; SUGIMURA, T; NAGAO, M			EXPRESSION OF THE RET PROTOONCOGENE IN HUMAN NEUROBLASTOMA CELL-LINES AND ITS INCREASE DURING NEURONAL DIFFERENTIATION INDUCED BY RETINOIC ACID	ONCOGENE			English	Article							BLASTOMA CELLS; MESSENGER-RNA; PROTOONCOGENE; SEQUENCE; MORPHOLOGY; INVITRO; TISSUES; FAMILY; GENE	Previously we observed specific expression of the ret proto-oncogene (proto-ret) in human neuroblastoma cell lines. A neuronal subline and non-neuronal sublines were isolated from the SK-N-SH cell line, which is composed of a heterogeneous cell population. Expression of proto-ret was defected in the neuronal subline, named SH-4305, but not in three non-neuronal sublines. Expression of proto-ret in the SH-4305 cells increased markedly after treatment with retinoic acid for 1 day, with concomitant morphological change, namely neurite outgrowth, and induction of neurofilament mRNA expression. Induction of proto-ret mRNA was observed in all seven neuroblastoma cell lines tested, being highest in the line with the lowest basal level of proto-ret expression. The induction of proto-ret expression seemed to be correlated with neurite outgrowth and increase of neurofilament mRNA expression. These data suggest that the proto-ret product plays a role in neuronal differentiation.	NATL CANC CTR,RES INST,DIV CARCINOGENESIS,1-1 TSUKIJI 5 CHOME,CHUO KU,TOKYO 104,JAPAN	National Cancer Center - Japan								ABEMAYOR E, 1989, ENVIRON HEALTH PERSP, V80, P3, DOI 10.2307/3430727; BIEDLER JL, 1973, CANCER RES, V33, P2643; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICCARONE V, 1989, CANCER RES, V49, P219; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HALL BK, 1988, NEURAL CREST, P96; IKEDA I, 1990, ONCOGENE, V5, P1291; ISHIKAWA S, 1977, ACTA PATHOL JAPON, V27, P697; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; ITOH F, 1989, Tumor Research, V24, P1; MYERS MW, 1987, EMBO J, V6, P1617, DOI 10.1002/j.1460-2075.1987.tb02409.x; NAGAO M, 1990, JPN J CANCER RES, V81, P309, DOI 10.1111/j.1349-7006.1990.tb02566.x; PAHLMAN S, 1984, CELL DIFFER DEV, V14, P135, DOI 10.1016/0045-6039(84)90038-1; RETTIG WJ, 1987, CANCER RES, V47, P1383; REYNOLDS CP, 1988, ADV NEUROBLASTOMA RE, V2, P291; ROSS RA, 1983, J NATL CANCER I, V71, P741; ROSS RA, 1980, ADV NEUROBLASTOMA RE, P151; SANTORO M, 1990, ONCOGENE, V5, P1595; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SIDELL N, 1986, EXP CELL BIOL, V54, P287; SZENTIRMAY Z, 1990, ONCOGENE, V5, P701; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; THIELE CJ, 1988, ONCOGENE, V3, P281; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; TSOKOS M, 1987, AM J PATHOL, V128, P484; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110	30	70	70	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2333	2338						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766678				2022-12-25	WOS:A1991GX73500023
J	HU, RJ; BENNETT, V				HU, RJ; BENNETT, V			INVITRO PROTEOLYSIS OF BRAIN SPECTRIN BY CALPAIN-I INHIBITS ASSOCIATION OF SPECTRIN WITH ANKYRIN-INDEPENDENT MEMBRANE-BINDING SITE(S)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE SPECTRIN; DEPENDENT PROTEASE-I; PROTEINS; ACTIN; CALMODULIN; FODRIN; CELLS; IDENTIFICATION; PURIFICATION; DEGRADATION	This report demonstrates that specific proteolysis of brain spectrin by a calcium-dependent protease, calpain I, abolishes association of brain spectrin with the ankyrin-independent binding site(s) in brain membranes. Calpain I cleaves the beta-subunit of spectrin at the N-terminal end leaving a 218-kDa fragment and cleaves the alpha-subunit in the midregion to produce 150- and 130-kDa fragments. Calpain-proteolyzed spectrin almost completely loses the capacity to displace binding of intact spectrin to membranes. Spectrin digested by calpain I under conditions that almost completely destroyed membrane-binding remained associated as a tetramer and retained about 60% of the ability to associate with actin filaments. Cleavage of spectrin occurred at sites distinct from the membrane-binding site which is located on the beta-subunit since the isolated 218-kDa fragment of the beta-subunit as well as a reconstituted complex of alpha and 218-kDa beta-subunit fragment partially regained binding activity. Moreover, cleavage of the alpha-subunit alone reduced the affinity of spectrin for membranes by 2-fold. A consequence of distinct sites for calpain I cleavage and membrane-binding is that calpain I can digest spectrin while spectrin is complexed with other proteins and therefore has the potential to mediate disassembly of a spectrin-actin network from membranes.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University	HU, RJ (corresponding author), DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA.				NIADDK NIH HHS [AM-19808] Funding Source: Medline; NIGMS NIH HHS [GM-33996] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM019808] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033996] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bennett V, 1990, CURR OPIN CELL BIOL, V2, P51, DOI 10.1016/S0955-0674(05)80030-4; BENNETT V, 1986, METHOD ENZYMOL, V134, P55; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; COLEMAN TR, 1989, CELL MOTIL CYTOSKEL, V12, P225, DOI 10.1002/cm.970120405; DAVIS J, 1983, J BIOL CHEM, V258, P7757; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FOX JEB, 1987, BLOOD, V69, P537; GOODMAN SR, 1988, CRIT REV BIOCHEM MOL, V23, P171, DOI 10.3109/10409238809088319; GOODMAN SR, 1989, BRAIN RES BULL, V23, P311, DOI 10.1016/0361-9230(89)90214-1; GOPALAKRISHNA R, 1985, ANAL BIOCHEM, V148, P413, DOI 10.1016/0003-2697(85)90247-7; HARRIS AS, 1989, J BIOL CHEM, V264, P17401; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; IVY G, 1988, BRAIN RES, V459, P233, DOI 10.1016/0006-8993(88)90639-7; JESAITIS AJ, 1988, J CELL BIOL, V107, P921, DOI 10.1083/jcb.107.3.921; KARINCH AM, 1990, J BIOL CHEM, V265, P11833; MORROW JS, 1980, P NATL ACAD SCI-BIOL, V77, P6592, DOI 10.1073/pnas.77.11.6592; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; PERRIN D, 1987, NATURE, V326, P498, DOI 10.1038/326498a0; POLLERBERG GE, 1987, CELL TISSUE RES, V250, P227, DOI 10.1007/BF00214676; PONTREMOLI S, 1986, ANNU REV BIOCHEM, V55, P455, DOI 10.1146/annurev.biochem.55.1.455; RIEDERER BM, 1986, J CELL BIOL, V102, P2088, DOI 10.1083/jcb.102.6.2088; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; SIMAN R, 1989, J NEUROSCI, V9, P1579; STEINER JP, 1988, J BIOL CHEM, V263, P14417; STEINER JP, 1989, J BIOL CHEM, V264, P2783; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693	28	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18200	18205						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1833394				2022-12-25	WOS:A1991GG55300074
J	YOSHIMORI, T; YAMAMOTO, A; MORIYAMA, Y; FUTAI, M; TASHIRO, Y				YOSHIMORI, T; YAMAMOTO, A; MORIYAMA, Y; FUTAI, M; TASHIRO, Y			BAFILOMYCIN-A1, A SPECIFIC INHIBITOR OF VACUOLAR-TYPE H+-ATPASE, INHIBITS ACIDIFICATION AND PROTEIN-DEGRADATION IN LYSOSOMES OF CULTURED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TRANSLOCATING ATPASE; MEMBRANES; TRANSPORT; TRIPHOSPHATASE; MICROORGANISMS; COMPLEX; SITE	Bafilomycin A1 is known as a strong inhibitor of the vacuolar type H+-ATPase in vitro, whereas other type ATPases, e.g. F1,F0-ATPase, are not affected by this antibiotic (Bowman, E. M., Siebers, A., and Altendorf, K. (1988) Proc. Natl. Acad. Sci. U.S.A. 85, 7972-7976). Effects of this inhibitor on lysosomes of living cultured cells were tested. The acidification of lysosomes revealed by the incubation with acridine orange was completely inhibited when BNL CL.2 and A431 cells were treated with 0.1-1-mu-M bafilomycin A1. The effect was reversed by washing the cells. Both studies using 3-(2,4-dinitroanilino)-3'-amino-N-methyldipropylamine and fluorescein isothiocyanate-dextran showed that the intralysosomal pH of A431 cells increased from about 5.1-5.5 to about 6.3 in the presence of 1-mu-M bafilomycin A1. The pH increased gradually in about 50 min. In the presence of 1-mu-M bafilomycin A1, I-125-labeled epidermal growth factor (EGF) bound to the cell surface at 4-degrees-C was internalized normally into the cells at 37-degrees-C but was not degraded at all, in marked contrast to the rapid degradation of I-125-EGF in the control cells without the drug. Immunogold electron microscopy showed that EGF was transported into lysosomes irrespective of the addition of bafilomycin A1. These results suggest that the vacuolar type H+-ATPase plays a pivotal role in acidification and protein degradation in the lysosomes in vivo.	KANSAI MED UNIV,DEPT PHYSIOL,FUMIZONO CHO 1,MORIGUCHI,OSAKA 570,JAPAN; OSAKA UNIV,INST SCI & IND RES,DEPT ORGAN CHEM & BIOCHEM,IBARAKI,OSAKA 567,JAPAN	Kansai Medical University; Osaka University								ALLISON AC, 1969, LYSOSOMES BIOLOGY PA, V2, P600; ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; BARRETT AJ, 1972, LYSOSOMES LABORATORY, P46; BOWMAN BJ, 1986, J MEMBRANE BIOL, V94, P83, DOI 10.1007/BF01871190; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; GEISOW MJ, 1980, EXP CELL RES, V126, P159, DOI 10.1016/0014-4827(80)90481-4; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HANADA H, 1990, BIOCHEM BIOPH RES CO, V170, P873, DOI 10.1016/0006-291X(90)92172-V; Holtzman E., 1989, LYSOSOMES, P95; KLAUSNER RD, 1989, CELL, V57, P703, DOI 10.1016/0092-8674(89)90783-6; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; MORIYAMA Y, 1990, J BIOL CHEM, V265, P9165; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; MORIYAMA Y, 1989, BIOCHIM BIOPHYS ACTA, V980, P241, DOI 10.1016/0005-2736(89)90405-7; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; ROTH J, 1981, J HISTOCHEM CYTOCHEM, V29, P663, DOI 10.1177/29.5.6166664; SUNDQUIST K, 1990, BIOCHEM BIOPH RES CO, V168, P309, DOI 10.1016/0006-291X(90)91709-2; TSUNODA Y, 1989, J HISTOCHEM CYTOCHEM, V37, P999, DOI 10.1177/37.7.2732461; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMATA T, 1990, J BIOL CHEM, V265, P21940; WERNER G, 1984, J ANTIBIOT, V37, P110, DOI 10.7164/antibiotics.37.110; XIE XS, 1986, J BIOL CHEM, V261, P2492; YOSHIMORI T, 1990, J BIOL CHEM, V265, P15984	30	1028	1040	2	49	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17707	17712						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1832676				2022-12-25	WOS:A1991GF44500107
J	AOKI, M; AKIYAMA, T; MIYOSHI, J; TOYOSHIMA, K				AOKI, M; AKIYAMA, T; MIYOSHI, J; TOYOSHIMA, K			IDENTIFICATION AND CHARACTERIZATION OF PROTEIN PRODUCTS OF THE COT ONCOGENE WITH SERINE KINASE-ACTIVITY	ONCOGENE			English	Article							GROWTH-FACTORS; ACTIVATION; INVITRO; INSULIN; FAMILY	The products of the cot gene, a novel oncogene isolated by DNA transfection assay using the hamster cell line SHOK, were identified as 46 kDa and 52 kDa proteins by using anti-peptide antibodies. The 46kDa and 52kDa proteins both showed autophosphorylation activity at serine residues. The two forms of the Cot protein were suggested to differ in their amino-terminal structures as a result of alternative initiation of translation. Subcellular fractionation revealed that the 46kDa and 52kDa proteins are both predominantly localized in the cytosol. These Cot proteins are the fourth oncogene products with serine kinase activity identified.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT ONCOGENE RES,3-1 YAMADA OKA,SUITA,OSAKA 565,JAPAN	Osaka University			Aoki, Masahiro/A-5149-2016	Aoki, Masahiro/0000-0003-4316-9490				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; ERIKSON E, 1987, MOL CELL BIOL, V7, P3147, DOI 10.1128/MCB.7.9.3147; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIGASHI T, 1990, P NATL ACAD SCI USA, V87, P2409, DOI 10.1073/pnas.87.7.2409; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KLOETZER WS, 1984, VIROLOGY, V138, P143, DOI 10.1016/0042-6822(84)90154-5; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MIYOSHI J, 1991, IN PRESS MOL CELL BI; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SELTEN G, 1986, CELL, V46, P606; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	25	37	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1515	1519						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1833717				2022-12-25	WOS:A1991GX27400004
J	RICHARDSON, JM; BALON, TW; TREADWAY, JL; PESSIN, JE				RICHARDSON, JM; BALON, TW; TREADWAY, JL; PESSIN, JE			DIFFERENTIAL REGULATION OF GLUCOSE TRANSPORTER ACTIVITY AND EXPRESSION IN RED AND WHITE SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOZOTOCIN DIABETIC RATS; INSULIN-RESPONSIVE TISSUES; PLASMA-MEMBRANE; MESSENGER-RNA; ADIPOSE-CELLS; PROTEIN; METABOLISM; TRANSLOCATION; CLONING; GLUT4	Insulin-stimulated glucose transport activity and GLUT4 glucose transporter protein expression in rat soleus, red-enriched, and white-enriched skeletal muscle were examined in streptozotocin (STZ)-induced insulin-deficient diabetes. Six days of STZ-diabetes resulted in a nearly complete inhibition of insulin-stimulated glucose transport activity in perfused soleus, red, and white muscle which recovered following insulin therapy. A specific decrease in the GLUT4 glucose transporter protein was observed in soleus (3-fold) and red (2-fold) muscle which also recovered to control values with insulin therapy. Similarly, cardiac muscle displayed a marked STZ-induced decrease in GLUT4 protein that was normalized by insulin therapy. White muscle displayed a small but statistically significant decrease in GLUT4 protein (23%), but this could not account for the marked inhibition of insulin-stimulated glucose transport activity observed in this tissue. In addition, GLUT4 mRNA was found to decrease in red muscle (2-fold) with no significant alteration in white muscle. The effect of STZ-induced diabetes was time-dependent with maximal inhibition of insulin-stimulated glucose transport activity at 24 h in both red and white skeletal muscle and half-maximal inhibition at approximately 8 h. In contrast, GLUT4 protein in red and white muscle remained unchanged until 4 and 7 days following STZ treatment, respectively. These data demonstrate that red skeletal muscle displays a more rapid hormonal/metabolic-dependent regulation of GLUT4 glucose transporter protein and mRNA expression than white skeletal muscle. In addition, the inhibition of insulin-stimulated glucose transport activity in both red and white muscle precedes the decrease in GLUT4 protein and mRNA levels. Thus, STZ treatment initially results in a rapid uncoupling of the insulin-mediated signaling of glucose transport activity which is independent of GLUT4 protein and mRNA levels.	UNIV IOWA, DEPT EXERCISE SCI, IOWA CITY, IA 52242 USA	University of Iowa	PESSIN, JE (corresponding author), UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA.			/0000-0003-1359-7830	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039974] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL14388] Funding Source: Medline; NIAMS NIH HHS [AR39974] Funding Source: Medline; NIDDK NIH HHS [DK25925] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARMSTRONG RB, 1984, AM J ANAT, V171, P259, DOI 10.1002/aja.1001710303; BARNARD RJ, 1990, ENDOCRINOLOGY, V126, P1921, DOI 10.1210/endo-126-4-1921; BARON AD, 1988, AM J PHYSIOL, V255, pE769, DOI 10.1152/ajpendo.1988.255.6.E769; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BURANT CF, 1986, J CLIN INVEST, V77, P260, DOI 10.1172/JCI112285; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DEFRONZO RA, 1985, J CLIN INVEST, V76, P149, DOI 10.1172/JCI111938; DOHM GL, 1991, AM J PHYSIOL, V260, pE459, DOI 10.1152/ajpendo.1991.260.3.E459; FLIER JS, 1987, J CLIN INVEST, V79, P657, DOI 10.1172/JCI112864; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; GHERZI R, 1986, BIOCHEM BIOPH RES CO, V140, P850, DOI 10.1016/0006-291X(86)90712-6; GOODMAN MN, 1974, DIABETES, V23, P881, DOI 10.2337/diab.23.11.881; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1985, AM J PHYSIOL, V248, pE567, DOI 10.1152/ajpendo.1985.248.5.E567; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAHN BB, 1989, J CLIN INVEST, V84, P404, DOI 10.1172/JCI114180; KATZ A, 1988, AM J PHYSIOL, V255, pE942, DOI 10.1152/ajpendo.1988.255.6.E942; KERN M, 1990, BIOCHEM J, V270, P397, DOI 10.1042/bj2700397; KLIP A, 1987, FEBS LETT, V224, P224, DOI 10.1016/0014-5793(87)80452-0; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; OKA Y, 1988, J BIOL CHEM, V263, P13432; PEDERSEN O, 1990, DIABETES, V39, P865, DOI 10.2337/diabetes.39.7.865; PETER JB, 1972, BIOCHEMISTRY-US, V11, P2627, DOI 10.1021/bi00764a013; RAMLAL T, 1989, ENDOCRINOLOGY, V125, P890, DOI 10.1210/endo-125-2-890; RICHTER EA, 1984, AM J PHYSIOL, V246, pE476, DOI 10.1152/ajpendo.1984.246.6.E476; RUDERMAN NB, 1971, BIOCHEM J, V124, P639, DOI 10.1042/bj1240639; SIVITZ WI, 1989, NATURE, V340, P72, DOI 10.1038/340072a0; STROUT HV, 1990, ENDOCRINOLOGY, V126, P2728, DOI 10.1210/endo-126-5-2728; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; WALLBERGHENRIKSSON H, 1986, ACTA PHYSIOL SCAND, V128, P647, DOI 10.1111/j.1748-1716.1986.tb08025.x; ZORZANO A, 1989, J BIOL CHEM, V264, P12358; ZORZANO A, 1985, AM J PHYSIOL, V248, pE546, DOI 10.1152/ajpendo.1985.248.5.E546	40	106	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12690	12694						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1829459				2022-12-25	WOS:A1991FV18000091
J	FANE, B; VILLAFANE, R; MITRAKI, A; KING, J				FANE, B; VILLAFANE, R; MITRAKI, A; KING, J			IDENTIFICATION OF GLOBAL SUPPRESSORS FOR TEMPERATURE-SENSITIVE FOLDING MUTATIONS OF THE P22 TAILSPIKE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAIL-SPIKE PROTEIN; AMINO-ACID REPLACEMENTS; SALMONELLA PHAGE-P22; NONSENSE MUTATIONS; RAMAN-SPECTROSCOPY; THERMAL-STABILITY; POLYPEPTIDE-CHAIN; ESCHERICHIA-COLI; GENETIC-ANALYSIS; MUTANT PROTEINS	Suppressor mutations which alleviate the defects in folding mutants of the P22 gene 9 tailspike protein have recently been isolated (Fane, B. and King, J. (1991) Genetics 127, 263-277). The starting folding defects were in missense polypeptide chains generated by host amino acid insertions at different amber mutant sites. Fragments of genes carrying the amber mutations with and without their independently isolated suppressor mutations were cloned and sequenced. The parental nonsense mutations were located at Q45, K122, E156, W202, W207, Y232, and W365. Their conformational suppressors were single amino acid substitutions at a limited set of sites, V84 > A, V331 > A, and A334 > V. The V331 > A or A334 > V suppressors were independently recovered starting with different mutant sites suggesting that they acted by some global or general mechanism. When the V331 > A and A334 > V mutations were crossed into well-characterized temperature-sensitive folding (tsf) mutants at various sites in the tailspike protein, they suppressed all of the eight tsf mutants tested. Since the tsf defects destabilize folding intermediates rather than the native conformation, this result implies that the suppressors act in the folding pathway. Strains carrying the isolated suppressor mutations displayed no obvious phenotypic defect and formed native biologically active tailspikes. Thus, these single amino acid substitutions have striking influences on the efficiency of intracellular chain folding, without causing functional defects in the native protein.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)			MITRAKI, Anna/A-6034-2014	MITRAKI, Anna/0000-0001-5072-1939				ALBER T, 1989, ANNU REV BIOCHEM, V58, P765, DOI 10.1146/annurev.biochem.58.1.765; ALBER T, 1985, P NATL ACAD SCI USA, V82, P747, DOI 10.1073/pnas.82.3.747; ALBER T, 1987, NATURE, V330, P41, DOI 10.1038/330041a0; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BERGET PB, 1980, J VIROL, V34, P234, DOI 10.1128/JVI.34.1.234-243.1980; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOTSTEIN D, 1973, J MOL BIOL, V80, P669, DOI 10.1016/0022-2836(73)90204-0; CHEN BL, 1991, IN PRESS BIOCHEMISTR, V30; FANE B, 1987, GENETICS, V117, P157; FANE B, 1991, GENETICS, V127, P263; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; GOLDENBERG DP, 1981, J MOL BIOL, V145, P633, DOI 10.1016/0022-2836(81)90307-7; GOLDENBERG DP, 1988, ANNU REV BIOPHYS BIO, V17, P481; GOLDENBERG DP, 1983, P NATL ACAD SCI-BIOL, V80, P7060, DOI 10.1073/pnas.80.23.7060; GOLDENBERG DP, 1982, J BIOL CHEM, V257, P7864; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRUTTER MG, 1987, J MOL BIOL, V197, P775; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; HECHT MH, 1984, P NATL ACAD SCI-BIOL, V81, P5685, DOI 10.1073/pnas.81.18.5685; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; IWASHITA S, 1976, EUR J BIOCHEM, V65, P87, DOI 10.1111/j.1432-1033.1976.tb10392.x; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KING J, 1990, N HORIZ TH, P59; KING J, 1971, J MOL BIOL, V62, P465, DOI 10.1016/0022-2836(71)90148-3; KING J, 1986, BIO-TECHNOL, V4, P297, DOI 10.1038/nbt0486-297; KING J, 1989, PROTEIN FOLDING DECI, P225; KING J, 1986, PROTEIN ENG APPLICAT, P275; KLIG LS, 1988, GENETICS, V120, P651; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MATSUMURA M, 1986, NATURE, V323, P356, DOI 10.1038/323356a0; MATSUMURA M, 1985, J BIOL CHEM, V260, P5298; MAURIDES PA, 1990, GENETICS, V125, P673; MILLER JH, 1979, J MOL BIOL, V131, P191, DOI 10.1016/0022-2836(79)90073-1; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; MITRAKI A, 1991, ACS SYM SER, V470; REIDHAAROLSON JF, 1988, SCIENCE, V241, P53, DOI 10.1126/science.3388019; SARGENT D, 1988, J MOL BIOL, V199, P491, DOI 10.1016/0022-2836(88)90620-1; SAUER RT, 1982, BIOCHEMISTRY-US, V21, P5811, DOI 10.1021/bi00266a014; SCHWARZ JJ, 1989, J BIOL CHEM, V264, P20112; SCHWARZ JJ, 1989, GENETICS, V125, P673; SECKLER R, 1989, J BIOL CHEM, V264, P11750; SHORTLE D, 1985, GENETICS, V110, P539; SHORTLE D, 1986, PROTEIN ENG APPLICAT, P233; SMITH DH, 1981, J MOL BIOL, V145, P653, DOI 10.1016/0022-2836(81)90308-9; SMITH DH, 1980, GENETICS, V96, P331; STROUP AN, 1990, BIOCHEMISTRY-US, V29, P9765, DOI 10.1021/bi00494a002; STURTEVANT JM, 1989, J BIOL CHEM, V264, P10693; THOMAS GJ, 1990, BIOCHEMISTRY-US, V29, P4181, DOI 10.1021/bi00469a022; VILLAFANE R, 1988, J MOL BIOL, V204, P607, DOI 10.1016/0022-2836(88)90359-2; WETZEL R, 1991, IN PRESS BIOTECHNOLO; WINSTON F, 1979, J BACTERIOL, V137, P433, DOI 10.1128/JB.137.1.433-439.1979; YU MH, 1988, J BIOL CHEM, V263, P1424; YU MH, 1984, P NATL ACAD SCI-BIOL, V81, P6584, DOI 10.1073/pnas.81.21.6584	55	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11640	11648						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1828803				2022-12-25	WOS:A1991FT76200037
J	SCHINZEL, R				SCHINZEL, R			ACTIVE-SITE LYSINE PROMOTES CATALYTIC FUNCTION OF PYRIDOXAL 5'-PHOSPHATE IN ALPHA-GLUCAN PHOSPHORYLASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI MALTODEXTRIN PHOSPHORYLASE; ESCHERICHIA-COLI; PHOSPHATE	Tight contact of pyridoxal 5'-phosphate to the substrate phosphate is considered to be a crucial requirement of the phosphorolytic cleavage of polysaccharides by glycogen phosphorylases. This study demonstrates an essential role of lysine 533, the only charged residue in hydrogen bond distance to the phosphate of pyridoxal 5'-phosphate in Escherichia coli maltodextrin phosphorylase. Substitution of Lys533 by Ser reduced the turnover number 600-fold. Addition of monovalent cations significantly increased activity of the Lys533-Ser mutant up to a factor of 10, whereas the apparent affinity for P(i) was decreased up to 80-fold. Although substitution of Lys533 by Gln caused a similar reduction of k(cat), the K(m) values remained unchanged, and no response to small cations was observed. These results suggest a key role of the positive charge contributed by Lys533 in catalysis, most probably in maintaining the electrostatic neutrality of the pyridoxal 5'-phosphate and aligning the close phosphate-phosphate contacts indispensable for the proton transfer mechanism.			SCHINZEL, R (corresponding author), UNIV WURZBURG BIOZENTRUM,DEPT PHYSIOL CHEM,W-8700 WURZBURG,GERMANY.							BLOCH MA, 1986, J BACTERIOL, V168, P1220, DOI 10.1128/jb.168.3.1220-1227.1986; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HELMREICH E, 1964, P NATL ACAD SCI USA, V51, P131, DOI 10.1073/pnas.51.1.131; HOWELL EE, 1986, SCIENCE, V231, P1123, DOI 10.1126/science.3511529; Johnson L. N., 1989, ALLOSTERIC ENZYMES, P81; JOHNSON LN, 1990, J MOL BIOL, V211, P645, DOI 10.1016/0022-2836(90)90271-M; KRAMER W, 1987, METHOD ENZYMOL, V154, P330; MADSEN NB, 1986, COENZYMES COFACTORS, P1; Maniatis T, 1989, DECONTAMINATION DILU; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; PALM D, 1985, NATURE, V313, P500, DOI 10.1038/313500a0; PALM D, 1990, BIOCHEMISTRY-US, V29, P1099, DOI 10.1021/bi00457a001; PALM D, 1986, Z NATURFORSCH C, V42, P394; Pauling L., 1948, NATURE CHEM BOND; SAHEKI S, 1985, ANAL BIOCHEM, V148, P277, DOI 10.1016/0003-2697(85)90229-5; SCHACHTELE KH, 1978, EUR J BIOCHEM, V92, P427, DOI 10.1111/j.1432-1033.1978.tb12763.x; SCHINZEL R, 1990, BIOCHEMISTRY-US, V29, P9956, DOI 10.1021/bi00494a028; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; WADA H, 1961, J BIOL CHEM, V236, P2089; [No title captured]	21	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9428	9431						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1827794				2022-12-25	WOS:A1991FM45900017
J	ENYEDI, A; FILOTEO, AG; GARDOS, G; PENNISTON, JT				ENYEDI, A; FILOTEO, AG; GARDOS, G; PENNISTON, JT			CALMODULIN-BINDING DOMAINS FROM ISOZYMES OF THE PLASMA-MEMBRANE CA2+ PUMP HAVE DIFFERENT REGULATORY PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+ PUMP; MOLECULAR-CLONING; CA-2+-TRANSPORTING ATPASE; ERYTHROCYTE-MEMBRANE; FUNCTIONAL DOMAINS; ISOFORMS; RECONSTITUTION; TRANSPORT; SITES; BRAIN	Peptides C28R2 and C28R1A, representing the two main alternative classes of calmodulin-binding domains from the plasma membrane Ca2+ pump, were tested for their calmodulin-binding properties and for their capacity to interact with pump from which the calmodulin-binding domain had been removed by chymotryptic proteolysis. Peptide C28R2 was more effective in both capacities. Binding of peptide to calmodulin was measured by competition experiments. Such experiments indicated that K(i) for C28R2 as an inhibitor of the pump-calmodulin interaction was 0.1 nM, whereas C28R1A had a K(i) of 1 nM. Interaction of peptide with chymotryptically activated Ca2+ pump was measured by observing the inhibition by peptide of active Ca2+ transport into inside-out membrane vesicles at low Ca2+. Those experiments showed that C28R2 interacted relatively strongly (an IC50 of 1-mu-M), whereas C28R1A had an IC50 of 15-mu-M. The calmodulin-binding peptides had effects on both the K1/2 for Ca2+ and the V(max) of the proteolyzed pump. The effects on the K1/2 for Ca2+ were related to the net plus charge on the peptide, with the most positive peptides being most effective in competing with Ca2+. The substantial differences between C28R2 and C28R1A suggest that Ca2+ pumps containing calmodulin-binding domains like C28R1A have lower calmodulin affinities and higher activities in the absence of activator.	MAYO CLIN & MAYO FDN, DEPT BIOCHEM & MOLEC BIOL, ROCHESTER, MN 55905 USA; NATL INST HAEMATOL & BLOOD TRANSFUS, H-1113 BUDAPEST, HUNGARY	Mayo Clinic			Enyedi, Agnes/N-9742-2013	Enyedi, Agnes/0000-0002-7366-9376	NIGMS NIH HHS [GM 28835] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ENYEDI A, 1989, J BIOL CHEM, V264, P12313; GREEB J, 1989, J BIOL CHEM, V264, P18569; JAMES P, 1988, J BIOL CHEM, V263, P2905; LINDBERG O, 1956, METHODS BIOCHEMICAL, V3, P1; MANN DM, 1990, ADV EXP MED BIOL, V255, P71; MCCORMICK DJ, 1987, J IMMUNOL, V139, P2615; NIGGLI V, 1981, J BIOL CHEM, V256, P395; PAPP B, 1989, J BIOL CHEM, V264, P4577; PENNISTON JT, 1988, METHOD ENZYMOL, V157, P340; SARKADI B, 1980, BIOCHIM BIOPHYS ACTA, V598, P326, DOI 10.1016/0005-2736(80)90010-3; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008	15	69	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8952	8956						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1827440				2022-12-25	WOS:A1991FM03800047
J	FUJIMOTO, K; KORNFELD, R				FUJIMOTO, K; KORNFELD, R			ALPHA-GLUCOSIDASE II-DEFICIENT CELLS USE ENDO ALPHA-MANNOSIDASE AS A BYPASS ROUTE FOR N-LINKED OLIGOSACCHARIDE PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; GLYCOPROTEIN; ENZYME	The kinetics of N-linked oligosaccharide processing and the structures of the processing intermediates have been examined in normal parental BW5147 mouse lymphoma cells and the alpha-glucosidase II-deficient PHA(R)2.7 mutant cells. The mutant cells accumulated glucosylated intermediates but were able to deglucosylate and process about 40% of their oligosaccharides to complex-type. This processing was not due to residual alpha-glucosidase II activity since the alpha-glucosidase inhibitors 1-deoxynojirimycin (DNJ) and N-butyl-DNJ did not prevent it. Parent cells also showed alpha-glucosidase II-independent processing in the presence of DNJ and N-butyl-DNJ. Membrane preparations from both parent and mutant cells had endo alpha-mannosidase activity, that is, split Glc1,2Man9GlcNAc to Glc1,2Man plus Man8GlcNAc, indicating that this was a candidate for an alternate route to complex oligosaccharide formation in the mutant cells. A balance study in which the cellular glycoproteins, intracellular water soluble saccharides, and saccharides secreted into the medium were isolated and analyzed from [2-H-3]mannose-labeled mutant cells showed that the cells formed the di- and trisaccharides Glc1Man and Glc2Man in amounts equivalent to the deglucosylated oligosaccharides found in the cellular glycoproteins. This result shows unequivocally that the alpha-glucosidase II-deficient mutant cells use endo alpha-mannosidase as a bypass route for N-linked oligosaccharide processing.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL)	FUJIMOTO, K (corresponding author), WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV HEMATOL ONCOL,ST LOUIS,MO 63110, USA.				NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NCI NIH HHS [CA08759] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISCHOFF J, 1986, J BIOL CHEM, V261, P4768; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; MELLIS SJ, 1981, ANAL BIOCHEM, V114, P276, DOI 10.1016/0003-2697(81)90480-2; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; REITMAN ML, 1982, J BIOL CHEM, V257, P357; ROMERO PA, 1986, J BIOL CHEM, V261, P5936; SAUNIER B, 1982, J BIOL CHEM, V257, P4155; TREVELYAN WE, 1950, NATURE, V166, P444, DOI 10.1038/166444b0; TROWBRIDGE IS, 1978, EUR J IMMUNOL, V8, P716, DOI 10.1002/eji.1830081009	14	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3571	3578						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1825311				2022-12-25	WOS:A1991EY68200037
J	OSHIMA, M; SITHANANDAM, G; RAPP, UR; GUROFF, G				OSHIMA, M; SITHANANDAM, G; RAPP, UR; GUROFF, G			THE PHOSPHORYLATION AND ACTIVATION OF B-RAF IN PC12-CELLS STIMULATED BY NERVE GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 PHEOCHROMOCYTOMA CELLS; PROTEIN KINASE-C; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; CHROMAFFIN CELLS; FIBER OUTGROWTH; FAMILY; INCREASE; K-252A; DIFFERENTIATION	Treatment of PC12 cells with nerve growth factor does not alter the levels of B-raf mRNA, but does induce rapid phosphorylation of B-raf proteins. Phosphorylation was observed after 1.5 min and reached a maximum by 10-15 min. B-raf protein was phosphorylated almost exclusively on serine residues; no tyrosine phosphorylation was detected. Nerve growth factor-induced phosphorylation was not affected by depletion of protein kinase C or by removal of extracellular calcium but was inhibited by K-252a. Concomitant with the increase in serine phosphorylation, nerve growth factor treatment also increased the serine/threonine kinase activity of B-raf protein within 1-2 min.	NCI, FREDERICK CANC RES & DEV CTR, VIRAL PATHOL SECT, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	OSHIMA, M (corresponding author), NICHHD, GROWTH FACTORS SECT, BLDG 6, RM 130, BETHESDA, MD 20892 USA.				OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74102] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALOE L, 1979, P NATL ACAD SCI USA, V76, P1246, DOI 10.1073/pnas.76.3.1246; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BERND P, 1984, J BIOL CHEM, V259, P5509; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CONTRERAS ML, 1987, J NEUROCHEM, V48, P1466, DOI 10.1111/j.1471-4159.1987.tb05687.x; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; GNAHN H, 1983, DEV BRAIN RES, V9, P45, DOI 10.1016/0165-3806(83)90107-4; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALEGOUA S, 1980, CELL, V22, P571, DOI 10.1016/0092-8674(80)90367-0; HAMA T, 1986, P NATL ACAD SCI USA, V83, P2353, DOI 10.1073/pnas.83.8.2353; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASHIMOTO S, 1986, J NEUROCHEM, V46, P1599, DOI 10.1111/j.1471-4159.1986.tb01782.x; HASHIMOTO S, 1988, J CELL BIOL, V107, P1531, DOI 10.1083/jcb.107.4.1531; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HEFTI F, 1985, NEUROSCIENCE, V14, P55, DOI 10.1016/0306-4522(85)90163-0; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KENNETH PL, 1991, CELL, V64, P479; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOIZUMI S, 1988, J NEUROSCI, V8, P715; KOLCH W, 1990, ONCOGENE, V5, P713; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRETH GE, 1985, J CELL BIOL, V100, P677, DOI 10.1083/jcb.100.3.677; LEVI A, 1991, ANNU REV PHARMACOL, V31, P205; LEVI-MONTALCINI RITA, 1966, HARVEY LECT, V60, P217; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MATSUDA Y, 1987, J BIOL CHEM, V262, P2832; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MUTOH T, 1989, Biofactors, V2, P71; NIKODIJEVIC B, 1990, J NEUROSCI RES, V26, P288, DOI 10.1002/jnr.490260304; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; ROWLAND EA, 1987, J BIOL CHEM, V262, P7504; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; STORM SM, 1990, ONCOGENE, V5, P345; TOGARI A, 1985, J NEUROSCI, V5, P307; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; UNSICKER K, 1978, P NATL ACAD SCI USA, V75, P3498, DOI 10.1073/pnas.75.7.3498; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WARIS T, 1973, EXPERIENTIA, V29, P1128, DOI 10.1007/BF01946760; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WOOD KW, 1991, J CELL BIOCH B S, V15, P220; YU MW, 1980, J BIOL CHEM, V255, P481	58	69	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23753	23760						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748651				2022-12-25	WOS:A1991GV31900037
J	BERGSMA, DJ; EDER, C; GROSS, M; KERSTEN, H; SYLVESTER, D; APPELBAUM, E; CUSIMANO, D; LIVI, GP; MCLAUGHLIN, MM; KASYAN, K; PORTER, TG; SILVERMAN, C; DUNNINGTON, D; HAND, A; PRICHETT, WP; BOSSARD, MJ; BRANDT, M; LEVY, MA				BERGSMA, DJ; EDER, C; GROSS, M; KERSTEN, H; SYLVESTER, D; APPELBAUM, E; CUSIMANO, D; LIVI, GP; MCLAUGHLIN, MM; KASYAN, K; PORTER, TG; SILVERMAN, C; DUNNINGTON, D; HAND, A; PRICHETT, WP; BOSSARD, MJ; BRANDT, M; LEVY, MA			THE CYCLOPHILIN MULTIGENE FAMILY OF PEPTIDYL-PROLYL ISOMERASES - CHARACTERIZATION OF 3 SEPARATE HUMAN ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS ISOMERASE; A-BINDING-PROTEIN; T-CELL ACTIVATION; CYCLOSPORINE-A; MESSENGER-RNA; IMMUNOSUPPRESSANT FK506; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; COMPLEMENTARY-DNA; ACTIN GENE	Cyclophilin (CyP), a major cytosolic protein possessing peptidyl-prolyl cis-trans isomerase activity, has been implicated as the specific receptor of the immunosuppressive drug cyclosporin A (CsA). To identify other potential CsA receptors related to CyP, two human cDNA libraries were screened under low stringency conditions using human CyP cDNA (encoding hCyP1) as a probe. Two cDNAs were identified which encode distinct proteins related to human hCyP1. These two novel proteins, designated hCyP2 and hCyP3, share 65 and 76% amino acid sequence homology with hCyP1, respectively. Both hCyP2 and hCyP3 contain NH2-terminal hydrophobic extensions of 32 and 42 amino acids, respectively. Protein-specific antibodies revealed the predominant association of hCyP2 and hCyP3 with membranes and subcellular organelles, which suggests that the amino-terminal leader sequences of the two CyP isoforms may act as signal peptides. In contrast to the results with hCyP1, Southern blot analysis indicated that both hCyP2 and hCyP3 gene sequences are represented infrequently in the human genome. Northern and Western blot analysis showed that the distribution of mRNA and proteins of the three hCyPs in differing tissues and cell types was similar. Each hCyP protein was expressed in Escherichia coli, purified, and shown to be an active peptidyl-prolyl isomerase. Substrate specificity was examined with 11 synthetic peptides (Suc-Xaa-Yaa-Pro-Phe-4-nitroanilide), and inhibition of the peptidyl-prolyl isomerase activities associated with hCyP1, hCyP2, and hCyP3 was studied with CsA, MeAla6-CsA and MeBm2t1-CsA. From both equilibrium considerations and the results of kinetic characterizations it is proposed that of these three CyP proteins, hCyP1 is the most likely intracellular target for CsA.	SMITHKLINE BEECHAM PHARMACEUT,DEPT GENE EXPRESS SCI,KING OF PRUSSIA,PA 19046; SMITHKLINE BEECHAM PHARMACEUT,DEPT PROT BIOCHEM,KING OF PRUSSIA,PA 19046; SMITHKLINE BEECHAM PHARMACEUT,DEPT CELL SCI,KING OF PRUSSIA,PA 19046; SMITHKLINE BEECHAM PHARMACEUT,DEPT MED CHEM,KING OF PRUSSIA,PA 19046	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	BERGSMA, DJ (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC GENET,SWEDELAND RD,BOX 1539,MAIL CODE L-48,KING OF PRUSSIA,PA 19046, USA.							AEBI JD, 1990, J MED CHEM, V33, P999, DOI 10.1021/jm00165a018; AUSUBEL FM, 1989, CURRENT PROTOCOLS MO, P401; BACHINGER HP, 1987, J BIOL CHEM, V262, P17144; BERGSMA DJ, 1990, INT COUNC SCI UNIONS, V10, P238; BICKEL M, 1987, P NATL ACAD SCI USA, V84, P3274, DOI 10.1073/pnas.84.10.3274; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOREL JF, 1986, CYCLOSPORIN, P9; BOSSARD MJ, 1991, BIOCHEM BIOPH RES CO, V176, P1142, DOI 10.1016/0006-291X(91)90404-U; CARROLL SL, 1986, J BIOL CHEM, V261, P8965; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DURETTE PL, 1988, TRANSPLANT P, V20, P51; ELLIOTT JF, 1984, SCIENCE, V226, P1439, DOI 10.1126/science.6334364; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FESIK SW, 1990, SCIENCE, V250, P1406, DOI 10.1126/science.2255910; FESIK SW, 1991, BIOCHEMISTRY-US, V30, P657; FISCHER G, 1985, BIOCHIM BIOPHYS ACTA, V828, P39, DOI 10.1016/0167-4838(85)90006-8; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; GOOLEY PR, 1991, INT J PEPT PROT RES, V37, P351; HAENDLER B, 1990, EUR J BIOCHEM, V190, P477, DOI 10.1111/j.1432-1033.1990.tb15598.x; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; HAENDLER B, 1989, GENE, V83, P39, DOI 10.1016/0378-1119(89)90401-0; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; HAYANO T, 1991, BIOCHEMISTRY-US, V30, P3041, DOI 10.1021/bi00226a009; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; IWAI N, 1990, KIDNEY INT, V37, P1460, DOI 10.1038/ki.1990.136; KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; KOSER PL, 1990, NUCLEIC ACIDS RES, V18, P1643, DOI 10.1093/nar/18.6.1643; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LEVY MA, 1991, TRANSPLANT P, V23, P319; LUI J, 1990, P NATL ACAD SCI USA, V87, P4028; LUI J, 1991, BIOCHEMISTRY-US, V30, P2306; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Morrison J.F., 1985, COMMENTS MOL CELL BI, V2, P347; MYERS BD, 1984, NEW ENGL J MED, V311, P699, DOI 10.1056/NEJM198409133111103; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RYFFEL B, 1991, IMMUNOLOGY, V72, P399; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SEGHAL SN, 1975, J ANTIBIOT, V28, P727; Shatzman A R, 1990, Curr Opin Biotechnol, V1, P5, DOI 10.1016/0958-1669(90)90004-5; SHATZMAN AR, 1987, METHOD ENZYMOL, V152, P661; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; SUTCLIFFE JG, 1980, NATURE, V287, P801, DOI 10.1038/287801a0; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029	67	196	219	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23204	23214						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744118				2022-12-25	WOS:A1991GT48300067
J	CLARKLEWIS, I; SCHUMACHER, C; BAGGIOLINI, M; MOSER, B				CLARKLEWIS, I; SCHUMACHER, C; BAGGIOLINI, M; MOSER, B			STRUCTURE-ACTIVITY-RELATIONSHIPS OF INTERLEUKIN-8 DETERMINED USING CHEMICALLY SYNTHESIZED ANALOGS - CRITICAL ROLE OF NH2-TERMINAL RESIDUES AND EVIDENCE FOR UNCOUPLING OF NEUTROPHIL CHEMOTAXIS, EXOCYTOSIS, AND RECEPTOR-BINDING ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; GROWTH STIMULATORY ACTIVITY; ACTIVATING FACTOR; BETA-THROMBOGLOBULIN; FACTOR MDNCF; 3-DIMENSIONAL STRUCTURE; PLATELET FACTOR-4; PEPTIDE; PROTEIN; PURIFICATION	Interleukin-8 (IL-8) is an inflammatory mediator that stimulates neutrophil migration and functional activation. Analogs of human IL-8 were chemically synthesized, purified, and compared with the full-length 72-residue synthetic IL-8 for their ability to stimulate neutrophil chemotaxis and exocytosis as measured by assaying for release of elastase, as well as their binding to specific receptors in competition assays. Analogs corresponding to the less abundant natural forms, 3-72, 4-72, and 77-residue IL-8, were evaluated and the 3-72 and 4-72 had 2-5-fold higher potencies, whereas the 77-residue IL-8 was 2-fold less potent. A major finding was that NH2-terminal residues 4, 5, and 6 were absolutely essential for IL-8 activity and receptor binding. Quantitative dissociation of elastase release and chemotaxis activity was detected with 5-72, which compared with 1-72, was 80-fold less potent in the elastase assay, but was only slightly less potent in stimulating chemotaxis. IL-8 6-72 lacked all the biological activities tested but had detectable receptor binding activity. The NH2-terminal peptide, AVLPRSAKEL, lacked activity and receptor binding, suggesting that the NH2-terminal region alone is not sufficient for function. Comparison of analogs shortened at the COOH terminus showed that potency was progressively reduced as the COOH-terminal residues were excluded. However activity was retained in an analog (1-51) with the entire COOH-terminal alpha-helix and beta-turn missing. A peptide corresponding to the COOH-terminal 22 residues, although inactive alone, synergized with the 1-51 analog in stimulating elastase release. The results suggest that the NH2-terminal residues 4, 5, and 6, which are disordered in the IL-8 solution structure, are directly involved in receptor binding, but the COOH-terminal alpha-helix is probably important for stabilizing the three-dimensional structure. Other regions within residues 7-51 are also functionally important.	UNIV BERN,THEODOR KOCHER INST,CH-3001 BERN,SWITZERLAND; UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1Z3,BC,CANADA	University of Bern; University of British Columbia	CLARKLEWIS, I (corresponding author), UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER V6T 1Z3,BC,CANADA.			Moser, Bernhard/0000-0002-4354-4572				BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BESEMER J, 1989, J BIOL CHEM, V264, P17409; BROWN T, 1981, J CHEM SOC CHEM COMM, P648, DOI 10.1039/c39810000648; CLARKLEWIS I, 1988, P NATL ACAD SCI USA, V85, P7897, DOI 10.1073/pnas.85.21.7897; CLARKLEWIS I, 1986, SCIENCE, V231, P134, DOI 10.1126/science.3079915; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; CLARKLEWIS I, 1989, USE HPLC RECEPTOR BI, P43; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; GREGORY H, 1988, BIOCHEM BIOPH RES CO, V151, P883, DOI 10.1016/S0006-291X(88)80364-4; GROB PM, 1990, J BIOL CHEM, V265, P8311; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; HOLT JC, 1986, BIOCHEMISTRY-US, V25, P1988, DOI 10.1021/bi00356a023; KENT SBH, 1988, ANNU REV BIOCHEM, V57, P957, DOI 10.1146/annurev.bi.57.070188.004521; LEONARD EJ, 1991, J LEUKOCYTE BIOL, V49, P258, DOI 10.1002/jlb.49.3.258; LEONARD EJ, 1990, IMMUNOL TODAY, V11, P223; LINDLEY I, 1988, P NATL ACAD SCI USA, V85, P9199, DOI 10.1073/pnas.85.23.9199; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MOSER B, 1990, J EXP MED, V171, P1797, DOI 10.1084/jem.171.5.1797; MOSER B, 1991, J BIOL CHEM, V266, P10666; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; SAMANTA AK, 1989, J EXP MED, V169, P1185, DOI 10.1084/jem.169.3.1185; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; SCHNEIDER J, 1988, CELL, V54, P363, DOI 10.1016/0092-8674(88)90199-7; SCHRODER JM, 1987, J IMMUNOL, V139, P3474; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; SUZUKI K, 1989, BIOCHEM BIOPH RES CO, V163, P1298, DOI 10.1016/0006-291X(89)91119-4; TANAKA S, 1988, FEBS LETT, V236, P467, DOI 10.1016/0014-5793(88)80078-4; TEKAMPOLSON P, 1990, J EXP MED, V172, P911, DOI 10.1084/jem.172.3.911; VANDAMME J, 1988, J EXP MED, V167, P1364, DOI 10.1084/jem.167.4.1364; WALZ A, 1989, BIOCHEM BIOPH RES CO, V159, P969, DOI 10.1016/0006-291X(89)92203-1; WALZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755, DOI 10.1016/0006-291X(87)90432-3; WESTWICK J, 1989, IMMUNOL TODAY, V10, P146, DOI 10.1016/0167-5699(89)90164-3; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; YOSHIMURA T, 1989, MOL IMMUNOL, V26, P87; YOSHIMURA T, 1987, J IMMUNOL, V139, P788	40	406	428	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23128	23134						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744111				2022-12-25	WOS:A1991GT48300055
J	KESSELS, GCR; ROOS, D; VERHOEVEN, AJ				KESSELS, GCR; ROOS, D; VERHOEVEN, AJ			FMET-LEU-PHE-INDUCED ACTIVATION OF PHOSPHOLIPASE-D IN HUMAN NEUTROPHILS - DEPENDENCE ON CHANGES IN CYTOSOLIC FREE CA2+ CONCENTRATION AND RELATION WITH RESPIRATORY BURST ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HL-60 GRANULOCYTES; PHOSPHATIDIC-ACID; PHOSPHATIDYLCHOLINE HYDROLYSIS; SUPEROXIDE PRODUCTION; PLASMA-MEMBRANE; NADPH OXIDASE; GENERATION; MECHANISMS; CALCIUM; STIMULATION	In this study, we have investigated the Ca2+ requirements for the activation of phospholipase D by the tripeptide fMet-Leu-Phe (fMLP) in human neutrophils. EGTA inhibited the activation of phospholipase D (PLD) by 55% (n = 4). When the initial transient rise in [Ca2+]i was prevented by loading the cells with limited amounts of the Ca2+ chelator 1,2-bis(O-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid acetoxymethyl ester (BAPTA/AM), PLD activation was inhibited by 92% (n = 4). In the presence of both chelators, PLD activation was only 4% of control. In electropermeabilized neutrophils, too, the activation of PLD after the addition of fMLP strongly depends on the Ca2+ concentration, being almost absent with 100 nM free Ca2+ present and reaching maximum activation with a free [Ca2+] of 500 nM. We Subsequently investigated the relationship between PLD activation and the activation of the respiratory burst. In neutrophils loaded with BAPTA/AM (10-mu-M), in which PLD activation was almost absent, a respiratory burst could be induced by fMLP, albeit with a much longer lag time. A respiratory burst could also be elicited by fMLP in electropermeabilized neutrophils incubated with 100 nM free Ca2+. This response, however, was strongly enhanced in the presence of 1-mu-M Ca2+. Our results indicate that changes in [Ca2+]i are essential for the activation of PLD by fMLP, but probably do not constitute the sole activation signal. In addition, our data provide evidence that PLD activation is important, but not necessary, for activation of the neutrophil respiratory burst.	UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL LAB,1006 AD AMSTERDAM,NETHERLANDS	University of Amsterdam	KESSELS, GCR (corresponding author), NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,1006 AD AMSTERDAM,NETHERLANDS.							AMBRUSO DR, 1990, J BIOL CHEM, V265, P924; ANTHES JC, 1989, BIOCHEM BIOPH RES CO, V163, P657, DOI 10.1016/0006-291X(89)92187-6; BALSINDE J, 1988, BIOCHEM BIOPH RES CO, V154, P502, DOI 10.1016/0006-291X(88)90168-4; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCKINO SB, 1987, J BIOL CHEM, V262, P15309; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; KESSELS GCR, 1991, J BIOL CHEM, V266, P15870; KISS Z, 1989, FEBS LETT, V257, P45, DOI 10.1016/0014-5793(89)81782-X; KOENDERMAN L, 1989, FEBS LETT, V243, P399, DOI 10.1016/0014-5793(89)80170-X; KOENDERMAN L, 1989, J IMMUNOL, V142, P623; KORCHAK HM, 1988, J BIOL CHEM, V263, P11098; MERRITT JE, 1990, BIOCHEM J, V269, P513, DOI 10.1042/bj2690513; PAI JK, 1988, J BIOL CHEM, V263, P12472; PEVERI T, 1990, BLOOD S1, V76, P751; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; ROSSI F, 1986, BIOCHEM BIOPH RES CO, V140, P1, DOI 10.1016/0006-291X(86)91050-8; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; TAKI T, 1979, J BIOL CHEM, V254, P9761; TAUBER AI, 1987, BLOOD, V69, P1711; THOMPSON NT, 1990, BIOCHEM J, V271, P209, DOI 10.1042/bj2710209; WITTER B, 1985, J NEUROCHEM, V44, P155, DOI 10.1111/j.1471-4159.1985.tb07125.x	27	77	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23152	23156						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744114				2022-12-25	WOS:A1991GT48300059
J	SANTALA, P; HEINO, J				SANTALA, P; HEINO, J			REGULATION OF INTEGRIN-TYPE CELL-ADHESION RECEPTORS BY CYTOKINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; MESSENGER-RNA LEVELS; STROMELYSIN GENE-EXPRESSION; HUMAN-MELANOMA CELLS; CULTURED HUMAN-CELLS; FIBRO-SARCOMA CELLS; FIBRONECTIN RECEPTOR; LAMININ RECEPTOR; RECOMBINANT INTERLEUKIN-1; VITRONECTIN RECEPTOR	Integrin heterodimers which share a common beta-1 subunit are the major cellular receptors for many extra-cellular matrix proteins. Here, we show that two inflammatory mediators, interleukin-1-beta (IL-1-beta) and tumor necrosis factor-alpha (TNF-alpha), can regulate the expression of the alpha-1-beta-1 integrin heterodimer, known to be a laminin and collagen receptor. In human skin fibroblasts 10 units/ml IL-1-beta increase the biosynthesis of the alpha-1 integrin subunit an average of 4.5-fold. Furthermore, IL-1-6 can turn on alpha-1 subunit expression in MG-63 human osteosarcoma cells even in conditions where the untreated MG-63 cells do not express it in detectable amounts. The effect of TNF-alpha on alpha-1 subunit expression is similar. Both IL-1-beta and TNF-alpha increased MG-63 cell adhesion on laminin. The effect of transforming growth factor-beta-1 (TGF-beta-1) on integrin expression in MG-63 cells has been previously described (Heino, J., and Massague, J. (1989) J. Biol. Chem. 264, 21806-21811). TGF-beta-1 decreases the biosynthesis of alpha-3 subunit but increases the production of alpha-2 subunit. IL-1-beta potentiates the effects of TGF-beta-1. Furthermore, in the presence of TGF-beta-1 the increase in the expression of alpha-1 subunit by IL-1-beta is even larger. Thus, IL-1-beta and TGF-beta-1, which usually have antagonistic functions in connective tissue, can regulate integrin expression in a synergistic way.			SANTALA, P (corresponding author), UNIV TURKU,DEPT MED BIOCHEM,SF-20520 TURKU 52,FINLAND.			Vihinen, Pia/0000-0003-1763-5363				ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; AKIYAMA SK, 1990, CANCER RES, V50, P1601; BODARY SC, 1990, J BIOL CHEM, V265, P5938; BRENNAN F M, 1991, British Journal of Rheumatology, V30, P76; DAHL SC, 1989, J CELL BIOL, V108, P183, DOI 10.1083/jcb.108.1.183; DEDHAR S, 1989, J CELL PHYSIOL, V138, P291, DOI 10.1002/jcp.1041380210; DINARELLO CA, 1991, BLOOD, V77, P1627; DUBOIS CM, 1990, J EXP MED, V172, P737, DOI 10.1084/jem.172.3.737; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; FINGERMAN E, 1988, EXP CELL RES, V177, P132, DOI 10.1016/0014-4827(88)90031-6; GOLDRING MB, 1987, J BIOL CHEM, V262, P16724; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HEINO J, 1989, J BIOL CHEM, V264, P21806; HEINO J, 1990, J BIOL CHEM, V265, P10181; HEINO J, 1988, BIOCHEM J, V252, P309, DOI 10.1042/bj2520309; HEINO J, 1990, BIOCHEM J, V271, P827, DOI 10.1042/bj2710827; HEINO J, 1989, J BIOL CHEM, V264, P380; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1989, J CELL BIOL, V109, P409, DOI 10.1083/jcb.109.1.409; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; IGNATIUS MJ, 1988, NEURON, V1, P713, DOI 10.1016/0896-6273(88)90170-5; IGNOTZ RA, 1989, J BIOL CHEM, V264, P389; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; KAHARI VM, 1987, BIOCHIM BIOPHYS ACTA, V929, P142, DOI 10.1016/0167-4889(87)90169-8; KANTOR RRS, 1987, J BIOL CHEM, V262, P15158; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; KRAMER RH, 1989, J BIOL CHEM, V264, P15642; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LARJAVA H, 1990, J CELL BIOL, V110, P803, DOI 10.1083/jcb.110.3.803; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PISCHEL KD, 1987, J IMMUNOL, V138, P226; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; RETTIG WJ, 1984, P NATL ACAD SCI-BIOL, V81, P6437, DOI 10.1073/pnas.81.20.6437; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; ROSSINO P, 1990, EXP CELL RES, V189, P100, DOI 10.1016/0014-4827(90)90262-9; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RUPP EA, 1986, J CLIN INVEST, V78, P836, DOI 10.1172/JCI112649; SANTORO SA, 1988, BIOCHEM BIOPH RES CO, V153, P217, DOI 10.1016/S0006-291X(88)81211-7; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; SYMINGTON BE, 1989, J BIOL CHEM, V264, P13258; TAKADA Y, 1988, J CELL BIOCHEM, V37, P385, DOI 10.1002/jcb.240370406; TAKADA Y, 1987, NATURE, V326, P607, DOI 10.1038/326607a0; TURNER DC, 1989, J NEUROSCI, V9, P3287; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; VILCEK J, 1991, J BIOL CHEM, V266, P7313; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; YLANNE J, 1989, INT J CANCER, V43, P1126, DOI 10.1002/ijc.2910430628	61	137	140	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23505	23509						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744142				2022-12-25	WOS:A1991GT48300109
J	SONNEMANN, J; BAUERLE, A; WINCKLER, T; MUTZEL, R				SONNEMANN, J; BAUERLE, A; WINCKLER, T; MUTZEL, R			A RIBOSOMAL CALMODULIN-BINDING PROTEIN FROM DICTYOSTELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-II; TRANSLATIONAL INITIATION; EUKARYOTIC CELLS; CDNA CLONES; DISCOIDEUM; SEQUENCE; PHOSPHORYLATION; IDENTIFICATION; EVOLUTIONARY; INHIBITION	Using I-125-calmodulin as a probe, we have recently identified specific Ca2+/calmodulin-binding proteins in cell extracts from the cellular slime mold, Dictyostelium discoideum: a major 22-kDa activity, a soluble 78/80-kDa protein, and several membrane-associated high M(r) proteins (Winckler, T., Dammann, H., and Mutzel, R. (1991) Res. Microbiol. 142, 509-519). cDNA clones for at least two of these proteins have been isolated by ligand screening of a lambda-gt11 prophage expression library. Antibodies directed against the lacZ-cDNA-encoded fusion protein from one of the clones recognized a single 22-kDa component in D. discoideum extracts which comigrated with the endogenous 22-kDa calmodulin-binding protein. The cDNA-derived nucleotide sequence predicts a protein of M(r) 21,659 with 56% sequence identity (69% homology) with rat ribosomal protein L19. The endogenous 22-kDa calmodulin-binding activity was associated with ribosomes. It was found to be an integral constituent of the large ribosomal subunit, since it cosedimented with 60 S ribosomal subunits in sucrose density gradients in the presence of 0.5 M NH4Cl. Our observations point to a physiological role for calmodulin in the Ca2+ regulation of eukaryotic protein synthesis. Support for this comes from recent studies showing inhibition of protein synthesis by calmodulin antagonists in Ehrlich ascites tumor cells (Kumar, R. V., Panniers, R., Wolfman, A., and Henshaw, E. C. (1991) Eur. J. Biochem. 195, 313-319).	UNIV CONSTANCE,FAK BIOL,W-7750 CONSTANCE,GERMANY	University of Konstanz			Sonnemann, Jürgen/H-9116-2019	Sonnemann, Jürgen/0000-0003-2993-9161				AUER J, 1989, J MOL BIOL, V209, P21, DOI 10.1016/0022-2836(89)90167-8; BROSTROM CO, 1989, J BIOL CHEM, V264, P1644; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; BULOS BA, 1979, ANAL BIOCHEM, V95, P62, DOI 10.1016/0003-2697(79)90185-4; CARLBERG U, 1990, EUR J BIOCHEM, V191, P639, DOI 10.1111/j.1432-1033.1990.tb19169.x; CHAN YL, 1987, J BIOL CHEM, V262, P1111; CHIN KV, 1987, J BIOL CHEM, V262, P16509; Cohen P, 1988, CALMODULIN MOL ASPEC, V5; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HATAKEYAMA T, 1989, EUR J BIOCHEM, V185, P685, DOI 10.1111/j.1432-1033.1989.tb15166.x; JULIANI MH, 1983, FEBS LETT, V154, P400, DOI 10.1016/0014-5793(83)80191-4; KUMAR RV, 1989, J CELL BIOL, V108, P2107, DOI 10.1083/jcb.108.6.2107; KUMAR RV, 1991, EUR J BIOCHEM, V195, P313, DOI 10.1111/j.1432-1033.1991.tb15708.x; LACOMBE ML, 1986, J BIOL CHEM, V261, P6811; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MARSHAK DR, 1981, P NATL ACAD SCI-BIOL, V78, P6793, DOI 10.1073/pnas.78.11.6793; MUTZEL R, 1990, GENE, V96, P205, DOI 10.1016/0378-1119(90)90254-O; MUTZEL R, 1988, BIOCHEMISTRY-US, V27, P481, DOI 10.1021/bi00401a069; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; OLSEN GJ, 1982, BIOCHEMISTRY-US, V21, P2335, DOI 10.1021/bi00539a010; ONEIL KT, 1987, SCIENCE, V236, P1454, DOI 10.1126/science.3589665; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAMAGOPAL S, 1980, EUR J BIOCHEM, V105, P245, DOI 10.1111/j.1432-1033.1980.tb04495.x; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINGLETON CK, 1989, NUCLEIC ACIDS RES, V17, P9679, DOI 10.1093/nar/17.23.9679; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; WINCKLER T, 1991, RES MICROBIOL, V14, P509	31	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23091	23096						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744106				2022-12-25	WOS:A1991GT48300050
J	CAPOBIANCO, AJ; GILMORE, TD				CAPOBIANCO, AJ; GILMORE, TD			REPRESSION OF THE CHICKEN C-REL PROMOTER BY VREL IN CHICKEN-EMBRYO FIBROBLASTS IS NOT MEDIATED THROUGH A CONSENSUS NF-KAPPA-B BINDING-SITE	ONCOGENE			English	Article							VIRUS STRAIN-T; V-REL; RETICULOENDOTHELIOSIS VIRUS; PROTO-ONCOGENE; CELLULAR HOMOLOG; MAMMALIAN-CELLS; SPLEEN-CELLS; DNA; EXPRESSION; GENE	To understand the regulation of expression of the chicken c-rel gene, we cloned genomic sequences upstream of the start site of transcription of c-rel Sequence analysis shows that the c-rel promoter is a GC-rich promoter that lacks a TATA box. In addition, there are putative binding sites for several transcription factors, including an NF-kappa-B consensus binding site. Primer extension showed that there is one major start site (site 1) for transcription in chicken embryo fibroblasts and two major start sites in a v-rel-transformed chicken spleen cell line. In transient assays using c-rel promoter sequences and the CAT reporter gene, we found that vRel repressed expression from the c-rel promoter. Other viral oncoproteins and a non-transforming v-rel deletion mutant did not repress the: c-rel promoter. Repression occurred through sequences located within 125 bp of the start of transcription. However, mutation of the consensus NF-kappa-B binding site did not affect the level of transcription from the c-rel promoter, nor did it interfere with repression by v-Rel, even though vRel could bind to the wild-type, but not the mutant, version of this sequence in vitro. These results suggest that the vRel protein can repress transcription through an indirect mechanism.	BOSTON UNIV, DEPT BIOL, BOSTON, MA 02215 USA	Boston University				Capobianco, Anthony/0000-0002-3706-6797	NCI NIH HHS [CA-47763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BARTH CF, 1990, J VIROL, V64, P6054, DOI 10.1128/JVI.64.12.6054-6062.1990; BOORSTEIN WR, 1989, METHOD ENZYMOL, V180, P347; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BRAVO R, 1988, COLD SPRING HARB SYM, V53, P901, DOI 10.1101/SQB.1988.053.01.103; BROWNELL E, 1988, ONCOGENE, V3, P93; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; BULL P, 1989, MOL CELL BIOL, V9, P5239, DOI 10.1128/MCB.9.11.5239; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CHEN ISY, 1983, J VIROL, V45, P104, DOI 10.1128/JVI.45.1.104-113.1983; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; EMBRETSON JE, 1987, J VIROL, V61, P3454, DOI 10.1128/JVI.61.11.3454-3462.1987; GARSON K, 1986, BIOCHEM BIOPH RES CO, V134, P716, DOI 10.1016/S0006-291X(86)80479-X; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1991, IN PRESS TRENDS GENE; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRUMONT RJ, 1990, ONCOGENE RES, V5, P245; HANNINK M, 1990, ONCOGENE, V5, P1843; HERZOG NK, 1986, P NATL ACAD SCI USA, V83, P812, DOI 10.1073/pnas.83.3.812; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; IP YT, 1991, CELL, V64, P439; JORCYK CL, 1991, ONCOGENE, V6, P523; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOHWISHIGEMATSU T, 1983, P NATL ACAD SCI-BIOL, V80, P4389, DOI 10.1073/pnas.80.14.4389; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOORE BE, 1989, ONCOGENE, V4, P845; MOSIALOS G, 1991, IN PRESS MOL CELL BI; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; RICE NR, 1986, VIROLOGY, V149, P217, DOI 10.1016/0042-6822(86)90123-6; RICE NR, 1988, ONCOGENE HDB, P495; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SALIER JP, 1989, BIOTECHNIQUES, V7, P30; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIMEK S, 1988, ONCOGENE RES, V2, P103; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; WILHELMSEN KC, 1984, J VIROL, V49, P521, DOI 10.1128/JVI.49.2.521-529.1984; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	55	39	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1991	6	12					2203	2210						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766669				2022-12-25	WOS:A1991GX73500005
J	BRAND, IA; HEINICKEL, A				BRAND, IA; HEINICKEL, A			KEY ENZYMES OF CARBOHYDRATE-METABOLISM AS TARGETS OF THE 11.5-KDA ZN2+-BINDING PROTEIN (PARATHYMOSIN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; SEQUENCE; ALDOLASE; PHOSPHOFRUCTOKINASE; RADIOIMMUNOASSAY; PHOSPHORYLATION; PEPTIDE; BINDING; ALPHA; ACTIN	The 11.5-kDa Zn2+-binding protein (ZnBP) was covalently linked to Sepharose. Affinity chromatography with a cytosolic subfraction from liver resulted in purification of a predominant 38-kDa protein. In comparable experiments with brain cytosol a 39-kDa protein was enriched. The ZnBP-protein interactions were zinc-specific. Both proteins were identified as fructose-1,6-bisphosphate aldolase. Experiments with crude cytosol showed zinc-specific interaction of additional enzymes involved in carbohydrate metabolism. From liver cytosol > 90% of the following enzymes were specifically retained: aldolase, phosphofructokinase-1, hexokinase/glucokinase, glucose-6-phosphate dehydrogenase, glycerol-3-phosphate dehydrogenase, glyceraldehyde-3-phosphate dehydrogenase, and fructose-1,6-bisphosphatase. Glucose-6-phosphate isomerase, phosphoglycerate kinase, enolase, lactate dehydrogenase, and most of triosephosphate isomerase remained unbound. From L-type pyruvate kinase only the phosphorylated form seems to interact with ZnBP. Using brain cytosol hexokinase, phosphofructokinase-1, and aldolase were completely bound to the affinity column, whereas glucose-6-phosphate isomerase, phosphoglycerate kinase, enolase, lactate dehydrogenase, pyruvate kinase, and most of triose-phosphate isomerase remained unbound. The behavior of glucose-6-phosphate dehydrogenase and glycerol-3-phosphate dehydrogenase from this tissue could not be followed. A possible function of ZnBP in supramolecular organization of carbohydrate metabolism is proposed.			BRAND, IA (corresponding author), UNIV GOTTINGEN, ZENTRUM INNERE MED, KLIN BIOCHEM ABT, ROBERT KOCH STR 40, W-3400 GOTTINGEN, GERMANY.							ALLEN G, 1981, LABORATORY TECHNIQUE, V9, P62; Bergmeyer HU, 1970, METHODEN ENZYMATISCH, V1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND IA, 1986, J BIOL CHEM, V261, P5892; BRAND IA, 1991, EUR J CELL BIOL, V54, P157; BRAND IA, 1988, EUR J BIOCHEM, V177, P561, DOI 10.1111/j.1432-1033.1988.tb14407.x; BRAND IA, 1982, EUR J BIOCHEM, V122, P175, DOI 10.1111/j.1432-1033.1982.tb05864.x; BROOKS SPJ, 1991, FEBS LETT, V278, P135, DOI 10.1016/0014-5793(91)80101-8; EKMAN P, 1976, BIOCHIM BIOPHYS ACTA, V429, P374, DOI 10.1016/0005-2744(76)90285-0; HARITOS AA, 1985, P NATL ACAD SCI USA, V82, P1050, DOI 10.1073/pnas.82.4.1050; KUTER MR, 1981, ARCH BIOCHEM BIOPHYS, V212, P306, DOI 10.1016/0003-9861(81)90370-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUTHER MA, 1986, J BIOL CHEM, V261, P1753; PANNEERSELVAM C, 1987, J IMMUNOL METHODS, V104, P131, DOI 10.1016/0022-1759(87)90496-0; PENHOET EE, 1975, METHOD ENZYMOL, V42, P241; SRIVASTAVA DK, 1986, CURR TOP CELL REGUL, V28, P1; THIELECZEK R, 1989, J BIOL CHEM, V264, P7349; TROMPETER HI, 1989, FEBS LETT, V253, P63, DOI 10.1016/0014-5793(89)80930-5; TSITSILONI OE, 1988, J IMMUNOL METHODS, V113, P175, DOI 10.1016/0022-1759(88)90330-4; TSUTSUMI K, 1984, J BIOL CHEM, V259, P4572	20	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20984	20989						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1834654				2022-12-25	WOS:A1991GN00100063
J	SHARKEY, DJ; KORNFELD, R				SHARKEY, DJ; KORNFELD, R			DEVELOPMENTAL REGULATION OF PROCESSING ALPHA-MANNOSIDASES AND INTERSECTING N-ACETYLGLUCOSAMINYLTRANSFERASE IN DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; HIGH MANNOSE OLIGOSACCHARIDES; LIVER GOLGI MEMBRANES; RAT-LIVER; GLYCOPROTEIN-BIOSYNTHESIS; ENDOPLASMIC-RETICULUM; IDENTIFICATION; PURIFICATION; 1-DEOXYMANNOJIRIMYCIN; RESIDUES	We have identified three developmentally regulated oligosaccharide-processing enzyme activities in Dictyostelium discoideum. Two different alpha-mannosidase activities present at extremely low levels in vegetative cells are expressed during development. The first of these activities (MI) rises sharply from 6 to 12 h of development whereas the second activity (MII) rises sharply from 12 to 18 h of development. MI acts on Man9GlcNAc, which it can degrade to Man5GlcNAc but is inactive toward p-nitrophenyl-alpha-D-mannoside (pnpMan). MII acts on pnpMan but not Man9GlcNAc. These activities are distinct from each other and from lysosomal alpha-mannosidase activity as demonstrated by pH optima, substrate specificity, sensitivity to inhibitors and divalent cations, developmental profiles, and solubility. The characteristics of these developmentally regulated alpha-mannosidase activities are similar to those of Golgi alpha-mannosidases I and II from higher eucaryotes, and they appear to catalyze the in vivo formation of processed asparagine-linked oligosaccharides by developed cells. In addition, developed cells have very low levels of a soluble alpha-mannosidase activity, which is the predominant activity in vegetative cells. This soluble vegetative alpha-mannosidase activity has properties that are reminiscent of the endoplasmic reticulum alpha-mannosidase from rat liver. The intersecting N-acetylglucosaminyltransferase activity that we have described recently in vegetative cells of D. discoideum (Sharkey, D.J., and Kornfeld, R. (1989) J. Biol. Chem. 264, 10411-10419) has a developmental profile that is distinct from that of either of the alpha-mannosidase activities. It has maximum activity at 6 h of development and decreases sharply to its minimum level by 12 h of development. The changes that occur in the levels of these three processing enzymes with development correlate well with the different arrays of asparagine-linked oligosaccharides found in early and late stages of development (Sharkey, D. J., and Kornfeld, R. (1991) J. Biol. Chem. 266, 18485-18497).	WASHINGTON UNIV,SCH MED,DEPT BIOL CHEM,ST LOUIS,MO 63110	Washington University (WUSTL)	SHARKEY, DJ (corresponding author), WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,ST LOUIS,MO 63110, USA.				NCI NIH HHS [CA08759] Funding Source: Medline; NIGMS NIH HHS [5T32GM07067] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007067] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BISCHOFF J, 1983, J BIOL CHEM, V258, P7907; BISCHOFF J, 1986, J BIOL CHEM, V261, P4766; BISCHOFF J, 1984, BIOCHEM BIOPH RES CO, V125, P324, DOI 10.1016/S0006-291X(84)80371-X; BISCHOFF J, 1986, J BIOL CHEM, V261, P4758; COUSO R, 1987, J BIOL CHEM, V262, P4521; DEWALD B, 1973, J BIOL CHEM, V248, P7223; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FREE SJ, 1974, BIOCHIMIE, V56, P1525; FREE SJ, 1976, DEV BIOL, V49, P539, DOI 10.1016/0012-1606(76)90195-0; FREEZE HH, 1983, J BIOL CHEM, V258, P4880; FREEZE HH, 1986, J BIOL CHEM, V261, P127; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; GABEL CA, 1984, J BIOL CHEM, V259, P3762; Henderson E.J., 1984, P371; HOHMANN HP, 1987, J BIOL CHEM, V262, P16618; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; ICHISHIMA E, 1981, BIOCHIM BIOPHYS ACTA, V658, P45, DOI 10.1016/0005-2744(81)90248-5; IVATT RL, 1984, CELL, V38, P561, DOI 10.1016/0092-8674(84)90510-5; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LACOSTE CH, 1989, ARCH BIOCHEM BIOPHYS, V273, P505, DOI 10.1016/0003-9861(89)90510-9; LOOMIS WF, 1982, DEV DICTYOSTELIUM DI; Loomis WF., 1975, DICTYOSTELIUM DISCOI; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McIlvaine TC, 1921, J BIOL CHEM, V49, P183; MELLIS SJ, 1981, ANAL BIOCHEM, V114, P276, DOI 10.1016/0003-2697(81)90480-2; MONIS E, 1987, EUR J BIOCHEM, V168, P287, DOI 10.1111/j.1432-1033.1987.tb13419.x; SHARKEY DJ, 1991, J BIOL CHEM, V266, P18485; SHARKEY DJ, 1989, J BIOL CHEM, V264, P10411; SHOUP VA, 1976, J BIOL CHEM, V251, P3845; TABAS I, 1978, J BIOL CHEM, V253, P7779; TABAS I, 1979, J BIOL CHEM, V254, P1655; TULSIANI DRP, 1982, J BIOL CHEM, V257, P3660; TULSIANI DRP, 1977, J BIOL CHEM, V252, P3227; TULSIANI DRP, 1982, J BIOL CHEM, V257, P7936; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171	35	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18477	18484						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1833397				2022-12-25	WOS:A1991GJ47200014
J	MONK, BC; MONTESINOS, C; FERGUSON, C; LEONARD, K; SERRANO, R				MONK, BC; MONTESINOS, C; FERGUSON, C; LEONARD, K; SERRANO, R			IMMUNOLOGICAL APPROACHES TO THE TRANSMEMBRANE TOPOLOGY AND CONFORMATIONAL-CHANGES OF THE CARBOXYL-TERMINAL REGULATORY DOMAIN OF YEAST PLASMA-MEMBRANE H+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; SENSITIVE METHOD; WESTERN BLOTS; CA-2+ PUMP; PROTEINS; IDENTIFICATION; ACTIVATION; GROWTH; IMMUNOLOCALIZATION; EXPRESSION	Molecular genetic experiments have suggested that the carboxyl terminus of the Saccharomyces cerevisiae plasma membrane H+-ATPase is an inhibitory domain involved in the "in vivo" regulation of the enzyme by glucose metabolism. An antibody prepared against a fusion protein including the last 59 amino acids of the ATPase sequence has been affinity purified to yield a preparation which requires the 18 carboxyl-terminal amino acids for recognition. Antibody binding experiments show that the carboxyl-terminal domain of the ATPase can be selectively exposed by concentrations of the detergent Tween-20 which do not break down the permeability barrier of the plasma membrane to the antibody. Both enzyme-linked immunosorbent assay and immunofluorescence analysis demonstrate that the accessibility of the carboxyl-terminal domain in isolated plasma membranes depends on the physiological state of the cell being increased by glucose metabolism. Immunofluorescence analysis of isolated plasma membrane vesicles, using a dual labeling protocol with concanavalin A and antibody to reveal the orientation of individual vesicles, and colloidal gold immunoelectron microscopy of ultrathin cryosections of whole yeast cells separately demonstrate that the ATPase carboxyl terminus is located in the cytoplasmic compartment. The application of a mutant deleted of the epitope(s) recognized by the affinity purified carboxyl-terminal antibody eliminates the possibility of artifacts arising from nonspecific antibody binding. The accessibility properties and cytoplasmic location of the carboxyl-terminal domain appear to be consistent with its role as a negative regulator of the ATPase.	EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)				Monk, Brian/0000-0003-2264-3480				BIRRELL GB, 1987, J HISTOCHEM CYTOCHEM, V35, P843, DOI 10.1177/35.8.2439584; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPIEAUX E, 1989, J BIOL CHEM, V264, P7437; CARAFOLI E, 1982, BIOCHIM BIOPHYS ACTA, V683, P279, DOI 10.1016/0304-4173(82)90004-0; CID A, 1988, J BIOL CHEM, V263, P14134; DAVIS CB, 1989, J BIOL CHEM, V264, P370; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; ERASO P, 1987, FEBS LETT, V224, P193, DOI 10.1016/0014-5793(87)80446-5; ERASO P, 1987, FEBS LETT, V224, P187, DOI 10.1016/0014-5793(87)80445-3; GRIFFITHS G, 1983, METHOD ENZYMOL, V96, P435; HENNESSEY JP, 1990, J BIOL CHEM, V265, P532; JAMES P, 1989, J BIOL CHEM, V264, P8289; JENNINGS ML, 1989, ANNU REV BIOCHEM, V58, P999; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDALA SM, 1989, J BIOL CHEM, V264, P16276; MANDALA SM, 1988, J BIOL CHEM, V263, P15122; MCCREA PD, 1988, TRENDS BIOCHEM SCI, V13, P289, DOI 10.1016/0968-0004(88)90120-X; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; MONK BC, 1989, BIOCHIM BIOPHYS ACTA, V981, P226, DOI 10.1016/0005-2736(89)90032-1; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P230, DOI 10.1016/0014-5793(88)80904-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PORTILLO F, 1989, EUR J BIOCHEM, V186, P501, DOI 10.1111/j.1432-1033.1989.tb15235.x; PORTILLO F, 1989, FEBS LETT, V247, P381, DOI 10.1016/0014-5793(89)81375-4; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SERRANO R, 1980, EUR J BIOCHEM, V105, P419, DOI 10.1111/j.1432-1033.1980.tb04516.x; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1989, PLANT MEMBRANE TRANS, P439; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; VALLEJO CG, 1989, YEAST, V5, P307, DOI 10.1002/yea.320050411; VANTUINEN E, 1987, J HISTOCHEM CYTOCHEM, V35, P327, DOI 10.1177/35.3.3546482; VERMA AK, 1988, J BIOL CHEM, V263, P14152	34	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18097	18103						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1833392				2022-12-25	WOS:A1991GG55300060
J	LYTTON, J; WESTLIN, M; HANLEY, MR				LYTTON, J; WESTLIN, M; HANLEY, MR			THAPSIGARGIN INHIBITS THE SARCOPLASMIC OR ENDOPLASMIC-RETICULUM CA-ATPASE FAMILY OF CALCIUM PUMPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROCYTE-MEMBRANE; MOLECULAR-CLONING; CA-2+ TRANSPORT; ACINAR-CELLS; CA-2+-ATPASE; MUSCLE; EXPRESSION; KIDNEY; PURIFICATION; CA2+-ATPASE	The role of ATP-dependent calcium uptake into intracellular storage compartments is an essential feature of hormonally induced calcium signaling. Thapsigargin, a non-phorboid tumor promoter, increasingly is being used to manipulate calcium stores because it induces a hormone-like elevation of cytosolic calcium. It has been suggested that thapsigargin acts through inhibition of the endoplasmic reticulum calcium pump. We have directly tested the specificity of thapsigargin on all of the known intracellular-type calcium pumps (referred to as the sarcoplasmic or endoplasmic reticulum Ca-ATPase family (SERCA)). Full-length cDNA clones encoding SERCA1, SERCA2a, SERCA2b, and SERCA3 enzymes were expressed in COS cells, and both calcium uptake and calcium-dependent ATPase activity were assayed in microsomes isolated from them. Thapsigargin inhibited all of the SERCA isozymes with equal potency. Furthermore, similar doses of thapsigargin abolished the calcium uptake and ATPase activity of sarcoplasmic reticulum isolated from fast twitch and cardiac muscle but had no influence on either the plasma membrane Ca-ATPase or Na,K-ATPase. The interaction of thapsigargin with the SERCA isoforms is rapid, stoichiometric, and essentially irreversible. These properties demonstrate that thapsigargin interacts with a recognition site found in, and only in, all members of the endoplasmic and sarcoplasmic reticulum calcium pump family.	BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; UNIV CALIF DAVIS, DEPT BIOL CHEM, DAVIS, CA 95616 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; University of California System; University of California Davis; Harvard University; Harvard Medical School	LYTTON, J (corresponding author), BRIGHAM & WOMENS HOSP, DIV RENAL, 75 FRANCIS ST, BOSTON, MA 02115 USA.			Lytton, Jonathan/0000-0003-4770-2512	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042879] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42879] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1991, CURRENT PROTOCOLS MO; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; CAMPBELL KP, 1981, J BIOL CHEM, V256, P4626; CHAMBERLAIN BK, 1988, METHOD ENZYMOL, V157, P91; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; DEMEIS L, 1991, J BIOL CHEM, V266, P5736; DESMEDT H, 1991, J BIOL CHEM, V266, P7092; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; FUJII J, 1990, FEBS LETT, V273, P232, DOI 10.1016/0014-5793(90)81092-3; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; IINO M, 1988, BIOCHEM BIOPH RES CO, V152, P417, DOI 10.1016/S0006-291X(88)80730-7; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1989, J BIOL CHEM, V264, P7059; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, CELL MOTIL CYTOSKEL, V14, P26, DOI 10.1002/cm.970140107; MEYER T, 1991, CELL, V64, P675, DOI 10.1016/0092-8674(91)90496-L; PEPPERELL JR, 1990, ENDOCRINOLOGY, V127, P1818, DOI 10.1210/endo-127-4-1818; ROSSI B, 1979, J BIOL CHEM, V254, P2302; Sambrook J, 1989, MOL CLONING LABORATO; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; SWEADNER KJ, 1988, METHOD ENZYMOL, V156, P65; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; THEVENOD F, 1989, J MEMBRANE BIOL, V109, P173, DOI 10.1007/BF01870856; VARGA S, 1986, J BIOL CHEM, V261, P13943; VERMA A, 1990, BIOCHEM BIOPH RES CO, V172, P811, DOI 10.1016/0006-291X(90)90747-B	39	1122	1135	1	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17067	17071						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1832668				2022-12-25	WOS:A1991GF44500018
J	IWAMOTO, A; OMOTE, H; HANADA, H; TOMIOKA, N; ITAI, A; MAEDA, M; FUTAI, M				IWAMOTO, A; OMOTE, H; HANADA, H; TOMIOKA, N; ITAI, A; MAEDA, M; FUTAI, M			MUTATIONS IN SER174 AND THE GLYCINE-RICH SEQUENCE (GLY149, GLY150, AND THR156) IN THE BETA-SUBUNIT OF ESCHERICHIA-COLI H+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; SITE-DIRECTED MUTAGENESIS; ADENOSINE-TRIPHOSPHATASE; MITOCHONDRIAL F1-ATPASE; ADENYLATE KINASE; ARGININE 246; REPLACEMENT; SYNTHASE; PROTEINS; BINDING	A sequence motif in the beta-subunit of Escherichia coli F1 (Gly-Gly-Ala-Gly-Val-Gly-Lys-Thr, residue 149-156, where conserved residues are underlined) is one of the glycine-rich sequences found in many nucleotide binding proteins. In this study, we constructed a plasmid carrying all the F0F1 genes. This plasmid gave the highest membrane ATPase activity so far reported. Substitution of beta-Gly149 by Ser suppressed the effect of the beta-Ser174 --> Phe mutation (defective H+-ATPase), but beta-Gly150 --> Ser substitution did not have this effect. A single mutation (beta-Gly149 --> Ser or beta-Gly150 --> Ser) gave active enzyme with altered divalent cation dependency and azide sensitivity: the beta-Gly149 --> Ser mutant enzyme had 100-fold lower azide sensitivity and essentially no Ca2+-dependent activity, but had the wild-type level of Mg2+-dependent activity with active oxidative phosphorylation. Introduction of a beta-Gly149 --> Ser or beta-Gly150 --> Ser mutation with the beta-Ser174 --> Phe mutation also lowered the Ca2+-dependent activity and azide sensitivity. Consistent with our previous findings (Takeyama, M., Ihara, K., Moriyama, Y., Noumi, T., Ida, K., Tomioka, N., Itai, A., Maeda, M., and Futai, M. (1990) J. Biol. Chem. 265, 21279-21284), a beta-Thr156 --> Ala or Cvs mutation impaired ATPase activity, suggesting that the hydroxyl moiety at position 156 is essential for the catalytic activity. The possible location of the catalytic site including divalent cation binding site(s) is discussed.	UNIV TOKYO,FAC PHARMACEUT SCI,TOKYO 113,JAPAN	University of Tokyo	IWAMOTO, A (corresponding author), OSAKA UNIV,INST SCI & IND RES,IBARAKI,OSAKA 567,JAPAN.		OMOTE, Hiroshi/B-1635-2011					ANDREWS WW, 1984, J BIOL CHEM, V259, P4378; CESARENI G, 1982, P NATL ACAD SCI-BIOL, V79, P6313, DOI 10.1073/pnas.79.20.6313; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; FALSON P, 1987, BIOCHEM BIOPH RES CO, V148, P1182, DOI 10.1016/S0006-291X(87)80257-7; FUTAI M, 1983, MICROBIOL REV, V47, P285, DOI 10.1128/MMBR.47.3.285-312.1983; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; HELL A, 1974, EUR J BIOCHEM, V43, P131; HOSHIDA M, 1982, J BIOL CHEM, V257, P10033; HSU SY, 1987, FEBS LETT, V218, P222, DOI 10.1016/0014-5793(87)81050-5; IDA K, 1991, J BIOL CHEM, V266, P5424; IDA K, 1991, J BIOL CHEM, V259, P5424; JAULT JM, 1989, BIOCHEM BIOPH RES CO, V158, P392, DOI 10.1016/S0006-291X(89)80060-9; JONES MD, 1980, EUR J BIOCHEM, V108, P507, DOI 10.1111/j.1432-1033.1980.tb04748.x; JOSHI VK, 1987, J BIOL CHEM, V262, P15721; KANAZAWA H, 1980, J BIOCHEM-TOKYO, V88, P695, DOI 10.1093/oxfordjournals.jbchem.a133022; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIKI JJ, 1990, J BIOL CHEM, V265, P21567; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILLER JH, 1972, EXPT MOL GENETICS, P113; MUELLER DM, 1989, J BIOL CHEM, V264, P16552; NOUMI T, 1986, J BIOL CHEM, V261, P9196; NOUMI T, 1984, J BIOL CHEM, V259, P71; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PARSONAGE D, 1988, FEBS LETT, V232, P111, DOI 10.1016/0014-5793(88)80397-1; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; PARSONAGE D, 1987, J BIOL CHEM, V262, P8022; PARSONAGE D, 1987, J BIOL CHEM, V262, P6301; PERLIN DS, 1984, BIOCHEMISTRY-US, V23, P4998, DOI 10.1021/bi00316a026; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SACHSENHEIMER W, 1977, J MOL BIOL, V114, P23, DOI 10.1016/0022-2836(77)90280-7; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SENIOR AE, 1984, ARCH BIOCHEM BIOPHYS, V228, P49, DOI 10.1016/0003-9861(84)90045-6; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SINGH VC, 1986, AMBER 30; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAKEDA K, 1985, J BIOCHEM-TOKYO, V97, P1401, DOI 10.1093/oxfordjournals.jbchem.a135194; TAKEYAMA M, 1990, J BIOL CHEM, V265, P21279; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5	44	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16350	16355						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1832155				2022-12-25	WOS:A1991GD63500020
J	THIEL, C; WEBER, K; GERKE, V				THIEL, C; WEBER, K; GERKE, V			CHARACTERIZATION OF A CA2+-BINDING SITE IN HUMAN ANNEXIN-II BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-DEPENDENT PHOSPHOLIPID-BINDING; TYROSINE-PROTEIN-KINASE; PLASMA-MEMBRANE; CA-2+ BINDING; P36 SUBSTRATE; CALCIUM; CALPACTIN; PHOSPHORYLATION; SEQUENCE; FAMILY	Annexin II, a major cytoplasmic substrate of the src tyrosine kinase, is a member of the annexin family of Ca2+/phospholipid-binding proteins. It is composed of a short N-terminal tail (30 residues) followed by four so-called annexin repeats (each 70-80 residues in length) which share sequence homologies and are thought to form (a) new type(s) of Ca2+-binding site(s). We have produced wild-type and site specifically mutated annexin II molecules to compare their structure and biochemistry. The recombinant wild-type annexin II displays biochemical and spectroscopical properties resembling those of the authentic protein purified from mammalian cells. In particular, it shows the Ca2+-induced blue shift in fluorescence emission which is typical for this annexin. Replacement of the single tryptophan in annexin II (Trp-212) by a phenylalanine abolishes the fluorescence signal and allows the unambiguous assignment of the Ca2+-sensitive spectroscopic properties to Trp-212. This residue is located in the third annexin repeat in a highly conserved stretch of 17 amino acids which are also found in the other repeats and known as the endonexin fold. To study the precise architecture of the Ca2+ site which must reside in close proximity to Trp-212, we changed several residues of the endonexin fold in repeat 3 by site-directed mutagenesis. An analysis of these mutants by fluorescence spectroscopy and Ca2+-dependent phospholipid binding reveals that Gly-206 and Thr-207 seem indispensible for a correct folding of this Ca2+-binding site.	MAX PLANCK INST BIOPHYS CHEM,DEPT BIOCHEM,POB 2841,W-3400 GOTTINGEN,GERMANY	Max Planck Society								BUJARD H, 1987, METHOD ENZYMOL, V155, P416; BURGOYNE RD, 1989, CELL CALCIUM, V10, P1, DOI 10.1016/0143-4160(89)90038-9; CAMPOSGONZALES R, 1990, STIMULUS RESPONSE CO, P339; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; GEISOW MJ, 1986, NATURE, V320, P636, DOI 10.1038/320636a0; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GERKE V, 1985, J BIOL CHEM, V260, P1688; GERKE V, 1989, CELL MOTIL CYTOSKEL, V14, P449, DOI 10.1002/cm.970140402; GERKE V, 1990, STIMULUS RESPONSE CO, P311; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; JOHNSSON N, 1988, FEBS LETT, V236, P201, DOI 10.1016/0014-5793(88)80314-4; JOHNSSON N, 1990, EUR J BIOCHEM, V188, P1, DOI 10.1111/j.1432-1033.1990.tb15363.x; JOHNSSON N, 1986, FEBS LETT, V198, P361, DOI 10.1016/0014-5793(86)80437-9; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; MARRIOTT G, 1990, BIOCHEMISTRY-US, V29, P7004, DOI 10.1021/bi00482a008; MEERS P, 1990, BIOCHEMISTRY-US, V29, P3325, DOI 10.1021/bi00465a025; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; OSBORN M, 1988, EXP CELL RES, V175, P81, DOI 10.1016/0014-4827(88)90257-1; OWENS RJ, 1984, BIOCHEM J, V219, P309, DOI 10.1042/bj2190309; PIGAULT C, 1990, BIOCHIM BIOPHYS ACTA, V1037, P106, DOI 10.1016/0167-4838(90)90108-R; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLAEPFER DD, 1987, J BIOL CHEM, V262, P6931; SEMICH R, 1989, EUR J CELL BIOL, V50, P313; SMITH VL, 1990, CELL REGUL, V1, P165, DOI 10.1091/mbc.1.2.165; SUDHOF TC, 1985, J NEUROCHEM, V44, P1302, DOI 10.1111/j.1471-4159.1985.tb08757.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZAKS WJ, 1990, J BIOENERG BIOMEMBR, V22, P97, DOI 10.1007/BF00762942	34	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14732	14739						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1830590				2022-12-25	WOS:A1991FZ35100096
J	REIFELMILLER, AE; BERG, DT; GRINNELL, BW				REIFELMILLER, AE; BERG, DT; GRINNELL, BW			REPRESSION OF ENHANCER ACTIVITY BY THE ADENOVIRUS E1A TUMOR PROTEIN(S) IS MEDIATED THROUGH A NOVEL HELA-CELL NUCLEAR FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN ENHANCER; LONG TERMINAL REPEAT; DNA-BINDING PROTEIN; SV40 EARLY PROMOTER; RNA POLYMERASE-III; BK VIRUS ENHANCER; GENE-TRANSCRIPTION; SIMIAN VIRUS-40; TRANS-ACTIVATION; FACTOR-I	We have examined the mechanism for the host cell-dependent repression of enhancer activity by the adenovirus early region IA (EIA) proteins. The enhancer used in this study, from the human BK virus P2, functions efficiently in cis to activate expression from the adenovirus major late promoter in the human kidney cell line, 293, and in a monkey kidney cell line, MK2. In addition, enhancer activity can be stimulated by the E1A gene products in these cells. However, cis-enhancer activity is repressed in the HeLa cell line, and we demonstrate here that further repression can be induced by the E1A proteins. We show that the binding site for the negative regulatory factor involved in cis-repression, designated BK virus enhancer factor 1 (BEF-1), is also required for E1A-induced repression. Using gel mobility retardation assays, we demonstrated a 4-fold increase in active BEF-1 in nuclear extracts containing the E1A proteins. However, the E1A proteins did not change the binding pattern or the strength of binding of BEF-1 to its target sequence. BEF-1 was identified as a 98-kDa nuclear factor, and phosphorylation was shown to be important for DNA binding. Three potential nuclear factor 1 (NF-1) sites are present in the BEF-1-binding site. Using a known NF-1 site as competitor DNA in a gel mobility retardation assay, we provide evidence that BEF-1 may be a newly identified NF-1 family member. In addition, the sequence TGA present in the repressor-binding site was shown to be essential for high affinity binding of BEF-1. Overall, our data demonstrate that an enhancer can be repressed by the trans-activation of a negative regulatory factor.	ELI LILLY & CO,LILLY RES LAB,LILLY CORP CTR,DEPT MOLEC GENET,INDIANAPOLIS,IN 46285	Eli Lilly								ATCHISON ML, 1987, CELL, V48, P121, DOI 10.1016/0092-8674(87)90362-X; ATCHISON ML, 1988, ANNU REV CELL BIOL, V4, P127, DOI 10.1146/annurev.cellbio.4.1.127; AUGEREAU P, 1986, EMBO J, V5, P1791, DOI 10.1002/j.1460-2075.1986.tb04428.x; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BERG DT, 1989, MOL CELL BIOL, V9, P5248, DOI 10.1128/MCB.9.11.5248; BERG DT, 1988, NUCLEIC ACIDS RES, V16, P9057, DOI 10.1093/nar/16.18.9057; BERGMAN Y, 1988, J IMMUNOL, V1040, P2073; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BORRELLI E, 1986, P NATL ACAD SCI USA, V83, P2846, DOI 10.1073/pnas.83.9.2846; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BRENT R, 1985, CELL, V42, P3, DOI 10.1016/S0092-8674(85)80091-X; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CASSILL JA, 1989, VIROLOGY, V169, P172, DOI 10.1016/0042-6822(89)90053-6; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; CROSS FR, 1983, J VIROL, V45, P683, DOI 10.1128/JVI.45.2.683-692.1983; DAVIDSON I, 1986, NATURE, V323, P544, DOI 10.1038/323544a0; DAVIDSON RL, 1966, P NATL ACAD SCI USA, V56, P1437, DOI 10.1073/pnas.56.5.1437; DEVAUX B, 1987, MOL CELL BIOL, V7, P4560, DOI 10.1128/MCB.7.12.4560; DEVILLIERS J, 1982, NUCLEIC ACIDS RES, V10, P7965, DOI 10.1093/nar/10.24.7965; DEVILLIERS J, 1981, NUCLEIC ACIDS RES, V9, P6251, DOI 10.1093/nar/9.23.6251; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EFRAT S, 1984, P NATL ACAD SCI-BIOL, V81, P2601, DOI 10.1073/pnas.81.9.2601; EGGERDING F, 1978, J VIROL, V25, P453, DOI 10.1128/JVI.25.1.453-458.1978; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; FUJITA T, 1985, CELL, V41, P489, DOI 10.1016/S0092-8674(85)80022-2; GAYNOR RB, 1988, P NATL ACAD SCI USA, V85, P9406, DOI 10.1073/pnas.85.24.9406; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GLUZMAN Y, 1983, ENHANCERS EUKARYOTIC; GLUZMAN Y, 1985, EUKARYOTIC TRNSCRIPT; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRINNELL BW, 1984, CELL, V36, P533, DOI 10.1016/0092-8674(84)90246-0; GRINNELL BW, 1988, MOL CELL BIOL, V8, P3448, DOI 10.1128/MCB.8.8.3448; GRINNELL BW, 1986, MOL CELL BIOL, V6, P3596, DOI 10.1128/MCB.6.11.3596; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P964, DOI 10.1128/MCB.5.5.964; GRUSS P, 1981, P NATL ACAD SCI-BIOL, V78, P943, DOI 10.1073/pnas.78.2.943; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HEARING P, 1983, CELL, V33, P695, DOI 10.1016/0092-8674(83)90012-0; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HOEFFLER WK, 1985, CELL, V41, P955, DOI 10.1016/S0092-8674(85)80076-3; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; ISRAEL A, 1987, P NATL ACAD SCI USA, V84, P2653, DOI 10.1073/pnas.84.9.2653; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KHOURY G, 1983, CELL, V33, P313, DOI 10.1016/0092-8674(83)90410-5; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; KOVESDI I, 1987, NATURE, V328, P87, DOI 10.1038/328087a0; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LAIMINS LA, 1982, P NATL ACAD SCI-BIOL, V79, P6453, DOI 10.1073/pnas.79.21.6453; LEEGWATER PAJ, 1985, EMBO J, V4, P1515, DOI 10.1002/j.1460-2075.1985.tb03811.x; LEFF T, 1986, MOL CELL BIOL, V6, P201, DOI 10.1128/MCB.6.1.201; LUSKY M, 1983, MOL CELL BIOL, V3, P1108, DOI 10.1128/MCB.3.6.1108; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; Maniatis T., 1982, MOL CLONING; MAROTEAUX L, 1983, J VIROL, V47, P89, DOI 10.1128/JVI.47.1.89-95.1983; NATARAJAN V, 1985, NUCLEIC ACIDS RES, V13, P4067, DOI 10.1093/nar/13.11.4067; NEUBERGER MS, 1983, EMBO J, V2, P1373, DOI 10.1002/j.1460-2075.1983.tb01594.x; NOWOCK J, 1985, NUCLEIC ACIDS RES, V13, P2045, DOI 10.1093/nar/13.6.2045; PAWLITA M, 1984, CURR TOP MICROBIOL, V113, P26; REZNIKOFF WS, 1985, ANNU REV GENET, V19, P355, DOI 10.1146/annurev.genet.19.1.355; RICHTER JD, 1988, J VIROL, V62, P1948, DOI 10.1128/JVI.62.6.1948-1955.1988; RINGOLD GM, 1984, P NATL ACAD SCI-BIOL, V81, P3964, DOI 10.1073/pnas.81.13.3964; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; ROSENTHAL N, 1983, SCIENCE, V222, P749, DOI 10.1126/science.6314501; SASSONECORSI P, 1988, P NATL ACAD SCI USA, V85, P7192, DOI 10.1073/pnas.85.19.7192; SCHNEIDE.JA, 1971, P NATL ACAD SCI USA, V68, P127, DOI 10.1073/pnas.68.1.127; SCHOLER HR, 1984, CELL, V36, P403, DOI 10.1016/0092-8674(84)90233-2; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; SHAUL Y, 1985, EMBO J, V4, P427, DOI 10.1002/j.1460-2075.1985.tb03646.x; SIVARAMAN L, 1986, P NATL ACAD SCI USA, V83, P5914, DOI 10.1073/pnas.83.16.5914; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; STEIN RW, 1989, MOL CELL BIOL, V9, P4531, DOI 10.1128/MCB.9.10.4531; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; TIMMERS HTM, 1989, J VIROL, V63, P1470, DOI 10.1128/JVI.63.3.1470-1473.1989; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; WALL R, 1986, P NATL ACAD SCI USA, V83, P295, DOI 10.1073/pnas.83.2.295; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005; WEINBERGER J, 1986, NATURE, V322, P846, DOI 10.1038/322846a0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YOSHINAGA S, 1986, EMBO J, V5, P343, DOI 10.1002/j.1460-2075.1986.tb04218.x; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x; [No title captured]	98	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13873	13882						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1830310				2022-12-25	WOS:A1991FY02700067
J	THIERINGER, R; KUNAU, WH				THIERINGER, R; KUNAU, WH			BETA-OXIDATION SYSTEM OF THE FILAMENTOUS FUNGUS NEUROSPORA-CRASSA - STRUCTURAL CHARACTERIZATION OF THE TRIFUNCTIONAL PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-HYDROXYACYL-COA DEHYDROGENASE; ESCHERICHIA-COLI; RAT-LIVER; PURIFICATION; ENZYMES; HYDRATASE	Treatment of the trifunctional protein from Neurospora crassa with various proteases produced almost identical patterns of proteolytic fragments. To study the structural features of the protein in more detail limited proteolysis with trypsin was carried out. Polyclonal antibodies were raised against three different tryptic fragments. With the help of immunological methods and amino-terminal sequence analysis we were able to monitor the sequential cleavage steps during proteolysis. Two major fragments (an amino-terminal one of 51 kDa and a carboxyl-terminal one of 46 kDa) were identified at the first cleavage step, dividing the 93-kDa subunit of the trifunctional protein almost in half. Additional proteolysis products, deriving from either half, were formed in subsequent proteolytic steps. Combining these results with those obtained from enzyme analysis of the proteolyzed protein, a domain structure of the trifunctional protein is proposed. According to our model each subunit of the tetrameric protein consists of at least two large domains, the amino-terminal one possessing 2-enoyl-CoA hydratase and L-3-hydroxyacyl-CoA dehydrogenase activity and the carboxyl-terminal one bearing 3-hydroxyacyl-CoA epimerase activity.	RUHR UNIV BOCHUM, INST PHYSIOL CHEM, ZELLBIOCHEM ABT, W-4630 BOCHUM 1, GERMANY	Ruhr University Bochum								ANDREWS P, 1965, BIOCHEM J, V96, P595, DOI 10.1042/bj0960595; BEHRENDS W, 1988, ARCH BIOCHEM BIOPHYS, V263, P170, DOI 10.1016/0003-9861(88)90625-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DELAGARZA MM, 1985, EUR J BIOCHEM, V148, P285, DOI 10.1111/j.1432-1033.1985.tb08837.x; FONG JC, 1977, J BIOL CHEM, V252, P542; GIVOL D, 1966, BIOCHIM BIOPHYS ACTA, V113, P120, DOI 10.1016/S0926-6593(66)80127-3; HASHIMOTO T, 1990, PROG CLIN BIOL RES, V321, P137; HASHIMOTO T, 1982, ANN NY ACAD SCI, V386, P5, DOI 10.1111/j.1749-6632.1982.tb21403.x; HESLER CB, 1989, J BIOL CHEM, V264, P11317; ISHII N, 1987, J BIOL CHEM, V262, P8144; KIRSCHNER K, 1976, ANNU REV BIOCHEM, V45, P143, DOI 10.1146/annurev.bi.45.070176.001043; KUNAU WH, 1978, EUR J BIOCHEM, V91, P533, DOI 10.1111/j.1432-1033.1978.tb12707.x; KUNAU WH, 1988, BIOCHEM SOC T, V16, P418, DOI 10.1042/bst0160418; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIURA R, 1987, J BIOCHEM-TOKYO, V102, P1311, DOI 10.1093/oxfordjournals.jbchem.a122169; NUTTLEY WM, 1988, GENE, V69, P171, DOI 10.1016/0378-1119(88)90428-3; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; OSUMI T, 1985, J BIOL CHEM, V260, P8905; OSUMI T, 1979, J BIOCHEM, V85, P131, DOI 10.1093/oxfordjournals.jbchem.a132302; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; REDDY MK, 1987, P NATL ACAD SCI USA, V84, P3214, DOI 10.1073/pnas.84.10.3214; SCHMINCKEOTT E, 1978, MULTIFUNCTIONAL PROT, P1; THIERINGER R, 1991, J BIOL CHEM, V266, P13110; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YANG SY, 1983, J BIOL CHEM, V258, P9780	25	19	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13118	13123						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1830049				2022-12-25	WOS:A1991FX13200052
J	MARUTA, H; HOLDEN, J; SIZELAND, A; DABACO, G				MARUTA, H; HOLDEN, J; SIZELAND, A; DABACO, G			THE RESIDUES OF RAS AND RAP PROTEINS THAT DETERMINE THEIR GAP SPECIFICITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; BOVINE BRAIN CYTOSOL; NUCLEOTIDE-SEQUENCE; SUPPRESSOR ACTIVITY; BINDING PROTEIN; EFFECTOR DOMAIN; GENE; IDENTIFICATION; PURIFICATION; CDNA	The oncogenic transformation of a normal fibroblast by mutated Ras genes can be reversed by overexpression of a Ras-related gene called Rap1A (or Krev1). Both Ras and Rap1A proteins are G proteins and appear to serve as signal transducers only in the GTP-bound form. Therefore, GAP1 and GAP3, which stimulate the intrinsic GTPase activities of normal Ras and Rap1A proteins, respectively, serve as attenuators of their signal transducing activities. In this paper, we describe the enzymatic properties of several mutated Rap1A and chimeric Ras/Rap1A (or -1B) proteins which lead to the following conclusions: (i) the GAP3-dependent activation of both Rap1A and -1B GTPases requires Gly12, but neither Thr61 nor Gln63; (ii) residues 64 to 70 of the Rap1 GTPases are sufficient to determine their specificities for GAP3; and (iii) residues 61 to 65 of the Ras GTPases are sufficient for determining their specificities for GAP1. Thus, the domains of the Ras or Rapl proteins that determine whether their signals are attenuated by GAP1 or GAP3 are distinct from the N-terminal domain (residues 21 to 54) that determines whether their signals are oncogenic or antioncogenic. The Arg12 mutant of chimeric HaRas(l-54)/Rap1A(55-184) protein has been previously reported to be oncogenic (Zhang, K., Noda, M., Vass, W. C., Papageorge, A. G., and Lowy, D. R. (1990) Science 249, 162-165). In this paper, we show that the Val12 mutant of chimeric HaRas(1-54)/Rap1B(55-184) protein is also oncogenic, suggesting that the C-terminal geranylgeranylation of the RaplB protein can replace functionally the C-terminal farnesylation of the Ras protein to allow the G protein to be oncogenic.			MARUTA, H (corresponding author), LUDWIG INST CANC RES, MELBOURNE TUMOR BIOL BRANCH, MELBOURNE, VIC 3050, AUSTRALIA.			D'ABACO, GIOVANNA MARISA/0000-0001-5793-4072				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P4357, DOI 10.1021/bi00288a002; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEFEOJONES D, 1983, NATURE, V306, P707, DOI 10.1038/306707a0; DEFEOJONES D, 1985, SCIENCE, V228, P179, DOI 10.1126/science.3883495; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HART PA, 1990, ONCOGENE, V5, P1099; HATA Y, 1990, J BIOL CHEM, V265, P7104; JOHN J, 1989, J BIOL CHEM, V264, P13086; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MARUTA H, 1989, NATO ADV SCI I A-LIF, V170, P255; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OHMSTEDE CA, 1990, P NATL ACAD SCI USA, V87, P6527, DOI 10.1073/pnas.87.17.6527; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	43	105	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11661	11668						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1828804				2022-12-25	WOS:A1991FT76200040
J	TAKEDA, J; MAEKAWA, T; SUDO, T; SEINO, Y; IMURA, H; SAITO, N; TANAKA, C; ISHII, S				TAKEDA, J; MAEKAWA, T; SUDO, T; SEINO, Y; IMURA, H; SAITO, N; TANAKA, C; ISHII, S			EXPRESSION OF THE CRE-BP1 TRANSCRIPTIONAL REGULATOR BINDING TO THE CYCLIC-AMP RESPONSE ELEMENT IN CENTRAL-NERVOUS-SYSTEM, REGENERATING LIVER, AND HUMAN TUMORS	ONCOGENE			English	Article							ADENYLATE-CYCLASE; PROTEIN-KINASE; GENE; FAMILY; BRAIN; YEAST; CDNA; FORM	CRE-BP1 is a transcriptional regulator binding to the cyclic AMP response element (CRE). To understand the role of CRE-BP1 in vivo, we studied the expression of the CRE-BP1 gene in monkey tissues including the central nervous system, in rat regenerating liver, and in human cancer tissues compared with normal tissues. The CRE-BP1 mRNA was detected in all tissues examined, and was fairly abundant in brain. The CRE-BP1 mRNA was expressed in monkey brain tissues with different region specificities. In the hippocampus, frontal lobe, and parietal lobe, the CRE-BP1 mRNA was abundant and two mRNA species 4.0 kb and 3.7 kb in length were expressed. In rat liver, the expression of the CRE-BP1 gene was increased up to 4- to 5-fold of the normal level within 12-24 h after partial hepatectomy. Furthermore, the levels of CRE-BP1 mRNA in some clinical samples of human tumors were apparently higher than that in normal tissues. These results suggest that CRE-BP1 may be important for both the signal transduction in brain and cellular proliferation.	KYOTO UNIV,SCH MED,DEPT INTERNAL MED 2,KYOTO 606,JAPAN; KYOTO UNIV,SCH MED,DIV METAB & CLIN NUTR,KYOTO 606,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC GENET LAB,IBARAKI 305,JAPAN; UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO 108,JAPAN; KOBE UNIV,SCH MED,DEPT PHARMACOL,KOBE 650,JAPAN	Kyoto University; Kyoto University; RIKEN; University of Tokyo; Kobe University	ISHII, S (corresponding author), KYOTO UNIV,SCH MED,DEPT INTERNAL MED 2,KYOTO 606,JAPAN.		Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				BLOOMFIELD CD, 1987, CYTOGENET CELL GENET, V46, P344, DOI 10.1159/000132485; BUCHANAN PD, 1983, AM J MED GENET, V15, P121, DOI 10.1002/ajmg.1320150116; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; Curran T, 1988, ONCOGENE HDB, P307; DALLAPICCOLA B, 1988, HUM GENET, V79, P92, DOI 10.1007/BF00291721; FRIEDMAN DL, 1984, HDB EXP PHARM, V58, P151; GONZALEZ GA, 1989, NATURE, V337, P794; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Higgins GM, 1931, ARCH PATHOL, V12, P186; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; ITO A, 1990, P NATL ACAD SCI USA, V87, P3195, DOI 10.1073/pnas.87.8.3195; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAEKAWA T, 1990, IN PRESS ONCOGENE; Maniatis T., 1982, MOL CLONING; MATSUMOTO K, 1983, CELL, V32, P417, DOI 10.1016/0092-8674(83)90461-0; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NAGASE T, 1990, J BIOL CHEM, V265, P17300; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; YAMADA Y, 1990, BIOCHEM BIOPH RES CO, V168, P1274, DOI 10.1016/0006-291X(90)91166-P; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	30	61	61	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1009	1014						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1829805				2022-12-25	WOS:A1991GU62200016
J	ADZUMA, K; MIZUUCHI, K				ADZUMA, K; MIZUUCHI, K			STEADY-STATE KINETIC-ANALYSIS OF ATP HYDROLYSIS BY THE B-PROTEIN OF BACTERIOPHAGE-MU - INVOLVEMENT OF PROTEIN OLIGOMERIZATION IN THE ATPASE CYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA STRAND-TRANSFER; TRANSPOSITION PROTEIN; ESCHERICHIA-COLI; TARGET IMMUNITY; RECA PROTEIN; RECOMBINATION; PURIFICATION; MECHANISM; SEQUENCE; GENE	The DNA strand-transfer reaction of bacteriophage Mu requires Mu B protein and ATP for high efficiency. These factors facilitate the capture of target DNA by the donor protein-DNA complex. To understand the mechanism of the Mu B ATPase cycle in the Mu DNA strand-transfer reaction, we undertook a steady-state kinetic analysis of Mu B ATPase. The results reveal complex properties of the ATPase activity; Mu B protein oligomerizes in the presence of ATP, and ATP hydrolysis by the Mu B ATPase is stimulated by the protein oligomerization and shows a positive cooperativity with respect to ATP concentration. Mu B ATPase activity is also modulated by DNA and Mu A protein. DNA alone suppresses the catalytic activity of Mu B ATPase, whereas DNA enhances the apparent binding affinity for ATP. In the presence of Mu A protein together with DNA, however, the catalytic activity is greatly stimulated. Based on these results, we propose a working hypothesis in which oligomerization of Mu B protein plays a key role in its ATPase cycle.			ADZUMA, K (corresponding author), NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.							ADZUMA K, 1989, CELL, V57, P41, DOI 10.1016/0092-8674(89)90170-0; ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; ADZUMA K, 1988, STRUCTURE EXPRESSION, V3, P97; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; CRAIGIE R, 1985, J BIOL CHEM, V260, P1832; DARZINS A, 1988, P NATL ACAD SCI USA, V85, P6826, DOI 10.1073/pnas.85.18.6826; GRINDLEY NDF, 1985, ANNU REV BIOCHEM, V54, P863, DOI 10.1146/annurev.biochem.54.1.863; HAUER B, 1984, MOL GEN GENET, V194, P149, DOI 10.1007/BF00383510; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P5872, DOI 10.1021/bi00368a006; MAXWELL A, 1984, J BIOL CHEM, V259, P4472; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; Miller J. H., 1972, EXPT MOL GENETICS, P431; MILLER JL, 1984, NUCLEIC ACIDS RES, V12, P8627, DOI 10.1093/nar/12.22.8627; MIZUUCHI K, 1986, ANNU REV GENET, V20, P385; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; REYES O, 1987, PLASMID, V18, P183, DOI 10.1016/0147-619X(87)90061-8; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; Symonds N., 1987, PHAGE MU; TEPLOW DB, 1988, J BIOL CHEM, V263, P10851; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8845	21	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6159	6167						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1826105				2022-12-25	WOS:A1991FE37300027
J	VELLARD, M; SORET, J; VIEGASPEQUIGNOT, E; GALIBERT, F; VANCONG, N; DUTRILLAUX, B; PERBAL, B				VELLARD, M; SORET, J; VIEGASPEQUIGNOT, E; GALIBERT, F; VANCONG, N; DUTRILLAUX, B; PERBAL, B			C-MYB PROTOONCOGENE - EVIDENCE FOR INTERMOLECULAR RECOMBINATION OF CODING SEQUENCES	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; HUMAN ACUTE LEUKEMIAS; GENE V-MYB; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; TRANSFORMING GENE; CHICKEN DNA; DIFFERENTIAL EXPRESSION; INSITU HYBRIDIZATION; ONC GENES	We have characterized a novel chicken c-myb exon whose sequences are specifically expressed in thymic cells. In situ hybridization experiments indicate that this thymus-specific coding exon is localized on a small chromosome, distinct from the large acrocentric chromosome 3 on which we recently mapped the bulk of 15 exons, common to the c-myb mRNA species expressed in hematopoietic cells of both B and T lineages. These observations indicate that intermolecular recombination is required for the tissue-specific expression of the c-myb proto-oncogene. We also show that these thymus-specific sequences are conserved in human DNA and lie on chromosome 17q25, whereas the human c-myb locus is localized on chromosome 6q22-23. Sequencing data obtained from genomic DNA and PCR analyses performed with c-myb mRNA species expressed in chicken thymic cells strongly suggest that a repeated decameric sequence plays a key role in the recombination process.	CTR UNIV ORSAY,INST CURIE,BATIMENT 110,F-91405 ORSAY,FRANCE; INST CURIE,F-75005 PARIS,FRANCE; CTR HAYEM,F-75010 PARIS,FRANCE; UNIV PARIS 06,F-75230 PARIS 05,FRANCE; HOP NECKER ENFANTS MALAD,F-75730 PARIS 15,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite								BADING H, 1908, ONCOGENE, V3, P257; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BLICK M, 1984, BLOOD, V64, P1234; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; CHEN JH, 1980, J VIROL, V36, P162, DOI 10.1128/JVI.36.1.162-170.1980; CHINSKY J, 1985, P NATL ACAD SCI USA, V82, P565, DOI 10.1073/pnas.82.2.565; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P4714, DOI 10.1073/pnas.79.15.4714; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DOZIER C, 1986, NUCLEIC ACIDS RES, V14, P1928, DOI 10.1093/nar/14.4.1928; DUDEK H, 1989, ONCOGENE, V4, P1061; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; DUTRILLAUX B, 1971, CR ACAD SCI D NAT, V272, P2638; FU XY, 1988, MOL CELL BIOL, V8, P3582, DOI 10.1128/MCB.8.9.3582; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HAHN SL, 1989, MOL CELL BIOL, V9, P837, DOI 10.1128/MCB.9.2.837; HARPER ME, 1983, NATURE, V304, P169, DOI 10.1038/304169a0; HILDEBRAND M, 1988, P NATL ACAD SCI USA, V85, P372, DOI 10.1073/pnas.85.2.372; HOLLIDAY R, 1989, TRENDS GENET, V5, P355, DOI 10.1016/0168-9525(89)90150-9; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; JANSSEN JWG, 1986, CYTOGENET CELL GENET, V41, P129, DOI 10.1159/000132217; KAHN PM, 1971, ARCH BIOCHEM BIOPHYS, V145, P470; KIM WK, 1989, MOL CELL BIOL, V9, P3771, DOI 10.1128/MCB.9.9.3771; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KUCK U, 1987, EMBO J, V6, P2185, DOI 10.1002/j.1460-2075.1987.tb02489.x; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MAVILIO F, 1986, P NATL ACAD SCI USA, V83, P4394, DOI 10.1073/pnas.83.12.4394; MCMAHON J, 1988, ONCOGENE, V3, P717; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; NGUYEN VC, 1986, ANN GENET-PARIS, V29, P20; PERBAL B, 1983, J VIROL, V45, P925, DOI 10.1128/JVI.45.3.925-940.1983; PERBAL B, 1982, J VIROL, V44, P586, DOI 10.1128/JVI.44.2.586-594.1982; PERBAL B, 1982, J VIROL, V41, P250, DOI 10.1128/JVI.41.1.250-257.1982; Perbal B., 1988, PRACTICAL GUIDE MOL; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; ROYBURMAN P, 1983, INT J CANCER, V32, P185, DOI 10.1002/ijc.2910320208; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SORET J, 1988, FEBS LETT, V232, P227, DOI 10.1016/0014-5793(88)80422-8; SORET J, 1990, FEBS LETT, V263, P254, DOI 10.1016/0014-5793(90)81387-4; SORET J, 1985, J VIROL, V55, P227; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; URBANEK P, 1988, NUCLEIC ACIDS RES, V16, P11521, DOI 10.1093/nar/16.24.11521; UZAN G, 1987, CYTOGENET CELL GENET, V46, P707; VIEGASPEQUIGNOT E, 1978, ANN GENET-PARIS, V21, P122; VIEGASPEQUIGNOT E, 1989, P NATL ACAD SCI USA, V86, P582, DOI 10.1073/pnas.86.2.582; VLACH J, 1989, BIOCHEM BIOPH RES CO, V158, P737, DOI 10.1016/0006-291X(89)92783-6; WALDER JA, 1986, SCIENCE, V233, P569, DOI 10.1126/science.3523758; WATSON RJ, 1987, EMBO J, V6, P1643, DOI 10.1002/j.1460-2075.1987.tb02413.x; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194	60	28	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					505	514						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1840680				2022-12-25	WOS:A1991FR93900003
J	KEAN, EL				KEAN, EL			TOPOGRAPHICAL ORIENTATION IN MICROSOMAL VESICLES OF THE N-ACETYLGLUCOSAMINYLTRANSFERASES WHICH CATALYZE THE BIOSYNTHESIS OF N-ACETYLGLUCOSAMINYLPYROPHOSPHORYLDOLICHOL AND N-ACETYLGLUCOSAMINYL-N-ACETYLGLUCOSAMINYLPYROPHOSPHORYLDOLICHOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; MEMBRANE-PERMEABILITY; LIPID SYNTHESIS; GLYCOSYLATION; TOPOLOGY; DOLICHOL; MANNOSE; ROUGH	The orientation of the N-acetylglucosaminyltransferases which catalyze the biosynthesis of N-acetylglucosaminylpyrophosphoryldolichol and N-acetylglucosaminyl-N-acetylglucosaminylpyrophosphoryldolichol was examined using microsomes isolated from livers of the embryonic chick. Dolichol phosphate liposomes were used as the exogenous substrate, thus avoiding the use of detergents. The formation of both of these intermediates of the dolichol pathway was almost completely inhibited after trypsinization of the microsomes under conditions in which microsomal integrity was maintained as evaluated by determining the latency of mannose-6-phosphatase. Using dolichol [P-32]phosphate liposomes, it was shown that trypsinization did not interfere with the binding of liposomes to the microsome, suggesting that the effect of trypsinization was on the GlcNAc-transferases. Although dolichol phosphate liposomes associate with the microsomes during incubation, it was possible by sucrose density centrifugation to separate a population of liposomes which were not bound in this manner. GlcNAc lipids isolated from the free liposomes were shown to contain both the mono-GlcNAc and (GlcNAc)2 derivatives in proportions similar to those obtained from the microsomes. The possibility of transfer of the GlcNAc lipids from endogenous sources on the microsome to the liposome was examined and shown to play little role in these processes. This study strongly suggests a nonluminal, cytoplasmic orientation of the N-acetylglucosaminyltransferases concerned with the biosynthesis of the first two intermediates of the dolichol pathway.	CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,CLEVELAND,OH 44106	Case Western Reserve University	KEAN, EL (corresponding author), CASE WESTERN RESERVE UNIV,DEPT SURG,DIV OPHTHALMOL,RM 653,WEARN BLDG,CLEVELAND,OH 44106, USA.				NEI NIH HHS [EY 00393, EY 03685] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY003685] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABEIJON C, 1990, J BIOL CHEM, V265, P14691; ARION WJ, 1976, J BIOL CHEM, V251, P4901; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; COLEMAN R, 1978, J CELL BIOL, V76, P245, DOI 10.1083/jcb.76.1.245; Dallner G, 1974, Methods Enzymol, V31, P191; EGGENS I, 1982, BIOCHIM BIOPHYS ACTA, V686, P77, DOI 10.1016/0005-2736(82)90153-5; HANOVER JA, 1982, J BIOL CHEM, V257, P2787; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; KEAN EL, 1985, J BIOL CHEM, V260, P2561; KEAN EL, 1990, FED PROC, V4, P1383; LENNARZ WJ, 1987, BIOCHEMISTRY-US, V26, P7205, DOI 10.1021/bi00397a001; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MONTI JA, 1987, BIOCHIM BIOPHYS ACTA, V905, P133, DOI 10.1016/0005-2736(87)90017-4; NILSSON OS, 1978, BIOCHIM BIOPHYS ACTA, V511, P93, DOI 10.1016/0005-2736(78)90067-6; SNIDER MD, 1980, CELL, V21, P385, DOI 10.1016/0092-8674(80)90475-4; TREVELYAN WE, 1950, NATURE, V166, P444, DOI 10.1038/166444b0	16	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					942	946						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1824703				2022-12-25	WOS:A1991ET17700043
J	DIPERSIO, JF; HEDVAT, C; FORD, CF; GOLDE, DW; GASSON, JC				DIPERSIO, JF; HEDVAT, C; FORD, CF; GOLDE, DW; GASSON, JC			CHARACTERIZATION OF THE SOLUBLE HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR RECEPTOR COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1 RECEPTORS; GONADOTROPIN-RECEPTOR; EXPRESSION CLONING; HUMAN-NEUTROPHILS; SURFACE-RECEPTOR; GROWTH-FACTOR; CELL LINES; AFFINITY; BINDING; DISTINCT	The human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor (GM-R) is expressed on both hematopoietic and non-hematopoietic tissues. Although the receptor has been identified by cross-linking studies as an 84,000-dalton protein, very little is known about its biochemistry. In this report, we describe a soluble binding assay for the human GM-R which allowed us to characterize the receptor complex from various sources, including plasma membranes of placenta, neutrophils, and human myeloid leukemia cell lines. Preparation of membranes as well as solubilization by Trition X-100 and N-octylglucoside resulted in a 5-10-fold lower affinity of the receptor for GM-CSF. The K(d) decreased from 20 to 80 pM in intact cells to 200-500 pM in both intact and solubilized membranes. Binding in solution was rapid, specific for GM-CSF, and best fit "one-site" model with an approximate K(d) of 500 pM. The dissociation rate constant for the soluble GM-R was very similar to that of intact cells (k2 = 0.013 min-1 versus 0.017 min-1, respectively). As expected, solubilized membranes obtained from those cells expressing the highest number of GM-R (neutrophils and dimethyl sulfoxide-induced HL-60 cells; almost-equal-to 500-800 sites/cell) possessed the highest the highest concentration of soluble GM-R (almost-equal-to 2- 3 X 10(8) GM-R/mu-g). Cross-linking of I-125-GM-CSF to soluble GM-R resulted in the appearance of two specifically labeled complexes. A major 110-kDa receptor-ligand complex is found when cross-linking is performed with intact cells; both 110- and 200-kDa species are seen when cross-linking is performed with either intact membranes or soluble GM-R. These studies define methods by which intact GM-R can be solubilized and measured in solution, permitting a more complete biochemical characterization of the intact GM-R complex.	UNIV CALIF LOS ANGELES,SCH MED,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,DIV HEMATOL ONCOL,LOS ANGELES,CA 90024	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	DIPERSIO, JF (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024, USA.				NATIONAL CANCER INSTITUTE [R01CA030388, R01CA040163, P01CA032737, R37CA030388] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40163, CA 30388, CA 32737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; BALDWIN GC, 1989, BLOOD, V73, P1033; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BELLISARIO R, 1975, J BIOL CHEM, V250, P3837; BOMSZTYK K, 1989, P NATL ACAD SCI USA, V86, P8034, DOI 10.1073/pnas.86.20.8034; CANNISTRA SA, 1990, P NATL ACAD SCI USA, V87, P93, DOI 10.1073/pnas.87.1.93; CHENG JB, 1985, J PHARMACOL EXP THER, V236, P128; CHIBA S, 1990, LEUKEMIA, V4, P29; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; DAHINDEN CA, 1988, J EXP MED, V167, P1281, DOI 10.1084/jem.167.4.1281; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DEDHAR S, 1988, P NATL ACAD SCI USA, V85, P9253, DOI 10.1073/pnas.85.23.9253; DIPERSIO J, 1988, J BIOL CHEM, V263, P1834; DIPERSIO JF, 1988, PROSTAGLANDINS, V36, P673, DOI 10.1016/0090-6980(88)90013-5; ELLIOTT MJ, 1989, BLOOD, V74, P2349; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GASSON JC, 1986, P NATL ACAD SCI USA, V83, P669, DOI 10.1073/pnas.83.3.669; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GESSNER TG, 1989, BLOOD, V74, P2652; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HAOUR F, 1974, J BIOL CHEM, V249, P2195; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; LOPEZ AF, 1989, P NATL ACAD SCI USA, V86, P7022, DOI 10.1073/pnas.86.18.7022; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; MATSUSHIMA K, 1986, J IMMUNOL, V136, P4496; METCALF D, 1990, P NATL ACAD SCI USA, V87, P4670, DOI 10.1073/pnas.87.12.4670; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NACCACHE PH, 1988, J IMMUNOL, V140, P3541; PARK LS, 1986, J EXP MED, V164, P251, DOI 10.1084/jem.164.1.251; POSNER BI, 1974, DIABETES, V23, P209, DOI 10.2337/diab.23.3.209; ROBB RJ, 1987, P NATL ACAD SCI USA, V84, P2002, DOI 10.1073/pnas.84.7.2002; SARAGOVI H, 1990, P NATL ACAD SCI USA, V87, P11, DOI 10.1073/pnas.87.1.11; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHEFFLER JE, 1990, IN PRESS ICN UCLA S; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; UNKELESS JC, 1988, ANNU REV IMMUNOL, V6, P251, DOI 10.1146/annurev.iy.06.040188.001343; UNKELESS JC, 1989, J CLIN INVEST, V83, P355, DOI 10.1172/JCI113891; WEISBART RH, 1986, J IMMUNOL, V137, P3584; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	45	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					279	286						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1824696				2022-12-25	WOS:A1991EQ33900042
J	TESSON, F; PRIPBUUS, C; LEMOINE, A; PEGORIER, JP; PARINI, A				TESSON, F; PRIPBUUS, C; LEMOINE, A; PEGORIER, JP; PARINI, A			SUBCELLULAR-DISTRIBUTION OF IMIDAZOLINE-GUANIDINIUM-RECEPTIVE SITES IN HUMAN AND RABBIT LIVER - MAJOR LOCALIZATION TO THE MITOCHONDRIAL OUTER-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; BENZODIAZEPINE RECEPTOR; PLASMA-MEMBRANES; BINDING-SITES; HIGH-AFFINITY; H-3 IDAZOXAN; OXIDATION; DRUGS; ACID	Imidazoline-guanidinium-receptive site (IGRS) is a membrane protein that, even if recognized by a series of imidazoline and guanidinium alpha-2-adrenergic compounds, is insensitive to catecholamine and physically distinct from alpha-2 receptors (Parini, A., Coupry, I., Graham, R. M., Uzielli, I., Atlas, D., and Lanier, S. M. (1989) J. Biol. Chem. 264, 11874-11878). In the present report, we defined the subcellular localization of IGRS by performing binding studies with the imidazoline radioligand [H-3]idazoxan. Binding studies on subcellular fractions of homogenates from human and rabbit liver showed a significant increase in [H-3]idazoxan binding in a membrane fraction enriched in cytochrome oxidase activity, a specific marker for mitochondria. The enrichment in [H-43]idazoxan binding sites correlates closely with cytochrome oxidase activity in the nuclear, mitochondrial, plasma membrane, microsomal, and soluble fractions (r = 0.966, p < 0.002) but not with the specific markers for other cell compartments, suggesting a major localization of IGRS in mitochondria. Separation of inner and outer mitochondrial membranes by digitonin treatment showed that [H-3]idazoxan binding correlates positively with monoamine oxidase (r = 0.960) and negatively with cytochrome oxidase (r = 0.950) activities. In addition, in highly purified preparations of outer mitochondrial membranes obtained by hypotonic shock, [H-3]idazoxan binding activity was 12.5-fold enriched with respect to intact mitochondria. Taken together, these data show, for the first time, that IGRS in human and rabbit liver are mainly associated with the outer mitochondrial membranes. This demonstration of the major mitochondrial localization of IGRS will facilitate the characterization of its functional activity in liver.	CNRS,CTR RECH NUTR,F-92195 MEUDON,FRANCE; CHU NECKER ENFANTS MALAD,BIOCHIM LAB,INSERM,U75,F-75730 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	TESSON, F (corresponding author), CHU NECKER ENFANTS MALAD,PHARMACOL LAB,CNRS I-61670,F-75730 PARIS 15,FRANCE.		PRIP-BUUS, Carina/P-9084-2017; Tesson, Frederique/A-3218-2013	Prip-Buus, Carina/0000-0002-2153-7857; Parini, Angelo/0000-0002-9848-8838				ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; APRILLE JR, 1980, ARCH BIOCHEM BIOPHYS, V201, P564, DOI 10.1016/0003-9861(80)90546-9; BIDET M, 1990, BIOCHIM BIOPHYS ACTA, V1024, P173, DOI 10.1016/0005-2736(90)90221-9; BOUSQUET P, 1984, J PHARMACOL EXP THER, V230, P232; BROWN CM, 1990, BRIT J PHARMACOL, V99, P803, DOI 10.1111/j.1476-5381.1990.tb13010.x; CAPUZZI DM, 1984, J CARDIOVASC PHARM, V6, pS847, DOI 10.1097/00005344-198400065-00024; CATRAVAS GN, 1977, BIOCHEM PHARMACOL, V26, P211, DOI 10.1016/0006-2952(77)90305-7; CLOUET P, 1989, BIOCHEM J, V263, P867, DOI 10.1042/bj2630867; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; COUPRY I, 1990, J PHARMACOL EXP THER, V252, P293; ERNSBERGER P, 1987, EUR J PHARMACOL, V134, P1, DOI 10.1016/0014-2999(87)90125-7; ESCRIVA F, 1986, EUR J BIOCHEM, V156, P603, DOI 10.1111/j.1432-1033.1986.tb09620.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GANDHI VC, 1987, ALCOHOL, V4, P25, DOI 10.1016/0741-8329(87)90056-5; KAWAI Y, 1986, J CLIN ENDOCR METAB, V62, P827, DOI 10.1210/jcem-62-5-827; KISSANE JM, 1958, J BIOL CHEM, V233, P184; LACHAUDPETTITI V, 1990, IN PRESS EUR J PHARM; LANGIN D, 1990, MOL PHARMACOL, V37, P876; LANGIN D, 1989, EUR J PHARMACOL, V159, P199, DOI 10.1016/0014-2999(89)90707-3; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MICHEL MC, 1989, MOL PHARMACOL, V35, P324; MICHEL MC, 1989, TRENDS PHARMACOL SCI, V10, P342, DOI 10.1016/0165-6147(89)90002-3; MICHEL MC, 1990, MOL PHARMACOL, V37, P65; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NATHAN N, 1974, METHOD ENZYMOL, V31, P93; PARINI A, 1989, J BIOL CHEM, V264, P11874; PARSONS DF, 1966, ANN NY ACAD SCI, V137, P643, DOI 10.1111/j.1749-6632.1966.tb50188.x; PEGORIER JP, 1989, EUR J BIOCHEM, V184, P681, DOI 10.1111/j.1432-1033.1989.tb15067.x; SNYDER SH, 1987, FASEB J, V1, P282, DOI 10.1096/fasebj.1.4.2820823; SWITZER BR, 1971, CLIN CHIM ACTA, V32, P203, DOI 10.1016/0009-8981(71)90333-0; VIGNE P, 1989, EUR J PHARMACOL, V160, P295, DOI 10.1016/0014-2999(89)90503-7; ZAMMIT VA, 1989, BIOCHEM J, V263, P89, DOI 10.1042/bj2630089	32	156	156	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					155	160						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1845963				2022-12-25	WOS:A1991EQ33900025
J	GHOSH, TK; BIAN, J; SHORT, AD; RYBAK, SL; GILL, DL				GHOSH, TK; BIAN, J; SHORT, AD; RYBAK, SL; GILL, DL			PERSISTENT INTRACELLULAR CALCIUM POOL DEPLETION BY THAPSIGARGIN AND ITS INFLUENCE ON CELL-GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; ENDOPLASMIC-RETICULUM; INOSITOL 1,4,5-TRISPHOSPHATE; TUMOR PROMOTER; REGULATORY MECHANISM; GUANINE-NUCLEOTIDES; PLASMA-MEMBRANE; CA-2+ RELEASE; GTP; LINE	The intracellular Ca2+ pump inhibitor, thapsigargin, added to DDT1MF-2 smooth muscle cells in culture, irreversibly inhibited accumulation of Ca2+ within cells, permanently emptied the inositol 1,4,5-trisphosphate (InsP3)-sensitive Ca2+ pool, and simultaneously induced profound alteration of cell growth. After only a brief (30-min) treatment of cultured cells with 3-mu-M thapsigargin followed by extensive washing, the total releasable InsP3-sensitive Ca2+ pool remained entirely empty, even after 7 days of culture without thapsigargin. After thapsigargin treatment, cells retained viability, usual morphology, and normal mitochondrial function. Despite the otherwise normal appearance and function of thapsigargin-treated cells, cell division was completely blocked by thapsigargin. DNA synthesis was completely inhibited when thapsigargin was added immediately after passaging, but was suppressed only slowly (4-6 h) when added to rapidly synthesizing cells (24 h after passaging). Protein synthesis was reduced by approximately 70% in thapsigargin-treated cells. The sensitivity of thapsigargin-mediated inhibition of cell division, DNA synthesis, protein synthesis, and Ca2+-pumping activity were all similar with the EC50 values for thapsigargin in each case being close to 10 nM. Upon application to DDT1MF-2 cells, thapsigargin transiently increased resting cytosolic Ca2+ (0.15-mu-M) to a peak of 0.3-mu-M within 50 s; thereafter, free Ca2+ declined to 0.2-mu-M by 150 s and continued to slowly decline toward resting levels. Cells treated with thapsigargin for 1-72 h in culture displayed normal resting cytosolic Ca" levels. However, application of thapsigargin or epinephrine to such cells resulted in no change in the intracellular Ca2+, indicating that the internal Ca2+ pool remained completely empty. These results suggest that emptying of Ca2+ from intracellular thapsigargin-sensitive Ca2+-pumping pools induces profound alteration of cell proliferation.	UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore					NINDS NIH HHS [NS19304] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019304] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; BROSTROM MA, 1991, J BIOL CHEM, V266, P7037; CHUEH SH, 1987, J BIOL CHEM, V262, P13857; CHUEH SH, 1986, J BIOL CHEM, V261, P13883; CORNETT LE, 1982, J BIOL CHEM, V257, P694; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GILL DL, 1989, CELL CALCIUM, V10, P363, DOI 10.1016/0143-4160(89)90062-6; GILL DL, 1985, J BIOL CHEM, V260, P9289; GILL DL, 1986, NATURE, V320, P461, DOI 10.1038/320461a0; GILL DL, 1984, J BIOL CHEM, V259, P807; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAKII H, 1986, J CANCER RES CLIN, V111, P177, DOI 10.1007/BF00389230; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; MULLANEY JM, 1987, J BIOL CHEM, V262, P13865; MULLANEY JM, 1988, P NATL ACAD SCI USA, V85, P2499, DOI 10.1073/pnas.85.8.2499; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; NORRIS JS, 1974, NATURE, V248, P422, DOI 10.1038/248422a0; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SCARPA A, 1979, MEMBRANE TRANSPORT B, V2, P263; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; UEDA T, 1986, J BIOL CHEM, V261, P3184	39	211	211	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24690	24697						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761564				2022-12-25	WOS:A1991GW84500070
J	HARRIS, SL; PERLIN, DS; SETOYOUNG, D; HABER, JE				HARRIS, SL; PERLIN, DS; SETOYOUNG, D; HABER, JE			EVIDENCE FOR COUPLING BETWEEN MEMBRANE AND CYTOPLASMIC DOMAINS OF THE YEAST PLASMA-MEMBRANE H+-ATPASE - AN ANALYSIS OF INTRAGENIC REVERTANTS OF PMA1-105	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SACCHAROMYCES-CEREVISIAE; NEUROSPORA-CRASSA; SCHIZOSACCHAROMYCES-POMBE; SARCOPLASMIC-RETICULUM; ARABIDOPSIS-THALIANA; DIRECTED MUTAGENESIS; MOLECULAR-CLONING; COMPLEMENTARY-DNA; PROTON PUMP	A genetic approach was used to identify interacting portions of the plasma membrane H+-ATPase from Saccharomyces cerevisiae. The cellular sensitivity of the pma1-105 strain (S368F) to low external pH and to NH4+ was used to select intragenic revertants of two classes: phenotypically wild-type full revertants and partial revertants that were low pH-resistant but retained resistance to hygromycin B. All 10 full revertants had S368 restored. Among five partial revertants mapping to the original site within the phosphorylation domain, S368L and S368V were each found twice. One revertant contained an E367V substitution adjacent to the original S368F alteration. Four of 13 independently isolated second-site revertants mapped to one site, V289F, in the proposed phosphatase domain. Mutations within the proposed phosphatase and phosphorylation domains resulted in enzymes with increased vanadate sensitivity relative to the vanadate-insensitive S368F enzyme. These results suggest that sites S368, E367, and V289 contribute to a vanadate (P(i)) binding domain or are able to interact with such a site within the catalytic domain. The remaining nine partial second-site revertants mapped to six sites within the putative transmembrane regions. Mutations within the transmembrane region had less of an effect on vanadate sensitivity. Most revertant enzymes showed small but significant increases in the rate of ATP hydrolysis relative to the S368F enzyme. Several enzymes no longer displayed the acid-sensitive pH-dependence seen in the S368F enzyme. These data provide novel evidence for an interaction between putative transmembrane helices 1-3 and 7 and the ATP hydrolytic portion of the enzyme.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; PUBL HLTH RES INST CITY NEW YORK INC,NEW YORK,NY 10016	Brandeis University; Brandeis University				Haber, James/0000-0002-1878-0610	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039739, R01GM038225] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38225, GM39739] Funding Source: Medline; PHS HHS [07122] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMORY A, 1982, J BIOL CHEM, V257, P4723; BOWMAN BJ, 1979, J BIOL CHEM, V254, P2928; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; DAME JB, 1980, BIOCHEMISTRY-US, V19, P2931, DOI 10.1021/bi00554a018; GHISLAIN M, 1987, J BIOL CHEM, V262, P17549; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HARPER JF, 1989, P NATL ACAD SCI USA, V86, P1234, DOI 10.1073/pnas.86.4.1234; HUANG W, 1984, J BIOL CHEM, V259, P3287; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MALPARTIDA F, 1981, EUR J BIOCHEM, V116, P413, DOI 10.1111/j.1432-1033.1981.tb05350.x; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PARDO JM, 1989, J BIOL CHEM, V264, P8557; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; PERLIN DS, 1988, J BIOL CHEM, V263, P18118; PICK U, 1982, J BIOL CHEM, V257, P6111; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; RAMIREZ JA, 1989, P NATL ACAD SCI USA, V86, P7866, DOI 10.1073/pnas.86.20.7866; RAO US, 1990, J BIOL CHEM, V265, P7227; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSER A, 1988, J BIOL CHEM, V263, P19480; SERRANO R, 1990, BIOCHIM BIOPHYS ACTA, V1018, P195, DOI 10.1016/0005-2728(90)90247-2; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1984, CURR TOP CELL REGUL, V23, P87; SETOYOUNG D, 1991, J BIOL CHEM, V266, P1383; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; VANDYCK L, 1991, EUR J BIOCHEM, V194, P785; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	36	68	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24439	24445						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1837022				2022-12-25	WOS:A1991GW84500033
J	WAGENKNECHT, T; GRASSUCCI, R; RADKE, GA; ROCHE, TE				WAGENKNECHT, T; GRASSUCCI, R; RADKE, GA; ROCHE, TE			CRYOELECTRON MICROSCOPY OF MAMMALIAN PYRUVATE-DEHYDROGENASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROLIPOYL TRANSACETYLASE COMPONENT; HYDRATED BIOLOGICAL SPECIMENS; BOVINE KIDNEY; PROTEIN-X; ELECTRON-MICROSCOPY; MULTIENZYME COMPLEXES; FROZEN; PURIFICATION; KINASE; DOMAIN	Cryoelectron microscopy has been performed on frozen-hydrated pyruvate dehydrogenase complexes from bovine heart and kidney and on various subcomplexes consisting of the dihydrolipoyl transacetylase-based (E2) core and substoichiometric levels of the other two major components, pyruvate dehydrogenase (E1) and dihydrolipoyl dehydrogenase (E3). The diameter of frozen-hydrated pyruvate dehydrogenase complex (PDC) is 50 nm, which is significantly larger than previously reported values. On the basis of micrographs of the subcomplexes, it is concluded that the E1 and E3 are attached to the E2-core complex by extended (4-6 nm maximally) flexible tethers. PDC constructed in this manner would probably collapse and appear smaller than its native size when dehydrated, as was the case in previous electron microscopy studies. The tether linking E1 to the core involves the hinge sequence located between the E1-binding and catalytic domains in the primary sequence of E2, whereas the tether linking E3 is probably derived from a similar hinge-type sequence in component X. Tilting of the E2-based cores and comparison with model structures confirmed that their overall shape is that of a pentagonal dodecahedron. The approximately 6 copies of protein X present in PDC do not appear to be clustered in one or two regions of the complex and are not likely to be symmetrically distributed.	SUNY ALBANY, SCH PUBL HLTH SCI, DEPT BIOMED SCI, ALBANY, NY 12222 USA; KANSAS STATE UNIV AGR & APPL SCI, DEPT BIOCHEM, MANHATTAN, KS 66506 USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany; Kansas State University	WAGENKNECHT, T (corresponding author), NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, POB 509, ALBANY, NY 12201 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK018320, R01DK018320] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038161] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18320] Funding Source: Medline; NIGMS NIH HHS [GM38161] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADRIAN M, 1984, NATURE, V308, P32, DOI 10.1038/308032a0; BARRERA CR, 1972, ARCH BIOCHEM BIOPHYS, V148, P343, DOI 10.1016/0003-9861(72)90152-X; BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P2966, DOI 10.1021/bi00281a028; CHIU W, 1986, ANNU REV BIOPHYS BIO, V15, P237; COPPEL RL, 1988, P NATL ACAD SCI USA, V85, P7317, DOI 10.1073/pnas.85.19.7317; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; EASOM RA, 1989, PROTEINS, V5, P224, DOI 10.1002/prot.340050306; FRANK J, 1978, ULTRAMICROSCOPY, V3, P283, DOI 10.1016/S0304-3991(78)80038-2; FRANK J, 1981, ULTRAMICROSCOPY, V6, P343, DOI 10.1016/S0304-3991(81)80236-7; FRANK J, 1985, NEW METHODOLOGIES ST, P36; GOPALAKRISHNAN S, 1989, BIOCHEM BIOPH RES CO, V160, P715, DOI 10.1016/0006-291X(89)92492-3; GRASSUCCI R, 1990, 12TH P INT C EL MICR, P260; HAYAKAWA T, 1969, J BIOL CHEM, V244, P3660; ISHIKAWA E, 1966, P NATL ACAD SCI USA, V56, P534, DOI 10.1073/pnas.56.2.534; JAFFE JS, 1987, ULTRAMICROSCOPY, V23, P17, DOI 10.1016/0304-3991(87)90223-3; JILKA JM, 1986, J BIOL CHEM, V261, P1858; JUNGER E, 1971, BIOCHIM BIOPHYS ACTA, V250, P478, DOI 10.1016/0005-2744(71)90248-8; JUNGER E, 1977, BIOCHIM BIOPHYS ACTA, V481, P364, DOI 10.1016/0005-2744(77)90270-4; LAWSON JE, 1991, BIOCHEMISTRY-US, V30, P2834, DOI 10.1021/bi00225a015; LEPAULT J, 1983, J MICROSC-OXFORD, V129, P89, DOI 10.1111/j.1365-2818.1983.tb04163.x; LINN TC, 1972, ARCH BIOCHEM BIOPHYS, V148, P327, DOI 10.1016/0003-9861(72)90151-8; MILLIGAN RA, 1984, ULTRAMICROSCOPY, V13, P1, DOI 10.1016/0304-3991(84)90051-2; OLIVER RM, 1982, ELECTRON MICROS, V2, P1; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; Perham R N, 1987, Biochem Soc Symp, V54, P67; PERHAM RN, 1989, ANN NY ACAD SCI, V573, P1, DOI 10.1111/j.1749-6632.1989.tb14983.x; POWERSGREENWOOD SL, 1989, J BIOL CHEM, V264, P3655; RAHMATULLAH M, 1990, J BIOL CHEM, V265, P14512; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P1245; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P2221; RAHMATULLAH M, 1987, J BIOL CHEM, V262, P10265; REED L J, 1968, Brookhaven Symposia in Biology, V21, P397; ROCHE TE, 1977, ARCH BIOCHEM BIOPHYS, V183, P664, DOI 10.1016/0003-9861(77)90400-3; ROCHE TE, 1991, FASEB J, V5, pA1202; STEPP LR, 1983, J BIOL CHEM, V258, P9454; TAYLOR KA, 1976, J ULTRA MOL STRUCT R, V55, P448, DOI 10.1016/S0022-5320(76)80099-8; THEKKUMKARA TJ, 1988, FEBS LETT, V240, P45, DOI 10.1016/0014-5793(88)80337-5; WAGENKNECHT T, 1988, J MOL BIOL, V199, P137, DOI 10.1016/0022-2836(88)90384-1; WAGENKNECHT T, 1990, J BIOL CHEM, V265, P22402; WU TL, 1984, BIOCHEMISTRY-US, V23, P221, DOI 10.1021/bi00297a008	40	43	45	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24650	24656						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761562				2022-12-25	WOS:A1991GW84500064
J	KUGE, O; NISHIJIMA, M; AKAMATSU, Y				KUGE, O; NISHIJIMA, M; AKAMATSU, Y			A CHINESE-HAMSTER CDNA-ENCODING A PROTEIN ESSENTIAL FOR PHOSPHATIDYLSERINE SYNTHASE-I ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARY CELLS; ESCHERICHIA-COLI; BIOSYNTHESIS; DNA; PHOSPHATIDYLETHANOLAMINE; CLONING; MUTANT; GENES	A phosphatidylserine-auxotrophic mutant of cultured Chinese hamster ovary (CHO) cells, PSA-3, is defective in phosphatidylserine synthase I activity. Transfection of PSA-3 cells with a cDNA expression library of CHO-K1 (the parent of PSA-3) yielded a phosphatidylserine-prototrophic transformant with normal phosphatidylserine synthase I activity. Using a cDNA segment retrieved from the transformant as a probe, a cDNA clone (pssA) responsible for phosphatidylserine prototrophy was isolated from the original cDNA library by colony filter hybridization. Introduction of the pssA cDNA into PSA-3 cells restored the phosphatidylserine content, and the resultant transformant exhibited 15-fold higher specific phosphatidylserine synthase I activity than CHO-KI cells. The nucleotide sequence of the pssA cDNA contained a single long open reading frame capable of encoding a protein of 471 amino acid residues with several putative membrane-spanning domains. Our results indicated that the pssA cDNA encodes an integral membrane protein essential for phosphatidylserine synthase I activity.	NATL INST HLTH,DEPT CHEM,SHINAGAWA KU,TOKYO 141,JAPAN		NISHIJIMA, M (corresponding author), NATL INST HLTH,DEPT CHEM,SHINAGAWA KU,TOKYO 141,JAPAN.			Kuge, Osamu/0000-0003-4962-3519				BRADY G, 1984, GENE, V27, P223, DOI 10.1016/0378-1119(84)90143-4; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; GERLACH E, 1963, BIOCHEM Z, V337, P477; GROSVELD FG, 1981, GENE, V13, P227, DOI 10.1016/0378-1119(81)90028-7; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HASEGAWA K, 1989, J BIOL CHEM, V264, P19887; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUGE O, 1986, J BIOL CHEM, V261, P5790; KUGE O, 1986, J BIOL CHEM, V261, P5795; KUGE O, 1985, P NATL ACAD SCI USA, V82, P1926, DOI 10.1073/pnas.82.7.1926; KUGE O, 1991, J BIOL CHEM, V266, P6370; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEWIS WH, 1980, SOMAT CELL GENET, V6, P333, DOI 10.1007/BF01542787; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NISHIJIMA M, 1986, J BIOL CHEM, V261, P5784; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; VOELKER DR, 1986, J BIOL CHEM, V261, P1002; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669	25	74	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					24184	24189						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748687				2022-12-25	WOS:A1991GV31900100
J	LIU, LW; YE, J; JOHNSON, AE; ESMON, CT				LIU, LW; YE, J; JOHNSON, AE; ESMON, CT			PROTEOLYTIC FORMATION OF EITHER OF THE 2 PROTHROMBIN ACTIVATION INTERMEDIATES RESULTS IN FORMATION OF A HIRUGEN-BINDING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-THROMBIN; FACTOR-VA; BOVINE PROTHROMBIN; FRAGMENT 2; HIRUDIN; MEIZOTHROMBIN; CONVERSION; INHIBITION; MECHANISM; COMPLEX	Hirugen, a synthetic dodecapeptide corresponding to the carboxyl-terminal amino acids 53-64 of hirudin, binds within a deep groove in thrombin that contains a cationic region referred to as the anion-binding exosite. This region is important in many of the binary interactions of thrombin with macromolecular substrates and cofactors. Fluorescein-labeled hirugen was used to probe which steps in the prothrombin activation process generate this anion-binding exosite. Two activation cleavage sites exist in bovine prothrombin. Cleavage at Arg274-Thr275 releases the activation fragments to generate the thrombin precursor, prethrombin 2. Cleavage of prothrombin within a disulfide loop at Arg 323-Ile324 leads to formation of meizothrombin with no loss of peptide material but with formation of amidolytic activity. Cleavage of the same bond in prethrombin 2 generates thrombin. Hirugen, labeled at the amino terminus with fluorescein isothiocyanate, does not bind to prothrombin but does bind to thrombin (K(d) = 9.6 +/- 1.2 x 10(-8) M), prethrombin 2 (K(d) = 1.3 +/- 0.1 x 10(-7) M), thrombin-fragment-2 complex (K(d) = 1.1 +/- 0.2 x 10(-6) M), and meizothrombin (K(d) = 1.6 +/- 0.5 x 10(-8) M). Prothrombin fragment-2 and hirugen both bind independently to thrombin. A ternary complex can form with hirugen and fragment-2 and either thrombin or prethrombin 2, suggesting that fragment-2 and hirugen bind to discrete sites. Hirugen also alters the active site conformation of thrombin as detected by modulation of synthetic substrate hydrolytic activity. These studies suggest that conformational changes, rather than alleviating steric hindrance, are responsible for the formation of the hirugen-binding site during prothrombin activation. Furthermore, this conformational change can be effected by the cleavage of either of the two bonds required for activation of prothrombin.	OKLAHOMA MED RES FDN,HOWARD HUGHES MED INST,825 NE 13,OKLAHOMA CITY,OK 73104; HOWARD HUGHES MED INST,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,DEPT BIOCHEM,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,DEPT CHEM & BIOCHEM,NORMAN,OK 73019; UNIV OKLAHOMA,DEPT PATHOL,OKLAHOMA CITY,OK 73104	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; Howard Hughes Medical Institute; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma - Norman; University of Oklahoma System; University of Oklahoma Health Sciences Center	ESMON, CT (corresponding author), OKLAHOMA MED RES FDN,HOWARD HUGHES MED INST,825 NE 13,OKLAHOMA CITY,OK 73104, USA.		Johnson, Arthur E/G-3457-2012		NHLBI NIH HHS [R37 HL30340, R01 HL29807, R01 HL32934] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029807, R01HL032934, R37HL030340] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; CHANG JY, 1989, J BIOL CHEM, V264, P7141; CONERY BG, 1983, BIOCHEMISTRY-US, V22, P369, DOI 10.1021/bi00271a021; DIMAIO J, 1990, J BIOL CHEM, V265, P21698; ESMON CT, 1974, J BIOL CHEM, V249, P7791; ESMON NL, 1988, CIRCULATION, V78, P317; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HORTIN GL, 1991, J BIOL CHEM, V266, P6866; JAKUBOWSKI JA, 1990, BLOOD, V75, P399; JOHNSON PH, 1989, SEMIN THROMB HEMOST, V15, P302, DOI 10.1055/s-2007-1002723; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; MARAGANORE JM, 1990, BIOCHEMISTRY-US, V29, P7095, DOI 10.1021/bi00482a021; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; MERCOLA DA, 1972, BIOCHEMISTRY-US, V11, P3860, DOI 10.1021/bi00771a005; MORITA T, 1976, J BIOCHEM, V79, P1089, DOI 10.1093/oxfordjournals.jbchem.a131150; MUSCI G, 1985, BIOCHEMISTRY-US, V24, P2034, DOI 10.1021/bi00329a035; MYRMEL KH, 1976, BIOCHEMISTRY-US, V15, P1767, DOI 10.1021/bi00653a027; NASKI MC, 1990, J BIOL CHEM, V265, P13484; OWEN WG, 1974, J BIOL CHEM, V249, P594	20	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23632	23636						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748641				2022-12-25	WOS:A1991GV31900020
J	TONEY, MD; KIRSCH, JF				TONEY, MD; KIRSCH, JF			THE K258R MUTANT OF ASPARTATE-AMINOTRANSFERASE STABILIZES THE QUINONOID INTERMEDIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; 5'-PHOSPHATE; SUBSTRATE; RESIDUE; ENZYME	Lys-258 of aspartate aminotransferase forms a Schiff base with pyridoxal phosphate and is responsible for catalysis of the 1,3-prototropic shift central to the transamination reaction sequence. Substitution of arginine for Lys-258 stabilizes the otherwise elusive quinonoid intermediate, as assessed by the long wave-length absorption bands observed in the reactions of this mutant with several amino acid substrates. The external aldimine intermediate is not detectable during reactions of this mutant with amino acids, although the inhibitor alpha-methylaspartate does slowly and stably form this species. These results suggest that external aldimine formation is one of the rate-determining steps of the reaction. The pyridoxamine-5'-phosphate-like enzyme form (330-nm absorption maximum) is unreactive toward keto acid substrates, and the coenzyme bound to this species is not dissociable from the protein.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	KIRSCH, JF (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA.				NIGMS NIH HHS [GM07232, GM35393] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035393, T32GM007232] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTT EH, 1973, BIOCHEMISTRY-US, V12, P842; BRAUNSHTEIN AE, 1953, BIOKHIMIYA, V18, P393; CHEN VJ, 1987, J BIOL CHEM, V262, P14422; Christen P, 1985, TRANSAMINASES; CRONIN CN, 1988, BIOCHEMISTRY-US, V27, P4572, DOI 10.1021/bi00412a052; DUNATHAN HC, 1971, ADV ENZYMOL RAMB, V35, P79; GEHRING H, 1986, EUR J BIOCHEM, V159, P291, DOI 10.1111/j.1432-1033.1986.tb09866.x; GEHRING H, 1987, BIOCH VITAMIN B6, P115; HEROLD M, 1990, BIOCHEMISTRY-US, V29, P1907, DOI 10.1021/bi00459a035; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; JENKINS WT, 1964, J BIOL CHEM, V239, P1742; JULIN DA, 1989, BIOCHEMISTRY-US, V28, P3825, DOI 10.1021/bi00435a031; KALLEN RG, 1985, TRANSAMINASES, P37; KAMITORI S, 1990, J BIOCHEM-TOKYO, V108, P175, DOI 10.1093/oxfordjournals.jbchem.a123178; KIICK DM, 1983, BIOCHEMISTRY-US, V22, P375, DOI 10.1021/bi00271a022; KURAMITSU S, 1987, BIOCHEM BIOPH RES CO, V146, P416, DOI 10.1016/0006-291X(87)90545-6; METZLER CM, 1988, BIOCHEMISTRY-US, V27, P4923, DOI 10.1021/bi00413a050; METZLER DE, 1954, J AM CHEM SOC, V76, P648, DOI 10.1021/ja01632a004; MOORE JW, 1981, KINETICS MECHANISM, P290; MORINO Y, 1990, ANN NY ACAD SCI, V585, P32, DOI 10.1111/j.1749-6632.1990.tb28039.x; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; TONEY MD, 1991, BIOCHEMISTRY-US, V30, P7456, DOI 10.1021/bi00244a013; TONEY MD, 1992, IN PRESS PROTEIN SCI; ULEVITCH RJ, 1977, BIOCHEMISTRY-US, V16, P5350, DOI 10.1021/bi00643a028; ZIAK M, 1990, EUR J BIOCHEM, V187, P329, DOI 10.1111/j.1432-1033.1990.tb15309.x	25	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23900	23903						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748661				2022-12-25	WOS:A1991GV31900058
J	BONAVENTURA, C; CASHON, R; BONAVENTURA, J; PERUTZ, M; FERMI, G; SHIH, DTB				BONAVENTURA, C; CASHON, R; BONAVENTURA, J; PERUTZ, M; FERMI, G; SHIH, DTB			INVOLVEMENT OF THE DISTAL HISTIDINE IN THE LOW AFFINITY EXHIBITED BY HB-CHICO (LYS-BETA-66-]THR) AND ITS ISOLATED BETA-CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; HUMAN-HEMOGLOBIN; OXYGEN-BINDING; CARBON-MONOXIDE; ALPHA; MYOGLOBIN; SITE; RESIDUES; KINETICS; DISSOCIATION	Hemoglobin (Hb) Chico (Lys(beta-66) --> Thr at E10) has a diminished oxygen affinity (Shih, D. T.-b., Jones, R. T., Shih, M. F.-C., Jones, M. B., Koler, R. D., and Howard, J. (1987) Hemoglobin 11, 453-464). Our studies show that its P50 is about twice that of Hb A and that its cooperativity, anion, and Bohr effects between pH 7 and 8 are normal. The Bohr effect above pH 8 is somewhat reduced, indicating a small but previously undocumented involvement of the ionic bond formed by Lys(beta-66)in the alkaline Bohr effect. Since the oxygen affinity of the alpha-hemes is likely to be normal, that of the beta-hemes in the tetramer is likely to be reduced by the equivalent of 1.2 kcal/mol beta-heme in binding energy. Remarkably, both initial and final stages of oxygen binding to Hb Chico are of lowered affinity relative to Hb A under all conditions examined. The isolated beta-chains also show diminished oxygen affinity. In T-state Hb A, Lys(E10-beta) forms a salt bridge with one of the heme propionates, but comparison with other hemoglobin variants shows that rupture of this bridge cannot be the cause of the low oxygen affinity. X-ray analysis of the deoxy structure has now shown that Thr(beta-66) either donates a hydrogen bond to or accepts one from His-beta-63 via a bridging water molecule. This introduces additional steric hindrance to ligand binding to the T-state that results in slower rates of ligand binding. We measured the O2/CO partition coefficient and the kinetics of oxygen dissociation and carbon monoxide binding and found that lowered O2 and CO affinity is also exhibited by the R-state tetramers and the isolated beta-chains of Hb Chico.	UNIV CAMBRIDGE,POSTGRAD MED SCH,MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; OREGON HLTH SCI UNIV,SCH MED,DEPT BIOCHEM,PORTLAND,OR 97201	MRC Laboratory Molecular Biology; University of Cambridge; Oregon Health & Science University	BONAVENTURA, C (corresponding author), DUKE UNIV,MARINE LAB,CTR MARINE BIOMED,BEAUFORT,NC 28516, USA.				NHLBI NIH HHS [HL 40573] Funding Source: Medline; NIEHS NIH HHS [ESO 1908, ESO 4287] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL040573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P50ES001908, R01ES004287, P30ES001908] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABRAHAM E C, 1976, Hemoglobin, V1, P27, DOI 10.3109/03630267609031020; ACKERS GK, 1985, ANNU REV BIOCHEM, V54, P597, DOI 10.1146/annurev.bi.54.070185.003121; [Anonymous], 1968, J CRYST GROWTH, DOI [rg/10.1016/00220248(68)900717, DOI 10.1016/0022-0248(68)90071-7]; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; Baldwin J.M., 1975, Progress Biophys Molec Biol, V29, P225; BOYER PD, 1954, J AM CHEM SOC, V76, P4331, DOI 10.1021/ja01646a025; BRAUNSTEIN D, 1988, P NATL ACAD SCI USA, V85, P8497, DOI 10.1073/pnas.85.22.8497; COLLMAN JP, 1977, ACCOUNTS CHEM RES, V10, P263; DICERA E, 1987, BIOCHEMISTRY-US, V26, P4003, DOI 10.1021/bi00387a039; GERACI G, 1969, J BIOL CHEM, V244, P4664; GIBSON QH, 1973, P NATL ACAD SCI USA, V70, P1, DOI 10.1073/pnas.70.1.1; GRAY RD, 1971, J BIOL CHEM, V246, P5176; HO C, 1987, BIOCHEMISTRY-US, V26, P6299, DOI 10.1021/bi00394a001; HUANG TH, 1976, J BIOL CHEM, V251, P7114; IMAI K, 1973, BIOCHEMISTRY-US, V12, P798, DOI 10.1021/bi00729a003; Imai K, 1981, Methods Enzymol, V76, P438; JOHNSON ME, 1974, BIOCHEMISTRY-US, V13, P3653, DOI 10.1021/bi00715a005; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; LABIE D, 1971, BIOCHIM BIOPHYS ACTA, V236, P201, DOI 10.1016/0005-2795(71)90166-8; LIN SH, 1990, BIOCHEMISTRY-US, V29, P5562, DOI 10.1021/bi00475a021; LINDSTROM TR, 1972, P NATL ACAD SCI USA, V69, P1707, DOI 10.1073/pnas.69.7.1707; MATHEWS AJ, 1989, J BIOL CHEM, V264, P16573; MATTHEW JB, 1979, BIOCHEMISTRY-US, V18, P1928, DOI 10.1021/bi00577a012; MIMS MP, 1983, J BIOL CHEM, V258, P4219; MOFFAT K, 1979, SCIENCE, V206, P1035, DOI 10.1126/science.493990; MORIKIS D, 1989, BIOCHEMISTRY-US, V28, P4791, DOI 10.1021/bi00437a041; NAGAI K, 1987, NATURE, V329, P858, DOI 10.1038/329858a0; NASUDAKOUYAMA A, 1983, J MOL BIOL, V164, P451, DOI 10.1016/0022-2836(83)90061-X; Nozaki Y, 1967, METHOD ENZYMOL, V11, P715, DOI DOI 10.1016/S0076-6879(67)11088-4; OGAWA S, 1967, P NATL ACAD SCI USA, V58, P19, DOI 10.1073/pnas.58.1.19; Olson J S, 1981, Methods Enzymol, V76, P631; OLSON JS, 1971, J BIOL CHEM, V246, P5919; OLSON JS, 1988, NATURE, V336, P265, DOI 10.1038/336265a0; PAULING L, 1964, NATURE, V203, P182, DOI 10.1038/203182b0; PERUTZ MF, 1983, MOL BIOL EVOL, V1, P1; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; PHILO JS, 1988, J BIOL CHEM, V263, P682; REISBERG PI, 1980, J BIOL CHEM, V255, P4151; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SHIH DT, 1987, FED PROC, V46, P1972; SHIH DTB, 1987, HEMOGLOBIN, V11, P453, DOI 10.3109/03630268708998005; SHIH DTB, 1986, METHODS HEMATOL, V15, P124; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; TRAYLOR TG, 1980, ADV CHEM SER, V191, P219; TUCKER PW, 1978, P NATL ACAD SCI USA, V75, P1076, DOI 10.1073/pnas.75.3.1076	46	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23033	23040						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744099				2022-12-25	WOS:A1991GT48300042
J	BURMEISTER, LA; MARIASH, CN				BURMEISTER, LA; MARIASH, CN			DIETARY SUCROSE ENHANCES PROCESSING OF MESSENGER RNA-S14 NUCLEAR PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER S14 GENE; HIGH-CARBOHYDRATE DIET; RIBONUCLEIC-ACID S14; THYROID-HORMONE; CIRCADIAN FACTORS; LIPID-METABOLISM; RAPID INDUCTION; RNA PRECURSOR; RAT; EXPRESSION	The rapid response of rat hepatic mRNA-S14 to hormonal or dietary manipulation makes it an excellent model to study the control of lipogenic enzyme mRNA. The mechanism of regulation of this mRNA by triiodothyronine (T3) or sucrose remains controversial. Although initial studies suggested that T3 stabilized the nuclear precursor, subsequent studies suggest that T3 acts by increasing the transcriptional rate of this gene. More recently, the induction of mRNA-S14 by sucrose administration was shown to be associated with an increase in transcriptional "run-on" activity. Because T3 and carbohydrate feeding synergistically regulate this mRNA, we studied the response to short and long term high carbohydrate feeding in hypothyroid and euthyroid rats. We found the response to the lipogenic diet was rapid in hypothyroid rats, with maximal levels of mRNA-S14 attained by 4 h (2.2 +/- 0.6 chow fed versus 13.5 +/- 2.5 pg/mu-g RNA on lipogenic diet). The rapid induction by the lipogenic diet contrasts with the diminished response to sucrose by gastric gavage (4.6 +/- 1.2 pg/mu-g RNA) over the same time interval. Despite the large increase in the mature mRNA induced by the lipogenic diet, the rise in the nuclear precursor was small and not different from that observed after sucrose gavage (0.14 +/- 0.01 chow, 0.26 +/- 0.03 sucrose gavage, 0.25 +/- 0.04 pg/mu-g RNA lipogenic diet). The molar ratio of the mature to precursor mRNA-S14 showed progressive increases with the smallest level in the fasting rat, an intermediate level in the chow-fed and sucrose gavaged rats, and the highest level in the animals fed a lipogenic diet (2.1, 16.5, 16.3, 62.7, respectively). Based on the previously reported half-life for the mature mRNA-S14, these data show that feeding sucrose by gavage or by a lipogenic diet leads to enhanced fractional conversion of precursor to mature mRNA-S14 with a simultaneous stabilization of the precursor mRNA-S14.	UNIV MINNESOTA, DEPT MED, DIV ENDOCRINOL & METAB, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT CELL BIOL & NEUROANAT, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Burmeister, Lynn/AAA-5434-2020	Burmeister, Lynn/0000-0003-4795-2546	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032885, T32DK007203] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32 DK007203, R01-DK 32885, T32-DK 07203] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOZIN B, 1986, P NATL ACAD SCI USA, V83, P4705, DOI 10.1073/pnas.83.13.4705; DURNAM DM, 1983, ANAL BIOCHEM, V131, P385, DOI 10.1016/0003-2697(83)90188-4; GOODRIDGE AG, 1987, ANNU REV NUTR, V7, P157, DOI 10.1146/annurev.nu.07.070187.001105; HAMBLIN PS, 1989, J BIOL CHEM, V264, P21646; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JUMP DB, 1990, J BIOL CHEM, V265, P3474; JUMP DB, 1985, ENDOCRINOLOGY, V117, P2259, DOI 10.1210/endo-117-6-2259; JUMP DB, 1984, J BIOL CHEM, V259, P2789; JUMP DB, 1988, J BIOL CHEM, V263, P7254; JUMP DB, 1986, ENDOCRINOLOGY, V118, P1892, DOI 10.1210/endo-118-5-1892; JUMP DB, 1989, J BIOL CHEM, V264, P4698; KILAW WB, 1988, ENDOCRINOLOGY, V123, P2255; KINLAW WB, 1987, MOL ENDOCRINOL, V1, P609, DOI 10.1210/mend-1-9-609; KINLAW WB, 1986, J CLIN INVEST, V78, P1091, DOI 10.1172/JCI112665; KINLAW WB, 1987, ENDOCRINOLOGY, V120, P1563, DOI 10.1210/endo-120-4-1563; LIAW CW, 1984, J BIOL CHEM, V259, P7253; MARIASH CN, 1986, J BIOL CHEM, V261, P9583; MARIASH CN, 1984, BIOCHEM BIOPH RES CO, V123, P1122; MARIASH CN, 1980, J CLIN INVEST, V65, P1126, DOI 10.1172/JCI109766; NARAYAN P, 1985, MOL CELL BIOL, V5, P2642, DOI 10.1128/MCB.5.10.2642; NARAYAN P, 1984, P NATL ACAD SCI-BIOL, V81, P4687, DOI 10.1073/pnas.81.15.4687; Romsos D R, 1974, Adv Lipid Res, V12, P97; SEELIG S, 1982, ENDOCRINOLOGY, V110, P671, DOI 10.1210/endo-110-2-671; STANLEY JC, 1985, BRIT J NUTR, V53, P215, DOI 10.1079/BJN19850029; TAO TY, 1986, ANN NY ACAD SCI, V478, P20, DOI 10.1111/j.1749-6632.1986.tb15518.x; TEPPERMAN HM, 1964, AM J PHYSIOL, V206, P357, DOI 10.1152/ajplegacy.1964.206.2.357; WONG NCW, 1987, MOL ENDOCRINOL, V1, P459, DOI 10.1210/mend-1-7-459; YAFFE BM, 1990, CLIN RES, V38, pA410	29	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22905	22911						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744084				2022-12-25	WOS:A1991GT48300023
J	GLINIAK, BC; KOZAK, SL; JONES, RT; KABAT, D				GLINIAK, BC; KOZAK, SL; JONES, RT; KABAT, D			DISULFIDE BONDING CONTROLS THE PROCESSING OF RETROVIRAL ENVELOPE GLYCOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCUS-FORMING VIRUS; MURINE LEUKEMIA-VIRUS; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; SARCOMA-VIRUS; MEMBRANE-GLYCOPROTEINS; CELL-SURFACE; PROTEIN; GENE; GLYCOSYLATION	The mitogenic membrane glycoprotein (gp55) encoded by Friend erythroleukemia virus is inefficiently processed from the rough endoplasmic reticulum (RER) and only 3-5% reaches plasma membranes. Because this processed component (gp55P) contains larger and more complex oligosaccharides, it can be separated from RER gp55. In nonreducing conditions, gp55P is a unique disulfide-bonded dimer, whereas RER gp55 consists of monomers and dimers with diverse intrachain and interchain disulfide bonds. This suggests that gp55 folds heterogeneously and that only one homodimer is competent for export from the RER. Pulse-chase analyses of gp55 components labeled with radioactive amino acids indicated that formation of diverse disulfide-bonded components occurred within minutes of polypeptide synthesis and that malfolded components did not later isomerize to generate dimers competent for export from the RER. Chemical studies suggested that all 12 cysteines of gp55 were oxidized within 5 min after synthesis of the protein. In contrast, the envelope glycoprotein precursor (gPr90) encoded by a replication-competent murine leukemia virus folds more homogeneously, and it is then processed and cleaved to form an extracellular glycoprotein gp70 plus a transmembrane protein p15E. The fully processed glycoprotein contains an unoxidized cysteine sulfhydryl that isomerizes reversibly with a disulfide bond that links gp70 to p15E. Consequently, only a proportion of gp70 and p15E is disulfide-bonded, and dissociation occurs when the environment becomes even slightly reducing. The gp55 glycoprotein appears to be an extreme example of protein malfolding associated with imprecise and irreversible disulfide bonding. We discuss evidence that folding inefficiencies are common for retroviral proteins that have newly evolving pathogenic functions.	OREGON HLTH SCI UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA	Oregon Health & Science University					NCI NIH HHS [CA25810] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA025810] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; ANDERSON SJ, 1984, J VIROL, V51, P730, DOI 10.1128/JVI.51.3.730-741.1984; BERGMAN LW, 1979, J BIOL CHEM, V254, P5690; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; CREIGHTON TE, 1980, J MOL BIOL, V142, P43, DOI 10.1016/0022-2836(80)90205-3; DRESLER S, 1979, J VIROL, V30, P564, DOI 10.1128/JVI.30.2.564-575.1979; FITTING T, 1982, J BIOL CHEM, V257, P4011; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; FRIEND C, 1957, J EXP MED, V105, P307, DOI 10.1084/jem.105.4.307; GLINIAK BC, 1989, J VIROL, V63, P3561, DOI 10.1128/JVI.63.9.3561-3568.1989; HOATLIN ME, 1990, P NATL ACAD SCI USA, V87, P9985, DOI 10.1073/pnas.87.24.9985; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; ISAACS J, 1977, BIOCHIM BIOPHYS ACTA, V497, P192, DOI 10.1016/0304-4165(77)90152-0; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KOCH W, 1984, J VIROL, V49, P828, DOI 10.1128/JVI.49.3.828-840.1984; KOCH W, 1983, J VIROL, V45, P1; KOSOWER NS, 1969, BIOCHEM BIOPH RES CO, V37, P593, DOI 10.1016/0006-291X(69)90850-X; LEAMNSON RN, 1977, VIROLOGY, V76, P437, DOI 10.1016/0042-6822(77)90318-X; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LOKESHWAR VB, 1990, J BIOL CHEM, V265, P1665; LYMAN SD, 1987, MOL CELL BIOL, V7, P3287, DOI 10.1128/MCB.7.9.3287; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; MORGAN EH, 1985, J BIOL CHEM, V260, P4793; MORRISON WT, 1981, HEMOGLOBIN, V5, P403; OWENS RJ, 1990, VIROLOGY, V179, P827, DOI 10.1016/0042-6822(90)90151-G; PETERS T, 1982, J BIOL CHEM, V257, P8847; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; PINTER A, 1985, VIROLOGY, V143, P646, DOI 10.1016/0042-6822(85)90406-4; PINTER A, 1978, VIROLOGY, V91, P345, DOI 10.1016/0042-6822(78)90382-3; PINTER A, 1988, J VIROL, V62, P1016, DOI 10.1128/JVI.62.3.1016-1021.1988; POSS ML, 1989, J VIROL, V63, P189, DOI 10.1128/JVI.63.1.189-195.1989; RANDERATH K, 1970, ANAL BIOCHEM, V34, P188, DOI 10.1016/0003-2697(70)90100-4; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTUNDO RL, 1988, J BIOL CHEM, V263, P19398; RUDDON RW, 1987, J BIOL CHEM, V262, P12533; RUSCETTI SK, 1990, J VIROL, V64, P1057, DOI 10.1128/JVI.64.3.1057-1062.1990; RUTA M, 1982, J BIOL CHEM, V257, P126; SCHMIDT JW, 1987, J BIOL CHEM, V262, P13713; SRINIVAS RV, 1983, VIROLOGY, V125, P274, DOI 10.1016/0042-6822(83)90201-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580; WILLIAMS DB, 1988, J BIOL CHEM, V263, P4549; WITTE ON, 1977, VIROLOGY, V76, P539, DOI 10.1016/0042-6822(77)90236-7; YANG Y, 1990, VIROLOGY, V177, P312, DOI 10.1016/0042-6822(90)90485-A	50	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22991	22997						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744094				2022-12-25	WOS:A1991GT48300035
J	WALSH, TA; MORGAN, AE; HEY, TD				WALSH, TA; MORGAN, AE; HEY, TD			CHARACTERIZATION AND MOLECULAR-CLONING OF A PROENZYME FORM OF A RIBOSOME-INACTIVATING PROTEIN FROM MAIZE - NOVEL MECHANISM OF PROENZYME ACTIVATION BY PROTEOLYTIC REMOVAL OF A 2.8-KILODALTON INTERNAL PEPTIDE SEGMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-GLYCOSIDASE ACTIVITY; EUKARYOTIC RIBOSOMES; ALPHA-TRICHOSANTHIN; STORAGE PROTEINS; BARLEY-SEEDS; A-CHAIN; SEQUENCE; RNA; INHIBITOR; CLEAVAGE	Ribosome-inactivating proteins (RIPs) are a widely distributed family of plant enzymes that are remarkably potent catalytic inactivators of eukaryotic protein synthesis. All RIPs described to date, including the A-chain of the plant cytotoxin ricin, are polypeptides of 25-32 kDa and share significant amino acid sequence homologies. We have characterized and cloned an RIP from maize (Zea mays). In contrast to previously described RIPs, we have found that maize RIP is synthesized and stored in the kernel as a 34-kDa inactive precursor (isoelectric point = 6.5). During germination, this neutral precursor is converted into a basic, active form (isoelectric point > 9) by limited proteolysis, which removes 25 amino acids (2.8 kDa) of net charge -6 from the center of the polypeptide chain. Additional processing also occurs at the amino and carboxyl termini of the polypeptide. The sequence of the internal processed region is unique and it is equivalent to an insertion centered around Thr-156 in the amino acid sequence of ricin toxin A-chain, i.e. in the center of the enzymatically active domain. The generation of an active enzyme by removal of a large amino acid segment from the middle of a precursor polypeptide chain represents a novel mechanism of proenzyme activation that is distinct from more conventional activation mechanisms involving NH2-terminal proteolytic processing. A two-chain active RIP (comprised of 16.5- and 8.5-kDa fragments that remain tightly associated) is produced from this processing event.			WALSH, TA (corresponding author), DOWELANCO,AGR BIOTECHNOL LAB,1701 BLDG,MIDLAND,MI 48674, USA.		Ankala, Arunkanth/G-6330-2011; Walsh, Terence A/K-1863-2012	Ankala, Arunkanth/0000-0002-6373-9916; Walsh, Terence A/0000-0003-2640-8189				ASANO K, 1986, CARLSBERG RES COMMUN, V51, P129, DOI 10.1007/BF02907320; ASANO K, 1984, CARLSBERG RES COMMUN, V49, P619, DOI 10.1007/BF02907494; BARBIERI L, 1982, CANCER SURV, V1, P489; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOW TP, 1990, J BIOL CHEM, V265, P8670; COLEMAN WH, 1982, BIOCHIM BIOPHYS ACTA, V696, P239, DOI 10.1016/0167-4781(82)90053-7; COLLINS EJ, 1990, J BIOL CHEM, V265, P8665; CROUCH M L, 1983, Journal of Molecular and Applied Genetics, V2, P273; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; ENDO Y, 1988, BIOCHEM BIOPH RES CO, V150, P1032, DOI 10.1016/0006-291X(88)90733-4; ENDO Y, 1987, J BIOL CHEM, V262, P8128; GATEHOUSE AMR, 1990, ENTOMOL EXP APPL, V54, P43, DOI 10.1007/BF00353985; HARLEY SM, 1985, PLANT SCI, V41, P111, DOI 10.1016/0168-9452(85)90111-6; HARTINGS H, 1990, PLANT MOL BIOL, V14, P1031, DOI 10.1007/BF00019399; HAY PC, 1991, PHYSIOL PLANTARUM, V81, P377; HO WKK, 1991, BIOCHIM BIOPHYS ACTA, V1088, P311, DOI 10.1016/0167-4781(91)90070-3; IRWIN SD, 1990, MOL GEN GENET, V222, P400, DOI 10.1007/BF00633846; JONES BN, 1986, METHODS PROTEIN MICR, P121; KATZIN BJ, 1991, PROTEINS, V10, P251, DOI 10.1002/prot.340100309; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB FI, 1985, EUR J BIOCHEM, V148, P265, DOI 10.1111/j.1432-1033.1985.tb08834.x; Lambert J M, 1988, Cancer Treat Res, V37, P175; LEAH R, 1991, J BIOL CHEM, V266, P1564; MCGRATH MS, 1989, P NATL ACAD SCI USA, V86, P2844, DOI 10.1073/pnas.86.8.2844; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; MUNTZ K, 1985, PHYSIOL VEG, V23, P75; NEURATH H, 1989, TRENDS BIOCHEM SCI, V14, P268, DOI 10.1016/0968-0004(89)90061-3; NEURATH H, 1976, P NATL ACAD SCI USA, V73, P3825, DOI 10.1073/pnas.73.11.3825; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PRICE NC, 1989, PROTEOLYTIC ENZYMES, P163; READY M, 1984, J BIOL CHEM, V259, P5252; ROBERTS WK, 1986, BIOCHIM BIOPHYS ACTA, V880, P161, DOI 10.1016/0304-4165(86)90076-0; ROBERTS WK, 1979, BIOCHEMISTRY-US, V18, P2615, DOI 10.1021/bi00579a028; ROBERTS WK, 1986, BIOSCIENCE REP, V6, P19, DOI 10.1007/BF01145175; SANSEGUNDO B, 1990, PLANTA, V181, P467, DOI 10.1007/BF00192999; STINISSEN HM, 1983, PLANT MOL BIOL, V3, P33; STIRPE F, 1988, NUCLEIC ACIDS RES, V16, P1349, DOI 10.1093/nar/16.4.1349; STIRPE F, 1986, FEBS LETT, V195, P1, DOI 10.1016/0014-5793(86)80118-1; TOMLINSON JA, 1974, J GEN VIROL, V22, P225, DOI 10.1099/0022-1317-22-2-225; VITETTA ES, 1987, SCIENCE, V238, P1098, DOI 10.1126/science.3317828; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17	41	121	126	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23422	23427						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744135				2022-12-25	WOS:A1991GT48300096
J	YATANI, A; BROWN, AM				YATANI, A; BROWN, AM			MECHANISM OF FLUORIDE ACTIVATION OF G-PROTEIN-GATED MUSCARINIC ATRIAL K+ CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; REGULATORY COMPONENT; ADENYLATE-CYCLASE; GAMMA-PHOSPHATE; CELL-MEMBRANE; ION CHANNELS; GTP; MAGNESIUM; ALUMINUM; MUSCLE	Aluminum fluoride (AlF4-) activates the heterotrimeric G protein G(s) (stimulatory G protein of adenylylcyclase) (Sternweis, P. C., and Gilman, A. G. (1982) Proc. Natl. Acad. Sci. U. S. A. 79, 4888-4891) and G(T) (transducin), and for G(T), Bigay et al. (Bigay, J., Deterre, P., Pfister, C., and Chabre, M. (1985) FEBS Lett. 191, 181-185) have made the intriguing proposal that AlF4- acts by mimicking the gamma-phosphate of GTP. The endogenous G protein (probably G(alpha-i-2) or G(alpha-i-3) (Yatani, A., Mattera, R., Codina, J., Graf, R., Okabe, K., Padrell, E., Iyengar, R., Brown, A. M., and Birnbaumer, L. (1988) Nature 336, 680-682) that stimulates the muscarinic atrial K+ (K+[ACh]) channel is also thought to be activated by AlF4- (Kurachi, Y., Nakajima, T., and Ito, H. (1987) Circulation 76, 105P). To investigate the AlF4- mechanism, we applied potassium fluoride (KF) to the cytoplasmic face of inside-out membrane patches excised from guinea pig atria. We found that KF activated single K+[ACh] channel currents in both a concentration- and a Mg2+-dependent manner. Activation persisted following removal of KF, but unlike activation by guanosine 5'-(3-thiotriphosphate) (GTP-gamma-S), was fully reversed by removal of Mg2+. Evidence for Al3+ involvement was that the Al3+ chelator deferoxamine (500-mu-M) inhibited KF activation and that at low concentrations of KF (< 1 mM), micromolar AlCl3 concentrations potentiated KF stimulation. The rate of activation produced by KF was far slower than the rate produced by GTP or GTP-gamma-S, and unlike these guanine nucleotides, the rate was unchanged in the presence of agonist. To test the gamma-phosphate-mimicking hypothesis, we evaluated the requirement for GDP; and to accomplish this, it was necessary to establish a condition that ensured exchange of guanine nucleotides. This condition was satisfied by using the muscarinic agonist carbachol because both the rate and the extent of activation of the K+[ACh] channels produced by GTP were much faster in carbachol, and both were greatly slowed when GDP was added along with GTP. By contrast, the effects of KF were unchanged by carbachol in the presence or absence of GDP. Further evidence that GDP is not essential for activation by AlF4- was provided by the observation that during carbachol activation and following extensive washing with GMP, guanosine 5'-O-(2-thiodiphosphate) at blocking concentrations had no effect on activation produced by KF. We conclude that AlF4- activates the endogenous G protein, but the mechanism appears to be more complicated than implied by the gamma-phosphate-mimicking hypothesis.			YATANI, A (corresponding author), BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039262, R01HL036930] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023877] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36930, HL39262] Funding Source: Medline; NINDS NIH HHS [NS23877] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKAIKE N, 1986, J PHYSIOL-LONDON, V379, P171, DOI 10.1113/jphysiol.1986.sp016246; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BLACKMORE PF, 1985, J BIOL CHEM, V260, P4477; BLATTER LA, 1986, Q J EXP PHYSIOL CMS, V71, P467, DOI 10.1113/expphysiol.1986.sp003005; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; BROWN AM, 1988, AM J PHYSIOL, V254, pH401, DOI 10.1152/ajpheart.1988.254.3.H401; BROWN AM, 1991, MG2 PLUS EXCITABLE M, P21; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; DUNNE MJ, 1989, EMBO J, V8, P413, DOI 10.1002/j.1460-2075.1989.tb03392.x; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HESS P, 1982, J PHYSIOL-LONDON, V333, P173, DOI 10.1113/jphysiol.1982.sp014447; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HORIE M, 1987, AM J PHYSIOL, V253, pH210, DOI 10.1152/ajpheart.1987.253.1.H210; HOWLETT AC, 1979, J BIOL CHEM, V254, P2287; KATADA T, 1984, J BIOL CHEM, V259, P3578; KURACHI Y, 1986, PFLUG ARCH EUR J PHY, V407, P264, DOI 10.1007/BF00585301; KURACHI Y, 1986, PFLUG ARCH EUR J PHY, V407, P572, DOI 10.1007/BF00657521; KURACHI Y, 1987, CIRCULATION, V76, P105; MATTERA R, 1989, J BIOL CHEM, V264, P465; OKABE K, 1991, J GEN PHYSIOL, V97, P1279, DOI 10.1085/jgp.97.6.1279; RALL TW, 1958, J BIOL CHEM, V232, P1065; SAKMANN B, 1983, NATURE, V303, P205; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; YATANI A, 1990, AM J PHYSIOL, V258, pH1507, DOI 10.1152/ajpheart.1990.258.5.H1507; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999; YATANI A, 1987, SCIENCE, V235, P207, DOI 10.1126/science.2432660	32	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22872	22877						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744080				2022-12-25	WOS:A1991GT48300018
J	LOKESHWAR, VB; BOURGUIGNON, LYW				LOKESHWAR, VB; BOURGUIGNON, LYW			POSTTRANSLATIONAL PROTEIN MODIFICATION AND EXPRESSION OF ANKYRIN-BINDING SITE(S) IN GP85 (PGP-1/CD44) AND ITS BIOSYNTHETIC PRECURSORS DURING T-LYMPHOMA MEMBRANE BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; TRANSMEMBRANE GLYCOPROTEIN; PROTEOGLYCAN CORE; HOMING RECEPTORS; HIGH ENDOTHELIUM; LINK PROTEINS; ANTIGEN; CELLS; PURIFICATION; OLIGOSACCHARIDES	In this study, we have investigated the biosynthesis and processing of GP85 (Pgp-1/CD44), a lymphoma transmembrane glycoprotein known to contain ankyrin-binding site(s). Using a standard pulse-chase protocol, we have detected a 52-kDa polypeptide precursor (p52) within the first 5 min of pulse labeling which contains a high mannose-type N-linked oligosaccharide chains. The conversion of p52 to GP85 requires further glycosylation (both complex type N-linked and O-linked) which takes place in the Golgi complex within 10-20 min after p52 is synthesized. GP85 is then incorporated into the plasma membrane where its turnover rate is relatively slow, a t1/2 of approximately 8 h. Following tunicamycin treatment, we have detected two other precursor proteins: p42 which is unglycosylated and p58 which is O-glycosylated. p42 appears to be an immediate precursor of p52 because p52 is converted to p42 upon deglycosylation. Therefore, the biosynthesis of GP85 appears to occur in the following sequence: p42 --> p52 --> GP85. Further analysis reveals that all of the GP85 precursors (i.e. p42, p52, and p58) contain ankyrin-binding site(s). Chemical composition analysis of GP85 indicates that this molecule contains approximately 3 N-linked and 4-5 O-linked oligosaccharide chains. Although neither N-glycosylation nor O-glycosylation appears to play an important role in the formation of ankyrin-binding site(s), O-glycosylation (and to a lesser extent N-glycosylation) of GP85 is required for T-lymphoma cell surface interaction with both collagen and hyaluronic acid. These findings suggest that GP85 (Pgp-1/CD44) and its biosynthetic precursors play a pivotal role in regulating adhesion functions such as lymphocyte homing and binding to the extracellular matrix.			LOKESHWAR, VB (corresponding author), UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,MIAMI,FL 33101, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036353] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 36353] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT V, 1980, J BIOL CHEM, V255, P2540; BERG EL, 1989, IMMUNOL REV, V108, P1; BOURGUIGNON LYW, 1986, J CELL BIOL, V102, P2115, DOI 10.1083/jcb.102.6.2115; BOURGUIGNON LYW, 1991, J BIOL CHEM, V261; BUDD RC, 1987, J IMMUNOL, V138, P3120; CATER WG, 1988, J BIOL CHEM, V263, P4193; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; ELHAMMER A, 1984, J CELL BIOL, V98, P327; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GALLATIN WM, 1989, P NATL ACAD SCI USA, V86, P4654, DOI 10.1073/pnas.86.12.4654; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; HUGHES EN, 1981, J BIOL CHEM, V256, P664; HUGHES EN, 1983, J BIOL CHEM, V258, P1014; HULL SR, 1990, BIOCHEM J, V265, P121, DOI 10.1042/bj2650121; ISACKE CM, 1986, IMMUNOGENETICS, V23, P326, DOI 10.1007/BF00398797; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; JALKANEN S, 1986, IMMUNOL REV, V91, P39, DOI 10.1111/j.1600-065X.1986.tb01483.x; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; KALOMIRIS EL, 1988, J CELL BIOL, V106, P319, DOI 10.1083/jcb.106.2.319; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LEDGER PW, 1980, J CELL BIOL, V87, P663, DOI 10.1083/jcb.87.3.663; LESLEY J, 1985, IMMUNOGENETICS, V22, P149, DOI 10.1007/BF00563512; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; LOTAN R, 1975, J BIOL CHEM, V250, P8518; LYNCH F, 1987, EUR J IMMUNOL, V1, P137; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; OMEMOTO J, 1977, J BIOL CHEM, V252, P8609; PARHAM P, 1977, J BIOL CHEM, V252, P7555; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; PILLER V, 1990, J BIOL CHEM, V265, P9264; PILLER V, 1989, EUR J BIOCHEM, V183, P123, DOI 10.1111/j.1432-1033.1989.tb14904.x; TAKACZ JS, 1975, BIOCHEM BIOPH RES CO, V65, P248; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TROWBRIDGE IS, 1985, NATURE, V315, P666, DOI 10.1038/315666a0; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; WOLFFE EJ, 1990, J BIOL CHEM, V265, P341; WYNER EA, 1987, J CELL BIOL, V105, P1873; ZHOU DFH, 1989, J IMMUNOL, V143, P3390	40	117	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17983	17989						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1833390				2022-12-25	WOS:A1991GG55300045
J	MONTESSUIT, C; CAVERZASIO, J; BONJOUR, JP				MONTESSUIT, C; CAVERZASIO, J; BONJOUR, JP			CHARACTERIZATION OF A PI TRANSPORT-SYSTEM IN CARTILAGE MATRIX VESICLES - POTENTIAL ROLE IN THE CALCIFICATION PROCESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PHOSPHATE-TRANSPORT; BRUSH-BORDER MEMBRANE; ALKALINE-PHOSPHATASE; EPIPHYSEAL CARTILAGE; PARATHYROID-HORMONE; CELLS; MINERALIZATION; INHIBITORS; CA-45	The mechanisms by which calcium (Ca2+) and inorganic phosphate (P(i)) accumulate into matrix vesicles (MV) have not been elucidated. In the present study the characteristics of P(i) uptake into MV isolated from mildly rachitic chicken growth plate cartilage have been investigated. The results indicate that P(i) accumulates into MV mainly via a Na+-dependent P(i) transport system. In the absence of NaCl in the extravesicular medium, P(i) uptake was a nonsaturable process. In the presence of 150 mM NaCl, the initial rate of P(i) uptake was 4.38 +/- 1.02-fold higher than with 150 mM choline chloride (mean +/- S.E., n = 8, p < 0.005). Other cations showed partial activity to drive P(i) into MV as compared to Na+:Li+ (64.4%) > K+ (39.8%) > choline (39.0%) > tetramethylammonium (30.0%) > N-methylglucamine (26.3%). Na+-dependent P(i) transport activity displayed saturability towards increasing extravesicular concentrations of Na+ and P(i). The apparent K(m) for P(i) was 0.68 +/- 0.16 mM. The Na+ concentration producing half-maximum P(i) transport activity was 106.2 +/- 11.0 mM. Kinetic analysis suggests that Na+ interacts with the P(i) carrier with a stoichiometry of more than one Na+ ion with one P(i) molecule. In MV isolated from normal chicken growth plate cartilage, this Na+-dependent P(i) transport system was barely expressed. In contrast to the effect on P(i) uptake by MV, the activity of alkaline phosphatase was not changed when NaCl was substituted for choline chloride in the assay medium. In addition to this observation which suggests that this enzyme is not related to the P(i) transport activity described in this study, levamisole, which inhibited alkaline phosphatase activity did not affect the Na+-dependent uptake of P(i). Both arsenate and phosphonoformic acid, two inhibitors of the epithelial Na+-dependent P(i) transport systems, were active inhibitors of the Na+-dependent P(i) uptake by MV with a higher potency for phosphonoformic acid. Associated with the expression of a facilitated Na+-coupled P(i) transport in MV, in vitro calcification assessed by Ca-45(2+) uptake also showed a marked dependence on extravesicular sodium. This relationship was markedly attenuated in MV isolated from normal chicken growth plate cartilage expressing a weak Na+-facilitated P(i) transport activity. In conclusion, a saturable Na+-dependent P(i) carrier has been characterized which facilitates P(i) transport in MV. Its potential role for Ca-P(i) accumulation into MV and subsequent development of vesicular calcification followed by mineralization of the osteogenic matrix is proposed and remains to be further investigated.	UNIV GENEVA,HOP CANTONAL,DEPT MED,DIV CLIN PATHOPHYSIOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva			Montessuit, Christophe/B-5650-2011	Montessuit, Christophe/0000-0002-2580-7711				ANDERSON HC, 1990, AM J PATHOL, V136, P391; ARSENAULT AL, 1988, CALCIFIED TISSUE INT, V42, P119, DOI 10.1007/BF02556344; BONUCCI E, 1967, J ULTRA MOL STRUCT R, V20, P33, DOI 10.1016/S0022-5320(67)80034-0; CAVERZASIO J, 1986, J BIOL CHEM, V261, P3233; CAVERZASIO J, 1988, CALCIFIED TISSUE INT, V43, P83, DOI 10.1007/BF02555151; CAVERZASIO J, 1990, Calcified Tissue International, V46, pA32; CAVERZASIO J, 1985, AM J PHYSIOL, V248, pF122, DOI 10.1152/ajprenal.1985.248.1.F122; CAVERZASIO J, 1989, J BONE MINER RES  S1, V4, pS338; CHENG L, 1981, J BIOL CHEM, V256, P1556; GENGE BR, 1988, J BIOL CHEM, V263, P18513; HALE JE, 1987, J BIOL CHEM, V262, P1916; HOFFMANN N, 1976, PFLUG ARCH EUR J PHY, V362, P147, DOI 10.1007/BF00583641; LOWRY OH, 1951, J BIOL CHEM, V193, P265; REGISTER TC, 1984, J BIOL CHEM, V259, P922; SELZ T, 1989, AM J PHYSIOL, V256, pE93, DOI 10.1152/ajpendo.1989.256.1.E93; SHAPIRO IM, 1984, METAB BONE DIS RELAT, V5, P317, DOI 10.1016/0221-8747(84)90019-5; SHIRAZI SP, 1981, BIOCHEM J, V194, P803, DOI 10.1042/bj1940803; SZCZEPANSKAKONKEL M, 1986, J BIOL CHEM, V261, P6375; VALHMU WB, 1990, J BONE MINER RES S2, V5, pS162; WEHRLE JP, 1989, J MEMBRANE BIOL, V111, P199, DOI 10.1007/BF01871006; WUTHIER RE, 1975, BIOCHIM BIOPHYS ACTA, V409, P128, DOI 10.1016/0005-2760(75)90087-9; WUTHIER RE, 1978, METAB BONE DIS RELAT, V1, P125, DOI 10.1016/0221-8747(78)90049-8; WUTHIER RE, 1988, ISI ATLAS-BIOCHEM, V1, P231	23	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17791	17797						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1833387				2022-12-25	WOS:A1991GG55300015
J	TIETJE, KM; NATHANSON, NM				TIETJE, KM; NATHANSON, NM			EMBRYONIC CHICK HEART EXPRESSES MULTIPLE MUSCARINIC ACETYLCHOLINE-RECEPTOR SUBTYPES - ISOLATION AND CHARACTERIZATION OF A GENE ENCODING A NOVEL M2-MUSCARINIC ACETYLCHOLINE-RECEPTOR WITH HIGH-AFFINITY FOR PIRENZEPINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHARACTERIZATION; BINDING-PROPERTIES; ASTROCYTOMA-CELLS; GUINEA-PIG; CLONING; CDNA; RAT; PHOSPHOINOSITIDE; ANTAGONIST; SEQUENCE	Muscarinic acetylcholine receptors (mAChR) are G protein-coupled receptors which are highly conserved across mammalian species. Chick cardiac mAChR, however, have been shown to be pharmacologically, immunologically, and biochemically distinct from m2 mAChR expressed in mammalian heart. We previously reported the isolation and characterization of a novel chicken mAChR, cm4, which is expressed in chick heart and brain. We report here the isolation of an additional chicken mAChR gene whose deduced amino acid sequence is most homologous to the mammalian m2 receptor. Northern blot analysis demonstrated that this chicken m2 gene is also expressed in chick heart and brain. When stably transfected into Chinese hamster ovary (CHO) cells and Y1 adrenal carcinoma cells, the chicken m2 gene expresses a receptor protein which exhibits high affinity binding for the muscarinic antagonist quinuclidinyl benzilate and atropine, as well as the M1-selective antagonist pirenzepine and the M2-selective antagonist AF-DX 116. Therefore, when expressed in two heterologous cell lines, the chick m2 receptor has pharmacological properties that are similar to the chick m4 receptor as well as those reported for endogenous mAChR in chick cardiac cells. Consistent with the properties of the chick m4, as well as mammalian m2 and m4 receptors, the chick m2 receptor was able to functionally couple to both the inhibition of adenylate cyclase and the stimulation of phosphoinositide metabolism when expressed in CHO cells, but only the inhibition of adenylate cyclase when expressed in Y1 cells. We conclude from this study that the embryonic chick heart expresses multiple subtypes of mAChR which are highly conserved with their mammalian counterparts. Furthermore, the high degree of conservation between the mammalian m2 and the chick m2 muscarinic receptors suggests that the pharmacological differences that exist between these receptors are due to a relatively small number of specific amino acid changes rather than larger changes in receptor sequence or structure.	UNIV WASHINGTON,DEPT PHARMACOL,SJ-30,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL30639, HL07312] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007312, R01HL030639] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BERSTEIN G, 1989, MOL PHARMACOL, V36, P601; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BRAUN T, 1987, BIOCHEM BIOPH RES CO, V149, P125, DOI 10.1016/0006-291X(87)91613-5; BROWN JH, 1985, MOL PHARMACOL, V27, P525; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHOO LK, 1988, J AUTON PHARMACOL, V8, P259, DOI 10.1111/j.1474-8673.1988.tb00189.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; FUKUDA K, 1987, NATURE, V327, P623, DOI 10.1038/327623a0; GALPER JB, 1977, J BIOL CHEM, V252, P8692; HALVORSEN SW, 1981, J BIOL CHEM, V256, P7941; HAMMER R, 1982, LIFE SCI, V31, P2991, DOI 10.1016/0024-3205(82)90066-2; HAMMER R, 1986, LIFE SCI, V38, P1653, DOI 10.1016/0024-3205(86)90409-1; HENIKOFF S, 1987, PROMEGA NOTES, V8, P1; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KUBO T, 1986, FEBS LETT, V209, P367, DOI 10.1016/0014-5793(86)81144-9; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; KWATRA MM, 1989, MOL PHARMACOL, V35, P553; LAZARENO S, 1990, MOL PHARMACOL, V38, P805; LINDMAR R, 1987, EUR J PHARMACOL, V139, P359, DOI 10.1016/0014-2999(87)90596-6; LUETJE CW, 1988, J BIOL CHEM, V263, P13357; LUETJE CW, 1987, BIOCHEMISTRY-US, V26, P4876, DOI 10.1021/bi00389a040; MASTERS SB, 1984, MOL PHARMACOL, V26, P149; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NATHANS J, 1987, ANNU REV NEUROSCI, V10, P163; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; SUBERS EM, 1988, J MOL CELL CARDIOL, V20, P131, DOI 10.1016/S0022-2828(88)80026-9; SUBERS EM, 1988, TRENDS PHARM SCI S, V8, P25; TIETJE KM, 1990, J BIOL CHEM, V265, P2828; TIETZ H, 1989, TRENDS PHARMACOL SCI, P107; WIGLER M, 1979, P NATL ACAD SCI USA, V83, P6795; YASAMURA Y, 1966, CANCER RES, V26, P529	46	80	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17382	17387						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1840593				2022-12-25	WOS:A1991GF44500062
J	VOSTAL, JG; JACKSON, WL; SHULMAN, NR				VOSTAL, JG; JACKSON, WL; SHULMAN, NR			CYTOSOLIC AND STORED CALCIUM ANTAGONISTICALLY CONTROL TYROSINE PHOSPHORYLATION OF SPECIFIC PLATELET PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULUM CA-2+-ATPASE; CA-2+ POOL; THROMBIN; THAPSIGARGIN; AGGREGATION; INDICATORS; GENISTEIN; PROTEASE; VANADATE; KINASE	Depletion of intracellular calcium stores appears to increase plasma membrane permeability for calcium by an as yet obscure mechanism. We found that the Ca2+ ionophore, A23187, and thrombin elevate cytosolic calcium ([Ca2+]i) equally and cause tyrosine phosphorylation of a 130-kDa protein and to a lesser extent 80- and 60-kDa proteins. Chelation of [Ca2+]i by 1,2bis(2-aminophenoxyethane)N,N,N',N'-tetraacetic acid/acetomethoxy ester decreased thrombin-induced tyrosine phosphorylation responses. These results suggested that [Ca2+]i elevation promotes tyrosine phosphorylation. Tyrosine phosphorylation persisted in the presence or absence of extracellular calcium after thrombin stimulation but subsided rapidly after A23187 addition if extracellular calcium was present. When Ca2+/ATPase activity, which is apparently required to maintain calcium stores, is inhibited by low temperature, tyrosine phosphorylation of the 130-kDa protein occurs. Rewarming platelets reverses tyrosine phosphorylation only if extracellular calcium is present. Thapsigargin, a calcium ATPase inhibitor, also induces tyrosine phosphorylation of the 130-kDa protein and prevents dephosphorylation of this protein when added prior to rewarming. These observations suggest that homeostatic levels of calcium in storage compartments favor tyrosine dephosphorylation of specific proteins. Thus the levels of [Ca2+]i and stored calcium appear to control tyrosine phosphorylation antagonistically. Tyrosine phosphorylation may play a role in regulating calcium channel function.			VOSTAL, JG (corresponding author), NIDDKD, CLIN HEMATOL BRANCH, BLDG 10, RM 8C-101, BETHESDA, MD 20892 USA.							BENNETT WF, 1980, J CELL BIOL, V86, P280, DOI 10.1083/jcb.86.1.280; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BRASS LF, 1984, J BIOL CHEM, V259, P2563; DAVIES TA, 1989, J BIOL CHEM, V264, P19600; DHAR A, 1990, MOL PHARMACOL, V37, P519; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FOX JEB, 1990, BLOOD, V76, P2510; GAUDETTE DC, 1990, BIOCHEM BIOPH RES CO, V170, P238, DOI 10.1016/0006-291X(90)91265-T; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HORAK ID, 1990, ONCOGENE, V5, P597; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; INAZU T, 1990, BIOCHEM BIOPH RES CO, V170, P259, DOI 10.1016/0006-291X(90)91268-W; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; JOHNSON PC, 1989, METHOD ENZYMOL, V169, P386; KATTLOVE HE, 1971, BLOOD-J HEMATOL, V38, P39, DOI 10.1182/blood.V38.1.39.39; LEREA KM, 1989, BIOCHEMISTRY-US, V28, P9286, DOI 10.1021/bi00450a008; LIU B, 1991, CELL CALCIUM, V12, P11, DOI 10.1016/0143-4160(91)90080-X; MERTZ LM, 1990, J BIOL CHEM, V265, P15010; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; Murachi T, 1980, Adv Enzyme Regul, V19, P407; NACHMIAS VT, 1985, NATURE, V313, P70, DOI 10.1038/313070a0; NAKAMURA J, 1989, J BIOL CHEM, V264, P17029; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; PHILLIPS DR, 1977, J BIOL CHEM, V252, P5602; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; REID DM, 1990, BLOOD, V75, P2194; RINK TJ, 1990, ANNU REV PHYSIOL, V52, P431, DOI 10.1146/annurev.ph.52.030190.002243; RINK TJ, 1989, CELL CALCIUM, V10, P385, DOI 10.1016/0143-4160(89)90064-X; ROBBLEE LS, 1979, TRANSFUSION, V19, P45, DOI 10.1046/j.1537-2995.1979.19179160265.x; SHUTTLEWORTH TJ, 1991, J BIOL CHEM, V266, P1410; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1987, BIOCHEM BIOPH RES CO, V142, P654, DOI 10.1016/0006-291X(87)91464-1; VERMA A, 1990, BIOCHEM BIOPH RES CO, V172, P811, DOI 10.1016/0006-291X(90)90747-B; WHITE GC, 1980, BIOCHIM BIOPHYS ACTA, V631, P130, DOI 10.1016/0304-4165(80)90061-6	38	171	173	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16911	16916						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1832159				2022-12-25	WOS:A1991GD63500105
J	TSUJI, M; VANDERVLIET, PC; KITCHINGMAN, GR				TSUJI, M; VANDERVLIET, PC; KITCHINGMAN, GR			TEMPERATURE-SENSITIVE MUTANTS OF ADENOVIRUS SINGLE-STRANDED DNA-BINDING PROTEIN - INABILITY TO SUPPORT DNA-REPLICATION IS ASSOCIATED WITH AN ALTERED DNA-BINDING ACTIVITY OF THE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANIMAL VIRUS-DNA; TERMINAL PROTEIN; TYPE-5 ADENOVIRUS; FUNCTIONAL-CHARACTERIZATION; PURIFIED PROTEINS; MESSENGER-RNA; ACID BINDING; HELA-CELLS; INVITRO; INITIATION	The adenovirus single-stranded DNA-binding protein (DBP) is an essential factor in viral DNA replication. Three temperature-sensitive (ts) adenoviruses (Ad2+ND1ts23, Ad2ts111A, and Ad5ts125) are known to have single amino acid substitutions in their DBPs that result in defective DNA replication at the nonpermissive temperature. To elucidate the mechanism(s) involved in the t8 phenotype, we purified the three mutant DBPs and studied their DNA-binding properties and their ability to support DNA replication in an in vitro system. The results confirm that the three ts DBPs were incapable of supporting DNA replication at the nonpermissive temperature (40-degrees-C). The defect was found at both the initiation and elongation steps of DNA replication. The 2-fold stimulation of pTP.dCMP formation by the DBP was lost by prior heating of the ts DBPs. The pronounced effect of the DBP on the early elongation process was severely diminished, but not abolished, by prior heating to 40-degrees-C. The functional change at 40-degrees-C was irreversible, as the ts DBPs preincubated at 40-degrees-C were no longer active when assayed at 30-degrees-C. Upon heating to 40-degrees-C, all three ts DBPs lost their ability to bind to oligonucleotides, although they still retained some binding activity for large single-stranded DNAs such as M13 DNA. Thus, the inability of these three ts DBPs to support DNA replication is attributable to their altered DNA-binding properties.	ST JUDE CHILDRENS RES HOSP, DEPT VIROL & MOLEC BIOL, MEMPHIS, TN 38101 USA; STATE UNIV UTRECHT, PHYSIOL CHEM LAB, UTRECHT, NETHERLANDS	St Jude Children's Research Hospital; Utrecht University					NIAID NIH HHS [AI-17654] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017654] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABICH A, 1981, CELL, V26, P371, DOI 10.1016/0092-8674(81)90206-3; BERG JM, 1990, J BIOL CHEM, V265, P6513; BRAYER GD, 1983, J MOL BIOL, V169, P565, DOI 10.1016/S0022-2836(83)80065-5; CARTER TH, 1982, VIROLOGY, V117, P519, DOI 10.1016/0042-6822(82)90493-7; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHALLBERG MD, 1980, P NATL ACAD SCI-BIOL, V77, P5105, DOI 10.1073/pnas.77.9.5105; CHALLBERG MD, 1979, P NATL ACAD SCI USA, V76, P655, DOI 10.1073/pnas.76.2.655; CLEAT PH, 1989, EMBO J, V8, P1841, DOI 10.1002/j.1460-2075.1989.tb03579.x; CLEGHON VG, 1986, P NATL ACAD SCI USA, V83, P8947, DOI 10.1073/pnas.83.23.8947; DEJONG EAM, 1989, J MOL BIOL, V206, P133, DOI 10.1016/0022-2836(89)90529-9; DESIDERIO SV, 1981, J MOL BIOL, V145, P319, DOI 10.1016/0022-2836(81)90208-4; DUNSWORTHBROWNE M, 1980, NUCLEIC ACIDS RES, V8, P543, DOI 10.1093/nar/8.3.543; ENOMOTO T, 1981, P NATL ACAD SCI-BIOL, V78, P6779, DOI 10.1073/pnas.78.11.6779; ENSINGER MJ, 1972, J VIROL, V10, P328, DOI 10.1128/JVI.10.3.328-339.1972; FIELD J, 1984, J BIOL CHEM, V259, P9487; FOWLKES DM, 1979, J MOL BIOL, V132, P163, DOI 10.1016/0022-2836(79)90389-9; FRIEFELD BR, 1983, VIROLOGY, V124, P380, DOI 10.1016/0042-6822(83)90354-9; FRIEFELD BR, 1983, CURR TOP MICROBIOL I, V110, P221; GINSBERG HS, 1977, J VIROL, V23, P142, DOI 10.1128/JVI.23.1.142-151.1977; Green M, 1979, Methods Enzymol, V58, P425; HAY RT, 1989, BIOCHEM J, V258, P3, DOI 10.1042/bj2580003; IKEDA JE, 1981, P NATL ACAD SCI-BIOL, V78, P884, DOI 10.1073/pnas.78.2.884; KAPLAN LM, 1979, P NATL ACAD SCI USA, V76, P5534, DOI 10.1073/pnas.76.11.5534; KENNY MK, 1988, J BIOL CHEM, V263, P9809; KLEIN H, 1979, J BIOL CHEM, V254, P1051; KREVOLIN MD, 1987, VIROLOGY, V156, P167, DOI 10.1016/0042-6822(87)90448-X; KRUIJER W, 1982, NUCLEIC ACIDS RES, V10, P4493, DOI 10.1093/nar/10.15.4493; KRUIJER W, 1983, VIROLOGY, V124, P425, DOI 10.1016/0042-6822(83)90358-6; KUIL ME, 1989, BIOCHEMISTRY-US, V28, P9795, DOI 10.1021/bi00451a038; LEEGWATER PAJ, 1988, BIOCHIM BIOPHYS ACTA, V951, P403, DOI 10.1016/0167-4781(88)90113-3; LICHY JH, 1982, P NATL ACAD SCI-BIOL, V79, P5225, DOI 10.1073/pnas.79.17.5225; LINDENBAUM JO, 1986, J BIOL CHEM, V261, P218; MAIZEL JV, 1971, METHOD VIROL, V5, P170; MANIATIS T., 1982, MOL CLONING LABORATO, P382; MEYERS ML, 1990, J BIOL CHEM, V265, P5875; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P4266, DOI 10.1073/pnas.80.14.4266; NEALE GAM, 1989, J BIOL CHEM, V264, P3153; NEVINS JR, 1980, P NATL ACAD SCI-BIOL, V77, P1893, DOI 10.1073/pnas.77.4.1893; NICOLAS JC, 1983, VIROLOGY, V126, P228, DOI 10.1016/0042-6822(83)90474-9; PRELICH G, 1986, J VIROL, V57, P883, DOI 10.1128/JVI.57.3.883-892.1986; PRUIJN GJM, 1986, NATURE, V322, P656, DOI 10.1038/322656a0; REICH NC, 1983, VIROLOGY, V128, P480, DOI 10.1016/0042-6822(83)90274-X; REKOSH DMK, 1977, CELL, V11, P283, DOI 10.1016/0092-8674(77)90045-9; RIVERA MJ, 1978, NUCLEIC ACIDS RES, V5, P2895, DOI 10.1093/nar/5.8.2895; SCHECHTER NM, 1980, BIOCHEMISTRY-US, V19, P2802, DOI 10.1021/bi00553a041; SEIBERG M, 1989, J VIROL, V63, P1134, DOI 10.1128/JVI.63.3.1134-1141.1989; STILLMAN BW, 1984, J VIROL, V50, P598, DOI 10.1128/JVI.50.2.598-605.1984; STUIVER MH, 1990, J VIROL, V64, P379, DOI 10.1128/JVI.64.1.379-386.1990; STUNNENBERG HG, 1988, NUCLEIC ACIDS RES, V16, P2431, DOI 10.1093/nar/16.6.2431; TAMANOI F, 1982, P NATL ACAD SCI-BIOL, V79, P2221, DOI 10.1073/pnas.79.7.2221; VANAMERONGEN H, 1987, BIOCHEMISTRY-US, V26, P4646, DOI 10.1021/bi00389a009; VANBERGEN BGM, 1983, J VIROL, V46, P642, DOI 10.1128/JVI.46.2.642-648.1983; VANDERVLIET PC, 1977, VIROLOGY, V80, P98, DOI 10.1016/0042-6822(77)90383-X; VANDERVLIET PC, 1975, VIROLOGY, V67, P415, DOI 10.1016/0042-6822(75)90443-2; VANDERVLIET PC, 1973, NATURE-NEW BIOL, V246, P170, DOI 10.1038/newbio246170a0; VANDERVLIET PC, 1975, J VIROL, V15, P348, DOI 10.1128/JVI.15.2.348-354.1975; VANDERVLIET PC, 1988, CANCER CELL, V6, P61; VOS HL, 1988, VIROLOGY, V163, P1, DOI 10.1016/0042-6822(88)90227-9	59	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16178	16187						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1831456				2022-12-25	WOS:A1991GB97700097
J	RUTHERFORD, RAD; WHARTON, J; NEEDLEMAN, P; POLAK, JM				RUTHERFORD, RAD; WHARTON, J; NEEDLEMAN, P; POLAK, JM			AUTORADIOGRAPHIC DISCRIMINATION OF BRAIN AND ATRIAL NATRIURETIC PEPTIDE-BINDING SITES IN THE RAT-KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARTICULATE GUANYLATE-CYCLASE; VASCULAR SMOOTH-MUSCLE; SEQUENCE-ANALYSIS; QUANTITATIVE AUTORADIOGRAPHY; RECEPTOR SUBTYPES; CYCLIC-GMP; FACTOR ANF; CELLS; LOCALIZATION; ACTIVATION	Brain (BNP) and atrial natriuretic peptides (ANP) have been identified which may represent endogenous agonists of kidney receptor subtypes. Quantitative in vitro autoradiography was used to investigate the regional distribution of receptor subpopulations and the competitive inhibition of I-125 porcine BNP1-26 (pBNP1-26) and I-125 rat alpha-ANP1-28 (rANP1-28) renal binding sites. Specific, high affinity binding (K(d) 0.2-1.37 nM range) was localized to glomeruli, inner medulla, interlobar and arcuate arteries, vasa recta bundles, and smooth muscle in the renal pelvis. pBNP1-26 competed for the same sites as rANP1-28 but displayed a lower potency and was less selective for nonclearance sites. Clearance binding sites were discriminated by competitive inhibition with C-ANP4-23 and comprised some 65% of glomerular sites as well as the vast majority of sites in the renal pelvis. Nonclearance sites predominated in the inner medulla and intrarenal arteries. C-terminal changes in amino acid sequence induced a significant loss of inhibitory potency. Immunohistochemical studies identified a distinct population of BNP-like immunoreactive renal nerve fibers, associated with intra-renal arteries. Circulating natriuretic peptides and BNP sequences derived from renal nerves may influence renal function by interacting with specific receptor subpopulations in the kidney.	ROYAL POSTGRAD MED SCH,DEPT HISTOCHEM,DU CANE RD,LONDON W12 0NN,ENGLAND; MOSANTO CO,ST LOUIS,MO 63198	Imperial College London								AALKJAER C, 1985, BRIT J PHARMACOL, V86, P447, DOI 10.1111/j.1476-5381.1985.tb08914.x; ALMEIDA FA, 1989, AM J PHYSIOL, V256, pR469, DOI 10.1152/ajpregu.1989.256.2.R469; ANANDSRIVASTAVA MB, 1990, J BIOL CHEM, V265, P8566; ANDERSON JV, 1986, NEUROPEPTIDES, V7, P159, DOI 10.1016/0143-4179(86)90092-2; BALLERMANN BJ, 1986, CIRC RES, V58, P619, DOI 10.1161/01.RES.58.5.619; BASKIN DG, 1989, NEUROSCI LETT, V104, P171, DOI 10.1016/0304-3940(89)90350-9; BROWN J, 1990, AM J PHYSIOL, V258, pR1078, DOI 10.1152/ajpregu.1990.258.4.R1078; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; DELEAN A, 1985, BIOCHEM BIOPH RES CO, V132, P360, DOI 10.1016/0006-291X(85)91030-7; FELLER SM, 1989, TRENDS PHARMACOL SCI, V10, P93, DOI 10.1016/0165-6147(89)90199-5; FETHIERE J, 1989, MOL PHARMACOL, V35, P584; FIGUEROA CD, 1990, NEPHROL DIAL TRANSPL, V5, P25, DOI 10.1093/ndt/5.1.25; FLYNN TG, 1989, BIOCHEM BIOPH RES CO, V161, P830, DOI 10.1016/0006-291X(89)92675-2; FONTOURA BMA, 1990, AM J PHYSIOL, V258, pC692, DOI 10.1152/ajpcell.1990.258.4.C692; FULLER F, 1988, J BIOL CHEM, V263, P9395; GARCIA R, 1985, BIOCHEM BIOPH RES CO, V126, P178, DOI 10.1016/0006-291X(85)90588-1; GUNNING M, 1990, AM J PHYSIOL, V258, pF467, DOI 10.1152/ajprenal.1990.258.3.F467; GUNNING M E, 1988, American Journal of Physiology, V255, pF324; HANCOCK AA, 1988, TRENDS PHARMACOL SCI, V9, P29, DOI 10.1016/0165-6147(88)90239-8; HEIM JM, 1989, BIOCHEM BIOPH RES CO, V163, P37, DOI 10.1016/0006-291X(89)92095-0; HINO J, 1990, BIOCHEM BIOPH RES CO, V167, P693, DOI 10.1016/0006-291X(90)92081-A; ITOH H, 1989, BIOCHEM BIOPH RES CO, V161, P732, DOI 10.1016/0006-291X(89)92661-2; IWATA T, 1989, EUR J PHARMACOL, V159, P321, DOI 10.1016/0014-2999(89)90166-0; KOJIMA M, 1989, BIOCHEM BIOPH RES CO, V159, P1420, DOI 10.1016/0006-291X(89)92268-7; KOLLENDA MC, 1990, AM J PHYSIOL, V258, pR1084, DOI 10.1152/ajpregu.1990.258.4.R1084; LEITMAN DC, 1986, J BIOL CHEM, V261, P1650; LEVIN ER, 1990, J BIOL CHEM, V265, P10019; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MAEDA T, 1990, EUR J PHARMACOL, V176, P341, DOI 10.1016/0014-2999(90)90028-5; MAEKAWA K, 1988, BIOCHEM BIOPH RES CO, V157, P410, DOI 10.1016/S0006-291X(88)80062-7; MARINGREZ M, 1986, NATURE, V324, P473, DOI 10.1038/324473a0; MARTIN ER, 1989, AM J PHYSIOL, V257, pF649, DOI 10.1152/ajprenal.1989.257.4.F649; MCKENZIE JC, 1985, J HISTOCHEM CYTOCHEM, V33, P828, DOI 10.1177/33.8.3160763; MILLER JA, 1987, NEUROSCI LETT, V81, P345, DOI 10.1016/0304-3940(87)90408-3; NEEDLEMAN P, 1986, NEW ENGL J MED, V314, P828; OEHLENSCHLAGER WF, 1989, EUR J PHARMACOL, V161, P159, DOI 10.1016/0014-2999(89)90838-8; OHISHI K, 1988, AM J PHYSIOL, V255, pF415, DOI 10.1152/ajprenal.1988.255.3.F415; PANDEY KN, 1988, J BIOL CHEM, V263, P13406; SAPER CB, 1989, NEUROSCI LETT, V96, P29, DOI 10.1016/0304-3940(89)90238-3; SAPER CB, 1985, SCIENCE, V227, P1047, DOI 10.1126/science.2858127; SCARBOROUGH RM, 1988, J BIOL CHEM, V263, P16818; SCARBOROUGH RM, 1986, J BIOL CHEM, V261, P2960; Schweder T., 1981, Applied Statistics, V30, P16, DOI 10.2307/2346653; SONG DL, 1988, FEBS LETT, V232, P125, DOI 10.1016/0014-5793(88)80400-9; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUDOH T, 1989, BIOCHEM BIOPH RES CO, V159, P1427, DOI 10.1016/0006-291X(89)92269-9; TOGASHI K, 1989, FEBS LETT, V250, P235, DOI 10.1016/0014-5793(89)80728-8; TORDA T, 1989, BIOCHEM BIOPH RES CO, V159, P1032, DOI 10.1016/0006-291X(89)92212-2; VELDKAMP PJ, 1988, AM J PHYSIOL, V254, pF440, DOI 10.1152/ajprenal.1988.254.3.F440; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; WHARTON J, 1988, CELL TISSUE RES, V254, P155; YIP CC, 1985, J BIOL CHEM, V260, P8229; [No title captured]	54	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5819	5826						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1826004				2022-12-25	WOS:A1991FD37000073
J	MASSEY, D; TRAVERSO, V; MAROUX, S				MASSEY, D; TRAVERSO, V; MAROUX, S			LIPOCORTIN-IV IS A BASOLATERAL CYTOSKELETON CONSTITUENT OF RABBIT ENTEROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL BRUSH-BORDER; LIPID-BINDING PROTEINS; PLACENTAL ANTICOAGULANT PROTEIN; CHROMAFFIN GRANULE MEMBRANE; PORCINE PANCREATIC LIPASE; AMINO-ACID SEQUENCE; AMINOPEPTIDASE-N; PHOSPHOLIPID-BINDING; DOMAIN-STRUCTURE; PLASMA-MEMBRANE	A monoclonal antibody, BL7B1, which specifically recognized rabbit lipocortin IV, was produced. The BL7B1 epitope is localized between the methionine residues that occupy positions 148 and 259 in human lipocortin IV. Immunofluorescence and subcellular fractionation studies showed that in the rabbit enterocytes, lipocortin IV is specifically associated with the basolateral membranes. When these membranes are solubilized by Triton X-100 in the presence of 1 mM of Ca2+ the lipocortin IV, like the cytoskeleton, remained insoluble suggesting that it might be associated with this structure in vivo. No lipocortin IV was detected in the brush border using immunofluorescence techniques and less than 10% of the amount present in the purified basolateral membranes was detected in the brush border membrane fraction.	CNRS,CTR BIOCHIM & BIOL MOLEC,BP 71,F-13402 MARSEILLE 9,FRANCE	Centre National de la Recherche Scientifique (CNRS)			Massey-Harroche, Dominique/A-4839-2018					BIANCHETTA JD, 1979, EUR J BIOCHEM, V97, P395, DOI 10.1111/j.1432-1033.1979.tb13126.x; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRUGGE JS, 1986, CELL, V46, P149, DOI 10.1016/0092-8674(86)90729-4; CRESFTFIELD AM, 1963, J BIOL CHEM, V238, P612; CREUTZ CE, 1981, BIOCHEM BIOPH RES CO, V103, P1395, DOI 10.1016/0006-291X(81)90278-3; CREUTZ CE, 1983, J BIOL CHEM, V258, P4664; CREUTZ CE, 1987, J BIOL CHEM, V262, P1860; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; DAVIDSON FF, 1987, J BIOL CHEM, V262, P1698; EDWARDS HC, 1987, J CELL BIOL, V105, P303, DOI 10.1083/jcb.105.1.303; ERNST JD, 1989, BIOCHEM BIOPH RES CO, V161, P959, DOI 10.1016/0006-291X(89)91336-3; FERACCI H, 1985, J MEMBRANE BIOL, V83, P139, DOI 10.1007/BF01868745; FERACCI H, 1982, GASTROENTEROLOGY, V82, P317; FUNAKOSHI T, 1987, BIOCHEMISTRY-US, V26, P8087, DOI 10.1021/bi00399a011; GASSAMADIAGNE A, 1990, J BIOL CHEM, V265, P4309; GEISOW M, 1984, EMBO J, V3, P2969, DOI 10.1002/j.1460-2075.1984.tb02242.x; GEISOW MJ, 1986, TRENDS BIOCHEM SCI, V11, P420, DOI 10.1016/0968-0004(86)90176-3; GEISOW MJ, 1986, FEBS LETT, V203, P99, DOI 10.1016/0014-5793(86)81445-4; GEISOW MJ, 1986, NATURE, V320, P633; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GERKE V, 1989, FEBS LETT, V258, P259, DOI 10.1016/0014-5793(89)81668-0; GORVEL JP, 1986, BIOL CELL, V56, P121, DOI 10.1111/j.1768-322X.1986.tb00449.x; GORVEL JP, 1989, J CELL BIOL, V108, P2193, DOI 10.1083/jcb.108.6.2193; GORVEL JP, 1986, BIOL CELL, V56, P157; GOULD KL, 1984, J CELL BIOL, V98, P487, DOI 10.1083/jcb.98.2.487; GREEN J, 1981, J MOL BIOL, V152, P663, DOI 10.1016/0022-2836(81)90122-4; GREENBERG ME, 1983, CELL, V33, P767, DOI 10.1016/0092-8674(83)90019-3; GRUNDMANN U, 1988, P NATL ACAD SCI USA, V85, P3708, DOI 10.1073/pnas.85.11.3708; HAIGLER HT, 1989, TRENDS BIOCHEM SCI, V14, P48, DOI 10.1016/0968-0004(89)90041-8; HAMMAN HC, 1988, BIOCHEM BIOPH RES CO, V156, P660, DOI 10.1016/S0006-291X(88)80893-3; Harlow E., 1988, ANTIBODIES LAB MANUA, P298; HASHIMOTO F, 1983, ANAL BIOCHEM, V129, P192, DOI 10.1016/0003-2697(83)90068-4; HOWARD SP, 1989, J BACTERIOL, V171, P410, DOI 10.1128/jb.171.1.410-418.1989; HUANG KS, 1987, J BIOL CHEM, V262, P7639; IWASAKI A, 1987, J BIOCHEM, V102, P1261, DOI 10.1093/oxfordjournals.jbchem.a122165; KAETZEL MA, 1989, BIOCHEM BIOPH RES CO, V160, P1233, DOI 10.1016/S0006-291X(89)80135-4; KAETZEL MA, 1989, J BIOL CHEM, V264, P14463; KAPLAN R, 1988, J BIOL CHEM, V263, P8037; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHTO VP, 1983, EMBO J, V2, P1701, DOI 10.1002/j.1460-2075.1983.tb01645.x; MACHOCZEK K, 1989, FEBS LETT, V251, P207, DOI 10.1016/0014-5793(89)81456-5; MANGEAT PH, 1988, BIOL CELL, V64, P261, DOI 10.1016/0248-4900(88)90001-9; MAROUX S, 1988, BIOCHIMIE, V70, P1297, DOI 10.1016/0300-9084(88)90198-8; MASSEY D, 1987, J MEMBRANE BIOL, V96, P19, DOI 10.1007/BF01869331; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOKTARI S, 1986, J MEMBRANE BIOL, V89, P53, DOI 10.1007/BF01870895; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; PEPINSKY RB, 1988, J BIOL CHEM, V263, P10799; PEPINSKY RB, 1990, FEBS LETT, V261, P247, DOI 10.1016/0014-5793(90)80564-Y; PHILIPPS C, 1989, BIOCHEM BIOPH RES CO, V159, P155, DOI 10.1016/0006-291X(89)92417-0; ROVERY M, 1973, BIOCHIM BIOPHYS ACTA, V328, P391, DOI 10.1016/0005-2795(73)90273-0; SCHMITZ J, 1973, BIOCHIM BIOPHYS ACTA, V323, P98, DOI 10.1016/0005-2736(73)90434-3; SHALDLE PJ, 1985, J BIOL CHEM, V260, P16354; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SUDHOF TC, 1982, EMBO J, V1, P1167, DOI 10.1002/j.1460-2075.1982.tb00008.x; SUDHOF TC, 1988, P NATL ACAD SCI USA, V85, P664, DOI 10.1073/pnas.85.3.664; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P6268, DOI 10.1021/bi00417a011; WALKER JH, 1982, J NEUROCHEM, V39, P815, DOI 10.1111/j.1471-4159.1982.tb07965.x; WALLNER BP, 1986, NATURE, V320, P77, DOI 10.1038/320077a0; WEBER K, 1987, EMBO J, V6, P1599, DOI 10.1002/j.1460-2075.1987.tb02406.x	61	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1991	266	5					3125	3130						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EX600	1825208				2022-12-25	WOS:A1991EX60000069
J	KNOCK, SL; MILLER, BT; BLANKENSHIP, JE; NAGLE, GT; SMITH, JS; KUROSKY, A				KNOCK, SL; MILLER, BT; BLANKENSHIP, JE; NAGLE, GT; SMITH, JS; KUROSKY, A			N-ACYLATION OF APLYSIA EGG-LAYING HORMONE WITH BIOTIN - CHARACTERIZATION OF BIOACTIVE AND INACTIVE DERIVATIVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BAG CELL NEURONS; ABDOMINAL-GANGLION; PROLONGED ACTIONS; ATRIAL GLAND; GENE FAMILY; CALIFORNICA; PEPTIDE; PRECURSORS; PACEMAKER; MULTIPLE	Chemical modification of the egg-laying hormone (ELH) of Aplysia by reaction with the N-hydroxysuccinimide ester of biotin, which contained 6-aminohexanoic acid as spacer, yielded seven distinct derivatives that were readily separated by reversed-phase high performance liquid chromatography. The derivatives were chemically characterized by amino acid compositional analysis, sequence analysis, and mass spectrometry. The seven derivatives resulted from combinations of differential modification of the three amino groups in the ELH molecule located at Ile1 (alpha-NH2), Lys8, and Lys36. Of the seven derivatives formed, only one, monobiotinyl Lys36-ELH, was biologically active in eliciting egg-laying activity and altering the electrophysiological activity of the abdominal ganglion neuron R15 and LB and LC cluster neurons. In addition, evaluation of the time course of biotinylation of ELH revealed that the relative rate of amino group reactivity was epsilon-NH2-Lys36 > epsilon-NH2-Lys8 >> alpha-NH2-Ile1. The slow rate of reaction of the terminal alpha-amino group suggested that it was relatively inaccessible to biotinylation, possibly due to conformational factors or to ion-pair formation with an unidentified carboxyl group. Loss of bioactivity of ELH monobiotinylated on the alpha-amino group, coupled with the unusually low reactivity of the alpha-amino group, provided strong evidence for the importance of the alpha-amino group in ELH function. Furthermore, the development and availability of a bioactive ELH probe should greatly facilitate the isolation, characterization, and localization of the ELH receptor.	UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,INST MARINE BIOMED,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DEPT ANAT & NEUROSCI,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston					NINDS NIH HHS [NS 29261, NS 07185] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029261] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARCH S, 1977, BEHAV BIOL, V19, P45, DOI 10.1016/S0091-6773(77)91331-1; ARCH S, 1989, BRAIN RES REV, V14, P181, DOI 10.1016/0165-0173(89)90014-3; BARBER M, 1981, J CHEM SOC CHEM COMM, V7, P325; BRANTON WD, 1978, P NATL ACAD SCI USA, V75, P5732, DOI 10.1073/pnas.75.11.5732; CHIU AY, 1979, P NATL ACAD SCI USA, V76, P6656, DOI 10.1073/pnas.76.12.6656; COBBS JS, 1982, J COMP PHYSIOL, V147, P523, DOI 10.1007/BF00612018; CONN PJ, 1989, MOL NEUROBIOL, V3, P237, DOI 10.1007/BF02740607; DAKSHINAMURTI K, 1974, ANAL BIOCHEM, V61, P225, DOI 10.1016/0003-2697(74)90348-0; KIRK MD, 1986, P NATL ACAD SCI USA, V83, P3017, DOI 10.1073/pnas.83.9.3017; KIRK MD, 1988, J NEUROSCI, V8, P1181; KNOCK S L, 1990, Society for Neuroscience Abstracts, V16, P1030; KUPFERMANN I, 1970, J NEUROPHYSIOL, V33, P865, DOI 10.1152/jn.1970.33.6.865; KUPFERMANN I, 1967, NATURE, V216, P814, DOI 10.1038/216814a0; LEVITAN ES, 1987, P NATL ACAD SCI USA, V84, P6307, DOI 10.1073/pnas.84.17.6307; MACKEY S, 1983, J NEUROSCI, V3, P1469; MAHON AC, 1985, J NEUROSCI, V5, P1872; MAYERI E, 1979, J NEUROPHYSIOL, V42, P1165, DOI 10.1152/jn.1979.42.4.1165; MAYERI E, 1979, J NEUROPHYSIOL, V42, P1185, DOI 10.1152/jn.1979.42.4.1185; MAYERI E, 1985, J NEUROSCI, V5, P2060; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; NAGLE GT, 1989, BIOL BULL, V177, P210, DOI 10.2307/1541935; NAGLE GT, 1988, PEPTIDES, V9, P867, DOI 10.1016/0196-9781(88)90135-0; NAGLE GT, 1988, J BIOL CHEM, V263, P9223; NAMBU JR, 1986, J NEUROSCI, V6, P2026; NEWCOMB R, 1988, J BIOL CHEM, V263, P12514; NEWCOMB R, 1987, J NEUROSCI, V7, P854; PAINTER SD, 1985, J MORPHOL, V186, P167, DOI 10.1002/jmor.1051860204; ROCK MK, 1986, J NEUROBIOL, V17, P273, DOI 10.1002/neu.480170403; ROTHMAN BS, 1983, GEN COMP ENDOCR, V52, P134, DOI 10.1016/0016-6480(83)90166-1; ROTHMAN BS, 1985, GENE EXPRESSION BRAI, P235; SCHELLER RH, 1983, CELL, V32, P7, DOI 10.1016/0092-8674(83)90492-0; SIGVARDT KA, 1986, J NEUROSCI, V6, P803; SMITH JS, 1991, ANAL BIOCHEM, V197, P247, DOI 10.1016/0003-2697(91)90384-6; SMITH JS, 1991, ANAL BIOCHEM, V197, P254, DOI 10.1016/0003-2697(91)90385-7; Stewart JM, 1984, SOLID PHASE PEPTIDE; STRUMWASSER F, 1987, Society for Neuroscience Abstracts, V13, P38; STRUMWASSER F, 1969, COMP BIOCHEM PHYSIOL, V29, P197, DOI 10.1016/0010-406X(69)91735-6; STRUMWASSER F, 1988, CURR TOP NEUROENDOCR, V9, P105; STUART DK, 1980, J NEUROPHYSIOL, V43, P499, DOI 10.1152/jn.1980.43.2.499; STUART DK, 1980, J NEUROPHYSIOL, V43, P488, DOI 10.1152/jn.1980.43.2.488	40	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24413	24419						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761543				2022-12-25	WOS:A1991GW84500029
J	MESTERS, RM; HOUGHTEN, RA; GRIFFIN, JH				MESTERS, RM; HOUGHTEN, RA; GRIFFIN, JH			IDENTIFICATION OF A SEQUENCE OF HUMAN ACTIVATED PROTEIN-C (RESIDUES 390-404) ESSENTIAL FOR ITS ANTICOAGULANT ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; MAMMALIAN SERINE PROTEASES; BETA-HYDROXYASPARTIC ACID; ANTI-HEMOPHILIC FACTOR; FACTOR-V; BLOOD-COAGULATION; BOVINE PLASMA; FACTOR-IX; LIGHT CHAIN; FACTOR-VIII	Activated protein C (APC) exerts its physiologic anticoagulant role by proteolytic inactivation of the blood coagulation cofactors Va and VIIIa. To identify the regions on the surface that mediate anticoagulant activity, 26 synthetic peptides were prepared representing 90% of the human protein C heavy chain primary structure and tested for their ability to inhibit APC anticoagulant activity. Peptide-(390-404) specifically inhibited APC activity in activated partial thromboplastin time and Xa-1-stage coagulation assays in normal, in protein S-depleted and Factor VIII-deficient plasma with 50% inhibition at 5-mu-M peptide. Polyclonal antibodies raised against this peptide and immunoaffinity-purified on a protein C-Sepharose column inhibited APC anticoagulant activity in activated partial thromboplastin time and Xa-1-stage assays in normal, protein S-depleted, and Factor VIII-deficient plasma with half-maximal inhibition at 30 nM anti-(390-404) antibody. Neither the peptide-(390-404) nor the anti-(390-404) antibodies inhibited APC amidolytic activity or the reaction of APC with recombinant [Arg358] alpha-1-antitrypsin. Furthermore, in a purified system, peptide-(390-404) inhibited APC-catalyzed inactivation of Factor Va in the presence as well as in the absence of phospholipids with 50% inhibition at 4-mu-M peptide. These data suggest that the region containing residues 390-404 in APC is essential for anticoagulant activity and is available to interact with antibodies or with other proteins such as the macromolecular substrates Factors Va or VIIIa.	Scripps Res Inst, RES INST,DEPT MOLEC & EXPTL MED,BCR-5, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA; Scripps Res Inst, RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA; TORREY PINES INST MOLEC STUDIES, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Torrey Pines Institute for Molecular Studies, California				Griffin, John/0000-0002-4302-2547	NCRR NIH HHS [M01-RR00833] Funding Source: Medline; NHLBI NIH HHS [HL-31950] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTREE O, 1989, GENOMICS, V4, P266, DOI 10.1016/0888-7543(89)90330-3; BECKMANN RJ, 1985, NUCLEIC ACIDS RES, V13, P5233, DOI 10.1093/nar/13.14.5233; BERZOFSKY JA, 1985, SCIENCE, V229, P932, DOI 10.1126/science.2410982; BRANSON HE, 1983, LANCET, V2, P1165; BROWN JR, 1966, BIOCHEM J, V101, P214, DOI 10.1042/bj1010214; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; CHOO KH, 1982, NATURE, V299, P178, DOI 10.1038/299178a0; CLEZARDIN P, 1985, J CHROMATOGR, V319, P67, DOI 10.1016/S0021-9673(01)90540-0; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; DYSON HJ, 1988, ANNU REV BIOPHYS BIO, V17, P305; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FOSTER PA, 1988, J BIOL CHEM, V263, P5230; FRANCIS RT, 1986, J BIOL CHEM, V261, P9787; FURIE B, 1982, J BIOL CHEM, V257, P3875; GEDDES VA, 1989, J BIOL CHEM, V264, P4689; GORDON RD, 1987, P NATL ACAD SCI USA, V84, P308, DOI 10.1073/pnas.84.1.308; GREER J, 1981, J MOL BIOL, V153, P1027, DOI 10.1016/0022-2836(81)90465-4; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; GRUBER A, 1989, BLOOD, V73, P639; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; HAMAGUCHI N, 1990, BLOOD S, V76, pA422; HEEB MJ, 1990, J BIOL CHEM, V265, P2365; HEEB MJ, 1987, J BIOL CHEM, V262, P15813; HEEB MJ, 1988, THROMB RES, V52, P33, DOI 10.1016/0049-3848(88)90038-2; Hewett-Emmett D, 1981, Ann N Y Acad Sci, V370, P511, DOI 10.1111/j.1749-6632.1981.tb29759.x; HILL KAW, 1987, J BIOL CHEM, V262, P9581; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; KIRSCHENBAUM DM, 1973, ANAL BIOCHEM, V56, P237, DOI 10.1016/0003-2697(73)90186-3; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; KISIEL W, 1979, J BIOL CHEM, V254, P2230; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; KUMAR A, 1991, J BIOL CHEM, V266, P915; LEYTUS SP, 1984, P NATL ACAD SCI-BIOL, V81, P3699, DOI 10.1073/pnas.81.12.3699; MARLAR RA, 1982, BLOOD, V59, P1067; MITCHELL CA, 1987, NEW ENGL J MED, V317, P1638, DOI 10.1056/NEJM198712243172606; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; OHLIN AK, 1987, J BIOL CHEM, V262, P13798; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; OHLIN AK, 1990, BIOCHEMISTRY-US, V29, P644; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; PEETERS JM, 1989, J IMMUNOL METHODS, V120, P133, DOI 10.1016/0022-1759(89)90298-6; PLUTZKY J, 1986, P NATL ACAD SCI USA, V83, P546, DOI 10.1073/pnas.83.3.546; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHWARZ HP, 1984, BLOOD, V64, P1297; SCHWARZ HP, 1986, THROMB HAEMOSTASIS, V56, P382; SELIGSOHN U, 1984, NEW ENGL J MED, V310, P559, DOI 10.1056/NEJM198403013100904; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; STENFLO J, 1976, J BIOL CHEM, V251, P355; STENFLO J, 1977, ANNU REV BIOCHEM, V46, P157, DOI 10.1146/annurev.bi.46.070177.001105; SUGO T, 1985, J BIOL CHEM, V260, P453; TANS G, 1991, BLOOD, V77, P2641; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1990, J BIOL CHEM, V265, P1484; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; WARE J, 1988, BLOOD, V72, P820	64	51	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24514	24519						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761551				2022-12-25	WOS:A1991GW84500044
J	RUBIN, BY; ANDERSON, SL; XING, L; POWELL, RJ; TATE, WP				RUBIN, BY; ANDERSON, SL; XING, L; POWELL, RJ; TATE, WP			INTERFERON INDUCES TRYPTOPHANYL-TRANSFER RNA-SYNTHETASE EXPRESSION IN HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-CELLS; GAMMA-INTERFERON; II INTERFERONS; MESSENGER-RNAS; BINDING; RECEPTORS; INDUCTION; ANTIBODY; PROTEIN; ALPHA	A cDNA clone complementary to an interferon (IFN)-induced mRNA was isolated and used to characterize the regulation of expression of its RNA by the IFNs and to identify the protein its RNA encodes. This cDNA hybridizes to IFN-induced 3.1- and 2.3-kilobase mRNAs that are synthesized in response to both IFN-alpha and IFN-gamma. IFN-gamma induces the sustained accumulation of these mRNAs while IFN-alpha induces their transient accumulation. Cycloheximide (50-mu-g/ml) failed to inhibit the induction of these mRNAs by either IFN-alpha or IFN-gamma, suggesting that their induction does not require de novo protein synthesis. DNA sequence analysis of this cDNA reveals that it encodes a protein of M(r) 53,168 that has sequence homology with and the biological activity of a tryptophanyl-tRNA synthetase, an enzymatic activity that has been demonstrated to play a role in and be modulated by the growth of cells. Elevated levels of this enzyme may be involved in the cell growth inhibitory activity of the IFNs.	UNIV OTAGO, DEPT BIOCHEM, DUNEDIN, NEW ZEALAND; UNIV OTAGO, CTR GENE RES, DUNEDIN, NEW ZEALAND	University of Otago; University of Otago	RUBIN, BY (corresponding author), FORDHAM UNIV, DEPT BIOL SCI, BRONX, NY 10458 USA.				NCI NIH HHS [CA-38861] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENECH P, 1985, EMBO J, V4, P2249, DOI 10.1002/j.1460-2075.1985.tb03922.x; BRANCA AA, 1981, NATURE, V294, P768, DOI 10.1038/294768a0; CHENG YSE, 1986, J INTERFERON RES, V6, P417, DOI 10.1089/jir.1986.6.417; FALTYNEK CR, 1984, MICROBIOL SCI, V1, P81; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRIEDMAN RM, 1965, J IMMUNOL, V95, P696; GABIUS HJ, 1983, EUR J BIOCHEM, V131, P231, DOI 10.1111/j.1432-1033.1983.tb07254.x; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOVANESSIAN AG, 1987, EMBO J, V6, P1273, DOI 10.1002/j.1460-2075.1987.tb02364.x; JOHNSON HM, 1987, MECHANISMS INTERFERO, V2, P59; Kisselev L L, 1979, Methods Enzymol, V59, P234; KUSARI J, 1987, MOL CELL BIOL, V7, P528, DOI 10.1128/MCB.7.1.528; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LEE CC, 1990, P NATL ACAD SCI USA, V87, P3508, DOI 10.1073/pnas.87.9.3508; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LITTMAN SJ, 1985, J BIOL CHEM, V260, P1191; LOCKART RZ, 1964, BIOCHEM BIOPH RES CO, V16, P513; MARGOLISNUNNO H, 1990, J INTERFERON RES, V10, P309, DOI 10.1089/jir.1990.10.309; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; RAPAPORT E, 1981, P NATL ACAD SCI-BIOL, V78, P838, DOI 10.1073/pnas.78.2.838; RUBIN BY, 1988, J VIROL, V62, P1875, DOI 10.1128/JVI.62.6.1875-1880.1988; RUBIN BY, 1988, J IMMUNOL, V141, P1180; RUBIN BY, 1988, J INTERFERON RES, V8, P691, DOI 10.1089/jir.1988.8.691; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR FH, 1984, P NATL ACAD SCI-BIOL, V81, P5160, DOI 10.1073/pnas.81.16.5160; SEGAL E, 1986, EXP CELL RES, V167, P119, DOI 10.1016/0014-4827(86)90209-0; SEN GC, 1991, HORMONAL CONTROL GEN, P349; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; TAYLOR J, 1964, BIOCHEM BIOPH RES CO, V14, P447, DOI 10.1016/0006-291X(64)90084-1; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	34	93	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24245	24248						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761529				2022-12-25	WOS:A1991GW84500004
J	SAUTERER, RA; EDDY, RJ; HALL, AL; CONDEELIS, JS				SAUTERER, RA; EDDY, RJ; HALL, AL; CONDEELIS, JS			PURIFICATION AND CHARACTERIZATION OF AGINACTIN, A NEWLY IDENTIFIED AGONIST-REGULATED ACTIN-CAPPING PROTEIN FROM DICTYOSTELIUM AMEBAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ADRENAL-MEDULLA; BARBED END; POLYMORPHONUCLEAR LEUKOCYTES; PSEUDOPOD EXTENSION; SEVERING PROTEIN; RATE CONSTANTS; AMEBOID CELLS; F-ACTIN; POLYMERIZATION; FILAMENTS	Amoeboid chemotaxis involves a regulated increase in actin nucleation activity that is correlated with an increase in actin polymerization occurring seconds after chemotactic stimulation (Carson, M., Weber, A., and Zigmond, S. H. (1986) J. Cell Biol. 103, 2707-2714; Hall, A. L., Warren, V., Dharmawardhane, S., and Condeelis, J. (1989) J. Cell Biol. 109, 2207-2213). We report the isolation and characterization of an agonist-regulated capping protein, aginactin, from Dictyostelium that may regulate these changes in actin nucleation activity. Aginactin is isolated from low speed supernatants of starved amoebae by sequential anion exchange, hydrophobic interaction, fast protein liquid chromatography anion exchange, and hydroxyapatite chromatography. Aginactin migrates with an apparent molecular weight of 70,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and gel filtration columns, suggesting that it is a globular monomer. Aginactin is a barbed-end capping protein by several criteria. It inhibits the rate and final extent of actin polymerization and increases the apparent critical concentration at substoichiometric ratios to actin. It also inhibits depolymerization of F-actin and inhibits polymerization at the barbed end of Limulus acrosomal bundles. Aginactin is unaffected by micromolar Ca2+, and it neither severs F-actin nor nucleates actin polymerization in either the presence or absence of Ca2+. Aginactin binds to and cosediments with F-actin and has an apparent K(d) for capping F-actin of 2.7 nM.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT ANAT & STRUCT BIOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine					NCI NIH HHS [TG CA09475] Funding Source: Medline; NIGMS NIH HHS [F32 GM 13312] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013312] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT H, 1988, CELL MOTIL CYTOSKEL, V11, P303, DOI 10.1002/cm.970110408; BONDER EM, 1983, J CELL BIOL, V96, P1097, DOI 10.1083/jcb.96.4.1097; BONDER EM, 1983, CELL, V34, P491, DOI 10.1016/0092-8674(83)90382-3; CALDWELL JE, 1989, BIOCHEMISTRY-US, V28, P8506, DOI 10.1021/bi00447a036; CARSON M, 1986, J CELL BIOL, V103, P2707, DOI 10.1083/jcb.103.6.2707; CONDEELIS J, 1988, CELL MOTIL CYTOSKEL, V10, P77, DOI 10.1002/cm.970100113; CONDEELIS J, 1991, METHOD ENZYMOL, V196, P486; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; GAERTNER A, 1989, J MUSCLE RES CELL M, V10, P1, DOI 10.1007/BF01739852; HALL AL, 1989, J CELL BIOL, V109, P2207, DOI 10.1083/jcb.109.5.2207; HALL AL, 1988, J CELL BIOCHEM, V37, P285, DOI 10.1002/jcb.240370304; HALL AL, 1989, DEV BIOL, V136, P517, DOI 10.1016/0012-1606(89)90277-7; HARTWIG JH, 1979, J MOL BIOL, V134, P539, DOI 10.1016/0022-2836(79)90366-8; HOWARD T, 1990, J CELL BIOL, V110, P1983, DOI 10.1083/jcb.110.6.1983; HOWARD TH, 1985, J CELL BIOL, V101, P1078, DOI 10.1083/jcb.101.3.1078; ISENBERG G, 1980, NATURE, V288, P455, DOI 10.1038/288455a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEKAWA S, 1989, J BIOL CHEM, V264, P7458; MAEKAWA S, 1990, J BIOL CHEM, V265, P10940; MATSUDAIRA P, 1988, CELL, V54, P139, DOI 10.1016/0092-8674(88)90542-9; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; RUHNAU K, 1989, J MOL BIOL, V210, P141, DOI 10.1016/0022-2836(89)90296-9; SCHLEICHER M, 1984, EMBO J, V3, P2095, DOI 10.1002/j.1460-2075.1984.tb02096.x; SELVE N, 1986, EUR J BIOCHEM, V160, P379, DOI 10.1111/j.1432-1033.1986.tb09982.x; SOUTHWICK FS, 1990, J CELL BIOL, V110, P1965, DOI 10.1083/jcb.110.6.1965; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TILNEY LG, 1981, J CELL BIOL, V90, P485, DOI 10.1083/jcb.90.2.485; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALSH TP, 1984, BIOCHEMISTRY-US, V23, P2613, DOI 10.1021/bi00307a012; WANGER M, 1985, BIOCHEMISTRY-US, V24, P1035, DOI 10.1021/bi00325a035; YAMAMOTO K, 1982, J CELL BIOL, V95, P711, DOI 10.1083/jcb.95.3.711; YOUNG CL, 1990, BIOCHEMISTRY-US, V29, P2232, DOI 10.1021/bi00461a005; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912	34	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24533	24539						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761553				2022-12-25	WOS:A1991GW84500047
J	MUSTAEV, A; KASHLEV, M; LEE, J; POLYAKOV, A; LEBEDEV, A; ZALENSKAYA, K; GRACHEV, M; GOLDFARB, A; NIKIFOROV, V				MUSTAEV, A; KASHLEV, M; LEE, J; POLYAKOV, A; LEBEDEV, A; ZALENSKAYA, K; GRACHEV, M; GOLDFARB, A; NIKIFOROV, V			MAPPING OF THE PRIMING SUBSTRATE CONTACTS IN THE ACTIVE-CENTER OF ESCHERICHIA-COLI RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC UV5 PROMOTER; NUCLEOTIDE-SEQUENCE; TRANSCRIPTION INITIATION; FUNCTIONAL TOPOGRAPHY; TERNARY COMPLEXES; GENE ORGANIZATION; BETA-SUBUNIT; DNA; SITE; PURIFICATION	The active center of DNA-dependent RNA polymerase performs the principal biochemical reaction of gene expression. Using cross-linkable substrate analogs and site-directed mutations, two evolutionarily invariant amino acids in the beta-subunit of the Escherichia coli enzyme (Lys1065 and His1237) were mapped close to the binding site of the priming substrate of the reaction. Surprisingly, the mutational substitution of these residues (Lys1065 --> Arg and His1237 --> Ala) did not inactivate the catalytic function, but inhibited transition from the initiation to the elongation stage of transcription.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,701 W 168TH ST,NEW YORK,NY 10032; ACAD SCI USSR,INST MOLEC GENET,MOSCOW 123182,USSR; ACAD SCI USSR,INST LIMNOL,IRKUTSK,USSR	Columbia University; Russian Academy of Sciences; Irkutsk Science Centre of the Russian Academy of Sciences; Russian Academy of Sciences; Limnological Institute SB RAS	GOLDFARB, A (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,701 W 168TH ST,NEW YORK,NY 10032, USA.		Grachev, Mikhail/J-9279-2018		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030717] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30717] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BIGGS J, 1985, CELL, V42, P611, DOI 10.1016/0092-8674(85)90118-7; BORODIN AM, 1988, DOKL AKAD NAUK SSSR+, V302, P1261; BORUKHOV S, 1991, J BIOL CHEM, V266, P23921; BORUKHOV S, 1991, J BIOL CHEM, V266, P23932; Burgess R.R., 1987, RNA POLYM REGULATION, P3; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DISSINGER S, 1990, J BIOL CHEM, V265, P7662; DISSINGER S, 1991, J MOL BIOL, V219, P11, DOI 10.1016/0022-2836(91)90853-X; FALKENBURG D, 1987, J MOL BIOL, V195, P929, DOI 10.1016/0022-2836(87)90496-7; GRACHEV MA, 1987, EUR J BIOCHEM, V163, P113, DOI 10.1111/j.1432-1033.1987.tb10743.x; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; GRACHEV MA, 1982, FEBS LETT, V137, P89, DOI 10.1016/0014-5793(82)80321-9; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HEUMANN H, 1988, J MOL BIOL, V201, P115, DOI 10.1016/0022-2836(88)90443-3; HUDSON GS, 1988, J MOL BIOL, V200, P639, DOI 10.1016/0022-2836(88)90477-9; IWABE N, 1991, J MOL EVOL, V32, P70, DOI 10.1007/BF02099931; JAMES P, 1991, J BIOL CHEM, V266, P5615; JOHNSTON DE, 1976, RNA POLYM, P101; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KUMAR S A, 1975, Journal of Biological Chemistry, V250, P2878; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6018, DOI 10.1073/pnas.88.14.6018; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; OVCHINNIKOV YA, 1981, EUR J BIOCHEM, V116, P621, DOI 10.1111/j.1432-1033.1981.tb05381.x; PUHLER G, 1989, NUCLEIC ACIDS RES, V17, P4517, DOI 10.1093/nar/17.12.4517; RIVA M, 1990, J BIOL CHEM, V265, P16498; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; STRANEY SB, 1987, BIOCHEMISTRY-US, V26, P5063, DOI 10.1021/bi00390a027; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2	41	78	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23927	23931						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748665				2022-12-25	WOS:A1991GV31900063
J	ARGENTIN, S; SUN, YL; LIHRMANN, I; SCHMIDT, TJ; DROUIN, J; NEMER, M				ARGENTIN, S; SUN, YL; LIHRMANN, I; SCHMIDT, TJ; DROUIN, J; NEMER, M			DISTAL CIS-ACTING PROMOTER SEQUENCES MEDIATE GLUCOCORTICOID STIMULATION OF CARDIAC ATRIAL-NATRIURETIC-FACTOR GENE-TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; MESSENGER-RNA LEVELS; MAMMALIAN-CELLS; RAT; RECEPTOR; EXPRESSION; BINDING; DEXAMETHASONE; PEPTIDE; DNA	Although receptors for most steroid hormones are present in the heart, few cardiac-specific target genes have been identified and studied at the molecular level. Transcription of the atrial natriuretic factor (ANF) gene, which encodes the major secretory product of the heart, is induced by glucocorticoids. In both atrial and ventricular cardiac cells in primary cultures, ANF mRNA levels are increased 3-4-fold after dexamethasone treatment in a time- and dose-dependent manner. This response to glucocorticoids is completely abolished by the antagonist RU486. Interestingly, ventricular myocytes appear to be more sensitive to glucocorticoids than atrial myocytes. DNA-mediated gene transfer studies indicate that glucocorticoids affect ANF gene transcription via a glucocorticoid response element located in the distal 5'-flanking sequences of the rat ANF gene between -697 and -1,029 base pairs. In vitro DNase I footprinting experiments reveal the presence of two binding sites for purified glucocorticoid receptor within this region. Mobility shift assays and competition experiments show that binding of the glucocorticoid receptor to both ANF sites results in a DNA-protein complex similar in affinity and specificity to that of the well characterized mammary tumor virus glucocorticoid response element. Since glucocorticoid activation of the ANF promoter appears specific to cardiac cells, the interaction between the glucocorticoid receptor binding sites and cardiac-specific regulatory elements of this promoter could provide a model to study a mechanism of hormone-dependent signal transduction in the heart.	INST RECH CLIN MONTREAL, GENET MOLEC LAB, 110 AVE DES PINS OUEST, MONTREAL H2W 1R7, QUEBEC, CANADA; MCGILL UNIV, DIV EXPTL MED, MONTREAL H3A 2T5, QUEBEC, CANADA; UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; UNIV MONTREAL, DEPT BIOCHEM, MONTREAL H3C 3J7, QUEBEC, CANADA; UNIV MONTREAL, DEPT PHARMACOL, MONTREAL H3C 3J7, QUEBEC, CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University; University of Iowa; Universite de Montreal; Universite de Montreal			Lihrmann, Isabelle/S-6464-2019	Lihrmann, Isabelle/0000-0002-4486-7074; Drouin, Jacques/0000-0001-8226-5691; Schmidt, Thomas/0000-0002-6792-9426				ANTAKLY T, 1990, ENDOCRINOLOGY, V126, P1821, DOI 10.1210/endo-126-4-1821; ANTAKLY T, 1985, SCIENCE, V229, P277, DOI 10.1126/science.3892690; ARGENTIN S, 1987, BIOCHEM BIOPH RES CO, V146, P1336, DOI 10.1016/0006-291X(87)90796-0; ARGENTIN S, 1985, J BIOL CHEM, V260, P4568; BAXTER JD, 1976, PHARMACOL THER PT B, V2, P605, DOI 10.1016/0306-039X(76)90010-6; BAXTER JD, 1979, GLUCOCORTICOID HORMO, P12; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUTARD M, 1985, J STEROID BIOCHEM, V23, P291, DOI 10.1016/0022-4731(85)90407-8; DAY ML, 1987, HYPERTENSION, V9, P485, DOI 10.1161/01.HYP.9.5.485; DELEAN A, 1984, ENDOCRINOLOGY, V115, P1636; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; ERIKSSON P, 1990, J BIOL CHEM, V265, P3535; FARMER SR, 1983, MOL CELL BIOL, V3, P182, DOI 10.1128/MCB.3.2.182; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUNDER JW, 1973, ENDOCRINOLOGY, V93, P1300, DOI 10.1210/endo-93-6-1300; GARCIA R, 1985, BIOCHEM BIOPH RES CO, V131, P806, DOI 10.1016/0006-291X(85)91311-7; GARDNER DG, 1986, BIOCHEM BIOPH RES CO, V139, P1047, DOI 10.1016/S0006-291X(86)80283-2; GARDNER DG, 1988, J CLIN INVEST, V82, P1275, DOI 10.1172/JCI113726; GUTKOWSKA J, 1989, ENDOCR REV, V10, P519, DOI 10.1210/edrv-10-4-519; HICKS DC, 1982, ANN CLIN LAB SCI, V12, P477; HOECK W, 1990, J BIOL CHEM, V265, P5403; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; ISAACS RE, 1987, MOL ENDOCRINOL, V1, P569, DOI 10.1210/mend-1-8-569; KELLY FJ, 1982, BIOCHEM J, V208, P147, DOI 10.1042/bj2080147; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; LEUNG K, 1975, ANNU REV PHYSIOL, V37, P245, DOI 10.1146/annurev.ph.37.030175.001333; MATSUBARA H, 1987, BIOCHEM BIOPH RES CO, V145, P336, DOI 10.1016/0006-291X(87)91326-X; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MILLER PA, 1988, ENDOCRINOLOGY, V122, P2990, DOI 10.1210/endo-122-6-2990; NEMER M, 1986, PEPTIDES, V7, P1147, DOI 10.1016/0196-9781(86)90145-2; NEMER M, 1986, Journal of Steroid Biochemistry, V25, p106S; Nichols N R, 1984, J Hypertens, V2, P663, DOI 10.1097/00004872-198412000-00012; NICHOLS NR, 1984, J STEROID BIOCHEM, V21, P487, DOI 10.1016/0022-4731(84)90321-2; PAEK I, 1987, MOL CELL BIOL, V7, P1496, DOI 10.1128/MCB.7.4.1496; SCHEIDEREIT C, 1984, P NATL ACAD SCI-BIOL, V81, P3029, DOI 10.1073/pnas.81.10.3029; SCHMIDT TJ, 1985, J BIOL CHEM, V260, P6255; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SEIDMAN CE, 1988, P NATL ACAD SCI USA, V85, P4104, DOI 10.1073/pnas.85.11.4104; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SELDEN RF, 1989, J ENDOCRINOL, V122, P49, DOI 10.1677/joe.0.1220049; SHIELDS PP, 1988, J BIOL CHEM, V263, P8091; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SIMONS SS, 1988, J STEROID BIOCHEM, V31, P1, DOI 10.1016/0022-4731(88)90198-7; SLATER EP, 1985, MOL CELL BIOL, V5, P2984, DOI 10.1128/MCB.5.11.2984; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; ZIVIN RA, 1984, P NATL ACAD SCI-BIOL, V81, P6325, DOI 10.1073/pnas.81.20.6325	50	55	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23315	23322						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1835978				2022-12-25	WOS:A1991GT48300081
J	BRASH, AR; HUGHES, MA; HAWKINS, DJ; BOEGLIN, WE; SONG, WC; MEIJER, L				BRASH, AR; HUGHES, MA; HAWKINS, DJ; BOEGLIN, WE; SONG, WC; MEIJER, L			ALLENE OXIDE AND ALDEHYDE BIOSYNTHESIS IN STARFISH OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINOLEIC-ACID HYDROPEROXIDE; CORAL PLEXAURA-HOMOMALLA; ARACHIDONIC-ACID; METABOLISM; MATURATION; LIPOXYGENASE; ISOMERASE; PHEROMONE; CONVERSION; INDUCTION	Allene oxides are a very unusual type of epoxide that, in biological systems, are formed by the enzymic dehydration of fatty acid hydroperoxides (lipoxygenase products). This reaction occurs widely in plants, in which allene oxide synthesis is a key step in the conversion of linolenic acid to jasmonic acid, the plant growth regulator. We report biosynthesis of the allene oxide (8R)-8,9-epoxyeicosa-(5Z,9,11Z,14Z)-tetraenoic acid via the (8R)-lipoxygenase metabolism of arachidonic acid in starfish oocytes. Formation of the allene oxide was deduced from high pressure liquid chromatography, UV, gas chromatography-mass spectrometry and H-1-NMR analyses of the precise structure and mechanism of biosynthesis of its major hydrolysis product, the alpha-ketol 8-hydroxy-9-ketoeicosa-(5Z,11Z,14Z)-trienoic acid. A second enzymic activity detected in the oocytes (hydroperoxide lyase) cleaves specifically the (8R)-hydroperoxy substrate into C7 and C13 fragments, identified as the hydroxyacid, (5Z)-7-hydroxyheptenoic acid, and two aldehydes, (2E,4Z,7Z)-tridecenal and its 4E isomer. Discovery of the allene oxide synthase and hydroperoxide lyase marks the first definitive localization of these enzymic activities to an animal cell. It was established previously that the (8R)-lipoxygenase metabolite (8R)-HETE will activate the maturation (re-initiation of meiosis) of starfish oocytes. The individual 8-lipoxygenase products may be involved at distinct stages of cell development.	STN BIOL, CNRS, F-29211 ROSCOFF, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	BRASH, AR (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, DEPT PHARMACOL, DIV CLIN PHARMACOL, NASHVILLE, TN 37232 USA.			, laurent/0000-0003-3511-4916	NICHD NIH HHS [HD-05797] Funding Source: Medline; NIDDK NIH HHS [DK-35275] Funding Source: Medline; NIGMS NIH HHS [GM-15431] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD005797] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAERTSCHI SW, 1989, J AM CHEM SOC, V111, P5003, DOI 10.1021/ja00195a077; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRASH AR, 1990, METHOD ENZYMOL, V187, P187; BRASH AR, 1989, J AM CHEM SOC, V111, P1891, DOI 10.1021/ja00187a060; BRASH AR, 1987, J BIOL CHEM, V262, P15829; BRASH AR, 1988, P NATL ACAD SCI USA, V85, P3382, DOI 10.1073/pnas.85.10.3382; BUNDY GL, 1986, J BIOL CHEM, V261, P747; CHAN TH, 1980, TETRAHEDRON, V36, P2269, DOI 10.1016/0040-4020(80)80123-2; COREY EJ, 1987, J AM CHEM SOC, V109, P289, DOI 10.1021/ja00235a053; COREY EJ, 1987, TETRAHEDRON LETT, V28, P4247, DOI 10.1016/S0040-4039(00)96476-1; CROMBIE L, 1988, J CHEM SOC CHEM COMM, P558, DOI 10.1039/c39880000558; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; GARDNER HW, 1979, LIPIDS, V14, P208, DOI 10.1007/BF02533872; GARDNER HW, 1989, FREE RADICAL BIO MED, V7, P65, DOI 10.1016/0891-5849(89)90102-0; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; GLASGOW WC, 1986, J BIOL CHEM, V261, P200; HAMBERG M, 1988, CHEM PHYS LIPIDS, V46, P235, DOI 10.1016/0009-3084(88)90037-0; HAMBERG M, 1987, BIOCHIM BIOPHYS ACTA, V920, P76, DOI 10.1016/0005-2760(87)90313-4; INGRAM CD, 1988, LIPIDS, V23, P340, DOI 10.1007/BF02537345; KISHIMOTO T, 1973, EXP CELL RES, V82, P296, DOI 10.1016/0014-4827(73)90344-3; MEIJER L, 1986, DEV BIOL, V114, P22, DOI 10.1016/0012-1606(86)90380-5; MEIJER L, 1986, J BIOL CHEM, V261, P7040; MEIJER L, 1986, PROSTAG LEUKOTR ESS, V23, P179, DOI 10.1016/0262-1746(86)90183-6; MEIJER L, 1984, DEV BIOL, V106, P368, DOI 10.1016/0012-1606(84)90235-5; MORSE D, 1990, J CHEM ECOL, V16, P1485, DOI 10.1007/BF01014083; PEERS KE, 1983, CHEM PHYS LIPIDS, V32, P49, DOI 10.1016/0009-3084(83)90069-5; PRESTWICH GD, 1987, SCIENCE, V237, P999, DOI 10.1126/science.3616631; RULE GS, 1989, ARCH INSECT BIOCHEM, V12, P89, DOI 10.1002/arch.940120203; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; TOSUJI H, 1987, ZOOL SCI, V4, P1046; TURNER E, 1987, BIOCHEMISTRY-US, V26, P4028, DOI 10.1021/bi00387a043; VELDINK GA, 1970, FEBS LETT, V7, P188, DOI 10.1016/0014-5793(70)80153-3; VICK BA, 1983, BIOCHEM BIOPH RES CO, V111, P470, DOI 10.1016/0006-291X(83)90330-3; ZHUKOVSKY EA, 1991, SCIENCE, V251, P558, DOI 10.1126/science.1990431; ZIMMERMAN DC, 1970, PLANT PHYSIOL, V46, P445, DOI 10.1104/pp.46.3.445	37	37	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22926	22931						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744085				2022-12-25	WOS:A1991GT48300026
J	KESSLER, DS; LEVY, DE				KESSLER, DS; LEVY, DE			PROTEIN-KINASE ACTIVITY REQUIRED FOR AN EARLY STEP IN INTERFERON-ALPHA SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED NUCLEAR FACTORS; DOUBLE-STRANDED-RNA; NF-KAPPA-B; INDUCED TRANSCRIPTION; GAMMA-INTERFERON; SYNTHETASE GENE; DNA-BINDING; HUMAN-CELLS; STIMULATED TRANSCRIPTION; TRANSDUCTION PATHWAYS	Interferon-alpha (IFN-alpha) induces an immediate transcriptional response of a restricted set of genes in target cells. Specific transcription is mediated by the cytoplasmic activation of a transcription factor complex termed ISGF3. ISGF3 is a multimeric protein complex composed of a regulatory component (ISGF3-alpha), which is activated following IFN-alpha treatment, and a DNA-binding component (ISGF3-gamma), which recognizes the IFN-alpha-stimulated response element (ISRE). Following activation, ISGF3-alpha translocates to the nucleus where ISGF3 assembles as a high affinity complex on the ISRE. The biochemical basis for receptor-mediated activation of ISGF3 is unknown. We report that two potent protein kinase inhibitors, staurosporine and K-252a, ablated the transcriptional response to IFN-alpha treatment. These inhibitors prevented the activation of the ISGF3-alpha component without affecting the ISGF3-gamma component, resulting in no accumulation of mature ISGF3 in nuclei of treated cells. Although these agents are potent inhibitors of protein kinase C (PKC), PKC does not mediate ISGF3-alpha activation. Down-regulation of PKC by chronic exposure of cells to 12-O-tetradecanoylphorbol-13-acetate, which led to complete loss of PKC-immunoreactive material, failed to ablate the transcriptional response to IFN-alpha or the activation of ISGF3-alpha. The PKC-specific inhibitor calphostin C did not perturb activation or nuclear accumulation of ISGF3. We conclude that a novel, staurosporine/K-252a-sensitive kinase is required for ISGF3 activity and may participate in receptor-mediated signal transduction.	NYU,SCH MED,KAPLAN CANC CTR,550 1ST AVE,NEW YORK,NY 10016; NYU,SCH MED,DEPT PATHOL,NEW YORK,NY 10016	New York University; New York University			Levy, David/GPS-4945-2022; Levy, David/AAG-6202-2019	Levy, David/0000-0002-7320-7788; KESSLER, DANIEL/0000-0002-3557-2434	NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028900] Funding Source: NIH RePORTER; NCI NIH HHS [CA16087] Funding Source: Medline; NIAID NIH HHS [R01-AI28900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BANDYOPADHYAY SK, 1990, MOL CELL BIOL, V10, P5055, DOI 10.1128/MCB.10.10.5055; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DALTYNEK CR, 1989, J BIOL CHEM, V264, P14305; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; Demaeyer E., 1988, INTERFERONS OTHER RE; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; FU YX, 1980, P NATL ACAD SCI USA, V87, P8555; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; HANNIGAN GE, 1991, SCIENCE, V251, P204, DOI 10.1126/science.1898993; HARLOW E, 1988, ANTIBODIES LABORATOR; HUBBELL HR, 1991, P NATL ACAD SCI USA, V88, P906, DOI 10.1073/pnas.88.3.906; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KESSLER DS, 1988, EMBO J, V7, P3779, DOI 10.1002/j.1460-2075.1988.tb03262.x; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KUSARI J, 1987, MOL CELL BIOL, V7, P528, DOI 10.1128/MCB.7.1.528; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LARNER AC, 1986, J BIOL CHEM, V261, P453; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LEVY D, 1990, New Biologist, V2, P923; LEVY D, 1986, P NATL ACAD SCI USA, V83, P8929, DOI 10.1073/pnas.83.23.8929; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MENON SD, 1990, LIPIDS, V25, P321, DOI 10.1007/BF02544341; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PFEFFER LM, 1990, P NATL ACAD SCI USA, V87, P6537, DOI 10.1073/pnas.87.17.6537; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; REICH NC, 1989, NUCLEIC ACIDS RES, V17, P3415, DOI 10.1093/nar/17.9.3415; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SHIRAYOSHI Y, 1988, P NATL ACAD SCI USA, V85, P5884, DOI 10.1073/pnas.85.16.5884; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; WEBER J, 1977, CELL, V10, P611, DOI 10.1016/0092-8674(77)90093-9; WOODGETT JR, 1987, MOL CELL BIOL, V7, P85, DOI 10.1128/MCB.7.1.85; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YAN C, 1989, P NATL ACAD SCI USA, V86, P2243, DOI 10.1073/pnas.86.7.2243; YAP WH, 1986, SCIENCE, V234, P355, DOI 10.1126/science.2429366	64	55	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23471	23476						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744140				2022-12-25	WOS:A1991GT48300104
J	SCHLUMBOHM, W; STEIN, T; ULLRICH, C; VATER, J; KRAUSE, M; MARAHIEL, MA; KRUFT, V; WITTMANNLIEBOLD, B				SCHLUMBOHM, W; STEIN, T; ULLRICH, C; VATER, J; KRAUSE, M; MARAHIEL, MA; KRUFT, V; WITTMANNLIEBOLD, B			AN ACTIVE SERINE IS INVOLVED IN COVALENT SUBSTRATE AMINO-ACID BINDING AT EACH REACTION CENTER OF GRAMICIDIN-S SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; COMPLETE NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; MULTIFUNCTIONAL POLYPEPTIDE; TYROCIDINE BIOSYNTHESIS; ACTIVATION REACTIONS; POLYKETIDE SYNTHASE; BACILLUS-BREVIS; GENE	The condensing peptide forming multienzyme of gramicidin S synthetase (gramicidin S synthetase 2) was specifically labeled at its putative thiotemplate sites for L-valine and L-leucine by covalent incorporation of the C-14-labeled substrate amino acids. The thioester complexes of the multienzyme were digested with CNBr, Staphylococcus aureus V8 protease, and pepsin. Reaction center peptides containing the [C-14] valine and [C-14]leucine labels were isolated in pure form. They show a high degree of sequence similarity and contain the same consensus sequence LGGH/DXL. The labels were eliminated in the first Edman degradation step. A dehydroalanine was identified which can originate from either a cysteine or a serine. The comparison of the chemical results with the deduced amino acid sequence of the grsB gene encoding the gramicidin S synthetase 2 revealed that 4 such motifs are located within the gene structure, each of them being localized in the 3'-terminal region of one of 4 gene segments grsB1-B4. They have a size of approximately 2 kilobases and presumably code for the 4 amino acid activating domains of the synthetase. Surprisingly a serine was found at each putative substrate amino acid-binding position instead of a cysteine as postulated by the thiotemplate mechanism. Therefore the data suggest that active serine residues are involved in nonribosomal peptide syntheses of microbial peptides.	TECH UNIV BERLIN,INST BIOCHEM & MOLEC BIOL,FRANKLINSTR 29,W-1000 BERLIN 10,GERMANY; MAX PLANCK INST MOLEC GENET,WITTMANN ABT,W-1000 BERLIN 33,GERMANY	Technical University of Berlin; Max Planck Society				Vater, Joachim/0000-0002-4478-4244				AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; ASHMAN K, 1985, MODERN METHODS PROTE, V2, P155; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; CHANG SI, 1988, BIOCHEMISTRY-US, V27, P4753, DOI 10.1021/bi00413a026; CHIRALA SS, 1989, J BIOL CHEM, V264, P3750; CHIU CW, 1984, THESIS TU BERLIN; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIEZ B, 1990, J BIOL CHEM, V265, P16358; FROSHOV O, 1970, FEBS LETT, V7, P68, DOI 10.1016/0014-5793(70)80620-2; GEVERS W, 1968, P NATL ACAD SCI USA, V60, P269, DOI 10.1073/pnas.60.1.269; GEVERS W, 1969, P NATL ACAD SCI USA, V63, P1335, DOI 10.1073/pnas.63.4.1335; GILHUUSMOE CC, 1970, FEBS LETT, V7, P287, DOI 10.1016/0014-5793(70)80183-1; GUITERREZ S, 1991, J BACTERIOL, V173, P2354; GUSHIMA H, 1984, NUCLEIC ACIDS RES, V12, P9299, DOI 10.1093/nar/12.24.9299; HALE RS, 1987, FEBS LETT, V224, P133, DOI 10.1016/0014-5793(87)80436-2; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; ISHIHARA H, 1975, FEBS LETT, V50, P43, DOI 10.1016/0014-5793(75)81036-2; ISHIHARA H, 1975, FEBS LETT, V60, P43; KANDA M, 1984, J BIOCHEM-TOKYO, V96, P701, DOI 10.1093/oxfordjournals.jbchem.a134888; KLEINKAUF H, 1971, P NATL ACAD SCI USA, V68, P2069, DOI 10.1073/pnas.68.9.2069; KLEINKAUF H, 1970, BIOCHEM BIOPH RES CO, V41, P1218, DOI 10.1016/0006-291X(70)90216-0; KLEINKAUF H, 1990, EUR J BIOCHEM, V192, P1, DOI 10.1111/j.1432-1033.1990.tb19188.x; KLEINKAUF H, 1978, PROG MOL SUBCELL BIO, V6, P59; KLEINKAUF H, 1980, MULTIFUNCTIONAL PROT, P217; KOISCHWITZ H, 1976, BIOCHIM BIOPHYS ACTA, V429, P1052, DOI 10.1016/0005-2744(76)90350-8; KRATZSCHMAR J, 1989, J BACTERIOL, V171, P5422; KRONAN JE, 1988, J BIOL CHEM, V263, P4641; KUO TM, 1984, ARCH BIOCHEM BIOPHYS, V234, P290, DOI 10.1016/0003-9861(84)90351-5; KURAHASHI K, 1974, ANNU REV BIOCHEM, V43, P445, DOI 10.1146/annurev.bi.43.070174.002305; Laland S G, 1973, Essays Biochem, V9, P31; LIPMANN F, 1971, ADV ENZYMOL RAMB, V35, P1; LIPMANN F, 1973, ACCOUNTS CHEM RES, V6, P361, DOI 10.1021/ar50071a001; LIPMANN F, 1954, MECHANISM ENZYME ACT, P599; LOZOYA E, 1988, EUR J BIOCHEM, V176, P661, DOI 10.1111/j.1432-1033.1988.tb14328.x; MACCABE AP, 1991, J BIOL CHEM, V266, P12646; MCCARTHY AD, 1983, EUR J BIOCHEM, V136, P501, DOI 10.1111/j.1432-1033.1983.tb07769.x; MIKKELSEN J, 1985, BIOCHEM J, V227, P21, DOI 10.1042/bj2270021; MOHAMED AH, 1988, J BIOL CHEM, V263, P12315; POULOSE AJ, 1984, ARCH BIOCHEM BIOPHYS, V230, P117, DOI 10.1016/0003-9861(84)90092-4; ROLAND I, 1975, FEBS LETT, V60, P305, DOI 10.1016/0014-5793(75)80736-8; RUSNAK F, 1991, BIOCHEMISTRY-US, V30, P2916, DOI 10.1021/bi00225a027; SCHLUMBOHM W, 1985, BIOL CHEM H-S, V366, P925, DOI 10.1515/bchm3.1985.366.2.925; SCHRECKENBACH T, 1977, EUR J BIOCHEM, V80, P13, DOI 10.1111/j.1432-1033.1977.tb11850.x; SCHROEDER WA, 1969, ARCH BIOCHEM BIOPHYS, V130, P551, DOI 10.1016/0003-9861(69)90069-1; SCHWEIZER M, 1986, MOL GEN GENET, V203, P479, DOI 10.1007/BF00422073; SCHWEIZER M, 1989, NUCLEIC ACIDS RES, V17, P567, DOI 10.1093/nar/17.2.567; SHERMAN DH, 1989, EMBO J, V8, P2717, DOI 10.1002/j.1460-2075.1989.tb08413.x; SKARPEID HJ, 1990, EUR J BIOCHEM, V187, P627, DOI 10.1111/j.1432-1033.1990.tb15346.x; SKARPEID HJ, 1990, EUR J BIOCHEM, V189, P517, DOI 10.1111/j.1432-1033.1990.tb15517.x; SMITH DJ, 1990, EMBO J, V9, P2743, DOI 10.1002/j.1460-2075.1990.tb07461.x; VANAMAN TC, 1968, J BIOL CHEM, V243, P6420; VATER J, 1989, BIOL CHEM H-S, V370, P1013, DOI 10.1515/bchm3.1989.370.2.1013; VATER J, 1987, EUR J BIOCHEM, V163, P297, DOI 10.1111/j.1432-1033.1987.tb10800.x; VATER J, 1985, BIOCHEMISTRY-US, V24, P2022, DOI 10.1021/bi00329a033; VATER J, 1990, BIOCH PEPTIDE ANTIBI, P33; WARDEN CH, 1989, J BIOL CHEM, V264, P21573; WATANABE K, 1986, NUCLEIC ACIDS RES, V14, P4393, DOI 10.1093/nar/14.11.4393; WECKERMANN R, 1988, NUCLEIC ACIDS RES, V16, P11841, DOI 10.1093/nar/16.24.11841; WITTKOWSKI A, 1987, EUR J BIOCHEM, V165, P601; YAN N, 1990, J BIOL CHEM, V265, P1588	61	114	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23135	23141						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744112				2022-12-25	WOS:A1991GT48300056
J	MASON, MJ; MAHAUTSMITH, MP; GRINSTEIN, S				MASON, MJ; MAHAUTSMITH, MP; GRINSTEIN, S			THE ROLE OF INTRACELLULAR CA-2+ IN THE REGULATION OF THE PLASMA-MEMBRANE CA-2+ PERMEABILITY OF UNSTIMULATED RAT LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FURA-2-LOADED HUMAN-PLATELETS; CALCIUM INFLUX; INOSITOL PHOSPHATES; THYMIC LYMPHOCYTES; CYTOPLASMIC CA-2+; HUMAN-NEUTROPHILS; ANTIGEN RECEPTOR; NA+/H+ EXCHANGE; CYTOSOLIC CA-2+; TUMOR PROMOTER	The mechanism responsible for the increase in cytosolic free Ca2+ concentration ([Ca2+]i) during mitogenic stimulation of lymphocytes has been widely investigated. By contrast, little is known about the processes underlying Ca2+i homeostasis in resting (unstimulated) cells. It has been suggested that [Ca2+]i is an important determinant of the rate of Ca2+ influx following mitogenic activation. Using rat thymic lymphocytes, we investigated whether the resting influx pathway is similarly controlled by [Ca2+]i. Otherwise untreated cells were Ca2+-depleted by loading with Ca2+ chelators while suspended in Ca2+-free solution. Ca2+ depletion induced an 8-fold increase in the rate of unidirectional Ca2+ uptake. The depletion-activated flux was voltage-sensitive and was blocked by La3+ and by compound SK&F 96365, a receptor-operated Ca2+ channel blocker. Upon reintroduction to Ca2+-containing solution, the increased influx brought about a rapid recovery of [Ca2+]i. Detailed analysis of the magnitude of the Ca-45(2+) flux during this recovery indicated that [Ca2+]i is not the primary determinant of the plasmalemmal Ca2+ permeability. Instead, depletion of an internal thapsigargin-sensitive store correlates with and appears to be responsible for the increased permeability of the plasma membrane. Accordingly, the Ca2+ fluxes induced by intracellular Ca2+ depletion and by thapsigargin were pharmacologically indistinguishable. Mitogenic lectins also released Ca2+ from a thapsigargin-sensitive store and activated a plasmalemmal Ca2+ permeability displaying identical pharmacology. The data support the existence of a coupling process whereby the degree of filling of an internal Ca2+ store dictates the Ca2+ permeability of the plasma membrane. This coupling mechanism is important not only in mediating the effects of mitogens and other agonists, as suggested before, but seemingly also in the control of resting Ca2+i homeostasis in unstimulated cells.	UNIV CALIF SAN DIEGO,LA JOLLA,CA 92093; UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A1,ONTARIO,CANADA	University of California System; University of California San Diego; University of Toronto	MASON, MJ (corresponding author), HOSP SICK CHILDREN,DIV CELL BIOL,TORONTO M5G 1X8,ONTARIO,CANADA.							BIJSTERBOSCH MK, 1986, BIOCHEM BIOPH RES CO, V137, P500, DOI 10.1016/0006-291X(86)91238-6; FREEDMAN MH, 1975, NATURE, V255, P378, DOI 10.1038/255378a0; GELFAND EW, 1984, J CELL PHYSIOL, V121, P533, DOI 10.1002/jcp.1041210312; GRAY LS, 1987, CELL, V50, P119, DOI 10.1016/0092-8674(87)90668-4; GRINSTEIN S, 1984, J GEN PHYSIOL, V83, P341, DOI 10.1085/jgp.83.3.341; GRINSTEIN S, 1984, J GEN PHYSIOL, V84, P565, DOI 10.1085/jgp.84.4.565; GRINSTEIN S, 1986, J BIOL CHEM, V261, P8009; GRINSTGEIN S, 1989, CELL CALCIUM METABOL, P283; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HESKETH TR, 1983, J BIOL CHEM, V258, P4876; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KUNO M, 1986, NATURE, V323, P269, DOI 10.1038/323269a0; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LIN J, 1985, J IMMUNOL, V135, P3403; MACDOUGALL SL, 1988, CELL, V54, P229, DOI 10.1016/0092-8674(88)90555-7; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; NASMITH PE, 1987, J BIOL CHEM, V262, P13558; NG J, 1990, BIOCHIM BIOPHYS ACTA, V1053, P97, DOI 10.1016/0167-4889(90)90031-8; NG J, 1988, BIOCHIM BIOPHYS ACTA, V971, P207, DOI 10.1016/S0005-2728(88)80108-7; OETTGEN HC, 1985, CELL, V40, P583, DOI 10.1016/0092-8674(85)90206-5; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; ROSOFF PM, 1988, J BIOL CHEM, V263, P19535; SAGE SO, 1990, BIOCHEM J, V265, P675, DOI 10.1042/bj2650675; SAGE SO, 1987, J BIOL CHEM, V262, P16364; SAGE SO, 1986, BIOCHEM BIOPH RES CO, V136, P1124, DOI 10.1016/0006-291X(86)90450-X; SCHARFF O, 1988, BIOCHIM BIOPHYS ACTA, V972, P257, DOI 10.1016/S0005-2728(88)80056-2; SEGAL J, 1984, ENDOCRINOLOGY, V115, P160, DOI 10.1210/endo-115-1-160; SEGAL J, 1986, BIOCHIM BIOPHYS ACTA, V886, P267, DOI 10.1016/0167-4889(86)90144-8; Smith RM, 1974, CRITICAL STABILITY C, V1-6; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAYLOR MV, 1984, NATURE, V312, P462, DOI 10.1038/312462a0; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0	36	91	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10872	10879						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1828246				2022-12-25	WOS:A1991FQ77400029
J	PAYNE, MA; RAO, GSJ; HARRIS, BG; COOK, PF				PAYNE, MA; RAO, GSJ; HARRIS, BG; COOK, PF			FRUCTOSE 2,6-BISPHOSPHATE AND AMP INCREASE THE AFFINITY OF THE ASCARIS-SUUM PHOSPHOFRUCTOKINASE FOR FRUCTOSE 6-PHOSPHATE IN A PROCESS SEPARATE FROM THE RELIEF OF ATP INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; MUSCLE PHOSPHOFRUCTOKINASE; PHYSIOLOGICAL CONDITIONS; ALLOSTERIC MODULATION; REGULATORY PROPERTIES; DIROFILARIA-IMMITIS; FASCIOLA-HEPATICA; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; BOVINE LIVER	Kinetic data have been collected suggesting that heterotropic activation by fructose 2,6-bisphosphate and AMP is a result not only of the relief of allosteric inhibition by ATP but is also the result of an increase in the affinity of phosphofructokinase for fructose 6-phosphate. Modification of the Ascaris suum phosphofructokinase at the ATP inhibitory site produces a form of the enzyme that no longer has hysteretic time courses or homotropic positive (fructose 6-phosphate) cooperativity or substrate inhibition (ATP) (Rao, G. S. J., Wariso, B. A., Cook, P. F., Hofer, H. W., and Harris, B. G. (1987a) J. Biol. Chem. 262, 14068-14073). This form of phosphofructokinase is Michaelis-Menten in its kinetic behavior but is still activated by fructose 2,6-bisphosphate and AMP and by phosphorylation using the catalytic subunit of cyclic AMP-dependent protein kinase (cAPK). Fructose 2,6-bisphosphate activates by decreasing K(F-6-P) by about 15-fold and has an activation constant of 92 nM, while AMP decreases K(F-6-P) about 6-fold and has an activation constant of 93-mu-M. Double activation experiments suggest that fructose 2,6-bisphosphate and AMP are synergistic in their activation. The desensitized form of the enzyme is phosphorylated by cAPK and has an increased affinity for fructose 6-phosphate in the absence of MgATP. The increased affinity results in a change in the order of addition of reactants from that with MgATP adding first for the nonphosphorylated enzyme to addition of fructose 6-phosphate first for the phosphorylated enzyme. The phosphorylated form of the enzyme is also still activated by fructose 2,6-bisphosphate and AMP.	TEXAS HEART INST,DEPT MICROBIOL & IMMUNOL,HOUSTON,TX 77025	Texas Heart Institute	PAYNE, MA (corresponding author), TEXAS HEART INST,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77025, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036799, R01GM037057] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24155] Funding Source: Medline; NIGMS NIH HHS [GM36799, GM37057] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cleland W W, 1979, Methods Enzymol, V63, P103; COOK PF, 1982, BIOCHEMISTRY-US, V21, P113, DOI 10.1021/bi00530a020; GOTTSCHALK ME, 1981, BIOCHEMISTRY-US, V20, P2245, DOI 10.1021/bi00511a027; HOFER HW, 1982, J BIOL CHEM, V257, P3807; HOFER HW, 1982, J BIOL CHEM, V257, P3801; KAMEMOTO ES, 1986, J BIOL CHEM, V261, P4346; KAMEMOTO ES, 1987, ARCH BIOCHEM BIOPHYS, V258, P101, DOI 10.1016/0003-9861(87)90327-4; KEMP RG, 1983, MOL CELL BIOCHEM, V57, P147, DOI 10.1007/BF00849191; KULKARNI G, 1987, J BIOL CHEM, V262, P32, DOI 10.1128/AAC.31.1.32; MERRY S, 1985, BIOCHEM J, V226, P13, DOI 10.1042/bj2260013; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PAYNE MA, 1991, J BIOL CHEM, V266, P8897; POORMAN RA, 1984, NATURE, V309, P467, DOI 10.1038/309467a0; RAO GSJ, 1991, J BIOL CHEM, V266, P8884; RAO GSJ, 1987, J BIOL CHEM, V262, P14074; RAO GSJ, 1987, J BIOL CHEM, V262, P14068; RYPNIEWSKI WR, 1989, J MOL BIOL, V207, P805, DOI 10.1016/0022-2836(89)90246-5; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; SRINIVASAN NG, 1990, MOL BIOCHEM PARASIT, V38, P151, DOI 10.1016/0166-6851(90)90215-8; SRINIVASAN NG, 1988, J BIOL CHEM, V263, P3482; STARLING JA, 1982, J BIOL CHEM, V257, P3795; SUGDEN PH, 1976, BIOCHEM J, V159, P409, DOI 10.1042/bj1590409; UYEDA K, 1981, J BIOL CHEM, V256, P8394; Uyeda K, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P193; VANSCHAFTINGEN E, 1981, P NATL ACAD SCI-BIOL, V78, P3483; YOON MY, 1987, BIOCHEMISTRY-US, V26, P4118, DOI 10.1021/bi00387a056	27	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8891	8896						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1827438				2022-12-25	WOS:A1991FM03800038
J	TOYOFUKU, T; ZAK, R				TOYOFUKU, T; ZAK, R			CHARACTERIZATION OF CDNA AND GENOMIC SEQUENCES ENCODING A CHICKEN PHOSPHOLAMBAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; FAST-TWITCH MUSCLE; SMOOTH-MUSCLE; SKELETAL-MUSCLE; MESSENGER-RNAS; POLYADENYLATION SITES; STRUCTURAL DOMAINS; GENE-EXPRESSION; KINASE GENE; TRANSCRIPTION	We report on the isolation and characterization of cDNA and genomic sequences encoding a chicken cardiac phospholamban. Three mRNAs, 0.6, 1.1, and 3.3 kilobase pairs in size, were detected in cardiac and slow-tonic muscle RNAs on Northern blots. We determined that these mRNAs differ in the length of their 3'-untranslated regions, perhaps because they utilize alternative polyadenylation signals. We studied the developmental and tissue-specific expression of phospholamban mRNA using nuclease mapping analysis. There appeared to be considerable homology between coding and 3'-untranslated regions of phospholamban mRNAs from cardiac and slow-tonic muscles during development, strongly suggesting that these mRNAs are encoded by the same gene. The phospholamban gene, which is present as a single copy in the chicken genome, is about 10 kilobase pairs long, with approximately 6.5 kilobase pairs representing the intron sequences. Primer extension and nuclease mapping analyses of the 5' end of the phospholamban mRNA showed that the three transcripts are initiated from the same initiation site. Analysis of the putative promoter region revealed "TATA box" and "CAAT box" sequences, putative muscle-specific elements, and a cyclic AMP-responsive element.	UNIV CHICAGO, DEPT MED, BOX 360, 5841 S MARYLAND AVE, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT ANAT, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago					NHLBI NIH HHS [HL-20592] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020592] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMARA SG, 1984, MOL CELL BIOL, V4, P2151, DOI 10.1128/MCB.4.10.2151; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BRANDEN CI, 1984, EMBO J, V3, P1307, DOI 10.1002/j.1460-2075.1984.tb01967.x; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRODERS F, 1990, P NATL ACAD SCI USA, V87, P503, DOI 10.1073/pnas.87.2.503; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHOWCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; CRABTREE GR, 1982, CELL, V31, P159, DOI 10.1016/0092-8674(82)90415-9; CRAIK CS, 1983, SCIENCE, V220, P1125, DOI 10.1126/science.6344214; EARLY P, 1980, CELL, V20, P3134; FRAYNE EG, 1984, MOL CELL BIOL, V4, P2921, DOI 10.1128/MCB.4.12.2921; FUJII J, 1988, FEBS LETT, V227, P51, DOI 10.1016/0014-5793(88)81412-1; FUJII J, 1989, J BIOL CHEM, V264, P12950; FUJII J, 1987, J CLIN INVEST, V79, P301, DOI 10.1172/JCI112799; GABELLA G, 1989, ANAT EMBRYOL, V180, P213, DOI 10.1007/BF00315880; GIL G, 1987, P NATL ACAD SCI USA, V84, P1863, DOI 10.1073/pnas.84.7.1863; GILBERT W, 1985, SCIENCE, V228, P823, DOI 10.1126/science.4001923; HARTSHORNE DJ, 1981, ANNU REV PHYSIOL, V43, P519, DOI 10.1146/annurev.ph.43.030181.002511; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; KAPRIELIAN Z, 1987, DEV BIOL, V124, P490, DOI 10.1016/0012-1606(87)90502-1; KIRCHBERGER MA, 1974, J BIOL CHEM, V249, P6166; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KOZAK M, 1983, MICROBIOL REV, V47, P1; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRANIAS EG, 1988, MOL CELL BIOCHEM, V82, P37; LEBERER E, 1989, EUR J BIOCHEM, V185, P51, DOI 10.1111/j.1432-1033.1989.tb15080.x; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LIU CC, 1984, NATURE, V309, P82, DOI 10.1038/309082a0; LONBERG N, 1985, CELL, V40, P81, DOI 10.1016/0092-8674(85)90311-3; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MATHER EL, 1984, CELL, V36, P329, DOI 10.1016/0092-8674(84)90226-5; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MUMENTHALER M, 1961, ACTA ANAT, V47, P274; NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851; NIKOVITS W, 1990, MOL CELL BIOL, V10, P3468, DOI 10.1128/MCB.10.7.3468; ORKIN SH, 1981, CELL, V24, P345, DOI 10.1016/0092-8674(81)90324-X; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PETTE D, 1977, BASIC RES CARDIOL, V72, P247, DOI 10.1007/BF01906369; RAEYMAEKERS L, 1986, BIOCHIM BIOPHYS ACTA, V882, P258, DOI 10.1016/0304-4165(86)90163-7; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SEIDMAN CE, 1988, P NATL ACAD SCI USA, V85, P4104, DOI 10.1073/pnas.85.11.4104; SHULL MM, 1989, J BIOL CHEM, V264, P17532; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; TADA M, 1983, J MOL CELL CARDIOL, V15, P335, DOI 10.1016/0022-2828(83)91345-7; TADA M, 1982, ANNU REV PHYSIOL, V44, P401, DOI 10.1146/annurev.ph.44.030182.002153; TADA M, 1988, METHOD ENZYMOL, V157, P107; VERBOOMEN H, 1989, BIOCHEM J, V262, P353, DOI 10.1042/bj2620353	55	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5375	5383						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1825996				2022-12-25	WOS:A1991FD37000006
J	MOULD, AP; KOMORIYA, A; YAMADA, KM; HUMPHRIES, MJ				MOULD, AP; KOMORIYA, A; YAMADA, KM; HUMPHRIES, MJ			THE CS5 PEPTIDE IS A 2ND SITE IN THE IIICS REGION OF FIBRONECTIN RECOGNIZED BY THE INTEGRIN ALPHA-4-BETA-1 - INHIBITION OF ALPHA-4-BETA-1 FUNCTION BY RGD PEPTIDE HOMOLOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; HUMAN-PLASMA FIBRONECTIN; CELL-BINDING DOMAIN; CONNECTING SEGMENT; ADHESION RECEPTOR; DIVALENT-CATIONS; MESSENGER-RNAS; BETA-SUBUNIT; GAMMA-CHAIN; IDENTIFICATION	The alternatively spliced type III connecting segment (IIICS) region of fibronectin contains two distinct sites that support the adhesion of melanoma cells. These sites are contained within the synthetic peptides CS1 and CS5 (residues 1-25 and 90-109 of the IIICS, respectively). Recently, the cellular receptor for the CS1 site has been identified as the integrin heterodimer alpha-4-beta-1. In this report, we have investigated the role of the CS5 sequence in melanoma cell adhesion and the identity of its receptor. Adhesion to CS5, when presented to cells as an immobilized IgG conjugate, was blocked by antifunctional monoclonal antibodies directed against either the alpha-4 or beta-1-integrin subunits, but not by antibodies against other subunits, implying that alpha-4-beta-1 is also the receptor for CS5. In peptide inhibition experiments, CS5 was inhibitory for melanoma cell spreading on both CS5-IgG and CS1-IgG conjugates; conversely, CS1 inhibited spreading on both CS1-IgG and CS5-IgG. In both cases, peptide inhibition could be outcompeted by increasing the concentration of substrate-bound conjugate. These results suggest that CS1 and CS5 are recognized by the same or overlapping sites on alpha-4-beta-1. The minimal active sequence within CS5, the tetrapeptide Arg-Glu-Asp-Val (REDV), is somewhat related to the Arg-Gly-Asp-Ser (RGDS) sequence that represents a major active site in the central cell-binding domain (CCBD) of fibronectin. When RGDS peptide homologues were tested for their ability to inhibit spreading of melanoma cells on CS1- and CS5-IgG conjugates, GRGDS, GRGES, and REDV were found to be inhibitory, while GRDGS had no effect. In contrast, spreading on a fibronectin fragment containing the CCBD was inhibited by GRGDS only. GRGDS was also able to elute alpha-4-beta-1 specifically from a CS1 affinity column, confirming directly that alpha-4-beta-1-IIICS interactions are sensitive to peptides containing this recognition motif. Because the minimal active sequence within CS1 is the tripeptide Leu-Asp-Val (LDV; Komoriya et al., manuscript submitted for publication), these findings together define a new adhesive recognition sequence, X-Asp-Y, used by alpha-4-beta-1 for binding to fibronectin. The central aspartate residue in this tripeptide is almost always essential, but some flexibility in the amino acid residues at X (glycine, leucine, or glutamic acid) and Y (serine or valine) is tolerated. Potential models for the interaction of the IIICS region with alpha-4-beta-1 are discussed.	NCI,MOLEC BIOL LAB,MEMBRANE BIOCHEM SECT,BETHESDA,MD 20892; US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA)	MOULD, AP (corresponding author), UNIV MANCHESTER,SCH MED,DEPT BIOCHEM & MOLEC BIOL,MANCHESTER M13 9PT,LANCS,ENGLAND.			Yamada, Kenneth/0000-0003-1512-6805; Mould, Paul/0000-0003-0076-6228; Humphries, Martin/0000-0002-4331-6967	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGER A, 1990, INT IMMUNOL, V2, P921, DOI 10.1093/intimm/2.10.921; AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; BERNARD MP, 1985, BIOCHEMISTRY-US, V24, P2698, DOI 10.1021/bi00332a016; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DUFOUR S, 1988, EMBO J, V7, P2661, DOI 10.1002/j.1460-2075.1988.tb03119.x; EDWARDS JG, 1988, J CELL SCI, V89, P507; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FERREIRA OC, 1990, J EXP MED, V171, P351, DOI 10.1084/jem.171.1.351; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GARCIAPARDO A, 1990, J IMMUNOL, V144, P3361; GARCIAPARDO A, 1987, BIOCHEM J, V241, P923, DOI 10.1042/bj2410923; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HAWIGER J, 1982, P NATL ACAD SCI-BIOL, V79, P2068, DOI 10.1073/pnas.79.6.2068; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HERSHBERGER RP, 1990, MOL CELL BIOL, V10, P662, DOI 10.1128/MCB.10.2.662; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; HUMPHRIES MJ, 1988, J CELL BIOL, V106, P1289, DOI 10.1083/jcb.106.4.1289; HUMPHRIES MJ, 1990, IN PRESS RECEPTORS E; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Hynes RO, 1990, FIBRONECTINS; KORNBLIHTT AR, 1984, NUCLEIC ACIDS RES, V12, P5853, DOI 10.1093/nar/12.14.5853; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOZLOWSKI JM, 1984, J NATL CANCER I, V72, P913; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM SCT, 1987, J BIOL CHEM, V262, P947; LEBIEN TW, 1982, J IMMUNOL, V129, P2287; LIAO NS, 1989, EXP CELL RES, V181, P348, DOI 10.1016/0014-4827(89)90093-1; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MCCARTHY JB, 1990, J CELL BIOL, V110, P777, DOI 10.1083/jcb.110.3.777; Mosher DF, 1988, FIBRONECTIN; MOULD AP, 1990, J BIOL CHEM, V265, P4020; NAGATA K, 1985, J CELL BIOL, V101, P386, DOI 10.1083/jcb.101.2.386; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; OYAMA F, 1989, BIOCHEMISTRY-US, V28, P1428, DOI 10.1021/bi00429a072; PAUL JI, 1986, J BIOL CHEM, V261, P2258; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985; RUGGERI ZM, 1986, P NATL ACAD SCI USA, V83, P5708, DOI 10.1073/pnas.83.15.5708; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SCHWARZBAUER JE, 1985, P NATL ACAD SCI USA, V82, P1424, DOI 10.1073/pnas.82.5.1424; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; SEKIGUCHI K, 1986, BIOCHEMISTRY-US, V25, P4936, DOI 10.1021/bi00365a032; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SMITH JW, 1988, J BIOL CHEM, V263, P18726; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29; YAMADA KM, 1985, J CELL BIOCHEM, V28, P99, DOI 10.1002/jcb.240280203; ZARDI L, 1985, EUR J BIOCHEM, V146, P571, DOI 10.1111/j.1432-1033.1985.tb08690.x	56	235	239	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3579	3585						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1750929				2022-12-25	WOS:A1991EY68200038
J	SHERLEY, JL				SHERLEY, JL			GUANINE-NUCLEOTIDE BIOSYNTHESIS IS REGULATED BY THE CELLULAR P53 CONCENTRATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROFIBROMATOSIS TYPE-1 GENE; TUMOR SUPPRESSOR GENES; WILD-TYPE P53; IMP DEHYDROGENASE; ACTIVATING MUTATIONS; MYCOPHENOLIC-ACID; THYMIDINE KINASE; TISSUE-EXTRACTS; PROTO-ONCOGENE; HAMSTER-CELLS	As an approach to defining the role of p53 in cellular proliferation, murine cell lines were derived which contain a stably transfected temperature-inducible p53 expression system. Cell lines derived with the system exhibited a 3-6-fold physiologic elevation in the cellular p53 concentration when grown at 32.5-degrees-C. A p53 induction phenotype was defined by examination of the growth properties of these lines at 32.5-degrees-C. The induction phenotype had three main features: 1) a 2-4-fold increase in doubling time and biphasic growth kinetics; 2) delayed early S phase transit; and 3) complete reversibility either by growth at 37-degrees-C or by growth in the presence of added hypoxanthine or xanthosine. The reversal of the induction phenotype by these purine salvage precursors implicated the purine nucleotide biosynthetic pathway as the cellular target for the antiproliferative action of p53. Subsequent genetic and biochemical analyses identified a p53 induction-related purine pathway defect which was localized to the step of inosine 5'-monophosphate conversion to xanthosine 5'-monophosphate. This enzymatic step catalyzed by inosine 5'-monophosphate dehydrogenase (EC 1.2.1.14) is the rate-limiting step for GTP synthesis. Extracts from p53-inducible cells growing at the induction temperature show a specific reduction in inosine 5'-monophosphate dehydrogenase enzymatic activity. These findings define p53 as a cellular regulator of the synthesis of GTP, a key regulatory nucleotide for many important cellular processes. Moreover, observations of the growth behavior of p53-inducible cells suggest that by regulating the production of GTP, p53 can control cellular quiescence.	PRINCETON UNIV, DEPT MOLEC BIOL, LEWIS THOMAS LAB, PRINCETON, NJ 08544 USA	Princeton University					NCI NIH HHS [CA41086, CA08562-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA008562, P01CA041086] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIBA I, 1990, ONCOGENE, V5, P1603; COHEN MB, 1983, CANCER RES, V43, P1587; COHEN MB, 1981, J BIOL CHEM, V256, P8713; COLLART FR, 1988, J BIOL CHEM, V263, P15769; COLLART FR, 1987, MOL CELL BIOL, V7, P3328, DOI 10.1128/MCB.7.9.3328; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DIMAIO D, 1988, EMBO J, V7, P1197, DOI 10.1002/j.1460-2075.1988.tb02931.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; Fenwick R. G., 1985, MOL CELL GENETICS, P333; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, CELL, V64, P5, DOI 10.1016/0092-8674(91)90200-I; HANSEN MF, 1988, CELL, V53, P172, DOI 10.1016/0092-8674(88)90376-5; HARKNESS R A, 1980, Biochemical Society Transactions, V8, P139; HAWLEYNELSON P, 1988, EMBO J, V7, P525, DOI 10.1002/j.1460-2075.1988.tb02841.x; HAYASHI Y, 1990, JPN J PHARMACOL, V53, P1, DOI 10.1254/jjp.53.1; HAYASHI Y, 1990, IN VITRO CELL DEV B, V26, P843, DOI 10.1007/BF02624607; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HODGES SD, 1989, J BIOL CHEM, V264, P18137; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HORWITZ BH, 1988, MOL CELL BIOL, V8, P4071, DOI 10.1128/MCB.8.10.4071; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JACKSON RC, 1977, BIOCHEM J, V166, P1; JACKSON RC, 1975, NATURE, V256, P331, DOI 10.1038/256331a0; JOHANSEN H, 1989, GENE DEV, V3, P882, DOI 10.1101/gad.3.6.882; KEMP AJ, 1986, J BIOL CHEM, V261, P4891; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KORNBERG A, 1980, DNA REPLICATION, P39; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; Lehninger A.L, 1975, BIOCHEMISTRY-US; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MERCER WE, 1990, ONCOGENE, V5, P973; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MUIRHEAD KA, 1985, BIO-TECHNOL, V3, P337, DOI 10.1038/nbt0485-337; NATSUMEDA Y, 1990, J BIOL CHEM, V265, P5292; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; OROURKE RW, 1990, ONCOGENE, V5, P1829; PROFFITT RT, 1983, CANCER RES, V43, P1620; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REED R R, 1990, New Biologist, V2, P957; RICCIARDI RP, 1979, P NATL ACAD SCI USA, V76, P4927, DOI 10.1073/pnas.76.10.4927; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHWEINFEST CW, 1988, MOL CELL BIOL, V8, P3080, DOI 10.1128/MCB.8.8.3080; SHERLEY JL, 1988, J BIOL CHEM, V263, P375; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; SHIMURA K, 1983, J BIOCHEM, V94, P1595; SMELLIE RMS, 1958, BIOCHIM BIOPHYS ACTA, V29, P59, DOI 10.1016/0006-3002(58)90146-X; SPALHOLZ BA, 1987, J VIROL, V61, P2128, DOI 10.1128/JVI.61.7.2128-2137.1987; SPALHOLZ BA, 1985, CELL, V42, P183, DOI 10.1016/S0092-8674(85)80114-8; SPYROU G, 1983, BIOCHEM BIOPH RES CO, V115, P1022, DOI 10.1016/S0006-291X(83)80037-0; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; WEBER G, 1983, CANCER RES, V43, P3466; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YANG YC, 1985, P NATL ACAD SCI USA, V82, P1030, DOI 10.1073/pnas.82.4.1030; YANG YC, 1985, NATURE, V318, P575, DOI 10.1038/318575a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	94	90	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24815	24828						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761576				2022-12-25	WOS:A1991GW84500087
J	SETH, A; ALVAREZ, E; GUPTA, S; DAVIS, RJ				SETH, A; ALVAREZ, E; GUPTA, S; DAVIS, RJ			A PHOSPHORYLATION SITE LOCATED IN THE NH2-TERMINAL DOMAIN OF C-MYC INCREASES TRANSACTIVATION OF GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CASEIN KINASE-II; CELL-CYCLE; PROTEIN; TRANSCRIPTION; ACTIVATION; INSULIN; TRANSFORMATION	The c-myc gene encodes a sequence-specific DNA-binding protein (c-Myc) that forms leucine zipper complexes and can act as a transcription factor. Growth factor stimulation of cells causes the phosphorylation of the c-Myc transcriptional activation domain at Ser62 within a proline-rich region that is highly conserved among members of the Myc family (Alvarez, E., Northwood, I.C., Gonzalez, F. A., Latour, D. A., Seth, A., Abate, C., Curran, T., and Davis, R. J. (1991) J. Biol. Chem. 266, 15277-15285). This phosphorylation site is a substrate for growth factor-regulated MAP kinases and for the cell cycle-dependent protein kinase p34cdc2. We report that serum treatment of cells results in a marked increase in the transactivation of gene expression mediated by the c-Myc transcriptional activation domain. A point mutation at the site of growth factor-stimulated phosphorylation (Ser62) decreases the serum induction of transactivation. These data indicate that the c-Myc transcriptional activation domain may be a direct target of signal transduction pathways.	UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	DAVIS, RJ (corresponding author), UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605, USA.		ALVAREZ, ELVIRA/F-2994-2017; ALVAREZ, ELVIRA/S-8977-2019	ALVAREZ, ELVIRA/0000-0002-9074-3857; 	NCI NIH HHS [CA39240] Funding Source: Medline; NIGMS NIH HHS [GM37845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA039240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037845] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PAYNE MD, 1991, EMBO J, V4, P885; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; WATERS C, 1991, ONCOGENE, V6, P101	29	241	242	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23521	23524						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748630				2022-12-25	WOS:A1991GV31900002
J	JONES, DA; FITZPATRICK, FA				JONES, DA; FITZPATRICK, FA			THROMBOXANE-A2 SYNTHASE - MODIFICATION DURING SUICIDE INACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM-BASED INACTIVATION; PROSTAGLANDIN-H-SYNTHASE; ARACHIDONIC-ACID; HUMAN-PLATELETS; FATTY-ACIDS; ENZYME; BIOSYNTHESIS; IDENTIFICATION; ENDOPEROXIDES; PROSTACYCLIN	Thromboxane synthase is a ferrihemoprotein which undergoes mechanism-based inactivation during catalysis. This "suicide" process may be an important factor for limiting thromboxane A2 biosynthesis in cells. Although the kinetics have been characterized for purified enzyme and platelets, the chemical basis for inactivation has remained unclear. Protein modification or alteration of the heme prosthetic group is each compatible with the irreversible nature of suicide inactivation of thromboxane synthase. We have investigated these two possibilities using enzyme purified to homogeneity. Our data show that the Soret absorbance spectrum of thromboxane synthase is unaltered by additions of prostaglandin endoperoxide H-2 which cause enzymatic inactivation. Using a coupled cyclooxygenase/thromboxane synthase system and polyacrylamide gel electrophoresis we have demonstrated that the enzyme retains radiolabel under nondenaturing gel conditions. Label incorporation is reduced by the competitive thromboxane synthase inhibitor U63557, an agent that also protects the enzyme from inactivation. Under denaturing conditions the radiolabel localizes with the released heme prosthetic group. In addition, interaction of the heme prosthetic group with cyanide was prevented by inactivating the enzyme with prostaglandin H-2. In similar experiments, the lipid hydroperoxide 15(S)-hydroperoxyeicosatetraenoic acid inactivated thromboxane synthase with concurrent bleaching of the Soret spectrum. Labeling studies with a coupled soybean lipoxygenase/thromboxane synthase system indicate that, in this case, the apoenzyme is modified. These results suggest that the mechanism of thromboxane synthase inactivation during thromboxane A2 biosynthesis involves a tight, nondestructive association of substrate or product with the prosthetic heme group. Inactivation by hydroperoxides, however, appears to result from apoenzyme modification. These reactions may have important implications for cellular physiology and pathophysiology of thrombosis.	UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL34303] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON A, 1979, PROSTAGLANDINS, V18, P409; [Anonymous], 1988, LANCET, V2, P349; BHAGWAT SS, 1985, NATURE, V315, P511, DOI 10.1038/315511a0; CHEN YNP, 1987, J BIOL CHEM, V262, P16892; DEWITT DL, 1983, J BIOL CHEM, V258, P3285; DIX TA, 1985, J BIOL CHEM, V260, P5351; FITZGERALD GA, 1987, FASEB J, V46, P154; FITZPATRICK FA, 1982, METHOD ENZYMOL, V86, P286; FITZPATRICK FA, 1977, PROSTAGLANDINS, V14, P881, DOI 10.1016/0090-6980(77)90304-5; GORMAN RR, 1983, PROSTAGLANDINS, V26, P325, DOI 10.1016/0090-6980(83)90099-0; HALL E, 1991, FATTY ACIDS, V42, P19; HALL ER, 1991, PROSTAG LEUKOTR ESS, V42, P31, DOI 10.1016/0952-3278(91)90063-B; HALL ER, 1986, BIOCHEM J, V233, P637, DOI 10.1042/bj2330637; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; HAMMARSTROM S, 1977, P NATL ACAD SCI USA, V74, P3691, DOI 10.1073/pnas.74.9.3691; HAURAND M, 1985, J BIOL CHEM, V260, P5059; HECKER M, 1989, J BIOL CHEM, V264, P141; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; JONES DA, 1990, J BIOL CHEM, V265, P20166; KIM MR, 1991, ARCH BIOCHEM BIOPHYS, V288, P270, DOI 10.1016/0003-9861(91)90194-N; LECOMTE M, 1990, J BIOL CHEM, V265, P5178; MACIAS P, 1991, BIOCHIM BIOPHYS ACTA, V1082, P310, DOI 10.1016/0005-2760(91)90207-X; MACLOUF J, 1980, EUR J BIOCHEM, V109, P561, DOI 10.1111/j.1432-1033.1980.tb04828.x; NEEDLEMAN P, 1976, NATURE, V261, P558, DOI 10.1038/261558a0; NUSING R, 1990, ARCH BIOCHEM BIOPHYS, V280, P325, DOI 10.1016/0003-9861(90)90337-X; OSAWA Y, 1989, DRUG METAB DISPOS, V17, P7; PARNHAM MJ, 1981, BIOCHIM BIOPHYS ACTA, V677, P165, DOI 10.1016/0304-4165(81)90081-7; PATRONO C, 1987, FED PROC, V72, P1177; ROTH GJ, 1975, J CLIN INVEST, V56, P624, DOI 10.1172/JCI108132; SCHAEFER WH, 1985, BIOCHEMISTRY-US, V24, P3254, DOI 10.1021/bi00334a027; SHEN RF, 1986, J BIOL CHEM, V261, P1592; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; SMITH WL, 1972, J BIOL CHEM, V247, P1038; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; VANOS CPA, 1981, BIOCHIM BIOPHYS ACTA, V663, P177, DOI 10.1016/0005-2760(81)90204-6	35	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23510	23514						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744143				2022-12-25	WOS:A1991GT48300110
J	SHAYMAN, JA; DESHMUKH, GD; MAHDIYOUN, S; THOMAS, TP; WU, D; BARCELON, FS; RADIN, NS				SHAYMAN, JA; DESHMUKH, GD; MAHDIYOUN, S; THOMAS, TP; WU, D; BARCELON, FS; RADIN, NS			MODULATION OF RENAL EPITHELIAL-CELL GROWTH BY GLUCOSYLCERAMIDE - ASSOCIATION WITH PROTEIN-KINASE-C, SPHINGOSINE, AND DIACYLGLYCEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAUCHERS-DISEASE; INHIBITION; GLYCOSPHINGOLIPIDS; GANGLIOSIDES; BIOSYNTHESIS; FIBROBLASTS; SYNTHETASE; ACTIVATION; PLATELETS; CERAMIDE	Two independent approaches were employed to explore the potential role of endogenous glucosylceramide or a closely related glucosphingolipid in mediating the cellular proliferation of Madin-Darby canine kidney cells. First, cultured cells were depleted of glucosphingolipids by exposure to a glucosylceramide synthase inhibitor, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol. This agent markedly inhibited cell growth and DNA synthesis in a time- and concentration-dependent manner. Second, cells were grown in the presence of conduritol B epoxide, an inhibitor of glucosylceramide beta-D-glucosidase. Exposure of cells to this inhibitor resulted in the time-dependent accumulation of glucosylceramide with a corresponding increase in cellular proliferation. Alterations in protein kinase C activity were evaluated as a potential mechanism for these effects on growth. Both membrane- and cytosol-associated protein kinase C (PKC) activity declined under conditions of glucosylceramide synthase inhibition and increased under conditions of beta-glucosidase inhibition. The changes in PKC activity were evident after DEAE-cellulose purification. Diacylglycerol levels increased in response to both glucosylceramide synthase and beta-glucosidase inhibition. Ceramide and sphingosine levels changed only in the presence of D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, increasing due to lack of conversion to glucosylceramide. However, the elevation in endogenous sphingosine was probably insufficient to account for the decrease in PKC, considering the high level of diacylglycerol in the cells. These data demonstrate an association between glucosylceramide levels, PKC activity, and cell growth.	UNIV MICHIGAN,MED CTR,MENTAL HLTH RES INST,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	SHAYMAN, JA (corresponding author), UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041487] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS003192] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK-41487] Funding Source: Medline; NINDS NIH HHS [NS03192-31] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barranger J. A., 1989, METABOLIC BASIS INHE, P1677; BERNERT JT, 1981, BIOCHIM BIOPHYS ACTA, V666, P99, DOI 10.1016/0005-2760(81)90095-3; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; BREMER EG, 1986, J BIOL CHEM, V261, P2434; CHIARUGI V, 1989, BIOCHEM BIOPH RES CO, V164, P816, DOI 10.1016/0006-291X(89)91532-5; DATTA SC, 1988, LIPIDS, V23, P508, DOI 10.1007/BF02535529; FELDINGHABERMANN B, 1990, BIOCHEMISTRY-US, V29, P6314, DOI 10.1021/bi00478a028; FOX H, 1984, CANCER, V54, P312, DOI 10.1002/1097-0142(19840715)54:2<312::AID-CNCR2820540222>3.0.CO;2-I; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HARA A, 1979, BIOCHIM BIOPHYS ACTA, V582, P423, DOI 10.1016/0304-4165(79)90134-X; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; INOKUCHI J, 1987, CANCER LETT, V38, P23, DOI 10.1016/0304-3835(87)90196-0; INOKUCHI J, 1990, CANCER RES, V50, P6731; INOKUCHI J, 1991, TRENDS GLYCOSCI GLYC, V3, P200; INOKUCHI JI, 1989, J CELL PHYSIOL, V141, P573, DOI 10.1002/jcp.1041410316; INOKUCHI JI, 1987, J LIPID RES, V28, P565; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KENNERLY DA, 1979, ANAL BIOCHEM, V98, P123, DOI 10.1016/0003-2697(79)90715-2; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LADISCH S, 1987, J CLIN INVEST, V79, P1879, DOI 10.1172/JCI113031; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; LEE KJ, 1985, CARBOHYD RES, V144, P148, DOI 10.1016/0008-6215(85)85015-1; MAKITA A, 1964, J BIOCHEM-TOKYO, V55, P269, DOI 10.1093/oxfordjournals.jbchem.a127880; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; OGURA K, 1991, GLYCOCONJUGATE J, V8, P160; PREISS J, 1986, J BIOL CHEM, V261, P8597; RADIN NS, 1976, J LIPID RES, V17, P290; RADIN NS, 1988, BIOCHEM PHARMACOL, V37, P2879, DOI 10.1016/0006-2952(88)90271-7; ROBERTS DD, 1988, ARCH BIOCHEM BIOPHYS, V267, P405, DOI 10.1016/0003-9861(88)90046-X; RYBAK SM, 1981, EXP CELL RES, V136, P263, DOI 10.1016/0014-4827(81)90004-5; SHAYMAN JA, 1990, J BIOL CHEM, V265, P12135; SHUKLA GS, 1991, BIOCHIM BIOPHYS ACTA, V1083, P101, DOI 10.1016/0005-2760(91)90130-A; STEVENS VL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P37, DOI 10.1016/0167-4889(90)90171-9; TAUB M, 1979, P NATL ACAD SCI USA, V76, P3338, DOI 10.1073/pnas.76.7.3338; THOMAS TP, 1987, METHOD ENZYMOL, V141, P399; WARREN KR, 1976, J LIPID RES, V17, P132	39	101	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22968	22974						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744091				2022-12-25	WOS:A1991GT48300032
J	AGHIB, DF; BISHOP, JM				AGHIB, DF; BISHOP, JM			A 3' TRUNCATION OF MYC CAUSED BY CHROMOSOMAL TRANSLOCATION IN A HUMAN T-CELL LEUKEMIA IS TUMORIGENIC WHEN TESTED IN ESTABLISHED RAT FIBROBLASTS	ONCOGENE			English	Note							HUMAN C-MYC; MESSENGER-RNA; GENE; TRANSFORMATION; EXPRESSION; ONCOGENE; ACTIVATION; ADJACENT; SEQUENCE; REGION	We have previously identified in human T-leukemia cells a myc gene with an unusual 3' rearrangement, and we have shown that expression of the gene is deregulated by stabilization of mRNA. Here we report that the rearranged gene transforms established rat fibroblasts to a tumorigenic phenotype. In hybrid genes, the transforming capability segregates with the 3' rearrangement. Transformation is apparently due to a more than fivefold enhancement in myc expression, attributable to stabilization of mRNA. The rearranged allele of myc also contains a point mutation in a region upstream of the gene, identified previously as a potential negative regulator of myc expression. The mutation may increase expression of myc, but not sufficiently to cause cellular transformation. Our findings enlarge the variety of genetic lesions that may activate myc to an oncogene and sustain the view that augmented expression of an otherwise normal allele of myc can be pathogenic.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,GW HOOPER RES FDN,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NCI NIH HHS [CA 44338] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044338] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGHIB D, 1987, GENETIC VARIATION VI, V354, P338; AGHIB DF, 1990, ONCOGENE, V5, P707; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BIGNAMI M, 1988, ONCOGENE, V2, P509; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; FINGER LR, 1988, P NATL ACAD SCI USA, V85, P9158, DOI 10.1073/pnas.85.23.9158; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; HOLLIS GF, 1988, MOL CELL BIOL, V8, P124, DOI 10.1128/MCB.8.1.124; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; MARTIN P, 1986, EMBO J, V5, P1529, DOI 10.1002/j.1460-2075.1986.tb04393.x; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; RICHMAN A, 1989, SCIENCE, V246, P494, DOI 10.1126/science.2683072; SAGLIO G, 1986, CANCER RES, V46, P1413; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; Sambrook J, 1989, MOL CLONING LABORATO; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SYMONDS G, 1989, ONCOGENE, V4, P285; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	24	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2371	2375						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766681				2022-12-25	WOS:A1991GX73500029
J	GROSS, G				GROSS, G			RNASE-E CLEAVAGE IN THE ATPE LEADER REGION OF ATPE/INTERFERON-BETA HYBRID TRANSCRIPTS IN ESCHERICHIA-COLI CAUSES ENHANCED RATES OF MESSENGER-RNA DECAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATIONAL INITIATION REGION; RIBONUCLEASE-E; POLYNUCLEOTIDE PHOSPHORYLASE; STRUCTURAL-ANALYSIS; RIBOSOMAL-RNA; STABILITY; SEQUENCE; INVIVO; GENES; IDENTIFICATION	Chimeric transcripts containing the ribosome binding site of the Escherichia coli atpE gene and variants of the human structural interferon-beta-gene are subject to RNase E processing in the 5'-untranslated atpE part of the transcripts. The absence of processing at two sites in the atpE leader-sequence caused by the RNase E deficiency in E. coli host N3431 leads to a considerable stabilization of the mRNA moiety. RNase E has originally been described as a processing enzyme for non-mRNAs such as precursor 5 S rRNA and RNA1, but cleavage mRNA substrates have also been reported. RNase E processing of the atpE gene leader sequence-containing transcripts leads to an increased rate of mRNA breakdown. The two RNase E-dependent processing sites in the atpE part of the mRNA transcripts exhibit some similarity to the other known RNase E processing sites. The influence of RNase E cleavage upon post-transcriptional regulation such as RNA stability and the efficiency of translational initiation is discussed.			GROSS, G (corresponding author), GESELL BIOTECHNOL FORSCH GMBH, GENET ABT, MASCHERODER WEG 1, W-3300 BRAUNSCHWEIG, GERMANY.							APIRION D, 1978, GENETICS, V90, P659; BELASCO JG, 1988, GENE, V72, P15, DOI 10.1016/0378-1119(88)90123-0; CANNISTRARO VJ, 1986, J MOL BIOL, V192, P257, DOI 10.1016/0022-2836(86)90363-3; CANNISTRARO VJ, 1989, EUR J BIOCHEM, V181, P363, DOI 10.1111/j.1432-1033.1989.tb14733.x; CHEN CYA, 1988, CELL, V52, P609, DOI 10.1016/0092-8674(88)90473-4; CHEVRIERMILLER M, 1990, NUCLEIC ACIDS RES, V18, P5787, DOI 10.1093/nar/18.19.5787; CHO KO, 1988, J MOL BIOL, V204, P51, DOI 10.1016/0022-2836(88)90598-0; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; DUNN JJ, 1973, P NATL ACAD SCI USA, V70, P3296, DOI 10.1073/pnas.70.12.3296; FOLLEY LS, 1989, J MOL BIOL, V209, P359, DOI 10.1016/0022-2836(89)90003-X; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; GORSKI K, 1985, CELL, V43, P461, DOI 10.1016/0092-8674(85)90176-X; GROSS G, 1988, GENE, V72, P119, DOI 10.1016/0378-1119(88)90133-3; GROSS G, 1990, J BIOL CHEM, V265, P17627; GUREVITZ M, 1983, P NATL ACAD SCI-BIOL, V80, P4450, DOI 10.1073/pnas.80.14.4450; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; HAYASHI MN, 1985, NUCLEIC ACIDS RES, V13, P5937, DOI 10.1093/nar/13.16.5937; MCCARTHY JEG, 1985, EMBO J, V4, P519, DOI 10.1002/j.1460-2075.1985.tb03659.x; MUDD EA, 1988, EMBO J, V7, P3601, DOI 10.1002/j.1460-2075.1988.tb03238.x; MUDD EA, 1990, GENE DEV, V4, P873, DOI 10.1101/gad.4.5.873; NEWBURY SF, 1987, CELL, V48, P297, DOI 10.1016/0092-8674(87)90433-8; NILSSON G, 1988, EMBO J, V7, P2269, DOI 10.1002/j.1460-2075.1988.tb03067.x; NILSSON G, 1984, NATURE, V312, P75, DOI 10.1038/312075a0; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; PANAYOTATOS N, 1985, NUCLEIC ACIDS RES, V13, P2227, DOI 10.1093/nar/13.7.2227; PEDERSEN S, 1978, MOL GEN GENET, V166, P329, DOI 10.1007/BF00267626; PORTIER C, 1987, EMBO J, V6, P2165, DOI 10.1002/j.1460-2075.1987.tb02484.x; PRAGAI B, 1982, J MOL BIOL, V154, P465, DOI 10.1016/S0022-2836(82)80007-7; ROY MK, 1983, EUR J BIOCHEM, V131, P119, DOI 10.1111/j.1432-1033.1983.tb07238.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; SCHMEISSNER U, 1984, J MOL BIOL, V176, P39, DOI 10.1016/0022-2836(84)90381-4; STANSSENS P, 1986, CELL, V44, P711, DOI 10.1016/0092-8674(86)90837-8; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; WONG HC, 1986, P NATL ACAD SCI USA, V83, P3233, DOI 10.1073/pnas.83.10.3233	38	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17880	17884						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1833388				2022-12-25	WOS:A1991GG55300029
J	LAM, E; CHUA, NH				LAM, E; CHUA, NH			TETRAMER OF A 21-BASE PAIR SYNTHETIC ELEMENT CONFERS SEED EXPRESSION AND TRANSCRIPTIONAL ENHANCEMENT IN RESPONSE TO WATER-STRESS AND ABSCISIC-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; DNA-BINDING PROTEIN; TRANSGENIC TOBACCO; REGULATORY ELEMENTS; BETA-GLUCURONIDASE; S-35 PROMOTER; GENE; PLANTS; SEQUENCES; WHEAT	A conserved 21-base pair element, designated as hex-1, located between -180 and -160 of the wheat histone H3 promoter, is known to interact with two tobacco nuclear factors, activating sequence factor 1 and hex-1-specific binding factor. We have shown previously that a mutant sequence (hex-3), which differs from hex-1 by three base pairs, can no longer bind these two factors significantly. In the present work, we examined the functional characteristics of these two sequences in transgenic tobacco. Surprisingly, we found that a tetramer of hex-3, but not of hex-1, confers high level expression in mature seeds. Expression of this synthetic promoter rapidly diminishes upon germination but can be reactivated in young seedlings and mature leaves by desiccation, NaCl, or the phytohormone abscisic acid (ABA). Treatment with auxin or cytokinin has no apparent effect on the expression. Since the endogenous ABA level of plant cells is known to increase upon water stress, our data suggest that hex-3, the mutated hex-1 sequence, is an abscisic acid-responsive element (abre). We propose that a tobacco nuclear factor, distinct from activating sequence factor 1 and hex-1-specific binding factor, interacts with this sequence and is involved in mediating the effects of ABA and water stress on gene expression.	RUTGERS STATE UNIV, WAKSMAN INST, DEPT BIOCHEM & MICROBIOL, PISCATAWAY, NJ 08855 USA; ROCKEFELLER UNIV, PLANT MOLEC BIOL LAB, NEW YORK, NY 10021 USA	Rutgers State University New Brunswick; Rockefeller University	LAM, E (corresponding author), RUTGERS STATE UNIV, WAKSMAN INST, AGBIOTECH CTR, BOX 759, PISCATAWAY, NJ 08855 USA.							BENFEY PN, 1989, EMBO J, V8, P2195, DOI 10.1002/j.1460-2075.1989.tb08342.x; BENFEY PN, 1990, EMBO J, V9, P1685, DOI 10.1002/j.1460-2075.1990.tb08292.x; BOUCHEZ D, 1989, EMBO J, V8, P4197, DOI 10.1002/j.1460-2075.1989.tb08605.x; BUSTOS MM, 1989, PLANT CELL, V1, P839, DOI 10.1105/tpc.1.9.839; COLOT V, 1987, EMBO J, V6, P3559, DOI 10.1002/j.1460-2075.1987.tb02685.x; FANG RX, 1989, PLANT CELL, V1, P141, DOI 10.1105/tpc.1.1.141; FLUHR R, 1986, EMBO J, V5, P2063, DOI 10.1002/j.1460-2075.1986.tb04467.x; FROMM H, 1989, PLANT CELL, V1, P977, DOI 10.1105/tpc.1.10.977; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; HESSE T, 1989, EMBO J, V8, P2453, DOI 10.1002/j.1460-2075.1989.tb08380.x; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; INOHARA N, 1989, P NATL ACAD SCI USA, V86, P3564, DOI 10.1073/pnas.86.10.3564; JEFFERSON RA, 1987, EMBO J, V6, P3901; KATAGIRI F, 1989, NATURE, V340, P727, DOI 10.1038/340727a0; KLAMBT D, 1990, PLANT MOL BIOL, V14, P1045, DOI 10.1007/BF00019401; LAM E, 1990, PLANT CELL, V2, P857, DOI 10.1105/tpc.2.9.857; LAM E, 1989, PLANT CELL, V1, P1147, DOI 10.1105/tpc.1.12.1147; LAM E, 1989, P NATL ACAD SCI USA, V86, P7890, DOI 10.1073/pnas.86.20.7890; LAM E, 1990, J BIOL CHEM, V265, P9909; LAM E, 1990, SCIENCE, V248, P471, DOI 10.1126/science.2330508; MARCOTTE WR, 1989, PLANT CELL, V1, P969, DOI 10.2307/3868997; MIKAMI K, 1987, FEBS LETT, V223, P273, DOI 10.1016/0014-5793(87)80303-4; MUNDY J, 1990, P NATL ACAD SCI USA, V87, P1406, DOI 10.1073/pnas.87.4.1406; MUNDY J, 1988, EMBO J, V7, P2279, DOI 10.1002/j.1460-2075.1988.tb03070.x; NAKAYAMA T, 1989, PLANT CELL PHYSIOL, V30, P825, DOI 10.1093/oxfordjournals.pcp.a077812; POULSEN C, 1988, MOL GEN GENET, V214, P16, DOI 10.1007/BF00340173; SKRIVER K, 1990, PLANT CELL, V2, P503, DOI 10.1105/tpc.2.6.503; SOUSA R, 1989, EMBO J, V8, P1801, DOI 10.1002/j.1460-2075.1989.tb03574.x; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WILLIAMSON JD, 1989, PLANT PHYSIOL, V90, P1570, DOI 10.1104/pp.90.4.1570; YAMAGUCHISHINOZAKI K, 1990, PLANT MOL BIOL, V14, P29, DOI 10.1007/BF00015652; YAMAZAKI K, 1990, P NATL ACAD SCI USA, V87, P7035, DOI 10.1073/pnas.87.18.7035; ZEEVAART JAD, 1988, ANNU REV PLANT PHYS, V39, P439, DOI 10.1146/annurev.pp.39.060188.002255	33	61	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17131	17135						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1832669				2022-12-25	WOS:A1991GF44500027
J	BERRY, MJ; KIEFFER, JD; HARNEY, JW; LARSEN, PR				BERRY, MJ; KIEFFER, JD; HARNEY, JW; LARSEN, PR			SELENOCYSTEINE CONFERS THE BIOCHEMICAL-PROPERTIES CHARACTERISTIC OF THE TYPE-I IODOTHYRONINE DEIODINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROWTH-HORMONE PROMOTER; THYROID-HORMONE; SELENIUM DEFICIENCY; L-THYROXINE; RAT-LIVER; INHIBITION; TRIIODOTHYRONINE; KIDNEY; PROPYLTHIOURACIL; 5'-DEIODINASE	The conversion of thyroxine to 3,5,3'-triiodothyronine (T3) is the first step in thyroid hormone action, and the Type I iodothyronine deiodinase supplies most of this extrathyroidal T3 in the rat. We found that the cDNA coding for this enzyme contains an in-frame UGA encoding the rare amino acid selenocysteine. Using site-directed mutagenesis, we have converted selenocysteine to cysteine and expressed the wild-type and cysteine mutant enzymes in JEG-3 cells by transient transfection. The kinetic properties of the transiently expressed wild-type enzyme are nearly identical to those reported for rat liver Type I deiodinase. Substitution of sulfur for selenium causes a 10-fold increase in the K(m) of the enzyme for the favored substrate 3,3',5'-triiodothyronine (rT3), a 100-fold decrease in the sensitivity of rT3 deiodination to competitive inhibition by gold and a 300-fold increase in the apparent K(i) for uncompetitive inhibition by 6-n-propylthiouracil. These results demonstrate that selenium is responsible for the biochemical properties which characterize Type I iodothyronine monodeiodination.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV THYROID,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	BERRY, MJ (corresponding author), BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST LAB,BOSTON,MA 02115, USA.				NIDDK NIH HHS [DK36256] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036256] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMS GM, 1973, J CLIN INVEST, V52, P2522, DOI 10.1172/JCI107443; ABUID J, 1974, J CLIN INVEST, V54, P201, DOI 10.1172/JCI107744; ARTHUR JR, 1990, BIOCHEM J, V272, P537, DOI 10.1042/bj2720537; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; AXLEY MJ, 1990, J BIOL CHEM, V265, P18213; BECKETT GJ, 1987, BIOCHEM J, V248, P443, DOI 10.1042/bj2480443; BECKETT GJ, 1989, BIOCHEM J, V259, P887, DOI 10.1042/bj2590887; BEHNE D, 1990, BIOCHEM BIOPH RES CO, V173, P1143, DOI 10.1016/S0006-291X(05)80905-2; BERRY MJ, 1990, MOL ENDOCRINOL, V4, P743, DOI 10.1210/mend-4-5-743; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BERRY MJ, 1991, IN PRESS ENDOCRINOLO; BRENT GA, 1989, J BIOL CHEM, V264, P178; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; CHAUDIERE J, 1984, J INORG BIOCHEM, V20, P313, DOI 10.1016/0162-0134(84)85030-8; LEONARD JL, 1978, ENDOCRINOLOGY, V103, P2137, DOI 10.1210/endo-103-6-2137; Leonard JL, 1986, THYROID HORMONE META, P189; NICOLOFF J T, 1970, Journal of Clinical Investigation, V49, P267, DOI 10.1172/JCI106236; OPPENHEI.JH, 1972, J CLIN INVEST, V51, P2493, DOI 10.1172/JCI107063; SCHWARTZ HL, 1971, J CLIN INVEST, V50, P1124, DOI 10.1172/JCI106584; SILVA JE, 1987, ENDOCRINOLOGY, V121, P650, DOI 10.1210/endo-121-2-650; STADTMAN TC, 1990, ANNU REV BIOCHEM, V59, P111, DOI 10.1146/annurev.bi.59.070190.000551; VISSER TJ, 1980, BIOCHIM BIOPHYS ACTA, V611, P371, DOI 10.1016/0005-2744(80)90074-1	22	191	194	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14155	14158						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1830583				2022-12-25	WOS:A1991FZ35100005
J	KUDO, S; FUKUDA, M				KUDO, S; FUKUDA, M			A SHORT, NOVEL PROMOTER SEQUENCE CONFERS THE EXPRESSION OF HUMAN LEUKOSIALIN, A MAJOR SIALOGLYCOPROTEIN ON LEUKOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH SYNDROME; ALU REPEAT SEQUENCES; SURFACE SIALOGLYCOPROTEIN; MONOCLONAL-ANTIBODY; SIALOPHORIN CD43; DNA-POLYMERASE; GENE; CELLS; ANTIGEN; ACTIVATION	Human leukosialin (CD43) is a major sialoglycoprotein expressed on leukocytes and platelets. In order to investigate the transcriptional regulation of this gene, we have isolated a genomic DNA of 12 kilobases in size that includes the 5'-flanking sequence. Comparison of the genomic and cDNA sequences revealed that the leukosialin gene consists of two exons, and that its entire translation product is encoded in the second exon. The transcriptional start site was determined by primer extension analysis in human T-cell line Jurkat. No canonical TATA or CAAT boxes were found in the prospected upstream region, but a guanine-rich region was observed on the sense strand. To localize the transcriptional regulatory region of this gene, various regions of 5' sequences were fused to the chloramphenicol acetyltransferase (CAT) gene, and transient expression assays were conducted in Jurkat cells. We employed the polymerase chain reaction to generate a series of clones containing 5' sequences of the leukosialin gene using primer sequences based on the genomic sequence. This strategy enabled us to narrow the search for a transcriptional regulatory element. In addition, we introduced site-directed mutations in the regulatory region by polymerase chain reaction to define it in detail. These studies showed that the sequence from -53 to -40 base pairs 5' to the transcriptional start site is critically involved in leukosialin expression. This sequence, 5'GGGTGGGTGGAGCC3', represents a novel promoter sequence which has not been reported in the promoters for other molecules expressed in T-lymphocytes.			KUDO, S (corresponding author), LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA033895] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA33895] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CALABRETTA B, 1982, NATURE, V296, P219, DOI 10.1038/296219a0; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CYSTER J, 1990, EUR J IMMUNOL, V20, P875, DOI 10.1002/eji.1830200424; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DYER MJS, 1981, J EXP MED, V154, P1164, DOI 10.1084/jem.154.4.1164; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEDRICH TD, 1981, VIROLOGY, V110, P159, DOI 10.1016/0042-6822(81)90017-9; FUKUDA M, 1980, NATURE, V285, P405, DOI 10.1038/285405a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GULLEY ML, 1988, J IMMUNOL, V140, P3751; JACKMAN RW, 1987, P NATL ACAD SCI USA, V84, P6425, DOI 10.1073/pnas.84.18.6425; KILLEEN N, 1987, EMBO J, V6, P4029, DOI 10.1002/j.1460-2075.1987.tb02747.x; KOPITO RR, 1987, P NATL ACAD SCI USA, V84, P7149, DOI 10.1073/pnas.84.20.7149; KUDO S, 1989, P NATL ACAD SCI USA, V86, P4619, DOI 10.1073/pnas.86.12.4619; LEDER P, 1977, SCIENCE, V196, P175, DOI 10.1126/science.322278; MENTZER SJ, 1987, J EXP MED, V165, P1383, DOI 10.1084/jem.165.5.1383; NONG YH, 1989, J EXP MED, V170, P259, DOI 10.1084/jem.170.1.259; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; PILLER F, 1988, J BIOL CHEM, V263, P15146; PILLER V, 1989, J BIOL CHEM, V264, P18824; PILLER V, 1990, J BIOL CHEM, V265, P9264; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID CW, 1982, SCIENCE, V216, P1065, DOI 10.1126/science.6281889; SHELLEY CS, 1989, P NATL ACAD SCI USA, V86, P2819, DOI 10.1073/pnas.86.8.2819; SHELLEY CS, 1990, BIOCHEM J, V270, P569, DOI 10.1042/bj2700569; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; VARGASCORTES M, 1988, SCAND J IMMUNOL, V27, P661, DOI 10.1111/j.1365-3083.1988.tb02399.x; WEISS A, 1984, J IMMUNOL, V133, P123; WENGER RH, 1988, BIOCHEM BIOPH RES CO, V156, P389, DOI 10.1016/S0006-291X(88)80853-2; WONG RCK, 1990, J IMMUNOL, V144, P1455; WU J, 1990, MOL CELL BIOL, V10, P1209, DOI 10.1128/MCB.10.3.1209	38	25	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8483	8489						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1827122				2022-12-25	WOS:A1991FK44100079
J	ROHRER, DK; HARTONG, R; DILLMANN, WH				ROHRER, DK; HARTONG, R; DILLMANN, WH			INFLUENCE OF THYROID-HORMONE AND RETINOIC ACID ON SLOW SARCOPLASMIC-RETICULUM CA2+ATPASE AND MYOSIN HEAVY-CHAIN ALPHA-GENE EXPRESSION IN CARDIAC MYOCYTES - DELINEATION OF CIS-ACTIVE DNA ELEMENTS THAT CONFER RESPONSIVENESS TO THYROID-HORMONE BUT NOT TO RETINOIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; RAT-HEART; RESPONSE ELEMENTS; RECEPTOR; GROWTH; RNA; IDENTIFICATION; SEQUENCE; PROTEIN; ATPASE	The mRNA encoding the sarcoplasmic reticulum (SR) Ca2+ ATPase is highly influenced by thyroid hormone (T3) in the hearts of intact animals. We show here that this effect of T3 can be mimicked in primary neonatal rat cardiocytes, both in serum-containing and in serum-free media; the expression of SR Ca2+ ATPase mRNA is myocyte-specific and is also modulated by retinoic acid (RA). RA also induces myosin heavy chain (MHC) alpha-mRNA in this system. The induction of Ca2+ ATPase mRNA is sensitive to T3 (EC50 approximately 30 pM) and less sensitive to RA (EC50 approximately 2 nM). Transient transfection experiments utilizing various segments of the Ca2+ ATPase promoter fused to the reporter gene chloramphenicol acetyltransferase (CAT) indicate a minimal thyroid hormone response element (TRE) between nucleotides -262 and -322, while sequences between -322 and -559 are required for maximal trans-activation. RA is not able to regulate these constructs. Likewise, a clear effect of T3 but no effect of RA was observed when the CAT gene was driven by a TRE derived from the rat alpha-MHC gene. In contrast, CAT expression was induced by either hormone when placed under the control of a synthetic palindromic TRE. Taken together, these results indicate that T3 and RA induce gene expression in primary cardiac myocytes, but through distinct response elements and/or mechanisms.	UNIV CALIF SAN DIEGO, MED CTR,DEPT MED,DIV ENDOCRINOL & METAB, 225 DICKINSON ST H-811-C, SAN DIEGO, CA 92103 USA	University of California System; University of California San Diego					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025022] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL25022] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BEDO G, 1989, NATURE, V339, P231, DOI 10.1038/339231a0; BERS DM, 1985, AM J PHYSIOL, V248, pH366, DOI 10.1152/ajpheart.1985.248.3.H366; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENT GA, 1989, J BIOL CHEM, V264, P178; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; GEBALLE AP, 1986, CELL, V46, P865, DOI 10.1016/0092-8674(86)90068-1; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; GUSTAFSON TA, 1987, J BIOL CHEM, V262, P13316; HARTONG R, 1987, ENDOCRINOLOGY, V120, P2460, DOI 10.1210/endo-120-6-2460; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; KIM D, 1987, J CLIN INVEST, V80, P88, DOI 10.1172/JCI113068; LIMAS CJ, 1978, AM J PHYSIOL, V235, pH745, DOI 10.1152/ajpheart.1978.235.6.H745; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MCCONNAUGHEY MM, 1979, J CARDIOVASC PHARM, V1, P609, DOI 10.1097/00005344-197911000-00002; MCNALLY EM, 1989, NUCLEIC ACIDS RES, V17, P7527, DOI 10.1093/nar/17.18.7527; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORKIN E, 1983, PROG CARDIOVASC DIS, V25, P435, DOI 10.1016/0033-0620(83)90004-X; NAGAI R, 1989, P NATL ACAD SCI USA, V86, P2966, DOI 10.1073/pnas.86.8.2966; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OMALLEY K, 1985, MOL CELL BIOL, V5, P3476, DOI 10.1128/MCB.5.12.3476; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; RODGERS RL, 1986, AM J PHYSIOL, V250, pH861, DOI 10.1152/ajpheart.1986.250.5.H861; ROHRER D, 1988, J BIOL CHEM, V263, P6941; ROHRER DK, 1989, J CELL BIOCH E S, V13, P210; RUDINGER A, 1984, ARCH BIOCHEM BIOPHYS, V229, P379, DOI 10.1016/0003-9861(84)90165-6; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHWARTZ K, 1981, J MOL CELL CARDIOL, V13, P1071, DOI 10.1016/0022-2828(81)90297-2; SEN A, 1988, J CLIN INVEST, V82, P1333, DOI 10.1172/JCI113735; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SINHA AM, 1982, P NATL ACAD SCI-BIOL, V79, P5847, DOI 10.1073/pnas.79.19.5847; SPINDLER SR, 1982, J BIOL CHEM, V257, P1627; SUKO J, 1973, J PHYSIOL-LONDON, V228, P563, DOI 10.1113/jphysiol.1973.sp010100; TAYLOR RR, 1969, J CLIN INVEST, V48, P775, DOI 10.1172/JCI106035; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WIESHAMMER S, 1989, CAN J PHYSIOL PHARM, V67, P1007, DOI 10.1139/y89-158; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670; ZILZ ND, 1990, J BIOL CHEM, V265, P8136	61	158	159	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8638	8646						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1827123				2022-12-25	WOS:A1991FK44100101
J	HAO, R; SCHMIT, JC				HAO, R; SCHMIT, JC			PURIFICATION AND CHARACTERIZATION OF GLUTAMATE-DECARBOXYLASE FROM NEUROSPORA-CRASSA CONIDIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID DECARBOXYLASE; ESCHERICHIA-COLI; GERMINATION; BRAIN; BARLEY; FORMS	L-Glutamate decarboxylase, an enzyme under the control of the asexual developmental cycle of Neurospora crassa, was purified to homogeneity from conidia. The purification procedure included ammonium sulfate fractionation and DEAE-Sephadex and cellulose phosphate column chromatography. The final preparation gave a single band on sodium dodecyl sulfate-polyacrylamide gels with a molecular weight of 33,200 +/- 200. A single band coincident with enzyme activity was found on native 7.5% polyacrylamide gels. The molecular weight of glutamate decarboxylase was 30,500 as determined by gel permeation column chromatography at pH 6.0. The enzyme had an acidic pH optimum and showed hyperbolic kinetics at pH 5.5 with a K(m) for glutamic acid of 2.2 mM and a K(m) for pyridoxal-5'-phosphate of 0.04-mu-M.	SO ILLINOIS UNIV, DEPT MED BIOCHEM, NECKERS BLDG, RM 229, CARBONDALE, IL 62901 USA; SO ILLINOIS UNIV, DEPT CHEM & BIOCHEM, CARBONDALE, IL 62901 USA	Southern Illinois University System; Southern Illinois University; Southern Illinois University System; Southern Illinois University								ARONSON JN, 1975, SPORES, V6, P404; BERLIN V, 1985, MOL CELL BIOL, V5, P839, DOI 10.1128/MCB.5.4.839; CHRISTENSEN RL, 1980, J BACTERIOL, V144, P983, DOI 10.1128/JB.144.3.983-990.1980; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; DENNER LA, 1987, P NATL ACAD SCI USA, V84, P668, DOI 10.1073/pnas.84.3.668; DUFFUS CM, 1972, EXPERIENTIA, V28, P635, DOI 10.1007/BF01944946; ELVING PJ, 1956, ANAL CHEM, V28, P1179, DOI 10.1021/ac60115a034; FOERSTER HF, 1972, J BACTERIOL, V111, P437, DOI 10.1128/JB.111.2.437-442.1972; FOERSTER HF, 1971, J BACTERIOL, V108, P817, DOI 10.1128/JB.108.2.817-823.1971; FONDA ML, 1985, METHOD ENZYMOL, V113, P11; GERIG JT, 1973, BIOCHEM BIOPH RES CO, V54, P937, DOI 10.1016/0006-291X(73)90784-5; GUIGNARD R, 1983, EXP MYCOL, V7, P133, DOI 10.1016/0147-5975(83)90056-7; GUJAR VP, 1983, NEUROSPORA NEWSL, V30, P15; INATOMI K, 1975, BIOCHEM J, V147, P479, DOI 10.1042/bj1470479; JACKSON FR, 1990, J NEUROCHEM, V54, P1068, DOI 10.1111/j.1471-4159.1990.tb02359.x; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMKIN WM, 1983, CEREAL CHEM, V60, P166; MATSUMOTO T, 1986, AGR BIOL CHEM TOKYO, V50, P143; MOORE S, 1963, METHOD ENZYMOL, V6, P819, DOI 10.1016/0076-6879(63)06257-1; OLEARY MH, 1970, J AM CHEM SOC, V92, P4435, DOI 10.1021/ja00717a048; OZOLS J, 1990, METHOD ENZYMOL, V182, P587; SCHMIT JC, 1975, J BACTERIOL, V124, P232, DOI 10.1128/JB.124.1.232-242.1975; SCHMIT JC, 1976, BACTERIOL REV, V40, P1; SCHMIT JC, 1981, EXP MYCOL, V5, P330, DOI 10.1016/0147-5975(81)90038-4; SPINK DC, 1983, J NEUROCHEM, V40, P1113, DOI 10.1111/j.1471-4159.1983.tb08101.x; STAPLETON A, 1989, J NEUROCHEM, V53, P1126, DOI 10.1111/j.1471-4159.1989.tb07405.x; STRAUSBA.PH, 1970, BIOCHEMISTRY-US, V9, P226, DOI 10.1021/bi00804a006; VOGEL HJ, 1964, AM NAT, V98, P435, DOI 10.1086/282338; WU JY, 1985, METHOD ENZYMOL, V113, P3; WU JY, 1973, J BIOL CHEM, V248, P3029	31	37	45	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					5135	5139						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1825829				2022-12-25	WOS:A1991FC21700068
J	ROSS, DC; DAVIDSON, GA; MCINTOSH, DB				ROSS, DC; DAVIDSON, GA; MCINTOSH, DB			MECHANISM OF INHIBITION OF SARCOPLASMIC-RETICULUM CA2+-ATPASE BY ACTIVE-SITE CROSS-LINKING - IMPAIRMENT OF NUCLEOTIDE BINDING SLOWS NUCLEOTIDE-DEPENDENT PHOSPHORYL TRANSFER, AND LOSS OF ACTIVE-SITE FLEXIBILITY STABILIZES OCCLUDED FORMS AND BLOCKS E2-P FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM ADENOSINE-TRIPHOSPHATASE; FUNCTIONAL CONSEQUENCES; CATALYTIC SITE; SEQUENTIAL DISSOCIATION; SKELETAL-MUSCLE; CA-2+-ATPASE; ATP; TRANSPORT; CA-2+; 5'-TRIPHOSPHATE	Investigation of the properties of Ca2+-ATPase of sarcoplasmic reticulum cross-linked at the active site with glutaraldehyde showed that ATP binding affinity and rate of ATP-dependent phosphorylation and Ca2+ occlusion were decreased 2-3 orders of magnitude compared with the native enzyme. Cross-linkage had little effect on or marginally increased the rate of acetyl phosphate- and p-nitrophenyl phosphate-supported Ca2+ occlusion. Ca2+ binding or Ca2+-induced changes in tryptophan fluorescence were unaffected. High levels of phosphoenzyme (up to 4 nmol/mg of protein) were obtained, with 2 mol of Ca2+ occluded/mol of E-P. Dephosphorylation and deocclusion occurred together at a slow rate (k = 0.01 s-1) and were stimulated in a monophasic manner up to 20-fold by ADP. Cross-linking inhibited E2-P formation from P(i) in 30% (v/v) dimethyl sulfoxide by more than 95%. Induction of turnover of the native ATPase, under conditions designed to yield high steady state levels of E1 approximately P(2Ca), results in a 3-4-fold increase in reactivity of active site residues to glutaraldehyde. The results show that cross-linkage sterically impairs nucleotide binding, changing ATP and ADP into relatively poor substrates, slowing nucleotide-dependent phosphoryl transfer and Ca2+ occlusion and deocclusion. The forward reaction with smaller substrates is unaffected. Another major effect of the cross-link is to inhibit E2-P formation, causing accumulation of E1 approximately P(2Ca) during enzyme turnover and preventing phosphorylation by P(i) in the reverse direction. We suggest that occlusion and deocclusion of cations at the transport site of the native enzyme are linked to a two-step cleft closure movement at the active site and that the cross-link stabilizes occluded forms of the pump because it blocks part of this tertiary structural change. The latter could normally be propagated through linking helices to the distal side of the pump to destabilize the cations and open the transport sites to the lumen.	UNIV CAPE TOWN,SCH MED,DEPT CHEM PATHOL,CAPE TOWN 7925,SOUTH AFRICA	University of Cape Town	ROSS, DC (corresponding author), UNIV CAPE TOWN,SCH MED,MRC,BIOMEMBRANE RES UNIT,CAPE TOWN 7925,SOUTH AFRICA.							ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; BARFORD D, 1989, NATURE, V340, P609, DOI 10.1038/340609a0; BERMAN MC, 1986, J BIOL CHEM, V261, P6494; BODLEY AL, 1987, J BIOL CHEM, V262, P13997; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHAMPEIL P, 1986, BIOCHEMISTRY-US, V25, P7623, DOI 10.1021/bi00371a053; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; CHIESI M, 1980, BIOCHEMISTRY-US, V19, P2912, DOI 10.1021/bi00554a015; CHIU VCK, 1980, J MEMBRANE BIOL, V56, P219, DOI 10.1007/BF01869478; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; DAVIDSON GA, 1987, J BIOL CHEM, V262, P7041; DEANCOS JG, 1988, BIOCHEMISTRY-US, V27, P1793; DEMEIS L, 1973, J BIOL CHEM, V48, P3691; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; DUPONT Y, 1983, FEBS LETT, V156, P93, DOI 10.1016/0014-5793(83)80255-5; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FERNANDEZBELDA F, 1986, BIOCHEMISTRY-US, V25, P8083, DOI 10.1021/bi00372a043; FORBUSH B, 1987, J BIOL CHEM, V262, P11104; FROEHLICH JP, 1975, J BIOL CHEM, V250, P2013; GLYNN IM, 1982, J PHYSIOL-LONDON, V330, P17, DOI 10.1113/jphysiol.1982.sp014326; INESI G, 1984, J BIOL CHEM, V259, P996; INESI G, 1987, J BIOL CHEM, V262, P16338; Jencks W P, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P75; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; KAWAKITA M, 1980, J BIOCHEM, V87, P609, DOI 10.1093/oxfordjournals.jbchem.a132785; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MCINTOSH DB, 1984, CURR TOP CELL REGUL, V24, P409; MEISSNER G, 1981, J BIOL CHEM, V256, P636; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; NAKAMOTO RK, 1984, J BIOL CHEM, V259, P2961; NAKAMURA J, 1987, J BIOL CHEM, V262, P14492; NAKAMURA Y, 1978, J BIOCHEM-TOKYO, V83, P571, DOI 10.1093/oxfordjournals.jbchem.a131945; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; PICKART CM, 1984, J BIOL CHEM, V259, P1629; PICKART CM, 1982, J BIOL CHEM, V257, P5319; POST RL, 1969, J GEN PHYSIOL, V54, pS306, DOI 10.1085/jgp.54.1.306; POST RL, 1972, J BIOL CHEM, V247, P6530; ROSS DC, 1987, J BIOL CHEM, V262, P12977; ROSS DC, 1987, J BIOL CHEM, V262, P2042; SEEBREGTS CJ, 1989, J BIOL CHEM, V264, P2043; SERPERSU EH, 1982, EUR J BIOCHEM, V122, P347, DOI 10.1111/j.1432-1033.1982.tb05887.x; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P8698; STAHL N, 1987, BIOCHEMISTRY-US, V26, P7654, DOI 10.1021/bi00398a019; SUMIDA M, 1980, J BIOL CHEM, V255, P1497; TAKISAWA H, 1983, J BIOL CHEM, V258, P2986; TERUEL JA, 1988, BIOCHEMISTRY-US, V27, P5885, DOI 10.1021/bi00416a010; VERJOVSKIALMEIDA S, 1978, BIOCHEMISTRY-US, V17, P5006, DOI 10.1021/bi00616a023; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WAKABAYASHI S, 1990, J BIOCHEM-TOKYO, V107, P563, DOI 10.1093/oxfordjournals.jbchem.a123087; WATANABE T, 1982, J BIOL CHEM, V257, P1510	54	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4613	4621						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1825656				2022-12-25	WOS:A1991FA69400091
J	VANHOVE, G; VANVELDHOVEN, PP; VANHOUTTE, F; PARMENTIER, G; EYSSEN, HJ; MANNAERTS, GP				VANHOVE, G; VANVELDHOVEN, PP; VANHOUTTE, F; PARMENTIER, G; EYSSEN, HJ; MANNAERTS, GP			MITOCHONDRIAL AND PEROXISOMAL-BETA OXIDATION OF THE BRANCHED-CHAIN FATTY-ACID 2-METHYLPALMITATE IN RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA SYNTHETASE; LONG-CHAIN	A number of isoprenoids (e.g. pristanic acid and the side chains of fat soluble-vitamins) is degraded or shortened via beta-oxidation. We synthesized 2-methyl-palmitate and 2-methyl[1-C-14]palmitate as a model substrate for the study of the beta-oxidation of branched (isoprenoid) fatty acids in rat liver. 2-Methylpalmitate was well oxidized by isolated hepatocytes and its oxidation was stimulated after treatment of the animals with a peroxisome proliferator. Subcellular fractionation of rat liver demonstrated that 2-methylpalmitate is activated to its CoA ester in endoplasmic reticulum, mitochondria, and peroxisomes and that mitochondria and peroxisomes are capable of beta-oxidizing 2-methylpalmitate. At low unbound 2-methylpalmitate concentrations and in the presence of competing straight chain fatty acids, a condition encountered in vivo, peroxisomal 2-methylpalmitate oxidation was 2- to 4-fold more active than mitochondrial oxidation. Treatment of rats with a peroxisome proliferator markedly stimulated mitochondrial but only slightly peroxisomal 2-methylpalmitate oxidation. The same treatment dramatically induced palmitoyl-CoA oxidase but did not change 2-methyl-palmitoyl-CoA oxidase activity. Our results indicate 1) that in untreated rats peroxisomes contribute for an important part to the oxidation of 2-methylpalmitate; 2) that treatment with a peroxisome proliferator stimulates mainly the mitochondrial component of 2-methylpalmitate oxidation; and 3) that palmitoyl-CoA and 2-methylpalmitoyl-CoA are oxidized by different peroxisomal oxidases.	CATHOLIC UNIV LEUVEN, AFDELING FARMACOL, CAMPUS GASTHUISBERG O & N, B-3000 LOUVAIN, BELGIUM; REGA INST, B-3000 LOUVAIN, BELGIUM	KU Leuven; KU Leuven			, Van Veldhoven Paul/U-6359-2019	, Van Veldhoven Paul/0000-0002-4478-2564				CASON J, 1953, J ORG CHEM, V18, P842, DOI 10.1021/jo50013a011; CASTEELS M, 1988, J BIOL CHEM, V263, P4654; CHEN RF, 1967, J BIOL CHEM, V242, P173; COOK FL, 1974, J ORG CHEM, V39, P3416, DOI 10.1021/jo00937a026; DECLERCQ PE, 1984, J BIOL CHEM, V259, P9064; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; FRIEDRICH W, 1988, VITAMINS, P217; KASE F, 1983, J LIPID RES, V24, P1560; KRISANS SK, 1980, J BIOL CHEM, V255, P9599; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; MANNAERTS GP, 1979, J BIOL CHEM, V254, P4585; MANNAERTS GP, 1982, BIOCHEM J, V204, P17, DOI 10.1042/bj2040017; POULOS A, 1988, EUR J PEDIATR, V147, P143, DOI 10.1007/BF00442211; ROUGHAN PG, 1977, BIOCHEM J, V162, P457, DOI 10.1042/bj1620457; SCHEPERS L, 1989, BIOCHEM J, V257, P221, DOI 10.1042/bj2570221; SINGH H, 1988, ARCH BIOCHEM BIOPHYS, V266, P486, DOI 10.1016/0003-9861(88)90281-0; SINGH H, 1990, J LIPID RES, V31, P217; Steinberg D, 1989, METABOLIC BASIS INHE, P1533; THOMAS J, 1980, BIOCHEM J, V190, P485, DOI 10.1042/bj1900485; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P24676	20	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24670	24675						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1837026				2022-12-25	WOS:A1991GW84500067
J	COLOMBO, MI; GONZALO, S; WEIDMAN, P; STAHL, P				COLOMBO, MI; GONZALO, S; WEIDMAN, P; STAHL, P			CHARACTERIZATION OF TRYPSIN-SENSITIVE FACTOR(S) REQUIRED FOR ENDOSOME-ENDOSOME FUSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; CELL-FREE SYSTEM; PROTEIN-TRANSPORT; VESICULAR TRANSPORT; ENDOPLASMIC-RETICULUM; SUCCESSIVE COMPARTMENTS; MEMBRANE-FUSION; GOLGI MEMBRANES; INVITRO; RECONSTITUTION	Fusion of endosomes appears to be required at early steps of receptor-mediated endocytosis. These fusion events have been reconstituted using a cell-free assay and have been shown to require both cytosolic and membrane-associated proteins. We report here that trypsinization of endosomes completely inhibited fusion. Addition of untreated cytosol cannot restore fusion of trypsinized endosomes. However, fusion activity is restored by the addition of either untreated vesicles or a high salt extract containing peripheral membrane proteins (KE). KE contains both the membrane-associated factor(s) required for the reconstitution of fusion using trypsinized endosomes and the factors that are normally provided by the cytosol. The restorative activity of KE was sensitive to trypsin treatment or incubation at 100-degrees-C, but was largely N-ethylmaleimide (NEM)-resistant. This and other criteria demonstrated that the trypsin-sensitive factor is distinct from N-ethylmaleimide-sensitive factor (NSF), an NEM-sensitive protein involved in vesicular fusion, and from other known factors that may participate in membrane fusion events. Preliminary fractionation studies indicate that the restorative activity of KE is associated with one or more high molecular weight proteins. The present study indicates that a novel trypsin-sensitive protein(s) is involved in endosome-endosome fusion. This factor is membrane-associated and is not found in an active form in cytosol as prepared.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,660 S EUCLID AVE,ST LOUIS,MO 63110; ST LOUIS UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,ST LOUIS,MO 63104	Washington University (WUSTL); Saint Louis University			Stahl, Philip/D-6315-2012	Gonzalo, Susana/0000-0001-9631-1206	NIAID NIH HHS [AI 20015] Funding Source: Medline; NIGMS NIH HHS [GM 42259] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020015, R01AI020015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIAZ R, 1989, J BIOL CHEM, V264, P13171; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HARDING C, 1983, J CELL BIOL, V97, P329, DOI 10.1083/jcb.97.2.329; KELLER RK, 1975, J BIOL CHEM, V250, P4765; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MAYORGA LS, 1991, J BIOL CHEM, V266, P6511; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; OTSUKA FL, 1984, J NUCL MED, V25, P1343; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; ROTH J, 1983, TECHNIQUES IMMUNOCYT, V2, P217; ROTHMAN JE, 1987, J BIOL CHEM, V262, P12502; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; WATTENBERG BW, 1990, J CELL BIOL, V110, P947, DOI 10.1083/jcb.110.4.947; WATTENBERG BW, 1986, J BIOL CHEM, V261, P2208; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WESSLINGRESNICK M, 1990, J BIOL CHEM, V265, P16751; WOODMAN PG, 1988, EUR J BIOCHEM, V173, P101, DOI 10.1111/j.1432-1033.1988.tb13972.x; WOODMAN PG, 1991, J CELL BIOL, V112, P1133, DOI 10.1083/jcb.112.6.1133	38	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23438	23445						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744137				2022-12-25	WOS:A1991GT48300099
J	PARK, PW; ROBERTS, DD; GROSSO, LE; PARKS, WC; ROSENBLOOM, J; ABRAMS, WR; MECHAM, RP				PARK, PW; ROBERTS, DD; GROSSO, LE; PARKS, WC; ROSENBLOOM, J; ABRAMS, WR; MECHAM, RP			BINDING OF ELASTIN TO STAPHYLOCOCCUS-AUREUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRONECTIN; LAMININ; STREPTOCOCCI; TROPOELASTIN; RECEPTOR; PROTEIN; MEMBRANE; CELLS	Many pathogenic bacteria specifically bind to components of the extracellular matrix. In this study, we report the specific association of Staphylococcus aureus with elastin, a major structural component of elastic tissue. Competition assays in which the binding of radiolabeled tropoelastin was inhibited by excess unlabeled elastin peptides, but not by other proteins, established the specificity of the interaction. Kinetic studies showed that tropoelastin binding to the bacteria was rapid and saturable. Scatchard analysis of the equilibrium binding data indicated the presence of a single class of high affinity binding sites (K(D) approximately 4-7 nM) with approximately 1000 sites per organism. Protease susceptibility suggested that the elastin binding moiety on S. aureus was a protein, which was confirmed by the isolation of a 25-kDa elastin-binding protein from S. aureus extracts through affinity chromatography. Using a truncated form of tropoelastin, the bacterial binding domain on elastin was mapped to a 30-kDa fragment at the amino end of the molecule. Although the precise amino acid sequence recognized by the staphylococcal elastin receptor has not been characterized, it is clearly different from the region of tropoelastin that specifies binding to mammalian elastin receptors.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; NCI,PATHOL LAB,BETHESDA,MD 20892; UNIV PENN,SCH DENT MED,PHILADELPHIA,PA 19104; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Pennsylvania; Barnes-Jewish Hospital; Washington University (WUSTL)			Parks, William C./AAH-6786-2021; Abrams, William R/A-5782-2008; Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981; Park, Pyong Woo/0000-0002-7979-4979	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041926, R01HL026499] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26499, HL41926] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BODEN MK, 1989, INFECT IMMUN, V57, P2358; CHHATWAL GS, 1987, INFECT IMMUN, V55, P1878, DOI 10.1128/IAI.55.8.1878-1883.1987; Franzblau C., 1977, ADV EXPT MED BIOL; FROMAN G, 1987, J BIOL CHEM, V262, P6564; GROSSO LE, 1991, BIOCHEM J, V273, P517, DOI 10.1042/bj2730517; HAAGEN IA, 1990, J INFECT DIS, V161, P266, DOI 10.1093/infdis/161.2.266; HOLDERBAUM D, 1986, INFECT IMMUN, V54, P359, DOI 10.1128/IAI.54.2.359-364.1986; INDIK Z, 1990, ARCH BIOCHEM BIOPHYS, V280, P80, DOI 10.1016/0003-9861(90)90521-Y; JOKLIK WK, 1988, ZINSSER MICROBIOLOGY, P343; KUUSELA P, 1984, INFECT IMMUN, V45, P433, DOI 10.1128/IAI.45.2.433-436.1984; KUUSELA P, 1978, NATURE, V276, P718, DOI 10.1038/276718a0; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LOPES JD, 1985, SCIENCE, V229, P275, DOI 10.1126/science.3160113; MECHAM RP, 1989, J BIOL CHEM, V264, P16652; MECHAM RP, 1982, METHOD ENZYMOL, V82, P744; MECHAM RP, 1989, BIOCHEMISTRY-US, V28, P3716, DOI 10.1021/bi00435a014; MURPHY RA, 1974, J DENT RES, V53, P832, DOI 10.1177/00220345740530041101; NOBLE WC, 1983, STAPHYLOCOCCI STAPHY, P165; OUIASSI MA, 1984, NATURE, V308, P380; OZ MC, 1989, J VASC SURG, V10, P439; PARKS WC, 1988, J BIOL CHEM, V263, P4416; PARTRIDGE SM, 1962, ADV PROTEIN CHEM, V17, P227; POTEMPA J, 1988, J BIOL CHEM, V263, P2664; POTTRATZ ST, 1990, J CLIN INVEST, V85, P351, DOI 10.1172/JCI114445; PROCTOR RA, 1982, J BIOL CHEM, V257, P4788; PROSSER IW, 1991, CONNECT TISSUE RES, V25, P265, DOI 10.3109/03008209109029162; ROSENBLOOM J, 1982, CONNECT TISSUE RES, V10, P73, DOI 10.3109/03008208209034408; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHEAGREN JN, 1984, NEW ENGL J MED, V310, P1437, DOI 10.1056/NEJM198405313102206; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; SWITALSKI LM, 1984, J BIOL CHEM, V259, P3734; SWITALSKI LM, 1987, J BACTERIOL, V169, P1095, DOI 10.1128/jb.169.3.1095-1101.1987; THOMAS DD, 1985, J EXP MED, V161, P513; WHET LJ, 1983, STAPHYLOCOCCI STAPHY, P121; WRENN DS, 1988, J BIOL CHEM, V263, P2280	36	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23399	23406						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744133				2022-12-25	WOS:A1991GT48300093
J	CASSATELLA, MA; BAZZONI, F; CALZETTI, F; GUASPARRI, I; ROSSI, F; TRINCHIERI, G				CASSATELLA, MA; BAZZONI, F; CALZETTI, F; GUASPARRI, I; ROSSI, F; TRINCHIERI, G			INTERFERON-GAMMA TRANSCRIPTIONALLY MODULATES THE EXPRESSION OF THE GENES FOR THE HIGH-AFFINITY IGG-FC RECEPTOR AND THE 47-KDA CYTOSOLIC COMPONENT OF NADPH OXIDASE IN HUMAN POLYMORPHONUCLEAR LEUKOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TUMOR NECROSIS FACTOR; PERIPHERAL-BLOOD GRANULOCYTES; MESSENGER-RNA; HUMAN-NEUTROPHILS; MYELOID CELLS; IFN-GAMMA; PROTOONCOGENE; METABOLISM; SEQUENCE; REGION	We examined the mechanisms responsible for the regulation by interferon-gamma (IFN-gamma) of the expression of the genes encoding the high affinity IgG-Fc receptor (Fc-gamma-R-I, CD64) and the NADPH oxidase 47-kDa cytosolic factor (p47-phox) in human polymorphonuclear leukocytes (PMN). Nuclear run-on transcriptional assays demonstrated that the Fc-gamma-R-I gene transcription is undetectable in untreated PMN but is significantly induced by IFN-gamma. Unlike Fc-gamma-R-I, p47-phox gene transcription is constitutively active in resting PMN and is down-regulated by a 2-h treatment of these cells with IFN-gamma. The transcriptional modulation by IFN-gamma of Fc-gamma-R-I and p47-phox genes is not influenced by the protein synthesis inhibitor cycloheximide. Moreover, Northern blot analysis revealed that cycloheximide superinduces p47-phox mRNA expression by increasing its half-life and without affecting p47-phox gene transcription. These findings indicate that human PMN can regulate gene expression by transcriptional and posttranscriptional events.	WISTAR INST,PHILADELPHIA,PA 19104	The Wistar Institute	CASSATELLA, MA (corresponding author), UNIV VERONA,INST GEN PATHOL,ST LE GRAZIE 4,I-37134 VERONA,ITALY.		Cassatella, M A/B-8037-2013; Bazzoni, Flavia/AAB-7674-2019	Cassatella, M A/0000-0001-7824-1806; Bazzoni, Flavia/0000-0001-6768-8012	NATIONAL CANCER INSTITUTE [P30CA010815, R01CA020833, R01CA032898, R37CA020833] Funding Source: NIH RePORTER; NCI NIH HHS [CA32898, CA20833, CA10815] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN JM, 1989, SCIENCE, V243, P378, DOI 10.1126/science.2911749; BAZZONI F, 1991, J EXP MED, V173, P771, DOI 10.1084/jem.173.3.771; BERTANI A, 1989, BLOOD, V74, P1811; BERTON G, 1986, BIOCHEM BIOPH RES CO, V138, P1276, DOI 10.1016/S0006-291X(86)80421-1; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CASSATELLA MA, 1990, J BIOL CHEM, V265, P20241; CASSATELLA MA, 1990, BIOCHEM BIOPH RES CO, V170, P582, DOI 10.1016/0006-291X(90)92131-I; CASSATELLA MA, 1988, IMMUNOLOGY, V63, P499; CASSATELLA MA, 1989, J CLIN INVEST, V83, P1570, DOI 10.1172/JCI114054; COLOTTA F, 1987, J EXP MED, V165, P1224, DOI 10.1084/jem.165.4.1224; DUBRAVEC DB, 1990, P NATL ACAD SCI USA, V87, P6758, DOI 10.1073/pnas.87.17.6758; EID NS, 1987, J EXP MED, V165, P1448, DOI 10.1084/jem.165.5.1448; FOURET P, 1989, J EXP MED, V169, P833, DOI 10.1084/jem.169.3.833; GRANELLIPIPERNO A, 1977, J EXP MED, V149, P284; JACK RM, 1988, J IMMUNOL, V140, P4286; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; NEWBURGER PE, 1988, P NATL ACAD SCI USA, V85, P5215, DOI 10.1073/pnas.85.14.5215; PAN L, 1990, J IMMUNOL, V145, P267; PERUSSIA B, 1983, J EXP MED, V158, P1092, DOI 10.1084/jem.158.4.1092; PERUSSIA B, 1987, J IMMUNOL, V138, P765; PETRONI KC, 1988, J IMMUNOL, V140, P3467; SHALABY MR, 1985, J IMMUNOL, V135, P2069; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; 1991, NEW ENGL J MED, V324, P509	24	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22079	22082						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1834666				2022-12-25	WOS:A1991GR56400004
J	COELHOSAMPAIO, T; FERREIRA, ST; BENAIM, G; VIEYRA, A				COELHOSAMPAIO, T; FERREIRA, ST; BENAIM, G; VIEYRA, A			DISSOCIATION OF PURIFIED ERYTHROCYTE CA2+-ATPASE BY HYDROSTATIC-PRESSURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM ATPASE; RED-CELL MEMBRANES; PLASMA-MEMBRANE; CA-2+ PUMP; ADENOSINE-TRIPHOSPHATASE; CONFORMATIONAL DRIFT; CIRCULAR-DICHROISM; SELF-ASSOCIATION; PROTEIN-KINASE; CALMODULIN	Subunit interactions in the Ca2+-ATPase from erythrocyte plasma membranes were investigated through a combination of fluorescence spectroscopy and high-pressure techniques. Application of hydrostatic pressure in the range of 1 bar to 2.4 kbar promoted full dissociation of the ATPase, as revealed by spectral shifts of the intrinsic fluorescence emission and by changes in the fluorescence polarization of dansyl-conjugated ATPase. Pressure dissociation of the ATPase displayed a dependence on protein concentration compatible with dissociation of a dimer. Calculated from pressure-dissociation curves, the standard volume change dV0 for the association of subunits was 43-50 ml/mol and K0, the dissociation constant at atmospheric pressure, was 6-9 x 10(-8) M. Addition of Ca2+ stabilized the dimeric ATPase structure against pressure dissociation, whereas addition of vanadate facilitated dissociation by pressure. These results suggest that inter-subunit interactions depend on the equilibrium between the two major conformational states E1 and E2 of the ATPase. Addition of calmodulin in the presence of Ca2+ had no additional effect when compared to that observed in the presence of Ca2+ alone. This finding is interpreted in terms of the mechanism of calmodulin activation of ATPase catalysis.	UNIV FED RIO DE JANEIRO,INST CIENCIAS BIOMED,DEPT BIOQUIM MED,BR-21944 RIO DE JANEIRO,BRAZIL; CENT UNIV VENEZUELA,FAC CIENCIAS,CTR BIOL CELULAR,CARACAS,VENEZUELA	Universidade Federal do Rio de Janeiro; University of Central Venezuela			Ferreira, Sergio/AAZ-1576-2020; Benaim, Gustavo/H-5552-2019	Ferreira, Sergio/0000-0001-7160-9866; Benaim, Gustavo/0000-0002-9359-5546	NCRR NIH HHS [RR03155-01] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADAMO HP, 1990, J BIOL CHEM, V265, P3789; ADAMO HP, 1988, J BIOL CHEM, V263, P17548; BARRABIN H, 1980, BIOCHIM BIOPHYS ACTA, V600, P796, DOI 10.1016/0005-2736(80)90482-4; BENAIM G, 1984, J BIOL CHEM, V259, P8471; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GOPINATH RM, 1977, BIOCHEM BIOPH RES CO, V77, P1203, DOI 10.1016/S0006-291X(77)80107-1; HEREMANS K, 1982, ANNU REV BIOPHYS BIO, V11, P1, DOI 10.1146/annurev.bb.11.060182.000245; KOSKKOSICKA D, 1988, J BIOL CHEM, V263, P18184; KOSKKOSICKA D, 1989, J BIOL CHEM, V264, P19495; KOSKKOSICKA D, 1990, BIOCHEMISTRY-US, V29, P3772, DOI 10.1021/bi00467a025; KOSKKOSICKA D, 1985, FEBS LETT, V189, P67, DOI 10.1016/0014-5793(85)80843-7; KREBS J, 1987, BIOCHEMISTRY-US, V26, P3921, DOI 10.1021/bi00387a027; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LEW VL, 1982, NATURE, V298, P478, DOI 10.1038/298478a0; MUALLEM S, 1980, BIOCHIM BIOPHYS ACTA, V597, P631, DOI 10.1016/0005-2736(80)90235-7; MUALLEM S, 1981, BIOCHIM BIOPHYS ACTA, V647, P73, DOI 10.1016/0005-2736(81)90296-0; NEUMAN RC, 1973, J PHYS CHEM-US, V77, P2687, DOI 10.1021/j100640a025; NEYSES L, 1985, J BIOL CHEM, V260, P283; NIGGLI V, 1982, J BIOL CHEM, V257, P2350; NIGGLI V, 1981, J BIOL CHEM, V256, P395; PALADINI AA, 1981, BIOCHEMISTRY-US, V20, P2587, DOI 10.1021/bi00512a034; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PIN S, 1990, BIOCHEMISTRY-US, V29, P9194, DOI 10.1021/bi00491a013; ROSS J B A, 1989, Biophysical Journal, V55, p517A; ROSSI JPFC, 1986, BIOCHIM BIOPHYS ACTA, V858, P21, DOI 10.1016/0005-2736(86)90287-7; RUAN K, 1989, BIOCHEMISTRY-US, V28, P2144, DOI 10.1021/bi00431a028; RUAN KC, 1988, BIOCHEMISTRY-US, V27, P3295, DOI 10.1021/bi00409a026; SCHATZMANN HJ, 1989, ANNU REV PHYSIOL, V51, P473, DOI 10.1146/annurev.ph.51.030189.002353; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; SENEAR DF, 1988, BIOPHYS J, V53, pA104; SILVA JL, 1986, BIOCHEMISTRY-US, V25, P5780, DOI 10.1021/bi00367a065; SMALLWOOD JI, 1988, J BIOL CHEM, V263, P2195; SORENSON MM, 1986, J MEMBRANE BIOL, V90, P219, DOI 10.1007/BF01870128; THOMPSON RB, 1984, BIOCHEMISTRY-US, V23, P3411, DOI 10.1021/bi00310a005; VERJOVSKIALMEIDA S, 1986, J BIOL CHEM, V261, P9872; VIEYRA A, 1979, BIOCHIM BIOPHYS ACTA, V568, P437, DOI 10.1016/0005-2744(79)90312-7; WEBER G, 1983, Q REV BIOPHYS, V16, P89, DOI 10.1017/S0033583500004935; WEBER G, 1987, NATO ASI SER C, V197, P401; WRZOSEK A, 1989, BIOCHIM BIOPHYS ACTA, V986, P263, DOI 10.1016/0005-2736(89)90476-8; XU GJ, 1982, P NATL ACAD SCI-BIOL, V79, P5268, DOI 10.1073/pnas.79.17.5268; YAMAMOTO T, 1984, J BIOCHEM, V95, P1783, DOI 10.1093/oxfordjournals.jbchem.a134791	44	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22266	22272						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1834668				2022-12-25	WOS:A1991GR56400034
J	NOLTA, KV; PADH, H; STECK, TL				NOLTA, KV; PADH, H; STECK, TL			ACIDOSOMES FROM DICTYOSTELIUM - INITIAL BIOCHEMICAL-CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; VESICLE PROTON PUMP; TRANSLOCATING ATPASE; NEUROSPORA-CRASSA; PLASMA-MEMBRANES; GOLGI-APPARATUS; DISCOIDEUM; PURIFICATION; COMPLEX; GLYCOSYLATION	The acidosome, a newly described organelle in Dictyostelium discoideum, is rich in vacuolar proton pumps (V-H+-ATPases) and is responsible for the acidification of endocytic vacuoles. Purified acidosomes were not significantly contaminated by lysosomes, endosomes, or plasma membranes but contained a small fraction of contractile vacuole markers. The specific activity of the proton pump in these acidosomes reached 30-mu-mol/min/mg protein, the highest yet reported for any V-H+-ATPase. The V-H+-ATPase was the predominant protein in acidosomes. Based on gel electrophoresis and densitometry, its 8 polypeptides had the following apparent molecular mass (in kDa) and stoichiometry: 90(1), 68(3), 53(3), 42(1), 37(3), 25(3), 17(6), and 15(1). These values suggested a M(r) congruent-to 8 X 10(5), consistent with the hydrodynamic properties and electron microscopic image of the purified pump. The 90- and 17-kDa polypeptides were integral, while the others were peripheral; only the 90-kDa subunit was biosynthetically labeled by [H-3]glucosamine and (SO4)-S-35. The specific content of phosphatidylcholine and phosphatidylserine in the acidosomes was the highest of any subcellular fraction tested, while sterols and sphingolipids were the lowest. Acidosomes had congruent-to 10% of the lipid biosynthetically labeled with [H-3]glucosamine. This organelle contributed 5% of cellular protein and 15% of the phospholipid in stationary cultures. We conclude that the acidosome in Dictyostelium is a biochemically discrete organelle, produced by the endoplasmic reticulum/Golgi apparatus but distinct from other endomembranes as well as from the plasma membrane.	UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, 920 E 58TH ST, CHICAGO, IL 60637 USA	University of Chicago				Padh, Harish/0000-0003-2305-6229	NIGMS NIH HHS [GM 07183] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007183] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P967; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ARAI H, 1988, J BIOL CHEM, V263, P8796; BOWMAN BJ, 1986, J MEMBRANE BIOL, V94, P83, DOI 10.1007/BF01871190; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1986, P NATL ACAD SCI USA, V83, P48, DOI 10.1073/pnas.83.1.48; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN D, 1987, J CELL BIOL, V105, P1637, DOI 10.1083/jcb.105.4.1637; CAPASSO JM, 1984, P NATL ACAD SCI-BIOL, V81, P7051, DOI 10.1073/pnas.81.22.7051; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GILKES NR, 1977, BIOCHIM BIOPHYS ACTA, V464, P142, DOI 10.1016/0005-2736(77)90377-7; GLUCK S, 1987, J BIOL CHEM, V262, P15780; HEFTMANN E, 1960, ARCH BIOCHEM BIOPHYS, V91, P266, DOI 10.1016/0003-9861(60)90500-2; HOLTZMAN E, 1989, LYSOSOMES, P93; Hubbard AL, 1989, CURR OPIN CELL BIOL, V1, P675, DOI 10.1016/0955-0674(89)90033-1; KANE PM, 1989, J BIOL CHEM, V264, P19236; KATES M, 1972, TECHNIQUES LIPIDOLOG, P354; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LACOSTE CH, 1989, ARCH BIOCHEM BIOPHYS, V273, P505, DOI 10.1016/0003-9861(89)90510-9; LONG BH, 1974, J BIOL CHEM, V249, P521; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MINTON AP, 1989, ANAL BIOCHEM, V176, P209, DOI 10.1016/0003-2697(89)90297-2; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; MORIYAMA Y, 1989, BIOCHIM BIOPHYS ACTA, V980, P241, DOI 10.1016/0005-2736(89)90405-7; NAOI M, 1974, ANAL BIOCHEM, V58, P571, DOI 10.1016/0003-2697(74)90226-7; PADH H, 1991, J BIOL CHEM, V266, P5514; PADH H, 1991, J BIOL CHEM, V266, P12123; PADH H, 1989, J CELL BIOL, V108, P865, DOI 10.1083/jcb.108.3.865; PADH H, 1989, BIOCHIM BIOPHYS ACTA, V982, P271, DOI 10.1016/0005-2736(89)90064-3; PARRY RV, 1989, J BIOL CHEM, V264, P20025; QUIVIGER B, 1978, J ULTRA MOL STRUCT R, V62, P228, DOI 10.1016/S0022-5320(78)80020-3; REINHART MP, 1987, J BIOL CHEM, V262, P9649; Rodman JS, 1990, CURR OPIN CELL BIOL, V2, P664, DOI 10.1016/0955-0674(90)90108-Q; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOLL DR, 1976, J CELL SCI, V20, P513; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; STECK TL, 1974, J BIOL CHEM, V249, P2135; STONE DK, 1990, SEMIN NEPHROL, V10, P159; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; XIE XS, 1986, J BIOL CHEM, V261, P2492	41	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18318	18323						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1833396				2022-12-25	WOS:A1991GG55300091
J	GRANJA, C; LIN, LL; YUNIS, EJ; RELIAS, V; DASGUPTA, JD				GRANJA, C; LIN, LL; YUNIS, EJ; RELIAS, V; DASGUPTA, JD			PLC-GAMMA-1, A POSSIBLE MEDIATOR OF T-CELL RECEPTOR FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHOSPHOLIPASE-C-GAMMA; PROTEIN-KINASE-C; CYTOPLASMIC FREE CALCIUM; TYROSINE PHOSPHORYLATION; ANTIGEN RECEPTOR; SIGNAL TRANSDUCTION; INOSITOL PHOSPHATES; ACTIVATION; COMPLEX; INHIBITION	Stimulation of T cell antigen receptor (TCR/CD3) following the recognition of peptide-major histocompatibility antigen complex induces phosphatidylinositol 4,5-biphosphate (PIP2) hydrolysis. However, the phospholipase C (PLC) enzyme mediating this process has not been identified. We report that PLC-gamma-1 protein is expressed in human T cells. It is a phosphoprotein, and the activation of cyclic AMP-dependent protein kinase (PKA) or of protein kinase C (PKC) with forskolin or phorbol ester, respectively, increases the level of phosphorylation. CD3 stimulation of T cells induces tyrosine phosphorylation of PLC-gamma-1 and causes 8-10-fold higher yield of PLC activity with anti-phosphotyrosine antibody (APTyr Ab) from activated cells than from non-activated cells. Genistein, an inhibitor of protein tyrosine kinase, decreases this yield of APTyr Ab-bound PLC activity from activated cells and lowers the level of Ca2+ mobilization. Furthermore, phorbol ester and forskolin treatment of cells before CD3 stimulation reduces the level of tyrosine phosphorylation of PLC-gamma-1 and the PLC activity associated with APTyr Ab. These results suggest that CD3 stimulation activates PIP2 hydrolysis by inducing tyrosine phosphorylation of PLC-gamma-1, which is regulated negatively by PKC and PKA.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV IMMUNOGENET,RM 740,44 BINNEY ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; GENET INST,CAMBRIDGE,MA 02140	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School								ABRAHAM RT, 1988, MOL CELL BIOL, V8, P5448, DOI 10.1128/MCB.8.12.5448; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; AUSSEL C, 1988, J IMMUNOL, V140, P215; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; CANTRELL DA, 1989, J IMMUNOL, V143, P3653; DASGUPTA JD, 1988, HUM IMMUNOL, V21, P133, DOI 10.1016/0198-8859(88)90088-2; DASGUPTA JD, 1990, EUR J IMMUNOL, V20, P1553, DOI 10.1002/eji.1830200722; DESAI DM, 1990, NATURE, V348, P66, DOI 10.1038/348066a0; EMORI Y, 1989, J BIOL CHEM, V264, P21885; HARA T, 1985, J EXP MED, V161, P641, DOI 10.1084/jem.161.4.641; HOFFMAN SL, 1982, J BIOL CHEM, V257, P14359; HUCKLE WR, 1990, ENDOCRINOLOGY, V127, P1697, DOI 10.1210/endo-127-4-1697; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KANAKURA Y, 1990, BLOOD, V76, P706; KIM UH, 1989, J BIOL CHEM, V264, P20167; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OHTA S, 1988, FEBS LETT, V242, P31, DOI 10.1016/0014-5793(88)80979-7; OSHEA JJ, 1987, J IMMUNOL, V139, P3463; PATEL MD, 1987, J BIOL CHEM, V262, P5831; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SHAPIRO DN, 1985, J IMMUNOL, V135, P2256; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; WAHL M, 1988, J BIOL CHEM, V263, P7581; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WEDNER HJ, 1986, J IMMUNOL, V136, P4226	33	81	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16277	16280						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1832154				2022-12-25	WOS:A1991GD63500006
J	MCCONVILLE, MJ; BLACKWELL, JM				MCCONVILLE, MJ; BLACKWELL, JM			DEVELOPMENTAL-CHANGES IN THE GLYCOSYLATED PHOSPHATIDYLINOSITOLS OF LEISHMANIA DONOVANI - CHARACTERIZATION OF THE PROMASTIGOTE AND AMASTIGOTE GLYCOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEINS; MEMBRANE ANCHOR; LIPOPHOSPHOGLYCAN EXPRESSION; MACROPHAGES; BIOSYNTHESIS; RECEPTOR; BINDING; FAMILY; COMPLEMENT; PRECURSORS	In addition to utilizing glycosylated phosphatidylinositols (GPIs) as anchors for surface proteins, protozoan parasites of the genus Leishmania synthesize two novel classes of GPI: the polydisperse lipophosphoglycans (LPGs) and a family of low molecular weight glycoinositol phospholipids (GIPLs). We now show that LPG is expressed in high copy number (6 x 10(6) molecules/cell) in the promastigote (insect) stage of L. donovani but not in the amastigote stage, which infects mammalian macrophages. Detection of these molecules was by gas chromatography-mass spectrometric analyses and by a sensitive radiolabeling procedure. In contrast, a novel family of GIPLs was present in high copy number (approximately 10(7) molecules/cell) in both promastigote and amastigote stages of L. donovani. These glycolipids were purified and analyzed by gas chromatography-mass spectrometry, methylation analysis, and by chemical and enzymatic sequencing after deamination and NaB3H4 reduction. Promastigotes contained three major GIPLs species with the following generalized structure [GRAPHICS] where R = H for isoM2, Man-alpha-1- for isoM3 or Man-alpha-1-2Man-alpha-1- for isoM4. Amastigotes contained two major GIPL species that lacked the alpha-1-3-linked mannose branch and had the linear structures Man-alpha-1-6Man-alpha-1-4GlcN (M2) and Man-alpha-1-2Man-alpha-1-6Man-alpha-1-4GlcN (M3) linked to alkylacyl-PI. The 1-O-alkyl-2-acyl-PI moieties of all these species contained predominantly C18:0 alkyl chains and C16:0 or C18:0 fatty acids. Amastigotes contained, in addition, a GalNAc-beta-1-3 terminating glycosphingolipid with homology to the mammalian para Forssman glycolipid. This glycolipid appeared to be a constituent of the parasite membrane but was not metabolically labeled with [H-3]glucose, suggesting that it was acquired from host cells. These results suggest that LPG may not be required for amastigote survival in the mammalian host and that the GIPLs are likely to be major components on the surface membrane in both stages.	SCH HYG & TROP MED,DEPT MED PARASITOL,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	MCCONVILLE, MJ (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND.		Blackwell, Jenefer M/H-3015-2015		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANGSTROM J, 1986, ARCH BIOCHEM BIOPHYS, V251, P440, DOI 10.1016/0003-9861(86)90350-4; BLACKWELL JM, 1985, J EXP MED, V162, P324, DOI 10.1084/jem.162.1.324; BORDIER C, 1987, PARASITOL TODAY, V3, P151, DOI 10.1016/0169-4758(87)90199-2; CHAN J, 1989, P NATL ACAD SCI USA, V86, P2453, DOI 10.1073/pnas.86.7.2453; CHANG KP, 1976, SCIENCE, V193, P678, DOI 10.1126/science.948742; CHANNON JY, 1984, IMMUNOLOGY, V53, P345; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DASILVA RP, 1989, J IMMUNOL, V143, P617; DAVIES CR, 1990, PARASITOLOGY, V101, P337, DOI 10.1017/S0031182000060522; DOERING TL, 1990, J BIOL CHEM, V265, P611; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; ELHAY M, 1990, MOL BIOCHEM PARASIT, V40, P255, DOI 10.1016/0166-6851(90)90047-P; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; GLASER TA, 1991, MOL BIOCHEM PARASIT, V45, P337, DOI 10.1016/0166-6851(91)90102-C; HANDMAN E, 1986, J IMMUNOL, V137, P3608; HANDMAN E, 1985, EMBO J, V4, P329, DOI 10.1002/j.1460-2075.1985.tb03633.x; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; HOMANS SW, 1990, TIGG, V2, P144; KANESHIRO ES, 1986, J LIPID RES, V27, P1294; KING DL, 1987, MOL BIOCHEM PARASIT, V24, P47, DOI 10.1016/0166-6851(87)90114-9; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MCCONVILLE MJ, 1987, P NATL ACAD SCI USA, V84, P8941, DOI 10.1073/pnas.84.24.8941; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, 1989, J BIOL CHEM, V264, P757; MCCONVILLE MJ, 1990, MOL BIOCHEM PARASIT, V38, P57, DOI 10.1016/0166-6851(90)90205-Z; MCNEELY TB, 1990, J IMMUNOL, V144, P2745; MEDINAACOSTA E, 1989, MOL BIOCHEM PARASIT, V37, P263, DOI 10.1016/0166-6851(89)90158-8; MENON AK, 1990, J BIOL CHEM, V265, P9033; MURRAY PJ, 1989, J IMMUNOL, V143, P4221; OLAFSON RW, 1990, J BIOL CHEM, V265, P12240; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; PIMENTA PFP, 1989, EUR J CELL BIOL, V48, P180; PUENTES SM, 1990, J IMMUNOL, V145, P4311; PUENTES SM, 1988, J EXP MED, V167, P887, DOI 10.1084/jem.167.3.887; ROSEN G, 1989, J BIOL CHEM, V264, P10457; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; TALAMASROHANA P, 1990, J IMMUNOL, V144, P4817; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; TURCO SJ, 1991, MOL BIOCHEM PARASIT, V45, P91, DOI 10.1016/0166-6851(91)90030-A; TURCO SJ, 1987, BIOCHEMISTRY-US, V26, P6233, DOI 10.1021/bi00393a042; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; WILSON ME, 1986, J IMMUNOL, V136, P4681	46	223	228	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15170	15179						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1831200				2022-12-25	WOS:A1991GB09700056
J	NISHIMOTO, J; TANAKA, A; NANBA, E; SUZUKI, K				NISHIMOTO, J; TANAKA, A; NANBA, E; SUZUKI, K			EXPRESSION OF THE BETA-HEXOSAMINIDASE-ALPHA SUBUNIT GENE WITH THE 4-BASE INSERTION OF INFANTILE JEWISH TAY-SACHS DISEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASHKENAZI JEWS; ALPHA-1-ANTITRYPSIN GENE; TERMINATION CODON; TROPOMYOSIN GENE; GLOBIN GENE; CODING EXON; MUTATION; CHAIN; DEFECT; BIOSYNTHESIS	One of the two mutations responsible for the classical infantile Jewish form of Tay-Sachs disease is a four-base insertion in exon 11 of the beta-hexosaminidase alpha-subunit gene. The gene is known to be transcribed normally, but the mRNA is essentially undetectable. It is not clear why such a relatively minor abnormality results in complete failure to generate stable mRNA. The four-base insertion was introduced into the normal beta-hexosaminidase cDNA by site-directed mutagenesis. When COS-1 cells were transfected with the resultant mutant cDNA, it generated stable mRNA and a truncated, relatively stable but catalytically inactive enzyme protein. The mutant enzyme protein was not processed nor released into the culture medium. The mutant cDNA also generated the truncated enzyme protein in an in vitro translation system with rabbit reticulocyte lysate. COS-1 cells transfected with a 3' end of the gene segment, from intron 8 through the 3' terminus, generated processed RNA of approximately 2 kilobases, the size expected from normal splicing, irrespective of presence or absence of the four-base insertion in exon 11. These results indicate that the four-base insertion does not destabilize properly spliced mRNA, nor does it interfere with normal splicing of the transcript, at least in the expression system utilized. If the four-base insertion is responsible for the undetectable mRNA in the mutant cells, it must interfere with some other steps in the processing/splicing/transport of the primary transcript yet to be examined. On the other hand, the possibility cannot be excluded definitively that another still unidentified abnormality in the same allele might be responsible for the nearly complete absence of mRNA.	UNIV N CAROLINA,SCH MED,BRAIN & DEV RES CTR,CB 7250,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT NEUROL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT PSYCHIAT,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD003110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024289, R01NS028997] Funding Source: NIH RePORTER; NICHD NIH HHS [P30-HD-03110] Funding Source: Medline; NINDS NIH HHS [R01-NS-28997, R01-NS-24289] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARPAIA E, 1988, NATURE, V333, P85, DOI 10.1038/333085a0; ATWEH GF, 1988, J CLIN INVEST, V82, P557, DOI 10.1172/JCI113632; BASERGA SJ, 1988, P NATL ACAD SCI USA, V85, P2056, DOI 10.1073/pnas.85.7.2056; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; CRYSTAL RG, 1989, CHEST, V95, P196, DOI 10.1378/chest.95.1.196; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; CURIEL D, 1988, AM REV RESPIR DIS, V137, pA270; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HUMPHRIES RK, 1984, BLOOD, V64, P23; LIBRI D, 1990, MOL CELL BIOL, V10, P5036, DOI 10.1128/MCB.10.10.5036; LIBRI D, 1989, NUCLEIC ACIDS RES, V17, P6449; MOSCHONAS N, 1981, NUCLEIC ACIDS RES, V9, P4391, DOI 10.1093/nar/9.17.4391; MYEROWITZ R, 1988, J BIOL CHEM, V263, P18587; MYEROWITZ R, 1988, P NATL ACAD SCI USA, V85, P3955, DOI 10.1073/pnas.85.11.3955; MYEROWITZ R, 1985, P NATL ACAD SCI USA, V82, P7830, DOI 10.1073/pnas.82.23.7830; NEUFELD EF, 1989, J BIOL CHEM, V264, P10927; NUKIWA T, 1987, J BIOL CHEM, V262, P11999; OHNO K, 1988, BIOCHEM BIOPH RES CO, V153, P463, DOI 10.1016/S0006-291X(88)81247-6; PAW BH, 1988, J BIOL CHEM, V263, P3012; PROIA RL, 1984, J BIOL CHEM, V259, P3350; PROIA RL, 1987, J BIOL CHEM, V262, P5677; Sambrook J, 1989, MOL CLONING LABORATO; SATOH K, 1988, AM J HUM GENET, V42, P77; SIFERS RN, 1988, J BIOL CHEM, V263, P7330; SUZUKI K, 1987, METHOD ENZYMOL, V138, P727; TAKESHITA K, 1984, BLOOD, V64, P13; TANAKA A, 1990, AM J HUM GENET, V46, P329; TRIGGSRAINE BL, 1990, NEW ENGL J MED, V323, P6, DOI 10.1056/NEJM199007053230102	29	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14306	14309						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1830584				2022-12-25	WOS:A1991FZ35100032
J	THIAGALINGAM, S; GROSSMAN, L				THIAGALINGAM, S; GROSSMAN, L			BOTH ATPASE SITES OF ESCHERICHIA-COLI UVRA HAVE FUNCTIONAL ROLES IN NUCLEOTIDE EXCISION REPAIR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL TRANSPORT PROTEINS; MULTIDRUG RESISTANCE GENE; DNA-SEQUENCE ANALYSIS; ADENYLATE KINASE; BINDING PROTEINS; P-GLYCOPROTEIN; HOMOLOGY; MUTATION; INCISION; SUBUNITS	The roles of the two tandemly arranged putative ATP binding sites of Escherichia coli UvrA in UvrABC endonuclease-mediated excision repair were analyzed by site-directed mutagenesis and biochemical characterization of the representative mutant proteins. Evidence is presented that UvrA has two functional ATPase sites which coincide with the putative ATP binding motifs predicted from its amino acid sequence. The individual ATPase sites can independently hydrolyze ATP. The C-terminal ATPase site has a higher affinity for ATP than the N-terminal site. The invariable lysine residues at the ends of the glycine-rich loops of the consensus Walker type "A" motifs are indispensable for ATP hydrolysis. However, the mutations at these lysine residues do not significantly affect ATP binding. UvrA, with bound ATP, forms the most favored conformation for DNA binding. The initial binding of UvrA to DNA is chiefly at the undamaged sites. In contrast to the wild type UvrA, the ATPase site mutants bind equally to damaged and undamaged sites. Dissociation of tightly bound nucleoprotein complexes from the undamaged sites requires hydrolysis of ATP by the C-terminal ATPase site of UvrA. Thus, both ATP binding and hydrolysis are required for the damage recognition step enabling UvrA to discriminate between damaged and undamaged sites on DNA.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21205	Johns Hopkins University				Thiagalingam, Sam/0000-0001-5211-266X	NIEHS NIH HHS [5P30ES038190] Funding Source: Medline; NIGMS NIH HHS [GM31110, GM22846] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031110, R01GM022846, R37GM022846] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIKAN E, 1986, NUCLEIC ACIDS RES, V14, P2637, DOI 10.1093/nar/14.6.2637; BACKENDORF C, 1986, NUCLEIC ACIDS RES, V14, P2877, DOI 10.1093/nar/14.7.2877; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BELL AW, 1986, J BIOL CHEM, V261, P7652; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P7855, DOI 10.1093/nar/16.16.7855; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11380; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11388; DIEZEL W, 1972, ANAL BIOCHEM, V48, P617, DOI 10.1016/0003-2697(72)90117-0; DOOLITTLE RF, 1986, NATURE, V323, P451, DOI 10.1038/323451a0; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GONSKY R, 1990, J BIOL CHEM, V265, P9083; GORBALENYA AE, 1990, J MOL BIOL, V213, P583, DOI 10.1016/S0022-2836(05)80243-8; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; GROSSMAN L, 1988, FASEB J, V2, P2696, DOI 10.1096/fasebj.2.11.3294078; HIGGINS CF, 1988, BIOESSAYS, V8, P111, DOI 10.1002/bies.950080406; HUSAIN I, 1986, J BIOL CHEM, V261, P4895; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EH, 1990, P NATL ACAD SCI USA, V87, P4620, DOI 10.1073/pnas.87.12.4620; MAZUR S, 1991, IN PRESS BIOCHEMISTR; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MILMAN G, 1987, METHOD ENZYMOL, V153, P482; NURSE P, 1990, P NATL ACAD SCI USA, V87, P4615, DOI 10.1073/pnas.87.12.4615; OH EY, 1989, NUCLEIC ACIDS RES, V17, P4145, DOI 10.1093/nar/17.11.4145; OH EY, 1989, J BIOL CHEM, V264, P1336; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; PU WT, 1989, J BIOL CHEM, V264, P20697; REINSTEIN J, 1988, BIOCHEMISTRY-US, V27, P4712, DOI 10.1021/bi00413a020; RIORDAN JR, 1989, SCIENCE, V245, P1066; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SANDER F, 1977, P NATL ACAD SCI USA, V74, P5463; SCHULZ GE, 1987, COLD SPRING HARB SYM, V52, P429, DOI 10.1101/SQB.1987.052.01.050; SEEBERG E, 1982, P NATL ACAD SCI-BIOL, V79, P988, DOI 10.1073/pnas.79.4.988; SEELEY TW, 1990, J BIOL CHEM, V265, P7158; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; SHIOTA S, 1989, MOL GEN GENET, V217, P332, DOI 10.1007/BF02464901; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P2567, DOI 10.1093/nar/14.6.2567; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157	53	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11395	11403						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1828249				2022-12-25	WOS:A1991FQ77400105
J	RAO, GSJ; COOK, PF; HARRIS, BG				RAO, GSJ; COOK, PF; HARRIS, BG			EFFECTOR-INDUCED CONFORMATIONAL TRANSITIONS IN ASCARIS-SUUM PHOSPHOFRUCTOKINASE - A FLUORESCENCE AND CIRCULAR-DICHROISM STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT-MUSCLE PHOSPHOFRUCTOKINASE; FRUCTOSE 2,6-BISPHOSPHATE; PHYSIOLOGICAL CONDITIONS; PHOSPHORYLATION; LIVER; PURIFICATION	Results of activity and spectral studies using fluorescence and circular dichroism show that AMP and fructose 2, 6-bisphosphate (F-2, 6-P2) activate Ascaris suum phosphofructokinase through specific and similar conformational changes. Inorganic compounds like (NH4)2SO4 and KH2PO4 also induce structural alterations in the enzyme in a manner different from those caused by AMP and F-2, 6-P2. The enzyme is activated by both AMP and F-2, 6-P2, in 20 mM phosphate buffer, pH 6.6, with 0.2 mM ATP and 1 mM F-6-P. The K(act) values for AMP and F-2, 6-P2 are 25 +/- 3-mu-M nad 1.5 +/- 0.2-mu-M, respectively. Both effectors quench enzyme tryptophan fluorescence in phosphate, pH 6.6, in a concentration-dependent manner. The K(d) values determined from the decrease in emission intensity at 342 nm as a function of effector concentration are 24 +/- 3-mu-M for AMP and 1.00 +/- 0.15-mu-M for F-2,6-P2, in excellent agreement with the values of K(act). Both effectors also produce dramatic changes in the CD spectrum of the enzyme, in the region from 240 to 190 nm representing the peptide backbone. Secondary structure calculations suggest an increase in the alpha-helical content of the enzyme in the presence of either effector. The K(d) values obtained from the concentration dependence of the decrease in ellipticity at 210 nm are 22.8 +/- 5.3-mu-M and 1.3 +/- 0.2-mu-M, respectively, for AMP and F-2,6-P2, once again in close agreement with the K(act) values for these effectors. The data imply that activation of phosphofructokinase by these effectors is concomitant with structural chagnes in the enzyme. Further, comparison of the difference CD spectra for the effects of AMP and F-2,6-P2 show that both of them produce similar conformational changes and probably stabilize a similar final activated state of the enzyme. Other hexose phosphate analogues such as fructose 6-phosphate, glucose 1,6-bisphosphate, and fructose 1,6-bisphosphate do not affect the CD spectrum of the enzyme. Ammonium sulfate has no effect on the CD spectrum of the enzyme in phosphate buffer but does cause a significant alteration in the spectrum obtained in Mes. Gel filtration high performance liquid chromatography using a Borosil TSK 400 column shows that the tetrameric state of the native enzyme is not affected by the presence of the effectors.	TEXAS HEART INST, DEPT MICROBIOL & IMMUNOL, HOUSTON, TX 77025 USA	Texas Heart Institute	RAO, GSJ (corresponding author), TEXAS HEART INST, DEPT BIOCHEM & MOLEC BIOL, HOUSTON, TX 77025 USA.				NIAID NIH HHS [AI24155] Funding Source: Medline; NIGMS NIH HHS [GM37057, GM36799] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036799, R01GM037057] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CLAUS TH, 1984, CURR TOP CELL REGUL, V23, P57; Cleland W W, 1979, Methods Enzymol, V63, P103; COOK PF, 1987, J BIOL CHEM, V262, P14063; EMERK K, 1975, ARCH BIOCHEM BIOPHYS, V168, P210, DOI 10.1016/0003-9861(75)90243-X; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HOFER HW, 1982, J BIOL CHEM, V257, P3807; HOFER HW, 1982, J BIOL CHEM, V257, P3801; KAMEMOTO ES, 1986, J BIOL CHEM, V261, P4346; KEMP RG, 1983, MOL CELL BIOCHEM, V57, P147, DOI 10.1007/BF00849191; KULKARNI G, 1987, J BIOL CHEM, V262, P32, DOI 10.1128/AAC.31.1.32; LAD PM, 1973, BIOCHEMISTRY-US, V12, P4303, DOI 10.1021/bi00746a001; LEONARD KR, 1972, EUR J BIOCHEM, V26, P442, DOI 10.1111/j.1432-1033.1972.tb01785.x; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PAYNE MA, 1991, J BIOL CHEM, V266, P8891; PAYNE MA, 1991, J BIOL CHEM, V266, P8897; RACKER E, 1947, J BIOL CHEM, V167, P843; RAO GSJ, 1987, J BIOL CHEM, V262, P14068; SHNYROV VL, 1988, BIOCHIM BIOPHYS ACTA, V953, P128, DOI 10.1016/0167-4838(88)90017-9; SRINIVASAN NG, 1990, MOL BIOCHEM PARASIT, V38, P151, DOI 10.1016/0166-6851(90)90215-8; STARLING JA, 1982, J BIOL CHEM, V257, P3795; UYEDA K, 1982, MOL CELL BIOCHEM, V48, P97; UYEDA K, 1981, J BIOL CHEM, V256, P8394; Uyeda K, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P193; VANSCHAFTINGEN E, 1981, P NATL ACAD SCI-BIOL, V78, P3483; VANSCHAFTINGEN E, 1987, ADV ENZYMOL RAMB, V59, P315	26	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8884	8890						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1827437				2022-12-25	WOS:A1991FM03800037
J	SHEN, JB; OROZCO, EM; OGREN, WL				SHEN, JB; OROZCO, EM; OGREN, WL			EXPRESSION OF THE 2 ISOFORMS OF SPINACH RIBULOSE 1,5-BISPHOSPHATE CARBOXYLASE ACTIVASE AND ESSENTIALITY OF THE CONSERVED LYSINE IN THE CONSENSUS NUCLEOTIDE-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; RUBISCO ACTIVASE; DIRECTED MUTAGENESIS; OXYGENASE ACTIVASE; BETA-SUBUNIT; PROTEIN; ATP; SITE; PURIFICATION; REPLACEMENT	The two isoforms of ribulose 1,2-bisphosphate carboxylase activase (Rbu-P2 carboxylase) from spinach (Spinacea oleracea L.) were individually purified from Escherichia coli transformed with expression vectors for the appropriate cDNAs. Both isoforms catalyzed activation of Rbu-P2 carboxylase (ribulose 1, 5-bisphosphate carboxylase/oxygenase, EC 4.1.1.39) and ATP hydrolysis. The kinetics of the two isoforms with respect to ATP concentration were different, in that the 45-kDa polypeptide exhibited a sigmoidal response while a rectangular response was observed with the 41-kDa isoform. These observations suggest that the additional domain at the C terminus of the 45-kDa isoform modulates the ATP regulation of activity. Lysine 169, at the putative ATP-binding site of the 41-kDa form of Rbu-P2 carboxylase activase, was changed to arginine, isoleucine, and threonine by directed mutagenesis. These mutations abolished Rbu-P2 carboxylase activase and ATPase activities, as well as the capability of the protein to bind ATP. These results confirm that lysine 169 is an essential residue.	UNIV ILLINOIS,DEPT AGRON,URBANA,IL 61801; USDA ARS,PHOTOSYNTH RES UNIT,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; United States Department of Agriculture (USDA)								BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; DENHEZ F, 1988, EMBO J, V7, P541, DOI 10.1002/j.1460-2075.1988.tb02843.x; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18802; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HSU SY, 1987, FEBS LETT, V218, P222, DOI 10.1016/0014-5793(87)81050-5; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; PARSONAGE D, 1987, J BIOL CHEM, V262, P8022; PORTIS AR, 1986, PLANT PHYSIOL, V82, P967, DOI 10.1104/pp.82.4.967; RAO R, 1988, J BIOL CHEM, V263, P15957; ROBINSON SP, 1988, FEBS LETT, V233, P413, DOI 10.1016/0014-5793(88)80473-3; ROBINSON SP, 1989, ARCH BIOCHEM BIOPHYS, V268, P93, DOI 10.1016/0003-9861(89)90568-7; ROBINSON SP, 1988, PLANT PHYSIOL, V86, P293, DOI 10.1104/pp.86.1.293; ROBINSON SP, 1988, PLANT PHYSIOL, V88, P1008, DOI 10.1104/pp.88.4.1008; ROBINSON SP, 1989, PLANT PHYSIOL, V90, P968, DOI 10.1104/pp.90.3.968; SALVUCCI ME, 1987, PLANT PHYSIOL, V84, P930, DOI 10.1104/pp.84.3.930; SALVUCCI ME, 1985, PHOTOSYNTH RES, V7, P193, DOI 10.1007/BF00037012; SCZAKIEL G, 1987, NUCLEIC ACIDS RES, V15, P1878, DOI 10.1093/nar/15.4.1878; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; STREUSAND VJ, 1987, PLANT PHYSIOL, V85, P152, DOI 10.1104/pp.85.1.152; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; WANG Z-Y, 1989, Plant Physiology (Rockville), V89, P78; WEINMASTER G, 1986, EMBO J, V5, P69, DOI 10.1002/j.1460-2075.1986.tb04179.x; WERNEKE JM, 1989, PLANT CELL, V1, P815, DOI 10.1105/tpc.1.8.815; WERNEKE JM, 1988, P NATL ACAD SCI USA, V85, P787, DOI 10.1073/pnas.85.3.787; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5; ZIELINSKI RE, 1989, PLANT PHYSIOL, V90, P516, DOI 10.1104/pp.90.2.516	29	71	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8963	8968						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1827441				2022-12-25	WOS:A1991FM03800049
J	WAKABAYASHI, GO; GELFAND, JA; BURKE, JF; THOMPSON, RC; DINARELLO, CA				WAKABAYASHI, GO; GELFAND, JA; BURKE, JF; THOMPSON, RC; DINARELLO, CA			A SPECIFIC RECEPTOR ANTAGONIST FOR INTERLEUKIN-1 PREVENTS ESCHERICHIA-COLI-INDUCED SHOCK IN RABBITS	FASEB JOURNAL			English	Note						INTERLEUKIN-1; TUMOR NECROSIS FACTOR; SEPTIC SHOCK; NEUTROPHILS; INTERLEUKIN-1 RECEPTOR ANTAGONIST	TUMOR NECROSIS FACTOR; LETHAL BACTEREMIA; CACHECTIN; HYPOTENSION; ENDOTOXEMIA; ANTIBODIES; APPEARANCE; INHIBITOR; INJURY	Despite antibiotic therapy, the septic shock syndrome continues to have a high mortality. Tumor necrosis factor (TNF) and interleukin 1 (IL 1), two polypeptide cytokines produced during sepsis, are thought to mediate the hypotension and tissue damage of shock. In the present studies, rabbits were infused with Escherichia coli organisms to produce shock. The IL 1 receptor antagonist (IL 1ra), which competes with IL 1 for occupancy of the IL 1 cell-surface receptors without agonist properties, was given 15 min before the bacterial infusion and during the subsequent 4 h. In saline-treated controls, hypotension was sustained for 4 h and death occurred for two of five rabbits; in rabbits treated with the IL 1ra, however, blood pressure was only transiently decreased, returned to pre-E. coli levels, and no deaths occurred. The associated leukopenia was also reduced by treatment with the antagonist (P < 0.05). Histological examination of lung tissues showed reduced infiltrating neutrophils in the IL 1ra treatment group. Despite the attenuated responses in animals treated with the IL 1ra, circulating TNF and IL 1 levels were nearly identical in both groups. We conclude that specific blockade of IL 1 at the receptor level demonstrates an essential role for this cytokine in the pathogenesis of septic shock.	NEW ENGLAND MED CTR HOSP, 750 WASHINGTON ST, BOSTON, MA 02111 USA; TUFTS UNIV, DEPT MED, DIV GEOG MED & INFECT DIS, BOSTON, MA 02111 USA; HARVARD UNIV, SCH MED, DEPT SURG, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA; SYNERGEN INC, BOULDER, CO 80301 USA	Tufts Medical Center; Tufts University; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital			Gelfand, Jeffrey A/G-1885-2018	Gelfand, Jeffrey A/0000-0002-4118-5676	NIAID NIH HHS [AI15614] Funding Source: Medline; NIGMS NIH HHS [GM21700] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015614, R01AI015614, R56AI015614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM021700] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AREND WP, 1990, J CLIN INVEST, V85, P1694, DOI 10.1172/JCI114622; AREND WP, 1985, J IMMUNOL, V134, P3868; BEASLEY D, 1989, J CLIN INVEST, V83, P331, DOI 10.1172/JCI113879; BUSSOLINO F, 1986, J CLIN INVEST, V77, P2027, DOI 10.1172/JCI112532; CANNON JG, 1989, J IMMUNOL, V142, P2299; CANNON JG, 1990, J INFECT DIS, V161, P79, DOI 10.1093/infdis/161.1.79; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CLARK BD, 1991, J APPL PHYSL; COMINELLI F, 1990, J CLIN INVEST, V86, P972, DOI 10.1172/JCI114799; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI [10.1016/s0065-2776(08)60642-2, 10.1016/S0065-2776(08)60642-2, DOI 10.1016/S0065-2776(08)60642-2]; DOEBBER TW, 1985, BIOCHEM BIOPH RES CO, V127, P799, DOI 10.1016/S0006-291X(85)80014-0; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; EISENBERG SP, 1989, CYTOKINE, V1, P90; FONG YM, 1989, J EXP MED, V170, P1627, DOI 10.1084/jem.170.5.1627; GIRARDIN E, 1988, NEW ENGL J MED, V319, P397, DOI 10.1056/NEJM198808183190703; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HESSE DG, 1988, SURG GYNECOL OBSTET, V166, P147; LEFER AM, 1985, FED PROC, V44, P275; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; OKUSAWA S, 1988, J EXP MED, V168, P443, DOI 10.1084/jem.168.1.443; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; PARRILLO JE, 1990, ANN INTERN MED, V113, P227, DOI 10.7326/0003-4819-113-3-227; ROSSI V, 1985, SCIENCE, V229, P174, DOI 10.1126/science.2409598; SECKINGER P, 1987, J IMMUNOL, V139, P1541; SMEDEGARD G, 1989, AM J PATHOL, V135, P489; SMITH J, 1990, LYMPHOKINE RES, V9, P568; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRACEY KJ, 1987, SURG GYNECOL OBSTET, V164, P415; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; VEDDER NB, 1988, J CLIN INVEST, V81, P939, DOI 10.1172/JCI113407; WAKABAYASHI G, 1991, IN PRESS CLIN RES; WAKABAYASHI G, 1991, IN PRESS J CLIN INVE; WEINBERG JR, 1988, CLIN SCI, V75, P251, DOI 10.1042/cs0750251	34	415	433	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR 1	1991	5	3					338	343		10.1096/fasebj.5.3.1825816	http://dx.doi.org/10.1096/fasebj.5.3.1825816			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FC556	1825816				2022-12-25	WOS:A1991FC55600013
J	GERKE, V				GERKE, V			IDENTIFICATION OF A HOMOLOG FOR ANNEXIN-VII (SYNEXIN) IN DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PROTEIN-KINASE; LIPID-BINDING PROTEINS; ROUS-SARCOMA VIRUS; PHOSPHOLIPID-BINDING; CALPACTIN FAMILY; GENE-PRODUCT; LIPOCORTIN; SUBSTRATE; GROWTH; TRANSFORMATION	Immunological and biochemical data have been used to show that the slime mold Dictyostelium discoideum expresses a Ca2+/phospholipid-binding protein related to vertebrate annexins. The Dictyostelium protein (apparent molecular mass 46 kDa) is recognized by an antibody directed against an annexin consensus peptide and exhibits the properties characteristic for annexins, i.e. it interacts in a Ca2+-dependent manner with negatively charged phospholipids. Limited proteolysis converts the 46-kDa protein into a 32-kDa derivative which retains the Ca2+/phospholipid-binding properties of the 46-kDa polypeptide. Partial protein sequence data identify the Dictyostelium protein as a typical annexin and indicate that the 46-kDa protein is an annexin VII (synexin) homologue. The identification of an annexin in a simple eucaryote should lead to the introduction of genetic approaches to analyze the physiological role of the annexins.			GERKE, V (corresponding author), MAX PLANCK INST BIOPHYS CHEM,DEPT BIOCHEM,W-3400 GOTTINGEN,GERMANY.							BOUSTEAD CM, 1989, FEBS LETT, V244, P456, DOI 10.1016/0014-5793(89)80582-4; BRUGGE JS, 1986, CELL, V46, P149, DOI 10.1016/0092-8674(86)90729-4; BURGOYNE RD, 1989, CELL CALCIUM, V10, P1, DOI 10.1016/0143-4160(89)90038-9; BURNS AL, 1989, P NATL ACAD SCI USA, V86, P3798, DOI 10.1073/pnas.86.10.3798; CLARKE M, 1987, METHOD CELL BIOL, V28, P157; CREUTZ CE, 1978, J BIOL CHEM, V253, P2858; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; CRUMPTON MJ, 1990, NATURE, V345, P212, DOI 10.1038/345212a0; DE BK, 1986, J BIOL CHEM, V261, P3784; DELOZANNE A, 1987, METHOD CELL BIOL, V28, P489; ERIKSON E, 1980, CELL, V21, P829, DOI 10.1016/0092-8674(80)90446-8; FLOWER RJ, 1988, BRIT J PHARMACOL, V94, P987, DOI 10.1111/j.1476-5381.1988.tb11614.x; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GERKE V, 1989, CELL MOTIL CYTOSKEL, V14, P449, DOI 10.1002/cm.970140402; GERKE V, 1989, FEBS LETT, V258, P259, DOI 10.1016/0014-5793(89)81668-0; GLENNEY JR, 1987, BIOESSAYS, V7, P173, DOI 10.1002/bies.950070408; HAIGLER HT, 1987, J BIOL CHEM, V262, P6921; HIRATA F, 1984, ADV INFLAMMAT RES, V7, P71; HORSEMAN ND, 1989, MOL ENDOCRINOL, V3, P773, DOI 10.1210/mend-3-5-773; JOHNSSON N, 1988, FEBS LETT, V236, P201, DOI 10.1016/0014-5793(88)80314-4; JOHNSSON N, 1990, EUR J BIOCHEM, V188, P1, DOI 10.1111/j.1432-1033.1990.tb15363.x; JOHNSTON PA, 1990, J BIOL CHEM, V265, P11382; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; PEPINSKY RB, 1986, J BIOL CHEM, V261, P4239; PFAFFLE M, 1988, EMBO J, V7, P2335, DOI 10.1002/j.1460-2075.1988.tb03077.x; POLLARD HB, 1988, J EXP BIOL, V139, P267; POLLARD HB, 1988, P NATL ACAD SCI USA, V85, P2974, DOI 10.1073/pnas.85.9.2974; RADKE K, 1980, CELL, V21, P821, DOI 10.1016/0092-8674(80)90445-6; SHADLE PJ, 1985, J BIOL CHEM, V260, P6354; SMITH VL, 1990, CELL REGUL, V1, P165, DOI 10.1091/mbc.1.2.165; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER JH, 1982, J NEUROCHEM, V39, P815, DOI 10.1111/j.1471-4159.1982.tb07965.x; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; ZAKS WJ, 1990, J BIOENERG BIOMEMBR, V22, P97, DOI 10.1007/BF00762942	34	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1697	1700						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1824843				2022-12-25	WOS:A1991EU49700054
J	MEDCALF, EA; TAKAHASHI, T; CHIBA, I; MINNA, J; MILNER, J				MEDCALF, EA; TAKAHASHI, T; CHIBA, I; MINNA, J; MILNER, J			TEMPERATURE-SENSITIVE MUTANTS OF P53 ASSOCIATED WITH HUMAN CARCINOMA OF THE LUNG	ONCOGENE			English	Article							TUMOR SUPPRESSOR PROTEIN; MONOCLONAL-ANTIBODIES; SIMIAN VIRUS-40; IMMUNOLOGICAL VARIANTS; GENE; TRANSFORMATION; ANTIGEN; CANCER; EXPRESSION; ONCOGENE	We have compared the effects of specific point mutations on the tertiary and quaternary structure of the human p53 protein. Eight mutants, each derived from primary resected tissues of lung carcinomas, were expressed in vitro under strictly defined conditions, such that the only known variant was the point mutation present in each p53 mRNA. All the mutations were located in highly conserved domains. The tertiary structure of each mutant protein was investigated by reactivity with anti-p53 monoclonal antibodies directed against conformation-dependent epitopes. Quaternary structure was examined by gel filtration. Although all the mutant proteins exhibited abnormal tertiary structures, their quaternary structures appeared similar to wild type, the one exception being p53-tyr135, which contains tyrosine in place of cysteine at residue 135. The conformational phenotype of mutant human p53 was found to be dependent upon (i) the locus of the mutation and (ii) the nature of the amino acid substitution: two different substitutions at residue 273 yielded two mutants with differing structural properties. We have discovered three mutants of human p53 that are temperature sensitive for conformation; one is mutated at codon 273, a 'hotspot' for p53 mutation in human cancer.	UNIV CAMBRIDGE,DEPT PATHOL,DIV VIROL,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND; USN HOSP,NCI,MED ONCOL BRANCH,BETHESDA,MD 20814	University of Cambridge; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy			Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001				BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIBA I, 1990, ONCOGENE, V5, P1603; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1990, EMBO J, V9, P1591; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MALKIN D, 1990, SCIENCE, V250, P1222; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1990, ONCOGENE, V5, P1683; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; MILNER J, 1991, CELL, V65, P1; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6567; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	32	38	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					71	76						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741167				2022-12-25	WOS:A1992HC22700010
J	CISMOWSKI, MJ; NARULA, SS; ARMITAGE, IM; CHERNAIK, ML; HUANG, PC				CISMOWSKI, MJ; NARULA, SS; ARMITAGE, IM; CHERNAIK, ML; HUANG, PC			MUTATION OF INVARIANT CYSTEINES OF MAMMALIAN METALLOTHIONEIN ALTERS METAL-BINDING CAPACITY, CADMIUM RESISTANCE, AND CD-113 NMR-SPECTRUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; RABBIT LIVER METALLOTHIONEIN-2; 3-DIMENSIONAL STRUCTURE; RAT-LIVER; YEAST; COPPER; CELLS; CONFORMATION; SPECTROSCOPY; MUTAGENESIS	Using a yeast expression vector system, we have expressed both wild type and six mutated Chinese hamster metallothionein coding sequences in a metal-sensitive yeast strain in which the endogenous metallothionein gene has been deleted. The mutant proteins have single or double cysteine to tyrosine replacements (C13Y, C50Y, and C13,50Y), single cysteine to serine replacements (C13S and C50S), or a single cysteine to alanine replacement (C50A). These proteins function in their yeast host in cadmium detoxification to differing extents. Metallothioneins which contain a cysteine mutation at position 50 (C50Y, C50S, C50A, and C13,50Y) conferred markedly less cadmium resistance than wild type metallothionein, or metallothionein with a single cysteine mutation at position 13 (C13Y and C13S). Wild type and three of the mutant Chinese hamster metallothioneins (C13Y, C50Y, and C13,50Y) were purified from yeast grown in subtoxic levels of either CdCl2 or (CdCl2)-Cd-113. All three of the mutant proteins bound less cadmium than the wild type protein when metal-binding stoichiometries were determined. The one-dimensional Cd-113 NMR spectrum of the recombinant wild type Chinese hamster metallothionein was compared to the spectra of native rat and rabbit liver metallothioneins. The close correspondence between the Cd-113 chemical shifts in these metallothioneins is consistent with the presence of two separate metal clusters, A and B, corresponding, respectively, to the alpha- and beta-domains, in the recombinant metallothionein. The one-dimensional Cd-113 NMR spectra recorded on each of the three mutant metallothioneins, on the other hand, provide some indication as to the structural basis for the reduced, by one, metal stoichiometry of each of the mutant metallothioneins. For the C13Y mutant, it appears that the beta-domain now binds a total of two metal ions whereas with the C50Y mutant, the alpha-domain appears metal-deficient. For the double mutant, C13,50Y, the Cd-113 resonances are indicative of major structural reorganizations in both domains.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT BIOCHEM, BALTIMORE, MD 21218 USA; YALE UNIV, SCH MED, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT DIAGNOST RADIOL, NEW HAVEN, CT 06510 USA	Johns Hopkins University; Yale University; Yale University			Cismowski, Mary/E-2897-2011		NCRR NIH HHS [RR03475] Funding Source: Medline; NIDDK NIH HHS [DK18778] Funding Source: Medline; NIGMS NIH HHS [GM32606] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018778] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032606] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMITAGE IM, 1984, ADV INORG BIOCHEM, V6, P113; ARMITAGE IM, 1983, NMR NEWLY ACCESSIBLE, V2, P337; ARMITAGE IM, 1982, BIOL MAGN RESON, V4, P79; ARSENIEV A, 1988, J MOL BIOL, V201, P637, DOI 10.1016/0022-2836(88)90644-4; Buhler R H, 1979, Experientia Suppl, V34, P211; CHERNAIK ML, 1991, P NATL ACAD SCI USA, V88, P3024, DOI 10.1073/pnas.88.8.3024; CISMOWSKI MJ, 1991, METHOD ENZYMOL, V205, P312; CISMOWSKI MJ, 1991, BIOCHEMISTRY-US, V30, P6626, DOI 10.1021/bi00240a036; ECKER DJ, 1986, J BIOL CHEM, V261, P6895; FREY MH, 1985, J AM CHEM SOC, V107, P6847, DOI 10.1021/ja00310a017; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GREENSTEIN JP, 1961, CHEM AMINO ACIDS, P497; GRIFFITH BB, 1983, NUCLEIC ACIDS RES, V11, P901, DOI 10.1093/nar/11.3.901; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENSEN R, 1983, P NATL ACAD SCI-BIOL, V80, P3035, DOI 10.1073/pnas.80.10.3035; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MESSERLE BA, 1990, J MOL BIOL, V214, P765, DOI 10.1016/0022-2836(90)90291-S; MORRIS S, 1987, MOL CELL BIOL, V7, P600, DOI 10.1128/MCB.7.2.600; NARULA SS, 1991, IN PRESS J AM CHEM S; NETTESHEIM DG, 1985, BIOCHEMISTRY-US, V24, P6744, DOI 10.1021/bi00345a003; OTSUKA F, 1988, ANAL BIOCHEM, V168, P184, DOI 10.1016/0003-2697(88)90027-9; Otvos J D, 1987, Experientia Suppl, V52, P171; Otvos J. D., 1982, BIOCH STRUCTURE DETE, P65; OTVOS JD, 1980, P NATL ACAD SCI-BIOL, V77, P7094, DOI 10.1073/pnas.77.12.7094; PINE R, 1985, DNA-J MOLEC CELL BIO, V4, P115, DOI 10.1089/dna.1985.4.115; PINE R, 1987, METHOD ENZYMOL, V154, P415; RHEE IK, 1990, PROTEIN ENG, V3, P205, DOI 10.1093/protein/3.3.205; ROBBINS AH, 1991, IN PRESS J MOL BIOL; SCHULTZE P, 1988, J MOL BIOL, V203, P251, DOI 10.1016/0022-2836(88)90106-4; SONE T, 1987, J BIOL CHEM, V262, P5878; STILLMAN MJ, 1989, BIOCHEM J, V262, P181, DOI 10.1042/bj2620181; SUISSA M, 1983, ANAL BIOCHEM, V133, P511, DOI 10.1016/0003-2697(83)90117-3; THIELE DJ, 1986, SCIENCE, V231, P854, DOI 10.1126/science.3080806; THROWER AR, 1988, J BIOL CHEM, V263, P7037; VASAK M, 1987, J MOL BIOL, V196, P711, DOI 10.1016/0022-2836(87)90042-8; WINGE DR, 1982, J BIOL CHEM, V257, P3471; WRIGHT CF, 1988, J BIOL CHEM, V263, P1570	40	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24390	24397						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761540				2022-12-25	WOS:A1991GW84500026
J	HENDRICK, JP; WICKNER, W				HENDRICK, JP; WICKNER, W			SECA PROTEIN NEEDS BOTH ACIDIC PHOSPHOLIPIDS AND SECY/E PROTEIN FOR FUNCTIONAL HIGH-AFFINITY BINDING TO THE ESCHERICHIA-COLI PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTRANSFERASE SYSTEM; CYTOPLASMIC MEMBRANE; PRECURSOR PROTEINS; TRIGGER FACTOR; PRO-OMPA; TRANSLOCATION ATPASE; SUGAR-TRANSPORT; COAT PROTEIN; LAMBDA-DNA; VESICLES	Translocation of preproteins across the Escherichia coli inner membrane requires acidic phospholipids. We have studied the translocation of the precursor protein proOmpA across inverted inner membrane vesicles prepared from cells depleted of phosphatidylglycerol and cardiolipin. These membranes support neither translocation nor the translocation ATPase activity of the SecA subunit of preprotein translocase. We now report that inner membrane vesicles which are depleted of acidic phospholipids are unable to bind SecA protein with high affinity. These membranes can be restored to translocation competence by fusion with liposomes containing phosphatidylglycerol, suggesting that the defect in SecA binding is a direct effect of phospholipid depletion rather than a general derangement of inner membrane structure. Reconstitution of SecY/E, the membrane-embedded domain of translocase, into proteoliposomes containing predominantly a single synthetic acidic lipid, dioleoylphosphatidvlglycerol, allows efficient catalysis of preprotein translocation.	UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	HENDRICK, JP (corresponding author), UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA.							ANHOLT R, 1984, ENZYMES BIOL MEMBR, V3, P335; BATENBURG AM, 1988, BIOCHEMISTRY-US, V27, P5678, DOI 10.1021/bi00415a043; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CHANG CN, 1978, P NATL ACAD SCI USA, V75, P361, DOI 10.1073/pnas.75.1.361; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DEKRUIJFF B, 1985, PROGR PROTEIN LIPID; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; DRIESSEN AJM, 1990, P NATL ACAD SCI USA, V87, P3107, DOI 10.1073/pnas.87.8.3107; DUMONT ME, 1984, J BIOL CHEM, V259, P4147; ERNI B, 1982, J BIOL CHEM, V257, P13726; ERNI B, 1987, J BIOL CHEM, V262, P5238; GELLER BL, 1989, J BIOL CHEM, V264, P16465; HABERLAND ME, 1989, J IMMUNOL, V142, P855; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HEACOCK PN, 1989, J BIOL CHEM, V264, P14972; ITO K, 1980, J BIOL CHEM, V255, P2123; KUNDIG W, 1971, J BIOL CHEM, V246, P1407; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LECKER SH, 1990, EMBO J, V9, P2309, DOI 10.1002/j.1460-2075.1990.tb07402.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MARKWELL MAK, 1978, BIOCHEMISTRY-US, V17, P4807, DOI 10.1021/bi00615a031; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; NESMEYANOVA MA, 1982, FEBS LETT, V142, P189, DOI 10.1016/0014-5793(82)80131-2; RIETVELD A, 1986, J BIOL CHEM, V261, P3846; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; TANI K, 1989, J BIOL CHEM, V264, P18582; TANI K, 1990, J BIOL CHEM, V265, P17341; THAKUR AK, 1980, ANAL BIOCHEM, V103, P240, DOI 10.1016/0003-2697(80)90263-8; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P1895, DOI 10.1073/pnas.86.6.1895; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WICKNER W, 1972, P NATL ACAD SCI USA, V69, P965, DOI 10.1073/pnas.69.4.965; WILLIAMS N, 1986, P NATL ACAD SCI USA, V83, P8934, DOI 10.1073/pnas.83.23.8934	40	134	134	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24596	24600						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1837025				2022-12-25	WOS:A1991GW84500055
J	SCHNAPP, A; GRUMMT, I				SCHNAPP, A; GRUMMT, I			TRANSCRIPTION COMPLEX-FORMATION AT THE MOUSE RDNA PROMOTER INVOLVES THE STEPWISE ASSOCIATION OF 4 TRANSCRIPTION FACTORS AND RNA POLYMERASE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL DNA-TRANSCRIPTION; FACTOR TIF-IA; INITIATION-FACTOR; ACCURATE TRANSCRIPTION; HORMONAL-REGULATION; FUNCTIONAL-ANALYSIS; FACTOR-IIE; INVITRO; PURIFICATION; SPECIFICITY	We have used purified transcription factors and RNA polymerase I (pol I) to analyze the individual steps involved in the formation of transcription initiation complexes at the mouse ribosomal gene promoter in vitro. Complete assembly of transcription complexes requires pol I and at least four auxiliary factors, termed TIF-IA, TIF-IB, TIF-IC, and UBF. Preincubation and template commitment, as well as order of addition protocols, were used to discriminate between various intermediate complexes generated during assembly of the initiation complex. As a first step, TIF-IB binds to the core promoter, a process that is facilitated by the upstream control element and the upstream binding factor (UBF). Binding of TIF-IB to the rDNA promoter results in the formation of a functional preinitiation complex (complex 1), which is stable for many rounds of transcription. UBF, which on its own does not stably associate with the rDNA promoter, triggers a 5-10-fold increase in the overall amount of this primary complex. Following binding of TIF-IB and UBF to the template DNA, pol I and TIF-IC successively bind, yielding complexes 2 and 3, respectively. Transcription-competent initiation complexes are built up by the final association of the growth-regulated factor TIF-IA. The various complexes can be distinguished by their different sensitivity to Sarkosyl. Only the complete complex consisting of all four factors and pol I shows resistance to intermediate concentrations of Sarkosyl (0.045%) and is competent to catalyze the formation of the first phosphodiester bond. The initiated complex is, on the other hand, resistant to high concentrations of Sarkosyl (0.3%). The hierarchical nature of the different complexes formed suggests a model for transcription initiation and predicts functions for the individual factors.			SCHNAPP, A (corresponding author), GERMAN CANC RES CTR,INST CELL & TUMOR BIOL,W-6900 HEIDELBERG,GERMANY.							ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BATEMAN E, 1988, MOL CELL BIOL, V8, P1940, DOI 10.1128/MCB.8.5.1940; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; BOGENHAGEN DF, 1982, CELL, V28, P413, DOI 10.1016/0092-8674(82)90359-2; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BUTTGEREIT D, 1985, NUCLEIC ACIDS RES, V13, P8165, DOI 10.1093/nar/13.22.8165; CIZEWSKI V, 1983, NUCLEIC ACIDS RES, V11, P7043, DOI 10.1093/nar/11.20.7043; CLOS J, 1986, NUCLEIC ACIDS RES, V14, P7581, DOI 10.1093/nar/14.19.7581; CLOS J, 1986, P NATL ACAD SCI USA, V83, P604, DOI 10.1073/pnas.83.3.604; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1990, J BIOL CHEM, V265, P7552; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1990, J BIOL CHEM, V265, P7559; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1988, J BIOL CHEM, V263, P10821; GOKAL PK, 1990, J BIOL CHEM, V265, P16234; GRUMMT I, 1982, NATURE, V296, P173, DOI 10.1038/296173a0; GRUMMT I, 1981, P NATL ACAD SCI-BIOL, V78, P727, DOI 10.1073/pnas.78.2.727; GRUMMT I, 1989, NUCLEIC ACIDS MOL BI, V3, P148; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; KATO H, 1986, MOL CELL BIOL, V6, P3418, DOI 10.1128/MCB.6.10.3418; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; MAHAJAN PB, 1990, J BIOL CHEM, V265, P16225; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MCSTAY B, 1991, EMBO J, V10, P2297, DOI 10.1002/j.1460-2075.1991.tb07766.x; MISHIMA Y, 1982, NUCLEIC ACIDS RES, V10, P6659, DOI 10.1093/nar/10.21.6659; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; ONISHI T, 1984, P NATL ACAD SCI-BIOL, V81, P484, DOI 10.1073/pnas.81.2.484; PALMER JM, 1990, TRENDS BIOCHEM SCI, V15, P300, DOI 10.1016/0968-0004(90)90018-7; REINBERG D, 1987, J BIOL CHEM, V262, P3310; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHNAPP A, 1990, NUCLEIC ACIDS RES, V18, P1385, DOI 10.1093/nar/18.6.1385; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; SCHNAPP A, 1991, MOL CELL BIOCHEM, V104, P137; SKINNER JA, 1984, P NATL ACAD SCI-BIOL, V81, P2137, DOI 10.1073/pnas.81.7.2137; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; TANAKA N, 1990, J BIOL CHEM, V265, P13836; TOWER J, 1987, CELL, V50, P873, DOI 10.1016/0092-8674(87)90514-9; TOWER J, 1986, MOL CELL BIOL, V6, P3451, DOI 10.1128/MCB.6.10.3451; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; WANDELT C, 1983, NUCLEIC ACIDS RES, V11, P3795, DOI 10.1093/nar/11.11.3795; WEIL PA, 1979, CELL, V18, P469	50	110	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24588	24595						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1761556				2022-12-25	WOS:A1991GW84500054
J	GLICK, GD; TOOGOOD, PL; WILEY, DC; SKEHEL, JJ; KNOWLES, JR				GLICK, GD; TOOGOOD, PL; WILEY, DC; SKEHEL, JJ; KNOWLES, JR			LIGAND RECOGNITION BY INFLUENZA-VIRUS - THE BINDING OF BIVALENT SIALOSIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMAGGLUTININ MEMBRANE GLYCOPROTEIN; SIALIC-ACID; ELECTRON-MICROSCOPY; RECEPTOR; INFECTION; INHIBITORS; EQUINE; NEURAMINIDASE; DERIVATIVES; SELECTIVITY	Infection by influenza virus is initiated by a cellular adhesion event that is mediated by the viral protein, hemagglutinin, which is exposed on the surface of the virion. Hemagglutinin recognizes and binds to cell surface sialic acid residues. Although each individual ligand binding interaction is weak, the high affinity of influenza virus for cells that bear sialic acid residues is thought to result from a multivalent attachment process involving many similar recognition events. To evaluate such binding we have synthesized three series of compounds, each containing two sialic acid residues separated by spacers of different length, and have tested them as ligands for influenza hemagglutinin. No increased binding to the bromelain-released hemagglutinin ectodomain was seen for any of the bivalent compounds as determined by H-1 NMR titration. In contrast, however, a spacer length between sialic acid residues of approximately 55 angstrom sharply increases the binding of these bidentate species to whole virus as determined by hemagglutination inhibition assays. The most effective compound containing glycines in the linking chain displayed 100-fold increased affinity for whole virus over the paradigm monovalent ligand, Neu5Ac-alpha-2Me.	HARVARD UNIV, DEPT CHEM, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, DEPT BIOCHEM, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, HOWARD HUGHES INST, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA; NATL INST MED RES, LONDON NW7 1AA, ENGLAND	Harvard University; Harvard University; Harvard University; Howard Hughes Medical Institute; MRC National Institute for Medical Research	KNOWLES, JR (corresponding author), HARVARD UNIV, DEPT CHEM, CAMBRIDGE, MA 02138 USA.							BARCLAY GR, 1969, BIOCHEM J, V111, P353, DOI 10.1042/bj1110353; BARRETT T, 1985, VIROLOGY PRACTICAL A, P125; BERGELSON LD, 1982, EUR J BIOCHEM, V128, P467; DESTGROTH SF, 1963, BIOCHIM BIOPHYS ACTA, V78, P248; DEVANAND K, 1990, NATURE, V343, P739, DOI 10.1038/343739a0; DWIVEDI AM, 1971, CHEM PHYS LETT, V8, P220, DOI 10.1016/0009-2614(71)80019-2; EILAT D, 1979, BIOCHEMISTRY-US, V18, P790, DOI 10.1021/bi00572a008; EREZ M, 1982, J MED CHEM, V25, P847, DOI 10.1021/jm00349a016; GLICK GD, 1991, J AM CHEM SOC, V113, P4701, DOI 10.1021/ja00012a060; GOPALAKRISHNAN PV, 1974, J IMMUNOL, V113, P769; HANAOKA K, 1989, J BIOL CHEM, V264, P9842; HEWAT EA, 1984, J MOL BIOL, V175, P175, DOI 10.1016/0022-2836(84)90473-X; Hirst GK, 1942, J EXP MED, V75, P49, DOI 10.1084/jem.75.1.49; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; JUNANKAR PR, 1986, BIOCHIM BIOPHYS ACTA, V854, P198, DOI 10.1016/0005-2736(86)90111-2; KIHLBERG J, 1989, J AM CHEM SOC, V111, P6364, DOI 10.1021/ja00198a056; KILBOURN.ED, 1969, B WORLD HEALTH ORGAN, V41, P643; LAVER WG, 1966, VIROLOGY, V30, P493, DOI 10.1016/0042-6822(66)90125-5; LAVER WG, 1973, ADV VIRUS RES, V18, P57; LEE RT, 1989, BIOCHEMISTRY-US, V28, P8351, DOI 10.1021/bi00447a013; MARAGANORE JM, 1990, BIOCHEMISTRY-US, V29, P7095, DOI 10.1021/bi00482a021; MATROSOVICH MN, 1990, FEBS LETT, V272, P209, DOI 10.1016/0014-5793(90)80486-3; MATSUURA H, 1985, J MOL STRUCT, V126, P251, DOI 10.1016/0022-2860(85)80118-6; MEINDL P, 1974, VIROLOGY, V58, P457, DOI 10.1016/0042-6822(74)90080-4; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; MORAWIEC.A, 1965, BIOCHEM BIOPH RES CO, V18, P606, DOI 10.1016/0006-291X(65)90798-9; MYERS RW, 1980, ANAL BIOCHEM, V101, P166, DOI 10.1016/0003-2697(80)90056-1; NISHIDE H, 1986, MACROMOLECULES, V19, P494, DOI 10.1021/ma00156a050; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Paulson J, 1985, THE RECEPTORS, V2, P131; PAULSON JC, 1979, J BIOL CHEM, V254, P2120; PORTOGHESE PS, 1986, J MED CHEM, V29, P1855, DOI 10.1021/jm00160a010; PRITCHETT TJ, 1989, J BIOL CHEM, V264, P9850; PRITCHETT TJ, 1987, VIROLOGY, V160, P502, DOI 10.1016/0042-6822(87)90026-2; PROVENCHER SW, 1983, PHOTON CORRELATION T, P322; ROGERS GN, 1983, VIROLOGY, V131, P394, DOI 10.1016/0042-6822(83)90507-X; RUIGROK RWH, 1984, J GEN VIROL, V65, P799, DOI 10.1099/0022-1317-65-4-799; SAUTER NK, 1989, BIOCHEMISTRY-US, V28, P8388, DOI 10.1021/bi00447a018; Schulze I. T., 1973, Advances in Virus Research, V18, P1, DOI 10.1016/S0065-3527(08)60818-0; SHIMOHIGASHI Y, 1982, NATURE, V297, P333, DOI 10.1038/297333a0; SMITH M, 1969, BIOPOLYMERS, V8, P29, DOI 10.1002/bip.1969.360080104; SPALTENSTEIN A, 1991, J AM CHEM SOC, V113, P686, DOI 10.1021/ja00002a053; STOCK RS, 1985, J POLYM SCI POL PHYS, V23, P1393, DOI 10.1002/pol.1985.180230707; SUZUKI Y, 1985, J BIOL CHEM, V260, P1362; WEINER PK, 1981, J COMPUT CHEM, V2, P287, DOI 10.1002/jcc.540020311; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WHITE J, 1983, Q REV BIOPHYS, V16, P151, DOI 10.1017/S0033583500005072; WHITEHEAD PH, 1968, ARCH BIOCHEM BIOPHYS, V126, P657, DOI 10.1016/0003-9861(68)90453-0; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0; WILEY DC, 1977, VIROLOGY, V79, P446, DOI 10.1016/0042-6822(77)90371-3; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; 1953, WHO TECH REP SER, V64, P1	54	110	114	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23660	23669						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1748643				2022-12-25	WOS:A1991GV31900025
J	FURUKAWA, T; KAWAICHI, M; MATSUNAMI, N; RYO, H; NISHIDA, Y; HONJO, T				FURUKAWA, T; KAWAICHI, M; MATSUNAMI, N; RYO, H; NISHIDA, Y; HONJO, T			THE DROSOPHILA RBP-J-KAPPA GENE ENCODES THE BINDING-PROTEIN FOR THE IMMUNOGLOBULIN J-KAPPA RECOMBINATION SIGNAL SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; V(D)J RECOMBINATION; CODING SEGMENTS; NUCLEAR-PROTEIN; DNA; LOCUS; MELANOGASTER; PRODUCT; ACID; ORGANIZATION	We previously isolated a cDNA encoding the 60-kDa murine protein (RBP-J(K) protein) that specifically binds to the immunoglobulin J. recombination signal sequence. The RBP-J(K) gene is highly conserved in a wide variety of organisms including man, Xenopus, Drosophila, and yeast. We have isolated and characterized the Drosophila homologue of the RBP-J(K) gene. The Drosophila RBP-J(K) gene was mapped to the polytene region 35BC of chromosome 2. The nucleotide sequence of this gene indicates that it is not one of the known genes located in the 35 BC region. The nucleotide and amino acid sequences of the Drosophila and mouse RBP-J(K) genes are 60 and 75% homologous, respectively. The central 248-residue regions of RBP-J(K) proteins of the two species are 93% homologous and include the 40-residue integrase motif. The Drosophila RBP-J(K) protein expressed in COS cells bound to the J(K) recognition sequence with the same specificity as the murine counterpart. These results suggest that Drosophila may have a site-specific recombination system which utilizes the immunoglobulin recombination signal sequence. Implications for evolution of immunoglobulin gene rearrangement were also discussed.	OSAKA UNIV,FAC MED,DEPT RADIAT BIOL,SUITA,OSAKA 565,JAPAN; AICHI CANC CTR,RES INST,MOLEC BIOL UNIT,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Osaka University; Aichi Cancer Center	FURUKAWA, T (corresponding author), KYOTO UNIV,FAC MED,DEPT MED CHEM,SAKYO KU,KYOTO 606,JAPAN.		Honjo, Tasuku/N-4470-2016					AKIRA S, 1987, SCIENCE, V238, P1134, DOI 10.1126/science.3120312; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; CRAIG NL, 1988, ANNU REV GENET, V22, P77; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRYBERG EA, 1983, CELL, V33, P115; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GUBB D, 1984, CHROMOSOMA, V91, P54, DOI 10.1007/BF00286485; HAMAGUCHI Y, 1989, NUCLEIC ACIDS RES, V17, P9015, DOI 10.1093/nar/17.22.9015; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HONJO T, 1983, ANNU REV IMMUNOL, V1, P499, DOI 10.1146/annurev.iy.01.040183.002435; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; LANGERSAFER PR, 1982, P NATL ACAD SCI-BIOL, V79, P4381, DOI 10.1073/pnas.79.14.4381; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LITMAN GW, 1985, P NATL ACAD SCI USA, V82, P844, DOI 10.1073/pnas.82.3.844; LITMAN GW, 1985, P NATL ACAD SCI USA, V82, P2082, DOI 10.1073/pnas.82.7.2082; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OKAZAKI K, 1988, J IMMUNOL, V141, P1348; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; PERSSON H, 1984, SCIENCE, V225, P687, DOI 10.1126/science.6431612; PIRROTTA V, 1987, EMBO J, V6, P791, DOI 10.1002/j.1460-2075.1987.tb04821.x; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; REGULSKI M, 1987, EMBO J, V6, P767, DOI 10.1002/j.1460-2075.1987.tb04819.x; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SAKANO H, 1979, NATURE, V280, P288, DOI 10.1038/280288a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHNEUWLY S, 1986, EMBO J, V5, P733, DOI 10.1002/j.1460-2075.1986.tb04275.x; SCHUEPBACH T, 1986, Wilhelm Roux's Archives of Developmental Biology, V195, P302; SCHWAGER J, 1988, EMBO J, V7, P2409, DOI 10.1002/j.1460-2075.1988.tb03086.x; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEIDMAN JG, 1979, NATURE, V280, P370, DOI 10.1038/280370a0; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; SUN SC, 1990, SCIENCE, V250, P1729, DOI 10.1126/science.2270488; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; WILLIAMS AF, 1989, IMMUNOGLOBULIN GENES, P361; WOODRUFF RC, 1979, GENETICS, V92, P117	54	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23334	23340						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1744127				2022-12-25	WOS:A1991GT48300084
J	BURNS, PA; KEMP, CJ; GANNON, JV; LANE, DP; BREMNER, R; BALMAIN, A				BURNS, PA; KEMP, CJ; GANNON, JV; LANE, DP; BREMNER, R; BALMAIN, A			LOSS OF HETEROZYGOSITY AND MUTATIONAL ALTERATIONS OF THE P53-GENE IN SKIN TUMORS OF INTERSPECIFIC HYBRID MICE	ONCOGENE			English	Article							MOUSE SKIN; CHEMICAL CARCINOGENESIS; P53 PROTEIN; WILD-TYPE; GENE; DNA; ACTIVATION; ONCOGENE; MODEL; RAS	Functional alterations or loss of tumor-suppressor genes are an important feature of neoplastic progression in humans. The employment of suitable animal model systems would greatly facilitate the detection and manipulation of such genes. We describe here an experimental approach to this problem based on the analysis of skin tumors induced in F1 hybrids between Mus musculus and Mus spretus mice. The results show that loss of heterozygosity on chromosome 11 occurred in 4/13 mouse skin carcinomas, but not in premalignant papillomas. Since the murine p53 gene is located on this chromosome, immunoprecipitation and DNA-sequencing studies were carried out on tumorigenic cell lines and primary tumor DNA respectively to determine the status of p53 alleles. These studies revealed the presence of p53 mutations, both frameshifts and missense, some of which are identical to those found in human tumors. Loss of normal p53 function is found in well-differentiated squamous-cell carcinomas and thus does not appear to be directly responsible for further progression to an undifferentiated spindle cell phenotype.	BEATSON INST CANC RES,GARSCUBE ESTATE,SWITCHBACK RD,GLASGOW G61 1BD,SCOTLAND; IMPERIAL CANC RES FUND,CLARE HALL LABS,MOLEC IMMUNOCHEM LAB,POTTERS BAR EN6 3LD,HERTS,ENGLAND; UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,CANC RES CAMPAIGN LABS,DUNDEE DD1 4HN,SCOTLAND; HOSP SICK CHILDREN,DEPT IMMUNOL & CANC,TORONTO M5G 1X8,ONTARIO,CANADA	Beatson Institute; University of Dundee; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Lane, David P/C-4920-2008; Bremner, Rod/I-6490-2012	Bremner, Rod/0000-0001-9184-7212; Lane, David/0000-0003-0551-3545				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BOYD P, 1986, HUM GENET, V73, P171, DOI 10.1007/BF00291609; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BRASH DE, 1991, IN PRESS P NATL ACAD; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUCHMANN A, 1991, CANCER RES, V51, P4097; CHENG SC, 1988, CARCINOGENESIS, V9, P1721, DOI 10.1093/carcin/9.9.1721; CHIBA I, 1990, ONCOGENE, V5, P1603; DIPPLE A, 1983, CANCER RES, V43, P4132; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUSENIG N E, 1973, INSERM (Institut National de la Sante et de la Recherche Medicale) Colloque, V19, P219; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GLASER T, 1990, SCIENCE, V250, P823, DOI 10.1126/science.2173141; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KLEINSZANTO AJP, 1989, CARCINOGENESIS, V10, P2169, DOI 10.1093/carcin/10.11.2169; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MUNKE M, 1987, J MOL EVOL, V25, P134, DOI 10.1007/BF02101755; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; QUINTANILLA M, 1991, IN PRESS CARCINOGENE; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROBERT B, 1985, NATURE, V314, P181, DOI 10.1038/314181a0; SOUSSI T, 1990, ONCOGENE, V5, P945; STONE JC, 1989, GENOMICS, V5, P70, DOI 10.1016/0888-7543(89)90088-8; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	43	176	182	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2363	2369						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766680				2022-12-25	WOS:A1991GX73500028
J	LAVIGUEUR, A; BERNSTEIN, A				LAVIGUEUR, A; BERNSTEIN, A			P53 TRANSGENIC MICE - ACCELERATED ERYTHROLEUKEMIA INDUCTION BY FRIEND-VIRUS	ONCOGENE			English	Article							MURINE LEUKEMIA-VIRUS; 2 DISTINCT STRAINS; WILD-TYPE P53; PUTATIVE ONCOGENE; BLAST CRISIS; CELL-GROWTH; LUNG-CANCER; GENE; MUTATIONS; LINE	Mutations in the p53 tumor-suppressor gene have been implicated in the pathogenesis of a significant proportion of human cancers and in a dominantly inherited familial cancer syndrome (Li-Fraumeni syndrome). Frequent rearrangements and point mutations have also been detected in the p53 gene in the murine erythroleukemias induced by Friend leukemia virus. We have previously reported that transgenic mice overproducing a mutated p53 protein are predisposed to the development of lung carcinomas, bone and soft-tissue sarcomas, as well as lymphoid malignancies. Here we report that p53 transgenic mice infected with the polycythemia-inducing strain of Friend virus (FV-P) progress to the late stage of erythroleukemia more rapidly than do normal mice. In addition, Friend leukemic cell lines derived from p53 transgenic mice overproduce mutant p53 protein and show a high frequency of rearrangement of the ets-related Spi-1 oncogene, as previously reported in Friend cell lines derived from non-transgenic animals. These results suggest that the same genetic changes involved in the evolution of Friend leukemia in normal mice are also required in mice with an inherited predisposition to cancer. The data also indicate that p53 transgenic mice provide an animal model in which to analyse the role that genetic and environmental factors play in influencing cancer predisposition.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto								AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BEN-DAVID Y, 1990, New Biologist, V2, P1015; BENDAVID Y, 1989, ANN NY ACAD SCI, V567, P165, DOI 10.1111/j.1749-6632.1989.tb16468.x; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; DAVID YB, 1988, ONCOGENE, V3, P179; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; HABER DA, 1991, CELL, V64, P5, DOI 10.1016/0092-8674(91)90200-I; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; HOATLIN ME, 1990, P NATL ACAD SCI USA, V87, P9985, DOI 10.1073/pnas.87.24.9985; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KNUDSON AG, 1985, CANCER RES, V45, P1437; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; MAGER D, 1981, MOL CELL BIOL, V1, P721, DOI 10.1128/MCB.1.8.721; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MASHAL R, 1990, BLOOD, V75, P180; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLER CW, 1990, CANCER RES, V50, P7950; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROVINSKI B, 1988, ONCOGENE, V2, P445; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRATTON MR, 1990, ONCOGENE, V5, P1297; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WEINBERG RA, 1989, CANCER RES, V49, P3713; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	52	42	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1991	6	12					2197	2201						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766668				2022-12-25	WOS:A1991GX73500004
J	BIRKENMEIER, TM; MCQUILLAN, JJ; BOEDEKER, ED; ARGRAVES, WS; RUOSLAHTI, E; DEAN, DC				BIRKENMEIER, TM; MCQUILLAN, JJ; BOEDEKER, ED; ARGRAVES, WS; RUOSLAHTI, E; DEAN, DC			THE ALPHA-5-BETA FIBRONECTIN RECEPTOR - CHARACTERIZATION OF THE ALPHA-5 GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET GLYCOPROTEIN IIB; AVIAN PRECARDIAC CELLS; OSTEO-SARCOMA CELLS; AMINO-ACID SEQUENCE; GROWTH FACTOR-BETA; TRANSFORMED PHENOTYPE; TRANSMEMBRANE LINKAGE; INTEGRIN RECEPTORS; AMPHIBIAN EMBRYOS; MESSENGER-RNA	A genomic clone containing the gene for the alpha-5 subunit of the human alpha-5-beta-1 integrin complex was isolated by screening a human genomic library with the previously described alpha-5 cDNA (Argraves, W. S., Suzuki, S., Arai, H., Thompson, K., Pierschbacher, M. D., and Ruoslahti, E. (1987) J. Cell Biol 105,1183-1190). The alpha-5 gene 5'-flanking region lacks both TATA and CCAAT boxes, and it is located in a CpG island. This region was an active promoter in transfection assays using the HT-1080 cell line (fibrosarcoma), which expresses alpha-5, but was inactive in the Raji cell line (B cell), which does not express alpha-5. These results indicate that the alpha-5 gene 5'-flanking region acts as a promoter that exhibits the expected cell-type specificity. Deletion of alpha-5 promoter sequences from position -657 to -178 caused transcription stimulation, suggesting that a silencer is located between these sites. Successive 5' deletions from position -178 decreased promoter activity until activity was essentially eliminated on deletion to position -27. Isolation of a functional promoter for the alpha-gene is a first step in understanding how expression of this gene is controlled at the molecular level.	WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,660 S EUCLID,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037	Washington University (WUSTL); Washington University (WUSTL); Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R35CA042507] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002428, R01HL043418] Funding Source: NIH RePORTER; NCI NIH HHS [CA42507] Funding Source: Medline; NHLBI NIH HHS [HL43418, HL02428] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLATTI SP, 1988, P NATL ACAD SCI USA, V85, P1119, DOI 10.1073/pnas.85.4.1119; BOUCAUT JC, 1984, J CELL BIOL, V99, P1822, DOI 10.1083/jcb.99.5.1822; BOUCAUT JC, 1984, NATURE, V307, P364, DOI 10.1038/307364a0; BRONNERFRASER M, 1986, DEV BIOL, V117, P528, DOI 10.1016/0012-1606(86)90320-9; BRONNERFRASER M, 1985, J CELL BIOL, V101, P610, DOI 10.1083/jcb.101.2.610; CARDARELLI PM, 1986, P NATL ACAD SCI USA, V83, P2647, DOI 10.1073/pnas.83.8.2647; CARDARELLI PM, 1988, J CELL BIOL, V106, P2183, DOI 10.1083/jcb.106.6.2183; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEAN DC, 1988, J CELL BIOL, V106, P2159, DOI 10.1083/jcb.106.6.2159; DEAN DC, 1987, P NATL ACAD SCI USA, V84, P1876, DOI 10.1073/pnas.84.7.1876; DEAN DC, 1989, MOL CELL BIOL, V9, P1498, DOI 10.1128/MCB.9.4.1498; DEDHAR S, 1989, J CELL PHYSIOL, V138, P291, DOI 10.1002/jcp.1041380210; DEDHAR S, 1987, J CELL BIOL, V105, P1175, DOI 10.1083/jcb.105.3.1175; DUBAND JL, 1986, J CELL BIOL, V102, P160, DOI 10.1083/jcb.102.1.160; GIANCOTTI FG, 1986, J CELL BIOL, V103, P429, DOI 10.1083/jcb.103.2.429; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GRINNELL F, 1984, J CELL BIOCHEM, V26, P107, DOI 10.1002/jcb.240260206; GUBLER U, 1983, GENE, V25, P283; HEIDENREICH R, 1990, BIOCHEMISTRY-US, V29, P1232, DOI 10.1021/bi00457a020; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; LINASK KK, 1988, DEV BIOL, V129, P324, DOI 10.1016/0012-1606(88)90379-X; LINASK KK, 1988, DEV BIOL, V129, P315, DOI 10.1016/0012-1606(88)90378-8; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; NGUYEN VT, 1988, ANAL BIOCHEM, V171, P404, DOI 10.1016/0003-2697(88)90505-2; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PATEL VP, 1986, J CELL BIOL, V102, P449, DOI 10.1083/jcb.102.2.449; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PRANDINI MH, 1988, BIOCHEM BIOPH RES CO, V156, P595, DOI 10.1016/S0006-291X(88)80884-2; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; ROSEN GD, 1991, P NATL ACAD SCI USA, V80, P4094; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; SYMINGTON BE, 1989, J BIOL CHEM, V264, P13258; SYMINGTON BE, 1990, CELL REGUL, V1, P637, DOI 10.1091/mbc.1.9.637; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; VUILLETGAUGLER MH, 1990, BLOOD, V75, P865; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877	58	77	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20544	20549						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1834647				2022-12-25	WOS:A1991GM03900100
J	ALEXANDRE, C; CHARNAY, P; VERRIER, B				ALEXANDRE, C; CHARNAY, P; VERRIER, B			TRANSACTIVATION OF KROX-20 AND KROX-24 PROMOTERS BY THE HTLV-1 TAX PROTEIN THROUGH COMMON REGULATORY ELEMENTS	ONCOGENE			English	Article							CELL LEUKEMIA-VIRUS; SERUM RESPONSE ELEMENT; ZINC-FINGER GENE; LONG TERMINAL REPEAT; RECEPTOR-ALPHA-GENE; NERVE GROWTH-FACTOR; C-FOS PROMOTER; TRANSCRIPTION FACTOR; CDNA CLONES; CYCLIC-AMP	The HTLV-1 Tax protein has been shown to induce the expression of host cellular genes, some of which play crucial roles in cell proliferation and differentiation. We have examined the effect of Tax on the expression of two immediate-early genes, Krox-20 and Krox-24, which encode transcription factors. Several HTLV-1-infected T-cell lines and a HeLa cell line that constitutively expresses the Tax protein have a high level of expression of the Krox-20 and Krox-24 genes. In addition, Tax transactivates the promoters of both Krox-20 and Krox-24 in a co-transfection assay. Tax-responsive elements in Krox-20 and Krox-24 include the serum response elements (SREs) and the putative cAMP-responsive element (CRE). A correlation exists between the ability of these elements to mediate Tax transactivation and their affinity for their cognate factors, the serum response factor (SRF) or the CRE-binding protein (CREB) respectively. Since Tax is also able to transactivate the human c-fos promoter through the SRE and the CRE-60, our findings support the idea that the HTLV-1 Tax protein uses common mechanisms for transactivation of these three immediate-early genes. Deregulation of their expression may contribute to malignant transformation associated with HTLV-1 infection.	ECOLE NORMALE SUPER LYON, CNRS, UNITE MIXTE 103, 46 ALLEE ITALIE, F-69364 Lyon 07, FRANCE; ECOLE NORM SUPER, GENET MOLEC LAB, CNRS D1302, F-75230 PARIS 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)				Charnay, Patrick/0000-0002-3847-6042				ALEXANDRE C, 1991, ONCOGENE, V6, P543; BALLARD D W, 1989, New Biologist, V1, P83; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BEIMLING P, 1990, ONCOGENE, V5, P361; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; GILARDI P, 1991, BIOCHIMIE, V73, P85, DOI 10.1016/0300-9084(91)90079-G; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JANSSENTIMMEN U, 1989, GENE, V80, P325, DOI 10.1016/0378-1119(89)90296-5; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LILIENBAUM A, 1990, J VIROL, V64, P256, DOI 10.1128/JVI.64.1.256-263.1990; LIM RW, 1987, ONCOGENE, V1, P263; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; POTEAT HT, 1989, J VIROL, V63, P1604, DOI 10.1128/JVI.63.4.1604-1611.1989; PRYWES R, 1987, MOL CELL BIOL, V7, P3482, DOI 10.1128/MCB.7.10.3482; RANGNEKAR VM, 1990, NUCLEIC ACIDS RES, V18, P2749, DOI 10.1093/nar/18.9.2749; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; RIVERA V M, 1990, New Biologist, V2, P751; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; RUBEN SM, 1989, NEW BIOL, V3, P275; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHROTER H, 1987, NUCLEIC ACIDS RES, V15, P10145, DOI 10.1093/nar/15.24.10145; SEIKI M, 1985, GANN, V76, P1127; SEYFERT VL, 1989, MOL CELL BIOL, V9, P2083, DOI 10.1128/MCB.9.5.2083; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOSHIDA M, 1989, GENOME, V31, P662, DOI 10.1139/g89-121; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	61	64	64	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1991	6	10					1851	1857						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1833716				2022-12-25	WOS:A1991GX11800018
J	METZ, CN; ZHANG, YY; GUO, Y; TSANG, TC; KOCHAN, JP; ALTSZULER, N; DAVITZ, MA				METZ, CN; ZHANG, YY; GUO, Y; TSANG, TC; KOCHAN, JP; ALTSZULER, N; DAVITZ, MA			PRODUCTION OF THE GLYCOSYLPHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE-D BY THE ISLETS OF LANGERHANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-CELL LINES; HUMAN-SERUM; PHOSPHATIDYLINOSITOL; EXPRESSION; ANCHOR; PURIFICATION; PROTEINS; PANCREAS; PLASMA	A large number of diverse cell surface proteins are anchored to the cell membrane by a glycosylphosphatidylinositol (GPI) anchor. One proposed function for the GPI anchor is that it facilitates the release of the protein from the cell by acting as a target for anchor-specific phospholipases. We and others have discovered that mammalian plasma contains a GPI-specific phospholipase D (GPI-PLD) (Cardoso de Almeida, M. L., Turner, M. J., Stambuk, B. V., and Schenkman S. (1988) Biochem. Biophys. Res. Commun. 150, 476-482; Davitz, M. A., Hereld, D., Shak, S., Krakow, J., Englund, P. T., and Nussenzweig, V. (1987) Science 238, 81-84; Low, M. G., and Prasad, A.R.S. (1988) Proc. Natl. Acad. Sci. U.S.A. 85, 980-984). Because the GPI-PLD recognizes a conserved portion of the anchor, all GPI-anchored proteins are potential substrates for the enzyme. We demonstrate in this communication the production of the plasma GPI-PLD by the islets of Langerhans. GPI-PLD enzymatic activity was found in dog pancreatic microsomes, but not pancreatic juice. Both the pancreatic and plasma enzymes were divalent cation-dependent and had identical substrate specificities. Purified murine islets of Langerhans, as well as alpha and beta-cells, contained and released GPI-PLD activity. A GPI-PLD DNA fragment was amplified by polymerase chain reaction from a normal human islet cDNA library; the amplified fragment hybridized with the GPI-PLD cDNA clone. These findings represent the first demonstration of the production of the plasma GPI-PLD by a specific tissue site as well as cell type.	NYU,SCH MED,DEPT PATHOL,DIV IMMUNOL,550 1ST AVE,NEW YORK,NY 10016; NYU,SCH MED,DEPT CELL BIOL,NEW YORK,NY 10016; NYU,SCH MED,DEPT PHARMACOL,NEW YORK,NY 10016; HOFFMANN LA ROCHE INC,DEPT MOLEC CELLULAR BIOL & BIOCHEM,NUTLEY,NJ 07110	New York University; New York University; New York University; Roche Holding				Christine, Metz/0000-0002-1013-1691				ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAMBRA R, 1990, ENDOCRINOLOGY, V126, P2815, DOI 10.1210/endo-126-6-2815; DAVITZ MA, 1989, J BIOL CHEM, V264, P13760; DAVITZ MA, 1987, SCIENCE, V238, P81, DOI 10.1126/science.2443973; DEALMEIDA MLC, 1988, BIOCHEM BIOPH RES CO, V150, P476; DRUUCKER DJ, 1988, J BIOL CHEM, V263, P13475; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; FRIEDMAN KD, 1989, PCR PROTOCOLS GUIDE, P253; FRIEDMAN SL, 1985, P NATL ACAD SCI USA, V82, P8681, DOI 10.1073/pnas.82.24.8681; GOTOH M, 1985, TRANSPLANTATION, V40, P427; HAMAGUCHI K, 1990, DIABETES, V39, P415, DOI 10.2337/diabetes.39.4.415; HERELD D, 1986, J BIOL CHEM, V261, P3813; HOENER MC, 1990, EUR J BIOCHEM, V190, P593, DOI 10.1111/j.1432-1033.1990.tb15614.x; HUANG KS, 1990, J BIOL CHEM, V265, P17738; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; LEDOUARIN NM, 1988, CELL, V53, P169, DOI 10.1016/0092-8674(88)90375-3; Low M. G., 1990, MOL CELL BIOL MEMBRA, P35; LOW MG, 1988, P NATL ACAD SCI USA, V85, P980, DOI 10.1073/pnas.85.4.980; LOW MG, 1991, IN PRESS BIOCH J; MANIATIS T, 1982, MOL CLONING LABORATO, P150; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MOJSOV S, 1986, J BIOL CHEM, V261, P1880; PERMUTT MA, 1989, P NATL ACAD SCI USA, V86, P8688, DOI 10.1073/pnas.86.22.8688; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; SCALLON BJ, 1991, SCIENCE, V252, P446, DOI 10.1126/science.2017684; SESKO AM, 1991, FASEB J, V5, pA839; UNGER RH, 1981, NEW ENGL J MED, V304, P1575, DOI 10.1056/NEJM198106253042604; UNGER RH, 1985, DIABETOLOGIA, V28, P274; YU YH, 1989, P NATL ACAD SCI USA, V86, P9931, DOI 10.1073/pnas.86.24.9931	32	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17733	17736						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1833386				2022-12-25	WOS:A1991GG55300004
J	TATE, CA; SHIN, G; WALSETH, TF; TAFFET, GE; BICK, RJ; ENTMAN, ML				TATE, CA; SHIN, G; WALSETH, TF; TAFFET, GE; BICK, RJ; ENTMAN, ML			NUCLEOTIDE SPECIFICITY OF CARDIAC SARCOPLASMIC-RETICULUM - INHIBITION OF GTPASE ACTIVITY BY ATP ANALOG IN FLUORESCEIN ISOTHIOCYANATE-MODIFIED CALCIUM ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPHOSPHATE UTILIZATION; BINDING-SITE; HYDROLYSIS CYCLE; CA-2+-ATPASE; PROTEIN; NA+,K+-ATPASE; TRANSLOCATION; PURIFICATION; SARCOLEMMA; MEMBRANES	Unlike skeletal muscle sarcoplasmic reticulum, canine cardiac sarcoplasmic reticulum hydrolyzes GTP in ways that are similar and different from ATP hydrolysis. Also, ATP and ATP analogues inhibit GTPase activity noncompetitively with a K(i) compatible with the high affinity ATP-binding site (c.f Tate, C. A., Bick, R. J., Blaylock, S., Youker, K., Scherer, N. M., and Entman, M. L. (1989) J. Biol. Chem. 264, 7809-7813). This suggested that ATP and GTP may enter the reaction pathway at separate nucleotide-binding sites on the CaATPase. To test this hypothesis, cardiac sarcoplasmic reticulum was incorporated with fluorescein isothiocyanate (FITC), which apparently binds at or near the ATP-binding site of the enzyme, preventing ATP binding. After FITC incorporation, calcium-dependent ATPase activity, but not GTPase activity, was completely inhibited. Adenyl-5'-yl imidodiphosphate (AMP-P(NH)P, but not guanyl-5'-yl imidodiphosphate, protected against FITC incorporation and the inhibition of calcium-dependent ATPase activity; at least 100-mu-M AMP-P(NH)P was required for some protection. Despite FITC incorporation, AMP-P(NH)P still inhibited the GTPase activity with a K(i) of 3-7-mu-M. Direct photo-affinity labeling with either 0.2-mu-M [alpha-P-32]ATP or 0.2-mu-M [alpha-P-32]GTP demonstrated that FITC incorporation did not prevent ATP or GTP binding. The mechanism of FITC inhibition of calcium-dependent ATPase activity was related to the prevention of all calcium-dependent, but not calcium-independent, reactions with both nucleotides.	UNIV HOUSTON, DEPT PHARMACOL, HOUSTON, TX 77204 USA; UNIV MINNESOTA, DEPT PHARMACOL, MINNEAPOLIS, MN 55455 USA	University of Houston System; University of Houston; University of Minnesota System; University of Minnesota Twin Cities	TATE, CA (corresponding author), METHODIST HOSP, BAYLOR COLL MED, DEPT MED, CARDIOVASC SCI SECT, HOUSTON, TX 77030 USA.		Walseth, Timothy F/F-9518-2010	Walseth, Timothy F/0000-0003-2558-7859	NHLBI NIH HHS [HL13870] Funding Source: Medline; NIA NIH HHS [AG00428, AG06221] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL013870, R37HL013870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006221] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BALL WJ, 1987, BIOCHEM BIOPH RES CO, V148, P246, DOI 10.1016/0006-291X(87)91102-8; BESCH HR, 1976, CIRC RES, V39, P586, DOI 10.1161/01.RES.39.4.586; BICK RJ, 1983, J BIOL CHEM, V258, P4447; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1197; CARVALHOALVES PC, 1987, J BIOL CHEM, V262, P6610; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; COLL RJ, 1991, BIOCHEMISTRY-US, V30, P1456, DOI 10.1021/bi00220a002; DAVIS RL, 1988, BIOCHIM BIOPHYS ACTA, V953, P26, DOI 10.1016/0167-4838(88)90006-4; DUNBAR BS, 1990, METHOD ENZYMOL, V182, P441; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; ENTMAN ML, 1986, J MOL CELL CARDIOL, V18, P781, DOI 10.1016/S0022-2828(86)80953-1; FROEHLICH JP, 1976, J BIOL CHEM, V251, P2307; HAMILTON SL, 1991, CELL CALCIUM PRACTIC; HIGHSMITH S, 1984, BIOCHEM BIOPH RES CO, V124, P183, DOI 10.1016/0006-291X(84)90934-3; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; KIRLEY TL, 1985, BIOCHEM BIOPH RES CO, V130, P732, DOI 10.1016/0006-291X(85)90477-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; MURPHY AJ, 1988, BIOCHIM BIOPHYS ACTA, V946, P57, DOI 10.1016/0005-2736(88)90457-9; OGURUSU T, 1989, J BIOCHEM-TOKYO, V106, P599, DOI 10.1093/oxfordjournals.jbchem.a122902; PANG DC, 1977, J BIOL CHEM, V252, P3262; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; PICK U, 1981, EUR J BIOCHEM, V121, P187, DOI 10.1111/j.1432-1033.1981.tb06448.x; SCHERER NM, 1987, ARCH BIOCHEM BIOPHYS, V259, P431, DOI 10.1016/0003-9861(87)90509-1; Singer T P, 1974, Methods Biochem Anal, V22, P123, DOI 10.1002/9780470110423.ch3; SWOBODA G, 1985, Z NATURFORSCH C, V40, P863; TATE CA, 1985, J BIOL CHEM, V260, P9618; TATE CA, 1989, J BIOL CHEM, V264, P7809; VANWINKLE WB, 1981, J BIOL CHEM, V256, P2268	30	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16165	16170						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1831455				2022-12-25	WOS:A1991GB97700095
J	KACINSKI, BM; SCATA, KA; CARTER, D; YEE, LD; SAPI, E; KING, BL; CHAMBERS, SK; JONES, MA; PIRRO, MH; STANLEY, ER; ROHRSCHNEIDER, LR				KACINSKI, BM; SCATA, KA; CARTER, D; YEE, LD; SAPI, E; KING, BL; CHAMBERS, SK; JONES, MA; PIRRO, MH; STANLEY, ER; ROHRSCHNEIDER, LR			FMS (CSF-1 RECEPTOR) AND CSF-1 TRANSCRIPTS AND PROTEIN ARE EXPRESSED BY HUMAN BREAST CARCINOMAS INVIVO AND INVITRO	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; CHORIOCARCINOMA CELL-LINES; FACTOR-I RECEPTOR; GROWTH-FACTOR; MESSENGER-RNA; OVARIAN ADENOCARCINOMAS; PLACENTAL DEVELOPMENT; INSITU HYBRIDIZATION; GENE-EXPRESSION; MAMMARY-GLAND	The expression in vivo of FMS transcripts and antigen by neoplastic epithelial cells was demonstrated immunohistochemically or by in situ hybridization in sixteen of seventeen human breast carcinoma specimens and one case of sclerosing adenosis. Expression of CSF-1 receptor (FMS) transcripts and protein was also observed in vitro in two or three breast carcinoma-derived cell lines and was dramatically increased by dexamethasone, a potent glucocorticoid and inducer of mammary epithelial cell differentiation. Immunohistochemical staining with an anti-CSF-1 antibody identified neoplastic epithelial cell co-expression of fms and CSF-1 antigens in more than one-third of the fms-positive invasive carcinoma specimens. These results suggest that autocrine and paracrine interactions of the lymphohematopoietic cytokine CSF-1 and its receptor may participate in the biology of human mammary neoplasms.	YALE UNIV,SCH MED,DEPT OBSTET & GYNECOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV BIOL & CANC,BRONX,NY 10461; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Yale University; Yale University; Yeshiva University; Albert Einstein College of Medicine; Fred Hutchinson Cancer Center	KACINSKI, BM (corresponding author), YALE UNIV,SCH MED,DEPT THERAPEUT RADIOL,333 CEDAR ST,NEW HAVEN,CT 06510, USA.				NCI NIH HHS [CA-26504, CA-47292, CA-08341] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA026504, R29CA047292, P01CA008341, R01CA047292, R01CA026504] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCECI RJ, 1989, P NATL ACAD SCI USA, V86, P8818, DOI 10.1073/pnas.86.22.8818; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; BOLIVAR F, 1977, GENE, V26, P197; BROWNING PJ, 1986, P NATL ACAD SCI USA, V83, P7800, DOI 10.1073/pnas.83.20.7800; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DEDHAR S, 1988, P NATL ACAD SCI USA, V85, P9253, DOI 10.1073/pnas.85.23.9253; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DISORBO D, 1977, ANN NY ACAD SCI, V286, P355, DOI 10.1111/j.1749-6632.1977.tb29429.x; DOWNING JR, 1988, MOL CELL BIOL, V8, P1795, DOI 10.1128/MCB.8.4.1795; FELDMAN M, 1988, SCI AM           NOV, P60; GODARD CM, 1983, HISTOCHEMISTRY, V77, P123, DOI 10.1007/BF00496643; HORIGUCHI J, 1988, BIOCHEM BIOPH RES CO, V157, P395, DOI 10.1016/S0006-291X(88)80060-3; HORWITZ KB, 1978, CANCER RES, V38, P2434; HUHN RD, 1989, J CELL BIOCHEM, V39, P129, DOI 10.1002/jcb.240390205; KACINSKI B M, 1989, Cancer Bulletin (Houston), V41, P44; KACINSKI BM, 1989, INT J RADIAT ONCOL, V17, P159, DOI 10.1016/0360-3016(89)90383-0; KACINSKI BM, 1990, PROG LEUC B, V10, P393; KACINSKI BM, 1989, YALE J BIOL MED, V62, P379; KACINSKI BM, 1990, INT J RADIAT ONCOL, V19, P619, DOI 10.1016/0360-3016(90)90488-6; KACINSKI BM, 1988, INT J RADIAT ONCOL, V15, P823, DOI 10.1016/0360-3016(88)90113-7; KACINSKI BM, 1989, CANCER CEL, V7, P333; KACINSKI BM, 1990, AM J PATHOL, V137, P135; KAMPS MP, 1988, ONCOGENE, V2, P305; KASID A, 1987, J STEROID BIOCHEM, V27, P465, DOI 10.1016/0022-4731(87)90341-4; KASUKABE T, 1977, GANN, V68, P765; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; LAWRENCE JB, 1985, NUCLEIC ACIDS RES, V13, P1777; MANIATIS T, 1982, MOL CLONING LABORATO, P75; MCDIVITT RW, 1968, ATLAS TUMOR PATHOLOG; MELAMED MR, 1961, CANCER, V14, P699, DOI 10.1002/1097-0142(199007/08)14:4<699::AID-CNCR2820140404>3.0.CO;2-3; MUELLER R, MOL CELL BIOL, V3, P1062; PATTILLO RA, 1968, CANCER RES, V28, P1231; PETERS GN, 1981, ANN SURG, V193, P138, DOI 10.1097/00000658-198102000-00003; POLLARD JW, 1987, NATURE, V330, P484, DOI 10.1038/330484a0; QUIRK SJ, 1990, J STEROID BIOCHEM, V35, P623, DOI 10.1016/0022-4731(90)90208-A; QUIRK SJ, 1989, MOL CELL ENDOCRINOL, V66, P135, DOI 10.1016/0303-7207(89)90025-7; RAJAVASHISTH TB, 1987, P NATL ACAD SCI USA, V84, P1157, DOI 10.1073/pnas.84.5.1157; RAMAKRISHNAN S, 1989, J CLIN INVEST, V83, P921, DOI 10.1172/JCI113977; REGENSTREIF LJ, 1989, DEV BIOL, V133, P284, DOI 10.1016/0012-1606(89)90319-9; RETTENMIER CW, 1986, J CLIN INVEST, V77, P1740, DOI 10.1172/JCI112496; ROHRSCHNEIDER LR, 1989, ONCOGENE, V4, P1015; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SAITO M, 1989, AM J REPROD IMMUNOL, V19, P114, DOI 10.1111/j.1600-0897.1989.tb00558.x; SCHAISON G, 1989, ANN ENDOCRINOL-PARIS, V50, P200; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; STANLEY ER, 1985, METHOD ENZYMOL, V116, P564; STANLEY ER, 1986, CIBA F SYMP, V118, P29, DOI 10.1002/9780470720998.ch3; STUART SG, 1989, EMBO J, V8, P3657, DOI 10.1002/j.1460-2075.1989.tb08540.x; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TANG RP, 1990, J CELL BIOCHEM, V44, P189, DOI 10.1002/jcb.240440307; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; TAYLOR HB, 1967, CANCER, V20, P2245, DOI 10.1002/1097-0142(196712)20:12<2245::AID-CNCR2820201227>3.0.CO;2-0; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VARLEY JM, 1987, ONCOGENE, V1, P423; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; WALKER C, 1987, P NATL ACAD SCI USA, V84, P1804, DOI 10.1073/pnas.84.7.1804; WHITTAKER JL, 1986, INT J CANCER, V38, P651, DOI 10.1002/ijc.2910380506; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; WOOLFORD J, 1985, MOL CELL BIOL, V5, P458; [No title captured]	67	138	140	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					941	952						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1829808				2022-12-25	WOS:A1991GU62200008
J	BOWMAN, S; ACKERMAN, SH; GRIFFITHS, DE; TZAGOLOFF, A				BOWMAN, S; ACKERMAN, SH; GRIFFITHS, DE; TZAGOLOFF, A			CHARACTERIZATION OF ATP12, A YEAST NUCLEAR GENE REQUIRED FOR THE ASSEMBLY OF THE MITOCHONDRIAL F1-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE SYSTEM; SACCHAROMYCES-CEREVISIAE; SEQUENCE-ANALYSIS; ESCHERICHIA-COLI; STRUCTURAL GENE; ATPASE COMPLEX; PROTEIN IMPORT; TRANSLOCATION; PRECURSOR; SUBUNIT	Mitochondrial F1-ATPase is an oligomeric enzyme composed of five distinct subunit polypeptides. The alpha and beta-subunits make up the bulk of protein mass of F1. In Saccharomyces cerevisiae both subunits are synthesized as precursors with amino-terminal targeting signals that are removed upon translocation of the proteins to the matrix compartment. Recently, two different complementation groups (G13, G57), consisting of yeast nuclear mutants with defective F1, have been described. Biochemical analyses indicate that the mutational block in both groups of mutants affects a critical step needed for the assembly of the alpha and beta-subunits into the F1 oligomer after their transport into mitochondria. In this study the ATP12 gene representative of the nuclear respiratory-deficient mutant of S. cerevisiae (pet) complementation group G57 has been cloned and the encoded product partially characterized. The ATP 12 reading frame is 975 base pairs long and codes for a protein of M(r) = 36,587. The ATP 12 protein is not homologous to the subunits of F1 whose sequences are known, nor does it exhibit significant primary structure similarity to any known protein. In vitro import assays indicate that ATP 12 protein is synthesized as a precursor approximately 3 kDa larger than the mature protein. The mitochondrial localization of the protein has been confirmed by Western blot analysis of mitochondrial proteins with an antibody against a hybrid protein expressed from a trpE-ATP 12 fusion. Fractionation of mitochondria indicates further that the ATP 12 protein is either a minor component of the matrix compartment or is weakly bound to the matrix side of the inner membrane. The molecular weight of the native protein, estimated from its sedimentation properties in sucrose gradients, is at least two times larger than the monomer. This suggests that the ATP 12 protein is probably part of a larger complex.	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University	BOWMAN, S (corresponding author), UNIV WARWICK, DEPT CHEM, COVENTRY CV4 7AL, W MIDLANDS, ENGLAND.				NHLBI NIH HHS [R01 HL022174, HL22174] Funding Source: Medline; NIGMS NIH HHS [GM12435] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022174, R01HL022174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM012435] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BOTSTEIN D, 1982, MOL BIOL YEAST SACCH, P607; BOWMAN S, 1989, THESIS U WARWICK COV, P68; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CRAIG EA, 1989, MOL CELL BIOL, V9, P3000, DOI 10.1128/MCB.9.7.3000; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HENSGENS LAM, 1979, P NATL ACAD SCI USA, V76, P1663, DOI 10.1073/pnas.76.4.1663; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Hill RL, 1969, METHOD ENZYMOL, V8, P91, DOI 10.1016/0076-6879(69)13021-9; King EJ, 1932, BIOCHEM J, V26, P292, DOI 10.1042/bj0260292; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MS, 1988, NUCLEIC ACIDS RES, V16, P8181, DOI 10.1093/nar/16.16.8181; LEWIN AS, 1980, P NATL ACAD SCI-BIOL, V77, P3998, DOI 10.1073/pnas.77.7.3998; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACCECCHINI ML, 1979, P NATL ACAD SCI USA, V76, P343, DOI 10.1073/pnas.76.1.343; MACINO G, 1980, CELL, V20, P507, DOI 10.1016/0092-8674(80)90637-6; MACREADIE IG, 1983, NUCLEIC ACIDS RES, V11, P4435, DOI 10.1093/nar/11.13.4435; Maniatis T., 1982, MOL CLONING; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; Reed L.J., 1966, METHOD ENZYMOL, V9, P247; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHATZ G, 1968, J BIOL CHEM, V243, P2192; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; TAKEDA M, 1985, J BIOL CHEM, V260, P5458; TAKEDA M, 1986, J BIOL CHEM, V261, P5126; ten Berge A M, 1974, Mol Gen Genet, V131, P113; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; VELOURS J, 1988, EUR J BIOCHEM, V170, P637, DOI 10.1111/j.1432-1033.1988.tb13745.x; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819	47	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7517	7523						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1826907				2022-12-25	WOS:A1991FJ34200033
J	HIBINO, Y; MARIANO, TM; KUMAR, CS; KOZAK, CA; PESTKA, S				HIBINO, Y; MARIANO, TM; KUMAR, CS; KOZAK, CA; PESTKA, S			EXPRESSION AND RECONSTITUTION OF A BIOLOGICALLY-ACTIVE MOUSE INTERFERON-GAMMA-RECEPTOR IN HAMSTER-CELLS - CHROMOSOMAL LOCATION OF AN ACCESSORY FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-INDUCING LOCUS; PROTEIN KINASE-C; IMMUNE INTERFERON; GENE; RECOMBINANT; LINKAGE; SYSTEM; CDNA; SENSITIVITY; BINDING	In order to localize the chromosome encoding the accessory factor required for function of the murine interferon-gamma (IFN-gamma) receptor, we transfected a cDNA expression vector encoding the receptor into several Chinese hamster x mouse somatic cell hydrids. As mouse Chromosome 10 carries the gene which encodes the interferon gamma-receptor (Ifgr), we used somatic cell hybrids that lack this chromosome. The presence of mouse Chromosome 16 was required to generate a response to murine IFN-gamma as assayed by stimulation of class I major histocompatibility complex antigen expression. These results demonstrate a species-specific accessory factor encoded on mouse Chromosome 16 (termed Ifgt) is necessary for mouse IFN-gamma to stimulate major histocompatibility complex expression through its receptor.	NIAID,MOLEC MICROBIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	HIBINO, Y (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MOLEC GENET & MICROBIOL,PISCATAWAY,NJ 08854, USA.		Kumar, Dr Suresh/HHZ-2615-2022; chitta, suresh kumar/N-1569-2016; KUMAR, P. SURESH/AAT-8951-2020	Kumar, Dr Suresh/0000-0002-2539-6553; KUMAR, P. SURESH/0000-0003-3222-2604	NCI NIH HHS [CA-46465] Funding Source: Medline; NIAID NIH HHS [AI-25914] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025914] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHEN CA, 1988, BIOTECHNIQUES, V6, P632; COFANO F, 1990, J BIOL CHEM, V265, P4064; ERUSALIMSKY JD, 1989, P NATL ACAD SCI USA, V86, P1973, DOI 10.1073/pnas.86.6.1973; FAN XD, 1988, P NATL ACAD SCI USA, V85, P5122, DOI 10.1073/pnas.85.14.5122; FIELDS R, 1988, J INTERFERON RES, V8, P549, DOI 10.1089/jir.1988.8.549; FRIEDMAN RM, 1983, ADV IMMUNOL, V34, P97, DOI 10.1016/S0065-2776(08)60378-8; GARIGLIO M, 1988, J INTERFERON RES, V8, P463, DOI 10.1089/jir.1988.8.463; GRAY PW, 1989, P NATL ACAD SCI USA, V86, P8497, DOI 10.1073/pnas.86.21.8497; GRESSER I, 1970, P NATL ACAD SCI USA, V66, P1052, DOI 10.1073/pnas.66.4.1052; HAMILTON TA, 1985, J BIOL CHEM, V260, P1378; HEMMI S, 1989, P NATL ACAD SCI USA, V86, P9901, DOI 10.1073/pnas.86.24.9901; HERSHEY GKK, 1989, J BIOL CHEM, V264, P11981; HOGGAN MD, 1986, J VIROL, V60, P980, DOI 10.1128/JVI.60.3.980-986.1986; JUNG V, 1988, SOMAT CELL MOLEC GEN, V14, P583, DOI 10.1007/BF01535312; JUNG V, 1990, J BIOL CHEM, V265, P1827; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; Klein J, 1978, Adv Immunol, V26, P55, DOI 10.1016/S0065-2776(08)60229-1; KNIGHT E, 1976, NATURE, V262, P302, DOI 10.1038/262302a0; KORBER B, 1987, P NATL ACAD SCI USA, V84, P3380, DOI 10.1073/pnas.84.10.3380; KOZAK C, 1975, SOMAT CELL GENET, V1, P371, DOI 10.1007/BF01538668; KOZAK CA, 1979, SCIENCE, V204, P69, DOI 10.1126/science.219475; KOZAK CA, 1990, GENOMICS, V8, P519, DOI 10.1016/0888-7543(90)90039-W; KOZAK CA, 1980, J EXP MED, V152, P1419, DOI 10.1084/jem.152.5.1419; KUMAR CS, 1988, J BIOL CHEM, V263, P13493; KUMAR CS, 1989, J BIOL CHEM, V264, P17939; KUNG HF, 1986, METHOD ENZYMOL, V119, P296; LANGER JA, 1990, SOMAT CELL MOLEC GEN, V16, P231, DOI 10.1007/BF01233359; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LANGER JA, 1986, METHOD ENZYMOL, V119, P248; MARIANO TM, 1987, J BIOL CHEM, V262, P5812; MUNRO S, 1989, P NATL ACAD SCI USA, V86, P9249; NADEAU JH, 1989, TRENDS GENET, V5, P82, DOI 10.1016/0168-9525(89)90031-0; NAGATA Y, 1984, J CELL BIOL, V98, P1342, DOI 10.1083/jcb.98.4.1342; OPDENAKKER G, 1989, EXPERIENTIA, V45, P513, DOI 10.1007/BF01990500; OZATO K, 1985, P NATL ACAD SCI USA, V82, P2427, DOI 10.1073/pnas.82.8.2427; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PERUSSIA B, 1983, J EXP MED, V158, P1092, DOI 10.1084/jem.158.4.1092; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PRPIC V, 1989, SCIENCE, V244, P469, DOI 10.1126/science.2541500; RASHIDBAIGI A, 1986, P NATL ACAD SCI USA, V83, P384, DOI 10.1073/pnas.83.2.384; RASHIDBAIGI A, 1985, J BIOL CHEM, V260, P8514; REHBERG E, 1982, J BIOL CHEM, V257, P1497; SCHNECK J, 1982, P NATL ACAD SCI-BIOL, V79, P1879, DOI 10.1073/pnas.79.6.1879; SMITH LL, 1988, J BIOL CHEM, V263, P7359; TAN YH, 1973, J EXP MED, V137, P317, DOI 10.1084/jem.137.2.317; VILCEK J, 1985, LYMPHOKINES, V11, P1; VILCEK J, 1984, INTERFERON IMMUNE SY	47	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6948	6951						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1826681				2022-12-25	WOS:A1991FG72700050
J	DOBROWOLSKI, Z; XU, GQ; HITCHCOCKDEGREGORI, SE				DOBROWOLSKI, Z; XU, GQ; HITCHCOCKDEGREGORI, SE			MODIFIED CALCIUM-DEPENDENT REGULATORY FUNCTION OF TROPONIN-C CENTRAL HELIX MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; PROTON MAGNETIC-RESONANCE; SITE-SPECIFIC MUTAGENESIS; AMINO-ACID-SEQUENCE; FLUORESCENCE STOPPED-FLOW; X-RAY-SCATTERING; CA2+ BINDING; PROTEOLYTIC FRAGMENTS; DIRECTED MUTAGENESIS; LYSINE REACTIVITIES	Mutations have been made in the exposed region of the avian troponin C central helix, the D/E linker, which change its length and the orientation of the Ca2+-binding domains relative to each other. The region 87Glu-Asp-Ala-Lys-Gly-Lys-Ser-Glu-Glu-Glu97 has been altered in five deletion (d) mutants: dEDA, dKG, dKGK, dSEEE, and dKEDAKGK. The recombinant troponin Cs were expressed in Escherichia coli, purified, and assayed for function. All mutants retained basic troponin C function. They all bound Ca2+ to the low and high affinity sites, and they all were able to confer Ca2+ sensitivity on the regulated actomyosin ATPase. However, the regulatory function of all mutants except dSEEE was defective in one part of the Ca2+ switch or the other. In certain conditions dKGK and dKEDAKGK failed to inhibit fully whereas dEDA and dKG failed to activate the regulated actomyosin ATPase fully. The following general conclusions have been made. (a) The length of the D/E linker per se (assuming the linker is helical) and the orientation of the two Ca2+-binding domains relative to each other are not crucial for regulation. (b) The conserved charge cluster 95Glu-Glu-Glu97, in a region of troponin C known to bind to troponin I and postulated to be required for regulation, appears to be unimportant for function. (c) Deletion of 88Glu-Asp-Ala90 resulted in a troponin C that could not activate the actomyosin (or S1) ATPase over the level of actomyosin alone, thus defining a role for troponin C in this aspect of thin filament regulation. The results have been interpreted in terms of the crystallographic structure of troponin C and related to results with analogous calmodulin mutants.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT NEUROSCI & CELL BIOL,675 HOES LA,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center					NIGMS NIH HHS [GM 36326] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036326] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABU A, 1988, J BIOL CHEM, V263, P15485; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BERGER SL, 1987, METHOD ENZYMOL, V152, P1; BRANDT PW, 1987, J MOL BIOL, V195, P885, DOI 10.1016/0022-2836(87)90492-X; BREMEL RD, 1972, NATURE-NEW BIOL, V238, P97, DOI 10.1038/newbio238097a0; CAREW EB, 1980, BIOPHYS J, V30, P351, DOI 10.1016/S0006-3495(80)85099-5; Cherry R J, 1978, Methods Enzymol, V54, P47; CHEUNG HC, 1982, BIOCHEMISTRY-US, V21, P5135, DOI 10.1021/bi00264a005; COLLINS JH, 1977, J BIOL CHEM, V252, P6356; CRAIG TA, 1987, J BIOL CHEM, V262, P3278; DALGARNO DC, 1982, FEBS LETT, V150, P54, DOI 10.1016/0014-5793(82)81303-3; DOBROVOLSKY AB, 1984, BIOCHIM BIOPHYS ACTA, V789, P144, DOI 10.1016/0167-4838(84)90198-5; DOBROWOLSKI Z, 1990, BIOPHYS J, V57, P144; DOBROWOLSKI Z, 1988, BIOPHYS J, V53, P587; DOBROWOLSKI Z, 1989, BIOPHYS J, V55, P274; FUJIMORI K, 1990, NATURE, V345, P182, DOI 10.1038/345182a0; FUJISAWA T, 1987, J APPL CRYSTALLOGR, V20, P349, DOI 10.1107/S0021889887086497; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GRABAREK Z, 1990, NATURE, V345, P132, DOI 10.1038/345132a0; GRABAREK Z, 1986, J BIOL CHEM, V261, P608; HARTSHOR.DJ, 1968, BIOCHEM BIOPH RES CO, V31, P647, DOI 10.1016/0006-291X(68)90610-4; HEAD JF, 1974, BIOCHEM J, V137, P145, DOI 10.1042/bj1370145; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HITCHCOCK SE, 1981, J MOL BIOL, V147, P153, DOI 10.1016/0022-2836(81)90083-8; HITCHCOCKDEGREGORI SE, 1982, J BIOL CHEM, V257, P2573; HITCHCOCKDEGREGORI SE, 1985, BIOCHEMISTRY-US, V24, P3305, DOI 10.1021/bi00334a035; HUBBARD SR, 1988, J BIOL CHEM, V263, P4151; IIO T, 1981, J BIOCHEM-TOKYO, V90, P163, DOI 10.1093/oxfordjournals.jbchem.a133446; ITZHAKI RF, 1964, ANAL BIOCHEM, V9, P401, DOI 10.1016/0003-2697(64)90200-3; JOHNSON BF, 1977, GENET RES, V30, P273, DOI 10.1017/S0016672300017687; JOHNSON JD, 1979, J BIOL CHEM, V254, P3497; JOHNSON JD, 1978, J BIOL CHEM, V253, P6451; KAREVA VV, 1986, BIOCHIM BIOPHYS ACTA, V869, P322, DOI 10.1016/0167-4838(86)90072-5; KOHN MC, 1979, COMPUT BIOMED RES, V12, P461, DOI 10.1016/0010-4809(79)90032-6; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7042, DOI 10.1021/bi00396a028; LESZYK J, 1988, BIOCHEMISTRY-US, V27, P6983, DOI 10.1021/bi00418a047; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; LEVINE BA, 1977, J MOL BIOL, V115, P743, DOI 10.1016/0022-2836(77)90113-9; LEVINE BA, 1978, BIOCHIM BIOPHYS ACTA, V535, P11, DOI 10.1016/0005-2795(78)90028-4; Maniatis T., 1982, MOL CLONING; MARGOSSIAN SS, 1982, J BIOL CHEM, V257, P1160; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; PERESCHINI A, 1988, J BIOL CHEM, V263, P12175; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; POTTER JD, 1975, J BIOL CHEM, V250, P4628; POTTER JD, 1976, J BIOL CHEM, V251, P7551; REID RE, 1985, J THEOR BIOL, V114, P353, DOI 10.1016/S0022-5193(85)80171-5; REINACH FC, 1988, J BIOL CHEM, V263, P2371; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SEAMON KB, 1977, BIOCHEMISTRY-US, V16, P4039, DOI 10.1021/bi00637a016; SHENG Z, 1991, J BIOL CHEM, V266, P5711; SILLEN LG, 1964, SPEC PUBL CHEM SOC, V17; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; SUNDARALINGAM M, 1985, P NATL ACAD SCI USA, V82, P7944, DOI 10.1073/pnas.82.23.7944; TAKAGI T, 1983, J BIOCHEM-TOKYO, V94, P1753, DOI 10.1093/oxfordjournals.jbchem.a134526; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALSH MP, 1984, BIOCHEM J, V224, P117, DOI 10.1042/bj2240117; WANG CK, 1985, BIOPHYS J, V48, P727, DOI 10.1016/S0006-3495(85)83831-5; WANG CK, 1986, J MOL BIOL, V191, P509, DOI 10.1016/0022-2836(86)90145-2; WANG CLA, 1986, EUR J BIOCHEM, V154, P225, DOI 10.1111/j.1432-1033.1986.tb09383.x; WANG CLA, 1983, J BIOL CHEM, V258, P9175; WANG CLA, 1987, J BIOL CHEM, V262, P9636; WANG ZY, 1990, J BIOL CHEM, V265, P4953; WEBER A, 1973, PHYSIOL REV, V53, P612, DOI 10.1152/physrev.1973.53.3.612; WEBER PC, 1989, PROTEINS, V6, P70, DOI 10.1002/prot.340060107; WEEKS RA, 1978, BIOCHEM J, V173, P449, DOI 10.1042/bj1730449; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; WILKINSON JM, 1976, FEBS LETT, V70, P254, DOI 10.1016/0014-5793(76)80769-7; WU R, 1987, METHOD ENZYMOL, V154, P1; WU R, 1983, METHOD ENZYMOL, V100, P1; WU R, 1983, METHOD ENZYMOL, V101, P1; XU GQ, 1988, J BIOL CHEM, V263, P13962; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	87	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5703	5710						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1826002				2022-12-25	WOS:A1991FD37000054
J	IDA, K; NOUMI, T; MAEDA, M; FUKUI, T; FUTAI, M				IDA, K; NOUMI, T; MAEDA, M; FUKUI, T; FUTAI, M			CATALYTIC SITE OF F1-ATPASE OF ESCHERICHIA-COLI - LYS-155 AND LYS-201 OF THE BETA-SUBUNIT ARE LOCATED NEAR THE GAMMA-PHOSPHATE GROUP OF ATP IN THE PRESENCE OF MG2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART MITOCHONDRIAL F1-ATPASE; PROTON-TRANSLOCATING ATPASE; AMINO-ACID RESIDUES; H+-ATPASE; ALPHA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; OXIDATIVE-PHOSPHORYLATION; EPSILON-SUBUNIT; BINDING-SITES; IDENTIFICATION	The catalytic site of Escherichia coli F1 was probed using a reactive ATP analogue, adenosine triphospho-pyridoxal (AP3-PL). For complete loss of enzyme activity, about 1 mol of AP3-PL bound to 1 mol of F1 was estimated to be required in the presence or absence of Mg2+. About 70% of the label was bound to the alpha-subunit and the rest to the beta-subunit in the absence of Mg2+, and the alpha-Lys-201 and beta-Lys-155 residues, respectively, were the major target residues (Tagaya, M., Noumi, T., Nakano, K., Futai, M., and Fukui, T. (1988) FEBS Lett. 233, 347-351). Addition of Mg2+ decreased the AP3-PL concentration required for half-maximal inhibition, and predominant labeling of the beta-subunit (beta-Lys-155 and beta-Lys-201) with the reagent. ATP and ADP were protective ligands in the presence and absence of Mg2+. The alpha-subunit mutation (alpha-Lys-201 --> Gln or alpha-Lys-201 deletion) were active in oxidative phosphorylation. However, purified mutant F1s showed impaired low multi-site activity, although their uni-site catalyses were essentially normal. Thus alpha-Lys-201 is not a catalytic residue, but may be important for catalytic cooperativity. Mutant F1s were inhibited less by AP3-PL in the absence of Mg2+, and consistent with this, modifications of their alpha-subunits by AP3-PL were reduced. AP3-PL was more inhibitory to the mutant enzymes in the presence of Mg2+, and bound to the beta-Lys-155 and beta-Lys-201 residues of mutant F1 (alpha-Lys-201 --> Gln). These results strongly suggest that alpha-Lys-201, beta-Lys-155, and beta-Lys-201 are located close together near the gamma-phosphate group of ATP bound to the catalytic site, and that the two beta-residues and the gamma-phosphate group become closer to each other in the presence of Mg2+.			IDA, K (corresponding author), OSAKA UNIV,INST SCI & IND RES,DEPT ORGAN CHEM & BIOCHEM,IBARAKI,OSAKA 567,JAPAN.							ADMON A, 1987, BIOCHEMISTRY-US, V26, P3193, DOI 10.1021/bi00385a038; ANDREWS WW, 1984, J BIOL CHEM, V259, P8219; ANDREWS WW, 1984, J BIOL CHEM, V259, P4378; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOUGH DA, 1986, J BIOL CHEM, V261, P14171; EYA S, 1988, J BIOL CHEM, V263, P10056; FUTAI M, 1983, MICROBIOL REV, V47, P285, DOI 10.1128/MMBR.47.3.285-312.1983; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; GARBOCZI DN, 1988, J BIOL CHEM, V263, P812; GARIN J, 1989, BIOCHEMISTRY-US, V28, P1442, DOI 10.1021/bi00430a003; GARIN J, 1986, BIOCHEMISTRY-US, V25, P4431, DOI 10.1021/bi00363a039; HANADA H, 1989, FEBS LETT, V257, P465, DOI 10.1016/0014-5793(89)81597-2; HOLLEMANS M, 1983, J BIOL CHEM, V258, P9307; HSU SY, 1987, FEBS LETT, V218, P222, DOI 10.1016/0014-5793(87)81050-5; KANAZAWA H, 1980, J BIOCHEM-TOKYO, V88, P695, DOI 10.1093/oxfordjournals.jbchem.a133022; KANAZAWA H, 1982, ANN NY ACAD SCI, V402, P45, DOI 10.1111/j.1749-6632.1982.tb25731.x; KANAZAWA H, 1980, P NATL ACAD SCI-BIOL, V77, P7005, DOI 10.1073/pnas.77.12.7005; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KUKI M, 1988, J BIOL CHEM, V263, P17437; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MICHEL L, 1989, BIOCHEMISTRY-US, V28, P10022, DOI 10.1021/bi00452a021; NOUMI T, 1987, J BIOL CHEM, V262, P7686; NOUMI T, 1984, J BIOL CHEM, V259, P76; NOUMI T, 1986, J BIOL CHEM, V261, P9196; NOUMI T, 1984, J BIOL CHEM, V259, P71; PARSONAGE D, 1987, J BIOL CHEM, V262, P6301; RAIBAUD O, 1974, FEBS LETT, V40, P41, DOI 10.1016/0014-5793(74)80889-6; RAO R, 1988, J BIOL CHEM, V263, P5640; SACHSENHEIMER W, 1977, J MOL BIOL, V114, P23, DOI 10.1016/0022-2836(77)90280-7; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHAFER HJ, 1989, FEBS LETT, V253, P264, DOI 10.1016/0014-5793(89)80972-X; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; TAGAYA M, 1986, BIOCHEMISTRY-US, V25, P2958, DOI 10.1021/bi00358a034; TAGAYA M, 1988, FEBS LETT, V233, P347, DOI 10.1016/0014-5793(88)80457-5; TAKEYAMA M, 1990, J BIOL CHEM, V265, P21279; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WILLIAMS N, 1982, J BIOL CHEM, V257, P2834; YOSHIDA M, 1981, J BIOL CHEM, V256, P148; YOSHIDA M, 1982, J BIOL CHEM, V257, P33	43	50	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5424	5429						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1825998				2022-12-25	WOS:A1991FD37000014
J	SHAPIRO, AB; HUBER, AH; MCCARTY, RE				SHAPIRO, AB; HUBER, AH; MCCARTY, RE			4 TIGHT NUCLEOTIDE BINDING-SITES OF CHLOROPLAST COUPLING FACTOR-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BEEF-HEART F1-ATPASE; FACTOR-I; ATP HYDROLYSIS; NONCATALYTIC SITES; BETA-SUBUNIT; MECHANISM; ASYMMETRY; CATALYSIS; SYNTHASE	We have examined the properties of the four tight nucleotide binding sites of reductively activated chloroplast coupling factor 1. Tight sites are here defined as those which retain bound nucleotides after passage of the chloroplast coupling factor 1 through Sephadex gel filtration centrifuge columns. Two of the sites, here called sites 4 and 5, have not been characterized in detail before. Site 4 has properties similar to those of site 1. It binds to ADP, ATP, and adenylyl-beta, gamma-imidodiphosphate (AMP-PNP) tightly in the presence or absence of Mg2+. Bound ADP exchanges rapidly with medium ADP, but rapid exchange with ATP or AMP-PNP requires Mg2+. Site 4 may slowly hydrolyze bound ATP in the absence of medium nucleotides. Site 5 has properties similar to those of site 2. Tight binding of ATP and AMP-PNP requires Mg2+, but Mg2+-ADP is not tightly bound. Site 5 does not hydrolyze bound ATP in the absence of medium nucleotides. Complete filling of all four tight nucleotide binding sites requires about one millimolar nucleotide, suggesting that low affinity binding sites are converted to tight binding via a nucleotide binding-induced conformational change.	CORNELL UNIV,DIV BIOL SCI,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853	Cornell University								ANTHON GE, 1983, BIOCHIM BIOPHYS ACTA, V723, P358, DOI 10.1016/0005-2728(83)90041-5; BICKELSANDKOTTER S, 1981, FEBS LETT, V125, P188, DOI 10.1016/0014-5793(81)80715-6; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BRUIST MF, 1981, BIOCHEMISTRY-US, V20, P6298, DOI 10.1021/bi00525a003; DU ZY, 1989, BIOCHEMISTRY-US, V28, P873, DOI 10.1021/bi00428a070; FEIERABEND B, 1988, BIOCHIM BIOPHYS ACTA, V932, P146, DOI 10.1016/0005-2728(88)90149-1; GIRAULT G, 1988, J BIOL CHEM, V263, P14690; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; HILLER R, 1985, J BIOL CHEM, V260, P1614; KIRONDE FAS, 1987, J BIOL CHEM, V262, P3488; LECKBAND D, 1987, BIOCHEMISTRY-US, V26, P2306, DOI 10.1021/bi00382a035; NALIN CM, 1982, J BIOL CHEM, V257, P8055; POSORSKE L, 1976, ARCH BIOCHEM BIOPHYS, V177, P276, DOI 10.1016/0003-9861(76)90437-9; SCHUMANN J, 1987, BIOCHIM BIOPHYS ACTA, V890, P326, DOI 10.1016/0005-2728(87)90160-5; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SHAPIRO AB, 1990, J BIOL CHEM, V265, P4340; SHAPIRO AB, 1988, J BIOL CHEM, V263, P14160; SHOSHAN V, 1980, J BIOL CHEM, V255, P384; XUE ZX, 1988, J BIOL CHEM, V263, P16880; XUE ZX, 1987, BIOCHEMISTRY-US, V26, P3749, DOI 10.1021/bi00387a001; XUE ZX, 1989, EUR J BIOCHEM, V179, P677, DOI 10.1111/j.1432-1033.1989.tb14600.x; XUE ZX, 1987, FEBS LETT, V223, P391, DOI 10.1016/0014-5793(87)80325-3	22	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4194	4200						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1825653				2022-12-25	WOS:A1991FA69400030
J	RAYMOND, JR; ALBERS, FJ; MIDDLETON, JP; LEFKOWITZ, RJ; CARON, MG; OBEID, LM; DENNIS, VW				RAYMOND, JR; ALBERS, FJ; MIDDLETON, JP; LEFKOWITZ, RJ; CARON, MG; OBEID, LM; DENNIS, VW			5-HT1A AND HISTAMINE H1 RECEPTORS IN HELA-CELLS STIMULATE PHOSPHOINOSITIDE HYDROLYSIS AND PHOSPHATE-UPTAKE VIA DISTINCT G-PROTEIN POOLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; OPOSSUM KIDNEY-CELLS; KINASE-C ACTIVATION; PARATHYROID-HORMONE; PERTUSSIS TOXIN; OK CELLS; GUANINE-NUCLEOTIDES; PHOSPHOLIPASE-C; SMALL-INTESTINE; PHORBOL ESTERS	Regulation of phosphate uptake was studied in a HeLa cell line after transfection with DNA encoding the human 5-HT1A receptor. In these cells, 5-HT stimulates sodium-dependent phosphate uptake via protein kinase C activation. Endogenous histamine H-1 receptors (739 +/- 20 fmol/mg protein) were identified with [H-3]pyrilamine. Histamine (i) stimulated phosphoinositide hydrolysis (EC50 = 8.6 +/- 4.1-mu-M), (ii) activated protein kinase C (2.4-fold increase in activity), and (iii) increased phosphate uptake (EC50 = 3.2 +/- 1.8-mu-M) by increasing maximal transport (V(max)(basal) = 6.2 +/- 0.3 versus V(max)(histamine) = 9.1 +/- 0.4) without changing the affinity of the transport process for phosphate. Prolonged treatment with 16-mu-M phormol 12-myristate 13-acetate completely blocked protein kinase C activation and markedly attenuated the stimulation of phosphate uptake induced by histamine, establishing that 5-HT and histamine stimulate phosphate uptake through the common pathway of protein kinase C activation. The linkages of the histamine H-1 and 5-HT1A receptors to G protein pools were assessed in two ways. (i) The stimulation of phosphoinositide hydrolysis, protein kinase C activity, and phosphate uptake associated with histamine were insensitive to pertussis toxin, whereas those associated with 5-HT were very sensitive to pertussis toxin. (ii) The stimulation of phosphoinositide hydrolysis, protein kinase C activity, and phosphate uptake induced by histamine and 5-HT were additive. These findings suggest that distinct receptor types can stimulate phosphoinositide hydrolysis protein kinase C, and phosphate uptake in an additive fashion through distinct pools of G proteins in a single cell type.	DUKE UNIV,MED CTR,DEPT MED CARDIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED ENDOCRINOL,DURHAM,NC 27710; VET ADM MED CTR,MED SERV,NEPHROL SECT,DURHAM,NC 27705; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710	Duke University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; Duke University; Duke University; Howard Hughes Medical Institute	RAYMOND, JR (corresponding author), DUKE UNIV,MED CTR,DEPT MED NEPHROL,BOX 3459,DURHAM,NC 27710, USA.		Lefkowitz, Robert/AAW-2649-2021	obeid, lina/0000-0002-0734-0847	NCRR NIH HHS [S07-RR-05405] Funding Source: Medline; NHLBI NIH HHS [HL-16038] Funding Source: Medline; NINDS NIH HHS [NS-19576] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005405] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BERNER W, 1976, BIOCHEM J, V160, P467, DOI 10.1042/bj1600467; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; CAVERZASIO J, 1986, J BIOL CHEM, V261, P3233; CHANG RSL, 1980, J NEUROCHEM, V34, P916, DOI 10.1111/j.1471-4159.1980.tb09666.x; CHENG L, 1988, BIOCHEM BIOPH RES CO, V155, P74, DOI 10.1016/S0006-291X(88)81051-9; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; COLE JA, 1988, ENDOCRINOLOGY, V122, P2981, DOI 10.1210/endo-122-6-2981; COLE JA, 1987, AM J PHYSIOL, V253, pE221, DOI 10.1152/ajpendo.1987.253.2.E221; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; DANISI G, 1984, ADV EXP MED BIOL, V178, P173; DELEAN A, 1982, MOL PHARMACOL, V21, P5; ESCOUBET B, 1989, AM J PHYSIOL, V256, pC322, DOI 10.1152/ajpcell.1989.256.2.C322; FARGIN A, 1989, J BIOL CHEM, V264, P14848; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; FRIEDLANDER G, 1989, J BIOL CHEM, V264, P3935; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAMILTON RT, 1978, J BIOL CHEM, V253, P8247; HAMMERMAN MR, 1986, AM J PHYSIOL, V251, pF385, DOI 10.1152/ajprenal.1986.251.3.F385; ISAKOV N, 1990, J BIOL CHEM, V265, P2091; JACK MG, 1989, J BIOL CHEM, V264, P3904; KEMPSON SA, 1989, J BIOL CHEM, V264, P18451; KINOSHITA Y, 1988, ENDOCRINOL JAPON, V35, P217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lever J E, 1980, Ann N Y Acad Sci, V341, P37, DOI 10.1111/j.1749-6632.1980.tb47158.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALMSTROM K, 1988, BIOCHEM J, V251, P207, DOI 10.1042/bj2510207; MALMSTROM K, 1986, AM J PHYSIOL, V251, pC23, DOI 10.1152/ajpcell.1986.251.1.C23; Maniatis T, 1982, MOL CLONING LABORATO; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MIDDLETON JP, 1989, AM J PHYSIOL, V257, pF631, DOI 10.1152/ajprenal.1989.257.4.F631; MITSUHASHI M, 1988, J CELL PHYSIOL, V134, P367, DOI 10.1002/jcp.1041340307; MITSUHASHI M, 1989, J BIOL CHEM, V264, P18356; MOHRMANN I, 1986, BIOCHIM BIOPHYS ACTA, V860, P35, DOI 10.1016/0005-2736(86)90495-5; NAKAHATA N, 1986, MOL PHARMACOL, V29, P188; NAKAI M, 1987, BIOCHEM BIOPH RES CO, V145, P303, DOI 10.1016/0006-291X(87)91321-0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1989, ANNU REV BIOCHEM, V58, P31; NORHONABLOB L, 1984, ARCH BIOCHEM BIOPHYS, V234, P265; OBEID LM, 1990, J BIOL CHEM, V265, P2370; POUJEOL P, 1985, AM J PHYSIOL, V249, pF74, DOI 10.1152/ajprenal.1985.249.1.F74; RAYMOND JR, 1990, AM J PHYSIOL, V258, pF433, DOI 10.1152/ajprenal.1990.258.2.F433; RAYMOND JR, 1989, J BIOL CHEM, V264, P21943; RAYMOND JR, 1991, IN PRESS MOL BIOL RE; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SAUVE R, 1987, J MEMBRANE BIOL, V96, P199, DOI 10.1007/BF01869302; SELZ T, 1989, AM J PHYSIOL, V256, pE93, DOI 10.1152/ajpendo.1989.256.1.E93; SHOEMAKER DG, 1988, J GEN PHYSIOL, V92, P449, DOI 10.1085/jgp.92.4.449; SPACH DH, 1986, J BIOL CHEM, V261, P2750; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TOLL L, 1982, J BIOL CHEM, V257, P13593; UI M, 1984, TRENDS PHARMACOL SCI, V5, P277, DOI 10.1016/0165-6147(84)90444-9; VOLPI M, 1988, J CELL BIOL, V107, P2533, DOI 10.1083/jcb.107.6.2533	59	66	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					372	379						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1845968				2022-12-25	WOS:A1991EQ33900054
